{
    "0": {
        "output": "To determine the trial-level eligibility for the patient described in the note, we must compare the patient's characteristics and situation with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions noted on CXR\n- No prior chemotherapy, candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Women of any age with clinical stage II breast cancer\n- Primary tumor \u2264 5 cm in size with axillary lymph nodes which are clinically [N0 or N1] [T1N1, T2N0, T2N1]\n- No definitive local therapy or prior chemotherapy\n- Histologic confirmation of invasive carcinoma\n- Geographically accessible for follow-up\n- Mentally competent to understand and give informed consent\n- ER status can be positive, negative, or unknown\n- Patients with prior cancers may be eligible if no evidence of recurrence for \u2265 10 years\n\nClinical Trial Exclusion Criteria:\n- Advanced local disease or distant metastases (stage III or IV)\n- Previous therapy to the breast other than excisional biopsy\n- Pregnancy\n- Unwillingness to use birth control during chemotherapy\n- Chronic disease that may affect the risk for surgery or chemotherapy\n\nBased on the patient note, the patient has stage II breast cancer with axillary lymph node involvement, and no previous chemotherapy, which aligns with the inclusion criteria. However, the patient has metastatic lesions as noted on CXR, which suggests advanced disease beyond stage II.\n\nThis falls under the exclusion criteria, which states that patients with advanced local disease or distant metastases (stage III or IV) are not eligible to participate.\n\nTherefore, the patient would be excluded from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, let's compare the patient note with the inclusion criteria of the trial:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes, axillary sampling\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female with histologically confirmed nonlobular invasive breast cancer (ductal, papillary, medullary, colloid (mucinous), or tubular)\n- Stage I/II (T1-2 N0-1 M0) tumor no greater than 3 cm\n- Prior tylectomy and axillary lymph node dissection required\n- No more than 3 positive axillary lymph nodes and no extracapsular extension\n- At least 6 lymph nodes sampled OR Negative sentinel node\n- Surgical clips in place delineating margins of tylectomy cavity\n- Negative, or close but negative, inked histologic margins of tylectomy or re-excision specimen\n- No extensive intraductal carcinoma by the Harvard definition\n- No proven multicentric carcinoma\n- No skin or chest wall invasion, matted or fixed axillary adenopathy, metastatic internal mammary or supraclavicular nodes, or Paget's disease of the nipple\n- No previously treated contralateral breast carcinoma or synchronous bilateral breast carcinoma\n- No prior chemotherapy for breast cancer\n- No prior radiotherapy for breast cancer\n- Planned chemotherapy may begin at least 2 weeks after removal of brachytherapy catheters\n\nAssessment:\n- The patient has ductal breast cancer, which is one of the eligible histologies.\n- The patient has a tumor no greater than 3 cm.\n- The patient has 5 positive lymph nodes, which exceeds the trial's maximum of 3 positive nodes.\n- The patient has metastatic lesions present on CXR, indicating metastasis (M1), which exceeds the Stage I/II (T1-2 N0-1 M0) requirement.\n- The patient is a candidate for tumor resection, which aligns with the requirement for prior tylectomy and axillary lymph node dissection.\n\nBased on the above comparison, the patient does not meet the trial's inclusion criteria due to having more than 3 positive lymph nodes and the presence of metastatic lesions. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial titled \"S9630, Medroxyprogesterone in Treating Women With Breast Cancer.\"\n\nPatient's characteristics and condition:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma (HER2-positive and ER/PR negative)\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions visible on chest x-ray (CXR)\n- Candidate for tumor resection followed by chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically proven diagnosis of one of the following:\n  - Primary invasive adenocarcinoma of the unilateral or bilateral breast\n  - Stage I, IIA, or IIB (T1-3, N0-1, M0)\n- No recurrent invasive breast cancer\n- No sarcoma, lymphoma, or specific types of cancer of the breast not mentioned in the patient's note\n- Currently free of breast cancer (no evidence of disease)\n- No evidence of distant disease on chest x-ray or chest CT scan\n- Prior definitive local treatment of primary lesion and axillary node or sentinel node biopsy\n- Postmenopausal status as defined in the criteria\n- Candidate for adjuvant tamoxifen therapy\n\nBased on the information provided:\n- The patient has histologically confirmed invasive ductal breast carcinoma and is postmenopausal, which aligns with the trial's requirements.\n- However, the patient is not currently free of breast cancer as she has metastatic lesions visible on CXR.\n- The patient is a candidate for tumor resection, which suggests she has not yet had definitive local treatment of the primary lesion.\n\nThe patient does not meet key inclusion criteria:\n- No evidence of distant disease on chest x-ray or chest CT scan.\n- Prior definitive local treatment of the primary lesion.\n\nDue to the presence of metastatic lesions and the lack of prior definitive local treatment, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "3": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Combination Chemotherapy in Treating Women With Breast Cancer\":\n\nPatient Characteristics:\n- Age: 45 years old (meets age criterion)\n- Sex: Female (trial is for women, meets sex criterion)\n- Menopausal status: Postmenopausal (not specified as a factor in the trial)\n- Disease: Cytologically confirmed breast cancer (meets disease characteristic)\n- Tumor size: 3 cm invasive ductal carcinoma (meets tumor size criterion)\n- Lymph nodes: 5 positive lymph nodes (trial specifies 1 to 3 positive lymph nodes)\n\nAdditional Considerations:\n- Metastatic lesions noted in CXR (the trial excludes metastatic breast cancer)\n- Hormone receptor status: HER2-positive and ER/PR negative (not specified as a factor in the trial)\n- No information on hematopoietic, hepatic, renal, or cardiovascular status is given, but these are part of the inclusion criteria to ensure adequate organ function.\n- No prior chemotherapy for the malignancy (meets prior/concurrent therapy criterion)\n- No information on prior radiotherapy specific to the malignancy in question.\n- The patient is a candidate for tumor resection and agrees to do so (meets surgical requirements if done within 84 days before beginning treatment on protocol).\n\nBased on the provided information, the patient meets some of the inclusion criteria (age, sex, disease confirmation, undergoing surgery), but the trial specifically excludes patients with locally advanced or inflammatory or metastatic breast cancer, which this patient has (metastatic lesions noted in CXR). Additionally, the patient has more positive lymph nodes (5) than the trial's specified range (1 to 3).\n\nTherefore, the patient is not eligible for the trial due to the exclusion criteria regarding metastatic cancer and the number of positive lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "4": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical trial's inclusion criteria:\n- Histologically or cytologically proven stage I or IIA invasive breast cancer\n- Tumor size T0, T1, or T2 (no greater than 3 cm)\n- N0 (no lymph node involvement)\n- Noninflammatory\n- Nonmetastatic\n- Eligible for breast-conserving surgery\n- Hormone receptor status: Positive or negative\n- No allergies to radiopharmaceuticals or blue dye\n- No prior breast surgical biopsy or axillary surgery\n- No prior neoadjuvant therapy (biological, chemotherapy, endocrine, or radiotherapy)\n\nComparing the patient's characteristics to the inclusion criteria:\n\n- The patient does have histologically confirmed invasive breast cancer, matching the trial criteria.\n- The tumor size is within the specified limit (3 cm), which is T2 and meets the trial criteria.\n- The patient has positive lymph nodes (N1), which is not compatible with the trial's requirement of N0.\n- The patient has metastatic lesions, which means she does not meet the nonmetastatic requirement of the trial.\n- The patient is postmenopausal, which is allowed in the trial as it accepts both pre- and postmenopausal women.\n\nBased on the above comparison, the patient does not meet the inclusion criteria due to the presence of positive lymph nodes and metastatic disease. The trial specifies N0 (no lymph node involvement) and nonmetastatic patients, which excludes this patient from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "5": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria Assessment:\n1. Disease Characteristics:\n   - Resectable invasive adenocarcinoma of the breast: The patient has invasive ductal breast carcinoma, which is a type of adenocarcinoma. It is not explicitly stated whether it is resectable, but the patient is a candidate for tumor resection, which implies that it is likely resectable.\n   - Clinically negative lymph nodes: The patient has 5 positive lymph nodes, which disqualify her based on this criterion.\n   - No positive ipsilateral axillary lymph nodes: The patient has positive lymph nodes, which disqualify her.\n   - No prior removal of ipsilateral axillary lymph nodes: There is no information provided that suggests prior removal.\n   - No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy: There is no information about this in the patient's note.\n   - No ulceration, erythema, infiltration of the skin or underlying chest wall, peau d'orange, or skin edema: There is no information about this in the patient's note.\n   - No bilateral malignancy or mass in the opposite breast that is suspicious for malignancy, unless proven nonmalignant by biopsy: There is no information suggesting a contralateral breast issue.\n   - No diffuse tumors or multiple malignant tumors in different quadrants of the breast: There is no information provided regarding this.\n   - No other prior breast malignancy except lobular carcinoma in situ: It is not mentioned if the patient has had any other prior breast malignancy.\n   - No prior or concurrent breast implants: There is no mention of breast implants.\n\n2. Patient Characteristics:\n   - Age: 18 years and older: The patient is 45 years old.\n   - Sex: Female: The patient is a postmenopausal woman.\n   - Life expectancy: At least 10 years (excluding diagnosis of cancer): There is no information provided regarding life expectancy, but nothing suggests it is less than 10 years.\n   - No hepatic systemic disease: There is no information about hepatic disease.\n   - No renal systemic disease: There is no information about renal disease.\n   - No cardiovascular systemic disease: There is no information about cardiovascular disease.\n   - No prior malignancy within the past 5 years except for certain exceptions: There is no information about previous malignancies.\n   - No concurrent psychiatric or addictive disorder: There is no information about psychiatric or addictive disorders.\n\n3. Prior Concurrent Therapy:\n   - No prior immunotherapy, chemotherapy, hormonal therapy, or radiotherapy for this cancer: The patient is not reported to have undergone any of these treatments.\n   - No prior breast reduction surgery: There is no information about previous breast reduction surgery.\n   - Prior excisional biopsy or lumpectomy allowed: The patient has had a core biopsy, which is not explicitly excluded.\n\nThe patient does not meet the inclusion criteria due to having positive lymph nodes, which is specifically mentioned as an exclusion under the disease characteristics.\n\nTherefore, the patient would be excluded from the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "6": {
        "output": "Based on the provided clinical trial inclusion criteria and the patient note, let's compare the relevant points:\n\nInclusion Criteria Check:\n\n1. **Histologically confirmed resectable adenocarcinoma of the breast**: The patient has cytologically confirmed breast cancer, which is an invasive ductal carcinoma. This meets the criterion for breast adenocarcinoma.\n\n2. **Postmenopausal**: The patient is described as postmenopausal which fits the inclusion criterion.\n\n3. **No distant metastases**: The patient has metastatic lesions as per the chest x-ray (CXR), indicating distant metastases. This does not meet the criterion that specifies no distant metastases.\n\n4. **Hormone receptor status**: The patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria specify that the tumor must have at least 10% hormone receptor-positive cells, which would include estrogen receptor (ER) and/or progesterone receptor (PR) positivity. The patient's tumor does not meet this criterion as it is ER/PR negative.\n\n5. **Agreement to tumor resection prior to chemotherapy**: The patient agrees to have tumor resection before chemotherapy, which aligns with the requirement for patients to have had surgery (total mastectomy, lumpectomy, or quadrantectomy).\n\nBased on the criteria mentioned above, the patient does not meet the hormone receptor status and has distant metastases, which excludes her from participating in this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "7": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient note to the inclusion criteria provided by the trial. Let's go through the main points:\n\nInclusion criteria for the trial:\n\n1. HER2 overexpressing (3+) metastatic breast cancer by immunohistochemistry, or amplified by FISH.\n2. No prior chemotherapy for breast cancer metastases.\n3. No bilateral disease.\n4. Bidimensionally measurable disease with at least one target lesion greater than 1 cm2.\n5. No significant lymphedema in the arm ipsilateral to the mastectomy site, unless the patient has an indwelling catheter for the purpose of chemotherapy infusion.\n6. No CNS metastases.\n7. Female patients aged 18 and over.\n8. Karnofsky performance status 70-100%.\n9. Adequate hematopoietic function (specific blood count levels).\n10. Adequate hepatic function (specific enzyme levels).\n11. Adequate renal function (creatinine no greater than 1.5 times ULN).\n12. No clinically significant cardiovascular disease.\n13. Left ventricular ejection fraction at least 50%.\n14. No severe hypersensitivity to products containing Cremophor EL.\n15. Not pregnant or nursing, and using effective contraception if fertile.\n\nPatient note:\n\n1. 45-year-old postmenopausal woman with cytologically confirmed breast cancer (meets gender and age criteria).\n2. HER2-positive and ER/PR negative tumor in the left upper outer quadrant (meets HER2 overexpression criteria).\n3. Axillary sampling revealed 5 positive lymph nodes (not specified as exclusion criteria).\n4. Tumor is 3 cm invasive ductal breast carcinoma, suggesting measurable disease (meets measurable disease criteria).\n5. CXR showed metastatic lesions (indicates metastatic breast cancer, but CNS involvement is not mentioned).\n6. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy (no prior chemotherapy for metastases is mentioned, which meets criteria).\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial. The patient has HER2-positive metastatic breast cancer, which is required by the trial, and there is no mention of any prior chemotherapy for metastases, bilateral disease, CNS metastases, or significant lymphedema that would exclude the patient. Additionally, there is no indication of any other serious medical conditions, which is also in line with the patient characteristics required by the trial.\n\nHowever, there are some criteria for which we do not have enough information, such as the Karnofsky performance status, hematopoietic, hepatic, renal function, cardiovascular health, and left ventricular ejection fraction. We also do not have information regarding any prior treatments such as chemotherapy in an adjuvant setting, which could potentially exclude the patient if the specific conditions are not met.\n\nGiven the available information, the patient appears to be potentially eligible, but there is insufficient information to definitively determine eligibility without further details on the patient's medical history and current health status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "8": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's information with the inclusion criteria of the clinical trial. Let's assess the patient's eligibility based on the provided inclusion criteria:\n\n1. **Age**: The patient is 45 years old, which meets the age requirement of being \u2265 18 years.\n2. **Diagnosis**: The patient has cytologically confirmed breast cancer, which meets the requirement of having operable, histologically confirmed adenocarcinoma of the female breast.\n3. **Tumor Characteristics**: The patient has a HER2-positive and ER/PR-negative invasive ductal carcinoma with 5 positive lymph nodes, which meets the criteria for node-positive disease with HER-2 positive status.\n4. **Surgical candidacy**: The patient is a candidate for tumor resection, which aligns with the requirement that all tumor should be removed via surgery.\n5. **Treatment History**: The patient note does not mention prior chemotherapy, hormonal therapy, or radiation therapy, which is consistent with the trial\u2019s requirements that certain treatments must not have been received before registration.\n6. **Other Health Conditions**: The patient note does not list any other health conditions that would exclude her from the trial based on the provided criteria.\n7. **Willingness**: The patient agrees to tumor resection, which indicates a willingness to undergo necessary treatments and potentially meet the requirement for informed consent.\n\nGiven the information in the patient note, the patient seems to meet all the mentioned inclusion criteria for the clinical trial. However, it is important to note that there are certain criteria for which we do not have information, such as laboratory values (ANC, PLT, bilirubin, AST, LVEF), willingness to discontinue sex hormonal therapy, and non-breast malignancies. The patient's eligibility would also be contingent on the results of these criteria.\n\nSince we do not have information about these factors, we cannot definitively determine the patient's eligibility. Therefore, based on the information provided and the fact that we lack some details necessary for a complete assessment, the trial-level eligibility would be:\n\n`Trial-level eligibility: 1) Not relevant.`",
        "label": 2
    },
    "9": {
        "output": "Let's evaluate the patient's eligibility based on the inclusion criteria provided for the clinical trial.\n\n**Patient Information:**\n- Age: 45 years old\n- Sex: Female\n- Menopausal status: Postmenopausal\n- Breast cancer: Cytologically confirmed\n- Tumor characteristics: 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative\n- Lymph nodes: 5 positive axillary lymph nodes\n- Metastasis: Presence of metastatic lesions (CXR)\n- Treatment plan: Candidate for tumor resection prior to chemotherapy\n\n**Clinical Trial Inclusion Criteria:**\n- Stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast\n- No excisional biopsy\n- Tumor size 2 nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0)\n- Any T with N2 (including axillary lymph nodes matted to one another) or N3\n- Any T4, including inflammatory breast cancer\n- Adjuvant patients with at least 4 positive lymph nodes and HER-2 overexpressing tumor\n- Supraclavicular or infraclavicular positive lymph nodes without distant metastases\n- Distant metastases with measurable disease in breast or lymph nodes\n- Synchronous bilateral primary breast cancer if the more serious cancer meets entry criteria\n- Measurable or evaluable disease\n- Female\n- Not pregnant or nursing\n- Negative pregnancy test\n- Fertile patients must use effective contraception\n- Hematopoietic and organ function criteria specified\n\n**Clinical Trial Exclusion Criteria:**\n- Prior malignancies except in specific cases\n\nThe patient has a confirmed diagnosis of breast cancer with positive lymph nodes and metastatic lesions, indicating advanced disease. The tumor is HER2-positive, which corresponds with the HER-2 overexpressing tumor criterion. The patient's cancer stage is not explicitly mentioned, but the presence of positive lymph nodes and distant metastases suggests that she could fall into the stage IIIB, IIIC, or IV categories, which are included in the trial. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the trial's treatment approach.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial: she has breast cancer with axillary lymph node involvement, HER2-positive tumor, and distant metastases, which are all characteristics specified in the inclusion criteria.\n\nTherefore, the patient is likely to be eligible for the trial unless there are other unstated exclusion criteria that she meets or if her tumor size and stage do not exactly match those specified.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "10": {
        "output": "To determine the patient's trial-level eligibility, we need to compare the patient's information to the inclusion and exclusion criteria of the clinical trial \"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study.\"\n\nPatient's characteristics:\n- Age: 45 years old\n- Postmenopausal (implied by the term \"postmenopausal woman\")\n- Cytologically confirmed breast cancer\n- Known tumor characteristics (HER2-positive, ER/PR negative)\n- Axillary sampling showed 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection\n- No mention of BRCA mutation or relationship to BRCA mutation carriers\n- No information about menstrual history or FSH level\n- No information on ECOG performance status\n- Willingness to undergo tumor resection implies ability to provide informed consent\n\nInclusion criteria for the Menstrual Cycle Study:\n- Must be at least 25 years old and less than 46 years old\n- Must be premenopausal with regular menstrual cycling\n- Must have a known BRCA mutation or be a relative of someone with a BRCA-associated cancer\n- Willing to use non-hormonal contraception\n- ECOG performance status of 0-1\n- Able to provide informed consent\n\nExclusion criteria for the Menstrual Cycle Study:\n- Menstrual cycle irregularities\n- Use of certain hormonal medications\n- Pregnancy or lactation within 12 months\n- History of certain medical conditions (e.g., invasive cancer, abnormal CA-125)\n- Over a certain weight limit\n- Allergies to specific substances\n\nBased on the provided information, the patient does not meet the inclusion criteria for the Menstrual Cycle Study as she is postmenopausal, which is directly in conflict with the requirement for participants to be premenopausal with regular menstrual cycling. Additionally, there is no information suggesting that the patient is a known BRCA mutation carrier or a relative of a BRCA mutation carrier, which is another key inclusion criterion. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "11": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman (meets age and sex criteria)\n- Breast cancer confirmed by core biopsy (meets criteria for confirmed invasive breast cancer)\n- HER2-positive and ER/PR negative (hormone receptor status not specified in the trial's criteria)\n- Has metastatic lesions (does not meet criteria as metastatic disease is excluded)\n- Candidate for tumor resection (implies the patient is fit for surgery, potentially meeting the fitness criteria)\n\nTrial Inclusion Criteria:\n- Histologically confirmed operable invasive breast cancer (met by patient)\n- T0-2, N0 (patient has positive lymph nodes, thus exceeding the N0 criteria)\n- Only 1 tumor in 1 breast (met by patient)\n- Tumor between 5 and 50 mm in largest diameter, within 1 quadrant (met by patient)\n- No metastatic disease (patient does not meet this criterion)\n- Clinically negative axillary lymph nodes (patient has 5 positive lymph nodes, thus not meeting this criterion)\n- Fit to undergo sentinel node biopsy, axillary clearance, breast surgery, and/or axillary radiotherapy (presumably met by patient)\n- No psychological, familial, sociological, or geographical condition that would preclude study compliance (there is no information to suggest non-compliance)\n- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix (met by patient)\n- Not pregnant (met by patient)\n\nThe patient does not meet the criteria for T0-2, N0 due to having positive lymph nodes and has disqualifying metastatic disease. Therefore, the patient would be excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "12": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically or cytologically confirmed metastatic breast cancer with HER2 overexpression (\u2713 the patient's tumor is HER2-positive)\n- Radiographically or physically measurable disease that can be biopsied safely under local anesthesia (\u2713 the patient has a 3 cm tumor and metastatic lesions)\n- Age 18 and over (\u2713 the patient is 45 years old)\n- Male or female (\u2713 the patient is female)\n- ECOG performance status 0-2 (not specified in the patient note, so we cannot confirm)\n- Neutrophil count at least 1,000/mm^3 (not specified in the patient note)\n- Platelet count at least 75,000/mm^3 (not specified in the patient note)\n- Bilirubin no greater than 3 times ULN (not specified in the patient note)\n- AST and ALT no greater than 5 times ULN (not specified in the patient note)\n- Not pregnant or nursing (\u2713 the patient is not sexually active and has no children)\n- Negative pregnancy test (not specified, but the patient is postmenopausal and not sexually active, so pregnancy is unlikely)\n- Fertile patients must use effective contraception (not applicable, the patient is postmenopausal)\n- No prior trastuzumab (not specified in the patient note, so we cannot confirm)\n- At least 2 weeks since prior hormonal therapy (not specified, but the patient is postmenopausal and no hormonal therapy is mentioned)\n- No concurrent hormone receptor therapy (e.g., tamoxifen or armidex) (not specified, but no current therapy is mentioned)\n- Localized palliative external beam radiotherapy allowed (not relevant to the patient's current treatments)\n\nBased on the information provided, the patient meets several of the specified inclusion criteria for the clinical trial. However, crucial information regarding performance status, blood counts (neutrophil and platelet), liver function (bilirubin, AST, ALT), and prior trastuzumab use is not provided in the patient note. Without this information, we cannot definitively determine the patient's eligibility. Therefore, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "13": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\n**Patient Note Analysis:**\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- Tumor characteristics: invasive ductal breast carcinoma, HER2-positive, ER/PR-negative.\n- The patient has metastatic lesions (indicating metastatic breast cancer).\n- The patient is using multivitamins and iron supplements.\n- The patient does not smoke or consume alcohol.\n- The patient is not sexually active and has no children.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\n**Clinical Trial Inclusion Criteria:**\n- Postmenopausal women.\n- Metastatic breast cancer suitable for endocrine therapy.\n- Positive hormone receptor status.\n- Human epidermal growth factor receptor 2 (HER2) overexpression.\n\n**Eligibility Assessment:**\n- The patient is a postmenopausal woman (meets criteria).\n- The patient has metastatic breast cancer (meets criteria).\n- The patient has a HER2 overexpressing tumor (meets criteria).\n- The inclusion criteria require a positive hormone receptor status (ER+ve and/or PR+ve), and the patient's tumor is ER/PR-negative, which does not meet the hormone receptor positivity requirement of the trial.\n\nSince the patient does not meet the requirement of having a positive hormone receptor status, as her tumor is ER/PR-negative, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "14": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition against the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical trial inclusion criteria for breast cancer and high-risk patients:\n- Age \u2265 18 years and \u2264 74 years (Patient is 45, so meets this criterion)\n- Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin (Patient has invasive ductal breast carcinoma, so meets this criterion)\n- Breast cancer may be invasive or noninvasive, and in the past or the present (Patient has current invasive breast cancer, so meets this criterion)\n- The contralateral breast must be free of any suspicious areas by physical examination and mammogram (There is no information about the contralateral breast, but since there is no mention of issues, we can assume it meets this criterion unless proven otherwise)\n- WBC greater than 2,500 (Not mentioned, so we don't know)\n- Platelets greater than 50,000 (Not mentioned, so we don't know)\n\nExclusion criteria for breast cancer patients:\n- Contralateral breast prosthesis (Not mentioned, so we assume it does not apply)\n- Pregnancy (Not mentioned, but given she is not sexually active, we can assume she is not pregnant)\n- History of radiation therapy to the contralateral breast (Not mentioned, so we assume it does not apply)\n- Lactating breasts (Not mentioned, but as she is postmenopausal and not sexually active, we assume it does not apply)\n- Chemotherapy within the past 1 month (Not mentioned, so we don't know)\n- Current antiestrogen therapy (Not mentioned, so we don't know)\n- Current hormonal replacement therapy or oral contraceptives (Not mentioned, but given she is postmenopausal and not sexually active, we assume she is not on contraceptives)\n- Concurrent infection (Not mentioned, so we assume it does not apply)\n- Previous contralateral major duct excision (Not mentioned, so we assume it does not apply)\n\nBased on the available information, the patient appears to meet the inclusion criteria, as she is a postmenopausal woman within the age range with confirmed breast cancer of epithelial origin. However, we lack information on her WBC and platelet counts, chemotherapy within the past month, and if she is currently on any antiestrogen therapy. \n\nWithout complete information, we cannot definitively include or exclude the patient; thus, she falls under the \"Not relevant\" category as we lack sufficient information to qualify her for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "15": {
        "output": "To determine the trial-level eligibility for this patient, we need to match the patient's details against the inclusion criteria of the clinical trial.\n\nPatient details:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor size: 3 cm\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions noted on CXR\n- No mention of previous chemotherapy or hormonal therapy for this malignancy\n- Candidate for tumor resection before chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically confirmed invasive carcinoma of the female breast\n- 0-3 positive axillary lymph nodes\n- Patients with 1-3 positive axillary nodes are eligible if chemotherapy is deemed potentially beneficial\n- Negative tumor margins for invasive cancer and DCIS\n- No previous trastuzumab, chemotherapy or hormonal therapy for this malignancy\n- No previous anthracycline chemotherapy for any disease\n- No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer\n- No involvement of dermal lymphatics on pathology\n- Disease-free from prior malignancies for > 5 years (with specific exceptions)\n- CTC performance status 0-1\n- Not pregnant or nursing\n- No concomitant exogenous hormone therapy\n- Adequate organ function\n- No active congestive heart failure or recent myocardial infarction\n\nBased on the information provided, the patient has metastatic breast cancer, which is indicated by the presence of metastatic lesions on CXR. As the clinical trial specifically excludes patients with metastatic breast cancer, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "16": {
        "output": "",
        "label": 2
    },
    "17": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,\" we need to compare the patient's characteristics and history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, located in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Metastatic lesions present (implying Stage IV or locally advanced disease)\n- Axillary sampling revealed 5 positive lymph nodes\n- Candidate for tumor resection, chemotherapy not started yet\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed breast cancer\n- Stage IV or locally advanced disease\n- HER2/neu positive by FISH (if 2+ by IHC) or 3+ by IHC\n- Measurable or evaluable disease\n- Estrogen receptor and/or progesterone receptor positive\n- Postmenopausal woman\n- Age 18 and over\n- ECOG performance status 0-2\n- Adequate hepatic and renal function\n- Ejection fraction greater than 50%\n- No prior treatment with trastuzumab or exemestane\n\nComparison:\n- The patient's breast cancer is histologically confirmed, meeting the trial requirement.\n- The patient has HER2-positive breast cancer, which is a requirement for the trial.\n- The patient's tumor size and the presence of metastatic lesions indicate that she has either stage IV or locally advanced disease.\n- The patient is postmenopausal, as per the information provided.\n- The patient's performance status is not mentioned, but since she is a candidate for surgery, it can be inferred that she likely has an ECOG performance status of 0-2.\n- The patient has not received trastuzumab or exemestane, which aligns with the trial's criteria.\n- The patient's hormone receptor status is negative for ER/PR, which does not meet the trial's requirement of being positive for estrogen receptor and/or progesterone receptor.\n\nBased on the provided information, the patient meets several of the trial's inclusion criteria. However, she does not meet the criteria for hormone receptor status, as she is ER/PR negative while the trial requires participants to be estrogen receptor and/or progesterone receptor positive.\n\nTherefore, the patient is not eligible for the trial due to a mismatch in hormone receptor status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "18": {
        "output": "To determine the trial-level eligibility of the patient for the \"Premenopausal Endocrine Responsive Chemotherapy Trial,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nBased on the patient note:\n- Age: 45 years old\n- Sex: Female\n- Menopausal status: Postmenopausal\n- Diagnosis: Invasive ductal breast carcinoma, HER2-positive and ER/PR negative\n- Additional details: Axillary sampling revealed 5 positive lymph nodes, metastatic lesions present on CXR, candidate for tumor resection prior to chemotherapy\n\nBased on the trial inclusion criteria:\n- Disease Characteristics: Breast cancer confined to breast and axillary nodes, no distant metastatic disease, certain surgical criteria\n- Hormone receptor status: Estrogen receptor and/or progesterone receptor positive\n- Patient Characteristics: Premenopausal, premenopausal estradiol levels, no prior or concurrent invasive malignancy other than specified exceptions\n- Other: No prior neoadjuvant or adjuvant chemotherapy or endocrine therapy, among other specific criteria\n\nComparison:\n- The patient's age and sex fit the trial criteria.\n- The patient is postmenopausal, which does not fit the premenopausal requirement of the trial.\n- The patient's tumor is HER2-positive and ER/PR-negative, which does not meet the hormone receptor positive requirement of the trial.\n- The patient has distant metastatic disease, as indicated by the metastatic lesions present on CXR, which does not meet the \"no distant metastatic disease\" requirement of the trial.\n\nTherefore, the patient does not meet the key inclusion criteria of being premenopausal and having hormone receptor positive breast cancer and does not fit the requirement of no distant metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "19": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer,\" we need to compare the patient's information to the trial's inclusion criteria.\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma (HER2-positive, ER/PR-negative)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically confirmed stage I-III invasive breast cancer (Patient meets this criterion)\n- Operable disease (Patient meets this criterion with planned tumor resection)\n- Stage I, II, IIIA, and IIIC (T1-3, N3a only) (Patient's disease seems to fit within these stages)\n- No T4 tumors (No T4 tumor mentioned in the patient note)\n- High-risk disease, defined by specific tumor sizes, node status, and other factors (Patient meets this criterion with a tumor \u2265 2 cm and positive lymph nodes)\n- HER2/neu-positive tumors allowed (Patient's tumor is HER2-positive)\n- Prior surgery requirements (Patient is a candidate for surgery)\n- Resection margins must be negative for invasive cancer (Patient has not yet had surgery, so this is not applicable yet)\n- Age 18 and over (Patient is 45 years old)\n- Zubrod performance status of 0-2 (Not mentioned, but nothing suggests the patient wouldn't meet this criterion)\n- Adequate hematopoietic, hepatic, renal, and cardiovascular function (No information given, but nothing suggests the patient wouldn't meet these criteria)\n- No other malignancy within the past 5 years (Patient note does not mention any other malignancy)\n- No prior cytotoxic chemotherapy for this breast cancer (Patient has not received chemotherapy yet)\n- No prior chemotherapy with an anthracycline, anthracenedione, or taxane (Patient has not received chemotherapy yet)\n- Not pregnant or nursing, and using effective contraception if fertile (Patient is postmenopausal and not sexually active)\n\nBased on the available information, the patient appears to meet all the disclosed inclusion criteria for the clinical trial. The patient note does not provide information that would lead to exclusion based on the trial criteria provided. Therefore, the patient seems eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "20": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nHere are the key inclusion criteria to consider:\n\n1. Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma.\n2. Largest tumor lesion \u2264 5 cm.\n3. Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions.\n4. Prior (preoperative) or planned (intraoperative) sentinel node biopsy required.\n5. At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension.\n6. No clinical evidence of distant metastases.\n7. No palpable axillary lymph node(s).\n8. No other prior or concurrent malignancy except for certain treated conditions.\n9. No prior systemic therapy for breast cancer.\n\nPatient note analysis:\n\n1. The patient has a diagnosis of breast cancer.\n2. The tumor is 3 cm, which is within the criterion of \u2264 5 cm.\n3. There is no mention of the method of localization for the tumor, but since surgery is planned, it is likely that some form of localization will be or has been used.\n4. The patient's note does not specify whether a sentinel node biopsy has been performed or planned.\n5. The patient has 5 positive lymph nodes, which indicates metastases larger than micrometastases and may have extracapsular extension.\n6. There is clinical evidence of distant metastases (CXR remarkable for metastatic lesions).\n7. Since there are 5 positive lymph nodes, it is likely that they are palpable, which is against the inclusion criteria.\n8. There is no mention of any other prior or concurrent malignancy.\n9. There is no prior systemic therapy for breast cancer mentioned.\n\nBased on the information provided, the patient does not meet the following key inclusion criteria: having only micrometastatic sentinel lymph nodes with no extracapsular extension and no clinical evidence of distant metastases. The presence of distant metastases and more than micrometastatic involvement of the lymph nodes excludes the patient from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "21": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nAccording to the patient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has a confirmed diagnosis of breast cancer, specifically invasive ductal breast carcinoma, which is different from ductal carcinoma in situ (DCIS).\n- The tumor is HER2-positive and ER/PR negative, which means it does not meet the hormone receptor status required for the trial (estrogen or progesterone receptor positive with at least 5% positive cells).\n- The patient has metastatic lesions, as indicated by the CXR results.\n\nNow, let's review the inclusion criteria of the clinical trial:\n- Diagnosis of ductal carcinoma in situ within the past 6 months.\n- Locally excised with tumor-free margins at least 1 mm.\n- Hormone receptor status: Estrogen or progesterone receptor positive with equal to or greater than 5% positive cells.\n- Age between 40 to 70 years.\n- Postmenopausal status (the patient is postmenopausal).\n- No prior deep vein thrombosis, transient ischemic attack, or cerebrovascular accident.\n- No prior pulmonary embolism.\n- No unexplained postmenopausal bleeding.\n- No other cancer within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix.\n- No other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results.\n- No evidence of osteoporosis, except allowed conditions.\n- No prior or concurrent tamoxifen use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No prior or concurrent raloxifene use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No other prior or concurrent selective estrogen-receptor modulator use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No concurrent systemic estrogen-based hormone replacement therapy, including vaginal estrogen preparations.\n- No prior mastectomy.\n- No planned prophylactic mastectomy.\n- At least 3 months since prior unapproved or experimental agents.\n- No concurrent anticoagulants.\n\nBased on the patient note and the clinical trial inclusion criteria, the patient does not meet the key eligibility requirement of having a diagnosis of ductal carcinoma in situ. Instead, she has invasive ductal breast carcinoma, which is not the focus of this trial. Additionally, her tumor does not meet the hormone receptor status required for the trial (the tumor is HER2-positive and ER/PR negative, whereas the trial requires ER or PR positivity). Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "22": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed metastatic breast cancer. The core biopsy has revealed invasive ductal breast carcinoma, HER2-positive and ER/PR negative, with axillary sampling indicating 5 positive lymph nodes and a chest X-ray showing metastatic lesions. The patient has not yet received chemotherapy for her metastatic breast cancer and is a candidate for tumor resection.\n\nThe clinical trial in question is seeking female patients with histologically/cytologically proven metastatic breast carcinoma who have not received prior chemotherapy for metastatic breast cancer. Adequate bone marrow, liver, and renal function are also required for inclusion, but the patient note does not provide specifics on the patient's bone marrow, liver, and renal function.\n\nHowever, based on the information given, the patient appears to meet the primary inclusion criteria:\n\n- Female patient: Yes, the patient is a postmenopausal woman.\n- Histologically/cytologically proven metastatic breast carcinoma: Yes, the patient has cytologically confirmed metastatic breast cancer.\n- Not received prior chemotherapy for metastatic breast cancer: There is no indication of prior chemotherapy for metastatic breast cancer mentioned in the patient note.\n\nSince the patient note does not provide information regarding the patient's bone marrow, liver, and renal function, we cannot fully ascertain her eligibility. Nonetheless, the patient meets the basic disease-specific criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "23": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial. \n\nLet's examine the inclusion criteria against the patient's information:\n\n1. Histologically or cytologically confirmed breast cancer: The patient has cytologically confirmed breast cancer.\n2. Locally advanced disease (stage II or III): The patient has metastatic lesions indicated by a CXR, which suggests that the cancer may be beyond stage III. However, the trial does not explicitly exclude stage IV patients.\n3. Not amenable to breast-conserving therapy at the time of diagnosis: The patient is a candidate for tumor resection, which suggests that the cancer may be amenable to breast-conserving therapy, but this is not explicitly stated.\n4. Measurable disease meeting the specified criteria: The patient has a 3 cm invasive ductal breast carcinoma, which meets the measurable disease criteria.\n5. No evidence of disease outside the breast or chest wall except ipsilateral axillary lymph nodes: The patient has metastatic lesions, which indicates evidence of disease outside the breast or chest wall. This would exclude the patient from the trial.\n6. Hormone receptor status: The tumor is HER2-positive and ER/PR negative. The trial requires estrogen and/or progesterone receptor positivity, which the patient does not have.\n7. Age: The patient is 45 years old and postmenopausal, which fits the age criterion.\n8. Sex: The patient is female.\n9. Menopausal status: The patient is postmenopausal.\n10. Performance status: Not specified for the patient, but there is no indication that the patient would not meet an ECOG 0-3 performance status.\n11. Hematopoietic, hepatic, and renal function: Not specified for the patient, but there is no indication of issues with these functions.\n12. No other prior or concurrent cancer except for certain exceptions: The patient note does not indicate any other prior or concurrent cancer.\n13. No prior biologic therapy, chemotherapy, endocrine therapy, or radiotherapy for breast cancer: The patient is indicated to be a candidate for surgery prior to chemotherapy, suggesting no prior chemotherapy for breast cancer has been administered.\n\nBased on the patient's cancer being metastatic (outside the breast or chest wall) and hormone receptor status being HER2-positive and ER/PR negative, the patient does not meet the inclusion criteria for the clinical trial. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "24": {
        "output": "To determine the patient's eligibility for the described clinical trial, we must evaluate the patient's information against the inclusion and exclusion criteria provided.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma, HER2-positive, and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present in CXR\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria Evaluation:\n- Patients must be greater than or equal to 18 years of age. (Patient is 45, meets criteria)\n- The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Not enough information to determine)\n- The interval between the last surgery for breast cancer treatment and randomization must be no more than 84 days. (Patient agrees to surgery prior to chemotherapy, meets criteria)\n- The tumor must be invasive adenocarcinoma on histologic examination. (Patient has invasive ductal carcinoma, meets criteria)\n- The primary tumor must be T1-3 by clinical and pathologic evaluation. (Patient's tumor is 3 cm, likely T1 or T2, meets criteria)\n- Lymph nodes obtained from all axillary staging procedures must be pN0. (Patient has 5 positive lymph nodes, does not meet criteria)\n- Patients must have no clinical or radiologic evidence of metastatic disease. (Patient has metastatic lesions, does not meet criteria)\n- The patient's menopausal status must be determined prior to randomization. Postmenopausal women are eligible. (Patient is postmenopausal, meets criteria)\n\nClinical Trial Exclusion Criteria Evaluation:\n- Male patients are not eligible for this study. (Patient is female, not excluded)\n- Pure tubular or mucinous adenocarcinomas. (Not the patient's diagnosis, not excluded)\n- Bilateral malignancy or a mass in the opposite breast suspicious for malignancy unless biopsied as benign. (No information provided, not excluded)\n- Primary tumor staged as T4. (Patient's tumor likely T1 or T2, not excluded)\n- Suspicious palpable nodes outside of the axilla or previous breast cancer. (Patient has positive lymph nodes but no mention of previous breast cancer, not excluded based on available info)\n- Treatment including certain therapies prior to randomization. (No information on previous treatments other than planned surgery, not excluded based on available info)\n- Prior anthracycline therapy for any malignancy. (No information provided, not excluded)\n- Cardiac disease that would preclude the use of anthracyclines. (No information provided, not excluded)\n- Non-malignant systemic disease that would preclude treatment options or follow-up. (No information provided, not excluded)\n- Pregnancy or lactation at the time of proposed randomization. (No information provided, not excluded)\n- Concurrent treatment with investigational agents. (No information provided, not excluded)\n- Psychiatric or addictive disorders or other conditions that would preclude meeting study requirements. (No information provided, not excluded)\n\nBased on the information provided, the patient does not meet the inclusion criteria due to the presence of positive lymph nodes and evidence of metastatic disease. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "25": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions evident in CXR\n- Planned for tumor resection before chemotherapy\n\nClinical trial:\n- Title: Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer\n- Inclusion criteria:\n  - Clinical stage I lung cancer\n  - Surgical resection planned\n  - Histologic confirmation of lung cancer not required\n  - Preoperative mediastinoscopy allowed\n  - No prior therapy for lung cancer diagnosis\n  - No prior mediastinal radiation therapy\n  - Age \u2265 18 years\n  - ECOG performance status: 0-2\n\nEligibility Assessment:\n- The trial is for patients with non-small cell lung cancer, whereas the patient has breast cancer. Therefore, the patient does not meet the disease-specific criteria.\n- The patient is of appropriate age (\u226518 years).\n- There's no mention of the patient's ECOG performance status.\n\nSince the patient does not have the specific type of cancer (non-small cell lung cancer) required for the clinical trial, she is not eligible to participate in this trial. Other details, such as ECOG performance status, are not relevant in this case because the primary disease criteria are not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "26": {
        "output": "The patient note describes a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient has invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative, with metastatic lesions and positive lymph nodes.\n\nComparing this patient note with the inclusion criteria of the clinical trial:\n\n1. Patients must be \u226518 years old. \u2013 The patient is 45 years old, which meets this criterion.\n2. Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter. \u2013 The patient is a candidate for tumor resection, but it has not been stated that it has been completed.\n3. Patients must be able to have catheters placed within 14 days of tumor resection \u2013 The patient agrees to tumor resection prior to chemotherapy, but there is no information about catheter placement or the timing of the surgery.\n4. Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA. \u2013 The patient has breast cancer, not glioma.\n5. Patients must be in adequate general condition and meet certain performance and hematologic criteria. \u2013 There is insufficient information about the patient's Karnofsky Performance Scale score, hematologic status, or other health conditions mentioned in the inclusion criteria.\n6. Female patients must not be pregnant or breast-feeding \u2013 The patient is postmenopausal, which implies she is not pregnant or breast-feeding.\n7. Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion \u2013 There is no information provided regarding this, but being postmenopausal usually means the patient is not fertile.\n8. Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure \u2013 There is no information provided regarding this.\n\nBased on the provided patient note and the clinical trial's inclusion criteria, the patient does not have malignant glioma, which is a key requirement for participation in the study. The patient has breast cancer, which is not the target disease for the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "27": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer,\" we need to assess the provided patient information against the inclusion and exclusion criteria of the trial.\n\nFrom the patient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There is evidence of metastatic lesions on CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nNow, comparing this information to the trial criteria:\n\nInclusion Criteria Assessment:\n1. The patient must consent to participate in the study (not specified, but she agrees to surgery, so likely to consent).\n2. Life expectancy of at least 10 years and Zubrod performance status of 0 or 1 (not specified).\n3. Interval between last surgery for breast cancer staging or treatment and randomization no more than 84 days (not yet undergone surgery, so potentially meets this criterion).\n4. The tumor must be invasive carcinoma of the breast (meets this criterion).\n5. All the following staging criteria must be met (meets clinical T1-3 and pathologic pN1).\n6. ER analysis performed, and if negative, then PgR analysis (ER/PR status is negative, so this is met).\n7. No clinical or radiologic evidence of metastatic disease (does not meet this criterion due to metastatic lesions on CXR).\n8. Postoperative AGC and platelet count requirements (not applicable yet; surgery not performed).\n9. Adequate hepatic function (not specified).\n10. History and physical exam, EKG, and imaging of the chest within the past 3 months, and bilateral mammogram within the past 6 months (not specified).\n11. LVEF greater than or equal to LLN (not specified).\n12. No history of non-breast malignancies within 5 years (not specified, but nothing indicated).\n13. Special conditions for lumpectomy or mastectomy patients (not yet undergone surgery).\n14. No clinical or radiologic evidence of metastatic disease (does not meet this criterion due to metastatic lesions on CXR).\n\nExclusion Criteria Assessment:\n1. Male patients are not eligible (patient is female, so this is met).\n2. HER2-positive tumors (patient's tumor is HER2-positive, so she does not meet this criterion).\n3. Other specified ineligibility factors (not enough information to assess others, but HER2 status is enough for exclusion).\n\nBased on the available information, especially the presence of metastatic lesions on CXR and the fact that the tumor is HER2-positive, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "28": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nThe patient:\n- Is a 45-year-old postmenopausal woman, which satisfies the trial's age and sex requirements.\n- Has a diagnosis of invasive ductal breast carcinoma larger than 3 cm, which meets the trial's disease characteristics.\n- The tumor is HER2-positive, which is allowed as per the trial's inclusion criteria.\n- Has positive axillary lymph nodes, which the trial allows.\n\nHowever, the patient note also mentions:\n- The patient has metastatic lesions as shown by a CXR, which indicates distant metastases.\n\nThe trial excludes individuals who have:\n- Distant metastases.\n\nSince the patient has distant metastases, she does not meet the trial's inclusion criteria that specifically exclude individuals with distant metastases. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "29": {
        "output": "",
        "label": 0
    },
    "30": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The inclusion criteria for the clinical trial are as follows:\n\n1. **Histological or cytological diagnoses of breast cancer, with metastases.**\n   - The patient has invasive ductal breast carcinoma with metastatic lesions noted on CXR.\n   \n2. **Metastatic lesions should not be curable with surgery or radiotherapy.**\n   - The presence of metastatic lesions suggests that the cancer is not curable with surgery or radiotherapy.\n   \n3. **Women of age > 18.**\n   - The patient is 45 years old.\n   \n4. **To have received a previous treatment with anthracyclines and taxanes.**\n   - There is no information provided about previous treatments; thus, it cannot be confirmed if she meets this criterion.\n   \n5. **A maximum of 2 previous chemotherapy treatment lines for metastatic disease.**\n   - Again, there is no information on the number of chemotherapy treatments she has received.\n   \n6. **Previous radiotherapy is allowed, whenever the radiated area is not the only disease location.**\n   - There is no information about any previous radiotherapy.\n   \n7. **At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities.**\n   - Since there is no information about the timing of previous treatments, this criterion cannot be assessed.\n   \n8. **Performance status < 2 in World Health Organization (WHO) scale.**\n   - The patient's performance status is not mentioned.\n   \n9. **Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.**\n   - The patient has clinically confirmed and measurable metastatic breast cancer.\n   \n10. **Life expectancy of at least 12 weeks.**\n   - Life expectancy is not provided in the patient note.\n   \n11. **Patients able to comply and to receive an adequate follow-up.**\n   - The patient agrees to tumor resection, which suggests willingness to comply with treatment, but this does not confirm her ability to comply with study follow-up specifically.\n   \n12. **Adequate bone marrow function: neutrophils \u2265 2 x 10^9/L; platelets \u2265 100 x 10^9/L; hemoglobin \u2265 100 g/L.**\n    - The patient's blood counts are not provided.\n   \n13. **Calcium within normal limits.**\n    - Calcium levels are not mentioned.\n   \n14. **Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization.**\n    - The patient is postmenopausal, so this criterion does not apply.\n\nGiven the information provided, the patient meets some of the inclusion criteria, such as age and the presence of metastatic breast cancer. However, there is insufficient information to determine if she meets all the inclusion criteria (previous treatments, performance status, bone marrow function, etc.). Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "31": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Clinically node negative operable breast cancer.\n- No prior incision or excision biopsy.\n\nAssessment:\n- The patient has operable breast cancer, which is a potential match for the trial.\n- However, the trial requires participants to be clinically node negative, meaning no lymph nodes are positive for cancer upon clinical examination.\n- The patient has 5 positive lymph nodes, as confirmed by axillary sampling.\n- Therefore, the patient does not meet the \"clinically node negative\" requirement.\n\nGiven that the patient has positive lymph nodes, she does not meet the inclusion criteria of being clinically node negative. Consequently, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "32": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial.\n\nPatient note key points:\n\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- No mention of bone lesions or their symptoms\n- Candidate for tumor resection prior to chemotherapy\n- No information on prior chemotherapy or hormone therapy for metastatic disease\n- No information on renal function or serum calcium levels\n- Performance status is not mentioned\n- No mention of current pregnancy status, but it is stated she is not sexually active\n\nClinical trial inclusion criteria:\n\n- Age \u2265 18 years old (patient is 45, meets this criterion)\n- Metastatic breast cancer patients with lytic, sclerotic, or mixed bone lesions (patient note does not mention bone lesions)\n- Non-symptomatic bone lesions (cannot be assessed without information on the presence of bone lesions)\n- A maximum of two chemotherapy lines for metastatic disease (not specified in the patient note)\n- A maximum of two hormone therapy lines for metastatic disease (not specified in the patient note)\n- Normal, minimally altered renal function (not specified in the patient note)\n- Normal serum calcium levels (not specified in the patient note)\n- Performance status 0,1 (WHO) (not specified in the patient note)\n- Negative pregnancy test before study recruitment (likely not pregnant as per patient note, but not confirmed)\n\nThe patient note does not provide sufficient information to determine the patient's eligibility based on several key inclusion criteria. Specifically, we do not have information about the presence of bone lesions, prior treatments for metastatic disease, renal function, serum calcium levels, performance status, or a confirmed pregnancy test.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "33": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed HER2-positive and ER/PR-negative invasive ductal breast carcinoma, with metastatic lesions and positive lymph nodes. The patient has not yet undergone chemotherapy but is a candidate for tumor resection.\n\nThe clinical trial is investigating the benefit of adding Trastuzumab to second-line chemotherapy in breast cancer patients who have been previously treated with Trastuzumab. The patient in question has HER2 positive breast cancer, which fits the criteria. However, the trial requires the patient to have non-operable locally advanced or metastatic disease previously treated with Trastuzumab and taxanes. The patient note does not indicate any previous treatment with Trastuzumab and taxanes, which is an essential inclusion criterion for this trial. Additionally, there is no information on whether the patient has measurable or non-measurable disease as per RECIST, the performance status, or other specific health criteria mentioned in the inclusion criteria.\n\nBased on the provided patient note and the inclusion criteria of the clinical trial, there is not enough information to determine if the patient has been previously treated with Trastuzumab and taxanes or meets other specific health criteria. Thus, the patient's trial-level eligibility cannot be determined as either eligible or excluded due to a lack of information on key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "34": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility.\n\nThe patient:\n- Is a 45-year-old postmenopausal woman.\n- Has cytologically confirmed breast cancer.\n- Has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Has metastatic lesions present on CXR.\n- Is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe inclusion criteria for the clinical trial:\n- Written informed consent.\n- Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3).\n- Tumors must be HER2 negative.\n- Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks; in patients receiving adjuvant radiotherapy, time window allowed between last session and randomization is 4 weeks.\n- Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and DCIS are required.\n- Node negative patients with tumor size > 2 cm or positive axillary lymph nodes defined as at least 1 out of 6 nodes with presence of disease.\n- Negative status of HER2 in primary tumor, known before randomization.\n- Adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines and/or taxanes.\n- Age >= 18 and <= 70 years old.\n- Performance status (Karnofsky index) >= 80.\n- Specific laboratory results within normal ranges.\n- No evidence of metastatic disease.\n- Able to comply with treatment and study follow-up.\n- Negative pregnancy test for women of childbearing potential.\n\nThe patient does not meet the following inclusion criteria:\n- The patient's tumor is HER2-positive, whereas the trial requires the tumor to be HER2 negative.\n- The patient presents evidence of metastatic disease, which is excluded by the trial criteria.\n\nGiven this information, the patient is excluded from the trial due to having a HER2-positive tumor and evidence of metastatic disease, both of which are in direct conflict with the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "35": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer,\" we need to match the patient's characteristics and medical history with the inclusion criteria provided.\n\nBased on the patient note, here's what we know about the patient:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- She has metastatic breast cancer with a positive core biopsy and positive axillary lymph nodes.\n- She is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n- It is not mentioned that she has had any prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer.\n\nNow, let's compare this information with the inclusion criteria:\n\n1. Female patient, postmenopausal - The patient is postmenopausal.\n2. Histologically or cytologically proven adenocarcinoma of the breast - The patient has cytologically confirmed breast cancer.\n3. HER2-positive disease - The patient has HER2-positive disease.\n4. ER-positive and/or PR-positive disease - The patient does NOT meet this criterion since she has ER/PR negative disease.\n5. ECOG performance status 0-2 - Not mentioned in the patient note.\n6. Life expectancy > 24 weeks - Not mentioned in the patient note, but typically assumed in a candidate for tumor resection.\n7. Left ventricular ejection fraction > lower limit of normal - Not mentioned in the patient note.\n8. No prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer - The patient note does not mention prior therapy, so we assume she meets this criterion.\n9. Prior adjuvant Herceptin permitted - Not mentioned in the patient note.\n10. At least 1 month since prior surgery, radiotherapy, or endocrine therapy, with complete recovery from these interventions - The patient is planned for surgery but has not yet undergone it.\n11. Patients must have ended any hormone replacement therapy at least 1 month prior to receiving the first dose of trial therapy - Not mentioned in the patient note.\n12. Patients treated with bisphosphonates may enroll - Not mentioned in the patient note.\n13. Patient is accessible and willing to comply with treatment and follow-up - The patient agrees to tumor resection, implying willingness to comply with treatment.\n14. Patient is willing to provide written informed consent - Not mentioned in the patient note, but typically assumed if the patient is considering clinical trial participation.\n15. Required laboratory values - Not mentioned in the patient note.\n\nBased on the information available, the patient does not meet the inclusion criterion of having ER-positive and/or PR-positive disease since her tumor is ER/PR negative. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "36": {
        "output": "",
        "label": 2
    },
    "37": {
        "output": "Based on the provided patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, with metastatic lesions and positive lymph nodes. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe clinical trial in question is looking at the correlation between tumor angiogenesis and the effect of radiation therapy in cervical cancer patients. The inclusion criteria for the clinical trial specifically states that it is for \"cervical cancer patients receiving radiotherapy or chemo-radiotherapy.\"\n\nGiven that the patient in the note has breast cancer, not cervical cancer, she does not meet the disease-specific inclusion criteria for the clinical trial. Therefore, the patient is not eligible to participate in this cervical cancer-focused clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "38": {
        "output": "Given Patient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women >= 40 with invasive ductal carcinoma or ductal carcinoma in situ\n- Patient chooses lumpectomy rather than mastectomy as treatment for breast cancer\n- Tumor < 2.5 cm in size, 2 mm margin of normal breast tissue between cancer and edge of specimen\n\nThe patient is a 45-year-old woman with invasive ductal breast carcinoma, which aligns with the first inclusion criterion of the clinical trial regarding the patient's sex and type of cancer. However, her tumor size is 3 cm, which exceeds the specified inclusion criterion of the clinical trial that requires the tumor to be less than 2.5 cm in size. Despite meeting the age and diagnosis criteria, the patient's tumor size makes her ineligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "39": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2,\" we need to compare the patient's information to the inclusion criteria provided.\n\nBased on the patient note provided, here is the relevant information:\n\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer, which is invasive ductal carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present as indicated by a remarkable CXR.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- There is no mention of the patient's ECOG performance status, but given she is a candidate for surgery, it may be assumed to be relatively good (<2).\n- There is no mention of other serious illnesses or medical conditions.\n- There is no mention of CNS metastases, and since it is stated that CXR was remarkable for metastatic lesions, it implies that metastases are not CNS.\n- There is no mention of rapidly progressive visceral metastases or an active concurrent infection.\n- There is no mention of current anti-cancer treatment, but she is a candidate for surgery and chemotherapy.\n- Previous therapies are not detailed, so we cannot confirm prior investigational biological agents or previous hormonal therapy.\n- There is no information about prior adjuvant and MBC chemotherapy or intervals since last chemotherapy administration.\n- There is no information on the cumulative dose of previous doxorubicin or epirubicin.\n- There is no mention of organ function tests, but we can assume they may be adequate given she is a candidate for surgery.\n- The tumor is HER2-positive.\n- There is no information on baseline LVEF.\n- There is no information on measurable disease according to RECIST criteria.\n- There is no information on pregnancy status or willingness to use birth control.\n- Psychological, familial, sociological or geographical conditions are not mentioned.\n- Informed consent is not mentioned, but it is typically obtained as part of the clinical trial process.\n\nGiven the information above, the patient seems to match many of the inclusion criteria, such as being a female over 18 years of age, having a histologically proven diagnosis of breast cancer with HER2-positive status, and having locally advanced/metastatic disease. \n\nHowever, some key pieces of information are missing to fully determine eligibility, such as:\n\n- ECOG performance status.\n- Detailed medical history regarding other serious illnesses or medical conditions.\n- Information on CNS metastases.\n- Information on current and past treatments, including chemotherapy intervals and prior use of investigational biological agents.\n- Lab results for organ function.\n- Baseline LVEF.\n- Measurable disease according to RECIST criteria.\n- Pregnancy status and willingness to use birth control.\n- Confirmation of informed consent.\n\nBecause of these missing pieces of information, we cannot definitively conclude that she is eligible for the trial. Therefore, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "40": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to assess the patient's eligibility for the trial:\n\nPatient information:\n- Age: 45 years old (meets age criterion of \u2265 18 years)\n- Diagnosis: Cytologically confirmed breast cancer (meets criterion of solid tumor treatment)\n- Treatment: Candidate for tumor resection and agrees to chemotherapy (meets criterion of planned chemotherapy cycles)\n- Additional information: The patient is using multivitamins and iron supplements, which could be related to managing anemia. However, the note does not specify the patient's hemoglobin levels to determine if they fall within the moderate anemia range required by the study.\n\nClinical trial inclusion criteria:\n- Age \u2265 18 years (patient meets this criterion)\n- Well-informed written consent, signed by the patient (not specified but assumed that patient can provide if eligible)\n- Patient picked up for solid tumor treatment, with or without metastasis (patient meets this criterion with breast cancer and metastatic lesions)\n- Patient revealing, before or during chemotherapy, a moderate anemia, that means: Women: 9<Hb<11 g/dl (not specified in the patient note)\n- Patient for whom at least four chemotherapy cycles are planned (eight in case of weekly chemotherapy) after inclusion in the study (the patient agrees to chemotherapy but the number of planned cycles is not specified)\n- Patients with life expectancy higher than three months (not specified but given the planned treatment, it is likely assumed)\n- Patient with general conditions compatible with the study's follow-up (not specified)\n\nThe patient note does not provide sufficient information regarding the patient's hemoglobin levels, the specific number of planned chemotherapy cycles, life expectancy, or whether the patient's general condition is compatible with the study's follow-up. Therefore, based on the available information, the patient's eligibility for this clinical trial cannot be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "41": {
        "output": "The patient in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which fits the criterion of a tumor stage T1 or T2 lesion being less than 3 cm. The patient also has positive lymph nodes, with axillary sampling revealing 5 positive nodes, which fits the N1 criterion of having 1-3 positive nodes. There is no mention of extracapsular extension, which meets the inclusion criteria of N0 or N1 without extracapsular extension. The patient is a candidate for tumor resection and agrees to undergo it prior to chemotherapy, which is in line with the intention of the trial to treat the tumor bed with radiation.\n\nThe clinical trial is investigating the use of Multi-catheter High Dose Rate (HDR) Breast Brachytherapy, specifically for patients with invasive breast cancer or DCIS, where the tumor stage is Tis, T1, or T2 if the lesion is less than 3 cm, and N0 or N1 if there are 1-3 positive nodes with no extracapsular extension. \n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial:\n\n- The patient has invasive breast cancer.\n- The tumor is T2 since it's a 3 cm lesion.\n- The patient has N1 disease (1-3 positive lymph nodes) with no mention of extracapsular extension.\n\nGiven this information, the patient appears to be eligible for the trial as there is no information suggesting that the exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "42": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The biopsy revealed invasive ductal breast carcinoma which is HER2-positive and ER/PR negative.\n- She has metastatic lesions as indicated by a CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Histologically confirmed invasive breast cancer by fine needle aspiration or biopsy: The patient has invasive ductal breast carcinoma confirmed by core biopsy, which meets this criterion.\n- Locally advanced or early metastatic disease: The patient has metastatic lesions, which meets this criterion.\n- Clinically or radiographically measurable disease: The tumor is measurable, which meets this criterion.\n- Planning to receive neoadjuvant chemotherapy for locally advanced or early metastatic disease: The patient agrees to undergo surgery prior to chemotherapy, which implies she is planning to receive neoadjuvant chemotherapy.\n- No prior chemotherapy for this malignancy: The patient note does not indicate any prior chemotherapy, meeting this criterion.\n\nThe patient meets all the inclusion criteria stated for the clinical trial. There is no mention of any exclusion criteria in the clinical trial information provided. Therefore, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "43": {
        "output": "",
        "label": 1
    },
    "44": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's compare the information step by step:\n\nPatient's characteristics:\n- The patient is a 45-year-old postmenopausal woman, which matches the age requirement of the clinical trial (18 years or older).\n- The patient has cytologically confirmed breast cancer, which is necessary for the trial (histologically or cytologically confirmed locally advanced or metastatic breast cancer).\n- The patient has a tumor that is HER2-positive and ER/PR negative, while the trial is looking for premenopausal patients with advanced ER and PR + breast cancer. This does not align with the patient's tumor profile.\n- The patient is a candidate for tumor resection before chemotherapy, which could imply that curative treatment is available, potentially conflicting with the trial's criterion of \"no curative treatment available.\"\n\nClinical trial's inclusion criteria:\n- Signed informed consent.\n- Premenopausal women 18 years or older.\n- Histologically or cytologically confirmed locally advanced or metastatic breast cancer.\n- Suitable for endocrine treatment.\n- No curative treatment available.\n- One or more measurable lesions.\n- Life expectancy more than 6 months.\n- Normal biological parameters.\n\nGiven that the trial specifically requires premenopausal women with ER and PR + breast cancer, and the patient is postmenopausal with HER2-positive and ER/PR-negative breast cancer, the patient does not meet the necessary inclusion criteria for this specific trial. Additionally, the patient is planning to undergo tumor resection which may suggest the availability of curative treatment, another mismatch with the trial criteria.\n\nTherefore, the patient does not qualify for the trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "45": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the inclusion criteria of the clinical trial, patients with pathological diagnoses of breast cancer are eligible.\n\nLet's break down the inclusion criteria and see if the patient matches:\n\n1. Patients with pathological diagnoses of breast, lung, and ovarian adenocarcinomas and soft tissue sarcoma.\n   - The patient has invasive ductal breast carcinoma, which fits the pathological diagnosis of breast cancer.\n\n2. Patients with de novo malignancies and no previous chemotherapy.\n   - The patient note does not mention any prior chemotherapy, suggesting the patient has a de novo malignancy.\n\n3. Patients with advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols.\n   - As there is no mention of previous chemotherapy, this criterion is not applicable.\n\n4. Patients of any age group.\n   - The patient is 45 years old, fitting this criterion.\n\n5. Patients must have tumor which is accessible and agree to undergo biopsies, or drainage of effusions.\n   - The patient is a candidate for tumor resection, which implies that the tumor is accessible. She agrees to undergo surgery, which can be seen as a willingness to undergo procedures to treat her condition.\n\n6. Patients for whom chemotherapy is a treatment option.\n   - The patient has not yet received chemotherapy but is a candidate for it post-surgery.\n\nBased on the above, the patient matches all the inclusion criteria for the clinical trial. There are no exclusion criteria mentioned, so we cannot determine if the patient would be excluded for any reason not covered in the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "46": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria set out by the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer (invasive ductal carcinoma)\n- HER2-positive and ER/PR-negative\n- 5 positive lymph nodes and metastatic lesions on CXR\n- Candidate for tumor resection, agreeing to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female, postmenopausal\n- Histologically confirmed breast cancer (DCIS or invasive carcinoma, Stage I-III disease)\n- Must have undergone breast cancer surgery within the past 6 months\n- Estrogen and/or progesterone receptor-positive tumor\n- No prior or concurrent adjuvant chemotherapy for breast cancer\n- No prior aromatase inhibitor, tamoxifen, or hormone replacement therapy (at least 6 weeks since any such prior therapy)\n- No prior radiation therapy or mastectomy for the breast cancer being studied\n\nAssessment:\n- The patient is postmenopausal and female, which fits the trial's patient characteristics.\n- The patient has confirmed invasive ductal breast carcinoma, which meets the trial's disease characteristics.\n- However, the trial requires the tumor to be estrogen and/or progesterone receptor-positive, and the patient's tumor is ER/PR-negative. This does not fit the hormone receptor status requirement of the trial.\n- The patient is a candidate for tumor resection but has not yet undergone surgery. The trial requires that the patient must have undergone surgery within the past 6 months.\n\nBased on these points, the patient does not meet all of the inclusion criteria due to the hormone receptor status and the fact that she has not yet undergone breast cancer surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "47": {
        "output": "The patient described in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer that is HER2-positive and ER/PR negative. She has a history of metastatic lesions and is a candidate for tumor resection before chemotherapy.\n\nComparing this patient's profile to the inclusion criteria of the clinical trial titled \"Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer,\" we observe the following:\n\n1. The clinical trial is looking for patients with recurrent or metastatic breast cancer, which matches the patient's condition of metastatic lesions.\n2. However, the inclusion criteria specify that the patient's cancer must be triple receptor negative (ER, PR, and HER2 negative). The patient's tumor is reported to be HER2-positive, which does not match the requirement for triple negative status.\n3. The inclusion criteria also require prior treatment with an anthracycline and a taxane, which is not mentioned in the patient's note.\n4. There is no information about relapse following adjuvant chemotherapy within 6 months of last treatment or treatment regimens for advanced disease in the patient's note.\n\nGiven the information provided, the patient does not meet the requirement for the receptor status, as her cancer is not triple receptor negative due to HER2 positivity. Therefore, she is not eligible for this clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "48": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Women or men > 18 years old with histologically confirmed, by needle core biopsy (not FNA), locally advanced or inflammatory breast cancer.\n- Tumor classification must fit into one of the following: T2 lesion initially resectable only through mastectomy; T3 N0-N2; T4 any N; or any T with N2 or N3 clinical evidence of disease.\n- Measurable disease defined as a breast lesion > 2 cm or with fixed or marked ipsilateral axillary nodes and/or ipsilateral internal mammary nodes.\n- Pre- and Post-menopausal female and male patients are eligible.\n- Negative scans for metastatic bone disease and CAT scan of chest and abdomen.\n\nThe patient does have a confirmed invasive ductal breast carcinoma which is > 2 cm and has positive lymph nodes, meeting part of the inclusion criteria regarding the disease's characteristics and extent. However, the patient's CXR indicating metastatic lesions is a disqualifying factor because the trial requires a negative scan for metastatic disease. The inclusion criteria specify that patients must have a bone scan and CAT scan of chest and abdomen negative for metastatic disease, which the patient does not have as there is evidence of metastatic lesions.\n\nTherefore, the patient is not eligible for the clinical trial due to the presence of metastatic lesions, which disqualify her based on the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "49": {
        "output": "To determine the patient's eligibility for the clinical trial, we must assess the patient's characteristics against the inclusion criteria stated in the clinical trial. Here is the breakdown:\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- Has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Has metastatic lesions (CXR).\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of breast cancer (confirmed).\n- T2-T4c, any N, M0 disease (patient has metastatic lesions, suggesting M1 disease).\n- The primary tumor must be palpable and measure > 2 cm in at least one dimension (confirmed).\n- Must agree to undergo mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy (agreed).\n- No inflammatory breast cancer (no information suggesting this in the patient note).\n- No distant metastasis (patient has distant metastasis).\n- Isolated ipsilateral supraclavicular node involvement allowed (not mentioned in the patient note).\n- Must have estrogen receptor (ER) positive tumor with an Allred score of 6, 7, or 8 (patient has ER/PR negative tumor).\n- Postmenopausal status verified (confirmed).\n\nBased on the available information, the patient does not meet all the needed inclusion criteria for the clinical trial. Specifically, the patient has distant metastasis (M1), and the tumor is ER/PR negative, which does not meet the requirement for an ER-positive tumor with an Allred score of 6, 7, or 8.\n\nGiven these discrepancies, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "50": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- She is a candidate for tumor resection and agrees to it prior to chemotherapy.\n- There is no indication that the patient has already undergone chemotherapy or radiation therapy, nor is there any mention of fatigue symptoms or their duration.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is seeking women who have moderate to severe fatigue for more than 6 months after their last chemotherapy or radiation treatment.\n- They should be more than 5 years from diagnosis.\n\nSince the patient is about to undergo chemotherapy, she would not meet the inclusion criteria of having had chemotherapy or radiation therapy and experiencing fatigue for more than 6 months after treatment. Additionally, the patient has not been indicated to be 5 years from diagnosis.\n\nTherefore, the patient does not have sufficient information available in the note to qualify for the trial, and the inclusion criteria clearly do not apply to her current situation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "51": {
        "output": "Given the patient note and the clinical trial information:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Chest X-Ray (CXR) showed metastatic lesions\n- Candidate for tumor resection, agreeing to undergo the procedure prior to chemotherapy\n\nClinical Trial:\n- Title: Detection of Genetic Markers of Lung Cancer\n- Inclusion Criteria:\n  - Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma, or a radiographic lesion highly suspicious for malignancy\n  - Written informed consent\n  - Must be scheduled for a biopsy or surgical resection\n\nThe patient in the note has breast cancer with metastatic lesions as observed on CXR. The clinical trial is specifically for lung cancer or lung metastases from a primary site other than the lung. Since the patient has breast cancer, not lung cancer, she does not meet the inclusion criteria for the lung cancer genetic markers study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "52": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman (meets age and menopausal status criteria)\n- Histologically confirmed breast cancer (meets disease characteristic)\n- Disease is not confined to the breast and axillary nodes as there are metastatic lesions (does not meet disease characteristic of being confined to the breast and axillary nodes without detected masses elsewhere)\n- The patient has positive lymph nodes and metastatic lesions, which suggests the disease may not be resected completely (potentially not meeting the criteria of resected disease with negative margins)\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy (does not clearly state whether surgery has already occurred, and if so, within the 16-week window)\n- No other malignancy within the past 5 years except for the conditions listed is mentioned (meets criteria if assuming no other malignancy)\n\nThe patient does not meet the criteria of having disease confined to the breast and axillary nodes as they have metastatic lesions, which is a clear exclusion based on the trial's inclusion criteria. Additionally, the status of tumor resection surgery and whether it occurred within the last 16 weeks is unclear, but given the presence of metastatic disease, this point may be moot for eligibility.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information. The correct assessment would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "53": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the eligibility of the patient for the trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Diagnosed with HER2-positive and ER/PR-negative invasive ductal breast carcinoma\n- Tumor in the left upper outer quadrant, 3 cm in size\n- 5 positive lymph nodes, metastatic lesions present on CXR (presumably in the lungs)\n- Non-smoker, non-alcoholic, not sexually active, no children\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patient (matches)\n- Diagnosis of stage IIB HER2/neu-expressing breast cancer 6\u00bd years ago (not specified in patient note)\n- Received a T-cell-depleted allogeneic SCT from a 6/6 HLA-matched sibling donor for refractory metastatic breast cancer (not specified in patient note)\n- Developed pulmonary metastases during adjuvant chemotherapy following modified radical mastectomy (not specified in patient note)\n- Pulmonary metastases progressed after prior allogeneic SCT (not specified in patient note)\n- Responded to prior allogeneic lymphocyte infusion, post-transplantation chemotherapy, and trastuzumab (not specified in patient note)\n- Disease limited to the thoracic cavity (patient has pulmonary metastases, which could be considered thoracic)\n- Operable tumor with at least 1 cm of surgically accessible lesion (patient is a candidate for tumor resection)\n- Preoperative risk assessment indicating \u2264 5% risk of mortality and < 15% risk of significant morbidity for pulmonary metastasectomy (not specified in patient note)\n- Enrolled on protocol CC# 00-C-0119 (not specified in patient note)\n- ECOG performance status 0-2 (not specified in patient note)\n- Life expectancy > 6 months (not specified in patient note)\n- Negative pregnancy test (assumed, but not specified)\n- Adequate pulmonary reserve (not specified in patient note)\n- Prior GVHD \u2264 grade 1 (not specified in patient note)\n- No concurrent GVHD (not specified in patient note)\n- No active infection nonresponsive to antimicrobial therapy (not specified in patient note)\n- No active psychiatric disorder (not specified in patient note)\n- At least 4 weeks since prior systemic immunosuppressive therapy (not specified in patient note)\n- At least 2 weeks since prior cytotoxic therapy and immunotherapy (patient agrees to surgery prior to chemotherapy, but timing is not specified)\n\nThe patient note does not provide sufficient information to determine if the patient meets many of the inclusion criteria, especially those related to previous treatments and conditions that are very specific to the clinical trial. Therefore, the patient cannot be deemed eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "54": {
        "output": "Let's evaluate the patient's eligibility based on the provided clinical trial inclusion criteria:\n\n1. Has metastatic breast cancer with documented HER2- or HER2+ (IHC3+ or FISH+) disease\n   - The patient has HER2-positive breast cancer, which meets this criterion.\n\n2. Has measurable MBC, with at least 1 measurable lesion per RECIST criteria (see Section 10). Irradiated lesions cannot be used to assess response but can be used to assess progression.\n   - The patient has a 3 cm invasive ductal breast carcinoma, which is considered a measurable lesion.\n\n3. Has had no prior treatment with Doxil or carboplatin; may have had adjuvant Herceptin if treatment was completed more than 1 year prior to study\n   - The patient note does not mention any prior treatment with Doxil or carboplatin, so this criterion appears to be met.\n\n4. Has had no adjuvant chemotherapy within 1 year prior to study, but may have received prior anthracyclines as adjuvant chemotherapy\n   - The patient is a candidate for tumor resection prior to chemotherapy, which indicates no adjuvant chemotherapy has been administered yet.\n\n5. For taxane-pretreated patients (adjuvant or metastatic), has had no more than 1 prior chemotherapy regimen for MBC\n   - The patient has not had chemotherapy yet, so this criterion is met.\n\n6. For taxane-na\u00efve patients, has had no prior chemotherapy for MBC\n   - The patient has not had chemotherapy yet, so this criterion is met.\n\n7. Has had cumulative doses of < 300 mg/m2 prior doxorubicin or < 450 mg/m2 prior epirubicin\n   - There is no information regarding prior doxorubicin or epirubicin, but since chemotherapy has not been started, this criterion is likely met.\n\n8. Has normal cardiac function as evidenced by a LVEF within institutional normal limits by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if MUGA is not available, but the same test must be used throughout the study to evaluate LVEF.\n   - There is no information on the patient's cardiac function, so this criterion cannot be confirmed.\n\n9. Has an ECOG Performance Status (PS) 0-2 (see Appendix I)\n   - The patient's ECOG Performance Status is not mentioned, so this criterion cannot be confirmed.\n\n10. Is a male or female greater than or equal to 18 years of age\n    - The patient is 45 years old, which meets this criterion.\n\n11. Laboratory Values - Please refer to protocol section 4.2 for specific laboratory values.\n    - Specific laboratory values are not provided in the patient note.\n\n12. Has a negative serum pregnancy test within 7 days prior to registration (woman of childbearing potential [WOCBP; not surgically sterilized and between menarche and 1 year postmenopause])\n    - The patient is postmenopausal, which meets this criterion.\n\n13. If fertile, patient (male or female) has agreed to use an acceptable method of birth control (eg, abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.\n    - As the patient is postmenopausal, this criterion is not applicable.\n\n14. Has signed a Patient Informed Consent Form\n    - There is no information on whether the patient has signed a consent form.\n\n15. Has signed a Patient Authorization Form (HIPAA Form)\n    - There is no information on whether the patient has signed an authorization form.\n\n16. Has a life expectancy of > 3 months\n    - There is no information provided about the patient's life expectancy.\n\nBased on the available information, the patient appears to meet most of the inclusion criteria for the clinical trial. However, there is insufficient information on some criteria (cardiac function, ECOG Performance Status, laboratory values, consent forms, and life expectancy) to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "55": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions evident on chest X-ray.\n- The patient is using multivitamins and iron supplements.\n- The patient is a candidate for tumor resection and agrees to undergo this procedure prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy).\n- Approval and informed consent.\n\nThe patient's condition matches the clinical trial's inclusion criteria of having infiltrative breast cancer diagnosed pre-operatively by core biopsy. Since the patient agrees to tumor resection, which is a part of the treatment process, it can be assumed that the patient is willing to participate in the trial and would provide informed consent.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria provided, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "56": {
        "output": "",
        "label": 0
    },
    "57": {
        "output": "To determine the patient's eligibility for the Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer clinical trial, we should compare the patient's characteristics and condition to the inclusion and exclusion criteria of the trial.\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes identified through axillary sampling\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer\n- Histologically negative tumor margin 2 mm or more\n- Certain histologic variants permitted\n- Women age 70 or older with specific tumor characteristics are eligible\n- T1N0 (i+) tumors acceptable with conditions\n- Prior treatment with adjuvant chemotherapy allowed; hormonal therapy allowed\n- Radiation therapy timeline after surgery or chemotherapy\n- Age >= 18 years\n- ECOG Performance Status 0-2\n- Signed Informed Consent\n\nClinical Trial Exclusion Criteria Include:\n- Multicentric or multifocal IDC of the breast\n- Tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement\n- Lymphovascular invasion or EIC (Extensive Intraductal Component)\n- Certain histologic types of breast cancer\n- Insufficient resection margins\n- History of certain surgeries or medical conditions\n- Active secondary malignancy\n- Pregnancy\n\nAssessment:\n- The patient does not have Unicentric Stage I (T1 N0 M0) breast cancer as required by the trial due to the presence of positive lymph nodes and metastatic lesions (exclusion criteria: tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement).\n- The patient's age and gender meet the inclusion criteria, but the stage and extent of the breast cancer do not align with the study's requirements for early breast cancer.\n\nGiven these points, the patient does not meet the inclusion criteria for the trial due to her breast cancer stage and the presence of metastatic disease, which are explicit exclusion criteria for the trial. Therefore:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "58": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"AZD1152 in Patients With Advanced Solid Malignancies,\" we must compare the patient's characteristics with the trial's inclusion criteria.\n\nPatient's Characteristics:\n- Age: 45 years\n- Gender: Female\n- Medical condition: Cytologically confirmed breast cancer\n- Tumor characteristics: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Metastatic disease: Yes, metastatic lesions noted on CXR\n- Treatment: Candidate for tumor resection, agreeing to proceed prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n1. Histological or cytological confirmation of a solid, malignant tumour\n2. At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n\nComparison:\n1. The patient has a cytologically confirmed diagnosis of breast cancer, which is a solid, malignant tumor. This meets the first inclusion criterion.\n2. The presence of a 3 cm invasive ductal breast carcinoma and metastatic lesions indicates the patient has at least one measurable or non-measurable site of disease according to RECIST criteria, fulfilling the second inclusion criterion.\n\nSince the patient's characteristics align with the inclusion criteria of the clinical trial and no exclusion criteria are provided, the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "59": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics with the inclusion criteria specified by the clinical trial. Here are the inclusion criteria for the trial:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the breast and appropriate for treatment with Doxorubicin and Cyclophosphamide.\n2. Age > 18 years and <45 years.\n3. ECOG performance status of 0 to 2.\n4. Signed informed consent.\n5. Premenopausal: defined as regularly occurring menstrual cycles or serologic estradiol and FSH levels consistent with premenopausal status.\n\nNow, let's analyze the patient note:\n\n1. The patient has a cytologically confirmed breast cancer, which is appropriate for the trial.\n2. The patient is a 45-year-old, which makes her ineligible based on the age criterion, which requires participants to be under 45 years of age.\n3. There is no information provided about the patient's ECOG performance status, so we cannot determine eligibility based on this criterion.\n4. The patient agrees to tumor resection, which suggests she may be willing to sign informed consent, but there's no explicit mention of signed informed consent for the trial.\n5. The patient is described as postmenopausal, which contrasts with the requirement for premenopausal status as defined by the trial.\n\nGiven that the patient is 45 years old and postmenopausal, she does not meet the age and menopausal status inclusion criteria of the clinical trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "60": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria specified for the trial.\n\nHere are the relevant details from the patient note:\n- The patient is a 45-year-old postmenopausal woman, which meets the age requirement of \"Women >/= 18 years of age.\"\n- The patient has cytologically confirmed breast cancer with a core biopsy revealing invasive ductal breast carcinoma, which meets the \"Histologically proven breast cancer\" criterion.\n- The patient has axillary sampling with 5 positive lymph nodes, which meets the \"lymph node-positive (pN1-3)\" criterion.\n- The tumor is HER2-positive, which is allowed as \"HER2/neu positive or negative tumors are eligible.\"\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the requirement for definitive breast surgery followed by study registration within < 60 days.\n\nHowever, the following information is missing from the patient's note to fully determine eligibility:\n- The interval between definitive breast surgery and study registration (must be < 60 days).\n- Margins of resected specimen need to be free from invasive adenocarcinoma and DCIS.\n- Normal cardiac function must be confirmed by LVEF or shortening fraction.\n- Hematology and hepatic function evaluation results.\n- Complete staging work-up to rule out metastatic disease.\n\nBased on the provided patient note, we do not have sufficient information about the completion of surgery, margins status, cardiac function, hematology and hepatic function evaluation results, and the complete staging work-up. Therefore, we cannot definitively include or exclude the patient from the trial at this point.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "61": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- Age: 45 years old (meets age-related inclusion criteria)\n- Diagnosis: Breast cancer (relevant to the trial's target disease)\n- Tumor specifics: HER2-positive and ER/PR negative (tumor over-expressing Her-2, which is relevant to the trial)\n- Disease status: Metastatic lesions present (evidence of metastatic disease)\n- Treatment history: Candidate for tumor resection and agrees to proceed prior to chemotherapy (has not received chemotherapy treatment in the advanced disease setting, which is relevant to the trial)\n\nClinical trial inclusion criteria:\n- Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease (patient has metastatic disease)\n- Tumors over-expressing Her-2 (patient's tumor is HER2-positive)\n- Candidate for treatment with docetaxel/trastuzumab (patient is a candidate for tumor resection and agrees to chemotherapy, which is likely to include docetaxel/trastuzumab)\n\nGiven this information, the patient appears to meet the inclusion criteria for the clinical trial as specified:\n\n- The patient's age is \u2265 18 years.\n- The patient has a diagnosis of breast cancer with metastatic disease, which is unresectable or locally recurrent.\n- The tumor is HER2-positive, hence over-expressing Her-2.\n- The patient has not received chemotherapy in the advanced disease setting and is a candidate for treatment that aligns with the trial's regimen (docetaxel/trastuzumab).\n\nThere is no mention of any exclusion criteria in the trial description, and the patient does not have any characteristics that would automatically exclude her from the trial based on the information provided.\n\nTherefore, the patient is eligible to participate in the clinical trial. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "62": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n1. The patient is a 45-year-old postmenopausal woman.\n2. She has cytologically confirmed breast cancer.\n3. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n4. The tumor is HER2-positive and ER/PR negative.\n5. Axillary sampling revealed 5 positive lymph nodes.\n6. CXR was remarkable for metastatic lesions.\n7. The patient is using multivitamins and iron supplements.\n8. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n1. Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone lesion.\n2. No treatment with bisphosphonates within 6 months prior to inclusion into the study.\n3. Good health status (ECOG Performance status 0-2).\n\nClinical Trial Exclusion Criteria:\n1. Patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening.\n2. Abnormal renal function.\n3. History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism.\n4. Pregnancy and lactation.\n5. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction, implants).\n\nEligibility Assessment:\n- The patient has a confirmed diagnosis of breast cancer with metastatic lesions, which likely includes bone lesions.\n- There is no mention of bisphosphonate treatment within the last 6 months.\n- The patient's health status is not explicitly mentioned, but she is a candidate for tumor resection which suggests a reasonable health status.\n- There is no mention of exclusion criteria such as abnormal renal function, history of diseases with influence on bone metabolism, pregnancy, lactation, or current active dental problems.\n\nGiven this information, the patient appears to meet the inclusion criteria and none of the exclusion criteria are explicitly mentioned or implied in the patient note. Thus, the patient seems eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "63": {
        "output": "Assessing the patient's eligibility for the trial:\n\n1. High risk lymph node positive breast cancer defined as 5 or more involved axillary lymph nodes.\n   - The patient's note confirms 5 positive lymph nodes.\n\n2. Must have undergone surgical local therapy (modified radical mastectomy or breast conserving surgery).\n   - The patient is a candidate for tumor resection, but it's not clear if surgery has already been performed.\n\n3. Negative tumor margins for invasive cancer.\n   - There's no information about the tumor margins post-surgery.\n\n4. No evidence of distant metastasis.\n   - The patient's note indicates the presence of metastatic lesions on the CXR.\n\n5. Normal cardiac ejection fraction.\n   - There's no information about the patient's cardiac ejection fraction.\n\n6. Adequate organ function defined as: ANC > 1200/mm3, Platelet count > 100,000/mm, Serum creatinine < 2.0 mg/dl, Serum bilirubin < 1.5 x ULN.\n   - There's no information provided about the patient's organ function.\n\n7. Performance status 0-1.\n   - There's no information provided on the patient's performance status.\n\n8. Age 18 years or older.\n   - The patient is 45 years old.\n\n9. No prior chemotherapy, hormonal therapy or radiation therapy for treatment of the primary breast cancer.\n   - There's no evidence that the patient has started any of these treatments.\n\n10. Bilateral synchronous breast cancer is allowed if other criteria are met.\n    - There's no indication of bilateral synchronous breast cancer.\n\n11. Patients may be ER/PR+ and receive treatment with hormonal therapy (tamoxifen or aromatase inhibitors).\n    - The patient is ER/PR negative.\n\n12. Use of effective means of contraception (men and women) in subjects of child-bearing potential.\n    - The patient is postmenopausal and not sexually active.\n\n13. Signed informed consent.\n    - There's no information about whether informed consent has been provided, but it is typically obtained during the trial recruitment process.\n\nBased on the patient note and the inclusion criteria:\n- The patient does meet the age criteria.\n- The patient does have high risk lymph node positive breast cancer with 5 involved axillary lymph nodes.\n- The patient has evidence of distant metastasis, which is an exclusion criterion as per the trial's requirement for no evidence of distant metastasis.\n- There is insufficient information on some criteria (e.g., surgery completion and status, cardiac function, organ function levels, performance status, informed consent).\n\nGiven the presence of distant metastasis, the patient would be excluded from the trial. Therefore:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "64": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Spousal Relationships and Pain in Metastatic Breast Cancer,\" we need to evaluate the provided patient note against the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are as follows:\n1. Being a female patient diagnosed with metastatic breast cancer.\n2. Initiating treatment for metastatic breast cancer.\n3. Having an ECOG Performance Status Score of 2 or less.\n4. For Spouses: Being the male spouse or significant other of a female patient diagnosed with metastatic breast cancer.\n5. For Spouses: Having the patient's consent to be contacted.\n6. For Patients and Spouses: Having the ability to read and speak English well enough to understand the consent form and complete the questionnaires.\n7. For Patients and Spouses: Being able to provide informed consent.\n\nNow, let's assess the patient based on the information provided in the patient note:\n1. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which meets the first criterion.\n2. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests that she is initiating treatment for metastatic breast cancer, thus meeting the second criterion.\n3. The ECOG Performance Status Score is not provided in the patient note, so we cannot confirm whether the patient meets the third criterion.\n4. There is no information given about a spouse or significant other, so we cannot assess the fourth and fifth criteria.\n5. The patient's ability to read and speak English is not mentioned, so we cannot confirm the sixth criterion.\n6. The patient's ability to provide informed consent is implied but not explicitly stated, meaning the seventh criterion is not fully confirmed.\n\nGiven that the patient note lacks specific information on the ECOG Performance Status Score, spouse or significant other's information, and the patient's ability to read and speak English, we cannot confirm the patient's eligibility for the trial.\n\nTherefore, based on the available information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "65": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to match the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Confirmed breast cancer diagnosis (cytologically confirmed, invasive ductal breast carcinoma)\n- HER2-positive, ER/PR negative\n- Metastatic lesions present (Stage IV breast cancer)\n- Candidate for tumor resection prior to chemotherapy\n- No mention of prior endocrine or chemotherapy treatment for breast cancer\n\nClinical trial inclusion criteria:\n- Histologic, pathologic, or cytologic diagnosis of cancer of the female breast (met)\n- Stage IV breast cancer or locally advanced (stage III) breast cancer not amenable to curative therapy (met)\n- Tumors must be hormone receptor-positive (ER and/or PgR positive) (not met, the patient's tumor is ER/PR negative)\n- HER2 status can be any (met)\n- Must have at least one measurable lesion as per the specified criteria (not enough information to determine)\n- Must have had one or two prior endocrine treatments for breast cancer (not met, no prior treatment mentioned)\n- Tumors potentially sensitive to endocrine therapy, defined as >= 3 months of prior endocrine therapy without disease progression (not met, no prior treatment mentioned)\n- Must have had prior treatment with a third-generation aromatase inhibitor (not met, no prior treatment mentioned)\n- May have received up to one prior chemotherapy regimen for stage IV breast cancer (not met, no prior treatment mentioned)\n- No prior fulvestrant therapy (met, no prior treatment mentioned)\n- Must be postmenopausal (met)\n- ECOG performance status 0-2 (not enough information to determine)\n- Must not have a visceral crisis, bleeding disorders, or need for therapeutic systemic anticoagulation (not enough information to determine)\n- Adequate organ function as specified by the listed laboratory values (not enough information to determine)\n\nGiven the information available in the patient note, the patient does not meet the inclusion criteria regarding hormone receptor status and prior treatments. The patient's tumor is HER2-positive and ER/PR negative, which does not align with the trial's requirement for hormone receptor-positive tumors. Also, there is no mention of prior endocrine or chemotherapy treatment, which is a requirement for the trial.\n\nTherefore, based on the available information, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "66": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer that is HER2-positive and ER/PR negative. The tumor is invasive, located in the left upper outer quadrant, and there is evidence of metastasis as indicated by the presence of 5 positive lymph nodes and metastatic lesions on the CXR. The patient is also a candidate for tumor resection, which she agrees to undergo prior to chemotherapy.\n\nNow, looking at the clinical trial's inclusion criteria, the trial is looking for patients with:\n\n- Breast cancer with evidence of unresectable locally recurrent, or metastatic disease\n- Her-2 negative tumors\n\nWhile the patient does have breast cancer with metastatic disease, which fits the first criterion, the tumor is HER2-positive. The inclusion criteria specifically require Her-2 negative tumors. Therefore, this patient does not meet the inclusion criteria because the tumor's HER2 status is positive, which is a mismatch with the trial's requirement for HER2-negative tumors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "67": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the clinical trial's inclusion criteria, the trial is looking for participants with:\n\n- Metastatic or locally advanced breast cancer not amenable to curative surgery\n- Life expectancy of greater than 12 months\n- English speaking\n- Pre- and postmenopausal\n- Performance status 0-1\n\nThe patient's note indicates that she has metastatic breast cancer, as evidenced by metastatic lesions noted in the CXR (chest X-ray). Although the patient's life expectancy is not explicitly mentioned, the fact that she is a candidate for tumor resection prior to chemotherapy suggests that her medical team believes she has a significant life expectancy, likely greater than 12 months. The patient's language abilities are not mentioned, but for the purpose of this eligibility check, we will assume she speaks English unless otherwise stated. The patient is postmenopausal, which fits the criteria. The performance status is not mentioned, but the patient is a candidate for surgery, which may suggest a good performance status (typically, a performance status of 0-1 indicates that the patient is fully active or restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).\n\nGiven the information available, the patient appears to meet the inclusion criteria for the clinical trial. However, without explicit details on her performance status and confirmation of her English-speaking ability, we cannot be certain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "68": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nHere are the relevant points from the patient's note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is a 3 cm invasive ductal carcinoma, HER2-positive, and ER/PR negative.\n- Five positive lymph nodes were found via axillary sampling.\n- Metastatic lesions were observed on CXR.\n- The patient is scheduled for tumor resection.\n\nNow, let's compare these to the inclusion criteria of the trial:\n\nInclusion Criteria Checklist:\n- Histologically or cytologically confirmed breast adenocarcinoma. [\u2713]\n- Within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed. [?]\n- Absence of lymph node involvement after eclosion and hormone (E&H) staining and light microscopy evaluation. [X] (The patient has positive lymph nodes.)\n- Premenopausal or postmenopausal women with at least one of the following tumor characteristics is required to characterize the tumor as high risk:\n  - Estrogen receptor (ER) (-) and progesterone receptor (PR)(-); [\u2713]\n  - Ki-67 + > 30%; Grade III; HER2 (3+) (after an amendment on 15.05.2008 women with HER2 (3+) were not included); Perineural infiltration or presence of tumor emboli in blood or lymph vessels. [?] (HER2-positive status is mentioned, but inclusion after amendment is unclear, as well as other factors.)\n- Postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of the above-mentioned high-risk criteria. [X] (The tumor is larger than 2 cm.)\n- Premenopausal and postmenopausal women with tumors measuring > 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria. [\u2713]\n- Absence of any clinical or radiological evidence of local or metastatic disease. [X] (The patient has metastatic lesions.)\n- Age > 18 years. [\u2713]\n- Performance status (WHO) < 3. [?]\n- Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9 gr/mm^3). [?]\n- Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function (creatinine < 2 mg/dl). [?]\n- Adequate cardiac function (LVEF > 50%). [?]\n- Negative pregnancy test. [N/A, postmenopausal]\n- Informed consent. [?]\n\nThe patient is excluded from the trial due to the presence of lymph node involvement and evidence of metastatic disease, both of which are contrary to the trial's inclusion criteria which require an absence of lymph node involvement and no clinical or radiological evidence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "69": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, we can assess the patient's eligibility as follows:\n\n1. Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma: The patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal carcinoma.\n\n2. Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, it is not stated whether the surgery has already been performed or that 10 lymph nodes have been removed.\n\n3. Tumor involvement of at least one axillary lymph node: The patient has 5 positive lymph nodes.\n\n4. Absence of any clinical or radiological evidence of local or metastatic disease: The patient's CXR was remarkable for metastatic lesions, which indicates the presence of metastatic disease.\n\n5. Premenopausal or postmenopausal women aged 18-75 years old: The patient is a 45-year-old postmenopausal woman.\n\n6. Adequate bone marrow function: The patient's bone marrow function is not mentioned.\n\n7. Adequate liver and renal function: The patient's liver and renal function are not mentioned.\n\n8. Adequate cardiac function (LVEF>50%): The patient's cardiac function is not mentioned.\n\n9. Written informed consent: The patient has agreed to tumor resection, which suggests a willingness to participate, but this does not confirm that informed consent for the trial has been provided.\n\nThe patient does not meet the inclusion criteria due to the presence of metastatic disease, which is explicitly excluded by the trial's requirement for an \"Absence of any clinical or radiological evidence of local or metastatic disease.\" Even though there is no specific exclusion criteria provided, the inclusion criteria itself serves to exclude this patient.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "70": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- Age: 45 years old\n- Gender: Female\n- Condition: Invasive ductal breast carcinoma, HER2-positive, ER/PR-negative\n- Other: Postmenopausal, candidate for tumor resection, agrees to chemotherapy prior to surgery\n\nClinical trial inclusion criteria:\n- Signed and dated informed consent form\n- Women \u2265 18 years, negative pregnancy test at screening, life expectancy of at least 6 months\n- Locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma of the breast\n- Measurable disease, defined as at least one lesion that is measurable in one dimension (RECIST)\n- HER-2/neu expression 1+ or 2+ / FISH negative\n- Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive\n- Prior adequate endocrine therapy for advanced or metastatic disease\n- Disease progression during or after endocrine therapy\n- No prior treatment with mouse or rat antibodies\n- ECOG performance score of \u2264 1\n- Adequate hematological, liver and kidney function\n\nComparison:\n- The patient is a 45-year-old woman, which meets the age and gender criteria.\n- The patient has metastatic breast cancer, meeting the condition of locally advanced or metastatic adenocarcinoma of the breast.\n- The patient's tumor is HER2-positive, which aligns with the HER-2/neu expression requirement.\n- The patient has measurable disease as the tumor is 3 cm, which fulfills the criteria of having at least one measurable lesion.\n- However, the patient's tumor is ER/PR-negative, which does not meet the requirement of ERs and/or PRs being positive.\n- There is no mention of prior endocrine therapy, disease progression during or after endocrine therapy, or prior treatment with mouse or rat antibodies. Additionally, the patient's ECOG performance score and organ function status are not specified.\n\nGiven the information, the patient does not meet the criteria of having ERs and/or PRs positive. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "71": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"TAC Versus TC for Adjuvant Breast Cancer,\" we need to compare the patient's characteristics and medical history with the inclusion criteria listed for the trial.\n\nLet's evaluate the patient based on the inclusion criteria:\n\n1. Age >18 to <70 years old: The patient is 45 years old, which meets the age criterion.\n2. Has known ER and PR status: The patient's tumor is ER/PR negative.\n3. Has HER2 nonamplified disease, confirmed by FISH: The patient's tumor is HER2 positive, which does not meet this criterion.\n4. Has known menopausal status: The patient is postmenopausal.\n5. Has operable, histologically confirmed, Stage I, IIA, IIB, or IIIA, IIIB, or IIIC invasive carcinoma of the breast: The patient has invasive ductal breast carcinoma, but the stage is not specified.\n6. Meets 1 of the 3 following criteria: The patient's tumor is ER and PR negative, which meets one of the criteria (T1N0M0 if ER and PR negative).\n7. Has complete surgical resection of the primary breast tumor: The patient is a candidate for tumor resection.\n8. Has had no prior chemotherapy: The patient has not undergone chemotherapy yet.\n9. Has an ECOG Performance Status (PS) 0-1: Not specified in the patient's note.\n10. Has laboratory values within the specified ranges: Not specified in the patient's note.\n11. Has normal cardiac function: Not specified in the patient's note.\n12. Has no evidence of metastatic disease outside of breast by physical examination and chest x-ray: The patient has metastatic lesions noted on CXR.\n13. Has had baseline bilateral mammography: Not specified in the patient's note.\n14. It has been <84 days since the date of definitive surgery: The patient has not had surgery yet.\n15. Has a negative serum pregnancy test within 7 calendar days prior to registration: Not applicable as the patient is postmenopausal.\n16. If fertile, has agreed to use an acceptable method of birth control: Not applicable as the patient is postmenopausal.\n17. Has adequate tumor specimen available for FISH analysis of TOP2A status: Not specified in the patient's note.\n18. Has signed a Patient Informed Consent Form and a Patient Authorization Form: Presumed to be obtainable if other criteria are met.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the following reasons:\n- The patient's tumor is HER2 positive, while the trial requires HER2 nonamplified disease.\n- The patient has evidence of metastatic disease, which is an exclusion criterion for the trial.\n\nGiven the mismatch with the HER2 status and the presence of metastatic disease, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "72": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,\" we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- Cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is a candidate for tumor resection prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Females age 18 years or older.\n- Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy, with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.\n- Clinical stage IIB - IIIC (T2-4, N0 or N1, M0 or - any T, N1-3, M0) breast cancer.\n- Clinically palpable tumor greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3).\n- Primary tumor may be estrogen or progesterone receptor negative or positive, and HER-2/neu negative as determined by FISH or 0-2+ staining by IHC.\n- Normal cardiac ejection fraction (EF \u2265 50%).\n- No prior history of myocardial infarction, congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias.\n- ECOG Performance Status of 0-1.\n- Ability to self administer daily subcutaneous injections.\n- Life expectancy greater than 6 months.\n\nComparison:\n- The patient meets the age criterion (45 years old).\n- The patient has histologically confirmed invasive breast cancer, satisfying this criterion.\n- The patient has a tumor greater than 2 cm and axillary nodal involvement, meeting this criterion.\n- The patient's tumor is HER2-positive, which does not meet the inclusion criterion of being HER-2/neu negative as determined by FISH or 0-2+ staining by IHC.\n- The presence of metastatic lesions on CXR indicates that the patient has evidence of metastatic disease beyond the ipsilateral axillary lymph nodes, which does not meet the inclusion criterion of having no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.\n\nBased on the provided information, the patient does not meet all of the inclusion criteria for the clinical trial due to having a HER2-positive tumor and the presence of metastatic disease beyond the ipsilateral axillary lymph nodes. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "73": {
        "output": "The patient in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, specifically invasive ductal breast carcinoma that is HER2-positive and ER/PR negative with axillary lymph node involvement and metastatic lesions. She is currently being considered for tumor resection prior to chemotherapy.\n\nThe clinical trial in question is focused on patients with stage IA non-small cell lung cancer (NSCLC) and compares the effectiveness of different types of surgery (wedge resection or segmentectomy versus lobectomy). The inclusion criteria for this trial specify that the patient must have a peripheral lung nodule presumed to be lung cancer, no prior malignancy within 3 years (with certain exceptions), no prior chemotherapy or radiation for this malignancy, no evidence of advanced or metastatic disease, an ECOG performance status of 0-2, and be at least 18 years of age.\n\nGiven that the patient has breast cancer with metastatic involvement, she does not meet the inclusion criteria for a trial focused on stage IA non-small cell lung cancer without evidence of metastatic or locally advanced disease. Additionally, there is no mention of lung cancer in the patient's diagnosis. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "74": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion criteria listed for the trial. Here are the relevant points from the patient note and the inclusion criteria:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection\n- No mention of ECOG performance status or left ventricular ejection fraction (LVEF)\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically confirmed invasive breast carcinoma\n- Early stage breast cancer - stage I (tumor size greater than 1 cm), II and IIA\n- 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity\n- Measurable disease as defined by the criteria mentioned\n- ECOG performance status 0 to 2 within 14 days of study entry\n- Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography\n- Must be 18 years of age or older\n- Women of childbearing potential must use appropriate contraceptive methods. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential\n\nComparison:\n\n- The patient has confirmed invasive breast carcinoma, fulfilling the first criterion.\n- The patient has early-stage breast cancer, and the tumor size is greater than 1 cm, fulfilling the second criterion.\n- The patient's tumor is HER2-positive, which meets the third criterion.\n- There is measurable disease as per the core biopsy and metastatic lesions, which seems to fulfill the fourth criterion.\n- The patient is over 18 years old, fulfilling the age requirement.\n- The patient is postmenopausal, which addresses the requirement for contraception.\n\nThe patient note does not provide information on the patient's ECOG performance status or LVEF. These are required for the clinical trial inclusion and are not mentioned in the patient note.\n\nBased on the information provided, the patient seems to meet most of the inclusion criteria. However, due to the lack of information on the ECOG performance status and LVEF, we cannot definitively determine eligibility without these key pieces of data.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "75": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n- The patient is a 45-year-old postmenopausal woman, which meets the trial's criterion of being female and 18 years of age or older.\n- The patient has a clinical tumor size of 3 cm, which could be classified as T1 or T2, thus meeting the criterion for tumor size (T1, T2, or T3).\n- The patient has a histopathologic tissue diagnosis of breast cancer by a core-type of breast biopsy, which meets the trial's requirement for a core biopsy.\n- The patient has biopsy-proven involvement of the axillary lymph nodes, based on the note that axillary sampling revealed 5 positive lymph nodes. This fits the requirement for biopsy-proven axillary lymph node involvement.\n- The patient note does not specify that the patient has undergone preoperative neoadjuvant systemic chemotherapy. Instead, it states that she is a candidate for tumor resection and agrees to proceed with it prior to chemotherapy. This suggests that neoadjuvant chemotherapy has not yet been administered, which does not meet the requirement of the trial that patients must have undergone preoperative neoadjuvant systemic chemotherapy.\n\nGiven this information, the patient does not meet all the inclusion criteria due to not having undergone neoadjuvant systemic chemotherapy prior to the potential resection. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "76": {
        "output": "",
        "label": 1
    },
    "77": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is focused on patients with epilepsy, specifically those with medically-refractory epilepsy, who have had treatment failure of at least 2 anti-epilepsy drugs and have a certain frequency of seizures.\n\nBased on the provided patient note, this patient does not meet the inclusion criteria for the epilepsy clinical trial as she has breast cancer and there is no mention of her having epilepsy or being treated for seizures. Therefore, she is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "78": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer,\" we need to compare the inclusion criteria with the patient's medical details.\n\nHere are the key points from the patient's medical history:\n- The patient is a 45-year-old postmenopausal woman with breast cancer.\n- Histologically confirmed invasive ductal carcinoma.\n- A tumor size of 3 cm (within the specified size of \u2264 3 cm).\n- Axillary sampling revealed 5 positive lymph nodes, which means the patient has more than the maximum allowed 3 positive lymph nodes according to the trial criteria.\n- The patient has distant metastatic lesions, as indicated by the CXR finding.\n\nAnd the relevant inclusion criteria for the trial:\n- Female patient (met).\n- Histologically confirmed breast cancer, with specific allowed subtypes including invasive ductal carcinoma (met).\n- Stage I or II disease with the lesion \u2264 3 cm (met in terms of lesion size, but not clearly stated stage).\n- No more than 3 positive lymph nodes (not met - the patient has 5 positive lymph nodes).\n- No distant metastatic disease (not met - the patient has metastatic lesions).\n\nBased on the information provided, the patient does not meet the eligibility criteria for the clinical trial due to having more than 3 positive lymph nodes and the presence of distant metastatic disease. Therefore, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "79": {
        "output": "Let's evaluate the eligibility of the patient for the clinical trial titled \"Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer\" based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, planning to undergo surgery prior to chemotherapy\n- No mention of prior treatment history\n- No mention of hematopoietic, renal, hepatic, cardiac, or mental function\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed and newly diagnosed breast cancer: node-positive stage IIA and any stage IIB, III\n- No prior hormonal, chemotherapy, or radiotherapy\n- No breast operation other than biopsy for diagnosis\n- Age: 18 years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)\n- Adequate hematopoietic function\n- Adequate renal function\n- Adequate hepatic function\n- Adequate cardiac function\n- Adequate mental function to understand and sign consent\n\nComparison:\n- The patient has histologically confirmed breast cancer and is postmenopausal, which aligns with the inclusion criteria.\n- The patient has positive lymph nodes and metastatic lesions, which would likely place her at a clinical stage consistent with the trial's inclusion criteria (IIA, IIB, III).\n- There is no mention of any prior hormonal, chemotherapy, or radiotherapy, so we can assume the patient has not received these treatments yet.\n- The patient is planning to have a tumor resection, which is not allowed by the trial if it happens before enrollment; however, as it is planned and not yet conducted, it does not currently exclude her.\n- The age of the patient is within the required range.\n- There are no details provided regarding the patient's performance status or her hematopoietic, renal, hepatic, cardiac, or mental function. \n\nBased on the information provided, the patient appears to meet most of the inclusion criteria. However, since there is no information on her performance status (ECOG 0-1), or her hematopoietic, renal, hepatic, cardiac, and mental function, we cannot definitively determine her eligibility. Therefore, the patient falls into the category of \"Not relevant\" due to insufficient information to confirm eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "80": {
        "output": "To assess the eligibility of the 45-year-old postmenopausal woman with breast cancer for the clinical trial titled \"Effect of SBG in Patients With Breast Cancer,\" we need to compare her patient note to the inclusion criteria of the trial.\n\nLet\u2019s evaluate each criterion one by one:\n\n1. Women with histologically/cytologically confirmed locally advanced or metastatic breast cancer.\n   - The patient note confirms that she has cytologically confirmed breast cancer with metastatic lesions seen on CXR.\n\n2. Primary tumor or metastases are HER2-ICH3+ or FISH+\n   - The patient note confirms that the tumor is HER2-positive.\n\n3. Measurable or non-measurable disease.\n   - The patient has a measurable 3 cm invasive ductal breast carcinoma.\n\n4. The patients must not have received treatment with the combination trastuzumab and vinorelbine previously.\n   - The patient note does not mention any previous treatment with trastuzumab and vinorelbine.\n\n5. Expected lifetime of more than 12 weeks.\n   - The patient note does not provide any details on the expected lifetime, but she is a candidate for tumor resection, which suggests that her expected lifetime might be more than 12 weeks.\n\n6. Age \u2265 18 years.\n   - The patient is 45 years old.\n\n7. Performance status \u2264 2 according to World Health Organization (WHO) scale.\n   - The patient note does not specify her performance status. However, because she is a candidate for tumor resection and agrees to proceed with it prior to chemotherapy, this may indicate a performance status of \u2264 2, but this is an assumption as the performance status is not explicitly stated.\n\n8. The patient must be able to comply with the protocol.\n   - The patient note does not provide information about her ability to comply with the protocol, but her agreement to tumor resection suggests she is willing to be treated, which may indicate compliance.\n\n9. Verbal and written informed consent.\n   - The patient note does not mention whether she has given informed consent, but since she is a candidate for tumor resection, we can assume she is capable of giving consent.\n\nBased on the information available in the patient note, the patient appears to meet all the inclusion criteria for the clinical trial. The only information not explicitly provided is her performance status and her ability to comply with the protocol. However, since she is a candidate for surgery, it is likely that her performance status is adequate and that she can comply with the trial requirements. Therefore, we can consider her eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "81": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's compare the patient's characteristics and condition with the trial's requirements:\n\nPatient Characteristics:\n- Age: 45 years old (meets the criterion of age \u2265 18 years)\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor Details: Invasive ductal breast carcinoma, 3 cm, left upper outer quadrant, HER2-positive, ER/PR-negative\n- Treatment Plan: Candidate for tumor resection, to be followed by chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 negative invasive breast cancer confirmed on core biopsy. (HER2 0 or 1+ by IHC acceptable)\n- Primary tumor size 2 cm or greater.\n- Assessment of pre-treatment axillary lymph nodal status.\n- Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3 (patient's bloodwork not provided in the note, so this remains unknown).\n- Normal myocardial left ventricular function (no information provided about the patient's cardiac function).\n- Serum creatinine < 2.0 mg/dl (no information provided about the patient's renal function).\n- Total bilirubin and AST < 3X upper limits normal (no information provided about the patient's liver function).\n\nEligibility Assessment:\n- The patient's tumor is HER2-positive, which does not meet the trial's requirement for HER2-negative status.\n- The patient does meet the age criterion.\n- The primary tumor size meets the trial's requirement (3 cm).\n- The patient has had axillary sampling with positive lymph nodes, which provides information on nodal status, although the specific method preferred by the trial is not mentioned.\n\nBased on the information provided, the patient does not meet the criteria for HER2 status, as the trial specifically requires HER2-negative patients and the patient's tumor is HER2-positive. Therefore, despite meeting other criteria, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "82": {
        "output": "To determine the patient's eligibility for the clinical trial \"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE),\" let's compare the patient's information with the inclusion criteria of the trial:\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer (invasive ductal breast carcinoma)\n- Tumor size: 3 cm\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR revealed metastatic lesions\n- Candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n- No mention of systemic metastasis exclusion by sonogram of the upper abdomen and skeletal scintiscan\n- Age fits the criteria (\u226518 years and \u226465 years)\n- No mention of ECOG/WHO performance status\n- No information about organ function or specific lab values\n- No information provided regarding heart echo results\n- No mention of hepatitis status\n- Willingness to participate (implied by agreement to tumor resection as part of treatment)\n\nInclusion criteria for the trial:\n- Histologically confirmed breast cancer with at least three fast biopsies\n- Primary tumor \u22652 cm according to clinical measurement or manifestation of an inflammatory breast cancer\n- No systemic metastasis, exclusion by chest x-ray, sonogram of the upper abdomen, and skeletal scintiscan\n- Age \u226518 years and \u226465 years\n- ECOG < 2/WHO 0-1\n- Adequate organ function (specific lab values provided)\n- Unremarkable heart echo\n- No florid hepatitis\n- Written consent to participate in the treatment optimization protocol\n\nBased on the given information, the patient has confirmed breast cancer with a tumor size that fits the criteria, and her age is within the required range. However, the patient's eligibility cannot be fully determined due to the following gaps in the information provided:\n- The patient has CXR showing metastatic lesions, which may indicate systemic metastasis. This would exclude her from the trial as per the \"no systemic metastasis\" criterion.\n- The patient's ECOG/WHO performance status is not mentioned.\n- There is no information about the patient's specific organ function through lab values, heart echo results, or hepatitis status.\n- While the patient's agreement to tumor resection implies willingness to participate in treatment, there is no explicit mention of written consent for the trial itself.\n\nGiven the presence of metastatic lesions, it is likely that the patient does not meet the \"no systemic metastasis\" criterion, which would exclude her from the trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "83": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer,\" we need to evaluate the patient's characteristics and medical history against the inclusion criteria of the trial:\n\nInclusion Criteria Assessment:\n1. Postmenopausal women: The patient is described as postmenopausal.\n2. Histologically or cytologically confirmed breast cancer: The patient has cytologically confirmed breast cancer.\n3. Metastatic breast cancer (Stage IV according to UICC criteria, Version 6): The patient has metastatic lesions noted on CXR.\n4. Progesterone receptor-positive tumors: The patient's tumor is HER2-positive and ER/PR negative, which means it does not have progesterone receptors.\n5. Candidates for endocrine therapy: The patient is a candidate for tumor resection before chemotherapy, but the eligibility requirement is for patients who are candidates for endocrine therapy.\n6. Disease progression after first-line endocrine therapy for advanced breast cancer: There is no information provided about the patient having previously received endocrine therapy or disease progression after such therapy.\n7. At least one measurable or non-measurable tumor lesion: The patient has a 3 cm invasive ductal breast carcinoma, which is a measurable lesion.\n8. WHO Performance status 1: There is no information provided on the patient's performance status.\n9. Adequate function of major organs and systems: There is no information provided on the patient's organ function.\n10. No other uncontrolled concurrent illness: There is no information provided about any concurrent illness.\n11. Adequate recovery from previous surgery, radiation, and chemotherapy: The patient agrees to undergo tumor resection, but there is no information about recovery as no treatment has been administered yet.\n12. Written informed consent: Not applicable for this assessment.\n\nThe patient does not meet eligibility on the basis of having a progesterone receptor-positive tumor, as her tumor is PR negative. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "84": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes, indicating that the lymph nodes are not negative.\n- There are metastatic lesions present, as indicated by the CXR.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria Analysis:\n- Female sex (Patient meets this criterion)\n- Age greater than or equal to 40 years (Patient meets this criterion)\n- Localized ductal carcinoma in situ (Patient does not meet this criterion as her cancer is invasive)\n- Clinically and/or histologically negative axillary lymph nodes (Patient does not meet this criterion as she has 5 positive lymph nodes)\n- No imaging or clinical findings suggestive of invasive carcinoma (Patient does not meet this criterion as she has invasive carcinoma and metastatic lesions)\n\nBased on the patient's diagnosis of invasive ductal carcinoma with positive lymph nodes and metastatic lesions, she does not meet the inclusion criteria for the clinical trial which specifically requires patients with localized ductal carcinoma in situ, negative axillary lymph nodes, and no findings of invasive carcinoma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "85": {
        "output": "",
        "label": 0
    },
    "86": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we have to compare the patient's information to the inclusion criteria of the clinical trial for preoperative cisplatin and bevacizumab in ER-, PR-, HER2-negative breast cancer.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR was remarkable for metastatic lesions (presence of metastases, which suggests stage M1)\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- All tumors must be ER-, PR- and HER2-negative\n- Clinical stage T2 or T3, N0-3, M0 (the trial excludes subjects with inflammatory breast cancer or metastatic disease, which would be stage M1)\n- 18 years of age or older\n- Performance status (PS) of 0 or 1\n- Use of an effective means of contraception in subjects of child-bearing potential\n- Normal organ function as described in the protocol\n\nComparison:\n- The patient is 45 years old, which meets the age criterion.\n- The patient has a performance status that is not explicitly stated but is likely to be 0 or 1, as she is a candidate for surgery.\n- The use of contraception is not relevant as the patient is postmenopausal.\n- The patient has ER/PR-negative breast cancer, which meets part of the trial's criteria for tumor characteristics. However, the patient's tumor is HER2-positive, which does not meet the trial's requirement for HER2-negative status.\n- The patient has metastatic lesions (M1), which do not meet the trial's requirement for M0 (no metastasis).\n\nBased on the comparison, the patient is not eligible for the trial because her tumor is HER2-positive, and she has metastatic disease, which are both exclusionary according to the trial's criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "87": {
        "output": "To determine the patient's eligibility for the clinical trial, I will compare the patient's information provided in the note with the inclusion criteria specified for the clinical trial:\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: metastatic lesions\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Unifocal histologically proven breast cancer, with or without calcifications in mammogram\n- DCIS (Ductal carcinoma in situ) (Tis, Stage 0)\n- Non-lobular infiltrating carcinoma, maximum of 2 cm in diameter (T1, Stage I)\n- Patient was operated on and the tumor was excised with lumpectomy\n- Tumor with negative margins >3 mm\n- For invasive carcinoma, axillary lymph nodes are negative\n- Patient is over 40 years old with life expectancy of at least 5 years\n- Karnofsky status must be at least 70\n- Pre- and post-menopausal women are eligible\n- Informed consent must be provided\n\nComparison:\n- The patient's age fits the trial criteria (over 40 years old).\n- The patient is postmenopausal, which is acceptable according to the trial criteria.\n- The patient has a histologically proven breast cancer, which fits the trial criteria.\n- The patient has not yet undergone tumor excision, which is required before participation in the trial.\n- The patient's tumor is larger than 2 cm in diameter, which exceeds the trial's size limit.\n- The patient has positive axillary lymph nodes, which is contrary to the trial's requirement of negative axillary lymph nodes.\n- The patient has metastatic lesions, and the trial specifies early-stage, lymph node negative breast cancer.\n\nBased on the comparison, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the tumor size and the status of axillary lymph nodes, as well as the early-stage breast cancer requirement, exclude the patient from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "88": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, let's analyze the compatibility step by step:\n\n1. Age: The patient is 45 years old, which meets the age inclusion criteria of \u2265 18 years.\n2. Disease: The patient has invasive ductal breast carcinoma, which is one of the eligible histologies mentioned in the trial inclusion criteria.\n3. AJCC Stage: The patient has metastatic lesions as per the CXR report, indicating that the cancer has spread beyond the local and regional lymph nodes. This suggests a stage beyond II, making the patient ineligible based on the AJCC stage 0, I, or II criteria.\n4. Treatment: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, the inclusion criteria specify that the patient must be treated with tylectomy. There is no information about whether the patient has undergone a tylectomy or is planning to undergo one.\n5. Axillary Nodes: The patient has 5 positive lymph nodes, which contradicts the trial's inclusion criteria of having no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\n6. Margins: There is no information provided about the margins of the patient's tumor resection.\n7. Chemotherapy or hormonal therapy: The patient is a candidate for chemotherapy after tumor resection, which is allowed in the trial criteria as long as it is planned for \u2265 2 weeks after removal of the brachytherapy catheters.\n8. Pregnancy: There is no mention of a pregnancy test, but the patient is postmenopausal, which implies a negative pregnancy status.\n\nBased on the available information, the patient does not meet the AJCC stage criteria and has positive axillary lymph nodes, which is not in line with the trial's inclusion criteria. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "89": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer,\" we need to compare the patient's characteristics and disease status with the inclusion criteria of the trial.\n\nHere are the relevant points from the patient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nAnd here are the key inclusion criteria from the clinical trial:\n- Female\n- Stage I-II invasive or intraductal breast cancer\n- Unifocal tumor \u2264 3.0 cm in size\n- Fewer than 4 positive nodes on adequate axillary lymph node dissection\n\nNow, let's compare the patient's data with the clinical trial's inclusion criteria:\n\n- The patient is a 45-year-old postmenopausal woman, which fits the gender requirement.\n- The tumor is unifocal and 3 cm in size, which is within the limit specified.\n- However, the patient has 5 positive lymph nodes, which exceeds the maximum of 3 positive nodes allowed by the trial's criteria.\n\nSince the patient does not meet the criteria regarding the number of positive lymph nodes, she is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "90": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- 3 cm tumor size\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Evidence of metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed primary invasive breast carcinoma\n- Stage I-IIA disease (T1, N0, M0 or T2, N0, M0)\n- Single, discrete, and well-defined primary tumor \u2264 5 cm in diameter\n- Pathologically negative surgical margins\n- No multicentric disease and/or diffuse malignant appearing microcalcifications\n- No axillary lymph node involvement\n- No evidence of metastatic breast cancer\n- ECOG performance status 0-2\n- Menopausal status not specified\n- No pre-existing collagen vascular disease except rheumatoid arthritis\n- Not pregnant or nursing\n- No prior irradiation to the area of planned radiation field\n- No prior placement of breast prosthesis in the treated breast\n- Concurrent hormonal therapy with external-beam irradiation allowed\n\nAssessment:\n- The patient has breast carcinoma, which matches the disease characteristic requirement.\n- The tumor size is within the required \u2264 5 cm in diameter.\n- The patient has axillary lymph node involvement (5 positive lymph nodes), which does not meet the 'No axillary lymph node involvement' criterion.\n- The patient has evidence of metastatic lesions, which contradicts the 'No evidence of metastatic breast cancer' criterion.\n\nThe patient does not meet the inclusion criteria due to positive lymph nodes and metastatic breast cancer presence. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "91": {
        "output": "To determine the patient's eligibility for the clinical trial, let's compare the patient's characteristics and medical history with the inclusion criteria of the trial:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, HER2-positive, ER/PR-negative\n- Positive lymph nodes and metastatic lesions\n- Candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Postmenopausal females\n- ER and/or PR-positive histologically confirmed adenocarcinoma of the breast\n- Measurable locally recurrent or metastatic disease\n- Must submit tissue blocks for retrospective analysis or provide slides if blocks are not available\n- Must be postmenopausal as defined by the criteria listed\n- No more than 1 prior chemotherapy regimen for metastatic disease\n- May have had 1 prior hormonal therapy for metastatic disease\n- No prior therapy with EGF receptor inhibitors\n- Previous but not concomitant therapy with trastuzumab (Herceptin) is allowed\n- ECOG performance status of 0, 1, or 2\n- Adequate organ function as defined in the criteria\n- Must be 18 years of age or older\n- No history of CNS metastases or unevaluated CNS symptoms\n- May receive concurrent radiation therapy to bone metastases if initiated prior to study entry\n- No history of invasive cancers other than exceptions listed\n- Must not have received LHRH antagonists within 3 months if < 55 years of age\n- Free from medical or psychiatric conditions that would interfere with compliance\n\nAssessment:\n- The patient has invasive ductal breast carcinoma which is HER2-positive and ER/PR-negative. The trial requires participants to have ER and/or PR-positive breast cancer. Since the patient's tumor is ER/PR-negative, she does not meet the inclusion criteria regarding the hormone receptor status of the tumor.\n- The patient has agreed to undergo tumor resection, which suggests her disease may be operable, whereas the trial requires the disease to be measurable but not operable.\n\nBased on the information provided, the patient does not meet the critical inclusion criteria of having ER and/or PR-positive breast cancer and having non-operable disease. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "92": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer,\" we need to review the patient note against the inclusion criteria listed.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which fits within the age range of 18-75 years old specified by the trial.\n- The patient has cytologically confirmed breast cancer, specifically invasive ductal carcinoma, which is included in the histological types mentioned.\n- The tumor is HER2-positive, which meets the criteria for HER2/c-neu overexpression as required.\n- The patient has axillary lymph node involvement with 5 positive lymph nodes, meeting the requirement for tumor involvement of at least one axillary lymph node.\n- The patient is a candidate for tumor resection and agrees to undergo surgery, which suggests that the surgery could be done within 60 days after excision as required by the trial.\n- The patient is using multivitamins and iron supplements, but there's no mention of inadequate bone marrow, liver, renal, or cardiac function, so we can't determine if these criteria are met based on the provided information.\n- There is a mention of metastatic lesions on a CXR, which indicates the presence of metastatic disease. This contradicts the requirement of \"absence of any clinical or radiological evidence of local or metastatic disease.\"\n\nBased on the information provided, the patient meets several inclusion criteria, such as age, histology, HER2 status, and lymph node involvement. However, the presence of metastatic lesions excludes the patient as the trial requires the absence of any clinical or radiological evidence of metastatic disease. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "93": {
        "output": "To determine the patient's eligibility, let's go through the inclusion criteria of the clinical trial one by one and see if this patient's note provides the necessary information:\n\n1. Patients must be women with a histologically confirmed diagnosis of breast cancer that is more than 1 cm and or lymph node positive: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and positive lymph nodes, meeting this criterion.\n\n2. Physical examination, and scans needed for tumor assessment must be performed within 90 days prior to registration: The patient note does not mention the timing of the physical examination and scans.\n\n3. Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible: The patient note does not mention either of these conditions, so we do not have information to exclude her based on this criterion.\n\n4. Serum creatinine within normal limits within 90 days prior to registration: The patient note does not provide information about serum creatinine levels.\n\n5. Bilirubin within normal limits within 90 days prior to registration: The patient note does not provide information about bilirubin levels.\n\n6. Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2 x the institutional upper limit of normal within 90 days prior to registration: The patient note does not provide information about liver enzyme levels.\n\n7. Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration: The patient note does not provide information about ANC levels.\n\n8. Platelet count of >= 100,000/microliters within 90 days prior to registration: The patient note does not provide information about platelet count.\n\n9. Patients must have a performance status of 0-2 by Zubrod criteria: The patient note does not provide information about performance status according to Zubrod criteria.\n\n10. Pregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potential: The patient is postmenopausal, which implies she is not of childbearing potential and not pregnant or nursing, so she meets this criterion.\n\n11. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines: The patient note does not mention consent, but this is typically obtained during the recruitment process, so we cannot determine eligibility based on this criterion at this stage.\n\nGiven that the patient meets some of the inclusion criteria but lacks sufficient information for a number of important criteria (particularly related to recent tests and specific health measurements), we cannot definitively classify her as eligible or excluded. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "94": {
        "output": "Based on the information provided, the patient has a diagnosis of invasive ductal breast carcinoma and is HER2-positive and ER/PR negative. The clinical trial in question is looking to recruit women who have atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS). \n\nThe patient note does not mention ADH, ALH, or LCIS; instead, it mentions invasive ductal breast carcinoma, which is a different condition. Therefore, the patient does not meet the inclusion criteria for this clinical trial as the criteria specifically require a diagnosis of ADH, ALH, or LCIS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "95": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion and exclusion criteria:\n\nInclusion criteria analysis:\n- Histologically proven invasive unilateral breast cancer: The patient has invasive ductal breast carcinoma.\n- Initial clinical condition compatible with complete initial resection: The patient is a candidate for tumor resection.\n- No residual macro or microscopic tumor after surgical excision: The patient agrees to tumor resection prior to chemotherapy, which suggests that no residual tumor is expected after surgery.\n- Node-positive disease (N+): The patient has 5 positive lymph nodes.\n- Stage II or III disease: This is not explicitly stated, but the presence of positive lymph nodes and the tumor size (3 cm) suggest stage II or III.\n- pT >20 mm (T1-4): The tumor is 3 cm, which is greater than 20 mm.\n- Patients must meet one of the following hormone-receptor criteria: The patient's tumor is HER2-positive and ER/PR negative, which does not meet the specified hormone-receptor criteria for node-positive patients in the trial.\n- Must be able to begin chemotherapy no later than day 49 after the initial surgery: This is not mentioned, but since the patient agrees to surgery prior to chemotherapy, it's plausible that the timing can be managed accordingly.\n  \nExclusion criteria analysis:\n- Clinically or radiologically detectable metastases (M0): The patient has metastatic lesions on CXR, which indicates the presence of metastases.\n- Bilateral breast cancer or contralateral ductal carcinoma in situ: There is no information suggesting bilateral breast cancer or contralateral DCIS.\n- Any metastatic impairment: The presence of metastatic lesions on CXR indicates metastatic impairment.\n- Any tumor \u2265T4a: There is no information provided about cutaneous invasion, deep adherence, or inflammatory breast cancer.\n- HER2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive: The patient's tumor is HER2-positive, which is an exclusion criterion.\n\nBased on the exclusion criteria, specifically the presence of metastatic lesions and HER2 overexpression, the patient would be excluded from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "96": {
        "output": "Based on the provided patient note and clinical trial information, let's analyze the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative breast cancer\n- Metastatic lesions present (indicating metastasis)\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Patients undergoing radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy\n- No evidence of metastases on imaging scans\n- Good surgical candidates\n- Signed informed consent\n- For patients of child-bearing age, a negative serum pregnancy test is required\n\nThe patient is postmenopausal, which satisfies the criteria concerning child-bearing potential. However, the patient has breast cancer with axillary involvement and metastatic lesions, which is not the target condition for the clinical trial. The trial is specifically targeting patients with cervical cancer undergoing a particular type of surgery (radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy), and there is no indication that the patient in question is having this surgery or has cervical cancer.\n\nGiven this information, the patient does not meet the trial's inclusion criteria, which are specific to patients with cervical cancer undergoing specific surgical procedures. Since the patient has breast cancer, not cervical cancer, she does not qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "97": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman, which matches the gender requirement of the clinical trial (female subjects).\n\nThe patient has invasive ductal breast carcinoma that is HER2-positive, which does not match the requirement of the clinical trial, which is looking for subjects with triple negative breast cancer (ER, PR, and HER2 negative).\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, indicating that she has not yet received the first-line treatment for her condition.\n\nThe clinical trial is looking for female subjects with triple negative breast cancer who have had prior adjuvant or neoadjuvant anthracycline-based chemotherapy, which this patient has not had.\n\nGiven that the patient's breast cancer is not triple negative and she has not received the specified type of chemotherapy, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "98": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, let's consider the key points:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant, 3 cm\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes from axillary sampling\n- Presence of metastatic lesions (CXR)\n- Candidate for tumor resection before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Patients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\n- ECOG performance status of equal to or less than 3.\n\nThe patient's note indicates that she has invasive ductal breast carcinoma and is a candidate for tumor resection, which may likely include axillary lymph node dissection as part of her treatment plan, aligning with the requirements of the trial. However, there is no mention of the patient's ECOG performance status, which is a necessary piece of information for determining her eligibility. Moreover, it is not specified whether the patient is planning to undergo her surgery specifically at M. D. Anderson Cancer Center, which is an inclusion criterion for the trial.\n\nGiven the information provided, the patient note does not contain sufficient information to determine the patient's ECOG performance status or confirm that her treatment will be at M. D. Anderson Cancer Center. Therefore, based on the available data, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "99": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's determine the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic breast cancer with 5 positive lymph nodes and metastatic lesions on CXR\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Signed study-specific Informed Consent Form(s)\n- Age \u2265 18 years\n- Histologically documented breast cancer\n- HER2-positive disease\n- Metastatic breast cancer\n- Disease progression on the last chemotherapy regimen received in the metastatic setting\n- Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting\n- Prior treatment with at least two lines of therapy in the metastatic setting, including at least two lines of anti-HER2 therapy\n- A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease\n- At least 14 days of exposure in the metastatic setting to lapatinib and capecitabine (given together or separately) unless intolerant\n\nComparing the patient to the inclusion criteria:\n\n- The patient has signed the informed consent form (assumed as it's not mentioned but necessary for trial participation).\n- The patient is over 18 years of age.\n- The patient has histologically documented breast cancer.\n- The patient has HER2-positive metastatic breast cancer.\n- There is no information provided in the patient note about disease progression on the last chemotherapy regimen, prior treatments received, or duration of treatments such as trastuzumab, lapatinib, and capecitabine.\n\nDue to the lack of information regarding the patient's prior treatments and disease progression, we cannot conclusively determine whether the patient meets all the inclusion criteria. The patient does have HER2-positive metastatic breast cancer, which aligns with the study's target population, but without details on treatment history, we cannot make a full assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "100": {
        "output": "Patient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma in the left upper outer quadrant, 3 cm in size, HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions noted on CXR.\n- The patient is a candidate for tumor resection and agrees to undergo the surgery before chemotherapy.\n\nClinical Trial Analysis:\n- The trial is looking for patients with histologically proven breast cancer (invasive adenocarcinoma).\n- The patients must have at least one axillary lymph node with evidence of tumor among a minimum of six resected lymph nodes.\n- Definitive surgical treatment must be either mastectomy or breast conserving surgery with axillary lymph node dissection.\n- Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma.\n- Patients must not have received any prior systemic anticancer therapy for breast cancer or prior anthracycline therapy or taxoids.\n\nComparison:\n- The patient in question has histologically proven breast cancer with positive axillary lymph nodes, which matches the inclusion criteria of the trial.\n- She is a candidate for tumor resection, which is required by the trial, though she has not yet undergone the surgery. To be eligible, the surgery must be completed with margins free of cancer.\n- She has not received prior systemic anticancer therapy for breast cancer, which meets the exclusion criteria.\n- However, we do not have information whether she has had a minimum of six lymph nodes resected or if the margins are free of cancer, as she has not yet undergone the surgery.\n\nConclusion:\nBased on the available information, the patient appears to meet some of the inclusion criteria but has not yet undergone the surgery required to confirm eligibility. The patient has not been excluded based on the exclusion criteria provided. However, without confirmation that the surgery has been completed and the outcome of the surgery, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "101": {
        "output": "Given the details of the patient and the inclusion criteria of the clinical trial titled \"National Survey on Infiltrative Breast Cancer,\" let's assess the eligibility:\n\nPatient Details:\n- 45-year-old postmenopausal woman (meets age criteria > 18 years)\n- Cytologically confirmed breast cancer (meets the criteria of having breast cancer)\n- A core biopsy revealed invasive ductal breast carcinoma (meets criteria for type of breast cancer - infiltrative)\n- Willing to undergo tumor resection and agrees to take part in the study (meets the criteria for agreement to participate)\n\nClinical Trial Inclusion Criteria:\n- Women \u2265 18 years old\n- Women with a newly diagnosis of infiltrative breast cancer\n- Agree to take part in this study\n\nThe patient is a woman over the age of 18 with a newly diagnosed infiltrative breast cancer and has agreed to participate in the study. Therefore, she meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "102": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive, and ER/PR negative.\n- There are metastatic lesions present, indicating an advanced stage of cancer.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- There is no mention of the patient's diet or lifestyle practices.\n\nClinical Trial Analysis:\n- The trial is investigating the role of diet and lifestyle in breast cancer survival.\n- It is an observational study focused on women with breast cancer.\n- It requires participants to be 9-15 months post-diagnosis.\n\nInclusion Criteria for the Trial:\n- Women with histologically confirmed invasive primary breast cancer grades I to III.\n- Age up to and including 75 years old.\n\nThe patient meets the age criterion (45 years old) and has histologically confirmed invasive primary breast cancer. The grade of the cancer is not specified in the patient note, but given the metastatic spread and the positive lymph nodes, it is likely to be at least grade II or III. However, there is a lack of information regarding how long it has been since her diagnosis, which is important to determine eligibility based on the trial's requirement of being 9-15 months post-diagnosis. Without this information, we cannot confirm whether she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "103": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, we need to match the patient's characteristics and condition to the trial's requirements.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma with a size of 3 cm\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions found in CXR\n- A candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Females with Stage II invasive breast cancer\n- Documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration\n- Scheduled to undergo an axillary lymph node dissection (ALND)\n- Females > 21 years of age\n\nAssessment:\n- The patient is a 45-year-old female, which satisfies the age criterion of being over 21 years of age.\n- The patient has invasive ductal breast carcinoma with positive axillary lymph nodes, meeting the requirement for documented axillary metastases.\n- The trial requires patients with Stage II breast cancer, but the provided patient note does not specify the stage of breast cancer. However, the presence of metastatic lesions in the CXR might suggest a more advanced stage than Stage II. \n- The patient is scheduled to undergo tumor resection, and while ALND is not specifically mentioned, it is often a part of the surgical management of invasive breast cancer with positive lymph nodes.\n\nGiven that the patient note does not specify the stage of breast cancer and that ALND is not explicitly mentioned as part of the patient's treatment plan, there is not enough information to determine with certainty whether the patient is scheduled for an ALND as required by the trial. Additionally, the presence of metastatic lesions suggests a more advanced stage than what the trial is looking for (Stage II).\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided in the note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "104": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The patient is scheduled for tumor resection and is a candidate for this procedure prior to chemotherapy.\n\nThe clinical trial is investigating the use of optical spectroscopy as an adjunct to core needle biopsy in the diagnosis of breast cancer. The inclusion criteria for the clinical trial are:\n\n- Patients having a needle biopsy of a breast mass.\n\nSince the patient has a confirmed breast cancer diagnosis and is a candidate for tumor resection, it is reasonable to assume she has already had or will have a needle biopsy of the breast mass as part of her diagnostic workup. Therefore, she meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "105": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection\n\nClinical trial:\n- Title: An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\n- Objective: To develop and test an optical assay system for intraoperative assessment of breast tumor margins\n- Inclusion Criteria: Clinical diagnosis of Breast Cancer\n\nThe patient has a clinical diagnosis of breast cancer, which matches the inclusion criteria of the clinical trial. Since no other specific inclusion or exclusion criteria are provided, and the patient is planning to undergo tumor resection, which is where the intraoperative assessment would be relevant, she appears to meet the criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "106": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer\n\nAssessment:\n- The patient is postmenopausal, which matches the inclusion criteria.\n- The patient has metastatic breast cancer, which matches the inclusion criteria for \"metastatic breast cancer.\"\n\nHowever, the inclusion criteria specifically mention \"hormone receptor-positive\" breast cancer. The patient note indicates that the tumor is \"HER2-positive and ER/PR negative.\" Hormone receptor-positive breast cancer typically refers to cancers that are positive for estrogen receptor (ER) and/or progesterone receptor (PR). Since the patient's tumor is ER/PR negative, she does not meet the criteria of having hormone receptor-positive breast cancer.\n\nGiven this information, the patient does not meet one of the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "107": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Intraoperative Gamma Camera for Breast Cancer Surgery,\" we can assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has a cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions noted in the chest X-ray (CXR).\n- She is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Patient major at the time of breast surgery.\n- Patient affiliated with a social security.\n- Consent dated and signed by the investigator and the subject.\n- Subject having been informed of the sentinel lymph node procedure during the visit prior to breast surgery.\n- Patient having a unifocal infiltrative breast cancer (less than 2 cm) diagnosed preoperatively by core biopsy or cytology.\n- Patient having a ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.\n\nComparison:\n- The patient is of age and presumably affiliated with social security.\n- The patient note does not mention consent but indicates readiness for tumor resection, which may imply consent to surgical procedures.\n- The patient's tumor size is 3 cm, which is larger than the specified \"less than 2 cm\" criterion.\n- The patient has invasive ductal breast carcinoma, which meets the criteria for ductal carcinoma. However, the size of the tumor does not meet the criteria, and there is no mention of the cancer being unifocal or multifocal.\n- There is no specific mention of being informed about the sentinel lymph node procedure before surgery in the patient note.\n\nGiven that the patient's tumor size exceeds the specified criterion for the clinical trial, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "108": {
        "output": "To assess the patient's eligibility for the given clinical trial, we must compare the patient's characteristics and condition with the inclusion criteria of the trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is 3 cm (T1c-T3 category)\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to proceed prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patients \u226518 years of age\n- Histologically confirmed invasive unilateral breast cancer\n- Early-stage breast cancer, node-positive disease, or node-negative with a primary tumor >1.0 cm\n- Must have completed definitive loco-regional surgery with histologically free margins of invasive adenocarcinoma and DCIS\n- Must have completed axillary lymph node sampling\n- HER2 negative tumors (confirmed by specific tests)\n- Estrogen receptor-negative (<10% staining by IHC for estrogen receptor)\n- ECOG Performance Status of 0 or 1\n- Within 84 days of having completed definitive primary breast surgery\n- Adequate hematologic, liver, renal, and cardiac function\n- Complete staging work-up \u226412 weeks prior to initiation of study treatment\n- Adequate recovery from recent surgery\n- No evidence of recurrent invasive cancers within the past 5 years (excluding non-invasive cancers)\n- Negative pregnancy test for women of childbearing potential and agreement to use birth control\n- Accessibility for treatment and follow-up\n- Understanding of the investigational nature of the study and written informed consent\n\nComparing the patient's characteristics with the trial's inclusion criteria, there are several points of contention:\n\n1. The patient has HER2-positive breast cancer, whereas the trial requires HER2-negative status.\n2. The patient has metastatic lesions present, which might not be considered \"early-stage\" breast cancer, as no specific mention of metastatic breast cancer is made in the trial's inclusion criteria.\n3. The patient has not yet completed the tumor resection or chemotherapy, so it is unclear if the patient will have adequate recovery from surgery within the required timeframe or if the surgical margins will be free of invasive adenocarcinoma and DCIS.\n\nBased on these factors, the patient does not meet the criteria for the clinical trial due to having HER2-positive status and potentially not being classified as having early-stage breast cancer due to metastatic lesions. Additionally, the patient has not yet completed surgery, which is a prerequisite for entry into the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "109": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The diagnosis is invasive ductal breast carcinoma, not ductal carcinoma in situ (DCIS).\n- The tumor is HER2-positive and ER/PR negative with axillary lymph node involvement and metastatic lesions.\n- The patient is scheduled for tumor resection and is planned to undergo chemotherapy afterward.\n\nClinical Trial Inclusion Criteria:\n- The trial is focused on patients with ductal carcinoma in situ (DCIS) of the breast.\n- Referrals to this trial must be through breast care clinicians only.\n- The patient must not be pregnant or nursing and must have a negative pregnancy test.\n- No contraindications to MRI.\n- No prior surgery to the ipsilateral breast within 2 years.\n- No prior radiotherapy to the ipsilateral breast.\n- No prior cytotoxic regimens.\n\nThe patient in the provided note has invasive ductal carcinoma, not ductal carcinoma in situ (DCIS), which is a specific criterion for the trial. Therefore, based on the disease characteristic requirements, this patient would not be eligible for this particular trial focused on DCIS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "110": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer,\" we need to assess the patient information against the inclusion criteria provided:\n\n1. **Histologically or cytologically confirmed metastatic carcinoma of the breast**: The patient has cytologically confirmed breast cancer with metastatic lesions noted on CXR.\n\n2. **Hormone receptor positive disease**: The patient's tumor is HER2-positive and ER/PR negative, which does not meet the criterion of ER and/or PR positivity as >= 5% staining.\n\n3. **Postmenopausal status**: The patient is described as postmenopausal, which fits the trial's requirement.\n\n4. **Disease recurrence while receiving hormonal therapy or progression following hormonal therapy**: This information is not provided in the patient note.\n\n5. **Measurable or non-measurable disease as per RECIST**: The patient has a 3 cm tumor, which is measurable disease.\n\n6. **ECOG performance status of 0-1**: The patient's performance status is not provided.\n\n7. **Adequate blood counts and liver function**: Specific lab values are not provided in the patient note.\n\n8. **Estimated life expectancy of greater than 6 months**: This is not explicitly stated in the patient note.\n\nThe most critical piece of information that excludes the patient is the hormone receptor status. The trial requires ER and/or PR positivity, while the patient's tumor is ER/PR negative. Therefore, based on the available information, the patient does not meet one of the key inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "111": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- Diagnosis: cytologically confirmed breast cancer.\n- Clinical details: invasive ductal breast carcinoma, HER2-positive, ER/PR negative, 5 positive lymph nodes, metastatic lesions on CXR.\n- The patient is preparing for tumor resection before chemotherapy.\n- No mention of brain/nervous system involvement.\n\nClinical Trial:\n- Title: Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers\n- Inclusion Criteria:\n  - All patients 18 years of age or older.\n  - Patients must sign an informed consent.\n  - Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks.\n\nAssessment:\n- The patient is 18 years of age or older.\n- There is no information on whether the patient has signed an informed consent, but this is a procedural step that could be completed if the patient is otherwise eligible.\n- The patient's health condition is not described in detail, but the note suggests that the patient is in a condition to undergo tumor resection, which may indicate a reasonable overall health status to consider the compassionate use of mifepristone.\n- The title of the trial indicates that it is focused on brain/nervous system and other cancers, and the patient has breast cancer with metastatic involvement, which could potentially make her a candidate for the trial if \"other cancers\" include breast cancer.\n\nHowever, the trial summary or inclusion criteria do not explicitly state that patients with breast cancer are eligible, nor do they specify the types of \"other cancers\" that are included. Therefore, based on the information provided, we cannot definitively determine if the patient's breast cancer qualifies for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "112": {
        "output": "Upon reviewing the patient note and the inclusion and exclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age requirement of the trial.\n- The patient has a confirmed diagnosis of breast cancer, which is relevant to the trial's focus on women who have been diagnosed with breast cancer, ductal carcinoma in situ, and/or atypical ductal hyperplasia.\n- The patient has undergone a core biopsy, indicating that she has had a biopsy, which is a requirement for the trial.\n- The patient is English speaking, which is one of the inclusion criteria.\n- There is no information suggesting the patient is pregnant, breastfeeding, has a significant active medical illness, history of or active liver disease, allergy or sensitivity to cruciferous vegetables, has used oral antibiotics within three months prior to randomization, is on oral steroid therapy, is currently taking valproate acid or SAHA, is currently using supplements or herbal remedies containing sulforaphane, or has received radiation or chemotherapy for the currently-diagnosed disease prior to or during study supplementation.\n\nSince the patient meets the inclusion criteria (diagnostic mammogram, English speaking, and having a biopsy), and none of the exclusion criteria are mentioned as being met, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "113": {
        "output": "Based on the information provided:\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- There is no mention of bladder cancer or any history of tobacco use.\n\nClinical trial:\n- The study is focused on genetic susceptibility to bladder cancer.\n- Inclusion criteria require a histologically confirmed diagnosis of bladder cancer.\n\nSince the patient has breast cancer and not bladder cancer, she does not meet the inclusion criteria for this clinical trial, which specifically requires a diagnosis of bladder cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "114": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient note with the inclusion criteria provided for the trial.\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Diagnosed with breast cancer\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Invasive breast cancer diagnosed by core needle or incisional biopsy\n- Hormone receptor-poor (ER and PgR negative or staining present in =< 10% of invasive cancer cells)\n- HER2-negative (IHC 0-1+ or FISH ratio < 2.0 if IHC 2+)\n- Clinical stage II-III with intent to perform surgical resection after neoadjuvant therapy\n- Target lesion must be >= 1 cm\n- No prior chemotherapy, hormone therapy, or radiation therapy for this cancer\n- No significant bleeding episodes within 6 months of registration\n- No serious or non-healing wound, ulcer, or fracture; no abdominal fistulae, GI perforation, or intra-abdominal abscess within the past 6 months\n- No major surgical procedure within 28 days prior to randomization\n- No baseline neuropathy grade >= 2\n- Zubrod performance status 0-1\n- Non-pregnant and non-nursing women, negative pregnancy test, agreement to use non-hormonal contraception\n- No history of congestive heart failure, myocardial infarction, unstable angina, arterial thrombotic event, stroke/TIA within the past 12 months, uncontrolled hypertension, uncontrolled/symptomatic arrhythmia, or grade II+ peripheral vascular disease\n- LVEF above institutional lower limit of normal\n- Adequate organ and marrow function (specific lab values provided)\n- No >= 2+ proteinuria, unless 24-hour urine collection demonstrates < 1 g of protein/24 hr, or UPC ratio < 1\n\nBased on the patient note and the inclusion criteria, the patient's eligibility can be assessed as follows:\n\n- The patient has invasive ductal breast carcinoma, which is consistent with the trial's requirement for invasive breast cancer.\n- The tumor is HER2-positive, which does not meet the HER2-negative requirement of the trial.\n- The patient's clinical stage is not specified, but the presence of axillary lymph node involvement and metastatic lesions suggest a stage that could be compatible with stage II-III; however, this would need to be clinically confirmed.\n- The patient is a candidate for tumor resection, which aligns with the trial's requirement for surgical intent after neoadjuvant therapy.\n- There is no information suggesting prior chemotherapy, hormone therapy, or radiation therapy for this cancer.\n- The patient's performance status and other health criteria are not provided, so these cannot be evaluated.\n- The patient agrees to undergo surgery prior to chemotherapy, which suggests she may be willing to undergo pretreatment research biopsies as required by the trial.\n\nThe primary disqualifying factor is the HER2 status of the patient's tumor, which does not meet the HER2-negative requirement of the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "115": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection and agrees to undergo surgery prior to chemotherapy\n- ECOG performance status is not explicitly stated but the patient is a candidate for surgery, which suggests a relatively good performance status\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically confirmed metastatic breast carcinoma that is HER2 positive\n- Measurable disease as defined by the RECIST criteria\n- Life expectancy greater than or equal to 6 months\n- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nBased on the patient note, the patient has confirmed HER2 positive metastatic breast carcinoma, which meets the first inclusion criterion. The patient also has measurable disease (a 3 cm tumor and axillary lymph nodes involvement), fulfilling the second inclusion criterion. Additionally, there is no indication that the patient's life expectancy is less than 6 months, so we can reasonably assume the third criterion is met. However, the ECOG performance status is not provided in the patient note. Since the patient is a candidate for tumor resection, it is likely that her performance status would be 0 or 1, meeting the fourth criterion. However, without explicit confirmation of the ECOG performance status, we cannot definitively determine eligibility.\n\nGiven the information provided, the patient appears to meet the inclusion criteria except for the unconfirmed ECOG performance status. Therefore, without further details, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "116": {
        "output": "Based on the provided patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient is scheduled for tumor resection and meets the following inclusion criteria for the clinical trial:\n\n- Diagnosed previously as breast cancer: The patient has invasive ductal breast carcinoma.\n- Patient scheduled for sentinel lymph node dissection: The patient had axillary sampling which revealed 5 positive lymph nodes, suggesting that she is a candidate for further surgical intervention, which could include a sentinel lymph node dissection.\n- 18 years or older: The patient is 45 years old.\n- Female or male: The patient is a female.\n- Able and willing to give consent to participate in the study: It's stated that the patient agrees to undergo tumor resection prior to chemotherapy, which implies a willingness to participate in treatment-related procedures, although consent to the study itself is not explicitly mentioned.\n\nBased on the information given, the patient appears to meet all the inclusion criteria for the GeneSearch\u2122 Breast Lymph Node (BLN) Assay China Registration Study. However, it is important to note that the patient's consent to participate specifically in the study is not explicitly stated in the patient note.\n\nGiven the information provided and assuming that the patient would consent to participate in the study, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "117": {
        "output": "",
        "label": 1
    },
    "118": {
        "output": "To determine the trial-level eligibility for the patient in question, let's assess the patient's characteristics against the inclusion criteria of the clinical trial:\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions present in CXR\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Invasive breast cancer with axillary staging\n- ER and PR analysis must be negative\n- Patient must be \u2265 18 years old\n- If the patient is older than 49 years, she must meet at least one of the following 2 conditions:\n  i. 1-3 histologically positive axillary nodes\n  ii. negative ER and PR analysis (since the patient is not older than 49, this condition is not applicable)\n- Life expectancy of at least 10 years, excluding the diagnosis of breast cancer\n- Tumor must be DCIS or invasive adenocarcinoma of the breast\n- Gross disease must be unifocal with pathologic tumor size 3.0 cm or less\n- Patient must have pathological stage 0, I, or II breast cancer\n- Surgical treatment of the breast must have been lumpectomy with histologically free margins\n- Patient must be registered within 42 days following the last surgery for breast cancer\n- Target lumpectomy cavity/whole breast reference volume must be \u2264 30% based on the postoperative CT scan\n\nComparison:\n- The patient has invasive breast cancer which meets the criteria.\n- ER and PR analysis is negative, which also meets the criteria.\n- The patient is 45 years old, satisfying the age requirement.\n- The patient has more than 3 histologically positive axillary nodes (5 positive nodes), which does not meet the specified criterion of 1-3 positive nodes for patients older than 49. However, since this patient is under 49, the number of positive nodes is not a disqualifying factor based on the provided criteria.\n- The life expectancy is not mentioned, but there is no indication that it is less than 10 years.\n- The tumor is invasive ductal carcinoma, which satisfies the criteria for tumor type.\n- The tumor size is 3.0 cm or less, meeting the size requirement.\n- The pathological stage is not explicitly provided, but the presence of positive lymph nodes and metastatic lesions might suggest a stage beyond II.\n- Surgical treatment plans include tumor resection, but it's not specified if this will be a lumpectomy or not.\n- The time frame for registration post-surgery cannot be determined from the available information.\n- The lumpectomy cavity/whole breast reference volume cannot be assessed without a postoperative CT scan.\n\nBased on the information provided, the patient does not have sufficient information to qualify for the trial, primarily due to the lack of details regarding the pathological stage of the cancer, the type of surgical treatment planned, and the absence of a postoperative CT scan to evaluate the target lumpectomy cavity/whole breast reference volume.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "119": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Detection of Aggressive Breast Tumors Using Tc-99m-NC100692,\" let's review the patient's information against the inclusion criteria:\n\nPatient Information:\n- 45 years old\n- Postmenopausal woman\n- Cytologically confirmed breast cancer\n- Lesion size: 3 cm invasive ductal breast carcinoma\n- Tumor characteristics: HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Scheduled for tumor resection\n\nInclusion Criteria for the Trial:\n- Have a lesion on mammogram, ultrasound, or breast MRI that is considered suggestive or highly suggestive of malignancy (BIRADS 4b, 4c, or 5) and is scheduled for biopsy OR known to be malignant and is scheduled for surgery.\n- Lesion size can be < 15 mm in diameter for biopsy or > 15 mm in diameter if known to be malignant.\n- Patient age > 18 years.\n- Have a negative pregnancy test on the first day of the study, or must be postmenopausal or surgically sterilized.\n\nBased on the information provided:\n\n- The patient's age meets the criteria (> 18 years).\n- The patient is postmenopausal.\n- The patient's tumor is known to be malignant and is scheduled for surgery.\n\nThe patient information does not specify the exact size of the lesion in terms of the imaging criteria provided (e.g., mammogram, ultrasound, or breast MRI sizes). However, it is mentioned that the core biopsy revealed a 3 cm invasive ductal breast carcinoma, which is larger than 15 mm in diameter and is consistent with being \"known to be malignant and is scheduled for surgery.\" This suggests that the patient meets the lesion size criterion for surgery as well.\n\nTherefore, the patient appears to meet all the specified inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "120": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is HER2-positive and ER/PR negative. There are also 5 positive lymph nodes and metastatic lesions noted on CXR. She is a candidate for tumor resection and agrees to do so prior to chemotherapy. She uses multivitamins and iron supplements, does not smoke or consume alcohol, is not sexually active, and has no children.\n\nThe clinical trial is looking for women with newly diagnosed ductal carcinoma in situ or stage I or stage II breast cancer, as well women at risk of developing breast cancer.\n\nBased on the inclusion criteria for the clinical trial, the patient seems to be eligible for the following reasons:\n\n- She has newly diagnosed stage I or II breast cancer (as indicated by the presence of positive lymph nodes and invasive characteristics of the tumor).\n- The patient has not undergone chemotherapy for breast cancer or any other cancer, which fits the trial's requirement of no prior chemotherapy.\n- The patient is postmenopausal, which fits the patient characteristics requirement of the trial.\n- There is no mention of the patient having received estrogen, other hormones, oral contraceptives, selective estrogen receptor modulators, or aromatase inhibitors within the last 3 months, which complies with the trial's exclusion criteria regarding prior/concurrent therapy.\n\nHowever, there are two points that need to be clarified:\n\n1. The trial specifies \"node-negative or node-positive disease\" and the patient has 5 positive lymph nodes, which means she is node-positive.\n2. The trial specifically excludes patients with advanced breast cancer, and the patient has metastatic lesions noted on CXR, which might be considered advanced disease.\n\nSince the clinical trial does not state \"no metastatic breast cancer\" but excludes \"advanced breast cancer,\" and given that metastatic lesions could be interpreted as advanced disease, this could potentially exclude the patient from the trial. However, without a specific definition of \"advanced\" in the context of this trial, there is a degree of ambiguity.\n\nGiven the information provided and the ambiguity around the term \"advanced breast cancer,\" the patient's eligibility for the trial is uncertain. Therefore, the trial-level eligibility based on the information provided would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "121": {
        "output": "To determine the trial-level eligibility for the patient based on the provided clinical trial's inclusion criteria, we need to assess the patient's characteristics and medical history against the criteria listed.\n\nPatient Information Summary:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions observed in CXR\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n- No systemic treatment started\n- No mention of prior invasive cancer diagnosis other than breast cancer\n- Karnofsky performance status is not provided\n- No indication of pregnancy\n- No mention of prior systemic therapy for breast cancer\n\nClinical Trial Inclusion Criteria Summary:\n- Biopsy-confirmed diagnosis of one of the following:\n  - Stage I-IV infiltrating ductal or infiltrating lobular carcinoma\n  - Patients with early-stage disease must not have started systemic treatment; if no systemic treatment is planned, patients must be either preoperative or \u2264 120 days since definitive breast surgery\n  - Patients with locally advanced disease must be scheduled for neoadjuvant chemotherapy prior to initiation of systemic treatment\n  - Ductal carcinoma in situ\n  - Lobular carcinoma in situ\n  - Benign breast disease\n- Karnofsky performance status 50-100%\n- Not pregnant\n- No prior invasive cancer diagnosis within the past 5 years except for squamous cell or basal cell carcinoma of the skin\n- No prior systemic therapy (chemotherapy or hormonal therapy) for patients with stage I-III disease\n\nComparison of Patient Information to Inclusion Criteria:\n- The patient has a biopsy-confirmed diagnosis of invasive ductal breast carcinoma, which fits the disease characteristics required for the trial.\n- There is no mention of prior invasive cancer diagnosis other than breast cancer, which meets the trial criteria.\n- The patient has not started systemic treatment and is a candidate for tumor resection, which aligns with the trial's requirement for early-stage disease patients.\n- The Karnofsky performance status is not mentioned, but there is no indication that the patient would not meet a 50-100% range based on the provided information.\n- The patient is not pregnant, meeting another trial criterion.\n- There is no mention of prior systemic therapy for breast cancer, which aligns with the trial criteria.\n\nBased on the information provided, the patient appears to meet all the mentioned inclusion criteria for the clinical trial. However, there are a few unknowns such as the patient's Karnofsky performance status which is not provided. Given the information we have, it seems that the patient would likely be eligible for the trial assuming her performance status is within the required range. Therefore, based on available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "122": {
        "output": "Based on the information provided:\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- She is undergoing surgery for breast cancer.\n\nClinical trial:\n- The phase I trial is studying genes and proteins in breast tissue from women undergoing surgery for breast cancer or core biopsy of the breast.\n- Inclusion criteria are broad and do not specify beyond the disease characteristics and the procedure of surgery or core biopsy.\n\nSince the patient is undergoing surgery for breast cancer, she meets the disease characteristic inclusion criteria of the clinical trial. There are no other patient characteristics or prior concurrent therapies specified that need to be matched. Therefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "123": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The breast cancer is invasive ductal HER2-positive and ER/PR negative.\n- There are 5 positive lymph nodes after axillary sampling.\n- The patient has metastatic lesions as indicated by CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n- There is no mention of prior endocrine therapy.\n\nClinical Trial Inclusion Criteria:\n- Female postmenopausal patient.\n- Must have undergone primary breast cancer surgery with axillary dissection or lumpectomy/quadrantectomy with breast radiotherapy.\n- Treatment may include radiotherapy, postoperative chemotherapy, and trastuzumab.\n- Pathologic primary invasive carcinoma confirmed by biopsy.\n- Endocrine therapy (letrozole or anastrozole) must start no more than 6 weeks from the end of chemotherapy or radiotherapy.\n- The date of randomization must be 2-3 years after letrozole treatment.\n- Positive lymph node involvement as defined by AJCC Criteria.\n- Hormone receptor-positive tumor, with any detectable estrogen or progesterone receptor expression.\n- Known HER2 status.\n- No evidence of metastatic or recurrent disease at the time of definitive surgery.\n- Postmenopausal status confirmed by age, bilateral oophorectomy, amenorrhea, or hormone levels.\n- WHO performance status of 0 or 1.\n- Adequate blood counts and liver and kidney function.\n\nEligibility Assessment:\n- The patient is female and postmenopausal, which meets the criteria.\n- The tumor is HER2-positive, and HER2 status must be known for the trial, which meets the criteria.\n- The patient has positive lymph nodes and invasive ductal carcinoma, which meets the criteria.\n- The patient is planning to undergo tumor resection, so she will potentially meet the surgical intervention criteria.\n- There's no information on the start of endocrine therapy or the duration of letrozole treatment, which is a critical aspect of the trial inclusion criteria.\n- There's no information on the patient's WHO performance status or laboratory values.\n\nThe patient appears to meet several of the inclusion criteria but there is insufficient information on some crucial aspects, such as the start and duration of endocrine therapy, the performance status, and the laboratory values. Without this information, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "124": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and disease status with the inclusion criteria of the clinical trial.\n\nPatient Characteristics and Disease Status:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed breast cancer, including invasive ductal carcinoma\n- Pathological stage 0-IIIA disease (pTis; pT1-2, N0-N2a, M0)\n- Tumor size \u2264 5 cm\n- Breast considered technically satisfactory for radiotherapy\n- Has undergone lumpectomy or mastectomy and either sentinel node biopsy or axillary dissection\n- Negative inked histological margins or confirmed negative re-excision specimen\n- Unifocal or multifocal disease confined to 1 quadrant\n- No more than 9 positive axillary lymph nodes\n- No distant metastases\n- Pre- or post-menopausal\n- ECOG performance status 0-1\n- No prior radiotherapy for the current breast cancer\n- No chemotherapy prior to radiotherapy as per the specified timeline\n- No other malignancy within the past 5 years except for nonmelanoma skin cancer\n- No collagen vascular disease\n- No psychiatric or addictive disorder that would preclude obtaining informed consent\n\nBased on the patient's information and the clinical trial inclusion criteria, we can determine the following:\n\n- The patient has invasive ductal carcinoma, which is one of the breast cancer subtypes eligible for the trial.\n- The tumor size is within the limit specified (< 5 cm).\n- The patient is a candidate for tumor resection, which could be followed by the radiotherapy mentioned in the trial.\n- The patient is postmenopausal, which is acceptable for the trial.\n- The patient's ECOG performance status is not mentioned, but there is no indication of a severe co-existing medical condition that would limit life expectancy to < 2 years.\n\nHowever, there are significant concerns that would likely exclude the patient from the trial:\n\n- The patient has distant metastases (CXR showed metastatic lesions), which is a disqualifying factor as the trial specifies \"No distant metastases.\"\n- The number of positive axillary lymph nodes may or may not exceed the trial's limit (not more than 9), but the presence of distant metastases is a more definitive exclusion criterion.\n\nGiven the presence of distant metastases, the patient does not meet the trial's inclusion criteria. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "125": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer,\" let's review the inclusion criteria against the patient's note:\n\nInclusion Criteria Review:\n- Women aged \u2265 18 years and < 70 years: The patient is a 45-year-old woman, which meets the age criterion.\n- Karnofsky performance status (KPS) \u2265 70: The patient note does not mention the patient's KPS.\n- At least one measurable disease according to RECIST: The patient has a 3 cm invasive ductal breast carcinoma, which is measurable and meets this criterion.\n- Histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), T2N1 or locally advanced breast cancer (T3-4N0-3 or T0-4N2-3): The patient has invasive ductal breast carcinoma with 5 positive lymph nodes, which meets the criteria for breast cancer stage and the requirement for histological confirmation.\n- Biopsy specimens are available for ER, PgR, and Her2 detection, patients should be with triple-negative or Her2 positive breast cancer: The patient's tumor is HER2-positive and ER/PR negative, making her eligible under this criterion.\n- Adequate bone marrow function: The patient note does not provide information about the patient's bone marrow function.\n- An estimated life expectancy of at least 12 months: The patient note does not comment on the estimated life expectancy.\n- Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up: The patient agrees to tumor resection, which suggests a willingness to undergo procedures, but it is not explicitly stated that the patient is willing to take a biopsy before neoadjuvant chemotherapy.\n- Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study: The patient note does not mention the patient's reproductive status or pregnancy test results.\n- Written informed consent according to GCP: The patient note does not mention if informed consent has been obtained.\n\nBased on the information provided in the patient note, the patient meets several of the inclusion criteria such as age, having measurable breast cancer, and having HER2-positive breast cancer. However, there is insufficient information regarding Karnofsky performance status, bone marrow function, life expectancy, willingness to take biopsy before neoadjuvant chemotherapy, reproductive status, pregnancy test results, and informed consent. Without this information, we cannot conclusively determine her eligibility. Therefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "126": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the trial. Let's examine the patient's details and the inclusion criteria:\n\nPatient's characteristics and condition:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions present (indicative of Stage IV)\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically or cytologically confirmed invasive breast cancer\n- HER2 positive disease is not allowed (excludes the patient)\n- Metastatic breast cancer (Stage IV) is not allowed (excludes the patient)\n- Presence of residual invasive disease on pathologic review following neoadjuvant chemotherapy\n- Various specifications for ER/PR status and stage, depending on neoadjuvant chemotherapy and surgery outcomes\n- No prior exposure to bevacizumab or other inhibitors of angiogenesis\n- Completion of definitive resection of primary tumor\n- LVEF equal to or greater than institutional limits of normal after preoperative chemotherapy\n- ECOG Performance Status 0-1 within 2 weeks of registration\n- 18 years of age or greater\n\nBased on the patient's note and the inclusion criteria:\n\n- The patient has HER2-positive breast cancer, which is not allowed in the trial.\n- The patient has metastatic breast cancer (Stage IV), which is excluded from the trial.\n\nGiven these two exclusion factors, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "127": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for the trial. The trial is focused on patients who have received percutaneous transhepatic biliary drainage (PTBD), which is not mentioned in the patient's note. The patient's note indicates a diagnosis of breast cancer with no mention of any conditions or treatments related to the biliary system.\n\nAs there is no information suggesting that the patient has undergone or will undergo PTBD, the patient does not meet the inclusion criteria for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "128": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is studying the effectiveness of implant radiation therapy compared with radiation therapy during surgery in treating patients with recurrent breast cancer.\n\nTo determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition to the inclusion criteria of the study:\n\n1. Histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies. The patient has invasive ductal breast carcinoma, which matches the criteria.\n\n2. Lesion size \u2264 3 cm treated with a tylectomy and whole breast irradiation (with or without tumor bed boost). The patient has a 3 cm tumor, which fits the size criterion; however, there is no information about prior treatments such as tylectomy or whole breast irradiation, which are required for eligibility.\n\n3. Unifocal breast cancer recurrence. The patient's note does not indicate if the cancer is a recurrence or if it is unifocal.\n\n4. Negative resection margins with at least a 2 mm margin from invasive and in situ cancer or a negative re-excision. The patient is a candidate for tumor resection, but surgery has not yet been performed, and therefore, we do not have information about the resection margins.\n\n5. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following the completion of radiation. The patient is a candidate for chemotherapy, but it is not clear if radiation will be administered before chemotherapy, as per the trial requirements.\n\n6. Signed study-specific informed consent prior to study entry. No information is provided regarding consent, but this is typically obtained after a patient is deemed eligible and agrees to participate.\n\nThe patient's note lacks sufficient information to qualify for the trial, particularly regarding prior treatment history and the specifics of the breast cancer recurrence. Therefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "129": {
        "output": "",
        "label": 0
    },
    "130": {
        "output": "To determine the patient's eligibility for the clinical trial, we must evaluate the provided patient note against the trial's inclusion and exclusion criteria.\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically proven primary invasive breast cancer suitable for neoadjuvant treatment\n- T2 tumor or greater or nodal disease\n- No evidence of distant metastatic disease\n- Definite indication for neoadjuvant and adjuvant chemotherapy\n- Primary tumor amenable to biopsy\n- No inoperable disease, inflammatory breast cancer, bilateral invasive breast cancer\n- HER-2 positivity is not an exclusion criterion\n- ER-positive tumor\n- Postmenopausal status\n- Good performance status (WHO 0 or 1)\n- Adequate blood counts and liver/renal function tests\n- No active, uncontrolled infection\n- No malignancy within the past 10 years except for certain conditions\n- No severe hypersensitivity to aromatase inhibitors or contraindications to their use\n- No other serious illness or medical conditions\n- No contraindications to combination anthracycline/taxane chemotherapy\n- Willing to undergo repeat biopsies\n\nThe patient's breast cancer is confirmed, and she is postmenopausal, which meets some of the inclusion criteria. However, there are several points of non-alignment with the inclusion criteria:\n\n1. The patient's tumor is HER2-positive and ER/PR-negative, while the trial requires an ER-positive tumor.\n2. The patient has evidence of distant metastatic disease as disclosed by CXR, while the trial requires no evidence of distant metastatic disease.\n\nGiven these discrepancies, the patient does not meet the necessary inclusion criteria for the clinical trial. The presence of metastatic lesions and the ER/PR-negative status are significant factors that exclude the patient from this trial.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "131": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and she has positive axillary lymph nodes as indicated by the axillary sampling revealing 5 positive lymph nodes. The clinical trial in question is examining the relationship of pAKT to survival in patients with node-positive breast cancer.\n\nThe inclusion criterion for the clinical trial is quite specific: it requires women who were enrolled in the NSABP B-28 trial from 1995 to 1998 with operable breast cancer and pathologically positive axillary lymph nodes. The patient note does not indicate that this specific patient was enrolled in the NSABP B-28 trial. Without this information, we cannot determine that the patient is eligible for the clinical trial, as the only described inclusion criterion is enrollment in a previous specific trial.\n\nThus, the trial-level eligibility for this patient based on the information given is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "132": {
        "output": "To assess the trial-level eligibility for this patient, we will need to compare the patient's characteristics and cancer status with the inclusion criteria listed for the study.\n\nThe patient note provides the following information:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- The patient has metastatic lesions (CXR indicating metastatic disease).\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe clinical trial inclusion criteria are as follows:\n- Histologically or cytologically confirmed invasive breast cancer (matches the patient's condition).\n- Complete resection of the primary tumor is required (the patient is a candidate for tumor resection, but it has not yet been done).\n- Stage I-III (T1-3, N0-3, M0) disease; however, the patient has metastases, which would be classified as stage IV or M1, not meeting this criterion.\n- Enrolled in clinical trial CAN-NCIC-MA27.\n- No locally recurrent or metastatic breast cancer (the patient does not meet this, as she has metastases).\n- Estrogen receptor- or progesterone receptor-positive disease (the patient's tumor is ER/PR negative, which does not meet this criterion).\n- Postmenopausal status (the patient is postmenopausal, which meets this criterion).\n\nBased on the patient's information and the study's inclusion criteria, the patient does not meet several key eligibility criteria: her breast cancer has metastasized (M1), and her tumor is ER/PR negative, both of which are exclusionary according to the trial's requirements for stage and hormone receptor status. Therefore, the patient is not eligible for the study.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "133": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- Age: 45 years old (within the trial's age range of 40 to 75 years)\n- Diagnosis: Invasive ductal breast carcinoma (aligns with the trial's focus on breast carcinoma)\n- Tumor size: A core biopsy revealed a 3 cm invasive ductal breast carcinoma (the trial requires a size of equal or less than 2.0 cm)\n- Axillary lymph nodes: Axillary sampling revealed 5 positive lymph nodes (the trial requires axillary lymph nodes that cannot be palpated or that are not clinically suspicious for metastasis)\n- Previous therapy: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy (the trial excludes patients with previously executed therapy at any outside institution; it is unclear if the biopsy and planned resection disqualify the patient)\n\nClinical Trial Inclusion Criteria:\n- Age between 40 and 75 years\n- Unicentric carcinoma with an ultrasonographic diameter of equal or less than 2.0 cm\n- Axillary lymph nodes that cannot be palpated or that are not clinically suspicious for metastasis\n- No previously executed therapy (including biopsy) at any outside institution\n\nThe patient does not meet the clinical trial inclusion criteria because the tumor size exceeds the specified 2.0 cm limit, and the patient has positive lymph nodes that have been identified as metastatic, which is contrary to the trial criteria requiring non-palpable or non-suspicious axillary lymph nodes. Additionally, the patient appears to have had a biopsy, which may conflict with the trial's exclusion of any prior therapy at outside institutions, depending on whether the biopsy is considered \"therapy\" and if it was performed outside the institution conducting the trial.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "134": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's review the eligibility of the patient:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive, ER/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n- No mention of prior breast cancer treatment in the affected breast\n- No mention of HIV status, diabetes, gastrointestinal complaints, or hypersensitivity to ritonavir\n- No mention of Karnofsky performance status or organ function tests\n\nClinical Trial Inclusion Criteria:\n- Newly diagnosed biopsy-proven breast cancer for which a lumpectomy or mastectomy is planned (Patient matches)\n- ER+/HER2- or ER+/HER2+ or ER-/HER2+ or ER-/PR+/HER2- or ER-/PR-/HER2- for Phase I Selection (Patient matches the ER-/HER2+ category)\n- Tumor must be greater than 1 centimeter (Patient matches, tumor is 3 cm)\n- No prior treatment for breast cancer in the affected breast (No prior treatment mentioned in the patient note)\n- Karnofsky performance status >70% (No information provided)\n- Adequate organ function for receiving study drug (No information provided)\n- Women of childbearing potential must use contraception (Patient is postmenopausal, so this is not relevant)\n- Voluntary written consent (Assumed if patient agrees to participate)\n- Sufficient tumor tissue from the diagnostic core biopsy (Assumed available since a core biopsy was performed)\n\nClinical Trial Exclusion Criteria:\n- Pregnant or lactating (Patient is postmenopausal and not sexually active, so this does not apply)\n- Known positive HIV status or on medications for HIV (No information provided)\n- Diagnosis of diabetes (No diabetes mentioned)\n- Any pre-existing gastrointestinal complaints (No complaints mentioned)\n- Known hypersensitivity to ritonavir or any of the tablet ingredients (No hypersensitivity mentioned)\n- Co-administration of ritonavir is contraindicated with certain drugs (No information provided on current medication apart from multivitamins and iron supplements)\n\nGiven the information from the patient note, the patient is postmenopausal with a newly diagnosed biopsy-proven HER2-positive breast cancer and a tumor size greater than 1 centimeter. The patient has not received any prior treatment for breast cancer. There is no information provided regarding the Karnofsky performance status or organ function tests, which are required for patient eligibility. Additionally, there is no information on whether the patient is on medications that might contraindicate ritonavir use or if she has any of the conditions listed in the exclusion criteria.\n\nSince the patient's note lacks specific information on some necessary eligibility aspects, such as Karnofsky performance status and adequate organ function, and there is no clear exclusion based on the provided data, the assessment falls under the category of \"Not relevant.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "135": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the study. Let's review the given patient note and the trial inclusion criteria.\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- The tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection\n- Agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patients, age \u226465 years\n- Biopsy-proven lymph node positive, estrogen receptor-positive primary breast cancer\n- Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard regimen (containing anthracycline or paclitaxel)\n- Must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision\n- Postoperative residual positive lymph nodes or G1/G2/G3 of Miller & Payne Grading System\n- Adequate recovery from recent surgery\n- No history of other malignancies\n- No currently uncontrolled diseased or active infection\n- Not pregnant or breastfeeding, and on appropriate birth control if of child-bearing potential\n- Adequate cardiovascular function reserve with a myocardial infarction within the past six month\n- Adequate hematologic function with specific blood count and chemistry requirements\n- Knowledge of the investigational nature of the study and ability to give informed consent\n- Ability and willingness to comply with study procedures\n\nComparing the patient note to the trial inclusion criteria:\n\n- The patient is a 45-year-old woman, which meets the age requirement of \u226465 years.\n- The patient has breast cancer with positive lymph nodes, which meets the requirement of lymph node-positive breast cancer.\n- The patient's tumor is HER2-positive and ER/PR negative, which does not meet the requirement of estrogen receptor-positive primary breast cancer.\n- The patient note does not mention if she has completed any chemotherapy, so we cannot assess if she has completed the required 4-cycle neo-adjuvant chemotherapy.\n- The patient is a candidate for tumor resection, but it is not specified if surgery has occurred yet, and therefore we cannot assess if she meets the surgery requirement.\n- The patient does not appear to have any history of other malignancies, which meets the criteria.\n- There is no mention of an uncontrolled disease, active infection, pregnancy, breastfeeding, or inadequate cardiovascular function, so we cannot assess these criteria.\n- The patient's hematologic, hepatic, and renal functions are not described, so we cannot assess these criteria.\n- The patient's understanding of the investigational nature of the study and willingness to comply is not mentioned.\n\nBased on the available information, the primary disqualifying factor is that the patient's breast cancer is not estrogen receptor-positive. Additionally, there is insufficient information to determine the patient's eligibility regarding chemotherapy history, surgical status, and various health criteria. Therefore, the patient does not meet sufficient inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "136": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nHere are the inclusion criteria for the clinical trial:\n- Signed and dated informed consent prior to participation.\n- Subjects in good health as determined by the Investigator.\n- Age 18-55.\n- Willing to abstain from any physical therapy, hard physical work, exercise or sauna during the study observation period (Screening to Final Visit).\n- For females, subjects of childbearing potential must be using appropriate birth control. Female subjects who are surgically sterile are also allowed for participation.\n\nNow, let's analyze the patient's information:\n- The patient is a 45-year-old postmenopausal woman, which fits the age criterion (18-55).\n- She has cytologically confirmed breast cancer with metastatic lesions, which suggests she may not be in 'good health' as required by the trial.\n- The trial is for the treatment of muscle pain induced by eccentric exercise, not for patients with cancer or undergoing cancer treatment.\n- There is no information to determine whether the patient is willing to abstain from physical therapy, hard physical work, exercise, or sauna during the study observation period.\n- There is no information provided about the use of birth control, but as a postmenopausal woman and not sexually active, it is likely not relevant.\n- The patient is a candidate for tumor resection prior to chemotherapy, which suggests she will be undergoing medical procedures that could conflict with the trial requirements.\n\nBased on the patient's condition (breast cancer with metastatic lesions and planned medical procedures for cancer treatment) and the focus of the clinical trial (treatment of muscle pain in individuals in good health), the patient does not meet the criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "137": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the clinical trial titled \"Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients.\"\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The patient is a candidate for tumor resection and chemotherapy.\n- There is no mention of HIV-1 infection, liver disease, or the need for a liver transplant.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age \u2265 18 (the patient meets this criterion).\n- Documented HIV-1 infection (the patient note does not mention HIV-1 infection).\n- Patient with severe liver failure or eligible for the liver transplant waiting list (the patient note does not mention liver disease or the need for a liver transplant).\n\nSince the patient does not have documented HIV-1 infection, nor is there any indication of severe liver failure or the need for a liver transplant, the patient does not meet the crucial inclusion criteria for the clinical trial regarding the condition being studied (HIV infection and liver disease).\n\nBased on the information provided, the patient is not eligible for the clinical trial because her medical condition (breast cancer) does not align with the target condition of the trial (HIV-1 infection and liver disease).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "138": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. \n\nThe clinical trial in question is looking to assess vaccine responses to novel adjuvanted influenza A(H1N1) vaccines in patients at high risks of influenza A(H1N1) complications. The inclusion criteria for the clinical trial are:\n1. medically recommended influenza A(H1N1) immunization\n2. signed informed consent\n\nThe patient note does not mention influenza A(H1N1) immunization or any indication that the patient is at high risk of influenza A(H1N1) complications. However, patients with metastatic cancer like the one described could be at higher risk for complications from influenza, and thus may be medically recommended for immunization. \n\nHowever, since the patient is not specifically indicated to be at high-risk for influenza A(H1N1) complications or medically recommended for influenza A(H1N1) immunization based on the information provided, and there is no mention of signed informed consent, the patient does not have sufficient information to qualify for the trial based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "139": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This patient note does not mention any psychiatric diagnosis, specifically nothing related to a first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS, which are the diseases targeted by the clinical trial's inclusion criteria.\n\nGiven that the clinical trial is aiming to investigate the efficacy and safety of aripiprazole in patients with first episode psychosis and the patient described does not fit this description, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "140": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient in question has breast cancer, which is not the target condition of the trial. The clinical trial is specifically for patients with metastatic melanoma and has various requirements related to the disease characteristics, prior/concurrent therapy, and patient characteristics that are unrelated to breast cancer.\n\nSince the patient has breast cancer and not melanoma, she does not meet the disease characteristic criteria for this trial. The inclusion criteria specifically mention metastatic melanoma, which is a different type of cancer. Therefore, the patient does not qualify for the trial based on the disease criteria alone, regardless of other factors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "141": {
        "output": "Given the patient note and the clinical trial information provided, let's determine the trial-level eligibility for the patient:\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions evident on CXR\n- Candidate for tumor resection\n- Agrees to tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- A signed informed consent\n- Known or suspected malignancy involving the breast as determined by biopsy, physical examination, or noninvasive imaging studies including plain films, CT, MR, ultrasound, or nuclear medicine imaging\n- Scheduled for routine clinical imaging at the ACB PET/CT facility\n- Participant must be at least 18 years of age\n\nAssessment:\n- The patient is 45 years old, so she meets the age requirement of being at least 18 years of age.\n- The patient has a cytologically confirmed breast cancer, which is a known malignancy involving the breast. This satisfies the requirement of having a known or suspected malignancy determined by biopsy.\n- The clinical trial does not specify any further details that the patient would need to meet, such as specific stages of cancer or previous treatments.\n- The patient note does not mention that the patient is scheduled for routine clinical imaging at the ACB PET/CT facility; however, given the context that she has a confirmed malignancy and is a candidate for tumor resection, it can be inferred that she may be scheduled for or would agree to such imaging as part of her treatment plan.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial, and there is no mention of any exclusion criteria that she would meet. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "142": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\nThe patient is described as:\n- A 45-year-old postmenopausal woman\n- Has cytologically confirmed breast cancer\n- Candidate for tumor resection, and agrees to do so prior to chemotherapy\n\nThe clinical trial's inclusion criteria are:\n- Postmenopausal women with breast cancer eligible for hormonal therapy\n\nGiven this information, the patient matches the inclusion criteria for the clinical trial because she is a postmenopausal woman with breast cancer and is a candidate for tumor resection. The trial seems to be open to patients with early or advanced breast cancer, and since the patient is postmenopausal and has breast cancer, she appears to be eligible for hormonal therapy, which Aromasin (Exemestane) is a part of.\n\nSince there are no additional exclusion criteria provided, and the patient fits the inclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "143": {
        "output": "",
        "label": 2
    },
    "144": {
        "output": "",
        "label": 0
    },
    "145": {
        "output": "The patient note describes a 45-year-old postmenopausal woman with cytologically confirmed HER2-positive, ER/PR-negative invasive ductal breast carcinoma with metastatic lesions and positive lymph nodes. The patient is a candidate for tumor resection and agrees to it prior to chemotherapy. She uses multivitamins and iron supplements and has no history of smoking, alcohol use, sexual activity, or children.\n\nTo determine the trial-level eligibility for the clinical trial studying Pixantrone Dimaleate in treating patients with HER2-negative metastatic breast cancer, we need to compare the patient's characteristics with the inclusion and exclusion criteria of the trial.\n\nInclusion Criteria Checklist:\n- Women or men: Patient is a woman. \u2713\n- \u226518 years of age: Patient is 45 years old. \u2713\n- Histologically or cytologically confirmed adenocarcinoma of the breast and clinical evidence of metastatic breast cancer: Patient has cytologically confirmed breast cancer with metastatic lesions. \u2713\n- Must have been previously treated with anthracycline and/or taxane: No information provided. ?\n- Must have received 2-3 prior chemotherapy treatment regimens: No information provided. ?\n- Patients must have measurable disease: Patient has measurable disease (3 cm tumor, metastatic lesions). \u2713\n- Negative pregnancy test: Not applicable as patient is postmenopausal. \u2713\n- Adequate blood counts and liver/renal function: No information provided. ?\n- LVEF \u226550% and normal EKG: No information provided. ?\n- ECOG Performance Status (PS) of 0, 1, or 2: No information provided. ?\n- Life expectancy >3 months: No information provided. ?\n- Ability to complete questionnaire(s): No information provided. ?\n- Patient has provided written informed consent: No information provided. ?\n- Willingness to return to NCCTG enrolling institution for follow-up: No information provided. ?\n\nExclusion Criteria Checklist:\n- Pregnant or nursing women: Patient is postmenopausal. \u2713\n- HER2 positive breast cancer: Patient has HER2 positive breast cancer. \u2717\n\nBased on the information provided, the patient is excluded from the clinical trial due to having HER2 positive breast cancer, which is explicitly stated in the trial's exclusion criteria. Although not all criteria can be assessed due to missing information, the presence of a disqualifying factor (HER2 positive status) is sufficient for exclusion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "146": {
        "output": "After reviewing the patient note and the clinical trial inclusion and exclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria met:\n- The patient has invasive ductal breast carcinoma, which is listed as one of the histologies allowed in the trial.\n- The patient is a candidate for tumor resection and is willing to undergo the procedure, which is consistent with the trial criteria that require surgery before radiation.\n- The patient's tumor is <= 5 cm, fitting the requirement for the dominant mass size.\n- The trial allows patients regardless of estrogen receptor, progesterone receptor, or Her-2/neu amplification status, so the patient's HER2-positive status is not an issue.\n\nClinical trial exclusion criteria met:\n- The patient has distant metastatic disease detected by radiographic imaging (CXR showing metastatic lesions), which is an exclusion criterion for the trial.\n- The trial excludes patients with distant metastatic disease, which the patient in the note clearly has.\n\nGiven the information provided and based on the exclusion criterion of distant metastatic disease being present, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "147": {
        "output": "",
        "label": 2
    },
    "148": {
        "output": "The patient in the note is a 45-year-old postmenopausal woman with HER2-positive and ER/PR negative invasive ductal breast carcinoma, with a tumor size of 3 cm in the left upper outer quadrant and 5 positive lymph nodes in the axillary sampling. The patient also has metastatic lesions as indicated by CXR. She has not yet received systemic treatment for breast cancer and is a candidate for tumor resection, which she agrees to do prior to chemotherapy.\n\nBased on the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\n- Histologically confirmed breast cancer: Yes, the patient has cytologically confirmed breast cancer.\n- T1c N1-2 or T2 N0-2 disease: The patient has a 3 cm tumor (T2) and positive lymph nodes (N1), which fits the criteria.\n- HER2-positive tumors: Yes, the tumor is HER2-positive.\n- No prior systemic treatment regimens for breast cancer: Yes, the patient has not received systemic treatment yet.\n- Adequate hematologic function: Not specified in the patient note.\n- Serum creatinine concentration: Not specified in the patient note.\n- Bilirubin level: Not specified in the patient note.\n- Normal cardiac function: Not specified in the patient note.\n- Karnofsky performance status 80%: Not specified in the patient note.\n- Age 18 years: Yes, the patient is 45 years old.\n- If of childbearing potential, agrees to comply with effective contraceptive measures and has a negative pregnancy test: The patient is postmenopausal, so this is not applicable.\n- Written informed consent prior to admission to this study: Presumably, the patient can consent if she agrees to participate in the study.\n\nThe patient meets many of the inclusion criteria, but there is insufficient information regarding hematologic function, serum creatinine concentration, bilirubin level, normal cardiac function, and Karnofsky performance status. Without this information, we cannot confirm the patient's eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "149": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we must compare key details to determine the patient's eligibility:\n\nThe patient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive, ER/PR negative invasive ductal breast carcinoma\n- Metastatic lesions observed\n- Candidate for tumor resection, agreeing to do so prior to chemotherapy\n\nThe clinical trial's inclusion criteria:\n- Histologically or cytologically confirmed metastatic invasive mammary carcinoma\n- The primary cancer must be HER2 negative\n- Patients must have circulating tumor cells (CTCs) with HER2 amplification\n- Measurable disease\n- Archival or metastatic tumor tissue available to confirm HER2 status\n- At least 1 prior chemotherapy regimen for metastatic breast cancer or disease progression within 6 months of completing adjuvant chemotherapy\n- 18 years of age or older\n- Life expectancy of greater than 3 months\n- ECOG Performance Status of 0, 1, or 2\n- Normal organ and marrow function\n- Agreement to use adequate contraception if of child-bearing potential\n\nThe patient's HER2-positive status for the primary tumor disqualifies her from the trial, which specifically requires the primary cancer to be HER2 negative. Despite other criteria potentially being met (such as age, measurable disease, and previous treatment), the HER2-positive status is a critical discrepancy with the trial's requirement that the primary cancer must be HER2 negative.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "150": {
        "output": "Based on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed invasive ductal breast cancer that is HER2-positive and ER/PR negative. She has metastatic lesions noted on a CXR and is a candidate for tumor resection prior to chemotherapy.\n\nThe clinical trial in question is observing the median time of treatment duration and the safety of Avastin (bevacizumab) as first-line treatment in patients with metastatic breast cancer. For inclusion in the trial, patients need to have metastatic breast cancer and must have completed treatment with Avastin as their first line of treatment.\n\nThe patient note does not specify that the patient has received any treatment with Avastin, much less completed it as a first-line treatment. Rather, it suggests that she is a candidate for surgery prior to chemotherapy, which implies that she has not yet started any systemic cancer therapy.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial because she has not completed treatment with Avastin, which is a prerequisite for participation in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "151": {
        "output": "To assess the eligibility of the patient for the clinical trial \"BRCA Mutations in Latinas,\" we need to compare the patient's characteristics against the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n1. The patient is a 45-year-old postmenopausal woman.\n2. She has a cytologically confirmed diagnosis of breast cancer.\n3. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n4. There is no mention of her ethnicity.\n\nClinical Trial Inclusion Criteria:\n1. Patient must be self-identified of Hispanic/Latino origin.\n2. Patients must have a histologically or cytologically confirmed diagnosis of breast cancer.\n3. Age greater than or equal to 18 years.\n4. Ability to understand and the willingness to sign a written informed consent document.\n5. Must be willing and able to provide a saliva sample, answer questionnaire data online or complete a paper questionnaire, and request a copy of their pathology report.\n\nClinical Trial Exclusion Criteria:\n1. Males and subjects under the age of 18.\n\nAssessment:\n- The patient meets the age criterion (45 years old).\n- The patient has a confirmed diagnosis of breast cancer.\n- There is no information provided about the patient's ability to consent, willingness to provide a saliva sample, or complete a questionnaire. However, these are actions the patient can perform if willing.\n- There is no information provided about the patient's ethnicity. Since the trial specifically requires participants to be of Hispanic/Latino origin, and this information is not mentioned in the patient note, it's not possible to determine eligibility based on the information provided.\n\nGiven the information in the patient note, it is unclear if the patient is of Hispanic/Latino origin, which is a key inclusion criterion for the trial. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "152": {
        "output": "Let's compare the patient's characteristics with the clinical trial's inclusion criteria:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive\n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection followed by chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed diagnosis of node-positive (1-3 nodes) invasive breast carcinoma\n- Positive estrogen and/or progesterone receptor status, and negative HER-2 status\n- Patients with multifocal, multicentric, and synchronous bilateral breast cancers are allowed\n- Patients will have undergone axillary staging by sentinel node biopsy or axillary lymph node dissection\n- Patients with a prior diagnosis of contralateral DCIS are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation\n- Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy\n- Patients must not have received an aromatase inhibitor or a selective estrogen receptor modulator within 5 years prior to registration\n- No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years\n- Patients must be females \u2265 18 years of age\n- Patients must have a performance status of 0-2 by Zubrod criteria\n- Patients must be able to receive taxane and/or anthracycline-based chemotherapy\n- Recurrence score (RS) by Oncotype DX must be \u2264 25 for Step 2 Registration\n\nBased on the provided information:\n\n- The patient has HER2-positive breast cancer, which is not eligible as the trial requires HER-2 negative status.\n- The patient's ER/PR status is negative, while the trial requires positive estrogen and/or progesterone receptor status.\n- The patient has 5 positive lymph nodes, which exceed the trial's maximum of 3 positive nodes.\n\nGiven these discrepancies, the patient does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "153": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,\" we need to compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nFrom the patient note, we can identify the following relevant information:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed invasive ductal breast carcinoma.\n- The tumor is 3 cm, HER2-positive, and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present (as indicated by CXR).\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nNow, let's review the inclusion criteria of the clinical trial:\n- Life expectancy of at least 10 years, excluding the diagnosis of breast cancer.\n- Agreement to use effective non-hormonal contraception during therapy and for a period after the last dose of study therapy.\n- Submission of tumor samples from the breast surgery is required.\n- Signed and dated IRB-approved consent form.\n- ECOG performance status of 0 or 1.\n- Unilateral invasive adenocarcinoma of the breast.\n- Pathologic evaluation: primary tumor must be pT1-3, ipsilateral nodes pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b.\n- HER2 status of the primary tumor must be evaluated prior to randomization, with specific conditions for HER2-low status.\n- Must have undergone breast-conserving surgery or mastectomy with specific requirements for margins.\n- Completion of certain procedures for evaluation of pathologic nodal status.\n- Interval between the last surgery for breast cancer and randomization no more than 84 days.\n- ER and possibly PgR analysis of the primary tumor prior to randomization.\n- Certain laboratory values for ANC, platelet count, hemoglobin, bilirubin, alkaline phosphatase, AST, and serum creatinine.\n- LVEF assessment within 90 days prior to randomization with specific thresholds for different chemotherapy regimens.\n\nBased on the patient note, the patient seems to meet several criteria: age, willingness to undergo surgery, and the presence of invasive breast carcinoma. However, crucial eligibility information is missing or not matching:\n- The patient has metastatic lesions as indicated by CXR, which suggests the presence of distant metastases not described in the inclusion criteria.\n- The HER2 status of the patient's tumor is HER2-positive, whereas the trial specifies the need for HER2-low status, with particular definitions provided in the criteria.\n\nGiven this information, the patient does not meet the inclusion criteria for HER2 status and potentially has metastatic disease, which is not addressed in the inclusion criteria. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "154": {
        "output": "To assess the eligibility of the patient for the trial titled \"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer,\" we will go through the inclusion criteria provided step by step and compare them with the patient's note.\n\n1. Age \u226518\n   - The patient is 45 years old, so she meets this criterion.\n\n2. Stage IV HER2 (+) breast cancer.\n   - The patient has metastatic lesions as evident by the CXR, which is indicative of Stage IV breast cancer, and the tumor is HER2-positive.\n\n3. Histologically documented HER2 (+) breast cancer.\n   - The patient's core biopsy revealed HER2-positive invasive ductal breast carcinoma.\n\n4. ECOG performance 0 -1 (Appendix A not provided, but this is typically an assessment of the patient's level of functioning).\n   - The patient's ECOG performance status is not mentioned in the note, so we cannot ascertain this from the information provided.\n\n5. 0-1 prior treatment in the metastatic setting.\n   - The patient's note does not mention any prior treatment in the metastatic setting, only that she is a candidate for tumor resection prior to chemotherapy.\n\n6. Measurable or non-measurable disease.\n   - The patient has measurable disease with a 3 cm tumor and positive lymph nodes.\n\n7. LVEF \u2265 50%\n   - The patient's left ventricular ejection fraction (LVEF) is not mentioned in the note, so we cannot ascertain this from the information provided.\n\n8. Hematologic parameters (WBC, ANC, platelets, hemoglobin).\n   - Hematologic parameters are not mentioned in the patient note.\n\n9. Non-hematologic parameters (bilirubin, AST/ALT, alkaline phosphatase).\n   - Non-hematologic parameters are not mentioned in the patient note.\n\n10. Creatinine \u2264 1.5 mg/dl\n    - Creatinine level is not mentioned in the patient note.\n\n11. Patients with stable and treated brain lesions of a duration of \u2265 2 months may be enrolled.\n    - There is no mention of brain lesions in the patient's note.\n\nBased on the information available, the patient meets some of the inclusion criteria (age, Stage IV HER2-positive breast cancer, histologically confirmed HER2-positive status), but there is insufficient information to fully determine eligibility for other criteria, such as ECOG performance status, LVEF, hematologic and non-hematologic parameters, creatinine level, and status of brain lesions if any. Therefore, we must classify the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "155": {
        "output": "",
        "label": 0
    },
    "156": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer,\" let's compare the patient note against the inclusion criteria step by step:\n\n1. Patient must be \u2265 18 years of age\n   - The patient is 45 years old, meeting this criterion.\n\n2. Patient must be a postmenopausal woman, defined by one of the following criteria:\n   - The patient is described as a postmenopausal woman, but we do not have detailed information on which specific condition applies. However, as she is aged 45-59, it is likely one of the conditions applies.\n\n3. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n   - The patient's ECOG performance status is not mentioned in the note.\n\n4. Patient must have histologically or cytologically confirmed invasive breast cancer that is stage IV or metastatic\n   - The patient has cytologically confirmed breast cancer with metastatic lesions, meeting this criterion.\n\n5. Patient must have a representative tumor tissue specimen available; archival tissue is allowed\n   - The note does not specify if tissue is available, but it is likely given the biopsy performed.\n\n6. Either the primary or the metastatic tumor must be positive for estrogen receptor (>= 1% tumor cell staining by immunohistochemistry or an Allred Score of >= 3 by immunohistochemistry)\n   - The patient's tumor is HER2-positive and ER/PR negative, not meeting this criterion.\n\n7. Patient must have at least one site of measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria\n   - The patient has a 3 cm invasive ductal breast carcinoma, which is likely to be considered measurable disease, meeting this criterion.\n\n8. Patient must have had no more than 3 lines of systemic therapy (including endocrine therapy) for metastatic disease to be eligible for phase IB and the last 10 patients of Cohort C; there is no limitation on the numbers of prior systemic therapies for phase IA and the first 2 patients of Cohort C\n   - The patient note does not mention any prior systemic therapy for metastatic disease.\n\n9. Patients who are currently taking fulvestrant without disease progression are eligible\n   - There is no information given about current treatments with fulvestrant.\n\n10. Patient must have adequate organ function as defined by a series of lab value criteria\n    - The patient note does not provide any lab values to confirm this.\n\nGiven the information provided, the patient does not meet one of the key inclusion criteria (being estrogen receptor-positive). Even though we lack some details, the failure to meet this critical criterion is sufficient to determine the patient's trial eligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "157": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Adjuvant AI Combined With Zoladex,\" we must assess the patient's characteristics and medical history against the inclusion criteria of the trial.\n\nHere are the key points from the patient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal carcinoma, 3 cm in size, located in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present.\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, let's compare this with the clinical trial's inclusion criteria:\n- All patients must have signed and dated an informed consent form (assumed to be possible for this patient).\n- Patients must be female (the patient is female).\n- Primary invasive breast cancer pathologically approved by core needle or open biopsy (the patient has this).\n- Ipsilateral axillary or internal mammary nodes positive, or tumor size is equal to or larger than 4cm (the patient has positive nodes but the tumor size is 3 cm, not \u22654 cm).\n- Patients must have undergone standard surgery for primary breast cancer (the patient is a candidate for tumor resection).\n- Treatment for confirmed breast cancer including surgery, radiotherapy, chemotherapy, and adjuvant endocrine therapy (the patient agrees to tumor resection prior to chemotherapy).\n- The date of randomization must be processed after taking TAM or Fareston for 2 or more than 2 years, but not more than 3 years of time (there is no information on this for the patient).\n- Patients must be premenopausal as defined by the criteria (the patient is postmenopausal).\n- Patients must have an ECOG performance status of 0 or 1 (no information provided).\n- Blood count and chemistry requirements (no information provided).\n- Patients can swallow pills (assumed to be possible for this patient).\n- Pregnancy testing is negative and are willing to do contraception during the treatment period (the patient is postmenopausal, so this is not applicable).\n\nThe patient does not meet the trial's inclusion criteria for being premenopausal. The requirement is clearly stated that patients must be premenopausal, and this patient is described as postmenopausal. Additionally, there is no information about the patient's use of TAM or Fareston, nor their ECOG performance status or blood counts. However, the postmenopausal status alone is sufficient to determine ineligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "158": {
        "output": "",
        "label": 0
    },
    "159": {
        "output": "",
        "label": 0
    },
    "160": {
        "output": "Based on the patient note provided:\n\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive, and ER/PR-negative.\n- She has metastatic lesions.\n- She is a candidate for tumor resection and agrees to proceed with it prior to chemotherapy.\n\nNow, comparing this to the clinical trial inclusion criteria:\n\n- The patient is 21 years of age or older. (Met)\n- Must sign informed consent. (Assumed to be met if the patient agrees to participate)\n- The participant has a breast biopsy consistent with Ductal Carcinoma in situ (DCIS). (Not Met - the patient has invasive ductal carcinoma, not DCIS)\n- Performance Status: ECOG 0-1 unless mobility is limited from chronic physical handicap. (Not enough information provided)\n- No clinical evidence of other malignancies (except Basal Cell carcinoma). (Met - no other malignancies are mentioned)\n- Complete blood count, differential, and platelet count must be WNL or verified to be related to conditions not interfering with normal health status. (Not enough information provided)\n- Adequate hepatic and renal function. (Not enough information provided)\n- Normal fasting glucose. (Not enough information provided)\n- No history of diabetes. (Met, no history of diabetes mentioned)\n- Medically and Psychologically able to comply with all study requirements. (Assumed to be met)\n- Accessible for Follow up. (Assumed to be met)\n\nThe key issue here is that the patient does not have DCIS, which is a requirement for the clinical trial. The trial is specifically for DCIS, and the patient has invasive ductal carcinoma, which is a different stage of breast cancer. Therefore, based on the information provided, the patient does not meet the trial inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "161": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial step by step:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has a diagnosis of invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of invasive breast cancer or DCIS.\n- Appropriate for genetic testing based on several criteria.\n- Must be a primary malignancy (not a recurrence), but can be a second diagnosis if it is a contralateral cancer and the first cancer was not treated with mastectomy.\n- Female age \u226518.\n- Criteria for genetic testing apply, but not all need to be met.\n- Have not completed definitive surgical treatment.\n- For patients planning mastectomy for treatment, has not yet undergone mastectomy.\n- For patients planning breast conservation for treatment, has not yet begun adjuvant radiation therapy.\n\nAssessment:\n- The patient is female and over 18 years of age, which meets the criteria.\n- The patient has a diagnosis of invasive breast cancer, which meets the criteria.\n- The patient has not yet completed definitive surgical treatment (planning to undergo tumor resection), which meets the criteria.\n- The patient note does not mention a prior history of breast cancer, so we must assume this is a primary malignancy, meeting the criteria.\n- The patient's ethnicity is not mentioned, so we cannot assess genetic testing criteria based on Ashkenazi Jewish descent. However, the criteria also state that patients may be appropriate for genetic testing even if they do not meet these specific criteria.\n\nGiven the information from the patient note, the patient appears to meet the inclusion criteria for the clinical trial. There is no information provided in the patient note that would exclude the patient based on the trial's inclusion criteria. Therefore, the patient would be considered eligible based on the available information.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "162": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 45 years old\n- Diagnosis: Invasive ductal breast carcinoma (IDBC), HER2-positive, ER/PR-negative\n- Tumor size: 3 cm\n- Treatment: Candidate for tumor resection, no mention of neoadjuvant therapy yet\n- Other: Postmenopausal status, 5 positive lymph nodes, metastatic lesions on CXR\n\nClinical Trial Inclusion Criteria:\n1. Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy.\n2. Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required.\n3. Residual tumor size \u2264 2.0 cm in greatest diameter after neoadjuvant therapy.\n4. Tumor enhancement on pre-registration MRI.\n5. Tumor with <25% intraductal components.\n6. Adequate breast size for safe cryoablation.\n7. Patients with prior in-situ or invasive breast carcinomas are eligible if in the contralateral breast. Prior ipsilateral carcinomas are not eligible.\n\nComparison:\n- The patient has invasive ductal breast carcinoma, which is eligible under criteria 1.\n- There is no indication that the patient has received neoadjuvant therapy, which is required according to criteria 2. The patient is a candidate for tumor resection prior to chemotherapy, which implies neoadjuvant therapy has not yet been administered.\n- The patient's tumor size is 3 cm, which exceeds the maximum residual tumor size of 2 cm specified in the criteria 3.\n- There is no mention of tumor enhancement on MRI or the percentage of intraductal components of the tumor, so we cannot assess criteria 4 and 5.\n- There is no information regarding the adequacy of breast size for safe cryoablation, so we cannot assess criteria 6.\n- The patient does not have a history of prior breast carcinoma as per the provided information, which meets criteria 7.\n\nBased on the information provided, the patient does not meet the inclusion criteria for neoadjuvant therapy or the residual tumor size requirement. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "163": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which matches the requirement for the trial that participants be female patients aged 18 years or older. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative, which fits the trial's inclusion of patients with histologically confirmed breast cancer prior to surgery. The staging of the cancer with 5 positive lymph nodes and metastatic lesions noted on CXR could correspond to one of the included stages, as the trial includes patients with staging criteria T1-T3, T4a, T4b, N0-N2, N3a, and M0 (excluding T1N0M0). However, the presence of metastatic lesions (implied by the mention of CXR) suggests that the patient may have metastatic breast cancer (stage M1), which is beyond the inclusion criteria of the trial as it specifies M0, indicating no distant metastasis.\n\nThe patient note does not provide information on the specifics of the neoadjuvant chemotherapy received, only that the patient is a candidate for tumor resection, which suggests that she has not yet received neoadjuvant treatment. Therefore, she does not meet the criterion of having completed a minimum of 4 cycles of neoadjuvant chemotherapy.\n\nFurthermore, the patient has not undergone breast surgery yet, as she is only a candidate for tumor resection at this point, so she cannot meet the requirement of being \u2265 21 days and \u2264 84 days from breast surgery and fully recovered.\n\nGiven the patient's metastatic lesions and the lack of information regarding the completion of neoadjuvant chemotherapy, as well as the fact that breast surgery has not yet occurred, the patient does not meet several key inclusion criteria for the clinical trial.\n\nTherefore, the appropriate scale for the assessment of this patient's eligibility for the clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "164": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial:\n\nThe patient is a 45-year-old postmenopausal woman, which matches the inclusion criteria of being a postmenopausal woman.\n\nThe patient has a diagnosis of invasive ductal breast carcinoma, which fits the inclusion criterion for \"diagnosis of early stage, invasive ductal carcinoma.\"\n\nHowever, the patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria specify that the tumor should be ER/PR positive. \n\nSince the patient's tumor does not meet the hormone receptor status requirement (ER/PR positive), the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "165": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This aligns with the age criterion (\u226518 years) for the clinical trial.\n\nThe tumor is HER2-positive and ER/PR negative, which matches the trial's requirement for histologically confirmed HER2 positive (defined as FISH amplification ratio more than 2.2) invasive carcinoma of the breast with locally recurrent or metastatic disease.\n\nThe patient has metastatic lesions, as indicated by the CXR, which is consistent with the trial's requirement for patients with FDG-PET positive metastatic lesions.\n\nThe patient is not reported to have brain metastases as the sole site of metastatic disease, which is compliant with the study's criteria. However, it is not specified whether any brain metastases are present and controlled, which is a part of the inclusion criteria.\n\nThere is no mention of the patient's Eastern Cooperative Oncology Group (ECOG) performance status (PS), which is required to be 0 to 1 for eligibility.\n\nThe patient is a woman of childbearing potential, but there is no information on whether she agrees to use a non-hormonal form of contraception, which is a requirement for the trial.\n\nThe patient agrees to tumor resection prior to chemotherapy, which suggests a willingness to participate in medical procedures, but there is no explicit statement regarding her agreement to participate in the imaging study or to biopsy accessible lesions as required by the trial.\n\nThere is no information provided regarding a signed written informed consent, which is necessary for participation in the study.\n\nThere is no indication that the patient meets any of the exclusion criteria, such as severe uncontrolled systemic disease, pregnancy, lactation, known infections with HIV, HBV, or HCV, known severe hypersensitivity to trastuzumab, psychiatric illness, or recent lapatinib use.\n\nGiven the available information, the patient appears to meet some of the inclusion criteria (age, confirmed HER2 positive breast cancer, metastatic lesions). However, there is insufficient information about the ECOG performance status, agreement to use contraception, consent to participate in the imaging study and biopsy, and signed informed consent. As a result, we cannot definitively determine if the patient is fully eligible without this additional information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "166": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nInclusion Criteria for the Clinical Trial:\n1. Women or men with histologic evidence of invasive breast cancer (ductal, lobular or mixed disease).\n2. Surgical resection including breast conserving surgery or modified radical mastectomy or simple mastectomy, within the last four months.\n3. Axillary lymph nodes assessed for tumor by:\n   (i) sentinel node biopsy, or \n   (ii) axillary node dissection, or \n   (iii) both\n4. Axillary lymph node assessment negative for cancer, or positive only for micrometastases (i.e., cancer <2mm by H&E stain).\n5. Tumor is estrogen receptor (ER) positive.\n6. Receiving or to receive adjuvant endocrine therapy (i.e., tamoxifen or aromatase inhibitor).\n7. Being considered for adjuvant chemotherapy.\n\nPatient's Information:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nBased on the patient's information and the clinical trial's inclusion criteria, we can make the following observations:\n- The patient has invasive ductal breast carcinoma, which meets criterion 1.\n- The patient is a candidate for tumor resection, but there is no information about whether the surgery has already been performed or the timeline, so we cannot fully assess criterion 2.\n- The patient has 5 positive lymph nodes, which does not meet criterion 4, as the trial specifies axillary lymph node assessment negative for cancer, or positive only for micrometastases (cancer <2mm by H&E stain).\n- The patient's tumor is ER/PR negative, which does not meet criterion 5 that requires the tumor to be ER positive.\n- There is no information provided about adjuvant endocrine therapy or whether the patient is being considered for adjuvant chemotherapy, so we cannot fully assess criteria 6 and 7.\n\nGiven the information provided, the patient does not meet the trial's inclusion criteria regarding the ER status of the tumor and the axillary lymph node status. Thus, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "167": {
        "output": "",
        "label": 0
    },
    "168": {
        "output": "",
        "label": 0
    },
    "169": {
        "output": "",
        "label": 0
    },
    "170": {
        "output": "To determine the patient's eligibility for the \"MINT I Multi-Institutional Neo-adjuvant Therapy MammaPrint Project I\" clinical trial, we must compare the provided patient note with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of \u2265 18 years.\n- The patient has histologically confirmed invasive ductal breast carcinoma, which is consistent with the requirement for invasive breast cancer.\n- The patient has 5 positive lymph nodes, indicating nodal involvement.\n- The clinical note does not mention the size of the tumor in centimeters but does say it is 3 cm, which could potentially meet the T2 classification requirement.\n- The patient has distant metastases, as indicated by the presence of metastatic lesions on the CXR.\n- The note does not provide information regarding bone marrow reserves, renal function, hepatic function, or signed informed consent.\n\nClinical Trial Inclusion Criteria Analysis:\n- Women with histologically proven invasive breast cancer and no distant metastases.\n- Lymph node negative or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4.\n- Age \u2265 18 years.\n- At least one lesion that can be accurately measured in two dimensions.\n- Adequate bone marrow, renal, and hepatic function.\n- Signed informed consent of the patient.\n\nBased on the provided information, the patient does not meet the following inclusion criteria:\n- The patient has distant metastases, as indicated by metastatic lesions on the CXR, which exclude the patient from the trial since the inclusion criteria specifically state \"no distant metastases.\"\n- The patient has 5 positive lymph nodes, which exceed the specified range of 1-3 positive lymph nodes for inclusion.\n\nGiven this information, the patient is not eligible for the trial due to not meeting the inclusion criteria regarding distant metastases and the number of positive lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "171": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion (>18 years old).\n- The patient has cytologically confirmed breast cancer, meeting the requirement of having invasive breast cancer.\n- The patient's cancer involves the axillary lymph nodes, with 5 positive nodes found, which may suggest that a sentinel node (SN) procedure could be indicated.\n- There is no information regarding the size of the tumor in the context of the T stage (T1-2), but it is mentioned that the tumor is 3 cm, which generally falls within the T1 or T2 classification.\n- The patient has metastatic lesions, which may or may not affect the eligibility depending on the specifics of the trial's inclusion/exclusion criteria not fully provided.\n- The patient has social security coverage.\n\nClinical Trial Inclusion Criteria:\n- Patients aged over 18 years old (the patient is 45 years old).\n- Patients with invasive breast cancer with an indication of SN procedure (the patient has invasive breast cancer and positive lymph nodes, which might suggest an indication for SN procedure).\n- T1-2 breast cancer (the patient has a 3 cm tumor, likely to be either T1 or T2).\n- Patients having social security coverage (the patient has social security coverage).\n\nGiven the information provided, the patient appears to meet the age requirement, has invasive breast cancer, and has social security coverage. However, there is insufficient information to determine if the patient's indication for an SN procedure aligns with the guidelines of Saint-Paul de VENCE from 2005 amended in 2009. Additionally, the presence of metastatic lesions in the patient's case may impact eligibility, but this cannot be determined without further specifics from the trial's exclusion criteria.\n\nTherefore, based on the available information, the patient's eligibility for the trial cannot be conclusively determined without additional details. This leads to the assessment:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "172": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient's tumor is invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative, and there are 5 positive lymph nodes in the axillary sampling. The patient also has metastatic lesions as revealed by CXR.\n\nNow, let's compare this to the inclusion and exclusion criteria of the clinical trial:\n\nInclusion criteria met by the patient:\n- Signed informed consent (assuming the patient agrees)\n- Social security coverage (not specified, but let's assume this is the case)\n- Age between 18 and 80 years (the patient is 45 years old)\n- Histologically proven breast cancer (confirmed)\n- Localised breast cancer with or without axillary or subclavicular lymph node involvement (the patient has axillary lymph node involvement)\n- Treatment by neoadjuvant chemotherapy (the patient is a candidate for chemotherapy)\n- Patient amenable to receiving adjuvant therapy (assuming the patient agrees)\n- Breast surgery planned after neoadjuvant chemotherapy (the patient agrees to tumor resection)\n\nExclusion criteria met by the patient:\n- Metastatic breast cancer (the patient has metastatic lesions as revealed by CXR)\n\nThe patient meets the inclusion criteria but is excluded from the trial based on the presence of metastatic breast cancer, which is an exclusion criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "173": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- The patient has metastatic lesions (suggesting advanced or metastatic breast cancer).\n\nThe inclusion criteria for the clinical trial are:\n- Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer.\n- Progression on or after endocrine treatment.\n- Measurable disease as per RECIST.\n- ECOG 0, 1 or 2.\n\nThe patient's characteristics are compared to the inclusion criteria as follows:\n- The patient is postmenopausal, which matches the inclusion criterion.\n- The patient's cancer is HER2-positive, which does not match the HER2- requirement.\n- There is no information provided on hormone receptor status (HR+ or HR-) in the patient note, but the trial requires HR+ status.\n- There is no indication of prior endocrine treatment for the patient, which is a requirement for the trial.\n- The patient does have measurable disease, as indicated by metastatic lesions on CXR.\n- There is no information on the patient's ECOG performance status.\n\nThe patient does not meet all the inclusion criteria for the clinical trial because her tumor is HER2-positive, which does not align with the HER2- requirement for the trial. Additionally, the patient's hormone receptor status and prior endocrine treatment history are not provided, and these are necessary to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "174": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- She has not started chemotherapy and is planning to undergo tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Male or Female > 18 years.\n- Newly diagnosed stage I-IV breast cancer as defined by the AJCC classification.\n- No prior therapy (other than surgery) for current disease.\n- Written informed consent (if required by local regulations).\n\nComparison:\n- The patient is over 18 years of age.\n- She has newly diagnosed stage I-IV breast cancer (metastatic lesions suggest stage IV).\n- She has not received any prior therapy for the current disease, except for the planned surgery, which is allowed.\n- The patient note does not mention whether she has given written informed consent, but we can assume this is a procedural step that can be completed if all other criteria are met.\n\nBased on the available information, the patient appears to meet all the listed inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "175": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion and exclusion criteria of the trial:\n\nPatient information:\n- Age: 45 years (meets age inclusion criteria of \u2265 40 years)\n- Gender: Female (meets gender inclusion criteria)\n- Breast cancer diagnosis: Yes, with cytologically confirmed breast cancer and a 3 cm invasive ductal carcinoma, HER2-positive, and ER/PR negative\n- Life expectancy: No information provided to suggest a life expectancy of less than 5 years\n- Foci of breast cancer: One focus of invasive breast carcinoma is mentioned (a 3 cm tumor); no information on additional foci or separation by normal breast tissue\n- Axillary involvement: Positive lymph nodes (meets staging cN1)\n- ECOG Performance Status: No information provided, but the patient is a candidate for surgery, which suggests a PS of 0, 1, or 2\n- Ability to complete questionnaires: No information provided, but nothing suggests an inability\n- Informed consent: The patient agrees to surgery, suggesting they are willing to provide consent\n- Willing to return to enrolling institution: No information provided\n- Exclusion criteria to consider:\n  - Metastatic disease: CXR reveals metastatic lesions, which excludes the patient\n  - Prior history of ipsilateral breast cancer: No information provided, but nothing suggests a prior history\n  - Staging of cancer: cN1 disease is mentioned, which is eligible\n  - Evidence of metastatic disease: Yes, CXR shows metastatic lesions, which leads to exclusion\n  - Other active malignancies: No information provided\n\nGiven the information provided, the patient does not meet all the inclusion criteria due to a lack of detail on the exact foci of breast cancer and separation by normal breast tissue. However, the exclusion criteria are met due to the presence of metastatic lesions revealed by CXR, which excludes the patient from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "176": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- The patient has metastatic lesions.\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Informed consent form signed by the patient to accept study enrollment.\n- Female with pathologically confirmed diagnosis of primary invasive operable breast cancer, stage IIa-IIIc.\n- Triple negative phenotype patients (RE and PR of less than 1% of stained cells by IHQ, IHC for HER2 of 0-1+ or ISH negative if 2/3+).\n- Age 18-75 years.\n- Adequate performance status (ECOG <2).\n- Adequate renal and liver function and bone marrow reserve.\n\nComparison:\n- The patient's age falls within the range required by the trial (18-75 years).\n- The patient is female and has a pathologically confirmed diagnosis of breast cancer.\n- The performance status of the patient is not mentioned, but the patient's agreement to undergo tumor resection suggests that she may have a reasonable performance status.\n- Adequate renal, liver function, and bone marrow reserve are not mentioned, and we would need that information to fully determine eligibility.\n\nHowever, the patient has HER2-positive breast cancer, which does not meet the trial's criteria for a triple negative phenotype (the trial requires HER2 0-1+ by IHC or ISH negative if 2/3+). Since the patient's tumor is HER2-positive, this does not align with the triple negative requirement of the trial.\n\nTherefore, based on the information provided, the patient does not meet the trial's requirement for a triple negative phenotype, which is a critical inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "177": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Assessment:\n- The patient is a 45-year-old postmenopausal woman which satisfies the age criterion (Age \u2265 18 years).\n- She has cytologically confirmed breast cancer (The patient must have histologically confirmed HER2 positive invasive carcinoma of the breast).\n- The tumor is HER2-positive and ER/PR negative, meeting the HER2 positive criteria.\n- She has metastatic lesions (The patient must have documented progressive disease and present with at least 2 non-bone target metastatic lesions).\n- There is no mention of the patient's performance status (ECOG PS 0 to 1), but given she is a candidate for tumor resection, it could be inferred that her performance status might be adequate. However, without explicit confirmation, this remains an assumption.\n- The patient agrees to tumor resection, which could be considered analogous to agreeing to a concurrent biopsy of a metastatic site (A concurrent biopsy of a metastatic site is mandatory).\n- No explicit information is provided regarding the patient's organ function, cardiac history, or compliance with the study protocol, which are part of the inclusion criteria.\n- The patient does not smoke or consume alcohol and has no children, which may indicate no psychological, familial, sociological, or geographical conditions potentially hampering compliance, but this is not explicitly stated.\n- It is not mentioned if the patient is using any form of contraception or if a pregnancy test has been done, which is a requirement for women of childbearing potential.\n- There is no information about written informed consent being obtained.\n\nGiven the available information, the patient meets several of the inclusion criteria (age, HER2 positive status, presence of metastatic lesions). However, there is insufficient information to determine if all inclusion criteria are met, particularly regarding performance status, organ function tests, cardiac history, compliance conditions, and written informed consent.\n\nTherefore, the patient's trial-level eligibility based on the available information would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "178": {
        "output": "Based on the patient's characteristics and the inclusion criteria of the clinical trial titled \"Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer,\" let's determine the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman (within age range of trial criteria)\n- Cytologically confirmed breast cancer (matches trial criteria for invasive breast cancer confirmed by core biopsy)\n- 3 cm invasive ductal breast carcinoma (matches trial criteria for tumor \u22652 cm)\n- HER2-positive and ER/PR negative (does not match trial criteria which require ER/PR positive and HER2 negative)\n- Axillary sampling revealed 5 positive lymph nodes (lymph node positive matches trial criteria)\n- No mention of previous treatment for breast cancer in the patient's note (since it is not mentioned, we must assume there was no previous treatment, which would match the trial criteria)\n- No information on liver, kidney, and blood tests or performance status (cannot determine eligibility based on these criteria due to lack of information)\n- No information on fasting glucose levels (cannot determine eligibility based on this criterion due to lack of information)\n- Willing to undergo tumor resection before chemotherapy (matches trial criteria for no previous treatment for breast cancer)\n- Signed consent can be assumed since the patient agrees to tumor resection prior to chemotherapy (matches trial criteria for signed consent)\n\nThe critical point of ineligibility for this trial is the patient's tumor markers. The trial specifically requires participants to have ER/PR positive and HER2 negative breast cancer, while the patient has HER2-positive and ER/PR negative breast cancer. All other inclusion criteria appear to be met, or there is insufficient information to determine eligibility.\n\nBased on this assessment, the patient does not meet the critical inclusion criterion regarding the tumor's hormone receptor status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "179": {
        "output": "After reviewing the patient's information and the clinical trial criteria, here's the assessment:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive, ER/PR negative breast carcinoma\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (implied by \"CXR was remarkable for metastatic lesions.\")\n- Candidate for tumor resection\n\nClinical Trial Criteria:\n- Age \u226518 years\n- Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary bladder\n- T2 to T4 disease, N0 M0 determined by CT imaging and biopsy or transurethral resection\n- ECOG Performance status 0 or 1\n- Glomerular filtration rate (GFR) \u226560ml/min.\n- Written, informed consent\n- Exclusion criteria include lymph node involvement or metastatic disease\n\nThe patient does not meet the inclusion criteria because she does not have transitional cell carcinoma of the urinary bladder, which is a requirement for the trial. Instead, she has breast cancer, which is not the focus of the Bristol Bladder Trial. Additionally, the patient has metastatic lesions, which would exclude her from the trial even if she did have TCC of the bladder, as the trial excludes individuals with lymph node involvement or metastatic disease.\n\nBased on this information, the patient is not a match for the clinical trial's requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "180": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor size 3 cm\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions noted on CXR\n- No history of chemotherapy or radiotherapy for the current breast cancer mentioned\n- Willing to undergo tumor resection\n\nClinical trial inclusion criteria:\n- Women or men > age 18\n- Ability to give informed consent\n- Archived tumor tissue must be available for genetic analysis\n- Patients with early-stage or locally advanced/metastatic breast cancer\n- Histologic documentation of invasive breast cancer\n- The invasive cancer must be triple-negative or HER2-positive\n- Clinical Stage II-III for early-stage or Stage III-IV for advanced/metastatic disease\n- Treatment plan includes neoadjuvant chemotherapy and surgery for early-stage disease, or DNA-damaging chemotherapy for advanced/metastatic disease\n- No prior chemotherapy, endocrine therapy, or radiotherapy with therapeutic intent for a prior malignancy\n\nThe patient is above 18 years of age, has a histologically confirmed invasive breast cancer, and the tumor is HER2-positive which fits the criteria for the trial. The patient has also not started chemotherapy or radiotherapy for the current breast cancer, which is in line with the criteria. The tumor resection is planned which aligns with the intent to treat with surgical resection after neoadjuvant chemotherapy as per the trial requirements. Furthermore, the patient has metastatic lesions which would classify her as having advanced/metastatic disease, making her fit the criteria for Stage III-IV breast cancer patients within the trial.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "181": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The cancer is invasive ductal carcinoma, HER2-positive, and ER/PR negative, with metastatic lesions and positive lymph nodes. The patient is a candidate for tumor resection and chemotherapy.\n\nThe clinical trial is looking to evaluate novel protein biomarkers in tumor specimens using advanced quantitative mass spectrometry (Super SILAC) and to compare the protein profile between different subtypes of breast cancer (ER positive, HER2 positive, triple negative).\n\nThe inclusion criteria for the clinical trial state that patients with breast cancer are eligible to participate.\n\nSince the patient has breast cancer and there is no further specificity in the inclusion criteria that would exclude her, she meets the inclusion criteria for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial, as no exclusion criteria have been provided, and the patient\u2019s condition matches the broad inclusion criterion of having breast cancer.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "182": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer,\" we need to compare the patient's characteristics and condition with the inclusion criteria provided for the trial.\n\nHere are the inclusion criteria for the trial:\n\n1. Invasive non-lobular breast cancer, histologically proven by biopsy.\n2. Tumour T2 - T3 regardless of nodal status, stemming from a primary surgery, in whom FDG-PET is performed for staging.\n3. Age greater than or equal to 18 years.\n4. Good condition: WHO lower 2.\n5. Women receiving effective contraception throughout the duration of treatment and 3 months after cessation of treatment.\n6. Patient has signed informed consent.\n\nNow let's assess the patient note:\n\n1. The patient is a 45-year-old postmenopausal woman, which meets the age criterion.\n2. She has cytologically confirmed breast cancer, and the tumor is invasive ductal carcinoma, which meets criterion 1 for the study.\n3. The tumor size is 3 cm, which is consistent with a T2 classification (2-5 cm in size), meeting criterion 2.\n4. It is not clearly stated whether the patient's general condition corresponds to WHO lower 2, but given that she is a candidate for tumor resection, it is likely that she is in a condition good enough for surgery, which suggests she meets criterion 4.\n5. As the patient is postmenopausal and not sexually active, the criterion about contraception may not be directly applicable, but it can still be assumed that she meets this requirement as there is no risk of pregnancy.\n6. It is not indicated whether the patient has signed informed consent, but this is a procedural step that can be completed if all other inclusion criteria are met.\n\nBased on the information provided, the patient appears to meet all the inclusion criteria for the clinical trial. Therefore, the patient seems eligible for the trial, assuming she provides informed consent.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "183": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient's characteristics and medical history:\n- 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histological confirmation of primary breast cancer, stage II or III, completely resected\n- Prior diagnosis of HER-2 positive primary breast cancer\n- Completion of surgery +/- radiation at least 30 days prior to registration\n- Must have received mastectomy or lumpectomy plus radiation\n- Must have received neoadjuvant and/or adjuvant chemotherapy for breast cancer\n- Must have received neoadjuvant and/or adjuvant trastuzumab for breast cancer\n- All chemotherapy, trastuzumab, and/or corticosteroids completed at least 90 days prior to registration\n- Clinically without evidence of disease recurrence/progression\n- Specific laboratory values met\n- Negative pregnancy test for women of childbearing potential\n- Capable of understanding and providing informed consent\n- Willing to return to enrolling institution for study visits\n- Willing to employ adequate contraception\n- Willing to provide blood samples\n- ECOG Performance Status (PS) 0 or 1\n- Willing to receive a tetanus vaccination if not had one within the past year\n\nBased on the patient's information, the patient has cytologically confirmed HER2-positive breast cancer and is a candidate for tumor resection, agreeing to surgery prior to chemotherapy. However, to be eligible for the trial, the patient must have already completed surgery and potentially radiation, and must have received specific treatments (chemotherapy and trastuzumab) with a clear period of 90 days before registration. Also, there must be no evidence of disease recurrence/progression.\n\nThe patient note does not provide information on whether the patient has already undergone surgery, radiation, or received the required treatments, nor does it mention the current disease status regarding recurrence or progression.\n\nGiven the lack of information on whether the patient has completed all required treatments and the status of the disease after these treatments, we cannot ascertain eligibility. Therefore, we classify the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "184": {
        "output": "To assess the eligibility of the patient for the clinical trial, we need to compare the patient\u2019s characteristics and condition with the inclusion criteria provided for the trial.\n\nPatient Note Analysis:\n1. The patient is a 45-year-old postmenopausal woman.\n2. She has cytologically confirmed breast cancer.\n3. Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n4. The tumor is HER2-positive and ER/PR negative.\n5. Axillary sampling revealed 5 positive lymph nodes.\n6. CXR was remarkable for metastatic lesions.\n7. The patient has not undergone chemotherapy, hormonal therapy, or radiation therapy.\n8. The patient is a candidate for tumor resection and agrees to proceed prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n1. Previously untreated invasive breast cancer (no chemotherapy, hormonal, or radiation therapy).\n2. Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS.\n3. Age \u2265 18 years.\n4. Only female patients are eligible.\n5. Tumor \u2265 1.0 cm by MRI and/or sonographic or clinical exam measurements, or biopsy-proven lymph node metastasis.\n6. Performance status ECOG \u2264 2 or Karnofsky \u2265 50%.\n7. Peripheral neuropathy \u2264 grade 1.\n8. Hematologic and hepatic function within specified ranges.\n9. Negative pregnancy test for women of childbearing potential.\n10. Willingness to consent to use effective contraception during the treatment and for at least 3 months thereafter.\n11. Adequate renal function as measured by UPC ratio or urine dipstick.\n\nComparison:\n- The patient is 45 years old and female, satisfying the age and gender criteria.\n- The patient has been diagnosed with invasive ductal breast carcinoma, which meets the diagnosis criteria.\n- The patient has not received any chemotherapy, hormonal therapy, or radiation therapy, which aligns with the criteria for previous treatment.\n- The tumor size is 3 cm, which exceeds the 1.0 cm minimum requirement.\n- There is no mention of the patient\u2019s performance status, peripheral neuropathy, or specific hematologic, hepatic, and renal functions, so these factors cannot be assessed from the information given. However, the patient is a candidate for tumor resection, which may imply an acceptable performance status.\n- The patient does not smoke or consume alcohol, which is not specified in the inclusion criteria but is generally favorable for treatment.\n- There is no mention of a pregnancy test or willingness to use contraception, but given that the patient is postmenopausal, this may not be relevant.\n\nGiven the information provided, the patient appears to meet many of the inclusion criteria for the clinical trial. However, there is insufficient information on certain eligibility aspects such as performance status, peripheral neuropathy, specific lab values, and willingness to use contraception. Therefore, based on the available information, the patient\u2019s trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "185": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Early Recovery After Gastric Cancer Surgery,\" here is the assessment:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showing metastatic lesions\n- The patient is a candidate for tumor resection before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Patients diagnosed with gastric adenocarcinoma\n- 65 years old and below\n- Patients expected to undergo distal subtotal gastrectomy\n- No complication by gastric cancer\n- No synchronous metastatic lesions\n- Laparoscopic or robotic surgery\n- Informed consent\n\nThe patient in the note has invasive ductal breast carcinoma, not gastric adenocarcinoma. Additionally, the clinical trial is focused on patients with gastric cancer who are going to undergo surgery specifically for that cancer, without complications or metastatic lesions. The patient described in the note has metastatic lesions and is dealing with a different type of cancer (breast cancer).\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on gastric cancer surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "186": {
        "output": "The patient note outlines the following characteristics:\n\n- The patient is a 45-year-old postmenopausal woman.\n- Diagnosis: cytologically confirmed breast cancer.\n- Histology: invasive ductal breast carcinoma, HER2-positive, ER/PR negative.\n- Tumor size: 3 cm.\n- Axillary sampling: 5 positive lymph nodes.\n- Metastatic lesions present on CXR.\n- The patient is pre-surgical for the tumor (planned resection before chemotherapy).\n\nThe clinical trial's inclusion criteria are:\n\n- The patient must consent to be in the study.\n- Patient must be > 50 years old.\n- The patient should have a life expectancy of at least two years with a Karnofsky performance status > 70.\n- The patient must have stage 0 or I breast cancer.\n- Histological examination: DCIS or invasive adenocarcinoma of the breast.\n- Surgical treatment with lumpectomy and histologically tumor-free margins (>2mm).\n- Gross disease must be unifocal with pathologic tumor size 2 cm or less.\n- Axillary staging is required for patients with invasive breast cancer.\n- Simulation within 8 weeks/56 days of final surgery for breast cancer.\n- Disease-free for 2 or more years if a history of non-ipsilateral breast malignancies (with exceptions).\n- Chemotherapy permitted if planned for \u2265 2 weeks after radiation.\n- Negative urine pregnancy test for applicable women.\n- Separate incisions for lumpectomy and sentinel node biopsy.\n- The patient must have a cavity which can be targeted with external beam APBI.\n\nComparison of the patient's characteristics with the clinical trial's inclusion criteria:\n\n- Age: Patient is 45 years old, trial requires > 50 years old.\n- Life expectancy and performance status: Not mentioned in the patient note.\n- Stage of cancer: Patient has metastatic lesions, indicating a stage beyond I.\n- Histology: The patient has invasive ductal carcinoma, which is eligible, but HER2-positive status is not specified in the inclusion criteria.\n- Tumor size: The patient's tumor is 3 cm, which exceeds the trial's limit of 2 cm or less.\n- Surgical treatment: The patient is a candidate for tumor resection, but the type of surgery (lumpectomy) has not been performed yet.\n- Axillary staging: The patient note indicates 5 positive lymph nodes, but does not specify the type of axillary staging done.\n- Timing of simulation: The patient is pre-surgical, so this criterion has not been met.\n- Previous malignancies: No history mentioned in the patient note.\n- Chemotherapy: Not yet started, but no indication it will adhere to the trial's requirement of being \u2265 2 weeks after radiation.\n- Urine pregnancy test: Not applicable as the patient is postmenopausal.\n- Separate incisions for surgery: Not mentioned in the patient note.\n- Cavity targeting with APBI: Not applicable as the patient is pre-surgical.\n\nBased on the comparison, the patient does not meet the age requirement, has a more advanced stage of cancer than allowed, and exceeds the tumor size limit. Other criteria cannot be confirmed due to a lack of information in the patient note.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "187": {
        "output": "To determine the trial-level eligibility, let's compare the patient's characteristics with the study's inclusion criteria:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Karnofsky \u2265 70 (not provided in patient note)\n- Provision of informed consent (the patient agrees to surgery, which indicates a willingness to undergo treatment, but explicit consent for the trial is not mentioned)\n- Pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive (the patient has invasive ductal carcinoma, but it is ER/PR negative, not positive)\n- Tumor stage(TNM): T2-4bN0-3M0 (the patient's tumor is T2-4 due to size and nodal involvement, but there's evidence of metastatic lesions, which could indicate a stage beyond M0)\n- Premenopausal woman (the patient is postmenopausal)\n- Not previously received treatment with bisphosphonate (not mentioned in patient note)\n- Laboratory criteria (not provided in patient note)\n\nFrom the information provided, the patient does not meet the following inclusion criteria:\n- Estrogen receptor must be positive (the patient's tumor is ER/PR negative)\n- Must be premenopausal (the patient is postmenopausal)\n- Tumor stage must be M0 (the patient has metastatic lesions, indicating a stage beyond M0)\n\nThese mismatches with the inclusion criteria suggest that the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "188": {
        "output": "",
        "label": 0
    },
    "189": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is looking for patients with unresectable (stage III) and/or metastatic (stage IV) melanoma or metastatic Merkel cell carcinoma.\n\nTo determine the patient's trial-level eligibility, let's compare the patient's characteristics to the inclusion and exclusion criteria of the clinical trial:\n\nInclusion criteria for the clinical trial:\n- Patients must have histologically or cytologically confirmed unresectable (stage III) and/or metastatic (stage IV) melanoma or unresectable and/or metastatic Merkel cell carcinoma.\n- Melanoma patients should have no mutation in BRAF and NRAS genes.\n- Patients should have lesions that can be biopsied, in addition measurable and non-measurable metastatic lesions and at 1 lesion suitable for 18FDG-PET scan or CT/MRI.\n- ECOG Performance Status of 0 or 1.\n- Presence of measurable or non-measurable disease according to RECIST 1.0.\n- Adequate organ function.\n\nExclusion criteria for the clinical trial:\n- Various criteria that do not directly apply to the patient based on the information provided.\n\nThe patient has breast cancer, which is not one of the conditions listed in the inclusion criteria (melanoma or Merkel cell carcinoma). Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nBased on this information, the patient does not have the type of cancer that the trial is studying, which means she is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "190": {
        "output": "",
        "label": 0
    },
    "191": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, let's compare the patient's information to the inclusion criteria of the trial:\n\n1. Patients with histologically proven invasive breast cancer - the patient has cytologically confirmed breast cancer, which meets this criterion.\n2. The primary tumor size is at least 5cm or cytologically proven axillary node metastasis - the patient has a 3 cm invasive ductal breast carcinoma and axillary sampling revealed 5 positive lymph nodes, which satisfies the second part of this criterion.\n3. No evidence of systemic metastasis pathologically or radiologically - the patient's CXR was remarkable for metastatic lesions, which indicates systemic metastasis, and therefore does not meet this criterion.\n4. Age at the time of diagnosis between 20 and 70 years - the patient is 45 years old, which meets this criterion.\n5. Patients with previously untreated primary breast cancer including chemotherapy - the patient note does not mention any prior treatment, so this criterion is potentially met, assuming no treatment has occurred yet.\n6. General performance status with ECOG 0-2 - there is no mention of the patient's ECOG performance status in the note, so we cannot confirm this.\n7. Sufficient hematopoietic function - without lab values, we cannot confirm this.\n8. Sufficient renal function - without lab values, we cannot confirm this.\n9. Sufficient liver function - without lab values, we cannot confirm this.\n10. Sufficient cardiac function - without cardiac function tests, we cannot confirm this.\n11. Patients who agree to enroll this clinical trial and sign the written informed consent voluntarily - the patient agrees to tumor resection prior to chemotherapy, which suggests a willingness to undergo treatment, but this does not confirm consent to this specific trial.\n\nThe patient does not meet one of the key inclusion criteria (no evidence of systemic metastasis pathologically or radiologically), as they have metastatic lesions according to the CXR. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "192": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Dose Dense TC + Pegfilgrastim Support for Breast Cancer,\" we must compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions evident on CXR\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n- No mention of smoking, alcohol consumption, sexual activity, or children\n- Uses multivitamins and iron supplements\n\nClinical trial inclusion criteria:\n- Histologically confirmed invasive carcinoma of the female breast\n- Status post definitive surgery (lumpectomy or mastectomy plus nodal evaluation if feasible)\n- Must initiate therapy within 84 days of the last surgery for curative intent\n- Candidate for chemotherapy by the treating oncologist\n- N2 or N3 disease must be reviewed before enrollment\n- Bilateral, synchronous invasive breast cancer is eligible if both tumors meet criteria\n- ER/PR negative or positive tumors are eligible\n- HER2 positive or negative disease is eligible, HER2 positive requires trastuzumab following chemotherapy\n- Negative surgical margins for invasive cancer and DCIS (LCIS at margin is acceptable)\n- Multi-centric breast cancer is eligible if all known disease is resected with negative margins\n- Age >18 years\n- ECOG performance status \u2264 1\n- Women of childbearing potential must not be pregnant or nursing and must agree to contraception\n- Must have negative pregnancy test\n- Ability to understand and sign informed consent\n- Platelets >/=100,000/\u03bcl within 4 weeks of registration\n- ANC >/= 1,500/\u03bcl within 4 weeks of registration\n- Total bilirubin within normal limits within 4 weeks of registration\n- Alkaline phosphatase \u2264 2.5 X ULN within 4 weeks of registration\n- AST/ALT \u2264 1.5X ULN\n- Creatinine within normal limits OR Creatinine clearance >/= 60 mL/min/1.73 m^2 for creatinine above normal\n- If patient has received tamoxifen or SERM for prevention or other indications, they have been discontinued prior to enrollment\n\nBased on the patient note, the patient meets several of the inclusion criteria:\n- She has histologically confirmed invasive carcinoma of the breast.\n- She is a candidate for tumor resection, which suggests she could be status post definitive surgery if she agrees to undergo it prior to chemotherapy.\n- Her age is >18 years.\n- She has HER2-positive disease and is therefore eligible for the trial; however, she will need trastuzumab following chemotherapy.\n\nHowever, there are some details missing from the patient note that are necessary to fully determine eligibility:\n- There is no mention of the ECOG performance status.\n- No lab values are provided, so we cannot assess platelets, ANC, bilirubin, alkaline phosphatase, AST/ALT, and creatinine levels.\n- It is not stated whether the patient has undergone surgery yet, which is a requirement to initiate therapy within 84 days post-surgery.\n- There is no information on whether she has negative surgical margins.\n- It is not mentioned whether she has discontinued any SERM if she was taking it.\n\nDue to the lack of information on the ECOG performance status, laboratory values, confirmation of surgery completion, and the status of surgical margins, we cannot confirm that the patient is eligible. Therefore, based on the current patient note provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "193": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer\", we will compare the patient's characteristics and medical history with the inclusion and exclusion criteria provided.\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- HER2-positive\n- ER/PR-negative\n- Presence of metastatic lesions\n- Positive lymph nodes (5 positive axillary nodes)\n- Candidate for tumor resection, prior to chemotherapy\n\nClinical trial inclusion criteria of relevance:\n- Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative HER2 status.\n\nBased on the information provided, the patient does not meet the primary disease characteristic inclusion criteria for the clinical trial. The patient has a HER2-positive status, which is contrary to the requirement of the trial for the breast cancer to be HER2-negative. Additionally, the ER/PR status is negative, while the trial requires positive ER and/or PR status. The trial also excludes patients with metastatic breast cancer (stage IV), and the patient note indicates the presence of metastatic lesions on CXR, which suggests metastatic disease.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "194": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer,\" we will compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Pathologically confirmed invasive ductal breast carcinoma\n- HER2-positive and ER/PR-negative\n- Metastatic lesions present (Stage IV disease)\n- Candidate for tumor resection, no prior systemic treatment mentioned for metastatic setting\n- Using multivitamins and iron supplements\n- No smoking or alcohol consumption\n- No children, not sexually active\n\nClinical trial inclusion criteria:\n- Pathologically confirmed diagnosis of invasive breast cancer. (Patient meets this criterion)\n- Stage IV disease. (Patient meets this criterion - metastatic lesions present)\n- Documented HER2 and hormonal receptor status per protocol. (Patient meets this criterion - HER2-positive and ER/PR-negative)\n- ECOG Performance status 0-1. (No information provided about ECOG Performance status)\n- Measurable disease per RECIST (1.1). (No information provided about the measurability of the disease per RECIST)\n- Adequate hematological function per protocol. (No information provided about hematological function)\n- Adequate hepatic function per protocol. (No information provided about hepatic function)\n- Adequate renal function per protocol. (No information provided about renal function)\n- Negative serum pregnancy test at study entry for patients of childbearing potential. (Assuming since the patient is postmenopausal, this is likely not an issue, but it is not explicitly mentioned)\n- Ability to understand and sign written consent and to comply with the study protocol. (Assuming the patient can comply as she agrees to tumor resection, but this is not explicitly mentioned)\n\nBased on the above information, the patient meets several key inclusion criteria: confirmed diagnosis of invasive breast cancer, stage IV disease, and documented HER2 and hormonal receptor status. However, there is insufficient information to fully ascertain her eligibility, as details regarding ECOG Performance status, measurability of disease per RECIST, hematological, hepatic, and renal function are not provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "195": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Single Fraction Intraoperative Radiotherapy,\" we need to compare the patient's characteristics and condition with the inclusion criteria provided for the trial.\n\nHere are the inclusion criteria for the trial:\n- Histologically proven invasive breast carcinoma ductal, lobular, and/or Ductal Carcinoma in situ\n- Age > 40 years\n- Karnofsky performance status > 70%\n- Tumor: Single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm\n- Nodal Status: preoperatively N0\n- Clear surgical margins: R0\n- All grades G1 - G3\n- Any hormonal receptor and HER-2 status\n- Informed consent\n\nNow let's analyze the patient's note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. (age > 40 years, meets criteria)\n- The core biopsy revealed a 3 cm invasive ductal breast carcinoma. (the tumor exceeds the maximum dimension of 2.5 cm, does not meet criteria)\n- Axillary sampling revealed 5 positive lymph nodes. (Nodal status is not N0, does not meet criteria)\n- The patient is willing to undergo tumor resection. (indicates willingness to consent, meets criteria)\n- Other factors such as Karnofsky performance status, clear surgical margins, and tumor grade are not mentioned in the patient note, so we cannot assess those.\n\nGiven that the tumor size exceeds the specified maximum and the nodal status is not N0, the patient does not meet at least two of the inclusion criteria for the trial.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "196": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient appears to meet the requirements for the clinical trial. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which is metastatic as indicated by the presence of metastatic lesions on the CXR. The trial is looking for female patients with metastatic breast cancer who are at least 18 years old. There is no upper age limit mentioned, and the patient's age falls within this range.\n\nThe trial does not specify any additional inclusion criteria that the patient must meet, nor does it list any exclusion criteria. Given the information provided, the patient seems to fit the inclusion criteria for the non-interventional study with Nab-Paclitaxel (Abraxane\u00ae).\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "197": {
        "output": "In this scenario, we need to compare the patient's characteristics to the inclusion criteria of the clinical trial to determine her eligibility.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma (HER2-positive and ER/PR negative)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Ability and willingness to sign a written informed consent document\n- Histologic diagnosis of locally unresectable, metastatic melanoma\n- Any BRAF status is permitted\n- Any prior therapy is permitted except prior therapy with ipilimumab\n- At least 2 distinct measurable metastatic sites, with one of at least 1 cm or larger\n- Adequate organ and marrow function as defined by initial lab tests\n- Performance status ECOG 0-1 or Karnofsky > 50%\n- Men and women, ages > 18 years old\n- Life expectancy > 3 months\n- Stable brain metastases for at least 4 weeks and not steroid dependent\n- Women of childbearing potential must be using contraception\n\nThe patient in question has a diagnosis of breast cancer, not metastatic melanoma, which is a requirement for the clinical trial. Therefore, the patient does not meet the essential inclusion criteria for a diagnosis of metastatic melanoma.\n\nGiven the information provided, we can determine that the patient is not eligible for this clinical trial based on the diagnosis alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "198": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Study of Ipilimumab in the Immune System,\" we need to assess whether the patient fits the criteria for inclusion in the study.\n\nPatient Note Summary:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma (HER2-positive, ER/PR-negative)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria Summary:\n- Written informed consent\n- Previously untreated Stage III (unresectable) or Stage IV melanoma with at least 2 metastatic lesions\n- At least 1 additional RECIST measurable lesion must be present\n- Subjects with asymptomatic or previously treated brain metastases must show 30-day stability\n- At least 28 days since treatment with surgery, radiation, or immunotherapy and recovered from toxicity\n- ECOG performance status of 0 or 1\n- Life expectancy of \u2265 16 weeks\n- Baseline radiographic images available\n- Specific initial laboratory test values required\n- No active or chronic infection with HIV, Hepatitis B, or Hepatitis C\n- Men and women, \u2265 18 years of age\n- Negative pregnancy test for women of childbearing potential\n\nComparison:\n- The patient has cytologically confirmed breast cancer, not melanoma as required by the trial.\n- The patient has not been described as having melanoma or the specific metastatic lesions as required by the study.\n- The patient's performance status, life expectancy, and laboratory values are not mentioned, and so cannot be assessed for eligibility based on these criteria.\n- The trial is specifically for melanoma patients, and the patient has breast cancer.\n\nBased on the available information, the patient does not meet the disease-specific criteria for the clinical trial, as the trial requires participants to have melanoma, and the patient has breast cancer. Therefore, the patient is not eligible for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "199": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery,\" we must compare the patient's characteristics to the inclusion criteria of the trial.\n\nHere are the inclusion criteria from the trial:\n1. Invasive mammary cancer confirmed by core needle biopsy (specific histologic types mentioned, invasive lobular cancer excluded)\n2. Age >= 50 years and postmenopausal with no menses for at least one year prior to study enrollment\n3. Specific criteria for age and invasive breast cancer clinical size (Age > 70 years with invasive cancer <= 3 cm; Age 50 - 70 years with invasive cancer <= 1.5 cm; Any postmenopausal age with DCIS <= 1.5 cm)\n4. Hormone receptor status (Estrogen or progesterone receptor positive or Estrogen and progesterone receptor negative and clinical tumor size <= 1.0 cm)\n5. HER2/neu negative on core biopsy analysis\n6. Tumor >= 0.5 cm from skin\n7. Unicentric tumor\n8. Axillary lymph nodes negative by examination and pathologic examination from surgery for invasive disease\n9. Negative surgical margins from margin evaluation\n\nNow, let's assess the patient's details:\n1. The patient has invasive ductal breast carcinoma confirmed by core biopsy, which meets the criteria of invasive mammary cancer.\n2. The patient is 45 years old, which does not meet the age criteria of being 50 years or older.\n3. The clinical size of the tumor is 3 cm, which does not meet the specified size criteria for her age group (should be <= 1.5 cm for age 50 - 70 years).\n4. The hormone receptor status is HER2-positive and ER/PR negative. This does not meet the criteria, as HER2 should be negative.\n5. There is no information about the tumor's distance from the skin.\n6. There is no information about whether the tumor is unicentric.\n7. The patient has 5 positive lymph nodes, which does not meet the criteria of axillary lymph nodes being negative.\n8. There is no information about the surgical margins.\n\nBased on the available information, the patient does not meet the age criteria, has a larger tumor size than allowed for her age group, has a positive HER2 status, and has positive axillary lymph nodes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "200": {
        "output": "",
        "label": 0
    },
    "201": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be a candidate for the trial mentioned.\n\nThe clinical trial is focused on patients with ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease, requiring multivessel stenting or staged percutaneous coronary intervention with Zotarolimus-eluting stents.\n\nThe patient in the note has breast cancer with confirmed metastatic lesions, but there is no mention of her having STEMI or coronary artery disease, which are the primary conditions required for participation in the trial. The treatment under investigation in the trial (multivessel stenting or staged revascularization with Zotarolimus-eluting stent) is not relevant to her condition.\n\nTherefore, the patient does not meet the inclusion criteria based on the disease under study and the intervention being tested.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "202": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed HER2-positive metastatic breast cancer, which fits the clinical trial's target population. The trial is seeking female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer, which the patient meets given her age and metastatic condition as evidenced by the presence of metastatic lesions on her CXR. The patient also has a documented metastatic disease with known date and histologically confirmed HER2+ breast cancer, which corresponds with the trial's inclusion criteria.\n\nBased on the information provided, the patient meets all the inclusion criteria specified by the clinical trial:\n\n- Female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer: The patient is 45 years old and has metastatic breast cancer.\n- Patients with a diagnosis of breast cancer with documented metastatic disease and with known date of metastatic disease: The patient's CXR showed metastatic lesions.\n- Patients with a histologically confirmed HER2+ breast cancer: The patient's tumor is reported to be HER2-positive based on a core biopsy.\n\nThere is no mention of any exclusion criteria in the clinical trial description.\n\nGiven this information, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "203": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Pre Operative Trastuzumab in Operable Breast Cancer,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient characteristics:\n- Female\n- 45 years old\n- Postmenopausal\n- Histologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- Tumor size: 3 cm (falls under T2 category)\n- HER2-positive\n- ER/PR-negative\n- Axillary sampling: 5 positive lymph nodes (indicating N1)\n- Metastatic lesions evident on CXR (chest x-ray)\n\nClinical trial inclusion criteria:\n- Female subjects aged 18 years or older: The patient is 45 years old, so she meets this criterion.\n- Histologically and/or cytologically confirmed diagnosis of breast cancer: The patient's breast cancer is confirmed histologically.\n- Clinical stages breast cancer: HER2 positive, T1 or T2 or T3, N0 or N1, resectable T4, or resectable N2, (all M0): The patient has T2, N1 breast cancer, which falls within the required stage. However, the presence of metastatic lesions (as indicated by the CXR) suggests that the patient may not be M0 (no distant metastasis), which is a requirement for the trial. The M0 status is essential for eligibility.\n- Documentation of erbB-2 gene amplification or overexpression: The patient's tumor is HER2-positive, which likely indicates erbB-2 overexpression.\n- LVEF within institutional range of normal: There is no information about the patient's left ventricular ejection fraction (LVEF).\n- Screening laboratory values within specified parameters: No information is provided about the patient's laboratory values.\n\nBased on the available information, the patient does not meet all the required inclusion criteria because:\n- There is evidence of metastatic disease (M1), while the trial requires M0 status.\n- LVEF status is unknown.\n- No laboratory values are provided to confirm eligibility.\n\nTherefore, the patient does not qualify for the trial based on the presence of metastatic lesions and the lack of information regarding LVEF and laboratory values.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "204": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer,\" we need to compare the patient's characteristics and cancer details with the inclusion criteria of the trial:\n\nInclusion Criteria:\n- Postmenopausal state\n- Histological diagnosis of breast invasive ductal carcinoma with receptor profiles obtained\n- MRI visible breast lesion\n- Unifocal cancer, less than 1.5 cm in maximum diameter (clinical stage T1), with no evidence of extensive in situ cancer surrounding the main tumor; eligibility determined by MR imaging\n- Clinical stage N0 (no metastatic axillary lymph node on physical examination or imaging work-up)\n- Ability to give informed consent\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman, which meets the postmenopausal state criteria.\n- She has a histological diagnosis of breast invasive ductal carcinoma, HER2-positive and ER/PR negative, aligning with the requirement for a histological diagnosis of breast invasive ductal carcinoma with receptor profiles.\n- The tumor is 3 cm in diameter, which exceeds the maximum diameter of 1.5 cm as per the trial criteria.\n- The patient has 5 positive lymph nodes, which indicates metastatic axillary lymph nodes and does not meet the Clinical stage N0 criteria.\n- The patient is able to give informed consent, which is one of the inclusion criteria.\n\nBased on the information provided, the patient does not meet the trial's inclusion criteria for the tumor size (maximum diameter of 1.5 cm) and the presence of positive lymph nodes (Clinical stage N0 requirement). Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "205": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical trial:\n- Title: Ultrasound Detection of Peripheral IV Infiltration\n- Inclusion Criteria: 18 years or older, signed consent, health form approved by professional practitioner\n\nThe patient is over 18 years old, which meets the age requirement of the clinical trial. However, there is no information provided regarding whether the patient has signed consent or whether they have a health form approved by a professional practitioner. Without this information, we cannot confirm the patient's eligibility for the trial.\n\nTherefore, the assessment of eligibility is 1) Not relevant, as there is insufficient information to determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "206": {
        "output": "Based on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions observed in a CXR. She is also a candidate for tumor resection and agrees to undergo the surgery prior to chemotherapy.\n\nAccording to the clinical trial's inclusion criteria, the trial is seeking female patients with metastatic breast cancer who are 21 or older and have suspected progression of metastatic disease.\n\nThe patient in the note fits the inclusion criteria as follows:\n- She is a female patient with breast cancer.\n- She has confirmed metastatic lesions.\n- She is 45 years old, which is above the minimum age requirement of 21.\n\nSince the patient meets all the stated inclusion criteria for the clinical trial, she is eligible to participate.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "207": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Patients must be greater than or equal to 18 years of age. (Patient is 45, meets this criterion)\n- Patients must have a newly diagnosed invasive ductal breast carcinoma, Stage I-II. (Patient has invasive ductal breast carcinoma, but the presence of metastatic lesions and positive lymph nodes may suggest a stage higher than II)\n- Patients who have completed their surgical and radiation therapy. (Patient agrees to tumor resection prior to chemotherapy, but has not completed surgery yet)\n- Patients must have SWOG performance status of 0, 1 or 2. (No information provided on SWOG performance status)\n- Patients must have adequate organ function as defined by certain laboratory values. (No information provided on laboratory values)\n- Patients must have a serum calcium - phosphate product that is less than 70. (No information provided)\n- Patients must have recovered from any prior surgery. (Patient has not yet undergone surgery)\n- Patients must be willing to use appropriate contraception if of child-bearing potential. (Patient is postmenopausal, so this may not be applicable)\n- Patients may be on standard of care maintenance dose Vit D3 (Patient is using multivitamins, but no specific mention of Vitamin D3 dosage)\n\nBased on the available information, the patient does not meet the criteria of having completed surgical and radiation therapy as she has agreed to undergo tumor resection prior to chemotherapy. Additionally, the stage of her breast cancer is not explicitly stated, but the presence of metastatic lesions and positive lymph nodes could suggest a stage higher than II, which would not meet the trial's criteria for Stage I-II breast cancer.\n\nTherefore, the patient does not have sufficient information to qualify for the trial, and based on the information provided, she may not meet some of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "208": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the patient note, the breast cancer is HER2-positive and ER/PR negative, and the patient has metastatic lesions.\n\nThe clinical trial's inclusion criteria specify that the study is looking for women with triple negative metastatic breast cancer, where triple negative is defined as estrogen, progesterone, and HER2 (tested by IHC or FISH) negative disease.\n\nSince the patient's tumor is HER2-positive, she does not meet the specific requirement of having a triple negative breast cancer for the clinical trial. All other inclusion criteria are either met or not mentioned in the patient note, but the mismatch in HER2 status is a disqualifying factor.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "209": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy,\" we need to assess the patient's characteristics against the trial's inclusion criteria:\n\n1. Patient must be female.\n   - The patient is a 45-year-old postmenopausal woman, which meets this criterion.\n\n2. Patient must be at least 18 years of age.\n   - The patient is 45 years old, which meets this criterion.\n\n3. Patient's clinical stage must be documented as tumor size less than 5 cm, with no palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0). For patients who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be used.\n   - The patient has a 3 cm invasive ductal breast carcinoma, which meets the size requirement. However, axillary sampling revealed 5 positive lymph nodes and CXR (Chest X-ray) was remarkable for metastatic lesions, indicating that the patient does not meet the clinical stage requirement of no evidence of metastatic disease.\n\n4. Patient must have a negative (normal) axillary ultrasound performed at Siteman Cancer Center.\n   - There is no information provided about an axillary ultrasound, so we cannot assess this criterion.\n\n5. Patient must have a tissue diagnosis of invasive breast carcinoma.\n   - The patient has a confirmed diagnosis of invasive ductal breast carcinoma, which meets this criterion.\n\n6. Patient must have Eastern Cooperative Oncology Group (ECOG) status </= 2, as documented in patient's medical record.\n   - There is no information provided about the patient's ECOG status, so we cannot assess this criterion.\n\n7. Patient must be available for follow-up.\n   - There is no information provided that suggests the patient would not be available for follow-up, but since it's not explicitly stated, we cannot fully assess this criterion.\n\n8. A patient with a history of previous malignancy is eligible for this study as long as certain criteria are met.\n   - There is no information about a history of other malignancies, so this criterion is not applicable.\n\n9. Patient must provide a signed and dated written informed consent.\n   - There is no information given about consent, so we cannot assess this criterion.\n\n10. Patient must provide written authorization to allow the use and disclosure of their protected health information.\n    - There is no information provided regarding this authorization, so we cannot assess this criterion.\n\n11. Patient must be a candidate for sentinel lymph node biopsy (SLNB).\n    - The patient is a candidate for tumor resection which could imply suitability for SLNB, but the presence of positive lymph nodes might contradict this suitability. Without more specific information, we cannot fully assess this criterion.\n\nBased on the information provided, the patient does not meet one of the critical clinical stage criteria, specifically the requirement for no evidence of metastatic disease as the patient has metastatic lesions. Therefore, this patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "210": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- Has cytologically confirmed breast cancer.\n- Tumor is invasive ductal carcinoma, HER2-positive, ER/PR-negative.\n- Has 5 positive lymph nodes.\n- Shows metastatic lesions on CXR.\n- Is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n- Does not mention any contraindications to the study drugs or other exclusion criteria from the trial.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 18-70 years female operable breast cancer patients (the patient is 45 years old and meets this criterion).\n- Patients required to register within 60 days from the final surgical procedure (the patient is a candidate for surgery and thus meets this criterion, assuming the trial registration would occur within this timeframe).\n- Histologically confirmed adenocarcinoma of the breast with involved positive lymph nodes (the patient has 5 positive lymph nodes, meeting this criterion).\n- HER2 positive and able to undergo treatment without herceptin if unable or intolerant (the patient is HER2 positive).\n- Karnofsky points greater than or equal to 70 (not mentioned in the patient note, so we cannot confirm this criterion).\n- Postmenopausal women or negative HCG test (the patient is postmenopausal).\n- Hematopoietic, hepatic, renal, and cardiovascular criteria are listed, but the patient note does not provide this specific information.\n- No history of other invasive malignancies within the past 5 years except certain treated skin cancers or carcinoma in situ of the cervix (no other malignancies are mentioned in the patient note).\n- No hypersensitivity to paclitaxel or docetaxel or other similarly formulated drugs (the patient note does not mention any such hypersensitivity).\n\nSince the patient note does not provide sufficient information to confirm all the inclusion criteria, particularly the Karnofsky performance status and the hematopoietic, hepatic, renal, and cardiovascular criteria, we cannot definitively say that the patient is eligible. Additionally, no exclusion criteria are explicitly mentioned in the patient note, so we cannot exclude the patient based on the provided information.\n\nTherefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "211": {
        "output": "",
        "label": 0
    },
    "212": {
        "output": "Let's evaluate the patient's eligibility based on the clinical trial's inclusion criteria:\n\n1. **Subjects with an invasive breast cancer 1.5 cm or less**: The patient has a 3 cm invasive ductal breast carcinoma, which exceeds the specified size limit.\n\n2. **The breast cancer must be of ductal histology**: The patient's breast cancer is of ductal histology, which meets this criterion.\n\n3. **Unifocal, estrogen receptor positive and her2/neu negative**: The patient's tumor is HER2-positive and ER/PR-negative, which does not meet the requirement of being estrogen receptor positive and her2/neu negative.\n\n4. **The tumor must be visible by ultrasound**: There is no information provided about the visibility of the tumor by ultrasound.\n\n5. **The subject must not have had prior surgical resection of the primary lesion**: The patient is a candidate for tumor resection, which implies that surgical resection has not yet occurred.\n\n6. **A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy**: There is no information provided about the placement of a clip.\n\n7. **The breast cancer must be amenable to cryoablation**: There is no information provided to assess this criterion.\n\n8. **Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment**: The patient's CXR was remarkable for metastatic lesions, which means she has metastatic disease, and she agrees to have the tumor excised prior to chemotherapy, meeting this criterion.\n\n9. **For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant**: There is no information provided about breast implants.\n\n10. **Subjects must be able to provide consent**: There is no information provided that suggests the patient cannot provide consent.\n\nBased on the provided patient note and the clinical trial criteria, the patient does not meet the size requirement (1.5 cm or less) and the tumor's receptor status (estrogen receptor positive and her2/neu negative). Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "213": {
        "output": "",
        "label": 0
    },
    "214": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Phase II Trial for Large ER-Negative Breast Cancers,\" we need to compare the patient note against the inclusion criteria listed for the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR-negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- She is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Informed consent can be assumed to be obtainable.\n- The diagnosis of breast cancer has been confirmed by core biopsy (invasive adenocarcinoma).\n- The patient must have a life expectancy of at least 1 year, excluding the diagnosis of cancer.\n- Patients must have a mass >1 cm, which our patient does (3 cm mass).\n- The patient may enter the trial prior to ER or Her2 status being known, but if Her2 is positive, then the patient is withdrawn from the treatment phase of the trial. The patient's tumor is HER2-positive, which makes her ineligible for the treatment phase.\n- Patients with palpable mass with distant metastasis are allowed if definitive local treatment is judged to be necessary. The patient has metastatic lesions, which suggests distant metastasis, and the patient is a candidate for tumor resection.\n- The patient can have inflammatory breast cancer, which is not mentioned in the patient note.\n- The patient must have had certain tests and exams prior to entry, which we cannot confirm from the patient note.\n- Blood counts and chemistry must be within specified ranges, which we cannot confirm from the patient note.\n- Patients with bone pain are eligible if the bone scan or roentgenological exam fail to disclose metastatic disease or if metastatic disease is found, definitive local treatment is to be performed. The patient has metastatic lesions, and definitive local treatment (tumor resection) is planned.\n- History of non-breast malignancies and other specific conditions are detailed, but there is no mention of such in the patient note.\n- A negative pregnancy test is required for females of childbearing potential, which is not relevant for this postmenopausal patient.\n\nBased on the information provided, the patient meets many of the inclusion criteria, but there is a critical point that makes her ineligible for the treatment phase of this trial: her tumor is HER2-positive. The inclusion criteria specifically state that if the patient is found to be HER2-positive, they are withdrawn from the treatment phase of the trial. Therefore, the patient would be ineligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "215": {
        "output": "",
        "label": 0
    },
    "216": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has had a core biopsy revealing a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, is HER2-positive, ER/PR negative, and has 5 positive lymph nodes found through axillary sampling. Additionally, she has metastatic lesions noted on CXR.\n\nNow, let's review the inclusion criteria for the clinical trial titled \"Selective Image Guided Resection of Axillary Lymph Nodes\":\n\n1. Greater than or equal to 18 years old.\n2. Histologic diagnosis of invasive breast cancer, clinical stage T0-3 N1 (maximum one or two abnormal axillary nodes on ultrasound exam) M0.\n3. FNA biopsy (or core needle biopsy) of an axillary node documenting nodal disease at time of diagnosis and prior to preoperative chemotherapy or surgery.\n4. Marker clip placed in the one or two abnormal axillary nodes identified at ultrasound.\n\nThe patient meets the age criterion (greater than or equal to 18 years old). She has a histologic diagnosis of invasive breast cancer. However, the clinical trial specifically requires a T0-3 N1 M0 stage, where N1 indicates one or two abnormal axillary nodes on ultrasound. The patient note states that there are 5 positive lymph nodes, which exceeds the specified requirement for the clinical trial (N1 stage). Additionally, the patient has metastatic lesions as evidenced by the CXR, which conflicts with the M0 requirement (no distant metastasis).\n\nGiven this information, the patient does not meet the inclusion criteria due to having more than two abnormal axillary nodes and the presence of metastatic lesions (exceeding N1 and not meeting M0). Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "217": {
        "output": "To evaluate the patient's eligibility for the clinical trial titled \"Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,\" we need to review the patient's information against the inclusion criteria listed for the trial.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection prior to chemotherapy\n- No prior chemotherapy or surgery for the malignancy\n- Willing to undergo surgery and chemotherapy\n\nInclusion Criteria for the Trial:\n- Histologically confirmed adenocarcinoma of the breast with clinical stage IIA, IIB, IIIA, IIIB, or IIIC; stage IV is also eligible with certain conditions\n- ER, PR, and HER2/neu status must be documented before systemic therapy\n- No prior chemotherapy, irradiation, or definitive therapeutic surgery for this malignancy\n- Suitable candidate for preoperative chemotherapy and surgery\n- Ability to understand and willingness to sign informed consent, and willing to provide blood samples\n\nComparison:\n- The patient has histologically confirmed adenocarcinoma of the breast and is in the appropriate clinical stage for the trial.\n- The HER2, ER, and PR status of the patient's tumor has been documented.\n- The patient has not received prior chemotherapy, irradiation, or definitive therapeutic surgery for the malignancy.\n- The patient is a candidate for tumor resection before chemotherapy, indicating that she is suitable for preoperative chemotherapy and surgery.\n- The patient's note does not mention any inability to understand or unwillingness to provide informed consent or blood samples.\n\nGiven the information provided, the patient appears to meet all of the inclusion criteria for the clinical trial. There are no exclusion criteria provided, so based on the available information, the patient seems eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "218": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition with the inclusion criteria of the trial. Let's go through the inclusion criteria and match them with the patient's information:\n\n1. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by AJCC staging 7th edition: The patient has invasive ductal breast carcinoma with 5 positive lymph nodes, indicating N1. However, the presence of metastatic lesions (as indicated by a remarkable CXR) suggests that the patient might not be M0, which would imply no distant metastases. This needs further clarification as the inclusion criteria specifically require M0.\n\n2. No inflammatory breast cancer: The patient note does not mention inflammatory breast cancer.\n\n3. No other malignancy within 5 years of registration: The patient note does not indicate any other malignancy.\n\n4. Axillary sampling documented axillary metastasis: The patient has 5 positive lymph nodes, which likely fulfills this criterion.\n\n5. Estrogen receptor, progesterone receptor, and HER2 status evaluated: The patient's tumor is HER2-positive and ER/PR negative, which matches the requirement.\n\n6. Completed all planned neoadjuvant chemotherapy prior to surgery: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies chemotherapy has not started yet. This does not meet the criterion of completing neoadjuvant chemotherapy prior to surgery.\n\n7. HER-2 positive tumors must have received neoadjuvant trastuzumab, or trastuzumab + pertuzumab, or other approved anti-HER-2 therapy: The patient has not started treatment yet, so this criterion has not been met.\n\n8. Clinically negative axilla on physical examination at the completion of neoadjuvant chemotherapy: Since the patient has not undergone chemotherapy yet, this cannot be confirmed.\n\n9. No more than 8 weeks of neoadjuvant endocrine therapy prior to the start of neoadjuvant chemotherapy: The patient note does not mention endocrine therapy.\n\n10. No neoadjuvant radiation therapy: The patient note does not mention radiation therapy.\n\n11. No SLN surgery/excisional biopsy for pathological confirmation of axillary status prior to or during neoadjuvant chemotherapy: The patient has undergone axillary sampling but is not reported to have had SLN surgery or excisional biopsy for axillary status.\n\n12. No prior history of ipsilateral breast cancer: The patient note does not indicate a prior history of breast cancer.\n\n13. No prior ipsilateral axillary surgery: The patient note does not mention any prior surgery.\n\n14. No history of prior or concurrent contralateral invasive breast cancer: The patient note does not indicate any contralateral breast cancer.\n\n15. Not pregnant or nursing: The patient is postmenopausal, which meets this criterion.\n\n16. ECOG performance status 0-1: The patient's ECOG performance status is not mentioned.\n\nThe patient does not meet several key criteria necessary for inclusion in the clinical trial, including the completion of neoadjuvant chemotherapy and the requirement for M0 status at diagnosis. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "219": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes and metastatic lesions on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Females \u2265 18 years of age (Patient is 45, meets criteria)\n- Histologically confirmed invasive breast cancer (Patient has invasive ductal breast carcinoma, meets criteria)\n- Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection (Patient is a candidate for tumor resection, meets criteria)\n- Planning neoadjuvant chemotherapy (Not explicitly stated, but implied since she agrees to surgery prior to chemotherapy, potentially meets criteria)\n- HER2 positive disease (Patient has HER2-positive disease, meets criteria)\n- Measurable disease in the breast after diagnostic biopsy, defined as longest diameter \u2265 2.0 cm (Patient's tumor is 3 cm, meets criteria)\n- Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry (Patient is ER/PR negative, meets criteria)\n- Normal bone marrow function (Not mentioned, not enough information)\n- Normal hepatic function (Not mentioned, not enough information)\n- Normal renal function (Not mentioned, not enough information)\n- Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form before any study specific procedures (Assuming the patient can sign consent if willing, potentially meets criteria)\n- For Randomization: Left ventricular ejection fraction (LVEF) of \u226555% by 2D echocardiogram (Not mentioned, not enough information)\n- For Randomization: Complete all 4 cycles of run-in chemotherapy (Not mentioned, not enough information)\n\nThe patient meets several of the inclusion criteria for the clinical trial. However, there is insufficient information provided regarding her bone marrow function, hepatic function, renal function, and LVEF. Additionally, it is not clear whether she has completed any chemotherapy, as the trial requires completion of 4 cycles of run-in chemotherapy before randomization.\n\nGiven the information available, the patient appears to potentially be a candidate for the trial, but there is not enough information to definitively determine her eligibility based on all the criteria. Therefore, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "220": {
        "output": "Given Patient Information:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer\n- Invasive ductal breast carcinoma (HER2-positive, ER/PR negative)\n- Metastatic lesions (including bone metastasis is inferred from \"CXR was remarkable for metastatic lesions\")\n- Candidate for tumor resection, agreeing to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Histological confirmation of breast carcinoma (met)\n- Progressive metastatic disease with predominantly bone metastasis with 1 or more lesions and at least 1 bone lesion pathologically confirmed (metastasis is present, but lack of information on the predominance of bone metastasis and pathological confirmation specifically of a bone lesion)\n- Positive ER expression in the primary tumor site by IHC (not met, patient's tumor is ER negative)\n- Adequate hematologic function (no information provided)\n- Adequate cardiac function if known cardiac dysfunction history (no information provided)\n- Adequate renal function (no information provided)\n- Adequate hepatic function (no information provided)\n- Serum calcium or albumin-adjusted serum calcium within specified range (no information provided)\n- Ability and willingness to sign written informed consent (presumed met)\n- Patients are 18 years of age or older (met)\n- Female patients of childbearing potential must be willing to use highly effective contraception or abstain from heterosexual activity (met, patient is postmenopausal)\n- Negative serum pregnancy test for females of childbearing potential (presumed met, patient is postmenopausal)\n- Patients have CTC \u22653 (no information provided)\n\nBased on the information provided, the patient meets some of the inclusion criteria, such as histological confirmation of breast carcinoma and being 18 years or older. However, the patient's tumor is ER-negative, which does not meet the trial's requirement for positive ER expression in the primary tumor site. Furthermore, there is insufficient information regarding other criteria such as the adequacy of hematologic, cardiac, renal, and hepatic functions, serum calcium levels, and the exact nature of the metastatic lesions (whether bone metastasis is predominant and pathologically confirmed).\n\nSince the patient does not meet the ER positivity criterion and there is a lack of sufficient information to confirm eligibility for other criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "221": {
        "output": "Let's go through the inclusion criteria for the clinical trial and the provided patient note step by step.\n\nInclusion Criteria Checklist:\n1. Female \u226518 years of age - The patient is a 45-year-old woman, so this criterion is met.\n2. ECOG performance status 0-2 - This information is not provided in the patient note.\n3. Postmenopausal, verified by:\n   - post bilateral surgical oophorectomy or\n   - no spontaneous menses \u2265 1 year or\n   - no menses for < 1 year with FSH and estradiol levels in postmenopausal range, according to institutional standards - The patient is described as postmenopausal, so this criterion is met.\n4. Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy - This criterion is met; the patient had a core biopsy revealing invasive ductal breast carcinoma.\n5. Clinical T2-T4c, any N, M0 invasive breast cancer, by AJCC 7th edition clinical staging - The tumor is described as having metastatic lesions (CXR), which suggests that the patient does not have M0 disease.\n6. Primary tumor must be palpable and its largest diameter is at least 2.0 cm by physical examination or by radiological assessment - The patient's tumor is 3 cm, so this criterion is met.\n7. Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7, or 8 - The patient's tumor is ER/PR negative, so this criterion is not met.\n8. Invasive breast cancer is Human Epidermal Growth Factor Receptor 2 (HER2)-negative - The patient's tumor is HER2-positive, so this criterion is not met.\n9. Documentation of mammogram and ultrasound of the diseased breast and mammogram for the unaffected contralateral breast within specified time frames - This information is not provided in the patient note.\n10. Laboratory values within specified ranges - This information is not provided in the patient note.\n11. Patient must agree to provide the required research biopsies at baseline, week 4, and at surgery - The patient agrees to tumor resection, which suggests she may agree to the required biopsies, but this is not explicit.\n\nBased on the provided patient note and the inclusion criteria, the patient does not meet the criteria for estrogen receptor positivity or HER2 negativity, and there is evidence of metastatic disease (which does not meet the M0 criteria). Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "222": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Exemestane and Cyclophosphamide for Metastatic Breast Cancer,\" we must compare the patient's characteristics and history with the inclusion criteria listed for the trial.\n\nThe patient's characteristics and history:\n- 45-year-old postmenopausal woman\n- Has cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Has metastatic disease (indicated by metastatic lesions on CXR)\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nThe trial's inclusion criteria:\n- Patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative and have disease that is metastatic (stage IV)\n- ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive\n- Histologic and/or cytologic confirmation of metastatic disease encouraged\n- Measurable disease or non-measurable (assessable) disease\n- Progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy\n- Female or male subjects age >= 18 years\n- Postmenopausal status\n- Ability to swallow and tolerate oral medications\n- Normal organ and marrow function as defined by various laboratory values\n\nBased on the information given for the patient and the inclusion criteria of the trial, the patient does not appear to be eligible for the trial for the following reasons:\n\n- The patient's tumor is HER2-positive, while the trial requires the breast cancer to be HER2-negative.\n- The patient's tumor is ER/PR negative, while the trial requires the cancer to be ER positive and/or PR positive.\n\nSince the patient does not meet crucial criteria regarding the receptor status of her breast cancer, she is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "223": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial is seeking patients with American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive melanoma. These are two distinct conditions, and the patient does not have melanoma; rather, she has breast cancer. Therefore, she does not meet the inclusion criteria for the clinical trial, which specifically requires a diagnosis of melanoma that is BRAF V600 mutation positive.\n\nAdditionally, the trial is for a neoadjuvant treatment of melanoma, aimed at improving clinical and pathological response after 12 weeks of treatment before surgery. The patient is a candidate for tumor resection for her breast cancer, which is not relevant to the treatment under study in the trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, as her diagnosis (breast cancer) does not match the target condition of the trial (melanoma). Therefore, we can conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "224": {
        "output": "",
        "label": 2
    },
    "225": {
        "output": "Assessment of the patient's eligibility for the clinical trial:\n\n1. Disease Criteria:\nThe patient has breast cancer, not acute lymphoblastic leukemia (ALL). The trial specifically requires patients with ALL in complete remission. Therefore, the patient does not meet the disease criteria.\n\n2. Age Criteria:\nThe patient is 45 years old, which falls within the age range specified by the trial (40 to 65 years). However, patients younger than 40 must have comorbidities that preclude them from undergoing a different conditioning regimen, which does not apply to this patient as she is not younger than 40.\n\n3. Organ Function Criteria:\nThe patient's note does not provide information regarding cardiac, pulmonary, renal, or hepatic function. Therefore, we cannot determine if she meets the organ function criteria.\n\n4. Performance Status:\nThe patient's note does not mention her Karnofsky performance status, so it is unclear whether she meets the performance status criterion.\n\n5. Consent:\nThere is no information provided about the patient's ability to give written informed consent or to comply with study requirements.\n\n6. Donor Availability:\nThe patient note does not mention the presence of a willing adult HLA-matched sibling or unrelated donor.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not have the disease (ALL) that is being studied in the trial. As such, she does not meet the primary disease criteria for inclusion. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "226": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The breast cancer is invasive ductal carcinoma that is HER2-positive and ER/PR negative, with axillary sampling revealing 5 positive lymph nodes. However, the patient also presents with metastatic lesions as indicated by the CXR.\n\nThe clinical trial in question is focused on chronic toxicities related to treatment in patients with localized cancer, specifically non-metastatic breast cancer. The inclusion criteria for this trial are:\n\n- Women\n- Aged 18 years and over\n- With an invasive breast cancer diagnosed by cytology or histology\n- Tumors cT0 to cT3, CN0-3\n- No clinical evidence of metastasis at the time of inclusion\n- Untreated including scored for breast cancer surgery in progress\n- Patient receiving a social security system\n- Patient mastering the French language\n- Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage\n- Since February 2022, patients must be:\n  - Age < 45 years at diagnosis\n  - Or CT2-3, cN0-3, HER2+(RH+ or RH-) or RH-HER2-\n\nGiven that the patient has metastatic lesions, she does not meet the inclusion criterion of \"No clinical evidence of metastasis at the time of inclusion.\" Therefore, despite meeting other criteria such as age, type of breast cancer, HER2 status, and being a candidate for tumor resection before chemotherapy, the presence of metastatic lesions excludes her from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "227": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Diagnosed with breast cancer (invasive ductal breast carcinoma)\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection, agrees to proceed before chemotherapy\n\nClinical Trial:\n- Title: Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients\n- Focus: Newly diagnosed thyroid cancer patients\n- Inclusion Criteria:\n  - Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (histologically confirmed thyroid cancer: papillary, follicular, or medullary type; TNM classification system)\n  - Willing to participate in the EG meetings\n  - >18 years\n  - Alert and capable of giving free and informed consent\n  - Able to speak and read English or French\n\nThe patient does not meet the inclusion criteria for this clinical trial because she has been diagnosed with breast cancer, not thyroid cancer. Therefore, she is not eligible to participate in this thyroid cancer-focused study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "228": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient in question:\n\n- Is a 45-year-old woman, which meets the gender and age requirement (women, more than eighteen years).\n- Has cytologically confirmed breast cancer, which is not related to chronic pelvic pain per the information provided.\n- There is no mention of chronic pelvic pain, non-menstrual or noncyclic pelvic pain, or the duration of any pelvic pain, which are required for inclusion in the study.\n\nSince the patient does not have a clinical diagnosis of chronic pelvic pain and there is no mention of chronic pelvic pain in her history, she does not meet the inclusion criteria for the clinical trial titled \"Pain in Women With Chronic Pelvic Pain.\"\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "229": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This information pertains to her diagnosis and demographics but does not directly relate to the inclusion criteria of the clinical trial.\n\nThe clinical trial is focused on angiographic non-inferiority for the BioNIR Ridaforolimus Eluting Coronary Stent System compared to the Resolute zotarolimus-eluting stent. The inclusion criteria for this trial are specific to patients with an indication for PCI (Percutaneous Coronary Intervention) due to various forms of cardiac disease, such as angina, silent ischemia, NSTEMI, or recent STEMI, and have detailed requirements about timing related to STEMI and non-target vessel PCI.\n\nThe patient note does not mention any cardiac disease, angina, ischemia, NSTEMI, STEMI, or any indication for PCI. Furthermore, the patient's condition revolves around breast cancer and its treatment, which is not relevant to the trial's focus on coronary stents.\n\nTherefore, the patient does not meet the inclusion criteria for the angiography study of the BioNIR Drug Eluting Stent System (NIREUS) because her medical condition (breast cancer) and treatment needs do not align with the requirements for the trial, which are specific to coronary artery disease and the need for PCI.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "230": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion criteria listed for the trial.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Life expectancy of at least 10 years, excluding breast cancer diagnosis\n- Agreement to use effective non-hormonal contraception, if of reproductive potential\n- Submission of tumor samples required\n- Signed and dated IRB-approved consent form\n- ECOG performance status of 0 or 1\n- Clinical staging for primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if clinically node negative; if nodes are cN1 and positive or cN2-N3, primary breast tumor can be cT0-T4\n- Diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy\n- Ipsilateral axillary lymph nodes evaluated by imaging within 6 weeks prior to randomization, and if suspicious, FNA or core biopsy recommended\n- Premenopausal or postmenopausal status\n- HER2-positive by IHC 3+ or ISH (ratio >= 2.0 or gene copy number >= 6)\n- ER and/or PgR positive\n- ANC >= 1200/mm^3\n- Platelet count >= 100,000/mm^3\n- Hemoglobin >= 10 g/dL\n- Total bilirubin <= ULN or slight elevation due to Gilbert's syndrome\n- Alkaline phosphatase <= 2.5 x ULN\n- AST <= 1.5 x ULN (or ALT if AST not available)\n- No metastatic disease on liver imaging if AST or alkaline phosphatase > ULN\n- Creatinine <= ULN or creatinine clearance > 60 mL/min\n- LVEF >= 50%\n\nBased on the given information, the patient appears to meet several inclusion criteria:\n\n- Postmenopausal status is confirmed.\n- HER2-positive status is confirmed.\n- ER/PR negative status is confirmed. (Note: The trial requires ER and/or PgR positive, so this is a potential mismatch)\n- Patient has agreed to a core biopsy, and tumor samples can be provided.\n- The patient's performance status is not directly mentioned, but there is no indication that it is not within the required range (ECOG 0 or 1).\n\nHowever, there are some discrepancies and missing information:\n- The patient's life expectancy is not mentioned, so we can't confirm if it meets the 10-year requirement.\n- Whether the patient agrees to use effective non-hormonal contraception is not specified.\n- ECOG performance status is not given.\n- The patient has metastatic lesions noted on CXR, which could indicate a stage beyond what is considered operable or locally advanced, potentially conflicting with the trial's focus.\n- Blood counts and chemistry results are not provided, so we cannot confirm if these meet the required levels.\n- LVEF status is not mentioned.\n\nBecause the patient has ER/PR negative breast cancer and the trial specifically requires ER and/or PgR positive status, this patient does not meet the eligibility criteria based on hormone receptor status alone. Additionally, the presence of metastatic lesions may further exclude the patient from a trial focused on operable or locally advanced cancer.\n\nGiven the information provided, the patient does not meet all of the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "231": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, it is clear that the patient does not meet the criteria for the clinical trial.\n\nThe patient has a diagnosis of breast cancer, specifically invasive ductal breast carcinoma, which is not one of the conditions listed in the trial's inclusion criteria. The trial is specifically for patients with Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb, and there is no indication that the patient has this diagnosis. Additionally, the patient is 45 years old, which does not meet the age inclusion criterion of being \u226560 years of age.\n\nTherefore, the patient is not eligible for this clinical trial based on her diagnosis and age. Other inclusion criteria such as ECOG performance status, hematologic, liver, and renal functions, as well as LVEF, are not relevant as the primary diagnosis and age already disqualify the patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "232": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Scheduled for tumor resection before chemotherapy\n\nClinical trial inclusion criteria:\n- Clinical status of lymph nodes must be available\n- Sonographical status of lymph nodes must be available\n- Patients must consent to documentation of cancer treatment\n- Histologic diagnosis of invasive breast cancer, clinical stage T1-4, M0 (non-inflammatory T4c)\n- Patients scheduled for neoadjuvant chemotherapy\n- Treatment with a 3-weekly FEC or AC regimen (3-4 cycles) followed by 3-4 cycles of q3 weekly docetaxel or paclitaxel\n- Local HER2 status of tumor biopsy must be negative\n\nAssessment:\nThe patient has a confirmed diagnosis of invasive breast cancer and is scheduled for tumor resection before chemotherapy, which aligns with the requirement of being scheduled for neoadjuvant chemotherapy. The clinical status of lymph nodes is known, as there are 5 positive lymph nodes from axillary sampling. However, the HER2 status of the patient's tumor is positive, which does not meet the inclusion criteria of the clinical trial that requires HER2 status to be negative. There is no mention of the sonographical status of lymph nodes, but this information may be available since the clinical status is known.\n\nDespite several matching criteria, the HER2-positive status of the tumor excludes the patient from participating in the trial, which specifically requires HER2-negative status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "233": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. There is no mention of her being a BRCA1/2 mutation carrier or having a strong family history of breast and/or ovarian cancer suggestive of a germ line mutation in a relevant gene. Since the inclusion criteria for the clinical trial specifically require participants to be either BRCA1/2 mutation carriers or to have a strong family history indicative of a hereditary cancer syndrome, and there is no information provided in the patient note about the patient's genetic status or family history, we cannot ascertain her eligibility for the trial.\n\nTherefore, based on the information available, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "234": {
        "output": "Given the patient note and the clinical trial information provided:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes on axillary sampling\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection\n- Willing to undergo resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Breast cancer patients eligible for sentinel node dissection\n- Invasive ductal or invasive lobular carcinoma\n- Ductal carcinoma in situ undergoing total mastectomy\n- Clinically node-negative\n- 18-100 years\n\nAnalysis:\n- The patient has invasive ductal carcinoma, which matches one of the types of carcinoma listed in the inclusion criteria.\n- The patient is 45 years old, which falls within the age range of 18-100 years stated in the inclusion criteria.\n- The trial requires patients to be clinically node-negative, whereas the patient has 5 positive lymph nodes, which indicates that she is not clinically node-negative.\n\nBased on the analysis, the patient does not meet all the inclusion criteria due to her positive lymph nodes. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "235": {
        "output": "",
        "label": 2
    },
    "236": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of being \u2265 18 years.\n- The patient has cytologically confirmed breast cancer, specifically invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, which is in line with the requirement for histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease.\n- It is mentioned that the patient has metastatic lesions, which satisfies the criterion for metastatic disease demonstration.\n- The tumor demonstrates HER2-neu overexpression, as indicated by being HER2-positive. However, the specific method and level of overexpression are not provided (IHC 3+ or specific HER2/CEP17 ratios), so it's not possible to confirm this criterion completely.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. Since she is planning to have surgery, it can be inferred that she has not progressed on at least two lines of HER2-directed therapy in the metastatic setting yet, which is required by the trial.\n- Information about prior therapy with pertuzumab and ado-trastuzumab is not provided.\n- The patient's performance status is not mentioned, so we cannot confirm if she meets the ECOG performance status criterion of 0-2.\n- No information is provided regarding the left ventricular ejection fraction, so we cannot confirm if it is \u2265 50%.\n- No QT interval information is provided.\n- The patient's organ and marrow function are not detailed in the note, so we cannot confirm if they meet the specified levels.\n- It is not mentioned if the patient is able to swallow, retain, and absorb oral medication.\n- Although the patient is postmenopausal and not sexually active, it's unclear if she meets the contraception requirement.\n- The patient's ability and willingness to sign informed consent are not stated, but she agrees to tumor resection, which indicates a willingness to participate in treatment.\n\nBased on the information given, there is not sufficient information to fully qualify the patient for the trial. There are several key pieces of information missing, such as the detailed HER2 overexpression level, ECOG performance status, organ function levels, and confirmation of progression on two lines of HER2-directed therapy in the metastatic setting.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "237": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial described, we need to compare the patient's information with the inclusion criteria listed for the trial.\n\nPatient's characteristics:\n- Gender: Female\n- Age: 45 years\n- Confirmed breast cancer (HER2-positive, ER/PR-negative)\n- Tumor size: 3 cm\n- Positive lymph nodes: 5\n- Metastatic lesions present\n- Candidate for tumor resection, and willing to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Female gender\n- Age \u226518 years\n- ECOG Performance Status 0-1\n- Histologically confirmed invasive breast cancer; primary tumor greater than 1 cm diameter\n- Any N (any node status)\n- No evidence of metastasis (M0)\n- Overexpression and/or amplification of HER2\n- Known hormone receptor status\n- Adequate hematopoietic, hepatic, renal, and cardiovascular status\n- Negative pregnancy test for patients of childbearing potential\n- Use of effective contraception (if of childbearing potential)\n- Signed informed consent form\n- Willingness to provide tumor samples for translational studies\n\nThe patient note indicates the presence of metastatic lesions (CXR was remarkable for metastatic lesions), which contradicts the trial's requirement of \"No evidence of metastasis (M0).\" Therefore, the patient does not meet one of the key inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "238": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor size 3 cm\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n\n- AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy\n- No positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node\n- Negative histologic margins of resection\n- Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm)\n- Systemic therapy, if planned, must be adjuvant in nature and not scheduled to begin for at least 4 weeks after completion of HG-PBI\n- Good candidate for treatment per protocol in the judgment of the PI and/or treating physician following simulation\n- Postmenopausal status\n- Age \u2265 50 years at diagnosis\n- Able to understand and willing to sign IRB-approved written informed consent document\n- English speaker\n\nEligibility Assessment:\n\n- The patient's age does not meet the criteria of being 50 years or older at diagnosis.\n- The patient's tumor (3 cm invasive ductal breast carcinoma with 5 positive lymph nodes) does not meet the stage criteria (stage 0 or I, TisN0 \u2264 2 cm or T1N0).\n- The patient's tumor is HER2-positive, which does not align with the receptor criteria of being estrogen or progesterone receptor positive without HER2/neu gene amplification.\n\nSince the patient does not meet the age, stage, and receptor criteria of the trial, she is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "239": {
        "output": "Based on the information provided:\n\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the criteria for age and gender as being female and under 65 years old.\n- The core biopsy revealed invasive ductal breast carcinoma, which fits the criteria for histologically confirmed stage I-III breast carcinoma.\n- The patient is a candidate for tumor resection and has agreed to undergo this procedure prior to chemotherapy.\n\nHowever, the inclusion criteria for the clinical trial require that the patient be scheduled to receive a specific chemotherapy regimen containing doxorubicin/cyclophosphamide once every 3 weeks for 4 cycles and weekly paclitaxel for 12 cycles starting in either the adjuvant or neoadjuvant setting.\n\nThe patient note does not mention the specific chemotherapy regimen that the patient will receive. Without this information, we cannot confirm whether the patient will be receiving the required chemotherapy regimen as per the trial's inclusion criteria.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as we don't know if the required chemotherapy regimen matches the trial's specifications.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "240": {
        "output": "The patient described in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient has invasive ductal breast carcinoma which is HER2-positive and ER/PR negative, with 5 positive lymph nodes and metastatic lesions. The patient is a candidate for tumor resection and plans to undergo this procedure prior to chemotherapy.\n\nThe clinical trial in question is for newly diagnosed glioblastoma (GBM) patients and involves surgical resection of the tumor, followed by radiation therapy with either standard radiation or GammaKnife, in combination with Temodar (a chemotherapy drug). The trial includes specific criteria such as having a single enhancing lesion of the brain consistent with GBM, the ability to have a Gliadel wafer implant, pathologic confirmation of GBM, no gross residual tumor on postoperative MRI, resection cavity margin < 50 cc, a Karnofsky performance status of 80% or better, the ability to undergo MRI with gadolinium, and the willingness to have follow-up visits at the Barrow Neurological Institute.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial because the patient has breast cancer, not glioblastoma. Moreover, the trial is specific to patients with a single enhancing brain lesion consistent with GBM, which is not applicable to this patient's condition.\n\nTherefore, the patient is not eligible for the GBM clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "241": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The biopsy showed invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative, and there are metastatic lesions indicated by the chest X-ray (CXR). The patient is also a candidate for tumor resection and agrees to proceed with this treatment.\n\nNow, let's compare the patient's information to the inclusion criteria of the clinical trial titled \"BIG Molecular Screening Feasibility Study\":\n\n1. Written informed consent for all study procedures according to local regulatory requirements prior to enrollment into the study.\n   - The patient note does not mention informed consent, but this is typically obtained during the recruitment process.\n\n2. Age \u2265 18 years.\n   - The patient is 45 years old, which meets this criterion.\n\n3. Histologically proven metastatic or locally recurrent invasive breast cancer.\n   - The patient has metastatic breast cancer, as indicated by the presence of metastatic lesions on the CXR.\n\n4. Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for research purposes.\n   - The patient note does not explicitly state that tumor tissue is available, but since she is a candidate for tumor resection, it can be assumed that samples will be available for research purposes.\n\nBased on the information available in the patient note and assuming that the patient will provide informed consent and that tumor tissue samples will be obtained during resection, the patient meets all the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "242": {
        "output": "To determine the patient's eligibility for the clinical trial, we should compare the patient note with the inclusion criteria of the trial. Here's the breakdown:\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present (implying stage IV).\n- The patient is not currently using hormonal or barrier methods of contraception (not specified but implied by not being sexually active).\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical trial inclusion criteria:\n- Age \u2265 18 years at the time of consent. (The patient meets this criterion.)\n- ECOG Performance Status 0 or 1 within 14 days prior to study registration. (Not specified in the patient note.)\n- Women of childbearing potential must be willing to use an effective method of contraception. (Not specified in the patient note but potentially met due to postmenopausal status.)\n- Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer. (The patient's tumor is HER2-positive, so she does not meet this criterion.)\n- Must have completed definitive resection of the primary tumor and preoperative (neoadjuvant) chemotherapy. (The patient has not yet undergone tumor resection or chemotherapy as per the note.)\n- No stage IV (metastatic) disease. (The patient has metastatic lesions, indicating stage IV disease, which excludes her from the trial.)\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient is not eligible because she does not have triple negative breast cancer (she has HER2-positive disease) and she has stage IV disease with metastatic lesions.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "243": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which fits the gender and age requirements of the trial. The patient has invasive ductal breast carcinoma in the left upper outer quadrant, with axillary lymph nodes involved and metastatic lesions present on CXR, indicating metastatic breast cancer. This meets the requirement of having metastatic or locally relapsed breast cancer manageable with systemic therapy.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests a willingness to comply with medical procedures, and thus, potentially, the provision of tissue samples as required by the trial. It is not explicitly stated, but the patient's agreement to tumor resection prior to chemotherapy could be viewed as suggestive of a willingness to provide consent and tissue samples. However, this assumption cannot be made without explicit confirmation.\n\nThe inclusion criteria also require the patient to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which is not mentioned in the patient note. If the patient's performance status is within this range, she would meet this criterion. However, without this information, we cannot determine this aspect of her eligibility. Additionally, the trial requires written informed consent, and agreement to provide archived primary tumor tissue, newly collected metastatic lesion tissue samples, as well as blood samples. These requirements are not confirmed in the patient note.\n\nGiven the information provided, the patient appears to meet several key aspects of the inclusion criteria, such as age, diagnosis of metastatic breast cancer, and willingness to undergo tumor resection (which suggests potential compliance with biopsy and blood sample collection). However, there is insufficient information to confirm the patient's ECOG Performance Status or explicit agreement to the trial-specific requirements (written informed consent and agreement to provide tissue samples). Therefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "244": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Impact of Chemo-induced Menopause on Quality of Life in Women <45 Years Old, Diagnosed With Non-metastatic Breast Cancer,\" we need to evaluate the patient's characteristics against the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are as follows:\n1. Patient aged over 18 and under 45\n2. Patient without amenorrhea at diagnosis\n3. Performance status less than 2 (according to WHO criteria)\n4. Patient diagnosed with histologically proven non-metastatic breast cancer\n5. Clinical Stages I, IIA, IIB, and IIIA\n6. Positive Hormone Receptors (defined by a rate of 10% of labeled cells and immunohistochemistry (IHC)) or negative\n7. Positive or negative HER2 status (defined a score of 0 or 1+ by IHC, or a 2+ score by IHC and FISH/ISH/SISH/CISH negative)\n8. Patients to be treated with neoadjuvant or adjuvant chemotherapy\n9. Satisfying hematological, renal, and hepatic functions: PNN > 2,109 / L, platelets > 100 . 109 / L, Hb > 10 g / dl, normal bilirubin, AST and ALT <2.5 upper normal value (VNS), alkaline phosphatase <2.5 VSN, creatinine clearance > 60 ml / min\n10. Obtaining informed consent in writing, signed and dated\n11. Affiliation to Social Security system (or being the beneficiary of such a plan) under the terms of the Act of August 9, 2004\n\nNow, we examine the patient note:\n\n- The patient is a 45-year-old postmenopausal woman, which means she is not within the age range specified in the inclusion criteria (under 45).\n- She has breast cancer, but the cancer is metastatic, as indicated by the presence of metastatic lesions on the CXR. The inclusion criteria specify a diagnosis of non-metastatic breast cancer.\n- The patient's tumor is HER2-positive, which fits the criteria for HER2 status.\n- The performance status, hematological, renal, and hepatic functions are not mentioned in the patient note, so we cannot assess those criteria.\n- It is not stated whether the patient is without amenorrhea at diagnosis, which is an inclusion criterion.\n- The patient is a candidate for tumor resection and agrees to undergo chemotherapy thereafter, which aligns with the criteria for patients to be treated with chemotherapy.\n- There is no information regarding the patient's affiliation to the Social Security system as per the Act of August 9, 2004.\n\nBased on the information provided:\n\n- The patient is not under the age of 45.\n- The patient has metastatic breast cancer, which is not included in the study criteria.\n\nGiven these points, the patient does not meet critical inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "245": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is focused on advanced gastric cancer and specifically mentions inclusion criteria for patients with histologically and CT confirmed resectable advanced gastric cancer, no prior treatment, and no metastases.\n\nSince the patient has breast cancer and not gastric cancer, she does not meet the disease-specific inclusion criteria for this trial. Additionally, the patient has metastatic lesions as indicated by the CXR findings, which would also exclude her from the trial that specifies no metastases.\n\nTherefore, the patient does not meet the inclusion criteria based on their diagnosis and the presence of metastatic disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "246": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto),\" we need to assess the information provided in the patient note against the inclusion criteria listed for the trial.\n\nLet's review the inclusion criteria against the patient's information:\n\n1. Written informed consent: Not mentioned, but we assume it can be obtained if all other criteria are met.\n2. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy: The patient has a core biopsy revealing a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n3. Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter: The patient's tumor is 3 cm, meeting this criterion.\n4. Patients must have stage cT1c - cT4a-d disease: The patient has metastatic lesions noted on CXR, indicating advanced disease, which could potentially exceed the stage limits of cT4a-d.\n5. Centrally confirmed ER, PR, and HER2 status: The patient has HER2-positive and ER/PR negative status, which aligns with the criteria.\n6. Age >=18 years: The patient is 45 years old, which meets this criterion.\n7. Karnofsky Performance status index 90%: Not mentioned in the patient note.\n8. Confirmed normal cardiac function: Not mentioned in the patient note.\n9. Negative pregnancy test for all women of childbearing potential: The patient is postmenopausal, which makes this criterion not applicable.\n10. Complete staging work-up: The patient has undergone a chest X-ray, indicating some level of staging work-up, but it's not clear if all required tests have been completed.\n11. Hemoglobin level <10g/dl: Not mentioned in the patient note.\n12. Body weight \u2265 40 kg: Not mentioned in the patient note.\n13. No need for immediate red blood cell transfusion: Not mentioned in the patient note.\n14. Transferrin saturation (TSAT) \u226420% and serum ferritin <300ng/ml: Not mentioned in the patient note.\n\nBased on the available information, the patient meets many of the inclusion criteria regarding diagnosis and tumor characteristics. However, there is a potential concern regarding the patient's disease stage since the presence of metastatic lesions could indicate a stage beyond cT4a-d. Also, there are several criteria for which the patient note does not provide information, such as Karnofsky Performance status, cardiac function, complete staging work-up, and specific laboratory values related to anemia treatment arms.\n\nGiven the uncertainty regarding the disease stage and the lack of information on several criteria, the patient cannot be considered fully eligible for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "247": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer\n- Candidate for breast conserving surgery or mastectomy\n\nThe patient has a clinical diagnosis of invasive ductal breast carcinoma, which falls under the inclusion criteria of the clinical trial. Additionally, she is a candidate for tumor resection, which can be presumed to be a form of breast conserving surgery or mastectomy. Therefore, she meets the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "248": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n- The patient's performance status is not explicitly mentioned.\n- The patient's LVEF is not mentioned.\n- The patient's contraception use is not mentioned but could be irrelevant due to her postmenopausal status.\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed invasive breast cancer with a primary tumor size of > 2 cm.\n- HER2-positive breast cancer.\n- Eligibility for participants with multifocal tumors.\n- Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to AJCC staging.\n- Known hormone receptor status of the primary tumor.\n- Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy.\n- ECOG performance status of 0 or 1.\n- Baseline LVEF \u2265 55% measured by ECHO or MUGA.\n- Effective contraception as defined by protocol.\n\nComparison:\n- The patient has a tumor size > 2 cm (3 cm invasive ductal breast carcinoma).\n- The patient's tumor is HER2-positive.\n- The patient's breast cancer stage at presentation can be inferred as cT2-cT4, cN1 (5 positive lymph nodes), but no mention of cM0 (metastatic lesions on CXR indicate possible cM1).\n- The patient has agreed to undergo surgery which is in line with the trial's requirement for surgery after neoadjuvant therapy.\n- The patient's ECOG performance status is not mentioned, but there are no indications of severe functional limitations.\n- The patient's LVEF is not mentioned, which is necessary to assess eligibility.\n- The patient's need for effective contraception as per the protocol might not apply due to her postmenopausal status.\n\nThe patient meets most of the inclusion criteria except for the LVEF assessment, which is not provided in the patient note, and the patient's performance status. However, the mention of metastatic lesions on CXR is concerning, as the inclusion criteria specify cM0 (no distant metastasis). If the \"CXR was remarkable for metastatic lesions\" implies distant metastasis, this would make the patient ineligible (cM1) for the trial.\n\nBased on the available information, and especially due to the potential distant metastasis (cM1), the patient would not be eligible for this trial, which requires participants to be cM0.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "249": {
        "output": "Based on the provided patient note and the clinical trial information, here is the assessment:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is focused on the management of common bile duct stones (CBDS) and particularly pertains to morbidity rates after ERCP treatment in patients with CBDS, with or without cholangitis.\n\nThe inclusion criteria for the clinical trial specify:\n- Patients with common bile duct stones (CBDS)\n\nThe patient described in the note has breast cancer and there is no mention of common bile duct stones or any related treatment like ERCP. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which is specifically for patients with CBDS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "250": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient's characteristics:\n- A 45-year-old postmenopausal woman\n- Diagnosed with invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Presence of metastatic lesions\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Stage I-III, HER2-neu positive invasive ductal carcinoma (patient matches)\n- Scheduled to receive adjuvant/neo-adjuvant FEC-D chemotherapy (not specified if the patient will receive this exact treatment, but she is a candidate for tumor resection before chemotherapy)\n- Scheduled to receive adjuvant Trastuzumab (not specified, but since the patient is HER2-positive, it's a reasonable assumption that Trastuzumab could be part of her treatment)\n- ECOG Performance status 0-2 (not specified, but nothing in the patient note suggests a performance status outside this range)\n- Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of \u2265 55% (not specified in the patient note)\n- Breast cancer patients \u226545 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans (the patient is 45 years old, but it is not specified if she will receive radiation therapy)\n\nSince the patient's note does not provide information about the chemotherapy regimen, performance status, cardiac function, or whether the patient will receive radiation therapy, we do not have enough data to conclusively determine if she meets all the inclusion criteria for the clinical trial. Therefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "251": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Tumor size: 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- Axillary sampling: 5 positive lymph nodes\n- Evidence of metastatic lesions on CXR\n- Using multivitamins and iron supplements\n- Non-smoker, no alcohol consumption\n- Not sexually active, no children\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Patient must consent to be in the study\n- Patient must be \u2265 50 years old\n- Core biopsy demonstrating breast cancer that is ER or PR positive\n- HER2 negative per ASCO/CAP guidelines\n- Clinical node negative, stage I breast cancer\n- Intended surgical treatment is a lumpectomy\n- Biopsy site demarcated by a clip(s)\n- Gross disease must be unifocal on Mammo/ MRI imaging\n- ER and PR analysis performed on core biopsy\n- Able to tolerate lying in the prone position with arms extended forward\n- Able to tolerate MRI scan with contrast\n- Bilateral mammograms within 6 months\n- Willing to undergo breast cancer surgery 4-6 weeks post APBI\n- History of non-breast malignancies eligible if disease-free for 5+ years, or specific cancers treated within the past 5 years\n\nDiscrepancies between the patient's case and the trial's inclusion criteria:\n- The patient is 45 years old, while the trial requires participants to be \u2265 50 years old.\n- The patient's tumor is HER2-positive, while the trial requires HER2-negative status.\n- The patient has metastatic lesions and positive lymph nodes, which indicates a more advanced stage than stage I breast cancer required by the trial.\n- The trial requires ER or PR positive status, while the patient's tumor is ER/PR negative.\n\nGiven these discrepancies, particularly the patient's age, HER2 status, ER/PR status, and cancer stage, the patient does not meet the necessary inclusion criteria for the clinical trial. Therefore, the patient is not eligible to participate in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "252": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment,\" let's assess the patient's eligibility:\n\nPatient's characteristics:\n- Female patient\n- 45 years old\n- Has breast cancer (stage not specified, but axillary sampling revealed 5 positive lymph nodes, and metastatic lesions were found on CXR, suggesting advanced disease)\n- Tumor size is 3 cm, which is greater than 2 cm on clinical examination\n- Invasive ductal breast carcinoma that is HER2-positive and ER/PR negative\n- Biopsy-proven invasive breast cancer diagnosed by core needle biopsy\n- No mention of prior chemotherapy or radiotherapy for the current breast cancer\n- The patient agrees to undergo tumor resection and is a candidate for neoadjuvant chemotherapy\n- There is no information about bilateral breast cancer, but this does not exclude her\n- No information regarding understanding, accepting, and signing an approved written consent form, but willingness to undergo treatment suggests potential to consent\n- The patient is using multivitamins and iron supplements\n\nClinical trial inclusion criteria:\n- Female patients\n- 18 years of age or older\n- Stage I, II, or III breast cancer that is greater or equal to 2 cm on clinical examination\n- Biopsy-proven invasive breast cancer diagnosed by core needle biopsy\n- Chemotherapy and radiotherapy na\u00efve for the treatment of current breast cancer\n- Acceptance to undergo neoadjuvant chemotherapy\n- Bilateral breast cancer is not an exclusion\n- Understanding, accepting, and signing the approved written consent form\n\nThe patient's characteristics match the inclusion criteria for the clinical trial: she is a female over 18 years of age with a tumor size greater than 2 cm, her cancer was confirmed by a core needle biopsy, and she has not received chemotherapy or radiotherapy for her current breast cancer. She also agrees to undergo neoadjuvant chemotherapy, which aligns with the trial requirements. The only criterion that we do not have explicit information on is whether she understands, accepts, and has signed the approved written consent form. However, since she is a candidate for tumor resection and agrees to do so prior to chemotherapy, it is likely she would be willing to consent to participate in the study.\n\nGiven this information, the patient appears to meet the inclusion criteria for the clinical trial. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "253": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer,\" let's assess the patient's eligibility.\n\nPatient Note Summary:\n- The patient is a 45-year-old postmenopausal woman.\n- Diagnosed with cytologically confirmed invasive ductal breast cancer.\n- A core biopsy revealed a 3 cm tumor in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR-negative.\n- Five positive lymph nodes found through axillary sampling.\n- Metastatic lesions observed on CXR.\n- No mention of prior breast cancer treatment.\n- No mention of overall health status (e.g., ECOG performance status).\n- No laboratory values provided (e.g., WBC, ANC, Platelets, Hb, AST, ALT, creatinine, bilirubin).\n- The patient agrees to undergo tumor resection before chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Women aged \u226518 years and \u226470 years (Patient is 45 years old, so she meets this criterion).\n- At least one measurable disease according to RECIST (The patient has a 3 cm tumor, meeting this criterion).\n- Histologically confirmed invasive breast cancer, tumor size \u22652 cm, T2-4 N0-2M0 (The patient's tumor size is 3 cm, HER2-positive, ER/PR-negative, and has positive lymph nodes, which aligns with this criterion).\n- No prior systemic or loco-regional treatment of breast cancer (No prior treatment is mentioned, so she potentially meets this criterion).\n- ECOG 0-2 (No ECOG score mentioned, cannot confirm eligibility based on this criterion).\n- Adequate bone marrow function and no obvious main organs dysfunction (The patient's laboratory values and organ function are not provided, so we cannot confirm eligibility based on these criteria).\n\nBased on the information given, the patient meets several inclusion criteria:\n- Age between 18 and 70 years.\n- Histologically confirmed invasive breast cancer with a measurable disease.\n- The tumor is HER2-positive.\n\nHowever, there is insufficient information to determine eligibility based on:\n- ECOG performance status.\n- Adequate organ function and bone marrow function, as lab values are not provided.\n\nGiven the lack of information regarding the patient's ECOG score and laboratory values, it is not possible to definitively determine her eligibility for the trial. Therefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "254": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"FBnTP Imaging of Breast Cancer,\" let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present (CXR).\n- The patient is a candidate for tumor resection and agrees to it prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer).\n- Age > 25.\n- Ability and willingness to sign informed consent prior to any study procedure.\n- Positive indication of disease on mammogram or MRI scan.\n- Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.\n- Ability to undergo up to 90 minutes of PEM imaging.\n\nComparison:\n- The patient is female, aligning with the gender requirement for the trial.\n- The patient is 45 years old, which meets the age criterion of being over 25.\n- The patient has newly-diagnosed invasive ductal breast carcinoma, which fits the trial's requirement of invasive and/or intraductal breast cancer detected via biopsy.\n- The patient is a candidate for tumor resection, which suggests she may be a candidate for breast cancer surgery as recommended by a surgeon.\n- There is no information suggesting that the patient is unable or unwilling to sign informed consent or undergo up to 90 minutes of PEM imaging.\n- The patient's cancer has been detected and confirmed, which likely means there is a positive indication of disease on mammogram or MRI scan, although this is not explicitly stated.\n\nThe patient appears to meet the inclusion criteria based on the information provided. However, we do not have explicit confirmation of a positive indication of disease on mammogram or MRI scan, nor do we have explicit confirmation that the patient has agreed to sign informed consent or undergo PEM imaging. Assuming these conditions could be met, the patient would be eligible. \n\nGiven the available information, we have to consider the possibility that not all conditions for eligibility are confirmed. Therefore, the patient's eligibility for the trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "255": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal carcinoma, not lobular\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed invasive lobular breast cancer\n- Hormone receptor-positive and HER2-negative\n- Tumor measuring at least 1 centimeter\n- Clinical stages I-III\n- Fully postmenopausal\n- ECOG performance status of 0, 1 or 2\n- Adequate organ and marrow function\n- Female patients only\n- Patients must understand the study and be willing to sign consent\n\nThe patient's breast cancer is invasive ductal carcinoma, not invasive lobular carcinoma, and her tumor is HER2-positive and ER/PR negative, which does not meet the hormone receptor-positive status required by the trial. Additionally, the trial is specific to hormone receptor-positive and HER2-negative breast cancer, which further disqualifies her.\n\nTherefore, based on the provided information, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "256": {
        "output": "Reviewing the provided patient note against the inclusion criteria of the clinical trial:\n\nPatient characteristics:\n\n- 45-year-old postmenopausal woman (meets age criteria of \u226518 years and \u226470 years)\n- Histologically confirmed invasive ductal breast carcinoma, size 3 cm (meets criteria of tumor size \u22652 cm, T2-4 N0-3M0)\n- HER2-positive and ER/PR negative (meets criteria for HER2-positive as defined)\n- No mention of prior systemic or loco-regional treatment of breast cancer (assumed to meet criteria since the patient is scheduled for tumor resection prior to chemotherapy)\n- No mention of adequate bone marrow function or organ function tests results (these are missing, so we cannot confirm eligibility based on these criteria)\n\nGiven that the patient note lacks information regarding the patient's bone marrow function tests and organ function, we cannot confirm if these specific inclusion criteria are met. Therefore, the trial-level eligibility cannot be assessed as '2) Eligible' since the patient note does not provide sufficient information to determine if all inclusion criteria are satisfied.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "257": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Patients with invasive breast cancer (T1-T3)\n- N0 on palpation\n- Preoperative ultrasound performed\n- Pathology report shows macrometastasis in 1-2 sentinel lymph nodes\n- Patients undergo breast-conserving therapy or mastectomy\n- The patient must have provided oral and written consent\n- Age \u2265 18 years\n\nComparing the above information:\n\n- The patient is within the correct age range (45 years old).\n- The patient has invasive breast cancer.\n- The patient's pathology report indicates positive lymph nodes.\n- However, the patient has more than 2 positive lymph nodes (5 positive lymph nodes), which exceeds the trial's inclusion criteria of 1-2 sentinel lymph nodes with macrometastasis.\n- There is no mention of an ultrasound, but this could have been part of the standard diagnostic workup.\n- The patient is a candidate for tumor resection, which may involve breast-conserving therapy or mastectomy, aligning with the trial criteria.\n- The patient's consent status is not explicitly mentioned but is indicated as she agrees to tumor resection.\n\nBased on the provided information, the critical factor that does not align with the trial's inclusion criteria is the number of positive lymph nodes. The trial specifies macrometastasis in 1-2 sentinel lymph nodes, while the patient has 5 positive lymph nodes. Therefore, the patient is not eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "258": {
        "output": "Based on the patient note provided:\n\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- She has metastatic lesions indicated by a CXR.\n- She is a candidate for tumor resection and agrees to it prior to chemotherapy.\n\nThe clinical trial's inclusion criteria are:\n\n- Known or suspected breast cancer.\n\nThe patient clearly meets the inclusion criteria as she has known breast cancer that is confirmed cytologically. Therefore, the patient can be considered for participation in the trial that aims to establish a breast tumor tissue repository from core biopsies.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "259": {
        "output": "Based on the information provided:\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman\n- Diagnosed with breast cancer (invasive ductal breast carcinoma)\n- HER2-positive and ER/PR negative\n- Has axillary lymph node involvement and metastatic lesions\n- Is not HIV positive (not mentioned, but the absence of this information can be inferred since the patient is being treated for breast cancer and no mention of HIV status is made)\n\nClinical trial:\n- Title: Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia\n- Inclusion criteria: female, age 30-49, able to give informed consent\n\nThe patient matches some of the inclusion criteria for the clinical trial: she is a female and within the age range of 30-49. However, the clinical trial is for cervical cancer screening in Cambodia, and the patient has breast cancer, not cervical. Additionally, there is no information provided about her geographical location or HIV status, which are relevant to the trial's focus.\n\nGiven that the patient does not have cervical cancer and the trial is specifically for cervical cancer screening, and there is no information about her HIV status or location, the patient does not have sufficient information to qualify for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "260": {
        "output": "Based on the provided patient note, let's evaluate the patient's eligibility against the inclusion criteria for the clinical trial titled \"A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)\":\n\n1. Female participants: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n2. Postmenopausal status: The patient is described as postmenopausal, so she meets this criterion.\n3. Histologically confirmed invasive breast carcinoma, with all of the following characteristics:\n   - (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm) in largest diameter (cT1-3) by MRI: The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n   - (ii) Stage I to operable Stage III breast cancer: The patient is a candidate for tumor resection, which suggests that the cancer is operable. However, the stage is not explicitly stated, but we can infer it might be Stage II or III due to axillary node involvement.\n   - (iii) Documented absence of distant metastases (M0): The patient has metastatic lesions noted on CXR, which indicates the presence of distant metastases (M1), thus not meeting this criterion.\n4. Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer: The patient has HER2-positive and ER/PR-negative breast cancer, which does not meet the criterion of ER+ and HER2-.\n5. Breast cancer eligible for primary surgery: The patient is a candidate for tumor resection, so she meets this criterion.\n6. Tumor tissue from FFPE core biopsy of breast primary tumor that is confirmed as evaluable for PIK3CA mutation status by central histopathology laboratory: There is no information provided about PIK3CA mutation status evaluation.\n7. ECOG performance status of 0 or 1: There is no information on the patient's ECOG performance status.\n8. Fasting glucose less than or equal to (</=) 125 mg/dL: There is no information on the patient's fasting glucose level.\n9. Adequate hematological, renal, and hepatic function: There is no information on the patient's hematological, renal, or hepatic function.\n10. Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule: There is no information on any conditions that might interfere with compliance.\n11. Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol, in the investigator's judgment: The patient agrees to tumor resection prior to chemotherapy, which suggests willingness to comply with treatment, but overall compliance with the study cannot be evaluated from the information provided.\n\nThe patient clearly does not meet two critical inclusion criteria: the absence of distant metastases (M0) and having ER+ HER2- breast cancer. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "261": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient's condition is invasive ductal breast carcinoma in the left upper outer quadrant with HER2-positive and ER/PR negative markers. She also has metastatic lesions and positive lymph nodes.\n\nThe clinical trial in question is looking for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The inclusion criteria specify that patients must have histologically confirmed HNSCC, be recurrent/metastatic, have been previously treated or unsuitable for platinum-containing therapy, and meet various other health and safety parameters.\n\nBased on the information provided in the patient note, the patient does not meet the primary disease condition for inclusion in the study, as she has breast cancer, not head and neck squamous cell carcinoma. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "262": {
        "output": "",
        "label": 0
    },
    "263": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the clinical trial criteria, to be eligible the patient must meet the following:\n\n- Histologically documented invasive adenocarcinoma (any subtype) of the breast with clinical stage T1-2 (0-5 cm) and pathologic stage N0-1, M0 disease\n- Lumpectomy with 1-2 cm margin required within 9 weeks of initiation of protocol radiotherapy\n- Axillary dissection required for premenopausal patients and recommended for postmenopausal patients (Irradiation of clinically negative axilla is an acceptable alternative to axillary dissection in postmenopausal patients)\n\nThe patient note provides the following relevant information:\n\n- The patient has invasive ductal breast carcinoma, which is a type of adenocarcinoma.\n- The tumor size is 3 cm, which fits within the clinical stage T1-2 criteria.\n- The patient has undergone axillary sampling with 5 positive lymph nodes, which fits within the pathologic stage N0-1 criteria.\n- The patient has metastatic lesions (CXR was remarkable for metastatic lesions), which suggests the presence of metastases and therefore may not fit the M0 disease criteria.\n- The patient is postmenopausal.\n- The patient is a candidate for tumor resection.\n\nGiven the information provided, there is a concern regarding the M0 criterion because the presence of metastatic lesions suggests that the patient may not have M0 disease. Since M0 implies no distant metastasis, and the patient's CXR indicates metastatic lesions, this patient would not meet the inclusion criteria for the trial, which requires M0 disease status.\n\nTherefore, based on the information provided, the patient is not eligible for the clinical trial due to not meeting the M0 disease criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "264": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria specified in the trial details.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria for Part A:\n- Women age greater than or equal to 18 years\n- AJCC 7 clinical stage II or III breast cancer\n- Biopsy-accessible breast tumor or participant candidates for primary surgery\n- Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\nClinical Trial Exclusion Criteria for Part A:\n- Prior history of non-breast malignancy within 5 years (excluding certain cases)\n- Bilateral invasive or in-situ breast cancer\n- Inflammatory breast cancer\n- Clinical or radiological evidence of distant metastases\n- Prior hormone therapy, chemotherapy, biologic, targeted therapies, or radiation therapy for this malignancy\n- Pregnant or lactating women\n- Certain medical conditions and lack of ability or willingness to give informed consent\n\nThe patient note indicates that the patient has metastatic lesions, which suggest the presence of distant metastases. According to the exclusion criteria for Part A of the study, clinical or radiological evidence of distant metastases would exclude a participant from the trial. Therefore, despite the patient meeting the age and diagnosis criteria, they would be excluded from the trial due to the presence of metastatic lesions.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "265": {
        "output": "Upon reviewing the patient note and the clinical trial criteria, we can ascertain the patient's eligibility for the trial.\n\nThe patient's characteristics based on the note provided:\n- 45-year-old postmenopausal woman\n- Diagnosed with invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Positive lymph node involvement (5 positive lymph nodes)\n- Metastatic lesions present on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nNow, let's compare these characteristics with the inclusion criteria for the advanced/metastatic setting of the clinical trial:\n\nInclusion Criteria for the advanced/metastatic setting:\n- Adult women aged \u226518 years (The patient is 45 years old, so she meets this criterion)\n- Patients with the diagnosis of invasive breast cancer (The patient has invasive ductal breast carcinoma, so she meets this criterion)\n- Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging) (The patient has metastatic lesions on CXR, so she meets this criterion)\n- Patients, who are willing and able to sign the informed consent form (The patient note does not mention any unwillingness or inability to consent, so we can assume for this assessment that she is able to sign the consent form)\n\nThe patient meets all the inclusion criteria for the advanced/metastatic setting of the clinical trial. There is no mention of exclusion criteria in the provided clinical trial information, so we cannot assess if any exclusion criteria would apply to this patient.\n\nTherefore, based on the information given, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "266": {
        "output": "Upon reviewing the patient's information against the eligibility criteria for the clinical trial titled \"The Impact of the Oncotype DX\u00ae Breast Cancer Assay on Treatment Decisions in a Canadian Population\", let's assess the match:\n\n1. Criterion: Patients must have undergone surgical treatment for breast cancer with adequate evaluation of lymph node status with a sentinel lymph node procedure or full axillary dissection, with positive involvement of 1-3 axillary lymph nodes as confirmed by histologic examination.\n- Patient status: The patient is a candidate for tumor resection and has 5 positive lymph nodes.\n- Assessment: The patient has not yet undergone surgical treatment but is eligible and planned for it, and the lymph node involvement exceeds the specified range of 1-3 positive lymph nodes.\n\n2. Criterion: ECOG performance status 0 or 1\n- Patient status: Not provided.\n- Assessment: Not enough information to determine eligibility based on ECOG performance status.\n\n3. Criterion: Patient must be a candidate for treatment of their cancer with systemic chemotherapy in addition to hormonal therapy.\n- Patient status: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- Assessment: The patient is considered a candidate for chemotherapy.\n\n4. Criterion: Eligible Staging Criteria: T1-3 N1 M0\n- Patient status: The patient has metastatic lesions (CXR).\n- Assessment: The patient does not meet the M0 criteria as they have metastatic lesions indicative of stage M1.\n\n5. Criterion: Breast tumor must undergo central pathology review at GHI and must be found adequate for the Oncotype DX assay.\n- Patient status: Not provided.\n- Assessment: Not enough information to determine eligibility based on the requirement for central pathology review.\n\n6. Criterion: Breast tumor must be estrogen-receptor positive and HER2 positive (IHC/FISH) as per institutional guidelines.\n- Patient status: The tumor is HER2 positive but ER/PR negative.\n- Assessment: The patient does not meet the criteria for an estrogen-receptor positive tumor.\n\nBased on the information provided and comparing it to the inclusion criteria, the patient does not meet several key criteria for the clinical trial, specifically, the lymph node involvement, M staging, and hormone receptor status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "267": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: metastatic lesions\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n- No mention of the specific years of treatment or the type of chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women with node-positive breast cancer\n- Treated with surgery\n- Anthracycline-based or similar cardiotoxic chemotherapy\n- Regional nodal irradiation\n- Treatment between 2000-2007\n\nComparing the two, the patient matches the following criteria:\n- Is a woman with node-positive breast cancer (5 positive lymph nodes)\n- Is a candidate for tumor resection (surgery)\n\nHowever, the patient does not clearly meet the following criteria:\n- No specific information on the type of chemotherapy (whether it is anthracycline-based or not)\n- No information on the years of treatment (must be between 2000-2007)\n\nThe patient's eligibility cannot be fully determined due to the lack of specific information regarding the chemotherapy regimen and the years of treatment. Thus, based on the available information, the patient would be considered:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "268": {
        "output": "Given the patient note:\n\n- The patient is a 45-year-old postmenopausal woman, which fits within the age range of the clinical trial (\u226518 and \u226470 years).\n- The patient has cytologically confirmed HER2-positive metastatic breast cancer, which meets the requirement of having \"histologically or cytologically confirmed HER2 positive metastatic breast cancer which failed prior therapies.\"\n- The patient is a candidate for tumor resection and plans to undergo this prior to chemotherapy. We do not have information about her previous therapies aside from no mention of capecitabine, which aligns with the trial's criterion of \"No previous treatment of capecitabine during the past 1 year.\"\n\nGiven the clinical trial details:\n\n- The trial is evaluating Pyrotinib in combination with Capecitabine in patients with HER2 Positive Metastatic Breast Cancer.\n- The inclusion criteria require patients to have measurable lesions, be between the ages of 18 and 70, have an ECOG performance status of 0 to 1, a life expectancy of more than 12 weeks, and specific laboratory values.\n\nHowever, the patient note does not provide the following information:\n\n- ECOG performance status.\n- Life expectancy.\n- Specific laboratory values (ANC, platelet count, hemoglobin, total bilirubin, ALT, AST, BUN, creatinine clearance rate, LVEF, QTcF).\n- Whether at least one measurable lesion exists that is in accordance with RECIST 1.1.\n\nSince we lack the complete information needed to determine if the patient meets all of the inclusion criteria, particularly the laboratory values, ECOG performance status, and specific lesion measurements according to RECIST 1.1, the patient's eligibility cannot be definitively assessed based on the information provided.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "269": {
        "output": "To determine the patient's eligibility for the \"Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)\" clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria provided for the trial.\n\nPatient Characteristics:\n- Gender: Female\n- Age: 45 years old\n- Medical Diagnosis: Operable invasive ductal breast carcinoma\n- Tumor Size: 3 cm (T2)\n- Lymph Nodes: 5 positive lymph nodes (N1)\n- Metastases: Distant metastases present (M1)\n- Candidate for tumor resection: Yes\n\nClinical Trial Inclusion Criteria:\n- Female\n- Age 45 or greater\n- Diagnosed with operable invasive breast cancer, T1 and T2 (< 3.5 cm)\n- N0, M0 (no lymph node involvement and no metastases), confirmed by cytological or histological examination\n- Suited for breast conserving surgery\n- Have had an ipsilateral diagnostic mammogram within 12 months of enrollment\n\nAssessment:\n- The patient is a 45-year-old female, which meets the gender and age criteria.\n- The patient has been diagnosed with operable invasive breast cancer and has a tumor size of 3 cm, which fits the T2 category and is suitable for breast conserving surgery. This aligns with the trial's inclusion criteria.\n- However, the patient has 5 positive lymph nodes, which indicates lymph node involvement (N1), whereas the trial requires N0 (no lymph node involvement).\n- The patient also has distant metastases (M1), while the trial specifies the need for M0 status (no metastases).\n- There is no information on whether the patient had an ipsilateral diagnostic mammogram within the past 12 months.\n\nConclusion:\nEven though the patient meets some of the inclusion criteria such as age, sex, and suitability for breast conserving surgery, she does not meet the criteria of N0, M0 status due to having positive lymph nodes and metastatic lesions. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "270": {
        "output": "",
        "label": 0
    },
    "271": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, it appears that the patient does not meet the criteria for participation in the clinical trial. The trial is focused on patients undergoing total knee replacement surgery with tranexamic acid single bolus infusion and is looking for patients with osteoarthrosis who are having an elective TKR operation and have an ASA score of I-III.\n\nThe patient in the note is described as having breast cancer with no mention of osteoarthrosis or a need for knee replacement surgery. Therefore, the patient does not fulfill the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "272": {
        "output": "",
        "label": 0
    },
    "273": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 45 years old\n- Diagnosis: Invasive ductal breast carcinoma \n- Tumor Size: 3 cm\n- HER2-positive and ER/PR negative\n- Metastatic lesions noted in CXR\n- No mention of ECOG performance status\n- Willing to provide informed consent, as indicated by her agreement for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Newly diagnosed infiltrating ductal carcinoma (IDC) of the breast\n- Primary tumor size >= 1.0 cm\n- Calculated creatinine clearance >= 50 mL/min (no data provided)\n- Willing and able to provide informed consent\n- Age \u2265 18 years\n- ECOG performance status 0-2 (no data provided)\n\nThe patient's age and the willingness to provide informed consent fulfill the trial's inclusion criteria. The primary tumor size of 3 cm also meets the trial's requirement of being at least 1.0 cm. The patient has been diagnosed with invasive ductal carcinoma (IDC), which is specified in the inclusion criteria.\n\nHowever, there is insufficient information regarding the patient's ECOG performance status and creatinine clearance. Additionally, the presence of metastatic lesions suggests that the patient may not have early-stage breast cancer, which is what the trial appears to be targeting, given that the study is evaluating the feasibility of CEST MRI in patients with early-stage breast cancer.\n\nGiven the lack of information on the patient's ECOG performance status and creatinine clearance, as well as potential concerns about the stage of the patient's breast cancer, the patient cannot be deemed eligible without further information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "274": {
        "output": "The patient in the provided note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has invasive ductal breast carcinoma in the left upper outer quadrant that is 3 cm in diameter, HER2-positive and ER/PR negative. Additionally, she has metastatic lesions noted on CXR and positive axillary lymph nodes.\n\nNow, let's compare this information to the inclusion criteria of the clinical trial:\n\n1. Tumor diameter \u22643 cm - The patient's tumor is 3 cm, which meets this criterion.\n2. Tumor from the papilla>2cm - The note does not specify the distance of the tumor from the papilla.\n3. Low grade ductal carcinoma in situ - The note specifies invasive ductal carcinoma, which does not meet the criterion of low-grade ductal carcinoma in situ.\n4. Candidate for breast-conserving surgery - She is a candidate for tumor resection, which could imply breast-conserving surgery, but this is not explicitly stated.\n5. Must have undergone lumpectomy with negative margins or minimal margin involvement - The patient agrees to tumor resection prior to chemotherapy, but it is not stated that she has already undergone a lumpectomy with negative margins or minimal margin involvement.\n6. Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection - It is mentioned that she has had axillary sampling and is a candidate for tumor resection, but there is no mention of current re-excision.\n7. No evidence of metastatic disease - The patient has metastatic lesions noted on CXR, which does not meet this criterion.\n8. Informed consent - There is no information about whether informed consent has been given, though it is mentioned that she agrees to the tumor resection.\n\nBased on the provided information, the patient does not meet several of the inclusion criteria, most notably the presence of metastatic disease, which explicitly excludes her from the trial. The information regarding whether the patient has already undergone lumpectomy or the distance of the tumor from the papilla is not provided, but given the presence of metastases, these details would not influence the eligibility decision.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "275": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy,\" we will compare the patient note with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- Core biopsy revealed invasive ductal breast carcinoma, HER2-positive, and ER/PR negative.\n- Axillary sampling showed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is not pregnant or breastfeeding.\n- The patient has a life expectancy of more than 6 months (implied as she is a candidate for tumor resection).\n- The patient is capable and willing to provide informed consent (implied as she agrees to tumor resection prior to chemotherapy).\n\nClinical Trial Inclusion Criteria:\n- Capable and willing to provide informed consent.\n- Women must not be pregnant or breastfeeding.\n- Patients must be postmenopausal, men, or premenopausal women for whom standard endocrine therapy is planned.\n- Medically stable as judged by the patient's physician.\n- Life expectancy estimated at > 6 months.\n- ECOG performance status of 0-3 (restricted to 0-2 if age > 70 years).\n- Histologically confirmed metastatic breast cancer.\n- Primary tumor and/or metastatic site must be ER+.\n- No history of allergic reaction to 18F-FES.\n- Not in liver failure.\n- No HER2+ metastatic disease.\n- No prior endocrine therapy for metastatic disease.\n- No history of > 1 line of administered chemotherapy for metastatic disease.\n- Disease must be present in at least one non-liver site and visualized on PET/CT.\n- Ability to lie still for a 20-30 minute PET/CT scan.\n- Weight within the maximum limit for the PET/CT scanner.\n- Participation in an institution that has completed scanner qualification procedures.\n\nBased on the patient note, the patient cannot be included in the trial for the following reasons:\n- The patient has HER2-positive metastatic breast cancer, while the trial explicitly excludes patients with HER2+ metastatic disease.\n- The patient's ER/PR status is negative, while the trial requires the primary tumor and/or metastatic site to be ER+.\n\nGiven this information, the patient does not meet two critical inclusion criteria for the trial: HER2 status and estrogen receptor status. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "276": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal carcinoma, 3 cm in size, in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is using multivitamins and iron supplements.\n- She has agreed to tumor resection prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Women, aged 18 years and older.\n- Able to give informed consent herself.\n- WHO performance score \u2264 2.\n- Biopsy proven cT1-2 N0-2 MX invasive breast cancer with a size of \u2264 3.0 cm.\n- Histological type of tumor: invasive ductal carcinoma (IDC), not otherwise specified (NOS) or no special type (NST).\n- The target breast fits in the cup of the dedicated MR-HIFU breast system.\n- Patient weight is limited to \u2264 90 kg.\n- The distance of the tumor, including a 5 mm margin around the tumor, from the skin, nipple and pectoral wall is at least 1.0 cm measured on MRI.\n- The tumor is located within the reach of the HIFU beam produced by the transducers in the HIFU breast system.\n\nThe patient appears to meet the age criterion, has given informed consent, and has an invasive ductal carcinoma with a size of \u2264 3.0 cm as required by the trial. However, the trial criteria specify a WHO performance score \u2264 2, but the patient's performance score is not mentioned in the note. Additionally, the patient has positive lymph nodes (N0-2) and the histological type matches the inclusion criteria (IDC). The patient's weight is not specified, and there is no information provided regarding the tumor's distance from the skin, nipple, and pectoral wall based on MRI measurements or whether the tumor is within the reach of the HIFU beam.\n\nGiven the available information, the patient could potentially be eligible for the trial, but there is insufficient information in the note to fully confirm eligibility based on the trial's inclusion criteria regarding WHO performance score, the patient's weight, and detailed MRI measurements. Therefore, the trial-level eligibility should be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "277": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Aged \u226518 and \u226470 years (Patient is 45 years old, so she meets this criterion)\n- ECOG performance status of 0 to 1 (Not specified in the patient note, so we cannot determine this)\n- Life expectancy of more than 12 weeks (Not specified in the patient note, so we cannot determine this)\n- At least one measurable lesion exists (The patient has a 3 cm invasive ductal carcinoma, meeting this criterion)\n- Histologically or cytologic confirmed HER2 positive advanced breast cancer which failed prior therapies (The patient is HER2 positive but has not received prior therapies, so does not meet this criterion)\n- Required laboratory values (Not specified in the patient note, so we cannot determine this)\n- Signed informed consent (The patient has agreed to tumor resection, which may indicate a willingness to consent, but this is not the same as signing informed consent for the trial)\n\nBased on the information provided, the patient does not meet the trial inclusion criteria regarding prior failed therapies for breast cancer. The patient's note also lacks information on her ECOG performance status, life expectancy, specific laboratory values, and written informed consent for the clinical trial itself.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "278": {
        "output": "Let's compare the patient's information with the clinical trial inclusion criteria:\n\nPatient's information:\n- 45-year-old postmenopausal woman\n- Diagnosed with breast cancer\n- Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (Stage IV)\n- Candidate for tumor resection\n- Non-smoker and non-alcoholic\n- No children\n- Using multivitamins and iron supplements\n\nClinical trial inclusion criteria:\n- Women aged 50 and over\n- Initially diagnosed with breast cancer by histological tissue diagnosis in 2003 or later\n- Currently Stage IV (metastatic) breast cancer with stable disease\n- ECOG Performance Score of 0 or 1\n- Able to participate in mildly strenuous physical effort\n- Able to read, speak, and write in English\n- Able to be accompanied by their spouse or significant other partner/friend\n- Able to travel to the retreat site\n- Must be right handed\n- Must have had a CT scan of the chest and abdomen within 2 months of study entry\n- (CAREGIVERS ONLY criteria not applicable to the patient)\n\nBased on the information provided and the inclusion criteria of the clinical trial, the patient does not meet the criteria due to the following reasons:\n\n- The patient is 45 years old, while the trial requires participants to be aged 50 and over.\n- There's no information regarding the patient's ECOG Performance Score.\n- The criteria require the patient to be right handed, which is not mentioned in the patient's information.\n- There's no information on whether the patient's disease is stable or not, as required by the inclusion criteria.\n- There's no mention of the patient being able to travel to the retreat site, nor about the accompaniment by a spouse or significant other partner/friend.\n\nDue to the age discrepancy and lack of information on several other criteria, the patient does not meet the sufficient criteria to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "279": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is evaluating the efficacy and safety of ustekinumab in the treatment of anti-TNF\u03b1 naive participants with active radiographic axial spondyloarthritis (AxSpA).\n\nTo assess the patient's eligibility for the trial, let's compare the patient's characteristics to the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n1. Participants must have a diagnosis of definite ankylosing spondylitis (AS), confirmed by a central x-ray reader and at least 1 clinical criterion met.\n2. Participants must have symptoms of active disease, evidenced by a BASDAI score of >=4 and a VAS score for total back pain of >=4.\n3. Participants with elevated hsCRP level of >=0.300 mg/dL at Screening.\n4. If using NSAIDs or other analgesics for AS, must be on a stable dose for at least 2 weeks prior to the first administration of study agent; or if not using NSAIDs/analgesics for AS, must not have received them for at least 2 weeks.\n5. A woman of childbearing potential must have a negative pregnancy test.\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman with breast cancer.\n- HER2-positive and ER/PR-negative invasive ductal breast carcinoma.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Metastatic lesions present on CXR.\n- Candidate for tumor resection and agrees to chemotherapy.\n\nThe patient does not have a diagnosis of ankylosing spondylitis (AS) nor is there any mention of symptoms related to AxSpA such as back pain or elevated hsCRP levels. The trial is specifically for participants with active radiographic AxSpA, and this does not apply to the patient based on the information provided.\n\nSince the patient does not meet the key disease-specific inclusion criteria for the trial (a diagnosis of AS and symptoms of active disease related to AS), the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "280": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial):\n\nInclusion Criteria Checklist:\n\n1. Female patients who are >18 years of age - The patient is a 45-year-old female, so she meets this criterion.\n2. ECOG 0 or 1 - There is no information provided about the patient's ECOG performance status, so we cannot confirm eligibility based on this criterion.\n3. Invasive carcinoma of the breast on histologic examination - The patient has invasive ductal breast carcinoma, which satisfies this requirement.\n4. HER2-negative tumor - The patient's tumor is HER2-positive, which does not meet the requirement of the trial for the tumor to be HER2-negative.\n5. ER- and PR-negative tumor - The patient's tumor is ER/PR negative, which meets this criterion.\n6. Lymph node-positive disease - The patient has 5 positive lymph nodes, meeting this criterion.\n7. Staging criteria must be met - The tumor size is >2.0 cm, and the patient has lymph node-positive disease, so this criterion appears to be met.\n8. Mastectomy or lumpectomy in the adjuvant group - The patient is a candidate for tumor resection, but it is not clear whether she is in the adjuvant group or will be having the surgery prior to chemotherapy (neoadjuvant).\n9. Nodal surgery procedure in the adjuvant group - There is no information provided about the type of nodal surgery procedure the patient has undergone.\n10. LVEF assessment must be >50% - There is no information on the patient's LVEF assessment.\n11. Adequate hepatic, renal, and bone marrow function - There is no information provided about the patient's hepatic, renal, and bone marrow function.\n12. Ability and willingness to comply with the study - The patient agrees to tumor resection prior to chemotherapy, which may indicate a willingness to comply with medical procedures, but this is not sufficient to confirm this criterion.\n\nBased on the available information, the patient does not meet the inclusion criteria due to the tumor being HER2-positive, which is explicitly excluded in the trial that requires HER2-negative status. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "281": {
        "output": "In this case, we have a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR-negative. The clinical trial in question is looking for postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer.\n\nBased on the information provided:\n\n- The patient is postmenopausal, which aligns with the study's inclusion criteria.\n- The patient has adenocarcinoma of the breast, which is required by the study.\n- The patient's tumor is \u22651 centimeter in diameter, which meets the study criteria.\n- Neoadjuvant endocrine monotherapy could be considered for the patient's treatment since she is a candidate for tumor resection prior to chemotherapy; however, the trial seems to be looking for HR+ candidates while the patient is ER/PR negative.\n- The patient's primary breast cancer is suitable for a baseline core biopsy, which is a requirement of the study.\n- There is no information given about the patient's organ function, but typically, it would be assessed before entering a clinical trial.\n\nThe critical discrepancy here is the tumor's biomarker status. The clinical trial requires the breast cancer to be HR+ and HER2-, but the patient's tumor is HER2+ and ER/PR-. This inconsistency means the patient does not meet the necessary inclusion criteria based on the hormonal receptor status of the tumor.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "282": {
        "output": "To assess the eligibility of the patient for the clinical trial, we must compare the patient's clinical characteristics against the inclusion criteria detailed in the trial description. \n\nThe patient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant, 3 cm\n- HER2-positive, ER/PR-negative\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nThe clinical trial's inclusion criteria:\n- ECOG performance status 0 or 1 within 2 weeks prior to screening\n- Histologically confirmed invasive breast cancer, stage II-III at diagnosis, no metastatic disease allowed\n- ER- and PR- should meet certain staining criteria (\u226410% cells stain positive with weak intensity score \u22643 or \u22641% cells stain positive, with weak or intermediate intensity score \u22643)\n- HER2 negative, not eligible for anti-HER2 therapy\n- Completed neoadjuvant taxane +/- anthracycline; no prior cisplatin, carboplatin or capecitabine\n- Patients must have completed definitive resection of primary tumor\n- Post neoadjuvant chemotherapy, patients must have residual invasive cancer in the breast at the time of surgery, measuring \u22651 cm in diameter\n- Hemoglobin > 9.0 g/dL, Platelets > 100,000 mm\u00b3, ANC > 1500 mm\u00b3\n- Calculated creatinine clearance of > 50 mL/min\n- Bilirubin \u2264 1.5 x ULN (except in patients with Gilbert\u2019s disease \u2264 3.0 mg/dL)\n- AST \u2264 2.5 x ULN, ALT \u2264 2.5 x ULN\n- No active \u2265 grade 2 neuropathy\n- No adjuvant chemotherapy other than specified in the protocol\n\nThe patient is not eligible for the clinical trial based on the following mismatches with the inclusion criteria:\n\n1. The patient has metastatic lesions present, which is explicitly not allowed in the trial as \"no metastatic disease allowed.\"\n2. The patient's tumor is HER2-positive, while the trial requires HER2-negative status that is not eligible for anti-HER2 therapy.\n\nGiven these discrepancies, the patient does not meet the essential inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "283": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Adjuvant FEC Versus EP in Breast Cancer (MIG5),\" we must compare the patient's information with the inclusion criteria of the trial. Let's go through the criteria one by one:\n\n1. **Women with histologically confirmed breast cancer who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection**: The patient has cytologically confirmed breast cancer and is a candidate for tumor resection, but it is not specified if she has already undergone surgery or lymph node dissection.\n\n2. **Lymph node-positive disease with less than 10 involved axillary lymph nodes**: The patient has 5 positive lymph nodes, which meets this criterion.\n\n3. **Surgery performed not more than 5 weeks before randomization**: There is no information on whether the surgery has been performed yet or the timing relative to randomization.\n\n4. **ECOG performance status 0**: The patient's ECOG performance status is not provided.\n\n5. **Absolute neutrophil count \u2265 2,000/mm\u00b3**: The patient's absolute neutrophil count is not provided.\n\n6. **WBC \u2265 3,000/mm\u00b3**: The patient's white blood cell count is not provided.\n\n7. **Platelet count \u2265 100,000/mm\u00b3**: The patient's platelet count is not provided.\n\n8. **Bilirubin \u2264 1.5 times upper limit of normal (ULN)**: The patient's bilirubin level is not provided.\n\n9. **AST and ALT \u2264 1.5 times ULN**: The patient's AST and ALT levels are not provided.\n\n10. **Postoperative regional radiotherapy limited to the remaining breast admitted for patients who received breast-conserving surgery**: This is applicable only if breast-conserving surgery is performed, but we do not have information on the type of surgery the patient will undergo.\n\n11. **Written informed consent**: It is not specified if the patient has provided written informed consent, but she agrees to undergo tumor resection prior to chemotherapy, suggesting a willingness to participate in treatment.\n\nBased on the information provided, the patient has not met several of the inclusion criteria due to the lack of specific information in the patient note. Therefore, the patient note does not contain sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "284": {
        "output": "Based on the provided information, let's assess the eligibility of the patient for the clinical trial.\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Written informed consent\n- ECOG performance status 0-1\n- Clinical stage IV invasive mammary carcinoma\n- HER2 negative (for phase II), any ER/PR can enroll in phase 1b\n- Androgen receptor-positive (>= 10% tumor cell nuclei immunoreactivity)\n- Measurable or bone-only evaluable disease\n- No limit on the number of prior therapies if performance status is adequate\n- Prior treatment with anti-androgens other than enzalutamide is acceptable\n- Adequate hematologic, hepatic, and renal function\n- Ability to swallow and retain oral medication\n- Postmenopausal or surgically sterile, or agreement to use contraception\n- Radiation therapy completed >= 2 weeks prior to the start of the trial and recovery from the toxicity (=< grade 1)\n- All screening assessments completed\n\nThe patient has HER2-positive breast cancer, whereas the trial requires HER2-negative status for phase II. The patient note does not provide information on the ECOG performance status or whether the patient has given written informed consent, has measurable or bone-only evaluable disease, has adequate hematologic, hepatic, and renal function, and whether all screening assessments have been completed.\n\nSince the HER2 status of the patient does not match the HER2-negative requirement for phase II of the trial, and there is insufficient information to determine eligibility based on other criteria, the patient cannot be considered eligible for the phase II part of the trial. However, it is not clear whether the patient could be eligible for the phase 1b part, as the HER2 status is not a disqualifying factor for that phase and other information is not provided.\n\nConsidering the information at hand, the patient does not meet the core requirement for phase II due to HER2 positivity. The eligibility for phase 1b cannot be determined without additional information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "285": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can make the following assessment:\n\nThe clinical trial is focused on patients with focal pancreatic masses and lymph nodes, requiring a diagnosis of solid pancreatic tumor masses with cytological/histological confirmation. The patient in the note has been diagnosed with invasive ductal breast carcinoma, which is unrelated to pancreatic tumors. Therefore, the patient's condition does not match the disease and organ specified in the inclusion criteria for the clinical trial.\n\nGiven this mismatch between the patient's condition and the target condition of the clinical trial, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "286": {
        "output": "Based on the patient note provided:\n\n- The patient is a 45-year-old postmenopausal woman, which matches the age criteria of 18 - 65 years old for the trial.\n- The patient has been diagnosed with breast cancer, which is a required condition for the trial.\n- The cancer is invasive ductal carcinoma, which is included in the \"all pathological types are applicable\" clause of the trial's inclusion criteria.\n- The tumor size and lymph node involvement (3 cm tumor, 5 positive lymph nodes) correspond to the staging criteria of cT1-2N0-1M0.\n- The tumor is HER2-positive, which does not meet the HER2-negative requirement of the trial. The trial specifically requires the tumor to be triple-negative (ER/PR/Her2 negative).\n- The patient has metastatic lesions as noted on the CXR, which is beyond the stage allowed by the trial (M0 indicates no distant metastasis).\n- There is no information on the patient's ECOG performance score, but given the severity of the cancer, it may or may not be 0 or 1.\n- The patient is willing to undergo tumor resection, which aligns with the trial's requirement of no mass or microscopic tumor residue after surgical resection.\n- There is no information on the patient's willingness to return to the enrolling institution for follow-up.\n\nThe primary reason the patient is not eligible for the clinical trial is due to the HER2-positive status of the tumor, which does not meet the trial's requirement for triple-negative breast cancer (all ER/PR/Her2 negative). Additionally, the presence of metastatic lesions excludes the patient, as the trial specifies an M0 staging (no distant metastasis).\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "287": {
        "output": "To assess the eligibility of the patient for the clinical trial, we need to check against the inclusion criteria provided:\n\n1. Invasive mamma carcinoma as verified by core cut biopsy: The patient note confirms the presence of invasive ductal breast carcinoma confirmed by a core biopsy.\n2. Extensive ductal carcinoma in situ as verified by core cut biopsy (at least 5 cm or at least 2,5 cm and G3 grading): The patient note does not provide information about ductal carcinoma in situ, but it does mention a 3 cm invasive carcinoma, which meets the criteria for invasive carcinoma.\n3. Clinical stage tumor T1-T3: The patient has been diagnosed with breast cancer, but the exact T stage is not specified in the patient note.\n4. No signs of axillary lymph node metastasis on clinical examination including ultrasound examination: The patient note states that axillary sampling revealed 5 positive lymph nodes, which indicates metastasis and hence does not meet this criterion.\n5. No signs of distant metastatic disease: The patient note mentions metastatic lesions found on CXR, which indicates the presence of distant metastasis and fails to meet this criterion.\n6. Male/ female patient in the age not less than 18 years: The patient is a 45-year-old woman, which meets the age criterion.\n7. Karnofsky performance status at least 70% or Eastern Cooperative Oncology Group (ECOG) score not higher than 1: There is no information provided about the patient's performance status or ECOG score.\n\nBased on the information provided, the patient does not meet the inclusion criteria regarding axillary lymph node metastasis and the presence of distant metastatic disease. Therefore, the patient is not eligible for the trial. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "288": {
        "output": "Patient Note Analysis:\n1. The patient is a 45-year-old postmenopausal woman, fitting the age criteria of being \u226518 years.\n2. Histologic documentation of invasive adenocarcinoma of the breast is confirmed.\n3. The pathology reveals a 3 cm invasive ductal breast carcinoma which is HER2-positive and ER/PR negative.\n4. Axillary sampling revealed 5 positive lymph nodes, indicating N1-N2a stage.\n5. The patient has not received neoadjuvant chemotherapy.\n6. The patient is a candidate for tumor resection, and the inclusion criteria require that the last surgery for breast cancer must be within 56 days prior to enrollment; however, the surgery has not yet been performed.\n7. The patient is using multivitamins and iron supplements and has no mention of other treatments that could interfere with radiation therapy.\n8. It is not specified whether the patient's recovery from surgery has had the incision completely healed and free of infection, as the surgery is planned but not yet completed.\n9. No mention of chemotherapy-related toxicity, as chemotherapy has not been started.\n10. The patient is postmenopausal, which aligns with the trial's requirements for postmenopausal status.\n11. The patient has a documented negative pregnancy test within the required timeframe is not mentioned, but as a postmenopausal woman, this may be less relevant.\n12. Whether the patient is willing to agree to use medically accepted forms of pregnancy prevention is not discussed, as it might not apply due to her postmenopausal status.\n13. There is no information given on the patient's Karnofsky performance status, which is required to be between 70-100%.\n14. The ability to understand and willingness to sign the consent form in English is not mentioned.\n\nBased on the information provided, the patient fits many of the inclusion criteria, such as age, postmenopausal status, and confirmed invasive adenocarcinoma of the breast with appropriate pathology staging. However, there is insufficient information about the Karnofsky performance status, the exact surgical status and healing, as well as understanding and consent in English.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "289": {
        "output": "Based on the provided clinical trial information and the patient note, the patient does not appear to meet the inclusion criteria for the clinical trial focused on cataract patients with corneal endothelial dysfunction. The patient has breast cancer and there is no mention of cataract or corneal endothelial dysfunction in the patient's note.\n\nThe inclusion criteria for the clinical trial are:\n\n- Subjects are older than 18 years.\n- Subjects have corneal endothelial dysfunction combined with cataract.\n- Subjects have mild to moderate cortical and/or nuclear cataract.\n- Subjects are able and willing to provide informed consent.\n\nThe patient's medical condition (breast cancer) is not relevant to the trial's focus (cataract and corneal endothelial dysfunction). Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "290": {
        "output": "To determine the trial-level eligibility for this patient, we need to assess each inclusion criterion against the patient's information:\n\n- Must sign informed consent: There is no information provided about whether the patient has signed an informed consent, but typically this is a procedural step that can be completed if the patient is willing to participate.\n- Surgical treatment of the breast must have been lumpectomy; the margins of the resected specimen must be histologically free of tumor (negative surgical margins per National Surgical Adjuvant Breast and Bowel Project [NSABP] criteria): The patient note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. Since the patient has not yet undergone surgery, this criterion cannot be assessed.\n- On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma: The patient has invasive ductal breast carcinoma, which meets this criterion.\n- For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy [SNB] alone or axillary dissection [with a minimum of six axillary nodes removed], and the axillary node[s] must be pathologically negative); patients over 70 with estrogen receptor positive (ER+) tumors no greater than 2 cm do not require axillary evaluation, but MUST be clinically node negative on examination and all available imaging (clinical N0): The patient had axillary sampling with 5 positive lymph nodes, which does not meet the criterion of having pathologically negative axillary nodes.\n- The T stage must be Tis, T1, or T2; if T2, the tumor must be =< 3.0 cm in maximum diameter: The tumor is 3 cm invasive ductal breast carcinoma, which aligns with the T2 stage requirement of being no larger than 3.0 cm in maximum diameter.\n- Estrogen receptor positive tumor and/or progesterone receptor positive tumor: The patient has an ER/PR negative tumor, which does not meet the criterion of having an estrogen receptor and/or progesterone receptor positive tumor.\n\nBased on the provided information, the patient does not meet the following key inclusion criteria:\n\n- The patient has not yet had a lumpectomy, so the status of the surgical margins is unknown.\n- The patient has positive axillary lymph nodes, whereas the trial requires them to be pathologically negative.\n- The patient's tumor is ER/PR negative, which does not meet the trial's requirement for hormone receptor-positive tumors.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "291": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is apparent that the patient is not eligible for the trial. The patient has cytologically confirmed breast cancer, while the clinical trial is focused on locally advanced rectal cancer. The inclusion criteria specifically require a diagnosis of rectal adenocarcinoma, which the patient does not have. Therefore, the patient does not meet the necessary condition to participate in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "292": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is HER2-positive and ER/PR negative. This information aligns with the inclusion criteria of the clinical trial which requires anatomopathological samples (surgical specimens or core needle biopsy) from female participants with a histopathological diagnosis of invasive breast cancer.\n\nThe patient's condition fits the trial's inclusion criteria since she is a female with a confirmed diagnosis of invasive breast cancer and has a core needle biopsy that revealed HER2-positive invasive ductal breast carcinoma.\n\nThere are no exclusion criteria provided in the trial description that would exclude the patient from participation. The patient's age, gender, and the diagnosis of breast cancer with HER2-positive status all qualify her for the observational study on HER2 status of breast invasive carcinoma in Latin American participants.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "293": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer,\" let's compare the patient's characteristics to the inclusion criteria:\n\nInclusion Criteria Assessment:\n- Women aged \u226518 years and < 70 years with life expectancy > 12 months: The patient is a 45-year-old woman, which meets this criterion.\n- Have finished radical operation, pathologically verified no lymph node involvement: The patient's note indicates axillary sampling revealed 5 positive lymph nodes, which does not meet this criterion.\n- Operation specimens are available for ER, progesterone receptor (PR), and Her2 detection, patients should be with ER positive, Her2 negative tumor: The patient's tumor is HER2-positive and ER/PR-negative, which does not meet the ER positive, Her2 negative requirement of the trial.\n- Adequate bone marrow function: There is no information provided about the patient's bone marrow function.\n- Adequate liver and renal function: There is no information provided about the patient's liver and renal function.\n- Has Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1: There is no information provided about the patient's ECOG Performance Score.\n- Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study; the patient is postmenopausal, which implies she is not of child-bearing potential, meeting this condition.\n- Written informed consent according to the local ethics committee requirements: The patient agrees to tumor resection prior to chemotherapy, which suggests a willingness to participate in treatment, but there is no direct information about consent to trial participation.\n\nThe patient does not meet the criteria for lymph node involvement and tumor receptor status (ER positive, Her2 negative). Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "294": {
        "output": "",
        "label": 0
    },
    "295": {
        "output": "Based on the provided patient note and the clinical trial information, we need to assess whether the patient meets the inclusion criteria for the trial:\n\n1. Gender: The trial requires participants to be women. The patient is a woman.\n2. Age: Participants need to be 18 years and older. The patient is 45 years old.\n3. Disease Condition: The trial is looking for participants with histologically proven infiltrating carcinoma of the breast on diagnostic biopsy. The patient has cytologically confirmed invasive ductal breast carcinoma.\n4. ER/PR/HER2 Status: The trial requires participants to be ER-negative, any PR status, and any HER2 status. The patient is HER2-positive and ER/PR-negative, which fits the criteria.\n5. Treatment Status: The trial seeks participants with unresected, untreated breast cancer planning surgical management with mastectomy. The patient is a candidate for tumor resection and agrees to have the surgery prior to chemotherapy, which aligns with this criterion.\n6. Consent: Participants must be willing and able to sign an informed consent form. While the patient note does not specifically mention the patient's willingness to sign an informed consent form, her agreement to undergo surgery prior to chemotherapy suggests a willingness to participate in treatment decisions, which may imply her willingness to consent to the study. However, without explicit mention of consent in the patient note, we cannot definitively assess this criterion.\n\nGiven the information provided, the patient appears to meet all the stated inclusion criteria except for the explicit mention of willingness to sign an informed consent form. Therefore, the patient could be considered eligible if consent is assumed based on her active participation in treatment decisions, or not relevant if we require explicit confirmation of her willingness to consent.\n\nTrial-level eligibility: 1) Not relevant. (due to the lack of explicit information regarding informed consent)",
        "label": 1
    },
    "296": {
        "output": "",
        "label": 2
    },
    "297": {
        "output": "The patient described in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is evaluating the diagnostic properties of intra-operative in-situ thyroglobulin levels in cervical lymph nodes to discriminate between benign and malignant lymph nodes in thyroid cancer patients.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Subject aged 18 years and above, male or female, with valid social security coverage;\n2. Subject willing to participate in the study with a signed informed consent;\n3. Subject being operated for a papillary thyroid cancer, re-operated for persistent/relapsed lymphadenopathy, or for benign thyroid pathology (Graves disease, multinodular goitre, toxic nodule);\n4. Subject having had a blood test for plasma Tg levels and circulating anti-Tg antibodies in the week preceding the surgical intervention.\n\nThe patient in the note does not meet the inclusion criteria as she is diagnosed with breast cancer, not thyroid cancer. Therefore, she is not eligible for this thyroid cancer-specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "298": {
        "output": "",
        "label": 1
    },
    "299": {
        "output": "",
        "label": 1
    },
    "300": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the clinical trial as follows:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- There are metastatic lesions present.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients 18 years of age or older.\n- Patients with choledocholithiasis, benign biliary strictures, malignant biliary strictures.\n- Biliary pathology suggested or confirmed by imaging with abdominal ultrasonography, CT scan, MRI/MRCP scan, or endoscopic ultrasonography (EUS).\n\nAssessment of Eligibility:\n- The patient is 45 years old, which meets the age criterion.\n- However, the patient's diagnosis is breast cancer with HER2-positive and ER/PR-negative status and does not have a condition related to biliary tract disease such as choledocholithiasis, benign biliary strictures, or malignant biliary strictures.\n- There is no indication in the patient note that she has biliary pathology that would make her eligible for a trial focused on cholangiography during ERCP.\n\nBased on this analysis, the patient does not meet the specific inclusion criteria related to the disease condition required for the clinical trial in question. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "301": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the study.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions evident on CXR\n- Candidate for tumor resection, agrees to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patients aged 18 years or older\n- Early high-risk and locally advanced or inflammatory breast cancers\n- Histologically confirmed unilateral breast cancer with invasive ductal histology not otherwise specified (NOS) of high proliferation or grade\n- HER2 negative disease\n- Negative estrogen receptor (ER) and progesterone receptor (PgR), both < 1% locally assessed\n- Representative paraffin-embedded (FFPE) tumor block available\n- ECOG performance status 0 or 1\n- Written informed consent obtained\n- Willing and able to comply with the protocol\n- Consent to the collection of blood samples\n- For non-postmenopausal or non-surgically sterile women: agreement to specific contraceptive methods\n\nComparison:\n- The patient is a female aged 18 years or older, satisfying this criterion.\n- The patient has a confirmed diagnosis of invasive ductal breast carcinoma, satisfying the histology requirement.\n- The patient's tumor is HER2-positive, which does not meet the \"HER2 negative disease\" criterion.\n- The patient has ER/PR negative status, which meets the negative ER and PgR criterion.\n- There is no information regarding the availability of a FFPE tumor block, ECOG performance status, informed consent, willingness to comply with the protocol, or consent to blood sample collection.\n- The patient is postmenopausal, so the requirement for contraceptive agreement does not apply.\n\nBased on this comparison, the patient does not meet the HER2 negative disease criterion of the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "302": {
        "output": "Assessment of the patient's eligibility for the clinical trial titled \"MK-3475 Immunotherapy in Endometrial Carcinoma\":\n\nPatient Characteristics:\n- Age: 45 years (meets age criterion of \u2265 18 years)\n- Diagnosis: Breast cancer (does not match the required diagnosis of endometrial cancer)\n- Stage: Metastatic (not specified as endometrial adenocarcinoma of stages III-IV as required)\n- Treatment Plan: Tumor resection and chemotherapy (does not specify the requirement of primary site biopsy followed by resection of primary tumor site and metastatic sites)\n- GOG performance status: Not mentioned (cannot determine if \u2264 2 as required)\n- Organ function: Not mentioned (cannot determine if within normal limits as defined)\n- Childbearing potential: Not relevant due to being postmenopausal\n\nThe patient does not meet the primary diagnosis criterion of having a FIGO grade 3 endometrioid cancer, serous, clear cell, or mixed high grade endometrial cancer. The patient has breast cancer, which is not the focus of this trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "303": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient appears to be eligible for the trial. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which matches the inclusion criteria of the trial that requires participants to be women with breast cancer. There are no exclusion criteria provided, so we cannot determine if the patient is excluded on any other grounds.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "304": {
        "output": "To determine if the patient is eligible for the clinical trial, we must assess each of the inclusion criteria against the patient's information:\n\nInclusion Criteria Assessment:\n1. Eligible to receive chemotherapy and endocrine therapy: The patient note does not provide information on the patient's Karnofsky index or any potential hematologic, cardiologic, or hepatic contraindications, nor does it mention any comorbidity. Therefore, we cannot confirm this criterion.\n2. Informed consent form signed on the same day or before enrollment: There is no information about the informed consent form being signed.\n3. \u2265 18 years of age at the time of consent: The patient is a 45-year-old woman, which meets this criterion.\n4. Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) & HER2 negative: The patient has HER2-positive and ER/PR-negative breast cancer, which does not meet this criterion.\n5. Axillary lymph node status: 0-3 involved: The patient has 5 positive lymph nodes, which exceeds the criterion of 0-3 involved nodes.\n6. Histologically proven invasive T1a or T1b breast cancer & Hormone receptor negative (ER- and PR-) & HER2 negative: The patient does not meet this criterion, as the tumor is not T1a or T1b and is HER2-positive.\n7. Histologically proven invasive T1a or T1b breast cancer & Hormone receptor negative or positive & HER2 positive & Axillary lymph node status: 0-1 involved: The patient does have HER2-positive breast cancer, but the tumor size (3 cm) suggests it is not T1a or T1b (which are \u2264 2 cm), and the number of positive lymph nodes (5) exceeds the criterion of 0-1 involved.\n\nBased on the information provided in the patient note, the patient does not meet several of the critical inclusion criteria for the clinical trial. Specifically, the patient's cancer is HER2-positive and ER/PR-negative with more than 3 positive lymph nodes, which does not align with the trial's requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "305": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's compare them:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which meets the criterion of the primary tumor being more than 2 cm.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is using multivitamins and iron supplements.\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Biopsy-verified breast cancer\n- Primary tumor more than 2 cm (ultrasound or clinically)\n- The participants must be capable of understanding and giving full informed written consent\n\nThe patient note indicates that the patient has biopsy-verified breast cancer with a primary tumor size more than 2 cm, and there is no indication that she would be unable to understand and give informed consent. Therefore, the patient meets all the inclusion criteria provided for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "306": {
        "output": "To determine the trial-level eligibility for this patient, let's compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer (invasive ductal carcinoma)\n- Tumor size: 3 cm (meets the requirement of a lesion with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter)\n- HER2-positive and ER/PR-negative status (meets the ER-negative and PR-negative status requirement)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions evident in CXR\n- No history of alcohol or smoking\n- No sexual activity, no children\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy\n- Tumor lesion in the breast with a specific measurable size\n- Patients must have stage cT1c - cT4a-d disease\n- Centrally confirmed ER-negative and PR-negative status, HER2-positive\n\nClinical Trial Exclusion Criteria:\n- Patients with stages cT1a, cT1b, or any M1 (the patient has metastatic lesions, which suggests M1 stage)\n- Prior chemotherapy or radiation therapy for breast cancer (the patient has not yet had chemotherapy)\n- History of disease with influence on bone metabolism\n- Use of bisphosphonates or denosumab within the past year\n- Significant dental/oral disease\n- Previous malignant disease being disease-free for less than 5 years\n- Known or suspected heart conditions\n- Currently active infection\n- Incomplete wound healing\n- Contraindications for the use of corticosteroids\n\nBased on the provided information, the patient does not meet one of the exclusion criteria due to the presence of metastatic lesions, which suggests a stage of M1. Therefore, the patient would be excluded from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "307": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The trial is focused on patients with muscle-invasive bladder cancer. The patient in question does not have bladder cancer, and therefore does not meet the basic disease-specific inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "308": {
        "output": "To determine the trial-level eligibility for the patient described, we must compare the patient's information with the inclusion criteria of the clinical trial. The inclusion criteria are as follows:\n\n1. ECOG (Eastern Cooperative Oncology Group): 0-2\n2. Histologic documentation of invasive duct or lobular adenocarcinoma of the breast\n3. If neoadjuvant chemotherapy was NOT administered: pathologic T1-3, N1-2 following definitive surgery\n4. If neoadjuvant chemotherapy was administered, pathology from the definitive surgery must confirm pathologic T1-3, N1-2 disease and also meet one of the following criteria:\n   - Clinical T1-3, N1-2 or\n   - Pathologic confirmation of axillary nodal involvement at presentation (i.e., before neoadjuvant therapy) based on any of the following: Positive fine-needle aspiration (FNA), Positive core needle biopsy.\n5. Complete resection of known breast disease by one of the following surgeries:\n   - Lumpectomy with axillary lymph node dissection with no more than 12 resected lymph nodes.\n   - Mastectomy and axillary lymph node dissection with no more than 12 resected lymph nodes.\n6. ER (estrogen-receptor), PR (progesterone-receptor), and HER2 (human epidermal growth factor receptor 2) testing performed on the primary breast tumor; when applicable, testing must have been performed before receiving neoadjuvant chemotherapy.\n7. Margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the pathologist.\n8. The surgical wound should be completely healed without any signs of infection.\n9. Interval between the last surgery for breast cancer or the completion of adjuvant chemotherapy and study enrollment must be \u2264 56 days (i.e., a maximum of 8 weeks).\n10. If adjuvant chemotherapy is received there should be at least a 10 days gap between the last day of chemotherapy and the enrollment in the study to avoid skin toxicity.\n11. Women of child-bearing potential must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment\n12. Ability to understand and willingness to sign the consent form written in Arabic\n\nBased on the patient note, the following is assessed:\n\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The patient has invasive ductal breast carcinoma, which fits the histologic documentation criterion.\n- There is no mention of whether the patient received neoadjuvant chemotherapy; however, the patient has pathologic T1-3, N1-2 following definitive surgery, which is part of the criteria.\n- The patient has had axillary sampling with 5 positive lymph nodes, which may indicate axillary nodal involvement.\n- There is no mention of the type of surgery, but the patient is a candidate for tumor resection.\n- The tumor is HER2-positive, and ER/PR negative, which meets the HER2 testing requirement.\n- There is no mention of the margins of the resected specimen.\n- There is no information provided about the surgical wound's healing status.\n- There is no information on the interval between the last surgery or chemotherapy and the enrollment.\n- There is no information on the timing of any adjuvant chemotherapy relative to the potential enrollment.\n- The patient's ability to use pregnancy prevention is not mentioned, but as a postmenopausal woman, this may be less relevant. \n- No information on the patient's ability to understand and willingness to sign the consent form written in Arabic.\n\nGiven the information provided, there is insufficient detail to determine that the patient meets all of the inclusion criteria, particularly regarding the surgical margins, healing status, timing of surgery or chemotherapy, and consent form language understanding. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "309": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones,\" let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of being 18 or older.\n- She has metastatic breast cancer, with metastatic lesions noted on CXR.\n- The primary tumor is invasive ductal breast carcinoma, which is a histologic diagnosis of the primary tumor.\n- The tumor is HER2-positive and ER/PR negative, which is consistent with a histologic diagnosis of breast cancer.\n- She has axillary lymph node involvement, but there is clear evidence of metastatic bone disease.\n\nClinical Trial Inclusion Criteria:\n- Aged 18 or older (the patient is 45 years old, so this criterion is met).\n- Radiographic or histologic proof of metastatic bone disease (the patient has a CXR showing metastatic lesions, meeting this criterion).\n- Histologic diagnosis of the primary tumor (the patient has a histologic diagnosis of invasive ductal breast carcinoma, meeting this criterion).\n- Bone metastasis deriving from the bones of the extremities (the patient note does not specify the location of the bone metastases, so it is unclear whether they are in the bones of the extremities).\n\nThe patient note does not provide specific information about the location of the bone metastases, which is necessary to determine eligibility based on the final inclusion criterion. Without this information, we cannot confirm that the patient's bone metastases are from the bones of the extremities, as required by the trial.\n\nTherefore, the trial-level eligibility based on the available information is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "310": {
        "output": "",
        "label": 0
    },
    "311": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old woman with cytologically confirmed breast cancer.\n- The tumor is HER2-positive (which means it is not HER2-negative).\n- The cancer is metastatic, as indicated by the presence of metastatic lesions on CXR.\n- The patient has not yet received chemotherapy but is a candidate for tumor resection prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Histologically/cytologically confirmed diagnosis of breast cancer (the patient meets this criterion).\n- Radiological evidence of inoperable locally advanced or metastatic breast cancer (the patient meets this criterion as there are metastatic lesions).\n- HER2 negative breast cancer (the patient does not meet this criterion as her cancer is HER2-positive).\n- Received at least 2 and no more than 5 prior chemotherapeutic regimens in locally advanced and/or metastatic setting (the patient does not meet this criterion as she has not yet received chemotherapy).\n- Prior therapy has to include an anthracycline and a taxane (not applicable since the patient has not received previous chemotherapy).\n- For the Expansion part: Triple-negative breast cancer (the patient does not meet this criterion as she is HER2-positive and thus not triple-negative).\n\nSince the patient has HER2-positive breast cancer and has not received prior chemotherapy, she does not meet the necessary inclusion criteria for the clinical trial, which requires HER2-negative status and previous chemotherapy.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "312": {
        "output": "Based on the information provided, let's review the patient's eligibility against the inclusion criteria of the clinical trial:\n\nInclusion Criteria Checklist:\n1. The patients signed the written informed consent - Not mentioned, but this is procedural and can be obtained if other criteria are met.\n2. The patients present with non-metastatic unilateral invasive ER-positive, HER2-negative breast cancer with a primary breast tumor > 2cm by imaging or an axillary lymph node > 2cm by imaging - The patient has HER2-positive cancer, which does not meet the HER2-negative requirement.\n3. Postmenopausal women with age less than 70 years old - The patient is a 45-year-old postmenopausal woman, which meets this criterion.\n4. The patients have no history of hormone therapy, chemotherapy, breast cancer surgery, and radiotherapy - The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests no prior treatment consistent with these criteria.\n5. The patients have normal cardiac functions by echocardiography - Not mentioned, not assessable with the provided information.\n6. The patients' ECOG scores are \u22642 - Not mentioned, not assessable with the provided information.\n7. The patients can swallow pills - Not mentioned, but we can assume the patient can swallow pills unless stated otherwise.\n8. The results of patients' blood tests meet specific thresholds - Blood test results are not provided, so this cannot be assessed.\n\nThe critical disqualifying element is the HER2 status of the breast cancer. The trial is explicitly for ER-positive, HER2-negative breast cancer, and the patient has HER2-positive breast cancer. Therefore, the patient does not meet the inclusion criteria based on the tumor's HER2 status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "313": {
        "output": "To assess the eligibility of the patient for the Breast Cancer Weight Loss Study (BWEL Study), we compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n1.1 Histologically confirmed invasive breast cancer within 14 months after first diagnosis\n1.2 HER2 negative\n1.3 Eligible TNM Stages: ER/PR negative: T2 or T3 N0, T0-3N1-3; ER/PR positive: T0-3N1-3 or T3N0\n1.4 No history of invasive breast cancer in 5 years other than current diagnosis\n1.5 Bilateral mammogram within 12 months prior to registration\n1.6 Chest X-Ray or CT, bone scan, and abdominal imaging as detailed\n2.1 All treatments completed at least 21 days prior to registration\n2.2-2.3 Specific requirements for chemotherapy\n2.4 Surgical margins clear of invasive carcinoma\n2.5 Sentinel lymph node biopsy and/or axillary lymph node dissection requirements\n2.6 Radiation and hormonal therapy requirements\n3. Participants must be women\n4. Age \u2265 18 years\n5. ECOG Performance Status 0 or 1\n6. Specific comorbid conditions and history limitations\n7.1 BMI \u226527 kg/m^2\n7.2 Ability to walk at least 2 blocks\n7.3 Not participating in another weight loss or dietary intervention clinical trial\n7.4 Able to read and comprehend English\n\nThe patient's breast cancer is HER2-positive, which does not meet the trial's requirement of HER2-negative (Inclusion 1.2). Additionally, the patient has metastatic lesions (contrary to \"No evidence of metastatic disease\" under Inclusion 1.1), which also excludes her from the trial. Therefore, the patient is not eligible for the Breast Cancer Weight Loss Study.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "314": {
        "output": "Based on the provided information, let's assess the patient's eligibility for the clinical trial:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Evidence of metastatic lesions on CXR\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Biopsy-proven breast cancer\n- Biopsy-proven axillary lymph node metastases\n- Candidates for Neoadjuvant Chemotherapy or Neoadjuvant Endocrine therapy\n\nThe patient has biopsy-proven breast cancer with positive lymph nodes, which matches the trial's inclusion criteria. However, she has not yet received neoadjuvant therapy, which is a prerequisite for participating in the trial according to the inclusion criteria.\n\nSince the patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy, it is not clear if she will receive neoadjuvant therapy (chemotherapy or endocrine therapy) before her surgery. This information is crucial to determine eligibility.\n\nDue to the lack of this specific information regarding the patient's treatment plan, we cannot definitively determine her eligibility for the trial. Therefore, she does not have sufficient information to qualify for the trial at this time.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "315": {
        "output": "",
        "label": 0
    },
    "316": {
        "output": "To determine the patient's eligibility for the PELOPS clinical trial, we need to assess the provided patient information against the trial's inclusion criteria. Let's go through the main points step by step.\n\n1. Patients must have Stage I to III histologically confirmed invasive carcinoma of the breast.\n   - The patient has cytologically confirmed breast cancer.\n\n2. A minimum tumor size of at least 1.5 cm determined by physical exam or imaging (whichever is larger) is required.\n   - The patient has a 3 cm invasive ductal breast carcinoma.\n\n3. Patients must have histologically confirmed hormone receptor positive (ER and/or PR), HER2 negative, invasive breast cancer.\n   - The patient has HER2-positive and ER/PR negative breast cancer.\n\n4. Women 18 years of age. Men are not eligible.\n   - The patient is a 45-year-old postmenopausal woman.\n\n5. ECOG performance status 0 or 1\n   - There is no information provided about the patient's ECOG performance status.\n\n6. Required laboratory values not provided in patient note.\n   - There is no information provided about the patient's laboratory values.\n\n7. Postmenopausal patients defined as no spontaneous menses \u22651 year.\n   - The patient is described as postmenopausal.\n\n8. Patient must agree to the required research biopsies.\n   - There is no information on whether the patient agrees to biopsies, but she agrees to tumor resection, which may indicate a willingness to undergo procedures.\n\n9. Patients must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption.\n   - There is no information provided about the patient's ability to swallow and retain oral medication.\n\n10. Breast imaging should include imaging of the ipsilateral axilla.\n    - There is no specific information provided, but axillary sampling was performed, which suggests appropriate imaging may have been done.\n\n11. Patients with multifocal or multicentric disease are eligible.\n    - There is no information on whether the patient's disease is multifocal or multicentric.\n\n12. Bilateral breast cancers are allowed.\n    - There is no mention of bilateral breast cancer in the patient's history.\n\n13. Serum or urine pregnancy test must be negative in women judged premenopausal.\n    - The patient is postmenopausal, so this is not applicable.\n\n14. Premenopausal patients must agree to use adequate contraception.\n    - The patient is postmenopausal, so this is not applicable.\n\n15. Patients with a history of ipsilateral or contralateral DCIS are eligible.\n    - There is no mention of a DCIS history in the patient's note.\n\n16. Patients may concurrently receive bisphosphonates or rank ligand inhibitors.\n    - There is no information regarding the patient's treatment with these medications.\n\nBased on these points, the key disqualifying factor is that the patient has HER2-positive breast cancer, which does not meet the trial's requirement for hormone receptor positive (ER and/or PR), HER2 negative invasive breast cancer. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "317": {
        "output": "",
        "label": 2
    },
    "318": {
        "output": "The patient note provides the following information:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive, and ER/PR negative.\n- There are 5 positive lymph nodes and metastatic lesions present (indicating stage IV).\n- The patient has not yet received chemotherapy as she is a candidate for tumor resection prior to chemotherapy.\n\nThe clinical trial has the following inclusion criteria:\n- Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases.\n- Patients between 18 and 80 years of age.\n- Patients who had undergone at least three lines of chemotherapy.\n- Patients with an expected survival time of at least 3 months.\n\nThe patient meets some of the inclusion criteria:\n- The patient is female.\n- The patient has metastatic breast cancer (stage IV) with measurable metastases.\n- The patient is between 18 and 80 years of age.\n\nHowever, the patient does not meet one of the crucial inclusion criteria:\n- The patient has not undergone any chemotherapy yet, let alone three lines of chemotherapy, as she is a candidate for tumor resection prior to starting chemotherapy.\n\nGiven that the patient has not received any chemotherapy, and the trial requires patients who have already undergone at least three lines of chemotherapy, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "319": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the information to determine the patient's eligibility.\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Signed written informed consent\n- Female patients aged 18 years or older\n- Histologically or cytologically confirmed untreated invasive carcinoma of the breast\n- Candidates for initial breast surgery with a minimum tumor size of 11 mm measured by breast ultrasound\n- HR-positive (ER and/or PR expression >10%)\n- No evidence of metastatic disease\n- ECOG performance status 0/1\n- LVEF of at least 50%\n- Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation\n- For women of childbearing potential who are sexually active, agreement to use effective contraception during and post-treatment\n- Patients must be affiliated to a social security system\n\nComparing the patient note to the inclusion criteria:\n\n- The patient is a 45-year-old woman, satisfying the age criterion.\n- She has a confirmed diagnosis of invasive breast carcinoma, which meets the requirement for histologically or cytologically confirmed untreated invasive carcinoma of the breast.\n- She is a candidate for initial breast surgery and the tumor size is more than 11 mm, meeting the related criteria.\n- However, the patient's tumor is HER2-positive and ER/PR negative, which does not meet the HR-positive criterion of the trial, as the trial requires ER and/or PR expression >10%.\n- The patient has metastatic lesions as per CXR, which does not meet the 'No evidence of metastatic disease' criterion.\n\nBased on the information given, the patient does not meet the HR-positive requirement and has evidence of metastatic disease, both of which are critical inclusion criteria for the trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "320": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, let's assess if the patient is eligible for the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman, which fits the age criterion of \"Women age 18 years or older.\"\n- Confirmed histologic diagnosis of invasive ductal breast carcinoma, meeting the \"Confirmed histologic diagnosis of invasive adenocarcinoma of the breast\" criterion.\n- HER2-positive pathology, which is permitted as per the trial criteria.\n- The tumor is operable and measures 3 cm, satisfying the requirement of \"Operable tumor measuring \u22651.5 cm in maximal diameter.\"\n- The patient has axillary lymph node involvement (\"Any nodal status\" is acceptable).\n- There is no information on tumor distance from the skin, but typically a 3 cm tumor would be more than 5 mm from the skin.\n- There is a mention of metastatic lesions on CXR, which would contradict the \"No indication of distant metastases\" criterion.\n- The patient is a candidate for tumor resection, aligning with \"Breast surgery planned.\"\n- No information is provided about ECOG performance status or the specific laboratory values required.\n- The patient has not been described as having HIV, Hepatitis B, or Hepatitis C.\n- The patient is postmenopausal and not sexually active, so contraception is not relevant, and she is not breastfeeding.\n\nConsidering the available information, the patient does not meet the eligibility criteria due to the presence of metastatic lesions, which contradicts the requirement for no distant metastases. Therefore, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "321": {
        "output": "To determine the trial-level eligibility for this patient, we must compare the patient's characteristics and condition with the inclusion criteria of the clinical trial. Let's review the inclusion criteria and the patient's information:\n\nInclusion Criteria for the Clinical Trial:\n- Participants with histologically or cytologically confirmed hormone receptor (HR)-positive, Her2-negative metastatic breast cancer.\n- Postmenopausal women, defined in multiple ways, including age >60 years, age >45 with amenorrhea for \u2265 12 months or FSH levels within postmenopausal range, or status post bilateral oophorectomy.\n- Men are eligible if on a GnRH agonist for at least 6 weeks prior to study entry.\n- Participants must have measurable disease as per RECIST 1.1.\n- Specific prior treatment history and progression requirements, including evidence of progression to a CDK4/6 inhibitor regimen and relapse/progression on an NSAI.\n- Participants may have received a certain number of endocrine/hormonal lines of therapy, chemotherapy, biologic treatments, and investigational drugs, with specific time frames before registration.\n- Age \u226518 years.\n- ECOG performance status \u22642.\n- Normal organ and marrow function, as defined by specific laboratory parameters.\n- For certain parts of the study, willingness to undergo research biopsies and provide archival tumor samples.\n- Ability to understand and willingness to sign a written informed consent document.\n\nPatient's Information:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR-negative.\n- She has metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial because her breast cancer is HER2-positive, while the trial specifically requires participants to have HER2-negative breast cancer. All other factors are irrelevant if she does not meet this primary inclusion criterion.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "322": {
        "output": "The patient note provides the following information:\n\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and is willing to undergo the procedure prior to chemotherapy.\n\nThe clinical trial has the following inclusion criteria:\n\n- Female patient with breast cancer.\n- Age > 18 years old.\n- Available primary breast tumor sample with adjacent normal epithelial structures.\n- Informed consent obtained and signed.\n\nBased on the patient note and the inclusion criteria of the clinical trial, the patient appears to be eligible for the clinical trial:\n\n- She is a female patient with breast cancer (matches the criteria).\n- She is 45 years old, which is greater than 18 years old (matches the criteria).\n- She has a primary breast tumor and is a candidate for tumor resection, which means a sample of the tumor with adjacent normal epithelial structures can likely be obtained (matches the criteria).\n- There is no mention of informed consent in the patient note, but it is stated that she agrees to undergo tumor resection, which suggests she is willing to provide consent for procedures related to her treatment (likely matches criteria, assuming consent for the trial can be obtained).\n\nSince there are no other exclusion criteria mentioned, and assuming that informed consent for the trial can be obtained, the patient appears to meet all the necessary criteria for inclusion in the study.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "323": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics with the inclusion criteria of the study.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER-/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection before chemotherapy\n\nClinical trial inclusion criteria:\n- Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer\n- Complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal\n- Tumor size at least 2 cm in one dimension by clinical or radiographic exam\n- At least 18 years of age\n- ECOG performance status \u2264 1\n- Normal bone marrow and organ function as defined by specific laboratory values\n- LVEF \u2265 50%\n- Baseline QTcF < 480 ms\n- Women of childbearing potential must agree to use adequate contraception\n- Ability to understand and sign an informed consent document\n\nComparison:\n- The patient is 45 years old and thus meets the age criterion.\n- The patient has a tumor size of 3 cm, which meets the tumor size criterion.\n- The patient is a candidate for tumor resection, aligning with the trial's treatment goal.\n- The patient's ECOG performance status is not mentioned, so we cannot assess this criterion.\n- Laboratory values for bone marrow and organ function are not provided, so we cannot assess this criterion.\n- LVEF and QTcF are not mentioned, so we cannot assess these criteria.\n- The patient is postmenopausal and not sexually active, which likely makes the contraception criterion not applicable, but this needs clarification regarding the study's specific requirements.\n- The ability to understand and sign an informed consent document is assumed but not explicitly stated.\n\nThe primary discrepancy lies in the ER/PR status of the breast cancer. The trial requires ER+ breast cancer, while the patient's cancer is ER-/PR-negative. This discrepancy excludes the patient from participating in the trial as the patient does not meet one of the key inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "324": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to go through the patient note and the inclusion and exclusion criteria of the clinical trial step by step and compare them.\n\n**Patient Note**:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Remarkable for metastatic lesions\n- Candidate for tumor resection\n- Agrees to tumor resection prior to chemotherapy\n\n**Clinical Trial Inclusion Criteria**:\n- Male or female subjects aged > 18 years\n- Signed written informed consent\n- ECOG performance status 0 or 1\n- Patients must have completed treatment with curative intent including surgery and adjuvant chemotherapy\n- Patients must have completed adjuvant chemotherapy including specific agents\n- No more than 10 weeks may elapse between the completion of last adjuvant treatment and randomization\n- Normal organ and marrow function (specific blood counts and levels)\n- Highly effective contraception if the risk of conception exists\n- Ability to understand and willingness to sign a written informed consent\n- For Stratum A: Non-metastatic, triple negative breast cancer, and specific surgical and lymph node criteria\n- For Stratum B: Non-metastatic, triple negative breast cancer, and specific surgical and lymph node criteria after preoperative chemotherapy\n\n**Clinical Trial Exclusion Criteria**:\n- Stage IV breast cancer\n- History of any prior invasive breast carcinoma within 10 years or other specific cancers\n- Prior organ transplantation\n- Prior or concomitant treatment with other investigational agents or immune-checkpoint inhibitors\n- Major surgery within 4 weeks of randomization\n- Concomitant treatment with certain drugs or herbal remedies\n- Significant acute or chronic infections\n- Active autoimmune disease with exceptions\n- Known severe hypersensitivity reactions to monoclonal antibodies or uncontrolled asthma\n- Clinically significant cardiovascular disease\n- Any other significant diseases that might impair tolerance of trial treatment\n- Any psychiatric condition preventing informed consent\n- Vaccination within 4 weeks of the first dose of avelumab and while on trial, except for inactivated vaccines\n- Known alcohol or drug abuse\n- Persisting toxicity related to prior therapy of Grade > 1\n- Current pregnancy and/or lactation, refusal of adequate contraception\n- For Stratum B: No invasive residual disease in the breast and axilla at pathological examination after neoadjuvant chemotherapy\n\n**Comparison**:\n- The patient is a 45-year-old woman, meeting the age criterion.\n- The patient has metastatic breast cancer (metastatic lesions on CXR), which is Stage IV breast cancer. This is an exclusion criterion for the trial as it states \"Stage IV breast cancer\" as an exclusion.\n- The patient has HER2-positive breast cancer, but the trial specifically targets triple-negative breast cancer (HER2 negative, ER/PR negative), which the patient does not have.\n- The patient has not yet received any chemotherapy, let alone completed treatment with curative intent including surgery and adjuvant chemotherapy, as is required for both Stratum A and B.\n\nGiven these points, the patient does not meet the inclusion criteria for the trial due to having metastatic (Stage IV) breast cancer, not having triple-negative breast cancer, and not having completed the required treatments prior to the trial. Therefore, the trial-level eligibility for this patient is:\n\n`Trial-level eligibility: 1) Not relevant.`",
        "label": 0
    },
    "325": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the information provided, she is scheduled for a tumor resection and is a candidate for lumpectomy, which aligns with the clinical trial's inclusion criterion of patients scheduled to undergo lumpectomy for breast cancer at BIDMC.\n\nThe clinical trial requires the following inclusion criteria to be met:\n\n1. Patient scheduled to undergo lumpectomy for breast cancer at BIDMC.\n2. Core needle biopsy revealing invasive breast cancer or DCIS.\n3. Female.\n4. Minimum age of 21 years.\n5. Eligible for breast conserving surgery, lumpectomy, and radiation.\n6. Estrogen receptor positive (ER+) on core needle biopsy, or if estrogen receptor negative (ER-), have evaluable estrogen receptor status with positive internal control on core biopsy.\n7. Progesterone receptor positive (PR+) on core needle biopsy if biopsy indicates invasive cancer, or if progesterone receptor negative (PR-) on biopsy indicating invasive cancer, have evaluable progesterone receptor status with positive internal control on core biopsy.\n8. HER2 IHC and/or FISH ordered on core biopsy, if biopsy indicates invasive cancer.\n9. Oncotype DX or other genetic assay performed on core biopsy or not requested.\n10. Ability to understand and the willingness to sign a written informed consent document.\n\nThe patient matches several of these criteria:\n\n- She is scheduled for tumor resection and is therefore scheduled to undergo lumpectomy for breast cancer.\n- She had a core needle biopsy revealing invasive ductal breast carcinoma, which meets the criterion of having invasive breast cancer.\n- She is female.\n- She is over the minimum age of 21 years.\n- She is a candidate for breast conserving surgery, which includes lumpectomy and likely radiation as part of her treatment plan.\n\nHowever, the patient's tumor is HER2-positive and ER/PR negative, which does not meet the trial's criteria requiring the estrogen receptor status to be positive (ER+) or evaluable with positive internal control, and the progesterone receptor status to be positive (PR+) when the biopsy indicates invasive cancer. Because the patient does not meet these specific criteria, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "326": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to match the patient's characteristics and diagnosis with the inclusion criteria of the trial. Let's analyze the patient note and the inclusion criteria in detail.\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Written informed consent\n- Adult women greater than 18 years old\n- ECOG performance status (PS) 0-2\n- New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer\n- Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater\n- Hormone receptor positive as defined as \u2265 10% positive stained cells\n- HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status])\n- Tumor size at least 5 mm with planned primary surgery at Mount Sinai\n- A negative urine dipstick pregnancy test\n\nComparison:\n- The patient is over 18 years old and could provide written informed consent, which matches the trial criteria.\n- The ECOG performance status is not mentioned in the patient note.\n- The patient's cancer is HER2-positive, but the trial requires HER2-normal (negative) patients.\n- The trial requires new diagnosis of ER+ breast cancer, whereas the patient's cancer is ER/PR negative.\n- Cyclin D1 status is not mentioned in the patient note, but the trial specifically requires a positive status defined by a score.\n- The trial requires hormone receptor positivity with a specific percentage of stained cells, which does not match the patient's ER/PR negative status.\n- There's no mention of the tumor size in relation to the 5 mm requirement, but it is noted that the tumor is 3 cm, which exceeds the minimum size requirement.\n- The patient's planned surgery could potentially be at Mount Sinai, but this is not specified.\n- The patient is postmenopausal, indicating that a pregnancy test result would not impact eligibility.\n\nBased on the information provided, the patient does not match the key inclusion criteria related to the molecular characteristics of the breast cancer (HER2 status, ER/PR status, and likely cyclin D1 status). Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "327": {
        "output": "Let's assess the patient's eligibility for each cohort in the clinical trial based on the provided inclusion criteria.\n\nFor Cohort A:\n- The patient has pathologically confirmed invasive breast cancer, which is HER2 positive and ER/PR negative, fitting the breast cancer criteria.\n- The patient's cancer is at a clinical stage with metastatic lesions (M stage is not M0), which does not meet the M0 criterion.\n- The patient is 45 years old, satisfying the age criterion.\n- The patient is female, meeting the sex criterion.\n- The patient has more than four suspicious lymph nodes, which does not meet the requirement of not demonstrating more than four suspicious lymph nodes.\n- The patient has a history of breast cancer only, with no mention of other non-breast cancers.\n\nFor Cohort B:\n- The patient does not meet the criteria because her cancer is HER2 positive and not ER and/or PR positive, HER2 negative.\n- Additionally, the patient does not meet the M0 criterion due to metastatic lesions.\n\nFor Cohort C:\n- The patient is HER2 positive, which meets part of the criteria.\n- The patient is 45 years old, satisfying the age requirement.\n- The patient is female, which fits the sex criterion.\n- The patient does not have a clinical stage of M0 due to metastatic lesions, which is not in line with the inclusion criteria.\n- There is no mention of the patient's desire for breast conserving therapy or evidence of no residual invasive tumor or DCIS on pathologic review, which are required.\n\nBased on the provided information, the patient does not meet the M0 criterion for any of the cohorts as she has metastatic lesions, which is indicative of stage M1 breast cancer. Additionally, there's a discrepancy in the number of positive lymph nodes for Cohort A and no information provided on the patient's desire for breast conserving therapy or the status of her residual tumor, which are necessary for Cohort C.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "328": {
        "output": "",
        "label": 0
    },
    "329": {
        "output": "Based on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The core biopsy revealed invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative. These details match the inclusion criteria of the clinical trial, which requires participants to be initially diagnosed with breast cancer and to have a proven result of HER2 testing.\n\nThe clinical trial does not specify additional criteria regarding the stage of cancer, treatment plans, or the current health status of the patient, and it includes both alive and deceased individuals since it's a retrospective study. Since the patient has HER2-positive breast cancer and there are no exclusion criteria provided, she meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "330": {
        "output": "",
        "label": 0
    },
    "331": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial titled \"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca\" according to the inclusion criteria:\n\n1. Invasive adenocarcinoma of the breast diagnosed by core needle biopsy - The patient has invasive ductal breast carcinoma confirmed by core biopsy.\n2. Breast cancer determined to be HER2-negative per current ASCO/CAP HER2 Guidelines - The patient's tumor is HER2-positive, which does not meet the HER2-negative requirement.\n3. Breast cancer determined to be hormone receptor-positive or hormone receptor-negative defined as follows:\n   - Hormone receptor-positive: \u2265 10% staining by IHC for either ER or PgR\n   - Hormone receptor-negative: < 10% staining by IHC for both ER and PgR - The patient's tumor is ER/PR negative.\n4. Locally advanced breast cancer defined as any of the following per AJCC Staging Criteria - The patient has metastatic lesions, which may indicate a stage beyond locally advanced, but there is not enough information to determine if the AJCC criteria for locally advanced are met.\n5. Ipsilateral axillary lymph nodes evaluated and nodal status determined - The patient has 5 positive lymph nodes, indicating positive nodal status.\n6. Breast imaging performed prior to study registration - The patient's note does not mention the timing of breast imaging in relation to the study registration.\n7. Age \u2265 18 years - The patient is 45 years old.\n8. ECOG performance status of 0 or 1 - The patient's ECOG performance status is not mentioned.\n9. Adequate bone marrow, renal, and hepatic function - The patient's note does not provide information regarding laboratory values for bone marrow, renal, and hepatic function.\n10. LVEF assessment indicates an LVEF \u2265 50% - There's no information on the patient's LVEF.\n11. For women who are not postmenopausal, a documented negative serum pregnancy test is required - The patient is postmenopausal.\n12. Willingness to use an accepted method for preventing pregnancy if applicable - The patient is not sexually active.\n13. Ability to understand and willingness to sign the consent form - The patient agrees to tumor resection, indicating possible willingness to participate in medical procedures after being informed, but this is not explicit consent for the trial.\n\nThe key disqualifying factor here is the HER2-positive status of the patient's breast cancer, which does not meet the HER2-negative requirement for the trial. All other factors could potentially be met if additional information were provided.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "332": {
        "output": "To determine the trial-level eligibility, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agreeing to surgery prior to chemotherapy\n- No mention of prior treatments with anthracyclin, taxane, or trastuzumab\n\nClinical Trial Inclusion Criteria:\n- Aged \u226518 and \u226475 years\n- ECOG performance status of 0 to 1\n- Life expectancy of more than 12 weeks\n- At least one measurable lesion according to RECIST 1.1\n- Histologically or cytologically confirmed HER2 positive advanced breast cancer which failed prior therapies\n- Prior treatment with trastuzumab (\u22652 cycles in the metastatic setting, or \u22653 months in adjuvant setting), and the patients are not available for the trastuzumab or lapatinib\n- Previously received both Anthracyclin and Taxane\n- Specific required laboratory values\n- Signed informed consent\n\nBased on the patient note, the patient meets the following criteria:\n- She is within the age requirement of \u226518 and \u226475 years.\n- She has confirmed HER2 positive advanced breast cancer.\n- The patient note does not provide information on the ECOG performance status, life expectancy, measurable lesion according to RECIST 1.1, prior treatment with trastuzumab, anthracyclin, taxane, or laboratory values.\n\nNo explicit mention is made of the patient's performance status, life expectancy, or whether she meets the specific laboratory value requirements. Additionally, there is no information provided on whether she has received prior treatments with trastuzumab, anthracyclin, and taxane, which are necessary according to the trial inclusion criteria.\n\nDue to the lack of sufficient information in the patient note regarding these criteria, we cannot conclude that the patient is eligible for this trial. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "333": {
        "output": "The patient described in the patient note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. Her tumor is HER2-positive and ER/PR-negative, with axillary sampling revealing 5 positive lymph nodes and metastatic lesions noted on a CXR. The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nNow, let's compare this patient's information to the inclusion criteria of the clinical trial:\n\n1. Estrogen receptor-positive and HER2-negative breast cancer patients: The patient's tumor is HER2-positive and ER/PR-negative, which does not meet the criterion of being ER-positive and HER2-negative.\n2. Histological stage of IIa-IIIc: The patient note does not provide information on the histological stage of the cancer.\n3. Without previous chemotherapy or endocrine therapy: The patient has not undergone chemotherapy or endocrine therapy, according to the patient note.\n4. ECOG scores of 0-2 points: The patient note does not include an ECOG performance status score.\n5. With measurable and evaluable breast tumor pathologically confirmed as invasive ductal carcinoma: The patient has a pathologically confirmed invasive ductal carcinoma.\n6. Age: 18-70 years: The patient is 45 years old, which falls within the required age range.\n7. Lateral breast cancer: The patient's cancer is in the left upper outer quadrant, which is consistent with lateral breast cancer.\n8. Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions: The patient note does not mention the status of these organ functions.\n\nThe primary reason the patient is not eligible for the trial is that her cancer is HER2-positive, which does not meet the trial's requirement for HER2-negative breast cancer. Despite the patient meeting some of the other inclusion criteria, this key discrepancy excludes her from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "334": {
        "output": "After reviewing the patient note against the inclusion criteria of the clinical trial, let's assess the eligibility:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of \u226518 years.\n- The patient has cytologically confirmed breast cancer, which fits the criteria for pathological diagnosis.\n- The core biopsy revealed invasive ductal breast carcinoma, indicating early-stage breast cancer.\n- The patient is set to undergo tumor resection before chemotherapy, which suggests she has not had neoadjuvant chemotherapy, endocrinotherapy, or targeted therapy previously.\n- It is not mentioned if the patient has had previous breast or axillary surgery, so we cannot confirm this criterion.\n- There is no information regarding the ejection fraction score or the Eastern Cooperative Oncology Group (ECOG) score.\n- The patient has positive axillary lymph nodes, which contradicts the inclusion criterion of axillary lymph node clinical negative.\n- The patient's CXR revealed metastatic lesions, which means the patient has distant metastasis. This disqualifies her since the trial requires patients without distant metastasis.\n\nBased on the available information, the patient does not meet all the inclusion criteria due to the presence of metastatic lesions and positive axillary lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "335": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma,\" we must compare the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nFrom the patient note, we know the following:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma, HER2-positive and ER/PR negative.\n- There are metastatic lesions present.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe inclusion criteria for the clinical trial are:\n- Adult patients with histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma (PDAC) that is metastatic.\n- No prior chemotherapy or investigational agent for the treatment of PDAC.\n- ECOG Performance Status of 0 or 1.\n- Life expectancy of > 12 weeks.\n- \u2265 18 years of age.\n- Certain requirements related to reproductive status and contraception.\n- Adequate biological parameters and blood chemistry levels.\n- No clinically significant abnormalities on urinalysis.\n- Adequate nutritional status with BMI > 18 kg/m^2 and body weight > 40 kg, serum albumin > 3 g/dL.\n- Consent for provision of a sample of blood and, if available, archival tumor tissue for correlative marker assays.\n- Accessible for treatment and follow up.\n- Not receiving therapy in a concurrent clinical study.\n\nBased on the patient note and the inclusion criteria for the trial, the patient would not be eligible for the clinical trial because:\n- The patient has breast cancer, not metastatic pancreatic ductal adenocarcinoma. The trial specifically requires the presence of pancreatic cancer.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "336": {
        "output": "Based on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and is a candidate for tumor resection. The clinical trial in question is investigating the use of the Magseed and Sentimag\u00ae system for lesion localization in patients undergoing surgical excision of a breast lesion.\n\nThe inclusion criteria for the clinical trial are:\n1. Subjects with a breast lesion requiring image-guided localization prior to excision.\n2. Subjects aged 18 years or more at the time of consent.\n\nThe patient in question meets both inclusion criteria:\n1. She has invasive ductal breast carcinoma in the left upper outer quadrant, which likely requires image-guided localization prior to excision (the trial's first inclusion criterion).\n2. She is 45 years old, which meets the age requirement (the trial's second inclusion criterion).\n\nGiven this information, the patient appears to be eligible for the clinical trial, as she meets all the stated inclusion criteria and there are no exclusion criteria provided that would disqualify her.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "337": {
        "output": "To determine the trial-level eligibility, we need to carefully compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nHere are the relevant points from the patient's note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer, which is invasive ductal carcinoma.\n- The cancer is HER2-positive and ER/PR negative.\n- The patient has metastatic lesions evidenced by CXR.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, let's compare this information with the clinical trial's inclusion criteria:\n- Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease. [The patient meets this criterion.]\n- Either the primary tumor and/or the metastasis must have been tested for ER, PR, and HER2. [The patient meets this criterion as the tumor is HER2-positive and ER/PR negative.]\n- History of prior therapy with trastuzumab and a taxane, separately or in combination, is required. [The patient note does not mention prior therapy with trastuzumab and a taxane.]\n- Patients must have either received one line of prior therapy for metastatic breast cancer, or have developed a disease recurrence during or within 6 months after completing adjuvant therapy. [The patient note does not provide information about prior therapy for metastatic breast cancer or recurrence after adjuvant therapy.]\n- No prior treatment with T-DM1 is allowed. [The patient note does not mention prior treatment with T-DM1, so we assume compliance.]\n- Last dose of chemotherapy must be at least 21 days prior to registration. [No information provided about chemotherapy timing.]\n- The other criteria pertain to the performance status, organ and marrow function, willingness to undergo biopsy, pregnancy status, LVEF, and informed consent, most of which cannot be assessed based on the provided patient note.\n\nBased on the information given, the patient has confirmed metastatic breast cancer that is HER2-positive, which aligns with the study requirements. However, there is insufficient information about prior therapy with trastuzumab and a taxane, which is a key inclusion criterion for this trial. Without this information, we cannot conclusively determine if the patient is eligible.\n\nTherefore, the trial-level eligibility for this patient would be:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "338": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's compare the information to make a trial-level eligibility assessment.\n\nPatient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma, HER2-positive, and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR (chest X-ray) showed metastatic lesions, which indicates that the cancer has spread beyond the primary site.\n- The patient is a candidate for tumor resection and agrees to undergo the procedure prior to chemotherapy.\n\nClinical trial inclusion criteria:\n- At least 18 years of age\n- Biopsy proven or clinically documented metastatic breast cancer with at least one lesion outside the liver by standard imaging\n- Plan to start new systemic therapy for metastatic disease\n- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures\n\nAssessment:\n- The patient is at least 18 years old.\n- The patient has metastatic breast cancer with at least one lesion outside the liver, as indicated by the CXR.\n- The patient is a candidate for tumor resection, which suggests she may be planning to start new systemic therapy for metastatic disease post-surgery.\n- There is no information indicating the patient wouldn't be willing to provide informed consent.\n\nGiven the information provided, the patient meets the age requirement, has a diagnosis of metastatic breast cancer with lesions outside the liver, and is planning for treatment which aligns with the criteria for starting new systemic therapy. Assuming she is willing to provide written informed consent, she would meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "339": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Tracking Triple-negative Breast Cancer Evolution Through Therapy,\" let's compare the information:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive, ER/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to proceed prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Age 18 years or older (Patient is 45 years old, so meets this criterion)\n- Histological confirmation of invasive breast cancer with known receptor status suitable for neoadjuvant chemotherapy (Patient has confirmed invasive breast cancer)\n- ER- and PR-negative as defined by \u22641% of positive staining on immunohistochemistry (Patient is ER/PR-negative)\n- HER2-negative as defined by American Society of Clinical Oncology / College of American Pathologists guidelines (Patient is HER2-positive, which does not meet this criterion)\n- T1c-4 tumors, with any nodal status non candidate for conservative surgery upfront (Patient has a tumor and positive lymph nodes and is a candidate for tumor resection prior to chemotherapy)\n- Provision of signed and dated, written informed consent (Assuming the patient can provide this if willing to participate)\n- Patient with social insurance coverage (This is not mentioned in the patient note, so we assume this can be met if necessary)\n\nThe key disqualifying factor here is that the patient's breast cancer is HER2-positive, whereas the clinical trial specifically requires patients to have HER2-negative breast cancer. Therefore, despite meeting several other criteria, the patient does not qualify for this trial based on her cancer's HER2 status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "340": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive, which does not meet the inclusion criteria for the clinical trial that is specifically looking for HER2-negative breast cancer patients. Despite the patient having metastatic breast cancer and being a candidate for chemotherapy, the HER2-positive status of her cancer excludes her from this specific study.\n\nTherefore, based on the provided information, the patient does not meet the inclusion criteria for the clinical trial titled \"International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "341": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility step by step:\n\n1. The patient has cytologically confirmed breast cancer, which matches the histological confirmation of breast cancer criterion in the trial.\n\n2. There is no information regarding the patient's ability to provide written informed consent, but we can assume that if the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, they would also be able to consent to the trial.\n\n3. The patient's performance status is not mentioned, but given that she is a candidate for surgery, it is likely that her ECOG performance status is \u2264 1.\n\n4. The patient's ability to swallow oral medication is not mentioned, but there is no indication that she has difficulty swallowing.\n\n5. There is no information provided about the patient's left ventricular ejection fraction (LVEF).\n\n6. There is no information on the patient's complete blood count, including absolute neutrophil count, platelets, and hemoglobin levels.\n\n7. There is no information on the patient's creatinine clearance or liver function tests, including total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels.\n\n8. The patient is postmenopausal, which means she is not of childbearing potential and thus the requirement for contraception and a negative pregnancy test does not apply to her.\n\n9. For Cohort 1: The patient's tumor is HER2-positive, which fits the requirement for HER2+ status for both phases of the trial.\n\n10. The patient has metastatic breast cancer with axillary involvement and metastatic lesions noted on CXR, which fits the criteria for metastatic or locally advanced breast cancer.\n\nThe patient note seems compatible with many of the trial's inclusion criteria, particularly with respect to the diagnosis of HER2-positive metastatic breast cancer. However, due to the lack of information on the patient's LVEF, blood counts, creatinine clearance, and liver function tests, we cannot definitively conclude that the patient is eligible. Without these key pieces of medical data, we cannot accurately assess the patient's eligibility.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "342": {
        "output": "Based on the information given:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- CCI/CLI to be operated\n- Grade SBR 1, 2, or 3\n- Undifferentiated RE/PR status\n- HER2 status undifferentiated\n- Ki 67 indifferent\n- Metastatic or not\n- ADP axillary invaded or not\n- Major Patients\n\nThe patient's characteristics appear to meet the clinical trial's inclusion criteria as follows:\n- The patient is a major patient (assumed to mean adult).\n- The patient's tumor is invasive ductal breast carcinoma, which implies that the patient is to be operated on.\n- The patient's breast cancer is HER2-positive and ER/PR negative, which aligns with the \"Undifferentiated RE/PR status\" and \"HER2 status undifferentiated\" criteria.\n- The presence of metastatic lesions and positive axillary lymph nodes matches the criteria of \"Metastatic or not\" and \"ADP axillary invaded or not.\"\n\nSince the trial does not specify a requirement for a particular SBR grade or Ki 67 status, and the patient note does not provide this information, these factors are considered \"indifferent\" by the trial criteria.\n\nGiven the information at hand, the patient appears to meet the inclusion criteria for the clinical trial. There is no mention of exclusion criteria or any other factors that would disqualify the patient from the trial. Therefore, the patient would be considered eligible for participation.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "343": {
        "output": "Based on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative, and axillary sampling revealed 5 positive lymph nodes. The patient has metastatic lesions evident on the CXR. She is a candidate for tumor resection and agrees to undergo the surgery prior to chemotherapy.\n\nThe clinical trial in question is studying the Axillary Reverse Mapping (ARM) Technique. The inclusion criteria for the trial are as follows:\n\n- Women diagnosed with invasive breast cancer or ductal carcinoma in situ receiving one of the following treatments:\n  - mastectomy and sentinel lymph node biopsy\n  - breast conserving surgery or mastectomy and axillary lymph node dissection\n  - completion axillary lymph node dissection after positive sentinel lymph node biopsy\n  - cases receiving neo-adjuvant therapy (chemotherapy or hormonal therapy) who are having axillary lymph node dissection as part of their surgical treatment\n\nThe patient meets the inclusion criteria as she has been diagnosed with invasive breast cancer and is a candidate for tumor resection, which could involve one of the surgical treatments listed in the inclusion criteria. Since the patient note does not mention any exclusion criteria and based on the information provided, it seems that the exclusion criteria of the trial do not apply to her. Therefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "344": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate whether the patient is eligible for the trial.\n\nPatient note indicates:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection.\n\nClinical trial inclusion criteria are:\n- Histologically confirmed invasive breast cancer.\n- With axillary lymph node with thickened cortex.\n- Planned for sentinel lymph node biopsy or axillary clearance.\n\nAssessment:\n- The patient has histologically confirmed invasive breast cancer.\n- The patient has positive lymph nodes, which may suggest a thickened cortex, but this is not explicitly stated.\n- The patient is a candidate for tumor resection, which may involve sentinel lymph node biopsy or axillary clearance, aligning with the trial criteria.\n\nGiven the available information, the patient appears to meet the inclusion criteria for the clinical trial, assuming that the positive lymph nodes equate to a thickened cortex and that the planned tumor resection includes sentinel lymph node biopsy or axillary clearance. However, this assumption about the lymph nodes and the specific surgical plan should be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "345": {
        "output": "",
        "label": 0
    },
    "346": {
        "output": "",
        "label": 0
    },
    "347": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patients, at least 18 years of age\n- Signed and dated informed consent form\n- Adequate samples of breast tissue available for use in the study\n- Diagnosis of low, intermediate, or high-grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion\n- Diagnosis of atypical ductal hyperplasia, lobular carcinoma in situ, or any preinvasive breast lesion\n- Ductal carcinoma in situ patients undergoing lumpectomy and radiation or mastectomy\n- Diagnosis of invasive ductal cancer\n\nThe patient in question has a diagnosis of invasive ductal breast carcinoma which is one of the conditions listed in the inclusion criteria. She is also a woman over 18 years of age, which matches the gender and age requirements. The patient note does not mention whether informed consent has been obtained, but since the patient has agreed to undergo tumor resection, it implies a level of consent for treatment. There are adequate samples of breast tissue available, as indicated by the core biopsy.\n\nHence, the patient meets the following inclusion criteria:\n- Female and over 18 years of age\n- Diagnosis of invasive ductal cancer\n- Implied consent for treatment (and likely for participation in the study)\n- Adequate tissue samples available from the core biopsy\n\nGiven this information, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "348": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, invasive ductal carcinoma, and she is scheduled for tumor resection prior to chemotherapy. The inclusion criteria for the clinical trial are simply stated as \"all patients undergoing breast MRI.\"\n\nThe patient note indicates that the patient has breast cancer and is a candidate for tumor resection, which likely means she will undergo breast MRI as part of her pretreatment evaluation. There are no additional specific criteria mentioned that the patient needs to meet, and no exclusion criteria are provided.\n\nTherefore, given that the patient has breast cancer and is likely to undergo breast MRI, she meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "349": {
        "output": "The patient note provides the following information that can be checked against the clinical trial's inclusion criteria:\n\n- Age \u2265 18 years of age: The patient is 45 years old, so this criterion is met.\n- Female gender: The patient is a woman, so this criterion is met.\n- Biopsy proven diagnosis of breast cancer: The patient has a core biopsy revealing invasive ductal breast cancer, so this criterion is met.\n- Stage IV disease diagnosed either by radiographic studies or biopsy: The patient has metastatic lesions evident on CXR, which indicates Stage IV disease, so this criterion is met.\n- ER+ by immunohistochemistry on primary and/or metastatic tissue biopsy (>10%): The patient's tumor is ER/PR negative, so this criterion is not met.\n- HER2 non-amplified (1+ or below by immunohistochemistry, and/or Her2 FISH <2 HER2-to-CEP17 ratio): The patient's tumor is HER2-positive, so this criterion is not met.\n- Progressed on at least one prior line of endocrine therapy for metastatic disease: The patient note does not indicate any prior endocrine therapy, so this criterion is not met.\n- Three or fewer prior endocrine-containing therapies for recurrent/metastatic disease: The patient note does not indicate any prior endocrine therapy, so this criterion cannot be evaluated.\n- Two or fewer prior lines of cytotoxic chemotherapy for recurrent/metastatic disease: The patient note does not indicate any prior chemotherapy, so this criterion cannot be evaluated.\n- Plans to initiate 2nd, 3rd, or 4th line endocrine therapy for metastatic disease: The patient note does not indicate any plans for endocrine therapy, as the patient agrees to tumor resection prior to chemotherapy, so this criterion is not met.\n- Recent re-staging scans within 4 weeks of study enrollment, with radiographically identifiable disease: The patient has recent staging indicating metastatic disease, but it is unclear if it is within 4 weeks, so this criterion cannot be evaluated.\n- No concurrent or prior diagnosis of malignancy other than breast cancer for the past 5 years: There is no information on prior malignancies, so this criterion cannot be evaluated.\n- Intends to pursue treatment as well as clinical and radiographic follow-up at UNC Health Care: There is no information about the patient's intent to pursue treatment at UNC Health Care, so this criterion cannot be evaluated.\n- Signed an IRB-approved informed consent document for this protocol and HIPAA consent form: There is no information provided regarding consent, so this criterion cannot be evaluated.\n\nGiven the provided patient note information, the patient does not meet the criteria for ER+ breast cancer, as they have ER/PR negative breast cancer, and their tumor is HER2-positive, which is contrary to the HER2 non-amplified criterion of the trial. Additionally, there is no mention of prior endocrine therapy, which is also an inclusion criterion for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "350": {
        "output": "Based on the provided information, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Signed informed consent\n- Male and female patients aged from 18 to 75 years\n- Histologically confirmed Colorectal cancer, Esophagus squamous cell carcinoma, biliary tract cancer, and digestive system tumor beyond CRC and GC&GEJA\n- Genetic testing conformed KRAS/NRAS/BRAF all wild type for colorectal cancer\n- Detection of a carcinoma with HER2 3+ (IHC) or HER2 2+ (IHC) with amplification proven by FISH, SISH, or CISH using gastric cancer criteria by an accredited local pathologist\n- Relapse or metastatic diseases, at least one measurable lesion according to RECIST 1.1, anticipated survival \u2265 12 weeks\n- ECOG Performance status 0-1\n- Patients who failed at least first line systemic therapy\n- Adequate organ function with specified laboratory results\n- If able to reproduce, must be willing to use highly effective methods of contraception during treatment and for 7 months after the end of treatment\n\nThe patient's case involves breast cancer, not carcinoma of the digestive system, which the clinical trial specifically aims to treat. Despite the patient's cancer being HER2-positive, which aligns with the requirement of the trial, the type of cancer (breast cancer) is not one of the specified types for inclusion (Colorectal cancer, Esophagus squamous cell carcinoma, biliary tract cancer, and digestive system tumor beyond CRC and GC&GEJA).\n\nTherefore, the patient does not meet the inclusion criteria based on the type of cancer. As the patient's cancer type does not match the specified criteria for the trial, we can conclude that the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "351": {
        "output": "",
        "label": 1
    },
    "352": {
        "output": "The patient in the provided note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. To determine her eligibility for the clinical trial titled \"A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer,\" we must compare her characteristics with the inclusion and exclusion criteria of the trial.\n\nInclusion criteria:\n- Age 18 years or older\n- Have documented or reported microscopic hematuria within 3 months of study enrollment\n- Willing and able to give written informed consent\n\nExclusion criteria:\n- Have history of BCa (Bladder Cancer)\n- History of previous cancer (excluding basal and squamous cell skin cancer)\n- Have a known active urinary tract infection or urinary retention\n- Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL)\n- Have ureteral stents, nephrostomy tubes or bowel interposition\n- Have recent genitourinary instrumentation (within 10 days prior to signing consent)\n- Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging)\n\nThe patient has a history of breast cancer, which is an exclusion criterion as participants must not have a history of previous cancer (excluding basal and squamous cell skin cancer). There is no mention of microscopic hematuria in the patient's note, which is a required condition for inclusion.\n\nBased on this information, the patient does not meet the inclusion criteria and is excluded due to the exclusion criterion regarding history of previous cancer other than basal and squamous cell skin cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "353": {
        "output": "",
        "label": 0
    },
    "354": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information against the inclusion criteria provided for the trial:\n\nInclusion Criteria Assessment:\n1. Female; age \u226518 years. - The patient is a 45-year-old woman, so this criterion is met.\n2. Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II. - The patient has invasive ductal breast carcinoma, but there is no specific information on the clinical stage in the provided note.\n3. Clinically lymph node negative, confirmed by clinical exam and/or ultrasound imaging. - Axillary sampling revealed 5 positive lymph nodes, which indicates the patient is not lymph node negative.\n4. Estrogen- and/or progesterone-receptor-positive tumor, defined \u22651% positively staining cells by immunohistochemistry. - The patient's tumor is ER/PR negative.\n5. HER2/neu must be negative by IHC or FISH. - The patient's tumor is HER2-positive.\n6. ECOG performance status 0-2. - There is no information provided about the patient's ECOG status.\n7. Pretreatment evaluations within 28 days prior to study. - There is no information on the timing of evaluations.\n8. Qualify for anti-endocrine treatment (per medical oncologist). - The patient does not qualify for anti-endocrine treatment as her tumor is ER/PR negative.\n9. Informed consent provided. - The patient agrees to tumor resection, which may suggest a willingness to consent, but this is not explicit informed consent for the trial.\n10. If history of contralateral breast cancer, patient completed all treatment two years prior. - There is no history provided of contralateral breast cancer.\n11. No treatment for this breast cancer or any malignancy within two years. - There is no information provided about prior treatments for other malignancies.\n12. Using adequate methods of contraception; negative pregnancy test. - The patient is postmenopausal and not sexually active, so this criterion is likely met.\n13. No strong CYP2D6 inhibitors. - There is no information on medication use that would include CYP2D6 inhibitors.\n14. Adequate organ function with baseline lab values. - There is no information provided about the patient's lab values.\n\nFrom the above assessment:\n\n- The patient does not meet the criteria for clinical stage (I-II) as she has metastatic lesions (implying at least stage IV breast cancer).\n- The patient is not clinically lymph node negative.\n- The patient's tumor is not estrogen- and/or progesterone-receptor-positive.\n- The patient's tumor is not HER2-negative.\n\nBecause the patient does not meet multiple key inclusion criteria (specifically 3, 4, and 5), she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "355": {
        "output": "",
        "label": 0
    },
    "356": {
        "output": "To assess the trial-level eligibility of the patient for the specified clinical trial, we need to go through the inclusion criteria and compare them with the patient's information provided in the patient note. Let's analyze the inclusion criteria one by one:\n\n1. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1: The patient's performance status is not mentioned in the patient note.\n\n2. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by needle core biopsy: The patient has a confirmed diagnosis of invasive ductal breast carcinoma by core biopsy, which fits this criterion.\n\n3. Study participants must be cT1c - cT4a-d, any node (N), no metastases (M0): The patient has a 3 cm tumor and positive lymph nodes, which indicates she could fit within the T and N descriptors. However, the patient note mentions metastatic lesions found on CXR, which indicates the presence of metastases (M1), excluding the patient from this criterion.\n\n4. Breast tumor must be >1.5 cm in maximum diameter by clinical or any radiologic measurement, if node negative: The tumor is 3 cm, but the patient is node positive, not node negative.\n\n5. Multifocal or multicentric breast cancer is allowed if all the lesions are biopsied and are HER2 positive: The patient note doesn't mention multifocal or multicentric disease. However, the tumor is HER2 positive.\n\n6. Must be HER2-positive in primary breast tumor or lymph node: The patient meets this criterion as the tumor is HER2-positive.\n\n7. Ejection fraction (EF) greater than 50% by MUGA or ECHO within 4 weeks prior to the first dose of study treatment: There is no information on the patient's ejection fraction in the note.\n\n8. No prior cancer chemotherapy allowed: The patient has not undergone chemotherapy yet, only surgery is planned, which meets this criterion.\n\n9. Adequate organ and marrow function as defined below: The patient note does not provide information on her organ and marrow function.\n\n10. Women of child-bearing potential must agree to use adequate contraception: The patient is postmenopausal, so this is not applicable.\n\n11. Negative pregnancy test within 14 days prior to randomization: There is no information on a pregnancy test, but since the patient is postmenopausal, this is likely not applicable.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria due to the presence of metastases, which is specifically excluded (\"no metastases (M0)\"). Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "357": {
        "output": "",
        "label": 1
    },
    "358": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Evaluation:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is using multivitamins and iron supplements.\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Invasive breast cancer with axillary lymph node metastasis confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB).\n- Underwent computed tomography (CT) reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy (NAC).\n- Attend the study voluntarily, sign the informed consent.\n\nComparison:\n- The patient has invasive breast cancer with confirmed axillary lymph node metastasis, meeting the first criterion.\n- However, it is not specified in the patient's note if she has undergone or is planning to undergo CT reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy, which is a requirement for the trial.\n- The patient note does not mention neoadjuvant chemotherapy; it only mentions the patient is a candidate for tumor resection prior to chemotherapy.\n- The willingness to attend the study voluntarily and sign the informed consent is assumed if the patient is being considered for the trial.\n\nGiven the available information, the patient does not meet all the specified inclusion criteria for the clinical trial, as there is no mention of CT reconstruction for assessment of axillary lymph node status or neoadjuvant chemotherapy. Therefore, the patient does not have sufficient information to qualify for the trial based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "359": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive, ER/PR negative.\n- She has metastatic lesions on CXR.\n- She is a candidate for tumor resection prior to chemotherapy.\n- There is no mention of haematuria.\n\nClinical Trial:\n- The trial is focused on detecting transitional cell carcinoma from haematuria.\n- Inclusion criteria include being capable of giving written informed consent, being aged \u226518 years, and referral to a haematuria clinic (gross or microscopic haematuria).\n\nAssessment:\nThe patient does not meet the inclusion criteria for the clinical trial because there is no mention of her having haematuria or being referred to a haematuria clinic. The trial is specific to bladder cancer detection in patients with haematuria, whereas the patient has breast cancer with no indication of urinary issues.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "360": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note assessment:\n1. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n2. Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n3. The tumor is HER2-positive and ER/PR negative.\n4. Axillary sampling revealed 5 positive lymph nodes.\n5. The patient has metastatic lesions on CXR.\n6. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical trial inclusion criteria assessment:\n1. Histologically proven invasive carcinoma of the breast. (The patient has this.)\n2. One to three positive axillary lymph nodes (pN1) proven in pathologic specimen. (The patient has five positive lymph nodes, which is more than the specified range.)\n3. Prior breast-conserving surgery and post-operative adjuvant chemotherapy including taxane. (The patient is a candidate for tumor resection, but there is no information if she has already undergone breast-conserving surgery or received chemotherapy.)\n4. Administering adjuvant hormonal therapy in cases with hormone receptor-positive tumor. (The tumor is ER/PR negative, so this is not applicable.)\n5. Administering anti-HER2 therapy in cases with HER2-positive tumor. (The patient's tumor is HER2-positive, so she may need this therapy.)\n\nThe patient does not meet the second criterion of having one to three positive axillary lymph nodes, as she has five positive lymph nodes. Additionally, there is insufficient information to determine if she has already undergone breast-conserving surgery and received adjuvant chemotherapy including taxane.\n\nTherefore, the patient does not meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "361": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Her2-BATS and Pembrolizumab in Metastatic Breast Cancer,\" we need to compare the patient's characteristics and medical history with the inclusion criteria provided for the trial:\n\n**Patient Characteristics:**\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal carcinoma\n- HER2-positive, ER/PR-negative\n- 3 cm tumor size\n- 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection prior to chemotherapy\n\n**Trial Inclusion Criteria:**\n- Histologically confirmed breast cancer with evidence of measurable metastatic disease\n- Measurable non-bone lesion \u226510 mm that has not been irradiated\n- HER2 status determined by FISH or IHC, with positive or negative results eligible\n- Female \u2265 18 years of age\n- Willing to provide written informed consent\n- Performance status (PS) ECOG 0-1\n- Life expectancy \u2265 3 months\n- Eligible for apheresis\n- Adequate organ function\n- Negative pregnancy test for women of childbearing potential\n- Willing to use an adequate method of contraception\n- Must have had two or more lines of prior therapy in the metastatic setting\n\nBased on the information provided, the patient appears to meet the following inclusion criteria:\n- She is a female over 18 years old.\n- She has a histologically confirmed diagnosis of breast cancer with a measurable metastatic lesion.\n- The tumor is HER2-positive, which means HER2 status is determined.\n- She is a candidate for tumor resection, indicating she is likely to have a reasonable performance status.\n- There is no mention of her life expectancy, but it is not indicated to be less than 3 months.\n- Willingness to consent to the trial is presumed as she is a candidate for tumor resection.\n- No information is provided regarding organ function or prior therapy lines, but these are clinical assessments that would be made during the screening process.\n\nHowever, there is not enough information to fully determine eligibility based on the inclusion criteria, particularly regarding the patient's performance status, organ function, and previous therapies. The patient would have to undergo further evaluation to determine these specific factors.\n\nConsidering the information given, the patient cannot be deemed fully eligible without additional details. Therefore, the trial-level eligibility for this patient is:\n\n`Trial-level eligibility: 1) Not relevant.`",
        "label": 2
    },
    "362": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is classified as invasive ductal breast carcinoma and is located in the left upper outer quadrant.\n- The tumor size is reported as 3 cm.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions noted on the chest x-ray (CXR).\n- The patient is scheduled for tumor resection and is willing to undergo the procedure prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- The study will include women with early-stage breast cancer.\n- Patients must have a pre-operative diagnosis of Tis, T1, and T2 tumors without extensive skin involvement.\n- Informed consent must be obtained for inclusion in the study, including the use of images.\n\nComparison:\n- The patient is a woman, which is consistent with the study's population.\n- The patient has early-stage breast cancer, as indicated by a 3 cm invasive ductal carcinoma and positive lymph nodes.\n- The patient has a pre-operative diagnosis and is scheduled for tumor resection, which aligns with the trial's requirement for pre-operative diagnosis and consent for surgery.\n\nHowever, there is a critical piece of information that may affect eligibility:\n- The presence of metastatic lesions on CXR suggests that the patient may not have early-stage breast cancer, as metastasis typically indicates a more advanced stage of the disease. The inclusion criteria specify early-stage breast cancer (Tis, T1, T2) without extensive skin involvement, and metastasis could exclude the patient from this definition.\n\nGiven the information provided, there is a possibility that the patient's breast cancer stage may not align with the \"early-stage\" requirement due to the presence of metastatic lesions. Without clear information on whether metastatic disease is an exclusion criterion or clarification of the stage, the patient's eligibility remains uncertain.\n\nTrial-level eligibility: 1) Not relevant.\n\nIt's important to note that further clarification from the clinical trial documentation would be needed to make a definitive assessment.",
        "label": 2
    },
    "363": {
        "output": "In order to determine the trial-level eligibility for the patient described in the note, let's go through the inclusion criteria for the clinical trial.\n\nThe patient's characteristics as per the note are:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nNow, let's match these characteristics against the clinical trial's inclusion criteria:\n\n- Women who have disease that is amenable to biopsy and agree to undergo a standard of care and/or research biopsy (The patient agrees to undergo surgery which could include a biopsy.)\n- Patients must satisfy criteria for prior therapy, which includes no prior endocrine therapy in the metastatic setting, and no more than one prior line of chemotherapy in the advanced/metastatic setting, or progression on one prior line of endocrine-based therapy monotherapy in the adjuvant or advanced/metastatic setting. (The patient note does not mention any prior chemotherapy or endocrine therapy in the metastatic setting, so we don't have enough information here.)\n- The intention to begin palbociclib and endocrine therapy as treatment for locally advanced or metastatic breast cancer (The patient note does not specify the patient's treatment plan regarding palbociclib and endocrine therapy.)\n- Measurable disease as defined by RECIST criteria or bone only disease are eligible (The patient has metastatic lesions, which likely means she has measurable disease.)\n- No current evidence of visceral crisis (The patient note does not mention a visceral crisis.)\n- History of central nervous system metastasis are allowed provided they have been treated and have stable neurologic function (The patient note does not mention CNS metastases.)\n- Pre or postmenopausal women with specific conditions (The patient is postmenopausal.)\n- ECOG performance status: 0, 1, or 2 (The patient note does not mention the ECOG performance status.)\n- Able to swallow oral formulation of drugs (No information provided, but this is generally assumed unless stated otherwise.)\n- Signed and dated informed consent document for study participation (The patient has agreed to tumor resection, so it's likely she would consent to study participation.)\n- Willing to submit tissue, blood, stool, and saliva and urine for required correlative research (Again, the patient's willingness to undergo surgery suggests she may be willing to provide samples for research, but this is not explicitly stated.)\n- Histologic confirmation from the pre-registration biopsy of locally advanced or metastatic breast cancer that is ER-positive and HER2-negative (The patient's tumor is HER2-positive and ER/PR-negative, which does not match the criteria.)\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not meet the trial's specific requirement for ER-positive and HER2-negative breast cancer, as her cancer is HER2-positive and ER/PR-negative. This mismatch is a critical exclusion factor for the clinical trial in question.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "364": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer,\" we must compare the patient's characteristics and condition to the inclusion criteria provided by the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Metastatic lesions present (indicating metastatic breast cancer)\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically or cytologically confirmed inoperable locally advanced or metastatic ER+ breast cancer (ER+ defined as expressing ER in \u226510% of cells or a determination of ER+ by IHC)\n- Documented HER2+ disease\n- Received prior therapy with Trastuzumab, Pertuzumab, and Ado-trastuzumab emtansine (T-DM1)\n- Agree to undergo a research biopsy or have archived tissue available for correlative studies\n- Women \u2265 18 years of age\n- ECOG performance status 0-2\n- Normal organ and marrow function as specified\n- Women of childbearing potential must have a negative pregnancy test and agree to use contraception\n- Ability to understand and willingness to sign a written informed consent document\n\nComparing the patient's characteristics to the inclusion criteria:\n- The patient is a woman and is above 18 years of age, which meets the age and gender inclusion criteria.\n- The patient has metastatic breast cancer, which meets the criteria for inoperable locally advanced or metastatic breast cancer.\n- The patient is HER2-positive, which meets the criteria for documented HER2+ disease.\n- The performance status of the patient is not provided, so we cannot assess the ECOG performance status (information is insufficient).\n- There is no information on the patient's organ and marrow function, so we cannot assess this criterion (information is insufficient).\n- The patient's ER/PR status is negative, which does not meet the ER+ requirement of the trial (expressing ER in \u226510% of cells).\n\nGiven the information provided, the patient does not meet the ER+ criteria required for the trial as her breast cancer is ER/PR negative. All other criteria cannot be fully assessed due to insufficient information. Therefore, the patient is not eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "365": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient Note Analysis:\n1. The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of being 18 years or older.\n2. The patient has a confirmed histologic diagnosis of invasive ductal breast carcinoma which is HER2-positive and ER/PR negative. This matches the requirement for HER2 overexpressing breast cancer with ER and PR less than 10%.\n3. The patient has metastatic lesions as per CXR, which indicates distant metastases (M1). This does not meet the inclusion criterion of \"No indication of distant metastases (M0).\"\n4. The patient is a candidate for tumor resection; however, there is no information regarding neoadjuvant chemotherapy (NAC) or a post-NAC clinical bilateral breast MRI.\n5. There is no information provided on the patient's ECOG or KPS performance status score.\n6. There is no indication that the patient is pregnant or breastfeeding, which aligns with the trial criteria.\n7. The patient has agreed to tumor resection, suggesting a willingness to participate in treatments, but her consent specifically to this trial's procedures is not mentioned.\n\nClinical Trial Inclusion Criteria Analysis:\n1. Women age 18 years or older - The patient meets this criterion.\n2. Confirmed histologic diagnosis of specific types of breast cancer - The patient meets the criterion for HER2 overexpressing breast cancer.\n3. Operable breast cancer treated with NAC and a complete imaging response on post-NAC MRI - Insufficient information.\n4. No distant metastases (M0) - The patient does not meet this criterion due to having metastatic lesions.\n5. Tumor site amenable to MRI guided biopsy - Insufficient information.\n6. Definitive surgery being performed within specified time from NAC - Insufficient information.\n7. ECOG or KPS performance status score specified - Insufficient information.\n8. Not pregnant or breastfeeding - The patient seems to meet this criterion.\n9. Willing and able to provide informed consent - Insufficient information regarding informed consent for this specific trial.\n\nBased on the available information, the patient does not meet all the inclusion criteria due to the presence of metastatic lesions (indication of distant metastases), and there is insufficient information on whether she has received NAC, her performance status, and her consent to participate in this specific trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "366": {
        "output": "To assess the trial-level eligibility of the patient, we must match the patient's characteristics to the inclusion criteria of the clinical trial.\n\nPatient's characteristics based on the note provided:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive breast cancer\n- Tumor size: 3 cm invasive ductal carcinoma\n- HER2-positive and ER/PR negative\n- Positive axillary lymph nodes (5 positive nodes)\n- Candidate for tumor resection prior to chemotherapy\n- No mention of ECOG Performance Status\n- No mention of Left ventricular ejection fraction (LVEF)\n- No mention of organ and marrow function\n- Non-pregnant status can be assumed due to postmenopausal status\n\nClinical trial inclusion criteria:\n- Histologically or cytologically confirmed invasive breast cancer\n- ER and PR-negative as defined by local standard clinical immunohistochemistry (IHC) < 1%\n- HER2-negative using local standard testing\n- Clinical tumor size of at least 2.1 cm (T2) or any tumor size with ipsilateral regional lymph nodes involved\n- Candidate for neoadjuvant chemotherapy\n- Age > 18 years and < 75 years\n- ECOG Performance Status < 1\n- Left ventricular ejection fraction (LVEF) \u2265 LLN\n- Adequate organ and marrow function as determined by study protocol\n- Non Pregnant, meets postmenopausal criteria or agrees to contraception\n- Ability to understand and willingness to sign the written informed consent document\n\nComparison of patient characteristics to trial criteria:\n- Age 45 years fits the age criterion (> 18 and < 75 years).\n- Postmenopausal status meets the non-pregnant and hormonal status requirement.\n- The patient is a candidate for neoadjuvant chemotherapy after planned tumor resection.\n- The tumor size is 3 cm, which meets the size requirement (at least 2.1 cm).\n- HER2 status is positive, which does not meet the criterion for HER2-negative.\n- There is no information on the patient's ECOG Performance Status or LVEF to determine eligibility based on these criteria.\n- There is no information on the patient's organ and marrow function as determined by the study protocol.\n\nThe patient does not meet the trial's inclusion criteria for HER2 status, as the trial requires HER2-negative and the patient has HER2-positive breast cancer. Other data needed for full eligibility assessment, such as ECOG Performance Status, LVEF, and organ and marrow function, are not provided.\n\nBased on the available information, the patient is not eligible for the trial due to the HER2-positive status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "367": {
        "output": "",
        "label": 0
    },
    "368": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's compare the details to determine the patient's eligibility for the trial:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the trial's age criterion of being \u2265 18 years old.\n- The patient has cytologically confirmed breast cancer, which is the target condition for the trial.\n- The patient has a 3 cm invasive ductal breast carcinoma, which is operable and hence meets the requirement for operable breast cancer.\n- The tumor is HER2-positive and ER/PR-negative, which is relevant for the trial as it is exploring different molecular typing and mentions the use of Trastuzumab for HER-2 positive patients.\n- The patient has not yet undergone chemotherapy, radiation therapy, hormone therapy, or surgical therapy, which aligns with the trial's criterion of no history of anti-cancer therapies.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy, which is a part of the trial protocol.\n- The patient's cardiac function is not mentioned, so we do not know if she meets the normal cardiac function requirement.\n- The patient's ECOG score is not provided, so we cannot confirm if it is \u2264 0-1.\n- The patient's disposition towards practicing contraception is not mentioned, so we cannot confirm if she meets this criterion.\n- The patient's blood test results are not provided, so we cannot confirm if she meets the specified blood test criteria.\n- The patient's note indicates the presence of metastatic lesions on CXR, which implies distant metastasis. This would exclude her from the trial, as the inclusion criteria specify no distant metastasis.\n\nGiven the available information, the most critical exclusionary detail we have is the presence of metastatic lesions, which indicates that the patient has distant metastasis. This does not meet the trial's inclusion criterion of having no distant metastasis.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "369": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare each point:\n\n1. **Invasive ductal carcinoma diagnosed by biopsy:** The patient has a core biopsy revealing a 3 cm invasive ductal breast carcinoma. This matches the trial criterion.\n   \n2. **Clinically positive node diagnosed by CECT, the number of strengthened nodes at Level I \u2265 1 with the longest diameter of the strengthened node \u2265 2cm:** The patient note indicates axillary sampling revealed 5 positive lymph nodes, but it does not specify the size of these nodes or if the diagnosis was by CECT. Therefore, we don't have enough information to confirm this criterion.\n\n3. **NAC regimen followed the NCCN guideline:** The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies she will undergo NAC following standard guidelines. However, it is not explicit that the regimen follows the NCCN guideline, so this remains somewhat unclear.\n\n4. **No prior history of breast cancer or other malignancies:** The patient note does not mention any prior history of breast cancer or other malignancies, which suggests she meets this criterion.\n\nGiven the available information from the patient note:\n\n- The patient has invasive ductal carcinoma diagnosed by biopsy.\n- It is not clear if the clinically positive lymph nodes meet the specified criteria of being diagnosed by CECT and having the longest diameter \u2265 2cm.\n- It is implied but not confirmed that the NAC regimen will follow NCCN guidelines.\n- There is no prior history of breast cancer or other malignancies mentioned.\n\nTherefore, due to the lack of detailed information about the size and diagnosis method of the lymph nodes and confirmation of the NAC regimen following NCCN guidelines, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "370": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the two:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed diagnosis of non-metastatic operable TNBC subjected to diagnostic core biopsy\n- TNBC defined as HER2/ER/PgR negative receptors\n- Female, aged \u2265 18 years\n- ECOG performance status \u2264 1\n- Clinical indication for a neoadjuvant approach according to the investigator's judgment\n- Availability of FFPE tumor block taken at diagnostic biopsy for IHC and RNA-Seq molecular determinations\n- Negative serum pregnancy test for patients with reproductive potential and agreement to use contraception\n- Written informed consent\n\nComparison:\n- The patient is a 45-year-old female, which meets the age and gender criteria.\n- The patient's tumor is HER2-positive, which does not meet the requirement for TNBC (which should be HER2-negative).\n- The patient has metastatic lesions, whereas the trial requires a non-metastatic operable tumor.\n\nGiven that the patient's breast cancer is HER2-positive and the presence of metastatic lesions, she does not meet the inclusion criteria for the trial, which is specifically for patients with triple-negative breast cancer without metastasis. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "371": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer,\" we need to match the patient's characteristics and condition to the inclusion criteria listed in the trial summary:\n\n- **Women age \u2265 18 years:** Our patient is a 45-year-old woman, so this criterion is met.\n- **Eastern Cooperative Oncology Group performance status 0-2 (Karnofsky >60%):** No specific performance status is mentioned in the patient note, so we cannot determine if this criterion is met.\n- **Patients with metastatic breast cancer:** The patient has metastatic lesions as noted in the CXR, meeting this criterion.\n- **HER2-positive breast cancer:** The patient's tumor is HER2-positive as confirmed by the core biopsy, meeting this criterion.\n- **Estrogen/progesterone receptor positive OR negative disease allowed:** The patient's tumor is ER/PR negative, which is allowable under the criteria.\n- **Patients must have measurable disease per the RECIST v1.1:** The presence of a 3 cm invasive ductal breast carcinoma and metastatic lesions indicate measurable disease, meeting this criterion.\n- **Patients that have failed at least one anti-HER2 therapy in the metastatic setting:** There is no information on previous anti-HER2 therapy, so this criterion is unknown.\n- **Patients must have normal organ and marrow function as defined:** No specific laboratory results are provided, so these criteria cannot be evaluated.\n- **Baseline left ventricular ejection fraction (LVEF) \u2265 50%:** No information on LVEF is provided, so this criterion cannot be evaluated.\n- **Willing and able to comply with the requirements of the protocol:** The patient agrees to tumor resection, indicating a willingness to undergo treatment, but this does not fully confirm compliance with the study protocol.\n- **Patient is able to take oral medication:** There is no information that suggests the patient cannot take oral medication.\n- **Signed informed consent:** This would be obtained if the patient agrees to participate in the trial.\n- **Female patients of childbearing potential must be willing to use contraception:** The patient is postmenopausal, so this criterion is not applicable.\n\nBased on the information provided, there is sufficient information to suggest the patient could be eligible for the trial; however, there are key details missing regarding performance status, previous anti-HER2 therapy, organ and marrow function, and LVEF. These are critical to fully determine eligibility. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "372": {
        "output": "Let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 3 cm tumor in the left upper outer quadrant\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions visible on CXR\n- Candidate for tumor resection, agreeing to proceed prior to chemotherapy\n- No history of chemotherapy mentioned in the note\n\nClinical trial inclusion criteria:\n- Written informed consent\n- Operable breast cancer diagnosed by histopathology, no distant metastasis\n- No history of anti-cancer therapies (chemotherapy, radiation therapy, hormone therapy, surgical therapy)\n- Normal cardiac function by echocardiography\n- ECOG scores are \u2264 0-1\n- Willingness to practice contraception during the trial\n- Blood test requirements (Hb, WBC, Plt, Neutrophils, ALT, AST, TBIL, Creatinine)\n- ER+ Her2- early-stage breast cancer\n\nBased on the information provided, the patient does not meet the inclusion criteria for the following reasons:\n\n- The patient's tumor is HER2-positive, while the trial requires HER2-negative.\n- The patient has metastatic lesions (distant metastasis), which is excluded by the trial criteria that specify no distant metastasis.\n- There is no information regarding the patient's cardiac functions, ECOG score, or blood test results, but these are secondary to the primary disqualifying criteria mentioned above.\n\nGiven these points, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "373": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative. She has positive lymph nodes and metastatic lesions, as indicated by the core biopsy and CXR results. The patient is a candidate for tumor resection before chemotherapy.\n\nNow let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\n1. Invasive breast cancer diagnosed with core needle biopsy: The patient note confirms that the breast cancer was diagnosed with a core biopsy.\n2. Staging cT1b-2N0M0: The patient has metastatic lesions and 5 positive lymph nodes, which indicates that she is beyond the N0 stage required by the trial.\n3. ER/PR positive cells ratio <10%, or HER2 positive: The patient is HER2 positive, meeting this criterion.\n4. Without chemotherapy contraindications, and planned or has started neoadjuvant chemotherapy: The patient note does not provide information about any contraindications, but it suggests that she is a candidate for tumor resection prior to chemotherapy, which implies that she might be planning to undergo neoadjuvant chemotherapy.\n5. With axillary sentinel lymph node biopsy indications confirmed prior to neoadjuvant therapy: The patient note mentions axillary sampling with 5 positive lymph nodes, but it does not confirm whether a sentinel lymph node biopsy was indicated or performed prior to any therapy.\n6. Voluntarily join the study and sign an informed consent form: The patient's willingness can be assumed based on the note, but it is not explicitly stated.\n\nThe primary issue with the patient's eligibility is the staging cT1b-2N0M0 requirement. Since the patient already has positive lymph nodes and metastatic lesions, she does not meet the trial's staging criteria, which require clinically node-negative status. Despite meeting some of the inclusion criteria, the patient's stage makes her ineligible for this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "374": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which is an invasive ductal carcinoma that is HER2-positive and ER/PR negative. The clinical trial has three cohorts, each with specific inclusion criteria:\n\n- Cohort 1 is for hormone receptor positive breast cancer, which our patient does not have since her tumor is ER/PR negative.\n- Cohort 2 is for triple negative breast cancer (TNBC), which requires the breast cancer to be ER and PR negative, and HER2 negative as well. However, our patient's tumor is HER2-positive, so she does not meet the criteria for this cohort.\n- Cohort 3 is for endometrial cancer, which is not applicable to our patient.\n\nSince the patient's breast cancer does not meet the inclusion criteria for any of the cohorts (not hormone receptor positive for Cohort 1, not triple negative for Cohort 2, and Cohort 3 is for a different cancer type), the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "375": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, undergoing tumor resection prior to chemotherapy. The clinical trial in question is examining two warming methods in knee arthroplasty surgery.\n\nTo determine the trial-level eligibility of the patient for this clinical trial, we need to compare the patient's characteristics to the inclusion criteria of the trial:\n\nInclusion Criteria for the clinical trial:\n- BMI 25-40\n- ASA class I-III\n- Elective primary unilateral knee arthroplasty\n- Spinal anaesthesia\n\nThe patient note does not provide information on the patient's BMI, ASA class, or any indication that the patient is scheduled for knee arthroplasty surgery or that spinal anaesthesia is planned. The patient's current medical condition is focused on breast cancer treatment, which is unrelated to the clinical trial's focus on knee arthroplasty.\n\nGiven the available information, the patient does not meet the inclusion criteria for the knee arthroplasty warming methods trial because the patient is being treated for breast cancer, not undergoing knee arthroplasty. Therefore, the patient is not relevant for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "376": {
        "output": "To determine the patient's trial-level eligibility, we have to compare the patient's condition and characteristics with the inclusion criteria of the clinical trial. Let's analyze the given information step by step:\n\n**Patient Information:**\n- 45-year-old postmenopausal woman\n- Diagnosis: Cytologically confirmed breast cancer\n- Core biopsy: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Agrees to tumor resection prior to chemotherapy\n\n**Clinical Trial Inclusion Criteria:**\n- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n- The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy.\n- The primary breast tumor must be palpable and measure greater than or equal to 2.0 cm on physical exam.\n- The regional lymph nodes can be cN0, cN1, or cN2a.\n- Histological grade II or III tumor.\n- Axillary lymph nodes evaluated by imaging and, if suspicious, FNA or core biopsy recommended.\n- Tumor must be HER2-negative as defined by specific IHC and ISH criteria.\n- Adequate blood counts.\n- Adequate hepatic function.\n- Serum creatinine less than or equal to 1.5 x ULN for the lab.\n- LVEF greater than or equal to 55 percent.\n- Use of effective non-hormonal contraception if with reproductive potential.\n- Abnormal HER2-driven signaling activity based on the CELx HSF test (for main study enrollment).\n\nBased on the patient note, the patient does not meet the inclusion criteria for the HER2 status. The patient's tumor is HER2-positive, which is contrary to the requirement of the clinical trial that the tumor must be HER2-negative. All other criteria such as age, diagnosis by core biopsy, palpable tumor size, lymph node involvement, and the patient's willingness to undergo tumor resection cannot be fully assessed for eligibility since the HER2 status alone disqualifies the patient.\n\nGiven that the inclusion criteria require the tumor to be HER2-negative and the patient's tumor is HER2-positive, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "377": {
        "output": "Let's compare the patient's characteristics against the inclusion criteria of the clinical trial to determine her eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection\n- No smoking or alcohol consumption\n- Not sexually active, no children\n- Using multivitamins and iron supplements\n\nClinical Trial Inclusion Criteria:\n- Signed and dated written informed consent\n- Female, \u226518 and \u226465 years of age\n- Histologically-confirmed invasive carcinoma of the breast (AJCC Stage II, IIIa)\n- Operable breast cancer, planned surgical resection of breast tumor and sentinel or axillary lymph nodes\n- Unilateral, measurable tumor of the breast >2 cm in diameter\n- HER2 positive tumor, as confirmed by central laboratory\n- Known ER and PrR status at study entry\n- Adequate bone marrow, hepatic, and renal function\n- ECOG score of 0 or 1\n- LVEF \u226555%\n- Negative pregnancy test, using adequate contraceptives or non-childbearing potential\n\nAssessment:\n- The patient is within the age range.\n- She has a histologically-confirmed invasive carcinoma of the breast.\n- The cancer is operable with planned surgical resection.\n- The tumor is >2 cm in diameter and HER2 positive.\n- The patient is postmenopausal, which meets the non-childbearing potential criterion.\n- The patient's ER and PrR status is known.\n- There is no information provided on the patient's bone marrow, hepatic, renal function, ECOG score, or LVEF, which are necessary to determine eligibility.\n- The presence of metastatic lesions on CXR may suggest that the patient's cancer stage could be beyond Stage IIIa, which would need clarification as the trial specifies up to Stage IIIa.\n\nGiven that the patient note lacks information on some critical inclusion criteria (e.g., bone marrow, hepatic, renal function, ECOG score, LVEF), and there is a potential concern with the cancer stage due to the presence of metastatic lesions, the patient cannot be confirmed eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "378": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which matches the inclusion criteria of the clinical trial that requires adult female patients with breast cancer. There is no additional exclusion criteria provided, and the patient's specific type of breast cancer (HER2-positive and ER/PR negative) and the stage (presence of metastatic lesions and positive lymph nodes) do not preclude participation based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "379": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is aimed at individuals with bilateral medication-refractory essential tremor (ET) who have previously undergone Exablate thalamotomy and are candidates for a second, staged bilateral thalamotomy.\n\nThe inclusion criteria for the trial include:\n\n- Previous Exablate thalamotomy for ET at least 9 months prior to enrolling in this study\n- Candidates for bilateral treatment for ET\n- Complete baseline CRST prior from first Exablate thalamotomy\n- Age 22 to 75 years\n- Minimum score of 24 on MoCA or 20 on MMSE\n- Able and willing to give consent and able to attend all study visits\n- Postural or intention tremor severity score of greater than or equal to 2 in both upper extremities\n- Thalamus can be targeted by the Exablate device, and the region must be apparent on MRI\n- Able to communicate sensations during the Exablate Thalamotomy treatment\n- Certain requirements regarding the original CRST score and stability on antidepressant medications\n\nThe patient's note does not mention essential tremor or any previous Exablate thalamotomy procedures. Instead, it describes a case of breast cancer with no relation to the conditions treated in the clinical trial for ET.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial focused on ET, as her medical condition (breast cancer) is unrelated to the target disease of the trial (essential tremor).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "380": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This corresponds to the inclusion criteria of the clinical trial, which states \"Every adult (above 18) y.o.patient with histologic diagnosis of Breast Cancer.\"\n\nThe patient has metastatic disease (CXR was remarkable for metastatic lesions), which also corresponds with the inclusion criteria of the clinical trial that includes patients with metastatic disease who are in active surveillance.\n\nHowever, the clinical trial specifically includes patients who refuse or are not suitable for surgical treatment. The patient note indicates the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies an intention to undergo surgical treatment.\n\nTherefore, while the patient initially appears to meet the age and diagnostic requirements, her agreement to undergo surgery prior to chemotherapy does not align with the trial's inclusion criteria for patients who refuse or are not suitable for surgical treatment.\n\nBased on this discrepancy, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "381": {
        "output": "",
        "label": 0
    },
    "382": {
        "output": "After reviewing the patient note and the clinical trial information, let's assess the patient's eligibility based on the provided inclusion criteria.\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- The patient is a candidate for tumor resection and chemotherapy.\n\nClinical Trial:\n- Title: Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis\n- Inclusion Criteria: Non-metastatic Pancreatic Cancer\n\nThe patient in the note has breast cancer, not pancreatic cancer. Therefore, she does not meet the inclusion criteria for the clinical trial, which is specific to non-metastatic pancreatic cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "383": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer scheduled for tumor resection. The clinical trial in question is investigating the plasma concentration of lidocaine and bupivacaine in patients undergoing trauma surgery of the hand and forearm with the use of an axillary approach to brachial plexus block (BPB).\n\nThe inclusion criteria for the clinical trial are:\n- Unpremedicated patients scheduled for elective or emergency trauma surgery of the hand and forearm under ultrasound-guided BPB.\n\nBased on the information provided in the patient note, the patient does not fit the criteria for the clinical trial because:\n1. The patient's surgery is related to breast cancer and not trauma surgery of the hand and forearm.\n2. There is no mention of the patient being scheduled for an ultrasound-guided BPB, which is a specific type of anesthesia for upper limb surgery.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "384": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial. Let's review the patient's information against the trial criteria:\n\n- Women age 18 years or older: The patient is 45 years old, which meets this criterion.\n- Confirmed histologic diagnosis of invasive carcinoma of the breast: The patient has a confirmed diagnosis of invasive ductal breast carcinoma, which meets this criterion.\n- ER, PR, and HER2 negative on outside or Cedars Sinai biopsy report: The patient is HER2-positive and ER/PR negative. The trial requires the tumor to be triple-negative, which means the patient does not meet this criterion.\n- Operable tumor measuring \u22651.0 cm in maximal diameter: The patient has a 3 cm tumor, which meets this criterion.\n- Any nodal status allowed, including negative nodal status: The patient has 5 positive lymph nodes, which meets this criterion.\n- No indication of distant metastases: The patient has metastatic lesions as per the CXR report, which means there is an indication of distant metastases, not meeting this criterion.\n- Total mastectomy or lumpectomy planned: The patient is a candidate for tumor resection, which meets this criterion.\n- Tumor amenable to cryoablation as determined by a study radiologist: There is no information provided regarding the tumor's amenability to cryoablation.\n- ECOG performance status score of 0 or 1: There is no information provided regarding the patient's ECOG performance status.\n- Screening laboratory values must meet certain criteria: No laboratory values are provided.\n- Women of childbearing potential must use appropriate methods of contraception and have a negative pregnancy test: The patient is postmenopausal, which may not be relevant, and there is no information about contraception or pregnancy test.\n- Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol: The patient agrees to undergo tumor resection, which might indicate willingness, but this is not sufficient evidence of willingness to adhere to the study visit schedule.\n\nBased on the available information, the patient does not meet the criteria of having a triple-negative breast tumor (ER, PR, and HER2-negative) and has distant metastases, which excludes her from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "385": {
        "output": "To determine the trial-level eligibility for the patient described, let's compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection and agrees to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Written informed consent\n- Age \u226518 years at time of study entry\n- Histologically confirmed MIUC of the bladder with a dominant transitional cell pattern (>50%)\n- Localized MIUC of the bladder with clinical stage T2-T4a and \u2264N1 disease\n- Bodyweight >45kg\n- Eligible for cisplatin-based neoadjuvant chemotherapy\n- Adequate organ and marrow function\n- Evidence of post-menopausal status (which the patient meets) or negative pregnancy test for pre-menopausal women\n- Willing to use contraceptive methods if of childbearing potential and sexually active\n- Willing and able to comply with the study protocol\n\nThe patient's cancer is breast cancer, not muscle-invasive urothelial carcinoma (MIUC) of the bladder. Since the trial specifically requires patients with histologically confirmed MIUC, the patient does not meet the primary disease criteria for this trial. Therefore, despite any other matching criteria, the patient is not eligible for this clinical trial based on the type of cancer alone.\n\nGiven this information, the trial-level eligibility for the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "386": {
        "output": "To determine the trial-level eligibility for the patient, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nPatient characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- The tumor is invasive ductal carcinoma, HER2-positive and ER/PR negative.\n- The patient has metastatic lesions and positive lymph nodes.\n- The patient is scheduled for tumor resection prior to chemotherapy.\n\nClinical trial inclusion criteria:\n- Female patients.\n- Age \u2265 18 years old.\n- Histologically confirmed HER2-/HR+ locally advanced or metastatic invasive breast carcinoma.\n- Willingness and ability to provide tissue for research.\n- Maintenance therapy must be preceded by at least 4 cycles of chemotherapy.\n- Previous therapy with maximum one line of anti-hormonal treatment is allowed.\n- Previous neoadjuvant/adjuvant therapy is allowed.\n- ECOG performance status (PS) 0-1.\n- Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade \u2264 1.\n- Life expectancy > 6 months.\n- Non-childbearing potential, or childbearing potential with negative pregnancy test and use of non-hormonal contraception.\n\nBased on the patient note and the inclusion criteria:\n- The patient's age fits the criteria.\n- The patient is female.\n- The patient has metastatic breast cancer but HER2-positive and ER/PR negative, which does not match the trial requirement of HER2-negative/HR+ breast carcinoma.\n- There is no information on the patient's ECOG performance status, resolution of toxic effects of prior therapy, or the number of chemotherapy cycles completed.\n- The patient is postmenopausal, fitting the non-childbearing potential criteria.\n\nThe patient does not meet the crucial criterion of having a HER2-negative/HR+ breast carcinoma, as her condition is HER2-positive and ER/PR negative. Therefore, she is not eligible for this trial that specifically targets HER2-negative/HR+ breast cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "387": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma (IDC) in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions visible on CXR\n- Candidate for tumor resection\n\nClinical trial inclusion criteria:\n- Informed Consent as documented by signature\n- WHO performance status \u2264 2\n- Body weight \u2264 80 kg\n- Biopsy proven invasive breast cancer with a size of \u22643.0 cm (TNM classification: cT1-2 N0-2 MX)\n- Histological type of tumor: IDC\n- Patient is scheduled for surgical resection of the tumor at the study site\n- Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor \u2265 1.0 cm\n- Target breast fits in the cup of the dedicated MR-HIFU breast system\n\nBased on the patient's information given:\n- The patient has biopsy-proven invasive ductal carcinoma, which matches one of the inclusion criteria.\n- The tumor size is 3 cm, which is within the size limit of the inclusion criteria.\n- The patient is scheduled for surgical resection, which is required by the trial.\n- There is no information provided about the patient's WHO performance status, body weight, or specific tumor location relative to skin and pectoral muscle, nor about the fit in the MR-HIFU system, which is necessary to assess the full eligibility.\n\nGiven the available information, the patient appears to meet several of the inclusion criteria, but there is insufficient information to determine eligibility for certain criteria, such as WHO performance status, body weight, and specific tumor location measurements. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.\n\nTo fully determine eligibility, additional information would be required.",
        "label": 2
    },
    "388": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The details provided about her condition and treatment plans are specific to breast cancer and do not mention bilateral knee arthroplasty, which is the subject of the clinical trial.\n\nThe clinical trial in question is titled \"Staged Versus Simultaneous Bilateral Knee Arthroplasty,\" which pertains to patients considering bilateral knee replacement surgery. There is no mention of knee problems, arthritis, or any indication that the patient is considering or is a candidate for bilateral knee arthroplasty in the patient note.\n\nGiven the available information, the patient does not meet the inclusion criteria for this specific clinical trial, since there is no relevance between her condition (breast cancer) and the focus of the trial (knee arthroplasty).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "389": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer,\" the following information is pertinent to determining eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- The patient's cancer is metastatic, as indicated by a CXR showing metastatic lesions.\n- The patient has not undergone any chemotherapy as she is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases.\n- Between 18 and 80 years of age.\n- Had undergone at least three lines of chemotherapy.\n- Expected survival time of at least 3 months.\n\nAssessment:\nThe patient is female and within the age range specified by the trial. She has metastatic breast cancer with measurable metastases, which aligns with the trial's target condition. However, the patient has not undergone any chemotherapy yet, as she is a candidate for tumor resection prior to chemotherapy. The inclusion criteria specify that participants must have undergone at least three lines of chemotherapy.\n\nBased on the information provided, the patient does not meet the inclusion criteria regarding previous chemotherapy treatment. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "390": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which qualifies as a solid tumor as per the clinical trial's inclusion criteria. The core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which satisfies the trial's requirement of at least one lesion >= 1.0 cm that is seen on standard imaging.\n\nGiven this information, the patient meets the inclusion criteria for the clinical trial:\n\n- History of known or suspected solid tumor (confirmed breast cancer).\n- At least one lesion >= 1.0 cm that is seen on standard imaging (3 cm invasive ductal breast carcinoma).\n\nTherefore, the patient appears to be eligible for the clinical trial as per the provided inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "391": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- Age: 45 years old\n- Diagnosis: Cytologically confirmed invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) breast carcinoma, treated with partial mastectomy\n- No positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node\n- Tumor histologies allowed are invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular, or mixed (lesions \u2264 2 cm) that are estrogen or progesterone receptor-positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm)\n- No neoadjuvant therapy (hormone, chemotherapy, or biologic) prior to TRI-APBI\n- Postmenopausal status\n- Age \u2265 50 years at diagnosis\n- Ability to understand and sign informed consent\n- English speaker\n- All radiation therapy must be planned for delivery at a specified institution\n\nComparing the patient characteristics to the trial inclusion criteria:\n\n1. The patient is 45 years old, which is younger than the minimum age requirement of \u2265 50 years old at diagnosis.\n2. The patient has invasive ductal breast carcinoma, but the tumor is HER2-positive and ER/PR negative, which does not meet the trial's requirement for estrogen or progesterone receptor-positive tumors without HER2/neu gene amplification.\n3. The patient has 5 positive axillary lymph nodes, whereas the trial requires no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\n4. The patient has metastatic lesions present, which typically indicates a stage beyond stage I breast cancer.\n5. The patient's postmenopausal status is not clearly mentioned, but given that she is described as postmenopausal, this would fit the criteria.\n6. The trial requires all participants to be English speakers, and there is no information on the patient's language abilities.\n7. The patient is planning to undergo tumor resection before chemotherapy, but the trial excludes patients who have had neoadjuvant therapy prior to TRI-APBI.\n\nGiven these discrepancies, particularly with age, hormone receptor status, presence of positive lymph nodes, and potentially the stage of cancer, the patient does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "392": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Scheduled for tumor resection before chemotherapy\n- No mention of orthopedic foot or ankle surgery or day case surgery\n\nClinical trial:\n- Title: Minimum Anaesthesia Concentration of Lidocaine Required for Sciatic Popliteal Block\n- Inclusion Criteria: Patients undergoing orthopedic foot or ankle surgery as a day case surgery\n- Exclusion Criteria: Patients <18 years, ASA class greater than III, obese (BMI >30), patients with low body weight requiring a lidocaine dose of more than 4.5mg/kg, peripheral neuropathy, motor weakness, infection at the injection site, any contraindications for medications in the study\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial, as there is no information suggesting she is undergoing orthopedic foot or ankle surgery, which is a requirement for the trial. Therefore, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "393": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative, and there is evidence of metastatic spread as indicated by positive axillary lymph nodes and metastatic lesions noted on CXR. She is planned for tumor resection before chemotherapy.\n\nThe clinical trial is looking for patients with histologically confirmed HER2 positive salivary duct carcinoma (SDC) or other similar salivary gland carcinomas. The inclusion criteria also specify stage IV or recurrent cancer, age \u2265 20 years, an ECOG performance status of 0-2, at least one measurable tumor lesion, an expected survival of approximately 12 weeks or longer, no prior systemic chemotherapy, and a waiting period of at least 4 weeks after surgery or radiotherapy.\n\nBased on the information provided:\n\n1. The patient has HER2-positive breast cancer, not salivary duct carcinoma or a similar salivary gland carcinoma as required by the trial.\n2. The patient does meet the age criterion (\u2265 20 years).\n3. The ECOG performance status is not mentioned in the patient's note.\n4. There is an indication of at least one measurable tumor lesion (3 cm invasive ductal breast carcinoma).\n5. Expected survival is not mentioned, though she is a candidate for surgery, which may imply a reasonable short-term survival expectation.\n6. The patient is a candidate for tumor resection, and chemotherapy has not yet been started, which may satisfy the criteria for no prior systemic chemotherapy and the waiting period post-surgery.\n\nThe patient does not meet the primary disease criterion of having salivary duct carcinoma or a similar salivary gland carcinoma. Therefore, she would not be eligible for this clinical trial based on the disease type alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "394": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions as indicated by CXR.\n- The patient is a candidate for tumor resection.\n\nThe clinical trial's inclusion criteria state:\n- Women age 18 and older.\n- Understand and provide informed consent and HIPAA Authorization prior to initiation of any study-specific procedures.\n- Cohort A: Recent abnormal mammogram followed by a breast biopsy with an initial diagnosis of Stage I, II, III, or IV invasive breast cancer.\n\nThe patient is a 45-year-old woman and thus meets the age requirement. She has an initial diagnosis of invasive breast cancer, which fits the criteria for Cohort A. The patient's condition does not match any of the situations described for the other cohorts (B, C, and D), as she does not have a benign breast tumor nor a normal screening mammogram.\n\nTherefore, provided that the patient understands and can provide informed consent and HIPAA Authorization, she appears to meet the inclusion criteria for Cohort A of the clinical trial. There are no exclusion criteria provided, so we cannot determine if she would be excluded for any other reason.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "395": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria specified by the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions present\n- Planned to undergo tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Premenopausal patients\n- Operable hormonal receptor (HR) positive (ER/PR greater than or equal to 10%), HER2-negative invasive early breast cancer\n- Suitable for neoadjuvant AI treatment and ovarian suppression\n- Diagnostic breast tissue with an Oncotype DX Breast Recurrence Score\u00ae of less than 26\n- No severe hypersensitivity reactions to compounds similar to palbociclib or its excipients or to endocrine treatments\n- A breast tumor with an ultrasound size of at least 2.0 cm\n- Ability to swallow oral medication\n- ECOG performance status of 0 or 1\n- Specific blood count, INR, hepatic function, and serum creatinine levels within defined ranges\n\nThe patient note reveals that the patient is postmenopausal, which conflicts with the inclusion criteria requiring premenopausal status. Furthermore, the patient's cancer is HER2-positive, whereas the trial requires HER2-negative status. Therefore, the patient does not meet two key inclusion criteria: premenopausal status and the requirement for the cancer to be HER2-negative.\n\nBased on this information, the patient is not eligible for the clinical trial as she does not meet the necessary inclusion criteria regarding menopausal status and cancer characteristics (HER2 status).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "396": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse\", let's compare the patient's characteristics and history with the inclusion criteria provided for the trial:\n\nPatient's characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions on CXR.\n- The patient is a candidate for tumor resection.\n\nClinical trial inclusion criteria to consider:\n- Patients \u2265 18 years old.\n- Invasive recurrence (ductal, lobular, other), homolateral breast carcinoma.\n- Size of the tumor with ultrasound \u2264 5cm.\n- Initial conservative surgery.\n- Patient who has already received SLND for her initial cancer, regardless of the SLND result.\n- Procedure for the detection of lymph node sentinel by isotopic method +/- colorimetric.\n- Minimum delay of one year between the end of radiotherapy for initial breast carcinoma and the treatment/management of ipsilateral recurrence.\n- Pregnancy test (urinary or blood) negative for premenopausal patients.\n- Information of the patient and obtaining written consent, signed by the patient and the investigator.\n\nAssessment:\n1) The patient is over 18 years old. (Meets criteria)\n2) The patient has invasive ductal breast carcinoma, which is a type of invasive recurrence. (Meets criteria)\n3) The tumor size is 3 cm, which is \u2264 5cm. (Meets criteria)\n4) The patient is a candidate for tumor resection, but the initial note does not specify whether the initial surgery was conservative (e.g., lumpectomy or breast-conserving surgery). (Not enough information)\n5) The note does not mention if the patient has already received SLND for her initial cancer. (Not enough information)\n6) The note does not mention the method planned for detecting the sentinel lymph node. (Not enough information)\n7) The note does not specify the time since the end of radiotherapy for the initial breast carcinoma. (Not enough information)\n8) The patient is postmenopausal, so a pregnancy test would not be applicable. (Not applicable)\n9) There is no mention of the patient being informed of the details of the trial or providing written consent; however, this is typically done after determining eligibility and prior to enrollment. (Not applicable at this stage)\n\nBased on the available information from the patient note, there is not enough information to conclusively determine if the patient meets all the necessary inclusion criteria for the clinical trial. The patient's eligibility cannot be confirmed without further details regarding the type of initial surgery, whether the patient received SLND previously, the method for detecting the sentinel lymph node, and the time since the end of radiotherapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "397": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Carbon Dye Tattooing of Biopsied Axillary Node in Breast Cancer.\"\n\nPatient Note Assessment:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is using multivitamins and iron supplements.\n- She is a candidate for tumor resection and agrees to undergo the procedure prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18\n- Male or female\n- Patients scheduled to undergo routine fine needle aspiration (FNA) or core biopsy of abnormal axillary lymph node\n- Invasive breast cancer\n- Written informed consent for the study\n\nThe patient meets the following inclusion criteria for the clinical trial:\n- She is over 18 years old.\n- She is female (gender requirement is not specific; both male and female are eligible).\n- She has invasive breast cancer.\n- She has abnormal axillary lymph nodes, as evidenced by 5 positive lymph nodes found during axillary sampling.\n- She is scheduled to undergo tumor resection, which may involve fine needle aspiration (FNA) or core biopsy of the axillary lymph node if not done previously.\n\nAssuming that the patient provides written informed consent for the study, she would meet all the listed inclusion criteria. There is no information in the patient note that indicates any exclusion criteria that would prevent her from participating in the study.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "398": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH),\" we need to compare the patient's characteristics and condition against the trial's inclusion criteria:\n\nInclusion Criteria Checklist:\n\n- Histologically confirmed invasive breast cancer: Yes, the patient has cytologically confirmed breast cancer.\n- Early breast cancer with tumor size >1 cm: Yes, the core biopsy revealed a 3 cm invasive ductal breast carcinoma.\n- No clinical evidence of regional lymph node metastasis (cN0) OR Clinical evidence of cN1 status: The patient has 5 positive lymph nodes, which suggests cN1 status.\n- No evidence of metastasis (M0): The patient has metastatic lesions according to the CXR, suggesting that the patient does have evidence of metastasis, which does not meet the trial's inclusion of M0 (no evidence of metastasis).\n- Postmenopausal: Yes, the patient is described as postmenopausal.\n- ECOG performance status 0 or 1: There is no information provided on the ECOG performance status.\n- Primary tumor must have positive estrogen receptor (ER) \u226510%: The tumor is ER/PR negative, which does not meet the trial's inclusion criterion of ER-positive.\n- Primary tumor must be HER2-positive: Yes, the tumor is HER2-positive.\n- Baseline LVEF \u226555%: There is no information provided on the LVEF.\n- Normal hematologic status: There is no information provided on the hematologic status.\n- Normal renal function: There is no information provided on renal function.\n- Normal liver function: There is no information provided on liver function.\n- Written Informed Consent (IC): The patient agrees to tumor resection, which suggests a willingness to participate, but this is not the same as having signed IC for this trial.\n- The patient agrees to make tumor available for central pathology review and translational studies: There is no information provided on this requirement.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial due to the presence of metastatic lesions (M1 status) and a negative status for estrogen receptors (ER-negative). Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "399": {
        "output": "Based on the provided patient note and clinical trial information:\n\nPatient Note Summary:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions seen in CXR\n- Using multivitamins and iron supplements\n- Non-smoker, non-alcoholic, not sexually active, no children\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Summary:\n- Title: Sentinel Lymph Node Biopsy in Porocarcinoma\n- Focus: Eccrine porocarcinoma (EPC) treatment and sentinel lymph node biopsy (SNLB)\n- Inclusion criteria for the clinical trial:\n  - Patients affected by moderate and high-risk porocarcinoma, as determined by histopathological findings\n  - Submitted to SNLB\n  - Thickness \u2265 5mm\n  - Mitoses per 10 high-power field \u2265 7\n  - Immunohistochemical (IHC) analysis positive for CEA, CK 5,7, and EMA\n  - Informed consent obtained for the SNLB procedure\n\nThe patient in question does not have porocarcinoma but rather breast cancer. The clinical trial is specifically for patients with porocarcinoma, which is a different type of cancer. The trial's inclusion criteria do not match the patient's diagnosis and condition. Therefore, the patient would not be eligible for the trial based on the disease being studied (breast cancer vs. porocarcinoma).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "400": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient appears to meet the requirements for the clinical trial. The patient note states that the patient has a cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma, which aligns with the trial's inclusion criteria of patients with invasive ductal carcinoma of the breast. Additionally, the patient is a candidate for tumor resection, which would satisfy the inclusion criterion of patients who received surgery for primary invasive breast cancer between 2010 and 2015, assuming the surgery takes place within that timeframe.\n\nHowever, the timeframe for the surgery specified in the inclusion criteria has already passed (2010-2015), and it is currently beyond 2015. If the study is still actively recruiting patients with past surgeries falling between those dates, the patient would not be eligible as the patient agrees to the surgery prospectively and thus has not yet undergone it. In this case, the patient does not have sufficient information to qualify for the trial, as the surgery has not taken place between the specified dates.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "401": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed metastatic breast cancer, which is HER2-positive and ER/PR negative. The clinical trial in question is focused on patients with metastatic breast cancer and aims to evaluate survival endpoints for treatment, specifically in relation to real-life databases and their correlation with clinical trial data.\n\nThe inclusion criteria for the clinical trial are simply stated as \"Metastatic breast cancer.\" Since the patient has metastatic breast cancer, as indicated by the presence of metastatic lesions on CXR and a confirmed diagnosis of breast cancer that is HER2-positive, she meets the inclusion criteria for the clinical trial.\n\nThere is no additional information provided regarding exclusion criteria, therefore based on the information available, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "402": {
        "output": "Based on the provided patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a core biopsy revealing a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, and axillary sampling revealed 5 positive lymph nodes. She is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nThe clinical trial in question is investigating the role of ultrasound-guided lymph node biopsy in axillary staging of breast cancer. The inclusion criteria for the trial are newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not.\n\nGiven that the patient has newly diagnosed operable breast cancer and is a candidate for tumor resection, she meets the inclusion criteria of the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "403": {
        "output": "Assessing the eligibility of the patient for the clinical trial involves comparing the patient's characteristics and condition to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes, metastatic lesions on CXR\n- Candidate for tumor resection, agrees to have it prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Written informed consent prior to participation\n- Women or men age 18+\n- Receiving neoadjuvant chemotherapy for breast cancer\n- Biopsy-confirmed diagnosis of invasive breast cancer (ER+/-, PR+/-, HER2+/-)\n- Stage I-III disease according to the AJCC v7 criteria\n\nComparison:\n- The patient is a woman over 18 years old and has biopsy-confirmed invasive ductal breast carcinoma, which is HER2-positive. This matches the requirement for a biopsy-confirmed diagnosis of invasive breast cancer of any ER/PR/HER2 status.\n- The patient is a candidate for tumor resection before chemotherapy, which suggests she has not yet started neoadjuvant chemotherapy. This does not meet the criterion of the trial that subjects must be receiving neoadjuvant chemotherapy for breast cancer at the time of enrollment.\n- The patient's cancer stage is not explicitly mentioned, but the presence of positive lymph nodes and metastatic lesions suggests the possibility of advanced disease, potentially stage III. However, without clear stage information, we cannot confirm this criterion.\n\nGiven the available information, the patient does not currently meet the criteria of receiving neoadjuvant chemotherapy, which is a requirement for the trial. Therefore, the patient cannot be considered eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "404": {
        "output": "The patient in question is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial provided is studying the use of the Kaffes Stent in the management of post-surgical biliary strictures.\n\nThe inclusion criteria for the clinical trial are:\n1. Confirmed benign postsurgical biliary stricture by presence of all three of the following:\n   - Ultrasound imaging or Magnetic resonance cholangiopancreatography (MRCP) showing biliary dilatation\n   - Raised bilirubin and/or alkaline phosphatase\n   - History of biliary tree surgery within the previous year\n2. Na\u00efve to endoscopic therapy\n3. Age > 18 years\n\nComparing the patient's provided information to the trial's inclusion criteria:\n- The patient is 45 years old, which satisfies the age criterion.\n- There is no information suggesting that the patient has a postsurgical biliary stricture. Instead, the patient has breast cancer with metastatic lesions.\n- There is no mention of the patient having had biliary tree surgery, nor any mention of biliary dilatation, raised bilirubin, or alkaline phosphatase levels.\n- The patient is a candidate for tumor resection, which is unrelated to biliary tree surgery.\n\nBased on the information given, the patient does not meet the specific inclusion criteria for the clinical trial focused on post-surgical biliary strictures, as the patient's medical condition is unrelated to the strictures that the trial is addressing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "405": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive, ER/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection\n\nClinical trial inclusion criteria:\n- Ability to understand study procedures and consent\n- Age \u2264 75 years old, female\n- Histologically confirmed breast cancer\n- Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis\n- cT0-T3\n- Low and moderate risk for anesthesia\n\nThe patient's note indicates that she has breast cancer with confirmed nodal involvement (axillary lymph nodes), but there is no mention of ipsilateral supraclavicular lymph node metastasis, which is a specific inclusion criterion for the trial. Without information confirming the involvement of supraclavicular lymph nodes, we cannot ascertain her eligibility for this trial.\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "406": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)\", we need to compare the patient's characteristics with the inclusion criteria of the trial:\n\n1. Has a localized invasive breast ductal adenocarcinoma, confirmed by the local pathologist, that includes either T1c-T2 (tumor size \u22652 cm), clinical node stage (cN)1-cN2, or T3-T4, cN0-cN2. Note: Inflammatory breast cancer is allowed.\n   - The patient has invasive ductal breast carcinoma, which fits the histological requirement.\n   - The tumor size is 3 cm, which is within the T1c-T2 size range.\n   - The patient has positive lymph nodes, which aligns with the clinical node stage requirement.\n\n2. Has centrally confirmed ER+/HER2-, Grade 3 breast cancer of ductal histology, according to the most recent ASCO/CAP guidelines.\n   - The patient's tumor is HER2-positive and ER/PR-negative, which does not match the ER+/HER2- requirement.\n\n3. Provides a new or recently obtained core needle biopsy, consisting of multiple cores, taken from the primary breast tumor(s) for central determination of HR status (ER and progesterone receptor), HER2, grade, and PD-L1 status.\n   - The patient had a core biopsy which revealed the tumor characteristics.\n\n4. Has an ECOG performance status of 0 or 1, as assessed within 10 days prior to initiation of study treatment.\n   - The patient's ECOG performance status is not mentioned in the note.\n\n5. Male participants must agree to use contraception...\n   - This is not applicable as the patient is female.\n\n6. Female participants must agree to use effective contraception...\n   - The patient's reproductive status is mentioned (not sexually active, postmenopausal), but her willingness to use contraception as per the study requirements is not stated.\n\n7. Has adequate organ function.\n   - The patient's organ function is not specifically mentioned, but there is no mention of organ dysfunction either.\n\nThe most critical point here is that the trial requires patients to have ER+/HER2- breast cancer, whereas the patient has HER2-positive and ER/PR-negative breast cancer. This discrepancy is a crucial factor and means that the patient does not meet the inclusion criteria.\n\nBased on the information provided, the patient does not match the requirement for ER+/HER2- status:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "407": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion criteria of the trial. Let's go through the inclusion criteria one by one:\n\n1. Be willing and able to provide written informed consent/assent for the trial.\n   - The patient note does not mention if the patient is willing and able to provide consent, but we will assume this is possible unless stated otherwise.\n\n2. Be 18 years of age on the day of signing informed consent.\n   - The patient is a 45-year-old woman, which meets this criterion.\n\n3. Patients must have metastatic confirmed breast cancer.\n   - The patient's note confirms metastatic breast cancer, as indicated by the presence of metastatic lesions on CXR.\n\n4. Disease progression by radiological techniques within 12 months prior to signing informed consent.\n   - The patient note does not specify when the disease progression was documented, so this information is not available.\n\n5. Documented mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (unknown significance variants).\n   - The patient note does not mention any BRCA1/2 mutation status.\n\n6. Have measurable disease based on RECIST 1.1.\n   - The patient has a 3 cm invasive ductal breast carcinoma, which is measurable disease.\n\n7. Prior chemotherapy with anthracyclines and taxanes has to be administered in neoadjuvant or adjuvant setting.\n   - The patient note does not indicate any prior chemotherapy, only that the patient is a candidate for tumor resection prior to chemotherapy.\n\n8. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.\n   - The patient has recently had a core biopsy, which implies that she may be willing to provide tissue. However, it is not clear if this is within the required time frame.\n\n9. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n   - The patient note does not provide information on the patient's ECOG Performance Status.\n\n10. Life expectancy of greater than 3 months.\n    - The patient note does not provide information on life expectancy.\n\n11. Demonstrate adequate organ function. All screening labs should be performed within 10 days of treatment initiation.\n    - The patient note does not provide information on organ function.\n\n12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.\n    - The patient is postmenopausal, which implies she is not of childbearing potential.\n\n13. Female subjects of childbearing potential must be willing to use an adequate method of contraception.\n    - As the patient is postmenopausal, this is not applicable.\n\n14. Male subjects of childbearing potential must agree to use an adequate method of contraception.\n    - This is not applicable as the patient is female.\n\nBased on the information available in the patient note, the patient does not meet several critical inclusion criteria, such as documented BRCA1/2 mutation status and prior chemotherapy with anthracyclines and taxanes. Therefore, without additional information confirming these criteria are met, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "408": {
        "output": "",
        "label": 0
    },
    "409": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and condition to the inclusion criteria of the clinical trial for Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- 5 positive lymph nodes and metastatic lesions on CXR\n- Candidate for tumor resection before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Postmenopausal female subjects \u226518 years of age\n- Clinical stage operable I, II or III invasive mammary carcinoma\n- ER-positive by IHC and HER2-negative\n- Measurable residual tumor at the primary site\n- Will undergo surgical treatment (segmental resection or total mastectomy)\n- Measurable disease: at least 1 cm in size\n- No prior chemotherapy for this primary breast cancer\n- No evidence of recurrence of a prior contralateral breast cancer\n- May have taken tamoxifen or raloxifene as a preventive agent but discontinued for at least 14 days prior to enrollment\n- Ended hormone replacement therapy at least 7 days prior to receiving the first dose of randomized therapy\n- Adequate hepatic and renal function\n- Able to swallow and retain oral medication\n- ECOG performance status 0-2\n\nBased on the provided information:\n- The patient is postmenopausal.\n- The patient has a confirmed diagnosis of breast cancer.\n- The tumor is HER2-positive, which does not match the trial's requirement of HER2-negative.\n- The patient is a candidate for tumor resection.\n- No information was provided regarding the patient's ECOG performance status, hepatic and renal function, or ability to swallow medication.\n\nSince the patient's tumor is HER2-positive and the inclusion criteria specify that the tumor must be HER2-negative, the patient does not meet one of the critical inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "410": {
        "output": "The patient in the note has invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. The clinical trial in question is for patients with oligo-metastatic ER-positive/HER2-negative breast cancer.\n\nLooking at the inclusion criteria for the clinical trial:\n\n- ER-positive/HER2-negative in primary tumor: The patient's tumor is HER2-positive and ER/PR negative, which does not match the trial's requirement for ER-positive/HER2-negative.\n- Oligometastases: The patient has metastatic lesions, but the note does not specify the number of lesions or if they are limited to \u2264 2 lesions in a single organ or site.\n- Recurrent cancer after completion of primary treatment (RFI\u22651year): There is no information provided in the patient note about the recurrence of cancer or the time since primary treatment.\n- Metastatic lesions are feasible for resection or radiotherapy (Size\u22643cm): While the patient is a candidate for tumor resection, there is no clear information on the size of the metastatic lesions or if they are feasible for resection or radiotherapy.\n\nGiven that the patient's tumor does not match the ER/HER2 status required by the trial and there is insufficient information regarding the other inclusion criteria, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "411": {
        "output": "The patient note describes a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive, and ER/PR negative breast cancer. There is no mention of psoriasis or nail changes that are associated with psoriasis.\n\nThe clinical trial's inclusion criteria specifically require patients with psoriatic changes in nails and distal interphalangeal (DIP) joint extensor tendon enthesopathy confirmed by ultrasound (US). The patient in question does not fit this description as there is no information provided about her having psoriasis or DIP joint extensor tendon enthesopathy.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial that is focused on treating DIP joint extensor tendon enthesopathy in nail psoriasis with methotrexate. Therefore, she is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "412": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative. According to the clinical trial's inclusion criteria, the trial is seeking patients with hormone receptor-positive metastatic breast cancer who are suitable to receive abemaciclib.\n\nGiven that HER2-positive and ER/PR negative indicates that the breast cancer is not hormone receptor-positive, this patient does not meet the inclusion criteria for the clinical trial, which specifically requires patients to have hormone receptor-positive metastatic breast cancer. \n\nTherefore, the patient is not eligible for the clinical trial titled \"Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "413": {
        "output": "",
        "label": 0
    },
    "414": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided patient note and the clinical trial inclusion criteria:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma, 3 cm in size, located in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- There are metastatic lesions present as indicated by CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Patients with first treated or recurrent metastatic breast cancer with at least one measurable lesion confirmed by CT or MRI.\n- HER2 positive or triple negative patients; (IHC++, fish amplification).\n- Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab.\n\nComparison:\n- The patient has metastatic breast cancer with HER2 positivity, which matches the inclusion criteria regarding cancer type and HER2 status.\n- There is no information provided about whether the patient has had prior anti-HER2 treatment or not, but the criteria do not exclude those who haven't had it.\n- The patient has confirmed metastatic lesions and is HER2 positive, meeting the criteria for tumor type and measurable disease.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient appears to meet all of the necessary criteria for participation in the study.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "415": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- ER-positive and/or PR-positive breast cancer\n- HER2-negative breast cancer\n- Unresectable locally advanced or metastatic breast cancer\n- Confirmed disease progression while on the last aromatase inhibition-containing regimen in the metastatic setting\n- At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting\n- Patients with no prior line of chemotherapy in the metastatic setting\n- At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting\n- ECOG score 0 or 1\n- Patients have adequate bone marrow and organ function\n- Patients must have measurable disease (RECIST v.1.1)\n- Premenopausal with LHRH analogues for at least 28 days) and postmenopausal women\n- Patients must agree to not breastfeed during the study and for 3 months after the last dose of study treatment\n- Life expectancy greater or equal to 12 weeks\n- Patients agree to collection of blood samples (liquid biopsy) and optional collection of metastatic tumour sample (biopsy) at the time of inclusion and progression (if appropriate)\n\nComparison:\n- The patient's breast cancer is HER2-positive, whereas the trial requires HER2-negative patients.\n- The patient's breast cancer is ER/PR negative, whereas the trial requires ER-positive and/or PR-positive breast cancer.\n\nThe patient does not meet the critical inclusion criteria for the trial due to the HER2 status and hormone receptor status of her breast cancer. Despite being postmenopausal and having metastatic breast cancer, the specific requirements regarding the breast cancer subtype exclude her from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "416": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\n1. The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form - Not mentioned, but this can typically be obtained if all other criteria are met.\n2. Patients must be female - The patient is female.\n3. Patients must be \u2265 18 years old - The patient is 45 years old.\n4. Patient must have an ECOG performance status of 0 or 1 - Not mentioned.\n5. The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy - The patient's diagnosis was made by core biopsy.\n6. The primary breast tumor must be palpable and measure \u2265 1.0 cm on physical exam - The tumor is 3 cm which meets this criterion.\n7. The regional lymph nodes can be cN0 or cN1 - Axillary sampling revealed 5 positive lymph nodes, which indicates cN1.\n8. The tumor size can be T1c or T2 - Not mentioned directly, but it is likely T2 given the size.\n9. Ipsilateral axillary lymph nodes must be evaluated by imaging within 6 weeks prior to initiating chemotherapy - Not mentioned.\n10. Nodal status must be determined - Nodal status is positive with 5 positive lymph nodes.\n11. Tumor specimen obtained at the time of diagnosis must have estrogen (ER) and progesterone (PR) receptors < 10% - The tumor is ER/PR negative.\n12. Tumor specimen obtained at the time of diagnosis must have been determined to be HER2-negative - The tumor is HER2-positive, which does not meet the criteria.\n13. Blood counts, hepatic function, and serum creatinine must meet certain criteria - Not mentioned.\n14. The left ventricular ejection fraction (LVEF) must be \u2265 50% - Not mentioned.\n15. Patients with reproductive potential must agree to use an effective non-hormonal method of contraception - Not mentioned but is applicable if the patient decides to participate.\n16. Patients are candidates for weekly paclitaxel and carboplatin chemotherapy - The patient is a candidate for tumor resection and agrees to chemotherapy, but the specific regimen is not mentioned.\n17. Patients with multifocal breast cancer are included as long as none of the tumors are HER2 positive - The patient's tumor is HER2 positive, which does not meet the criteria.\n18. The patient must have consented to participate in the FACT-2 study treatment - Not mentioned, but this can typically be obtained if all other criteria are met.\n19. Tumor determined to have abnormal HER2-driven signaling activity based on the CELx HSF test - Not mentioned.\n\nThe key exclusionary point here is that the patient's tumor is HER2-positive, which does not meet the criteria for a HER2-negative required by the trial. Thus, despite meeting many of the other inclusion criteria, this factor excludes the patient from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "417": {
        "output": "To determine the trial-level eligibility for the patient described, we need to cross-reference the patient's characteristics and condition with the inclusion criteria of the clinical trial for Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions present on CXR\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed invasive breast cancer\n- First proven ipsilateral local and/or regional recurrence of a primary invasive breast cancer\n- Completion of locoregional therapy\n- Negative or microscopically involved margins\n- Female or male aged 18 years or older\n- ECOG performance status 0 or 1\n- Recurrent tumor must be hormone receptor positive: ER+ and/or PgR+ \u22651% by IHC\n- Recurrent tumor must be HER2-negative\n- Normal hematological, renal, and liver function\n- Patient agrees to make tumor tissue available for central pathology review\n- Patients must either be planned to initiate, or have already started, endocrine therapy for recurrence\n- Written Informed Consent prior to randomization\n\nBased on the information given, the patient does not meet all of the inclusion criteria for the following reasons:\n\n- The patient's tumor is HER2-positive, which is not compliant with the trial's requirement for the recurrent tumor to be HER2-negative.\n- The trial specifically calls for a hormone receptor-positive tumor (ER+ and/or PgR+), but the patient's tumor is ER/PR negative.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial as the patient does not meet two critical inclusion criteria regarding the hormonal status of the tumor (HER2-negative and hormone receptor positive).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "418": {
        "output": "To assess the eligibility of the patient for the \"HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer\" clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the study.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection\n- No mention of HER2 status being confirmed within the last 12 months specifically by IHC, SISH, or FISH\n- No indication of the patient's ECOG performance status\n- No information on organ function or recent FDG-PET staging\n\nClinical Trial Inclusion Criteria:\n- Female patients with a histological diagnosis of breast cancer with known HER2 status (both positive and negative required for the study)\n- Written informed consent prior to admission in the study\n- Target lesion diameter of \u226515mm that has not been previously irradiated\n- Female patients aged \u2265 18 years of age\n- Histologically confirmed locally advanced/metastatic breast cancer with biopsy confirming HER2 status by IHC, SISH, or FISH within the last 12 months\n- ECOG performance status 0-2\n- Negative urine pregnancy test in women of childbearing age and willingness to use contraception\n- Life expectancy > 3 months\n- Adequate organ function as defined by specific laboratory values\n- Patients must have been appropriately staged using FDG-PET within 42 days of study entry and additional imaging according to local standard of care\n\nThe patient is a 45-year-old woman with HER2-positive breast cancer, which matches some of the inclusion criteria. However, there are several key pieces of information missing that are necessary to determine her full eligibility:\n\n- The patient's HER2 status needs to have been confirmed by IHC, SISH, or FISH within the last 12 months specifically.\n- We do not have the patient's ECOG performance status.\n- There is no available information about the patient's organ function or recent FDG-PET staging.\n- It is not mentioned if the patient has given written informed consent, but we can assume this would be obtained if she were to participate.\n- There is no information on pregnancy test or willingness to use contraception, although given that she is postmenopausal and not sexually active, this may be less relevant.\n\nBecause the patient note does not provide enough information to satisfy all the inclusion criteria, the eligibility determination is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "419": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial is focused on patients with Intraductal Papillary Neoplasm of the Bile Duct (IPNB), which is a different disease entity altogether.\n\nThe inclusion criteria for the clinical trial are:\n1. Clinical diagnosis of IPNBs.\n2. ECOG Performance status of 0, 1, or 2.\n3. Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN.\n4. Adequate renal function: creatinine < 1.8.\n5. Must be at least 18 years of age.\n\nThe patient in the note does not have a clinical diagnosis of IPNBs, but rather has breast cancer. Therefore, the patient does not meet the disease-specific inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "420": {
        "output": "After carefully reviewing the patient's information and the clinical trial's inclusion criteria, let's assess the patient's eligibility step by step:\n\nPatient's Characteristics:\n- Age: 45 years old\n- Diagnosis: Breast cancer\n- Tumor size: 3 cm (greater than 0.5 cm, satisfying one of the inclusion criteria)\n- Tumor characteristics: HER2-positive (conflicts with the trial requirement of HER2-negative)\n- Estrogen and progesterone receptor status: ER/PR negative (ER-/PR-, which conflicts with the trial requirement of hormone receptor positive)\n- Lymph node status: 5 positive lymph nodes (conflicts with the trial requirement of lymph nodes negative)\n- Treatment plan: Candidate for tumor resection followed by chemotherapy (the inclusion criteria specify endocrine therapy only)\n- Medical record: Presumably has integrated medical records but not specifically stated\n\nInclusion Criteria for the Clinical Trial:\n- Breast cancer in stage I-III\n- Tumor size >0.5 cm\n- Lymph nodes negative\n- Hormone receptor positive (ER+/PR+, ER+/PR-, ER-/PR+)\n- HER2 negative (IHC 0 or +, FISH negative)\n- Receive endocrine therapy only\n- Enough FFPE samples within 10 years (3 6 10\u03bcm)\n\nThe patient does not meet several key inclusion criteria for the clinical trial:\n- The patient's tumor is HER2 positive, whereas the trial requires HER2 negative.\n- The patient has positive lymph nodes, whereas the trial requires lymph nodes to be negative.\n- The patient's hormone receptor status is negative for both estrogen and progesterone, whereas the trial requires at least one to be positive.\n- The patient is planned to receive chemotherapy, not just endocrine therapy as required by the trial.\n\nBased on the provided information, the patient is not eligible for the clinical trial as her breast cancer does not meet the specified inclusion criteria regarding HER2 status, lymph node status, hormone receptor status, and treatment plan.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "421": {
        "output": "The patient in the provided note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The cancer is invasive ductal carcinoma, HER2-positive, and ER/PR-negative, with metastatic lesions and positive lymph nodes.\n\nWe'll assess the patient's eligibility for the clinical trial titled \"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors.\"\n\nBased on the inclusion criteria provided for the clinical trial, the patient must have:\n\n1. Metastatic disease defined by certain criteria.\n2. Histologically confirmed diagnosis of specific rare genitourinary tumors.\n3. A maximum of two systemic anti-cancer treatments, or be treatment-naive.\n4. Specific performance status, organ function, and laboratory test requirements.\n\nThe patient's cancer is breast cancer, not a genitourinary tumor. The inclusion criteria for the trial specifically list types of rare genitourinary tumors such as small cell/neuroendocrine carcinoma of the bladder, adenocarcinoma of the bladder, and others. Breast cancer is not listed among the eligible disease types for the trial.\n\nTherefore, the patient does not meet the inclusion criteria based on the type of cancer she has. Her disease is not one of the specific genitourinary tumors that the trial is targeting.\n\nGiven this information, the patient is not eligible for the trial based on the disease criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "422": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial is focused on women who have high-risk or borderline, non-malignant breast lesions. Since the patient has invasive ductal breast carcinoma, which is malignant, she does not meet the inclusion criteria for the clinical trial that is specifically targeting non-malignant breast lesions.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "423": {
        "output": "Given Patient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which meets the age criterion of \"Age >= 18 years old.\"\n- She has cytologically confirmed breast cancer, which is relevant to the trial's focus on breast cancer.\n- She is a candidate for tumor resection and agrees to undergo this prior to chemotherapy. However, there is no mention of the specific type of chemotherapy she will be receiving. The inclusion criteria specify that the breast cancer requires treatment by paclitaxel, which is not mentioned in the patient note.\n- The patient note does not mention her ability to understand, read, and write the French language, which is a requirement.\n- There is no information provided about the patient's coverage by social insurance or whether she has signed informed consent, although these are administrative details that could potentially be addressed if the patient were otherwise eligible.\n- The patient note does not specify the number of chemotherapy cycles planned, which is required to be at least 8 according to the trial's inclusion criteria.\n\nGiven Clinical Trial Analysis:\n- Age >= 18 years old: The patient meets this criterion.\n- Breast cancer requiring treatment by paclitaxel: There is no information in the patient note about the type of chemotherapy planned.\n- At least 8 chemotherapy cycles planned: There is no information in the patient note regarding the number of chemotherapy cycles.\n- Able to understand, read and write French language: This is not specified in the patient note.\n- Covered by a social insurance: This is not specified in the patient note.\n- Dated and signed informed consent: This is not specified in the patient note, but it's an administrative step that can be completed if eligible otherwise.\n\nBased on the available information, the patient does not have sufficient information to qualify for the trial since there are several criteria for which there is no information provided in the patient note. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "424": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB),\" we need to compare the patient's characteristics and condition to the trial's inclusion criteria. Let's review the details provided in the patient note:\n\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is using multivitamins and iron supplements.\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, let's match this information with the inclusion criteria of the clinical trial:\n\n- Patient aged 18 years or older. (The patient is 45 years old, so this criterion is met)\n- Written informed consent provided. (Not mentioned, but we will assume it can be provided if all other criteria are met)\n- Triple negative or HER2-positive / ER-negative or HER2-positive / ER-positive breast tumours. (The patient has a HER2-positive / ER-negative tumor, so this criterion is met)\n- Patients eligible for breast conservation after NAC. (Not enough information provided regarding the eligibility for breast conservation post-NAC)\n- Patients with T2-T3 N0 invasive breast cancer initially treated by NAC to allow breast conservation, who have received a minimum of 6 cycles of adequate NAC +/- anti-HER2. (The patient has not yet started chemotherapy, so this criterion is not met)\n- Clinical complete response after NAC. (Not applicable as the patient has not undergone NAC)\n- Radiological (mammography, breast US, breast MRI) complete response after NAC. (Not applicable as the patient has not undergone NAC)\n- Patients predicted to be node-negative at treatment initiation. (The patient has 5 positive lymph nodes, so this criterion is not met)\n\nBased on the available information, the patient does not meet several key inclusion criteria for the clinical trial, most notably having undergone NAC with a minimum of 6 cycles, having a clinical and radiological complete response post-NAC, and being node-negative at treatment initiation.\n\nTherefore, the eligibility assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "425": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's assess the eligibility of the patient:\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman (within the age range of 18 to 70 years)\n- Histologically confirmed breast cancer (matches requirement)\n- HER2-positive status (matches requirement)\n- ER/PR negative status (not specified in inclusion criteria, so not relevant for assessment)\n- Clinical stage not explicitly mentioned but presence of metastatic lesions could suggest stage IV (trial requires stages IIA - IIIC)\n- Chemotherapy-na\u00efve (matches requirement)\n- Performance status is not mentioned (ECOG 0-1 required)\n- Not pregnant or nursing as per patient's note (matches requirement)\n- No laboratory data provided to assess hematologic, renal, and hepatic function (required for eligibility)\n\nClinical Trial Inclusion Criteria:\n- Women ages 18 to 70 years old (patient is 45 years old)\n- Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (\u2265 2cm) (patient has a 3 cm tumor)\n- Patients with histologically confirmed carcinoma of the female breast with 3+ positive HER2 status by IHC (patient's tumor is HER2-positive)\n- Clinical stages IIA -IIIC (AJCC 2009) (patient's clinical stage is not mentioned, and the presence of metastatic lesions could be beyond the required stages)\n- Chemotherapy-na\u00efve patients (patient is chemotherapy-na\u00efve)\n- Performance status: ECOG performance status 0-1 (not mentioned in the patient's note)\n- Non-pregnant and not nursing (patient meets this condition)\n- Adequate hematologic, renal, and hepatic function (laboratory data not provided)\n\nThe main issues with eligibility are:\n- The clinical stage of the patient's breast cancer is not explicitly mentioned, but the presence of metastatic lesions suggests a stage that may not fall within the IIA - IIIC range required by the trial.\n- The patient's ECOG performance status is not mentioned, which is necessary for determining eligibility.\n- Laboratory data necessary to confirm adequate hematologic, renal, and hepatic function are not provided.\n\nGiven the information available, the patient does not have sufficient information to qualify for the trial, particularly due to the lack of clinical stage details, performance status, and laboratory data required by the inclusion criteria of the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "426": {
        "output": "",
        "label": 0
    },
    "427": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has invasive ductal breast carcinoma in the left upper outer quadrant with HER2-positive and ER/PR negative receptors, and metastatic lesions are noted. The patient is a candidate for tumor resection before chemotherapy.\n\nThe clinical trial in question is studying the effectiveness of transcranial direct current stimulation (tDCS) for postoperative pain after total knee replacement surgery. The inclusion criteria for the clinical trial are subjects who have scheduled elective spine surgery.\n\nThe patient does not meet the inclusion criteria for this clinical trial, as she is not scheduled for elective spine surgery, but rather has breast cancer and is a candidate for tumor resection.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "428": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the eligibility step by step:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection\n\nClinical trial inclusion criteria:\n- Core needle biopsy demonstrating DCIS of non-palpable, image-detected breast abnormality\n- Signed and dated IRB-approved written informed consent\n- Mammographic or MRI non-mass lesion measuring 4 cm or less in greatest dimension\n- Estrogen receptor positive or negative, progesterone receptor positive or negative DCIS; HER2 positive, negative or unknown DCIS is allowed.\n- Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging and evidence of residual radiographic abnormality.\n- Placement of Savi scout optical reflectance marker is preferred but not required\n- Planned lumpectomy or mastectomy if necessary\n- Review by Radiation Oncologist to ascertain feasibility of PBI\n- Patients who had a prior contralateral cancer are eligible\n- ECOG performance status 0, 1, or 2\n- Concurrent foci of atypia or lobular carcinoma in situ are allowed\n\nThe patient's diagnosis of invasive ductal breast carcinoma does not align with the inclusion criteria specifying DCIS (ductal carcinoma in situ). Furthermore, the presence of metastatic lesions also suggests that the patient's condition is beyond the early stage DCIS that the trial is aiming to treat.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires a diagnosis of ductal carcinoma in situ without mention of invasive cancer or metastatic disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "429": {
        "output": "",
        "label": 0
    },
    "430": {
        "output": "",
        "label": 0
    },
    "431": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?\", we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 45 years old\n- Gender: Female (postmenopausal)\n- Condition: Cytologically confirmed breast cancer\n- Specifics: \n  - Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n  - The tumor is HER2-positive and ER/PR negative\n  - Axillary sampling revealed 5 positive lymph nodes\n  - Presence of metastatic lesions (CXR)\n- Treatment Plan: Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n- Other: Using multivitamins and iron supplements, non-smoker, does not consume alcohol, not sexually active, no children\n\nClinical Trial Inclusion Criteria:\n- Patients with pathologically confirmed invasive ductal carcinoma (Grade 2 or 3)\n- Undergoing wide local excision surgery or mastectomy\n\nComparison:\n- The patient has a pathologically confirmed invasive ductal carcinoma, which matches the trial's requirement.\n- The patient is a candidate for tumor resection, which implies she will undergo surgery. The trial's inclusion criteria specify that patients should be undergoing wide local excision surgery or mastectomy.\n\nSince the patient has a confirmed diagnosis of invasive ductal carcinoma and is about to undergo surgery (either wide local excision or mastectomy), she meets the inclusion criteria of the clinical trial. There are no exclusion criteria provided, and the inclusion criteria listed are met by the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "432": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Cyberknife for Early Stage Breast Cancer,\" we need to assess the patient's eligibility for the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR remarkable for metastatic lesions\n- A candidate for tumor resection\n\nClinical trial inclusion criteria:\n- Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & N0) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.\n- Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DCIS by at least 2mm\n- Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.\n- No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.\n- Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment.\n\nDiscrepancies with inclusion criteria:\n- The patient has 5 positive lymph nodes, which is not consistent with the \"No involved axillary lymph nodes\" inclusion criterion.\n- CXR showed metastatic lesions, which is beyond early-stage breast cancer (stage 0, I, or II).\n\nDue to the positive lymph nodes and the presence of metastatic lesions, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "433": {
        "output": "To determine the trial-level eligibility for the clinical trial titled \"Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR,\" we need to compare the patient's information with the inclusion criteria listed for the trial.\n\nThe inclusion criteria are as follows:\n1. Confirmed by pathology and/or histology/cytology as breast cancer;\n2. Patients with recurrent or metastatic breast cancer who are 18 to 75 years old, not limited to the first relapse or metastasis;\n3. There are evaluable tumor lesions;\n4. Physical strength: ECOG score 0-1;\n5. The expected survival period is more than 3 months;\n6. Agree to be collected tissue specimen;\n7. The patient has no major organ dysfunction, agrees and can implement a treatment plan based on the patient's condition.\n8. Voluntary enrollment, good compliance, can be followed up and observed.\n\nNow let's assess the information provided in the patient note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which meets criterion 1.\n- The core biopsy revealed invasive ductal breast carcinoma with HER2-positive status, and the patient has metastatic lesions as indicated by a CXR, meeting criterion 2.\n- The presence of a 3 cm tumor and metastatic lesions suggest there are evaluable tumor lesions, satisfying criterion 3.\n- The patient is a candidate for tumor resection, which suggests she may have an ECOG score of 0-1, although this is not explicitly stated. Therefore, criterion 4 is likely met, but it is not confirmed from the information provided.\n- The patient's expected survival period is not mentioned, so we cannot confirm criterion 5.\n- The patient agrees to tumor resection, which could imply a willingness to have tissue collected, potentially fulfilling criterion 6.\n- There is no information provided about major organ dysfunction or the ability to implement a treatment plan, so criterion 7 is not confirmed.\n- There is no information about the patient's willingness to enroll, compliance, or the ability to be followed up and observed, leaving criterion 8 unconfirmed.\n\nThe patient note does not provide sufficient information to determine if the patient meets all the inclusion criteria, particularly criteria 4, 5, 7, and 8. Thus, the patient's eligibility for the trial cannot be fully assessed based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "434": {
        "output": "Based on the provided patient note and the clinical trial information, the patient does not appear to meet the inclusion criteria for the Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study. The patient has cytologically confirmed breast cancer and there is no mention of indeterminate biliary or pancreatic duct strictures, which are the focus of the VLE study. The study is specifically looking for participants with VLE clips featuring indeterminate biliary or pancreatic duct strictures with confirmed diagnosis on pathology, which does not apply to this patient's situation.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as her condition does not match the target condition of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "435": {
        "output": "Assessing the eligibility of the patient for the clinical trial titled \"Evaluation of NeoNavia\u00ae Biopsy System in Axillary Lymph Nodes\" involves comparing the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- cT1-4c (multifocality / multicentricity permitted)\n- Female / male patient aged \u2265 18 years\n- cN+ based on at least one of the following criteria:\n  - Lymph node is palpable\n  - Cortical asymmetry (focal or diffuse cortical thickening of >3mm) under ultrasound (US)\n  - Cortex:hilum ratio >2:1 under US\n  - Loss of hilum/cortex structure under US\n- Written informed consent (ICF)\n\nComparison:\n- The patient is a female aged \u2265 18 years, which meets the age and gender criteria.\n- The patient has a confirmed diagnosis of breast cancer with a tumor size that fits within the cT1-4c range.\n- Axillary sampling has revealed 5 positive lymph nodes, which indicates that the patient is cN+.\n\nBased on the information provided, the patient appears to meet all the inclusion criteria specified for the clinical trial. The patient has confirmed breast cancer, is of the appropriate age, and has positive lymph nodes, which qualifies as cN+ status. The patient is a suitable candidate for the trial assuming there are no other exclusion criteria not mentioned in the patient note. Since the patient note does not provide information on whether the informed consent has been obtained, we will assume that it can be or has been obtained for this assessment.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "436": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer\n- Invasive ductal carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive, ER/PR-negative\n- Axillary sampling with 5 positive lymph nodes\n- Metastatic lesions present in CXR\n- No mention of prior chemotherapy or performance status\n- Willing to undergo tumor resection, which indicates potential willingness to undergo biopsy and provide samples\n- No mention of any contraindication to oral medication or specific information about ECOG performance status\n- There is no indication that the patient is unable to swallow oral medications or is unwilling to provide consent or samples for research purposes.\n\nClinical Trial Inclusion Criteria:\n- Women of age >=18 years (Patient meets this criterion)\n- PRE-REGISTRATION: Clinical T1-4, N0-3, M0 breast cancer at diagnosis (Patient meets T and N criteria but has metastatic lesions, which may indicate M1 status)\n- PRE-REGISTRATION: Histological confirmation of triple negative invasive breast cancer (Patient's cancer is HER2-positive, not triple-negative)\n- There is no information given about the patient's previous treatment with neoadjuvant chemotherapy, which is a requirement for pre-registration in the trial.\n- The trial is specific for triple-negative breast cancer which is resistant to chemotherapy, and this does not apply to the patient as her cancer is HER2-positive and there is no mention of chemotherapy resistance.\n- The patient is postmenopausal and thus will not require a pregnancy test, but it's not relevant as she does not meet other criteria.\n\nSince the patient's breast cancer is not triple-negative (as it is HER2-positive) and there is no information on chemotherapy resistance or previous neoadjuvant chemotherapy, the patient does not meet the essential histological and treatment history criteria for the trial. Therefore, she would not be eligible to participate in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "437": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection, willing to undergo surgery prior to chemotherapy\n\nClinical trial criteria:\n- Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned\n- A biopsy clip placed at the time of diagnostic biopsy\n- 18 years of age or older\n- Must be able to read and write in English\n- Able to provide written consent prior to any research related activities\n\nThe patient is a 45-year-old woman, thus meeting the age criteria. The tumor is HER2-positive, which aligns with one of the types of breast cancer specified in the inclusion criteria (HER2 positive). The patient note does not mention a biopsy clip, but this information could be missing rather than indicating that a clip was not placed. Additionally, there is no information regarding the patient's ability to read and write in English, but it is not stated that this is an issue, so we may give the benefit of the doubt here. The patient is also willing to undergo surgery which aligns with the trial's treatment plan involving neoadjuvant chemotherapy followed by surgery.\n\nHowever, the trial is assessing the pathologic response after neoadjuvant chemotherapy, and the patient has not yet started chemotherapy, as indicated by the statement \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\"\n\nGiven the information provided, the patient meets several of the key inclusion criteria, including the diagnosis and the age requirement. Since the patient has not undergone chemotherapy yet, it is not possible to assess complete pathologic response, which is a central aspect of the trial. However, the study is looking to enroll patients for whom neoadjuvant chemotherapy is planned, not necessarily already completed.\n\nTherefore, the patient appears to meet the requirements for the clinical trial, assuming she can read and write in English and a biopsy clip was placed or will be placed at the time of diagnostic biopsy. There is no information provided that would exclude her based on the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "438": {
        "output": "In this scenario, let's assess the patient's eligibility for the clinical trial based on the provided information and inclusion criteria.\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Women with newly diagnosed human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor (ER) positive or negative, progesterone receptor (PR) positive or negative infiltrating ductal carcinoma (IDC) of the breast\n- Clinically stage II-III\n- Measurable, biopsied mass within the breast pre-chemotherapy (if inflammatory breast cancer)\n- Willing and able to provide informed consent\n- Age \u2265 18 years\n- Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1\n- Adequate bone marrow, renal, and liver function\n- Normal left ventricular ejection fraction (LVEF)\n- Women of reproductive potential must agree to use adequate contraception\n- Ability to co-enroll in trials that compare local therapies, or compare systemic adjuvant therapies\n- Pre neoadjuvant chemotherapy MRI of the breast with gadolinium contrast\n\nFrom the information provided, the patient does not meet the inclusion criteria for the following reason(s):\n\n- The patient has HER2-positive breast cancer, while the inclusion criteria specify HER2-negative breast cancer.\n\nGiven that the patient does not meet one of the critical inclusion criteria (HER2-negative status), she would not be eligible to participate in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "439": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Histological diagnosis of breast cancer\n- Availability of primary tumor tissue\n- Plasma DNA with a high ctDNA content\n\nThe patient has a histological diagnosis of breast cancer, which is one of the inclusion criteria for the clinical trial. Additionally, she has a confirmed invasive ductal breast carcinoma, and the trial does not specify the subtype of breast cancer required, so this further supports her eligibility. Since she is a candidate for tumor resection, it is likely that primary tumor tissue is available for the trial's purposes. Also, with the presence of metastatic lesions, there is a high likelihood that there would be a high content of ctDNA in her plasma.\n\nThus, given the information provided, the patient appears to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "440": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial. Let's examine the patient note against each criterion:\n\n- Ability to comply with the study protocol: This is subjective and cannot be determined from the patient note.\n- ECOG Performance Status \u22641: The patient note does not provide information on the ECOG Performance Status.\n- Stage II-IIIC breast cancer: The patient has invasive ductal breast carcinoma and positive lymph nodes, which fits the stage criteria.\n- Primary tumor >2 cm in diameter, or node-positive disease: The patient has a 3 cm tumor and positive lymph nodes.\n- HER2-positive breast cancer: The patient's tumor is HER2-positive.\n- Hormone receptor status of the primary tumor: The tumor is ER/PR negative.\n- Agreement to undergo surgery after neoadjuvant therapy: The patient agrees to tumor resection prior to chemotherapy.\n- Availability of FFPE tumor tissue: This is not mentioned in the patient note.\n- Baseline LVEF \u226555%: The patient note does not provide information on LVEF.\n- Contraceptive use for women of childbearing potential: The patient is not sexually active, which satisfies the criteria for non-pregnancy risk.\n- Negative serum pregnancy test for WOCBP: Not applicable since the patient is not sexually active and postmenopausal.\n- No major surgical procedure unrelated to breast cancer within 28 days prior to randomization: The patient note does not indicate any recent major surgery.\n\nBased on the information provided, the patient meets several of the inclusion criteria, including having HER2-positive breast cancer, agreement to surgery, and being postmenopausal (thus not requiring a pregnancy test). However, there is insufficient information on the patient's ECOG Performance Status, availability of FFPE tumor tissue, and baseline LVEF. Without this information, we cannot definitively determine if the patient is eligible.\n\nGiven the information at hand, the patient note does not provide sufficient evidence to conclude eligibility for the clinical trial because critical information is missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "441": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery,\" we need to compare the patient's information with the inclusion criteria of the trial.\n\nHere is a breakdown of the patient's information against the clinical trial's inclusion criteria:\n\n1. Female: The patient is a postmenopausal woman, so this criterion is met.\n2. Age 18-70 years: The patient is 45 years old, so this criterion is met.\n3. Imaging examination confirmed single lesion: The patient note indicates a single invasive ductal carcinoma, so this criterion is met.\n4. Receive breast conserving surgery with negative margins: The patient is a candidate for tumor resection, but it is not stated whether this has occurred yet or if the margins are negative.\n5. Axillary lymph nodes treatment: The patient has had axillary sampling with 5 positive lymph nodes, but it does not specify the level of axillary lymph node dissection.\n6. The tumor bed is labeled with clips and it can be drawn on the treatment planning system: Not mentioned in the patient note.\n7. Pathologically confirmed invasive breast cancer: The patient has invasive ductal breast carcinoma, so this criterion is met.\n8. Pathologically stage is T1-3N0-3M0: The patient has positive lymph nodes and metastatic lesions, indicating stage M1.\n9. Immunohistochemical examination is conducted to determine the status of ER, PR, HER2, Ki67 after surgery: The patient's tumor is HER2-positive and ER/PR negative, but Ki67 status and timing of the examination are not mentioned.\n10. No distant metastases: The patient has metastatic lesions, so this criterion is not met.\n11. No supraclavicular or internal mammary nodes metastases: Not mentioned in the patient note.\n12. No neoadjuvant chemotherapy: Not mentioned in the patient note, but patient agrees to tumor resection prior to chemotherapy, suggesting no prior chemotherapy.\n13. Fit for postoperative radiotherapy. No contraindications to radiotherapy: Not mentioned in the patient note, but there is no indication of contraindications.\n14. KPS\u226580: Not mentioned in the patient note.\n15. Signed informed consent: The patient agrees to tumor resection, but consent for the trial is not mentioned.\n\nBased on the information provided, the patient does not meet the criteria of no distant metastases, as they have metastatic lesions. This is a clear exclusion factor. Since this exclusionary point is critical and not dependent on the missing information, we can confidently assess the patient's eligibility without needing additional details.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "442": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's trial-level eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- 3 cm tumor size\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection, agrees to proceed prior to chemotherapy\n- Using multivitamins and iron supplements\n- No smoking or alcohol consumption\n- Not sexually active and has no children\n\nClinical Trial Inclusion Criteria:\n- Women aged 18-75 years old\n- HR positive and HER2 positive (confirmed by immunohistochemistry or FISH test)\n- ECOG score \u2264 2\n- Expected survival \u2265 3 months\n- Histology or cytology confirmed as breast cancer\n- Prior to trastuzumab and endocrine therapy and progression/recurrence\n- At least one RECIST 1.1 defined measurable lesion\n- Normal function of major organs\n\nComparison:\n- The patient is a 45-year-old woman, fitting the age criteria.\n- The patient's breast cancer is HER2-positive, which meets part of the criteria.\n- There is no mention of the patient's ECOG performance status or expected survival, so we cannot confirm these criteria.\n- The patient's cancer is confirmed by cytology, meeting the criteria.\n- There is no information on prior treatment with trastuzumab and endocrine therapy, so we cannot confirm this criterion.\n- The patient has measurable lesions (a 3 cm tumor), which meets the criteria.\n- There is no information on the patient's organ function, so we cannot confirm this criterion.\n\nThe patient note does not provide enough information to confirm all the inclusion criteria for the clinical trial. Specifically, the note does not mention the patient's hormone receptor (HR) status, ECOG performance status, expected survival, prior treatments, and organ function. Without this information, we cannot ascertain that the patient meets all the necessary criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "443": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the necessary information:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Node-positive breast cancer patients confirmed by biopsy or cytology.\n- Positivity confirmed before the surgical treatment.\n\nThe patient has node-positive breast cancer confirmed by biopsy, as indicated by the axillary sampling that revealed 5 positive lymph nodes. The patient's positivity is confirmed before the surgical treatment, which she has agreed to undergo prior to chemotherapy.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial as specified.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "444": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The biopsy revealed invasive ductal breast carcinoma, which is HER2-positive and ER/PR-negative.\n- There are metastatic lesions present.\n- The patient is a candidate for tumor resection and is willing to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.\n- It is for postmenopausal patients.\n- Patients must be eligible for and receiving treatment at the center conducting the trial.\n- Patients must provide written informed consent.\n\nComparison:\n- The patient is postmenopausal, which matches the trial's criteria.\n- However, the patient has HER2-positive breast cancer, which does not match the trial's criteria for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.\n\nConclusion:\n- The patient does not meet the inclusion criteria for the clinical trial because her breast cancer is HER2-positive, while the trial is specifically for patients with HER2-negative breast cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "445": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Estrogen receptor (\u2265 10%)\n- Progesterone receptor (\u2265 10%)\n- Epidermal growth factor receptor 2 negative\n- Proliferation index Ki-67 < 20%\n- No lymph node metastasis\n- Systemic therapy in accordance with the NCCN guidelines\n- Provision of informed consent\n\nComparing the patient's characteristics to the trial inclusion criteria:\n\n- The patient's tumor is HER2-positive, which conflicts with the trial's requirement for epidermal growth factor receptor 2 to be negative.\n- The patient has lymph node metastasis (5 positive lymph nodes), whereas the trial specifies no lymph node metastasis.\n- The patient's hormone receptor status is ER/PR negative, while the trial requires estrogen and progesterone receptors to be \u2265 10%.\n\nGiven these discrepancies, the patient does not meet several key inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "446": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman (meets age and gender criteria)\n- Has cytologically confirmed invasive ductal breast carcinoma (meets diagnosis criteria)\n- The tumor size is 3 cm (within the \u2264 5cm inclusion criteria)\n- HER2-positive and ER/PR-negative (not specified in inclusion criteria)\n- Positive axillary lymph nodes (does not meet the negative preoperative axillary assessment criteria)\n- Candidate for tumor resection (patient is accessible for the following axillary surgery and pathological test)\n\nClinical trial inclusion criteria for stage 1 (relevant to this patient as she is preoperative):\n- Female (meets criteria)\n- \u226518 years old (meets criteria)\n- Invasive ductal carcinoma or DCIS proved by core needle biopsy (meets criteria)\n- Tumor size \u2264 5cm (meets criteria)\n- Negative preoperative axillary assessment (does not meet criteria; the patient has positive lymph nodes)\n- Patient is accessible for the following axillary surgery and pathological test (meets criteria)\n\nSince the patient has positive axillary lymph nodes, she does not have a negative preoperative axillary assessment, which is a requirement for inclusion in the trial. Therefore, despite meeting other inclusion criteria, she is not eligible for this clinical trial due to her positive lymph node status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "447": {
        "output": "Given the information provided for the patient and the clinical trial, we need to compare the patient's characteristics and medical condition against the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection, agrees to proceed prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Patients scheduled for elective craniotomy for the resection of a tumor under general anesthesia\n- American Society of Anesthesiologists (ASA) physical status of I, II, or III\n- Participates with an anticipated full recovery within 2 hours postoperatively\n\nThe clinical trial is focused on patients undergoing elective craniotomy for the resection of a tumor and is studying the impact of pre-emptive scalp infiltration with methylprednisolone plus ropivacaine on postoperative pain. The patient in question has invasive ductal breast carcinoma with metastatic involvement and is scheduled for tumor resection, not craniotomy. The patient's condition does not align with the inclusion criteria of the trial, which specifically targets patients undergoing craniotomy.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial as their medical procedure (tumor resection for breast cancer) is not related to the procedure of interest in the trial (craniotomy for tumor resection). \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "448": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is focused on the use of Indocyanine Green (ICG) for the identification of neoplastic disease during surgery in pediatric and adolescent patients with various types of solid tumors or lymphoma.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Patients with a primary or relapsed solid tumor or lymphoma who require excision of the tumor or metastatic lesions.\n\nThe patient note indicates that the patient has breast cancer and is a candidate for tumor resection. However, the trial specifies that it is for pediatric and adolescent patients. Although it is not explicitly stated as an exclusion criterion, the context implies that the trial is not intended for adults.\n\nSince the patient in question is 45 years old and thus not a pediatric or adolescent patient, she would not meet the age demographic that the trial seems to be targeting. Furthermore, the list of specific tumor types included in the trial does not mention breast cancer.\n\nGiven this information, the patient does not meet the inclusion criteria based on age and possibly the type of cancer. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "449": {
        "output": "Patient Note Analysis:\n- Female patient\n- Age: 45 years\n- Condition: Invasive ductal breast carcinoma, cytologically confirmed\n- Tumor size: 3 cm in the left upper outer quadrant\n- Tumor characteristics: HER2-positive, ER/PR negative\n- Axillary node involvement: 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Postmenopausal\n- Lifestyle: Non-smoker, no alcohol consumption, not sexually active, no children\n- Treatment plan: Candidate for tumor resection, followed by chemotherapy\n\nClinical Trial Inclusion Criteria Analysis:\n- Gender: Female (Patient meets criteria)\n- Age: \u2265 45 years (Patient meets criteria)\n- Pathological stage I (pT1 or T2 pN0_M0) invasive ductal breast cancer or DCIS measuring <3 cm in longest diameter (Patient does not meet this criterion as there is axillary node involvement and metastatic lesions, indicating a stage beyond stage I)\n- Histologically negative tumor margin or no tumor in re-excision specimen (Not yet applicable as patient has not undergone tumor resection yet)\n- ECOG Performance Status of 0 or 1 (Insufficient information to determine)\n- Placement of clips in the lumpectomy cavity (Not yet applicable as patient has not undergone surgery yet)\n- Negative serum pregnancy test within 14 days prior to study treatment for women of child-bearing potential (Presumed to meet criteria based on postmenopausal status)\n- Written informed consent and ability to comply with study requirements (Presumed to meet criterion based on patient's agreement to undergo tumor resection)\n- Willingness to use birth control or meet criteria for exclusion of child-bearing potential (Presumed to meet criteria based on postmenopausal status)\n- Additional criteria for intermediate risk substudy (Patient does not meet criteria as she has invasive ductal carcinoma with positive lymph nodes and metastatic lesions)\n\nThe patient does not meet the inclusion criteria for the clinical trial due to having a more advanced stage of breast cancer than the trial specifies (presence of positive lymph nodes and metastatic lesions). The trial is focused on early-stage breast cancer patients (stage I), with specific requirements regarding tumor size and lymph node involvement that the patient does not fulfill.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "450": {
        "output": "Based on the provided patient note and the clinical trial information, the patient has breast cancer, not cervical cancer. The inclusion criteria for the clinical trial specifically require a histopathological diagnosis of cervical cancer and treatment with radical hysterectomy with bilateral pelvic lymphadenectomy in patients with clinical stage IB1 or IIA1 cervical cancer.\n\nSince the patient's condition does not match the target disease of the trial, she does not meet the inclusion criteria for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "451": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma, 3 cm in size, located in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes and there are metastatic lesions present (indicating metastasis).\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent prior to breast-conserving surgery.\n- Histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy).\n- Age at diagnosis at least 18 years.\n- Imaging techniques with estimated tumor stage between cT1-T3 prior to NAST.\n- Triple-negative or HER2-positive invasive breast cancer.\n- Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0).\n- In cases with cN0 and iN+, a negative core biopsy or FNA biopsy of the sonographically suspected lymph node is required.\n- No evidence for distant metastasis (M0).\n- Standard NAST with radiologic complete response (rCR).\n- Planned breast-conserving surgery with postoperative external whole-breast irradiation.\n\nComparing the patient's condition with the clinical trial's inclusion criteria:\n- The patient's age is consistent with the trial's requirement (\u2265 18 years).\n- She has histologically confirmed unilateral primary invasive carcinoma of the breast.\n- The patient's tumor is HER2-positive, which is one of the breast cancer subtypes the trial is including (triple-negative or HER2-positive).\n- The trial requires a clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0), but the patient has 5 positive lymph nodes, indicating that she does not meet this criterion.\n- The patient has evidence of distant metastasis (metastatic lesions on CXR), which contradicts the trial's requirement of no evidence for distant metastasis (M0).\n\nThe patient does not meet the trial's criteria of a tumor-free axilla and the absence of distant metastasis. Therefore, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "452": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nPatient's characteristics and condition:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- cT1-3N1M0 breast cancer at diagnosis (prior to NACT) by AJCC staging 8th edition\n- Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at presentation\n- Estrogen receptor and HER2 status evaluated on primary tumor\n- Received standard NACT as per local guidelines\n- Imaging of the axilla to assess response to NACT\n- Undergo dual tracer sentinel node biopsy (SNB) after NACT and at least 3 nodes removed in total\n- No evidence of nodal metastases post NACT (isolated tumor cells, micro or macro metastasis)\n\nBased on the patient note, we can determine the following:\n- The patient has breast cancer with confirmed axillary nodal metastases (5 positive lymph nodes).\n- The tumor's HER2 status has been evaluated and is HER2-positive.\n\nHowever, the patient note does not mention:\n- The AJCC staging of the breast cancer at diagnosis, specifically whether it is cT1-3N1M0.\n- Whether the patient has received neoadjuvant chemotherapy (NACT) yet.\n- Any imaging of the axilla to assess response to NACT.\n- The plan to undergo or the result of a sentinel node biopsy (SNB) after NACT.\n\nSince the patient note lacks information on the AJCC staging, whether NACT has been received, and the results of a sentinel node biopsy (SNB) after NACT, we cannot confirm eligibility for the trial based on the information provided. Therefore, the patient does not have sufficient information to qualify for the trial at this time.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "453": {
        "output": "",
        "label": 0
    },
    "454": {
        "output": "",
        "label": 1
    },
    "455": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma 3 cm in size\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n1. Newly treated female patients aged \u226518 years and \u226460 years\n2. ECOG score 0-1 points\n3. Pathologically confirmed TNBC breast cancer (ER and PR \u2264 10%, HER2 negative)\n4. Measurable tumor lesions by ultrasound or MRI within 21 days before enrollment, size \u22652cm\n5. Normal main organ function, with specific laboratory values\n6. No evidence of distant metastases\n7. Provide core biopsies from tumor lesions before treatment begins to confirm TNBC status and biomarker analysis\n8. Agree to contraception methods if not menopausal or surgically sterilized\n9. Sign the informed consent\n\nAssessment:\n- The patient is within the age criteria (\u226518 years and \u226460 years).\n- The ECOG score is not mentioned in the patient note.\n- The patient has breast cancer, but it is HER2-positive, not triple-negative as required by the trial (HER2 should be negative).\n- The tumor size meets the criterion (size \u22652cm).\n- Main organ function cannot be assessed without specific laboratory values.\n- The patient has metastatic lesions, which is evidence of distant metastases, and this excludes her from the trial based on criterion 6.\n- The patient is willing to undergo a core biopsy.\n- The patient is postmenopausal, so criterion 8 regarding contraception does not apply.\n- There is no information about the patient's consent to participate in the trial.\n\nGiven the information provided, the patient does not meet the inclusion criteria regarding the subtype of breast cancer (the trial requires TNBC and the patient has HER2-positive cancer) and has evidence of distant metastases, which explicitly excludes her from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "456": {
        "output": "To determine the eligibility of the patient for the clinical trial \"CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,\" we need to assess the patient's characteristics against the inclusion criteria of the trial.\n\nHere are the inclusion criteria of the trial:\n1. Female \u2265 18 years of age pre and post-menopausal\n2. Oligometastatic disease (\u2264 5 sites of disease)\n3. For premenopausal status: Last menstrual period within the last 12 months, or certain hormone levels if on tamoxifen or toremifene or therapy-induced amenorrhea, or bilateral oophorectomy\n4. For postmenopausal status: At least 2 years without menstrual period, or patients older than 50 with serological evidence of post-menopausal status, or hysterectomized patients of any age with FSH confirmation\n5. ECOG performance status 0-1\n6. Biopsy proven diagnosis of HR+HER2- metastatic breast cancer. ER expression is >10%\n7. Ability to understand and sign a written informed consent\n8. Hematological and organ function within specific ranges\n\nHere is the patient's information:\n- The patient is a 45-year-old postmenopausal woman\n- Has cytologically confirmed breast cancer with metastatic lesions (metastatic disease is present but the number of sites is not specified)\n- HER2-positive and ER/PR negative breast cancer (this does not meet the criteria for HR+HER2-)\n- Candidate for tumor resection and agrees to sign informed consent\n\nBased on the provided information:\n- The patient is female and over 18 years of age, meeting criterion 1.\n- The patient has metastatic breast cancer; however, the number of metastatic sites is not provided, making it unclear if it meets criterion 2.\n- The patient is postmenopausal, which meets criterion 4.\n- There is no information about the patient's ECOG performance status, so we cannot assess criterion 5.\n- The patient does not meet criterion 6 because her tumor is HER2-positive and ER/PR negative, not HR+HER2- as required by the trial.\n- The patient is able to understand and demonstrate willingness to sign a written informed consent document, meeting criterion 7.\n- There is no information on the patient's hematological and organ function status, so we cannot assess the last criterion.\n\nSince the patient's breast cancer is HER2-positive and ER/PR negative, this does not align with the specified requirement for HR+HER2- breast cancer for the trial. Therefore, despite meeting some of the other criteria, the patient is not eligible for the trial based on the mismatch in cancer subtype.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "457": {
        "output": "To determine the trial-level eligibility for the patient, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions present on CXR\n- Candidate for tumor resection before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women, aged \u2265 18 years\n- Invasive HER2+ (HR+/-) or TN breast cancer\n- Primary tumor (T), clinical stage T1-3\n- Neoadjuvant systemic therapy (NST), at least 3 cycles\n- Tumor stage assessed with breast MRI before start NST\n- Clinically node-negative before start NST (no suspect ALNs on ultrasound and FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes)\n- MRI after or during NST shows radiologic complete response\n- Written and signed informed consent\n\nAssessment:\n- The patient is a woman and is aged \u2265 18 years (meets criteria).\n- The patient has invasive ductal breast carcinoma that is HER2-positive (meets criteria).\n- The primary tumor stage is not explicitly stated, but given that it's a 3 cm tumor, it falls within the T1-3 range assuming no direct extension to chest wall or skin (likely meets criteria).\n- The patient has not yet received neoadjuvant systemic therapy; she is a candidate for tumor resection prior to chemotherapy (does not meet criteria).\n- There is no information about the assessment of the tumor stage with breast MRI before starting NST (does not meet criteria due to lack of information).\n- The patient has 5 positive lymph nodes, which indicates she is not clinically node-negative before starting NST (does not meet criteria).\n- There is no information about an MRI showing a radiologic complete response after or during NST (does not meet criteria due to lack of information and because NST has not been started).\n\nBased on the information provided, the patient does not meet several key inclusion criteria for the clinical trial. The patient has positive lymph nodes and has not yet undergone neoadjuvant systemic therapy, which is required before assessing for a radiologic complete response on MRI.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "458": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Sacituzumab Govitecan In TNBC,\" let's evaluate the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which meets the age requirement of the trial.\n- The patient has a cytologically confirmed diagnosis of invasive breast cancer, which is required.\n- The tumor is HER2-positive and ER/PR negative. However, the trial requires the tumor to be ER-negative, PR-negative, and HER2-negative (Triple Negative Breast Cancer - TNBC).\n- The patient has metastatic lesions, which suggests distant metastasis and does not meet the trial requirement of absence of distant metastatic disease (AJCC TNM stage M0).\n- There's no information provided on the patient's ECOG performance status or laboratory values, which are part of the inclusion criteria.\n\nClinical Trial Inclusion Criteria Analysis:\n- Female or male patients \u2265 18 years of age (The patient meets this criterion).\n- Histologically confirmed diagnosis of invasive breast cancer, previously untreated (The patient meets this criterion as the cancer is confirmed and not treated).\n- Participants must have biopsy-proven ER-negative, PR-negative, HER2-negative invasive breast cancer (The patient does not meet this criterion as her tumor is HER2-positive).\n- Primary tumor 1 cm or greater (The patient meets this criterion with a 3 cm tumor).\n- Regional lymph node AJCC (v7) TNM stages N0-N2 (It's not clear if the patient meets this criterion as the stage is not provided, but there are positive lymph nodes).\n- Absence of distant metastatic disease (The patient does not meet this criterion as there are metastatic lesions).\n- Pre- and postmenopausal women are eligible (The patient meets this criterion).\n- ECOG performance status = 0, 1 (No information provided on the patient's ECOG status).\n- Adequate bone marrow and organ function as defined by laboratory values (No information provided on the patient's lab values).\n\nGiven the information in the patient note, the patient does not meet the criteria for having a HER2-negative tumor and has distant metastatic lesions, which excludes her from the trial based on the inclusion criteria requiring absence of distant metastasis. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "459": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the gender and age requirements of the trial as the inclusion criteria specify \"Female\" and \"Age 18 years or older.\"\n- The patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma, which is within the scope of the trial as it is looking for participants with \"Invasive ductal breast carcinoma and ductal carcinoma in situ.\"\n- The patient is a candidate for tumor resection, which aligns with the trial's inclusion of subjects \"having undergone breast conservation surgery.\"\n- The trial includes subjects who may have received neo-adjuvant treatments, which does not exclude the patient who has not yet started chemotherapy.\n- The patient is capable of understanding and agreeing to sign a written informed consent document, which is an assumption we can make as she is described as agreeing to undergo tumor resection prior to chemotherapy.\n\nGiven that the patient's characteristics and situation meet the inclusion criteria specified for the clinical trial and no exclusion criteria were provided, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "460": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\n1. Pathologically proven diagnosis of invasive breast cancer - The patient has cytologically confirmed breast cancer.\n2. Clinical stage tumor 1-3 (cT1-T3) - The patient has a 3 cm invasive ductal breast carcinoma, which likely corresponds to T1-T3, but the exact clinical stage is not given.\n3. Node 0-3 (cN0-N3) - The patient has 5 positive lymph nodes, which corresponds to N3.\n4. Metastasis 0 (cM0) - The patient has metastatic lesions evident on CXR, which indicates metastasis, and does not meet the requirement of cM0.\n5. HR+ (ER+ and/or PR+) HER2 negative or HR- (ER- and PR-) HER2 negative/triple-negative breast cancer - The patient has HER2-positive and ER/PR-negative breast cancer, which does not meet the criteria.\n6. Tumors with positive PD-L1 and/or PD-L1 protein expression - There is no information on PD-L1 or PD-L2 expression provided.\n7. Candidate for neoadjuvant chemotherapy - The patient is a candidate for tumor resection prior to chemotherapy.\n8. LVEF \u2265 lower limit of normal - No information is provided regarding the patient's LVEF.\n9. The patient must be female - The patient is a postmenopausal woman.\n10. Age \u226518 years - The patient is 45 years old.\n11. ECOG performance status 0 to 2 - There is no information on the patient's ECOG performance status.\n12. Specific informed consent, adequate organ function, and other lab-related criteria - No information is provided on these aspects.\n13. Postmenopausal for at least one year - The patient is postmenopausal.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial due to the presence of metastatic disease (criterion 4: cM0 is required) and because the patient's breast cancer is HER2-positive (criterion 5: requires HER2 negative). Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "461": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's compare the information:\n\nPatient note details:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present in CXR\n- Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n- No mention of undergoing breast conserving surgery or adjuvant radiation yet\n\nClinical trial inclusion criteria:\n- Breast cancer patients with DCIS or invasive breast cancer\n- Undergoing breast conserving surgery and adjuvant radiation\n- Must be willing and able to provide breast skin samples\n\nThe patient has invasive breast cancer, which aligns with the trial's inclusion criteria. However, the trial specifically requires patients who are undergoing breast conserving surgery and adjuvant radiation. The patient note indicates that the patient agrees to tumor resection prior to chemotherapy, but there is no information about whether the patient will undergo breast conserving surgery or adjuvant radiation. Without clear information that she is undergoing the required treatment steps, we cannot confirm her eligibility for the trial.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "462": {
        "output": "The patient described in the patient note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. However, the tumor is described as HER2-positive and ER/PR negative. This does not match the inclusion criteria for the clinical trial, which specifically requires the breast cancer to be ER/PR positive and HER2-negative.\n\nGiven this discrepancy, the patient does not meet the inclusion criteria for the trial focused on ER/PR positive, HER2-negative metastatic breast cancer (MBC). All other inclusion criteria such as age and being a candidate for therapy are potentially met, but the hormone receptor status mismatch is critical and cannot be overlooked. Without further information, we cannot assess other aspects such as hematologic, renal, and hepatic function, but the core disqualifying factor is clear.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "463": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma, HER2-positive and ER/PR negative. This patient does not meet the specific inclusion criterion of having \"Histologically confirmed invasive lobular carcinoma within the past 12 weeks confirmed from biopsy of primary tumor or metastasis.\" The patient has invasive ductal carcinoma rather than lobular carcinoma.\n\nGiven this discrepancy between the patient's diagnosis and the trial's inclusion criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "464": {
        "output": "To determine the trial-level eligibility for the patient, let's compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Adult female patients with advanced breast cancer diagnosed by pathology (aged 18-75, including 18 and 75 years old)\n- Not suitable for surgical resection or radiation therapy for the purpose of cure (but our patient is a candidate for tumor resection, which implies she is suitable for it)\n- Pathological examination confirmed ER and/or PR positive, HER-2 negative\n- No disease progression after a 4-8-course first-line chemotherapy regimen\n- WHO physical status 0-1 points, estimated lifetime at least 3 months\n- Required imaging examinations within 3 weeks before enrollment\n- Previous treatment-related toxicity should be relieved to \u2264 Grade 1\n- Normal routine blood test within 1 week before enrollment\n- Normal liver and kidney function test within 1 week before enrollment\n- Signed informed consent form before enrollment\n\nBased on the information provided, the patient does not meet the following inclusion criteria:\n\n- The patient's tumor is HER2-positive, whereas the trial requires HER2-negative.\n- The patient is ER/PR negative, whereas the trial requires ER and/or PR positive.\n- The patient is considered a suitable candidate for tumor resection, which contradicts the trial's condition of patients not being suitable for surgical resection for the purpose of cure.\n\nTherefore, the patient does not meet the necessary inclusion criteria for this clinical trial due to discrepancies in tumor characteristics and treatment plan eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "465": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer,\" we need to assess the patient's characteristics against the inclusion criteria provided for the study.\n\nThe given patient note provides the following information:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, let's compare this with the inclusion criteria of the trial:\n\nInclusion Criteria:\n- Male or female, aged \u226518 years. (The patient is 45 years old, so she meets this criterion.)\n- Phase 2a Cohort A: HR+/HER2- locally advanced, recurrent, or metastatic breast cancer with disease progression after first-line endocrine therapy or intolerant of it. (The patient's tumor is HER2-positive, so she does not meet this criterion.)\n- Phase 2a Cohort B: Not applicable as no prior systemic therapy information is given.\n- Postmenopausal status with specific criteria. (The patient is described as postmenopausal, meeting this criterion.)\n- At least 1 measurable lesion based on the RECIST v1.1 criteria. (The patient has a 3 cm tumor and metastatic lesions, likely meeting this criterion.)\n- Life expectancy \u2265 12 weeks. (Not specified in the patient note.)\n- ECOG Performance Status (PS)\u22641. (Not specified in the patient note.)\n- Adequate bone marrow and organ function as specified. (Not specified in the patient note.)\n- LVEF \u2265 50%. (Not specified in the patient note.)\n- Corrected QT interval (QTcF) < 450ms for men and < 470ms for women at resting. (Not specified in the patient note.)\n\nBased on the information provided, the patient does not meet the inclusion criteria for Phase 2a Cohort A as her tumor is HER2-positive, and the trial specifies the need for HR+/HER2- breast cancer. Additionally, there is not enough information to confirm other criteria, such as life expectancy, performance status, organ function, and cardiac metrics. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "466": {
        "output": "Based on the patient note provided:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive, ER/PR negative, with axillary sampling revealing 5 positive lymph nodes and metastatic lesions found in the CXR. She is preparing for tumor resection before commencing chemotherapy.\n\nNow, let's look at the clinical trial's inclusion criteria:\n\nThe clinical trial is focused on the Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors (OGCTs). The study is concerned with tumors that are based in the ovaries and has specified the types of tumors they are including: 20 benign mature cystic teratomas, 22 malignant OGCTs (5 dysgerminomas, 8 immature teratomas, and 9 yolk sac tumors), and 20 normal ovaries for comparison.\n\nThe patient in question has breast cancer, not an ovarian germ cell tumor. Therefore, based on the information given, the patient does not meet the inclusion criteria for this clinical trial, which is specific to ovarian germ cell tumors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "467": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female breast cancer patients at the age of >= 18 years and <= 65 years who received the first treatment\n- Pathologically confirmed HER2-positive invasive breast cancer\n- Tumor larger than 2 cm according to the 2019 CSCO BC guidelines for neoadjuvant therapy\n- ECOG physical status score of \u22641\n- Main organ function levels within specified ranges\n- Negative serum pregnancy test for women of childbearing age and willingness to use contraception\n- Voluntary participation with written informed consent and good compliance for follow-up\n\nComparison:\n- The patient is a 45-year-old woman, which meets the age criterion of >= 18 years and <= 65 years.\n- The patient has HER2-positive breast cancer, satisfying the requirement of pathologically confirmed HER2-positive invasive breast cancer.\n- The patient's tumor is 3 cm, which is larger than the 2 cm size requirement.\n- There is no information about the patient's ECOG status, but given she is a candidate for tumor resection, it can be inferred that her ECOG status might be \u22641.\n- The patient is postmenopausal, which addresses the concern for pregnancy, but there is no explicit information about willingness to use contraception.\n- The patient agrees to tumor resection, indicating a willingness to participate in treatment, which may imply consent to participate in a trial.\n\nBased on the information provided, the patient appears to meet most of the inclusion criteria. However, there is not enough information about the patient's ECOG status, organ function levels, and willingness to use contraception to make a definitive eligibility determination.\n\nTrial-level eligibility: 1) Not relevant.\n\nPlease note that the final determination of eligibility would require more detailed information and should be made by the clinical trial team after a thorough review of the patient's medical records and possibly further assessments.",
        "label": 2
    },
    "468": {
        "output": "",
        "label": 0
    },
    "469": {
        "output": "",
        "label": 2
    },
    "470": {
        "output": "The patient described in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive, and ER/PR negative. The patient has metastatic lesions and is a candidate for tumor resection prior to chemotherapy.\n\nNow, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\n1. Patients must have a diagnosis of HR+ breast cancer: The patient has HER2-positive but ER/PR-negative breast cancer, which does not meet the criterion of hormone receptor positive (HR+) as defined by immunohistochemistry (IHC).\n2. Patients must have Loco regional breast cancer (Stage I, Stage II, and Stage III per AJCC 8th edition criteria for staging of breast cancer): The patient has metastatic lesions, indicating that the cancer has spread beyond local or regional areas.\n3. Patients must have localized recurrence while on adjuvant endocrine therapy: There is no information suggesting that the patient had a localized recurrence while on adjuvant endocrine therapy.\n4. Patients must have any known molecular evidence of endocrine resistance by next-generation sequencing: There is no information provided about molecular evidence of endocrine resistance.\n5. Age \u2265 18 years: The patient meets this criterion.\n6. ECOG performance status 0-1: There is no information provided about the patient's ECOG performance status.\n7. Have post-menopausal status: The patient is postmenopausal.\n8. Have at least one measurable disease as defined per RECIST 1.1: The patient has a measurable tumor and metastatic lesions.\n9. Adequate organ and marrow function: There is no information provided about the patient's organ and marrow function.\n10. Able to swallow oral medications: There is no information provided about the patient's ability to swallow oral medications.\n11. Patients who received adjuvant radiotherapy or chemotherapy must have recovered from the acute effects of treatment and met the washout period requirements: The patient is a candidate for tumor resection prior to chemotherapy, which does not indicate prior chemotherapy or radiotherapy.\n12. Any known markers of response or resistance to CDK 4/6 inhibitors to be present in the biopsy specimen: There is no information provided about markers of response or resistance.\n13. If patients have been treated with prior Neo-Adjuvant chemotherapy at the time of primary diagnosis and not at the time of recurrence, they will be included in the study: There is no information provided about prior Neo-Adjuvant chemotherapy.\n14. Must be able to sign a written informed consent, are reliable, willing to be available for the duration of the study, and are willing to follow study procedures: There is no information provided about the patient's ability to consent, reliability, or willingness to follow study procedures.\n\nBased on the provided patient note and the clinical trial criteria, the patient does not meet the primary inclusion criterion of having HR+ breast cancer, as the patient has HER2-positive and ER/PR-negative breast cancer. Additionally, the patient has metastatic lesions, which does not align with the requirement for locoregional breast cancer. There is also no information about localized recurrence while on adjuvant endocrine therapy or molecular evidence of endocrine resistance, which are required by the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "471": {
        "output": "Let's assess the eligibility of the patient for the clinical trial based on the provided inclusion criteria:\n\nPatient's Characteristics:\n- Female\n- 45 years old\n- Invasive ductal carcinoma confirmed by core biopsy\n- HER2-positive, ER/PR-negative\n- Tumor size 3 cm\n- Axillary lymph nodes positive (5 nodes)\n- Metastatic lesions present\n- Not pregnant and no plan for pregnancy in 2 years (postmenopausal)\n- ECOG level not specified\n- Serum creatinine not specified\n- The patient agrees to tumor resection\n\nClinical Trial Inclusion Criteria (for both stages 1 and 2):\n- Female\n- \u226518 years old\n- Invasive ductal carcinoma proved by core needle biopsy\n- The tumor must be single-center\n- For stage 1: the maximum diameter of the lump <2cm\n- For stage 2: the maximum diameter of the lump <1.5cm\n- Enough breast tissue and space from lump to skin\n- Not pregnant and no plan for pregnancy in 2 years\n- ECOG level: 0-2\n- Serum creatinine \u22641.1 mg/dl\n- For bilateral breast cancer, both tumors must meet the inclusion criteria\n- Patients are accessible for follow-up and mentally healthy\n\nBased on the available information, the patient does not meet the following criteria:\n- The maximum diameter of the lump <2cm for stage 1 (the patient's tumor is 3 cm)\n- The maximum diameter of the lump <1.5cm for stage 2 (the patient's tumor is 3 cm)\n- Clinically N0 before cryo-ablation (the patient has 5 positive lymph nodes)\n\nThe patient's tumor size exceeds the specified limit for both stages 1 and 2, and she does not have clinically N0 status due to the positive lymph nodes. Additionally, the presence of metastatic lesions suggests the cancer is not early-stage, which is a requirement for this trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "472": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR-negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present in the CXR\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Written informed consent provided\n- Postmenopausal or premenopausal or perimenopausal women aged 18-75 years\n- Histologically or cytologically confirmed HR-positive (ER/PR\u226510%), HER2-positive breast cancer\n- At least one measurable non-visceral metastatic lesion\n- No prior chemotherapy, biological or target therapy to recurrent or metastatic disease\n- ECOG performance score of 0 to 2\n- Life expectancy > 24 weeks\n- LVEF of 50% or higher at baseline\n- Compliance with the study requirements\n- Recovery to baseline or CTCAE v. 5.0 grade \u2264 1 from side effects of previous treatments\n- No HIV infection\n- Certain laboratory values within specified ranges\n\nBased on the patient note:\n- The patient has confirmed breast cancer and is postmenopausal, which fits the criteria.\n- The tumor is HER2-positive, which meets the trial requirement.\n- However, the patient is ER/PR-negative, which does not meet the requirement for HR-positive status (ER/PR\u226510%).\n- The presence of metastatic lesions needs clarification if they are non-visceral to meet the trial's requirement for measurable non-visceral metastatic lesion.\n- There is no information on the patient's ECOG performance score, life expectancy, LVEF, compliance, recovery status, HIV status, or laboratory values.\n\nDue to the mismatch in ER/PR status and the insufficient information to confirm the other inclusion criteria, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "473": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Diagnosed with breast cancer (cytologically confirmed)\n- Tumor is invasive ductal carcinoma, HER2-positive, ER/PR negative\n- Has metastatic lesions (indicating advanced/metastatic breast cancer)\n- Candidate for tumor resection before chemotherapy\n- Does not meet the criteria of being sexually active or having children, but these are not specified as inclusion or exclusion criteria for the trial\n\nClinical trial inclusion criteria:\n- Female or male sex (patient is female, so this is met)\n- Diagnosis of advanced/metastatic breast cancer (A/MBC) at stage IIIB, IIIC, stage IV or identified as having distant metastasis (patient has metastatic lesions, so this is met)\n- Age \u226518 years at A/MBC diagnosis (patient is 45, so this is met)\n- Initiated a CDK4/6i in combination with an AI as initial endocrine-based therapy after A/MBC diagnosis between specific dates (there is no information provided about treatment initiation dates or specific treatments used)\n- Evidence of ER or PR positive disease, or absence of any indication of ER and PR negative disease (patient has ER/PR negative disease, which does not meet this criterion)\n- Evidence of HER2 negative disease, or absence of any indication of HER2 positive disease (patient has HER2 positive disease, which does not meet this criterion)\n\nThe patient does not meet the criteria for ER/PR status and HER2 status as specified by the trial. The patient has ER/PR negative and HER2 positive disease, whereas the trial is seeking patients with HR+/HER2- disease.\n\nTherefore, the patient is not eligible for the clinical trial based on the mismatch of hormone receptor status and HER2 status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "474": {
        "output": "To determine the patient's eligibility for the MARGetuximab Or Trastuzumab (MARGOT) clinical trial, we need to compare the patient's characteristics and condition with the trial's inclusion criteria:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy showed a 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection, agrees to pre-operative chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Stage II or III invasive carcinoma of the breast (AJCC 8th edition)\n- Minimum tumor size of 1.5 cm\n- Inflammatory breast carcinoma (T4d) not eligible\n- Centrally confirmed low affinity CD16 germline genotype (FF or FV)\n- HER2-positive by ASCO/CAP criteria\n- ER/PR determination required\n- Bilateral breast cancers allowed if both are HER2-positive or contralateral is <1 cm, ER+\n- Patients with multifocal or multicentric disease eligible\n- Dedicated ultrasound of ipsilateral axilla required\n- Men and women \u226518 years of age\n- ECOG performance status 0 or 1\n- Adequate organ function (specific lab values provided)\n- LVEF \u2265 50%\n- Negative serum pregnancy test for women of childbearing potential\n- Willing to use effective contraception\n- History of ipsilateral or contralateral DCIS or LCIS is eligible\n- No contraindications to radiation therapy for those undergoing breast conservation therapy\n- Able and willing to sign informed consent\n- Willing to undergo breast biopsy for research purposes\n\nAssessment:\n- The patient's age and gender meet the criteria.\n- The patient has stage II or III invasive carcinoma of the breast, which meets the criteria.\n- The tumor size is 3 cm, which exceeds the minimum size requirement.\n- HER2-positive status is confirmed, which meets the criteria.\n- The patient is ER/PR negative, which meets the ER/PR determination requirement.\n- There's no indication that the patient has a low affinity CD16 germline genotype (FF or FV), which is required for inclusion. This information is not provided in the patient note.\n- Other specific inclusion criteria like ECOG performance status, lab values, and LVEF are not mentioned in the patient note.\n- The patient fits the criteria for women of childbearing potential and agrees to pre-operative chemotherapy.\n\nBased on the information given in the patient note, there is not enough information to confirm eligibility for several criteria, such as the CD16 germline genotype, ECOG performance status, organ function lab values, and LVEF. These omissions are crucial for determining eligibility.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "475": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The core biopsy revealed a 3 cm invasive ductal carcinoma in the left upper outer quadrant, which is consistent with a T2 classification (tumor size greater than 2 cm but not more than 5 cm). The patient has HER2-positive and ER/PR-negative breast cancer. Furthermore, axillary sampling revealed 5 positive lymph nodes, indicating that the cancer has spread to the axillary lymph nodes (N1).\n\nThe clinical trial is looking for patients with cT2 cN0/1 breast cancer who are scheduled for neoadjuvant chemotherapy. The patient fits the criteria of having cT2 cN1 breast cancer and is a candidate for tumor resection, which aligns with the requirement of being scheduled for pre-operative (neoadjuvant) chemotherapy. In addition, the patient has given informed consent to proceed with the surgery, which is another requirement for the trial.\n\nBased on the provided information, the patient meets all the inclusion criteria for the clinical trial:\n\n- cT2 cN0/1 breast cancer (confirmed by the biopsy and the presence of positive lymph nodes).\n- Scheduled for neoadjuvant chemotherapy (implied as the patient agrees to tumor resection prior to chemotherapy).\n- Informed consent (implied as the patient agrees to tumor resection).\n\nNo exclusion criteria are provided, and therefore none can be applied to exclude the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "476": {
        "output": "Based on the patient note provided and the clinical trial criteria, let's evaluate the patient's eligibility step by step:\n\n1. The patient has histologically confirmed invasive adenocarcinoma of the breast, which meets the first inclusion criterion.\n2. The patient's cancer is HER2-positive and ER/PR-negative. However, the clinical trial specifically requires Triple negative breast cancer, which is hormone receptor negative and HER2 negative. Since the patient's tumor is HER2-positive, this does not meet the trial's requirement of HER2 negativity.\n3. There is no information provided about the clinical stage at presentation; however, the presence of metastatic lesions (CXR remarkable for metastatic lesions) suggests that the patient may not fit the M0 (no distant metastasis) inclusion criterion required by the trial.\n4. The patient note does not mention receiving any neoadjuvant chemotherapy, let alone platinum and taxanes specifically.\n5. There is no information about the patient having undergone tumor excision after neoadjuvant chemotherapy.\n6. Since the patient has not yet had surgery as indicated by the note stating \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy,\" we cannot confirm the presence of residual invasive disease post-surgery.\n7. There are no details on the patient's ECOG Performance Status.\n8. The patient note does not report severe heart, lung, liver, or kidney disease.\n9. There is no information on hematologic and end-organ function.\n10. The timing between surgery and randomization is not relevant yet as the patient has not undergone surgery.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial, specifically the requirement for Triple negative breast cancer (HER2 negativity), prior receipt of platinum and taxanes based neoadjuvant chemotherapy, and no information regarding surgery or residual disease. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "477": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Functional Precision Oncology for Metastatic Breast Cancer,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nHere are the key points from the patient's note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm in size\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Axillary sampling revealed 5 positive lymph nodes\n- Candidate for tumor resection prior to chemotherapy\n- Life expectancy and performance status are not mentioned\n- Willingness to undergo tumor resection indicates potential willingness to provide informed consent for tumor collection\n\nAnd here are the inclusion criteria for the clinical trial:\n- Male or female subject aged \u2265 18 years\n- Her2 negative on immunohistochemistry or nonamplified breast cancer\n- Metastatic or recurrent unresectable breast cancer\n- Specific criteria for triple-negative and hormone receptor-positive breast cancer\n- Willing and capable to undergo baseline tumor collection\n- Safe to undergo tumor collection\n- Life expectancy of \u2265 6 months\n- ECOG Performance Status \u2264 2\n- Evidence of post-menopausal status\n- Able to provide informed consent and sign an approved consent form\n- At least one lesion suitable for assessment\n\nBased on the patient's HER2-positive status, she would not meet the inclusion criterion requiring Her2 negative status. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "478": {
        "output": "Based on the patient's note, we can identify the following information:\n\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Metastatic lesions are present on CXR.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, let's compare this information with the inclusion criteria of the clinical trial titled \"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial\":\n\n- HER2-positive status is confirmed by the patient's biopsy material.\n- Hormone receptor (HR) status is known and negative, as the patient is ER/PR negative.\n- The patient has clinical stage T1-4, N0-3 disease at presentation and is likely to have residual invasive disease postoperatively, as indicated by the positive lymph nodes.\n- The patient has residual HR-negative, HER2-positive disease, which makes her eligible.\n- The patient has not received neoadjuvant chemotherapy yet, as she is a candidate for tumor resection prior to chemotherapy, which means prior receipt of T-DM1 in the neoadjuvant setting is not applicable.\n- The patient is planning to have surgery before chemotherapy, so the requirement for systemic chemotherapy to be completed preoperatively does not apply yet.\n- There is no information provided about toxicities related to prior systemic treatment, as the patient has not received systemic treatment yet.\n- Adequate excision will be planned as the patient agrees to tumor resection.\n- There's no information about the patient's ECOG performance status, blood counts, liver and kidney function tests, or LVEF assessment.\n\nBased on the available information, the patient has not yet received the required neoadjuvant chemotherapy and other treatments that are prerequisites for eligibility in the trial. Therefore, we cannot confirm her eligibility at this point.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "479": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility for the trial:\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Patient is a candidate for tumor resection and agrees to it prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Triple-negative or HER2-positive invasive breast cancer with axillary lymph node metastasis confirmed by fine needle aspiration or core needle biopsy\n- Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy\n- Attend the study voluntarily, sign the informed consent\n\nThe patient has HER2-positive invasive breast cancer with confirmed axillary lymph node metastasis, which aligns with the trial's inclusion criteria. However, there is no information provided about whether the patient underwent computed tomography (CT) for assessment of the axillary lymph node status before and after neoadjuvant chemotherapy, which is a requirement for the trial. \n\nSince the patient appears to meet some of the inclusion criteria but lacks sufficient information regarding the CT assessment of axillary lymph nodes before and after neoadjuvant chemotherapy, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "480": {
        "output": "Given the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and she is a candidate for tumor resection and agrees to do so prior to chemotherapy. This aligns with the inclusion criteria of the clinical trial, which specifies that all female participants eligible for neoadjuvant chemotherapy and planning surgical treatment are included. The patient also appears to be able to give informed consent, which is another requirement for inclusion in the trial.\n\nSince the patient fits the inclusion criteria for the clinical trial titled \"Role of ABUS as an Alternative to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy\" and there are no exclusion criteria provided that she meets, the patient is eligible to participate in the study.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "481": {
        "output": "Based on the patient note and the clinical trial inclusion and exclusion criteria provided, let's evaluate the patient's eligibility:\n\n- The patient is a 45-year-old postmenopausal woman, which satisfies the age and postmenopausal status criteria.\n- The patient has cytologically confirmed breast cancer with a HER2-positive status.\n- The clinical trial is for patients with hormone receptor-positive, HER2-negative advanced breast cancer, which does not match the patient's HER2-positive status.\n- There is no mention of a PIK3CA gene mutation in the patient's note, which is a requirement for the trial.\n- There is no information provided regarding the patient's recurrence or progression during or after AI therapy, which is a necessary criterion for the trial.\n- The patient's ER/PR status is negative, which does not meet the trial's requirement for ER-positive and/or PgR-positive breast cancer.\n\nGiven the above points, particularly the mismatch in HER2 status and the absence of information on the PIK3CA mutation and AI therapy progression, the patient does not meet all of the necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "482": {
        "output": "",
        "label": 0
    },
    "483": {
        "output": "",
        "label": 2
    },
    "484": {
        "output": "",
        "label": 2
    },
    "485": {
        "output": "Let's compare the patient's information with the inclusion criteria of the clinical trial:\n\n- The patient is a 45-year-old postmenopausal woman, which meets the criteria of \"Females (regardless of menopausal status), or males.\"\n- The patient's tumor is HER2-positive, which does not meet the HER2 non-amplified criteria required for the trial.\n- The patient's ER/PR status is negative, which does not meet the criteria of being estrogen receptor (ER) and/or progesterone receptor (PR) positive.\n- The patient has metastatic lesions (CXR was remarkable for metastatic lesions), which does not meet the clinical T1-T3, any N, M0 invasive breast cancer criteria, as M0 indicates no distant metastasis.\n- There is no information on the patient's ECOG performance status, lab results, or other specific criteria mentioned in the inclusion criteria.\n\nBased on this information, the patient does not meet the eligibility criteria of the clinical trial due to HER2 positivity, negative ER/PR status, and the presence of metastatic lesions. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "486": {
        "output": "The patient note outlines a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the details provided, she has a 3 cm invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative, with metastatic lesions and positive axillary lymph nodes. This indicates that the patient has advanced breast cancer.\n\nThe clinical trial in question is focused on the Prospective Breast Cancer Biobanking study (PBCB), which aims to monitor various aspects of early-stage breast cancer through liquid biopsies.\n\nThe inclusion criteria for the clinical trial specify \"Early stage Breast Cancer\" and \"DCIS gr III\" (Ductal Carcinoma In Situ grade III).\n\nGiven that the patient has metastatic lesions and positive axillary lymph nodes, her condition exceeds early-stage breast cancer (which does not typically involve lymph node involvement or distant metastases). Therefore, she does not meet the inclusion criteria for a trial focused on early-stage breast cancer and DCIS grade III.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "487": {
        "output": "",
        "label": 0
    },
    "488": {
        "output": "Based on the provided patient information and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Women aged 18 years or older\n- Breast masses scored as:\n  - M3, M4, or M5 (mammographically uncertain, suspicious, or highly suspicious of malignancy)\n  - MRI5 (highly suspicious of malignancy on MRI)\n  - U3, U4, or U5 (ultrasonically uncertain, suspicious, or highly suspicious of malignancy)\n- Histologically proven breast cancer\n- Ipsilateral axillary lymph nodes described as indeterminate or suspicious for metastatic disease and indicated for biopsy\n- Able to give informed consent for the study\n\nThe patient has histologically proven breast cancer and suspicious axillary lymph nodes, which matches the inclusion criteria for the clinical trial. Furthermore, there is no information suggesting that she would not be able to give informed consent for the study. Therefore, the patient appears to meet the inclusion criteria of the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "489": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial. Let's go through the inclusion criteria step by step:\n\n1. The patient volunteers and signs an informed consent form;\n   - This condition cannot be assessed from the note provided as it requires the patient's action and consent.\n\n2. Age \u226518 years old, female;\n   - The patient is a 45-year-old woman, so this criterion is met.\n\n3. The patient was diagnosed as triple-negative breast cancer by histopathology (ER negative (IHC ER positive percentage <1%), PR negative (IHC PR positive percentage <1%), HER2 negative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis;\n   - The patient note indicates that the tumor is HER2-positive, which does not meet the requirement for triple-negative breast cancer (which should be HER2-negative). Furthermore, the patient has metastatic lesions, indicating evidence of metastasis. This criterion is not met.\n\n4. Patients underwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary breast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.\n   - The patient is a candidate for tumor resection but has not yet undergone the surgery. This criterion is not met at this time.\n\n5. For patients who have previously received neoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the postoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is, the primary breast and/or metastatic regional lymph nodes still have histological evidence of malignant tumors other than carcinoma in situ;\n   - This is not applicable as the patient has not received neoadjuvant therapy yet, and the tumor is not triple-negative.\n\n6. For patients who have not received neoadjuvant therapy for triple-negative breast cancer, \u22651 ipsilateral axillary lymph nodes have pathological tumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at least meet one of the following conditions:\n   - This is not applicable as the patient has not undergone surgery yet, and the tumor is not triple-negative.\n\nThe subsequent criteria are not relevant to assess as the patient has already failed to meet several key inclusion criteria, specifically the requirement for triple-negative breast cancer and the absence of metastasis.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial due to having a HER2-positive breast cancer and the presence of metastatic lesions.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "490": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- The cancer is invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- The patient has metastatic lesions on CXR.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Brain tumor subjects\n- Informed consent\n- Age equal to or greater than 19 years (age of majority in Nebraska)\n- Brain tumor that requires surgery\n- Primary or metastatic brain tumor\n\nThe patient in the note has breast cancer with metastatic lesions and is a candidate for tumor resection, but there is no mention of a brain tumor. The clinical trial is specifically looking for patients with brain tumors that require surgery. Since the patient has a breast tumor and not a brain tumor, she does not meet the inclusion criteria for this particular trial.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "491": {
        "output": "To determine the patient's eligibility for the clinical trial, we must assess whether she meets the inclusion criteria provided:\n\n1. Age between 18 and 65 years: The patient is 45 years old, which meets the criterion.\n2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1: The patient's ECOG performance status is not mentioned; however, she is a candidate for tumor resection, which can imply that her performance status might be adequate.\n3. Clinical T2-T4d, or T1c with axillary LN+: The patient has invasive ductal breast carcinoma with 5 positive lymph nodes, which meets this criterion.\n4. HER2 + invasive breast cancer confirmed by histopathology: The patient has HER2-positive invasive breast cancer, which meets the criterion.\n5. Clinically measurable lesions: The patient has a 3 cm tumor which is clinically measurable, meeting the criterion.\n6. Organ and bone marrow function tests within one month before chemotherapy showing no chemotherapy contraindication: Specific lab values are not provided, but there is no mention of contraindications to chemotherapy.\n7. Absolute neutrophil count, hemoglobin, platelet count, total bilirubin, creatinine, AST/ALT, and LVEF: These specific values are not mentioned in the patient note.\n8. For women of childbearing age, serum pregnancy test was negative 14 days before randomization: The patient is postmenopausal and not sexually active, so this is likely not applicable.\n9. KPS score \u2265 80 points: The patient's Karnofsky Performance Scale (KPS) score is not mentioned.\n10. Signed the informed consent form prior to patient entry: The patient agrees to tumor resection, which suggests she may be agreeable to participating in the trial, but this is not sufficient evidence that informed consent for the trial has been signed.\n\nBased on the information provided, the patient meets several of the inclusion criteria: age, tumor characteristics, and the presence of a clinically measurable lesion. However, there is insufficient information regarding her performance status (ECOG), organ and bone marrow function, and KPS score. Without this information, we cannot definitively determine her eligibility.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "492": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, here is the assessment:\n\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant that is HER2-positive and ER/PR negative. The patient has also been found to have metastatic lesions and five positive lymph nodes from axillary sampling.\n\nThe clinical trial in question is looking at the response of neoadjuvant chemotherapy in metaplastic carcinoma of triple-negative breast cancer. The inclusion criteria for the trial are as follows:\n\n1. The patient must be over 20 years old.\n2. The patient must have triple-negative breast cancer diagnosed at Seoul National University Hospital.\n3. The patient must have decided to perform neoadjuvant chemotherapy under clinical judgment.\n\nThe patient in the note is over 20 years old and is a candidate for tumor resection and agrees to do so prior to chemotherapy, which indicates a willingness to undergo chemotherapy. However, the patient's tumor is described as HER2-positive and ER/PR negative, which does not meet the definition of triple-negative breast cancer (which is characterized by the absence of expression of ER, PR, and HER2).\n\nSince the patient does not have triple-negative breast cancer, she does not meet the specific inclusion criteria for the trial, despite her willingness to undergo chemotherapy and her age being within the acceptable range.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "493": {
        "output": "The given patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The cancer is described as invasive ductal breast carcinoma (IDBC), HER2-positive, and ER/PR-negative.\n\nNow, let's compare this to the clinical trial inclusion criteria:\n\n1. Female: The patient is female.\n2. Age \u2265 18 years: The patient is 45 years old.\n3. Histological diagnosis of invasive lobular breast adenocarcinoma that is ER+, and HER2-: The patient has invasive ductal carcinoma, not lobular, and is HER2-positive, not HER2-negative, as required.\n4. ER positive: The patient is ER/PR-negative.\n5. HER2 negative: The patient is HER2-positive.\n6. A primary non-metastatic or locally advanced tumor of 15 mm or more: The patient's tumor is 3 cm, but has metastatic lesions.\n7. ECOG Performance Status (PS) 0 or 1: The patient's ECOG PS is not mentioned.\n8. Adequate Bone Marrow Function: No information provided regarding bone marrow function.\n9. Adequate Renal Function: No information provided regarding renal function.\n10. Adequate Liver Function: No information provided regarding liver function.\n11. Signed Informed Consent form (ICF): The patient agrees to tumor resection, which could indicate a willingness to consent, but this is not explicit consent for the trial.\n12. Completion of all necessary screening procedures: No information provided regarding completion of screening procedures.\n13. Subject is willing and able to comply with the protocol: No information provided regarding compliance.\n14. Women who are not postmenopausal must have a negative pregnancy test: The patient is described as postmenopausal.\n15. Women of childbearing potential must agree to use contraception: The patient is postmenopausal, so this is not applicable.\n16. Inclusion criterion applicable to FRANCE only: No information provided regarding the patient's affiliation to the French Social Security System.\n\nBased on the available information, the patient does not meet the histological diagnosis criteria (IDBC instead of ILBC), ER/PR status (the trial requires ER+ and HER2-, the patient is ER-/PR- and HER2+), and also has metastatic lesions which is not mentioned in the inclusion criteria but could be an exclusion factor. Without more specific information on some of the other inclusion criteria, we cannot fully assess the bone marrow, renal, and liver function, but the discrepancies in diagnosis and receptor status alone are sufficient to determine that the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "494": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The details of the patient's condition and characteristics need to be compared to the inclusion criteria of the clinical trial to determine eligibility.\n\nClinical Trial Inclusion Criteria:\n1. Female \u2265 18 years of age pre and post-menopausal.\n2. Metastatic disease (\u2264 5 sites of measurable disease).\n3. Eligible for treatment with CDK4/6 + aromatase inhibitors.\n4. Premenopausal or post-menopausal status defined with specific criteria.\n5. ECOG performance status 0-1.\n6. Biopsy proven diagnosis of HR+HER2- metastatic breast cancer. ER expression is >10%.\n7. Hematological, renal, hepatic, and coagulation parameters within specified ranges.\n\nPatient Characteristics:\n- 45 years old, postmenopausal.\n- Diagnosed with breast cancer, HER2-positive, ER/PR-negative.\n- Metastatic disease present as indicated by CXR showing metastatic lesions.\n- No mention of ECOG performance status.\n- HER2-positive status (trial requires HER2-negative).\n- Hematological, renal, hepatic, and coagulation status unknown.\n\nBased on the information provided, the patient does not meet all the inclusion criteria for the clinical trial. Specifically, the trial requires patients to have HR+HER2- metastatic breast cancer, whereas the patient has HER2-positive breast cancer. Additionally, the ER status does not match since the trial requires ER expression to be >10%, and the patient's cancer is ER-negative.\n\nTherefore, the patient is not eligible for this clinical trial due to not meeting the critical inclusion criteria regarding the breast cancer subtype.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "495": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- Candidate for tumor resection prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Male or female patients (\u226518 years of age)\n- Patients with stage IV breast cancer\n- Patients with HER2+ status in metastatic setting\n- Patients that received at least two lines of active anti-cancer drugs due to disease progression.\n- Patients that began third-line therapy prior to October 31, 2018.\n\nComparison:\n- The patient is a female and over 18 years of age.\n- The patient has stage IV breast cancer, as indicated by the presence of metastatic lesions.\n- The patient's tumor is HER2-positive.\n- It is not explicitly stated that the patient has received two lines of active anti-cancer drugs or that she has begun third-line therapy, let alone the specific start date of any third-line therapy.\n\nSince there is insufficient information regarding the patient's treatment history, particularly whether she has received two lines of therapy and if she started the third-line therapy prior to October 31, 2018, we cannot conclusively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "496": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion and exclusion criteria of the trial.\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nClinical trial inclusion criteria:\n- Stage II or III, HER2 negative, ER positive invasive breast cancer\n- Currently taking an aromatase inhibitor, or tamoxifen, as adjuvant endocrine therapy for at least 6 months but no more than 7 years\n- Clinical and pathological high risk for recurrence as defined in the criteria\n- FFPE tissue from primary tumor available for submission\n- Signed and dated informed consent\n- ctDNA positivity by the Signatera assay\n- No evidence of metastatic disease on CT scan\n- Adequate method of contraception for pre-menopausal women and male patients; post-menopausal status is defined in the criteria\n\nClinical trial exclusion criteria:\n- Prior or current treatment with fulvestrant, or current treatment with a CDK4/6 inhibitor, or treatment in the prior 12 months\n- Participation in another therapeutic clinical trial for breast cancer after enrollment\n- Current or past invasive cancer, other than breast cancer, with exceptions listed\n- Second HER2 positive or triple negative synchronous breast cancer\n- Known contraindications to receive fulvestrant and palbociclib\n- Any concurrent severe and uncontrolled medical condition\n\nThe patient does not meet the primary inclusion criteria of having an ER positive, HER2 negative breast cancer, as the patient's tumor is HER2-positive and ER/PR negative. Therefore, based on this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "497": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)\", we need to assess the patient's characteristics against the trial's inclusion criteria:\n\n1. Histologic documentation of invasive breast cancer by core needle or incisional biopsy. \n   - The patient has a core biopsy revealing invasive ductal breast carcinoma.\n\n2. Excess baseline biopsy tumor tissue sufficient to make ten 5-micron sections must be available for research use as part of this study.\n   - This information is not provided in the patient note.\n\n3. The invasive cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% of invasive cancer cells by IHC.\n   - The patient's tumor is ER/PR negative, so it does not meet this criterion.\n\n4. The invasive cancer must be HER2-negative (IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done).\n   - The patient's tumor is HER2-positive, which does not meet this criterion.\n\n5. Clinical Stage I-III invasive breast cancer with the intent to treat with surgical resection of the primary tumor. Baseline tumor must be \u22651 cm to provide adequate tissue.\n   - The patient has a 3 cm invasive ductal breast carcinoma and is a candidate for tumor resection, which satisfies this part of the criteria.\n\n6. Patients with multicentric or bilateral disease are eligible if the subject is a candidate for clinically indicated neoadjuvant endocrine therapy. Samples from all available tumors are requested for research purposes.\n   - The patient has metastatic lesions, which may indicate a stage beyond III, but this is unclear from the provided note.\n\n7. Women over 18 years of age, for whom neoadjuvant treatment with an aromatase inhibitor would be clinically indicated. Women must be surgically, medically, or naturally post-menopausal.\n   - The patient is a 45-year-old postmenopausal woman, which fits this criterion.\n\n8. Patients must meet the following clinical laboratory criteria:\n   - Specific laboratory values are not provided in the patient note.\n\n9. Ability to give informed consent.\n   - The patient agrees to tumor resection prior to chemotherapy, which implies the ability to consent, but explicit information on informed consent for the trial is not provided.\n\nGiven the information in the patient note, the patient does not meet the criteria for ER positivity and HER2 negativity required for the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "498": {
        "output": "",
        "label": 1
    },
    "499": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can evaluate the eligibility of the patient:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic lesions present\n- Candidate for tumor resection and agrees to undergo surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Patients diagnosed with metastatic HER2-negative breast cancer\n- AR expression of \u2265 10%\n\nThe patient in the note has HER2-positive breast cancer, which does not meet the inclusion criteria for the clinical trial that requires participants to have HER2-negative breast cancer. The patient's HER2-positive status is a critical factor, and since the trial is specifically evaluating patients with HER2-negative breast cancer, this patient would not qualify for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "500": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the details to determine the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- HER2-positive and ER/PR negative breast cancer.\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- Axillary sampling revealed 5 positive lymph nodes, indicating nodal involvement.\n- Presence of metastatic lesions on CXR.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Female participants who are at least 40 years of age on the day of signing the informed consent form.\n- Histologically confirmed invasive adenocarcinoma of the breast that is HER2-positive.\n- PAM50 HER2-enriched subtype and ERBB2-high as predefined cutoff.\n- Unifocal invasive carcinoma with only 1 invasive focus.\n- Tumor largest diameter \u22644 cm as defined by breast MRI.\n- No nodal involvement (cN0).\n- No evidence of distant metastasis (M0).\n- Patient must have known ER and PR status.\n- Eligible for taxane therapy.\n- Willingness to omit surgery if criteria are met following neoadjuvant therapy.\n- Estimated life expectancy of at least 5 years.\n- Breast cancer eligible for primary surgery.\n- Have provided archival tumor tissue sample or newly obtained core biopsy.\n- ECOG performance status of 0 to 1.\n- Adequate organ function.\n\nComparison:\n- The patient is within the age criterion.\n- The patient has HER2-positive invasive breast cancer.\n- The tumor size (3 cm) is within the specified criterion (\u22644 cm).\n- The patient has known ER and PR status.\n\nHowever:\n- The patient has nodal involvement (5 positive lymph nodes), whereas the trial requires no nodal involvement (cN0).\n- The patient has evidence of distant metastasis, whereas the trial requires no evidence of distant metastasis (M0).\n- The trial specifies a willingness to omit surgery if criteria are met after neoadjuvant therapy, but the patient is already a candidate for tumor resection before chemotherapy, which may not align with the trial's design.\n\nBased on the discrepancies between the patient note and the inclusion criteria of the clinical trial, particularly the nodal involvement and the presence of metastatic lesions, the patient does not meet the key inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "501": {
        "output": "",
        "label": 0
    },
    "502": {
        "output": "The patient is a 45-year-old postmenopausal woman, which satisfies the age criterion of \"Age 18+\" for the clinical trial.\n\nThe patient has cytologically confirmed breast cancer with a core biopsy revealing a 3 cm invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative. She also has metastatic lesions as indicated by the CXR (chest X-ray), which fulfills the criteria of \"Metastatic breast cancer irrespective of subtype\" and \"Metastatic disease involving the lymph nodes and/or visceral organs is required.\"\n\nThe disease appears to be measurable as per RECIST 1.1 criteria, given the specific information about tumor size and location, although the note does not explicitly state that it has been measured according to these criteria. Nonetheless, the details provided suggest that the disease could be measured according to RECIST 1.1.\n\nThe patient is a candidate for tumor resection and agrees to undergo this before chemotherapy, which aligns with the willingness to undergo a biopsy prior to the start of planned systemic therapy.\n\nBased on the provided patient note, the patient meets all the inclusion criteria for the clinical trial titled \"Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "503": {
        "output": "Patient note analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- Diagnosis: Invasive ductal breast carcinoma.\n- Tumor size: 3 cm (within the criteria of 50mm or smaller).\n- Tumor location: Left upper outer quadrant.\n- HER2-positive and ER/PR negative.\n- Axillary sampling: 5 positive lymph nodes.\n- Presence of metastatic lesions on CXR.\n- The patient is using multivitamins and iron supplements.\n- She is a candidate for tumor resection.\n\nClinical trial inclusion criteria analysis:\n- Gender: women (the patient is a woman).\n- Diagnosis: invasive ductal carcinoma of the breast (the patient has this diagnosis).\n- Tumor size: 50mm or smaller (the patient's tumor is 3 cm, which is within this limit).\n- Axillary lymph node metastasis: no metastasis or Ipsilateral grade I and II axillary lymph node metastasis (the patient has 5 positive lymph nodes, which suggests at least Ipsilateral grade II metastasis, but the presence of metastatic lesions on CXR might indicate a stage beyond the allowed N1).\n- Tumor mobility: movable (pT0-2N0-1M0) (the presence of metastatic lesions on CXR suggests that the patient might not be M0, which is a requirement).\n\nThe patient meets some of the inclusion criteria (gender, invasive ductal carcinoma diagnosis, tumor size, and tumor location). However, the clinical trial requires no axillary lymph node metastasis or only Ipsilateral grade I and II, and the patient has 5 positive lymph nodes, which at least meets the criteria for grade II. The trial also requires the tumor to be classified as movable pT0-2N0-1M0, but the presence of metastatic lesions suggests that the patient might not be M0, which would be a requirement for the trial. Therefore, the patient does not meet all the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "504": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, it is clear that the patient does not fit the criteria for the trial. The patient has breast cancer, not rectal adenocarcinoma, which is the focus of the clinical trial. The trial specifically includes patients with mid to low-lying rectal adenocarcinoma and enlarged lateral lymph nodes. Thus, the patient's condition is not relevant to the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "505": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Refining Local-Regional Therapy for IBC\", we need to assess the patient's characteristics and medical history against the inclusion criteria of the trial.\n\nThe inclusion criteria are as follows:\n1. Stage III IBC (cT4d cN0-2)\n2. Inflammatory breast cancer symptoms, including:\n   - Rapid onset symptoms (6 months or less from time of diagnosis)\n   - Breast erythema, edema and/or peau d'orange and/or warm breast with or without an underlying palpable mass\n   - Erythema occupying at least one-third of the breast\n3. Pathologic confirmation (biopsy-proven) invasive breast carcinoma\n4. Women age \u226518 years\n5. ECOG performance status \u22642\n6. Ability and willingness to sign informed consent document and comply with study procedures\n\nThe patient note provides the following information:\n- The patient is a 45-year-old postmenopausal woman, meeting the age criterion.\n- She has cytologically confirmed breast cancer, satisfying the pathologic confirmation criterion.\n- There is no mention of the breast cancer being inflammatory (IBC), nor symptoms such as rapid onset, erythema, edema, peau d'orange, or warmth of the breast. Specifically, inflammatory breast cancer (IBC) has distinctive criteria that are not indicated in the patient's note.\n- The patient has agreed to tumor resection and is compliant with procedures, potentially satisfying the consent and compliance criteria.\n- The patient's ECOG performance status is not mentioned, but there is no indication of significant disability that would suggest a status above 2.\n\nThe critical missing information here is whether or not the patient's breast cancer is inflammatory (IBC), meeting the specific definition required by the trial. Since this information is not provided in the patient note, we cannot confirm eligibility based on the IBC criteria.\n\nBased on the available information, the patient does not have sufficient information to qualify for the trial because the nature of the breast cancer (whether it is inflammatory or not) is not specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "506": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer\" based on the provided patient note and inclusion criteria:\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Diagnosis: cytologically confirmed breast cancer\n- Core biopsy: 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- Tumor characteristics: HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions on CXR\n- No mention of alcohol, smoking, or sexual activity\n- No children\n- Candidate for tumor resection, agrees to proceed before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Participants must be \u2265 18 years old.\n- Participants with a clinical T1 or T2 invasive ductal or lobular breast carcinoma, regardless of estrogen/progesterone/human epidermal growth factor receptor 2 (HER2) receptor status.\n- Participants with clinical (on palpation) N0 and up to two suspicious lymph nodes on axillary ultrasound.\n- Participant with biopsy-proven positive axillary disease made by core needle biopsy or fine-needle aspiration.\n- Participants must have an Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status less than 2.\n- Participants must understand, accept, and have signed the approved consent form.\n\nComparison:\n- The patient is over 18 years old, which meets the age criterion.\n- The patient has an invasive ductal carcinoma, which meets the requirement regarding cancer type.\n- The patient's HER2 positive status is irrelevant to the inclusion criteria, as all statuses are accepted.\n- The patient has more than two positive lymph nodes, which exceeds the trial's limit of up to two suspicious lymph nodes.\n- There is no information on the patient's ECOG Performance Status, but this information could be ascertained through further clinical assessment.\n- The patient is a candidate for tumor resection and agrees to chemotherapy, which suggests she might be willing to understand, accept, and sign the consent form, but this is not confirmed in the note.\n\nBased on the information provided, the patient does not meet the trial criteria of having two or fewer suspicious lymph nodes, as she has five positive lymph nodes identified. Therefore, this patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "507": {
        "output": "",
        "label": 2
    },
    "508": {
        "output": "Based on the information provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and there is no mention of her needing a pancreatic or biliary stent. The clinical trial in question is specifically evaluating the safety and clinical performance of biodegradable biliary and pancreatic stents. The inclusion criteria for this trial require a patient to be eligible for the implantation of a pancreatic or biliary stent prior to participation in the study.\n\nGiven that the patient's condition (breast cancer with metastatic lesions) does not indicate a need for a pancreatic or biliary stent, she does not meet the inclusion criteria for this trial. Additionally, there is no information suggesting that she requires or is a candidate for such a stent.\n\nTherefore, the patient does not qualify for this clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "509": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is using multivitamins and iron supplements.\n- The patient does not smoke or consume alcohol.\n- The patient is not sexually active and has no children.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Age over 19 years old.\n- Patients who are expected to undergo surgery under the diagnosis of ipsilateral breast tumor recurrence (histologically confirmed in situ disease or invasive disease).\n- Patients who had partial mastectomy and sentinel lymph node biopsy for prior operation for the initially diagnosed breast cancer.\n- Patients considered to be axillary lymph node negative from clinical findings.\n- Patients who understand and willingly participate in the study.\n\nThe patient is 45 years old, which meets the age criterion. However, the trial specifically requires patients who have had ipsilateral breast tumor recurrence and who had a previous partial mastectomy and sentinel lymph node biopsy. The patient note does not mention any prior surgery that the patient has undergone for breast cancer, nor does it indicate whether there is a recurrence of the tumor. Additionally, the patient note states that there are metastatic lesions present, which would not be consistent with being considered axillary lymph node negative from clinical findings.\n\nGiven the information we have, the patient does not meet the inclusion criteria regarding previous surgery and the status of axillary lymph nodes. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "510": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative, and the patient has metastatic disease as evidenced by axillary lymph node involvement and metastatic lesions noted on the chest X-ray (CXR). The patient is a candidate for tumor resection and agrees to undergo this procedure prior to chemotherapy.\n\nNow, let's review the clinical trial's inclusion criteria:\n\n1. Pathologically confirmed HER2 positive breast cancer.\n2. Treated with Pyrotinib in the metastatic setting.\n3. Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine.\n\nThe patient in the note has pathologically confirmed HER2-positive breast cancer, which meets the first criterion. However, the note does not specify whether the patient has been treated with Pyrotinib in the metastatic setting or has undergone a whole-body FDG PET/CT within the specified timeframe before the initiation of pyrotinib and capecitabine. Without this information, we cannot confirm whether the patient meets the second and third inclusion criteria.\n\nGiven the available information, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "511": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial. \n\nThe patient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed invasive ductal breast carcinoma\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection before chemotherapy\n\nThe clinical trial's inclusion criteria:\n- Female\n- Age 20-65 years\n- Invasive carcinoma confirmed by core biopsy\n- Newly diagnosed breast cancer patients, without adjuvant therapy\n- Imaging findings showed a single breast tumor with a maximum diameter of 3 cm, no distant metastasis, and no invasion of the skin and chest wall\n- Surgical treatment was planned\n- The functional level of major organs must meet specific requirements\n\nComparing the criteria, the patient matches the trial's requirements on gender and age. The patient has invasive carcinoma confirmed by core biopsy which also matches the criteria. However, the patient does not meet the following criteria:\n\n- The patient has metastatic lesions (CXR remarkable for metastatic lesions), which contradicts the trial criterion of \"no distant metastasis.\"\n- The patient is planned to have tumor resection prior to chemotherapy, this does not necessarily exclude her but it is unclear whether she has already had adjuvant therapy or not. If she has not had adjuvant therapy, she could still be eligible.\n\nBased on the presence of distant metastasis, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "512": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical condition to the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n1. Histology-confirmed epithelial cancer of the mammary gland.\n2. Pre and postmenopausal patients with early breast cancer and involved axillary lymph nodes (T 1-3 N1 M0) or high-risk N0 patients.\n   - High-risk criteria for N0 patients include one of the following: T>= 2cm, ER/PgR negative, HER-2 3+, infiltration of blood or lymphatic vessels or nerves, grade 3.\n3. WBC > 4 x 10^9 / l, platelets > 100 x 10^9 / l (patient's blood work values not provided, assuming normal as not mentioned otherwise).\n4. Serum creatinine, AST/SGOT, ALT/SGPT, gamma-glutamyltransferase, serum bilirubin \u2264 1.3 mg/ml inside the normal range of the participating hospital (patient's lab values not provided, assuming normal as not mentioned otherwise).\n5. Performance status (WHO) 0 or 1 (not mentioned, but the patient agrees to surgery, implying good performance status).\n6. Age \u226518 years.\n7. Previous surgical treatment: Either radical surgery or, for a partial mastectomy, a histologically confirmed safe margin of 2 cm or more and the results of the axillary node dissection available (patient is a candidate for tumor resection).\n8. No evidence of significant cardiac disease (not mentioned, assuming none as not mentioned otherwise).\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman, which satisfies the age criterion and menopausal status.\n- Diagnosed with breast cancer, satisfying the requirement for histology-confirmed epithelial cancer of the mammary gland.\n- The tumor is classified as invasive ductal breast carcinoma, which fits the criteria for breast cancer.\n- HER2-positive, ER/PR negative, and positive axillary lymph nodes (5 positive nodes), meeting the criteria for high-risk early breast cancer (T 1-3 N1 M0).\n- The patient is a candidate for tumor resection, which aligns with the requirement for previous surgical treatment.\n- No mention of significant cardiac disease, performance status, or lab values, but given the information provided, we can assume the patient would likely meet these criteria unless further information suggests otherwise.\n\nBased on the available information, the patient appears to meet the inclusion criteria for the clinical trial. Without any explicit exclusion criteria provided or met, and assuming normal lab values and performance status, the patient is likely eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "513": {
        "output": "",
        "label": 0
    },
    "514": {
        "output": "The patient in the provided note is a 46-year-old man who presents with symptoms that are not directly related to coronary artery disease, but rather to carotid artery disease. He has extremely high LDL-C levels which are not consistent with the normocholesterolemia required by the trial. Additionally, there is no mention of coronary artery disease or any coronary arteriography performed, which is a requirement for the clinical trial.\n\nConsidering the clinical trial's inclusion criteria requires normocholesterolemia and documented coronary artery disease with narrowing of a coronary artery lumen by 30 percent or greater, the patient does not meet the specific inclusion criteria based on the provided information. The patient has high LDL-C levels, which is contrary to being normocholesterolemic, and there is no documentation of coronary heart disease or coronary arteriography results.\n\nTherefore, based on the information given, the patient does not qualify for the Harvard Atherosclerosis Reversibility Project (HARP) clinical trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "515": {
        "output": "For this patient to be eligible for the \"Action to Control Cardiovascular Risk in Diabetes (ACCORD)\" clinical trial, they must meet the inclusion criteria specified. Let's review the patient note against the inclusion criteria:\n\n1. Diagnosed with type 2 diabetes mellitus: The patient note does not mention a diagnosis of type 2 diabetes mellitus, only that the fasting glucose level is within normal limits (85 mg/dL). This does not meet the criteria of a fasting plasma glucose level greater than 126 mg/dl or a 2-hour postload value in the oral glucose tolerance test of more than 200 mg/dl.\n\n2. For participants aged 40 years or older, a history of CVD: The patient has severe and moderate stenosis in the internal carotid arteries, which could be indicative of cardiovascular disease (CVD), but there is no explicit mention of a history of heart attack, stroke, coronary revascularization, peripheral or carotid revascularization, or demonstrated angina.\n\n3. For participants aged 55 years or older, a history of CVD is not required, but they must be at high risk for a CVD event: The patient is 46 years old, so this criterion does not apply.\n\n4. HbA1c 7.5%-9% (if on more drugs) or 7.5%-11% (if on fewer drugs): There is no information provided on the patient's HbA1c levels.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the ACCORD clinical trial. Specifically, there is no evidence of a type 2 diabetes mellitus diagnosis, nor is there sufficient information to conclude a definitive history of CVD or the required HbA1c levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "516": {
        "output": "The patient in the note is a 46-year-old man presenting with dizziness and frequent headaches, with a family history of coronary artery disease (CAD). He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient has hypercholesterolemia with very high LDL-C levels and is not on lipid-lowering medications.\n\nNow let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\nInclusion criteria for the trial:\n1. Patient must be over 18 years old.\n2. Requiring diagnostic cardiac catheterization.\n3. Women on chronic estrogen therapy are eligible.\n4. Patients investigated for chest pain syndrome with normal coronary arteries with and without risk factors for atherosclerosis, patients with coronary artery disease, and patients with heart failure are eligible.\n5. Excludes patients with unstable angina; significant left main disease (greater than 50% stenosis); recent myocardial infarction (less than 1 month); pregnancy, lactation; allergy to losartan; renal failure (creatinine greater than 2.5 mg/dl); inability to withdraw ACE inhibitors.\n\nThe patient meets the age criterion and has severe stenosis in the carotid arteries, which could be associated with coronary artery disease. However, the patient note does not explicitly mention chest pain syndrome, heart failure, or whether the patient requires diagnostic cardiac catheterization. The note also does not provide details about certain exclusion criteria, such as recent myocardial infarction, renal failure, or an allergy to losartan. Since the patient does not clearly meet all the specific inclusion or exclusion criteria based on the information provided, it is difficult to determine eligibility without additional information.\n\nTherefore, based on the information given, the patient's trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "517": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can assess the eligibility of the patient as follows:\n\nThe patient is a 46-year-old man, and the clinical trial is for postmenopausal women, which already disqualifies him based on gender. Additionally, the patient has a severe stenosis in the left internal carotid artery, indicating carotid artery disease, which is also listed in the exclusion criteria of the clinical trial. Therefore, regardless of the other criteria, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "518": {
        "output": "",
        "label": 1
    },
    "519": {
        "output": "Based on the provided information, the patient note describes a 46-year-old man who presents with symptoms consistent with carotid artery disease, such as dizziness, frequent headaches, and a systolic murmur. Ultrasonography confirms severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient's condition appears relevant to the study of carotid atherosclerosis.\n\nThe clinical trial described is focused on the follow-up of carotid atherosclerosis and its potential to predict cardiovascular events and all-cause mortality in patients. The inclusion criteria for the clinical trial are not specified, which means that any patient with issues related to carotid atherosclerosis could potentially be eligible.\n\nGiven that the patient has documented severe carotid atherosclerosis and there are no specific inclusion or exclusion criteria provided for the clinical trial, the patient would be considered eligible based on the information available.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "520": {
        "output": "Based on the patient note, the 46-year-old man has an extremely high LDL-C level of 545 mg/dL, indicative of hypercholesterolemia. He also presents with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, which are clinical findings but not directly related to the inclusion criteria of the clinical trial.\n\nThe clinical trial in question is investigating the genetics of low-density lipoprotein (LDL) subclasses in hypercholesterolemia. Since the trial summary mentions that it is focused on metabolically defined hypercholesterolemia and the patient shows a high LDL-C level, he potentially fits into the category of interest for the study.\n\nHowever, since the inclusion criteria for the clinical trial are not specified (\"No eligibility criteria\"), we cannot definitively determine if the patient is eligible or not based on the information provided. In clinical trial terms, this typically means that the trial is open to a wide range of participants, possibly only excluding those who do not have the condition of interest\u2014in this case, hypercholesterolemia.\n\nGiven that the patient does have hypercholesterolemia and no other eligibility criteria are specified, we can infer that the patient may be eligible for the study. However, without explicit inclusion criteria, we must be cautious and assume that not enough information is provided to make a definitive eligibility determination.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "521": {
        "output": "Given the patient note and the clinical trial provided:\n\nPatient note:\n- The patient is a 46-year-old man with dizziness and frequent headaches.\n- The patient has a family history of CAD but no other cardiovascular risk factors and is physically active.\n- The patient has high LDL-C levels and normal glucose and triglyceride levels.\n- No use of lipid-lowering medications is reported.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery were found.\n\nClinical trial:\n- Title: Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study)\n- The purpose is to investigate the role of serum and dietary antioxidants, serum pro-oxidants, and smoking on the progression/regression of carotid intima-media thickness (IMT).\n- Inclusion criteria: No eligibility criteria\n\nSince the clinical trial has \"No eligibility criteria\" specified, it means there are no specific inclusion or exclusion criteria provided to evaluate the patient against. Therefore, any patient would technically be eligible to participate based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "522": {
        "output": "Based on the information provided, the patient note describes a 46-year-old man with dizziness, frequent headaches, high LDL-C levels, a family history of coronary artery disease (CAD), and severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. The trial is focused on the molecular and clinical evaluation of low HDL syndromes with a specific interest in the genetic causes of low HDL-C, which is a risk factor for premature atherosclerotic vascular disease in patients with normal total cholesterol.\n\nThe inclusion criteria for the clinical trial are not explicitly stated, which implies that there are no specific requirements for participation in the study. Given that the patient has an HDL-C level of 53 mg/dL, which is considered low, and there are no other eligibility criteria mentioned for the trial, the patient could potentially be relevant for the study's objective of evaluating low HDL syndromes.\n\nHowever, since the trial aims to identify a genetic cause and the patient note does not mention any genetic testing or known genetic mutations related to low HDL-C levels, there isn't sufficient information to determine the patient's eligibility for participation based solely on the genetic focus of the trial.\n\nGiven that no explicit inclusion or exclusion criteria are provided, and the patient has low HDL-C, which aligns with the trial's focus on low HDL syndromes, the patient could be considered for the trial. However, without more detailed information on the genetic aspects of the trial's objectives and the genetic background of the patient, a definitive assessment cannot be made.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "523": {
        "output": "",
        "label": 1
    },
    "524": {
        "output": "",
        "label": 2
    },
    "525": {
        "output": "To determine if the patient is eligible for the Carotid Occlusion Surgery Study, we need to compare the patient's characteristics and medical history with the inclusion criteria stated by the clinical trial. Let's analyze the provided information:\n\n1. Vascular imaging demonstrating occlusion of one or both internal carotid arteries.\n   - The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, stenosis is not the same as occlusion. There is no mention of occlusion, so this criterion may not be met.\n\n2. Transient ischemic attack (TIA) or ischemic stroke in the hemispheric carotid territory of one occluded carotid artery.\n   - The patient note does not mention a TIA or ischemic stroke.\n\n3. Most recent qualifying TIA or stroke occurring within 120 days prior to projected performance date of PET.\n   - Since there's no mention of a TIA or stroke, this criterion cannot be evaluated.\n\n4. Modified Barthel Index > 12/20 (60/100).\n   - The patient note does not provide information about the patient's functional status or Modified Barthel Index score.\n\n5. Language comprehension intact, motor aphasia mild or absent.\n   - The patient note does not mention any language or speech difficulties, so we can assume this criterion might be met.\n\n6. Age 18-85 inclusive.\n   - The patient is 46 years old, which meets the age criterion.\n\n7. Competent to give informed consent.\n   - There is no information that suggests the patient is not competent to give informed consent.\n\n8. Legally an adult.\n   - The patient is 46 years old, so he is legally an adult.\n\n9. Geographically accessible and reliable for follow-up.\n   - There is no information regarding the patient\u2019s geographical accessibility or reliability for follow-up.\n\nBased on the information provided in the patient note, we do not have enough evidence that the patient meets all the necessary inclusion criteria, particularly the criteria related to carotid artery occlusion and the history of TIA or ischemic stroke. Therefore, the patient does not seem to have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "526": {
        "output": "The patient note presents a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His LDL-C level is 545 mg/dL, which is indicative of primary hypercholesterolemia, and he has a systolic murmur, which may suggest some underlying cardiovascular issues. It appears he has not had any event like a transient ischemic attack (TIA) or ischemic stroke (IS), nor does he have documented peripheral artery disease (PAD), coronary artery disease (CAD), or diabetes that require drug therapy.\n\nLooking at the inclusion criteria of the clinical trial:\n- The patient is at least 45 years old.\n- The patient does not have a documented combination of atherothrombotic risk factors as specified; he has primary hypercholesterolemia (a minor risk factor) but there is no mention of diabetes, diabetic nephropathy, ABI < 0.9, asymptomatic carotid stenosis >= 70%, or presence of at least one carotid plaque as evidenced by IMT (major risk factors). He also does not have documented cerebrovascular disease (TIA or IS within 5 years), documented coronary artery disease, or documented symptomatic PAD, which are other categories of inclusion criteria.\n\nThe patient does meet one of the minor atherothrombotic risk factors (primary hypercholesterolemia), but there is no evidence of enough risk factors to meet the inclusion criteria (he would need one more minor factor or a major factor).\n\nGiven the information provided in the patient note, the patient does not meet the full inclusion criteria for the clinical trial. However, he is not explicitly excluded by any of the exclusion criteria provided. Since the patient does not sufficiently meet the inclusion criteria, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "527": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,\" I will compare the patient's characteristics and condition as described in the patient note against the inclusion and exclusion criteria of the trial.\n\nPatient Note Summary:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- Very high LDL-C levels\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications reported\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of hypertension or renal dysfunction\n\nClinical Trial Inclusion Criteria Summary:\n- Either hypertension on two or more anti-hypertensive medications OR renal dysfunction (Stage 3 or greater CKD)\n- Severe renal artery stenoses confirmed by one of several methods\n- Age greater than 18 years\n\nClinical Trial Exclusion Criteria Summary:\n- Unable to provide informed consent\n- Unable or unwilling to comply with study protocol or procedures\n- Must be greater than 18 years of age\n- Various medical conditions and history restrictions\n- Allergies to materials and medications relevant to the study\n- Certain renal-related exclusions\n\nAssessment:\n- The patient is over 18 years old.\n- There is no mention of hypertension or being on any anti-hypertensive medications.\n- The patient does not have a documented history of renal dysfunction.\n- The patient has severe stenosis in the carotid arteries, not the renal arteries.\n- The stenosis is not described using any of the measures specified for renal artery stenosis (e.g., angiographic, duplex, MRA, CTA).\n- There is no information to suggest the patient meets the specific renal-related criteria for this trial.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial as there is no mention of hypertension requiring multiple anti-hypertensive medications, renal dysfunction, or renal artery stenosis. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "528": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I),\" let's evaluate the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which fits within the age range of > 18 and < 80 years required by the trial.\n- There's no information regarding the patient's childbearing potential, but as the patient is male, this criterion is not applicable.\n- The patient presents with dizziness and frequent headaches, which could be symptoms of a stroke or TIA. However, there is no explicit mention of a stroke or TIA, and the symptoms could be related to carotid stenosis rather than neurological events. Additional clarification from a neurologist or neurosurgeon would be required to confirm the patient's neurological status as asymptomatic according to the trial's definition.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which likely meets the trial's requirement for carotid stenosis \u2265 70% and \u2264 99% by carotid ultrasound. However, the exact percentage of stenosis for the left ICA is not provided and would need to be confirmed to ensure eligibility.\n- There is no information on whether the patient is taking warfarin or about their willingness to sign a written informed consent or return for follow-up visits.\n- The patient has a discrete lesion located in the internal carotid artery, which is a requirement.\n- There is no mention of the target ICA vessel diameter, so it's unclear if it meets the specified criteria for the stent treatment segment.\n- The note does not describe the patient's anatomy in terms of tortuosity or other factors that would affect the successful delivery of the stent to the target lesion.\n- No information is provided about whether the lesion is de novo or if it can be treated with a single stent.\n\nGiven the information in the patient note, the patient seems potentially eligible based on age and the presence of carotid artery stenosis. However, there's insufficient information on several key criteria, such as confirmation of being asymptomatic, the exact percentage of stenosis, vessel diameter, patient consent and compliance, and specific anatomical details required for stent delivery.\n\nTherefore, based on the available information, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "529": {
        "output": "",
        "label": 0
    },
    "530": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis,\" we need to compare the patient's information to the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the trial are:\n1. Age at least 18 years.\n2. Presence of symptoms of an ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) scale of one up to 20 or due to an ipsilateral atherosclerotic >50% stenosis of the extracranial internal carotid artery (ICA) as shown by ultrasonography.\n3. Latency between the onset of stroke symptoms and intended administration of the study drugs is not more than 24 hours.\n4. Latency between the intended administration of the study drugs and intended carotid endarterectomy is at least three days.\n\nNow, let's review the patient's note:\n- The patient is a 46-year-old man, which meets the age criteria (1).\n- The patient presents with dizziness and frequent headaches, but there is no mention of symptoms of an ischemic stroke or a baseline NIHSS scale rating (2).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the stenosis in the right ICA is estimated between 40% and 50%, which does not clearly meet the >50% stenosis criteria (2).\n- There is no information provided about the latency between the onset of stroke symptoms and the intended administration of study drugs, or the latency between the administration of study drugs and intended carotid endarterectomy (3 and 4).\n\nDue to the lack of clear documentation of ischemic stroke symptoms and the absence of information regarding the NIHSS scale and latencies, as well as the ambiguity regarding the exact percentage of stenosis (>50% required), the patient does not appear to meet all the necessary inclusion criteria based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "531": {
        "output": "Based on the patient note provided, the 46-year-old man has extremely high LDL-C levels (545 mg/dL) and a family history of CAD, but no other cardiovascular risk factors and is physically active. The patient is also not currently using any lipid-lowering medications. These characteristics are suggestive of heterozygous familial hypercholesterolemia (HeFH), even though it is not explicitly stated as \"diagnosed\" in the note. For a clinical trial recruitment, typically a confirmed diagnosis would be necessary; however, given the high LDL-C levels and family history, it is plausible that this patient has HeFH. The patient also meets the age criterion of being at least 18 years old.\n\nThe clinical trial in question was terminated in 2006, which means it is no longer recruiting or active. However, for the purpose of this exercise, we will ignore the termination note and assess the patient's eligibility based on the inclusion criteria provided.\n\nGiven the information in the patient note, the patient appears to meet the inclusion criteria for the clinical trial, which are:\n\n1. Diagnosis of Heterozygous Familial Hypercholesterolemia\n2. At least 18 years of age\n\nSince both the high LDL-C level and the family history of CAD suggest a diagnosis of HeFH, and the patient is 46 years old, he seems to meet the requirements for the trial. There is no information provided that would exclude the patient based on the trial's exclusion criteria, as these have not been listed.\n\nTherefore, the patient would be potentially eligible for the clinical trial based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "532": {
        "output": "Based on the information provided in the patient note, the 46-year-old man presents with extremely high LDL-C levels (545 mg/dL) and has severe stenosis in the left internal carotid artery, but there is no explicit mention of a diagnosis of Homozygous Familial Hypercholesterolemia (HoFH). Homozygous Familial Hypercholesterolemia is a genetic disorder characterized by extremely high levels of cholesterol present from birth, and it typically requires genetic confirmation or a clear family history of the condition.\n\nThe patient note does not provide sufficient information to confirm a diagnosis of Homozygous Familial Hypercholesterolemia; it only mentions high LDL-C levels and a family history of coronary artery disease (CAD), which is not the same as HoFH. Without a confirmed diagnosis of Homozygous Familial Hypercholesterolemia, we cannot determine that the patient meets the required inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "533": {
        "output": "Based on the information provided in the patient note, the 46-year-old man presents with dizziness, frequent headaches, and severely elevated LDL-C levels, which is a characteristic feature of familial hypercholesterolemia. The patient also has carotid artery disease, as indicated by the severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial in question is looking for individuals with a diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH) and who are at least 18 years of age. The patient fits the age criterion as he is 46 years old. While the patient's LDL-C levels are significantly high, which is suggestive of HeFH, the patient note does not explicitly confirm a diagnosis of Heterozygous Familial Hypercholesterolemia.\n\nSince the diagnosis of HeFH is a critical inclusion criterion for the trial, and this specific diagnosis is not confirmed in the patient note, we do not have sufficient information to qualify the patient for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "534": {
        "output": "In order to determine the trial-level eligibility for the patient, we need to assess whether the patient meets the inclusion criteria of the clinical trial based on the patient note provided.\n\nThe inclusion criteria for the clinical trial \"Stop Atherosclerosis in Native Diabetics Study\" are as follows:\n1. American Indian men and women 40 years of age or older\n2. Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or WHO criteria): fasting plasma glucose >= 7.0 mmol/L (126 mg/dL) or 2-hour glucose >= 11.0 mmol/L (>200 mg/dL) after a 75-gram oral glucose tolerance test.\n3. LDL cholesterol >= 100 mg/dL. within the previous 12 months.\n4. Systolic BP >= 130 mm Hg. within the previous 12 months.\n\nNow, let's compare the patient's information with these criteria:\n1. The patient is a 46-year-old man, which satisfies the age criterion.\n2. There is no mention of the patient being American Indian, which is a required demographic for the study.\n3. The patient's LDL-C level is 545 mg/dL, which meets the criterion for LDL cholesterol levels.\n4. There is no indication in the patient note of the patient having Type 2 Diabetes Mellitus (DM); the patient's fasting glucose level is within normal limits.\n5. There is no mention of the patient's blood pressure, so we cannot assess this criterion.\n\nBased on the information provided, the patient does not meet the criteria for being American Indian nor is there an indication of the patient having Type 2 DM. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "535": {
        "output": "Based on the patient note, the 46-year-old man presents with untreated dyslipidemia (LDL cholesterol of 545 mg/dL), which meets the trial's requirement for untreated dyslipidemic subjects (LDL cholesterol >110 mg/dl). Additionally, he has documented atherosclerosis in at least one vascular territory, with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery by ultrasonography. This fulfills the criterion of ultrasonographically documented significant extracranial arterial stenosis (\u226750%).\n\nThe patient does not report any acute illness, infection, inflammation, or major systemic diseases, and no laboratory values indicative of T-Bil or Creatinine above exclusion thresholds are provided. Therefore, the patient does not meet any of the exclusion criteria listed.\n\nHence, the patient appears to meet the inclusion criteria for the clinical trial and none of the exclusion criteria are met based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "536": {
        "output": "Given the patient note and the clinical trial information provided, let's evaluate the patient's eligibility step by step:\n\nPatient Note:\n- A 46-year-old man with dizziness and frequent headaches.\n- Family history of CAD, but no other cardiovascular risk factors.\n- LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- Fasting glucose and triglyceride levels within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical Trial Inclusion Criteria:\n- Male or non-pregnant female > 18 years of age.\n- Stenosis in the common or internal carotid artery of at least 70%.\n- Considered a relatively high risk for carotid endarterectomy.\n- Can be either clinically symptomatic or asymptomatic.\n- Other specific conditions related to health status and consent.\n\nMatching Criteria:\n- The patient is a 46-year-old man which satisfies the age and gender criteria (> 18 years of age).\n- The patient has severe stenosis in the left internal carotid artery which likely meets the requirement for at least 70% stenosis.\n- The patient's risk for carotid endarterectomy is not explicitly mentioned, but given his severe stenosis, he may be a candidate for this trial, although this would need to be determined and documented by two physicians.\n- The patient has not been described as having experienced recent TIAs or strokes, so we do not have information on symptomatic status related to the carotid artery.\n- There is no information on the patient's anesthetic risk or other high-risk considerations.\n- The patient's consent to participate and a negative pregnancy test for females (not applicable here) are procedural and would be obtained if the patient is otherwise eligible.\n\nBased on the provided information, the patient appears to satisfy most of the inclusion criteria but the lack of some specific information regarding his risk for carotid endarterectomy and symptomatic status related to the carotid artery, which are important factors for trial inclusion, suggests that we cannot definitively determine his eligibility. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "537": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No history of smoking, hypertension, or diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL\n- Triglycerides: 158 mg/dL\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Systolic murmur heard on neck auscultation\n- No mention of TIAs or strokes\n\nClinical trial inclusion criteria:\n- Patient must be > 18 years of age. (The patient is 46 years old, which meets this criterion.)\n- Must be clinically symptomatic with either TIAs or completed strokes in the previous 120 days. (The patient note does not mention TIAs or completed strokes.)\n- Must have documented stenosis > 60% for symptomatic patients or > 70% for asymptomatic patients. (The patient has severe stenosis in the LICA, which would likely meet the > 70% stenosis requirement for asymptomatic patients.)\n- An angiogram is required, and an ultrasound must be performed less than 30 days prior to study entry. (The patient has had an ultrasound, but it is unclear if it was within 30 days and there is no mention of an angiogram.)\n- The stenosis must be of presumed atherosclerotic origin or secondary to restenosis after previous endarterectomy. (The patient's stenosis is described as atherosclerotic in origin.)\n- Must be possible to provide temporary cardiac pacing if necessary. (There is no information given about this.)\n- Patients taking warfarin may be included under certain conditions. (There is no mention of warfarin use by the patient.)\n- Female patients of childbearing potential must have a negative pregnancy test. (This is not applicable since the patient is a man.)\n- The patient or legally authorized representative must sign a written informed consent. (This is a procedural requirement, so we'll assume it can be met if all other criteria are satisfied.)\n\nBased on the available information, the patient is over 18 years old and has significant carotid artery disease, which could potentially qualify them for the study. However, the trial specifically requires patients to have had TIAs or completed strokes, which is not mentioned in the patient's history. Also, the requirement for an angiogram and the timing of the ultrasound are not clearly met based on the information provided.\n\nTherefore, the patient does not meet all the necessary inclusion criteria based on the information provided. The main disqualifying factor is the lack of documented TIAs or strokes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "538": {
        "output": "Let's evaluate the patient's eligibility for the ACCULINK for Revascularization of Carotids in High Risk Patients (The ARCHeR Trial) based on the provided information:\n\n**Patient Information:**\n- Age: 46-year-old man\n- Symptoms: Dizziness, frequent headaches\n- Family history: CAD (no other cardiovascular risk factors mentioned)\n- LDL-C and HDL-C levels: 545 and 53 mg/dL, respectively\n- Fasting glucose and triglyceride levels: 85 and 158 mg/dL, respectively (within normal limits)\n- No use of lipid-lowering medications\n- Carotid artery stenosis: Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of childbearing potential (irrelevant as the patient is male)\n- No information on the patient's consent or willingness to return for follow-up\n\n**Clinical Trial Inclusion Criteria:**\n1. Patient age >=18. \u2705 (Patient is 46)\n2. Symptomatic patient: TIA, amaurosis fugax, or minor stroke within 180 days of enrollment; or asymptomatic patient meets angiographic and clinical inclusion criteria. \u2753 (Patient has dizziness and headaches, but no specific mention of TIA, amaurosis fugax, or stroke)\n3. No childbearing potential or a negative pregnancy test within 30 days of study procedure. \u2705 (Patient is male)\n4. Patient or legal representative agrees to study follow-up contacts. \u2753 (No information)\n5. Patient or legal representative has provided written informed consent. \u2753 (No information)\n6. Patient meets two or more of the criteria listed in a-e OR one or more of the criteria listed in f-q. \u2753 (No specific information provided regarding these criteria)\n   - Knowledge of two or more diseased coronary arteries, unstable angina, MI, concurrent surgical requirements, contralateral occlusion, etc. \u2753 (No information)\n7. Anatomic Inclusion Criteria: ICA lesion, carotid stenosis >= 50% symptomatic or >= 80% asymptomatic, target ICA vessel reference diameter. \u2705 (Patient has severe stenosis in LICA and moderate stenosis in RICA)\n\nBased on the patient's information and the clinical trial inclusion criteria, there is insufficient information to determine whether the patient meets the symptomatic requirements or the additional criteria listed in 6a-e or 6f-q. The patient does meet the age requirement, and the angiographic criteria for carotid stenosis are satisfied. However, without more information on the patient's symptoms being directly related to TIA, amaurosis fugax, or minor stroke, and without confirmation of the patient's consent and willingness to comply with the study follow-up, we cannot definitively include the patient in the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "539": {
        "output": "To assess the patient's eligibility for the \"Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS),\" we need to review the patient's information against the trial's inclusion criteria. Here are the relevant points from the patient's note and the inclusion criteria:\n\nPatient Note:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- LDL-C level: 545 mg/dL and HDL-C level: 53 mg/dL.\n- Fasting glucose and triglyceride levels are within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery (LICA), and moderate stenosis in the right internal carotid artery (RICA).\n- LICA PSV: 208.5 cm/s and LICA EDV: 54.5 cm/s.\n- RICA PSV: 91.72 cm/s and RICA EDV: 37.37 cm/s.\n\nInclusion Criteria for CASES-PMS:\n1. The patient must be > 18 years of age. (Patient is 46 years old, meets this criterion)\n2. The patient has a 50% stenosis of the common or internal carotid artery and is clinically symptomatic; or the patient must have a >80% diameter stenosis of the internal or common carotid artery without neurological symptoms. (Patient has severe stenosis in LICA and moderate stenosis in RICA; however, the patient's symptomatic status is not clear regarding TIA or stroke)\n3. The patient must have one or more of the specified conditions. (No information provided about these conditions)\n4. The qualifying ultrasound or angiogram was performed less than 30 days prior to study entry. (No information regarding the timing of the ultrasound)\n5. The target vessel is in the native common or internal carotid artery, with a diameter between 4 mm and 9 mm. (No information provided about the vessel diameter)\n\nThe patient's note lacks specific details regarding the symptomatic status related to TIA or completed stroke, as well as the timing of the ultrasound and the detailed measurements of the carotid artery that are required by the inclusion criteria. In addition, there is no information provided about any of the specified conditions mentioned in the inclusion criteria.\n\nGiven these gaps, we do not have sufficient information to qualify the patient for the trial based on the information provided. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "540": {
        "output": "The patient is a 46-year-old man presenting with dizziness and frequent headaches. Based on the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\n1. The patient must be > 18 years of age.\n   - The patient is 46 years old, which meets this criterion.\n\n2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:\n   - one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or\n   - one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery.\n   \n   OR\n   \n   The patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms.\n\n   - The patient note reveals severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. This suggests that the patient has a significant carotid artery disease. However, there is no specific mention of transient ischemic attacks (TIAs), strokes, or other neurologic symptoms related to carotid artery disease within the previous 180 days.\n\n3. To be entered into the study, the patient must have one or more of the following conditions:\n   - congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%\n   - open heart surgery within six weeks\n   - recent MI (>24 hours and <4 weeks)\n   - unstable angina (CCS class III/IV)\n   - synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization\n   - Age greater than 80 years as a single risk factor.\n\n   - The patient's note does not indicate any of the listed cardiac conditions or surgeries. The patient is not over 80 years old.\n\nBased on the information provided in the patient note, there is insufficient evidence to confirm that the patient has experienced symptoms that would classify them as clinically symptomatic according to the trial's inclusion criteria. Therefore, the patient does not have sufficient information to qualify for the trial based on the given criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "541": {
        "output": "The patient in the note presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient's left internal carotid artery stenosis is severe, as indicated by peak-systolic and end-diastolic velocity measurements, which are above the normal thresholds. However, the inclusion criteria for the clinical trial specifically require coronary artery stenosis greater than 50% and either carotid or brain artery stenosis greater than 50%.\n\nThe patient note does not mention the presence of coronary artery disease or stenosis, only that the patient has a family history of CAD. There is no indication that the patient's coronary arteries are stenosed above the 50% threshold required by the clinical trial's inclusion criteria. Therefore, since there is not enough information to determine if the patient has the required coronary artery stenosis, the patient does not clearly meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "542": {
        "output": "",
        "label": 1
    },
    "543": {
        "output": "Patient note analysis:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Family history of CAD, but no other cardiovascular risk factors.\n- Physically active.\n- LDL-C levels are significantly elevated at 545 mg/dL, which is above the typical threshold for high risk.\n- HDL-C level is 53 mg/dL.\n- Fasting glucose and triglyceride levels are within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical trial analysis:\n- The trial is investigating a drug called SB-480848 in subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent.\n- Inclusion criteria require stable CHD or CHD-risk equivalent, and the patient needs to have been on a stable dose of statin with specific LDL levels or off statin therapy with LDL <160 mg/dL.\n- The patient must also be on a stable dose of at least one oral antiplatelet agent.\n- Several exclusion criteria are listed, including poorly controlled diabetes mellitus, severe heart failure, and recent cardiovascular events, among others.\n\nAssessment:\n- The patient's LDL-C level is well above the required level for inclusion (545 mg/dL compared to the <160 mg/dL criterion), and there is no indication that he is on a stable dose of a statin or any antiplatelet agent.\n- The patient has severe carotid stenosis, which may be considered a CHD-risk equivalent, but this is not explicitly stated, and the patient's stability regarding this condition is not mentioned.\n\nGiven the available information, the patient does not meet the inclusion criteria due to the high LDL-C levels and lack of treatment with statins or antiplatelet agents. Additionally, there is no sufficient information to definitively include the patient based on CHD-risk equivalent status, and there is no mention of the patient's use of lipid-lowering medications or antiplatelet agents. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "544": {
        "output": "To determine the patient's eligibility for the CAPITAL clinical trial, let's compare the patient's characteristics and condition with the inclusion criteria of the trial:\n\nInclusion Criteria for CAPITAL Trial:\n1. >18 years of age\n2. Patient must be:\n   - Symptomatic with lesions >/= to 50% stenosis, or\n   - Asymptomatic with lesions of >/= to 75% stenosis in at least one carotid artery, specific to the internal carotid artery, common carotid artery or bifurcated region; documented through acceptable ultrasound studies, completed within 30 days of recruitment.\n3. For patients with bilateral carotid disease- procedures need to be staged greater than 30 days apart. The lesion that has a greater degree of stenosis will be considered as the index procedure.\n4. Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment.\n5. The patient is able to give informed consent.\n\nPatient's Characteristics:\n- 46-year-old man (meets age criterion)\n- Presents with dizziness and frequent headaches (symptomatic)\n- Severe stenosis in the left internal carotid artery (meets the stenosis criterion for symptomatic patients)\n- No mention of lipid-lowering medications or pregnancy (not relevant to this male patient)\n- No information provided about informed consent, but we can assume the patient is capable unless stated otherwise.\n\nBased on the patient note, the patient is over 18 years old and has symptomatic carotid artery disease with severe stenosis (>50%) in the left internal carotid artery, meeting the trial's stenosis criterion for symptomatic patients. Since the patient is male, the pregnancy test criterion is not applicable. There is no indication that the patient would not be able to give informed consent.\n\nTherefore, the patient appears to be eligible for the CAPITAL clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "545": {
        "output": "Given the information provided in the patient note, the patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as well as high LDL-C levels, but he has not reported any use of lipid-lowering medications. There is no mention of gastrointestinal cancer, oxaliplatin-based chemotherapy, or neurotoxicity, which are critical aspects of the inclusion criteria for the clinical trial provided.\n\nThe clinical trial is specifically for patients who:\n- Have a diagnosis of gastrointestinal cancer.\n- Are receiving or planning to receive 8 months of oxaliplatin-based chemotherapy.\n- Do not have pre-existing neuropathy.\n- Do not have CNS disease or cerebral metastases.\n- Have a WHO performance status of 0-1.\n- Have an expected life expectancy of at least 12 weeks.\n- Do not have other exclusionary conditions such as biliary or gastro-duodenal obstruction or conditions that would preclude study treatment.\n\nSince the patient does not have a diagnosis of gastrointestinal cancer and is not receiving or planning to receive oxaliplatin-based chemotherapy, he does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "546": {
        "output": "",
        "label": 1
    },
    "547": {
        "output": "",
        "label": 0
    },
    "548": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Carotid Atherosclerosis Regression at Magnetic Resonance Assessment,\" let's assess the patient's eligibility:\n\n1. The patient's age is 46 years old, which meets the trial's age criterion of being over 18 and under 90 years of age.\n2. The patient has the capacity for giving written informed consent (this is assumed as there is no information suggesting otherwise).\n3. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which meets the trial's criterion of carotid stenosis of > 30% by ultrasound criteria.\n4. The patient's LDL cholesterol level is 545 mg/dl, which is above the trial's required level of > 100mg/dl.\n5. The patient's systolic and diastolic blood pressure levels are not mentioned, but there is no indication that they are above the trial's cutoffs of systolic BP < 170 and diastolic BP < 100 under resting conditions.\n6. The patient is male, so the negative pregnancy test criterion is not applicable.\n\nSince the patient meets all applicable inclusion criteria and there is no information suggesting the patient meets any exclusion criteria, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "549": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we must compare the patient's information to the inclusion criteria of the clinical trial titled \"Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients.\"\n\nPatient's Profile:\n- 46-year-old man\n- LDL-C level of 545 mg/dL (exceeding the NCEP goals)\n- HDL-C level of 53 mg/dL\n- Fasting glucose level of 85 mg/dL (within normal limits)\n- Triglyceride level of 158 mg/dL (within specified range of 100 to 500 mg/dL)\n- No use of lipid-lowering medications\n- Normal thyroid function tests are not mentioned\n- No mention of being on a stable lipid modification pharmacotherapy for at least 2 weeks prior to study entry\n- The ability to give informed consent can be assumed if not stated otherwise\n\nClinical Trial Inclusion Criteria:\n- Male or female \u226518 years of age\n- LDL-C level greater than the NCEP goals (the patient has an LDL-C of 545 mg/dL)\n- Baseline lipid criteria: LDL-C = 100 to 160 mg/dL and triglyceride level = 100 to 500 mg/dL (the patient's LDL-C exceeds this range, and their triglyceride level is within this range)\n- Normal thyroid function tests required (not mentioned in the patient's profile)\n- Hemoglobin A1C < 8.5% (not mentioned in the patient's profile)\n- On stable lipid modification pharmacotherapy for at least 2 weeks prior to study entry (the patient reported no use of lipid-lowering medications)\n- Able to give informed consent\n\nBased on the information provided in the patient note, the patient's LDL-C level exceeds the inclusion criteria range for the study, and there is no mention of normal thyroid function tests or Hemoglobin A1C levels. Additionally, the patient is not on any lipid-lowering medication, which is a requirement for the study.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial because the LDL-C level is too high, and there is no evidence of being on a stable lipid modification pharmacotherapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "550": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nThe patient is a 46-year-old man who presents with dizziness and frequent headaches. He has elevated LDL-C levels (545 mg/dL) and no reported use of lipid-lowering medications, which suggests he may be eligible for statin therapy. Additionally, ultrasonography of his carotid arteries revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with plaque observed in the internal carotid and common carotid arteries.\n\nThe clinical trial is evaluating the effect of atorvastatin treatment on carotid plaque morphology. The inclusion criteria for the trial are subjects with measurable carotid plaque with lipid who are eligible for statin therapy.\n\nThe patient's condition matches the inclusion criteria since he has measurable carotid plaque with lipid and has not been on lipid-lowering medications, indicating he is eligible for statin therapy.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial. Assuming there are no exclusion criteria provided in the trial that would disqualify the patient, the patient would be eligible to participate.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "551": {
        "output": "To assess the eligibility of the patient for the clinical trial \"Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nHere's what we know about the patient:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose and triglycerides within normal limits\n- Not using lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Systolic murmur in the neck\n\nInclusion criteria for the trial:\n- 18 to 85 years of age\n- Symptomatic ischemic heart disease (various classes or objective evidence of myocardial ischemia)\n- Treatment of 1 or 2 de novo lesions\n- Target lesion(s) in a native coronary artery, which can be covered by one single stent of maximum 33 mm\n- Lesion \u226427 mm in length and covered by one single Genous Bio-engineered R stentTM\n- Reference vessel diameter \u2265 2.5 and \u2264 3.75 mm by visual estimate\n- Acceptable candidate for coronary artery bypass surgery (CABG)\n- Target lesion stenosis is \u226550% and <100%\n- Willing to comply with follow-up evaluation\n- Informed consent provided\n\nBased on the information provided, the patient does show evidence of significant cardiovascular disease through the presence of severe stenosis in the left internal carotid artery. However, the study specifically mentions \"symptomatic ischemic heart disease\" and treatment of \"de novo lesions\" in a \"native coronary artery,\" and the patient's condition seems to involve the carotid artery, not the coronary artery.\n\nSince the patient's condition does not clearly match the criteria related to ischemic heart disease and lesions in the coronary artery, and there is no mention of symptomatic ischemic heart disease or that he has de novo lesions in a coronary artery, we cannot establish that he is eligible based on the information provided. There is insufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "552": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided information:\n\nPatient's characteristics:\n- 46-year-old man with dizziness and frequent headaches.\n- Family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. Physically active.\n- LDL-C level of 545 mg/dL, which is high.\n- HDL-C level of 53 mg/dL.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical trial inclusion criteria:\n- Any adult patient with carotid artery disease or known atherosclerosis capable of giving informed consent.\n\nThe patient in question has severe carotid artery stenosis, which is a form of atherosclerosis. The patient is also an adult and there is no indication that he is incapable of giving informed consent. Therefore, he meets the basic inclusion criteria for the clinical trial.\n\nClinical trial exclusion criteria:\n- Unable to give consent\n- History of chronic infections, vasculitis, or any other inflammatory disease\n- History of neoplastic disease or chemotherapy treatment\n- Immunosuppressive medications other than common over-the-counter drugs\n- For medication-treated subjects: abnormal liver and renal function tests on pretreatment screening or currently taking a statin or ACE inhibitor medication.\n- For normal bronchoscopy subjects: any exclusion criteria listed in Protocol 99-H-0068.\n\nThe patient note does not mention any of the exclusion criteria such as chronic infections, vasculitis, neoplastic disease, chemotherapy treatment, or the use of immunosuppressive medications. Moreover, the patient is not described as taking statin or ACE inhibitor medications, and there is no information on liver and renal function tests to suggest exclusion under those grounds.\n\nBased on the available information, the patient appears to meet the inclusion criteria and none of the exclusion criteria are mentioned as being applicable. Therefore, the patient seems to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "553": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Pioglitazone for PrEvention of Restenosis in Diabetic Patients,\" we must compare the patient's characteristics and medical history to the trial's inclusion and exclusion criteria.\n\nPatient Characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physical activity\n- High LDL-C levels (545 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with type 2 diabetes with documented treatment (insulin, oral hypoglycemics, or diet controlled)\n- Diagnosis of angina pectoris (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR documented silent ischemia\n- De novo coronary lesion eligible for coronary revascularization\n- Target lesion is \u22652.5 mm to \u22643.5mm in diameter\n- Target lesion stenosis is \u226550%\n- Male or Female age >18 years old\n- Lesions to be treated with a sirolimus eluting stent\n- Written informed consent\n- At least one lesion must be a complex lesion\n\nClinical Trial Exclusion Criteria:\n- Under 18 years old\n- ST-segment elevation myocardial infarction within the preceding 30 days\n- Active liver disease\n- Impaired renal function\n- Previous brachytherapy of target vessel\n- Lesion of the Left Main trunk > 50%\n- Lesion is in a graft\n- Lesion due to restenosis\n- Recipient of heart transplant\n- Women who are pregnant\n- Life expectancy of less than one year\n- Bleeding diathesis\n- Intolerance/contraindication to Aspirin, Ticlopidine/Clopidogrel, or pioglitazone\n- Currently participating in another study\n- Leukopenia\n- Neutropenia\n- Documented peptic ulcer or gastric/intestinal bleeding in the last 6 months\n- Thrombocytopenia\n\nAssessment:\nThe patient does not have documented type 2 diabetes, which is a requirement for inclusion in the trial. Therefore, the patient does not meet the primary inclusion criteria for the trial.\n\nBased on the information provided in the patient note, there is no indication that the patient has been diagnosed with type 2 diabetes or is currently being treated for it. Additionally, the patient's cardiovascular condition pertains to carotid artery stenosis rather than coronary lesion, which is the focus of the clinical trial.\n\nTherefore, the patient is not eligible for the trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "554": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis,\" we need to assess whether the patient meets the inclusion criteria based on the provided patient note.\n\nInclusion Criteria for the trial:\n- Male and female subjects, \u2265 30 years old\n- Known atherosclerotic coronary or vascular disease OR coronary risk equivalents defined as either:\n    - diabetes mellitus,\n    - multiple coronary risk factors with a Framingham Risk Score > 2% per year, or\n    - an elevated coronary calcium score (> 400 for men, > 200 for women)\n- Currently being treated with a statin (Simvastatin 20 mg/d or its equivalent) as monotherapy for treatment of hyperlipidemia\n- Recent lipids showing both: LDL-C < 100 mg/dL and HDL-C < 50 mg/dL (men) or < 55 mg/dL (women)\n\nPatient Note Assessment:\n- The patient is a 46-year-old man, which meets the age requirement.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which indicates atherosclerotic vascular disease.\n- The patient's LDL-C level is 545 mg/dL, which is above the required < 100 mg/dL.\n- The patient's HDL-C level is 53 mg/dL, which is above the required < 50 mg/dL for men.\n- The patient reported no use of lipid-lowering medications, which means he is not currently being treated with a statin.\n\nBased on the patient note, the patient does not meet the criteria regarding LDL-C levels, HDL-C levels, and current statin treatment. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "555": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the ViVEXX Carotid Revascularization Trial (VIVA), we can determine the patient's eligibility as follows:\n\nThe patient is a 46-year-old man who presents with dizziness and frequent headaches, which could be symptoms related to carotid artery stenosis. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery as determined by ultrasonography. The patient's LDL-C levels are significantly elevated, and he has a family history of CAD. However, there is no mention of the patient having had a non-disabling stroke, transient ischemic attack (TIA), or neurological symptoms directly attributed to the carotid stenosis.\n\nThe inclusion criteria for the trial state that a patient must have either:\n1. Symptomatic >50% carotid stenosis by angiography and a history of non-disabling stroke or TIA in the hemisphere supplied by the target vessel within 180 days of the procedure.\n2. Asymptomatic >80% carotid stenosis by angiography without neurological symptoms.\n\nThe patient note does not provide information about a history of stroke or TIA, nor does it specify the exact percentage of stenosis by angiography, which is the method of measurement specified in the inclusion criteria. The ultrasonography results indicate severe stenosis, which could potentially meet the trial's requirement for asymptomatic stenosis if it is indeed greater than 80%, but this is not confirmed with the appropriate method (angiography).\n\nGiven this information, the patient cannot be confidently classified as eligible since we lack information about the percentage of stenosis determined by angiography and a history of stroke or TIA. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "556": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man with dizziness, headaches, and a family history of coronary artery disease (CAD). He is physically active, with high LDL-C levels but no mention of diabetes mellitus or use of lipid-lowering medications. He has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial in question is seeking to enroll patients with type 2 diabetes mellitus, aged between 50 and 75 years, with a duration of diabetes of more than 5 years, and who have more than two of the following risk factors in addition to diabetes: dyslipidemia, hypertension, smoking, family history of premature coronary artery disease.\n\nThe patient does not meet the inclusion criteria for the clinical trial because:\n\n1. The patient does not have a diagnosis of type 2 diabetes mellitus.\n2. The patient's age is below the specified range (46 years old vs. the required 50-75 years).\n3. There is no information suggesting that the patient has had diabetes for more than 5 years (in fact, diabetes is not mentioned at all).\n4. Although the patient has dyslipidemia and a family history of CAD, it is not clear if this qualifies as a family history of premature coronary artery disease, and even if it did, without the diabetes diagnosis, the patient still would not qualify.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "557": {
        "output": "",
        "label": 2
    },
    "558": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Prevention of Diabetes and Hypertension,\" we must match the patient's characteristics and medical profile against the trial's inclusion criteria.\n\nThe inclusion criteria are as follows:\n1. Men or women of any racial background\n2. Age >= 40 years and <= 75 years\n3. SBP >= 130 mmHg and < 140 mmHg or DBP >= 85 mmHg and < 90 mmHg, average of screening and randomisation visits (in absence of any antihypertensive medication)\n4. FG >=100 mg/dl (5.6 mmol/l) and < 126 mg/dl (7.0 mmol/l) between screening and randomisation (in absence of any antidiabetic medication)\n5. Waist circumference >= 102 cm in men and >= 88 cm in women.\n\nNow let's evaluate the patient's information against these criteria:\n\n1. The patient is a 46-year-old man, which satisfies the age criterion (40-75 years).\n2. There is no information on the patient's blood pressure, so we cannot assess if the patient meets the blood pressure criteria.\n3. The patient's fasting glucose level is 85 mg/dl, which is within the required range of >=100 mg/dl and < 126 mg/dl.\n4. There is no information provided on the patient's waist circumference.\n\nThe patient's LDL-C level is extremely high at 545 mg/dL, which is indicative of a possible lipid disorder, but this is not relevant to the inclusion criteria. The patient also has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, these conditions are not part of the inclusion or exclusion criteria for this trial.\n\nDespite the patient's fasting glucose level falling within the specified range, there is insufficient information to determine if the patient meets all inclusion criteria, specifically the criteria for blood pressure and waist circumference. Furthermore, the patient must not be on any antihypertensive or antidiabetic medication, and no such information is provided.\n\nGiven the available information, we cannot conclusively determine whether the patient is eligible for the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "559": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial titled \"Effect of 5 Years of GH Replacement on Atherosclerosis,\" let's assess the patient's eligibility:\n\nPatient note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- High LDL-C levels (545 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of body mass index (BMI), personal history of cardiovascular diseases, concomitant treatment with drugs that could interfere with metabolic parameters, or previous GH treatment\n\nClinical trial inclusion criteria:\n- Male gender \u2713 (patient is male)\n- Age <50 yrs \u2713 (patient is 46 years old)\n- Body mass index <30 Kg/m2 (information not provided in the patient note)\n- No familial or personal history of cardiovascular diseases \u2717 (patient has a family history of CAD, which could be considered under the familial history exclusion)\n- No concomitant treatment with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure at the time of study entry (information not provided in the patient note)\n- No previous GH treatment (information not provided in the patient note)\n\nBased on the information provided in the patient note, we can determine the following:\n- The patient is male and under the age of 50, which meets two inclusion criteria.\n- There is no information about the patient's BMI, treatment with drugs, or previous GH treatment.\n- The patient does have a family history of CAD, which would likely exclude him because the trial specifies \"no familial or personal history of cardiovascular diseases.\"\n\nDue to the family history of CAD, the patient does not meet all the inclusion criteria. Furthermore, there is insufficient information to confirm the patient's eligibility regarding BMI, concomitant treatment, and previous GH treatment.\n\nTherefore, the patient would not be eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "560": {
        "output": "Based on the information provided:\n\nThe patient is a 46-year-old man presenting with dizziness and frequent headaches. He has a family history of CAD, high LDL-C levels, and carotid artery stenosis, but there is no mention of Langerhans-cell histiocytosis (LCH). The clinical trial is specifically looking for patients with a definitive diagnosis of LCH to investigate cardiovascular risk factors and properties in such patients.\n\nSince there is no indication that the patient has LCH, he does not meet the inclusion criteria for the clinical trial, which requires a definitive diagnosis of LCH.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "561": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Stenting Versus Best Medical Treatment of Asymptomatic High-Grade Carotid Artery Stenosis,\" we must match the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient characteristics from the patient note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n- LICA peak-systolic velocity (PSV) and end-diastolic velocity (EDV) are 208.5 cm/s and 54.5 cm/s, respectively\n- RICA PSV and EDV are 91.72 cm/s and 37.37 cm/s, respectively\n- Plaque characterized as bulky plates, predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces\n\nClinical trial inclusion criteria:\n- Atherosclerosis as the underlying disease\n- Patients with an asymptomatic stenosis >80% (NASCET)\n- Documented progression of the degree of stenosis to >80% within 6 months OR\n- Very tight stenosis \u226590% at initial presentation OR\n- >80% stenosis plus silent ipsilateral ischemia documented by CCT or MRI OR\n- Ipsilateral >80% stenosis plus contralateral >80% stenosis or occlusion OR\n- >80% stenosis plus planned major surgery\n- Neurologist's explicit consent to potentially perform CAS\n\nThe patient's note mentions severe stenosis of the LICA, which could be indicative of a stenosis >80%. However, we do not have explicit measurements in NASCET criteria, nor do we have information about the progression of the stenosis within the previous 6 months or any of the other specific conditions listed in the inclusion criteria. Additionally, the patient does present with symptoms (dizziness and frequent headaches), which may exclude him since the trial specifies \"asymptomatic\" patients.\n\nBased on the information provided, there is insufficient evidence to confirm whether the stenosis is asymptomatic and greater than 80% by NASCET criteria, or if other specific conditions listed in the inclusion criteria are met. There is also no mention of neurologist's consent, which is a requirement.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "562": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 46-year-old man\n- No history of smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C level: 545 mg/dL (which far exceeds the trial's upper limit for LDL-C of <189 mg/dL)\n- HDL-C level: 53 mg/dL (which is above the trial's risk factor threshold for men of <40 mg/dL)\n- Family history of CAD (which is considered a risk factor according to the trial)\n- No use of lipid-lowering medications\n- Carotid artery stenosis (not directly relevant to the trial inclusion criteria)\n\nClinical Trial Inclusion Criteria:\n- LDL-c levels between >130 mg/dl and <189 mg/dl\n- Presence of at least 1 cardiovascular risk factor:\n  - Age above 45 years in men and 55 years in women\n  - Smoker\n  - High blood pressure\n  - HDL-c < 40 mg/dl in men and <46 mg/dl in women\n  - Family background of early heart disease\n- Patients who have given informed consent\n- Patients who will be capable of following diet guidelines\n\nEvaluation:\n- The patient is 46 years old, which satisfies the age criterion for men.\n- The patient has a family history of CAD, which satisfies the criterion for a cardiovascular risk factor.\n- The patient does not smoke, does not have high blood pressure, and has an HDL-c level above the risk threshold, which means he does not meet these risk factors, but only one is needed.\n- The patient's LDL-c level is significantly higher than the upper limit set by the trial's inclusion criteria (>130 mg/dl and <189 mg/dl).\n\nConclusion:\nThe patient does not meet the trial's inclusion criteria due to his exceedingly high LDL-c level of 545 mg/dL, which is outside the specified range for the study. Therefore, despite meeting other aspects of the inclusion criteria, this key criterion excludes him.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "563": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man who presents with dizziness and frequent headaches and has been diagnosed with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The velocities measured by ultrasonography corroborate the presence of significant stenosis. \n\nThe clinical trial in question is focused on the observation of patients with cerebrovascular symptoms and their outcomes in relation to the timing of Carotid Endarterectomy (CEA). The inclusion criteria for the trial specify that participants must have carotid stenosis greater than 50% according to NASCET criteria.\n\nGiven that the patient has severe stenosis in the LICA and moderate stenosis in the RICA, and the report includes specific measurements that indicate the severity of the stenosis, it appears that the patient has carotid stenosis greater than 50% at least in the LICA, which would satisfy the inclusion criteria for the trial.\n\nThere is no further information provided about other potential exclusion criteria for the trial. Therefore, based on the information available in the patient note and the inclusion criteria provided for the clinical trial, the patient appears to meet the inclusion criteria and there is no information suggesting he would be excluded based on the trial's exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "564": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Effect of Exercise Training on the Function of the High Density Lipoprotein (HDL)-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Metabolic Syndrome (HERMET-Study),\" we need to compare the patient's characteristics to the inclusion criteria of the trial.\n\nInclusion Criteria for the trial are:\n1. Reduced HDL-Cholesterol levels in blood: < 40 mg/dl in male, < 50 mg/dl in female\n2. Plus two of the following criteria:\n   - Elevated waist circumference: \u2265 102 cm in men or \u2265 88 cm in women\n   - Elevated triglycerides: \u2265 150 mg/dL\n   - Elevated blood pressure: \u2265 130 mmHg systolic or \u2265 80 mmHg diastolic or anti-hypertensive treatment\n   - Elevated fasting glucose: \u2265 100 mg/dL or on drug treatment for elevated fasting glucose\n\nPatient's characteristics from the note:\n- A 46-year-old man (gender matches the male criteria for HDL levels)\n- HDL-C levels: 53 mg/dL (above the threshold for reduced HDL-C levels)\n- Patient reported no use of lipid-lowering medications.\n- No mention of elevated waist circumference, blood pressure, or fasting glucose.\n- Triglyceride levels: 158 mg/dL (meets the elevated triglycerides criterion)\n\nFrom the patient's note, we only have information about the patient's HDL-C levels, which do not meet the criterion for reduced HDL-C levels in the trial (his HDL-C is higher than the threshold). The patient's triglyceride levels meet one of the additional criteria, but we need at least one more to qualify according to the study's requirements. There is no information provided about the patient's waist circumference, blood pressure, or fasting glucose levels. As such, the patient does not meet enough criteria to be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "565": {
        "output": "",
        "label": 1
    },
    "566": {
        "output": "Based on the information provided, the 46-year-old man presents with dizziness, frequent headaches, and a family history of CAD. His LDL-C level is significantly elevated at 545 mg/dL, and he has severe carotid stenosis. However, there is no mention of him being on a low-carbohydrate diet or of his obesity status. The inclusion criteria for the clinical trial require the subject to be moderately obese with hyperlipidemia.\n\nGiven that the patient note does not indicate that the man is following a low-carbohydrate diet or that he is moderately obese, but only mentions hyperlipidemia (elevated LDL-C levels), we do not have sufficient information to determine if he meets the specific criteria for the trial. Therefore, the patient's eligibility for the trial is undetermined based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "567": {
        "output": "Based on the information provided, the 46-year-old man does not meet the inclusion criteria for the clinical trial titled \"Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation.\" The inclusion criteria specifically require individuals who had scalp irradiation during childhood or match controls. There is no indication in the patient's note that he underwent scalp irradiation as a child.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "568": {
        "output": "The patient in the provided note is a 46-year-old man with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. His LDL-C level is 545 mg/dL, and his HDL-C level is 53 mg/dL. The patient has not been using any lipid-lowering medications.\n\nThe clinical trial is investigating the benefit of elevating HDL-C on cardiovascular outcomes in women. The inclusion criteria for the trial specify that participants must be stable women on statin therapy with LDL-C levels between 90-135mg/dl and triglycerides > 150mg/dl.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the trial for several reasons:\n1. The patient is a man, and the trial is specifically for women.\n2. The patient's LDL-C level is 545 mg/dl, which is well above the required range of 90-135mg/dl for the trial.\n3. The patient is not currently on statin therapy, which is a requirement for the trial.\n\nGiven these discrepancies, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "569": {
        "output": "To assess the patient's eligibility for the \"GORE Embolic Protection With Reverse Flow\" clinical trial, we must compare the patient's clinical profile with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n- Carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis \u2265 50% OR asymptomatic status with carotid stenosis \u2265 80%\n- Target lesion is located in one of the following: (a) internal carotid artery (ICA) (b) bifurcation (c) common carotid artery (CCA) proximal to the bifurcation\n- At Anatomic risk for adverse events from CEA (e.g., restenosis after a prior CEA) OR at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)\n\nFrom the patient note, we have the following information:\n- The patient is a 46-year-old man, which satisfies the age criterion (age \u2265 18 years).\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient is symptomatic, as evidenced by dizziness and frequent headaches.\n- The patient's LICA stenosis is not quantified in terms of percentage, but the PSV and EDV values suggest severe stenosis, which could potentially meet the requirement of \u2265 50% stenosis for symptomatic patients.\n- The target lesion is located in the internal carotid artery (ICA), which meets the location requirements.\n- There is no mention of the patient being at anatomic or co-morbid risk for adverse events from carotid endarterectomy (CEA), such as restenosis after a prior CEA or unstable angina with ECG changes.\n\nSince the patient note does not provide the exact percentage of stenosis for LICA but indicates severe stenosis and the patient is symptomatic, it suggests that the patient could potentially meet the criteria for carotid stenosis requiring revascularization with symptomatic status. Furthermore, as the lesions are located in the ICA, this criterion is also met.\n\nHowever, because the note does not provide specific percentages or mention prior CEA or co-morbidities that would put the patient at risk for adverse events from CEA, we cannot definitively determine if all criteria are met. Therefore, the patient's eligibility based on the available information is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "570": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients,\" we must compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nInclusion Criteria:\n1. LDL < 2.5 mmol/L and total cholesterol: HDL-cholesterol ratio < 4.0\n2. Blood pressure \u2264 130/80 mmHg\n3. No personal or family history of CVD\n4. No history of proteinuria or renal failure\n5. Taking atorvastatin (lipitor) with a dosage \u2264 10 mg, equivalent dosages for other statins follow this requirement (Simvastatin \u2264 20 mg, pravastatin \u2264 40 mg, rosuvastatin \u2264 5 mg, fluvastatin \u2264 40 mg and lovastatin \u2264 40 mg)\n6. Calculated by the UKPDS Risk Engine to be low risk (risk is less than 15%) for Coronary Heart Disease (CHD), fatal CHD, stroke and fatal stroke\n\nPatient Note:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- Family history of CAD (coronary artery disease), which is a form of CVD.\n- No other cardiovascular risk factors mentioned, and the patient is physically active.\n- LDL-C level is 545 mg/dL (which is above the desired level for the trial when converted to mmol/L).\n- The patient has not been reported to be on lipid-lowering medications.\n- There is no mention of the patient's blood pressure.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- There is no indication that the patient has type 2 diabetes or that a UKPDS Risk Engine calculation has been performed.\n\nBased on this information:\n\n- The patient's LDL-C is significantly above the acceptable level for the trial. 545 mg/dL converts to approximately 14.1 mmol/L, which is well above the <2.5 mmol/L required.\n- The patient has a family history of CAD, which is considered CVD, thus not meeting the criterion of no personal or family history of CVD.\n- There is no mention of the patient's blood pressure values to assess against the \u2264 130/80 mmHg criterion.\n- The patient is not reported to be taking any statin medication.\n- It is not clear if the patient has been assessed for CHD risk using the UKPDS Risk Engine.\n\nWith these points in consideration, the patient does not meet multiple critical inclusion criteria (specifically regarding LDL levels and family history of CVD). Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "571": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's compare the relevant details:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, diabetes mellitus\n- Physically active\n- High LDL-C levels (545 mg/dL) and normal HDL-C levels (53 mg/dL)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Plaque observed in the carotid arteries\n\nClinical Trial Inclusion Criteria:\n- Men or women\n- >18 years old\n- Expected to have an endarterectomy on each carotid artery\n- No contraindications for atorvastatin\n- Stable cardiovascular health\n- Lipid-lowering treatment less than 6 months duration\n- Diabetics included if diabetes is controlled\n- Patient is not claustrophobic\n- Patient has evaluable carotid plaques\n\nComparison:\n- The patient is a man, which meets the gender criterion.\n- The patient is over 18 years old, which meets the age criterion.\n- The patient has not reported using lipid-lowering medications, which aligns with the criterion of lipid-lowering treatment less than 6 months duration.\n- The patient has severe and moderate stenosis in the carotid arteries and plaque, suggesting that he has evaluable carotid plaques.\n- There is no mention of the patient expecting to have an endarterectomy on each carotid artery. This is a crucial piece of information required to determine eligibility.\n- The patient's cardiovascular health is not explicitly stated as stable, although no acute cardiovascular events are mentioned.\n- There is no information on whether the patient is claustrophobic.\n\nGiven the information available in the patient note, we cannot confirm whether the patient is expected to have an endarterectomy, which is a key inclusion criterion for the trial. Furthermore, the stability of cardiovascular health is not explicitly mentioned. Therefore, based on the information provided, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "572": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396),\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the study.\n\nPatient information:\n- 46-year-old man\n- LDL-C: 545 mg/dL (which is equivalent to 14.1 mmol/L, far exceeding the trial's specified range)\n- HDL-C: 53 mg/dL\n- Triglyceride levels: 158 mg/dL (within the trial's specified range)\n- No use of lipid-lowering medications\n- No documented coronary heart disease (CHD), only carotid stenosis\n\nClinical trial inclusion criteria relevant to the patient:\n- Ages between >=18 years and <=75 years\n- LDL-C concentration between >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL)\n- Triglyceride concentrations of <3.99 mmol/L (350 mg/dL)\n- Documented CHD\n- No current use of an approved statin\n- Not currently taking an approved statin and without statin use for at least 6 months\n- Certain clinical laboratory parameters within specified limits\n\nAssessment:\n- The patient's LDL-C levels are significantly higher than the required range for the trial (14.1 mmol/L vs. the maximum of 4.6 mmol/L specified by the trial).\n- There is no mention of the patient having documented coronary heart disease, which is a requirement for the trial.\n- The patient is not currently taking any statin medications, which aligns with the trial's criteria.\n\nBased on this information, the patient does not meet the LDL-C concentration criterion and does not appear to have documented coronary heart disease. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "573": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches, has a family history of coronary artery disease (CAD), extremely elevated LDL-C levels, and has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient has not reported the use of lipid-lowering medications, which can be indicative of the fact that he is not on chronic ASA (aspirin) therapy, which is an inclusion criterion for the clinical trial.\n\nGiven that the clinical trial's inclusion criteria specifically require patients to be suffering from stable coronary artery disease (CAD) and to be on chronic aspirin therapy, this patient does not appear to meet these criteria. The patient's condition has not been specified as stable CAD, and there is no mention of him being on chronic ASA therapy; in fact, the patient reported no use of lipid-lowering medications, which includes aspirin.\n\nTherefore, this patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "574": {
        "output": "The patient in the note is a 46-year-old man who presents with dizziness, frequent headaches, and has been found to have severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. He has not been reported to use any lipid-lowering medications and is physically active. The clinical trial is looking for subjects with >70% carotid artery stenosis who are scheduled for carotid endarterectomy.\n\nThe patient meets the age criterion of being 18 years or older. The patient has severe stenosis in the left internal carotid artery, which could potentially qualify as >70% stenosis, though this is not directly stated in percentages. However, the patient's eligibility depends on whether he is scheduled for carotid endarterectomy, which is not mentioned in the patient note. Without this information, we cannot conclude that the patient meets all the inclusion criteria. The patient does not mention informed consent but this could be obtained if other criteria are met.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "575": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient note against the inclusion criteria for the trial.\n\nIn the patient note, we have the following information:\n- 46-year-old man (within the age limit of 18 to 65 years old)\n- Presents with dizziness and frequent headaches\n- Family history of CAD, but no smoking, high blood pressure, or diabetes mellitus\n- LDL-C level: 545 mg/dL (14.1 mmol/L; conversion factor: 1 mg/dL = 0.0259 mmol/L)\n- HDL-C level: 53 mg/dL (1.37 mmol/L)\n- Triglyceride level: 158 mg/dL (1.78 mmol/L)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n\nThe inclusion criteria for the clinical trial are:\n- Patients with Type II hyperlipidaemia\n- HDL-C < 1.6 mmol/L\n- TG < 4.5 mmol/L\n- Male and females between 18 and 65 years old\n- For females: post-menopausal, surgically sterile, or using an acceptable form of contraception\n\nComparing the criteria:\n- The patient is a 46-year-old man, which fits within the 18 to 65 years age range.\n- The patient's HDL-C level is 1.37 mmol/L, which is below the inclusion requirement of 1.6 mmol/L.\n- The patient's triglyceride level is 1.78 mmol/L, which is below the inclusion requirement of 4.5 mmol/L.\n- Gender criteria are met, as the patient is male.\n- The patient has high LDL-C, which suggests hyperlipidaemia, and the trial is for patients with Type II hyperlipidaemia.\n\nBased on the information provided and the inclusion criteria of the clinical trial, the patient appears to meet all the necessary criteria for the trial. However, the trial specifically mentions \"mild dyslipidaemia,\" and the patient has a very high LDL-C level, which might indicate a more severe form of hyperlipidaemia. The trial's summary does not provide a clear definition of \"mild dyslipidaemia,\" which could be a determining factor for eligibility. Given the information available, the patient seems to have the type of lipid disorder the trial is targeting, so I would assess the patient's eligibility as follows:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "576": {
        "output": "In reviewing the patient note and the clinical trial inclusion criteria:\n\nPatient characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No smoking, no high blood pressure, no diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL (high)\n- HDL-C: 53 mg/dL (normal)\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nClinical trial inclusion criteria:\n- Male subject aged 45 years or above\n- At least another risk factor for CVD: cigarette smoking, hypertension, low HDL cholesterol or high LDL cholesterol, family history of premature coronary heart disease, elevated waist circumference\n- Willingness to participate in the survey and complying with the study by signing a written informed consent\n\nThe patient is a 46-year-old man, which meets the age criterion. The patient has a high LDL cholesterol level, which is a risk factor for CVD, and a family history of premature coronary heart disease. These details align with the inclusion criteria for the clinical trial. The patient would need to express willingness to participate and sign a written informed consent to be fully eligible. However, there is no information about the patient's willingness or consent in the patient note provided. Therefore, assuming the patient is willing and consents to participate, he would meet the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "577": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\n- The patient is a 46-year-old man, which meets the age requirement of \u2265 18 years.\n- He presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which aligns with the inclusion criterion of carotid artery disease with greater than 15% stenosis by ultrasound.\n- The patient has a family history of cardiovascular disease (CAD), meeting another inclusion criterion.\n- The patient's LDL-C level is reported as 545 mg/dL. While this is significantly above the specified range of 100-190 mg/dL without medication, the criteria only state that the LDL level should be within this range without medication. It does not explicitly exclude patients with higher levels.\n- The patient has not been using lipid-lowering medications, which complies with the criterion of having been undergoing lipid therapy for no more than 12 months before study entry since he has not started such therapy.\n- There is no information provided about the patient's Apolipoprotein B level or whether they are medically stable or able to undergo an MRI procedure.\n\nGiven the available information, the patient meets several of the inclusion criteria: age, carotid artery disease, and family history of cardiovascular disease. However, due to the lack of information on the patient's Apolipoprotein B level, his medical stability, and his ability to undergo MRI, we cannot definitively determine his eligibility.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "578": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial.\n\nPatient note assessment:\n- The patient is a 46-year-old man, which meets the age criterion for most adult clinical trials.\n- The patient presents with dizziness and frequent headaches.\n- There is no mention of hip and/or groin pain, which is one of the inclusion criteria.\n- The patient is physically active, which aligns with the inclusion criteria of being physically active.\n- The main medical issues in the patient note pertain to high LDL cholesterol and carotid artery stenosis, not hip or groin pain.\n\nClinical trial inclusion criteria:\n- Hip and/or groin pain more than 6 weeks\n- Physically active\n\nThe patient note does not mention that the patient has hip and/or groin pain, which is a specific requirement for the clinical trial in question. Even though the patient is physically active, the absence of documented hip and/or groin pain means the patient does not meet the necessary inclusion criteria for the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "579": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nThe patient is a 46-year-old man with the following relevant medical information:\n\n- Presents with dizziness and frequent headaches.\n- Family history of CAD.\n- No other cardiovascular risk factors such as smoking, high blood pressure, or diabetes mellitus.\n- Physically active.\n- LDL-C level of 545 mg/dL (which is high).\n- HDL-C level of 53 mg/dL.\n- Fasting glucose and triglyceride levels within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe inclusion criteria for the clinical trial are one or more of the following:\n\n- Familiar History of early-onset cardiovascular disease (male < 55 or female < 65).\n- Type 2 Diabetes mellitus or type 1 with microalbuminuria.\n- Essential High Blood Pressure.\n- Chronic Kidney Disease.\n- Primary hyperlipidemia.\n\nThe patient meets one of the inclusion criteria through the family history of early-onset cardiovascular disease (CAD in a male < 55). Furthermore, the presence of severe stenosis and high LDL-C levels could be indicative of primary hyperlipidemia, which is another inclusion criterion.\n\nThe trial also includes patients with two or more of the following risk factors:\n\n- Current smoker.\n- Physical inactivity.\n- High blood pressure (recently diagnosed).\n- Abdominal perimeter: > 102 cm. males; > 88 cm. females.\n- Total cholesterol > 240 mg/dL.\n- HDL cholesterol \u2264 40 mg/dL males, \u2264 50 mg/dL females.\n\nThe patient has a total cholesterol level of > 240 mg/dL, which is another risk factor. However, since the patient's HDL-C is 53 mg/dL, this particular criterion is not met. The patient does not appear to have other risk factors listed as they are physically active and have no high blood pressure or diabetes.\n\nGiven this information, the patient meets the inclusion criteria for the trial through a family history of early-onset cardiovascular disease and likely primary hyperlipidemia due to high LDL-C levels. The patient does not seem to meet any exclusion criteria based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "580": {
        "output": "Based on the information provided, the patient is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient has not used lipid-lowering medications and has a family history of coronary artery disease (CAD).\n\nThe clinical trial in question is assessing cerebral ischemia during carotid endarterectomy (CEA) using EEG, cerebral oximetry, and arterial to jugular venous lactate concentration differences. The inclusion criteria for the trial are simple: all adult patients undergoing carotid endarterectomy will be approached in the Pre-Anesthetic Clinic.\n\nSince the patient note does not specify that the patient is undergoing carotid endarterectomy, we cannot confirm if they meet the inclusion criteria for this trial. The patient has severe and moderate stenosis in the carotid arteries, which could potentially make him a candidate for CEA, but this is not explicitly stated. Therefore, based on the available information, we do not have sufficient evidence to determine if the patient is scheduled for a carotid endarterectomy and therefore cannot confirm his eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "581": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Proximal Protection With The Mo.Ma Device During Carotid Stenting,\" we need to compare the patient note with the inclusion and exclusion criteria provided in the trial summary.\n\nPatient Note:\n- 46-year-old man (meets the age criterion of \u2265 18 years)\n- Presents with dizziness and frequent headaches (potentially symptomatic carotid stenosis but not clearly stated)\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery (relevant to the trial target lesion criteria)\n- No use of lipid-lowering medications (not directly relevant to trial criteria)\n- Not pregnant or at risk of becoming pregnant (meets criteria if female, not applicable to this male patient)\n\nClinical Trial Inclusion Criteria:\n- Subject is \u2265 18 years old (patient meets this criterion)\n- Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach (patient appears to be a candidate based on carotid artery stenosis)\n- Subject is willing and able to comply with follow-up evaluations at the specified times (no information provided)\n- Subject (or legal representative) understands the nature of the procedure and provides informed consent, prior to enrollment in the study (no information provided)\n- If female subject, is not currently pregnant (not applicable)\n- Angiographic inclusion criteria relevant to the patient: \u2265 50% stenosis for symptomatic subjects (patient has severe and moderate stenosis in the carotid arteries)\n\nClinical Trial Exclusion Criteria:\n- The patient note does not mention any of the factors that would exclude the patient, such as participation in another clinical study, atrial fibrillation, prior stenting, life expectancy less than twelve months, inability to respond to external questions and stimuli, documented allergies to the device materials or drugs mentioned, recent history of bleeding, stroke, TIA, abnormal blood counts, severe chronic renal failure, or peripheral vascular disease that precludes safe femoral artery sheath insertion.\n- However, due to the lack of detail in the patient note, it is unclear whether any of these exclusion conditions apply.\n\nGiven the information provided, the patient meets the age criterion and has carotid artery stenosis, which is relevant to the trial. However, there is no clear indication that the patient has experienced symptoms related to the carotid stenosis within the last 6 months (e.g., amaurosis fugax, ipsilateral hemispheric TIAs, or ipsilateral ischemic stroke), which is part of the inclusion criteria for symptomatic patients.\n\nBased on the available information, we cannot definitively determine if the patient is symptomatic as defined by the trial criteria. Therefore, we must classify the trial-level eligibility based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "582": {
        "output": "Assessing the patient note against the clinical trial inclusion and exclusion criteria:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, diabetes mellitus; physically active\n- Abnormal lipid levels (LDL-C: 545 mg/dL, HDL-C: 53 mg/dL)\n- No use of lipid-lowering medications\n- Systolic murmur in the neck\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of coronary artery disease, LVEF, or having undergone percutaneous coronary intervention (PCI)\n\nClinical Trial Inclusion Criteria:\n- Patient is \u2265 18 years of age (met)\n- Patient with coronary artery disease, eligible for PCI (not met, no evidence in the note)\n- Patient demonstrates a LVEF of \u2265 25% (not met, no information provided)\n- Written informed consent (not applicable for assessment)\n- Target lesion is de novo native coronary artery lesion (not met, no evidence in the note)\n- Lesion treatable with one stent (not applicable, as no CAD mentioned)\n- Lesion length and vessel diameter specifications (not applicable, as no CAD mentioned)\n- Lesion stenosis specifications and pre-dilated (not applicable, as no CAD mentioned)\n\nClinical Trial Exclusion Criteria:\n- Life expectancy, hypersensitivity, cardiogenic shock, renal dysfunction, surgery, myocardial infarction, ST segment elevation MI, CVA/TIA, blood disorders, medication contraindications, chemotherapeutic agents, drug eluting stent history, intravascular brachytherapy, allergies, reproductive intentions, pregnancy, angiographic exclusions (none of these are explicitly mentioned or met in the patient note)\n\nThe provided patient note does not mention coronary artery disease, left ventricular ejection fraction (LVEF), or any previous percutaneous coronary intervention (PCI), which are necessary to meet the inclusion criteria for the clinical trial. The patient has carotid artery disease, not coronary artery disease, which is not relevant to the trial. Therefore, the patient does not meet the inclusion criteria for the JACTAX LD Drug Eluting Stent Trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "583": {
        "output": "",
        "label": 1
    },
    "584": {
        "output": "Based on the patient note provided, the 46-year-old man presents with cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His condition does not match the target patient population for the clinical trial, which is looking for patients with advanced refractory malignancies.\n\nThe patient does not have a history or diagnosis of a solid malignant tumor or malignant lymphoma, nor is there any indication that he has a condition that is refractory to currently available treatment or for which no standard treatment exists. Furthermore, there is no mention of any malignancy-related treatment that the patient has undergone, such as chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy, or surgery, which would be necessary to meet the inclusion criteria of the clinical trial.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "585": {
        "output": "Based on the patient note provided, the 46-year-old man does not have an intracranial aneurysm; rather, he has carotid artery stenosis. The clinical trial in question is specifically looking for participants with uncoilable or failed wide-necked intracranial aneurysms. Since the patient's condition does not match the target condition for the trial, he does not meet the inclusion criteria for this particular study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "586": {
        "output": "Based on the patient note provided, the 46-year-old man presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, dizziness, and frequent headaches. There is no mention of him having multi-vessel coronary heart disease or requiring on-pump saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery, which is a key requirement for the clinical trial in question.\n\nThe inclusion criteria for the eSVS\u2122 Mesh External Saphenous Vein Support Trial specifically require that participants:\n- Require on-pump SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic coronary artery disease, with \u2265 75% stenosis in each of these vessels\n- Have appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and a lack of calcification at the anastomotic site\n- Are able to give their informed written consent\n- Are \u2265 21 years of age\n\nThe provided patient note does not indicate that the patient has coronary artery disease or requires CABG surgery, which are the primary conditions for inclusion in the trial. Therefore, the patient does not meet the inclusion criteria based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "587": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Systolic murmur heard in the neck\n- Normal fasting glucose and triglyceride levels\n- High LDL-C level\n\nClinical trial inclusion criteria:\n- First time appointment for a patient at designated optometry office for treatment of symptoms associated with Vertical Heterophoria\n- Must have symptoms of dizziness or headache or both\n- Duration of symptoms greater than 4 months\n- Evaluated for these symptoms previously by at least 1 other doctor\n- Age >14\n- Willing and able to fill out extra paperwork\n- Seen by the same optometrist for all visits\n- Willing to wear glasses\n- Able to sign informed consent\n- Must have a driver for Follow Up visits\n- Must have previous negative Neuroimaging (HCT or MRI) that was ordered to assess for headache and/or dizziness\n\nPatient note assessment against inclusion criteria:\n- The patient is over 14 years old.\n- The patient has symptoms of dizziness and headaches.\n- There is no information about the duration of symptoms or whether they have been evaluated for these symptoms previously by at least 1 other doctor.\n- There is no information on whether this would be the patient's first appointment at the designated optometry office.\n- There is no information on the patient's willingness to fill out extra paperwork, wear glasses, sign informed consent, or have a driver for follow-up visits.\n- There is no information on whether the patient has had previous neuroimaging (HCT or MRI) to assess for headache and/or dizziness.\n\nGiven the information provided, there is not enough information to determine if the patient meets all the inclusion criteria for the clinical trial. Specifically, the trial requires the patient to have been seen by other doctors for their symptoms, to have had previous negative neuroimaging, and other logistics related to the trial participation that are not mentioned in the patient note.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "588": {
        "output": "The patient note presents a 46-year-old man who experiences dizziness and frequent headaches. From the information provided:\n\n- The patient has a family history of coronary artery disease (CAD), which matches one of the inclusion criteria.\n- His LDL-C level is 545 mg/dL, which is significantly higher than the threshold of 130 mg/dL set in the trial's inclusion criteria.\n- The patient's HDL-C level is 53 mg/dL, which is above the trial's requirement of being less than 40 mg/dL.\n- He is physically active, and it is not mentioned that he has a Body Mass Index (BMI) of 30 kg/m^2 or a waist circumference greater than 40 inches, which are part of the inclusion criteria.\n- There is no information provided about his alcohol intake, but the inclusion criteria require a report of at least one drink in the last month.\n- He is not mentioned to have diabetes, be a current smoker, or have hypertension, which are included in the inclusion criteria.\n- The patient is a man, therefore, the post-menopause criterion is not applicable.\n\nGiven the information available, the patient meets some of the inclusion criteria (family history of heart disease and high LDL cholesterol). However, there is insufficient information on alcohol intake, BMI, and waist circumference, and he does not meet other criteria such as age (he is 46, while the trial requires participants to be 55 or older), current smoking, diabetes, hypertension, and being post-menopausal (not applicable).\n\nTherefore, based on the provided information, the patient does not have sufficient information to qualify for the trial:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "589": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient does not appear to meet the specific inclusion criteria for the clinical trial provided. The trial is focused on patients with diabetes mellitus, specifically those with very early coronary artery disease, and it aims to assess the prediction of invasive findings on intravascular ultrasound (IVUS) and noninvasive findings on cardiac magnetic resonance (CMR) imaging based on risk factors for the metabolic syndrome.\n\nThe patient note indicates that the patient has a high LDL-C level and carotid artery stenosis, but there is no mention of the patient having diabetes mellitus or metabolic syndrome. The patient's fasting glucose level is within normal limits, which does not support a diagnosis of diabetes. Therefore, based on the information provided in the patient note, the patient does not meet the specific inclusion criteria for Type 2 Diabetes or Metabolic Syndrome that are required for participation in the trial.\n\nGiven the absence of information that would qualify the patient for the trial, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "590": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, there is no mention of symptomatic carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke, or retinal infarction within 6 months prior to enrollment, which are required to be considered symptomatic according to the clinical trial's inclusion criteria.\n\nThe inclusion criteria for the clinical trial require:\n\n1. Age \u2265 18 years old, which the patient meets.\n2. Eligibility for carotid artery revascularization. Given the severe stenosis in the LICA, the patient might be eligible for revascularization.\n3. A significant stenosis in symptomatic patients with \u2265 50% Diameter Stenosis (%DS) or asymptomatic \u2265 80 %DS as defined by angiography. The patient has severe stenosis in the LICA, which likely meets the stenosis criteria. However, it is not clear if the stenosis is symptomatic or if the stenosis is \u226580% for the patient to be considered asymptomatic.\n4. Symptomatic as defined by the trial (with specifics of associated conditions within the past 6 months), which is not clearly met as there is no mention of any qualifying events.\n5. Suitable clinical conditions to perform DW-MRI, which is not mentioned but could potentially be met.\n6. Written informed consent as approved by the Ethics Committee of the respective clinical site, which is procedural and can be obtained if other criteria are met.\n\nThe patient note does not provide sufficient information to confirm eligibility based on the trial's definition of a symptomatic patient or the degree of stenosis for asymptomatic patients. Consequently, the patient cannot be confirmed as eligible due to the lack of information regarding the symptomatic nature of his condition and the exact percentage of stenosis. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "591": {
        "output": "Given the patient note:\n\n- A 46-year-old man presents with dizziness and frequent headaches.\n- Family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus.\n- Physically active.\n- LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- Fasting glucose and triglyceride levels were within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nAnd the clinical trial's inclusion criteria:\n\n- Men and women over the age of 50 years.\n\nThe patient is a 46-year-old man, which does not meet the age requirement of over 50 years for the clinical trial. Therefore, the patient is not eligible to participate in the trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "592": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis\", let's consider the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He has dizziness and frequent headaches.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient has not reported any neurological symptoms such as stroke or transient cerebral ischemia in the past 6 months.\n- The patient has not used any lipid-lowering medications.\n- There is no mention of the patient's or doctor's uncertainty regarding the immediate need for carotid endarterectomy (CEA).\n- There is no mention of any conditions that would preclude long-term follow-up.\n- There is no mention of a neurologist's consent regarding CEA.\n\nClinical Trial Inclusion Criteria:\n- Carotid artery stenosis severe (70%-79% on ultrasound).\n- No stroke, transient cerebral ischemia, or other relevant neurological symptoms in the past 6 months.\n- Uncertainty whether to choose immediate CEA or deferral.\n- No condition likely to preclude long-term follow-up.\n- Neurologist's explicit consent to potentially perform CEA.\n\nBased on the provided criteria and patient note, the patient appears to have severe carotid artery stenosis, which fits the trial's criteria. However, there is not enough information to determine if there is uncertainty about the immediate need for CEA, nor is there any information about the neurologist's consent. Therefore, we do not have sufficient information to definitively include the patient in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "593": {
        "output": "The patient in the note presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, high LDL-C levels, and a systolic murmur. However, there is no mention of heart failure, left ventricular systolic dysfunction, or any measurement of left ventricular ejection fraction (LVEF). The inclusion criteria for the clinical trial focus solely on patients with LVEF of 40% or less, which is a measure of left ventricular systolic dysfunction.\n\nGiven that the patient note does not provide information on the patient's LVEF or any indication of heart failure, we cannot determine whether the patient meets the trial's inclusion criteria. Therefore, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "594": {
        "output": "The patient is a 46-year-old man presenting with dizziness and frequent headaches, and has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial is evaluating the safety and efficacy of carotid artery stenting using Angiomax (bivalirudin) versus heparin. To be included in the trial, the patient must meet the following inclusion criteria:\n\n1. The patient must be at least 18 years of age.\n2. The patient must have a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as \u226550% stenosis for symptomatic patients or \u226580% stenosis for asymptomatic patients determined by carotid duplex ultrasound scan and/or carotid angiography.\n3. Female patients with childbearing potential must have a negative pregnancy test.\n4. The patient and the patient's physician must agree to have the patient return for a 30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated in the protocol.\n5. Reference vessel diameter \u2265 3.5 mm - \u2264 9.0 mm diameter.\n\nConsidering the patient note, the following applies:\n\n1. The patient is 46 years old, which satisfies the age criterion.\n2. The patient has severe stenosis in the left internal carotid artery, which is confirmed by ultrasonography, meeting the criterion for significant diameter reduction (the exact percentage of stenosis is not provided but \"severe stenosis\" suggests it may be \u226550% or \u226580%).\n3. The patient is male, so the pregnancy test criterion is not applicable.\n4. There is no information provided about the patient's willingness to return for follow-up evaluations, but this is typically confirmed at the time of consent.\n5. There is no information provided on the reference vessel diameter.\n\nBased on the information provided, the patient seems to meet the age and stenosis criteria. However, there is insufficient information to determine if the stenosis meets the \u226550% for symptomatic or \u226580% for asymptomatic patients required by the trial, and there is also no information provided on the reference vessel diameter. Additionally, we do not have explicit confirmation of the patient's willingness to return for follow-up evaluations.\n\nDue to these gaps in information, particularly regarding the severity of the stenosis in terms of percentage required by the trial criteria and the lack of information on the reference vessel diameter and agreement for follow-up, the patient cannot be confirmed as eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "595": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we need to match the patient's characteristics and condition with the inclusion and exclusion criteria of the provided clinical trial:\n\nPatient Note Characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- High LDL-C level (545 mg/dL), normal HDL-C level (53 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of any malignancies or cancer\n\nClinical Trial Inclusion Criteria:\n- Subjects with histologically and/or cytologically confirmed solid malignant tumor or hematologic malignancy\n- Age \u2265 18 years\n- ECOG performance status \u2264 2\n- Life expectancy of at least 4 months\n- Adequate hematologic and organ function as defined by specific laboratory values\n- Ability to understand and willingness to sign a written informed consent document\n\nClinical Trial Exclusion Criteria:\n- Recent receipt of radiotherapy, chemotherapy, or other anticancer agents\n- Bone marrow transplant within 6 months\n- Known brain metastases\n- Receipt of other investigational drugs within a specified period\n- Allergic reactions to compounds similar to P1446A-05\n- Unstable angina, myocardial infarction, or stroke\n- Uncontrolled inter-current illness\n- Infections with HIV, Tuberculosis, Hepatitis C or B\n- History of other prior malignancy with specific exceptions\n- Women who are pregnant or lactating\n- Unwillingness to use adequate contraception or surgically sterilised status\n\nAssessment:\nThe patient note does not mention any cancer diagnosis, which is a primary requirement for the clinical trial. Since the patient does not have a confirmed solid malignant tumor or hematologic malignancy, they do not meet the inclusion criteria for this study.\n\nTherefore, based on the information provided in the patient note, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "596": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- Physically active\n- No history of diabetes mellitus\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL (within normal limits)\n- Triglycerides: 158 mg/dL (within normal limits)\n- No use of lipid-lowering medications\n\nClinical trial inclusion criteria:\n- Patients diagnosed with type 2 diabetes mellitus\n- Aged over 18 years, either sex\n- HbA1c level more than 7%\n- Patients treated only with oral anti-diabetic drugs or diet\n\nThe patient in the note does not have a diagnosis of type 2 diabetes mellitus, which is a primary requirement for the clinical trial. Additionally, there is no mention of HbA1c levels, which need to be more than 7% for inclusion in the trial. The patient is only described as having high LDL-C levels and other cardiovascular risk factors, not diabetes.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "597": {
        "output": "Given the patient's note, the individual is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL cholesterol levels but is not on any lipid-lowering medications. There is no mention of HIV infection or treatment with antiretroviral therapy.\n\nThe clinical trial in question is examining the impact of antiretroviral therapy on metabolic, skeletal, and cardiovascular parameters in patients who are HIV-infected and have never received antiretroviral therapy.\n\nThe inclusion criteria for the trial are:\n1. Enrollment in A5257 and intent to enroll in A5001 (ALLRT)\n2. Signed informed consent\n3. For A5257 inclusion criteria, please see ClinicalTrials.gov identifier NCT00811954 (not provided here, but it seems to pertain to HIV-infected patients based on the summary)\n\nSince the patient in question does not mention an HIV infection and the study is specific to HIV-infected patients who have never received antiretroviral therapy, the patient does not meet the inclusion criteria for this clinical trial. Thus, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "598": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms of dizziness and frequent headaches, has severe stenosis in the left internal carotid artery, and has high LDL-C levels. There is no mention of heart failure, decreased kidney function, or any indication that he fits the New York Heart Association (NYHA) class II, III, or IV for heart failure severity. The patient does not exhibit any clinical findings of heart failure that have been present for at least three months before screening, nor is there any information provided about his left ventricular ejection fraction or GFR.\n\nSince the clinical trial in question is specifically looking for participants who have a history and clinical findings of heart failure for at least three months, who are in specific NYHA classes, have a left ventricular ejection fraction below 50%, and have a GFR \u2264 40 ml/min/1.73m\u00b2, this patient does not meet the inclusion criteria as there is insufficient information to qualify him for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "599": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, the patient does not meet the specified inclusion criteria for the trial. The trial is focused on individuals with spinal cord injury (SCI) and the patient note does not mention a spinal cord injury, but rather carotid artery disease. Since there is no indication that the patient has a spinal cord injury, they are not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "600": {
        "output": "To determine the patient's eligibility for the \"Evaluation of the Remote Intervention for Diet and Exercise (RIDE)\" clinical trial, we must compare the patient's characteristics and medical information with the trial's inclusion criteria:\n\nInclusion Criteria for RIDE Trial:\n1. Body mass index (BMI) is > 25 kg/m^2 and < 35 kg/m^2.\n2. Willing to use cell phones provided by the PBRC or personal cell phones to take pictures of foods during the study and to receive messages from study personnel.\n3. Willing to wear an activity monitor on your shoe and to use the internet to send information as frequently as once daily.\n4. Willing to weigh on a scale provided by the PBRC as frequently as once per day.\n5. Willing to accept random assignment to either the e-Health (RIDE group) or control group.\n6. Weight stable, defined as no greater than 4.4 lbs. (2 kg) weight change over the previous 60 days.\n\nPatient Note:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No smoking, high blood pressure, diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL\n- Triglycerides: 158 mg/dL\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No use of lipid-lowering medications\n\nFrom the patient's note, there is no information provided about the patient's BMI, willingness to use cell phones, wear an activity monitor, weigh on a scale provided by the PBRC, accept random assignment, or weight stability. The patient's eligibility for the RIDE trial cannot be determined based on the given information. Therefore, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "601": {
        "output": "In the given patient note, the patient is a 46-year-old man with dizziness, frequent headaches, a family history of CAD, and has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels and no use of lipid-lowering medications. His BMI is not mentioned, and there is no information to assess his overall health conditions besides the cardiovascular issues presented.\n\nThe clinical trial in question is a relative bioavailability study between two formulations of sildenafil citrate. The inclusion criteria for the trial are:\n\n1. Body mass index higher or equal to 18.5 and lower or equal than 29.9 kg/m2.\n2. Good health conditions or without significant disease, at medical discretion, based on evaluations including clinical history, pulse and blood pressure measurements, physical and psychological examination, ECG, and complementary laboratory examination.\n3. Ability to understand the study's nature and objective, including the risks and adverse effects, and willingness to cooperate with the investigator and act according to all the trial requirements, which is confirmed by signing the Informed Consent Form.\n\nBased on the patient note, there is insufficient information to determine if the patient meets the BMI criterion. Additionally, the patient does not appear to be in \"good health conditions\" due to the severe carotid artery stenosis and the related symptoms, which may be considered a significant disease. Therefore, the patient does not meet the second inclusion criterion. While the patient's ability to understand the study and willingness to participate cannot be assessed from the note, the critical factor is his health condition, which likely disqualifies him from participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "602": {
        "output": "",
        "label": 1
    },
    "603": {
        "output": "",
        "label": 0
    },
    "604": {
        "output": "",
        "label": 0
    },
    "605": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches, and he has severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. He has a family history of coronary artery disease (CAD), but he does not have diabetes mellitus and is physically active. There is no mention of the patient having type 2 diabetes, which is a specific inclusion criterion for the clinical trial mentioned.\n\nThe clinical trial is looking to recruit type 2 diabetic patients who have multiple cardiovascular risk factors or who have had atypical chest pain, EKG abnormalities, or a history of previous cardiovascular disease. Although the patient does have severe carotid stenosis, which is a form of cardiovascular disease, there is no information suggesting that he is a type 2 diabetic patient, which is a key inclusion criterion for this specific trial.\n\nTherefore, since the patient does not meet the specific inclusion criterion of being a type 2 diabetic patient, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "606": {
        "output": "Based on the information provided in the patient note, the 46-year-old man presents with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA). He has high LDL-C levels and a systolic murmur but is not currently on any lipid-lowering medications.\n\nThe clinical trial in question is evaluating the effect of statins on the progression of radial intima-media thickness (IMT) after transradial coronary intervention.\n\nThe inclusion criteria for the clinical trial are:\n- Patients undergoing coronary intervention via the radial artery\n\nThe patient in the note does not mention undergoing any coronary intervention, let alone via the radial artery. Therefore, based on the available information, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "607": {
        "output": "Upon reviewing the patient's note and comparing it with the inclusion and exclusion criteria of the CYPRESS clinical trial, we can determine the patient's eligibility for the trial.\n\nPatient's characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No history of cardiovascular risk factors except a family history of CAD\n- Physically active\n- LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively\n- Fasting glucose and triglyceride levels are within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- Auscultation revealed a systolic murmur in the neck\n\nCYPRESS trial inclusion criteria relevant to the patient:\n- The subject must be 18 years of age or older (patient is 46 years old)\n- Subjects undergoing percutaneous intervention with stent deployment (not indicated in the patient note)\n- Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation (no contraindication mentioned in the patient note)\n- The subject or Legally Authorized Representative has consented to participate (not applicable for this assessment)\n\nCYPRESS trial exclusion criteria relevant to the patient:\n- Index procedure requiring use of a stent with a nominal diameter < 2.25 mm or > 3.5 mm (not applicable as no stent procedure mentioned)\n- Current medical condition with a life expectancy of less than 3 years (not mentioned in the patient note)\n- Concurrent enrollment in another device or drug study (not mentioned in the patient note)\n- Subjects on warfarin or similar anticoagulant therapy (not mentioned in the patient note)\n- Subjects with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use for the device implanted (not mentioned in the patient note)\n- Subject treated with both DES and BMS during the index procedure (not mentioned in the patient note)\n\nSince the patient note does not mention that the patient is undergoing or has undergone percutaneous intervention with stent deployment, which is a key inclusion criterion for the CYPRESS study, we cannot establish that the patient is suitable for the trial based on the information provided. There is no indication that the patient has had a stent deployed or has a plan for such a procedure, which is a prerequisite for inclusion in the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the CYPRESS study based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "608": {
        "output": "The patient is a 46-year-old man, which fits within the age range of 20-79 years specified in the inclusion criteria of the clinical trial. However, we need to assess other factors to determine his eligibility.\n\nInclusion Criteria Analysis:\n1. Definite DM (diabetes mellitus) or atherosclerotic vascular diseases with metabolic syndrome: The patient does not have diabetes mellitus, as his fasting glucose level is normal (85 mg/dL). However, he does have severe stenosis in the left internal carotid artery, indicating atherosclerotic vascular disease.\n\n2. Metabolic syndrome is defined by the presence of three or more of the following risk factors:\n   - Abdominal obesity: Not mentioned in the patient note.\n   - Triglycerides > 150 mg/dL: The patient's triglyceride level is 158 mg/dL, which meets this criterion.\n   - HDL-C < 40 mg/dL in men: The patient's HDL-C level is 53 mg/dL, which does not meet this criterion.\n   - Blood pressure > 130/85 mm Hg: Not mentioned in the patient note.\n   - Fasting glucose > 100 mg/dL: The patient's fasting glucose is 85 mg/dL, which does not meet this criterion.\n\nGiven the available information, the patient meets at least one of the criteria for metabolic syndrome (high triglycerides), but there is not enough information to confirm at least two more criteria, which is necessary to meet the definition of metabolic syndrome for the trial.\n\n3. Qualified for lipid-lowering therapy according to the Taiwanese national guidelines: The patient's LDL-C level is 545 mg/dL, which is well above the specified range of 130-190 mg/dL for eligibility. His triglyceride levels are within the specified range but his LDL-C level is too high.\n\nExclusion Criteria:\nThe patient note does not indicate any of the exclusion criteria such as known contraindications to statin or fibrate therapy, uncontrolled diabetes mellitus, liver enzyme levels more than 3 times the upper limit of normal, etc. However, with the patient's LDL-C level higher than 190 mg/dL, he meets one of the exclusion criteria.\n\nBased on the information provided, the patient does not qualify for the trial, as he does not meet all the inclusion criteria (specifically, the full criteria for metabolic syndrome and the LDL-C range) and meets at least one exclusion criterion (plasma LDL-C level higher than 190 mg/dL).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "609": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- No history of cardiovascular risk factors apart from a family history of CAD.\n- He is physically active.\n- He has high LDL-C levels but normal fasting glucose and triglyceride levels.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No mention of illiteracy or inadequate German language ability.\n\nClinical Trial Inclusion Criteria:\n- Capable of exercising on their own at the minimum level recommended by the according rehabilitation clinic.\n- Able to fill out a questionnaire (no illiteracy).\n- Adequate German language ability.\n\nBased on the information available, the patient is physically active, which suggests that he may be capable of exercising on his own at a minimum level. There is no indication of illiteracy or inadequate German language skills. However, the provided patient note does not explicitly confirm the patient's ability to exercise according to the rehabilitation clinic's recommendations, literacy status, or German language skills. Therefore, we do not have sufficient information to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "610": {
        "output": "",
        "label": 0
    },
    "611": {
        "output": "Based on the patient note, the 46-year-old man has severe stenosis in his left internal carotid artery, as well as moderate stenosis in his right internal carotid artery. He has elevated LDL cholesterol levels (545 mg/dL, which is equivalent to 14.1 mmol/L), which is well above the inclusion threshold of >3.5 mmol/L for the clinical trial, and no history of lipid-lowering medication use. However, the patient does not have a confirmed diagnosis of coronary heart disease (CHD) or a high risk of cardiovascular complications such as Diabetes Mellitus II, Myocardial Infarction, Heart Failure, or Arterial Hypertension mentioned in the note.\n\nThough the patient presents with risk factors (severe stenosis in the LICA and elevated LDL cholesterol), without explicit mention of CHD or other listed high-risk conditions, we do not have sufficient information to determine if he meets the specific inclusion criteria for the study on Liprimar (Atorvastatin) in patients with CHD and a high risk of cardiovascular complications.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "612": {
        "output": "Patient Note Analysis:\n- The patient is a 46-year-old man, meeting the age criterion of being above 18 years old.\n- He presents with dizziness and frequent headaches, which could be consistent with tension-type headache (TTH).\n- There is no mention of the patient's headaches meeting the criteria of the International Classification of Headache of the International Headache Society.\n- There is no indication that the headaches are episodic tension-type headaches (ETTH) specifically.\n- The patient has not used any lipid-lowering medications which imply no prior treatment with acetylsalicylic acid (Aspirin) is indicated in the patient note.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which may or may not be relevant to the trial's focus.\n\nClinical Trial Analysis:\n- The trial is focused on patients with episodic tension-type headache (TTH).\n- Participants must agree to sign informed consent.\n- Participants must have a clinical history of TTH according to the International Classification of Headache of the International Headache Society.\n\nGiven the information in the patient note, it is not clear whether the patient's frequent headaches are tension-type headaches, as there is no detailed description that aligns with the criteria of the International Classification of Headache of the International Headache Society. Additionally, there is no mention of the frequency or characteristics of the headaches to conclusively diagnose them as episodic tension-type headaches. Therefore, the patient does not have sufficient information to qualify for the trial based on the provided clinical history of TTH.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "613": {
        "output": "The patient in question is a 46-year-old man with dizziness, frequent headaches, a family history of CAD, high LDL-C levels, and significant carotid artery stenosis. He is not on lipid-lowering medications and has no history mentioned of stable atherosclerosis, coronary artery disease, acute coronary syndrome, or previous coronary revascularization.\n\nThe clinical trial is focused on subjects with a history of stable atherosclerosis represented by Coronary Artery disease, including chronic stable angina, prior history of acute coronary syndrome, or previous coronary revascularization.\n\nThe patient does not have any documentation of coronary artery disease or other qualifying cardiovascular conditions as specified by the trial's inclusion criteria. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "614": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility:\n\nPatient's characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- Physically active\n- Abnormal lipid profile with very high LDL-C\n- No history of diabetes mentioned\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nClinical trial's inclusion criteria:\n- Nondiabetic controls:\n  - High-risk (n=5)\n  - Completed visit 6yr f/u CACTI Trial\n  - No history of previous MI, revascularization or angina\n  - CAC > 100\n- T1Diabetic subjects:\n  - High-risk group (n= 10)\n    - Completed visit 6yr f/u CACTI Trial\n    - No history of previous MI, revascularization or angina\n    - CAC > 100\n    - Preferably MPR of > 1.5\n  - Lower-risk group (n= 10)\n    - Completed visit 1.A and 1.B CACTI Trial\n    - No history of previous MI, revascularization or angina\n    - CAC < 100\n\nBased on the information provided in the patient note, the patient does not have a documented history of type 1 diabetes, which is a key element for the diabetic group in the trial. Furthermore, there is no information indicating that the patient has completed any visits associated with the CACTI Trial, which is a requirement for both the nondiabetic control group and the T1 diabetic groups in the trial. Additionally, there is no mention of the patient's coronary artery calcification (CAC) score, which is a critical inclusion criterion for the trial.\n\nTherefore, due to insufficient information regarding the patient's potential participation in the CACTI Trial, history of diabetes, and CAC score, the patient does not meet the inclusion criteria for the RABIT1D clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "615": {
        "output": "",
        "label": 1
    },
    "616": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of HIV, liver disease, or transplantation\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18\n- Documented HIV-1 infection\n- Plasma viral load at screening visit below 50 copies per mL for at least 6 months\n- Patient with severe liver failure or eligible for liver transplant\n- Abstinence from alcohol and intravenous drug use for at least 6 months\n- No ongoing class C opportunistic infection\n- Clinical and immunovirological condition allowing certain HIV treatments\n- No resistance profile to raltegravir and sensitivity to at least two fully active agents\n- No viral escape during treatment with specific antiretroviral medications\n- Registered with or covered by a social security scheme\n- For women of child-bearing potential, negative pregnancy test and use of barrier contraceptive method\n\nAssessment:\nThe patient does not meet the inclusion criteria for the clinical trial. The trial is specifically designed for patients with end-stage liver disease and/or liver transplant recipients who have an HIV-1 infection. The patient in the provided note does not have any documented HIV-1 infection, nor is there any mention of liver disease or transplantation. Therefore, there is insufficient information regarding the trial's focus on the patient's condition. The patient's medical issues (carotid artery stenosis, high LDL-C) are unrelated to the trial's target population.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "617": {
        "output": "Based on the information provided, the patient is a 46-year-old man with high LDL-C levels, carotid artery stenosis, and symptoms of dizziness and frequent headaches. There is no mention of influenza A(H1N1) risk, nor is there any indication that the patient has been medically recommended for influenza A(H1N1) immunization. There is also no information regarding informed consent for the trial.\n\nTo be included in the trial, the patient must have a medical recommendation for influenza A(H1N1) immunization and must have signed informed consent. However, the patient note does not provide sufficient information to determine if the patient meets these criteria. Therefore, we have to assume that the patient has not been medically recommended for the immunization and has not provided informed consent, as these are not standard procedures for someone with the symptoms and medical history described.\n\nHence, the patient does not meet the inclusion criteria based on the available information. The trial-level eligibility should, therefore, be categorized as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "618": {
        "output": "Based on the patient note, the 46-year-old man presents with cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient's issues are related to high LDL cholesterol levels and carotid artery disease, but there is no mention of any psychotic symptoms or diagnoses related to psychosis.\n\nThe clinical trial in question is focused on the efficacy and safety of aripiprazole in patients with a first episode of psychosis, including schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS as per DSM-IV criteria.\n\nSince the patient's described medical condition does not align with the inclusion criteria of the clinical trial, which specifically targets individuals with a first episode of psychosis and there is no indication that the patient has experienced such an episode, the patient would not be relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "619": {
        "output": "In this scenario, the patient is a 46-year-old man presenting with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. The patient's condition appears to be related to cardiovascular issues rather than cancer.\n\nThe clinical trial in question is for patients with metastatic melanoma and is looking to evaluate the safety and anti-tumor responses of ALT-801 combined with cisplatin in patients who are chemotherapy na\u00efve and have metastatic melanoma that is considered surgically incurable.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial, as he does not have a diagnosis of locally advanced or metastatic melanoma, nor is there any indication of cancer in the patient note. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "620": {
        "output": "To assess the eligibility of the patient for the given clinical trial, let's compare the patient's characteristics and medical conditions with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 46 years old (fits within the 40 to 70 years range)\n- Untreated for hypertension: Not mentioned (patient has no history of taking lipid-lowering medications, but this does not necessarily relate to antihypertensive medications)\n- Blood pressure levels: Not provided (no information on the patient's blood pressure readings)\n- Patient consent: Not mentioned (we do not know if the patient is willing to sign the consent form)\n- Ability to visit the outpatient clinic: Not mentioned\n\nClinical Trial Inclusion Criteria:\n- Age: 40 to 70 years old\n- Untreated patients or those on monotherapy of antihypertensive drugs but with uncontrolled blood pressure in the ranges of 140-160/90-100 mmHg\n- Patients on antihypertensive medication should discontinue their treatment for at least 4 weeks\n- Blood pressure measurements that fit the specified ranges\n- Must sign the consent form and adhere to the study design\n- Ability to visit the outpatient clinic\n\nThe patient note lacks sufficient information to determine whether the patient meets the specific blood pressure criteria or is on any antihypertensive medication. Additionally, there is no mention of whether the patient is willing to consent to the trial or can adhere to the study design, including visiting the outpatient clinic.\n\nGiven the lack of information on blood pressure measurements, medication status, consent, and adherence capabilities, the assessment for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "621": {
        "output": "The patient presented is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as confirmed by ultrasonography. He exhibits symptoms that may be suggestive of carotid artery disease, such as dizziness and frequent headaches. Additionally, he has a systolic murmur audible on neck auscultation, which radiates to the skull.\n\nThe clinical trial is focused on determining if carotid artery stenosis can be detected using an electronic stethoscope, with the inclusion criteria being an age between 40 and 80 and an indication for diagnostic ultrasound related to carotid artery stenosis.\n\nBased on the information provided in the patient note, the patient falls within the age range specified by the trial (46 years old) and has an indication for diagnostic ultrasound due to the detected carotid artery stenosis. Therefore, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "622": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients,\" we need to compare the patient's characteristics and medical history with the trial's inclusion and exclusion criteria.\n\nPatient Characteristics:\n- Age: 46-year-old man\n- No history of smoking, high blood pressure, or diabetes mellitus; physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No information on left ventricular systolic dysfunction or ejection fraction\n\nClinical Trial Inclusion Criteria:\n- Male or female \u2265 18 years; signed informed consent\n- Outpatient CAD patients on statin therapy\n- HDL-C < 40 mg/dL in males and < 50 mg/dL in females\n- Left ventricular (LV) systolic dysfunction \u2265 40% measured within the past 6 months\n- No changes in cardiac medications during 2 weeks prior to enrollment\n\nClinical Trial Exclusion Criteria:\n- Presence of transplanted tissue or organ or LVAD\n- AICD or CRT or CRTD patients\n- Acute MI, CABG, PCI within past 3 months\n- Congestive heart failure (CHF) \u2265 NYHA 2\n- Ejection fraction < 40% measured within the past 6 months\n- Malignancy, active myocarditis, or cardiomyopathy\n- HIV infection or immunodeficiency state\n- Chronic viral infection\n- Acute systemic infection requiring antibiotics\n- Chronic diarrhea or malabsorption\n- Statin therapy initiation \u2264 3 months\n- Diabetes mellitus type 1\n- Diabetes mellitus type 2 with HbA1C > 7%\n- Low-density lipoprotein cholesterol (LDL-C) > 100 mg/dL\n- Not on statin therapy\n- Liver function tests (LFT) \u2265 x 3 upper limit of normal (ULN) or creatinine kinase (CPK) \u2265 x 10 ULN\n- Hypo/hyperthyroidism\n- Liver dysfunction\n- Renal failure with serum creatinine \u2265 2 mg/dL\n- Alcohol or drug abuse\n- Refuse to sign informed consent\n\nBased on the information provided in the patient note:\n- The patient is not on statin therapy, which is a requirement for inclusion in the trial.\n- The patient's LDL-C level is above the exclusion criterion of 100 mg/dL.\n- There is no information on the patient's left ventricular systolic dysfunction or ejection fraction, but this information is required for inclusion.\n- The patient does not have any of the exclusion conditions listed, as far as the information provided.\n\nSince the patient is not on statin therapy and the LDL-C level exceeds the exclusion threshold, the patient is not eligible for the trial based on the exclusion criteria. Additionally, the patient does not meet the inclusion criteria regarding being an outpatient CAD patient on statin therapy. Therefore, the patient would be excluded from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "623": {
        "output": "To determine the trial-level eligibility, we must compare the patient's condition with the inclusion criteria of the clinical trial.\n\nPatient's condition:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- LDL-C level: 545 mg/dL (very high)\n- HDL-C level: 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Carotid artery plaque characterized as bulky plates extending to the middle third of the ICAs\n\nClinical trial inclusion criteria:\n- Adult patients over the age of 18 years\n- Angiographic evidence of coronary artery disease\n- Ultrasound evidence of carotid artery disease\n- Treated appropriately for dyslipidemia\n\nNow, let's match the patient's condition with the trial's inclusion criteria:\n\n- The patient is 46 years old, which meets the criterion of being an adult over the age of 18.\n- The patient's family history of CAD and very high LDL-C level suggest he may have coronary artery disease, although the note does not explicitly state that he has angiographic evidence of CAD. This information is not entirely clear from the patient note.\n- The patient has ultrasound evidence of carotid artery disease, with severe stenosis in the LICA and moderate stenosis in the RICA, along with the presence of carotid artery plaque.\n- The patient is not currently on lipid-lowering medications, which may not fulfill the criterion of being treated appropriately for dyslipidemia, especially given his very high LDL-C level.\n\nBased on this information, the patient seems to meet most of the inclusion criteria except for the explicit mention of angiographic evidence of coronary artery disease and current treatment for dyslipidemia. Due to the missing information about previous or current treatment for dyslipidemia and the lack of explicit mention of angiographic evidence, he would be considered:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "624": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man presenting with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery. He has high LDL cholesterol levels and a family history of coronary artery disease (CAD) but does not have a history of prostate cancer or any mention of undergoing radical prostatectomy. Additionally, there is no mention of erectile dysfunction or penile vascular abnormalities that would be detected through echo-Doppler investigations.\n\nThe clinical trial in question is focused on the treatment of post-prostatectomy erectile dysfunction using intracavernous bone marrow stem-cell injections. The inclusion criteria for the trial require patients to have localized prostate cancer with certain characteristics, a PSA level of 0 ng/ml 6 months after radical prostatectomy, normal erectile function prior to prostatectomy, and specific penile arterial insufficiency or venous leakage as determined by Doppler measurements.\n\nSince the patient in the note does not have a history of prostate cancer or radical prostatectomy, and there is no information about his erectile function or penile vascular status, he does not meet the inclusion criteria for the clinical trial. There is insufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "625": {
        "output": "Based on the clinical trial information provided, let's go through the inclusion criteria step by step and compare them with the patient's information:\n\nInclusion Criteria:\n1. High-risk for carotid endarterectomy due to anatomical or co-morbid conditions and either has neurological symptoms and \u2265 50% stenosis, via angiography or is asymptomatic and has \u2265 80% stenosis, via angiography.\n2. Target lesion located in the common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation.\n3. Arterial segment to be stented has a diameter between 4mm and 9mm.\n4. Age \u2265 18 years.\n5. Life expectancy > 12 months from the date of the index procedure.\n\nPatient's Information:\n- The patient is a 46-year-old man, which meets the age requirement (4).\n- He presents with dizziness and frequent headaches, which could be considered neurological symptoms (1).\n- Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. Severe stenosis might be consistent with \u2265 50% stenosis (1).\n- The location of the stenosis is in the internal carotid artery (ICA), which meets the location requirement (2).\n- No information is provided regarding the diameter of the arterial segment to be stented (3).\n- No information is provided regarding the patient's life expectancy, but there is no indication of a condition that would suggest life expectancy of less than 12 months (5).\n\nGiven the information available, the patient appears to potentially meet most of the inclusion criteria, but there is a lack of specific data regarding the arterial segment diameter and life expectancy, and it's also mentioned that the stenosis is determined by ultrasonography, not specifically by angiography as required by the trial criteria.\n\nHowever, since the patient presents with neurological symptoms (dizziness and frequent headaches) and there is evidence of \u2265 50% stenosis in the left internal carotid artery, he might be considered at high risk for carotid endarterectomy, which could potentially make him eligible for the trial.\n\nWith the information provided, the patient's eligibility cannot be definitively determined without additional information about the arterial diameter and life expectancy, as well as confirmation of the stenosis percentage via angiography as required by the trial. However, based on the information available, it seems likely that the patient could be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "626": {
        "output": "Based on the provided patient note and the clinical trial information, here is the assessment:\n\nPatient Note Analysis: \n- The patient is a 46-year-old man who presents with dizziness and frequent headaches. \n- He has a family history of coronary artery disease (CAD), but no other cardiovascular risk factors such as smoking, high blood pressure, or diabetes, and is physically active.\n- He has high LDL cholesterol levels and has been found to have severe and moderate stenosis in the left and right internal carotid arteries, respectively.\n\nClinical Trial Analysis:\n- The title of the trial is \"The Clinical Course of Coronary Artery Disease in Coronary Multidetector Computed Tomographic Angiogram.\"\n- The study is observational and looking at the natural history of coronary artery disease.\n- The inclusion criteria specifically mention patients with known or suspected coronary artery disease.\n\nAssessment:\n- The patient has a family history of CAD and has now presented with severe stenosis in the left internal carotid artery, which may be related to or indicative of coronary artery disease.\n- Although coronary artery disease is not explicitly diagnosed in the patient's note, the presence of severe stenosis in the carotid artery, along with his symptoms and family history, could suggest a suspicion of CAD, which fits the inclusion criteria of known or suspected coronary artery disease.\n\nTherefore, based on the information provided, the patient seems to fit the inclusion criteria of the clinical trial for patients with known or suspected coronary artery disease, as the evidence points towards a possible cardiovascular issue related to CAD.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "627": {
        "output": "",
        "label": 1
    },
    "628": {
        "output": "",
        "label": 1
    },
    "629": {
        "output": "Based on the provided patient note, the 46-year-old man with dizziness, frequent headaches, and severe carotid artery stenosis does not appear to have any condition directly related to blood pressure measurement issues. He has not reported any use of lipid-lowering medications which could interfere with blood pressure. His physical activity is noted, and his arm circumference is not mentioned but is not likely to be a disqualifying factor based on the general population.\n\nFor the clinical trial \"Accuracy of Non-Invasive Blood Pressure Measurement in Adults,\" the inclusion criteria are:\n\n1. Subject is greater than 12 years of age at the time of screening.\n2. Subject's upper arm circumference is between 20cm and 55cm.\n3. Subject is willing to undergo the Informed Consent process prior to enrollment in the study.\n4. Subject is willing and able to participate for up to 60 minutes.\n\nThe patient note indicates that:\n\n- The patient is 46 years old which meets criterion 1.\n- There is no information about the patient's upper arm circumference, which is criterion 2, but it is a common measurement and unlikely to be an issue.\n- The patient's willingness to consent and participate is not given, which are criteria 3 and 4. \n\nSince the patient note does not provide information about the patient's upper arm circumference or his willingness to undergo the Informed Consent process and participate in the study, we cannot definitively determine if he meets all the inclusion criteria. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "630": {
        "output": "The patient note presents a 46-year-old man with dizziness and frequent headaches, severe stenosis in the left internal carotid artery, and moderate stenosis in the right internal carotid artery. No mention of planned endarterectomy is made, which aligns with the clinical trial's inclusion criteria that stipulate patients should not be going for endarterectomy. The stenosis percentages are not explicitly given for both arteries, but the severe stenosis in the LICA and the moderate stenosis in the RICA, along with provided PSV and EDV values, suggest that the stenosis is likely within the 30 to 70% range, which fits the trial's inclusion criteria.\n\nGiven the information provided and assuming that severe stenosis implies a percentage greater than 70% and moderate stenosis implies a percentage between 30% and 70%, the patient may not be eligible because the severe stenosis in the LICA could exceed the trial's upper limit of 70%. However, the moderate stenosis in the RICA likely falls within the eligible range. The trial's inclusion criteria do not specify that both carotid arteries must be within the 30 to 70% stenosis range, only that patients must have carotid artery plaques within that range. Therefore, the patient could be eligible based on the RICA stenosis.\n\nGiven that there is no mention of treatment plans like endarterectomy, which could exclude the patient from the trial, and considering the moderate stenosis in the RICA likely falls within the inclusion criteria's stenosis range, the patient appears to meet the trial's inclusion criteria. \n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "631": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's compare the details:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No neurological symptoms due to ischemia in the carotid artery territory are explicitly mentioned.\n- There is no mention of an anamnesis, physical examination, and brain imaging (CT or MRI) confirming neurological symptoms due to ischemia.\n- There is no information provided about the patient's consent to participate in the trial.\n\nClinical Trial Inclusion Criteria:\n- Neurological symptoms due to ischemia in the carotid artery territory diagnosed by a neurologist based on anamneses, physical examination, and brain imaging (CT or MRI).\n- Carotid artery stenosis < 70%.\n- Written informed consent.\n\nThe patient note does not explicitly mention neurological symptoms due to ischemia, which is a requirement for the trial. Therefore, the patient does not meet the specific inclusion criteria as outlined. Additionally, there is no information about the patient giving informed consent for participation in the trial.\n\nGiven the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "632": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches. He has elevated LDL-C levels but is otherwise physically active and does not have any other cardiovascular risk factors. There is no indication of a diagnosis of postural tachycardia syndrome (POTS), nor is there evidence of a tilt table test being conducted to diagnose POTS. Additionally, the patient has carotid artery stenosis, which is a form of cardiovascular disease and could possibly be associated with endothelial cell dysfunction. This condition might exclude him from the trial that specifically excludes patients with diseases known to be associated with endothelial cell dysfunction.\n\nAccording to the inclusion criteria of the clinical trial, participants must be between 14 and 29 years old, which this patient is not, as he is 46 years old. Furthermore, the trial is looking for cases of symptomatic postural tachycardia syndrome diagnosed during a screening tilt table test, and there is no mention of this diagnosis or test in the patient's note.\n\nTherefore, the patient does not meet the age criteria, there is no information on a POTS diagnosis, and the patient has a condition that could be associated with endothelial dysfunction, which is an exclusion criterion for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "633": {
        "output": "",
        "label": 1
    },
    "634": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Sorafenib in Urothelium Cancer of Bladder,\" we can make the following assessment:\n\nPatient's Characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- LDL-C at 545 mg/dL and HDL-C at 53 mg/dL\n- No cardiovascular risk factors other than family history\n- Physically active\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of cancer, specifically urothelial carcinoma\n\nClinical Trial Inclusion Criteria:\n- Men and Women > 18 years\n- ECOG 0-1\n- Life expectancy at least 12 weeks\n- Histologically or cytologically proven urothelial carcinoma of the bladder or upper urinary tract\n- Locally advanced or metastatic urothelial carcinoma (T3b, T4/N+/M+)\n- At least one unidimensional measurable lesion on CT or MRI per RECIST criteria\n- Adequate organ and coagulation-physiological functions\n\nThe patient's note does not mention a diagnosis of urothelial carcinoma or any cancer of the bladder or upper urinary tract. The patient's condition and medical history provided do not align with the specific inclusion criteria of the clinical trial for urothelial carcinoma of the bladder.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "635": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the eligibility of the patient:\n\nPatient Note Summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No history of psychiatric disorder mentioned\n- Has cardiovascular issues, high LDL-C levels, and carotid artery stenosis\n- No mention of antipsychotic medication use or psychiatric conditions\n\nClinical Trial Summary:\n- Focus on psychiatric patients with schizophrenia, schizoaffective, or bipolar disorder\n- Investigating the functional properties of HDL before and during antipsychotic therapy\n- Inclusion criteria specifically require a diagnosis of schizophrenia, schizoaffective, or bipolar disorder and the use of antipsychotic therapy\n\nThe patient in the note does not have a documented psychiatric disorder such as schizophrenia, schizoaffective, or bipolar disorder, which are required according to the trial's inclusion criteria. Additionally, there is no information about antipsychotic therapy, which is a necessary condition for participation in the study.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial focused on HDL properties in psychiatric patients with and without antipsychotic therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "636": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- A 46-year-old man\n- LDL-C level: 545 mg/dL\n- HDL-C level: 53 mg/dL\n- Triglyceride level: 158 mg/dL\n- No mention of waist circumference or BMI\n- No mention of overweight or obesity status\n- No current use of lipid-lowering medications\n\nClinical trial inclusion criteria:\n- Waist circumference > 94cm\n- Triglyceride concentration between 150mg/dL and 400mg/dL\n- HDL-c < 60mg/dL\n- Body mass index: 27 to 35 kg/m\u00b2\n\nPatient eligibility assessment:\n- The patient's triglyceride level of 158 mg/dL falls within the 150-400 mg/dL range.\n- The patient's HDL-c is below 60 mg/dL, meeting this criterion.\n- There is no information on the patient's waist circumference or BMI.\n\nThe patient meets some of the inclusion criteria based on triglyceride and HDL-c levels. However, there is insufficient information regarding the patient's waist circumference and BMI, which are necessary to determine eligibility for this clinical trial. Therefore, we cannot conclude that the patient is eligible without this information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "637": {
        "output": "",
        "label": 0
    },
    "638": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting,\" we will compare the patient's medical condition with the inclusion criteria listed for the trial.\n\nPatient note summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- High LDL-C level (545 mg/dL); normal HDL-C, fasting glucose, and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery; moderate stenosis in the right internal carotid artery\n- Plaque observed in carotid arteries\n\nClinical trial inclusion criteria:\n1. Subject is \u226518 years old\n2. Eligible for percutaneous endovascular intervention\n3. Documented severe (70%) symptomatic intracranial stenosis\n4. Acceptable candidate for intracranial stenting\n5. Subject understands the study requirements and provides written informed consent\n6. Subject willing to comply with follow-up evaluations\n7. Target lesion located in intracranial internal artery, intracranial vertebral artery, basilar artery, or middle cerebral artery\n8. Target lesion must be symptomatic\n9. Target lesion diameter stenosis \u226570%\n10. Reference vessel diameter (RVD): \u22652.0 mm to \u22646.0 mm\n11. Cumulative target lesion length (area to be treated must be completely coverable by one study stent) \u226430 mm\n12. Target lesion is presumed accessible by endovascular treatment\n\nAssessment:\n- The patient is over 18 years old (meets criterion 1).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the stenosis is not specified to be intracranial, nor is it quantified as 70% or greater (may not meet criteria 3, 7, 8, and 9).\n- There is no mention of the patient being an acceptable candidate for intracranial stenting or whether the patient has been evaluated for endovascular intervention (insufficient information for criterion 4).\n- The patient has not provided informed consent as this is only a patient note, and there is no indication of the patient's willingness to comply with follow-up evaluations (criteria 5 and 6 cannot be assessed).\n- There is no detailed information on the target lesion's location within the intracranial arteries, its diameter stenosis being \u226570%, RVD, or lesion length (criteria 7 to 11 cannot be confirmed).\n- There is no information provided on the accessibility of the target lesion by endovascular treatment (criterion 12 cannot be assessed).\n\nBased on the available patient information and the clinical trial's inclusion criteria, the patient does not have sufficient information to qualify for the trial. The provided patient note does not confirm that the patient's condition meets the specific requirements outlined in the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "639": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Carotid Artery Stenting With Cilostazol Addition for Restenosis\", we must compare the patient's characteristics and medical history with the trial's inclusion criteria:\n\nInclusion Criteria for the trial:\n1. 50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid artery stenosis\n2. Scheduled for carotid artery stenting within 30 days\n3. 45 or more years old and less than 80 years old\n4. Antiplatelet agents can be administered orally\n5. Follow-up is anticipated possible for 2 years after CAS\n6. Self-supported in daily activities (modified Rankin Scale 2 or less)\n7. Patients who have given informed consent to participation in the study\n\nPatient's characteristics:\n- A 46-year-old man\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- No mention of carotid artery stenting (CAS) being scheduled within 30 days\n- Physically active, indicating potential self-support in daily activities\n- No mention of inability to take oral medication\n- No mention of refusal to give informed consent\n\nBased on the patient note:\n\n1. The patient is 46 years old, which meets the age criterion.\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, there is no explicit mention of the percentage of stenosis, only that the left is severe and the right is estimated between 40% and 50%. The criterion requires 50% or more symptomatic stenosis or 80% or more asymptomatic stenosis. The note does not provide enough information to determine if the stenosis is symptomatic or asymptomatic and it only provides estimated values for the right side.\n3. There is no information about a scheduled carotid artery stenting within the next 30 days.\n4. There is no information that suggests the patient cannot take antiplatelet agents orally.\n5. There is no information to suggest the patient cannot be followed up for 2 years after CAS.\n6. The patient is physically active, which suggests he might be self-supported in daily activities.\n7. There is no information regarding informed consent, but this is typically obtained during the trial enrollment process, so it should not exclude the patient at this stage.\n\nBased on the available information, we cannot confirm that the patient meets all the inclusion criteria, particularly regarding the specificity of the stenosis and the scheduling for CAS. Therefore, the patient does not have sufficient information to qualify for the trial as it stands.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "640": {
        "output": "",
        "label": 2
    },
    "641": {
        "output": "",
        "label": 1
    },
    "642": {
        "output": "Based on the information provided, the patient is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The condition described in the patient note appears to match the target condition for the clinical trial, which is looking at patients with significant carotid stenosis for carotid stenting.\n\nThe patient note does not mention the use of any cerebral protection systems or previous treatments for the carotid stenosis, which could be potential exclusion criteria. However, since no exclusion criteria are provided, we can only base our assessment on the inclusion criteria mentioned.\n\nThe trial's inclusion criteria are:\n- patients with monolateral, significant, soft carotid stenosis\n\nThe patient has severe stenosis in the left internal carotid artery, which would likely be considered a \"significant\" stenosis, and there is mention of \"bulky plates\" which could be indicative of \"soft plaque.\"\n\nTherefore, based on the available information, it appears that the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "643": {
        "output": "Based on the patient note, the 46-year-old man presents with symptoms (dizziness, frequent headaches) and findings (severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery) that are associated with atherosclerosis. The patient's high LDL-C level, although not explicitly stated as being due to atherosclerosis of the coronary arteries, could be related to the same underlying atherosclerotic process that affects the carotid arteries. The patient has not been described as having undergone coronary angiography, nor is there any indication that he is scheduled to undergo this procedure.\n\nThe clinical trial in question is seeking to find a correlation between certain blood markers and the growth of plaques in the context of coronary artery disease (CAD). The inclusion criteria are specifically:\n\n1. Age \u226518 years\n2. Subjects scheduled for coronary angiography\n3. Subjects who have undergone coronary angiography within 5 years\n\nThe patient is over 18 years old, which meets the first criterion. However, there is no mention of the patient being scheduled for coronary angiography or having undergone coronary angiography within the last 5 years. Therefore, the patient does not meet the second or third inclusion criteria based on the information provided in the patient note.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria stated, so the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "644": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Carotid Plaque Imaging in Acute Stroke,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 46 years old\n- Symptoms: Dizziness and frequent headaches\n- Medical history: No cardiovascular risk factors other than family history of CAD; physically active\n- Diagnostic findings: Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery; presence of plaque\n\nClinical Trial Inclusion Criteria:\n- Age > 49 years old\n- Acute ischemic stroke or transient ischemic attack (TIA)\n- Neurological symptoms compatible with a stroke or TIA in the anterior circulation (territory of the internal carotid artery)\n- Onset of symptoms within the last 7 days\n- 1 or more acute ischemic lesion(s) visible on MR diffusion-weighted imaging (DWI) in the territory of a single internal carotid artery\n- Presence of carotid artery plaques in the ipsilateral or contralateral carotid artery as defined by ultrasound (criteria: plaque thickness at least 2mm; located within 1cm proximal or distal to the carotid bifurcation)\n- Written informed consent\n\nBased on the information provided, the patient does not meet the following inclusion criteria:\n\n- Age: The patient is 46 years old, which is younger than the required age of over 49 years old for the trial.\n- Acute ischemic stroke or TIA: There is no information provided that the patient has had an acute ischemic stroke or TIA.\n- Neurological symptoms compatible with a stroke or TIA: The patient reported dizziness and headaches, but there is no clear indication that these are symptoms of a stroke or TIA.\n- Onset of symptoms within the last 7 days: The onset of symptoms is not specified.\n- Acute ischemic lesion(s) on MR DWI: There is no information to suggest that the patient has had MR diffusion-weighted imaging performed or that any acute ischemic lesions have been found.\n\nThe patient does have carotid artery plaques, which is one of the inclusion criteria, but this alone is not sufficient for eligibility.\n\nGiven the information available, the patient does not meet the age requirement and there is no sufficient information to determine the presence of an acute ischemic stroke or TIA and other related inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "645": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information with the inclusion and exclusion criteria of the study.\n\nPatient information:\n- A 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, diabetes mellitus\n- Physically active\n- LDL-C level: 545 mg/dL\n- HDL-C level: 53 mg/dL\n- Fasting glucose level: 85 mg/dL\n- Triglyceride level: 158 mg/dL\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Systolic murmur detected on neck auscultation\n\nClinical trial inclusion criteria:\n- Male or female (non-pregnant) patients\n- Between 18 and 70 years\n- Elective non-cardiac surgery with an estimated operation duration of 2 hours or longer\n- General anesthesia\n- Voluntary consent\n\nClinical trial exclusion criteria:\n- ASA-class III or IV\n- Cardiac insufficiency NYHA classes III. IV\n- BMI < 18 or > 29\n- Daily urine output < 1L\n- On hemodialysis\n- Abnormal liver or renal function\n- Abnormal coagulation function\n- Hgb < 10g/dl or HCT < 30%\n- Electrolytes above the upper limit of normal\n- History of diabetes mellitus\n- Known history of a mental or neurological disorder\n- History of hypertension and/or taking a beta-receptor blocker or history of atrial fibrillation\n- Known hypersensitivity and contraindications to HES or any of the excipients\n\nAssessment:\nThe patient does not appear to be scheduled for elective surgery, which is a primary requirement for the trial. Even though the patient is within the age range and is male, without information on an upcoming non-cardiac surgery, we cannot consider him for this specific trial. There is insufficient information to say if the patient would be excluded based on the exclusion criteria, but the lack of relevance to the trial's main focus (elective non-cardiac surgery) means the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "646": {
        "output": "To determine the trial-level eligibility of the patient for the ABSORB PHYSIOLOGY Clinical Investigation, we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- Physically active\n- LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- Evidence of plaque in the carotid arteries\n\nClinical Trial Inclusion Criteria (Relevant to the Patient):\n- Participant must be a male of at least 18 years of age (the patient is a 46-year-old man)\n- Evidence of myocardial ischemia (not specified in the patient note)\n- Acceptable candidate for coronary artery bypass graft (CABG) surgery (not specified in the patient note)\n- Agree to follow-up visits and not participate in other clinical investigations (not specified in the patient note)\n- Angiographic criteria regarding coronary arteries (patient has carotid artery disease, not coronary artery disease)\n\nClinical Trial Exclusion Criteria (Relevant to the Patient):\n- Known diagnosis of spontaneous acute myocardial infarction (AMI) within 14 days preceding the index procedure (not mentioned in the patient note)\n- High-risk acute coronary syndrome (not mentioned in the patient note)\n- Evidence of myocardial infarct in the territory subtended by the proposed target vessel or self-control vessel (not mentioned in the patient note)\n- Chronic systemic condition or medication likely to interfere with coronary physiology (not mentioned in the patient note)\n- Known renal insufficiency (not mentioned in the patient note)\n- Participant is receiving chronic anticoagulation therapy (not mentioned in the patient note)\n- Cerebrovascular accident/stroke (CVA) or transient ischemic neurological attack (TIA) within the past 6 months (not mentioned in the patient note)\n- Other medical illness that may confound the data interpretation (not mentioned in the patient note)\n- Participant is currently participating in another clinical investigation (not mentioned in the patient note)\n- The target vessel or the self-control vessel has previously been treated by any PCI procedures (not mentioned in the patient note)\n\nThe patient does not appear to have myocardial ischemia or other specified coronary issues that are the focus of the clinical trial, and the information provided does not indicate that the patient has coronary artery disease, which is a requirement for the trial. Instead, the patient has carotid artery disease, which is not the focus of the ABSORB PHYSIOLOGY Clinical Investigation. Therefore, the patient does not meet the inclusion criteria related to the type of vascular disease under investigation.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial; therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "647": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Dietary Protein Requirements on Unbalanced Diets,\" let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL (normal)\n- Triglyceride levels: 158 mg/dL (normal)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Neck auscultation: systolic murmur 3+/6+\n- Not mentioned: BMI, alcohol consumption, weight stability, medication or supplement use (excluding the possibility of lipid-lowering medications)\n\nClinical Trial Inclusion Criteria:\n- BMI 18-35 kg/m2\n- Age between 18-70 years\n- Healthy\n- Non-smoking\n- Not using a more than moderate amount of alcohol (> 10 consumptions/wk)\n- Weight stable (weight change < 3 kg during the last 6 months)\n- Not using medication or supplements except for oral contraceptives in women\n\nAssessment:\n- Age: 46 years (matches criteria)\n- The patient is described as physically active, which could suggest a healthy status, but no specific mention of being \"healthy\" per the trial's definition.\n- Non-smoking status is not mentioned.\n- Alcohol consumption is not mentioned.\n- Weight stability is not mentioned.\n- No mention of medication or supplements, except for the specification of no lipid-lowering medications.\n- BMI is not provided, but it is a critical criterion to determine eligibility.\n\nGiven the information, the patient appears to meet some of the inclusion criteria such as age, and there is no evidence of smoking or excessive alcohol consumption. However, the trial requires participants to be healthy, and the patient has severe carotid artery stenosis, which may not be considered healthy. Additionally, there is insufficient information regarding the patient's BMI, weight stability, and complete non-use of medication or supplements to determine if the patient fully meets the inclusion criteria.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "648": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the trial. Let's review the information provided:\n\nPatient Note:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- No significant cardiovascular risk factors other than a family history of CAD.\n- LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No mention of prostate cancer or hormone-refractory status.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of histologically or cytologically proven prostate adenocarcinoma, refractory to hormone therapy.\n- Patients who have been treated previously with docetaxel.\n- PSA >20 ng/mL at screening.\n- Signed informed consent.\n\nClinical Trial Exclusion Criteria:\n- Age <20 and >74.\n- ECOG performance status \u22652.\n- Prior surgery \u22644 weeks of registration in the study.\n- Active secondary cancer or prior malignancy from which the patient has been disease-free for \u22645 years, with some exceptions.\n- Inadequate organ function as defined by specific laboratory values.\n- Previous treatment with <225 mg/m^2 cumulative dose of Taxotere\u00ae (or docetaxel).\n\nThe 46-year-old male patient does not meet the clinical trial inclusion criteria as there is no documentation of prostate adenocarcinoma or hormone-refractory status. Additionally, there is no mention of previous treatment with docetaxel, nor is there any PSA level provided. The patient's symptoms and medical history are not relevant to the trial's focus on prostate cancer.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "649": {
        "output": "The patient is a 46-year-old man with severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery, and high LDL-C levels. No history of cardiovascular events like myocardial infarction, stroke, or revascularisation procedures is mentioned, but he does have significant subclinical atherosclerosis.\n\nThe clinical trial in question is looking for individuals with either established atherothrombotic cardiovascular disease or a high cardiovascular risk. This patient does not seem to have a history of the specific cardiovascular events outlined in the inclusion criteria, but he may still qualify based on his high cardiovascular risk due to the presence of severe subclinical atherosclerosis and very high LDL-C levels.\n\nHowever, the inclusion criteria also mention a calculated 5-year CVD risk of 15% or greater is required for those without established cardiovascular disease. The patient's note does not provide a calculated CVD risk score, so we cannot confirm eligibility based on that specific criterion. Additionally, since we do not have information about the patient's calculated CVD risk or confirmation from the trial investigator that the polypill components are indicated at the doses in the Red Heart Pill, we cannot determine the patient's eligibility with certainty.\n\nBased on the information provided, the patient does not have established cardiovascular disease as defined by the trial's criteria, but he does have high LDL-C and evidence of severe subclinical atherosclerosis, which could place him at high cardiovascular risk. Given that the information is not sufficient to ascertain his risk score or the trial investigator's assessment, the patient would be classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "650": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial on febuxostat, blood pressure, and the intrarenal renin-angiotensin system (RAS), we need to compare the patient's characteristics with the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n1. Mild to moderate hypertension - on no more than 1-2 antihypertensive medications and blood pressure <140 mm Hg systolic and <90 mm Hg diastolic.\n2. Age 18 to 60.\n3. Uric acid \u22655.8 mg/dl.\n\nPatient Characteristics:\n1. The patient's blood pressure is not mentioned, so we cannot confirm hypertension status or medication use.\n2. The patient is 46 years old, which fits within the age range of 18 to 60.\n3. The patient has a high uric acid level of 545 mg/dL, which exceeds the required minimum of 5.8 mg/dl.\n\nWe do not have sufficient information regarding the patient's blood pressure or hypertension treatment status. While the patient's age and uric acid levels meet the trial's inclusion criteria, without information on blood pressure or hypertension treatment, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "651": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"A Study of LY2484595 in Japanese Subjects,\" we need to closely examine the patient note and the inclusion criteria provided for the trial.\n\nFrom the patient note:\n- The patient is a 46-year-old man with dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors.\n- He is physically active.\n- His LDL-C level is 545 mg/dL, which is considered high.\n- His HDL-C level is 53 mg/dL, which is above the low HDL-C criteria specified in the trial.\n- His fasting glucose and triglyceride levels are within normal limits.\n- There is no mention of diabetes, which would be considered as 3+ risk factors.\n- The patient is not on any lipid-lowering medications.\n- There is no information on the patient's nationality, but we need to assume based on the clinical trial title that the patient should be Japanese.\n\nNow, let's review the inclusion criteria for the clinical trial:\n- The trial is looking for participants with either low HDL-C or high LDL-C.\n- For low HDL-C, the criteria are HDL-C <45 mg/dL for men, and LDL-C and fasting triglyceride levels within specified limits.\n- For high LDL-C, the criteria are HDL-C <100 mg/dL, LDL-C within specified limits based on risk factors, and fasting triglycerides <400 mg/dL.\n- Male subjects must agree to use reliable birth control during the study.\n- Subjects must have given informed consent to participate in the study.\n\nBased on the patient note:\n- The patient's LDL-C level is high at 545 mg/dL, which fits the high LDL-C lipid criteria.\n- The patient does not have a low HDL-C level as it is 53 mg/dL, which is above the threshold for men.\n- Fasting triglyceride levels are below 400 mg/dL.\n- There is no mention of informed consent or agreement to use birth control, but these are procedural requirements that the patient can fulfill if he decides to participate.\n\nGiven the information provided:\n- We do not have information on whether the patient is Japanese, which is a requirement mentioned in the trial title.\n- The patient's LDL-C level qualifies him for the study based on high LDL-C criteria.\n\nSince we do not have information about the patient's nationality and assuming all procedural requirements such as informed consent and agreement to use birth control can be met, the patient would potentially be eligible if he is indeed Japanese. However, because the patient's nationality is not stated, we cannot confirm eligibility based solely on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "652": {
        "output": "",
        "label": 1
    },
    "653": {
        "output": "To determine the patient's eligibility for the clinical trial on Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease, we need to review the patient's information against the trial's inclusion criteria.\n\nInclusion Criteria for the trial:\n1. Only patients with also Calcium Score\n2. \u226564-slice CT technology (or 16-slice CT technology with >4 year follow-up)\n3. Number of patients of at least 100 with complete clinical file and follow-up\n4. Minimum follow-up of 12 months\n5. Only patients with suspected Coronary Artery Disease (CAD)\n\nPatient's information:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- High LDL-C level (545 mg/dL) and normal HDL-C level (53 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Plaque observed in the carotid arteries\n\nBased on the patient's information, there are several points to consider:\n- The patient has a family history of CAD and presents with severe stenosis in the left internal carotid artery, which could indicate suspected CAD.\n- There is no mention of a Calcium Score or CTCA being performed.\n- There is no information on the technology used for any potential CT scans (i.e., whether it is \u226564-slice or 16-slice CT technology).\n- The follow-up duration is not mentioned.\n- The patient's clinical file completeness and follow-up status are not provided.\n\nThe patient note does not provide sufficient information to determine if the patient meets all the inclusion criteria for the trial. Specifically, we do not have information about a Calcium Score or details of any CT technology used. Additionally, there is no mention of follow-up duration or the completeness of the patient's clinical file.\n\nTherefore, based on the information provided, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "654": {
        "output": "Based on the patient note and the inclusion criteria of the SUPER Study clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 46-year-old man (meets age criterion).\n- Presents with dizziness and frequent headaches.\n- No mention of Intermittent Claudication (IC) in the history provided.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No mention of Ankle/Brachial Index (ABI) values or exercise test results.\n- Stenosis observed in the carotid arteries, not specifically the common or external iliac artery.\n- No information provided about lesions in the superficial femoral artery or classification of lesions according to the TASC.\n- No information on the patient's walking distance or ability to walk on a treadmill.\n\nClinical Trial Inclusion Criteria:\n- Age 18 years or older (patient meets this criterion).\n- Disabling claudication as defined by surgeon based on patient's history (no mention of this in the patient note).\n- ABI < 0.9 or drop in ABI > 0.15 after exercise test (no ABI values provided).\n- Hemodynamic stenosis of the common or external iliac artery on CDS (PSV ratio \u2265 2.5 or EDV \u2265 0.6 m/s) or significant stenosis or occlusion on MRA or CTA (patient has stenosis in carotid arteries, not iliac).\n- Iliac artery lesion and a concomitant stenosis in the superficial femoral artery (no information on this provided).\n- Lesion classified A, B or C according to the TASC classification (no information on this provided).\n- Patient is able to walk at least 2 minutes on a treadmill (no information on this provided).\n- The Maximum Walking Distance on a treadmill < 300 meters (no information on this provided).\n\nGiven the information in the patient note, there is not enough evidence to conclude that the patient has disabling claudication or any iliac artery obstruction, which is a necessary condition to meet the trial's inclusion criteria. Furthermore, the required specific diagnostic information, such as ABI values, lesion classification, and treadmill test results, are not provided in the patient note.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the SUPER Study clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "655": {
        "output": "",
        "label": 2
    },
    "656": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches, and his condition is related to severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He does not have a diagnosis of mitral stenosis, nor is there any mention of mitral stenosis symptoms or findings in the patient's description. The clinical trial in question is specifically looking for asymptomatic patients with moderate mitral stenosis who are potential candidates for early percutaneous mitral commissurotomy.\n\nSince the patient does not have mitral stenosis and there is no indication that he is a candidate for percutaneous mitral commissurotomy, he does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "657": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- He has no history of TIAs or stroke.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- He has not been reported to be on any lipid-lowering medications.\n\nClinical Trial Inclusion Criteria:\n- Patient must be at least 18 years old (the patient is 46, which meets this criterion).\n- Patient must be willing and capable of complying with study protocol requirements (not enough information provided to assess this).\n- Patient must be willing to provide written informed consent (not enough information provided to assess this).\n- Male, infertile female, or non-lactating female of childbearing potential practicing an acceptable method of birth control (the patient is male, which meets this criterion).\n- Patient must be either symptomatic, i.e., with a history of TIAs or non-disabling stroke within 6 months of the procedure, with carotid stenosis \u2265 50%, or asymptomatic with carotid stenosis \u2265 80%, as diagnosed by angiography using NASCET methodology (the patient does not have a history of TIAs or stroke; however, he does have severe stenosis in LICA which could potentially meet the stenosis criterion if it's \u2265 80%).\n- The target lesion must be located in the ICA and the reference vessel diameter, i.e., the CCA is < 10 mm based on angiographic assessment (the patient has severe stenosis in LICA, which is a part of the ICA, but there is no information on the reference vessel diameter).\n\nGiven the information in the patient note, the key eligibility factors that can be confirmed are the patient's age and gender. However, we do not have enough information regarding his willingness to comply with the study protocol, his informed consent, or the exact stenosis percentage of the LICA by NASCET methodology. Additionally, there is no information on the reference vessel diameter. The patient does not have a history of TIAs or stroke, which might be crucial for determining symptomatic status.\n\nSince the patient does not have a history of TIAs or non-disabling stroke, which is a requirement for symptomatic patients with carotid stenosis \u2265 50%, and there is not enough information to confirm asymptomatic carotid stenosis \u2265 80%, the patient does not clearly meet the symptomatic or asymptomatic stenosis criteria for inclusion based on the available information.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided patient note and the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "658": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- No history of cardiovascular disease other than a family history of CAD; no smoking, high blood pressure, or diabetes.\n- High LDL-C level and normal fasting glucose and triglyceride levels.\n- No use of lipid-lowering medications.\n- Systolic murmur heard in the neck.\n- Severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery as shown by ultrasonography.\n\nClinical Trial Inclusion Criteria:\n- Patients (male-female) over 18 years old.\n- Presenting an internal carotid stenosis requiring surgery.\n- Mini Mental State Examination >24 during preoperative examination.\n- Informed written consent.\n\nBased on these criteria, the patient appears to be a candidate for the trial as he is over 18 years old, has internal carotid stenosis requiring surgery, and there is no evidence provided that suggests a Mini Mental State Examination score less than 24. The patient has not expressed any inability to provide informed consent, nor is there any mention of exclusion criteria being met.\n\nTherefore, the patient is likely eligible for the trial as no exclusion criteria are mentioned in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "659": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Ultrasound and Other Images of Artery Blockages,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- Age: 46 years old\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of atrial fibrillation or other irregular rhythm\n- No mention of contraindications for the ultrasound contrast agent\n- No mention of pacemakers, defibrillators, cerebral aneurysm clips, neural stimulators, ear implants, or other contraindications for MRI\n- No mention of renal function or eGFR\n- No information on pregnancy or lactation status (irrelevant as the patient is male)\n- No mention of being unable to give informed consent\n\nInclusion Criteria for the trial:\n- Adult subjects age greater than or equal to 21 years\n- Able to give written informed consent\n- Prior clinical ultrasound exam showing a carotid stenosis of greater than or equal to 50 percent (for Group A)\nOR\n- Prior clinical ultrasound exam showing a carotid stenosis suspected of causing symptoms and/or clinical recommendation to undergo carotid endarterectomy (for Group B)\n\nExclusion Criteria for the trial:\n- Atrial fibrillation or other irregular rhythm that would preclude adequate image acquisition\n- Subjects with a contraindication for the ultrasound contrast agent\n- Subjects with pacemakers, defibrillators, cerebral aneurysm clips, neural stimulators, ear implants, or other clinical contraindications for MRI\n- Subjects with an estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73 m^2 body surface area will be excluded from the contrast MRI portion of the study but will still undergo non-contrast imaging\n- Pregnant or lactating women\n\nThe patient is 46 years old and has had an ultrasound exam showing severe stenosis in the left internal carotid artery, which qualifies as greater than or equal to 50 percent stenosis required for Group A. There is no information suggesting that the patient meets any of the exclusion criteria.\n\nGiven the available information, the patient appears to meet the inclusion criteria for Group A and does not meet any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "660": {
        "output": "",
        "label": 1
    },
    "661": {
        "output": "Based on the information provided, the patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery as shown by ultrasonography. However, there is no mention of the patient undergoing carotid endarterectomy (CEA), which is the only inclusion criteria specified for the clinical trial regarding the enzyme Paraoxigenase 1 (PON1) and its relationship to carotid artery atheromatous plaque.\n\nSince the patient note does not indicate that the patient is undergoing CEA, we do not have sufficient information to determine whether the patient is eligible for the trial based on the inclusion criteria provided. Therefore, the patient would be categorized as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "662": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 46-year-old man (meets age criterion)\n- Presents with dizziness and frequent headaches\n- Severe stenosis in the left internal carotid artery by ultrasonography\n\nClinical Trial Inclusion Criteria:\n- Subject must be \u2265 18 years of age. (patient meets this criterion)\n- Subject does not have any condition that limits their anticipated survival to less than 3 years. (there is no information suggesting the patient has a limited survival)\n- Subject or a legally authorized representative must provide written informed consent prior to any trial-related procedure. (assuming the patient can provide consent, this criterion is met)\n- Subjects with neurological symptoms within 180 days of the procedure and \u2265 70% stenosis of the common or internal carotid artery by ultrasound or \u2265 50% stenosis of the common or internal carotid artery by angiogram - OR - Subjects without neurological symptoms within 180 days of the procedure and \u2265 70% stenosis of the common or internal carotid artery by ultrasound or \u2265 60% stenosis of the common or internal carotid artery by angiogram. (the patient has neurological symptoms - dizziness and headaches - and severe stenosis in the LICA, which meets the stenosis criterion)\n- Subject with all the following target vessel characteristics:\n  - Discrete lesion in internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA). (the patient has plaque in the ICAs, which could meet this criterion)\n  - Vessel diameter \u2265 4.0 mm and \u2264 9.0 mm from reference or contralateral artery. (there is no information provided about vessel diameter)\n  - Absence of excessive vessel tortuosity that would impede delivery of devices. (there is no information provided about vessel tortuosity)\n- Subject must agree not to participate in any other clinical trial for a period of 1 year following the index procedure. (assuming the patient agrees, this criterion is met)\n\nGiven the information provided, the patient appears to meet most of the inclusion criteria, but there is insufficient information regarding the vessel diameter and vessel tortuosity. Therefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "663": {
        "output": "",
        "label": 2
    },
    "664": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Physically active\n- LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nClinical trial inclusion criteria:\n- Ambulatory male or female, 18 to 65 years of age\n- Normal blood pressure\n- Patients suffering from episodic tension-type headache\n- Headache lasting from 30 minutes to 7 days\n- Headache with at least two of the following characteristics: Bilateral location, Pressing/tightening (non-pulsating), Mild or moderate intensity, Not aggravated by routine physical activity\n- No nausea or vomiting\n- No more than one of photophobia or phonophobia\n\nAssessment:\n- The patient is a 46-year-old man, which meets the age criterion of 18 to 65 years.\n- The patient note does not mention the patient's blood pressure, so we cannot confirm normal blood pressure.\n- The patient has frequent headaches; however, there is no information indicating that these headaches are of the tension-type.\n- There is no information provided about the duration of the headaches or their characteristics to meet the specific headache criteria required by the trial.\n- The patient has a severe stenosis in the left internal carotid artery, which may indicate a different etiology for the headaches, rather than tension-type.\n\nBased on the information given, there is not enough information to confirm that the patient's headaches are episodic tension-type headaches as required by the study. Additionally, the severe stenosis could be relevant to the patient's symptoms, which may not align with the study's focus. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "665": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial titled \"International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA).\"\n\nPatient note key points:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- He has not been reported to use lipid-lowering medications.\n- No mention of ischemic heart disease or stress testing results.\n\nClinical trial inclusion criteria key points:\n- At least moderate ischemia on a qualifying stress test.\n- Participant is willing to comply with all aspects of the protocol, including adherence to the assigned strategy, medical therapy, and follow-up visits.\n- Participant is willing to give written informed consent.\n- Age \u2265 21 years.\n\nAssessment:\n- The patient is 46 years old, which satisfies the age criterion.\n- There is no information provided about the patient having stable ischemic heart disease (SIHD) or results from a stress test indicating at least moderate ischemia, which is a specific requirement for the trial.\n- The patient has carotid artery stenosis, which is not the same as coronary artery disease, which is the focus of the ISCHEMIA trial.\n- Willingness to comply and consent can be assumed if the other criteria are met, but they are not relevant if the primary medical condition does not match.\n\nTherefore, due to the lack of information on whether the patient has stable ischemic heart disease or moderate ischemia as proven by a stress test, the patient does not meet the necessary inclusion criteria for the ISCHEMIA trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "666": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery\n- Ultrasonography showing plaque in the internal and common carotid arteries\n\nClinical Trial Inclusion Criteria:\n- Males and non-pregnant females > 18 and < 79 years of age\n- Patients referred for diagnostic coronary angiography who are found to have lesions in native coronary arteries which will be treated by PCI (or patients with known coronary lesions who are referred for planned PCI)\n- Able to give written informed consent\n- Lesion in native coronary artery\n- Angiographic stenosis > 50%\n- Reference vessel diameter 2.5 mm - 4.0 mm by visual estimation\n- Subjects who have successful PCI and OCT\n\nClinical Trial Exclusion Criteria:\n- Subjects with serious co-morbid conditions\n- NYHA class III or IV heart failure or known left ventricular ejection fraction < 30%\n- STEMI within 72 hours prior to the procedure\n- Hemodynamic or electrical instability\n- Severe, non-catheter-related coronary artery spasm\n- Pregnancy\n- Allergies to contrast media\n- Renal failure (eGFR < 60)\n- History of TIA or stroke < 6 months\n- Lesion located in the left main coronary artery\n- Heavily calcified lesions\n- Lesions where OCT cannot be performed\n- Other lesions deemed inappropriate by the investigator\n\nAssessment:\n\n- The patient is a 46-year-old male, meeting the age criterion.\n- The patient presents with carotid artery stenosis, not coronary artery lesions, and there is no mention of coronary artery stenting or OCT imaging, which are required for the trial.\n- The patient has not been referred for PCI, nor is there any information on successful PCI and OCT, which are inclusion criteria.\n- The patient does not meet the lesion-specific requirements for the trial.\n\nBased on the information provided, the patient does not meet sufficient inclusion criteria for the trial, particularly those related to the coronary arteries and PCI. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "667": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we need to determine the patient's eligibility for the clinical trial titled \"Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma.\"\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- No mention of Head and Neck Squamous Cell Carcinoma (HNSCC).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No use of lipid-lowering medications is reported.\n- No mention of any cancer treatment or surgery.\n\nClinical Trial Inclusion Criteria Analysis:\n- Histologically or cytologically confirmed, previously untreated HNSCC.\n- Clinical stage II, III, or IVA disease without distant metastasis.\n- Macroscopic complete resection of the primary tumor must be planned.\n- Patients will be willing to receive postoperative therapy with platinum and radiation if qualified.\n- Age 18 years or older.\n- ECOG performance status 0-1.\n- Adequate hematologic, renal, and hepatic function.\n- Signed written informed consent.\n\nComparison:\n- The patient's age meets the inclusion criterion (18 years or older).\n- There is no information on the patient's ECOG performance status.\n- There is no information about the patient's hematologic, renal, and hepatic function.\n- Most importantly, the patient does not have a diagnosis of HNSCC.\n\nConclusion:\nThe patient does not have a confirmed diagnosis of Head and Neck Squamous Cell Carcinoma, which is a primary inclusion criterion for the clinical trial. Therefore, the patient is not relevant for this clinical trial as they do not meet the essential disease-specific inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "668": {
        "output": "The patient in the note is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels but no mention of HIV infection or treatment for such an infection.\n\nThe clinical trial in question is focused on HIV-infected patients who have been on stable antiretroviral therapy for at least 12 months, with specific requirements regarding their plasma HIV RNA levels and medical treatment records.\n\nSince there is no mention of HIV infection or antiretroviral therapy in the patient's note, this patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this particular study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "669": {
        "output": "",
        "label": 1
    },
    "670": {
        "output": "The patient is a 46-year-old man presenting with dizziness and frequent headaches. He has a family history of CAD, elevated LDL-C levels, and has been found to have severe stenosis in the left internal carotid artery on ultrasonography. Despite these findings, the patient has no documented prior history of coronary artery disease and is physically active.\n\nComparing this patient's profile with the inclusion criteria of the clinical trial:\n\n- The patient is above 40 years old which meets the trial's age criterion.\n- He is presenting for the first time to the cardiologist with symptoms that could be related to coronary artery disease.\n- There is no documented prior history of coronary artery disease, which complies with the inclusion criteria.\n- The patient has symptoms (dizziness and headaches) and evidence from ultrasonography that might suggest an intermediate pre-test likelihood for coronary artery disease.\n- The inclusion criteria specify that the patient must be clinically referred for invasive coronary angiography. While this is not explicitly stated in the patient note, the severity of his condition as indicated by his symptoms and ultrasonography findings could imply that such a referral would be clinically appropriate.\n\nThe patient note does not provide enough information to confirm whether he has been clinically referred for invasive coronary angiography, which is part of the inclusion criteria. However, based on the available information, which strongly suggests that he could be a candidate for such a referral, the patient's profile seems to align with the inclusion criteria of the trial. Since the likelihood is high but not confirmed, some assumption is used in the absence of explicit information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "671": {
        "output": "",
        "label": 1
    },
    "672": {
        "output": "The patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels and a family history of CAD (coronary artery disease), but no mention is made of any previous coronary angiography. Additionally, there is no indication that the patient has any allergic diseases or that he has undergone any form of allergy testing or spirometry, which are necessary to satisfy the inclusion criteria of the clinical trial.\n\nThe clinical trial is looking to estimate the prevalence of allergic diseases and atopy among patients with angiographically confirmed coronary artery disease. While the patient does have a family history of CAD and findings that could suggest a predisposition to CAD (severe stenosis of the carotid arteries), there is no mention of coronary angiography results, which is an explicit inclusion criterion for the trial. Furthermore, the trial requires the ability to perform a forced expiratory maneuver for spirometry, and there is no information provided about the patient's ability to do so.\n\nSince the patient does not clearly meet the inclusion criteria for the clinical trial (no confirmed coronary angiography result and no information about allergic diseases, atopy, or ability to perform spirometry), the patient would be considered as not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "673": {
        "output": "The patient in question is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The velocities measured for the LICA and RICA are given, and it is noted that plaque is present.\n\nThe clinical trial is looking specifically for patients with Intracranial Arterial Prominent Stenosis (IAPS) and has specific criteria related to the Transcranial Doppler Sonography results for the middle cerebral artery (MCA) and the basilar artery (BA), along with age and consent requirements.\n\nThe inclusion criteria for the clinical trial are:\n1. Had received Transcranial Doppler Sonography.\n2. Age >40 years old.\n3. Gender: Male or female.\n4. The subject or their legal representative gave written informed consent to participate.\n5. Meet with one of the two Transcranial Doppler Sonography results below for MCA M1 or BA stenosis of 50-99%.\n\nThe patient meets some of the inclusion criteria such as:\n- Age >40 years old\n- Gender: Male\n\nHowever, the patient's medical information provided does not mention IAPS or the specific Transcranial Doppler Sonography results for the MCA or BA, which are necessary to meet the trial's inclusion criteria. The sonography results provided are for the carotid arteries, not the intracranial arteries required by the trial.\n\nSince there is insufficient information to determine if the patient's condition matches the specific type of stenosis (IAPS) being studied in the trial, and no information about the required Transcranial Doppler Sonography results for the MCA or BA, the patient does not meet the necessary inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "674": {
        "output": "",
        "label": 1
    },
    "675": {
        "output": "Based on the provided patient note, the 46-year-old man has an LDL-C level of 545 mg/dL, which is well above the normal range. The clinical trial in question has an inclusion criterion of total fasting cholesterol > 200 mg/dL.\n\nGiven that LDL-C contributes to total cholesterol, and the patient's LDL-C alone is significantly higher than 200 mg/dL, it can be inferred that the patient's total fasting cholesterol level also exceeds the inclusion criterion threshold.\n\nTherefore, the patient appears to meet the inclusion criterion specified for the clinical trial. There is no other information provided in the patient note that would suggest the patient meets any exclusion criteria for this trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "676": {
        "output": "",
        "label": 1
    },
    "677": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He has high LDL-C levels (545 mg/dL) and normal HDL-C, fasting glucose, and triglycerides levels.\n- He reports no use of lipid-lowering medications.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical Trial Inclusion Criteria:\n- Subjects should be receiving a stable dose of any statin for at least 6 weeks and continue the same dose for the duration of the trial.\n- Fasting LDL-C should be greater than or equal to 80 mg/dL on background treatment with a statin at two screening visits.\n- Fasting TG should be less than or equal to 400 mg/dL on a background treatment with a statin at two screening visits.\n- The LDL-C value at the second visit within 7 days of randomization must not be lower than 20% of the initial value to meet the eligibility criterion.\n\nThe patient's LDL-C level is significantly higher than the threshold mentioned in the trial inclusion criteria. However, the patient is not currently on statin therapy. Since one of the key inclusion criteria is that the subject must be on a stable dose of a statin for at least 6 weeks, this patient would not qualify for the trial based on the information provided. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "678": {
        "output": "",
        "label": 2
    },
    "679": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis,\" we must compare the patient's characteristics and condition to the inclusion criteria of the trial.\n\nInclusion Criteria Checklist:\n- Participant is a female or male of any race/ethnicity >18 years old at the time of the investigational product administration. \u2714 (The patient is a 46-year-old man.)\n- Participant or participant's legally acceptable representative provides written informed consent. \u2714/\u2716 (Not specified, but we can assume the patient can provide consent if eligible.)\n- Participant is capable of complying with study procedures. \u2714/\u2716 (Not specified, but no information suggests the patient is incapable.)\n- Participant has known carotid artery stenosis of >69% luminal diameter as based on carotid ultrasound and who is deemed to be a surgical candidate for endarterectomy as determined by the vascular surgeon. \u2716 (The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but there is no information that it is >69%.)\n- Participant has had a carotid ultrasound and the report is available for collection. \u2714 (The patient had an ultrasonography of the carotid arteries.)\n- Participant has had or is scheduled to have a carotid CT angiogram for plaque localization within 30 days of signing ICF (or else scheduled Carotid CT angiogram). CTA must be performed on a separate day and prior to the investigational PET procedure. \u2714/\u2716 (Not specified if the patient is scheduled for a carotid CT angiogram.)\n- Participant has consented to have an endarterectomy. \u2716 (Not mentioned if the patient has consented to endarterectomy.)\n- Participant will be scheduled for an investigational [F-18]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy. \u2714/\u2716 (Not specified if the patient is scheduled for the PET/CT scan.)\n- Participant must have renal function values as defined by laboratory results within the following ranges:\n  - Serum creatinine \u2264 1.5 mg/dL. \u2714/\u2716 (Not specified.)\n  - Estimated glomerular filtration rate (eGFR) \u2265 45mL/min. \u2714/\u2716 (Not specified.)\n\nBased on the patient note and the inclusion criteria, there are several pieces of required information not provided in the patient note. Specifically, we do not have information on the patient's renal function values, whether they are scheduled for a carotid CT angiogram, or if they have consented to an endarterectomy. Furthermore, the patient's stenosis is described as severe but not quantified as >69% luminal diameter, which is a specific requirement.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "680": {
        "output": "The patient note describes a 46-year-old man with dizziness and frequent headaches who has a family history of CAD. He has high LDL-C levels but normal fasting glucose and triglyceride levels. He has not used lipid-lowering medications. He was found to have severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The note mentions a systolic murmur found upon neck auscultation and plaque in the carotid arteries based on ultrasonography.\n\nThe clinical trial is looking for subjects with asymptomatic aortic stenosis (AS) documented by prior echocardiographic examination. The inclusion criteria for the trial are as follows:\n\n1. Male and female subjects 18 years of age and older.\n2. Subjects must have asymptomatic Aortic Stenosis documented by prior echocardiographic examination.\n3. Subjects must be able to sit for auscultation examination.\n4. Subject must be able to complete a TTE.\n5. Subjects must voluntarily agree to participate in the study and sign the informed consent and healthcare information authorization forms.\n\nThe patient's note does not mention aortic stenosis; instead, it describes carotid artery stenosis. The murmur mentioned is in the neck, radiating to the skull, which does not specifically indicate that it is related to aortic stenosis. There is no mention of echocardiographic examination results related to aortic stenosis, which is a requirement for the trial's inclusion. Therefore, the patient does not appear to meet the inclusion criteria for this trial based on available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "681": {
        "output": "The patient is a 46-year-old man with dizziness and frequent headaches. He has a family history of coronary artery disease (CAD), which is a risk factor for coronary heart disease (CHD). His LDL cholesterol level is very high at 545 mg/dL, and he presents with severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. This indicates the presence of carotid disease, which is one of the CHD risk equivalent conditions listed in the inclusion criteria for the clinical trial.\n\nThe patient has not reported using any lipid-lowering medications, which means he does not meet the criterion of using a standard-of-care statin at a stable dose or having intolerance of statins. However, since he has carotid disease and at least one additional CHD risk factor (age > 45 years for men), he meets part of the inclusion criteria for having a CHD risk equivalent condition and a high risk of a cardiovascular event.\n\nSince the patient has not been reported to be on a statin regimen or has a documented statin intolerance, he does not completely fulfill the inclusion criteria for the trial, which requires the use of a standard-of-care statin at a stable dose or intolerance of statins without the use of other lipid-modifying therapies.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided clinical trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "682": {
        "output": "",
        "label": 1
    },
    "683": {
        "output": "",
        "label": 2
    },
    "684": {
        "output": "Based on the patient note, the 46-year-old man presents with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The patient's stenosis degree meets the inclusion criteria for symptomatic patients of more than 60% stenosis, based on NASCET Criteria, which is indicated by the PSV and EDV cutoff values provided.\n\nThe patient appears to be tolerant to the study medications as there is no mention of intolerance to clopidogrel, aspirin, and statins. The patient is a man, so the pregnancy test criterion is not applicable. There is no mention of intravascular thrombosis or unstable plaques, hemorrhagic tendency, or abnormal renal and hepatic function, which suggests that these considerations are not exclusionary for this patient. The patient's ability to cooperate with and complete a brain MRI examination is not mentioned, but there is no indication that he would be unable to do so.\n\nGiven the information provided, the patient seems to meet the inclusion criteria for the clinical trial on the protective effects of long-term remote limb ischemic preconditioning for carotid artery stenting. However, without explicit confirmation of certain criteria such as MRI cooperation, absence of intravascular thrombosis and unstable plaques, and normal renal and hepatic functions, we cannot definitively say the patient is eligible. Therefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "685": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which satisfies the \"Adult Age \u2265 18 years\" criterion.\n- The patient presents with dizziness and frequent headaches, which are not directly specified as symptoms suggestive of CAD requiring diagnostic/prognostic workup according to the trial's inclusion criteria. However, the patient has severe stenosis in the left internal carotid artery, which could potentially be related to CAD symptoms.\n- The patient has not been reported to use lipid-lowering medications, which is not relevant to the inclusion criteria.\n- The patient is able and willing to provide consent assuming since this has not been reported otherwise.\n\nClinical Trial Inclusion Criteria:\n- Adult Age \u2265 18 years (the patient is 46 years old)\n- Presenting with symptoms suggestive of CAD requiring diagnostic/prognostic workup (the patient has dizziness and headaches, but this is ambiguous regarding CAD)\n- Suitable for Contrast Stress Echocardiography, SPECT, and CCTA (no information provided in the patient note suggests he is unsuitable)\n- Able and willing to provide consent (no information provided suggests inability or unwillingness)\n\nThe patient's presentation does not clearly align with typical symptoms of CAD, such as chest pain or exertional discomfort. The headaches and dizziness experienced by the patient are not definitive symptoms of CAD. The severe stenosis in the carotid artery may suggest vascular disease, but this is not the same as CAD, and the clinical trial is specifically assessing patients with suspected CAD.\n\nGiven the information provided, the patient does not clearly meet the criteria for presenting with symptoms suggestive of CAD. Therefore, the patient is not clearly eligible based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "686": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"A Study of Evacetrapib in High-Risk Vascular Disease,\" we need to match the patient's characteristics and medical condition to the inclusion criteria of the trial.\n\nPatient's Characteristics:\n- Age: 46 years old\n- Diagnosis: The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could be considered a form of cerebrovascular atherosclerotic disease.\n- Treatment: The patient reported no use of lipid-lowering medications, which means they are not currently treated with a statin.\n- LDL-C and HDL-C levels: 545 mg/dL (LDL-C), 53 mg/dL (HDL-C)\n- Triglyceride levels: 158 mg/dL\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of high-risk vascular disease (HRVD) including cerebrovascular atherosclerotic disease.\n- Must be treated with a statin for at least 30 days prior to screening, have documented statin intolerance, or contraindication to statin.\n- HDL-C \u226480 mg/dL.\n- Triglycerides \u2264400 mg/dL.\n- LDL-C no more than 10 mg/dL above the target chosen by the investigator, OR\n- If LDL-C is greater than target, the participant must be on maximum tolerated statin dose (for at least 30 days), have documented statin intolerance, or contraindication to statin.\n\nBased on the patient note:\n- The patient likely qualifies as having cerebrovascular atherosclerotic disease due to the severe stenosis in the LICA and moderate stenosis in the RICA, meeting one of the diagnostic criteria for HRVD.\n- The patient is not currently treated with a statin and there is no mention of statin intolerance or contraindication to statin use, which is required by the trial.\n- The patient's HDL-C level is less than 80 mg/dL, which meets the trial's criteria.\n- The patient's triglyceride levels are less than 400 mg/dL, which meets the trial's criteria.\n- The patient's LDL-C is significantly above any typical target, and there is no indication of being on a statin, let alone a maximum tolerated dose, nor is there any documented statin intolerance or contraindication.\n\nThe major disqualifying factor is that the patient is not currently on a statin regimen, which is a criterion for this trial. Therefore, the patient does not meet all necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "687": {
        "output": "To determine the trial-level eligibility of the patient for the \"Building Resiliency and Increasing Community Hope\" clinical trial, we need to assess the provided patient note against the trial's inclusion and exclusion criteria.\n\nPatient note summary:\n- 46-year-old man\n- Dizziness and frequent headaches\n- No use of lipid-lowering medications\n- No depressive symptoms mentioned\n- Physically active\n\nClinical trial inclusion criteria summary:\n- Age 18 or older\n- Endorse one of the first two items on the PHQ-8 (depressive symptoms screener)\n- Able to be contacted by phone, email, or Facebook\n- Able to participate in the weekly sessions\n- English or Spanish speaker\n\nClinical trial exclusion criteria summary:\n- PHQ-8 score of 20 or greater\n- PHQ-8 score of 15 or greater and not currently in care and unwilling to get a referral for care\n- Currently homeless\n- Prior diagnosis of Bipolar Disorder or Schizophrenia\n- Current alcohol and substance abuse\n- Unable to attend the weekly resiliency classes\n- Does not currently have a phone, an email address, or a Facebook profile\n\nAssessment:\n- The patient is 46 years old, meeting the age criterion.\n- There is no mention of depressive symptoms, so we cannot confirm if the patient endorses one of the first two items on the PHQ-8.\n- The patient note does not provide information on the ability to be contacted or language proficiency.\n\nGiven the information in the patient note, we cannot confirm if the patient endorses any items on the PHQ-8 related to depressive symptoms, which is a requirement for inclusion in the clinical trial. Therefore, we do not have sufficient information to determine if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "688": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use,\" we must compare the patient's characteristics with the trial's inclusion criteria.\n\nInclusion Criteria for the trial:\n\n1. Carotid ultrasound examination: presence of carotid plaque or abnormal CIMT of between 0.9 and 1.2mm.\n2. Lipid profile: LDL \u2264 3.12 mmol/L (\u2248 120.56 mg/dL), TC \u2264 5.2 mmol/L (\u2248 200.88 mg/dL).\n3. No lipid-lowering treatment within the past 6 months.\n\nPatient characteristics:\n\n1. Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery with plaque observed. This indicates the presence of carotid plaque, satisfying the first criterion.\n2. LDL-C levels are 545 mg/dL, which far exceeds the maximum allowed LDL level of 120.56 mg/dL for the trial. This does not meet the second criterion.\n3. The patient reported no use of lipid-lowering medications, which satisfies the third criterion.\n\nSince the patient does not meet the trial's lipid profile criterion, specifically the LDL-C level requirement, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "689": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events,\" we must compare the patient's clinical information with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n1. Patients who are according to the II, III stage in CHD (Coronary Heart Disease) western medical diagnosis standard.\n2. Age between 18 and 75 (including 18 and 75).\n3. Signed the informed consent voluntarily.\n\nThe patient's note provides the following information:\n- The patient is a 46-year-old man, which fits within the age range of 18 to 75 years required by the trial.\n- The patient presents with dizziness and frequent headaches, and there is a severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient's LDL-C is significantly elevated at 545 mg/dL.\n- The patient has a family history of coronary artery disease (CAD) but no other cardiovascular risk factors and is physically active.\n- There is no mention of the patient suffering from stable angina or being in the II or III stage of CHD according to the western medical diagnosis standard.\n\nBased on the patient note, there is not sufficient information to conclude that the patient has stable angina or is in the II or III stage of CHD, which are the conditions specified in the inclusion criteria for the trial. Therefore, the patient does not meet the specific inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "690": {
        "output": "Based on the patient note provided:\n\n- The patient is a 46-year-old man, which satisfies the age criterion.\n- The patient has extremely high LDL-C levels (545 mg/dL), which is well above the trial's inclusion criteria of LDL-C greater than or equal to 70 mg/dL or LDL-C greater than or equal to 100 mg/dL.\n- The patient is not reported to be on a stable daily dose of rosuvastatin or any other lipid-lowering medications. This does not meet the inclusion criteria specifying the need for being \"not adequately controlled with a stable daily dose of rosuvastatin, with or without other LMT.\"\n\nBecause the patient is not currently on a stable regimen of rosuvastatin, he does not meet all the inclusion criteria specified for the clinical trial. Therefore, the patient cannot be considered eligible for this trial since they do not fulfill the trial requirement regarding treatment status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "691": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to meet the criteria for Postural Tachycardia Syndrome (POTS). The patient note mentions symptoms of dizziness and frequent headaches, as well as findings related to severe carotid artery stenosis, but there is no mention of the characteristic orthostatic symptoms of POTS persisting for at least six months or of an increase in heart rate by at least 30 beats per minute upon standing, which are required for a diagnosis of POTS according to the trial's inclusion criteria.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as there is no indication that the patient has been diagnosed with POTS or experiences the specific symptoms and heart rate changes associated with POTS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "692": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Ekvasis of Atorvastatin (Antorcin\u00ae) Treatment in Patients With Acute Cardiovascular Events,\" we must compare the patient's characteristics and condition with the trial's inclusion criteria.\n\nPatient characteristics:\n- 46-year-old man\n- Hypercholesterolemia (LDL-C level of 545 mg/dL)\n- Dizziness and frequent headaches\n- No history of cardiovascular risk factors other than family history of CAD\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No use of lipid-lowering medications\n- Not currently described as having an acute cardiovascular event\n\nClinical trial inclusion criteria:\n- Outpatients (External Ambulatory) Patients\n- Male or female patients\n- 18 to 99 years\n- Patients with Hypercholesterolemia\n- Patients with and without treatment with statin\n- Patients enrolled in any of the study sites with acute cardiovascular event\n- Patients discharged with study medication (Antorcin\u00ae)\n- Patients who have agreed and signed the consent form for the recording and processing of their personal data\n\nBased on the patient's characteristics, he meets several of the inclusion criteria:\n- He is an outpatient.\n- He is male.\n- He is within the age range of 18 to 99 years.\n- He has hypercholesterolemia.\n- He is not currently on statin treatment.\n\nHowever, the patient does not meet the criterion of having an acute cardiovascular event, which is required for enrollment in the study. Since this is a key criterion for the trial and the patient does not meet it, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "693": {
        "output": "",
        "label": 1
    },
    "694": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility:\n\nThe patient is a 46-year-old man who presents with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. He has high LDL-C levels but no indication of critical limb ischemia, which is what the NanoCross BTK trial is targeting. The patient does not present with rest pain or tissue loss, which are symptoms of Rutherford class 4 or 5 \u2013 criteria for the trial.\n\nThe clinical trial is focused on patients with critical limb ischemia due to lesions in the below-the-knee arteries. There is no mention of the patient having critical limb ischemia or lesions in the infrapopliteal arteries in the patient note.\n\nTherefore, the patient does not meet the inclusion criteria of the NanoCross BTK clinical trial, as the patient's condition (severe carotid stenosis) is not relevant to the conditions being studied in the trial (critical limb ischemia with infrapopliteal lesions).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "695": {
        "output": "Given the patient note and the inclusion criteria of the Engager Direct Aortic Clinical Study, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 46-year-old man, which meets the age criterion of \u2265 18 years.\n- The patient has severe stenosis in the left internal carotid artery, but there is no mention of aortic stenosis.\n- There is no information on the patient's NYHA Functional Class, which is a criterion for heart function.\n- There is no mention of Logistic EuroSCORE I or any comorbidities that would pose a contraindication for conventional aortic valve replacement.\n- There is no information provided regarding the patient's ascending aortic site measurements.\n- The patient's consent to participate in a study is not mentioned; however, this is typically obtained after determining eligibility.\n\nClinical Trial Inclusion Criteria:\n- Severe aortic stenosis as defined by specific echocardiographic criteria.\n- NYHA Functional Class II or greater.\n- Logistic EuroSCORE I \u2265 20%, or certain comorbidities.\n- Non-calcified ascending aortic site \u2265 50 mm from the aortic valve basal plane.\n- Age \u2265 18 years.\n- Patient Informed Consent.\n\nBased on the information provided in the patient note, the patient does not clearly meet the specific criteria for severe aortic stenosis, nor is there any information on his NYHA Functional Class, EuroSCORE, or measurements of the ascending aortic site. \n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "696": {
        "output": "The patient note details a 46-year-old man who presents with dizziness and frequent headaches, with high LDL cholesterol and carotid artery stenosis. There is no mention of neurological deficits, Parkinson disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or autonomic impairments such as constipation, urinary difficulties, sexual dysfunction, or orthostatic hypotension. The dizziness reported by the patient is not specifically connected to a change in position (i.e., standing versus supine), which would be required to define orthostatic intolerance.\n\nThe clinical trial is a natural history study of synucleinopathies, which include neurological conditions like PD, DLB, and MSA. The inclusion criteria for the trial specify that patients must be referred with orthostatic intolerance, defined as symptoms of dizziness or lightheadedness in the standing position that disappear when supine. The patient does not meet this criterion as there is no indication that his dizziness is related to orthostatic intolerance. There are also no indications of synucleinopathies or related symptoms in the patient's note.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the synucleinopathy clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "697": {
        "output": "Based on the information provided in the patient note:\n\n- The patient is a 46-year-old man, which fulfills the age criterion of 18-60 years.\n- The patient has extremely high LDL-C levels (545 mg/dL), which suggests possible familial hypercholesterolemia; however, there is no explicit documentation of a familial hypercholesterolemia diagnosis.\n- The patient reported no use of lipid-lowering medications, which means he does not meet the criterion of being on statin treatment for at least 12 months.\n\nGiven that the patient does not have documented familial hypercholesterolemia and is not on statin treatment, he does not meet two of the inclusion criteria. Therefore, he would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "698": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Note Information:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No history of cardiovascular risk factors except family history of CAD\n- Physically active\n- LDL-C: 545 mg/dL (elevated)\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL (normal)\n- Triglycerides: 158 mg/dL (normal)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- Plaque in the internal carotid artery and common carotid artery\n\nClinical Trial Inclusion Criteria:\n1. Clinical diagnosis of coronary artery disease (CAD): CAD patients must be identified as having at least 50% stenosis of one major coronary artery by cardiac catheterization or have received PTCA.\n2. Healthy subjects: Must not have any illnesses and exhibit normal blood biochemical values.\n3. Must be able to swallow tablets.\n\nThe patient has severe stenosis in the left internal carotid artery, which is an indicator of coronary artery disease (CAD). However, the patient note does not specifically mention that the patient has been diagnosed with CAD through cardiac catheterization or has received PTCA, nor does it state that the stenosis is of a major coronary artery. The elevated LDL-C level is also a risk factor for CAD but does not confirm a diagnosis on its own.\n\nGiven the information, we do not have conclusive evidence that the patient meets the clinical diagnosis criteria for CAD as required by the trial (at least 50% stenosis of one major coronary artery by cardiac catheterization or PTCA). The patient's stenosis is described, but without confirmation that it meets the specific criteria of the trial, we must classify this as not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "699": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, we need to assess the patient's eligibility for participation in the study. Here's a comparison:\n\nPatient Note:\n- Age: 46-year-old man\n- No mention of maintenance hemodialysis or dialytic vintage\n- No mention of intact parathyroid hormone (iPTH) levels\n- No mention of serum calcium levels\n\nClinical Trial Inclusion Criteria:\n- Age 18-65\n- Maintenance hemodialysis\n- Dialytic vintage \u226512 months\n- iPTH 150-300pg/ml\n- Serum calcium<2.5mmol/L\n\nAnalysis:\n- The patient's age falls within the trial's inclusion criteria (18-65 years).\n- There is no information provided about the patient being on maintenance hemodialysis or about the dialytic vintage, which is a specific requirement for the trial.\n- The patient's iPTH levels are not mentioned, which is a vital inclusion criterion for the trial.\n- Serum calcium levels are necessary for inclusion and are not provided in the patient note.\n\nConclusion:\nThe patient note does not contain sufficient information to determine if the patient meets the specific inclusion criteria related to maintenance hemodialysis, dialytic vintage, iPTH, and serum calcium levels required for the clinical trial. Therefore, based on the available information, the patient cannot be deemed eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "700": {
        "output": "Based on the patient note provided, the 46-year-old man has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery. These are characterized as bulky plates extending to the middle third of the internal coronary arteries, indicating the presence of carotid plaques.\n\nThe clinical trial's inclusion criteria specify that patients with carotid plaques size more than 2mm by carotid ultrasound are eligible to participate. The patient note does not provide the exact size of the plaques, but the description of \"bulky plates\" and the presence of severe and moderate stenosis suggest that the plaques are likely to be more than 2mm in size.\n\nTherefore, given the evidence of carotid plaques in the patient, he appears to meet the inclusion criteria for the clinical trial. However, without explicit confirmation of the plaque size being more than 2mm, it is not possible to make a definite determination of eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "701": {
        "output": "Given the patient note and the clinical trial information, we need to assess if the patient is eligible for the clinical trial based on the inclusion criteria provided.\n\nThe clinical trial in question is focused on evaluating the impact of a limitations section in systematic review abstracts on results' interpretation by readers. It is a randomized controlled trial that involves an online survey. The participants they are looking for are corresponding authors of randomized controlled trials published between 2010 and 2012 and referenced in PubMed.\n\nThe inclusion criteria for the clinical trial are:\n- Abstract of meta-analysis published in the journal Annals of Internal Medicine between 2006 and 2012.\n- About health care intervention with a conclusion in favor of the experimental treatment.\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, a family history of CAD, high LDL-C levels, and carotid artery stenosis. This patient does not meet any of the inclusion criteria for the clinical trial, as there is no indication that he is a corresponding author of a randomized controlled trial, nor is there any mention of him having published any meta-analysis in the specified journal within the specified time frame.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "702": {
        "output": "Based on the patient note provided, we have the following information:\n\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- He has not been on lipid-lowering medications.\n\nThe clinical trial in question is looking to enroll patients for a study evaluating debris captured in a filter during a transcarotid stenting procedure with the MICHI Neuroprotection System. The inclusion criteria for the trial are:\n\n- Adequate central venous access.\n- Common carotid artery reference diameter of at least 6 mm.\n- Carotid bifurcation is a minimum of 5 cm above the clavicle as measured by duplex Doppler ultrasound (DUS) or computerized axial tomography (CT) angiography or magnetic resonance (MR) angiography.\n\nBased on the information given in the patient note, there is no mention of the patient's central venous access, the diameter of the common carotid artery, or the location of the carotid bifurcation relative to the clavicle. Therefore, we do not have enough information to determine if the patient meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "703": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient described does not meet the specific inclusion criteria for the trial. The clinical trial is targeted towards patients rostered to family physicians with diabetes, hypertension, or ischemic heart disease and involves audit and feedback for primary care.\n\nThe patient in the note presents with dizziness, frequent headaches, a family history of CAD (coronary artery disease), high LDL-C levels, and carotid artery stenosis. There is no mention of the patient having diabetes, hypertension, or ischemic heart disease, which are the conditions specified in the inclusion criteria for the clinical trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "704": {
        "output": "Based on the information provided, the 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery may be a potential candidate for the clinical trial titled \"Pilot Study of Ultrasonic Determined Carotid Plaque Composition.\"\n\nThe inclusion criteria for the clinical trial require:\n\n1. Age \u226540 years\n2. Scheduled to undergo CEA for clinically significant carotid stenosis\n3. CEA is being performed for carotid stenosis of one or more of the following vessels: Internal Carotid Artery (ICA), distal end of the Common Carotid Artery (CCA), and/or CCA bulb.\n\nThe patient note indicates that the patient is 46 years old, which meets the age criterion. Furthermore, the patient has severe stenosis in the left internal carotid artery, which suggests that they may be a candidate for carotid endarterectomy (CEA). However, the note does not mention that the patient is scheduled to undergo CEA or any other treatment plans. Without this specific information, we cannot confirm that the patient fully meets the inclusion criteria.\n\nThus, given the data available, the patient does not have sufficient information to qualify for the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "705": {
        "output": "The patient described in the note is a 46-year-old man with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. He has high LDL-C levels and a family history of coronary artery disease (CAD). There is no mention of facial asymmetry, mandibular deviation, or any issues related to dental or facial midlines.\n\nThe clinical trial in question is focused on computer-assisted orthognathic surgery and is specifically concerned with patients who have facial asymmetry or mandibular deviation. The inclusion criteria require the presence of facial asymmetry or mandibular deviation with certain specifications, all central incisors, pre- and postoperative radiographs and plaster casts for group 1, cranial CBCT images for group 2, and pre- and postoperative digital photographs.\n\nGiven that the patient's clinical note does not mention any issues related to facial asymmetry, mandibular deviation, or any related dental concerns, there is insufficient information to determine eligibility based on the inclusion criteria provided for this clinical trial. Thus, the patient's information is not relevant to the criteria specified for this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "706": {
        "output": "",
        "label": 0
    },
    "707": {
        "output": "Given the patient's note, the individual is a 46-year-old man with dizziness, frequent headaches, and severe stenosis in the carotid arteries. There is no mention of diabetes or hemoglobin A1c levels in the patient's note. The clinical trial in question is focused on Joslin Clinic adult patients with diabetes who are looking to adopt a physically active lifestyle through participation in organized walk events.\n\nTo determine the trial-level eligibility:\n\n- The patient must be a Joslin Clinic patient (not mentioned in the patient note).\n- The patient must be 18 years or older (the patient is 46 years old, so this criterion is met).\n- The patient must have an A1C between 7.5% - 12.0% (there is no information on the patient's A1C levels).\n- The patient must have received physician clearance indicating safe to participate in the walk club events (not mentioned in the patient note).\n- The patient must reside within Boston and Greater Boston Area (not mentioned in the patient note).\n- The patient must have the ability to communicate in English and/or Chinese (not mentioned in the patient note, but likely met).\n- The patient must agree to participate in the intervention walk club for 6 consecutive weeks (not mentioned in the patient note).\n\nThe patient note does not provide sufficient information to qualify for the trial, as there is no mention of diabetes or A1C levels, nor any indication that the patient is a Joslin Clinic patient or has agreed to participate in the study. Therefore, the patient does not meet the inclusion criteria based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "708": {
        "output": "",
        "label": 0
    },
    "709": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, and has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). However, the patient does not have a history of coronary artery disease (CAD) as defined by the clinical trial's inclusion criteria (previous myocardial infarction, coronary angioplasty, CABG surgery, or coronariography showing obstruction of at least 50% in one of the major epicardial vessels). Additionally, there is no mention of the patient being treated with Acetylsalicylic Acid (ASA) 100 mg/day, which is another inclusion criterion for the trial.\n\nGiven the information in the patient note, the patient does not meet the inclusion criteria for the clinical trial entitled \"Ranitidin Versus Omeprazole in Patients Taking Clopidogrel.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "710": {
        "output": "To determine the patient's eligibility for the \"Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals\" clinical trial, we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nInclusion Criteria:\n1. Adult men and women older than 40 years and less than 75 years.\n2. Newly Diagnosed T2DM (NEWDM). NEWDM is a subject without previous history of diabetes who has laboratory evidence consistent with diabetes (American Diabetes Association) within the last year.\n\nExclusion Criteria:\n- Previous cardiovascular events such as, but not limited to, myocardial infarction, acute coronary syndrome or chronic stroke, peripheral arterial disease, or revascularization surgery in any territory.\n- Congestive heart failure (class III-IV).\n- Cancer of any kind (except basal cell or for cervical carcinoma insitu) unless disease free is documented in the past five years.\n- Anemia or known coagulopathy.\n- Serum creatinine greater than 1.5 mg / dl or MDRD (Modification of Diet in Renal Disease) equation <50.\n- Any organ transplant (except cornea)\n- Known HIV-positive, active tuberculosis, malaria, chronic viral hepatitis B or C, cirrhosis of any aetiology.\n- Pregnant or gestational idea in the next 2-3 years to inclusion.\n- History of alcohol dependence (or abusive consumption) or other drugs in the past five years.\n- Psychiatric illness that would entail adherence problems.\n- Participation in a clinical trial protocol or investigational drugs.\n- Debilitating chronic illness or short life expectancy to prevent adherence or therapeutic intensification is not the goal of managing your diabetes.\n- ECG signs of ischemic heart disease.\n- Diabetes type 1 or anti-GAD antibody positive.\n\nPatient's Characteristics:\n- A 46-year-old man.\n- No history of diabetes mentioned.\n- No previous history of cardiovascular events mentioned.\n- The patient has high LDL-C levels, but we have no information about a diagnosis of T2DM.\n\nBased on the patient's characteristics and the information provided, the patient does not meet the key inclusion criterion of having a newly diagnosed T2DM within the last year. Although the patient has high LDL-C levels, there is no explicit mention of a diabetes diagnosis. Therefore, we cannot conclude that he is eligible based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "711": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the GORE\u00ae Carotid Stent clinical study:\n\nPatient Note:\n- The patient is a 46-year-old man, which satisfies the age requirement of being at least 18 years old.\n- The note does not mention the patient's willingness to comply with study protocol or availability for follow-up, nor does it state if the patient is willing to provide written informed consent. However, these are procedural issues that can typically be resolved if the patient is otherwise eligible.\n- The patient presents with symptoms of dizziness and frequent headaches, but these are not specified as amaurosis fugax, TIA, or stroke.\n- There is severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The stenosis is quantified with PSV and EDV values, but there is no direct mention of the percentage of stenosis using the NASCET methodology.\n- The note does not mention if the patient is considered high risk for adverse events during carotid endarterectomy.\n\nClinical Trial Inclusion Criteria:\n- The patient must be at least 18 years old.\n- The patient must be willing and capable of complying with all study protocol requirements.\n- The patient must provide written informed consent.\n- The patient must be symptomatic with carotid stenosis \u226550% or asymptomatic with carotid stenosis \u226580%, as determined by angiography using NASCET methodology.\n- The patient must be considered high risk for adverse events during carotid endarterectomy.\n\nBased on the information provided in the patient note, the patient appears to meet the age criterion and has carotid artery stenosis. However, the patient's symptoms are not clearly defined as being related to carotid stenosis, and the percentage of stenosis is not evaluated using the NASCET methodology. Additionally, there is no information regarding the patient's risk level for carotid endarterectomy.\n\nTherefore, the patient does not have sufficient information provided to qualify for the trial based on the information in the note, primarily because we cannot confirm the percentage of stenosis using NASCET methodology, nor can we confirm the patient's high risk for carotid endarterectomy or willingness to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "712": {
        "output": "Patient Note Summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, or diabetes mellitus\n- Physical activity is not mentioned as limited or restricted\n- High LDL-C level (545 mg/dL) and normal HDL-C level (53 mg/dL)\n- Normal fasting glucose (85 mg/dL) and triglyceride levels (158 mg/dL)\n- No use of lipid-lowering medications prior to presentation\n- Auscultation revealed a systolic murmur in the neck\n- Carotid ultrasonography showed severe stenosis in LICA and moderate stenosis in RICA\n- Plaque in carotid arteries\n\nClinical Trial Summary:\n- Focuses on the effect of intensive statin therapy in patients with acute myocardial infarction (AMI)\n- Compares intensive statin treatment (rosuvastatin) to usual statin therapy (simvastatin) in AMI patients\n- Inclusion criteria: All patients with NSTEMI and STEMI\n\nComparison:\n- The patient does not have a diagnosis of acute myocardial infarction (AMI), either NSTEMI or STEMI. The patient's symptoms and clinical findings do not indicate he is currently suffering from AMI.\n- The trial is specifically designed for patients who have experienced AMI. The patient's high LDL-C levels and carotid stenosis are cardiovascular concerns, but they do not align with the trial's focus on post-AMI treatment.\n\nConclusion:\nThe patient does not meet the inclusion criteria for the clinical trial which specifically requires patients to have NSTEMI or STEMI. Therefore, based on the information provided in the patient note and the clinical trial's inclusion criteria, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "713": {
        "output": "",
        "label": 1
    },
    "714": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man with dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors.\n- He has high LDL-C levels and normal fasting glucose and triglyceride levels.\n- No use of lipid-lowering medications is reported.\n- Carotid artery ultrasound revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical Trial Criteria:\n- The trial is investigating the effect of garlic tablets on some indicators related to atherosclerosis in CAD patients.\n- The inclusion criteria require angiography-confirmed coronary artery disease and a lack of consistent use of garlic in the last month.\n\nComparison:\n- The patient has symptoms and findings suggestive of atherosclerotic disease, as indicated by severe stenosis in the carotid arteries and a high LDL-C level.\n- However, there is no mention in the patient note of angiography-confirmed coronary artery disease, which is a specific requirement for the clinical trial.\n- The patient has not been using garlic, so he meets that part of the inclusion criteria.\n\nConclusion:\n- The patient does not have sufficient information to qualify for the trial as it lacks confirmation of coronary artery disease through angiography, which is a specific inclusion criterion for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "715": {
        "output": "",
        "label": 2
    },
    "716": {
        "output": "Given the information from the patient note, the patient is a 46-year-old man presenting with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. There is no mention of the patient having coronary artery disease (CAD) or being treated in an outpatient clinic associated with the clinical trial, nor is there any mention of the patient presenting 12 months after the introduction of the hs-TnT test in June 2009.\n\nThe trial in question is focusing on patients with stable coronary artery disease and is investigating the prevalence, causes, and prognosis of elevated troponin values in these patients. The inclusion criteria specify that patients should be from the outpatient clinic presenting 12 months after the introduction of the high-sensitivity troponin T assay in June 2009.\n\nBased on the information provided in the patient note, there is no clear indication that this patient was part of the outpatient clinic or that he was presenting within the timeframe specified by the inclusion criteria (12 months after June 2009). Additionally, the patient note does not indicate that the patient has stable coronary artery disease or any history of elevated troponin levels.\n\nTherefore, there is insufficient information to determine that the patient meets the specific inclusion criteria for the clinical trial. The assessment of eligibility for this patient in relation to this clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "717": {
        "output": "Given the patient's history and presentation:\n\n- The patient is a 46-year-old man.\n- He has symptoms of dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors.\n- The patient's LDL-C and HDL-C levels are 545 and 53\u2009mg/dL, respectively.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient has not been reported to use lipid-lowering medications.\n- There is no mention of the patient's ability to understand and cooperate with study procedures, but this could be assumed based on the information provided.\n- There is no mention of the patient's INR value.\n- The patient's life expectancy is not mentioned, but there is no indication of an issue that would limit it to less than one year.\n- The patient has a lesion located in the internal carotid artery.\n\nNow, let's match these details against the clinical trial's inclusion criteria:\n\n- Subject must be > 21 years of age. (The patient is 46, so this criterion is met)\n- Subject has the ability to understand and cooperate with study procedures and agrees to return for all required follow-up visits, tests, and exams. (Not explicitly mentioned, but not contradicted either)\n- International Normalized Ratio (INR) must be \u2264 1.5 at the time of the procedure. (INR not reported in the patient note)\n- The subject must sign a written informed consent prior to the procedure. (Assumed possible if the patient agrees to participate)\n- The life expectancy of the subject is at least one year. (Not reported, but no indication of a life expectancy less than one year)\n- The subject has a lesion located in the internal carotid artery; the carotid bifurcation may be involved. (This criterion is met, as the patient has severe stenosis in the LICA and moderate stenosis in the RICA)\n- The subject must have a minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, CT angiography, or MR angiography. (This information is not provided)\n\nThere is insufficient information to determine the patient's eligibility regarding his ability to cooperate with the study and his INR levels. Additionally, the distance between the clavicle and bifurcation is not mentioned. Therefore, the patient falls into the \"Not relevant\" category until further information is obtained.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "718": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"TRACER RGD-K5 Carotid Plaque Imaging Study,\" let's assess the patient's eligibility:\n\nPatient's characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Physically active with no cardiovascular risk factors except a family history of CAD\n- LDL-C and HDL-C levels are 545 and 53\u2009mg/dL, respectively\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA) (>50%)\n- Moderate stenosis in the right internal carotid artery (RICA) (40-50%)\n- Carotid ultrasound and plaque characteristics are documented\n\nClinical trial inclusion criteria:\n- Male or female of any race/ethnicity >18 years old at the time of the investigational product administration\n- Written informed consent provided\n- Capable of complying with study procedures\n- Known carotid artery stenosis of >50% luminal diameter\n- Carotid ultrasound or CTA report available\n- Scheduled or already had a carotid CT angiogram for plaque localization within 60 days of signing ICF\n- Consent to have an endarterectomy\n- Scheduled for an investigational [F-18]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy\n- Serum creatinine \u2264 1.5 mg/dL\n- Estimated glomerular filtration rate (eGFR) \u2265 45mL/min\n\nThe patient's note indicates that he has severe stenosis in the left internal carotid artery, which meets the criterion of >50% luminal diameter stenosis. However, the note does not mention consent to endarterectomy or scheduled [F-18]RGD-K5 PET/CT scan, which are necessary according to the trial's inclusion criteria. Additionally, there is no information provided about the patient's renal function values (serum creatinine and eGFR), which are also part of the inclusion criteria.\n\nGiven the information available, the patient's eligibility cannot be confirmed due to missing details about consent to endarterectomy, the PET/CT scan schedule, and renal function values. Therefore, the patient falls into the \"Not relevant\" category due to insufficient information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "719": {
        "output": "",
        "label": 0
    },
    "720": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's assess the patient's eligibility step by step:\n\n**Patient Note Analysis:**\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- He has elevated LDL-C levels but normal fasting glucose and triglyceride levels.\n- He is not on lipid-lowering medications.\n- There is severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- There is no mention of acute lymphoblastic leukemia (ALL) or any hematologic malignancy.\n\n**Clinical Trial Inclusion Criteria Analysis:**\n- Disease Criteria: The patient must have ALL in complete remission.\n- Age Criteria: Equal or above age 40 and up to 65 years, or younger than 40 with specific comorbidities.\n- Organ Function Criteria: Specific cardiac, pulmonary, renal, and hepatic function requirements.\n- Performance status: Karnofsky \u2265 70%.\n- Consent: Ability to provide written informed consent and comply with study requirements.\n- Donor Availability: Presence of a willing adult HLA-matched sibling or HLA-matched unrelated donor.\n\n**Eligibility Assessment:**\n- The patient is within the age criteria (46 years old).\n- There is no information about the patient's diagnosis with ALL, remission status, organ function, performance status, consent capacity, or availability of an HLA-matched donor.\n- The patient's note indicates he has cardiovascular issues but does not mention any hematological conditions, specifically ALL.\n\nBased on the information provided, the patient does not meet the disease criteria for the clinical trial as there is no indication that he has ALL, which is a fundamental requirement for this trial. Therefore, we cannot consider the patient eligible for the trial.\n\n**Trial-level eligibility:** 1) Not relevant.",
        "label": 0
    },
    "721": {
        "output": "Based on the information provided, the patient in the note is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, along with other cardiovascular symptoms. The clinical trial in question is focused on chronic toxicities related to cancer treatment in patients with non-metastatic cancer, specifically localized breast cancer and potentially other localizations like lung cancer.\n\nThe inclusion criteria for the clinical trial require participants to be:\n\n- Women\n- Aged 18 years and over\n- With an invasive breast cancer diagnosed by cytology or histology\n- Tumors cT0 to cT3, CN0-3\n- No clinical evidence of metastasis at the time of inclusion\n- Untreated including scored for breast cancer surgery in progress\n- Patient receiving a social security system\n- Patient mastering the French language\n- Free and informed consent for additional biological samples, different questionnaires, and collecting information on resource usage\n- (Since February 2022) Patient:\n  - Age < 45 years at diagnostic\n  - Or cT2-3, cN0-3, HER2+ (RH+ or RH-) or RH-HER2-\n\nThe patient in the note is a man and does not have a diagnosis of invasive breast cancer or any other cancer specified by the trial. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "722": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of prior carotid stenosis revascularization procedures (CEA or CAS)\n\nClinical Trial:\n- Title: Revascularization of Extracranial Carotid Artery Stenosis\n- Inclusion Criteria: All the consecutive cases of carotid stenosis which received carotid endarterectomy (CEA) or carotid artery stenting (CAS) in the central hospital during the study (up to 2015)\n- Exclusion Criteria: The cases of carotid stenosis which received CEA or/and CAS in other hospitals (not enrolling in this study) will be excluded\n\nAssessment:\nThe patient presents with carotid stenosis but there's no information indicating that he has undergone a revascularization procedure (CEA or CAS) in the central hospital (or any hospital) up to 2015. Therefore, the patient does not meet the inclusion criteria which specifically require a history of carotid stenosis revascularization. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "723": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial. The patient note describes a 46-year-old man with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, among other cardiovascular issues. There is no mention of thyroid cancer or a recent diagnosis of thyroid cancer, which is a key inclusion criterion for the trial.\n\nThe clinical trial is specifically aiming to evaluate the impact of an interdisciplinary team-based care approach for newly diagnosed thyroid cancer patients. To be included in the study, patients must be newly diagnosed with a first occurrence of thyroid cancer within 2-4 weeks of diagnosis, be willing to participate in educational group meetings, be over 18 years old, alert and capable of giving informed consent, and be able to speak and read English or French.\n\nSince the patient in the note does not meet the primary condition of being newly diagnosed with thyroid cancer, he does not qualify for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "724": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient described is not eligible for this clinical trial. The trial is specifically looking to recruit adult women with a clinical diagnosis of chronic pelvic pain, while the patient note refers to a 46-year-old man with cardiovascular issues.\n\nTherefore, the patient does not meet the inclusion criteria for the study, which requires participants to be women with chronic pelvic pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "725": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Cilostazol Stroke Prevention Study for Antiplatelet Combination,\" we will compare the patient's information with the inclusion criteria of the trial.\n\nPatient's information:\n- 46-year-old man\n- Diagnosis of severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Not currently using lipid-lowering medications\n- No history of ischemic stroke (IS) mentioned\n- No information on antiplatelet therapy usage\n\nClinical trial inclusion criteria:\n- Diagnosis of noncardioembolic ischemic stroke (IS) that developed between 8 and 180 days before the start of the protocol treatment\n- A responsible lesion identified by MRI\n- Patients aged 20 to 85 years old when providing informed consent\n- Patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing informed consent\n- Patients meeting at least one of the following criteria a-c:\n    a) at least 50% stenosis of a major intracranial artery\n    b) at least 50% stenosis of an extracranial artery\n    c) Two or more of the following risk factors (the patient has no other cardiovascular risk factors mentioned, so this does not apply)\n- Patients considered to be able to visit the study site for ambulatory care throughout the observation period\n- Patients who provided written informed consent\n\nBased on the information provided, the patient has severe and moderate stenosis in the left and right internal carotid arteries, respectively. However, there is no mention of an ischemic stroke in the patient's history. The trial specifically requires patients to have had a noncardioembolic ischemic stroke within a specific timeframe, and there is no indication that the patient meets this criterion. Additionally, there is no information about whether the patient is taking clopidogrel or aspirin alone as antiplatelet therapy, nor is there any mention of an MRI identifying a responsible lesion.\n\nTherefore, because the patient does not meet the essential criteria of having had a noncardioembolic ischemic stroke and having a responsible lesion identified by MRI, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "726": {
        "output": "Patient Note Analysis:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No indication of angina, silent ischemia, NSTEMI, or STEMI is mentioned.\n- No mention of a procedure for coronary intervention (PCI).\n\nClinical Trial Inclusion Criteria Analysis:\n- Age \u2265 18 years \u2714\n- Indication for PCI including angina, silent ischemia, NSTEMI, or recent STEMI \u2716 (No indication that the patient has these conditions)\n- Willing and able to provide informed consent (Assumed, but not specifically mentioned) \u2714/\u2716\n- Angiographic criteria for coronary artery disease \u2716 (The patient has carotid artery disease, not coronary artery disease)\n\nBased on the available information, the patient does not meet the clinical trial's inclusion criteria because the condition being treated in the trial is related to coronary artery disease and the use of a specific stent system, not carotid artery disease. There is no mention of the patient requiring PCI or having conditions that would indicate the need for such a procedure. Therefore, the patient is not relevant for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "727": {
        "output": "Based on the provided clinical trial information and the patient note, the patient appears to be a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, along with hyperlipidemia. The patient does not have documented symptomatic ischemic heart disease or objective evidence of myocardial ischemia; instead, he presents with carotid artery disease, which is not the same as coronary artery disease.\n\nThe inclusion criteria for the clinical trial specifically mention symptomatic ischemic heart disease and/or objective evidence of myocardial ischemia including chronic stable coronary artery disease, or acute coronary syndrome including non-ST-elevation and ST-elevation myocardial infarction. Additionally, there is a requirement for at least one lesion with a diameter stenosis >50% or more suitable for coronary stent implantation, which does not seem to be the case for this patient, as his condition pertains to carotid arteries, not coronary arteries.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, as his condition does not match the target disease or condition for which the trial is recruiting.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "728": {
        "output": "",
        "label": 1
    },
    "729": {
        "output": "",
        "label": 0
    },
    "730": {
        "output": "Based on the patient note, the 46-year-old man presents with symptoms potentially related to cardiovascular issues (dizziness, frequent headaches, and a systolic murmur). His lipid profile shows a very high LDL-C level of 545 mg/dL, which is an abnormal plasma lipid parameter. He also has severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery, indicating atherosclerosis. The patient reported no use of lipid-lowering medications.\n\nThe clinical trial in question is investigating the relationship between CETP, HDL efflux capacity, and the development of atherosclerosis, with the aim of identifying CETP as a biomarker of atherosclerosis distribution. The inclusion criteria for this trial are:\n\n- Signed informed consent prior to initiation of the study\n- Men and women aged 18 or more years\n- Patients displaying at least one abnormal plasma lipid parameter and/or receiving a lipid-lowering therapy unchanged for at least 3 months.\n\nThe patient meets the age criteria and has an abnormal plasma lipid parameter, which is his high LDL-C level. The note does not mention any lipid-lowering therapy, which is not an exclusion in this case since the criteria specify \"and/or\".\n\nTherefore, the patient is eligible for the trial based on the information provided in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "731": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He does not have any cardiovascular risk factors like smoking, high blood pressure, or diabetes, and is physically active. His LDL-C is high and HDL-C is within normal limits. His fasting glucose and triglyceride levels are normal. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as well as plaque in the carotid arteries.\n\nNow let's compare this patient's information with the inclusion criteria for the clinical trial on Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction:\n\nInclusion Criteria:\n1. Males Age 18 and 80 years.\n2. Penile arterial insufficiency and or venous leakage (doppler) at the time of inclusion: PSV <25 cm/sec, PSV >25 cm/sec, EDV>5cm/sec, RI<0,75.\n3. Up to date on all age and gender appropriate cancer screening per American Cancer Society\n\nExclusion Criteria Include:\n- Severe co-morbidities like cardiac insufficiency, congestive cardiac failure (NYHA \u2265 III), malignancy, infection, sepsis, and bed sores.\n- Life expectancy < 6 months due to concomitant illnesses.\n- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.\n- Active infectious disease.\n- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.\n- Patients on chronic immunosuppressive transplant therapy.\n- Systolic blood pressure (supine) \u226490 mmHg or greater than 200mmHg.\n- Resting heart rate > 100 bpm;\n- Active clinical infection within one week of enrollment.\n- Known drug or alcohol dependence.\n- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.\n- Unwilling and/or not able to give written informed consent.\n\nBased on the patient's information provided in the patient note, there is no mention of Erectile Dysfunction or any evaluation of penile arterial insufficiency or venous leakage. The patient's symptoms and medical evaluation focus on cardiovascular health and carotid artery stenosis. There is no information available to suggest that the patient has been screened for Erectile Dysfunction using Doppler ultrasound or any other method that could provide the required penile arterial insufficiency measurements.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial since there is no documented diagnosis or screening for Erectile Dysfunction, nor is there any reported measurement of penile arterial insufficiency.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "732": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's assess the patient's eligibility for the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial.\n\nPatient Note Review:\n- The patient is a 46-year-old man, which satisfies the age requirement of \u226535 years old.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with DUS showing PSV and EDV below the trial's specified cutoff for severe stenosis (PSV < 230 cm/s and EDV < 100 cm/s for severe stenosis).\n- No medical history of stroke or TIA is mentioned, meeting the criterion of no stroke or TIA ipsilateral to the stenosis within 180 days of randomization.\n- No information is given about the patient's modified Rankin Scale score, pregnancy status, or willingness to comply with follow-up appointments, but based on the provided information, these factors can't be assessed.\n- There is no mention of intolerance or allergic reactions to study medications, GI hemorrhage, prior major ipsilateral stroke with substantial residual disability, severe dementia, history of major symptomatic intracranial hemorrhage, current neurologic illness, objection to future blood transfusions, platelet count issues, chronic atrial fibrillation or other cardiac sources of emboli, unstable angina, severe cardiac or respiratory conditions, malignancy, recent major surgery, revascularization or acute coronary syndrome, renal insufficiency, major upcoming surgery, organ transplantation listing, participation in other drug/device trials, inability to understand and cooperate with study procedures, non-atherosclerotic carotid stenosis, previous ipsilateral CEA or CAS, ipsilateral internal or common carotid artery occlusion, intra-carotid floating thrombus, ipsilateral intracranial aneurysm, morbid obesity, or coronary artery disease as defined in the exclusion criteria.\n\nBased on the information available in the patient note, the patient does not have stenosis \u226570% as defined by the trial's criteria, which is a key inclusion criterion for this trial. The patient's stenosis measurements do not meet the trial's threshold for severe stenosis (PSV \u2265 230 cm/s and EDV \u2265 100 cm/s or other specified criteria). Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "733": {
        "output": "Assessing the eligibility of the patient for the clinical trial titled \"Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD\" based on the provided patient note and the inclusion criteria of the trial:\n\nThe inclusion criteria for the trial are:\n1. CVD patients 45-65 years old\n2. Patients with \u2265 50% stenosis in at least one coronary angiogram demonstrated\n3. Body mass index in the range 18.5-35\n4. Avoidance of dietary supplements, vitamins, and herbal products at least 3 months before and throughout the intervention\n5. Willingness to participate\n\nThe patient's information:\n- 46-year-old man (meets age criteria)\n- Presents with dizziness and frequent headaches\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery (does not mention coronary angiogram or stenosis \u2265 50% in coronary arteries)\n- No use of lipid-lowering medications (does not mention other dietary supplements, vitamins, and herbal products)\n- There is no information about the patient's body mass index (BMI) or willingness to participate.\n\nBased on the information available, the patient does not clearly meet the criteria for having \u2265 50% stenosis in at least one coronary artery as demonstrated by coronary angiogram, which is a specific requirement. The stenosis described is in the carotid arteries, not coronary arteries, and this does not fulfill the trial's criteria for cardiovascular disease as specified. Additionally, there is no information on BMI or the patient's willingness to participate, which are also part of the inclusion criteria.\n\nTherefore, the patient does not have sufficient information to qualify for the trial. The trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "734": {
        "output": "",
        "label": 0
    },
    "735": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to match the patient's characteristics and medical history against the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL (above normal)\n- HDL-C: 53 mg/dL (within the range specified for men in the trial)\n- Fasting glucose: 85 mg/dL (within normal limits)\n- Triglycerides: 158 mg/dL (below the minimum specified in the trial)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nClinical Trial Inclusion Criteria:\n- Men or women, \u226518 years of age\n- On a stable diet and statin therapy at least 4 weeks prior to randomization\n- LDL-C <100 mg/dL\n- TG level \u2265180 and <500 mg/dL\n- HDL-C <42 mg/dL for men or <47 mg/dL for women\n- High risk for a future cardiovascular event (via patient history, physical exam, or medical records at the time of screening)\n\nKey Exclusion Criteria:\n- Allergy or intolerance to specific substances\n- Use of fibrates, bile acid sequestrants, or niacin (>250 mg/day) within 4 weeks prior to Visit 2\n- Statin na\u00efve at Visit 1\n\nFrom the patient note, it is clear that the patient has not been on statin therapy, which is an inclusion criterion for the trial. Additionally, the patient's triglyceride level does not meet the minimum requirement of \u2265180 mg/dL as specified in the inclusion criteria.\n\nSince the patient does not meet these two key inclusion criteria (stable statin therapy and triglyceride level), the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "736": {
        "output": "",
        "label": 1
    },
    "737": {
        "output": "To determine the trial-level eligibility for the patient, we need to assess whether the patient meets the clinical trial's inclusion criteria. The inclusion criteria for the Early Aortic Valve Lipoprotein(a) Lowering Trial are:\n\n1. Age >50 years and < 85 years\n2. Aortic sclerosis OR mild AS\n   - Aortic sclerosis: diffuse or focal (at least 2 areas) thickening or calcification (highly echodense lesions) on aortic leaflets seen in at least 2 contiguous views with normal leaflet excursion and peak aortic jet velocity < 2 m/s.\n   - Mild AS: peak aortic jet velocity 2-3 cm/s, AVA >1.5cm2, mean gradient <25 mmHg\n3. Elevated Lp(a) > 50 mg/dL (>80th percentile)\n\nNow, let's compare these criteria with the patient's note:\n\n- The patient is a 46-year-old man, which does not meet the age criterion (>50 years and <85 years).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, there is no mention of aortic sclerosis or mild aortic stenosis (AS), which are conditions related to the aortic valve rather than the carotid arteries.\n- The patient's LDL-C level is high at 545 mg/dL, but the note does not specify the patient's Lp(a) levels. Elevated Lp(a) is a specific inclusion criterion for the trial.\n\nGiven the information from the patient note, the patient does not meet the age criterion and there is no relevant information regarding the patient's aortic valve condition or Lp(a) levels. Therefore, the patient is not eligible for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "738": {
        "output": "To determine the trial-level eligibility of the patient, we must compare the patient's characteristics and medical history to the inclusion criteria of the clinical trial.\n\nHere is the patient's information:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- High LDL-C level of 545 mg/dL and normal HDL-C level of 53 mg/dL\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Systolic murmur on neck auscultation\n\nHere are the inclusion criteria for the clinical trial:\n- Histologically or flow cytometry confirmed diagnosis of B-CLL/SLL\n- Active disease meeting at least one of the IWCLL 2008 criteria for requiring treatment\n- Relapsed/refractory CLL defined as having received \u22652 treatment regimens\n- Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n- Patients \u226518 years old\n- Specific organ function parameters\n- Ability to understand and sign informed consent\n- Ability to swallow and retain oral medication\n- Not on warfarin or closely monitored if on warfarin\n- Negative pregnancy test for women of childbearing potential and use of contraception for all patients of reproductive potential\n\nThe patient in question does not have a diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), nor is there any indication that the patient has received treatments for CLL. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "739": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 46-year-old man (age fits the criteria of 45-65 years old)\n- Presents with dizziness and frequent headaches\n- Family history of CAD (coronary artery disease)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- No mention of coronary angiogram results\n- No information on body mass index (BMI)\n- No mention of avoidance of dietary supplements, vitamins, and herbal products for the required duration\n- Willingness to participate is not mentioned\n\nClinical trial inclusion criteria:\n- CVD patients 45-65 years old (patient's age fits)\n- Patients with \u2265 50% stenosis in at least one coronary angiogram demonstrated (patient has severe stenosis in carotid arteries, not specifically mentioned to be coronary arteries)\n- Body mass index in the range 18.5-35 (no information provided)\n- Avoidance of dietary supplements, vitamins, and herbal products at least 3 months before and throughout the intervention (no information provided)\n- Willingness to participation (no information provided)\n\nThe patient's eligibility cannot be confirmed as there is insufficient information provided regarding coronary angiogram results, BMI, the use of dietary supplements, vitamins, and herbal products, and willingness to participate in the trial. The stenosis is mentioned in the carotid arteries, not the coronary arteries; thus, it cannot be assumed the patient meets the stenosis criterion for the coronary arteries as required by the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "740": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial based on the provided patient note and the inclusion criteria of the trial, we need to assess whether the patient's characteristics and condition match the inclusion criteria of the trial.\n\nPatient Note Summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes\n- Physically active\n- LDL-C level: 545 mg/dL\n- HDL-C level: 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Systolic murmur in the neck\n- Severe stenosis in the left internal carotid artery (LICA): >70%\n- Moderate stenosis in the right internal carotid artery (RICA): 40-50%\n- Plaque observed in the internal carotid artery and common carotid artery\n\nClinical Trial Inclusion Criteria:\n- Asymptomatic stenosis of the internal carotid artery >70%\n- Symptomatic stenosis of the internal carotid artery >60%\n- Planned surgical treatment of the stenosis\n\nComparison:\n- The patient has severe stenosis in the LICA, which is over 70%, meeting the criterion for asymptomatic stenosis of the internal carotid artery >70%. However, the patient note does not mention symptoms directly related to the stenosis itself, such as transient ischemic attacks (TIAs) or stroke.\n- The patient presents with dizziness and frequent headaches, which could be related to the carotid artery stenosis but are not specifically described as symptoms of the stenosis.\n- The patient note does not mention any planned surgical treatment for the stenosis.\n\nGiven that the patient has severe stenosis in the LICA (>70%), he meets one of the inclusion criteria for the trial. However, the patient note does not clearly state whether the stenosis is symptomatic or if there is a planned surgical treatment for the stenosis. Therefore, while the patient could potentially be eligible, we do not have enough information to determine eligibility definitively. \n\nThus, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "741": {
        "output": "To determine the patient's eligibility for the SINGA-PACLI trial, I will compare the patient\u2019s clinical information to the trial's inclusion criteria:\n\nInclusion Criteria Breakdown:\n1. Written informed consent - Not specified in the patient note.\n2. Age > 21 years - The patient is 46 years old, which meets this criterion.\n3. If a female patient with childbearing potential, the patient may not be pregnant at the study entry and must utilize reliable birth control for the duration of her participation in the study - Not applicable as the patient is male.\n4. Patient is willing and able to comply with the specified follow-up evaluation - Not specified in the patient note, but generally assumed if other criteria are met.\n5. Critical Limb Ischaemia, Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss) or 6 (major tissue loss) - There is no mention of critical limb ischemia or symptoms that would suggest Rutherford categories 4, 5, or 6 in the patient note.\n6. Stenosis (>50% luminal loss) or occlusion of infra-genicular arteries (defined as distal to the infra-popliteal artery), including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery, and the peroneal artery - The patient note describes carotid artery stenosis, not infra-genicular artery stenosis.\n7. Infragenicular arterial lesions with a length of <20cm - No infragenicular arterial lesions are mentioned in the patient note.\n8. At least one crural (anterior tibial, posterior tibial, or peroneal) artery with expected unobstructed runoff to ankle level after treatment - The patient note does not provide information on the crural arteries.\n9. Successful guidewire crossing of the trial lesion - This is a procedural step that would be determined during the intervention, not from the patient note.\n\nBased on the patient note and the criteria provided, the patient does not have critical limb ischemia, nor is there any mention of infragenicular arterial disease or lesions. The patient's condition (carotid artery stenosis) does not match the target condition for the trial (critical limb ischemia with infragenicular arterial lesions).\n\nTherefore, the patient is not eligible for the SINGA-PACLI trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "742": {
        "output": "The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD (coronary artery disease). He has high LDL-C levels (545 mg/dL), normal fasting glucose (85 mg/dL), and normal triglyceride levels (158 mg/dL). He has no history of smoking, high blood pressure, or diabetes mellitus, and he has not been using any lipid-lowering medications. He exhibits severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nGiven the provided clinical trial information, we need to determine if the patient meets the inclusion criteria for a study designed to investigate the efficacy of moderate lifestyle modification for improving the clinical status of patients with coronary artery disease or patients with risk factors that promote coronary artery disease.\n\nThe inclusion criteria for the clinical trial are:\n\n- At least one known risk factor for cardiovascular disease, which includes:\n  - Family history of CAD (first-degree relative)\n  - Physician-diagnosed diabetes or stroke\n  - Overweight (BMI \u2265 25) or obese (BMI \u2265 30)\n  - Total cholesterol \u2265 200, documented history of hypercholesterolemia, or currently taking lipid-lowering medications\n  - History of smoking\n  - HDL \u2264 44 mg/dl\n  - LDL \u2265 130 mg/dl or documented history of hyperlipidemia\n  - Elevated triglycerides (\u2265 200 mg/dl)\n  - Hypertension (systolic blood pressure \u2265 130 mmHg, diastolic blood pressure \u2265 85 mmHg, documented diagnosis of hypertension, or currently taking antihypertensive medications)\n  - Diabetes (fasting glucose \u2265 100 mg/dl, physician diagnosis of diabetes/pre-diabetes, or currently taking anti-glycemic medications)\n  - Post-traumatic stress disorder (PTSD) or at risk for PTSD\n  - Insomnia (five hours of sleep per night or less) or sleep apnea\n\nThe patient has a family history of CAD and an LDL level of 545 mg/dL, which are both risk factors for cardiovascular disease that meet the inclusion criteria of the trial. The patient's HDL level is 53 mg/dL, which is above the threshold specified in the trial's inclusion criteria. His triglyceride levels are below 200 mg/dL, and his fasting glucose level is within normal limits, meaning he does not have diabetes according to the criteria.\n\nBased on the patient's family history of CAD and his high LDL levels, he meets the inclusion criteria for the clinical trial. There is no information provided that would suggest the patient meets any exclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "743": {
        "output": "To determine the eligibility of the patient for the \"Effects of Yoga on Metabolic Syndrome\" clinical trial, we need to compare the patient's characteristics with the inclusion criteria listed for the trial.\n\nInclusion Criteria for the clinical trial:\n1. Central obesity - Waist circumference >= 90 cm (Asian male); 80 cm (Asian female)\n2. High blood pressure - Systolic blood pressure/diastolic blood pressure >= 130/85 mmHg or use of hypertension drug\n3. Elevated blood glucose - Fasting blood glucose >= 100 mg/dL or use of hyperglycemia drug\n4. Elevated blood triglyceride - Blood triglyceride >= 150 mg/dL\n5. Reduced HDL-cholesterol - HDL-C <= 40 mg/dL (male); <= 50 mg/dL (female)\n\nPatient characteristics from the patient note:\n- The patient is a 46-year-old man.\n- The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively.\n- His fasting glucose and triglyceride levels were 85 and 158 mg/dL, respectively.\n- The patient reported no use of lipid-lowering medications.\n- There is no mention of the patient's waist circumference or blood pressure levels.\n- The patient does not have a history of using hypertension drugs or drugs for hyperglycemia.\n\nMatching patient characteristics against the inclusion criteria:\n1. The waist circumference of the patient is not mentioned in the patient note.\n2. The patient's blood pressure is not provided, nor is there any mention of hypertension medication use.\n3. The patient's fasting blood glucose is 85 mg/dL, which is below the threshold mentioned in the inclusion criteria.\n4. The patient's blood triglyceride level is 158 mg/dL, which meets the criteria for elevated blood triglyceride.\n5. The patient's HDL-C is 53 mg/dL, which does not meet the criterion for reduced HDL-cholesterol, as the cutoff is <= 40 mg/dL for males.\n\nBased on the information provided in the patient note, the patient does not meet three or more of the conditions required for a diagnosis of MetS according to the inclusion criteria. Specifically, the patient only meets one of the criteria (elevated blood triglyceride), while the criterion for reduced HDL-cholesterol is not met, and there is insufficient information for the other criteria (waist circumference, blood pressure, and elevated blood glucose).\n\nTherefore, the patient does not have sufficient information to qualify for the trial as they do not meet at least three of the conditions specified in the inclusion criteria for MetS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "744": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as well as high LDL-C levels. However, there is no mention of psoriasis in his medical profile.\n\nThe clinical trial is investigating the effects of treatment with biological agents on vascular and cardiac function in patients with psoriasis. The inclusion criteria specifically require patients to have psoriasis.\n\nSince the patient does not have a diagnosis of psoriasis, he does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "745": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, and has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His LDL-C is extremely high at 545 mg/dL, and his HDL-C is at 53 mg/dL. His fasting glucose and triglyceride levels are within normal limits, and he has no history of using lipid-lowering medications.\n\nNow, let's assess the patient's eligibility for the clinical trial titled \"Blopress Tablets Specified Drug-use Survey Hypertension: Survey on Patients With Metabolic Syndrome\" based on the inclusion and exclusion criteria provided:\n\nInclusion Criteria:\n- Hypertensive patients with at least one of the following risk factors:\n  - Waist circumference \u2265 85 cm for males\n  - Fasting triglyceride level \u2265 150 mg/dL\n  - HDL cholesterol level < 40 mg/dL\n  - Fasting blood glucose level \u2265 110 mg/dL\n  - BMI \u2265 25.0\n  - Patients currently taking medications for hypertriglyceridemia, hypo-HDL-cholesterolemia, or diabetes mellitus are also regarded as meeting the criteria for inclusion in the surveillance\n\nExclusion Criteria:\n- Hypertensive patients who meet all of the following conditions:\n  - Patients receiving continuous therapy with Blopress Tablets\n  - Patients aged < 20 years or \u2265 75 years\n  - Patients with a history of cerebrovascular or coronary artery disease within 6 months before the start of the surveillance\n\nThe patient note indicates that the patient has a high LDL cholesterol level, but there is no mention of hypertension or blood pressure values. The patient also does not meet the inclusion criteria based on the waist circumference, fasting triglyceride level, HDL cholesterol level, fasting blood glucose level, or BMI (as this information is not provided). Additionally, the patient is not reported to be on medications for hypertriglyceridemia, hypo-HDL-cholesterolemia, or diabetes mellitus. Without information on the patient's blood pressure or confirmation of a diagnosis of hypertension, we cannot determine that the patient is hypertensive, which is a requirement for inclusion in the study.\n\nMoreover, the patient doesn't seem to meet any of the exclusion criteria as there's no mention of him receiving continuous therapy with Blopress Tablets, being outside the age range, or having a history of cerebrovascular or coronary artery disease within 6 months before the start of the surveillance.\n\nGiven the information available, the patient does not have sufficient information to qualify for the trial as a hypertensive patient with metabolic syndrome-related risk factors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "746": {
        "output": "Based on the provided patient note, the 46-year-old man presents with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, among other symptoms. However, there is no mention of a concussion or head injury. The patient does not meet the specific inclusion criteria related to a history of concussion within the prior 6 months, which is required for the clinical trial mentioned.\n\nTherefore, the patient does not have sufficient information to qualify for the clinical trial focused on evaluating a novel assessment tool in patients with dizziness and balance problems following a concussion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "747": {
        "output": "Based on the information provided in the patient note, the patient is a 46-year-old man who has a family history of CAD and has presented with dizziness and frequent headaches. His LDL-C level is significantly elevated at 545 mg/dL, and HDL-C level is 53 mg/dL, which is above the threshold specified in the inclusion criteria for males (<50 mg/dL). The patient's triglyceride levels are slightly elevated at 158 mg/dL, which is above the 150 mg/dL threshold. His fasting plasma glucose is within normal limits at 85 mg/dL.\n\nThe patient has not reported the use of any lipid-lowering medications. Additionally, there is no mention of a liver transplant, which is a key inclusion criterion for the clinical trial in question.\n\nGiven that the patient does not have a history of liver transplant, he would not be eligible for the clinical trial, which specifically targets patients who have had a liver transplant and are experiencing metabolic complications as a result.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "748": {
        "output": "",
        "label": 2
    },
    "749": {
        "output": "Based on the patient note provided, the 46-year-old man has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The clinical trial in question is focused on individuals with aneurysms of the extracranial carotid artery. The inclusion criteria specify that the individual must have one or more aneurysms of the extracranial carotid artery, be at least 18 years of age, and have signed informed consent.\n\nThe patient described in the note does not have an aneurysm; instead, he has carotid artery stenosis. As such, he does not meet the specific inclusion criterion of having an extracranial carotid artery aneurysm, despite meeting the age criterion and potentially being able to provide informed consent.\n\nTherefore, the patient is not eligible for the Carotid Aneurysm Registry clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "750": {
        "output": "Upon reviewing the patient note and the clinical trial information provided, the following assessment of eligibility can be made:\n\nThe clinical trial is focused on individuals with moderate to severe plaque psoriasis and is assessing the effectiveness of biologics in treating this condition. The inclusion criteria specify that subjects must be diagnosed with moderate to severe plaque psoriasis, be initiating or switching to a biologic treatment for psoriasis, be able to complete questionnaires, and provide written informed consent.\n\nThe patient described in the patient note presents with dizziness, frequent headaches, high LDL cholesterol, and significant carotid artery stenosis. The patient has a family history of coronary artery disease (CAD) but does not mention any diagnosis of psoriasis, let alone the moderate to severe plaque psoriasis required for inclusion in the trial.\n\nGiven the information available in the patient note, there is no indication that the patient has been diagnosed with psoriasis. Therefore, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "751": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Mesoglycan, Vascular Reactivity and Metabolic Syndrome,\" we need to compare the patient's characteristics and medical condition against the inclusion criteria provided by the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Increased abdominal circumference \u2265102 cm in man, \u226588 cm in women\n2. Triglycerides \u2265150 mg/dL\n3. HDL-cholesterol <40 mg/dL in men, <50 mg/dL in women\n4. Systolic blood pressure > 130 mm Hg or diastolic blood pressure > 85 mm Hg\n5. Blood glucose > 100 mg/dL\n\nA patient must meet at least 3 of these criteria to qualify for the trial.\n\nFrom the patient note, we have the following information:\n\n1. The patient's triglyceride level is 158 mg/dL, which meets the second criterion.\n2. The patient's HDL-cholesterol level is 53 mg/dL. This does not meet the third criterion, as the patient's level is above the threshold for men.\n3. The patient's blood glucose level is 85 mg/dL, which is within normal limits and does not meet the fifth criterion.\n4. There is no mention of the patient's blood pressure, so we cannot assess whether he meets the fourth criterion.\n5. There is no information provided about the patient's abdominal circumference, so we cannot assess whether he meets the first criterion.\n\nSince the patient note lacks information on abdominal circumference and blood pressure, and because the patient's HDL cholesterol and blood glucose do not meet the thresholds set by the inclusion criteria, we do not have sufficient evidence to conclude that the patient meets at least 3 of the required criteria.\n\nTherefore, based on the available information, the patient would be classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "752": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the EXTEND Exercise Trial, it is clear that the patient in question does not meet the specific requirements for participation in the trial. The trial is focused on men with non-metastatic, hormone-na\u00efve prostate cancer who are receiving the combination of enzalutamide (ENZ) and androgen deprivation therapy (ADT). The patient's note does not mention prostate cancer or any treatment related to it. Instead, the patient presents with cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, and has no mention of prostate cancer or the required treatments.\n\nTherefore, the patient does not meet the trial's inclusion criteria, which require a diagnosis of prostate cancer, among other specific criteria related to that condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "753": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, and cardiovascular issues including severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as evidenced by ultrasonography. He also has a family history of CAD and elevated LDL-C levels, but he does not have hypertension or diabetes and is physically active.\n\nThe clinical trial in question is looking to understand how red blood cells reflect age-dependent changes in endothelial function in old age. The inclusion criteria state that the subjects should be healthy and must provide informed consent.\n\nSince the patient has significant cardiovascular issues, including carotid artery stenosis, and the study is looking for healthy subjects, the patient does not meet the inclusion criteria for being a healthy subject. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "754": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, no cardiovascular risk factors other than a family history of coronary artery disease (CAD), and is physically active. His LDL-C level is extremely high at 545 mg/dL, while his HDL-C, fasting glucose, and triglyceride levels are within normal limits. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no mention of the patient being diagnosed with homozygous familial hypercholesterolemia (HoFH), only that he has very high LDL-C levels.\n\nThe clinical trial is studying REGN1500 in participants with homozygous familial hypercholesterolemia (HoFH).\n\nTo be eligible for the trial, the inclusion criteria are:\n1. Men and women \u226518 years of age at the time of the screening visit.\n2. Diagnosis of homozygous familial hypercholesterolemia (HoFH).\n3. Willing to consistently maintain usual diet for the duration of the study.\n\nAlthough the patient has very high LDL-C levels, the patient note does not specify a diagnosis of HoFH. Without a confirmed diagnosis of HoFH, we do not have sufficient information to determine the patient's eligibility for the trial based on the inclusion criteria provided.\n\nTherefore, the trial-level eligibility is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "755": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial titled \"Postcath Radial Arterial Clamp Time In the Cath Lab.\"\n\nThe patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He presents with dizziness and frequent headaches and has high LDL-C levels. However, there is no mention of the patient requiring cardiac catheterization via the radial approach or evidence of radial artery patency, nor is there any indication that the patient has coronary artery disease or that he has undergone or is scheduled for a procedure that would involve the use of a radial clamp post-procedure.\n\nThe clinical trial's inclusion criteria specifically require:\n\n1. Patients who require cardiac catheterization via the radial approach for the investigation and treatment of coronary artery disease.\n2. Evidence of pre-procedural radial artery patency using the Barbeau test.\n3. The ability of patients to give informed consent.\n\nGiven that there is insufficient information to suggest that this patient meets the inclusion criteria for the clinical trial, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "756": {
        "output": "The patient in the provided note is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He presents with dizziness and frequent headaches, and his LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively. There is no mention of pulmonary arterial hypertension (PAH) or participation in Study APD811-003 or being assigned to placebo in that study.\n\nThe clinical trial in question is focused on the long-term safety and efficacy of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003 or were assigned to receive placebo and were discontinued due to clinical worsening.\n\nBased on the information provided in the patient note, the patient does not meet the specific inclusion criteria for the clinical trial, which requires a diagnosis of WHO Group 1 PAH and previous participation in Study APD811-003. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "757": {
        "output": "",
        "label": 0
    },
    "758": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches. However, there is no mention of orthostatic hypotension or any blood pressure measurements after standing, which are required to meet the inclusion criteria for the clinical trial on neurogenic orthostatic hypotension. The patient does have significant carotid artery stenosis, but this is not necessarily related to orthostatic hypotension, nor is it mentioned as an inclusion or exclusion factor for the trial.\n\nSince the patient's symptoms of dizziness and headaches could be due to many different causes, and there is no specific information on orthostatic blood pressure measurements, we cannot determine if he meets the inclusion criteria of having orthostatic hypotension. Therefore, without this information, we cannot assess if he is eligible for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "759": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus; physically active\n- LDL-C level of 545 mg/dL and HDL-C level of 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Systolic murmur detected in the neck\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%\n- Peak-systolic velocity (PSV) and end-diastolic velocity (EDV) for LICA and RICA provided\n- Presence of plaque in the internal and common carotid arteries\n\nClinical Trial Inclusion Criteria:\n- Patients with 50% stenosis of the carotid arteries that are safe to undergo MRI imaging\n\nThe patient's condition meets the inclusion criteria for the clinical trial since the ultrasonography revealed severe stenosis in the left internal carotid artery, which qualifies as more than 50% stenosis. Additionally, there is no mention of any contraindications for MRI imaging for the patient, suggesting that they are safe to undergo such imaging.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "760": {
        "output": "Based on the information provided and comparing it with the clinical trial's inclusion criteria, let's break down the patient's eligibility:\n\nThe inclusion criteria for the clinical trial are:\n\n1. Women with urgency, nocturia, and frequency.\n2. Abdominal obesity, defined as a waist circumference in men \u226588 cm.\n3. Serum triglycerides \u2265150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides.\n4. Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C.\n5. Blood pressure \u2265130/85 mmHg or drug treatment for elevated blood pressure.\n6. Fasting plasma glucose (FPG) \u2265100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose.\n\nThe patient's characteristics are:\n\n1. A 46-year-old man.\n2. Presents with dizziness and frequent headaches.\n3. No history of lipid-lowering medication use.\n4. Serum triglycerides at 158 mg/dL.\n5. Serum HDL cholesterol at 53 mg/dL.\n6. Fasting plasma glucose at 85 mg/dL.\n\nEven though the patient's triglyceride levels meet the inclusion criteria (\u2265150 mg/dL), he does not meet the criteria for abdominal obesity, and his HDL cholesterol and fasting plasma glucose levels do not fall into the required ranges. Additionally, the patient is male, and the trial specifically includes women with urgency, nocturia, and frequency, which are not mentioned in the patient's note.\n\nTherefore, the patient does not meet sufficient inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "761": {
        "output": "",
        "label": 1
    },
    "762": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Maintaining Suppression of Testosterone With Transdermal Estradiol Gel,\" we can analyze the patient's eligibility as follows:\n\nPatient Information:\n- 46-year-old man (meets age criterion)\n- Presents with dizziness and frequent headaches (not relevant to prostate cancer)\n- No mention of prostate cancer or any treatment related to Androgen Deprivation Therapy (ADT)\n- No mention of testosterone levels or WHO/ECOG performance status\n- No indication of renal function tests\n\nClinical Trial Inclusion Criteria:\n- Males, Ages 18 and older (patient meets this criterion)\n- BMI between 18 and 35 kg/m2 (no BMI provided)\n- Not currently hospitalized (no information on hospitalization)\n- Clinical indication of adenocarcinoma of the prostate evidenced by a biopsy report on record (no indication of prostate cancer)\n- At present receiving ADT treatment with a GnRH agonist for at least 2 months but not longer than 36 months without interruption (no ADT treatment mentioned)\n- Able to initiate Screening procedures 2 weeks prior to the next scheduled injection with a GnRH agonist (no relevant information)\n- Willing to discontinue current ADT regimen for the duration of the study (no ADT regimen mentioned)\n- T level less than 50 ng/dL at Screening (no testosterone level provided)\n- WHO/ECOG performance status of 0 or 1 (no performance status provided)\n- Life expectancy of at least 1 year (no information on life expectancy)\n- Adequate renal function demonstrated by having normal BUN and Creatinine Screening lab values (no renal function information provided)\n\nThe patient does not have sufficient information to be considered for the clinical trial, as there is no mention of prostate cancer, ADT treatment, testosterone levels, WHO/ECOG performance status, life expectancy, or renal function\u2014all of which are necessary to determine eligibility for this particular study. Therefore, the patient is classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "763": {
        "output": "The patient presented is a 46-year-old man with dizziness, frequent headaches, and a family history of CAD. His symptoms and investigations, including elevated LDL-C levels and carotid artery stenosis, suggest cardiovascular issues but do not confirm the presence of a chronic total occlusion (CTO) of a coronary artery. The clinical trial in question is specifically looking to enroll patients who are undergoing elective percutaneous revascularization of a CTO. A CTO is defined as an occluded coronary artery with TIMI 0 flow that has been occluded for 3 months or more.\n\nSince the patient note does not mention a CTO or that the patient is being considered for percutaneous revascularization of a CTO, there is insufficient information to determine if the patient meets the inclusion criteria for the Chronic Total Occlusion Registry clinical trial. Therefore, the patient would be classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "764": {
        "output": "",
        "label": 0
    },
    "765": {
        "output": "The patient described in the note is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels and has been diagnosed with dizziness and frequent headaches. There is no mention of coronary artery disease (CAD) as a current condition, but he has a family history of CAD.\n\nThe clinical trial in question is seeking participants over 18 years of age with stable coronary artery disease and is focused on the analysis of provisional main vessel stenting on side branches. The inclusion criteria specify that patients must be presenting with stable coronary artery disease.\n\nGiven the information in the patient note, the patient does not clearly meet the criteria for having stable coronary artery disease; rather, he has carotid artery stenosis, which is a different condition. Therefore, based on the information provided, there is not enough evidence to determine that he has stable coronary artery disease, which is required for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "766": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient described does not appear to have chronic hepatitis B, which is a requirement for participating in the trial. The patient presents with cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, and has abnormal lipid levels. These conditions are not related to chronic hepatitis B or the treatment being studied in the clinical trial.\n\nGiven that the patient's condition (severe carotid artery stenosis) does not match the target disease (chronic hepatitis B) of the clinical trial, and none of the inclusion criteria are met, the patient would not be relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "767": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches, with a family history of CAD but no other cardiovascular risk factors. His LDL-C level is significantly elevated at 545 mg/dL, and he has severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery.\n\nComparing this to the inclusion criteria of the clinical trial:\n\n1. Arteriosclerotic cardiovascular disease: While there's no clear indication that the patient has had acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary revascularization, stroke, or transient ischemic attack, the severe stenosis in the carotid arteries could potentially be considered under \"revascularization\" if it is presumed to be of atherosclerotic origin. However, without additional information, we cannot definitively conclude this.\n\n2. Moderate-High CVD risk according to the WHO charts adapted by the National MoH (estimated 10-year CVD risk \u2265 20%): This is not provided in the patient note, so we cannot determine the patient's CVD risk according to WHO charts.\n\n3. LDL-C level \u2265 190 mg/dL: The patient meets this criterion with an LDL-C level of 545 mg/dL.\n\n4. Type 2 diabetes in patients between 40 and 75 years of age: The patient does not have type 2 diabetes as per the information provided.\n\nGiven that the patient does have an LDL-C level significantly higher than the threshold specified in the inclusion criteria and is within the age range specified for diabetes patients, but there is no mention of diabetes, the patient could potentially be eligible based on the LDL-C criterion alone. However, the lack of information on his actual CVD risk (which is required to determine moderate-high risk status) means we cannot fully assess his eligibility. Without full information on arteriosclerotic cardiovascular disease and CVD risk according to WHO charts, the patient's eligibility remains unclear.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "768": {
        "output": "In this scenario, we need to determine the trial-level eligibility of a 46-year-old man presenting with dizziness, frequent headaches, and a significant finding of severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery for a clinical trial on the relationship between diet, lifestyle, and the severity of coronary artery disease (CAD).\n\nThe inclusion criteria for the clinical trial are:\n- Patients fluent in English or Spanish\n- Referred for coronary angiography\n- Fully able to fill out the baseline questionnaires\n\nThe patient's note provides the following relevant information:\n- The patient is a 46-year-old man, which satisfies the age requirement.\n- There is no mention of language fluency, but we do not have any information that suggests he is not fluent in English or Spanish.\n- The patient has been referred for ultrasonography of the carotid arteries, which is not the same as a coronary angiography. Coronary angiography is a procedure that visualizes the arteries of the heart, while ultrasonography of the carotid arteries visualizes the arteries in the neck. Therefore, it does not directly state that the patient is referred for coronary angiography.\n- There is no mention of whether the patient is able to fill out questionnaires, but there is also no indication that he is unable to do so.\n\nSince the key requirement for inclusion in the trial is being referred for coronary angiography, and the patient's note does not indicate that the patient has been referred for this specific procedure, the patient does not meet the inclusion criteria based on the information provided. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "769": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient characteristics:\n- 46-year-old man (within the 45-65 years age range for the trial)\n- Presents with dizziness and frequent headaches\n- Family history of CAD (coronary artery disease)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- Physically active\n- LDL-C and HDL-C levels are provided, with LDL-C being elevated\n\nClinical trial inclusion criteria:\n- Cardiovascular disease patients 45-65 years old\n- Patients with \u2265 50% stenosis in at least one coronary angiogram demonstrated\n- Body mass index in the range 18.5-35\n- Avoidance of dietary supplements, vitamins, and herbal products at least 3 months before and throughout the intervention\n- Willingness to participate\n\nAssessment:\n- Age: The patient is 46 years old, which fits the trial's age criterion.\n- The patient has a family history of CAD, but the inclusion criteria specifically require patients with cardiovascular disease. The provided note does not confirm a diagnosis of CAD; rather, it mentions severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. Carotid artery stenosis is not the same as coronary artery disease, and the trial's inclusion criteria specify stenosis in at least one coronary angiogram.\n- There is no information about the patient's BMI.\n- The patient has not been reported to be using dietary supplements, vitamins, or herbal products, which complies with the trial's criteria.\n- The patient's willingness to participate is not mentioned in the note.\n\nGiven the information, the patient does not meet the specific disease criteria for the trial (CAD with \u2265 50% stenosis in at least one coronary angiogram), as the stenosis is in the carotid arteries, not the coronary arteries. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "770": {
        "output": "Based on the patient note provided:\n\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Family history of CAD, no other cardiovascular risk factors.\n- Physically active.\n- LDL-C level is 545 mg/dL, which is significantly higher than the normal range and thus could be considered hypercholesteremia.\n- HDL-C, fasting glucose, and triglyceride levels are within normal limits.\n- No use of lipid-lowering medications.\n- Carotid ultrasonography revealed severe stenosis in the LICA and moderate stenosis in the RICA.\n- The patient has a systolic murmur.\n\nThe clinical trial's inclusion criteria are:\n\n- Both sexes.\n- Coronary heart disease (CHD) (angiographically or clinically approved).\n- Sufficient knowledge of the German language.\n- At least one not sufficiently controlled risk factor: Diabetes mellitus (HbA1c>7.5%), smoking, lack of physical activity (less than 60 minutes of light physical exercise per week), heightened stress level (PSS-4 >5), arterial hypertension (blood pressure despite medication repeatedly heightened >140/90 or in a 24-hour measurement >135/85 mmHg), hypercholesteremia (LDL >130 mg/dL).\n- Written informed consent to participate.\n\nThe patient's LDL-C level is much higher than 130 mg/dL, indicating hypercholesteremia, which is one of the risk factors mentioned in the inclusion criteria. However, there is no direct mention of CHD in the patient's note, only a family history of CAD and symptoms that might be related to his carotid artery condition. There is no clear indication that he has been angiographically or clinically diagnosed with CHD.\n\nGiven the information in the note, the patient does have a risk factor (hypercholesteremia) that is not sufficiently controlled. However, without a clear indication of a CHD diagnosis, we cannot conclusively say that he meets all the inclusion criteria. Therefore, the patient might not be relevant for this trial due to a lack of information confirming a diagnosis of CHD, which is a core criterion for inclusion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "771": {
        "output": "To determine the trial-level eligibility of the patient, we must compare the patient note with the inclusion criteria of the clinical trial.\n\nHere are the inclusion criteria for the clinical trial:\n1. Subject has a symptomatic or asymptomatic internal carotid artery (ICA) stenosis \u2265 70% as detected by a duplex sonography and confirmed using CTA, MRA, or DSA.\n2. Subject is indicated for carotid endarterectomy (CEA) according to the criteria set by the American Heart Association.\n3. Subject is aged 40 - 85 years.\n4. Subject has a sufficient temporal bone window for transcranial Doppler (TCD) with detectable blood flow in the middle cerebral artery (MCA).\n5. Subject is functionally independent with a modified Rankin score value of 0 - 2 points.\n6. Informed consent is signed by the subject.\n\nNow, let's assess the patient note:\n- The patient is a 46-year-old man, which meets the age criterion (3).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the values provided (PSV and EDV for LICA and RICA) do not confirm if the stenosis is \u2265 70%, as required by the first criterion. Without this confirmation, we cannot conclusively determine whether the patient meets criterion (1).\n- There is no information regarding the indication for CEA per American Heart Association criteria, so we cannot assess the patient against criterion (2).\n- The patient note does not provide information about the patient's temporal bone window or the detectability of blood flow in the MCA, leaving criterion (4) unassessed.\n- There is no information regarding the patient's functional independence or modified Rankin score, so we cannot assess criterion (5).\n- The patient note does not mention informed consent, but this is typically obtained after determining eligibility, so we will not use this criterion for the assessment.\n\nThe patient note does not provide enough information to determine eligibility based on the trial's inclusion criteria. Specifically, we lack confirmation of \u2265 70% ICA stenosis, an indication for CEA, sufficient temporal bone window, and functional independence score.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "772": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\n**Patient Note Review:**\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- No history of cardiovascular risk factors except for a family history of CAD.\n- Elevated LDL-C levels.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- Ultrasonography findings consistent with carotid artery disease.\n\n**Clinical Trial Inclusion Criteria Review:**\n- The patient must be \u226518 years of age. (Patient is 46, so meets this criterion.)\n- Patient is an acceptable candidate for PTCA, Stenting, or Emergent CABG. (Based on the patient note, there is no explicit information on whether the patient is an acceptable candidate for these procedures, but carotid artery stenosis might require intervention.)\n- Symptomatic ischemic heart disease (CCS class 1-4, Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) and/or objective evidence of myocardial ischemia. (The patient note does not mention ischemic heart disease or myocardial ischemia.)\n- TIMI (Thrombolysis In Myocardial Infarction) flow grade \u2265 2. (No information provided on TIMI flow grade.)\n- C.T.O's (Chronic Total Occlusions) and Bifurcation Lesions may also be attempted. (No information on Chronic Total Occlusions or Bifurcation Lesions.)\n- Target lesion stenosis is >50% and <100%. (The patient has severe stenosis in the left internal carotid artery, but this does not specify coronary artery stenosis.)\n- Target lesions are de novo. (No information provided if lesions are de novo.)\n- Target lesions \u2264 35mm in length that can be treated (covered) by one single study stent. (No information on the length of target lesions in coronary arteries.)\n- Target lesion located in a major epicardial coronary vessel with reference of \u2265 2.5 - \u2264 3.5mm in diameter. (No information on coronary vessel involvement; the stenosis mentioned is in carotid arteries.)\n- Target lesions which can be covered by one stent, no overlapping allowed (lesion stent ratio of at least 1.5). (No information on ability to cover lesions with one stent.)\n- The patient has provided a written informed consent. (No information on consent given.)\n\n**Eligibility Assessment:**\nThe patient does not have sufficient information to qualify for the trial based on the note provided. The trial is focused on coronary artery disease and stenting, while the patient's note discusses carotid artery disease. There is no mention of coronary artery disease or related interventions in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "773": {
        "output": "The patient note describes a 46-year-old man who presents with dizziness and frequent headaches. There is no mention of a diagnosis of tension-type headache (TTH) by a neurologist, nor is there any indication that the patient's headaches match the characteristics established by the International Headache Society. Furthermore, the patient is not reported to be on controlled pharmacological treatment for headaches.\n\nThe clinical trial in question is targeting patients with tension-type headache diagnosed by a neurologist and controlled pharmacologically. Since the patient's headache type has not been specified as tension-type headache and there is no evidence of a neurologist's diagnosis or controlled pharmacological treatment, this patient's information does not meet the inclusion criteria set forth by the clinical trial.\n\nTherefore, based on the information provided in the patient note and the specified inclusion criteria for the clinical trial, the patient would not be eligible for this trial. The assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "774": {
        "output": "Given the patient note, we have a 46-year-old man with dizziness and frequent headaches. He has a family history of coronary artery disease (CAD), but does not have cardiovascular risk factors such as smoking, high blood pressure, or diabetes mellitus, and he is physically active. The patient also has hyperlipidemia, as indicated by his LDL-C levels, and carotid artery stenosis, as indicated by neck ultrasonography.\n\nNow, let's review the inclusion criteria of the clinical trial:\n\n1. Patient has a new, unrated histologic diagnosis of cervical or vaginal cancer in specific stages.\n2. Patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan.\n3. Patient must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2 or equivalent.\n4. Blood count and chemistry values within a certain range.\n5. No uncontrolled diabetes mellitus.\n6. A life expectancy of greater than 20 weeks.\n7. No known brain metastases.\n8. No known human immunodeficiency virus syndrome (HIV).\n9. No known allergy to compounds of similar or biologic composition as triapine.\n10. No known glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n11. Not actively breastfeeding.\n\nThe patient note does not mention cervical or vaginal cancer, which is a key inclusion criterion for the trial, nor does it specify any cancer. There is no information provided that would align the patient's condition with the target conditions of the trial. Based on the available information, the patient does not meet the inclusion criteria for the study because the patient does not have the condition the study is targeting.\n\nTherefore, the assessment of trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "775": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, I will analyze the patient's eligibility.\n\nPatient Note:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, diabetes mellitus\n- Physically active\n- High LDL-C levels and normal HDL-C levels\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Systolic murmur in the neck\n\nClinical Trial Inclusion Criteria:\n- Male patients with locally advanced or metastatic prostate cancer or high-risk prostate cancer\n- Scheduled to start ADT for at least one year\n- History of cardiovascular conditions (various listed)\n- Life expectancy of over 12 months\n- WHO performance status of 0-2\n- Ability and agreement to sign a consent form\n\nFrom the patient note, there is no mention of the patient having prostate cancer or being scheduled to start androgen deprivation therapy (ADT). The cardiovascular conditions listed are part of the patient's history, but the trial specifically requires patients with prostate cancer.\n\nTherefore, the patient does not meet the necessary inclusion criteria for the clinical trial, as there is no information indicating that the patient has prostate cancer or is scheduled to start ADT.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "776": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE),\" we need to go through the inclusion and exclusion criteria and compare them to the patient's note.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Patients with either heterozygous familial hypercholesterolemia or established cardiovascular disease.\n- LDL-C concentrations of a certain level depending on the patient's condition.\n- Not adequately controlled with a maximally tolerated dose of statin with or without other lipid-modifying therapies.\n\nThe patient's note indicates that:\n- The patient is a 46-year-old man with severe hypercholesterolemia (LDL-C levels were 545 mg/dL).\n- The patient has not been reported to use lipid-lowering medications, which could be interpreted as not being adequately controlled with lipid-modifying therapy.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nFrom the information given, the patient fits the following inclusion criteria:\n- Non-FH participants suffering from established CHD or other CVD (carotid artery stenosis >=50%) and with LDL-C concentrations >=130 mg/dL (the patient's LDL-C is 545 mg/dL).\n\nHowever, there are also exclusion criteria to consider:\n- Not on a stable dose of lipid-modifying therapy (LMT) for at least 4 weeks prior to the screening visit.\n- Fasting serum TG >400 mg/dL at the screening visit, but the patient's TG levels are 158 mg/dL.\n- The patient has not been reported to be on any lipid-modifying therapy, so we cannot confirm whether they have been on a stable dose for 4 weeks.\n\nGiven the information provided, the patient has severe hypercholesterolemia, which is a target condition for the clinical trial. However, the patient is not on lipid-modifying therapy, which is required as per the trial inclusion criteria. This information is crucial and puts the patient at a position where, without additional information, they could potentially be eligible if they meet the requirement of being on a stable dose of LMT for at least 4 weeks prior to the screening visit.\n\nThe absence of this information leads to a rating of:\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "777": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Structural Stability of Carotid Plaque and Symptomatology,\" we need to compare the patient's information with the inclusion and exclusion criteria of the trial.\n\nPatient Information:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No previous history of carotid artery surgery mentioned\n- No mention of contraindication to MRI scans\n- Not stated if the patient is undergoing carotid endarterectomy or stenting\n- English-speaking\n- No mention of impaired consent capacity\n- No mention of prisoner status\n- No history of stroke or TIAs mentioned\n\nInclusion Criteria (Patients):\n- Patients undergoing carotid endarterectomy or stenting for established clinical criteria\n- Age > 18 years\n- Male or Female\n- English speaking\n- Patients must sign written informed consent form\n\nExclusion Criteria (Patients):\n- Previous history of carotid artery surgery on the same side\n- Previous cervical radiation\n- Patients not felt to be suitable for carotid endarterectomy or stenting\n- Patients with impaired consent capacity\n- Contraindication to MRI scans\n- Prisoner status\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria: he is over 18 years old, male, and English-speaking. However, there is no information indicating that the patient is undergoing carotid endarterectomy or stenting, which is a specific inclusion criterion for the trial. Therefore, we cannot determine from the provided information whether the patient is eligible or not for the trial.\n\nGiven the lack of information about whether the patient is undergoing carotid endarterectomy or stenting, the patient is classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "778": {
        "output": "The patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has significantly elevated LDL-C levels and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. These medical issues indicate that the patient has cardiovascular disease and is not healthy on the basis of physical examination and potentially other diagnostic criteria such as vital signs and laboratory tests.\n\nThe clinical trial in question is looking for healthy adults to compare the pharmacokinetic properties of two tablet formulations of macitentan. The inclusion criteria specifically require that participants be healthy based on physical examination, vital signs, ECG, and laboratory tests.\n\nGiven that the patient has severe cardiovascular issues, he does not meet the criteria of being healthy as required by the clinical trial. Therefore, the patient is not eligible for participation in the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "779": {
        "output": "The patient in question is a 46-year-old man who presents with dizziness and frequent headaches. He has elevated LDL-C levels, severe stenosis in the left internal carotid artery, and moderate stenosis in the right internal carotid artery. These findings indicate the presence of subclinical atherosclerosis, which is a form of arterial atherosclerotic disease.\n\nThe clinical trial is investigating factors influencing high-risk subclinical atherosclerosis, but the inclusion criteria specify that individuals must be free of clinical manifested arterial atherosclerotic disease. Since the patient has evidence of subclinical atherosclerosis, they do not meet the inclusion criteria for the trial, which requires participants to be free of clinical and manifested arterial atherosclerotic disease.\n\nTherefore, the trial-level eligibility for the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "780": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility:\n\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient is symptomatic, as indicated by dizziness and frequent headaches.\n- The ultrasonography of the carotid arteries revealed severe stenosis in the LICA, which could potentially meet the requirement for symptomatic patients with carotid stenosis \u2265 50% by angiography, considering that ultrasonography is often used as a non-invasive alternative to angiography.\n- There is no mention of the target lesion length or if it can be covered by a single stent of no more than 40 mm in length.\n- There is no mention of the reference vessel diameter (RVD).\n- There is no information provided regarding the landing zone for the integrated embolic protection filter.\n- The patient is willing to comply with all follow-up required study visits as this is not contradicted in the note.\n- The patient has not provided written informed consent, but this is typically obtained after determining eligibility.\n\nGiven the above points, the patient appears to meet some of the inclusion criteria (documented stenotic atherosclerotic lesion, symptomatic status, and severe stenosis), but there is insufficient information to determine if all the inclusion criteria are met. Particularly, there is no information about the length of the lesion, the reference vessel diameter, and landing zone for filter deployment. Therefore, the patient cannot be deemed eligible without this additional information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "781": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient's Characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Severe stenosis in the left internal carotid artery\n- No mention of transient ischemic attack or recent ischemic stroke\n- No mention of undergoing carotid endarterectomy\n- No mention of MRI confirmation of ischemic stroke\n\nClinical Trial Inclusion Criteria:\n- Man with transient ischemic attack or recent ischemic stroke (<15 days) in the carotid territory, confirmed by MRI\n- Man with carotid stenosis > 50% on the side of stroke\n- Male candidate for carotid endarterectomy\n- Subject affiliated or beneficiary of a social security scheme\n- Informed written consent\n\nComparison:\n- The patient is a man, which aligns with the trial's requirements.\n- The patient has severe stenosis in the left internal carotid artery, but the degree of stenosis in the right internal carotid artery is between 40% and 50%, which does not meet the criterion of carotid stenosis > 50%.\n- There is no information provided about a transient ischemic attack or recent ischemic stroke, nor is there any mention of MRI confirmation, which is a requirement for the trial.\n- There is no information on whether the patient is a candidate for carotid endarterectomy or about his affiliation with a social security scheme.\n\nGiven the information provided in the patient note, the patient does not meet several key inclusion criteria for the clinical trial: no mention of a transient ischemic attack or recent ischemic stroke confirmed by MRI and no indication that the patient is a candidate for carotid endarterectomy. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "782": {
        "output": "To determine the patient's eligibility for the MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR) clinical trial, we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- Aged 46 years (meets inclusion criteria of 40-60 years)\n- LDL-C level of 545 mg/dL (meets high cardiovascular risk criterion of LDL-C > 250 mg/dL)\n- Family history of CAD (meets high cardiovascular risk criterion of family history of premature onset CHD)\n- Has not reported use of lipid-lowering medications (cannot determine if treated or untreated by lipid lowering treatment)\n- Asymptomatic (meets inclusion criteria)\n- No EKG sign of ischemia reported (cannot determine if there is an EKG sign of ischemia)\n- No personal history of CHD mentioned (meets inclusion criteria)\n\nNotable findings:\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n\nExclusion criteria to consider:\n- No mention of genetic mutation identification (LDL-R, ApoB, PCSK9) for heterozygous familial hypercholesterolemia\n- No information about EKG signs of ischemia\n- No information on the patient's affiliation to a healthcare system\n- No contraindications to MRI or gadolinium injection mentioned\n- No mention of renal failure or diabetes mellitus\n- No mention of uncontrolled hypertension\n- No mention of previous use of an Amgen product in the past 12 months\n\nGiven the information provided, the patient is asymptomatic, within the age range, and has a very high LDL-C level with a family history of CAD, which could meet the high cardiovascular risk criteria. However, there is insufficient information about the presence of a genetic mutation for familial hypercholesterolemia, EKG signs of ischemia, and previous treatments with lipid-lowering medications. Additionally, we lack information about any contraindications to MRI, the patient's healthcare system affiliation, and other exclusion criteria.\n\nBased on the available information, the patient note does not provide sufficient information to confirm eligibility for the trial, specifically regarding the genetic mutation required for familial hypercholesterolemia and other necessary medical history details.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "783": {
        "output": "To determine the eligibility of the patient for the B-HIVE study based on the provided inclusion criteria, we need to analyze the patient's medical information:\n\n1. Signed informed consent: The patient note does not mention whether the patient has provided informed consent, but this is typically obtained before the start of the study.\n2. Willing to comply with study requirements: This information is not provided in the patient note.\n3. Age greater than 40 years: The patient is 46 years old, which meets this criterion.\n4. Documented HIV infection: There is no mention of HIV infection in the patient's history.\n5. Moderate or high CVD risk as defined by the criteria: The patient has severe stenosis in the left internal carotid artery, which could potentially meet the cerebrovascular disease criterion if it is deemed to have carotid origin. However, there is no mention of prior ischemic stroke of carotid origin, carotid endarterectomy or stenting, or angiographic carotid stenosis of at least 50%. Thus, it is not clear whether the patient meets this criterion based on the information provided.\n6. CVD risk factors: The patient does not have controlled type II diabetes mellitus, is not a current smoker, does not have hypertension, and while he has dyslipidemia, the HDL levels are not below the specified thresholds.\n7. Lipid levels: The patient's fasting LDL-C level is 545 mg/dL, which is above the threshold of 70 mg/dL.\n8. Contraception: The patient is male, so the criteria regarding female contraception do not apply.\n\nBased on the available information, the determining factors for the patient's eligibility are the documented HIV infection and the unclear status of the cerebrovascular disease criterion. Since there is no mention of an HIV infection and it is not clear whether the patient's carotid stenosis would qualify as cerebrovascular disease under the study's criteria, the patient does not meet the necessary inclusion criteria for the B-HIVE study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "784": {
        "output": "To determine the trial-level eligibility of the patient for the Clear-Road Trial, we need to verify if the patient meets the inclusion criteria based on the provided patient note.\n\nHere are the inclusion criteria for the clinical trial:\n1. High risk for carotid endarterectomy due to anatomical or co-morbid conditions and either:\n   a. Has neurological symptoms and \u2265 50% stenosis via angiography, or\n   b. Is asymptomatic and has \u2265 80% stenosis via angiography.\n2. Target lesion located in the distal common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation.\n3. Arterial segment to be stented has a diameter between 4mm and 9mm.\n4. Age \u2265 18 years.\n5. Life expectancy > 12 months from the date of the index procedure.\n6. Provides a signed, IRB/IEC approved informed consent form prior to participation.\n7. Willing and able to comply with follow-up requirements.\n\nFrom the patient note:\n- The patient is 46 years old, so criterion 4 (Age \u2265 18 years) is met.\n- There is no mention of the patient's life expectancy. However, there are no indications of a condition that would suggest the patient has a life expectancy of less than 12 months. We can tentatively assume criterion 5 is met.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The degree of stenosis for LICA is not quantified in the note as \u2265 80%, which would be required if the patient is asymptomatic according to the clinical trial inclusion criteria. However, the patient presents with dizziness and frequent headaches, which could be considered neurological symptoms. If these symptoms are related to the carotid stenosis, criterion 1a could potentially be met, but this would need confirmation via angiography, not just ultrasonography.\n- The target lesion's location in the ICA meets criterion 2.\n- The arterial segment diameter is not provided in the patient note, so criterion 3 cannot be confirmed.\n- The patient's willingness and ability to comply with follow-up requirements, as well as providing a signed consent form as per criterion 6 and 7, cannot be determined from the note.\n\nBased on the available information, the patient note does not provide sufficient data to confirm eligibility for the trial, particularly the degree of stenosis via angiography, the arterial segment diameter, and the patient's consent and ability to comply with the trial's requirements. Therefore, the patient falls under the \"Not relevant\" category due to insufficient information for a conclusive assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "785": {
        "output": "Based on the patient note, the 46-year-old man has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The peak-systolic velocity (PSV) and end-diastolic velocity (EDV) cutoff values for the left internal carotid artery are provided, which suggests significant stenosis.\n\nThe clinical trial in question is recruiting patients with carotid stenosis > 70% who will be undergoing carotid endarterectomy or carotid artery stenting. Although the provided patient note does not explicitly state the percentage of stenosis in numerical terms, the use of the term \"severe stenosis\" in the context of the left internal carotid artery and the provided PSV and EDV values suggests that the patient could potentially meet the criteria for severe stenosis, which is commonly considered to be >70%.\n\nGiven that the patient has severe stenosis and the trial is looking for patients with >70% stenosis for treatment, it seems reasonable to conclude that the patient may be eligible for the trial. However, the final determination of eligibility would require confirmation of the exact percentage of stenosis, which is typically done through a diagnostic imaging interpretation by a medical professional.\n\nWithout explicit confirmation of the stenosis percentage, we must be cautious in our assessment. However, for the purpose of this exercise and based on the evidence provided, I will consider the patient as potentially meeting the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "786": {
        "output": "",
        "label": 1
    },
    "787": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- He has a family history of CAD.\n- His LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient is not currently using lipid-lowering medications.\n\nClinical Trial Inclusion Criteria:\n- Healthy volunteers, male and/or female aged 18-30 years.\n- Subject affiliated to a social security scheme, agreeing to participate in the study, and who provided informed consent.\n\nComparison:\n- The patient is 46 years old, which is outside of the 18-30 years age range required by the trial.\n- There is no information on the patient's health status being classified as \"healthy,\" but given the significant carotid artery stenosis, he may not be considered healthy.\n- The patient is a male, which fits the gender requirement.\n- There is no information provided about the patient's affiliation to a social security scheme or his consent to participate.\n\nConclusion:\nThe patient does not meet the age criterion of the clinical trial, which is a critical inclusion criterion. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "788": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, a family history of CAD, high LDL-C levels, and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. There is no mention of diabetes, erectile dysfunction, or any other criteria related to the clinical trial's inclusion criteria.\n\nThe clinical trial is focused on the improvement of erectile function in men with diabetes using Collagen Scaffolds Loaded With HUCMSCs. The inclusion criteria for the trial require participants to have type 1 or 2 diabetes, blood glucose controlled well, and specific characteristics regarding erectile dysfunction, among other things.\n\nSince the patient does not have a diagnosis of diabetes or any mention of erectile dysfunction, he does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "789": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific diagnosis required for the trial. The trial is focused on patients with Pulmonary Arterial Hypertension (PAH), while the patient presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with no mention of PAH or right heart catheterism confirming such a diagnosis.\n\nThe patient note does not indicate the patient has PAH; instead, it details issues related to carotid artery stenosis and high LDL cholesterol levels. There is no evidence of PAH or a history of right heart catheterism to confirm such a diagnosis. Therefore, the patient does not meet the inclusion criteria for the clinical trial on PAH.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "790": {
        "output": "",
        "label": 2
    },
    "791": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the patient's eligibility as follows:\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No prior use of lipid-lowering medications\n- Carotid ultrasonography revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No information on any malaria-related condition or treatment history\n\nClinical trial inclusion criteria:\n- Male or female \u22653 years to \u226450 years\n- Good general health by medical history, physical examination, baseline electrocardiographs, and laboratory tests\n- No clinically relevant abnormalities in blood pressure and heart rate\n- No clinically relevant abnormalities in 12-lead ECG results\n- QTcB or QTcF greater than 450 ms or clinically significant abnormalities of rhythm at Screening are not eligible\n\nBased on the information provided, the patient is within the age range required for the trial. However, there is no information regarding the patient's general health status (beyond the specific cardiovascular issues mentioned), electrocardiographic safety (QTcB or QTcF measurements), blood pressure, heart rate, or any other laboratory tests that may be relevant to determining their eligibility based on the trial's inclusion criteria. The patient has a severe stenosis in the left internal carotid artery, which could be considered a clinically relevant abnormality, but it is not specified whether this would affect the ECG results or the patient's general health in the context of the trial criteria for cardiac safety.\n\nGiven the lack of specific information on the patient's overall health, ECG results, and the fact that the patient has severe carotid artery stenosis, which may or may not be considered a clinically relevant abnormality without more data, we do not have sufficient information to determine the patient's eligibility for the trial based on the criteria provided.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "792": {
        "output": "Based on the information provided in the patient note, the 46-year-old man presents with dizziness and frequent headaches, and he has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His condition involves the carotid arteries rather than peripheral arteries, and there is no mention of peripheral artery disease (PAD) or an ankle-brachial index (ABI) measurement, which are part of the inclusion criteria for the clinical trial.\n\nThe clinical trial in question is focused on patients with a diagnosis of peripheral arterial disease (PAD) or an ABI of less than 0.9, who are planned to undergo endovascular revascularization within 6 months. The trial aims to examine the effects of exercise rehabilitation or neuromuscular stimulation on patients with PAD.\n\nSince the patient has carotid artery disease and there is no mention of PAD or an ABI measurement, there is insufficient information to qualify for the trial based on the provided inclusion criteria. The patient does not meet the specified condition (PAD) for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "793": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Treatment Decisions for Multi-vessel CAD,\" we need to compare the inclusion criteria of the trial with the patient's clinical information provided in the patient note.\n\nThe inclusion criteria for the trial are:\n1. Stable multi-vessel coronary artery disease diagnosed by coronary angiography defined as left main disease (>50% stenosis) or multi-vessel coronary artery disease (>70% stenosis in two or more coronary arteries).\n2. At relative equipoise for at least two potential treatment options, in which the treating cardiologist or surgeon has determined the treatments are anatomically feasible and safe.\n\nThe patient note indicates the following:\n- The patient is a 46-year-old man with dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors.\n- He has elevated LDL-C levels but normal fasting glucose and triglyceride levels.\n- He is not using any lipid-lowering medications.\n- Neck auscultation revealed a systolic murmur, suggesting a cardiovascular issue.\n- Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nThe patient's symptoms and findings from neck auscultation and ultrasonography of the carotid arteries suggest a significant cardiovascular issue. However, the trial specifically requires a diagnosis of stable multi-vessel coronary artery disease diagnosed by coronary angiography, which is not mentioned in the patient note. Also, there is no indication that the patient has been evaluated and found to be at equipoise for at least two potential treatment options by a treating cardiologist or surgeon.\n\nWithout any mention of a coronary angiography diagnosis of multi-vessel coronary artery disease or any information regarding treatment options, we cannot confirm that the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "794": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial.\n\nPatient note:\n- 46-year-old man\n- Physically active\n- No use of lipid-lowering medications\n- Presents with dizziness and frequent headaches\n- High LDL cholesterol levels, normal fasting glucose, and triglyceride levels\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of BMI, height, waist circumference, mental health status, willingness to participate, ability to be assigned randomly, psychological and medical screening results, Slovenian social insurance, or English language fluency\n\nClinical trial inclusion criteria:\n- Physically and mentally healthy subjects\n- Body mass index < 25 kg/m2\n- Height 158 - 190 cm\n- Waist circumference < 94 cm\n- Volunteers that are able to declare their willingness to participate in the entire study\n- Willing to be assigned randomly to the three groups\n- Successfully passing the psychological and medical screening\n- Competent to sign informed consent\n- Slovenian social insurance\n- English language fluency\n\nGiven the patient's presentation with severe stenosis, he may not qualify as \"physically and mentally healthy,\" which is one of the inclusion criteria of the trial. Furthermore, there is insufficient information regarding his BMI, height, waist circumference, mental health status, willingness to participate, ability to comply with the study requirements, psychological and medical screening results, Slovenian social insurance, and English language fluency to determine if he meets the other inclusion criteria.\n\nTherefore, the patient does not have sufficient information to qualify for the trial because critical information needed to assess eligibility is missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "795": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C: 545 mg/dL (high)\n- HDL-C: 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Systolic murmur heard in the neck\n- Carotid ultrasonography revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Plaque characterized as bulky plates, predominantly echogenic and hyperechoic\n\nClinical Trial Inclusion Criteria:\n- Patients known with symptomatic carotid artery stenosis (\u22652 mm carotid plaque on duplex ultrasound)\n- Scheduled to undergo carotid endarterectomy or referred to conservative therapy\n- Age 18 years and older\n- Informed consent by signing informed consent form regarding this study\n\nComparison:\n- The patient is 46 years old, meeting the age criterion.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with the presence of bulky plaques as indicated by carotid ultrasonography. This suggests symptomatic carotid artery stenosis, meeting the stipulated condition of \u22652 mm carotid plaque.\n- The patient note does not mention if the patient is scheduled for a carotid endarterectomy or referred to conservative therapy, which is a necessary criterion for inclusion.\n- The patient's informed consent status is not mentioned in the note.\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria (age and symptomatic carotid artery stenosis). However, there is insufficient information regarding whether the patient is scheduled for carotid endarterectomy or conservative therapy and whether informed consent can be obtained. Therefore, we cannot conclude that the patient is eligible without this additional information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "796": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, here\u2019s the assessment:\n\nPatient Note:\n- The patient is a 46-year-old man presenting with dizziness and frequent headaches.\n- No history of myocardial infarction is mentioned; the focus is on severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- There is no mention of ST elevation myocardial infarction or any indication that the patient is experiencing an acute myocardial infarction.\n\nClinical Trial:\n- The trial is focusing on patients with acute myocardial infarction, specifically with ST elevation myocardial infarction (STEMI) diagnosed within the last 12 hours and who are included in a specific revascularization program.\n\nBased on the provided information:\n\n- The patient does not meet the inclusion criteria because there is no indication that he has had an ST elevation myocardial infarction, which is a requirement for participation in the study.\n\nTherefore, the patient is not relevant for this trial because the patient's condition does not match the specific conditions under investigation in the trial (acute STEMI patients).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "797": {
        "output": "",
        "label": 1
    },
    "798": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, and a severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. He has not been described as awaiting carotid artery endarterectomy, nor does the note mention any planned surgery or use of the specific medical equipment stated in the inclusion criteria of the clinical trial (venous catheter, arterial catheter, Transcranial Doppler, INVOS monitor).\n\nGiven that the patient does not appear to be awaiting carotid artery endarterectomy, and there is no information provided on whether the patient will be undergoing the procedure with the specific medical equipment required for the study, we cannot establish that the patient meets the inclusion criteria listed for the clinical trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided in the patient note and the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "799": {
        "output": "The patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL cholesterol levels and a family history of coronary artery disease (CAD). He presents with dizziness and frequent headaches and has not been using lipid-lowering medications. His condition has been evaluated with ultrasonography of the carotid arteries.\n\nThe clinical trial in question is seeking to recruit patients undergoing percutaneous coronary intervention (PCI) for coronary lesions. The inclusion criteria are specifically for \"Hospitalized patients undergoing a PCI for coronary lesions.\"\n\nThe patient in the note has not been described as undergoing PCI or having coronary lesions that require PCI; instead, his condition is related to carotid artery stenosis. There is no indication that he is hospitalized or scheduled for PCI based on the information provided. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "800": {
        "output": "The patient note indicates that the patient is a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has extremely high LDL cholesterol levels, but normal fasting glucose and triglyceride levels. There is no mention of a genetic diagnosis of familial hypercholesterolemia (FH), nor is there any indication that the patient or any of his relatives have been tested for it. \n\nThe clinical trial in question is looking for index cases with a genetic diagnosis of FH and their relatives. Since the patient note does not provide evidence of a genetic diagnosis of FH for the patient or his relatives, we cannot confidently conclude that this patient is eligible for the SAFEHEART registry study.\n\nBased on this information, the patient does not have sufficient information to qualify for the trial because there is no mention of a genetic diagnosis of FH, which is an essential inclusion criterion for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "801": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's compare the two to determine the patient's eligibility:\n\nPatient Note:\n- 46-year-old man (meets age criteria)\n- Presents with dizziness and frequent headaches\n- Family history of CAD, no other cardiovascular risk factors, physically active\n- Elevated LDL-C levels and normal HDL-C, glucose, and triglycerides\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Systolic murmur in the neck\n\nClinical Trial Inclusion Criteria:\n- Patients suspected of having symptomatic intracranial atherosclerotic disease (ICAD)\n- Ischemic stroke or transient ischemic attack (TIA) in the target territories of the intracranial anterior or posterior circulation within 90 days\n- Lack of coexistent \u226550% ipsilateral extracranial carotid artery or vertebral artery stenosis\n- No potential sources of cardio-aortic embolism\n- Age \u226518 years\n- One or more atherosclerotic risk factors including hypertension, hypercholesterolemia, diabetes mellitus, cigarette smoking, and obesity\n\nAnalysis:\n- The patient's age qualifies him for the trial.\n- The patient has hypercholesterolemia, which is one of the atherosclerotic risk factors listed in the trial's inclusion criteria.\n- The patient note does not mention a recent ischemic stroke or TIA, which is a key inclusion criterion for the trial.\n- There is no information provided about the presence or absence of cardio-aortic embolism sources.\n- The patient has severe stenosis in the left internal carotid artery, which may not meet the \"lack of coexistent \u226550% ipsilateral extracranial carotid artery or vertebral artery stenosis\" criterion, depending on whether the stenosis is considered extracranial.\n\nGiven the information provided, the patient does not appear to meet all the inclusion criteria for the clinical trial, specifically the requirement for a recent ischemic stroke or TIA and potential exclusion due to severe extracranial carotid artery stenosis. Therefore, the patient is not eligible based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "802": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- The patient has dizziness and frequent headaches.\n- There is no mention of abdominal perimeter.\n- The patient's LDL-C level is 545 mg/dL, which is significantly higher than the inclusion criteria, but there's no specific mention of LDL-C in the inclusion criteria.\n- The patient's HDL-C level is 53 mg/dL, which is above the threshold for men (<50 mg/dL) in the inclusion criteria.\n- The patient's fasting glucose is 85 mg/dL, which is below the 110-128 mg/dL range in the inclusion criteria.\n- The patient's triglycerides level is 158 mg/dL, which falls within the 150-195 mg/dL range in the inclusion criteria.\n- There is no blood pressure reading provided in the patient note.\n\nClinical Trial Inclusion Criteria Analysis:\n- Abdominal perimeter \u2265102 cm for male participants.\n- Fasting glucose values between 110-128 mg/dL.\n- Triglycerides = 150-195 mg/dL.\n- HDL-cholesterol: < 50 mg/dL for men.\n- Blood pressure: systolic > 130 mm Hg; diastolic > 85 mm Hg.\n\nThe patient note does not provide data on the patient's abdominal perimeter or blood pressure, which are part of the inclusion criteria. The patient's HDL-C level is above the threshold for men, and the fasting glucose is below the specified range. The only criterion the patient meets is the triglyceride level.\n\nGiven the lack of information on abdominal perimeter and blood pressure, and the patient's non-conformance to the fasting glucose and HDL-C criteria, the patient does not meet sufficient inclusion criteria to qualify for the trial.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "803": {
        "output": "The patient is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). According to the information provided, the stenosis in the LICA is severe, but the exact percentage is not stated. However, the PSV and EDV cutoff values are indicative of significant stenosis.\n\nThe clinical trial in question is looking at the safety of using transfemoral and transradial approaches in patients undergoing carotid arteries stenting. The inclusion criteria are:\n- Symptomatic patients with internal carotid artery stenosis (>50%)\n- Asymptomatic patients with internal carotid artery stenosis (>60%)\n- Anatomy of internal carotid artery applicable for stent implantation and use of embolic protection device\n\nThe patient has symptoms (dizziness and frequent headaches), which could be related to the carotid artery stenosis. Since the patient has severe stenosis in the LICA, it is reasonable to infer that it could be over 50%, which would meet the inclusion criteria for symptomatic patients. Moreover, the patient has not been reported to be on lipid-lowering medications, and the trial does not specify this as an exclusion criterion.\n\nGiven the information provided and assuming that the \"severe\" stenosis of the LICA translates into >50% stenosis, the patient appears to meet the inclusion criteria for the clinical trial. However, without exact numerical values of the stenosis percentage, this assessment is made with a degree of uncertainty. Nevertheless, based on the available information, the patient seems eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "804": {
        "output": "Given the information provided in the patient note, we can assess the patient's eligibility for the clinical trial titled \"Trial of Exercise to Prevent Hypertension in Young Adults\" based on the inclusion criteria listed.\n\nThe inclusion criteria for the trial are as follows:\n1. Participant is willing and able to give informed consent for participation in the study.\n2. Male or Female, from 18 to 35 years old.\n3. Verified birth history: preterm birth (<37 weeks) or full-term birth (>37 weeks)\n4. Ability to access and use computer/internet\n5. Willing to complete duration of intervention, follow-up and attend study visits at the John Radcliffe Hospital (participants may still withdraw at any time without providing an explanation or rationale)\n6. 24 hour awake ABP greater than 115/75 mmHg\n7. Able (in the investigator's opinion) and willing to comply with all study requirements.\n\nNow, let's evaluate the patient based on the provided note:\n- The patient is a 46-year-old man, which exceeds the age range of 18 to 35 years required by the study.\n- There is no information on the patient's birth history (whether preterm or full-term).\n- No data is provided on the patient's ability to access and use a computer/internet.\n- No information is given on the patient's willingness to complete the duration of the intervention, follow-up, and attend study visits at the specified location.\n- The patient's 24-hour awake ABP is not provided in the note.\n\nBased on the patient's age alone, which is outside the specified range for the study (18 to 35 years old), the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "805": {
        "output": "Based on the information provided, the patient is a 46-year-old man who presents with dizziness and frequent headaches. He has high LDL-C levels and ultrasound findings that indicate severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. This patient has not been specifically referred for an elective cardiac CT examination for evaluation of coronary artery disease, nor is there information suggesting that this is planned or that he has been diagnosed with coronary artery disease. The patient does have carotid artery disease, which is different from coronary artery disease, and the inclusion criteria for the clinical trial specifically mentions coronary artery disease.\n\nGiven that the patient note does not indicate the patient has been referred for a cardiac CT examination to evaluate coronary artery disease, there is insufficient information to determine if the patient meets the specific inclusion criteria of the clinical trial. Therefore, the patient would be rated as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "806": {
        "output": "",
        "label": 2
    },
    "807": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we have the following information:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- Elevated LDL-C level, normal fasting glucose, and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Carotid ultrasonography findings of plaque\n\nClinical Trial Inclusion Criteria:\n- Patients scheduled for primary total knee arthroplasty\n- American Society of Anesthesiologists (ASA) physical status I-III\n- Mentally competent and able to give consent for enrollment in the study\n\nThe patient note does not indicate that the patient is scheduled for primary total knee arthroplasty or has any issues related to his knees that would require such a procedure. The patient presents with symptoms and conditions related to cardiovascular health rather than orthopedic issues. Therefore, the patient does not meet the specific inclusion criteria for the clinical trial primarily focused on patients undergoing total knee arthroplasty.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "808": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the given clinical trial. The trial is focused on patients who are scheduled for open reduction and internal fixation of a distal radius fracture, which is a specific surgical procedure. The patient's note does not mention any such injury or surgery. Instead, the patient presents with cardiovascular issues related to carotid artery stenosis.\n\nThe patient note does not provide any information suggesting that the patient has a distal radius fracture or is scheduled for the surgery mentioned in the clinical trial's inclusion criteria. Additionally, the trial is related to pain management post-surgery, which is not relevant to the patient's current medical condition as described.\n\nTherefore, on the three-point scale of eligibility:\n\n- 0) Excluded: The patient does not meet the inclusion criteria based on the trial's focus on distal radius fractures and post-operative pain management.\n- 1) Not relevant: The information provided in the patient's note is not relevant to the trial's focus and inclusion criteria.\n- 2) Eligible: The patient does not meet the criteria for eligibility.\n\nThe patient is not relevant for this clinical trial based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "809": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the patient's characteristics with the trial requirements:\n\n**Patient Characteristics:**\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors (no smoking, high blood pressure, diabetes)\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL (normal)\n- Triglycerides: 158 mg/dL (normal)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of diabetes or erectile dysfunction\n\n**Clinical Trial Inclusion Criteria:**\n- Type 1 or 2 diabetes\n- Blood glucose controlled well\n- No effective with oral PDE-5i\n- Have a consistent partner willing to engage in sexual activity more than twice per month\n- Males, age 20-65 years\n- IIEF-5 score is under 16\n- Penile arterial insufficiency or venous leakage (doppler)\n- HbA1c between 6.5%-10%\n- Physical examination with no abnormalities\n- Willingness to participate and follow study requirements\n\nThe patient does not meet the inclusion criteria for the clinical trial. There is no indication in the patient note that he has diabetes or erectile dysfunction, which are required conditions for the trial. Additionally, there's no mention of the patient's IIEF-5 score or HbA1c levels, nor is there any information provided regarding the patient's sexual activity or partner, which are part of the trial's inclusion criteria.\n\nBased on this information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "810": {
        "output": "The patient note provides information about a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as determined by ultrasonography. The patient has not been described as having had a transient ischemic attack, amaurosis fugax, or minor nondisabling stroke, which are symptoms required for the symptomatic patient inclusion criteria in the clinical trial. However, he is asymptomatic regarding these specific symptoms.\n\nThe clinical trial in question is looking to include:\n1. Symptomatic patients with specific recent cardiovascular events related to the study artery and a certain level of carotid artery stenosis.\n2. Asymptomatic patients with a significant degree of carotid artery stenosis.\n\nThe patient has severe stenosis in the LICA well above the 70% threshold needed for asymptomatic patients by ultrasound criteria. This means that even though the patient has not had any of the symptomatic events mentioned in the inclusion criteria (i.e., transient ischemic attack, amaurosis fugax, or minor nondisabling stroke), he qualifies under the criteria for asymptomatic patients due to his severe stenosis.\n\nTherefore, based on the provided patient note and the clinical trial inclusion criteria, the patient appears to meet the requirements for inclusion in the clinical trial as an asymptomatic patient with significant carotid artery stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "811": {
        "output": "Based on the information provided, the patient is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He presents with symptoms of dizziness and frequent headaches, which could be indicative of cerebral ischemia related to his carotid artery disease. The clinical trial in question is interested in patients with symptomatic or asymptomatic carotid artery disease, and there's no mention of specific exclusion criteria that would apply to this patient.\n\nGiven that the patient has symptoms that could be related to his carotid artery disease (dizziness and headaches) and has significant stenosis of the carotid arteries as revealed by ultrasonography, he appears to meet the inclusion criteria for the Norwegian Carotid Plaque Study, which is looking at symptomatic and asymptomatic carotid artery disease.\n\nTherefore, the patient is likely eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "812": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The Effects of Anaesthesia on Cerebral Oxygenation and Cognitive Function in Carotid Endarterectomy,\" we must compare the patient's characteristics and condition with the trial's inclusion criteria.\n\nInclusion Criteria for the trial:\n- Age > 18 years\n- Male gender\n- Informed consent\n- Symptomatic carotid stenosis > 75%\n\nPatient characteristics and condition:\n- The patient is a 46-year-old man, which meets the age and gender criteria.\n- The patient presents with dizziness and frequent headaches, which could be symptoms related to carotid stenosis.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The degree of stenosis for the LICA is not specified in terms of percentage, but the provided PSV and EDV values indicate significant stenosis.\n\nThe inclusion criteria require symptomatic carotid stenosis greater than 75%. While the patient's symptoms and the presence of carotid artery stenosis are noted, the exact degree of stenosis for the LICA is not quantified in terms of percentage. However, the presence of severe stenosis and symptoms suggests that the stenosis may well be over the 75% threshold. The patient has not indicated whether they have given informed consent, but since this is generally obtained as part of the trial screening process, it should not exclude them at this stage.\n\nBased on the information given, and assuming that the severe stenosis in the LICA implies a stenosis greater than 75%, the patient appears to meet the inclusion criteria for the trial. Therefore, the patient is potentially eligible for the trial, pending the provision of informed consent and the confirmation of the stenosis percentage.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "813": {
        "output": "Based on the patient note provided:\n\n- The patient is a 46-year-old man, which satisfies the age criterion of being over 18 years.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which aligns with the inclusion criterion of internal carotid stenosis. However, the trial specifies the inclusion criterion for \"internal carotid stenosis: open surgical revascularization.\" It is not clear from the patient note whether the patient is scheduled for or has consented to open surgical revascularization.\n- Written informed consent is required, but there is no information about whether the patient has provided this.\n\nThe patient meets the age and internal carotid stenosis criteria (assuming the stenosis is significant enough to require open surgical revascularization); however, the patient note does not mention if the patient is scheduled for or has consented to open surgical revascularization nor if the patient has given written informed consent for the trial.\n\nWithout this information, we cannot determine if the patient is fully eligible for the trial. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "814": {
        "output": "",
        "label": 2
    },
    "815": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\n- The patient is a 46-year-old man, which fits within the age range of 18-75 years specified in the trial's inclusion criteria.\n- The patient has carotid artery stenosis, as evidenced by ultrasonography showing severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The severity of the stenosis in the left internal carotid artery meets the trial's criterion of severe carotid artery stenosis (unilateral stenosis > 70%) according to the provided peak-systolic velocity (PSV) and end-diastolic velocity (EDV) cutoff values.\n- The patient is of the specified sex since the trial includes either sex.\n- There is no information provided about the patient's provision of informed consent, but this is typically obtained after eligibility is determined and before participation in the trial.\n\nThere is no mention of the patient having an ischemic stroke, which is part of the trial's title, suggesting that the trial is focused on patients with carotid artery stenosis who have experienced an ischemic stroke. If the ischemic stroke is a requirement for the trial, the patient note does not provide sufficient information to determine if the patient has had one. Therefore, we cannot confirm the patient's eligibility without this information.\n\nGiven the information provided, the patient meets the age, sex, and severe carotid artery stenosis criteria. However, due to the lack of explicit information about the patient's history of ischemic stroke, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "816": {
        "output": "",
        "label": 0
    },
    "817": {
        "output": "To assess the eligibility of the patient for the clinical trial, we need to compare the patient's information with the inclusion criteria of the trial.\n\nHere are the inclusion criteria we need to consider:\n1. Age \u2265 18 years of age.\n2. Patient is currently on atorvastatin or simvastatin or rosuvastatin or statin na\u00efve (no statins in the last 30 days).\n3. The patient has unilateral or bilateral carotid artery stenosis that is considered severe (carotid artery diameter reduction \u2265 70%) as defined by:\n   - Peak systolic velocity of at least 230 cm/s plus at least one of these:\n     - End diastolic velocity \u2265 100 cm/s OR\n     - CTA showing \u2265 70% stenosis OR\n     - MRA showing \u2265 70% stenosis\n4. This stenosis has not caused any stroke, transient cerebral ischemia, or other relevant neurological symptoms in the past.\n5. The patient's attending doctor(s) (PMD, cardiologist, vascular/neurosurgeon) AND the patient have decided to proceed with a CEA to treat the patient's severe carotid stenosis.\n6. The patient has no known circumstance or condition likely to preclude 1 year follow-up or adherence to the study protocol.\n7. The patient is independent in their Activities of Daily Living at baseline.\n8. The patient has the ability to provide informed consent.\n\nNow, let's match the patient's information to these criteria:\n\n1. The patient is a 46-year-old man, so he meets the age criterion.\n2. The patient reported no use of lipid-lowering medications, which means he is statin na\u00efve.\n3. The patient has severe stenosis in the left internal carotid artery with PSV of 208.5 cm/s and EDV of 54.5 cm/s. Although the PSV does not meet the \u2265 230 cm/s criterion, it indicates severe stenosis, but the EDV does not meet the criterion of \u2265 100 cm/s. This might not necessarily exclude the patient as the criteria also mention CTA or MRA showing \u2265 70% stenosis, but we don't have that information.\n4. There is no mention of the patient having had a stroke, transient cerebral ischemia, or other relevant neurological symptoms, so the patient appears to meet this criterion.\n5. There is no information provided about the patient and doctor(s) having decided to proceed with CEA.\n6. There is no information suggesting that the patient has a condition likely to preclude 1 year follow-up or adherence to the study protocol.\n7. The patient's independence in daily living activities is not mentioned.\n8. There is no information on the patient's ability to provide informed consent.\n\nBased on the available information, the patient does not clearly meet all the inclusion criteria, particularly the specifics about the severity of carotid artery stenosis using the defined velocities or alternative imaging results, nor is there confirmation of the decision to proceed with CEA, independence in daily activities, or ability to provide informed consent.\n\nTherefore, the patient's eligibility would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "818": {
        "output": "",
        "label": 1
    },
    "819": {
        "output": "",
        "label": 0
    },
    "820": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches and has been found to have severe and moderate stenosis in the left and right internal carotid arteries, respectively. The patient has a family history of coronary artery disease (CAD) but has not had a sudden cardiac arrest (SCA) or out-of-hospital cardiac arrest (OHCA).\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Age > 18 years\n2. OHCA of assumed cardiac etiology\n3. Documented first recorded heart rhythm\n\nThe patient note does not mention that the patient has experienced an OHCA. Therefore, the patient does not meet all of the inclusion criteria for the clinical trial, specifically the requirement for an OHCA of assumed cardiac etiology and a documented first recorded heart rhythm.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "821": {
        "output": "",
        "label": 0
    },
    "822": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Carotid Atherosclerosis and Vascular Events in People With Diabetes.\"\n\nPatient Information:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C level: 545 mg/dL\n- HDL-C level: 53 mg/dL\n- Fasting glucose level: 85 mg/dL (normal limits)\n- Triglyceride levels: 158 mg/dL (normal limits)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery from ultrasonography\n- No mention of diabetes\n\nClinical Trial Inclusion Criteria:\n- Age >18 years\n- Diabetes\n- Carotid duplex ultrasonography in 2012\n\nThe patient is over 18 years of age and has undergone carotid duplex ultrasonography, which are both in line with the trial's inclusion criteria. However, the patient does not have diabetes, which is a necessary condition for inclusion in the trial.\n\nTherefore, based on the information provided, the patient does not meet all of the inclusion criteria for the clinical trial because he does not have a diagnosis of diabetes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "823": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms and medical findings that include dizziness, frequent headaches, high LDL-C levels, a systolic murmur, and carotid artery stenosis. There is no mention of the patient undergoing a cardiac stress PET, nor is there any indication that the patient is scheduled for or has undergone coronary angiography and mechanical revascularization, which could be PCI and/or CABG.\n\nThe inclusion criteria for the clinical trial require individuals who:\n1. Undergo cardiac stress PET.\n2. Subsequently undergo coronary angiography and mechanical revascularization (PCI and/or CABG).\n3. Are adults \u226518 and able to give informed consent.\n\nSince the patient note does not provide information that the patient has undergone or is scheduled to undergo a cardiac stress PET, followed by coronary angiography and mechanical revascularization, the patient does not currently meet the specific inclusion criteria for the trial. Additionally, there is no indication that the patient has ischemic heart disease or is being considered for revascularization, which is the focus of the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "824": {
        "output": "In order to determine the trial-level eligibility of the patient for the clinical trial titled \"Remote Endarterectomy and Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease,\" we must compare the patient's characteristics and conditions with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are as follows: \n1. Patients with occlusive lesions of C and D type femoral artery\n2. Patients with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford)\n3. Patients who consented to participate in this study\n\nThe patient note presents a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient's symptoms include dizziness and frequent headaches, and there is no mention of lower limb ischemia or occlusive lesions in the femoral artery which are required for inclusion in the study. Additionally, there is no information suggesting that the patient has consented to participate in any study.\n\nSince the patient does not have occlusive lesions of the femoral artery nor is there any indication of chronic lower limb ischemia, which are both required according to the inclusion criteria, the patient does not qualify for this clinical trial. Moreover, there is no information about the patient's consent to participate in the study.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "825": {
        "output": "Based on the information from the patient note and the inclusion criteria of the clinical trial for patients with Metabolic Syndrome (MetS), let's determine the patient's eligibility:\n\nPatient's characteristics and results:\n- Age: 46 years old (meets age criterion of 25-65 years)\n- Waist circumference: Not mentioned\n- Blood pressure: Not mentioned (but no history of high blood pressure indicated)\n- Fasting glucose level: 85 mg/dL (below the criterion of \u2265 110mg/dL)\n- Triglycerides: 158 mg/dL (meets criterion of \u2265 150 mg/dL)\n- HDL cholesterol: 53 mg/dL (above the criterion of \u2264 40 mg/dL for men)\n\nThe patient does not meet all of the inclusion criteria for the clinical trial. Specifically, the patient's fasting glucose level is within normal limits and does not meet the threshold for inclusion, and the HDL cholesterol level is higher than the maximum allowed for inclusion in the study.\n\nTherefore, the patient does not fulfill sufficient inclusion criteria to qualify for the clinical trial on Multimodal Intervention Program for Patients With Metabolic Syndrome.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "826": {
        "output": "The patient in the note is a 46-year-old man who presents with dizziness, frequent headaches, and has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient has extremely high LDL cholesterol levels but does not mention being on any statin therapy. The patient also does not mention having peripheral arterial disease (PAD) or an ankle brachial index (ABI) measurement, which are required for the clinical trial in question.\n\nThe clinical trial is looking for patients between the ages of 35-85 with a clinical diagnosis of peripheral arterial disease and an ABI of 0.4-0.9. Additionally, the trial requires patients to either be on a statin for at least 6 months or be statin intolerant.\n\nBased on the information provided in the patient note, we do not have sufficient information to confirm a diagnosis of PAD, an ABI measurement, or a history of statin use, which are key inclusion criteria for the clinical trial. Therefore, the patient does not meet the necessary inclusion criteria based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "827": {
        "output": "In this scenario, we need to assess if the patient is eligible for the clinical trial based on the provided inclusion criteria.\n\nThe inclusion criteria for the trial are:\n1. The coronary artery disease was defined by one of the following criteria:\n   - Elevations of cardiac enzymes, electrocardiography (ECG) and clinical symptoms (angina, chest pressure, or shortness of breath);\n   - Angiographic evidence of more than 50% stenosis in one or more major coronary arteries;\n   - Previous history of PCI (percutaneous coronary intervention) or CABG (coronary artery bypass graft).\n\nThe patient's note indicates the following relevant information:\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient has a family history of CAD but no clinical symptoms of CAD themselves.\n- The patient has high LDL-C levels, which could be a risk factor for CAD, but the patient is not diagnosed with CAD based on the criteria listed for the study.\n\nThe patient does not meet the CAD diagnosis criteria as specified by the study (no mention of cardiac enzyme elevations, ECG changes, clinical symptoms related to CAD, angiographic evidence of more than 50% stenosis in a major coronary artery, or history of PCI/CABG). The stenosis mentioned is in the carotid arteries, not the coronary arteries. Although the patient has a family history of CAD, they do not exhibit clinical symptoms of CAD themselves, and there is no indication that the patient would be eligible for control selection based on the provided information.\n\nBased on the information provided in the patient's note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial, as they do not have a diagnosis of CAD or meet the criteria for being a control within the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "828": {
        "output": "",
        "label": 0
    },
    "829": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to meet the specific condition for which the clinical trial is recruiting. The trial is focused on patients who are scheduled for wrist arthroscopy surgery, and there is no mention of this patient requiring or being scheduled for such a procedure. The trial also requires participants to be mentally competent and able to give consent, and to have an ASA physical status I-III, which is not specified in the patient note but could be assumed given the patient's physical activity level.\n\nHowever, because the trial is specific to wrist arthroscopy and the patient note does not indicate that the patient is scheduled for or requires this type of surgery, we cannot consider the patient relevant for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "830": {
        "output": "",
        "label": 0
    },
    "831": {
        "output": "Based on the provided patient note, the 46-year-old man presents with dizziness, frequent headaches, and a severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. He has a high LDL cholesterol level and a systolic murmur, but there is no mention of a need for internal jugular vein (IJV) catheterization.\n\nThe clinical trial in question is investigating a novel device designed to increase the success rate and safety of internal jugular vein cannulation. The inclusion criteria for this trial are quite broad, stating that all patients indicated for IJV catheterization can be included.\n\nSince the patient note does not indicate that the patient requires or is indicated for IJV catheterization, there is insufficient information to determine if the patient would be eligible for the trial based on the trial inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "832": {
        "output": "The patient note describes a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with a systolic murmur noted on auscultation. However, there is no mention of aortic stenosis, mitral regurgitation, or aortic regurgitation, which are the conditions specified in the clinical trial's inclusion criteria. The trial is centered around valvular heart diseases and requires the presence of one of these conditions at the time of an echocardiography at the Cliniques Universitaires Saint Luc.\n\nSince the patient's condition does not match the specified inclusion criteria for valvular heart diseases, and there is no evidence of aortic stenosis, mitral regurgitation, or aortic regurgitation from the information provided, the patient would be assessed as not meeting the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "833": {
        "output": "Based on the information provided in the patient note, the patient is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery as detected by ultrasonography. However, there is no mention of an acute stroke or related symptoms such as weakness, facial droop, or aphasia. The patient note does not provide an ASPECTS score, NIHSS score, or any indication that endovascular treatment can be initiated within 6 hours of symptom onset, which are part of the inclusion criteria for the clinical trial. Additionally, there is no mention of written informed consent.\n\nGiven that the patient note lacks information on the acute stroke, ASPECTS score, NIHSS score, the timing of treatment initiation, and informed consent, the patient does not meet the inclusion criteria for the clinical trial titled \"Carotid Duplex Ultrasound for Selecting Patients for Endovascular Thrombectomy in Acute Stroke Patients.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "834": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Evaluation:\n- The patient is a 46-year-old man, which satisfies the age requirement of \u226518 years.\n- He has not been reported to be on lipid-lowering medications, which suggests he may be intolerant to high-intensity statin therapy.\n- His LDL-C level is 545 mg/dL, which is well above the \u226570 mg/dL requirement.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery are noted, indicating the presence of significant carotid artery plaque.\n- The plaque described suggests that there could be a lipid-rich necrotic core (LRNC), but an MRI scan would be needed to confirm this, as per the trial criteria.\n- There is no mention of the patient's medication doses, but the fact that he is not on lipid-lowering medications may align with the trial's requirement for subjects who are only able to tolerate low potency statin or low weekly dose of high potency statin.\n\nClinical Trial Inclusion Criteria:\n- Men and women \u226518 years of age. (Met)\n- Subjects with documented inability to consistently take or tolerate high intensity statin therapy and LDL-C \u226570 mg/dL. (Met, assuming intolerance due to no current use of lipid-lowering medications)\n- Subjects are only able or allowed to take lower potency statin or low weekly dose of high potency statin. (Unclear, no specific information given)\n- Subjects must have significant carotid artery plaque with maximum wall thickness \u22652 mm on ultrasound. (Met, severe stenosis indicates significant plaque)\n- Subject must present with a LRNC on baseline MRI scan. (Not met, LRNC presence not confirmed without MRI)\n- Subjects must show an adequate image quality for MRI analysis. (Not met, MRI analysis not mentioned)\n- Medically stable. (Unclear, no specific information given)\n- Willing to participate and sign informed consent. (Not met, no information on willingness)\n\nThe patient meets some of the inclusion criteria, such as age, high LDL-C levels, and significant carotid artery plaque. However, there is insufficient information to determine if he meets all the criteria, especially concerning his statin tolerance, the presence of an LRNC on MRI, and his willingness to participate. Therefore, the patient note does not provide enough information to definitively include or exclude the patient from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "835": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria for the clinical trial titled \"Outcomes of Surgically Ineligible Patients With Multivessel CAD,\" we need to compare the specific details.\n\nPatient Note Analysis:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors other than family history\n- Physically active\n- Elevated LDL-C levels\n- Normal fasting glucose and triglyceride levels\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- No mention of coronary artery disease (CAD) or its symptoms\n- No mention of surgical ineligibility or coronary angiography results\n- No mention of FFR evidence or clinical symptoms consistent with obstructive CAD\n\nClinical Trial Inclusion Criteria:\n- Participant undergoes coronary angiography revealing significant coronary stenosis or has FFR evidence of flow-limiting stenosis\n- Patient considered high risk for coronary artery bypass surgery and declared ineligible for surgery by the heart team\n- Patient experiencing clinical symptoms consistent with obstructive coronary artery disease or with evidence of coronary ischemia\n- Subject is \u2265 18 years of age\n- Patient is able to speak English\n\nBased on the inclusion criteria, the patient would need to have significant coronary stenosis or evidence of coronary ischemia and be declared surgically ineligible for coronary artery bypass surgery. The patient note does not provide information on coronary angiography, FFR measurements, or any declaration of surgical ineligibility related to coronary artery disease. The stenosis mentioned in the patient note refers to the carotid arteries, not the coronary arteries.\n\nSince the patient's note does not mention any signs or diagnosis of coronary artery disease, which is the focus of the clinical trial, and there is no mention of the patient being evaluated and declared ineligible for coronary artery bypass surgery, we do not have sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "836": {
        "output": "Given the patient note, let's assess the eligibility of the patient for the clinical trial based on the provided inclusion and exclusion criteria:\n\nPatient note summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No cardiovascular risk factors besides family history of CAD\n- Severe stenosis in left internal carotid artery, moderate stenosis in right internal carotid artery\n- No use of lipid-lowering medications\n- Not currently known to have cancer or be on any anti-cancer drugs\n\nClinical trial summary:\n- Trial for advanced head and neck squamous cell carcinoma (HNSCC) patients\n- Requires a histologically confirmed diagnosis of HNSCC in the oral cavity, pharynx, or larynx\n- Patients must be in Stage III/IV with recurrent or metastatic disease\n- Must have had at least one line of prior anticancer therapy for recurrent or metastatic disease\n- Patients should have no other therapeutic options left\n- Excludes patients with known or suspected CNS metastases or active leptomeningeal disease, history of other malignancies unless in remission for at least 3 years, etc.\n\nThe patient in the note does not have a diagnosis of head and neck squamous cell carcinoma or any cancer as specified in the trial's inclusion criteria. The patient's medical issues revolve around cardiovascular health rather than oncology.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial because they do not have the specific type of cancer the trial is targeting (HNSCC), nor is there any indication of cancer in the patient's provided history.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "837": {
        "output": "The patient in the note presents with a history of dizziness, frequent headaches, and a family history of coronary artery disease (CAD). The patient has significantly elevated LDL cholesterol levels and carotid artery stenosis. However, there is no mention of the patient having stable exertional angina or type 2 diabetes mellitus, which are part of the inclusion criteria for the clinical trial.\n\nThe clinical trial is focused on the effect of pioglitazone on patients with coronary artery disease and specifically includes patients with stable exertional angina and type 2 diabetes mellitus, neither of which has been mentioned in the patient's history. Furthermore, the patient is not reported to be on any injectable antidiabetic drugs, which is consistent with the inclusion criteria, but this is irrelevant as the diagnosis of type 2 diabetes mellitus itself is not established in the patient's note.\n\nWithout information indicating that the patient has both stable exertional angina and type 2 diabetes mellitus, the patient does not meet the inclusion criteria for the clinical trial. Therefore, based on the available information, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "838": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not have Type 1 or Type 2 diabetes mellitus, which is a requirement for the trial. The note indicates that the patient's fasting glucose level is within normal limits, and there is no mention of a diabetes diagnosis. Therefore, the patient does not meet the inclusion criteria for the clinical trial focused on Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "839": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, a severe stenosis in the left internal carotid artery (LICA), and moderate stenosis in the right internal carotid artery (RICA), but there is no mention of a venous bypass graft or (re)stenosis in such a graft that would warrant intervention.\n\nThe clinical trial in question is looking to enroll individuals with any venous bypass with stenosis warranting intervention. Since the patient does not have a venous bypass, nor is there any indication of stenosis in a venous bypass that would warrant intervention, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "840": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- High LDL-C level (545 mg/dL) and normal HDL-C level (53 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n- Plaque present in the carotid arteries\n- No use of lipid-lowering medications\n- The length of the atherosclerotic plaques is not specified\n\nClinical Trial Inclusion Criteria:\n- Stenotic lesions of the extracranial part of carotid arteries requiring surgical treatment according to national treatment guidelines\n  - Asymptomatic ICA stenosis more than 70%\n  - Symptomatic ICA stenosis more than 65%\n- The length of the atherosclerotic plaques in the ICA than 1 cm\n- Personally signed informed consent for participation in the study\n\nComparison:\n- The patient has severe stenosis in the left internal carotid artery, which may meet the clinical trial requirement for surgical treatment, but the exact percentage of stenosis is not provided in the patient note.\n- The patient has symptomatic conditions (dizziness and headaches) that may or may not be related to the carotid artery stenosis.\n- The trial requires a stenosis of more than 70% for asymptomatic patients and more than 65% for symptomatic patients. Since the values for PSV and EDV suggest severe stenosis, it is likely that the patient meets the stenosis criteria, but the percentage is not explicitly stated.\n- The length of the atherosclerotic plaques is mentioned in the patient note, but it is not quantified, so we cannot confirm if it meets the criterion of being longer than 1 cm.\n\nGiven the information provided in the patient note, we cannot confirm that the length of the atherosclerotic plaques is greater than 1 cm, which is necessary to determine eligibility for the trial. Additionally, while the patient appears to have severe stenosis, the exact percentage is not provided, so we cannot conclusively determine if the stenosis meets the trial's criteria.\n\nBased on the available information, the patient note does not provide sufficient information to qualify for the trial, as key details required by the inclusion criteria (percentage of stenosis and plaque length) are not explicitly stated.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "841": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial:\n\nPatient note summary:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus; physically active\n- High LDL-C level (545 mg/dL) and normal HDL-C, fasting glucose, and triglycerides levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery observed via ultrasonography\n- A systolic murmur was heard during neck auscultation\n\nClinical trial summary:\n- Title: Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease\n- Study on platelet P-ACC in patients with CAD\n- Inclusion criteria:\n  - Signed informed consent\n  - Planned angiography within the next 3 days, whatever the indication\n\nBased on the information provided, the patient has not been explicitly stated to have CAD (Coronary Artery Disease) or to have an angiography planned within the next 3 days. While the patient has a family history of CAD and symptoms that may be associated with cardiovascular issues (e.g., dizziness, headaches, severe stenosis in the LICA), there is insufficient information to determine if the patient indeed has CAD or if an angiography is scheduled.\n\nTherefore, based on the information given, the patient does not meet the inclusion criteria as per the trial's requirements. The patient note does not provide enough detail to confirm the patient's eligibility for the clinical trial focused on CAD patients undergoing angiography.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "842": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the eligibility:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- High LDL-C levels, normal fasting glucose and triglycerides\n- Severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery\n- Presence of plaque in the internal carotid artery and common carotid artery\n\nClinical Trial Inclusion Criteria:\n- Asymmetrical (side difference) plaque distribution in carotids/femoral arteries\n- Tested in at least two prior 3D-ultrasound examinations\n- Absolute side difference in carotid arteries \u2265 30 mm3 or in femoral arteries \u226550 mm3\n- Relative side difference in carotid arteries/femoral arteries \u226550%\n\nThe patient note provides information on severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as well as the presence of bulky plaques. However, there is no specific information given about asymmetrical plaque distribution that has been tested with prior 3D-ultrasound examinations, nor is there any quantifiable data provided that would allow us to affirm an absolute or relative side difference as required by the trial's inclusion criteria.\n\nTherefore, we do not have sufficient information to determine if the patient has an asymmetrical plaque distribution that meets the trial's requirements. It's important to note that while the patient has atherosclerotic alterations, without the specific measurements from the 3D-ultrasound examinations, we cannot conclude eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "843": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, a family history of CAD, extremely high LDL-C levels, and significant stenosis in the carotid arteries. He is not currently on any lipid-lowering medications, and there is no mention of any heart failure, hypertrophic cardiomyopathy, pulmonary arterial hypertension, or any other specific condition related to the subprojects of the clinical trial.\n\nThe inclusion criteria for the clinical trial \"Stress Echo 2020 - The International Stress Echo Study\" require that participants are between the ages of 18 and 85 years and have a technically acceptable acoustic window at rest. The exclusion criteria include the presence of prognosis-limiting comorbidities, pregnancy/lactation, and unwillingness to give informed consent and to enter a regular follow-up program.\n\nThe patient falls within the age range for the trial and there is no information suggesting that he would not have a technically acceptable acoustic window. Additionally, there is no information indicating that he has any prognosis-limiting comorbidity, is pregnant/lactating, or is unwilling to consent or follow-up. However, the patient's condition does not seem to directly align with the study's focus areas, as the study is centered on stress echocardiography applications in several specified cardiac conditions and the patient's primary issue appears to be related to the carotid arteries rather than a cardiac condition that is the focus of the study.\n\nGiven that the patient's condition does not match any of the specific applications mentioned in the study (such as heart failure, hypertrophic cardiomyopathy, or CAD), and there is no mention of the necessity of a stress echocardiography in his case, it seems that the patient's condition is not relevant to the trial's objectives.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "844": {
        "output": "Based on the information provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient's information:\n- 46-year-old man presents with dizziness and frequent headaches.\n- LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively.\n- Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- Plaque in the carotid arteries is characterized as bulky plates extending to the internal coronary arteries, predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n- No mention of the plaque being specified as unstable.\n\nClinical trial inclusion criteria:\n- Meet the diagnostic criteria of carotid artery atherosclerosis.\n- Ultrasound of carotid artery atherosclerosis plaque specifies it as unstable plaque (including malacoplakia and mixed plaque).\n\nThe patient does meet the diagnostic criteria for carotid artery atherosclerosis, as indicated by the presence of severe and moderate stenosis in the carotid arteries and the presence of plaque characterized by ultrasonography. However, the patient note does not specify whether the plaque is unstable, which is a requirement for the trial.\n\nDue to the lack of information about the stability of the plaque, we cannot conclusively determine if the patient is eligible for the trial. As such, the patient falls under the \"Not relevant\" category because we do not have sufficient information to qualify them for the trial based on the inclusion criteria requiring unstable plaque.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "845": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting,\" we need to compare the patient's characteristics and condition with the trial's inclusion criteria.\n\nPatient Characteristics:\n- 46-year-old man\n- Presenting symptoms: dizziness and frequent headaches\n- No history of cardiovascular risk factors except for a family history of CAD\n- High LDL-C level: 545 mg/dL\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n\nClinical Trial Inclusion Criteria:\n- \u2265 50% stenosis of internal carotid artery in symptomatic patients or \u2265 70% stenosis of internal carotid artery in asymptomatic patients\n- Received statin therapy for \u2265 2 weeks before inclusion\n\nComparison:\n- The patient has severe stenosis in the LICA, which fulfills the criterion of having at least 50% stenosis of the internal carotid artery in a symptomatic patient.\n- However, the patient has not been on statin therapy, which is a requirement for inclusion in the trial.\n\nBased on this comparison, the patient does not meet all the inclusion criteria for the trial since he has not received statin therapy for the required duration before inclusion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "846": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to compare the relevant data to assess the patient's eligibility:\n\n**Patient Note:**\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- LDL-C 545 mg/dL and HDL-C 53 mg/dL\n- Fasting glucose and triglyceride levels were within normal limits\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of renal artery stenosis or related conditions\n\n**Clinical Trial Inclusion Criteria:**\n- Age \u2265 14 at the time of informed consent\n- Diameter reduction of renal artery or main branch of renal artery \u2265 60%\n- \u22652 of the following conditions met: systolic hyperemic pressure gradient >20 mm Hg, captopril renoscitigraphy positive in the lesion side, renin-angiotensin-aldosterone system significantly activated, severe reduction (>25%) of glomerular filtration rate in the lesion side\n- Office systolic blood pressure \u2265140 mmHg and/or diastolic blood pressure \u226590 mmHg while receiving 3 antihypertensive drugs, or office systolic blood pressure \u2265160 mmHg and/or diastolic blood pressure \u2265100 mmHg without antihypertensive drugs\n- Serum creatinine level <264 \u00b5mol/L\n- Length of ipsilateral kidney \u22657.0 cm and glomerular filtration rate \u226510 ml/min\n- Urine protein <2+\n\nThere is no information in the patient note that suggests the patient has renal artery stenosis or meets the specific conditions related to the clinical trial's focus on renal artery stenosis. While the patient's age fits the inclusion criteria, none of the other specific conditions for renal artery stenosis or its associated symptoms and tests are mentioned. Therefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "847": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial in question. The patient presents with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery, but there is no mention of renal cell carcinoma (RCC) or any renal tumor of \u22644 cm maximum diameter, which is the specific condition the clinical trial is addressing.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on renal tumors since the patient's medical condition (cardiovascular issues) is not relevant to the criteria specified for the renal tumor study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "848": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 46-year-old man (meets age criteria of 45 to 80 years)\n- Diagnosis includes severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of an ischemic stroke or TIA before admission\n- No indication of the patient's mRS score or ABCD2 score\n- No information on informed consent\n\nClinical Trial Inclusion Criteria:\n1. Age ranging from 45 to 80 years of age, both genders (patient meets this criterion)\n2. Patients diagnosed with an ischemic stroke or TIA before admission and the following requirements should be satisfied as well:\n   - The occurrence of an ischemic stroke within 30 days and with a baseline mRS score \u22644.\n   - The occurrence of a TIA within 15 days and with a baseline ABCD2 score \u22654.\n   (patient does not meet this criterion as there's no mention of a stroke or TIA)\n3. Patients with symptomatic intracranial atherosclerotic stenosis (sIAS) that is attributed to at least 50% stenosis of the diameter of a major intracranial artery (carotid artery, or middle cerebral artery (M1)) verified by MRA or CTA.\n   (patient has severe stenosis in the LICA but no confirmation of symptomatic intracranial atherosclerotic stenosis \u226550% or verification by MRA or CTA)\n4. Informed consent obtained patients or health care proxy, as appropriate, able to cooperate and participate follow-up visits. (no information provided)\n\nBased on the information provided, the patient does not meet all of the inclusion criteria for the clinical trial. Specifically, the patient does not have documented evidence of an ischemic stroke or TIA, and there is no information on the mRS or ABCD2 scores. Additionally, while the patient has carotid artery stenosis, it is not specified as symptomatic intracranial atherosclerotic stenosis, nor is there verification by MRA or CTA as required by the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "849": {
        "output": "Based on the provided patient note and inclusion criteria for the clinical trial, let's evaluate the patient's eligibility for the trial titled \"Trial of Different Dietary Fats on Blood Lipids and Metabolic Measures in Healthy Participants.\"\n\nThe inclusion criteria for the clinical trial are as follows:\n- Willing to participate in the trial of dietary interventions for one month within the age range\n\nUnfortunately, the age range required by the trial is not specified in the inclusion criteria provided. However, since the summary mentions an age range of 50-75 years, we can use this information for our assessment.\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which is outside the age range of 50-75 years mentioned in the trial summary.\n- The patient's LDL-C level is elevated at 545 mg/dL, which suggests that he may not be \"healthy\" as per the usual clinical standards, given the high cholesterol levels.\n- The patient has severe stenosis in the carotid arteries, which is a significant health issue and likely excludes him from being considered a \"healthy volunteer.\"\n\nSince the patient does not meet the age criteria and presents with significant health issues (elevated LDL-C and severe carotid stenosis), he does not qualify as a \"healthy participant\" for this dietary intervention trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "850": {
        "output": "Given the patient note, we have a 46-year-old man with dizziness, frequent headaches, and significant carotid artery stenosis. He does not have a history of lipid-lowering medication use, and there is no mention of enrollment in the CREST-2 parent study.\n\nTo assess the patient's eligibility for the CREST-H clinical trial, we need to consider the inclusion criteria provided:\n\n1. Enrolled and randomized into CREST-2 (parent study)\n2. Inclusion criteria for CREST-2\n   - age 35-86\n3. Exclusion Criteria (in addition to the exclusion criteria for CREST-2):\n   - unable to undergo MRI (e.g., metal in body, pacemaker)\n   - known allergy gadolinium contrast dye\n   - pre-existing diagnosis of dementia\n   - contralateral ICA stenosis >70% by MRA, CTA, or Doppler ultrasound\n   - history of severe head trauma\n   - major depression\n   - education less than 8 years\n\nThe patient note does not provide any information about the patient's enrollment or randomization into CREST-2, which is a fundamental requirement for inclusion in the CREST-H study. Without this information, we cannot consider the patient to be eligible. Additionally, there is no mention of cognitive impairment, which seems to be a relevant aspect of the study's focus, although it is not explicitly listed as an inclusion criterion. \n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria due to the lack of information about enrollment in the CREST-2 study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "851": {
        "output": "Based on the information provided:\n\nThe patient is a 46-year-old man with dizziness, frequent headaches, a family history of CAD, and severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. His LDL-C levels are very high, and he has a systolic murmur. He does not use any lipid-lowering medications.\n\nThe clinical trial is investigating the association between habitual coffee consumption and the presence of subclinical atherosclerosis measured as coronary artery calcium (CAC) in participants living in S\u00e3o Paulo with no prior history of CVD aged 35 to 74 years who underwent a CAC measurement.\n\nThe inclusion criteria for the clinical trial are:\n- Participants of the ELSA-Brasil of S\u00e3o Paulo Research Center who submitted to CAC determination.\n\nThe patient note does not provide information on the following:\n- Whether the patient is a participant of the ELSA-Brasil of S\u00e3o Paulo Research Center.\n- Whether the patient has submitted to CAC determination.\n- The patient's coffee consumption habits.\n- The patient's location (whether he is living in S\u00e3o Paulo or not).\n\nGiven the lack of information on these specific points, we cannot conclude whether the patient is eligible for this trial or not. The patient does not have a prior history of cardiovascular disease (CVD), which matches one of the inclusion criteria, but without more information on his participation in the ELSA-Brasil study and whether he has undergone CAC determination, we cannot determine his eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "852": {
        "output": "Based on the information provided, the patient is a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL cholesterol but no other cardiovascular risk factors and is physically active. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as revealed by ultrasonography. The patient has not been reported to use any lipid-lowering medications.\n\nThe clinical trial in question is validating a CT-based fractional flow reserve (FFR) software using a 320-detector CT scanner. The inclusion criteria for the trial are patients over 18 years of age who are undergoing CCTA and angio-FFR and are either scheduled for clinically mandated elective invasive coronary angiography (ICA) or clinically mandated CTA.\n\nThe patient note does not mention whether the patient is undergoing CCTA or angio-FFR, nor does it mention any scheduling for invasive coronary angiography (ICA) or CTA. Without this specific information, we cannot confirm that the patient meets the inclusion criteria for the clinical trial. Thus, we must conclude that there is not sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "853": {
        "output": "Based on the information provided in the patient note and the clinical trial description, the patient presents with extremely high LDL-C levels, which is a characteristic feature of Familial Hypercholesterolemia (FH). However, the clinical trial information does not provide specific inclusion criteria beyond stating that it follows the Taiwan FH Diagnostic Criteria revised from the Dutch Lipid Clinic Network (DLCN) Criteria.\n\nGiven that the patient has markedly high LDL cholesterol levels and no use of lipid-lowering medications, and considering the absence of other cardiovascular risk factors, the patient presents with a clinical picture that could be consistent with FH. However, without more information on the specific diagnostic criteria being used in the trial or additional patient information such as genetic testing or the presence of tendon xanthomas, it is not possible to definitively determine the patient's eligibility.\n\nTherefore, based on the available information, the patient's eligibility for the clinical trial titled \"A Registration Study for Familial Hypercholesterolemia in Taiwan\" would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "854": {
        "output": "The patient in question is a 46-year-old man presenting with symptoms not directly related to the focus of the clinical trial, which is concerned with paediatric obesity and cardiovascular dysfunction in children and adolescents aged 6-16 years.\n\nThe inclusion criteria for the trial are as follows:\n- Children and adolescents (6-16 years);\n- Obese (OB) and normal weight (NW, control group) according to the International Obesity Task Force (IOTF) criteria;\n- Both genders;\n- Diet na\u00efve.\n\nThe patient does not meet the inclusion criteria regarding age, as he is 46 years old and the trial is specifically for children and adolescents between 6 and 16 years old. Additionally, there is no indication of obesity or of the patient being diet na\u00efve as required for the trial participants. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "855": {
        "output": "The clinical trial is focused on evaluating the cardiovascular risk of soccer referees, specifically those who are elite referees of the gold series of the Paulista Soccer Federation and registered for participation in the S\u00e3o Paulo professional soccer championship in 2009. The inclusion criteria are very specific to this population, requiring that participants be elite referees and have completed a series of tests for the study.\n\nThe patient note describes a 46-year-old man with cardiovascular issues, including severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as well as high LDL-C levels. However, there is no mention of the patient being a soccer referee or having any connection to the Paulista Soccer Federation. Furthermore, the patient's cardiovascular condition and medical history do not align with the focus of the study, which is on the cardiovascular health of soccer referees.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, as he is not an elite referee of the gold series of the Paulista Soccer Federation, nor is he registered for participation in the S\u00e3o Paulo professional soccer championship in 2009. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "856": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He presents with dizziness and frequent headaches.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- There is no mention of a history of TIA (transient ischemic attack) or stroke.\n- The patient has not been described as having given informed consent for ICA stenting or endarterectomy.\n- There is no mention of contraindications to MRI.\n- The LDL-C level is elevated, but this is not relevant to the trial's inclusion criteria.\n\nClinical Trial Inclusion Criteria:\n- Informed patient's consent for ICA stenting or endarterectomy.\n- Lack of contraindications to MRI.\n- Symptomatic, unilateral ICA stenosis of 70-99%; irrelevant stenosis <50% of the contralateral ICA.\n- TIA or stroke within the past 360 days.\n\nComparison:\n- The patient has severe stenosis in the left ICA, which could potentially meet the criteria if it is within the 70-99% range, but the exact percentage is not mentioned.\n- There is no information provided about a recent TIA or stroke within the past 360 days.\n- There is no information about the patient's consent for ICA stenting or endarterectomy or about any contraindications to MRI.\n\nThe patient's eligibility cannot be determined with certainty without additional information regarding the severity of the ICA stenosis (to confirm it falls within the 70-99% range), whether the patient has experienced a TIA or stroke within the past 360 days, and whether the patient has consented to treatment and does not have contraindications to MRI.\n\nBased on the information provided, we do not have sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "857": {
        "output": "Given the patient note:\n\n- The patient is a 46-year-old man, which fits within the age range of 45-65 years for men specified in the trial's inclusion criteria.\n- The patient has dyslipidemia, as indicated by the high LDL-C level of 545 mg/dL without the current use of lipid-lowering medications.\n- The patient has a family history of CAD, which is a first-degree family history of early cardiovascular disease.\n\nThese factors align with the inclusion criteria for the trial, which require participants to be within certain age ranges and have at least one cardiovascular risk factor.\n\nHowever, the clinical trial's inclusion criteria specifically state that participants should not have a previous history of cardiovascular disease. The patient's carotid stenosis and the presence of plaques may be considered as existing cardiovascular conditions. However, the trial's inclusion criteria do not explicitly exclude individuals with such conditions, as it does not state that participants with any sign of cardiovascular disease are excluded. The trial is assessing the prevalence of subclinical vascular disease in a population with low/moderate risk, and the patient's condition could be considered part of this assessment. Unless further exclusion criteria are provided that would disqualify the patient, based on the information available, the patient appears to meet the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "858": {
        "output": "Based on the information provided in the patient note, the 46-year-old man presents with symptoms that may be related to cerebral vascular disease, such as dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, there is no mention of an acute infarct in diffusion-weighted MRI, which is one of the inclusion criteria for the symptomatic group in the clinical trial. Moreover, the trial is specifically about intracranial atherosclerotic disease (IAD), and the provided patient note discusses carotid artery stenosis, not necessarily intracranial stenosis or artery-to-artery thrombo-embolism.\n\nThe patient also does not meet the criteria for the asymptomatic group since there is no information provided about the presence or absence of high-grade (>60%) intracranial stenosis or about MES (micro-embolic signals) detected on TCD examination. There is also no information about the patient's understanding of the study or whether informed consent has been provided.\n\nGiven the lack of specific information aligning with the trial's inclusion criteria and the absence of details necessary to determine eligibility, we have to consider the patient as not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "859": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's compare the details:\n\nPatient details:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- No mention of symptomatic (ipsilateral ischemic stroke, TIA, or retinal ischemia) or asymptomatic carotid stenosis fitting the specified criteria\n\nClinical trial inclusion criteria:\n- Symptomatic carotid stenosis between 50% and 99%\n- Asymptomatic carotid stenosis between 60% and 99%\n- Patients who accept the informed consent\n\nThe patient has severe stenosis in the LICA and moderate stenosis in the RICA. However, there is no mention of the stenosis being in the range of 50% to 99% for symptomatic or 60% to 99% for asymptomatic, according to NASCET and ECST criteria. Moreover, there is no information provided about symptoms of ipsilateral ischemic stroke, TIA located in the carotid artery territory, or retinal ischemia, which would classify the carotid stenosis as symptomatic.\n\nWithout the specific percentage of stenosis based on the NASCET and ECST criteria and a lack of information on symptoms that could classify the stenosis as symptomatic, we do not have sufficient information to determine the patient's eligibility for the trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "860": {
        "output": "Given the patient note, the patient presents with dizziness, frequent headaches, and a significant family history of CAD, but he does not have classical cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus. His lipid levels are abnormal with an LDL-C level of 545 mg/dL, which is considerably high. The patient has severe carotid artery stenosis as detected by ultrasonography.\n\nThe clinical trial in question is looking to evaluate the relationship between morbid obesity and carotid artery stenosis. The inclusion criteria explicitly mention \"Candidates for first bariatric surgery.\" There is no information in the patient note suggesting that the patient is morbidly obese or a candidate for bariatric surgery.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial as there is no indication the patient is a candidate for bariatric surgery or morbidly obese. Therefore, the patient note is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "861": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His LDL-C levels are elevated, and he has a systolic murmur in the neck. The ultrasonography of his carotid arteries revealed severe stenosis in the LICA and moderate stenosis in the RICA.\n\nThe inclusion criteria for the clinical trial are:\n1. Subject has carotid plaque with > 50% stenosis\n2. Subject is able to understand the study procedure and provide informed consent\n\nThe patient note confirms that the patient has severe stenosis in the left internal carotid artery, which indicates that the stenosis is likely to be more than 50%. Therefore, the patient meets the first inclusion criterion. There is no information suggesting that the patient is unable to understand the study procedure or provide informed consent. Assuming the patient is able to provide informed consent, he would meet the second inclusion criterion as well.\n\nTherefore, based on the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "862": {
        "output": "Based on the provided patient note and the inclusion criteria of the MIMIRA study, the patient does not appear to meet the inclusion criteria. The patient note does not mention a recent coronary artery event such as myocardial infarction or unstable angina pectoris, nor does it mention any treatment with percutaneous coronary intervention (PCI) or coronary artery by-pass graft surgery (CABG). The note also lacks any information about the presence of depressive symptoms or a score on the CES-D scale, and there is no mention of the patient's interest in participating in MBSR (Mindfulness Based Stress Reduction).\n\nTherefore, given the information from the patient note, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "863": {
        "output": "In assessing the eligibility of the 46-year-old man for the clinical trial titled \"Assessing Neurocognition After Cerebrovascular Intervention,\" we need to compare his characteristics and medical findings with the inclusion criteria of the trial:\n\nPatient characteristics:\n- Age: 46 years old\n- Symptoms: Dizziness and frequent headaches\n- Medical History: Family history of CAD, physically active, no cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus\n- Lab Results: LDL-C 545 mg/dL, HDL-C 53 mg/dL, fasting glucose 85 mg/dL, triglycerides 158 mg/dL\n- Medication: No use of lipid-lowering medications\n- Clinical Findings: Systolic murmur, severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery\n\nClinical trial inclusion criteria:\n- Age \u2265 18 years\n- Ultrasound evidence of carotid stenosis; 50% or greater symptomatic carotid stenosis or 70% or greater asymptomatic carotid stenosis\n\nThe patient is over 18 years of age and has ultrasound evidence of carotid stenosis. The patient's ultrasonography reveals severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient\u2019s stenosis is severe in the left internal carotid artery, which is indicative of 50% or greater carotid stenosis. Although the document does not specify if the stenosis is symptomatic or asymptomatic, the patient does present with symptoms (dizziness and frequent headaches) that could be related to the stenosis.\n\nBased on the information provided and the inclusion criteria of the clinical trial, the patient appears to be eligible as he meets the age requirement and has ultrasound evidence of carotid stenosis, which is greater than 50% on the left side and could be associated with his symptoms.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "864": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, a family history of CAD, and severe and moderate stenosis in the left and right internal carotid arteries, respectively. The patient has significantly elevated LDL-C levels but reports no use of lipid-lowering medications. \n\nThe clinical trial is investigating the effect of psyllium fibre on LDL-C, non-HDL-C, and apoB levels in human trials through randomized controlled trials (RCTs). The inclusion criteria for the trial are:\n\n1. Human trials.\n2. RCT that investigates the effect of psyllium fibre on LDL-C, non-HDL-C, and/or apoB.\n3. Suitable control.\n4. Minimum follow-up period \u2265 3 weeks.\n5. Amount of psyllium fibre must be reported and effect on outcomes isolatable.\n\nThe patient's LDL-C levels are elevated, which is relevant to the trial's focus on lipid parameters. However, the patient note does not indicate that the patient is part of an RCT or that the patient has been or will be administered psyllium fibre. Moreover, there is no information provided about the patient being part of a control group or the follow-up period.\n\nGiven the information provided, the patient does not meet the inclusion criteria because there is no indication that he is participating in an RCT or that the effect of psyllium fibre on his lipid levels is being studied. Therefore, we assign the following trial-level eligibility:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "865": {
        "output": "",
        "label": 2
    },
    "866": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms that include dizziness and frequent headaches, which aligns with the inclusion criteria for the clinical trial. The trial is focused on patients who arrive at the emergency room with decreased consciousness, severe headaches, or dizziness for the evaluation of a tool for detecting CVA (cerebrovascular accident) using EEG data analysis.\n\nThe patient's symptoms of dizziness and frequent headaches fit the inclusion criteria of \"severe headaches or dizziness\". Furthermore, there is no information provided in the patient note that would suggest the patient meets any exclusion criteria for the trial. Hence, the patient appears to be a potential candidate for the clinical trial based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "867": {
        "output": "The patient is a 46-year-old man who presents with dizziness and frequent headaches. His LDL-C levels are significantly high at 545 mg/dL, which is above the trial's inclusion criterion of an LDL-c level below 100 mg/dL. Additionally, there is no information provided about his blood pressure or HbA1c levels to assess whether they are well-controlled as per the trial's inclusion criteria. However, the patient does have carotid atherosclerotic plaque with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which meets the criterion of 30%-70% stenosis by ultrasound and plaque thickness >2.5 mm.\n\nThe patient does not report any transient ischemic attack, minor stroke, or amaurosis fugax within the last 6 months, which aligns with the inclusion criteria. However, the high LDL-C level is a significant deviation from the trial's requirements.\n\nGiven the information provided, the patient does not meet all the inclusion criteria due to his LDL-C levels. There is insufficient information regarding blood pressure and diabetes control to fully assess eligibility, but the provided LDL-C level alone is enough to determine that the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "868": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms that include dizziness, frequent headaches, and a severe stenosis in the left internal carotid artery. His lipid levels are abnormal with an LDL-C level of 545 mg/dL and an HDL-C of 53 mg/dL. He is not currently using lipid-lowering medications. There is no mention of hypertension or any previous history related to salt sensitivity or resistance, nor is there any mention of lens opacities or evaluations related to the patient's vision.\n\nThe clinical trial is focused on salt-sensitive hypertension (SSH) and its relationship to lens opacities. The inclusion criteria for the trial are:\n1. Salt Sensitivity Hypertension patients\n2. Non-SSH, salt-resistant HT (SRH) patients\n3. Control patients without HT, aged 40-80 years.\n\nThe patient does not present any information regarding hypertension or salt sensitivity/resistance, and no information is provided about lens opacities. Therefore, there is insufficient information to determine if he meets the inclusion criteria for the study based on the patient note. His age fits within the specified range, but without further details on his hypertension status or lens health, we cannot definitively conclude his eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "869": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, we can determine the patient's eligibility for the study.\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of cardiovascular disease (CAD)\n- No other cardiovascular risk factors\n- Physically active\n- High LDL-C level (545 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery observed on ultrasonography\n\nClinical trial inclusion criteria:\n- Willing to participate in the trial of dietary interventions for one month\n- Within the age range (the specific age range is not provided, but the patient note mentions \"men and women aged 50-75 years,\" which might suggest the intended age range)\n\nGiven that the patient is 46 years old, they do not meet the age criteria specified in the patient note for the clinical trial, which states that participants should be aged 50-75 years. However, the inclusion criteria listed at the end do not specify an age range, which might be an oversight or an incomplete listing of the criteria.\n\nBecause of this discrepancy and lack of clarity in the inclusion criteria regarding the age range, we cannot definitively determine the patient's eligibility based on the information given. Therefore, we must conclude that the patient does not have sufficient information to qualify for the trial, as the age range for eligibility is not clearly defined.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "870": {
        "output": "Upon reviewing the patient note and comparing it with the inclusion criteria of the SWIDINEP clinical trial, it is clear that the patient does not meet the specified inclusion criteria for the trial. The patient is described as having severe stenosis in the carotid arteries but there is no mention of Type 2 diabetes, eGFR values, or albumin/creatinine ratio. Furthermore, there is no indication in the patient note that the patient has chronic kidney disease (CKD), which is a focus of the SWIDINEP cohort study.\n\nThe inclusion criteria for the SWIDINEP study are:\n1. Type 2 diabetes\n2. eGFR <60ml/min or albumin/creatinine ratio >3mg/mmol\n3. Can understand French and has signed the consent form.\n\nThe patient note mentions neither Type 2 diabetes nor any kidney function test results (eGFR or albumin/creatinine ratio). Additionally, there is no information regarding the patient's ability to understand French or whether they have signed a consent form. Based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTherefore, the patient\u2019s eligibility for the SWIDINEP clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "871": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient note summary:\n- A 46-year-old man\n- LDL-C level of 545 mg/dL\n- No use of lipid-lowering medications\n- No mention of being on a cholesterol-lowering diet\n- TG level of 158 mg/dL\n\nClinical trial inclusion criteria:\n- Age 18 to 75 years\n- LDL-C 130 to 189 mg/dL on a cholesterol-lowering diet but no lipid-modifying drug treatment for at least 6 weeks\n- TG \u2264 350 mg/dL on a cholesterol-lowering diet but no lipid-modifying drug treatment for at least 6 weeks\n- Signed written informed consent\n\nPatient's eligibility:\n- The patient's age (46 years) falls within the required age range of 18 to 75 years.\n- The patient's LDL-C level (545 mg/dL) is significantly higher than the required range of 130 to 189 mg/dL, which makes him ineligible based on this criterion alone.\n- The patient's TG level (158 mg/dL) is within the acceptable range (\u2264 350 mg/dL).\n- There is no information provided about the patient being on a cholesterol-lowering diet.\n\nSince the patient's LDL-C level exceeds the maximum level specified in the trial inclusion criteria, and there is no mention of the patient being on a cholesterol-lowering diet as required, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "872": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches, and he has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The stenosis is characterized by ultrasound and is in the extracranial internal carotid arteries, not the intracranial arteries as specified by the trial's inclusion criteria.\n\nThe clinical trial is specifically looking for patients who have had a recent transient ischemic attack or ischemic stroke within two weeks after symptom onset and who have intracranial artery stenosis (30%-99%) in specific intracranial arteries as determined by computed tomography angiography or magnetic resonance (MR) angiography.\n\nThe patient in the note does not mention a recent transient ischemic attack or ischemic stroke, nor does it specify that the stenosis is in the intracranial arteries. It also does not specify that the stenosis was determined by computed tomography angiography or MR angiography, which are required for the trial's inclusion.\n\nTherefore, based on the provided information, there is not enough evidence to say that the patient meets the trial's inclusion criteria. The patient's stenosis is not clearly identified as intracranial, and there is no mention of a recent transient ischemic attack or ischemic stroke.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "873": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has not used lipid-lowering medications and presents with dizziness and frequent headaches.\n\nThe clinical trial in question is focused on insulin resistance in patients after carotid revascularization surgery.\n\nTo determine the patient's eligibility for the clinical trial, we must assess whether the patient meets the inclusion criteria:\n\n1. Diagnosed with carotid stenosis: The patient has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which meets this criterion.\n2. Had indications for carotid revascularization: The patient's condition of severe stenosis in the left internal carotid artery would likely indicate the need for carotid revascularization, although the note does not explicitly state that the patient has been recommended for or has undergone such surgery.\n\nThe inclusion criteria are met if we assume that severe stenosis is an indication for carotid revascularization. However, the patient note does not mention that the patient has undergone or is scheduled for carotid revascularization surgery. To be eligible for the study, the patient must have had indications for carotid revascularization, which the severity of the stenosis suggests, but without explicit confirmation of the patient's treatment plan, we cannot be certain of eligibility.\n\nGiven the information provided, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.\n\nThe patient has diagnosed carotid stenosis but there is no clear indication that he has had or is scheduled for carotid revascularization, which is a requirement for inclusion in the study. Additional information regarding the patient's treatment plan would be necessary to make a definitive assessment of eligibility.",
        "label": 2
    },
    "874": {
        "output": "After reviewing the patient's note and comparing it to the inclusion criteria of the clinical trial in question, we can determine the patient's eligibility as follows:\n\n- Age: The patient is 46 years old, which does not fall within the specified age range of 20-40 years for the trial.\n- Apical periodontitis: There is no mention of apical periodontitis, dental symptoms, or any dental examination findings in the patient's note.\n- Number of teeth: The patient's note does not provide any information regarding the number of teeth.\n- Echocardiographic Left Ventricle Ejection Fraction (LVEF): There is no information provided about the patient's LVEF in the note.\n- Hepatic and renal function: The patient's note does not mention any liver or kidney function tests.\n\nBased on the available information, the patient does not meet the age criterion, and there is insufficient information to assess the other criteria. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "875": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has extremely high LDL-cholesterol (LDL-C) levels of 545 mg/dL, which is significantly above the normal range and well above the inclusion criteria threshold of >100 mg/dL for the clinical trial. His HDL-C, fasting glucose, and triglyceride levels are within normal limits, with triglycerides being below the trial's cutoff of <400 mg/dL. The patient is not on any lipid-lowering medications, which is not contraindicated by the trial's inclusion criteria.\n\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the key exclusion criteria for the trial include \"History or presence of coronary heart disease, peripheral artery disease, or cerebrovascular disease,\" which the patient's carotid artery stenosis would fall under, categorizing as cerebrovascular disease.\n\nBased on the information provided in the patient note and the clinical trial's inclusion and exclusion criteria, the patient would be excluded from participating in the trial due to the presence of cerebrovascular disease (carotid artery stenosis).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "876": {
        "output": "",
        "label": 0
    },
    "877": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- No history of neck pain mentioned\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n\nClinical trial inclusion criteria:\n- Being between 20-40 years of age\n- Having non-specific mechanical neck pain for more than 3 months with symptoms provoked by neck postures, movements, or palpation\n- Willingly participating in the study\n- Signing the confirmation form\n\nThe patient is 46 years old, which exceeds the age range of 20-40 years required by the trial. Additionally, there is no mention of non-specific mechanical neck pain in the patient's history, which is a necessary condition for inclusion in the trial. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "878": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery (LICA) with PSV of 208.5 cm/s and EDV of 54.5 cm/s.\n- Moderate stenosis in the right internal carotid artery (RICA) with PSV of 91.72 cm/s and EDV of 37.37 cm/s.\n- The patient has carotid artery disease as indicated by the presence of stenosis in both ICAs.\n\nClinical Trial Inclusion Criteria:\n- Outpatients age > 18 years sent to the vascular laboratory for carotid duplex examination for initial carotid ultrasound study or for follow-up of known carotid disease.\n- Enrolled patients will include at least 100 subjects with at least moderate known stenosis (50-69% or greater, PSV > 125 cm/sec) or occlusion of one or both ICAs\n- Up to 25 patients with known fibromuscular dysplasia (FMD) of the internal carotid arteries.\n\nComparison:\n- The patient is over 18 years old.\n- The patient has been evaluated with an initial carotid ultrasound study, indicating severe stenosis in LICA and moderate stenosis in RICA.\n- The PSV of LICA is greater than 125 cm/sec, indicating at least moderate stenosis, which meets the requirement for the trial.\n\nGiven this information, the patient appears to meet the criteria for the clinical trial as he is an outpatient over 18 years of age with known carotid disease and a PSV indicating at least moderate stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "879": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Cognitive and Blood Flow Effects of Mountain Tea,\" we need to compare the patient's information with the inclusion criteria listed for the trial.\n\nPatient's characteristics:\n- Age: 46 years old\n- Health issues: Dizziness, frequent headaches, severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery, hypercholesterolemia (high LDL-C level)\n\nClinical trial inclusion criteria:\n- Age: 50-70 years old\n- No underlying health problem which would prevent engagement with the study\n\nThe patient is 46 years old, which does not meet the age criterion of the clinical trial (50-70 years old). Furthermore, the patient has significant health issues, including severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could be considered underlying health problems that might prevent engagement with the study.\n\nBased on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "880": {
        "output": "The patient described in the note is a 46-year-old man presenting with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but there is no mention of chronic total occlusion (CTO) of the coronary arteries, which is the focus of the clinical trial. The trial is looking specifically for patients with a history of CTO recanalization or untreated CTO.\n\nBased on the information provided in the patient note, there is no indication that the patient has been diagnosed with or treated for CTO. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which requires the presence of CTO and specific conditions related to CTO recanalization history or status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "881": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let us assess the patient's eligibility for the clinical trial titled \"Stratification of Patient With Carotid Disease.\"\n\nPatient Note:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD, no other cardiovascular risk factors\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Systolic murmur in the neck\n- Carotid ultrasonography showing severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Left Internal Carotid Artery (LICA) stenosis is severe, with PSV and EDV above the specified cutoff values\n- Right Internal Carotid Artery (RICA) stenosis is moderate, with PSV and EDV below the specified cutoff values for severe stenosis\n\nClinical Trial Inclusion Criteria:\n- Extracranial carotid stenosis greater than 50% (NASCET) in the carotid bifurcation or internal carotid artery assessed by ultrasound\n- Ability of the patient for follow-up examinations\n- Personally signed informed consent\n\nAccording to the patient note, the patient has severe stenosis in the left internal carotid artery, which meets the trial's inclusion criterion of having extracranial carotid stenosis greater than 50%. The patient note does not mention any issues with the patient's ability to attend follow-up examinations or provide informed consent, so we do not have information to suggest the patient cannot meet these criteria.\n\nBased on the available information, the patient appears to meet the inclusion criteria for the clinical trial. The patient note does not provide any reason to believe the patient would be excluded based on the provided trial inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "882": {
        "output": "",
        "label": 2
    },
    "883": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we need to assess whether the patient qualifies for the trial. \n\nThe inclusion criteria for the clinical trial are:\n1. BMI \u2265 18.5 kg/m2\n2. Fasting blood glucose \u22647 mmol/L (\u2264126 mg/dL)\n3. Physically active\n4. Percent body fat, 5-25 % for men and 12-35 % for women\n\nThe patient note provides the following relevant information:\n- The patient is a physically active 46-year-old man.\n- The patient's fasting glucose level is 85 mg/dL, which is within normal limits and below the clinical trial's requirement of \u22647 mmol/L.\n- The patient has not reported using any lipid-lowering medications.\n\nHowever, the patient note does not provide information on the patient's BMI or percent body fat. Without these two pieces of information, we cannot fully determine whether the patient meets all the inclusion criteria for the trial, specifically regarding BMI and body fat percentage.\n\nTherefore, based on the available information, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "884": {
        "output": "",
        "label": 0
    },
    "885": {
        "output": "Based on the provided patient note, the patient is a 46-year-old man who presents with dizziness and frequent headaches, has a family history of CAD, extremely high LDL-C levels, and carotid artery stenosis. There is no mention of ischemic sounding chest pain or a visit to the emergency department due to suspected acute coronary syndrome (ACS). Also, there is no information provided about an ECG or initial troponin levels, which are required to meet the inclusion criteria for the clinical trial.\n\nGiven the lack of information regarding chest pain, ECG changes, and troponin levels, we cannot determine if the patient qualifies for the trial based on the inclusion criteria provided. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "886": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No use of lipid-lowering medications.\n- No cardiovascular risk factors other than family history of CAD.\n- Physically active.\n\nClinical Trial Inclusion Criteria:\n- Male or female.\n- Age 25 - 70 years.\n- Suspicion of cervical or intracranial vascular pathology.\n- Signed informed consent.\n\nThe patient is a 46-year-old man, which fits the age criterion. He presents with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which can be considered a suspicion of cervical vascular pathology. \n\nThe patient would need to provide signed informed consent to participate in the trial. Assuming that the patient would provide consent if interested, the patient appears to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "887": {
        "output": "Based on the patient note provided, the 46-year-old man has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels, a systolic murmur, and frequent headaches and dizziness. There is no mention of him having fibromuscular dysplasia (FMD) or vascular Ehlers-Danlos Syndrome (V-EDS), which are the target diseases for the clinical trial described.\n\nThe clinical trial has specific inclusion criteria for patients with FMD or V-EDS, which includes a confirmed diagnosis of these conditions, age between 18 and 80, informed consent signed, and affiliation to a social security. Since the patient does not have a diagnosis of either FMD or V-EDS and considering the information provided does not suggest the presence of these conditions, the patient does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the patient is not relevant for the clinical trial as there is no sufficient information to qualify for the trial based on the inclusion criteria outlined.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "888": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can make the following assessment:\n\nPatient Note:\n- The patient is a 46-year-old man, which fits within the age range of the inclusion criteria (18-65 years).\n- The patient presents with dizziness, frequent headaches, and has familial CAD but is otherwise active and has no other cardiovascular risk factors.\n- His LDL-C is elevated, and HDL-C levels are within a normal range.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient has not used any lipid-lowering medications.\n\nClinical Trial Inclusion Criteria:\n- Age: 18-65 years.\n\nThe patient meets the age requirement for the clinical trial. However, the clinical trial is focused on the health effects of reducing sedentary behavior and mentions looking at outcomes related to physical fitness, stress, blood lipids, blood glucose, blood pressure, resting energy expenditure, and body composition.\n\nThe patient note does not provide enough information to determine whether the patient's lifestyle is sedentary or not, which is a key aspect of the trial's focus. Additionally, there's no mention of the patient's current level of physical activity, cortisol levels, or whether he is experiencing stress that requires management, which are factors that the trial seems to be interested in investigating.\n\nBased on the information provided, while the patient falls within the age range, there is not enough information to determine if he fits the other aspects of the inclusion criteria related to the trial's focus on sedentary behavior and related health outcomes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "889": {
        "output": "Based on the provided patient note and the inclusion criteria for the TREAT NL clinical trial, the patient in question does not meet the inclusion criteria for the trial.\n\nThe patient's primary issues are cardiovascular in nature, with no mention of atopic eczema, which is the condition under consideration for the TREAT NL registry. The trial is specifically recruiting individuals with moderate-to-severe atopic eczema who are starting phototherapy or systemic immunomodulating therapy. The patient note does not indicate a diagnosis of atopic eczema, nor does it mention the patient starting any therapies related to the treatment of atopic eczema.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as they do not have the target disease (atopic eczema) that is required for inclusion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "890": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we will assess the patient's eligibility for the trial.\n\nPatient Note Summary:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- No history of smoking, high blood pressure, or diabetes mellitus.\n- LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively.\n- Fasting glucose and triglyceride levels within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nClinical Trial Inclusion Criteria:\n- Male and female patients aged between 18 to 65 years (both inclusive).\n- Clinical signs and symptoms of Visceral Leishmaniasis.\n- Presence of amastigotes (Leishmania Donovani bodies) detected by rK39 dipstick test.\n- For females, negative serum pregnancy test and reliable birth control method.\n- Ability to comply with all study requirements.\n- Hb \u2265 6.0 g/dl.\n- Platelets count \u2265 60,000/mm3.\n- Immunocompetent (white blood cell count \u2265 2500/mm3).\n- Written informed consent.\n- Clinically acceptable results from all the screening laboratory parameters and investigations.\n\nComparison:\n- The patient is within the age range required by the trial (18 to 65 years).\n- There is no indication that the patient has Visceral Leishmaniasis or any related symptoms.\n- No information is provided about the presence of Leishmania Donovani bodies.\n- The patient is male, so the criteria regarding pregnancy and birth control do not apply.\n- The patient's ability to comply with study requirements, blood parameters, or immunocompetence is not mentioned.\n- No information is given about informed consent or the results of screening laboratory parameters and investigations.\n\nThe patient does not meet the specific disease criteria for Visceral Leishmaniasis, which is the focus of the clinical trial. Therefore, the patient does not fulfill the necessary inclusion criteria for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "891": {
        "output": "Based on the patient note provided, the 46-year-old man does not have type 1 diabetes mellitus; instead, he presents with dizziness, frequent headaches, and cardiovascular issues, including severe stenosis in the left internal carotid artery. Since the inclusion criteria for the clinical trial explicitly states that participants must have diabetes mellitus type 1, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "892": {
        "output": "The patient is a 46-year-old man presenting with dizziness and frequent headaches. He has a family history of coronary artery disease (CAD), but no other cardiovascular risk factors, and he is physically active. The patient has high LDL cholesterol levels but normal fasting glucose and triglyceride levels. He has not used any lipid-lowering medications. There is evidence of severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating the presence of significant atherosclerosis.\n\nThe clinical trial is looking for patients with no previous history of CAD who are admitted to the chest pain unit after presenting to the emergency department with acute chest pain, suspected to be of cardiac origin, and who are suitable for further investigation by a cardiac CT scan. The E.C.G at admission must show no signs of myocardial ischemia, and cardiac biomarkers must be normal.\n\nThe patient note does not mention acute chest pain or a presentation to the emergency department with symptoms of cardiac origin. There's also no information on the patient's E.C.G results or cardiac biomarker levels. However, the presence of significant atherosclerosis (severe stenosis) could be indicative of underlying CAD, which is a condition the study is specifically excluding.\n\nGiven the lack of information regarding the acute chest pain presentation, normal E.C.G, and cardiac biomarkers, and the potential presence of underlying CAD suggested by severe carotid stenosis, the patient does not clearly meet the inclusion criteria for the trial. Therefore, based on the information available, the patient would be classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "893": {
        "output": "",
        "label": 2
    },
    "894": {
        "output": "The patient in question is a 46-year-old man with significant cardiovascular findings, including severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. Additionally, he has a family history of CAD, extremely elevated LDL-C levels, but no other cardiovascular risk factors. He has not been on lipid-lowering medications.\n\nNow, let's match the patient's characteristics with the inclusion criteria of the trial:\n\n1. Age \u226518 years and \u2264 75 Years: The patient is 46 years old, which fits within the age range.\n2. Documented stable CAD: The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which may indicate CAD, but there is no explicit mention of stable angina pectoris, previous MI, or revascularization procedures.\n3. Women must be postmenopausal or surgically sterile: Not applicable, as the patient is male.\n4. Patients who were taking clopidogrel or ticagrelor must discontinue these agents at least 14 days before randomization: The patient reported no use of lipid-lowering medications, and there is no mention of clopidogrel or ticagrelor, implying that he is not taking these medications.\n\nThe key concern here is whether or not the patient's condition can be classified as stable CAD as per the trial's definition. The patient's severe and moderate carotid artery stenosis and the presence of plaques could be suggestive of CAD, but the trial specifically mentions stable angina pectoris, previous MI, or previous revascularization, none of which are mentioned in the patient's note. Therefore, there is insufficient information to determine if the patient's condition qualifies as \"stable CAD\" under the trial's terms.\n\nGiven this lack of information, the assessment of eligibility according to the provided scale would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "895": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"MR Antagonist and STRIATIN,\" we must assess the inclusion and exclusion criteria against the patient's clinical presentation.\n\nPatient note analysis:\n- The patient is a 46-year-old man, which fits the age criterion of >17 years.\n- The patient presents with dizziness and frequent headaches, and there's no mention of hypertension, but given the severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, hypertension could be a related condition. However, without a clear diagnosis of hypertension from a primary physician, we cannot confirm this.\n- No current use of lipid-lowering medications is reported, which is consistent with the trial's requirement of not being on any drug therapy except for anti-hypertensives and replacement thyroid medication.\n- The patient has not been described as taking any anti-hypertensive medications, nor is there a mention of a washout period for such medications.\n- There is no mention of the patient carrying the Striatin rs254093 risk allele or both Striatin rs888083 and rs6744560 risk alleles, which are required for eligibility.\n- Laboratory values are provided for LDL-C and HDL-C levels, fasting glucose, and triglycerides, but there's no comprehensive lipid profile, renal, metabolic, electrolyte, or complete blood cell count provided to confirm normalcy according to the trial's criteria.\n- There's no information on whether the patient is a smoker, which is relevant as smokers are excluded from the trial.\n- No explicit mention of known cardiac disease other than hypertension, renal, circulatory, or neurologic diseases, diabetes, or secondary hypertension, which are part of the exclusion criteria.\n- No information on weight, alcohol use, or recreational drug use, which are also factors in the exclusion criteria.\n\nGiven the information available in the patient note, we do not have sufficient evidence to determine if the patient meets the specific genetic criteria for inclusion, nor do we have a clear diagnosis of hypertension. Additionally, necessary laboratory values and medical history details are missing, which are required to rule out exclusion criteria. Therefore, we cannot conclude that the patient is eligible or excluded based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "896": {
        "output": "The patient in the note presents with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL cholesterol levels and carotid artery stenosis but does not report any use of lipid-lowering medications or symptoms related to a prosthetic joint infection. There is no mention of the patient having a prosthetic joint or symptoms associated with a prosthetic joint infection such as fever, pain, fistula, redness, swelling, hotness, or loss of function. Additionally, there is no mention of radiological evidence to suggest a prosthetic joint infection.\n\nThe clinical trial is specifically looking to include patients with a suspected prosthetic joint infection, as indicated by clinical manifestations and radiological evidence. Since the patient note does not provide any information suggesting that the patient has a prosthetic joint or symptoms of an infection in such a joint, we cannot affirm that this patient meets the inclusion criteria for the trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "897": {
        "output": "The patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He presents with dizziness and frequent headaches, but there is no mention of him suffering from a Partial Anterior Circulatory Stroke (PACS) or Transient Ischaemic Attack (TIA).\n\nThe clinical trial \"Carotid Artery Disease After Stroke (CADAS)\" includes patients who have suffered a PACS or TIA and have carotid stenosis >50%. \n\nWhile the patient has carotid stenosis, without evidence of having suffered from PACS or TIA, we cannot confirm that he meets all the inclusion criteria for the trial. Therefore, the patient cannot be considered eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "898": {
        "output": "Given the information from the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility.\n\nPatient note:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- No history of transient ischemic attack, stroke, or related neurological symptoms in the past 6 months (only dizziness and mild headache are reported).\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery diagnosed by ultrasonography.\n\nClinical trial inclusion criteria:\n- Age \u2265 50 years; the patient is 46 years old, which is below the required age.\n- Asymptomatic carotid stenosis; the patient has dizziness and headaches, but these symptoms are considered consistent with asymptomatic carotid stenosis for the purposes of the trial.\n- Patient willing to comply with study requirements and sign informed consent.\n- Internal carotid artery independent disease; the patient has disease in both the internal and common carotid arteries.\n- Criteria for carotid stenosis: either ultrasonography suggests stenosis \u2265 70%, or angiography shows stenosis \u2265 60%; the patient's ultrasonography suggests severe stenosis in the left internal carotid artery.\n\nThe patient does not meet the age criterion, as he is 46 years old and the trial requires participants to be at least 50 years old. Therefore, despite meeting other clinical and anatomical criteria, the patient is not eligible for the trial based on age.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "899": {
        "output": "Based on the patient note provided and the inclusion and exclusion criteria for the mHealth Lifestyle Intervention on CHD Primary Prevention clinical trial, let's assess the patient's eligibility:\n\nPatient Note Characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- High LDL-C levels and normal HDL-C, fasting glucose, and triglyceride levels\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No use of lipid-lowering medications\n- No clinical diagnosis of CHD or other heart diseases mentioned\n\nClinical Trial Inclusion Criteria:\n- Working full-time\n- Aged between 21-65 years\n- Use a smartphone in their daily lives frequently\n- Able to read, speak, and understand English\n\nClinical Trial Exclusion Criteria:\n- Have a clinical diagnosis of CHD or other heart diseases\n- Work in a health-relevant school/department/environment\n- Have reading difficulties\n\nAssessment:\n- The patient's age falls within the required range (21-65 years).\n- There is no information about the patient's employment status, so it is unclear whether the patient is working full-time.\n- There is no information about the patient's smartphone usage.\n- There is no indication that the patient cannot read, speak, and understand English.\n- The patient has no mentioned clinical diagnosis of CHD or other heart diseases, nor is there an indication that the patient works in a health-relevant environment or has reading difficulties.\n\nGiven that the patient's employment status and smartphone usage are not specified, we do not have sufficient information to fully assess eligibility. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "900": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, high LDL-C levels, and a systolic murmur in the neck. There is no mention of any histologically or cytologically confirmed renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, or melanoma. Additionally, there is no information provided that suggests that the patient has recurrent or metastatic disease that is not amenable to local therapy with curative intent.\n\nSince the patient does not have a specified type of solid tumor required by the inclusion criteria of the clinical trial and there is no indication of metastatic or recurrent disease, the patient does not meet the inclusion criteria for the trial titled \"IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors.\"\n\nTherefore, the assessment of the patient's eligibility for the trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "901": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to match the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- High LDL-C level (545 mg/dL)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No history of stroke, transient ischaemic attack, or reversible ischaemic neurological deficit mentioned\n- No other medical history is provided\n\nClinical trial inclusion criteria:\n- Patient's age \u2265 18 years\n- 60-99% stenosis of the internal carotid artery\n- Diameter of the target internal carotid artery not more than 7 mm\n- Symptomatic lesion (a history of ipsilateral stroke, transient ischaemic attack or reversible ischaemic neurological deficit)\n- Localisation and morphology of the lesion making possible surgical eversion endarterectomy or endovascular angioplasty with stent implantation\n- Written informed consent\n\nClinical trial exclusion criteria:\n- Target lesion that has been previously stented\n- Highly calcified lesions\n- Very tortuous common and internal carotid arteries\n- Occlusion of the contralateral carotid artery without adequate collateral circulation\n- Anatomical contraindications for eversion endarterectomy\n- Acute ipsilateral stroke\n- Disabling stroke at any side\n- Other severe pathologies of the brain resulting in significant loss of cerebral tissue and/or significant neurological deficits\n- History of haemorrhagic transformation of ischaemic stroke\n- Severe comorbidities\n- Allergy to aspirin, clopidogrel, or ticlopidine\n- Allergy to iodinated contrast media\n- Pregnant women\n- Women of reproductive age who do not use effective contraception\n- Metallic implants or other known contraindications for MRI\n\nAssessment:\n- The patient is over 18 years old.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could potentially fall within the 60-99% stenosis range required for the trial.\n- There is no information on the diameter of the target internal carotid artery.\n- The patient does not have a documented history of ipsilateral stroke, transient ischaemic attack, or reversible ischaemic neurological deficit, which is required to be considered a symptomatic lesion for this trial.\n- There is no information on the localisation and morphology of the lesion in relation to the possibility of surgical eversion endarterectomy or endovascular angioplasty with stent implantation.\n- There is no information on the patient giving written informed consent, but this is usually obtained after confirming eligibility.\n\nBased on the information provided, the patient's eligibility cannot be confirmed due to insufficient information about the symptomatic nature of the carotid artery stenosis (no history of ipsilateral neurological events is mentioned) and the lack of detail on the localisation and morphology of the lesion. Therefore, the patient does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "902": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial as follows:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which fits within the age range of 18-80 years specified in the trial's inclusion criteria.\n- The patient presents with dizziness and frequent headaches.\n- There is no mention of unilateral lower extremity radiculopathy or degenerative foraminal stenosis, which are conditions required by the trial.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. This finding is unrelated to lumbar radiculopathy or degenerative foraminal stenosis.\n- The patient has not been reported to be scheduled for a lumbar foraminotomy procedure.\n- There is no evidence provided in the patient note that would indicate a diagnosis of radiculopathy, nor is there any mention of imaging or clinical history supporting such a diagnosis.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age 18-80 (Patient matches this criterion)\n- Diagnosis of unilateral lower extremity radiculopathy due to degenerative foraminal stenosis (No information provided)\n- Patients scheduled for an associated lumbar foraminotomy procedure (No information provided)\n- Diagnosis of radiculopathy with imaging and/or clinical history or physical exam that does not demonstrate a clear neurogenic source of their pain (No information provided)\n- Subjects must be available for the entire study duration (12 months) (Assumed feasible, but not confirmed)\n\nBased on the information available, the patient does not meet the specific diagnostic criteria for unilateral lower extremity radiculopathy due to degenerative foraminal stenosis, nor is there any indication that the patient is scheduled for a lumbar foraminotomy procedure. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "903": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the trial:\n\nPatient note summary:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C level of 545 mg/dL and HDL-C level of 53 mg/dL\n- Fasting glucose and triglyceride levels within normal limits\n- No use of lipid-lowering medications\n- Carotid artery stenosis detected via ultrasonography\n- No mention of pulmonary arterial hypertension or related symptoms\n\nClinical trial inclusion criteria summary:\n- Non-smoker or tobacco stopped for a minimum of 2 years\n- Diagnosis of pulmonary arterial hypertension (PAH) with specific subtypes (idiopathic, heritable, related to drug or toxics, associated with controlled PAH)\n- Treatment of PAH for more than 4 months\n- Optimal control of PAH demonstrated by specific clinical and hemodynamic measures\n- Informed and written consent\n- Non-affiliation to a social security\n\nComparison:\n- The patient does not have a diagnosis of pulmonary arterial hypertension (PAH), which is a key inclusion criterion for the trial.\n- There is no mention of the patient's smoking status, but this information is irrelevant as the patient does not have PAH.\n- The patient's current medical concerns (high LDL-C levels, carotid artery stenosis) are unrelated to the focus of the trial, which is on patients with controlled PAH and the prevalence of the hyperventilation syndrome in this population.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial, as there is no mention of a diagnosis or treatment of pulmonary arterial hypertension. Therefore, the patient would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "904": {
        "output": "Based on the patient note, the 46-year-old man does not have diabetes mellitus; instead, he presents with dizziness, frequent headaches, and cardiovascular issues, such as severe stenosis in the left internal carotid artery. The clinical trial is specifically targeting diabetic patients who are on treatment with dulaglutide to evaluate arterial stiffness and endothelial function.\n\nSince the patient does not have diabetes mellitus, which is one of the inclusion criteria for the clinical trial, he would not be eligible to participate in this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "905": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 46-year-old man who presents with dizziness, frequent headaches, and has been found to have severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. His LDL-C levels are high, but there is no mention of a diagnosis of essential thrombocythemia (ET) or the presence of the JAK2 V617F mutation.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Patients with JAK2 V617F positive essential thrombocythemia.\n2. Age- and sex-matched apparently healthy control subjects.\n\nThe patient note does not indicate that the patient has essential thrombocythemia or that he has been tested for the JAK2 V617F mutation. Therefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "906": {
        "output": "Patient Note Analysis:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No use of lipid-lowering medications.\n- No other cardiovascular risk factors mentioned besides a family history of CAD.\n\nClinical Trial Analysis:\n- The trial is focused on evaluating cerebrovascular events in patients with occlusive carotid artery disorders.\n- The trial aims to establish a stroke risk prediction algorithm for patients with asymptomatic carotid stenosis.\n- Inclusion criteria include signed informed consent and significant carotid artery stenosis.\n\nComparison:\n- The patient has severe stenosis in the left internal carotid artery, which aligns with the inclusion criteria of significant carotid artery stenosis.\n- There is no information given about informed consent, but we can assume that it can be obtained if the patient agrees to participate in the trial.\n- Other factors such as lipid levels, dizziness, and headaches are not specified as inclusion or exclusion criteria in the trial information provided.\n\nBased on the comparison, the patient appears to meet the inclusion criteria of having significant carotid artery stenosis. Assuming that informed consent can be obtained, the patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "907": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Sonodynamic Therapy in the Treatment of Carotid Atherosclerosis,\" let us assess the patient's eligibility:\n\nPatient Information:\n- Age: 46 years old (meets age criteria of 18-80 years)\n- Condition: Carotid atherosclerotic plaque with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery (meets stenosis criteria of 30%-70% by ultrasound)\n- LDL-C level: 545 mg/dL (does not meet the LDL-c level criteria of below 100 mg/dL)\n- Blood pressure: Not mentioned (cannot assess if blood pressure is well-controlled)\n- Diabetes status: Fasting glucose within normal limits, but HbA1c not mentioned (cannot assess if diabetes is well-controlled)\n- History of transient ischemic attack, minor stroke, or amaurosis fugax: Not mentioned (cannot assess exclusion based on this)\n- Informed consent: Not mentioned (cannot assess if the patient is willing to provide consent)\n\nClinical Trial Inclusion Criteria:\n- Age 18-80 years\n- Carotid artery with 30%-70% stenosis by ultrasound and plaque thickness >2.5mm\n- Patients without transient ischemic attack, minor stroke, or amaurosis fugax within 6 months\n- Patients' LDL-c level below 100 mg/dL (2.6mmol/L), well-controlled blood pressure (systolic BP<140 and diastolic BP<90 under resting conditions) and diabetes (HbA1c<7%)\n- Written informed consent\n\nThe patient does not meet the LDL-c level criteria for inclusion in the trial, as the patient's LDL-C level is significantly higher than the required level. This makes the patient ineligible for the trial. Therefore, the patient's information is sufficient to determine that they do not qualify for the trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "908": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial on cognitive rehabilitation of working memory after moderate to severe traumatic brain injury (TBI), we can evaluate the patient's eligibility:\n\nPatient note:\n- A 46-year-old man, which fits the age criteria of 18 - 65 years.\n- The patient presents with dizziness and frequent headaches, but there is no mention of a traumatic brain injury.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery but no mention of cognitive issues or working memory complaints.\n- There is also no mention of a Glasgow score, which is required to determine the severity of TBI.\n- There is no information suggesting a complaint related to working memory in daily life or established deficits of working memory through specific tests.\n\nInclusion criteria:\n- Aged between 18 - 65 years (patient meets this criteria).\n- Moderate to severe TBI (Glasgow score between 3 and 12 in the first 24 hours) (no information provided).\n- At least 6 months following TBI (no information provided).\n- Complaint related to working memory in daily life (no information provided).\n- Established deficit of working memory by specific criteria (no information provided).\n- Prior medical examination (assumed, but not specified).\n- Correct vision after visual acuity correction (no information provided).\n- Stable neurological or psychoactive treatment for at least 4 weeks, if applicable (no information provided).\n- Able to move to the center where rehabilitation will be performed (no information provided).\n- Covered by health insurance (no information provided).\n- Signed consent of patient or of the guardian (no information provided).\n\nGiven that the patient's note does not provide sufficient information to determine if the patient has suffered from a moderate to severe TBI, nor does it mention any working memory deficits or related complaints, we cannot assume the patient meets the specific inclusion criteria for the TBI rehabilitation trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "909": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Physically Active During Cancer Treatment (FAKT),\" we can determine the trial-level eligibility as follows:\n\nThe inclusion criteria for the FAKT trial are:\n1. Radical resection for colon- or rectal cancer in the past 3 months, and scheduled for adjuvant, Oxaliplatin-based, combination chemotherapy.\n2. Histologically confirmed adenocarcinoma.\n3. Able to read and understand Norwegian.\n4. Able to carry out the intervention.\n5. Performance Status (PS) 0 - 2.\n\nNow reviewing the patient note:\n- The patient is a 46-year-old man presenting with dizziness and frequent headaches.\n- There is no mention of cancer, specifically colon or rectal cancer, in the patient's history.\n- There is no indication that the patient has undergone radical resection for cancer or is scheduled for adjuvant chemotherapy.\n- There is no mention of the patient's ability to read and understand Norwegian.\n- The patient's performance status is not stated.\n\nSince the patient does not meet any of the listed inclusion criteria for the FAKT trial, particularly lacking a diagnosis of colon or rectal cancer, not being scheduled for the specified chemotherapy, and no indication of cancer treatment or surgical history, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "910": {
        "output": "The patient note describes a 46-year-old man who presents with dizziness and frequent headaches. He has a family history of coronary artery disease (CAD), but no other cardiovascular risk factors and maintains physical activity. This patient has very high LDL-C levels and has severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery, as detected by ultrasonography.\n\nThe clinical trial is seeking participants who have confirmed coronary heart disease (CHD) and aims to assess the quality of life in these patients.\n\nTo determine the eligibility of the patient for this clinical trial, we need to compare the patient's condition with the inclusion criteria:\n\nInclusion Criteria:\n- Confirmed coronary disease\n\nThe patient's note does not explicitly mention that the patient has confirmed coronary heart disease, although it does suggest cardiovascular issues with the presence of a systolic murmur and severe stenosis in the carotid arteries. Carotid artery stenosis is not the same as coronary artery disease; the former refers to narrowing of the arteries that supply the brain, while the latter refers to the arteries that supply the heart.\n\nSince there is no explicit confirmation of coronary heart disease in the patient's history or diagnosis within the provided note, we cannot conclusively state that the patient has the condition required by the trial's inclusion criteria. Therefore, based on the information provided, the patient does not meet the inclusion criteria of having confirmed coronary disease for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "911": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man who presents with symptoms that are not directly associated with diabetes (dizziness and frequent headaches). His LDL-C and HDL-C levels are abnormal, but there is no mention of diabetes mellitus, which is a key inclusion criterion for the clinical trial. Additionally, there is no information provided about whether the patient has a coronary artery calcium score or a toe-brachial index available, which are also part of the inclusion criteria for the trial.\n\nGiven the information, the patient does not meet the necessary criteria for the clinical trial focused on the association between toe-brachial index and coronary artery calcification score in asymptomatic patients with type 1 or 2 diabetes, as there is no mention of him having diabetes or the required assessments.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "912": {
        "output": "The patient note describes a 46-year-old man with dizziness and frequent headaches. He has severe and moderate stenosis in the left and right internal carotid arteries, respectively. However, the stenosis is carotid (extracranial), not intracranial, and there is no mention of a recent stroke or transient ischemic attack (TIA). Additionally, the patient does not meet the age criterion of being over 21 years old, as he is exactly 21 years old, which meets the criterion.\n\nThe clinical trial in question is focused on patients with severe intracranial stenosis, a history of recent stroke/TIA, and impaired cerebrovascular reserve (CVR). \n\nComparing the patient note to the inclusion criteria of the clinical trial:\n\n1. Age: The patient is 46 years old, which satisfies the age criterion of being over 21 years.\n2. Recent stroke/TIA and severe stenosis: The patient note does not mention a recent stroke or TIA, nor does it describe severe intracranial stenosis. The stenosis is of the carotid arteries, which is extracranial.\n\nGiven that the patient does not have a documented recent stroke/TIA or intracranial stenosis, he does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "913": {
        "output": "Based on the clinical trial information provided and the patient note, we can assess the patient's eligibility for the trial as follows:\n\nThe inclusion criteria for the trial are:\n1. Have a previous history of elbow joint fracture or dislocation that is diagnosed by X-ray test, with heterotopic ossification (HO) confirmed by imaging.\n2. Have complete clinical and imaging data.\n3. Age >18 and no gender limitation.\n4. The patient is in a relatively stable physical and mental state without acute infection or diseases.\n\nThe patient note details:\n- A 46-year-old man with dizziness and frequent headaches.\n- No history of elbow joint fracture or dislocation mentioned.\n- No mention of heterotopic ossification (HO).\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No mention of acute infection or diseases.\n\nThe critical factor for inclusion in this trial is a history of elbow joint fracture or dislocation with heterotopic ossification. The patient's note does not provide any information suggesting that the patient has a history of elbow joint issues or heterotopic ossification. Therefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "914": {
        "output": "",
        "label": 1
    },
    "915": {
        "output": "",
        "label": 1
    },
    "916": {
        "output": "The patient in the note is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no mention of any revascularization procedure being performed or scheduled. The clinical trial is looking for patients aged 18 or over who have an indication of treatment with a carotid revascularization procedure (conventional surgery or angioplasty and stent) and who accept to participate in the protocol.\n\nThe patient note does not provide information on whether the patient has accepted to participate in any protocol or if he has an indication for a carotid revascularization procedure. Since the patient has severe stenosis of the LICA, it can be inferred that he may be a candidate for such a procedure, but there is no direct indication that such a treatment is planned or has been accepted by the patient.\n\nGiven the information provided, the patient cannot be definitively classified as eligible or excluded due to the lack of detail regarding his treatment plan. Therefore, the patient falls under the \"Not relevant\" category because there is insufficient information to determine if he meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "917": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the Ezetimibe-Rosuvastatin Evaluation Study, let's assess the patient's eligibility:\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors (non-smoker, normal blood pressure, no diabetes)\n- Physically active\n- LDL-C: 545 mg/dL (high)\n- HDL-C: 53 mg/dL\n- Normal fasting glucose and triglycerides\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- Carotid plaque observed\n\nClinical Trial Inclusion Criteria:\n- Adult patients who have voluntarily consented to participate in the study\n- Adult patients who are already on treatment with the stable combination of ezetimibe-rosuvastatin (Lipopen)\n- Adult patient adequately controlled with rosuvastatin and ezetimibe according to ESC / EAS 2019 guidelines\n\nAssessment:\nThe patient is an adult and presents with hypercholesterolemia (high LDL-C level), which could make him a potential candidate for a trial evaluating a treatment for primary hypercholesterolemia. However, the patient is not currently on any lipid-lowering medications, let alone the specific combination of ezetimibe-rosuvastatin required by the trial's inclusion criteria. The trial specifically calls for patients who are already on this treatment and are controlled according to specific guidelines, which does not apply to this patient.\n\nTherefore, the patient does not meet the inclusion criteria for the Ezetimibe-Rosuvastatin Evaluation Study as they are not currently being treated with the stable combination of ezetimibe-rosuvastatin.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "918": {
        "output": "Based on the provided patient note and clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL (within normal limits)\n- Triglycerides: 158 mg/dL (within normal limits)\n- No use of lipid-lowering medications\n- Carotid ultrasonography: Severe stenosis in LICA and moderate stenosis in RICA\n\nClinical Trial Inclusion Criteria:\n- Evidence of carotid artery atherosclerosis with endoluminal stenosis > 60%\n- Aged >18 years\n- Aged <75 years\n\nThe patient's carotid ultrasonography results show severe stenosis in the left internal carotid artery, which is consistent with the trial's inclusion criterion of having carotid artery atherosclerosis with endoluminal stenosis > 60%. The patient is also within the age range specified by the trial (aged >18 years and <75 years).\n\nTherefore, based on the available information, the patient meets the inclusion criteria for the clinical trial:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "919": {
        "output": "Based on the information provided, the patient is a 46-year-old man who presents with symptoms related to cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient's condition is not related to the clinical trial's focus, which is evaluating reader performance of breast ultrasound and mammography in women with dense breast parenchyma.\n\nThe inclusion criteria for the clinical trial are specific to radiologists who are qualified to read and interpret mammography and breast ultrasound images. The patient in question is not a radiologist, does not have the specified qualifications, and his medical condition is unrelated to the trial's purpose.\n\nTherefore, the patient does not meet the inclusion criteria for the Delphinus SoftVue\u2122 ROC Reader Study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "920": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\n- Age: The patient is a 46-year-old man, which falls within the age criteria of \u226518 and \u226460 years.\n- BMI: The patient's BMI is not provided.\n- Waist circumference: The patient's waist circumference is not provided.\n- Triglycerides: The patient has a triglyceride level of 158 mg/dL, which meets the criterion of >150 mg/dL.\n- Blood pressure: The patient's blood pressure is not provided, but he has no reported history of high blood pressure.\n- Fasting blood glucose: The patient has a fasting glucose level of 85 mg/dL, which is below the criterion of \u2265100 mg/dL.\n- Low HDL level: The patient's HDL-C level is 53 mg/dL, which does not meet the criterion of <40 mg/dL for men.\n- Consent: There is no information given about the patient's willingness to give consent.\n\nThere is insufficient information about the patient's BMI, waist circumference, blood pressure, and readiness to consent to determine eligibility. The patient does not meet the criteria for fasting blood glucose and HDL level requirements. Therefore, based on the available information, the patient does not meet sufficient inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "921": {
        "output": "To assess the eligibility of the patient for the ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation clinical trial, we need to compare the patient's medical history and current condition with the inclusion and exclusion criteria of the trial.\n\nPatient Note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in left internal carotid artery (> 80% stenosis)\n- Moderate stenosis in right internal carotid artery (40-50% stenosis)\n- No history of stroke, TIA, or amaurosis fugax mentioned\n- No other medical history provided that matches the exclusion criteria\n\nClinical Trial Inclusion Criteria:\n1. Stenosis must be >50% as determined by ultrasound or angiogram, with a history of stroke (minor or non-disabling; NIHSS \u22644 or mRS \u22642), TIA, and/or amaurosis fugax within 180 days of the procedure ipsilateral to the carotid artery to be stented.\n2. Stenosis must be >80% as determined by ultrasound or angiogram without any neurological symptoms within the prior 180 days.\n3. Target vessel must meet diameter requirements for stent.\n4. Patient has a discrete lesion located in the ICA with or without involvement of the CCA.\n5. Patient is willing to comply with protocol requirements.\n6. Patient must have a life expectancy \u2265 3 years.\n7. Patient meets at least one of the surgical high-risk criteria listed in CMS NCD.\n\nThe patient has severe stenosis in the left internal carotid artery, which meets one of the inclusion criteria (stenosis >80%). However, there is no information provided about a history of stroke, TIA, or amaurosis fugax, which is necessary to meet the first inclusion criterion. Additionally, there is no information about the patient's life expectancy, willingness to comply with protocol requirements, or whether the patient meets the surgical high-risk criteria listed in CMS NCD.\n\nGiven the information provided, the patient does not meet the full inclusion criteria as there is insufficient information regarding the patient's medical history related to neurological symptoms and other specific requirements mentioned in the criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "922": {
        "output": "To determine the trial-level eligibility of the 46-year-old male patient for the clinical trial titled \"Characterization of Fatigue in Military Personnel With Traumatic Brain Injuries,\" we need to assess the patient's information against the trial's inclusion and exclusion criteria.\n\nInclusion Criteria Assessment:\n- Age: The patient is 46 years old, which falls outside the inclusion criteria range of 25 to 40 years of age.\n- The patient must be an active duty service member or veteran. The patient's note does not mention any military service.\n- TBI: The trial requires participants to have sustained at least one TBI more than 6 months but less than 5 years ago. The patient's note does not mention a history of TBI.\n- The patient must be able to provide their own consent and understand the protocol, which cannot be determined from the patient's note.\n- The patient must score a 6 out of 6 on a consent quiz, which also cannot be determined from the patient's note.\n\nExclusion Criteria Assessment:\n- The exclusion criteria mostly pertain to conditions that could interfere with the study or are related to fatigue from another medical illness. The patient's note does not mention any current treatment for medical illnesses that preclude participation, current unstable endocrine disorders, major medical illnesses associated with fatigue, consumption of sleep modifying medications, current psychiatric conditions requiring immediate treatment, pregnancy, severe OSA, or CPAP use.\n- Since the patient does not meet the inclusion criteria, assessing the exclusion criteria is not necessary.\n\nGiven that the patient does not meet the age requirement and there is no information regarding military service or a history of TBI, the patient does not fulfill the necessary inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "923": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effects of Selenium and Melatonin on Ocular Ischemic Syndrome,\" we need to compare the patient's characteristics with the inclusion criteria provided for the trial.\n\nThe inclusion criteria for the trial are:\n1. The patients of Ocular ischemic syndrome (OIS) where the stenosis of the ipsilateral (to the affected eye) internal carotid artery (ICA) was >50%\n2. The patients of Ocular ischemic syndrome (OIS) where the ICA blood flow velocity was abnormal\n3. Abnormal ocular symptoms and/or signs that could not be explained by other ocular diseases.\n\nThe patient's note indicates the following:\n- A 46-year-old man presents with dizziness and frequent headaches.\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient's LDL-C and HDL-C levels are mentioned, as well as fasting glucose and triglyceride levels.\n- The patient reported no use of lipid-lowering medications.\n- There are abnormal findings in the carotid arteries, including plaque and stenosis.\n\nHowever, the patient note does not mention Ocular ischemic syndrome (OIS) or any abnormal ocular symptoms/signs. While the patient does have severe stenosis in the LICA, which is related to ICA blood flow, there's no information provided about ocular ischemic syndrome or ipsilateral ocular symptoms to the affected carotid artery. Moreover, the report mentions carotid artery stenosis but does not specify that it is causing OIS or any ocular symptoms.\n\nGiven the information provided, we do not have sufficient evidence that the patient has Ocular ischemic syndrome or abnormal ocular symptoms and/or signs that could not be explained by other ocular diseases. Therefore, the patient does not meet the inclusion criteria based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "924": {
        "output": "To assess the trial-level eligibility of the patient for the OPTIMAL-DIABETES trial based on the provided patient note, we need to compare the patient's characteristics with the inclusion criteria of the trial:\n\n1. Systolic Blood Pressure (SBP) between 130 and 180 mm Hg: The patient's SBP is not mentioned in the note.\n2. Type 2 diabetes: The patient's note does not mention a diagnosis of diabetes.\n3. High cardiovascular risk, including at least one of the following factors:\n   - Established cardiovascular disease (CVD): The patient's note mentions severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which may qualify under carotid artery disease with at least 50% stenosis.\n   - Subclinical CVD: Not mentioned.\n   - Chronic kidney disease (CKD): Not mentioned.\n   - Additional cardiovascular risk factors: The patient has dyslipidemia as defined by the trial (LDL cholesterol > 100 mg/dL).\n\nThe patient appears to have carotid artery disease and dyslipidemia, which are considered high cardiovascular risk factors according to the trial's inclusion criteria. However, there's insufficient information regarding the patient's SBP and whether the patient has Type 2 diabetes, which are also required for inclusion.\n\nGiven the available information, the patient does not have sufficient information to qualify for the trial, as the note lacks details on the patient's SBP and a diagnosis of diabetes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "925": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial for \"Individualized Physical Activity and Carotid Plaque Instability,\" we can determine the patient's trial-level eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which meets the age criterion of being over 18 years old.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The stenosis is above 50%, which meets the trial's requirement for an atheromatous plaque with \u2265 50% NASCET stenosis.\n- There is no indication that the patient is from the vascular surgery department of the Louis Pradel Hospital, nor is there any information about the patient being operated on or not. However, the inclusion criteria specify the patient should be from the specific hospital department but not necessarily operated on.\n- The patient is male and there is no contra-indication to physical activity mentioned.\n- Information about the patient's ability to understand, read, and write French, their social security system or similar, and having dated and signed informed consent is not provided in the note.\n\nGiven the information provided, the patient meets some of the inclusion criteria, such as age, gender, and having significant carotid stenosis. However, the patient note does not provide sufficient information to fully determine eligibility. Specifically, it is not clear if the patient is from the required hospital department, if they meet the index performance requirement, if they are able to participate in terms of language and informed consent, and if they have a social security system or similar.\n\nBased on the provided information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "926": {
        "output": "Based on the information provided in the patient note, the patient is a 46-year-old man with dizziness and headaches, presenting with extremely high LDL cholesterol levels and severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery as shown by carotid ultrasonography. He has a family history of coronary artery disease (CAD) but does not have other cardiovascular risk factors such as hypertension, diabetes, or tobacco usage. He is not on lipid-lowering medications.\n\nThe clinical trial in question is seeking to determine the accuracy of a new non-invasive device for carotid artery stenosis and has specific inclusion criteria: patients must be 65 years or older, scheduled for a diagnostic carotid duplex ultrasound, and must have one or more of the following: hypertension, hyperlipidemia, diabetes, tobacco usage, known CAD/PAD, or family history of early-onset atherosclerotic disease.\n\nAlthough the patient has hyperlipidemia and a family history of CAD, which aligns with the trial inclusion criteria, he does not meet the age requirement of being 65 years or older. Therefore, he is not eligible for this clinical trial based on the age criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "927": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Short Physical Activity Program in Coronary Artery Disease,\" let's assess the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 46-year-old man.\n- He presents with symptoms like dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors.\n- His LDL-C level is significantly elevated at 545 mg/dL, while HDL-C level is 53 mg/dL.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient is physically active and reported no use of lipid-lowering medications.\n\nClinical Trial Inclusion Criteria:\n- Age 18 years and older.\n- Stable coronary artery disease with appropriate medical certificate of fitness.\n- No current medical conditions affecting sports participation.\n\nComparison:\n- The patient is 46 years old, which meets the age criterion.\n- The patient has a family history of CAD and severe stenosis in the carotid arteries, which could suggest the presence of CAD.\n- The patient is physically active, which may indicate a certain level of fitness.\n- There is no explicit mention of a medical certificate of fitness or the stability of any coronary artery disease he might have.\n- There is no information on whether the patient has any medical conditions that would affect sports participation, although the significant elevation in LDL-C and cardiovascular symptoms could potentially be concerns.\n\nGiven the information provided, the patient note suggests a possible but not confirmed presence of coronary artery disease and does not state whether the patient's condition is stable or if he has a medical certificate of fitness required by the trial's inclusion criteria. Additionally, the patient's high LDL-C level and symptoms could potentially affect sports participation, which might need to be assessed by a medical professional.\n\nTherefore, on the three-point scale, the assessment of this patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "928": {
        "output": "The patient in question is a 46-year-old man who presents with dizziness, frequent headaches, and has been found to have severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no mention in the patient's note of aortic stenosis or referral for transthoracic echocardiography, which is relevant to the inclusion criteria of the clinical trial.\n\nThe clinical trial in question is focused on evaluating a system for detecting heart sounds associated with severe aortic stenosis and has specific inclusion criteria:\n- Adult subjects (21 years of age or older).\n- Referred for transthoracic echocardiography by a physician/primary care provider/cardiologist.\n- Willing and able to participate in all study evaluations and allow access to medical testing and records.\n- Signed informed consent or have a legally authorized representative who provides informed consent on behalf of the subject.\n\nSince the patient's note does not indicate that the patient has been referred for transthoracic echocardiography nor that they have aortic stenosis, the patient does not meet the inclusion criteria based on the information provided. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "929": {
        "output": "Based on the patient note provided:\n\n- The patient is a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. He has high LDL-C levels and a systolic murmur but no mention of dry eye disease or any other eye-related symptoms.\n\nThe clinical trial is looking for participants with:\n\n- A confirmed diagnosis of moderate to severe dry eye associated with certain conditions (none of which are mentioned in the patient note).\n- Specific diagnostic criteria related to dry eye severity such as a Schirmer tear test result, a visual analog score for comfort, and an OSDI score.\n\nSince the patient note does not mention any diagnosis or symptoms associated with dry eye disease, nor does it provide any test results related to the inclusion criteria of the trial, the patient does not appear to meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "930": {
        "output": "",
        "label": 0
    },
    "931": {
        "output": "",
        "label": 1
    },
    "932": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches, severe stenosis in the left internal carotid artery, and moderate stenosis in the right internal carotid artery. He has a family history of CAD, but does not have other cardiovascular risk factors. Furthermore, there is no mention of aortic valve stenosis or treatment with a TAVR device, which are specific to the clinical trial's inclusion criteria.\n\nThe clinical trial entitled \"PROTECTED TAVR: Stroke PROTECTION With Sentinel During Transcatheter Aortic Valve Replacement\" is looking for subjects who have documented aortic valve stenosis and are being treated with an approved TAVR device via transfemoral access. There is no information in the patient note to suggest that the patient has aortic valve stenosis or that he is being treated or scheduled to be treated with a TAVR device. Additionally, the trial specifies artery diameter requirements for the placement of the Sentinel\u00ae Cerebral Protection System, but there is no such information provided in the patient note.\n\nGiven that the patient note lacks sufficient information to meet the trial's inclusion criteria, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "933": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Arterial Composition and Cardiovascular Outcome in DIabeteS,\" we can assess the patient's eligibility for the trial.\n\nPatient Note Review:\n- The patient is a 46-year-old man with dizziness and frequent headaches.\n- He has a family history of CAD but no major cardiovascular risk factors and is physically active.\n- The patient has extremely high LDL-C levels and normal fasting glucose and triglyceride levels.\n- He has not used any lipid-lowering medications.\n- There is severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- There is no mention of the patient having diabetes or undergoing coronary artery bypass surgery.\n\nClinical Trial Inclusion Criteria Review:\n- Coronary artery bypass surgery performed at Odense University Hospital.\n- Useful sample of internal mammary artery.\n- Willingness to participate.\n\nAssessment:\nThe patient does not meet the inclusion criteria for the clinical trial as there is no indication that he has undergone coronary artery bypass surgery, nor is there any mention of a sample of the internal mammary artery being taken or available. Additionally, there is no mention of diabetes, which is a focus of the study. The patient's eligibility for this trial is therefore not relevant, as the information provided does not align with the specific requirements of the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "934": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can analyze the patient's eligibility.\n\nPatient note:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- Has a family history of CAD (coronary artery disease), but no other cardiovascular risk factors.\n- Physically active.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- No mention of a transient ischemic attack (TIA) or ischemic stroke.\n- The patient reported no use of lipid-lowering medications.\n\nClinical trial inclusion criteria:\n- Carotid TIA or ischemic stroke involving carotid territory.\n- Asymptomatic patients with carotid stenosis or anterior circulation stenosis discovered accidentally.\n\nThe patient has carotid stenosis, which could potentially align with the \"asymptomatic patients with carotid stenosis\" part of the inclusion criteria. However, the patient has presented with symptoms (dizziness and frequent headaches), and there is no mention of a transient ischemic attack (TIA) or ischemic stroke, which are specifically mentioned in the inclusion criteria.\n\nGiven that the patient does not have a documented TIA or ischemic stroke and is not asymptomatic, the patient does not appear to meet the inclusion criteria for the trial as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "935": {
        "output": "Given the patient note, the patient is a 46-year-old man with a history of dizziness, frequent headaches, and severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. The patient does not report any use of lipid-lowering medications, and there is no mention of Psoriatic Arthritis (PsA) or that he fulfills the Classification of Psoriatic Arthritis (CASPAR) criteria.\n\nThe clinical trial is specifically targeting patients with Psoriatic Arthritis (PsA) who have asymptomatic carotid plaques with less than 50% stenosis. The inclusion criteria for the trial specify that participants must fulfill the CASPAR criteria for Psoriatic Arthritis, which is not indicated in the patient's note. There is no information to suggest that the patient has PsA or meets the CASPAR criteria.\n\nBased on the available information, the patient does not meet the inclusion criteria for the PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis because there is no evidence that he has Psoriatic Arthritis, which is a requirement for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "936": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Cardiovascular Events in GnRH Agonist vs. Antagonist,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- Physically active\n- LDL-C level: 545 mg/dL (high)\n- HDL-C level: 53 mg/dL\n- Fasting glucose: 85 mg/dL (normal)\n- Triglycerides: 158 mg/dL (normal)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No history of prostate cancer mentioned\n\nClinical trial inclusion criteria:\n- Locally advanced high-risk prostate cancer OR metastatic prostate cancer patients.\n- Scheduled to receive a combination of ADT + chemotherapy or second line hormonal treatment\n- Medical history of cardiovascular conditions or risk factors\n- Two out of three cardiovascular risk factors: hypertension, diabetes, current smoking\n- Age 18-90 years\n- Life expectancy of over 12 months\n- WHO performance status of 0-2\n- Able to sign a consent form\n\nThe patient in the note does have cardiovascular issues, which are part of the inclusion criteria. However, there is no mention of prostate cancer in the patient's history, which is a key requirement for participation in this trial. The trial is specifically for patients with either locally advanced high-risk prostate cancer or metastatic prostate cancer. Since the patient does not fit this crucial criterion, he is not eligible for the trial.\n\nTherefore, the patient's trial-level eligibility for this clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "937": {
        "output": "",
        "label": 0
    },
    "938": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial concerning the Neuroguard IEP System for the treatment of carotid artery stenosis, we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n\n- A 46-year-old man (meets age criterion of \u2265 20 years and \u2264 80)\n- Presents with dizziness and frequent headaches\n- No history of cardiovascular risk factors except for a family history of CAD\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of prior stroke or TIA\n- No mention of being at high operative risk for CEA\n- No information on the subject's willingness or ability to comply with study protocol requirements\n\nInclusion Criteria:\n\n- Age \u2265 20 years and \u2264 80\n- Willing and capable of complying with all study protocol requirements\n- Patient diagnosed with carotid artery stenosis treatable with carotid artery stenting and is considered a high operative risk for CEA\n- Symptomatic carotid stenosis \u2265 50% or Asymptomatic carotid stenosis \u2265 80%\n- Modified Rankin Scale score of \u2264 2\n- Willing and able to take dual antiplatelet therapy for a minimum of 30 days\n\nFrom the information provided, the patient meets the age criterion. However, there is insufficient information to determine whether the patient meets all the other general and specific inclusion criteria. For example, there is no information about the patient's willingness to comply with the study protocol, whether the patient has a modified Rankin Scale score of \u2264 2, or if the patient is at high operative risk for CEA. It is also not clear if the patient's carotid stenosis is symptomatic or asymptomatic, which affects the percentage of stenosis required for eligibility. Additionally, there is no mention of the patient's willingness or ability to take dual antiplatelet therapy.\n\nBased on the available information, we cannot conclusively determine whether the patient would be eligible for the trial due to missing details regarding the specific inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "939": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- A 46-year-old man with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has high LDL-C levels but is not on lipid-lowering medications.\n- There is no mention of previous carotid surgery or intervention.\n\nClinical Trial Inclusion Criteria:\n- Patients with stenosis of the internal carotid artery (ICA) 70-99% (assessed by ultrasound - NASCET and CT angiography).\n- Patients with an extensive lesion of the ICA (plaque < 2 cm) by ultrasound - NASCET and CT angiography.\n\nThe patient note indicates that the patient has severe stenosis in the LICA and moderate stenosis in the RICA, but it does not specify the percentage of stenosis in terms of the NASCET criteria. However, the peak systolic velocity (PSV) and end-diastolic velocity (EDV) values suggest significant stenosis, especially in the LICA. Without the specific percentage of stenosis, it is difficult to determine if the stenosis meets the 70-99% criteria. Additionally, it is not clear if the plaque size is less than 2 cm as required by the trial's inclusion criteria.\n\nGiven the available information, we cannot conclusively determine if the patient meets the inclusion criteria for the trial. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "940": {
        "output": "Based on the information provided in the patient note, the patient presents with dizziness and frequent headaches, which could be relevant to a study on Persistent Postural Perceptual Dizziness (3PD). However, there is no indication in the patient note that this individual has been diagnosed with 3PD. Moreover, the clinical trial in question is specifically looking to recruit patients who have received a new diagnosis of 3PD from the balance clinic at Guy's Hospital in London, UK.\n\nThe patient note does not mention a diagnosis of 3PD, nor does it state that the patient has attended the balance clinic at Guy's Hospital. Therefore, there is insufficient information to determine whether this patient meets the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "941": {
        "output": "Based on the patient's note and the clinical trial's inclusion and exclusion criteria, let's evaluate the patient's eligibility for the Abbott Next Generation Drug Eluting Stent 48mm Study.\n\nPatient's characteristics from the note:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- High levels of LDL-C (545 mg/dL)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No evidence of myocardial ischemia mentioned\n\nClinical trial's inclusion criteria highlights:\n- At least 18 years of age\n- Evidence of myocardial ischemia suitable for non-emergent PCI\n- Acceptable candidate for coronary artery bypass graft (CABG) surgery\n- Specific requirements for the target lesion in a native coronary artery\n\nClinical trial's exclusion criteria highlights:\n- Known hypersensitivities or contraindications to device materials or medications required for the study\n- Planned surgery or procedure necessitating discontinuation of aspirin or P2Y12 inhibitor within 12 months following the index procedure\n- Acute myocardial infarction within 48 hours of the index procedure\n- Left ventricular ejection fraction (LVEF) < 30%\n- Prior PCI within the target vessel during the last 12 months\n- Life-threatening immunosuppressive or severe autoimmune disease\n- Prior intracranial bleed, or any permanent neurologic defect\n- Active symptoms or a positive test result of COVID-19 or other novel infectious agents within the prior 2 months\n\nThe patient's note does not mention myocardial ischemia or any other form of coronary artery disease that would be treated with the investigational stent in the trial. The patient does have severe stenosis in the left internal carotid artery, but this condition is not related to coronary artery disease and is not an indication for the treatment being studied in the trial. Furthermore, the inclusion criteria require evidence of myocardial ischemia suitable for non-emergent PCI, which is not present in the patient's note.\n\nBased on the available information, the patient does not meet the inclusion criteria for the coronary artery disease clinical trial because there is no mention of myocardial ischemia or coronary artery disease that requires treatment with a stent. Therefore, the patient's information is not sufficient to qualify for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "942": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms and findings that are not directly related to Coronary Artery Disease (CAD), such as dizziness, frequent headaches, and particularly severe stenosis in the left internal carotid artery. Although he has a family history of CAD, the patient note does not explicitly mention that he is being evaluated for or suspected of having CAD, nor does it mention that he is undergoing or scheduled to undergo a Coronary CT Angiography (CCTA), which is a specific requirement in the inclusion criteria for the clinical trial.\n\nThe clinical trial's inclusion criteria state that participants must be:\n1. Age > 18 years\n2. Patients visiting the hospital for suspected CAD and undergoing CCTA\n3. Signed informed consent as an acceptance to participate in the trial\n\nThe patient is over 18 years of age, which meets the age criterion. However, without information that explicitly states the patient is suspected of having CAD or is undergoing a CCTA, we cannot conclude that he is relevant for this trial. Therefore, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "943": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness and frequent headaches, has a family history of CAD, and exhibits severe stenosis in the left internal carotid artery as well as moderate stenosis in the right internal carotid artery. There is no mention of the patient experiencing shock, septic or cardiogenic, which are the conditions specified in the inclusion criteria for the clinical trial titled \"Brain Ultrasound With Contrast Microbubbles Injection in Shock Status.\"\n\nThe inclusion criteria for the clinical trial specifically require patients to have septic shock criteria (e.g., refractory arterial hypotension or hypoperfusion abnormalities after fluid resuscitation with serum lactate > 4mmmol/dl, oliguria, and mental status alteration or delirium) or cardiogenic shock (e.g., refractory shock associated with oliguria and mental status alteration following acute myocardial infarction or post-cardiac surgery).\n\nGiven that the patient's note does not mention any of these symptoms or conditions, the information provided does not qualify the patient for participation in the trial. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "944": {
        "output": "Patient Note Analysis:\n- The patient is a 46-year-old man.\n- The patient has dizziness, frequent headaches, and a family history of CAD.\n- No smoking, high blood pressure, or diabetes mellitus.\n- LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively.\n- Fasting glucose and triglyceride levels are normal.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- There is plaque characterized as bulky plates.\n\nClinical Trial Inclusion Criteria:\n1. Signed informed consent form.\n2. Age: 18-80 years old.\n3. Occlusion of the common carotid artery or internal carotid artery (mTICI=0) confirmed by DSA.\n4. The origin of occlusive segment is from the common carotid artery or the initial segment of the internal carotid artery to the petrous segment and above, and does not exceed the bifurcation of the internal carotid artery (C7 segment). The distal occluded vessels, including the middle cerebral artery, have no severe stenosis or occlusion confirmed by angiography.\n5. Occlusion over 24 hours (confirmed by imaging or according to the patient's condition change).\n6. Ischemic stroke, TIA or progressive visual/cognition impairment associated with occlusion.\n7. Distinguishable hypoperfusion area indicated by CT perfusion (CBF decrease).\n\nEligibility Assessment:\n- The patient is within the age range specified by the trial (18-80 years old).\n- The patient has severe stenosis in the LICA and moderate stenosis in the RICA, which suggests that there is no complete occlusion (mTICI=0) as required by the trial. The information provided does not indicate a total occlusion, which is a key inclusion criterion for the trial.\n- The patient's symptoms (dizziness and headaches) do not clearly align with ischemic stroke, TIA, or progressive visual/cognition impairment specifically associated with occlusion.\n- There is no mention of the patient's consent or a distinguishable hypoperfusion area indicated by CT perfusion, which are necessary for the trial.\n\nGiven the information provided, the patient does not clearly meet all the inclusion criteria, particularly the requirement for carotid artery occlusion (mTICI=0) and the associated symptoms of ischemic stroke, TIA, or progressive visual/cognition impairment. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "945": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 46-year-old man who presents with dizziness and frequent headaches.\n- He has a family history of CAD but no other cardiovascular risk factors and is physically active.\n- The patient has elevated LDL-C levels, but no mention is made of a cardiorespiratory arrest or resuscitation.\n- He has not been described as an ICU patient or as having experienced a cardiorespiratory arrest.\n\nClinical Trial Inclusion Criteria:\n- The trial is investigating brain microcirculation in patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest.\n- Participants must be ICU patients who have been successfully resuscitated after such an event.\n\nComparing the patient note to the trial inclusion criteria, it is evident that the patient does not meet the specific criteria required for the trial. The patient has not been described as having experienced a cardiorespiratory arrest nor is there any indication that he has been resuscitated and is in the ICU for such an event.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "946": {
        "output": "After reviewing the provided patient note and the clinical trial inclusion criteria, it's clear that the patient and the trial are not a match. The clinical trial is looking for patients with Takayasu arteritis (TAK) and specifies certain criteria related to the disease, including a Kerr score \u2265 2 and specific blood pressure and arterial involvement conditions.\n\nThe patient note, however, does not mention Takayasu arteritis; instead, it describes a patient with severe stenosis in the carotid arteries, high LDL cholesterol levels, and symptoms like dizziness and frequent headaches. None of the patient's described conditions or symptoms align with the disease or the symptoms the clinical trial is targeting.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial since they do not have a diagnosis of Takayasu arteritis or any of the conditions mentioned in the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "947": {
        "output": "Based on the information provided, the patient is a 46-year-old man with dizziness, frequent headaches, severe stenosis in the left internal carotid artery, and moderate stenosis in the right internal carotid artery. The clinical trial in question is focused on patients with Takayasu arteritis (TAK), a specific type of chronic inflammatory arteritis.\n\nTo determine the trial-level eligibility, we need to see if the patient meets the inclusion criteria of the clinical trial:\n\n1. Age \u2265 14 years old: The patient is 46 years old, which meets this criterion.\n2. Active: Kerr score \u2265 2: There is no information about the Kerr score in the patient note.\n3. Severe conditions:\n   - Blood pressure > 180/110mmHg: There is no information about the patient's blood pressure.\n   - \u2265 3 branches with the stenotic rate > 70% involved: There is information about severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but it does not specify the stenotic rate in terms of percentage nor does it mention the involvement of three or more branches.\n   - High degree of organ insufficiency: NYHF III-IV; eGFR (MRDR) 15-60ml/min: There is no information provided about the patient's organ insufficiency, New York Heart Failure class, or estimated Glomerular Filtration Rate.\n\nThe trial is for severe Takayasu arteritis, and there is no mention of Takayasu arteritis in the patient's diagnosis. The patient has carotid artery stenosis, which is not the same as Takayasu arteritis. Therefore, the patient does not meet the disease-specific inclusion criteria for this trial.\n\nBased on the information given, the patient does not have sufficient information to qualify for the trial and does not have the target condition of Takayasu arteritis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "948": {
        "output": "Based on the patient note provided, the 46-year-old man presents with dizziness, frequent headaches, a history of CAD in the family, high LDL-C levels, and severe stenosis in the left internal carotid artery. There is no mention of the patient undergoing multi-level posterior cervical fusion surgery or any related procedures.\n\nThe clinical trial in question is specifically targeting patients who are undergoing multi-level posterior cervical fusion surgery and are 18 years of age or older.\n\nGiven the information in the patient note, there is nothing to suggest that the patient has undergone or is scheduled to undergo multi-level posterior cervical fusion surgery. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "949": {
        "output": "The patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, along with other clinical findings. The clinical trial in question is targeting patients with carotid artery stenosis and is using optical coherence tomography angiography to evaluate ocular changes before and after revascularization procedures.\n\nTo determine the patient's eligibility for the clinical trial, we need to compare the inclusion criteria with the patient's characteristics:\n\nInclusion Criteria for the Trial:\n1. Clinical diagnosis of carotid artery stenosis\n2. Age-gender-race-matched controls\n\nPatient Characteristics:\n1. Diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery as per the ultrasonography report\n2. A 46-year-old man, which satisfies the usual \"age-gender\" part of the inclusion criteria. However, the trial also mentions \"race-matched controls,\" and the patient note does not provide information about the patient's race.\n\nThe patient has a clinical diagnosis of carotid artery stenosis, which matches the first criterion. However, without information regarding the patient's race, we cannot conclusively determine if he is matchable to the controls for the trial as the inclusion criteria specify \"age-gender-race-matched controls.\"\n\nTherefore, based on the available information, the patient appears to meet the clinical diagnosis requirement but lacks complete information to assess race matching. Thus, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "950": {
        "output": "Based on the information provided in the patient note, the patient is a 46-year-old man presenting with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no mention of erectile dysfunction or any treatments related to it, such as the use of oral phosphodiesterase-5-inhibitors (PDE5-i), which is necessary to meet the inclusion criteria of the clinical trial. Furthermore, there is no provided baseline International Index of Erectile Function (IIEF-5) score, which is required to be less than 15 according to the trial's criteria. The patient's peak-systolic velocity (PSV) in the carotid arteries does not meet the criterion for PSV < 25 cm/sec in the pudendal arteries, which is specific for diagnosing arteriogenic erectile dysfunction.\n\nGiven the lack of specific information regarding erectile dysfunction, his treatment history concerning PDE5-i, and the IIEF-5 score, as well as the fact that the patient\u2019s PSV measurements are not relevant to the pudendal arteries, we do not have sufficient information to determine trial eligibility.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "951": {
        "output": "Based on the patient note, the 46-year-old man presents with dizziness and frequent headaches, and he has severe stenosis in the left internal carotid artery, as well as moderate stenosis in the right internal carotid artery. He has high LDL-C levels but no mention of a STEMI or NSTEMI (ST-Elevation Myocardial Infarction or Non-ST-Elevation Myocardial Infarction) is made. There is also no information provided regarding troponin I and CPK-MB levels, or coronary angiography results, which are necessary to confirm a diagnosis of STEMI or NSTEMI.\n\nThe inclusion criteria for the clinical trial require:\n1. Signed Informed Consent Form\n2. Primary STEMI or NSTEMI confirmed by ECG, troponin I and CPK-MB levels, coronary angiography.\n3. Presence of an infarct-related artery according to coronary angiography.\n\nSince the patient note does not confirm the presence of a STEMI or NSTEMI, nor does it mention an infarct-related artery as confirmed by coronary angiography, the patient does not meet the inclusion criteria based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "952": {
        "output": "Based on the information given, the patient note describes a 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The patient has high LDL-C levels and a systolic murmur, but there is no mention of the patient having undergone a transcatheter aortic valve implantation (TAVI) procedure.\n\nThe clinical trial in question is looking for patients who have undergone a TAVI procedure at \u00d6rebro University Hospital between 2009 and December 1st, 2019. \n\nSince the patient note does not indicate that the patient has undergone a TAVI procedure, nor does it mention any connection to \u00d6rebro University Hospital within the specified time frame, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "953": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, we need to assess whether this particular patient is eligible for the trial focused on Omega 3 and ischemic stroke.\n\nThe patient note indicates:\n\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- High LDL-C level and normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- No mention of an ischemic stroke or reperfusion therapy\n- No information on whether the patient can be fed by nasogastric tube or by himself\n- No information on MRI imaging taken in the first 24 hours\n\nThe inclusion criteria for the clinical trial are:\n\n- Admitted ischemic occlusive stroke after successful reperfusion therapy\n- Stabilized in ICU or the inward\n- Attack started 48 hours or less\n- Can be fed by nasogastric tube or by himself\n- MRI imaging was taken in the first 24 hours\n\nBased on the information provided, the patient does not clearly meet the inclusion criteria as there is no mention of an ischemic stroke or successful reperfusion therapy. The patient does present with severe carotid stenosis, which is a risk factor for ischemic stroke, but the criteria specifically require an admission for ischemic occlusive stroke with successful reperfusion therapy.\n\nTherefore, due to insufficient information to confirm eligibility based on the trial's specific inclusion criteria, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "954": {
        "output": "The provided patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). The patient has high LDL-C levels but no other cardiovascular risk factors like smoking, hypertension, or diabetes mellitus. He is physically active and does not use lipid-lowering medications. He has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but there is no mention of diabetes or target organ damage due to diabetes.\n\nThe clinical trial in question is seeking asymptomatic high-risk diabetic patients older than 30 years, with a duration of diabetes for 10 years or more, plus any other additional risk factor such as age, hypertension, dyslipidemia, smoking, and obesity.\n\nBased on the information provided, the patient does not have sufficient information to qualify for the trial. There is no indication of the patient having diabetes, which is a primary inclusion criterion for the trial. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "955": {
        "output": "Based on the information provided:\n\nPatient Characteristics:\n- 46-year-old man\n- Presents with dizziness and frequent headaches\n- High LDL-C level (545 mg/dL) and normal HDL-C level (53 mg/dL)\n- No use of lipid-lowering medications\n- Severe stenosis in the left internal carotid artery\n- Moderate stenosis in the right internal carotid artery\n- No mention of participation in a vestibular rehabilitation program\n\nClinical Trial Inclusion Criteria:\n- Aged above 18 years old\n- Enrolled onto the vestibular rehabilitation programme due to chronic dizziness\n\nThe patient is over 18 years old and presents with dizziness, which aligns with part of the inclusion criteria. However, there is no information indicating that the patient is enrolled in a vestibular rehabilitation program due to chronic dizziness. Since enrollment in a vestibular rehabilitation program is a specific requirement for the study, and there is insufficient information provided to confirm the patient's enrollment, the patient cannot be considered eligible at this time.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "956": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to meet the inclusion criteria for the clinical trial in question. The clinical trial is specifically evaluating the efficacy of Enbrel (etanercept) in patients with moderate to severe plaque psoriasis. The patient note does not mention psoriasis or treatment with etanercept; instead, it describes a 46-year-old man with severe carotid artery stenosis, dizziness, frequent headaches, and abnormal lipid levels.\n\nSince there is no mention of plaque psoriasis or treatment with etanercept as required by the trial's inclusion criteria, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "957": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information with the inclusion criteria of the clinical trial. Here are the inclusion criteria for the trial:\n\n1. Adults aged 18 years and older\n2. Patient or patient's legal healthcare proxy consents to participation\n3. Have an audible heart murmur in at least one auscultation position, as heard by a clinician\n4. Undergoing or have undergone a complete (i.e., not limited) echocardiogram\n5. Willing to have heart recordings done with two different electronic stethoscopes\n\nNow, let's evaluate the patient's information against these criteria:\n\n1. The patient is a 46-year-old man, which satisfies the age requirement.\n2. There is no information provided about consent, but for the purpose of this assessment, we will assume that if the patient meets the other criteria, they or their healthcare proxy would consent to participation.\n3. The patient has an audible heart murmur (3+/6+ systolic murmur in the neck), as mentioned in the patient note.\n4. The patient underwent ultrasonography of the carotid arteries, which is not the same as an echocardiogram. There is no indication in the patient note that a complete echocardiogram has been performed or is planned.\n5. There is no information about the patient's willingness to have heart recordings done with electronic stethoscopes, but as with consent, we will assume willingness if other criteria are met.\n\nGiven the available information, the patient meets the age and heart murmur criteria but does not have documented evidence of having undergone a complete echocardiogram, which is a necessary condition for inclusion in the trial. Therefore, based on the provided patient note, the patient does not meet all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "958": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- A 46-year-old man with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient has atherosclerotic plaques in the carotid arteries, which are described as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic.\n- The plaque characterization does not explicitly state whether the plaques are uniformly or predominantly echolucent, which is a key criterion for the study.\n- The patient is not currently on lipid-lowering medications.\n- The patient agreed to undergo follow-up, which is implied by the detailed reporting of his condition, but this is not clearly stated as an agreement to follow-up for the clinical trial.\n\nClinical Trial Inclusion Criteria:\n1. Must have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography.\n2. Patients were referred for optimal medical treatment.\n3. Patients agreed to undergo follow-up CEUS at a half-year and 1-year interval.\n\nAssessment:\n- The patient note indicates the presence of atherosclerotic plaques, but it does not provide information about the echogenicity of the plaques in terms of being uniformly or predominantly echolucent.\n- It is not clear if the patient has been referred for optimal medical treatment, which is part of the inclusion criteria.\n- While the patient seems to be under close medical observation, there is no explicit confirmation that he has agreed to the specific follow-up schedule required by the trial.\n\nGiven the information available from the patient note, the patient cannot be confirmed as meeting all the inclusion criteria, particularly the necessary echogenicity of the plaque and the agreement to the follow-up schedule. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "959": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nPatient's Characteristics:\n- 46 years old\n- Presents with dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus\n- Physically active\n- Has not used lipid-lowering medications\n- Severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- High LDL-C levels\n\nClinical Trial Inclusion Criteria:\n- Patients with stable symptoms and low to intermediate probability of coronary artery disease (CAD) referred for evaluation\n- Patients without known history of CAD\n- Patients older than 18 years\n- Patients giving voluntary written consent to participate in the study\n- Subject is willing to comply with study follow-up requirements\n\nAssessment:\n- The patient is older than 18 years old (meets criteria).\n- The patient has stable symptoms with dizziness and frequent headaches, which could be related to CAD, especially considering his high LDL-C levels and the findings of carotid stenosis (meets criteria).\n- There is no mention of a known history of CAD, only a family history and current symptoms suggesting undiagnosed CAD (meets criteria).\n- Assuming the patient is willing to give consent and comply with study requirements, which cannot be determined from the provided note (requires further information).\n\nSince the note does not explicitly state that the patient has been diagnosed with CAD, but rather has symptoms and findings (e.g., severe stenosis in the LICA and high LDL-C levels) that suggest the possibility of CAD, it appears that the patient has a low to intermediate probability of CAD and may be suitable for further evaluation within the context of the trial. However, the final determination of eligibility would require the patient's consent and willingness to comply with the study.\n\nBased on the available information and assuming no other exclusion criteria apply, the patient may be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "960": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 46-year-old man, which meets the age criterion (\u226518 years).\n- The patient presents with dizziness and frequent headaches.\n- The patient's LDL-C and HDL-C levels are 545 and 53\u2009mg/dL, respectively, with no mention of psoriasis.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which is unrelated to psoriasis.\n- There is no mention of the patient having psoriasis or being treated with etanercept or any other biological treatment.\n\nClinical Trial Inclusion Criteria:\n- Moderate-to-severe plaque psoriasis patients.\n- Patients who have been receiving etanercept for at least 1 year.\n- Have difficult to treat sites at presentation.\n- Age \u226518 years.\n- No history of using other biological treatments for moderate-to-severe plaque psoriasis other than etanercept.\n\nThe patient's note does not mention moderate-to-severe plaque psoriasis, nor does it indicate that the patient has been receiving etanercept treatment. Without this information, the patient does not meet the specific inclusion criteria related to the disease and treatment required for the clinical trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "961": {
        "output": "",
        "label": 0
    },
    "962": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Carotid Web Associated With Cerebral Infarctions,\" we can assess the eligibility of the patient as follows:\n\nThe patient is a 46-year-old man, which satisfies the age criterion of being \u226518 years old.\n\nThe clinical findings in the patient note indicate severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, there is no mention of a carotid web or cerebral infarction/transient ischemic attack in the carotid area downstream of a carotid web lesion. A carotid web is a specific type of lesion and not merely an arterial stenosis or plaque, which seems to be the finding in this patient.\n\nThe inclusion criteria require available imaging revealing the presence of a carotid web and cerebral infarction or transient ischemic attack in the carotid area downstream of a carotid web lesion, which must be validated by a pair of experts (Neurologist and Neuroradiologist). There is no indication in the patient note that such a condition has been diagnosed or validated in this patient.\n\nFurthermore, there is no mention of the patient having experienced a cerebral infarction or transient ischemic attack, which is also a requirement for inclusion.\n\nGiven that the patient note does not provide evidence of a carotid web or associated cerebral infarction or transient ischemic attack, the patient does not meet the inclusion criteria for the clinical trial as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "963": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, we can analyze the patient's eligibility step by step:\n\n1. The patient is a 46-year-old man, which meets the age requirement of \u2265 18 years stated in the inclusion criteria.\n2. The patient has extremely high LDL-C levels at 545 mg/dL, which exceeds the threshold for the third inclusion group, which is LDL levels above 160 mg/dL.\n3. The patient does have evidence of atherosclerosis, as indicated by severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery observed in the ultrasonography of the carotid arteries. This fits with the third group of participants for the trial, which includes participants with evidence of atherosclerosis.\n4. The patient has not been described to be using any lipid-lowering medications, which is consistent with the trial's criteria, as it does not specify the need for medication status.\n5. The patient does not have any other cardiovascular risk factors noted other than the family history of CAD.\n\nGiven these findings, the patient appears to meet the inclusion criteria for the clinical trial. He is of the appropriate age, has high LDL levels, and has evidence of atherosclerosis, as required by the trial. There is no mention of exclusion criteria, so we cannot determine if the patient is excluded for any reason not stated in the inclusion criteria. Therefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "964": {
        "output": "To assess the patient's eligibility for the clinical trial \"Lowering Blood Pressure by Changing Lifestyle,\" we need to compare the patient's characteristics and conditions with the inclusion criteria of the study.\n\nThe inclusion criteria for the clinical trial are:\n1. Participants with clinic blood pressure more than or equal to 130/80 mm Hg who are not taking medication.\n2. Participants with controlled blood pressure defined as < 130/80 using anti-hypertensive medication for a minimum of six weeks.\n3. Participants live in Banshgram Union only.\n\nThe patient in the note presents with:\n- No mention of high blood pressure or use of antihypertensive medication.\n- LDL-C level of 545 mg/dL, which indicates dyslipidemia, but this is not relevant to the trial's focus on blood pressure.\n- No mention of residence, so we cannot ascertain if the patient lives in Banshgram Union.\n\nSince the patient note does not provide information about the patient's blood pressure or location, and the patient is not reported to be on any blood pressure medication, we do not have sufficient information to determine if the patient meets the inclusion criteria based on blood pressure levels or residence.\n\nTherefore, the trial-level eligibility for this patient, based on the information provided, is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "965": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Reveal LINQ Respiration Clinical Study,\" we must compare the patient's information with the trial's inclusion criteria.\n\nThe clinical trial's inclusion criteria are:\n1. Patient is \u2265 55 years old\n2. Patient (or patient's legally authorized representative) is willing and able to provide written informed consent\n3. Patient is willing and able to comply with the study procedures\n4. Patient has an active Medtronic Reveal LINQ device that has been implanted for \u2265 60 days and no more than 3 years\n\nThe patient note provides the following information:\n- The patient is a 46-year-old man\n- The patient presents with dizziness and frequent headaches\n- The patient has a family history of CAD\n- The patient is physically active\n- The patient's lipid levels are provided\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- The patient has not used lipid-lowering medications\n- There is no mention of a Medtronic Reveal LINQ device\n\nBased on this information, the patient does not meet the age criterion (he is 46, and the study requires participants to be \u2265 55 years old). Furthermore, there is no information suggesting that the patient has a Medtronic Reveal LINQ device implanted.\n\nSince the patient does not meet the age requirement and there is no indication of an implanted Medtronic Reveal LINQ device, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "966": {
        "output": "After analyzing the provided patient note and the inclusion criteria for the clinical trial titled \"Universal Familial Hypercholesterolemia Screening in Children,\" the assessment of eligibility can be determined as follows:\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, a family history of CAD, extremely high LDL-C levels, and carotid artery stenosis. However, the clinical trial is focused on universal familial hypercholesterolemia screening in children, and the inclusion criteria are specifically related to children with elevated cholesterol levels or those who have completed FH genetic analysis, or who are family members of a child with confirmed familial hypercholesterolemia.\n\nGiven that the patient in the note is an adult and there is no mention of him having a child with familial hypercholesterolemia or having completed FH genetic analysis himself, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "967": {
        "output": "",
        "label": 0
    },
    "968": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function,\" we need to evaluate the patient's information against the trial's inclusion criteria:\n\nInclusion Criteria:\n1. Age <70 years\n2. Stable coronary heart disease\n3. Patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 2 months must have passed since the incident\n4. High LDL levels, low HDL, high triglycerides\n\nPatient Information:\n- Age: 46 years old\n- Stable coronary heart disease: Not specifically mentioned\n- History of PCI or CABG: Not mentioned\n- High LDL levels: 545 mg/dL (high)\n- Low HDL levels: 53 mg/dL (considered low)\n- High triglycerides: 158 mg/dL (within normal limits, not high)\n\nThe patient satisfies the age criterion (1) and has high LDL levels (4). There is no information on whether the patient has stable coronary heart disease or a history of PCI or CABG. However, the patient has severe stenosis in the left internal carotid artery, which could be related to coronary artery disease (CAD), but there's no confirmation that the condition is stable or that the patient has had an acute coronary syndrome event followed by PCI or CABG.\n\nSince we have insufficient information to conclusively determine the patient has stable coronary heart disease or a history of acute coronary syndrome treated with PCI or CABG, the patient does not clearly meet all the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "969": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's consider the eligibility of the patient for the clinical trial titled \"Epidemiology and Long-term Outcome of Patients With VHD.\"\n\nPatient Note Analysis:\n- The patient is a 46-year-old man presenting with dizziness and frequent headaches.\n- His LDL-C and HDL-C levels are high and normal, respectively.\n- He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- There is a presence of plaque in the carotid arteries.\n- No mention of valvular heart disease (VHD) is made in the patient's note.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on patients with valvular heart disease in moderate and severe stages.\n\nMatching the Patient to the Trial Criteria:\n- The trial is specifically looking for patients with valvular heart disease.\n- The patient's note does not mention valvular heart disease; instead, it focuses on carotid artery stenosis and its related symptoms.\n\nAs the patient's condition (carotid artery stenosis) does not match the inclusion criteria for the clinical trial (valvular heart disease in moderate and severe stages), the patient would not be eligible for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "970": {
        "output": "The patient is a 46-year-old man with high LDL cholesterol levels, dizziness, and frequent headaches. He also has carotid artery stenosis but no cardiovascular risk factors like smoking, high blood pressure, or diabetes and is physically active. The patient has not been using any lipid-lowering medications.\n\nNow, let's assess his eligibility for the clinical trial titled \"Oral Nutritional Supplement Effect on HDL Function\" based on the inclusion criteria provided:\n\n1. Age 18-80 years: The patient is 46 years old, which fits within the specified age range.\n2. Male and non-pregnant female patients: The patient is male, so he meets this criterion.\n3. Total HDL level 38mg/dL or lower in men: The patient's HDL-C level is 53 mg/dL, which does not meet the criterion of having an HDL level of 38 mg/dL or lower.\n4. HDL-P defined as less than 7000 by Spectracell LPP Plus: There is no information on the patient's HDL particle number (HDL-P).\n5. CHL HDL Fx score equal to or greater than 0.9: There is no information on the patient's CHL HDL Fx score.\n6. Patients will remain on their present diet, exercise program, medications, etc.: The patient can potentially comply with this requirement, but there's no specific information provided.\n7. No other lipid-lowering supplement can be taken during the study: The patient is not currently taking lipid-lowering medications or supplements.\n8. All lipid-lowering supplements must have been discontinued at least 30 days prior to study entry: Since the patient has not been taking any such supplements, this criterion is met.\n\nThe critical exclusionary criterion here is the HDL level. Since the patient's HDL-C level is above the threshold for the trial inclusion (53 mg/dL vs. the required 38 mg/dL or lower for men), he would not be eligible for this study.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria due to his HDL level being too high.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "971": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Investigation of Multiple Ultrasound Techniques for the Assessment of Carotid Plaque Vulnerability,\" let's assess the patient's eligibility:\n\nPatient Note Summary:\n- A 46-year-old man\n- Presents with dizziness and frequent headaches\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery\n- Ultrasonography revealed the presence of plaque characterized as bulky plates and predominantly echogenic and hyperechoic\n\nClinical Trial Inclusion Criteria:\n- At least one examination suggested the presence of carotid plaque\n- Suitable for CEUS examination (Contrast-Enhanced Ultrasound)\n- Voluntary enrollment in this study and signing of informed consent\n\nEligibility Assessment:\n1. The patient has undergone ultrasonography, which revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with the presence of carotid plaque.\n2. The details about the patient's suitability for CEUS examination have not been explicitly mentioned, but since the patient has already undergone ultrasonography with the presence of plaque being documented, it is likely that the patient is suitable for further ultrasound examinations.\n3. Assuming the patient is willing to enroll and provide informed consent, the final criterion would also be met.\n\nThe patient appears to meet all the listed inclusion criteria for the clinical trial. There is no information provided on any exclusion criteria or factors that would make the patient unsuitable for the trial. Thus, the patient seems to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "972": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to review the patient's information against the inclusion criteria listed for the trial. \n\nInclusion Criteria for the Trial:\n1. Age \u2265 40 years old\n2. Significant (70-99%) carotid artery stenosis on one side, as measured by duplex ultrasound or angiogram\n3. Asymptomatic carotid stenosis (no history of ipsilateral stroke or TIA within 180 days)\n4. Deemed to be fit for carotid endarterectomy\n5. At least one of the following high-risk features:\n   a) prior stroke >6months prior to randomization\n   b) peripheral artery disease\n   c) current smoker\n   d) type 2 diabetes\n   e) eGFR \u2265 30 mL/min/1.73m2 and <60 ml/min/1.73m2\n   f) hsCRP > 2mg/L in the absence of alternative known causes of hsCRP elevations including autoimmune diseases or active infections.\n6. On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily, rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin or non-statin therapy is clinically justified\n\nPatient's Information:\n- 46 years old (meets age criteria)\n- Severe stenosis in the left internal carotid artery, moderate stenosis in the right internal carotid artery (criteria specify 70-99% stenosis; severity in the patient is not quantified with a percentage, but the description of \"severe\" could potentially meet this criterion)\n- Asymptomatic (no mention of stroke or TIA, so likely meets this criterion)\n- No information on fitness for carotid endarterectomy\n- No high-risk features mentioned (no prior stroke, peripheral artery disease, smoking, type 2 diabetes, eGFR, or hsCRP levels)\n- Not on statin therapy (does not meet this criterion)\n\nBased on the information provided, the patient does not meet all the inclusion criteria for the clinical trial. Specifically, the patient is not on a statin therapy, which is required by the trial, and there is no mention of high-risk features or confirmation of the exact severity of stenosis in percentage terms or fitness for carotid endarterectomy.\n\nTherefore, the patient does not have sufficient information to qualify for the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "973": {
        "output": "Given the patient's information, we need to assess if he meets the inclusion criteria for the clinical trial titled \"Artificial Intelligence Based Comprehensive Assessment System of Carotid Plaque Stability.\"\n\nThe inclusion criteria for the clinical trial are:\n1. Age between 18 years and 80 years.\n2. At least one imaging examination suggested the presence of carotid plaque.\n3. No allergy to contrast-enhanced ultrasound and other contraindications.\n4. Voluntary enrollment in this study.\n\nThe patient presented:\n- Is a 46-year-old man, which meets the age criterion.\n- Has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as shown by ultrasonography. This suggests the presence of carotid plaque, meeting the second criterion.\n- There is no information provided about allergies to contrast-enhanced ultrasound or other contraindications, but we have no reason to assume their presence.\n- Since the patient's willingness to enroll is not mentioned, we must assume the patient's consent, as the patient note is a hypothetical exercise and not a real-world scenario where explicit consent is required.\n\nWith the information provided, the patient meets all the specified inclusion criteria of the clinical trial. There are no exclusion criteria specified.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "974": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Manual Therapy in Tension-type Headache,\" we must compare the patient's clinical presentation with the inclusion criteria specified by the trial. Let's go through the criteria one by one:\n\n1. Diagnosis of Tension-Type Headache (TTH) based on the ICHD-3 beta:\n   - The patient presents with dizziness and frequent headaches. However, the note does not specify if the headaches are of the tension-type according to the ICHD-3 criteria.\n\n2. Headache characteristics:\n   - Bilateral localization: The patient note does not mention the localization of the headache.\n   - Pressing and tightening pain: Not described in the patient note.\n   - Mild-moderate intensity (\u22647.0 on a visual analog scale (VAS)): Intensity is not mentioned.\n   - No increase in pain during physical activity: Not mentioned.\n\n3. Absence of certain symptoms:\n   - No photophobia, phonophobia, vomiting, or nausea: The note does not mention the existence or absence of these symptoms.\n\n4. Duration of symptoms:\n   - Had symptoms for more than 3 months: The note does not specify the duration of the headaches.\n\n5. Headache frequency:\n   - The patient note does not mention how frequently the headaches occur.\n\n6. Segmental dysfunction of the upper cervical spine:\n   - The patient underwent neck auscultation and carotid ultrasonography, but there's no mention of segmental dysfunction diagnosed by functional and pain-provocation tests.\n\nThe patient note does include a report of dizziness and frequent headaches, which could be related to TTH, but there is insufficient information to definitively classify the headaches as tension-type based on the trial's inclusion criteria. Additionally, there is no information on the duration of symptoms, headache characteristics, or segmental dysfunction of the upper cervical spine.\n\nWithout this essential information, we cannot determine that the patient meets the inclusion criteria for the clinical trial on manual therapy in tension-type headaches.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "975": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), as determined by ultrasonography.\n- The patient has carotid plaque characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs).\n- There is no mention of the patient being informed about the study or having signed an informed consent form, but this is something that can potentially be addressed if all other criteria are met.\n\nClinical Trial Inclusion Criteria:\n- Patients with a carotid plaque \u2265 2 mm thick based on ultrasound or CTA.\n- Age 18 years or older (no maximum age).\n- Informed consent by signing informed consent form regarding this study.\n\nComparison:\n- The patient's age of 46 years meets the age inclusion criterion (18 years or older).\n- The patient has a carotid plaque, as evidenced by ultrasonography. However, the exact thickness of the plaque is not mentioned in the note. Since the inclusion criterion specifically requires a plaque thickness \u2265 2 mm, without this information, we cannot definitively determine eligibility.\n- Informed consent has not been discussed in the note provided, but this does not preclude eligibility as consent can be sought if the patient meets other criteria.\n\nGiven that the patient note does not provide the specific thickness of the carotid plaque, we do not have sufficient information to qualify the patient for the trial. Therefore, the patient's trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "976": {
        "output": "The patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of CAD. His lipid profile is abnormal with high LDL-C levels, but he has no other cardiovascular risk factors and is physically active. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no mention of hammertoe deformity or any surgical intervention related to it.\n\nThe clinical trial is focused on the treatment of lesser toe deformities, specifically rigid hammertoe, and compares two different surgical techniques. The inclusion criteria for the trial specify that the patient must have clinical and radiological evidence of rigid hammertoe and should not have significant medical comorbidities, among other requirements.\n\nBased on the provided patient note, there is no information suggesting that the patient has a hammertoe deformity or that he requires surgical intervention for such a condition. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which is specifically focused on the treatment of rigid hammertoe.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "977": {
        "output": "",
        "label": 2
    },
    "978": {
        "output": "The patient in question is a 46-year-old man who presents with dizziness and frequent headaches. He has severe and moderate stenosis in the left and right internal carotid arteries, respectively, and a family history of CAD. His condition appears to be related to cardiovascular issues, with no mention of any unilateral motor impairments of one lower limb as required by the clinical trial's inclusion criteria.\n\nThe clinical trial is focused on the efficacy of split gait in the treatment of dynamic asymmetries in subjects with pathologic claudication. The inclusion criteria specify that the subjects should have unilateral motor impairments of one lower limb due to various pathologic conditions such as post-stroke hemiparesis, Parkinson's disease with lateral asymmetry in the motor symptoms, multiple sclerosis with lateral asymmetry in the motor symptoms, unilateral amputation with prosthetic correction, surgical orthopedic interventions, or unilateral lesions of peripheral nerves.\n\nSince the patient's note does not mention any of the conditions listed in the inclusion criteria for the clinical trial, specifically related to unilateral motor impairments, and instead discusses carotid artery disease, the patient does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "979": {
        "output": "The patient in the note is a 46-year-old man who presents with dizziness and frequent headaches. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The ultrasound findings provide evidence of significant carotid artery disease.\n\nNow, let's compare the patient's characteristics and condition with the inclusion criteria of the clinical trial:\n\n1. Age: 35-80 years old - The patient is 46 years old, which fits within the age range.\n2. Severe carotid stenosis (MRA or CTA confirmed stenosis rate of 70% - 99%, NASCET standard) - The patient has severe stenosis in the left internal carotid artery. However, the exact percentage of stenosis is not provided, but a PSV of 208.5 cm/s and an EDV of 54.5 cm/s suggest severe stenosis which often corresponds to >70% stenosis.\n3. Asymptomatic or mild stroke (NIHSS \u2264 3) or TIA - The patient note does not mention a history of stroke or TIA, only dizziness and headaches.\n4. Agree to participate in the clinical trial and sign the informed consent - There is no information provided about the patient's willingness or consent.\n\nBased on the available information, the patient meets the age criterion and likely meets the criterion for severe carotid stenosis. However, there is no direct mention of a TIA or stroke with an NIHSS score \u2264 3. Additionally, there is no information about the patient's consent to participate. Therefore, we do not have sufficient information to determine if the patient is eligible for the trial on all inclusion criteria points.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "980": {
        "output": "Based on the information provided, the patient in the note has not been described as having COVID-19 ARDS (Acute Respiratory Distress Syndrome). The patient's clinical presentation is focused on symptoms relating to high LDL cholesterol levels and stenosis in the carotid arteries, with no mention of respiratory illness or COVID-19 infection. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires participants to have moderate to severe COVID-19 ARDS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "981": {
        "output": "To determine the trial-level eligibility of the 46-year-old man for the clinical trial titled \"Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nThe inclusion criteria for the trial are:\n1. Age > 18 years old\n2. CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care.\n3. Treated with aspirin prior to the PCI procedure per standard of care\n\nThe patient's characteristics and medical information:\n- 46 years old (meets age criterion)\n- Has a family history of CAD, which is noted, but it is not explicitly stated that the patient is diagnosed with CAD or undergoing PCI.\n- No mention of the patient being treated with cangrelor or aspirin prior to any PCI procedure.\n\nBased on the information provided in the patient note, we do not have evidence that the patient has been diagnosed with CAD or that they are undergoing PCI. Furthermore, there is no information about treatment with cangrelor or aspirin prior to PCI. Therefore, we do not have sufficient information to determine if the patient meets the clinical trial's inclusion criteria related to CAD diagnosis, PCI procedure, and treatment specifics.\n\nGiven the lack of specific information regarding the patient's CAD status and treatment related to the inclusion criteria, the patient would be considered:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "982": {
        "output": "After reviewing the patient note and comparing it with the inclusion criteria of the clinical trial titled \"Obesity in Pediatric Sickle Cell Disease: A New Phenomenon,\" it is clear that the patient does not meet the necessary criteria to participate in the trial. The inclusion criteria specify that participants must be between 10-19 years of age, diagnosed with sickle cell disease (SCD) of specific genotypes, and must be regularly followed by the UMMC Pediatric SCD clinic.\n\nThe patient in question is a 46-year-old man with no mention of sickle cell disease or any genotype associated with it. Moreover, the patient is well outside the specified age range for the study participants. Therefore, the patient does not have sufficient information to qualify for the trial based on the details provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "983": {
        "output": "To determine the trial-level eligibility for the patient based on the inclusion criteria provided for the Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study, we must compare the patient's characteristics and medical findings with the criteria listed.\n\nThe inclusion criteria for the CAMP Study are:\n1. Asymptomatic carotid artery lesions between 40 and 60% at carotid artery ultrasound.\n2. Patients with asymptomatic carotid artery stenosis higher than 60% will be enrolled when revascularization by either carotid endarterectomy (CEA) or stenting will be considered not indicated or not feasible.\n3. Both genders (with capping implemented in order to ensure a 50\u00b15% balance of males to females).\n\nThe patient note provides the following relevant information:\n- The patient is a 46-year-old man.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has not undergone any revascularization procedures like CEA or stenting, and there is no mention that such procedures have been considered or deemed infeasible.\n- The patient is not described as having any symptoms directly attributed to carotid artery disease such as stroke or transient ischemic attacks (TIAs).\n\nBased on the provided information:\n- The patient has stenosis within the inclusion criteria range (40% to 60% for RICA, severe stenosis for LICA which could be over 60% but there is no indication that revascularization is indicated or feasible).\n- The patient is male, which fits the gender inclusion criterion, assuming the study has not reached its male participant cap.\n- There are no other exclusion criteria provided that would exclude this patient.\n\nAssuming that the severe stenosis in the LICA is higher than 60% and revascularization is not indicated or not feasible (which is not explicitly stated but could be inferred from the absence of any mention of planned interventions), and assuming that the gender balance within the study allows for the inclusion of additional male participants, the patient could potentially be eligible for the study.\n\nHowever, since the trial specifically mentions \"asymptomatic\" carotid artery lesions and the patient is presenting with dizziness and frequent headaches, this could be a gray area. If the dizziness and headaches are not considered related symptoms of carotid artery disease, the patient might still be eligible. Without further information, we cannot definitively determine if these symptoms are related or not.\n\nGiven the information at hand and the potential gray area regarding symptomatology:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "984": {
        "output": "",
        "label": 0
    },
    "985": {
        "output": "Based on the patient note, the 46-year-old man does not have a history of acute myocardial infarction (AMI) mentioned, which is a requirement for the clinical trial titled \"Ezetimibe Utilization Early After Acute Myocardial Infarction, EzAMI Trial.\" The patient presents with symptoms of dizziness and frequent headaches, and there is a finding of severe stenosis in the left internal carotid artery, but no mention of a recent AMI.\n\nThe inclusion criteria for the trial are:\n\n1. Age more than 18 years. Both genders are eligible.\n2. Acute myocardial infarction (STEMI or NSTEMI) within 48 hours from the onset of symptoms.\n3. Baseline LDL-C above 125 mg/dl for those who were not on consistent lipid lowering therapy; or above 100 mg/dl for those who were compliant (\u2265 90 days) on moderate intensity statin therapy.\n\nWhile the patient does have a baseline LDL-C level above 125 mg/dL (545 mg/dL), which meets one of the inclusion criteria, they do not meet the criteria related to the recent acute myocardial infarction. Therefore, the patient is not relevant for this clinical trial because the patient note lacks sufficient information indicating a recent AMI, which is a critical inclusion criterion for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "986": {
        "output": "Based on the patient note and the inclusion criteria of the CARUSO trial, let\u2019s analyze the patient\u2019s eligibility:\n\n1. The patient is a 46-year-old man, which satisfies the age criterion (age \u2265 18 years).\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The trial requires asymptomatic patients with uni- or bilateral carotid artery stenosis \u226550%. The patient's stenosis in the left internal carotid artery fulfills this requirement.\n3. The patient's LDL-C level is 545 mg/dL, which is well above the threshold of \u2265100 mg/dL as per the trial's inclusion criteria.\n4. The patient reported no use of lipid-lowering medications, which does not meet the trial's inclusion criteria that require ongoing lipid-lowering therapy (LLT).\n\nGiven the patient has not been on lipid-lowering therapy, they do not meet all of the inclusion criteria for the trial. Therefore, the patient is not eligible for the CARUSO trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "987": {
        "output": "",
        "label": 0
    },
    "988": {
        "output": "First, I will analyze the patient's information based on the inclusion criteria of the clinical trial.\n\nThe patient is a 46-year-old man. This meets the age requirement of \u2265 45 years of age stated in the inclusion criteria.\n\nThe patient has not provided any information regarding a planned surgery, let alone the duration of such surgery. Therefore, we cannot confirm if the patient fulfills the criterion of having a surgery planned for more than two hours.\n\nThe patient has not provided written informed consent, as this is a hypothetical scenario and such consent cannot be determined from the provided information.\n\nNow, let's examine if the patient fulfills at least one of the additional inclusion criteria (A-K):\n\nA) NT-proBNP \u2265 200 ng/L - Not mentioned in the patient note.\nB) Troponin T > 25 ng/L - Not mentioned in the patient note.\nC) History of coronary artery disease (CAD) - The patient has a family history of CAD, but no personal history is mentioned.\nD) History of peripheral artery disease (PAD) - Not mentioned in the patient note.\nE) 75 years or older - The patient is 46 years old.\nF) History of transient ischemic attack (TIA) or stroke - Not mentioned in the patient note.\nG) Current smoking or cessation of smoking within 2 years - The patient does not smoke.\nH) Diabetes or currently taking anti-diabetic drug - The patient's fasting glucose levels are within normal limits, and there is no mention of diabetes or anti-diabetic drugs.\nI) Hyperlipidemia - The patient has a very high LDL-C level, which suggests hyperlipidemia.\nJ) History of hypertension or currently taking an antihypertensive drug - Not mentioned in the patient note.\nK) Atrial fibrillation - Not mentioned in the patient note.\n\nThe patient does have hyperlipidemia which is one of the inclusion criteria under letter I. However, due to the lack of information on the planned surgery and the absence of written informed consent, we cannot determine the patient's eligibility definitively.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "989": {
        "output": "Based on the patient note provided, the 46-year-old man presents with symptoms and findings that are suggestive of cardiovascular issues, specifically severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the clinical trial in question is focused on patients with either stable coronary artery disease or stabilized acute coronary syndrome who have undergone invasive Fractional Flow Reserve (FFR) measurement \u22640.80. \n\nThe patient note does not mention the patient having stable coronary artery disease or acute coronary syndrome, nor does it state that the patient has undergone an FFR measurement. Although the patient has carotid artery disease, this does not necessarily imply that the patient has coronary artery disease or that they have had an FFR measurement. \n\nGiven that the information provided does not confirm the patient has the specific conditions required by the trial's inclusion criteria (stable coronary artery disease or stabilized acute coronary syndrome), and there is no information regarding an FFR measurement, the patient does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "990": {
        "output": "",
        "label": 0
    },
    "991": {
        "output": "To determine the trial-level eligibility, we must compare the patient's characteristics and conditions with the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the trial are as follows:\n1. Patient's written informed consent.\n2. The presence of metabolic syndrome: as having three or more of the following traits, including traits you're taking medication to control:\n   - Large waist - A waistline that measures at least 35 inches (89 centimeters) for women and 40 inches (102 centimeters) for men;\n   - High triglyceride level - 150 milligrams per deciliter (mg/dL), or 1.7 millimoles per liter (mmol/L), or higher of this type of fat found in blood;\n   - Reduced good or HDL cholesterol - Less than 40 mg/dL (1.04 mmol/L) in men or less than 50 mg/dL (1.3 mmol/L) in women of high-density lipoprotein (HDL) cholesterol;\n   - Increased blood pressure - 130/85 millimeters of mercury (mm Hg) or higher;\n   - Elevated fasting blood sugar - 100 mg/dL (5.6 mmol/L) or higher.\n3. Must be able to come to the hospital 5 days per week, for 3 weeks.\n\nThe patient note provides the following relevant information:\n- 46-year-old man presents with dizziness and frequent headaches.\n- LDL-C level: 545 mg/dL.\n- HDL-C level: 53 mg/dL.\n- Fasting glucose level: 85 mg/dL.\n- Triglyceride level: 158 mg/dL.\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n- The patient reported no use of lipid-lowering medications.\n- There is no information provided about the patient's waist measurement or blood pressure.\n\nAccording to the clinical trial inclusion criteria for metabolic syndrome, the patient needs to have at least three of the following traits:\n\nThe patient meets the following criteria:\n- High triglyceride level: The patient's triglyceride level is 158 mg/dL, which is above the 150 mg/dL threshold.\n- Reduced HDL cholesterol: The patient's HDL-C level is 53 mg/dL, which is above the threshold of less than 40 mg/dL for men, so this criterion is not met.\n- Elevated fasting blood sugar: The patient's fasting glucose level is 85 mg/dL, which is below the 100 mg/dL threshold.\n\nThe patient does not meet the reduced HDL cholesterol or elevated fasting blood sugar criteria, and there is no information regarding the patient's waist size or blood pressure. Thus, based on the information provided, the patient only meets one of the criteria for metabolic syndrome. Additionally, there is no mention of the patient's ability to attend the hospital 5 days per week for 3 weeks. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "992": {
        "output": "Reviewing the patient note and the clinical trial inclusion criteria:\n\nPatient Note:\n- The patient is a 46-year-old man.\n- Presents with dizziness and frequent headaches.\n- No history of smoking, high blood pressure, or diabetes mellitus.\n- LDL-C level: 545\u2009mg/dL.\n- HDL-C level: 53\u2009mg/dL.\n- Fasting glucose and triglyceride levels are within normal limits.\n- No use of lipid-lowering medications.\n- Severe stenosis in the left internal carotid artery (LICA) with PSV: 208.5\u2009cm/s and EDV: 54.5\u2009cm/s.\n- Moderate stenosis in the right internal carotid artery (RICA) with PSV: 91.72\u2009cm/s and EDV: 37.37\u2009cm/s.\n\nClinical Trial Inclusion Criteria:\n- Age > 18 years\n- Carotid stenosis defined as:\n  - Stenosis \u226570% by computer tomography angiography (NASCET criteria); OR\n  - By duplex-ultrasound with \u226570% stenosis defined by a peak systolic velocity of at least 230 cm/s\n- Carotid stenosis is treatable with CAS (Carotid Artery Stenting)\n\nBased on the patient note, the patient is over 18 years old and has severe carotid stenosis, which could potentially be treatable with CAS. However, the duplex-ultrasound criteria specified in the trial's inclusion criteria require a peak systolic velocity of at least 230 cm/s to define \u226570% stenosis. The patient's LICA PSV is 208.5 cm/s, which is below the trial's specified threshold for \u226570% stenosis. Thus, based on the provided patient note and the trial's inclusion criteria, the patient does not meet the specific ultrasound velocity criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "993": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial described, we need to match the patient's characteristics and condition with the inclusion criteria of the trial. Let's go through the inclusion criteria and check them against the patient's note:\n\n1. Age \u2265 18 years: The patient is 46 years old, which meets this criterion.\n\n2. Informed written consent: This is not mentioned in the patient note, but it is a procedural step that the patient can complete if they agree to participate.\n\n3. At least one major or two minor bleeding risk criteria of Academic Research Consortium (ARC):\n   - Major Criteria: There is no mention of the patient having any of the major bleeding risk criteria.\n   - Minor Criteria: The patient does not appear to be over 75 years old, and there is no mention of moderate CKD, low hemoglobin levels, spontaneous bleeding, long-term use of NSAIDs or steroids, or any ischemic stroke.\n\n4. Either of the following:\n   - Stabile angina or dyspnea and a coronary narrowing causing myocardial ischemia detected in the angiogram. The patient presents with dizziness and frequent headaches, which are not direct indicators of stable angina or dyspnea, and there is no mention of myocardial ischemia.\n   - ACS (UAP or NSTEMI): The patient does not report symptoms that suggest unstable angina pectoris (UAP) or non-ST-elevation myocardial infarction (NSTEMI).\n\n5. At least one of the following:\n   - \u22651 de novo lesions in native coronary arteries or bypass vein grafts: There is no mention of coronary artery lesions or bypass grafts in the patient's note.\n   - Reference diameter of the vessel is 2.0-5.0mm: This is a specification for the lesions, which are not mentioned.\n   - Lesion length \u2264 40mm: Again, this relates to lesions not mentioned in the patient's note.\n   - Lesion or lesions are suitable for PCI: There is no indication that the patient has lesions suitable for PCI.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial as they do not have a documented history of ACS, stable angina, or any coronary artery lesions suitable for PCI. Additionally, there is no mention of any major or minor bleeding risk factors as defined by the ARC.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "994": {
        "output": "Based on the information provided, the patient is a 46-year-old man who presents with dizziness and frequent headaches. He has been diagnosed with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. There is no indication that the patient has undergone or will undergo invasive coronary angiography or percutaneous coronary intervention, which are the procedures specified in the inclusion criteria of the clinical trial titled \"Registry of Patients That Have Undergone ICA or PCI.\"\n\nTo determine the patient's eligibility for this clinical trial, we must evaluate whether he meets the inclusion criteria:\n\n1. Age \u2265 18 years: The patient is 46 years old, which meets this criterion.\n2. Has undergone or will undergo a clinically indicated invasive coronary angiography: The patient note does not state that the patient has undergone or is scheduled to undergo invasive coronary angiography.\n3. Has undergone or will undergo a clinically indicated percutaneous coronary intervention: Similarly, there is no information to suggest that the patient has undergone or is scheduled to undergo percutaneous coronary intervention.\n\nGiven that the patient does not meet the second and third inclusion criteria because there is no information about him undergoing or planning to undergo invasive coronary angiography or percutaneous coronary intervention, the patient would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "995": {
        "output": "The patient in question is a 46-year-old man who presents with dizziness and frequent headaches, which could be symptomatic rather than asymptomatic. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. According to the clinical trial's inclusion criteria, participants must have asymptomatic carotid artery stenosis greater than 60%.\n\nThe patient's carotid stenosis is significant, with severe stenosis in the LICA and moderate stenosis in the RICA. However, the patient's presentation of dizziness and frequent headaches may not align with the trial's requirement of being asymptomatic. The description of the patient's condition does not explicitly state that these symptoms are directly attributable to the carotid artery stenosis, but they could potentially be related to the condition.\n\nGiven that the clinical trial is specifically focusing on asymptomatic carotid artery stenosis and the patient has reported symptoms that could be related to his carotid condition, it is uncertain if he would be considered asymptomatic as per the trial's definition. The patient does not clearly meet the trial's inclusion criteria for being asymptomatic, which is a critical factor for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "996": {
        "output": "",
        "label": 1
    },
    "997": {
        "output": "Based on the information provided in the patient note, the patient presents with symptoms of dizziness and frequent headaches and has a significant elevation in LDL-C levels, but there is no mention of familial partial lipodystrophy or any genetic testing results, specifically the R482 codon mutation of the LMNA gene which is required for inclusion in the clinical trial. \n\nWithout evidence of the patient having Familial Partial Lipodystrophy Type 2 (FPL2) with the R482 codon mutation of the LMNA gene, the patient does not meet the inclusion criteria for the clinical trial. Additionally, the patient's symptoms and clinical findings do not align with the focus of the study, which is on cortisol metabolism in individuals with a specific genetic form of lipodystrophy.\n\nTherefore, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "998": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, it appears that the patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. The inclusion criteria for the clinical trial specifically require patients with intracranial stenosis of 50% or more in the intracranial segment of the internal carotid artery and the middle cerebral artery. The patient's condition is described with measurements taken by ultrasonography of the carotid arteries, which shows extracranial, not intracranial, stenosis.\n\nSince the trial's focus is on intracranial stenosis and the patient's diagnosis is of extracranial stenosis (left and right internal carotid arteries), there is insufficient information to determine whether the patient also has the specific type of intracranial stenosis required by the trial's inclusion criteria. No information is provided about stenosis in the intracranial segment of the internal carotid artery or the middle cerebral artery, nor is there any mention of the required diagnostic methods such as transcranial doppler, computed magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA).\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "999": {
        "output": "Based on the patient note provided, the 54-year-old woman does not meet the inclusion criteria for the clinical trial described. The inclusion criteria for the trial specifically require the participant to be an HIV-positive pregnant woman or to have had a baby on or after January 1, 1998, and be receiving care at a study site during the study period.\n\nThe patient note contains no information indicating that the woman is HIV-positive, pregnant, or has given birth on or after the specified date. Instead, the patient presents with symptoms that suggest gallstones and possible cholecystitis, which are unrelated to the clinical trial's focus.\n\nTherefore, the patient does not have sufficient information to qualify for the trial, and the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1000": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain is related to gallstones and biliary sludge as revealed by the ultrasound. She has a history of hypercholesterolemia but there is no mention of lung cancer or any symptoms related to intrathoracic lung cancer.\n\nThe clinical trial in question is looking for patients with non-small cell lung cancer who have specific symptoms related to the lung cancer that can be palliated by radiation therapy. The patient does not fit the disease characteristics required for the trial as there is no mention of her having lung cancer, let alone non-small cell lung cancer. Therefore, the patient does not meet the inclusion criteria for the trial based on the disease characteristics.\n\nSince the patient does not have the target disease for the clinical trial (non-small cell lung cancer), her eligibility is assessed as 1) Not relevant because there is insufficient information to qualify her for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1001": {
        "output": "The patient note describes a 54-year-old obese woman with symptoms and diagnostic findings consistent with gallstones and biliary colic. Her medical history includes hypercholesterolemia. There is no mention of cystic fibrosis (CF) or any related symptoms or diagnostic findings such as sweat chloride levels, clinical manifestations specific to CF, or the presence of a homozygous delta F508 mutation or compound heterozygosity for the F508 mutation.\n\nThe clinical trial in question is specifically for patients with cystic fibrosis, as outlined by its inclusion criteria. Since the patient does not have a diagnosis of cystic fibrosis and none of her symptoms or history suggest CF, she does not meet the inclusion criteria of the trial.\n\nGiven the information provided in the patient note, we can conclude that the patient is not eligible for the clinical trial because she does not have cystic fibrosis, which is a fundamental requirement for inclusion in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1002": {
        "output": "To determine the patient's eligibility for the \"Lithotripsy for the Treatment of Gallstones\" clinical trial, we need to assess the information provided in the patient note against the inclusion and exclusion criteria listed for the trial.\n\nPatient Note Analysis:\n- 54-year-old woman (meets age criterion of \u2265 18 years)\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant, worse after eating fatty food\n- History of similar pain in the past (indicates a history of biliary pain)\n- Remarkable for hypercholesterolemia\n- Menopausal, does not smoke, drink alcohol, or use illicit drugs\n- Mildly febrile, elevated BP and HR, normal RR and SpO2\n- Obese, epigastric tenderness, and right upper quadrant tenderness without rebound\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm\n\nClinical Trial Inclusion Criteria:\n- History of biliary pain (patient has a history of similar pain, indicating biliary pain)\n- Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (the patient has several gallstones with the smallest being 14mm; it is unclear if there is a single stone meeting the criteria)\n- HIDA scan demonstrating patency of cystic bile duct (no information provided)\n- No cardiac pacemaker (no information provided)\n- No allergy to radioopaque dye, iodine, bile acids (no information provided)\n- No spontaneous or iatrogenic bleeding disorder (no information provided)\n- No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis (the patient's ultrasound shows CBD stones which could indicate bile duct obstruction)\n- Not pregnant (no information provided, but the patient is menopausal which suggests she is unlikely to be pregnant)\n\nBased on the information provided, the patient does have a history of biliary pain and gallstones within the size range required by the trial. However, there are several issues that need clarification:\n\n1. The presence of multiple gallstones and biliary sludge may not meet the trial's criteria for a single noncalcified, radiolucent gallstone.\n2. The patient has CBD stones, which could indicate a prior bile duct obstruction, potentially excluding her from the trial.\n3. There is no information on a HIDA scan, cardiac pacemaker status, allergy to radioopaque dye, iodine, bile acids, bleeding disorders, or pregnancy status.\n\nBecause the patient note does not provide sufficient information to definitively include or exclude the patient based on the trial's criteria, and there is a concern regarding multiple gallstones and prior bile duct obstruction, the patient would be rated as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1003": {
        "output": "Based on the patient note, the 54-year-old woman does not have a confirmed diagnosis of cancer and is not currently receiving chemotherapy. Therefore, she does not meet the primary inclusion criteria for the clinical trial on ginger for the control of chemotherapy-induced nausea and vomiting.\n\nThe inclusion criteria for the clinical trial specifically require the following:\n- Confirmed diagnosis of cancer and currently receiving chemotherapy\n- Experience of nausea and/or vomiting from a previous round of chemotherapy\n- Scheduled to receive specific antiemetic medication\n- Ability to swallow capsules\n- Ability to understand English or Spanish to complete questionnaires\n- Women of childbearing age to use appropriate birth control\n\nThe patient presented with abdominal pain, nausea, and vomiting, likely due to gallstones and not due to chemotherapy. Since the patient is not undergoing chemotherapy and does not have a confirmed diagnosis of cancer, she does not qualify for the trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1004": {
        "output": "To assess this patient's eligibility for the clinical trial titled \"Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis,\" let's compare the patient's information to the inclusion criteria of the study:\n\nInclusion Criteria:\n1. At least three of the following signs or symptoms of an acute attack of sigmoid diverticulitis must be present:\n   - Fever (body temperature > 38\u00b0C, sublingual)\n   - Abdominal tenderness\n   - Leukocytosis (leukocytes > 10,000/\u00b5l) and left shift of the differential blood count (>1% band forms)\n   - Elevated CRP (> 20 mg/l)\n2. Evidence of sigmoid diverticulitis by contrast enema\n3. CT evidence of wall thickening in the sigmoid intestine\n4. Decision in favor of conservative therapy on the basis of the case history and diagnosis\n\nPatient Information:\n- The patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting.\n- The pain is epigastric, radiates to the right upper quadrant, and worsens after eating fatty food.\n- The patient is mildly febrile with a temperature of 38.2\u00b0C and has leukocytosis with a left shift.\n- The pain has occurred twice in the past year.\n- An ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n\nFrom the patient information, we can confirm that the patient has a fever and abdominal tenderness, which are two of the four needed signs or symptoms. Leukocytosis with a left shift is also present. However, there is no mention of CRP levels. Furthermore, the provided symptoms and the ultrasound findings suggest that the patient might have gallstones and biliary issues rather than sigmoid diverticulitis. There is no mention of evidence of sigmoid diverticulitis by contrast enema or CT evidence of wall thickening in the sigmoid intestine.\n\nBased on the information given, the patient does not have a confirmed diagnosis of acute sigmoid diverticulitis, which is necessary for inclusion in the study. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1005": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the study:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain episodes in the past\n- Remarkable for hypercholesterolemia\n- No history of smoking, alcohol, or illicit drug use\n- Mild fever, elevated blood pressure, and heart rate\n- Epigastric and right upper quadrant tenderness on palpation\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones (smallest stone is 14mm)\n\nClinical Trial Inclusion Criteria:\n- Ability to give informed consent preoperatively (elective procedures only)\n- Patients at higher than normal risk of having CBD stones identified at OC, which includes:\n  - CBD stones identified at ultrasound\n  - Wide CBD (>6mm) at ultrasound\n  - Previous, recent, current cholangitis, jaundice, or biliary pancreatitis\n  - Abnormal AST and ALT levels (>2 times normal)\n\nThe patient\u2019s ultrasound has revealed several gallstones and CBD stones, which means the patient meets the criterion of having CBD stones identified at ultrasound. Additionally, the presence of gallstones and CBD stones puts the patient at a higher than normal risk of having CBD stones identified at operative cholangiography (OC). The patient note does not explicitly mention the size of the CBD, nor does it state if the patient has abnormal AST and ALT levels. However, the identification of CBD stones on ultrasound is sufficient for the trial's inclusion criteria.\n\nThe patient note does not mention any inability to give informed consent nor does it suggest that the procedure would not be elective.\n\nTherefore, based on the information provided, the patient appears to meet the clinical trial's inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1006": {
        "output": "Based on the patient note, the 54-year-old woman is obese, which is potentially relevant to a study related to weight loss. She has a history of hypercholesterolemia, which may be considered a comorbidity according to the trial's inclusion criteria. However, to accurately assess her eligibility for the clinical trial, we need to know her Body Mass Index (BMI). The inclusion criteria for the clinical trial require a BMI \u226530 and <40 kg/m^2 for subjects with no additional comorbidities, or a BMI \u226527 kg/m^2 and <40 kg/m^2 for subjects with comorbidities such as essential hypertension and/or dyslipidemia.\n\nThe patient note indicates she has hypercholesterolemia and is described as obese, so her BMI is likely to be over 27 kg/m^2. She also has an elevated blood pressure reading (150/85), suggesting the possibility of hypertension. However, without the exact BMI value, we cannot conclusively determine her eligibility. Since the patient's BMI is not provided, we do not have sufficient information to qualify her for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1007": {
        "output": "The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and a history of similar episodes in the past. She has been found to have gallstones and biliary sludge based on ultrasound imaging. The clinical trial in question is focused on the management of malignant large bowel obstruction with either colorectal stents or surgery, and is assessing the quality of life and bowel symptoms after treatment.\n\nTo assess the patient's eligibility for this trial, we must compare her situation with the inclusion criteria:\n\nInclusion Criteria for the Clinical Trial:\n- Men and women over 18 years of age\n- Presentation of large bowel obstruction based on clinical symptoms AND an imaging study\n- Clinical symptoms: one of progressive constipation, multiple small liquid bowel movements daily, abdominal distention, abdominal pain, or nausea and vomiting\n- Imaging study: one of CT scan, barium or gastrograffin enema, flexible sigmoidoscopy, or colonoscopy, showing any degree of colonic narrowing by tumor\n- Large bowel obstruction due to stage IV colorectal cancer unresectable for cure OR unresectable local-regional colorectal cancer OR unresectable extra-colonic cancer (such as gastric, ovarian, prostate, pancreatic cancers)\n- Ability to give informed consent, indicating the investigational nature of this study in keeping with the policies of Memorial Sloan-Kettering Cancer Center\n\nBased on the patient note, the woman has not been diagnosed with a large bowel obstruction, nor is there any mention of her having colorectal or other forms of cancer required by the trial criteria. Her symptoms and imaging findings suggest a diagnosis related to gallstones and possibly cholecystitis, but not large bowel obstruction or colorectal cancer.\n\nSince the patient's presentation and diagnosis do not meet the inclusion criteria of the clinical trial, which specifically requires a diagnosis of malignant large bowel obstruction and related conditions, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1008": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the clinical trial focused on tailored treatment of H. Pylori infection based on polymorphisms of CYP2C19 and 23S rRNA of H. Pylori.\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Pain worse after eating fatty food\n- Past medical history: hypercholesterolemia, 2 NVDs (Natural Vaginal Deliveries), menopausal\n- Lifestyle: no smoking, no alcohol, no illicit drugs\n- Vital signs: mild fever, elevated blood pressure, increased heart rate\n- Physical exam: epigastric and right upper quadrant tenderness\n- Laboratory: elevated ESR, leukocytosis\n- Ultrasound: gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Patients with H. pylori infection\n\nAssessment:\nThe patient's current medical condition and her symptoms (abdominal pain, nausea, vomiting) could suggest a gastrointestinal issue, but there is no information provided in the patient note about an H. pylori infection. The clinical trial specifically requires patients with an H. pylori infection. Therefore, there is not enough information to determine if the patient has H. pylori, which is the requirement for inclusion in the trial.\n\nGiven the information provided, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1009": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar episodes.\n- Past medical history includes hypercholesterolemia and 2 natural vaginal deliveries (NVDs).\n- No history of smoking, alcohol, or illicit drug use.\n- Current symptoms and laboratory findings suggest gallstones, biliary sludge, and common bile duct stones.\n- There is no mention of biliary atresia or post-Kasai operation status.\n\nClinical trial:\n- Title: Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice\n- Inclusion Criteria: Biliary atresia patients older than 1-year-old status post Kasai operation.\n\nThe patient described in the note does not have biliary atresia nor is there any indication that she has had a Kasai operation. The clinical trial specifically targets biliary atresia patients who have undergone a Kasai operation. Therefore, the patient in the note does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1010": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which is within the age range of 18 to 75 years required by the trial.\n- She has been admitted to the emergency department with abdominal pain that started 4 days ago, accompanied by nausea and vomiting.\n- The pain is epigastric, radiating to the right upper quadrant, and worsens after eating fatty food.\n- She has experienced similar pain twice in the past year, which may be indicative of recurring biliary pain.\n- The ultrasound revealed several gallstones and biliary sludge, but there is no mention of bile duct stones or bile duct dilatation.\n- The patient has not been explicitly stated to be on the waiting list for elective cholecystectomy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must be between 18 and 75 years of age.\n- They must be on the waiting list for elective cholecystectomy for symptomatic cholecystolithiasis, defined as:\n  - Presence of gallbladder stones or sludge, without bile duct stones or bile duct dilatation at ultrasonography.\n  - At least one episode of severe right upper quadrant or midline epigastric pain of at least 30 min. duration, with radiation and/or movement urge, or at least three episodes of severe right upper quadrant or midline epigastric pain of at least 30 min. duration without such radiation or movement urge, in the previous 12 months.\n\nComparing the patient note with the trial inclusion criteria:\n- The patient's age fits the criteria.\n- She has gallbladder stones and sludge, which fits the criteria.\n- She has experienced episodes of the required pain, fitting the criteria for symptomatic presentation.\n- There is no mention of bile duct stones or dilatation, fitting the criteria.\n- It is not explicitly stated that the patient is on the waiting list for elective cholecystectomy, which is a requirement for the study.\n\nGiven the information provided, the patient appears to meet the symptomatic and diagnostic criteria for the trial, but we lack the information about her being on a waiting list for elective cholecystectomy. Therefore, based on the information available:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1011": {
        "output": "Based on the provided patient note, the 54-year-old woman is presenting with symptoms and findings that are suggestive of gallbladder pathology, such as abdominal pain that worsens after eating fatty food, nausea, vomiting, epigastric and right upper quadrant tenderness, as well as ultrasound findings of gallstones and biliary sludge.\n\nThe clinical trial in question is focused on identifying patients with intestinal metaplasia of the esophagus, commonly known as Barrett's esophagus, which is a condition that can develop due to long-term acid reflux. The inclusion criteria for the trial specify that participants should have dyspeptic symptoms, upper abdominal pain, heartburn, or regurgitation, and the esophagogastroduodenoscopy (EGD) findings should be either normal-appearing gastroesophageal junction, irregular Z-line, or erosive esophagitis up to Grade 2.\n\nThe patient\u2019s current symptoms and diagnosis do not align with the inclusion criteria of the trial since her symptoms are related to gallbladder stones rather than reflux or esophageal abnormalities. There is no mention of dyspeptic symptoms specifically related to acid reflux, such as heartburn or regurgitation, nor is there any indication that the patient has had an endoscopy performed to assess for esophageal changes. Therefore, the patient does not meet the inclusion criteria for the clinical trial on esophageal metaplasia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1012": {
        "output": "After reviewing the patient note and the clinical trial information, it is clear that the patient described does not meet the inclusion criteria for the trial. The patient is a 54-year-old obese woman with abdominal pain and diagnosed gallstones, while the clinical trial is focused on children aged 0 to 3 years with biliary atresia who have undergone a Kasai portoenterostomy.\n\nSince the patient's condition and age do not align with the target population for the trial (which is specifically for biliary atresia patients aged 0 to 3 years who have had a Kasai operation), the patient is not relevant for this clinical trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1013": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient Characteristics:\n- Age: 54 years old\n- Symptoms: Abdominal pain, nausea, vomiting\n- Medical history: Hypercholesterolemia, gallstones, biliary sludge, and CBD stones\n- No mention of abdominal pain of at least 8 weeks duration or diagnosis of FD, IBS, or FD/IBS\n\nClinical Trial Inclusion Criteria:\n- Ages 8 - 17 years\n- Evaluated for abdominal pain of at least 8 weeks duration\n- Fulfilling symptom-based criteria for FD, IBS, or FD/IBS\n\nThe patient does not meet the age criterion nor is there any information to suggest she has been evaluated for abdominal pain of at least 8 weeks duration or fulfills the criteria for FD, IBS, or FD/IBS. Consequently, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1014": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient's eligibility can be assessed as follows:\n\nPatient Note Assessment:\n- The patient is a 54-year-old woman with abdominal pain, nausea, vomiting, and a history of gallstones and hypercholesterolemia.\n- There is no mention of Helicobacter pylori (H. pylori) infection in the patient's history or current symptoms.\n\nClinical Trial Inclusion Criteria:\n- Patients with H. pylori infection\n\nThe given patient note does not indicate that the patient has an H. pylori infection. Since the inclusion criteria specifically require patients to have an H. pylori infection, there is not enough information in the patient note to determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1015": {
        "output": "In this scenario, we need to compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial titled \"Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)\".\n\nInclusion criteria for the trial:\n1. Age 40 to 65 years\n2. Sedentary (exercise less than two times per week)\n3. Overweight or mildly obese (BMI 25 to 35 kg/m2)\n4. Mild to moderate lipid abnormalities (either LDL cholesterol 130 to 190 mg/dl; or HDL cholesterol < 40 mg/dl for men, or < 45 mg/dl for women)\n5. Women must be postmenopausal.\n\nExclusion criteria for the trial:\n1. Diabetes\n2. Hypertension\n3. Other metabolic or musculoskeletal diseases\n4. Current use of or intent to diet\n5. Use of confounding medications\n6. Overt presence of coronary heart disease\n7. Unwillingness to be randomized to any group.\n\nPatient characteristics:\n- 54-year-old woman (meets age criteria)\n- Obese (potential to meet BMI criteria, but actual BMI not provided)\n- Presented with abdominal pain (not relevant to exclusion criteria)\n- Past medical history is remarkable for hypercholesterolemia (this could potentially meet the lipid abnormality criteria, but specific lipid levels are not provided)\n- Postmenopausal (meets criteria)\n- Mildly febrile with elevated ESR and leukocytosis (indicative of an active infection, but not explicitly listed in exclusion criteria)\n- History of gallstones and CBD stones (not relevant to exclusion criteria)\n- No mention of current exercise habits (unclear if sedentary or not)\n- No mention of hypertension (though BP is elevated at 150/85, which could suggest hypertension, but a diagnosis is not explicitly stated)\n- No mention of diabetes or other metabolic diseases\n- No mention of current use of or intent to diet\n- No mention of use of confounding medications\n- No mention of coronary heart disease\n- No mention of unwillingness to be randomized\n\nBased on the available information, the patient is a 54-year-old postmenopausal woman with hypercholesterolemia, which could potentially meet the criteria for lipid abnormalities. However, there is not enough information to determine if she is sedentary, her exact BMI, or whether she has mild to moderate lipid abnormalities with specific cholesterol levels. Additionally, her elevated blood pressure could suggest undiagnosed hypertension, which would exclude her from the trial. Without this information, we cannot definitively determine her eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1016": {
        "output": "Based on the provided patient note and clinical trial inclusion and exclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- Presents with abdominal pain, nausea, and vomiting.\n- History of hypercholesterolemia and 2 NVDs.\n- No mention of epigastric pain/discomfort occurring at least 3 times per week for 12 weeks.\n- The ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria:\nA. Males and females of age 18-55.\nB. A diagnosis of epigastric pain/discomfort (located in the upper abdomen) rated by the patient as moderate to severe in intensity, which has been present at least 3 times per week for 12 weeks, unrelated to exercise.\nC. Other symptoms of NUD may be present but the dominant symptom must be epigastric pain/discomfort.\nD. Capable of and willing to give informed consent and comply with all study requirements.\n\nClinical Trial Exclusion Criteria:\nI. History or presence of other known organic disease that might explain the dyspepsia symptoms (e.g., symptomatic gallstones).\n\nAssessment:\n- The patient's age falls within the inclusion criteria (A).\n- There is no sufficient information provided to confirm that the patient's epigastric pain/discomfort has been present at least 3 times per week for 12 weeks and is the dominant symptom, as required by the inclusion criteria (B and C).\n- The patient has gallstones, which could explain her epigastric symptoms, and this is an exclusion criterion (I).\n\nThe patient does not meet the inclusion criteria B and C because there is insufficient information regarding the frequency and duration of her epigastric pain/discomfort, and she also meets an exclusion criterion due to her gallstones. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1017": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note Recap:\n- 54-year-old obese woman\n- Symptoms: Abdominal pain, nausea, vomiting, pain after eating fatty food\n- Past medical history: Hypercholesterolemia, 2 NVDs (normal vaginal deliveries)\n- Menopausal\n- Non-smoker, non-drinker, no illicit drug use\n- Mild fever, elevated blood pressure and heart rate\n- Epigastric and right upper quadrant tenderness\n- Elevated ESR, leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria Recap:\n- Digestive symptoms suggestive of GORD (heartburn, regurgitation, epigastric pain), or dyspeptic syndrome (nausea, belch, bloating, epigastric discomfort)\n- Need of upper GI endoscopy and pH monitoring\n- Normal propagation of oesophageal peristaltic waves (manometry < 6 months)\n- Age 18 -70 yrs\n- Signed informed consent\n- Normal coagulation\n\nEligibility Assessment:\n- The patient is within the age range required for the trial (18-70 years).\n- The patient experiences epigastric pain, which is one of the digestive symptoms suggestive of GORD.\n- The patient has nausea, which is a part of the dyspeptic syndrome symptoms listed.\n- There is no information available about whether the patient needs an upper GI endoscopy and pH monitoring, or about the propagation of oesophageal peristaltic waves from manometry results.\n- The patient's coagulation status is not provided in the note.\n\nBased on the information provided in the patient note, the patient has some of the symptoms that are suggestive of GORD (epigastric pain) and dyspeptic syndrome (nausea), which align with the main inclusion criteria of the clinical trial. However, there is not enough information to confirm the need for upper GI endoscopy and pH monitoring, the status of oesophageal peristaltic waves, or the patient's coagulation status. Without this information, we cannot conclusively determine that the patient meets all the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1018": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers,\" we must compare the patient's characteristics with the trial's inclusion criteria:\n\nInclusion criteria for the trial:\n- Male and females, 18-75 years of age.\n- Chronic renal failure with hemodialysis 3x/week for at least 6 months and adequate dialysis as judged by a nephrologist who is not a study investigator.\n- Fasting TG <600 mg/dl, LDL cholesterol <190 mg/dl (off lipid-lowering medication)\n- Willing and able to change Renagel (a noncalcemic phosphate binder) to another phosphate binder for 1 month prior to the screening visit until the completion of the study.\n- Willing and able to temporarily stop Sensipar (cinacalcet) for 1 week before the study admission until completion of the study (a total of 2 weeks).\n- Willing and able to stop ASA (except low dose ASA in patients with vascular disease), NSAID, fish oil, psyllium, other nonprescribed vitamins/supplements for 1 week prior to study until completion of study.\n- Willing and able to sign an informed consent.\n- Willing to refrain from participation in an investigational drug study for the duration of the study.\n\nPatient note summary:\n- A 54-year-old obese woman.\n- Presented with abdominal pain, nausea, vomiting, and fever.\n- Past medical history includes hypercholesterolemia, but no mention of renal failure or hemodialysis.\n- Elevated ESR and leukocytosis with a left shift.\n- Ultrasound revealed gallstones and CBD stones.\n\nBased on the information provided:\n- The patient is within the age range of 18-75 years.\n- There is no mention of the patient having chronic renal failure or being on hemodialysis, which is a key criterion for the trial.\n- Other inclusion criteria such as fasting TG, LDL cholesterol levels, and willingness to change or stop certain medications cannot be determined from the patient note, but these are secondary to the primary requirement of chronic renal failure and hemodialysis.\n\nSince the patient note does not indicate that the patient has chronic renal failure or is receiving hemodialysis treatment, the patient does not meet the primary inclusion criteria for the clinical trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1019": {
        "output": "Based on the patient note provided, the 54-year-old woman is admitted with symptoms of abdominal pain that started 4 days ago, with associated nausea and vomiting. The pain is related to eating fatty food, and she has a history of similar pain in the past. Her current condition involves gallstones and biliary sludge, as indicated by the ultrasound findings. She has a history of hypercholesterolemia and has had two normal vaginal deliveries (NVDs). There is no mention of upper abdominal discomfort, bloating, or belching following meals for at least 12 months, nor is there any indication that she has had a normal upper gastrointestinal endoscopy and/or upper GI series in the preceding three years, which are part of the inclusion criteria for the clinical trial.\n\nGiven the information in the patient note, we do not have enough evidence to determine whether she has had bothersome upper abdominal discomfort, bloating, or belching following meals for the required duration, nor do we have information about her having the necessary tests within the required timeframe. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1020": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the patient does not seem to be eligible for the trial focused on Clostridium difficile-associated diarrhea (CDAD). The patient's symptoms are related to gallstones and biliary sludge as indicated by the ultrasound results, and they are presenting with abdominal pain, nausea, and vomiting, specifically worsening after eating fatty food. There's no mention of diarrhea or a positive Clostridium difficile stool toxin assay, which are required according to the trial's inclusion criteria.\n\nTherefore, the patient does not meet the necessary inclusion criteria for the trial, which explicitly requires acute diarrhea and a positive C. difficile stool toxin assay.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1021": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility:\n\nPatient Characteristics:\n- 54-year-old woman\n- Obese\n- Admitted with abdominal pain, nausea, and vomiting\n- History of hypercholesterolemia\n- Menopausal\n- Does not smoke, drink alcohol, or use illicit drugs\n- Laboratory analysis showing elevated ESR, leukocytosis, and gallstones on ultrasound\n\nClinical Trial Inclusion Criteria:\n- Pre-menopausal women\n- History of cyclical mastalgia for each of the four months prior to study entry\n- Moderate or severe mastalgia as determined by certain criteria\n- History of regular menstrual cycles of 28 \u00b1 3 days\n\nAssessment:\nThe patient is menopausal, which directly conflicts with the requirement for the clinical trial participants to be pre-menopausal. Additionally, there is no information provided about the patient experiencing cyclical mastalgia, which is a specific condition required for the study. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1022": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstone issues. Her symptoms are related to her gallbladder and there is no mention of her having a migraine headache.\n\nThe clinical trial is looking for participants who have migraine headaches to evaluate the efficacy of octreotide versus Compazine for emergency department treatment of migraine headache.\n\nGiven the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial as there is no mention of migraine headaches. The patient's symptoms and medical history do not align with the target condition of the clinical trial, which is specifically migraine headaches.\n\nTherefore, based on the provided information, the patient would not be eligible for the clinical trial mentioned.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1023": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial with the title \"Effects of Resistance and Aerobic Exercise on Cardiovascular Health.\"\n\nPatient Information:\n- Age: 54 years old\n- Gender: Woman\n- Medical history: Abdominal pain, nausea, vomiting, hypercholesterolemia, obesity\n- Lifestyle: Sedentary not mentioned\n- BMI: Indicated as obese but exact BMI not provided\n- Lipid levels: Not provided, but hypercholesterolemia is mentioned\n\nClinical Trial Inclusion Criteria:\n- Sedentary lifestyle (exercises fewer than two times per week)\n- Overweight or mildly obese (BMI of 25 to 35 kg/m2)\n- Mild to moderate lipid abnormalities (either LDL cholesterol 130 to 190 mg/dl or HDL cholesterol less than 40 mg/dl for men or less than 45 mg/dl for women)\n\nThe patient's note indicates she is obese, which may imply that her BMI falls within the inclusion range. However, there is no specific information about her exercise habits, nor are her exact lipid levels provided. Therefore, we do not have sufficient information to determine her eligibility based on the clinical trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1024": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial provided, let's evaluate the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Abdominal pain, nausea, vomiting\n- Pain worse after eating fatty food\n- History of hypercholesterolemia\n- Two natural vaginal deliveries (NVDs)\n- Menopausal status\n- Epigastric and right upper quadrant tenderness\n- Elevated ESR and leukocytosis\n- Gallstones, biliary sludge, and CBD stones identified on ultrasound\n\nClinical Trial Summary:\n- Aimed at infants with biliary atresia undergoing the Kasai or gall-bladder Kasai procedure\n- Must start treatment within 72 hours of the operation\n- Post-conception age \u2265 36 weeks\n- Weight at enrolment \u2265 2000 gm\n- Written informed consent obtained prior to or within 72 hours of completion of portoenterostomy\n\nThe patient is a 54-year-old woman with gallstones and other related issues, while the clinical trial is focused on infants with biliary atresia following a specific surgical procedure (Kasai or gall bladder Kasai operation). The inclusion criteria for the trial clearly do not match the patient's condition; she is not an infant, does not have biliary atresia, and has not undergone the specified surgical procedure.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1025": {
        "output": "The patient described in the note is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of gallstones. She has been diagnosed with gallstones, biliary sludge, and CBD stones as per the ultrasound results. The clinical trial is a case-control study focusing on biliary tract cancers and their associated risk factors in the Shanghai population, including gallstones, diet, obesity, and other factors.\n\nTo determine the patient's eligibility for the clinical trial, we need to compare her characteristics and condition with the inclusion criteria of the trial. The inclusion criteria for the clinical trial are as follows:\n- Cases of biliary tract cancer newly diagnosed between September 1, 1996, and August 31, 1999, among residents of urban Shanghai.\n- Must be under the age of 75 at the time of diagnosis.\n\nBased on the information provided in the patient note, the patient has not been diagnosed with biliary tract cancer, and there is no indication that she is a resident of urban Shanghai or that her diagnosis (if she had cancer) would fall within the specified date range. Instead, she has been diagnosed with gallstones and CBD stones.\n\nSince the patient does not have biliary tract cancer, which is a requirement for inclusion in the study, she does not meet the inclusion criteria for the clinical trial. Therefore, her trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1026": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the study. The patient has presented with symptoms suggestive of gallstones and biliary sludge, as indicated by abdominal pain, nausea, vomiting, and the presence of gallstones and CBD stones on ultrasound. The patient's medical history includes hypercholesterolemia.\n\nThe clinical trial is specifically targeting individuals with a confirmed diagnosis of biliary atresia (BA), which is a condition that typically presents in infancy and is characterized by the blockage of bile ducts. The inclusion criteria for the trial require a confirmed diagnosis of BA, participants being over 6 months of age up to and equal to the age of 20, and either having their native liver or a confirmed liver transplantation. Additionally, informed consent is required from a parent, guardian, or participant if they are 18 years of age or older.\n\nSince the patient in the note does not have a diagnosis of biliary atresia, they do not meet the inclusion criteria for this clinical trial. Therefore, the patient is not eligible for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1027": {
        "output": "The patient in question is a 54-year-old obese woman with abdominal pain, nausea, and vomiting, which appears to be related to gallstones and biliary sludge as revealed by ultrasound. Her past medical history is notable for hypercholesterolemia. \n\nThe clinical trial in question is looking for participants with various forms of dyslipidemia, as indicated by plasma cholesterol, LDL-C, HDL-C, and triglyceride levels. Specific diagnoses that are included in the trial are familial hypercholesterolemia, familial combined hyperlipidemia, and other related conditions.\n\nTo determine the patient's eligibility for the trial, let's compare the patient note with the inclusion criteria of the clinical trial:\n\nInclusion Criteria for the Clinical Trial:\n- Children >= 2 years of age and >12 kg and adults\n- Dyslipidemia subjects of interest the group with the following conditions:\n  - Plasma cholesterol levels >200 mg/dl or <120 mg/dl\n  - Plasma LDL-C levels >130 mg/dl or <70 mg/dl\n  - Plasma HDL-C levels >70 mg/dl or <25 mg/dl\n  - Plasma triglyceride levels >150 mg/dl\n\nThe patient note indicates that the patient has a history of hypercholesterolemia, which falls under the umbrella of dyslipidemia. However, the specific lipid levels (cholesterol, LDL-C, HDL-C, and triglycerides) are not provided in the patient note. Without this information, we cannot definitively determine whether her lipid levels meet the criteria set by the trial.\n\nBased on the information provided, the patient could potentially be of interest to the trial due to her history of hypercholesterolemia, but we do not have enough information to confirm her eligibility. Therefore, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1028": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it appears that the patient does not meet the requirements for participation in the study. The study is evaluating a medication for its effects on gastrointestinal ulcers in healthy adults, while the patient is presenting with abdominal pain associated with gallstones and accompanying symptoms, which does not align with the trial's focus on osteoarthritis treatment and prevention of ulcers. Additionally, the patient's condition with elevated ESR and leukocytosis suggests an active medical issue, which contradicts the requirement for the participant to have no clinically relevant abnormalities.\n\nInclusion Criteria Analysis:\n- The patient is within the age range of 18 to 75 years.\n- The patient has a clinically relevant abnormality (gallstones and signs of infection), which disqualifies her from being considered \"healthy\" as per the trial's definition.\n- There is no information provided about the patient's use of contraception or pregnancy status, but this is largely irrelevant as she does not meet the \"healthy\" requirement.\n\nGiven that the patient is not a healthy adult due to her current medical issues, she would not be eligible for this clinical trial focused on a medication for osteoarthritis and the prevention of ulcers.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1029": {
        "output": "Based on the information provided in the patient note, the 54-year-old obese woman is presenting with symptoms indicative of gallbladder issues, such as abdominal pain, nausea, vomiting, and the presence of gallstones as identified by ultrasound. Her medical history includes hypercholesterolemia, and there is no mention of any form of leukemia or lymphoma.\n\nThe clinical trial in question is focused on treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma using combination chemotherapy. The inclusion criteria specify that patients must have newly diagnosed T-ALL or T-lineage lymphoblastic lymphoma at certain stages, and there are specific requirements regarding prior treatments and diagnostic criteria.\n\nAs the patient in the note does not have a diagnosis of T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, she does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1030": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which meets the age criterion of \u226518 years.\n- She presented with abdominal pain, nausea, vomiting, and her symptoms worsened after eating fatty food, consistent with cholelithiasis/choledocholithiasis.\n- The ultrasound revealed gallstones and common bile duct (CBD) stones, which indicates cholelithiasis/choledocholithiasis.\n- The patient's lab analysis shows leukocytosis, which could be consistent with an infection such as cholangitis, although this is not explicitly stated.\n- The patient's vital signs include a mild fever and elevated blood pressure.\n\nClinical Trial Inclusion Criteria:\n- Patients must be able to give informed consent preoperatively.\n- ASA (American Society of Anesthesiologists) physical status classification I-III.\n- Patients at high risk to have CBD stones (jaundice, cholangitis, grossly deranged LFTs, CBD stones found on US or MRCP).\n\nAlignment with Inclusion Criteria:\n- The patient's condition of having CBD stones found on ultrasound fulfills one of the clinical trial's inclusion criteria for patients at high risk to have CBD stones.\n- There is no information provided about the patient's ASA classification, but given the information provided, there are no indications that the patient would be ASA IV or above.\n- The patient's ability to give informed consent is not mentioned, but there is no indication in the patient note that she would be unable to do so.\n\nGiven the available information, the patient appears to meet the inclusion criteria for the clinical trial. There is no indication in the patient note that the patient would not be able to give informed consent or that her ASA status would exclude her from the trial. Thus, the patient seems eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1031": {
        "output": "To determine this patient's eligibility for the clinical trial, let's analyze the patient's information and the trial's inclusion and exclusion criteria:\n\nPatient information:\n- Age: 54 years old (meets the inclusion criterion of 19-65 years)\n- BMI: Described as obese, but the specific BMI value is not provided (required to be 35-65 Kg/m^2)\n- Pregnancy test: Not mentioned (should be negative on the day of the study)\n- BP: 150/85 (below the exclusion criterion of BP \u2265 160/90)\n- Temperature: 38.2\u00b0C (exceeds the exclusion criterion of > 37.5\u00b0C)\n- Medications: Not mentioned\n- Past medical history: Not mentioned in detail, but there are no explicit mentions of the exclusion conditions\n- Laboratory values: Elevated ESR and leukocytosis are mentioned, but specific laboratory exclusion criteria such as platelet count, hemoglobin level, prothrombin time, PTT, ALT, bilirubin, and estimated urinary creatinine clearance are not provided. Hematuria is not mentioned.\n\nClinical trial inclusion criteria:\n- Age 19-65 years (patient meets this criterion)\n- BMI 35-65 Kg/m^2 (patient's specific BMI is unknown)\n- Pregnancy test Negative on day of study (not mentioned for the patient)\n\nClinical trial exclusion criteria (relevant to the patient's data):\n- BP \u2265 160/90 (patient does not meet this exclusion criterion)\n- Temperature > 37.5\u00b0C (patient meets this exclusion criterion, which excludes her)\n\nBased on the provided information, the patient does not meet the trial's inclusion criteria because we do not have the patient's specific BMI. Furthermore, the patient's temperature exceeds the exclusion criterion. Therefore, the patient is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1032": {
        "output": "The patient in question is a 54-year-old obese woman who presented with abdominal pain, nausea, vomiting, and has a medical history of hypercholesterolemia and is currently experiencing an episode likely related to gallstones and biliary sludge as indicated by an ultrasound. The patient does not have any mention of taking non-steroidal anti-inflammatory drugs (NSAIDs) or presenting with dyspeptic symptoms, which are necessary conditions for inclusion in the clinical trial.\n\nThe clinical trial's inclusion criteria specify that participants must be 18 years old and older, capable of providing informed consent, and must be taking NSAIDs on a daily basis with at least a 1-week history of dyspeptic symptoms. The patient does not meet the key criteria of NSAID use and dyspeptic symptoms. Therefore, based on the available information, the patient does not qualify for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1033": {
        "output": "The patient is a 54-year-old obese woman with symptoms and investigation findings consistent with acute cholecystitis. She presents with abdominal pain in the upper right quadrant, nausea and vomiting, epigastric pain radiating to the right upper quadrant that worsens after eating fatty food, mild fever, and elevated ESR and leukocytosis. Ultrasound findings include gallstones, biliary sludge, and common bile duct stones.\n\nLet's compare the patient's information to the trial's inclusion criteria:\n\n1. Patients of age > 18 years \u2013 The patient is 54 years old, so this criterion is met.\n2. Patients with acute cholecystitis based on three of the following signs:\n   - Abdominal pain in the upper right quadrant \u2013 The patient has this symptom.\n   - Murphy's sign \u2013 This is not documented in the patient note.\n   - Leucocytosis > 10 /ml \u2013 The patient has leukocytosis with a left shift, indicating that this criterion is likely met.\n   - Rectal temperature > 38 \u00b0C \u2013 The patient's temperature is 38.2\u00b0C, meeting this criterion.\n   - Cholecystolithiasis (stones / sludge) or sonographic signs of cholecystitis \u2013 The patient's ultrasound revealed gallstones and biliary sludge, meeting this criterion.\n3. Immediate antibiotic therapy (400 mg Moxifloxacin i.v. once a day) \u2013 This is an intervention criterion; the patient note does not mention receiving this therapy, but eligibility is not dependent on having received it prior to the trial.\n4. Laparoscopic cholecystectomy possible within 24 hours after presentation of the patient \u2013 This is an intervention criterion; the patient note does not mention whether surgery is planned, but the patient's condition does not indicate that such a procedure would be impossible.\n5. Informed consent \u2013 While the patient note does not mention informed consent, it is a procedural step that would be addressed upon recruitment into the trial.\n\nBased on the available information, the patient meets the age criterion, presents with symptoms of acute cholecystitis, and has diagnostic evidence of cholecystolithiasis. The other criteria concerning interventions and informed consent are procedural and would follow the patient's agreement to participate in the trial. Since the patient meets the necessary clinical and demographic criteria and there are no indications that the patient could not undergo the interventions or provide informed consent, she appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1034": {
        "output": "Based on the patient note and the clinical trial inclusion and exclusion criteria provided, let's evaluate the patient's eligibility step by step:\n\nPatient characteristics:\n- Age: 54 years (meets age criteria 18-65)\n- Condition: Suspected functional pancreatic/biliary pain, potentially Sphincter of Oddi Dysfunction (SOD) (relevant to the study)\n- Medical history: No mention of prior cholecystectomy, which is a requirement\n- Symptom severity: At least 2 pain attacks in the previous month are mentioned, but the severity on the RAPID Start scale is not specified\n- Imaging and laboratory investigations: Ultrasound revealed gallstones, biliary sludge, and CBD stones, which may not exclude the patient as these could be structural causes for pain\n- Contraception: The patient is menopausal, so the contraception requirement is not applicable\n- Geographical accessibility: Not mentioned\n\nExclusion criteria check:\n- No history of psychosis, bipolar disorder, suicidal ideation, or significant suicide risk mentioned\n- No history of alcohol or psychoactive substance abuse or dependence mentioned\n- Abnormal Liver Function Tests: Not specified, but the presence of CBD stones might imply liver function issues\n- Known hypersensitivity to Duloxetine: Not mentioned\n- Treatment with MAOI: Not mentioned\n- Serious medical illness: The patient has hypercholesterolemia, but it's not clear if there are any cardiovascular issues or other serious illnesses\n- Uncontrolled narrow-angle glaucoma: Not mentioned\n- Acute liver injury or severe cirrhosis: Not mentioned, though liver function is in question due to CBD stones\n- Prior lack of tolerability to duloxetine: Not mentioned\n- Pregnancy and breastfeeding: The patient is menopausal, so this is not applicable\n\nThe patient appears to potentially meet some of the inclusion criteria, such as age and experiencing functional upper abdominal pain. However, the patient's note does not provide sufficient information regarding prior cholecystectomy, detailed symptom severity on the specified scale, and the absence of serious medical illnesses or abnormal liver function tests.\n\nBased on the available information, we cannot definitively exclude the patient on the grounds of the trial's exclusion criteria, but we also cannot confirm that they meet all the inclusion criteria. The patient note does not mention a prior cholecystectomy, which is a specific requirement for the trial. Additionally, the presence of gallstones and CBD stones could point to structural causes of pain, which should be excluded by standard imaging and laboratory investigations according to the inclusion criteria.\n\nTherefore, the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1035": {
        "output": "Based on the information provided, the patient in the note does not meet the inclusion criteria for the clinical trial. The trial is specifically for liver transplanted patients with a diagnosis of biliary obstruction based on endoscopic cholangiopancreaticography. The patient note describes a case of a 54-year-old woman with abdominal pain, nausea, vomiting, and gallstones, but it does not mention that the patient has had a liver transplant or has a confirmed diagnosis of biliary obstruction based on the specified diagnostic method.\n\nTherefore, this patient would not be eligible for participation in the clinical trial as described.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1036": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- The patient is admitted with abdominal pain, nausea, and vomiting.\n- The pain is related to gallstones, as indicated by the ultrasound.\n- The patient has hypercholesterolemia and is menopausal.\n\nClinical Trial Inclusion Criteria:\n- The trial is for children who have experienced at least 3 episodes of abdominal pain over a 3-month period.\n- The primary caregiver must be willing and able to complete questionnaires.\n- The child must be aged 7-17.\n- The child has lived with the primary caregiver full-time for at least the past 5 years and for at least half of his/her lifetime.\n\nThe patient in the note is a 54-year-old woman, which does not meet the age criterion of the clinical trial, which requires children aged 7-17. Furthermore, the trial is focused on Recurrent Abdominal Pain (RAP) in children, whereas the patient's abdominal pain is associated with gallstones.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1037": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for acute alcoholic pancreatitis, let's evaluate whether this patient is eligible for the trial:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presented with abdominal pain, nausea, and vomiting.\n- The pain worsens after eating fatty food, suggesting a biliary etiology.\n- She has a history of hypercholesterolemia.\n- No mention of alcohol use.\n- Elevated ESR and leukocytosis are present, indicating inflammation or infection.\n- Ultrasound revealed gallstones and common bile duct stones, which is consistent with biliary pathology.\n- No mention of serum amylase, serum CRP levels, or imaging specific to acute pancreatitis.\n\nClinical Trial Criteria Analysis:\n- The trial is seeking patients who survived their first acute alcoholic pancreatitis.\n- Required diagnostic criteria include epigastric pain, elevated serum amylase, elevated serum CRP, and imaging evidence of acute pancreatitis.\n- High alcohol consumption must be confirmed.\n- Other etiologies for pancreatitis must be excluded.\n\nFrom the information given, this patient does not clearly meet the criteria for acute alcoholic pancreatitis. There is no mention of alcohol consumption, which is a key inclusion criterion for the trial. Additionally, while the patient presents with epigastric pain, there is no indication that she has elevated serum amylase or serum CRP, nor is there any mention of imaging that confirms acute pancreatitis. Instead, her symptoms and ultrasound findings point towards gallstones and biliary pathology rather than pancreatitis.\n\nGiven that the patient's presentation does not align with the specific inclusion criteria of the trial, and there is insufficient information to confirm a diagnosis of acute alcoholic pancreatitis or high alcohol consumption, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1038": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, nausea, and vomiting. The pain is associated with the consumption of fatty food, and she has a history of similar pains. Laboratory analysis and ultrasound have confirmed the presence of gallstones and biliary sludge, indicating a likely diagnosis of gallbladder-related issues. The patient's vital signs are provided, and she is mentioned to be in the emergency department.\n\nThe clinical trial's title \"Prevention of Narcotic-Induced Nausea\" suggests that it is focused on patients who require narcotics for pain management and may experience nausea as a side effect. The inclusion criteria for the trial are:\n- Patient in Christian Care Emergency Department\n- Require intravenous narcotics for painful condition\n- \u226518 years of age\n- Able to visually rate the amount of pain and nausea\n\nThe patient note indicates that the woman is currently in the emergency department, which aligns with the first criterion of the trial. While the patient's need for intravenous narcotics is not explicitly mentioned, the severity of her condition (abdominal pain with nausea and vomiting) may infer the potential requirement for pain management that could include narcotics. She is above 18 years of age and, based on the information given, appears to have the capacity to visually rate her pain and nausea, as she has not been described to have any cognitive impairments.\n\nGiven the information provided in the patient note, the patient seems to meet the inclusion criteria for the clinical trial. However, since the patient note does not explicitly state that she requires intravenous narcotics for her condition, we cannot definitively conclude eligibility without this key piece of information. Therefore, the trial-level eligibility based on the information provided is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1039": {
        "output": "Based on the provided patient note, the 54-year-old woman presented with abdominal pain, nausea, vomiting, and was found to have gallstones and biliary sludge on ultrasound. Her medical history includes hypercholesterolemia and she is menopausal. There is no mention of any sexually transmitted disease evaluation or history, pregnancy, clinical condition suggesting immunodeficiency, history of illicit drug use, chronic viral hepatitis, unexplained or recurrent pneumonia, being a male with a history of sex with men, or trauma.\n\nThe clinical trial's inclusion criteria specify that the patient must have one of the listed conditions and be 18 years old or older. While the patient is of age, there is insufficient information in the patient note to determine if she meets any of the other specific conditions required for the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided in the note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1040": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 54-year-old woman\n- Admitted to the emergency department with abdominal pain\n- Presenting symptoms: abdominal pain, nausea, vomiting, pain after eating fatty food, fever, elevated ESR, leukocytosis, gallstones, biliary sludge, and CBD stones found on ultrasound\n\nClinical Trial Inclusion Criteria:\n- Admitted to emergency ward for abdominal pain\n- 18 years or older\n\nThe patient meets the age requirement as she is 54 years old, and she has been admitted to the emergency department for abdominal pain, which aligns with the inclusion criteria of the clinical trial.\n\nThere is no information in the patient note that would explicitly exclude the patient based on exclusion criteria for the clinical trial, as no exclusion criteria are provided. Therefore, the patient appears to be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1041": {
        "output": "In assessing the eligibility of the 54-year-old obese woman for the clinical trial on nutrition in acute pancreatitis, we need to carefully compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nLet's review the inclusion criteria for the clinical trial:\n\n1. Patients over the age of 18 years.\n2. A typical history of abdominal pain for over 24h with raised (>3-fold) serum pancreatic enzymes on admission.\n3. Severe pancreatitis, as defined by one or more of the following:\n   - The presence of organ failure (MOF) resistant to early aggressive IV fluid resuscitation as defined by a Marshall score of \u22652 in any one organ (excluding the liver component).\n   - Pancreatic necrosis >30% on CT scan or a modified CT severity index (CTSI) of \u22658.\n   - APACHE score \u2265 8.\n   - Ranson's criteria \u22653.\n\nNow, let's analyze the patient's information:\n\n- The patient is 54 years old, which satisfies the age criteria.\n- She has a history of abdominal pain for over 24 hours, with the pain worsening after eating fatty food.\n- The patient has elevated ESR and leukocytosis, which may suggest an inflammatory process, but it is not specified that she has raised serum pancreatic enzymes.\n- There is no mention of severe pancreatitis according to the Atlanta classification or any of the specific criteria such as MOF, pancreatic necrosis, APACHE score, or Ranson's criteria.\n- The patient has been diagnosed with gallstones and biliary sludge, but there is no mention of acute pancreatitis or severity as per the provided criteria.\n\nBased on the given patient note, there is insufficient information to determine whether she has acute pancreatitis, let alone severe pancreatitis as defined by the trial's inclusion criteria. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1042": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- 54-year-old obese woman\n- Chief complaint: abdominal pain with nausea and vomiting\n- Relevant medical history: hypercholesterolemia, gallstones, biliary sludge, and CBD stones\n- No mention of malignant glioma or any treatment with temozolomide\n\nClinical trial inclusion criteria:\n- Patients have recurrent/progressive Malignant Glioma (MG)\n- MG resistant to Temodar (temozolomide)\n- Age > or = to 18 years\n- Measurable enhancing disease on contrast-enhanced MRI\n- Specific intervals between prior treatments and enrollment\n- Karnofsky performance score > or = to 60 percent\n- Specific hematologic and biochemical criteria\n- Stable corticosteroid dose, if applicable\n- Signed informed consent\n- Use of contraceptives if sexually active\n\nThe patient note does not mention any history of malignant glioma or treatment with temozolomide, which are key inclusion criteria for the clinical trial. Therefore, the patient does not meet the necessary criteria to be eligible for the clinical trial focused on Temodar-resistant malignant glioma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1043": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to determine if the patient is eligible for the trial.\n\nThe patient note states:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history includes hypercholesterolemia\n- No mention of chronic acalculous cholecystitis or a HIDA scan result\n\nThe clinical trial inclusion criteria are:\n- Subjects with typical biliary pain and ejection fraction <30% on a HIDA scan\n- Must be > 18 years of age\n\nThe patient is over 18 years of age, which meets one of the inclusion criteria. However, there is no information provided about a HIDA scan or whether her ejection fraction is less than 30%. The patient's pain and ultrasound findings suggest gallstones and biliary sludge, which are not the same as chronic acalculous cholecystitis (a condition where the gallbladder must be inflamed without the presence of gallstones).\n\nWithout information on a HIDA scan or confirmation of chronic acalculous cholecystitis, we cannot conclude that the patient meets all the inclusion criteria for the trial. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1044": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial as follows:\n\nThe patient is a 54-year-old woman with abdominal pain, nausea, and vomiting, with an ultrasound revealing gallstones. Her medical history includes hypercholesterolemia and she has had 2 normal vaginal deliveries (NVDs). She is also menopausal, does not smoke, drink alcohol, or use illicit drugs. There is no mention of the patient having end-stage renal disease (ESRD) or undergoing hemodialysis (HD), which are essential inclusion criteria for the trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Male or female and aged 18 years or over;\n2. Clinical diagnosis of ESRD;\n3. Demonstrated requirement to undergo maintenance HD 3 times per week for sessions at least 3 hours in duration;\n4. Medical history consistent with IDH existing for at least 1 month;\n5. Observed symptomatic intradialytic hypotension in 3 of 6 HD sessions during screening;\n6. Provide written informed consent.\n\nThe patient does not meet several of the key inclusion criteria for the clinical trial, specifically points 2, 3, 4, and 5 regarding ESRD and intradialytic hypotension during HD sessions as she does not have a history indicating she is undergoing dialysis or has ESRD.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1045": {
        "output": "Based on the information provided, the patient is a 54-year-old woman admitted to the emergency department with non-traumatic abdominal pain and tenderness that fits the criteria outlined in the clinical trial's inclusion criteria. The pain is located in the epigastric region and radiates to the right upper quadrant, which falls within the region anterior to the mid-axillary line bilaterally, from the costal margins to the inguinal ligaments. The patient is also undergoing abdominal CT for the evaluation of this abdominal pain, as indicated by the presence of gallstones, biliary sludge, and CBD stones on ultrasound, which suggests that a CT would be a reasonable next step for further assessment.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial, which are:\n\n- Emergency department patient\n- Undergoing abdominal CT for non-traumatic abdominal pain and tenderness\n\nSince no additional exclusion criteria are provided and the patient's condition appears to be relevant for the study outlined, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1046": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old female.\n- She presents with abdominal pain, nausea, and vomiting; these symptoms are related to gallstones and biliary sludge and are not relevant to the trial's focus.\n- There is no mention of the patient having hepatitis B or being in need of hepatitis B vaccination, which the trial's vaccine targets.\n- Her medical history includes hypercholesterolemia and she is menopausal, but these are not relevant to the inclusion criteria.\n- There are no indications that she has health problems that would exclude her from vaccination trials in general.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking for healthy volunteers aged \u2265 15 years (\u2265 18 years for specific centers).\n- Participants should be free of obvious health problems, as determined by medical history and clinical examination.\n- Participants must provide written informed consent.\n- Female participants of childbearing potential must be abstinent or use adequate contraceptive precautions.\n\nGiven the information provided, the patient does not appear to meet the specific focus of the clinical trial, which is concerning the safety and immunogenicity of a hepatitis B vaccine. There is no indication that the patient is seeking a hepatitis B vaccine, nor are her current medical issues related to the study's purpose. Therefore, based on the available information, she does not fulfill the inclusion criteria for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1047": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial for the safety and immunogenicity of GSK Bio's candidate HBV-MPL vaccines, we can compare the details to determine the eligibility of the patient.\n\nPatient Characteristics:\n- 54-year-old woman\n- Obese\n- Past medical history: hypercholesterolemia\n- Current health issue: abdominal pain associated with gallstones\n- No mention of hepatitis B or vaccination requirements\n\nClinical Trial Inclusion Criteria:\n- Age: between 11 and 15 years at the time of the first vaccination\n- Free of obvious health problems as established by medical history and clinical examination before entering into the study\n- For female subjects, non-childbearing potential or following strict contraception guidelines\n\nAssessment:\n- The patient is a 54-year-old woman, which does not fit the age criterion of 11 to 15 years.\n- The patient is currently experiencing a health issue (abdominal pain associated with gallstones), which likely disqualifies her from being considered \"free of obvious health problems.\"\n\nThe patient does not meet the inclusion criteria based on age and current health status. There is no need to consider other criteria since these two points already determine the patient's ineligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1048": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer,\" we need to determine the trial-level eligibility of the patient:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- No mention of cancer or metastatic disease\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones and CBD stones\n\nClinical Trial Inclusion Criteria Summary:\n- Confirmed adenocarcinoma of the pancreas\n- Metastatic disease\n- Received \u2265 1 prior chemotherapy regimen\n- ECOG performance status 0-2 OR Karnofsky PS 60-100%\n- No known brain metastases\n- Adequate blood cell counts and organ function\n- No pregnancy\n- No history of allergic reactions to similar compounds\n- No poorly controlled hypertension or significant cardiac dysfunction\n- Ability to swallow medication\n- No uncontrolled concurrent illness\n- No other malignancy within the past 5 years (with exceptions)\n- Recovered from all prior therapy\n- Appropriate washout period since prior chemotherapy and radiotherapy\n- No ongoing adverse events due to prior treatments\n- No concurrent investigational agents or certain medications\n\nBased on the information at hand, the patient's diagnosis is not provided as metastatic pancreatic cancer or any cancer at all. Instead, the patient's symptoms and ultrasound findings suggest gallstones and biliary issues. There is no mention of previous cancer treatment, and the clinical trial specifically requires a confirmed diagnosis of metastatic pancreatic cancer and treatment with at least one prior chemotherapy regimen.\n\nWithout evidence of the required diagnosis or previous treatment for metastatic pancreatic cancer, the patient does not meet the necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1049": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient in question does not meet the eligibility requirements for the trial. The trial is focused on acute pain episodes in patients under opioid maintenance therapy, specifically requiring that participants are currently on methadone or buprenorphine and have been treated by the same drug for at least 3 months.\n\nThe patient note does not mention anything about the patient being under opioid maintenance therapy; instead, it details a case of abdominal pain likely due to gallstones, as well as the patient's medical history, which includes hypercholesterolemia and menopause.\n\nThere is no information provided that suggests the patient is undergoing opioid maintenance therapy. Therefore, we do not have sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1050": {
        "output": "",
        "label": 0
    },
    "1051": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be a match for the trial focused on Functional Dyspepsia.\n\nThe patient's symptoms are abdominal pain that radiates to the right upper quadrant, getting worse after eating fatty food, with associated nausea and vomiting. The ultrasound findings of gallstones, biliary sludge, and CBD stones suggest that the patient's symptoms are likely due to gallbladder disease rather than functional dyspepsia. Functional dyspepsia is characterized by chronic or recurrent pain or discomfort centered in the upper abdomen without an organic cause that can be found. The patient's symptoms are acute in nature, as the abdominal pain started 4 days ago, and the presence of gallstones and biliary sludge indicates an organic cause of the symptoms.\n\nThe inclusion criteria for the trial require subjects to have had symptoms for at least 6 months and to show two or more specified symptoms for at least 3 months, with post-prandial fullness, upper abdominal bloating, or early satiety being bothersome at the time of obtaining informed consent. The patient's presentation does not clearly indicate that she meets these criteria, as there is no mention of chronic symptoms over the 6-month or 3-month periods outlined in the inclusion criteria, and the bothersome symptoms mentioned are not solely related to functional dyspepsia but could be due to gallbladder disease.\n\nTherefore, the patient does not have sufficient information to qualify for the trial on the efficacy of Z-338 in subjects with Functional Dyspepsia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1052": {
        "output": "To determine the patient's trial-level eligibility for the clinical trial titled \"Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)\", we will compare the patient's characteristics and circumstances with the inclusion criteria provided for the trial.\n\nPatient Characteristics:\n- 54-year-old female\n- History of abdominal pain, nausea, and vomiting\n- Past medical history includes hypercholesterolemia\n- Non-smoker\n- Presented with symptoms suggesting gallstones and biliary sludge (possible need for surgery)\n\nClinical Trial Inclusion Criteria:\n- Age 18-65\n- Female\n- Health patient or acute illness\n- Undergoing outpatient-type general surgery, especially those associated with increased incidence of PONV such as gynecological procedures\n- Undergoing general anesthesia for the surgery\n- Receiving opioids during surgery\n- Non-smokers\n\nBased on the information provided, the patient is a 54-year-old female and a non-smoker, which fits the age and gender requirements of the trial. The patient presents with acute illness (gallstones and biliary sludge) that may require surgical intervention, potentially qualifying her for the trial if the surgery is an outpatient-type general surgery and involves general anesthesia and opioids during surgery. However, the patient note does not specify that the patient is scheduled for surgery, nor does it mention the type of surgery or anesthesia.\n\nBecause the patient note does not confirm that she is undergoing surgery or provide details about the type of surgery and anesthesia, we cannot definitively determine her eligibility. Therefore, based on the information given, the patient is categorized as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1053": {
        "output": "Based on the information provided, the patient is a 54-year-old woman who presented to the emergency department with nausea and vomiting, in addition to abdominal pain. The inclusion criteria for the clinical trial are individuals who are 18 years or older with nausea and at least one episode of vomiting in the last 12 hours presenting to the York Hospital Emergency Department.\n\nThe patient note confirms that the patient meets the age requirement (>18 years old) and has experienced nausea and vomiting. There is no indication that the patient would not meet the specified inclusion criteria for the clinical trial. However, it should be noted that the patient's nausea and vomiting are related to gallstones and biliary sludge, which might be an important consideration for the trial if the cause of nausea and vomiting is relevant to the study.\n\nSince the trial is focused on uncomplicated nausea and vomiting in the emergency department and does not specify exclusion criteria based on underlying causes, the patient appears to meet the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1054": {
        "output": "The patient described in the note is a 54-year-old obese woman with symptoms consistent with gallstone-related issues, such as abdominal pain, nausea, vomiting, and pain after eating fatty food. The ultrasound confirmed the presence of gallstones, biliary sludge, and common bile duct stones. There is no mention of pelvic inflammatory disease (PID) or tubo-ovarian abscess (TOA) in her condition.\n\nThe clinical trial in question is looking for women admitted to the emergency department with PID or TOA between 1995 and 2000. Since the patient does not have a diagnosis of PID or TOA and there is no indication that the events described occurred within the specified time frame, she does not meet the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for the given patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1055": {
        "output": "Based on the provided information:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and a history of similar pain related to gallstones. She has hypercholesterolemia and is menopausal.\n\nThe clinical trial is looking for subjects with lateral epicondylitis (tennis elbow) and requires that symptoms have started no more than 12 weeks prior to study entry. Additionally, female patients of childbearing potential must agree to use a medically accepted form of birth control.\n\nThe patient's medical condition (abdominal pain and gallstones) does not match the target condition of the clinical trial (lateral epicondylitis). Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1056": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain exacerbated by fatty food\n- History of similar pain in the past\n- Past medical history includes hypercholesterolemia\n- No history of smoking, drinking alcohol, or using illicit drugs\n- Vital signs indicate mild fever, elevated blood pressure, and increased heart rate\n- Clinical signs of epigastric and right upper quadrant tenderness\n- Laboratory findings include elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones\n\nClinical Trial Summary:\n- Investigating preoperative biliary drainage for resectable hilar cholangiocarcinoma\n\nInclusion Criteria for the Trial:\n- Newly diagnosed patients\n- Patients with resectable hilar cholangiocarcinoma\n- Total bilirubin (TB) > 85\u03bcmol/L\n- White blood cell (WBC) count more than 1.5\u00d710^9/L\n- Platelet (PLT) count more than 100\u00d710^9/L\n- Hemoglobin (HB) account more than 100g/L\n- No serious disease in heart, lung, and kidney\n- Written informed consent\n\nAssessment:\nThe patient's diagnosis from the patient note is related to gallstones and biliary sludge, not hilar cholangiocarcinoma. While there are some similarities in the region of the disease (biliary system), the patient has not been diagnosed with hilar cholangiocarcinoma, which is a specific type of cancer and the focus of the clinical trial. Additionally, there is no information provided about the patient's total bilirubin levels, WBC, PLT, and HB, which are specific inclusion criteria for the trial. There is also no mention of the status of the patient's heart, lung, and kidney health.\n\nGiven the information presented, the patient does not meet the inclusion criteria for the clinical trial, as they have not been diagnosed with hilar cholangiocarcinoma, nor do we have sufficient information on their lab values or general health status regarding the required criteria. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1057": {
        "output": "Based on the provided patient note and the clinical trial information, the patient does not meet the inclusion criteria for the clinical trial. The inclusion criteria specify that the trial is for children aged 1 to 18 years who present with acute abdominal pain and signs of peritoneal irritation of less than 5 days duration. The patient in the note is a 54-year-old woman, which is outside of the age range specified for the trial participants. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1058": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. Her medical history includes hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs). She is menopausal and does not meet the criteria of being pregnant or in the first 12 weeks of gestation, as required by the clinical trial's inclusion criteria.\n\nThe clinical trial is focused on the effects of thiamine on nausea and vomiting in pregnancy, specifically in women who are until the 12th week of gestation and who have not yet received thiamine. Since the patient is not pregnant, she does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1059": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Early Versus Delayed Surgery for Gallstone Pancreatitis,\" we need to compare the patient's medical information with the trial's inclusion criteria.\n\nPatient Note Assessment:\n- The patient is a 54-year-old woman, which fits the age criterion of 18 to 100 years old.\n- The patient presents with upper abdominal pain, nausea, vomiting, and epigastric tenderness, which aligns with the symptoms required for gallstone pancreatitis.\n- There is no mention of ethanol abuse in the patient's history.\n- The patient has an ultrasound confirming the presence of gallstones.\n- The diagnosis of gallstone pancreatitis is not explicitly stated; however, the symptoms and presence of gallstones suggest this diagnosis.\n\nHowever, we do not have information on the following:\n- The patient's amylase and lipase levels, which need to be elevated according to the inclusion criteria.\n- The presence of fewer than three Ranson's criteria on admission.\n- Clinical stability with admission to a non-monitored ward bed.\n- Absence of acute cholangitis (the patient has a mild fever, but not >38.6\u00b0C, and there's no mention of significant hyperbilirubinemia).\n- Low suspicion for a retained CBD stone (no bilirubin levels are provided).\n\nBased on the information given, we cannot confirm the patient's eligibility for the trial because key laboratory values and detailed clinical criteria are not provided. The patient's presentation is consistent with gallstone pancreatitis, but without the specific diagnostic criteria outlined in the trial's inclusion criteria, we cannot definitively include her.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1060": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 54-year-old obese woman with a history of gallstones and cholelithiasis attacks, which fits the \"Attacks of cholelithiasis\" inclusion criterion of the trial. However, the patient is also described as obese, and the inclusion criterion for the trial specifies a Body Mass Index (BMI) of less than 30. While the exact BMI is not provided in the patient note, the term \"obese\" implies a BMI of 30 or higher, which would not meet the trial's inclusion criterion.\n\nTherefore, the patient does not meet all the inclusion criteria required for the clinical trial on \"Pain in Single Incision Laparoscopic Surgery Cholecystectomy\" due to the BMI requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1061": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, here's the analysis:\n\nPatient characteristics:\n- 54-year-old woman\n- Presents with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- History of similar pain\n- Remarkable for hypercholesterolemia\n- Menopausal\n- Non-smoker, non-alcoholic, no illicit drug use\n- Mild fever, high blood pressure, elevated heart rate\n- Laboratory analysis shows elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones\n\nClinical trial inclusion criteria:\n- Age older than 15 years\n- Elective surgery\n- Normal intraoperative cholangiography\n- Normal preoperative serum amylase and lipase values\n\nThe patient is over 15 years of age and may potentially require elective surgery given the diagnosis of gallstones and biliary sludge. However, the patient has not undergone surgery yet, nor is there information about her undergoing elective surgery specifically for the purpose of the study. Additionally, there is no information provided about her serum amylase and lipase values being normal, which is a requirement for the trial. Therefore, based on the lack of information regarding elective surgery status and normal serum amylase and lipase values, the patient does not meet enough of the inclusion criteria to determine eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1062": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess,\" we need to compare the patient's characteristics and condition with the inclusion criteria for the trial. \n\nPatient characteristics and condition based on the provided note:\n- 54-year-old woman (meets the age requirement of \u2265 20 years)\n- Presented with abdominal pain, nausea, and vomiting (could be consistent with symptoms of a liver abscess)\n- Elevated ESR and leukocytosis (indicates infection, which is consistent with liver abscess)\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones (the presence of stones needs to be considered regarding inclusion criteria)\n- No mention of a CT scan or a confirmed diagnosis of liver abscess\n\nInclusion criteria for the trial:\n- Age \u2265 20 years (patient meets this criterion)\n- Clinical diagnosis of liver abscess, supported by an abdominal CT scan (patient has not had a CT scan to confirm liver abscess, only ultrasound)\n- Absence of biliary tract stones (except for gallstones without biliary tract dilatation), biliary tract dilatation, and biliary tract tumors (patient has gallstones and CBD stones, which may be a concern)\n- Read, understood, and signed informed consent form (not applicable for this assessment)\n\nBased on the information provided, the patient has not been confirmed to have a liver abscess via a CT scan, which is a requirement for inclusion. Additionally, the patient has CBD stones, and it is unclear if there is biliary tract dilatation or not. Therefore, the patient does not have sufficient information to qualify for the trial based on the current diagnosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1063": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)\", we need to assess whether the patient is eligible for the trial.\n\nPatient note summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- No history of smoking, drinking alcohol, or drug use\n- Elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical trial inclusion criteria:\n- Angina pectoris or equivalent acute symptoms\n- ECG change suggestive for ischemia\n- Elevated troponin T level > 0.01 ng/ml\n- Risk factors for ACS\n\nThe patient in the note presents with abdominal pain that is associated with eating fatty food, which is more indicative of gallbladder disease such as cholecystitis or gallstones rather than acute coronary syndrome (ACS). The patient's symptoms do not clearly align with the typical presentation of angina pectoris or equivalent acute symptoms mentioned in the inclusion criteria. There is no mention of ECG changes or elevated troponin T levels, which are required to diagnose ACS.\n\nFurthermore, while the patient does have a risk factor for ACS (hypercholesterolemia), the other necessary criteria to qualify for the trial, such as symptoms and diagnostic test results indicative of ACS, are not present in the patient note.\n\nTherefore, based on the available information, the patient does not have sufficient evidence of ACS to meet the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1064": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria of the trial:\n\nPatient Note Analysis:\n- Patient is a 54-year-old woman, which fits the age criterion of >25 and <65 years.\n- The patient is postmenopausal, meeting the criterion regarding reproductive status.\n- She is presenting with symptoms and ultrasound findings consistent with biliary disease requiring cholecystectomy, which fits the diagnosis criterion.\n- No information is provided regarding the American Society of Anesthesiology (ASA) Class, which is required to be I or II for inclusion.\n- The patient's ability to understand and willingness to sign an informed consent document is not mentioned, but this is typically assessed during the consent process.\n\nClinical Trial Inclusion Criteria:\n- Females who are postmenopausal or who no longer wish to bear children (the patient is postmenopausal)\n- Females >25 years old and <65 years old (the patient is 54 years old)\n- Diagnosis of biliary disease requiring cholecystectomy (the patient has gallstones, biliary sludge, and CBD stones, indicating a need for cholecystectomy)\n- American Society of Anesthesiology (ASA) Class I or II (not specified in the patient note)\n- Females who are able to understand and willing to sign an informed consent document (not specified in the patient note)\n\nBased on the information provided in the patient note, the patient meets most of the stated inclusion criteria except for the ASA class and confirmation of willingness to sign informed consent, which are not addressed in the note. However, since these are typically assessed in person during the recruitment process, the lack of this information in the patient note does not automatically exclude the patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1065": {
        "output": "",
        "label": 0
    },
    "1066": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, it is clear that the patient does not meet the necessary conditions for participation in the trial. The patient has been admitted with symptoms associated with gallstones, not multiple myeloma. The clinical trial is specifically for participants with relapsed and/or refractory multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.\n\nThe patient note does not mention multiple myeloma or any history of cancer treatment, which are both requirements for the trial. Instead, the patient's symptoms and ultrasound findings suggest a diagnosis more likely related to gallbladder disease. Furthermore, the patient's ECOG performance status is not mentioned, and there is no indication that the patient has measurable disease relevant to multiple myeloma.\n\nTherefore, based on the information provided in the patient note:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1067": {
        "output": "Based on the provided patient note, let's evaluate the patient's eligibility according to the inclusion criteria of the clinical trial:\n\nInclusion Criteria for the clinical trial:\n1. Female - The patient is female.\n2. At least 18 years of age - The patient is 54 years old.\n3. Non-smoking - The patient does not smoke.\n4. At high risk for PONV - This information is not provided in the patient note, but as she is presenting with nausea and vomiting, it could be inferred that she might be at risk.\n5. Obese with a BMI of at least 45 kg/m^2 - The patient is described as obese, but the exact BMI is not provided.\n6. Undergoing upper gastrointestinal surgery requiring postoperative opioid analgesia - The patient has symptoms (abdominal pain, gallstones) that might necessitate surgery, but it is not confirmed if she will undergo surgery and whether it will require postoperative opioid analgesia.\n\nThe patient note does not contain sufficient information to determine if the patient is at high risk for PONV, her exact BMI, or if she is scheduled for upper gastrointestinal surgery requiring postoperative opioid analgesia. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1068": {
        "output": "Based on the patient note, the 54-year-old woman presents with abdominal pain, nausea, vomiting, and a history of similar pain. The pain is associated with eating fatty food and there are findings of gallstones and biliary sludge on an ultrasound, which suggests an organic disease likely to explain her symptoms. The clinical trial in question is seeking participants with functional dyspepsia (FD) and explicitly requires an absence of organic disease that could explain the symptoms.\n\nThe patient's symptoms and ultrasound findings are indicative of gallbladder pathology, likely cholecystitis or biliary colic, rather than functional dyspepsia. Since one of the inclusion criteria for the trial is the absence of organic disease likely to explain the symptoms, and the patient shows evidence of organic disease (gallstones and biliary sludge), she would not be eligible for this clinical trial.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1069": {
        "output": "Given the patient note and the clinical trial information, let's evaluate the eligibility of the patient for the trial:\n\nPatient Note Analysis:\n- 54-year-old woman (meets the age criteria of \u226518 years)\n- Currently experiencing abdominal pain, nausea, and vomiting\n- Has a medical history of hypercholesterolemia, but no mention of previous surgical operations or anesthesia\n- No mention of PONV history or motion sickness susceptibility\n- Non-smoking status (absence of information regarding smoking, assumed non-smoker)\n- No information provided about planned surgeries or anesthesia\n- Female of childbearing potential is defined as post-menopausal (meets criteria as she is menopausal)\n\nClinical Trial Inclusion Criteria Analysis:\n- Male or female \u226518 years of age (patient meets this criterion)\n- ASA physical status 1 to 3 (no ASA status provided for the patient)\n- Presence of at least 2 PONV risk factors (patient is female and non-smoking; however, no information on history of PONV or motion sickness)\n- Outpatient undergoing elective laparoscopic gynecological or abdominal surgery (no information on the patient undergoing such surgery)\n- Surgery for which anesthesia is expected to last at least 30 minutes (no information on the patient undergoing such surgery)\n- General endotracheal anesthesia conducted (no information on the patient undergoing such anesthesia)\n- If a subject has a known hepatic, renal or cardiovascular impairment, enrollment is at the Investigator's discretion (no relevant information provided)\n- If a subject has or may develop prolongation of cardiac conduction intervals, enrollment is at the Investigator's discretion (no relevant information provided)\n- If a subject is female of childbearing potential, she must be using reliable contraceptive measures and have a negative pregnancy test prior to surgery (the patient is post-menopausal so this is not applicable)\n\nBased on the available information, the patient does not appear to be currently scheduled for surgery, especially not elective laparoscopic gynecological or abdominal surgery, which is a specific requirement for this clinical trial. Without this information, we cannot determine that the patient meets enough of the inclusion criteria to be considered for the clinical trial. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1070": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility.\n\nThe trial is focused on patients with relapsed esophageal cancer or stomach cancer and outlines specific criteria for inclusion:\n\n- Histologically confirmed adenocarcinoma of the esophagus or stomach, including adenocarcinoma of the esophagogastric junction.\n- Advanced disease not amenable to curative treatment.\n- Documented progressive disease while receiving or within 6 months of completion of first-line chemotherapy with platinum and fluoropyrimidine-based therapy.\n- No cerebral or leptomeningeal metastasis.\n- ECOG performance status 0-2.\n- Life expectancy \u2265 12 weeks.\n- Adequate blood counts and organ function.\n- No prior chemotherapy with taxanes.\n- No significant peripheral neuropathy.\n- No prior malignancy except for specific non-invasive cancers.\n- No serious uncontrolled illness or medical/psychiatric condition that would preclude informed consent.\n\nThe patient described in the note is a 54-year-old woman with symptoms indicating gallbladder issues (gallstones, biliary sludge, and CBD stones) and no mention of esophageal or stomach cancer. The symptoms and medical history provided do not align with the cancer-related inclusion criteria specified by the trial.\n\nGiven this information, the patient does not meet the disease characteristic criteria for the clinical trial, which is centered on patients with esophageal or stomach cancer. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1071": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting due to gallstones and biliary sludge. She does not have a terminal diagnosis with an estimated survival of 6 months or less, which is one of the inclusion criteria for the clinical trial.\n\nHere are the points from the trial inclusion criteria to consider:\n\n1. Patient must be at least 18 years old. - This criterion is met; the patient is 54 years old.\n2. Patient must have a terminal diagnosis, with estimated survival of 6 months or less. - This criterion is not met as there is no indication that the patient has a terminal diagnosis.\n3. Patients must have nausea and/or vomiting, not relieved with 1 or more anti-nausea medications. - While the patient does have nausea and vomiting, there is no information to suggest that these symptoms are not relieved by anti-nausea medications or that she has tried any.\n4. Patient's medications must be reviewed. - There is no information on the patient's medication review.\n5. Patient must be able to understand and sign informed consent. - There is no information regarding the patient's ability to understand and consent.\n6. Patients who have a bowel obstruction that will not be relieved by surgery may be enrolled. - There is no indication that the patient has a bowel obstruction.\n\nSince the patient does not have a terminal diagnosis, she would not be eligible for this trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1072": {
        "output": "",
        "label": 0
    },
    "1073": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nPatient Characteristics:\n- Age: 54 years old\n- Health status: The patient presents with abdominal pain, nausea, vomiting, febrile, and signs consistent with gallstones and biliary sludge on ultrasound.\n- Medications and other factors: No information on current medications is given, but the patient has hypercholesterolemia and a history of two natural vaginal deliveries (NVDs). The patient does not smoke, drink alcohol, or use illicit drugs.\n\nClinical Trial Inclusion Criteria:\n1. Signed and dated informed consent prior to participation.\n2. Subjects in good health as determined by the Investigator.\n3. Age 18-55.\n4. Willing to abstain from any physical therapy, hard physical work, exercise, or sauna during the study observation period (Screening to Final Visit).\n5. For females of childbearing potential, must be using appropriate birth control. If surgically sterile, they are allowed for participation.\n\nComparison:\n- The patient's age falls within the trial's age range.\n- However, the patient is not in good health as determined by the Investigator, due to the current presentation of abdominal pain and related symptoms.\n- There is no information provided on the patient's willingness to abstain from physical therapy, hard physical work, exercise, or sauna use.\n- There is no need to assess birth control methods as the patient is menopausal.\n\nGiven the information, the patient does not meet the inclusion criterion number 2 regarding the health status. Therefore, the patient is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1074": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of gallstones, hypercholesterolemia, and two normal vaginal deliveries (NVDs). There is no mention of HIV, hepatitis B or C co-infection, liver failure, or liver transplantation. The clinical trial is assessing the pharmacokinetics of Raltegravir in patients with end stage liver disease or post liver transplantation.\n\nTo determine the patient's eligibility for the clinical trial, let's compare the patient's characteristics with the inclusion criteria:\n\nInclusion Criteria for the Clinical Trial:\n1. Age \u2265 18 - The patient is 54 years old, so this criterion is met.\n2. Documented HIV-1 infection, hepatitis B or C co-infection is allowed - There is no information in the patient note about an HIV-1 infection or hepatitis B/C co-infection.\n3. Plasma viral load at screening visit below 50 copies per mL for at least 6 months - There is no information provided on viral load.\n4. Patient with severe liver failure for taking part into period 1 - The patient has not been described as having liver failure.\n5. Patient eligible for the liver transplant waiting list or immediate post transplantation for taking part into period 2 - The patient is not described as being on a liver transplant waiting list or post liver transplant.\n6. Abstinence from alcohol intake for at least 6 months (WHO norm) - There is no information on the patient's alcohol intake history.\n7. Withdrawal from intravenous drug use for at least 6 months (methadone substitution is permitted) - There is no information on intravenous drug use.\n8. No ongoing class C opportunistic infection (1993 CDC classification) - There is no information on opportunistic infections.\n9. Clinical and immunovirological condition allows certain HIV treatments - There is no information regarding HIV treatment.\n10. HIV population does not present a profile of mutations associated with resistance to raltegravir - There is no information on HIV genotype or resistance.\n11. Patient not having experienced viral escape during treatment with certain HIV medications - There is no information on this.\n12. Patient registered with or covered by a social security scheme - There is no information on this.\n13. For women of child-bearing potential, use of a barrier contraceptive method during sexual intercourse and negative pregnancy test at screening visit - The patient is menopausal, so this criterion doesn't apply.\n14. Informed consent form signed at screening visit at the latest - There is no information on consent.\n\nBased on the information provided in the patient note, the patient does not meet the specific inclusion criteria for documented HIV-1 infection, liver failure, or liver transplantation status, which are necessary to qualify for the clinical trial. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1075": {
        "output": "Given the information in the patient note and the clinical trial inclusion criteria, the patient does not appear to meet the inclusion criteria for the clinical trial. The trial is assessing vaccine responses to influenza A(H1N1) in high-risk patients, and the inclusion criteria are:\n\n1. Medically recommended influenza A(H1N1) immunization\n2. Signed informed consent\n\nThe patient note describes a 54-year-old woman with symptoms suggestive of gallstone-related issues (such as abdominal pain, nausea, vomiting, and findings of gallstones on ultrasound) and does not mention influenza A(H1N1) or any recommendations for this patient to receive an influenza A(H1N1) immunization. Therefore, with the information provided, there is not sufficient evidence that this patient would be eligible for the influenza A(H1N1) vaccine response trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1076": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and a clinical picture suggesting gallbladder disease (gallstones, biliary sludge, and CBD stones). Her medical history includes hypercholesterolemia. There is no mention of any psychotic symptoms or diagnoses related to schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS.\n\nSince the clinical trial in question is focused on the efficacy and safety of aripiprazole in patients with a first episode of psychosis and the patient does not meet the DSM-IV diagnostic criteria for any of the psychotic disorders mentioned in the inclusion criteria, she would not be eligible for this trial.\n\nTherefore, the assessment of eligibility for this patient with respect to the provided clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1077": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of gallstones, hypercholesterolemia, and menopause.\n- No mention of melanoma or any type of cancer.\n\nClinical Trial Inclusion Criteria:\n- Locally advanced or metastatic melanoma that is measurable, histologically or cytologically confirmed, and surgically incurable.\n- HLA-A2 positive and tumors that present HLA-A2.1/p53aa264-272 complexes.\n- No prior systemic cytotoxic chemotherapy for melanoma.\n- Life expectancy > 3 months, ECOG performance status 0 or 1.\n- Specific requirements for bone marrow reserve, renal function, hepatic function, cardiovascular and pulmonary health, and other general health conditions.\n\nThe patient's medical history and symptoms do not mention melanoma or any type of cancer. The clinical trial is specifically looking for patients with metastatic melanoma, which the patient does not have. Therefore, the patient does not meet the disease characteristics required for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1078": {
        "output": "Based on the information provided, the patient in question is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and other symptoms consistent with gallstone-related issues, as evidenced by the ultrasound findings of gallstones, biliary sludge, and CBD stones. Her condition with gallstones and associated symptoms does not align with a diagnosis of functional dyspepsia, for which the clinical trial is focused.\n\nThe inclusion criteria for the clinical trial are:\n\n- Dyspeptic adult outpatients\n- Characteristic dyspeptic symptoms according to Rome III criteria (bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning)\n- Upper gastrointestinal endoscopy excluding structural diseases\n\nThe patient does not meet these criteria since she has structural diseases (gallstones and CBD stones) that explain her symptoms, and there is no mention of an upper gastrointestinal endoscopy being performed to exclude other structural diseases. Moreover, her symptoms are more indicative of gallbladder pathology rather than functional dyspepsia. Without evidence of functional dyspepsia according to Rome III criteria and given the presence of structural diseases, she does not qualify for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1079": {
        "output": "Upon reviewing the patient's information and comparing it to the inclusion and exclusion criteria of the clinical trial for eosinophilic esophagitis (EoE), we can determine the trial-level eligibility as follows:\n\nThe patient is a 54-year-old woman, which falls within the age range required by the trial (12-76 years). However, her symptoms and medical history suggest she is experiencing gallstones, biliary sludge, and CBD stones, with accompanying abdominal pain, nausea, and vomiting. There is no indication in the patient\u2019s note that she has been diagnosed with eosinophilic esophagitis or exhibits the specific symptoms associated with EoE such as dysphagia or heartburn, nor is there any mention of eosinophils >15/high power field in the distal esophagus.\n\nMoreover, the clinical trial specifies that the patients included must have an established diagnosis of eosinophilic esophagitis, which the patient note does not indicate. The patient also does not meet any of the other specific inclusion criteria related to EoE treatment history or symptoms.\n\nBased on the information given in the patient note, there is not enough evidence to suggest that this patient has eosinophilic esophagitis or that she would be a candidate for a trial focused on EoE and the treatment with Omalizumab. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1080": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nThe patient is a 54-year-old obese woman admitted with abdominal pain, nausea, and vomiting, suspected to be related to gallstones. Her medical history includes hypercholesterolemia, and she is menopausal.\n\nThe clinical trial is focused on comparing the success rate of cannulation between the Accuvein apparatus and standard technique in patients undergoing elective surgery or similar procedures who do not have existing intravenous access.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Infants and children under 18 years of age.\n- American Society of Anesthesiologist (ASA) Physical Status I, II, or III.\n- Patients undergoing elective surgery, examination under anesthesia, or MRI who do not have existing intravenous access.\n- Able to understand English.\n- Parent/guardian willing to sign consent.\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial for the following reasons:\n- The patient is 54 years old, which is above the age limit of 18 years set by the trial.\n- The patient is not described as undergoing elective surgery, examination under anesthesia, or MRI.\n- The trial is specifically targeted at infants and children, which the patient is not.\n\nTherefore, the patient is not eligible for the clinical trial based on the age requirement and the nature of the patient's current medical needs as described in the note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1081": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient appears to be eligible for the clinical trial. The patient has been diagnosed with gallstones and common bile duct (CBD) stones, as evidenced by the ultrasound findings. The clinical trial is looking for patients with gallstones and CBD stones. There is no additional information provided that would exclude the patient from the trial based on the given inclusion criteria.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1082": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 54-year-old woman.\n- There is no mention of HIV-1 infection.\n- The patient's current medical issues are related to abdominal pain, likely due to gallstones, and not related to HIV treatment.\n- There is no information provided regarding the patient being treated with Kaletra\u00ae or any novel antiretroviral therapy.\n  \nClinical Trial Inclusion Criteria:\n- Patients \u2265 18 years of age\n- Written informed consent\n- HIV-1 infection\n- Patients treated with Kaletra\u00ae\n- Patients treated with novel antiretroviral therapy (for at least 8 weeks)\n\nThe patient in the note does not have an HIV-1 infection (or at least it is not mentioned), nor is there any indication that they are being treated with Kaletra\u00ae or any novel antiretroviral therapy. Therefore, based on the information given in the patient note, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1083": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who presented to the emergency department with abdominal pain that started 4 days ago, accompanied by nausea and vomiting. The pain, which radiates to the right upper quadrant and worsens after eating fatty food, is consistent with the symptom of acute right side abdominal pain as mentioned in the inclusion criteria of the clinical trial.\n\nThe clinical trial \"Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)\" has the following inclusion criteria:\n\n1. Acute right side abdominal pain\n2. Willing to participate in the study\n\nThe patient note indicates that she experiences acute right side abdominal pain, which aligns with the first inclusion criterion. There is no information regarding her willingness to participate in the study, but for the sake of this eligibility assessment, we will assume that if the patient were to be informed about the trial, she could express her willingness to participate.\n\nTherefore, based on the information available and the assumptions made, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1084": {
        "output": "The patient described in the note is a 54-year-old woman who presents with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She has gallstones and biliary sludge indicated by an ultrasound. Her condition seems to be related to gallbladder issues and not to low back pain or radiculopathy. \n\nThe clinical trial is focused on patients with low back pain, with or without radiculopathy, who are scheduled for epiduroscopy assisted epidural neurolysis. The patient in the note does not mention having low back pain, radiculopathy, or being scheduled for the mentioned procedure.\n\nGiven the information from the patient note and the inclusion criteria for the clinical trial, the patient does not meet the necessary criteria for the study, as there is no indication she has low back pain or is scheduled for the specific procedure required for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1085": {
        "output": "Given the patient's note and the inclusion criteria of the clinical trial for NAFLD and NASH, let's evaluate the patient's eligibility:\n\nPatient note:\n- Patient is a 54-year-old woman (within the age range of 18 to 70 years).\n- Presented with abdominal pain and has findings on ultrasound suggestive of gallstones, biliary sludge, and CBD stones.\n\nClinical trial inclusion criteria:\n- Patients 18 to 70 years of age (the patient meets this criterion).\n- Recruited from the Primary Care Clinics or the Gastroenterology Clinic (the patient was admitted to the emergency department, but this does not necessarily exclude her from being recruited).\n- After completing a baseline questionnaire, all patients had a right upper quadrant ultrasound (the patient had an ultrasound, but there is no mention of NAFLD or NASH).\n\nIn this scenario, the patient does not have a confirmed diagnosis of NAFLD or NASH, which seems to be a requirement for the clinical trial. The ultrasound revealed gallstones and biliary sludge, but there is no indication that a fatty liver was identified, which is a prerequisite for further laboratory data and liver biopsy within the context of the trial.\n\nTherefore, based on the provided information, there is not enough evidence to confirm that the patient meets the specific inclusion criteria for the clinical trial focused on NAFLD and NASH. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1086": {
        "output": "The patient in question is a 54-year-old obese woman with abdominal pain that started 4 days ago, associated with nausea and vomiting. The pain worsens after eating fatty food, and she has had similar incidences in the past. Her medical history includes hypercholesterolemia. She is febrile and has elevated ESR and leukocytosis, and her ultrasound revealed gallstones and biliary sludge.\n\nThe clinical trial in question is studying the use of morphine in elderly patients with acute abdominal pain (UAP) of less than 48 hours' duration. The inclusion criteria specify that participants need to be 65 years or older and report non-traumatic UAP with a specified pain intensity.\n\nBased on the information provided, the patient does not meet the age criterion specified in the inclusion criteria of the clinical trial. Since the inclusion criteria require participants to be 65 years or older, the 54-year-old patient does not qualify for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1087": {
        "output": "",
        "label": 0
    },
    "1088": {
        "output": "",
        "label": 0
    },
    "1089": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman with symptoms suggestive of biliary colic, likely secondary to gallstones as indicated by the ultrasound findings. She has presented with abdominal pain, nausea, vomiting, and radiological evidence of gallstones and biliary sludge.\n\nThe clinical trial in question is focused on patients with biliary anastomotic stenosis after orthotopic liver transplantation (OLT). The inclusion criteria for the trial are:\n\n1. Post-OLT biliary anastomotic stenosis (at least 1 month post-operative)\n2. Jaundice, cholestasis and/or biliary tree dilation on ultrasound\n\nThe patient in the note does not mention having undergone orthotopic liver transplantation, nor does the note refer to biliary anastomotic stenosis. Instead, the patient's symptoms and ultrasound findings are suggestive of gallstones and common bile duct stones, which are not related to the post-transplant complications the trial is investigating.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial as she does not have a history of liver transplantation or the specific condition of biliary anastomotic stenosis post-OLT.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1090": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and pain that worsens after eating fatty food. The pain radiates from the epigastric region to the right upper quadrant. She has a history of similar pain previously, is febrile, and has elevated ESR and leukocytosis. An ultrasound revealed gallstones, biliary sludge, and CBD stones. This patient scenario suggests she may be suffering from gallstones and possible cholecystitis or choledocholithiasis.\n\nThe clinical trial in question is looking to assess the safety and efficacy of Mucosta (Rebamipide), in combination with Omeprazole, as adjuvant therapy in Gastric Ulcer Patients. To qualify for the trial, patients must have dyspepsia or epigastric pain and endoscopically proven gastric and duodenal ulcers. They must also meet certain laboratory parameter requirements and be over the age of 18, along with having signed an informed consent form.\n\nBased on the information in the patient note, there is no mention of endoscopically proven gastric or duodenal ulcers; rather, the symptoms and findings suggest gallbladder-related issues. Therefore, we do not have sufficient information to determine if this patient has a gastric or duodenal ulcer, which is required for inclusion in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1091": {
        "output": "The patient in the note is a 54-year-old obese woman presenting with abdominal pain that is likely due to gallstones and biliary sludge as indicated by the ultrasound. Her medical history includes hypercholesterolemia, and she has a history of two natural vaginal deliveries (NVDs). She is menopausal and does not smoke, drink alcohol, or use illicit drugs.\n\nThe clinical trial is looking for patients with Irritable Bowel Syndrome (IBS) as defined by the Rome III criteria. The inclusion criteria also specify that participants above age 40 must have had a colonoscopy within the last 5 years, should not have started any new treatments in the last 2 weeks, and should not have received any antibiotics in the last 2 weeks.\n\nThe patient's presenting symptoms and diagnosis (gallstones and biliary sludge) do not align with IBS, and there is no indication in the patient note that she has been diagnosed with IBS or meets the Rome III criteria for IBS. Additionally, there is no mention of a recent colonoscopy, which is required for participants over 40 years of age.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial, as she does not have a diagnosis of IBS mentioned in the patient note. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1092": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient appears to have preoperatively diagnosed common bile duct stones as indicated by the ultrasound which revealed several gallstones, biliary sludge, and CBD stones. Since the inclusion criteria for the clinical trial is simply having preoperatively diagnosed common bile duct stones, this patient meets the criteria for inclusion in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1093": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Assessment:\n- The patient is a 54-year-old woman with symptomatic gallstone disease, experiencing episodes of pain in the epigastric area that radiates to the right upper quadrant, which worsens after eating fatty food. The pain has been present for more than 30 minutes, which fits the description of symptomatic gallstone disease in the inclusion criteria.\n- The patient has had similar pain in the past, indicating recurrent episodes.\n- Ultrasound findings confirm the presence of gallstones and biliary sludge, with the smallest stone being 14mm.\n- The patient experiences tenderness in the right upper quadrant on palpation, which can be associated with acute cholecystitis.\n- The patient has elevated ESR and leukocytosis with a left shift, which can be indicative of inflammation and potentially acute cholecystitis.\n- The patient is mildly febrile, which is another sign that could be consistent with acute cholecystitis.\n\nClinical Trial Inclusion Criteria Assessment:\n- The patient has symptomatic gallstone disease with episodes of pain and ultrasound signs of gallstones, which meets the inclusion criteria for symptomatic gallstone disease (SGBS).\n- The patient's symptoms and ultrasound findings could also suggest acute cholecystitis (AC), but further clinical biochemistry data would be required to confirm this.\n- The patient's age is within the acceptable range (not below 18 or above 80).\n\nClinical Trial Exclusion Criteria Assessment:\n- There is no information about the patient needing only very occasional medication for pain, which would suggest infrequent and/or minimal pain.\n- There is no mention of severe concomitant disease.\n- The presence of common bile duct (CBD) stones is noted in the patient's ultrasound, which is listed as an exclusion criterion for acute cholecystitis.\n- There is no indication of acalculous cholecystitis, gallbladder perforation, or gangrenous cholecystitis.\n- The patient is not part of the 1983 cohort mentioned in the inclusion criteria.\n\nThe presence of CBD stones is a concern regarding the exclusion criteria for acute cholecystitis, and it's not clear whether the trial is intended to include patients with acute cholecystitis and CBD stones or only those with gallbladder stones.\n\nGiven the information provided, the patient meets the inclusion criteria for symptomatic gallstone disease but is excluded due to the presence of CBD stones, which is an exclusion criterion for acute cholecystitis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1094": {
        "output": "Patient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presented with abdominal pain, nausea, and vomiting.\n- She has a history of hypercholesterolemia.\n- She is febrile with slightly elevated blood pressure and heart rate.\n- Laboratory analysis indicates elevated ESR and leukocytosis with a left shift.\n- Ultrasound revealed gallstones and biliary sludge.\n- There is no mention of leukemia or lymphoma.\n\nClinical Trial Analysis:\n- The trial is focused on younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).\n- Patients must be enrolled in specific classification trials before treatment.\n- B-ALL patients must have a white blood cell count < 50,000/uL.\n- Patients must be diagnosed with NCI Standard Risk B-ALL or B-LLy Murphy stages I or II.\n- Patients with Down syndrome are eligible.\n- Consent must be obtained, and all regulatory requirements must be met.\n\nComparison for Eligibility:\n- The patient does not have a diagnosis of B-ALL or B-LLy.\n- There is no mention of the patient having leukemia or lymphoma, let alone a newly diagnosed or standard-risk case.\n- The inclusion criteria are very specific to a certain disease and patient population, which the patient does not appear to fit.\n- The patient's information does not meet any of the specific inclusion criteria for the clinical trial.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the specified clinical trial, as her medical condition (gallstones and related issues) is unrelated to the diseases being studied in the trial (B-ALL or B-LLy).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1095": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- Age: 54 years old\n- Increased Body Mass Index (BMI): The patient is described as obese, but the exact BMI is not provided.\n- History of chronic obstructive pulmonary disease (COPD): Not mentioned.\n- History of Sleep Apnea: Not mentioned.\n\nGiven the information in the patient note, we know that the patient is over 18 and is described as obese. However, to meet the inclusion criteria fully, we would need confirmation of a BMI greater than 31 and a history of either COPD or sleep apnea. The patient note does not mention COPD, sleep apnea, or the exact BMI.\n\nSince we do not have complete information to confirm eligibility based on the inclusion criteria, the patient cannot be classified as eligible (2). Moreover, there is no mention of the patient meeting any of the exclusion criteria either. Therefore, we cannot classify the patient as excluded (0).\n\nHence, the patient note does not provide sufficient information to qualify the patient for the trial based on the trial's specific inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1096": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's condition does not match the disease and symptoms that the trial is investigating. The clinical trial is for patients undergoing a laparoscopic appendectomy, and the inclusion criteria specifically mention symptoms related to appendicitis such as right lower quadrant pain or periumbilical pain migrating to the right lower quadrant. The patient in the note is presenting with symptoms of gallstone-related issues (e.g., pain radiating to the right upper quadrant, nausea and vomiting after eating fatty food, and ultrasound revealing gallstones and biliary sludge), which is not related to appendicitis.\n\nTherefore, the patient does not meet the inclusion criteria for the specified clinical trial and is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1097": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,\" we need to compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nInclusion criteria for the trial:\n- Histologically or cytologically proven adenocarcinoma of the pancreas\n- Locally advanced unresectable disease or extrapancreatic metastases\n- Radiographically measurable disease or a serum CA19-9 measurement > 2 x ULN\n- One prior line of systemic therapy for advanced disease\n- Life expectancy of greater than 8 weeks\n- ECOG performance status of 0 or 1\n- Adequate organ function as measured by blood counts and biochemical tests\n- Signed informed consent\n- Agreement to use adequate contraception\n\nThe patient note indicates that the woman is presenting with symptoms and lab findings suggestive of gallstones and biliary issues, not pancreatic cancer. There is no mention of a diagnosis of pancreatic cancer, adenocarcinoma, or any treatment related to such a diagnosis. Thus, the patient does not meet the basic disease-specific inclusion criteria for the clinical trial.\n\nBased on the information given, the patient does not have a diagnosis of pancreatic cancer, which is a fundamental criterion for eligibility in the trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1098": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial for Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers, let's assess the eligibility:\n\nPatient Note Assessment:\n- The patient is a 54-year-old obese woman with symptoms suggesting a biliary condition (abdominal pain, nausea, vomiting, pain after eating fatty food).\n- The ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n- The patient's medical history includes hypercholesterolemia.\n\nClinical Trial Inclusion Criteria Assessment:\n- Patients with a diagnosis of advanced biliary carcinoma (gallbladder cancer, cholangiocarcinoma, ampullary cancer) not amenable to a conventional surgical approach are eligible.\n- Patients must have measurable disease.\n- Patients must not have untreated brain metastases.\n- Life expectancy of greater than 12 weeks.\n- Certain laboratory values must be met (WBC, platelets, hemoglobin, etc.).\n- Performance status, cardiac health, and absence of certain health conditions are required.\n\nBased on the information given in the patient note, we cannot confirm a diagnosis of advanced biliary carcinoma or any form of cancer. The presence of gallstones and biliary sludge does not necessarily indicate cancer. Additionally, the patient note does not provide information on whether the patient has a measurable disease, her laboratory values, performance status, or other health conditions that are specified in the inclusion criteria of the trial.\n\nAs there is not enough information to confirm the patient\u2019s eligibility, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1099": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient appears to match the requirement for the trial. The patient has symptomatic gallbladder stones, as indicated by the abdominal pain that worsens after eating fatty food, the presence of nausea and vomiting, and the ultrasound findings of gallstones and biliary sludge. The inclusion criteria for the clinical trial specify patients with symptomatic gallbladder stones, which the patient in the note has.\n\nThe trial's inclusion criteria do not list any additional specific requirements such as age, gender, or other health conditions. Therefore, assuming no other exclusion criteria are provided that the patient would not meet, the patient appears to be a candidate for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1100": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and other related symptoms. She has a history of hypercholesterolemia and is presenting with symptoms suggestive of gallstones and biliary sludge.\n\nThe clinical trial in question is assessing the impact of pain scores on the use of intrauterine lidocaine versus normal saline infusion at the time of IUD placement.\n\nThe inclusion criteria for the clinical trial are:\n- Women eligible for IUD insertion\n- Willing to give consent\n\nThe patient note does not mention any need for IUD insertion or any related gynecological issues. Additionally, there is no information given about the patient's willingness to give consent or any interest in contraception or IUD placement. Therefore, there is not enough information to determine if the patient is relevant for the trial based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1101": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the clinical trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman with abdominal pain that worsens after eating fatty food, accompanied by nausea and vomiting.\n- The pain has occurred twice in the past year.\n- The patient has hypercholesterolemia and a history of natural vaginal deliveries (NVDs).\n- She does not have a history of smoking, alcohol, or illicit drug use.\n- She is febrile and has increased blood pressure and heart rate.\n- Laboratory results show elevated ESR and leukocytosis with a left shift.\n- Ultrasound reveals gallstones, biliary sludge, and CBD stones.\n- There is no mention of GERD or typical/atypical reflux symptoms persisting despite treatment.\n- There is no information provided about esophageal acid exposure or DeMeester score.\n\nClinical Trial Inclusion Criteria:\n- Persistent or recurrent symptoms despite continuous medical treatment.\n- At least one typical reflux symptom (heartburn/regurgitation/dysphagia/epigastric pain) and/or at least one atypical reflux symptom (cough/asthma/hoarseness/distortion of taste).\n- Pathologic esophageal acid exposure as documented by a reflux-related DeMeester score \u226514.7.\n- Symptom correlation \u226550%, and/or reflux episodes >73.\n\nComparative Analysis:\n- The patient presents with epigastric pain; however, the pain is associated with gallstones and biliary issues as opposed to GERD. There is no mention of continuous medical treatment for GERD or typical/atypical GERD symptoms.\n- There is no documentation of a DeMeester score or symptom correlation percentage, which are needed to meet the trial's inclusion criteria related to GERD.\n\nConclusion:\n- The patient does not have documented GERD or related symptoms as described in the inclusion criteria for the trial.\n- Based on the available information, the patient does not meet the inclusion criteria for the clinical trial on the effectiveness of laparoscopic fundoplication on extraesophageal manifestations of GERD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1102": {
        "output": "Based on the patient note provided, the 54-year-old woman presents with abdominal pain, nausea, vomiting, epigastric pain after eating fatty food, and a history of similar pain in the past. She has been diagnosed with gallstones and biliary sludge based on the ultrasound. Her medical history includes hypercholesterolemia.\n\nThe clinical trial is focused on functional dyspepsia and the effects of proton pump inhibitors on acid rebound. The inclusion criteria for the trial are:\n- Symptoms indicating dyspepsia, including:\n  - Epigastric pain or epigastric discomfort\n  - Bothersome postprandial fullness\n  - Early satiation\n  - Epigastric burning\n- Access to the internet\n\nThe patient's note indicates epigastric pain, which is one of the symptoms required for the trial. However, the patient's symptoms are associated with gallstones and biliary sludge, which are not related to functional dyspepsia. Additionally, there is no information on whether the patient has access to the internet, but since this is a minor criterion, and the major issue is the cause of the patient's symptoms, the lack of information regarding internet access is not the primary reason for exclusion.\n\nGiven that the patient's symptoms are more likely attributed to gallstones rather than functional dyspepsia, the patient does not meet the trial's inclusion criteria for the diagnosis of functional dyspepsia.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1103": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- History of similar pain in the past\n- Past medical history includes hypercholesterolemia\n- Menopausal, no smoking, alcohol, or illicit drug use\n- Mild fever, elevated blood pressure, and heart rate\n- Laboratory analysis showed elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Informed consent\n- Ages of 18 to 80 years\n- Symptoms consistent with gallbladder disease including biliary colic or chronic right upper quadrant pain\n- Ultrasound confirming gallstones\n\nComparison:\n- The patient is within the age range of 18 to 80 years.\n- The patient's symptoms are consistent with gallbladder disease (biliary colic or chronic right upper quadrant pain).\n- The patient has an ultrasound confirming gallstones.\n\nThe patient meets all the stated inclusion criteria for the clinical trial. There are no exclusion criteria provided, so we cannot assess for any exclusions based on the information given.\n\nTherefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1104": {
        "output": "Based on the patient note, the 54-year-old woman presents with abdominal pain, nausea, vomiting, and a history of similar episodes in the past. The diagnostic ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones, with the smallest being 14mm. Her medical condition fits the profile for someone who may need therapeutic ERCP for CBD stone removal, which is relevant to the clinical trial's focus.\n\nThe inclusion criteria for the clinical trial are:\n- Patients treated with CBD stone removal during therapeutic ERCP after finding CBD stones with CT, ultrasound, or MRCP.\n- Patients treated with CBD stone removal during diagnostic ERCP because of cholangitis or cholecystitis.\n\nThe patient has been diagnosed with CBD stones, which aligns with the first part of the inclusion criteria. As the patient's condition might require therapeutic ERCP, she potentially meets the criteria for the clinical trial. However, the patient note does not indicate that she has already undergone ERCP, which is a key requirement for inclusion. Therefore, we do not have sufficient information to confirm her eligibility at this point.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1105": {
        "output": "In reviewing the patient note and the clinical trial information provided, we need to assess whether the patient meets the inclusion criteria specified for the trial. \n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presents with abdominal pain, nausea, and vomiting.\n- The pain worsens after eating fatty food.\n- She has a history of hypercholesterolemia and has given birth to two children (NVDs).\n- She's menopausal.\n- She experiences epigastric and right upper quadrant tenderness.\n- She has gallstones and biliary sludge indicated by ultrasound.\n- There is no mention of gastroesophageal reflux disease (GERD) symptoms or any previous diagnosis or treatment related to GERD.\n\nClinical Trial Inclusion Criteria:\n- Persistent or recurrent symptoms despite continuous medical treatment.\n- At least one typical reflux symptom (heartburn/regurgitation/dysphagia/epigastric pain) and/or at least one atypical reflux symptom (cough/asthma/hoarseness/distortion of taste).\n- Pathologic esophageal acid exposure as documented by a reflux-related DeMeester score \u226514.7, and symptom correlation \u226550%, and/or reflux episodes >73.\n\nComparison:\n- The patient does report epigastric pain, which could be considered a typical reflux symptom.\n- However, there is no evidence of continuous medical treatment for GERD, which is a requirement.\n- There is no documented DeMeester score, symptom correlation percentage, or number of reflux episodes.\n- The patient's symptoms and diagnosis seem to be related to gallstones and biliary issues, rather than GERD.\n\nGiven the information available, the patient does not clearly meet the inclusion criteria for the clinical trial. There is insufficient evidence that the patient has GERD or has been treated for GERD, which is central to the study. Therefore, the patient's eligibility for this trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1106": {
        "output": "To assess the patient's eligibility for the clinical trial, we will compare the patient's characteristics and clinical presentation with the inclusion criteria listed for the trial.\n\nPatient characteristics:\n- A 54-year-old woman\n- Clinical diagnosis of gallstone migration\n- Symptoms include abdominal pain radiating to the right upper quadrant, nausea, vomiting, and pain worsening after eating fatty food\n- Mild fever\n- Elevated ESR and leukocytosis with a left shift indicating an inflammatory response or infection\n- Ultrasound showing gallstones and biliary sludge, with the presence of common bile duct (CBD) stones\n- Abnormal liver function is not explicitly stated, but gallstone migration typically results in abnormal liver function tests\n\nClinical trial inclusion criteria:\n- Clinical diagnosis of gallstone migration\n- Abnormal liver function tests with at least two common hepatic parameters increased, with one being either AST or ALT at least two times higher than the norm\n- Presence of an associated cholecystitis is allowed\n- Age \u2265 16 years\n\nBased on the given information, the patient has a clinical diagnosis consistent with gallstone migration and associated symptoms. However, the patient note does not specifically mention the liver function test results, which are required by the inclusion criteria to determine the elevation of hepatic parameters. Without this specific information, we cannot confirm the patient's eligibility based on the trial's inclusion criteria.\n\nGiven the available information in the patient note, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1107": {
        "output": "In this case, the patient is a 54-year-old obese woman who has presented with abdominal pain, nausea, and vomiting. The pain is related to gallstones and biliary sludge as revealed by an ultrasound. Her medical history includes hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs).\n\nLet's compare the patient's information to the clinical trial's inclusion criteria:\n\n1. The patient is a multiparous woman, as indicated by her having two children (2 NVDs).\n2. However, the patient is not in spontaneous labor, nor is she presenting for vaginal delivery. The trial specifically targets women who are in labor, experiencing back pain during childbirth, and are at a cervical dilation of 4 centimeters or less.\n3. The patient is at least 18 years of age, which fits the age criterion.\n\nDespite the patient meeting the age criterion and being multiparous, she is not currently in labor and not seeking treatment for labor pain, which is the focus of the clinical trial. Therefore, she does not meet the essential inclusion criteria related to the trial's specific population and purpose.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1108": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant, worse after eating fatty food\n- History of similar pain episodes\n- Past medical history: hypercholesterolemia, 2 NVDs (natural vaginal deliveries)\n- No history of smoking, alcohol, or illicit drug use\n- Vital signs indicate mild fever and elevated heart rate\n- Physical exam shows epigastric and right upper quadrant tenderness\n- Laboratory analysis: elevated ESR, leukocytosis with a left shift\n- Ultrasound: gallstones, biliary sludge, and CBD (common bile duct) stones\n\nClinical Trial Inclusion Criteria:\n- Epigastric pain +/- radiation at least thrice in one month over the past three months\n- Endotherapy/Surgery and ductal clearance\n\nComparison:\n- The patient has experienced abdominal pain, which suggests a gastrointestinal issue.\n- The patient has had similar pain episodes in the past year, but it is unclear if it occurred thrice in one month.\n- The clinical trial is specific to chronic pancreatitis, which has not been mentioned in the patient's diagnosis.\n- There is no mention of the patient having undergone endotherapy/surgery and ductal clearance.\n\nConclusion:\nThe patient's diagnosis appears to be related to gallstones and not chronic pancreatitis. Additionally, there is insufficient information to confirm whether the patient fulfills the frequency of pain episodes required by the trial inclusion criteria, nor is there any mention of endotherapy/surgery and ductal clearance. Therefore, based on the information provided, the patient does not meet the necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1109": {
        "output": "Based on the patient note provided, the 54-year-old woman is admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain is worse after eating fatty food, and this is not the first occurrence of such symptoms. The ultrasound revealed several gallstones and common bile duct (CBD) stones, which indicates that she might have cholecystitis or is at least suffering from complications of gallstones.\n\nThe clinical trial in question is looking for patients undergoing emergency cholecystectomy for cholecystitis or gall stone pancreatitis. The patient's symptoms and ultrasound findings are consistent with the conditions that make someone eligible for the trial. However, the note does not explicitly state that the patient is scheduled for an emergency cholecystectomy, which is a requirement for the trial. Without confirmation that the patient is indeed undergoing the specified procedure, we cannot absolutely confirm her eligibility.\n\nGiven the information presented, we know the patient has gallstones and symptoms suggestive of cholecystitis, which could lead to an emergency cholecystectomy. Therefore, if we assume that the patient will undergo this procedure based on the symptoms and findings, she would be eligible. However, without explicit confirmation of the planned emergency cholecystectomy, we cannot be certain. Therefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1110": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the eligibility of the patient:\n\nPatient Note Analysis:\n- Age: 54 years old (meets age criteria)\n- Gender: Woman and menopausal (meets criteria for menopausal women)\n- BMI: Obese (likely meets the BMI >30 kg/m^2 criterion given the term \"obese\")\n- Medical history: No mention of diabetes (assumed non-diabetic, meets criteria)\n- Smoking status: Non-smoker (meets criteria)\n- Inflammatory disease: No explicit mention of an inflammatory disease, but the presence of elevated ESR and leukocytosis could indicate an inflammatory process\n- First-degree relatives with diabetes: Not mentioned (cannot determine relevance)\n- Medication: No mention of treatment that could interfere with insulin sensitivity (cannot determine relevance)\n- Infection: The presence of abdominal pain, leukocytosis, and gallstones may indicate an ongoing infection (which would not meet criteria)\n\nInclusion Criteria for the Trial:\n- Age between 50 and 65 years old (patient meets this criterion)\n- Menopausal women (patient meets this criterion)\n- BMI >30 kg/m^2 for the obese group (patient likely meets this criterion)\n- Non-diabetic patients (patient assumed to meet this criterion)\n- Non-smoking (patient meets this criterion)\n- Without any inflammatory disease (patient's current condition might not meet this criterion)\n- Without any first-degree relative with diabetes (information not provided)\n- Without any treatment that could interfere with insulin sensitivity (information not provided)\n- Without any infection (patient's current condition might not meet this criterion)\n\nGiven the information in the patient note, the patient meets several of the inclusion criteria but there are concerns regarding the presence of an ongoing infection and potential inflammatory disease due to the elevated ESR and leukocytosis, and insufficient information about the patient's family history of diabetes and current treatments. Therefore, the patient does not have sufficient information to qualify for the trial or may potentially be excluded due to the current infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1111": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient note summary:\n- 54-year-old woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsened after eating fatty food\n- Past medical history: hypercholesterolemia, 2 normal vaginal deliveries (NVDs)\n- No mention of cancer treatment, oral mucositis, or prior chemotherapy or radiation treatment\n- The current medical issue is related to gallstones and biliary sludge, not mucositis\n\nClinical trial inclusion criteria:\n- Patient has oral mucositis pain that is grade 3 or 4 according to the WHO Oral Mucositis Scale\n- Patient has received at least one prior chemotherapy or radiation treatment\n- Patient is at least 18 years old\n- Patient or their legally authorized representative understands and voluntarily signs the written informed consent\n\nThe patient in the note does not have any information indicating that they have oral mucositis or that they have received chemotherapy or radiation treatment. The current medical issues seem unrelated to the conditions being studied in the clinical trial.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial on the treatment of severe mucositis pain with oral Ketamine mouthwash.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1112": {
        "output": "",
        "label": 0
    },
    "1113": {
        "output": "",
        "label": 0
    },
    "1114": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the trial on Reletex for Nausea in GERD Patients.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, and vomiting, especially after eating fatty food. She has a history of similar pain in the past and a current diagnosis of gallstones and biliary sludge based on ultrasound. Her medical history includes hypercholesterolemia. There is no mention of gastroesophageal reflux disease (GERD) or the use of proton-pump inhibitors (PPIs), which are part of the inclusion criteria for the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Any patient over the age of 18 with clinically diagnosed GERD as evidenced by the GerdQ assessment tool and/or ambulatory pH/pH-impedance monitoring with a component of nausea with or without vomiting.\n2. Continued symptoms despite a stable dose of FDA approved daily PPI therapy in addition to or without supportive anti-emetics.\n3. Previous gastric emptying study performed as part of the standard care work-up of nausea and vomiting.\n\nAs the patient in the note does not have a documented diagnosis of GERD, there is no information on PPI therapy, and no mention of a gastric emptying study, she does not meet the inclusion criteria for the clinical trial. Therefore, she is not eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1115": {
        "output": "Based on the patient note, the 54-year-old obese woman presents with abdominal pain, nausea, vomiting, and a history suggestive of gallstone-related issues. Her medical history includes hypercholesterolemia and two natural vaginal deliveries (NVDs). She has no history of smoking, alcohol, or illicit drug use.\n\nThe clinical trial titled \"Scribes in the Emergency Department\" has inclusion criteria that are very broad:\n\n1. All consecutive patients during the study period\n2. Age > 18 years old\n\nThe patient in question is an adult over 18 years old and thus meets the age criterion. Since the trial does not specify any additional medical or health-related criteria and includes all patients during the study period, the patient appears to meet the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for the patient for the clinical trial \"Scribes in the Emergency Department\" is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1116": {
        "output": "Based on the patient note provided, the 54-year-old woman does not appear to be eligible for the clinical trial focused on rheumatoid arthritis. She presented with abdominal pain, nausea, vomiting, and was found to have gallstones and biliary sludge on ultrasound. Her medical history includes hypercholesterolemia, and she has been through menopause. There is no mention of rheumatoid arthritis, swollen or tender joints, or meeting the 1987 revised American College of Rheumatology criteria for diagnosis of RA.\n\nThe inclusion criteria for the clinical trial require participants to have active RA, defined by specific joint symptoms and an elevated ESR, among other requirements. None of these criteria appear to be met by the information provided in the patient note.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1117": {
        "output": "Based on the patient's note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presented with abdominal pain, nausea, and vomiting, symptoms that are not specifically related to eosinophilic esophagitis.\n- There is no mention of dysphagia, emesis, or food impaction that are characteristic symptoms of eosinophilic esophagitis.\n- The patient has gallstones and biliary sludge indicated by ultrasound, which suggests a diagnosis unrelated to eosinophilic esophagitis.\n- There is no mention of a previous diagnosis of eosinophilic esophagitis or gastroesophageal reflux disease (GERD).\n- There is no information about esophageal biopsies or eosinophil counts.\n\nClinical Trial Inclusion Criteria:\n- Male and female subjects 18 years and older (the patient meets this criterion).\n- Previous diagnosis of eosinophilic esophagitis with clinical symptoms including heartburn, dysphagia, vomiting, epigastric pain, recurrent vomiting, food impaction as well as > 15 eosinophils per high powered field by endoscopic esophageal biopsy in both the proximal and distal esophagus, or previous diagnosis of gastroesophageal reflux with < 15 eosinophils per high powered field by endoscopic biopsy (the patient note does not provide sufficient information to confirm this criterion).\n\nAssessment of Eligibility:\n- The patient's age aligns with the inclusion criteria.\n- There is insufficient information regarding a diagnosis of eosinophilic esophagitis or gastroesophageal reflux; thus, we cannot determine if the patient meets the disease-specific criteria.\n- The symptoms described in the patient note (abdominal pain, nausea, vomiting) could be consistent with epigastric pain, but without confirmation of eosinophilic esophagitis or esophageal eosinophil counts, we cannot definitively include them in the clinical trial based on the information provided.\n\nGiven the information from the patient note and the specified inclusion criteria of the clinical trial, the patient does not have sufficient information to qualify for the trial based on the available data.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1118": {
        "output": "Based on the information provided, the patient is a 54-year-old woman presenting with abdominal pain, nausea, and vomiting. The pain radiates to the right upper quadrant and worsens after eating fatty food. She has a history of similar pain incidents, hypercholesterolemia, and is menopausal. She does not have any reported symptoms of heartburn or regurgitation, which are common symptoms of gastroesophageal reflux disease (GERD). The ultrasound revealed gallstones, biliary sludge, and common bile duct stones, which are not directly indicative of GERD.\n\nThe clinical trial is looking to calculate the prevalence of GERD in patients with upper gastrointestinal tract symptoms in Egypt by using the GERD-Q questionnaire. The inclusion criteria specify that participants must be 18 years and above and report symptoms suggestive of upper gastrointestinal tract symptoms, including heartburn/regurgitation, abdominal pain, bloating, belching, and nausea/vomiting.\n\nThe patient does have upper gastrointestinal tract symptoms such as abdominal pain and nausea/vomiting. However, the trial specifically mentions symptoms suggestive of GERD, such as heartburn/regurgitation, which are not mentioned in the patient's note. While the patient does have some overlapping symptoms (abdominal pain and nausea/vomiting), without clear information on heartburn or regurgitation, it is not certain that her symptoms are suggestive of GERD. Therefore, we cannot confidently determine her eligibility solely based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1119": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and a diagnosis of gallstones, biliary sludge and CBD stones. Her symptoms and diagnosis do not align with the clinical trial's inclusion criteria explicitly.\n\nThe trial is specifically looking for participants with symptoms of idiopathic gastroparesis for at least 6 months and documented abnormal solid phase gastric emptying scintigraphy. Although the patient has symptoms like nausea and vomiting, there is no information suggesting that she has been diagnosed with gastroparesis, idiopathic or otherwise, nor is there any mention of gastric emptying studies.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial on acupuncture treatment for gastroparesis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1120": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The pain is epigastric, radiating to the right upper quadrant and worsening after eating fatty food. The patient has a history of similar pain, hypercholesterolemia, and is menopausal. The ultrasound revealed several gallstones, biliary sludge, and CBD stones, indicating that her symptoms are likely related to gallbladder disease rather than acute appendicitis.\n\nTo determine the eligibility for the clinical trial titled \"The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis,\" we need to compare the patient's characteristics and presentation with the inclusion criteria of the trial:\n\nInclusion criteria for the trial:\n- 2 to 20 years old (up until the 21st birthday),\n- Right lower quadrant or poorly localized abdominal pain, or tenderness that includes the right lower quadrant, and/or other features including, but not limited to, nausea, vomiting, and/or anorexia, requiring acute appendicitis to be added to the differential,\n- Onset of abdominal pain within 72 hours or less,\n- Patients of either gender may participate,\n- Patient or accompanying parent or guardian is able to provide informed consent.\n\nThe patient does not meet the age criterion, as she is 54 years old, which is well above the maximum age of 20 years stated in the trial's inclusion criteria. Moreover, although she presents with abdominal pain and symptoms that may include nausea and vomiting, her pain is located in the epigastric and right upper quadrant areas, which is not specific to the right lower quadrant as indicated for potential acute appendicitis. Additionally, the onset of her abdominal pain was 4 days ago, exceeding the 72-hour limit specified for potential acute appendicitis.\n\nTherefore, based on the provided information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1121": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 54-year-old obese woman\n- Abdominal pain with nausea and vomiting, exacerbated by eating fatty food\n- History of hypercholesterolemia and two natural vaginal deliveries (NVDs)\n- Menopausal, does not smoke, drink alcohol, or use illicit drugs\n- Symptoms and tests suggest gallstones and biliary sludge\n\nClinical trial inclusion criteria:\n- \u22651 year history of migraine with or without aura as defined by IHS criteria 1.1 and/or 1.2\n- Migraines typically last between 4 to 72 hours, untreated\n- \u22652 and \u22648 moderate or severe migraine attacks per month in the two months prior to screening\n- Male, female who is not of reproductive potential, or female of reproductive potential with a not-pregnant state confirmed by serum \u03b2-hCG, and agrees to use acceptable contraception\n\nBased on the provided patient note, there is no information about the patient having a history of migraine, which is a key condition for inclusion in the study. The patient's condition seems to be related to gallstones and biliary issues, which is not relevant to the inclusion criteria focusing on migraine.\n\nTherefore, the patient does not meet the necessary inclusion criteria for the clinical trial on MK-1602 for the treatment of acute migraine.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1122": {
        "output": "To assess the patient's eligibility for the clinical trial \"Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,\" we need to compare the patient's characteristics and condition to the inclusion criteria of the trial. Let's review the patient note and the inclusion criteria step by step:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Pain worse after eating fatty food\n- Has experienced similar pain in the past\n- Past medical history: hypercholesterolemia, 2 NVDs, menopausal, no smoking or alcohol or illicit drug use\n- Mild fever, BP 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA\n- Tenderness in epigastric area and right upper quadrant without rebound\n- Normal bowel sounds\n- Elevated ESR, leukocytosis with left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nInclusion Criteria for the Trial:\n- Histologically confirmed malignancy that is metastatic or unresectable\n- Histologically or cytologically confirmed diagnosis of pancreatic cancer or poorly differentiated neuroendocrine tumor (for MTD expansion cohort)\n- Measurable disease\n- Disease accessible for core biopsy\n- Age \u2265 18 years\n- ECOG performance status of 0 or 1\n- Normal bone marrow and organ function as defined\n- Willingness to use acceptable birth control methods if of childbearing potential\n- Ability to take oral medication and maintain a fast\n- Willingness to sign an informed consent document\n\nBased on the information provided in the patient note, the patient does not have a confirmed diagnosis of malignancy, either metastatic or unresectable. The symptoms described (abdominal pain, nausea, vomiting) and findings (gallstones, biliary sludge, CBD stones) suggest she may have gallbladder disease but do not indicate the presence of a solid malignancy that meets the trial's inclusion criteria. Additionally, there is no mention of prior treatment for a malignancy, which further suggests that this patient does not have the type of cancer specified in the inclusion criteria.\n\nAs a result, the patient does not meet the necessary inclusion criteria for the clinical trial focused on treating patients with solid malignancies using MLN8237 and Nab-Paclitaxel.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1123": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones.\n- No mention of multiple myeloma (MM) or any related symptoms or treatments.\n- No indication of previous treatment with IV bortezomib.\n\nClinical Trial Inclusion Criteria Analysis:\n- Diagnosis of MM, with specific diagnostic criteria outlined.\n- Measurable disease as defined by specific criteria.\n- Progressive MM after at least one IV bortezomib-containing regimen.\n- ECOG performance status of \u2264 2 at study entry.\n- Life expectancy > 3 months.\n- Specific laboratory test results within defined ranges.\n- Consent and ability to adhere to the study visit schedule and protocol requirements.\n\nThe patient in the note does not have a diagnosis of multiple myeloma, nor is there any indication that she has been treated for such a condition. The clinical trial is specifically for patients with relapsed or refractory MM who have been previously treated with IV bortezomib. Since the patient's condition and medical history do not match the trial's disease focus and inclusion criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1124": {
        "output": "To determine the patient's eligibility for the clinical trial, we should compare the patient's characteristics and medical condition with the inclusion criteria provided by the clinical trial.\n\nHere are the inclusion criteria for the clinical trial:\n\n1. Be female.\n2. Have a diagnosis of breast cancer, any stage.\n3. Be chemotherapy na\u00efve and about to begin her first course of chemotherapy.\n4. Be scheduled to receive one of the specified chemotherapy regimens with the specified antiemetic regimen.\n5. Have a response of >3 or greater on a question assessing expected nausea on a 5-point Likert-scale.\n6. Be able to read English.\n7. Be 18 years of age or older and give written informed consent.\n\nNow, let's assess the patient's information:\n\n- The patient is a 54-year-old female (meets age and gender criteria).\n- The patient's medical issue is related to abdominal pain, gallstones, biliary sludge, and CBD stones.\n- There is no mention of breast cancer or any cancer diagnosis.\n- There is no indication that the patient is about to begin chemotherapy.\n- Since the patient does not have breast cancer or is not about to begin chemotherapy, criteria 4 and 5 do not apply.\n- There is no information regarding her ability to read English, but since this is a less critical factor, we will not consider it as a disqualifying point.\n- The patient is 18 years of age or older and could potentially give written informed consent.\n\nBased on the patient's note, the patient does not meet the critical inclusion criteria of having a diagnosis of breast cancer and being about to begin chemotherapy. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1125": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which fits within the age range of 18 to 75 years required for the trial.\n- She presented to the emergency department with abdominal pain, nausea, and vomiting. The pain is worse after eating fatty food, which is consistent with biliary colic.\n- She has a history of similar pain twice in the past year.\n- Laboratory analysis and ultrasound results are consistent with acute biliary disease, including the presence of gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nClinical Trial Inclusion Criteria:\n- Patients from age 18 and up to 75 years old. (The patient is 54 years old, so this criterion is met.)\n- Causes of admission to the ED are acute cholecystitis, biliary colic, acute cholangitis. (The patient's symptoms and ultrasound findings are suggestive of acute biliary disease, likely acute cholecystitis or biliary colic.)\n- The patient is willing to participate in the study and is able to sign an informed consent form. (There is no information provided about the patient's willingness or ability to consent, so we must assume that if approached, the patient can make this decision.)\n\nConclusion:\nThe patient appears to meet the age criterion and the condition for admission to the ED (acute cholecystitis or biliary colic). The only aspect not covered in the patient note is the patient's willingness and ability to consent, which cannot be determined from the information given. However, because this is a procedural step that is typically confirmed after determining initial eligibility, the patient can be considered eligible based on the medical information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1126": {
        "output": "Based on the patient note provided, the 54-year-old woman was admitted to the emergency department with abdominal pain, nausea, vomiting, and a history of similar pains in the past. The ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones with the smallest stone being 14mm in size.\n\nThe clinical trial in question is focused on the natural process of gallstones in the common bile duct, specifically stones that are less than or equal to 6 mm, and the complications that may arise under a 1-year follow-up. The inclusion criteria for the trial mention \"cholecystectomy\" without further specification.\n\nThe patient note does not indicate that the patient has undergone a cholecystectomy (surgical removal of the gallbladder). The trial appears to be looking for participants who have had a cholecystectomy and have stones less than or equal to 6 mm to study their natural process and potential complications.\n\nSince there is insufficient information from the patient note to determine whether the patient meets the inclusion criteria for the trial (i.e., no mention of a cholecystectomy), the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1127": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- She was admitted with abdominal pain that started 4 days ago.\n- The pain gets worse after eating fatty food.\n- The ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n- No mention of using drugs for erectile dysfunction, alcohol use, or any of the other exclusion conditions.\n\nClinical Trial Inclusion Criteria:\n- Patients with right upper quadrant abdominal pain of less than 24 hours' duration.\n- Ages 18 and 60 years of age.\n\nClinical Trial Exclusion Criteria:\n- Obstructive hypertrophic cardiomyopathy, pronounced hypovolemia, alcohol use in the last 8 hours, clinical intoxication, STEMI or presumed cardiac chest pain, inferior myocardial infarction with right ventricular involvement, raised intracranial pressure, cardiac tamponade, patients taking certain drugs for erectile dysfunction, pregnancy, known allergy to nitroglycerin, unable to give consent.\n\nAssessment:\nThe patient is 54 years old, which falls within the age range specified by the trial. She has upper quadrant abdominal pain due to gallstones, which aligns with the suspected symptomatic cholelithiasis mentioned in the trial summary. However, the duration of her pain is 4 days, which exceeds the trial's inclusion criterion of pain of less than 24 hours' duration. Therefore, she does not meet all the inclusion criteria. There is no information given suggesting that she meets any of the exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1128": {
        "output": "",
        "label": 0
    },
    "1129": {
        "output": "Based on the patient note provided, the 54-year-old woman presents with symptoms indicative of common bile duct stones (CBDS), which is confirmed by the ultrasound revealing several gallstones, biliary sludge and CBD stones. The clinical trial's inclusion criteria specify that participants must have common bile duct stones. Given that the patient's clinical presentation and diagnostic findings match the trial's inclusion criteria, she is potentially eligible to participate in the study.\n\nHowever, as the assistant, I am not privy to the full protocol of the trial, including any exclusion criteria that might disqualify the patient from participation. Assuming there are no exclusion criteria that apply to this patient based on the information provided, the patient would be considered eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1130": {
        "output": "Based on the information provided, the patient is a 54-year-old woman presenting with epigastric pain that radiates to the right upper quadrant, which worsens after eating fatty food \u2013 a symptom common in dyspepsia. She is older than 18 years old, which meets the age requirement specified in the clinical trial inclusion criteria. The clinical trial is focused on the comparison of Pantoprazole and Ranitidine in the treatment of patients with dyspepsia.\n\nGiven that the patient has epigastric pain and is above the age of 18 years, she meets the inclusion criteria for the clinical trial comparing Pantoprazole and Ranitidine in Dyspepsia.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1131": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman.\n- The patient's medical issue is abdominal pain, likely related to gallstones, not a sexual pain disorder like provoked vestibulodynia (PVD).\n- The patient's past medical history includes hypercholesterolemia.\n- The patient's demographic information does not include any mention of current or planned hormonal contraceptive (HC) use.\n- The patient's age is outside the specified range for the clinical trial (18-35 years).\n\nClinical Trial Inclusion Criteria Analysis:\n- The study is looking for non-pregnant women aged 18-35 who are na\u00efve to hormonal contraceptives or other hormonal medications.\n- Participants must be able to provide informed consent and complete questionnaires.\n- They must intend to use HCs for at least one year.\n- They should not have primary PVD, pelvic floor hypertonicity, vaginismus, or congenital abnormalities on examination before initiation of HCs.\n- They must be available for follow-up appointments and willing to undergo a gynecologic examination if dyspareunia develops.\n\nThe patient does not meet the following eligibility criteria for the clinical trial:\n- The patient's age is outside the specified range (54 years old versus 18-35 years required).\n- There is no information suggesting that the patient is either na\u00efve to HCs or planning to initiate HC use.\n- The patient's current medical issues are unrelated to the focus of the study, which is on PVD and HC use.\n\nTherefore, the patient does not qualify for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1132": {
        "output": "The patient in the provided note is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and pain that worsens after eating fatty food. Her medical history includes hypercholesterolemia and she's had two normal vaginal deliveries (NVDs). The ultrasound shows gallstones, biliary sludge, and common bile duct (CBD) stones. Her symptoms and history suggest that she is experiencing complications related to gallstones, which is consistent with biliary colic and possible cholecystitis.\n\nThe clinical trial in question is focusing on the detection of Minimal Change Esophagitis (MCE) in dyspeptic patients. The inclusion criteria are:\n\n- Patients with one or more of the following symptoms: epigastric pain or discomfort, postprandial fullness, and early satiety with or without symptoms suggesting GERD.\n- Patients able to give informed consent.\n\nThe patient does exhibit epigastric pain, which is one of the symptoms listed in the inclusion criteria for the trial. However, the trial seems to be specifically targeting patients with dyspepsia and potential GERD, which is not clearly indicated in the patient's note.\n\nSince the patient's symptoms could be considered relevant to dyspepsia, but there is no conclusive information on GERD or the specific diagnosis of dyspepsia, we can't definitively include her in the trial based on the available information. Therefore, the patient falls into category 1) Not relevant, as there is insufficient information to qualify her for the trial based on the symptoms alone, and there is no direct mention of dyspepsia or GERD as a diagnosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1133": {
        "output": "The patient described in the note is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. Her symptoms and ultrasound findings suggest gallbladder issues, possibly cholecystitis or cholelithiasis, given the presence of gallstones and biliary sludge. There is no mention of her undergoing ERCP (endoscopic retrograde cholangiopancreatography) or incidental pancreatic duct cannulation.\n\nThe clinical trial provided is focused on patients who have undergone ERCP and where pancreatic duct cannulation occurred by chance. The inclusion criteria explicitly state that the trial is for ERCP patients over 20 years old who experienced accidental pancreatic duct cannulation.\n\nSince there is no mention of the patient having undergone ERCP or experiencing accidental pancreatic duct cannulation, she does not meet the inclusion criteria for this specific clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1134": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility:\n\nPatient Information:\n- The patient is a 54-year-old obese woman.\n- She presented with abdominal pain, nausea, and vomiting.\n- Past medical history includes hypercholesterolemia and 2 NVDs (Natural Vaginal Deliveries).\n- The patient is menopausal, does not smoke or drink alcohol, and does not use illicit drugs.\n- She is experiencing symptoms consistent with gallstones and biliary issues.\n- There is no mention of pancreatic cancer or any treatment related to it.\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed, unresectable pancreatic adenocarcinoma.\n- Patients must have already received or refused 1st-line treatment.\n- Measurable and biopsiable disease required.\n- ECOG performance status =< 1.\n- Life expectancy of greater than 16 weeks.\n- Specific blood work and organ function criteria.\n- Ability to swallow whole tablets and willingness to use contraception if applicable.\n- Ability to understand and sign informed consent.\n\nThe patient described in the note does not meet the necessary inclusion criteria for the clinical trial. The trial is specifically for patients with unresectable pancreatic adenocarcinoma, and there is no indication in the patient's note that she has pancreatic cancer or any type of cancer diagnosis. Therefore, the patient is not relevant for this trial since she does not have the disease that the trial is studying.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1135": {
        "output": "",
        "label": 0
    },
    "1136": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient Note:\n- 54-year-old woman\n- Abdominal pain, nausea, vomiting\n- Pain worsens after eating fatty food\n- Past medical history includes hypercholesterolemia\n- No mention of gastroesophageal reflux disease (GERD) symptoms or diagnosis\n- Ultrasound revealed gallstones and biliary sludge\n- Symptoms are more indicative of gallbladder disease rather than GERD\n\nClinical Trial Inclusion Criteria:\n- Subject age \u2265 18 years\n- Written informed consent\n- Referred for pH monitoring to detect acid reflux for symptoms including:\n  - Heartburn\n  - Regurgitation\n  - Dysphagia\n  - Epigastric pain\n  - Non-erosive reflux disease (NERD)\n  - Chest pain\n  - Cough\n  - Hoarseness\n  - Asthma\n  - Lower pharyngeal irritation, need to clear throat\n\nThe patient does exhibit epigastric pain, which is one of the listed symptoms for inclusion in the trial. However, the context of the epigastric pain is important\u2014it is related to gallstones and biliary sludge rather than being indicative of GERD. There is no mention of the patient having symptoms specifically associated with acid reflux or a diagnosis of GERD.\n\nSince the trial is focused on patients with known or suspected GERD and the patient's symptoms seem to be related to a different condition (gallstones), there is not enough evidence to suggest that she fits the criteria for GERD-related epigastric pain.\n\nTherefore, the patient does not meet the inclusion criteria based specifically on the available information, which does not provide a clear connection to GERD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1137": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's analyze the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presents with abdominal pain, nausea, and vomiting.\n- The pain is described as epigastric, radiating to the right upper quadrant, and worsening after eating fatty food.\n- She has a history of similar episodes in the past.\n- Her past medical history includes hypercholesterolemia.\n- She has had 2 normal vaginal deliveries (NVDs).\n- She does not have a history of smoking, alcohol, or illicit drug use.\n- She is menopausal.\n- Current vitals indicate mild fever and tachycardia.\n- She has epigastric and right upper quadrant tenderness on examination.\n- Laboratory findings show elevated ESR and leukocytosis with a left shift.\n- Ultrasound reveals gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nClinical Trial Criteria Analysis:\n- The trial is investigating the presence of H. Pylori in patients with symptomatic gallstones undergoing cholecystectomy.\n- Patients with acute cholecystitis, cholangitis, biliary and hepatic tumors, Crohn's disease, and previous gastric surgery are not suitable for the trial.\n\nThe patient note indicates that the woman has symptomatic gallstones, as evidenced by her symptoms and the ultrasound findings. However, there is no mention of acute cholecystitis or cholangitis, nor is there any mention of biliary or hepatic tumors, Crohn's disease, or previous gastric surgery in the patient's history.\n\nGiven the information available, the patient does not fall under any of the exclusion conditions explicitly mentioned in the trial criteria. However, to fully determine eligibility, additional information would be needed to confirm the absence of acute cholecystitis or cholangitis, as these could be potential complicating factors given her symptoms and ultrasound findings. Since the patient is being considered for a cholecystectomy due to symptomatic gallstones, it is possible she could be eligible for the trial if these conditions are ruled out.\n\nDue to the lack of explicit exclusion based on the information provided, but with the caveat that more information is necessary to rule out acute cholecystitis or cholangitis, the patient's trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1138": {
        "output": "",
        "label": 0
    },
    "1139": {
        "output": "",
        "label": 0
    },
    "1140": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient appears to be eligible for the trial. The patient has abdominal pain that is consistent with symptomatic gallstones, and the ultrasound confirmed the presence of gallstones, which is the specific condition required for inclusion in the trial.\n\nThe clinical trial does not list any other specific inclusion criteria such as age or gender, and no exclusion criteria have been provided. Since the patient's condition of symptomatic gallstones matches the inclusion criteria, and there is no information suggesting exclusion, the patient can be considered for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1141": {
        "output": "Based on the patient note provided, there is no information suggesting that the 54-year-old obese woman has been engaging in vaginal or anal sexual intercourse in exchange for money, alcohol, or other goods. Nor is there any indication that she has had unprotected vaginal or anal sexual intercourse with a paying sexual partner in the past 90 days. Additionally, there is no information about her interest in learning about and developing her own small business.\n\nThe clinical trial in question is specifically looking to recruit women who are engaged in high-risk sexual activities and are interested in a microfinance intervention aimed at reducing sexual risk and developing their own small business. The patient described in the note does not meet the inclusion criteria for this trial as there is no information to suggest she is a sex worker or interested in microfinance.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1142": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific conditions required for participation in the trial. The clinical trial is observing the safety and efficacy of celecoxib in patients with traumatic pain, post-surgical pain, and tooth extraction pain. \n\nThe patient is described as having acute abdominal pain due to gallstones, which is not among the types of pain specified in the inclusion criteria. There is no mention of the patient suffering from traumatic pain, having recently undergone surgery, or having tooth extraction pain. \n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1143": {
        "output": "Based on the information given, the patient is a 54-year-old obese woman who has been admitted to the emergency department with abdominal pain, nausea, and vomiting due to gallstones. Her medical history includes hypercholesterolemia. There is no mention of her undergoing a hysterectomy of any kind, let alone specifically in Denmark 15 years ago, which is a requirement for the clinical trial in question.\n\nThe clinical trial is looking to follow up on women who underwent abdominal hysterectomy for benign uterine disease at a gynecological department in Denmark 15 years ago. Since there is no information indicating that the patient meets this very specific inclusion criterion, she is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1144": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Improving Pain Management for Older Adults in the Emergency Department (ED),\" let's assess the patient's eligibility:\n\nPatient Information:\n- 54-year-old woman\n- Presented with severe abdominal pain, nausea, and vomiting\n- History of similar pain episodes\n- Medical history includes hypercholesterolemia\n- Non-smoker, does not consume alcohol or use illicit drugs\n- Mild fever, elevated blood pressure, and heart rate\n- Ultrasound revealed gallstones and biliary sludge\n\nClinical Trial Inclusion Criteria:\n- Adult patients (\u226520 years)\n- Seen in the Icahn School of Medicine at Mount Sinai's ED\n- With severe pain (\u226510 on a verbal pain scale of 0-10)\n- Chief complaints of abdominal pain\n\nThe patient note indicates that the woman has severe abdominal pain, but it does not specifically mention that her pain is rated \u226510 on a verbal pain scale of 0-10. Since the severity of her pain has not been quantified as required by the trial's inclusion criteria, we cannot conclusively determine whether she meets the severity threshold for inclusion. Therefore, there is not sufficient information to qualify the patient for the trial based on the provided details.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1145": {
        "output": "",
        "label": 0
    },
    "1146": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman admitted with abdominal pain, nausea, vomiting, and other symptoms consistent with gallstones and biliary sludge, as revealed by an ultrasound. There is no mention of acute osteoporotic vertebral fractures or low back pain, which are the primary focus of the clinical trial in question.\n\nThe clinical trial seeks to enroll patients with acute osteoporotic vertebral fractures. Since the patient does not have information suggesting an acute osteoporotic vertebral fracture diagnosis, she does not meet the inclusion criteria specified for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1147": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones. There is no mention of acute lymphoblastic leukemia (ALL) or any form of cancer, which is a primary disease criterion for the clinical trial. Furthermore, the trial is specific to patients with ALL who are in complete remission at the time of the transplant, and there is no indication that the patient meets this condition.\n\nThe clinical trial is investigating a conditioning regimen for stem cell transplant in patients with ALL, and it requires specific organ function criteria and performance status, among other things. However, since the patient does not have ALL, we do not need to assess further criteria.\n\nGiven that the patient does not have the target disease (ALL) for which the clinical trial is being conducted, she does not meet the inclusion criteria. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1148": {
        "output": "Based on the information provided, the patient in the note is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones. She does not have any mention of diabetes or insulin pump use in her medical history.\n\nThe clinical trial is evaluating user acceptance of a new insulin pump and requires participants to have type 1 or type 2 diabetes, currently use an insulin pump, and have experience with a continuous glucose monitor (CGM). Since the patient does not meet the inclusion criteria for having a clinical diagnosis of diabetes and there is no indication of her using an insulin pump, she would not be eligible for this study.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1149": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's analyze the eligibility:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted with abdominal pain\n- Past medical history: hypercholesterolemia, 2 NVDs, menopausal\n- Symptoms and findings: epigastric pain, nausea, vomiting, gallstones, and biliary sludge\n- No mention of cancer\n\nClinical Trial Inclusion Criteria:\n- Women\n- Aged 18 years and over\n- With an invasive breast cancer diagnosed by cytology or histology\n- Tumors cT0 to cT3, CN0-3\n- No clinical evidence of metastasis at the time of inclusion\n- Untreated including scored for breast cancer surgery in progress\n- Patient receiving a social security system\n- Patient mastering the French language\n- Free and informed consent for additional biological samples, different questionnaires, and collecting information on resource usage\n- (Since February 2022) Patient:\n  - Age < 45 years at diagnosis\n  - Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-\n\nThe patient in the note does not mention having breast cancer or any type of cancer. The clinical trial is looking specifically for women with localized (non-metastatic) invasive breast cancer. As the patient note does not fulfill the primary requirement of having invasive breast cancer, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1150": {
        "output": "Based on the patient note provided, the 54-year-old woman is admitted to the emergency department with symptoms indicative of gallstones and biliary sludge, as evidenced by abdominal pain, radiating epigastric pain, nausea, vomiting, and findings from the ultrasound. Her medical history includes hypercholesterolemia.\n\nThe clinical trial in question is looking to recruit newly diagnosed thyroid cancer patients for a study evaluating the impact of an interdisciplinary team-based care approach. The inclusion criteria for the trial are as follows:\n\n- Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (histologically confirmed thyroid cancer of specified types);\n- Willingness to participate in the study's activities;\n- Over 18 years of age;\n- Alert and capable of giving free and informed consent;\n- Ability to speak and read English or French.\n\nThe patient described in the note does not have thyroid cancer; rather, she is presenting with symptoms consistent with gallstones and related issues. There is no mention of thyroid cancer or related treatments in her medical history. Therefore, she does not meet the specific inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1151": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the following:\n\n- The patient is a 54-year-old woman, which fits the \"Women\" criterion.\n- However, the patient was admitted with abdominal pain that is episodic and associated with fatty food intake, suggesting a gastrointestinal etiology, likely gallbladder-related given the ultrasound findings of gallstones and biliary sludge. This pain does not fit the description of \"chronic pelvic pain,\" which is typically non-menstrual or noncyclic and located in the pelvic area.\n- There is no information given about the duration of the abdominal pain other than it started 4 days ago and that similar episodes occurred twice in the past year, which does not necessarily imply a chronic condition with a duration of at least 6 months.\n- The clinical diagnosis mentioned in the patient note does not include chronic pelvic pain.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial focused on women with chronic pelvic pain, specifically due to the lack of a clinical diagnosis of chronic pelvic pain and insufficient evidence of the pain duration being at least 6 months.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1152": {
        "output": "Based on the information provided in the patient note and the clinical trial, the patient does not appear to meet the inclusion criteria for the clinical trial. The clinical trial is focused on patients who require percutaneous coronary intervention (PCI) for conditions such as angina, silent ischemia, NSTEMI, or recent STEMI. The patient in the note has been admitted with symptoms suggestive of gallstones and biliary issues, which are not related to the conditions being studied in the angiography trial.\n\nThe patient note does not mention any cardiac conditions or the need for PCI, which are essential for inclusion in the trial. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1153": {
        "output": "Based on the information provided, the patient in the note is a 54-year-old obese woman with symptoms that suggest gallbladder pathology, likely cholecystitis or cholelithiasis, given the presence of several gallstones and biliary sludge on ultrasound. \n\nThe clinical trial in question is evaluating the use of preoperative glucocorticoids in patients undergoing major hepatectomy. The inclusion criteria for this trial are adult patients who are scheduled to undergo elective hepatectomy at a specific medical facility within a specified timeframe.\n\nThe patient described in the note does not appear to be scheduled for elective hepatectomy; instead, she is presenting with acute symptoms likely related to gallbladder disease. There is no mention of hepatectomy being planned for her, nor is there an indication that her current treatment involves the medical center conducting the trial or that the timeframe aligns with the trial's enrollment period.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, as she is not scheduled for hepatectomy, nor is there any data suggesting that she is an elective surgery patient at the specified facility within the trial's timeframe.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1154": {
        "output": "The patient described in the note is a 54-year-old woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain is associated with gallstones and CBD stones based on ultrasound findings. Her medical history is significant for hypercholesterolemia. She has undergone natural vaginal deliveries (NVDs) twice, is menopausal, and does not have any history of substance abuse. There is no mention of her undergoing any surgery or being scheduled for elective orthopaedic surgery.\n\nThe clinical trial in question is focused on the relationship between short and long-term mood problems and short and long-term pain and quality of life after orthopaedic surgery. The inclusion criteria for the trial are very specific: all inpatients on certain wards following elective orthopaedic surgery carried out from Monday to Thursday each week.\n\nGiven the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial as she is not scheduled for, nor has she undergone, elective orthopaedic surgery. Therefore, she is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1155": {
        "output": "Based on the provided patient note, the 54-year-old woman has a history of hypercholesterolemia. The clinical trial in question is recruiting subjects for a registry of familial hypercholesterolemia (FH) across Canada. The inclusion criteria for the trial include:\n\n- Clinical diagnostic criteria for FH, which are:\n  - Family and/or personal history of high cholesterol\n  - Family and/or personal history of heart disease\n  - Abnormal growth on tendons, accumulation of fatty material in the eye\n  - Family history of FH\n  - Severe disorder of cholesterol and other lipids in the blood\n\nThe patient note mentions that the woman has hypercholesterolemia, which could align with the personal history of high cholesterol required by the trial. However, additional information is needed to confirm a diagnosis of FH. Specifically, we would need to know if there is a family history of high cholesterol or heart disease, the presence of abnormal growths on tendons or fatty material in the eye, and the severity of her lipid disorder.\n\nSince the patient note does not provide sufficient information regarding the family history or the specific clinical diagnostic criteria for FH, we cannot definitively determine her eligibility for the trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1156": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa,\" we must compare the patient's characteristics to the inclusion criteria provided by the study.\n\nPatient Characteristics:\n- A 54-year-old obese woman\n- Abdominal pain with nausea and vomiting\n- Epigastric pain radiates to the right upper quadrant\n- Past medical history of hypercholesterolemia\n- Menopausal\n- Non-smoker, non-alcoholic, no illicit drug use\n- Mildly febrile\n- Elevated ESR and leukocytosis\n- Imaging reveals gallstones and CBD stones\n\nInclusion Criteria for the clinical trial:\n- Age \u2265 18 years\n- Both males and females are eligible\n- Members of all racial and ethnic groups are eligible\n- Smoking and non-smoking people are eligible\n- No current or former diagnosis of cancer (with specified exceptions)\n- No use of chronic prescribed medications which are potent inducers or inhibitors of CYP3A4\n- No chronic anticoagulation\n- No chronic use of steroids\n- Karnofsky Performance Scale \u226590%\n- Able to provide written, informed consent\n- Negative urine pregnancy test for women of child-bearing potential\n- No history of food intolerance to broccoli or pineapple and lime juices\n- Willing to avoid cruciferous vegetables during the study\n- Willing to avoid grapefruit or grapefruit juice and daily vitamins and anti-inflammatory medications prior to and during the study\n- Use adequate contraception if of child-bearing potential or if male\n\nThe patient note does not mention any current or former diagnosis of cancer, the use of chronic medications that could affect CYP3A4, anticoagulation, or steroid use. The patient is able to provide consent and is not currently on anticoagulation or steroid treatment. There is no information about her Karnofsky Performance Scale score, but the fact that she is presenting to the emergency department with acute symptoms could suggest that her score might be lower than 90%. There is also no information about her potential food intolerances or her willingness to comply with the dietary restrictions during the study.\n\nHowever, because this patient is currently seeking treatment for gallstones and associated symptoms (which may include pain medication that could be a CYP3A4 inducer or inhibitor), we cannot definitively establish if she meets all the health-related criteria for the study. Additionally, the requirement for a Karnofsky Performance Scale score of \u226590% suggests that participants should not have significant health issues, so her current health condition might affect her eligibility.\n\nConsidering the information provided, we cannot confirm her eligibility fully. Therefore, the most appropriate classification is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1157": {
        "output": "The patient note describes a 54-year-old obese woman with symptoms indicative of gallbladder issues (abdominal pain, elevated ESR, leukocytosis, and ultrasound revealing gallstones and biliary sludge). Her symptoms are triggered by eating fatty food and she has experienced similar pain in the past, which likely points to a gallbladder-related issue rather than Functional Dyspepsia (FD).\n\nThe clinical trial is looking for patients with Functional Dyspepsia according to the ROME III criteria, which include symptoms like bothersome postprandial fullness, early satiation, epigastric pain, and epigastric burning without evidence of structural/organic disease. The patient's symptoms do not clearly align with the ROME III criteria for FD; instead, they suggest a structural problem with gallstones, which is an exclusion factor for FD.\n\nGiven the patient's clinical presentation and the ultrasound findings, her condition does not match the inclusion criteria for the clinical trial, which specifically seeks patients diagnosed with Functional Dyspepsia without evidence of structural/organic disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1158": {
        "output": "Given the patient note and the clinical trial information provided, here is the assessment:\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- She presents with abdominal pain, which is her main complaint.\n- The pain gets worse after eating fatty food, suggesting a condition related to gallbladder pathology.\n- The ultrasound revealed gallstones and common bile duct stones, which is consistent with the symptoms described.\n- She has a history of hypercholesterolemia and is menopausal.\n\nClinical Trial:\n- Title: Triage of Abdominal Pain in the Emergency Department\n- The study aims to evaluate the performance of a triage scale for patients with abdominal pain in the Emergency Department.\n- Inclusion Criteria: Patients aged 16 years or older with abdominal pain as the main complaint.\n\nAssessment:\nThe patient is 54 years old and her main complaint is abdominal pain, which meets the age and condition criteria specified in the clinical trial's inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1159": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nThe clinical trial in question is focused on patients with BRAF-mutant melanoma or solid tumors that are metastatic or cannot be removed by surgery. The patient in the note is admitted for abdominal pain related to gallstones, biliary sludge, and CBD stones. There is no mention of melanoma or any solid tumor, nor is there any indication that the patient has a BRAF mutation.\n\nThe patient's current medical condition does not align with the target disease of the clinical trial. The patient's history and symptoms are related to gallstones and potential cholecystitis, which are unrelated to the requirements of the clinical trial for BRAF-mutant tumors.\n\nConsidering the inclusion criteria for the trial, which require a confirmed BRAF-mutant solid tumor that is metastatic or unresectable and other specific requirements such as prior therapy and certain laboratory values, none of these criteria can be confirmed from the patient's note. Therefore, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1160": {
        "output": "Given the information in the patient note, this patient does not meet the inclusion criteria for the clinical trial titled \"The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.\" The trial is specifically looking for patients who are over 18 years of age, have an American Society of Anesthesiologists (ASA) class I-III, and are presenting for elective cesarean section.\n\nThe patient in the note is a 54-year-old obese woman admitted with abdominal pain and other symptoms that suggest gallbladder issues (gallstones, biliary sludge, and CBD stones), not someone who is presenting for an elective cesarean section. Therefore, based on the available information, the patient does not match the criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1161": {
        "output": "Reviewing the patient note:\n\n- The patient is a 54-year-old obese woman.\n- She presents with dyspeptic symptoms such as abdominal pain that radiates to the right upper quadrant and gets worse after eating fatty food.\n- She also has nausea and vomiting, which can be associated with dyspeptic symptoms.\n- The patient's condition has been ongoing for 4 days, indicating that these are not new or acute symptoms.\n- She has a history of similar pain episodes in the past.\n- Laboratory findings are relevant to her current condition and the ultrasound revealed gallstones, which could explain her symptoms.\n\nNow comparing this with the clinical trial inclusion criteria:\n\n- Adult females and males over 45 years of age with dyspeptic symptoms (epigastric pain, bloating and epigastric discomfort).\n\nThe patient is over 45 years of age and presents with epigastric pain and discomfort, which aligns with the inclusion criteria for dyspeptic symptoms required by the clinical trial. Therefore, the patient appears to meet the trial's inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1162": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Cramer Sports Motion Tape and Low Back Pain EMG.\"\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant\n- Pain worsens after eating fatty food\n- History of similar pain\n- Remarkable for hypercholesterolemia\n- No mention of low back pain or chronic mechanical low back pain\n- No mention of therapy visits\n- Age fits the inclusion criteria (18-65 years)\n\nClinical Trial Inclusion Criteria:\n- Must be recruited within the first 2 to 3 therapy visits\n- Have a diagnosis of chronic mechanical low back pain\n- Age 18-65\n\nAssessment:\nThe patient's age falls within the age range specified by the trial (18-65 years). However, the patient does not have a stated diagnosis of chronic mechanical low back pain, which is a requirement for the trial. There is also no information provided that indicates the patient has visited therapy for low back pain, let alone within the first 2 to 3 visits as required by the trial.\n\nSince there is no information on chronic mechanical low back pain or therapy visits for the same, the patient does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1163": {
        "output": "Based on the patient note provided, the 54-year-old woman was admitted with abdominal pain, nausea, vomiting, and has been found to have gallstones and CBD stones on ultrasound. Her medical history includes hypercholesterolemia. She has been diagnosed with common bile duct stones, which is relevant to the clinical trial's focus.\n\nThe clinical trial in question is investigating risk factors for the recurrence of primary bile duct stones. The inclusion criteria specify patients who underwent ERCP due to CBD stone or calculous cholangitis.\n\nIt is not explicitly stated in the patient note that the patient underwent ERCP, but she has been diagnosed with CBD stones, which makes her a potential candidate for such a procedure. However, without confirmation that ERCP was performed or planned, we cannot definitively say she meets all the inclusion criteria.\n\nGiven the information available, it seems the patient could be relevant for the trial, but there is insufficient information to determine if she has undergone or is scheduled for ERCP, which is a requirement per the inclusion criteria. Therefore, the trial-level eligibility based on the information provided would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1164": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, we can determine the patient's eligibility for the trial as follows:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman.\n- She presented with acute nontraumatic abdominal pain and tenderness that started 4 days ago.\n- She has undergone an ultrasound revealing gallstones and biliary sludge.\n- The patient is in the emergency department and might need a CT evaluation.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is studying emergency department patients.\n- The patients must be undergoing CT evaluation for acute abdominal pain and tenderness.\n- Acute is defined as the onset of the current episode within 7 days of emergency department presentation.\n\nComparison:\n- The patient is within the emergency department with acute abdominal pain and tenderness, which started 4 days ago, fitting the definition of \"acute\" as per the trial's inclusion criteria.\n- The patient's condition warrants a CT evaluation for her abdominal pain, which matches the criteria of the study.\n\nConclusion:\nThe patient meets the inclusion criteria for the clinical trial as she is an emergency department patient undergoing evaluation for acute abdominal pain, which could include a CT scan as part of her evaluation.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1165": {
        "output": "Based on the provided patient note and the inclusion criteria of the MATCH study, we need to determine if the patient is eligible for the clinical trial. Let's compare the information:\n\nPatient's characteristics:\n- Age: 54 years old\n- Smoking status: Not mentioned\n- Intention to quit smoking: Not mentioned\n\nClinical trial MATCH study inclusion criteria:\n- At least 19 years of age: The patient meets this criterion.\n- Smoking at least 10 cigarettes per day: There is no information on the patient's smoking habits.\n- Smoked daily for at least the past year: There is no information on the patient's smoking habits.\n- Have an intention to quit smoking in the next 30 days: There is no information regarding the patient's intention to quit smoking.\n\nThe patient note does not provide sufficient information to determine eligibility based on the smoking-related criteria of the clinical trial. The patient's smoking status and intention to quit smoking are not mentioned in the note.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1166": {
        "output": "Based on the information provided, the 54-year-old obese woman has been admitted with symptoms consistent with common bile duct stones (CBDS), which is confirmed by the ultrasound revealing several gallstones and CBD stones. The clinical trial in question is focused on the management of common bile duct stones, specifically looking at the morbidity rate after ERCP treatment and considering the impact of leaving the gallbladder in situ.\n\nThe inclusion criteria for the clinical trial are simply:\n\n- Patients with common bile duct stones (CBDS)\n\nThe patient note confirms that the patient has CBD stones, which makes her a potential candidate for the trial. There are no exclusion criteria provided, so there is no basis to exclude the patient from the trial based on the information given.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1167": {
        "output": "Based on the patient note provided:\n\n- The patient is a 54-year-old woman, which satisfies the age criterion of being \u226518 years.\n- She presented with abdominal pain that worsened after eating fatty food, nausea, and vomiting, which are consistent with gallbladder issues.\n- The ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones, which aligns with the condition of cholelithiasis.\n- The laboratory analysis shows leukocytosis, which could be indicative of an inflammatory response, possibly due to acute cholecystitis.\n\nAccording to the clinical trial's inclusion criteria:\n\n- The patient must have symptomatic chronic cholelithiasis and be accepted to laparoscopic cholecystectomy or\n- Have acute cholelithiasis and be accepted to laparoscopic cholecystectomy within the first 72-96 hours from the onset of symptoms, with a diagnosis of acute cholecystitis supported by specific clinical and sonographic findings.\n\nThe patient note indicates that the patient has experienced similar pain twice in the past year, which may suggest chronic cholelithiasis. In addition, the current symptoms and ultrasound findings are consistent with acute cholelithiasis. However, the note does not explicitly state whether the patient has been accepted for laparoscopic cholecystectomy, which is a key component of the trial's inclusion criteria. Without this information, we cannot definitively ascertain her eligibility for the trial.\n\nConsidering the available information, the patient appears to meet some of the trial's inclusion criteria (symptoms and ultrasound findings consistent with acute/chronic cholelithiasis), but the lack of information regarding the acceptance for laparoscopic cholecystectomy leads to an incomplete assessment. Therefore, the eligibility rating for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1168": {
        "output": "The patient presented is a 54-year-old obese woman who has been admitted to the emergency department with abdominal pain, nausea and vomiting, and an ultrasound revealing gallstones and other related issues. Her medical history includes hypercholesterolemia. Based on the clinical trial's inclusion criteria, the trial is looking for patients with advanced or metastatic cancer that is refractory to standard therapy, or relapsed after standard therapy, and which is metastatic or unresectable. The patient's condition described in the note does not mention any cancer diagnosis, let alone metastatic or unresectable cancer. Therefore, the patient does not meet the disease-specific inclusion criteria for the clinical trial.\n\nAdditionally, the patient's current health issue does not appear to be related to a malignancy, but rather to gallstone-related complications. There is no information to suggest that the patient has a histologically confirmed malignancy as required by the trial's inclusion criteria.\n\nGiven the lack of information on a metastatic or unresectable malignancy, the patient does not meet the inclusion criteria for the clinical trial on sapanisertib and ziv-aflibercept in treating patients with recurrent solid tumors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1169": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient note describes a 54-year-old woman with abdominal pain, nausea, vomiting, and a history of similar pain episodes. The ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones, which are indicative of biliary colic or possible cholecystitis, not small bowel obstruction. The patient does not present with symptoms or a diagnosis that would suggest small bowel obstruction. Therefore, she does not meet the inclusion criteria of the clinical trial, which requires patients to have abdominal pain with clinical suspicion for small bowel obstruction.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1170": {
        "output": "The patient is a 54-year-old woman presenting with abdominal pain, nausea, vomiting, and a history significant for hypercholesterolemia and childbirth. Laboratory results indicate an inflammatory process, and an ultrasound revealed gallstones and biliary sludge, suggesting a diagnosis of gallbladder disease, likely cholecystitis or choledocholithiasis.\n\nThe clinical trial in question is investigating a model for acute ischemic pain in humans, specifically focusing on peripheral nerve damage and acute inflammation during short episodes of acute ischemia. The inclusion criteria for this trial are patients over 40 years of age with unilateral femoral-popliteal peripheral artery disease (PAD), Fontaine grade II.\n\nBased on the information provided, the patient does not meet the specified inclusion criteria for the trial as there is no mention of peripheral artery disease or any related ischemic conditions. The patient's symptoms and diagnosis are more consistent with gallbladder disease rather than PAD.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1171": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial.\n\nPatient characteristics:\n- 54-year-old obese woman\n- Abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant, worse after fatty food\n- Hypercholesterolemia\n- Menopausal\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n- No indication of NAFLD diagnosis or liver enzyme levels provided\n\nClinical trial inclusion criteria for NAFLD patients:\n- Presence of NAFLD as defined by specific criteria\n- Age 18-70 years old\n- Written informed consent\n\nClinical trial exclusion criteria for NAFLD patients:\n- Serum ALT > 3 times ULN at baseline\n- Evidence of other forms of liver disease\n- History of excess alcohol ingestion\n- Evidence of liver cirrhosis on labs or imaging\n- History of gastrointestinal bypass surgery or certain medications\n- Significant systemic or major illnesses other than liver disease\n- Positive test for anti-HIV\n- Active substance abuse\n- Pregnancy or inability to practice adequate contraception\n- Evidence of hepatocellular carcinoma\n- Serum creatinine >1.5 mg/dl\n- Starting medications known to cause DILI within one month prior to enrollment\n\nThe patient's note does not provide information indicating a diagnosis of NAFLD, nor does it mention the patient's liver enzyme levels. The presence of gallstones, biliary sludge, and CBD stones are not related to NAFLD, and these symptoms do not fit the inclusion criteria for NAFLD as defined by the study.\n\nGiven the information provided in the patient note, there is no sufficient evidence to qualify the patient for the clinical trial focused on NAFLD patients. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1172": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pain episodes. The symptoms described and the results of the ultrasound suggest a diagnosis of gallstones and biliary sludge, rather than preeclampsia. The patient's presentation does not include any symptoms or conditions related to preeclampsia such as hypertension and proteinuria, oliguria, cerebral or visual disturbances, or signs of HELLP syndrome, which are relevant to the clinical trial's inclusion criteria.\n\nThe clinical trial in question is focused on severe preeclampsia and the impact of restrictive fluid therapy during cesarean section on renal function. The inclusion criteria specifically mention severe preeclampsia with a defined set of symptoms and conditions, none of which are noted in the patient's record.\n\nSince the patient is not pregnant, does not have preeclampsia, and does not meet any of the inclusion criteria for the clinical trial on severe preeclampsia, she would not be eligible to participate in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1173": {
        "output": "Based on the information provided, let's compare the patient note and the inclusion criteria of the clinical trial:\n\nPatient note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worse after eating fatty food\n- History of hypercholesterolemia and 2 NVDs (normal vaginal deliveries)\n- Menopausal\n- No mention of multiple sclerosis (MS)\n\nClinical trial inclusion criteria:\n- Male or female adult patients\n- 18-60 years of age\n- Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)\n- Patients naive to MS therapy or patients switching from an FDA-approved MS therapy to BG-12\n- EDSS score 0 to 5.5 inclusive\n\nThe patient does not have a diagnosis of multiple sclerosis, which is a required condition for the clinical trial. Therefore, she does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1174": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's examine the patient's eligibility:\n\nThe patient is a 54-year-old woman who presented with abdominal pain, nausea, and vomiting. The pain is described as epigastric, radiating to the right upper quadrant, and worsens after eating fatty food. The patient has a history of similar pain, hypercholesterolemia, and is menopausal. She has elevated ESR and leukocytosis, and the ultrasound revealed gallstones, biliary sludge and CBD stones, which is indicative of gallstone disease rather than diverticular disease.\n\nThe clinical trial is focused on patients with acute diverticulitis or asymptomatic diverticulosis, and the study aims to examine the gut microbiome composition in these patients.\n\nThe inclusion criteria for the trial are:\n- Groups A and B: Patients with acute diverticulitis presenting to A&E with new onset abdominal pain, with or without a known diagnosis of diverticulitis.\n- Groups C and D: Patients with asymptomatic diverticulosis and normal controls who are being assessed for possible colorectal cancer with specific symptoms (fresh PR bleeding) and no other 'red flag' symptoms.\n\nThe patient in question does not fit the criteria for either acute diverticulitis or asymptomatic diverticulosis as described by the trial's inclusion criteria. Instead, she has symptoms suggestive of gallstone disease, which is not related to the conditions being studied in the trial.\n\nTherefore, the patient is not relevant to the clinical trial as her condition does not match the target diseases of the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1175": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient's characteristics:\n- 54-year-old obese woman\n- Abdominal pain radiating to the right upper quadrant, worsened after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Experiences nausea and vomiting\n- Epigastric tenderness on palpation, leukocytosis with a left shift, and gallstones present on ultrasound\n\nClinical trial's inclusion criteria:\n- Written Informed Consent given by the patient\n- Male and female patients aging from 18 to 70\n- Subjects with occasional or recurrent episodes of gastric or intestinal spasm-like pain or discomfort, such as occur e.g., in irritable bowel syndrome, which has been present for at least 3 months\n- The pain intensity score upon screening is at least 4 cm in VAS score\n\nThe patient appears to have symptoms that could be related to gastric or intestinal spasm-like pain, as indicated by the epigastric pain that worsens after eating fatty food. However, the pain may also be due to gallstones and biliary sludge, as revealed by the ultrasound. The inclusion criteria specify that the pain should be like that which occurs in conditions such as irritable bowel syndrome.\n\nGiven that the patient's symptoms seem to be related to gallstones and not necessarily a chronic condition like irritable bowel syndrome, and there is no information about the duration of her condition being at least 3 months or the pain intensity score upon screening, it is not clear if she fits the criteria for the clinical trial based on the information provided.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1176": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we can assess the eligibility of the patient for the trial.\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- Menopausal with two children\n- No history of smoking, alcohol, or illicit drug use\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Patient with esophageal varices having upper GIT endoscopy\n\nThe patient in the note has been diagnosed with gallstones and related conditions but does not mention esophageal varices or having undergone an upper GIT endoscopy. Therefore, there is not enough information to determine that this patient has the condition required by the trial's inclusion criteria, which specifically requires patients with esophageal varices that are being or have been assessed through an upper GIT endoscopy.\n\nThus, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1177": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic,\" let's assess the patient's eligibility:\n\nInclusion Criteria Assessment:\n- Patients ages 18-55: The patient is 54 years old, which meets the age criteria.\n- Present to ED with right upper quadrant (RUQ) abdominal pain: The patient has epigastric pain that radiates to the right upper quadrant, consistent with RUQ abdominal pain.\n- Suspected diagnosis of biliary colic: The patient's symptoms and ultrasound findings of gallstones and biliary sludge suggest a diagnosis of biliary colic.\n- Negative pregnancy test for women of childbearing potential: While the patient note does not explicitly mention a pregnancy test, the patient is menopausal, which typically implies that she is not of childbearing potential. However, to meet the trial criteria, a negative pregnancy test result would still be needed unless the trial specifies an exception for menopausal women.\n- No history of cholecystectomy: The patient note does not mention a history of cholecystectomy.\n\nGiven the available information, the patient appears to meet the age, clinical presentation, and suspected diagnosis criteria. However, the note does not provide information about the pregnancy test, which is a required criterion for inclusion. \n\nThus, the patient's eligibility cannot be confirmed without additional information regarding the pregnancy test. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1178": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the characteristics of the patient with the requirements for participation in the study:\n\nPatient Characteristics:\n- A 54-year-old obese woman\n- Presented with abdominal pain, nausea, and vomiting\n- History of hypercholesterolemia\n- Has gallstones and biliary sludge revealed by ultrasound\n- No mention of ST segment elevation acute coronary syndrome (STEAMI) or hyperfibrinogenemia\n\nClinical Trial Inclusion Criteria:\n- Patients >18 years of age\n- Admitted with ST segment elevation acute coronary syndrome (ACS)\n- Hyperfibrinogenemia within 72 h of symptom onset\n\nThe patient in the note does not have any information indicating that she has been diagnosed with ST segment elevation acute coronary syndrome or hyperfibrinogenemia, which are both required to be eligible for the clinical trial. The patient's presentation is consistent with gallstone-related issues rather than acute myocardial infarction.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1179": {
        "output": "Based on the patient note, the patient is a 54-year-old obese woman who is currently admitted to the emergency department for abdominal pain, with a history of hypercholesterolemia. There is no indication that the patient is pregnant or has any form of diabetes mellitus. The clinical trial in question is focused on pregnant women with various classifications of diabetes mellitus and the levels of fatty acid ethyl esters in the meconium of their babies.\n\nSince the patient in the note is not described as being pregnant, and there is no mention of diabetes mellitus, she does not meet the inclusion criteria for the clinical trial, which specifically requires pregnant women with diabetes mellitus.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1180": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the study.\n\nHere are the key points from the patient note:\n- 54-year-old woman\n- Presenting with abdominal pain, nausea, vomiting, and pain after eating fatty food\n- Past medical history includes hypercholesterolemia\n- No mention of bariatric surgery\n- Ultrasound revealed gallstones with the smallest being 14mm\n\nNow let's compare this with the inclusion criteria of the clinical trial:\n- Male or female age 18 to 75 years. (The patient is 54 years old, so she meets this criterion.)\n- Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound. (The patient has gallstones, but they are larger than 6 mm and there is no mention of bariatric surgery or the timeline of the formation of gallstones.)\n- Bariatric surgery conducted during the last 12 months. (There is no mention of bariatric surgery in the patient's history.)\n- Patients with sleeve gastrectomy or laparoscopic banding of the upper stomach will be included. (No mention of the patient having had this procedure.)\n- Signature of the written informed consent. (This is a procedural requirement that can be fulfilled if other criteria are met.)\n- Negative pregnancy test at study entry for females of childbearing potential. (This is a procedural requirement that can be fulfilled if other criteria are met.)\n- Females of childbearing potential practicing reliable contraception throughout the study period (not including oral contraceptives). (This is a procedural requirement that can be fulfilled if other criteria are met.)\n- Hypertensive patients must be well controlled by a stable dose of anti-hypertensive medication for at least 2 months prior to screening. (The patient has hypertension, but there is no information on the control or medication stability.)\n- Patients treated with certain medications must have stopped them at least 3 months prior to enrollment. (There is no information on the patient taking these medications.)\n- For patients with type 2 Diabetes, glycaemia must be controlled. (There is no mention of the patient having diabetes.)\n\nBased on the provided information, the patient does not meet several of the critical inclusion criteria, specifically those related to the gallstone size, the requirement of having undergone bariatric surgery, and the timing of gallstone formation after the surgery.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1181": {
        "output": "Based on the information provided, the patient in the note is a 54-year-old obese woman with symptoms suggestive of gallstones and common bile duct stones (CBDS), as evidenced by abdominal pain, nausea, vomiting, and the ultrasound findings. The clinical trial is focused on patients who have had recurrent common bile duct stones after undergoing an ERCP (Endoscopic Retrograde Cholangiopancreatography) procedure.\n\nThe inclusion criteria for the trial are:\n\n1. Patients with common bile duct stone underwent successful stone removal by ERCP in Xijing Hospital of Digestive Diseases.\n\nThe patient note does not mention that the patient has had an ERCP procedure or that she has been treated at Xijing Hospital of Digestive Diseases. It also does not specify if the stones are recurrent. The information about the patient is insufficient to determine if she meets the specific inclusion criteria of having had an ERCP procedure for stone removal, and especially in the specified hospital. Therefore, based on the available information, the patient does not meet the inclusion criteria due to a lack of relevant information concerning treatment history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1182": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones evident on ultrasound. She does not meet the inclusion criteria for the clinical trial as specified:\n\n- The patient is described as obese, which does not meet the \"Non-obese\" requirement stated multiple times in the inclusion criteria.\n- The inclusion criteria specify certain conditions related to lipid disorders and liver conditions, but the patient note does not mention these specific conditions.\n- There is no information provided about the patient's LDL, HDL levels, liver transaminases, hepatomegaly, cryptogenic cirrhosis, or biopsy-proven microvesicular or mixed micro/macrovesicular steatosis without a known etiology.\n- The patient has hypercholesterolemia, but there is no information regarding familial hypercholesterolemia or genetic testing for LDLR, Apo-B, or PCSK9 genes.\n- The patient note does not indicate a suspicion for Lysosomal Acid Lipase Deficiency (LAL-D).\n\nGiven the information in the patient note, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1183": {
        "output": "Based on the information provided, the patient is a 54-year-old woman presenting with abdominal pain, nausea, vomiting, and a history of similar pain. The ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones. Her clinical presentation and ultrasound findings are consistent with the inclusion criteria of the clinical trial, which requires a history of biliary pain or recent cholangitis and dilatation of the CBD and/or CBD stone detected by trans-abdominal ultrasound and/or computed tomography.\n\nThe patient's symptoms (biliary pain) and the ultrasound findings (CBD stones) match the inclusion criteria of the clinical trial assessing the cost-effectiveness of an endoscopic ultrasound (EUS) based strategy in the diagnosis of CBD stones.\n\nTherefore, the assessment of eligibility for the patient to participate in the clinical trial is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1184": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Radiological Investigation of Bile Duct Obstruction,\" let's determine the patient's eligibility.\n\nPatient Note Recap:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant and worsens after eating fatty food\n- History of similar pain episodes, hypercholesterolemia, and 2 NVDs\n- Menopausal with no history of smoking, alcohol, or illicit drug use\n- Mild fever, elevated blood pressure, and heart rate\n- Palpation reveals epigastric tenderness and right upper quadrant tenderness\n- Laboratory results show elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm\n\nClinical Trial Inclusion Criteria Recap:\n- Patients presenting with cholecystolithiasis and suspected CBD stones\n- Indication for CBD investigation requires one of the following:\n  i. Elevated bilirubin\n  ii. ASAT/ALAT or gGT or aP above the normal range (two of them)\n  iii. Choledocholithiasis in ultrasound\n  iv. Dilated bile ducts in ultrasound\n- Written informed consent\n\nAssessment:\nThe patient has been admitted with symptoms and ultrasound findings consistent with gallstones and CBD stones, which fits the trial's target condition of cholecystolithiasis with suspected CBD stones. The inclusion criteria specifically mention choledocholithiasis in ultrasound as one of the indicators for CBD investigation, which is present in the patient's case.\n\nThe patient note does not mention specific laboratory values for bilirubin or liver enzymes such as ASAT/ALAT, gGT, or aP, but leukocytosis and elevated ESR are indicative of an inflammatory process, which could be related to the presence of CBD stones. The patient's ultrasound results confirm the presence of CBD stones.\n\nGiven the information available, the patient appears to meet the inclusion criteria for the trial. However, without the specific liver enzyme levels, we cannot be certain that she meets all the laboratory-based criteria. Additionally, the patient would need to provide written informed consent to participate in the trial.\n\nSince not all the laboratory values required by the inclusion criteria are provided, we cannot definitively state that the patient is eligible. Therefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1185": {
        "output": "Based on the provided clinical trial information and the patient note, we need to determine the trial-level eligibility of the 54-year-old woman for the trial concerning unenhanced CT in elderly patients with acute abdominal pain.\n\nThe inclusion criteria for the trial are:\n1. Elderly patients admitted to the emergency department (aged 75 years old and older)\n2. Acute abdominal pain\n3. Informed consent\n\nThe exclusion criteria are:\n1. Traumatic pain\n2. Symptom duration of more than a week\n3. Inability for the patient to give informed consent\n\nThe patient in the note is a 54-year-old woman, which does not meet the age criterion of the trial (75 years old and older). Therefore, we do not need to assess the rest of the inclusion or exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1186": {
        "output": "Given the details in the patient note, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones. She is not reported to have corticotropic pituitary insufficiency, which is a requirement for the clinical trial in question. The clinical trial is assessing the effect of hydrocortisone dosages on ectopic lipid depots in patients with corticotropic pituitary insufficiency. \n\nThe patient does not meet the main inclusion criterion, which is having corticotropic pituitary insufficiency. There is no information provided in the patient note indicating that she has this condition or that she is taking hydrocortisone for any reason. Furthermore, the patient's abdominal pain and gallstone diagnosis are unrelated to the study's focus.\n\nTherefore, the patient does not have sufficient information to qualify for the trial, and it's not relevant to her current medical condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1187": {
        "output": "The patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting. The pain seems to be related to gallstones and a possible biliary condition given the laboratory findings and ultrasound results. The clinical trial in question is for a medication targeting patients with Primary Biliary Cirrhosis (PBC) or PBC-Autoimmune hepatitis overlap.\n\nThe inclusion criteria for the clinical trial are specific to patients diagnosed with PBC or PBC-Autoimmune hepatitis overlap, as defined by certain diagnostic factors, non-responders to ursodeoxycholic acid (UDCA), and certain laboratory markers of cholestasis. Additionally, the patient must have a specific level of itchiness associated with cholestasis (VAS-Itch of at least 30 mm), be within a certain age and BMI range, and not have any exclusion criteria that would pose a risk or interfere with the study.\n\nThe patient note does not mention PBC, pruritus (itchiness), or any other details that would indicate a diagnosis of PBC or PBC-Autoimmune hepatitis overlap. Instead, her symptoms and ultrasound results suggest gallstones and potential choledocholithiasis. There is no indication of elevated alkaline phosphatase levels for at least 6 months, positive antimitochondrial antibodies, or a liver biopsy consistent with PBC. There is also no mention of the patient's response to ursodeoxycholic acid treatment or any measures of itchiness.\n\nBased on the provided patient note, the patient does not meet the inclusion criteria for the clinical trial as there is insufficient information to qualify her for the trial focused on PBC and associated pruritus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1188": {
        "output": "Based on the provided patient note and the clinical trial details, let's evaluate the patient's eligibility:\n\nPatient Note Recap:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history: hypercholesterolemia, 2 NVDs (normal vaginal deliveries)\n- Menopausal, does not smoke, drink alcohol, or use illicit drugs\n- Mildly febrile, elevated BP, HR, and ESR, leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n- No mention of current or planned radiation therapy\n\nClinical Trial Recap:\n- Study of palonosetron in radiation-induced nausea and vomiting (RINV)\n- Patients with pre-existing nausea and vomiting versus no current nausea or vomiting\n- Patients must be receiving radiotherapy of low or moderate emetogenic risk\n- Two groups based on nausea and vomiting status at baseline\n\nInclusion Criteria for the Trial:\n- Informed consent\n- Patient will receive radiation therapy to areas of moderate or low emetogenic risk\n- Patients are grouped by nausea and vomiting status at baseline\n\nComparison:\n- The patient in the note is experiencing nausea and vomiting, which is relevant to the trial's interest in patients with these symptoms.\n- However, the patient is not currently receiving, nor is there any indication that she will receive radiation therapy, which is a key inclusion criterion for the trial.\n\nTherefore, although the patient experiences nausea and vomiting, which could potentially place her in Group 2 of the trial, she does not meet the essential inclusion criterion of receiving radiation therapy for a condition with a low or moderate risk of emetogenicity.\n\nGiven this information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1189": {
        "output": "Based on the provided patient note, the 54-year-old woman presents with abdominal pain, nausea, and vomiting. The pain is described as epigastric, radiating to the right upper quadrant and worsening after eating fatty food. The patient has a history of similar pain in the past and has been diagnosed with gallstones and biliary sludge via ultrasound. The patient's medical history includes hypercholesterolemia. She is also menopausal.\n\nThe clinical trial in question is focused on the clinical effect of Rebamipide on chronic gastritis patients. The inclusion criteria for this trial are the presence of symptoms such as epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting, etc., a diagnosis of chronic gastritis confirmed by endoscopic and pathological methods, and agreement to join the clinical trial.\n\nWhile the patient does have symptoms that are similar to those listed in the inclusion criteria (epigastric pain, nausea, vomiting), there is no confirmation in the patient note that she has been diagnosed with chronic gastritis via endoscopic and pathological methods. The symptoms the patient is experiencing could be related to gallstones and not necessarily indicative of chronic gastritis.\n\nTherefore, there is not enough information from the patient note to conclude that the patient has been diagnosed with chronic gastritis, which is a requirement for the trial. The patient note suggests a different gastrointestinal issue (gallstones) rather than chronic gastritis.\n\nAs a result, the assessment for this patient's eligibility for the clinical trial on the clinical effect of Rebamipide on chronic gastritis is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1190": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the trial:\n\nPatient Note:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history: hypercholesterolemia\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones (with the smallest stone being 14mm)\n\nClinical Trial Inclusion Criteria:\n- Grade II or III acute cholecystitis met Tokyo 13 diagnostic criteria\n- A high suspicion of CBD stone based on laboratory and imaging study\n- Informed consent given\n\nThe patient's presentation with abdominal pain radiating to the right upper quadrant, nausea, vomiting, and the finding of gallstones, biliary sludge, and CBD stones on ultrasound suggest that she might have acute cholecystitis. However, the patient note does not specify whether the patient's condition meets the Tokyo 13 diagnostic criteria for grade II or III acute cholecystitis.\n\nGiven that there is no direct mention of the severity of cholecystitis as per the Tokyo 13 diagnostic criteria, we do not have enough information to definitively conclude whether the patient is eligible for the trial. Therefore, the patient would be assessed as not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1191": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the following analysis can be made:\n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting. Her symptoms and the ultrasound findings suggest that she has gallstones, biliary sludge, and common bile duct stones. Her medical history includes hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs). She is menopausal, does not smoke or drink alcohol, and does not use illicit drugs. She is experiencing symptoms consistent with a gallbladder attack or cholecystitis.\n\nThe clinical trial in question is focused on preemptive analgesia in patients undergoing ano-rectal surgery, specifically for anal fistula repairs, anal sphincterotomies, hemorrhoidectomies, and anal condyloma excisions that are recalcitrant to non-surgical management. Additionally, patients must have an ASA Physical Status Classification System score of I, II, or III.\n\nThe patient in the provided note does not meet the inclusion criteria for the clinical trial because she is not undergoing any of the specified ano-rectal surgeries. Instead, her condition is related to gallstones and biliary issues, which are unrelated to the focus of the clinical trial. Additionally, there is no mention of her ASA Physical Status Classification System score, which is a requirement for inclusion in the trial.\n\nTherefore, since the patient's condition and the upcoming surgical intervention (if any) are not relevant to the clinical trial's focus, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1192": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting, likely due to gallstones and biliary sludge.\n- The patient's medical history includes hypercholesterolemia.\n- There is no mention of polycythemia vera (PV) or essential thrombocythemia (ET).\n- There is no indication that the patient has been diagnosed with JAK2V617F-positive PV or ET.\n- There is no information on previous treatments for PV or ET, such as hydroxyurea, interferon, or anagrelide.\n- No performance status is mentioned (ECOG).\n\nClinical Trial Inclusion Criteria:\n- Must have a diagnosis of JAK2V617F-positive PV or JAK2V617F-positive ET confirmed by WHO diagnostic criteria.\n- Must have high-risk ET/PV or low-risk disease with symptoms.\n- Must have been previously treated with at least one other agent for PV or ET and determined to be either intolerant or resistant.\n- Must be \u226518 years of age (the patient meets this criterion).\n- ECOG Performance status 0-2 (no information provided for the patient).\n- Must have acceptable pre-study organ function (no information provided for the patient).\n- Women of childbearing potential and males must agree to use adequate contraception (no information provided for the patient).\n- Must be able to understand and sign a written informed consent document (no information provided for the patient).\n\nThe patient does not meet the clinical trial's inclusion criteria as there is no indication that she has been diagnosed with PV or ET, which are the target diseases for the trial. The patient's current medical issue seems unrelated to the conditions being studied in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1193": {
        "output": "Based on the patient note provided, the patient does not meet the inclusion criteria for the clinical trial. The clinical trial is designed to study the effect of misoprostol on blood loss in women who have just given birth vaginally. The inclusion criteria for the trial specifically require that the patient:\n\n1. Has a term (\u226537 completed weeks) live singleton gestation in cephalic presentation and has been admitted to the Labor and Delivery Unit.\n2. Is in the latent phase of labor or has been admitted for induction of labor or at a prenatal clinic visit.\n3. Has had fewer than four prior vaginal deliveries.\n4. Reports no allergy to misoprostol.\n\nThe patient in the note is a 54-year-old obese woman admitted to the emergency department with abdominal pain related to gallstones, not a woman in labor or who has just given birth. Therefore, she does not qualify for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1194": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient.\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman.\n- She presented with abdominal pain, nausea, and vomiting.\n- The pain is worse after eating fatty food, indicating a biliary etiology.\n- She has experienced similar pain in the past.\n- She has a history of hypercholesterolemia.\n- The patient has an elevated ESR and leukocytosis, which can be associated with inflammation or infection.\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on patients with possible acute biliary pancreatitis.\n- All consecutive patients entering the emergency department for possible acute biliary pancreatitis are to be included.\n\nComparison:\n- The patient presented to the emergency department with symptoms suggestive of biliary pathology.\n- The ultrasound findings are consistent with biliary stones, which can lead to acute biliary pancreatitis.\n- The trial is looking to enroll patients with possible acute biliary pancreatitis.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial, as she has presented with symptoms and findings consistent with possible acute biliary pancreatitis. Since there are no other specific inclusion criteria detailed and no exclusion criteria provided, we can conclude that the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1195": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient is a 54-year-old obese woman who presented with abdominal pain, nausea, vomiting, and other symptoms indicative of gallstones and common bile duct (CBD) stones. The ultrasound revealed several gallstones, biliary sludge, and CBD stones. She would be considered for a study that is comparing early versus late cholecystectomy after clearance of CBD stones.\n\nThe inclusion criteria for the clinical trial are patients with CBD stones treated by ERCP (endoscopic retrograde cholangiopancreatography).\n\nThe patient note indicates that the woman has CBD stones, which aligns with the inclusion criteria of the clinical trial. However, there is no mention of her being treated with ERCP. Without confirmation that the patient has been treated by ERCP for her CBD stones, we cannot assume she meets the inclusion criteria based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1196": {
        "output": "Based on the patient note, the patient is a 54-year-old woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain radiates to the right upper quadrant and worsens after eating fatty food. Laboratory analysis showed elevated ESR and leukocytosis. An ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones, indicating a gallstone-related condition.\n\nThe clinical trial's inclusion criteria are for patients admitted through the emergency department for an acute gallstone-related condition. The conditions listed include cholecystitis, gallstone pancreatitis, ascending cholangitis, suspicion of gallstone migration, and choledocholithiasis.\n\nThe patient's symptoms and ultrasound findings support a diagnosis that fits into the acute gallstone-related conditions described in the trial's inclusion criteria, specifically choledocholithiasis, which refers to stones in the common bile duct.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1197": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, let's analyze the patient's eligibility:\n\nPatient note mentions:\n- A 54-year-old obese woman with abdominal pain, nausea, and vomiting.\n- Pain exacerbated after eating fatty food, indicating a possible gallbladder issue.\n- Past medical history includes hypercholesterolemia and 2 normal vaginal deliveries (NVDs).\n- No mention of the need for hip arthroplasty or any other orthopedic surgery.\n- No information provided regarding the need for a lumbar plexus block or any form of anesthesia related to surgery.\n\nClinical trial inclusion criteria:\n- Primary elective total hip arthroplasty surgery.\n- Candidate for placement of a lumbar plexus block under anatomic landmark technique using electrical stimulation.\n- Must give written informed consent for anesthesia.\n- Must be reliable and able to give accurate verbal pain scores postoperatively.\n\nThe patient does not meet the inclusion criteria for the clinical trial because there is no mention of her undergoing elective total hip arthroplasty surgery or needing a lumbar plexus block. Therefore, she does not qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1198": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate whether the patient is eligible for the trial.\n\nPatient Note Summary:\n- 54-year-old woman\n- Symptoms: abdominal pain, nausea, vomiting, pain worse after eating fatty food, epigastric and right upper quadrant tenderness\n- Medical history: hypercholesterolemia, menopause\n- Current findings: mild fever, elevated ESR, leukocytosis with a left shift\n- Imaging: ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Patients referred for an abdominal ultrasound\n- Age > 18 years\n\nThe patient in the note is over 18 years old and has been referred to the emergency department with symptoms that led to an ultrasound revealing gallstones. Despite not being explicitly stated that the patient was referred to the radiology department for the ultrasound, it can be inferred from the context that the patient's condition required an ultrasound and thus she was effectively referred for such a procedure as part of her evaluation.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial on the accuracy of surgeon-performed ultrasound in detecting gallstones.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1199": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note:\n- A 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar episodes in the past.\n- Past medical history includes hypercholesterolemia.\n- Current symptoms suggest gallbladder issues, and ultrasound confirms gallstones and biliary sludge.\n- No mention of a hemolytic disorder in the patient's medical history.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of a hemolytic disorder (spherocytosis, G6PD deficiency, thalassemia, or sickle cell disease).\n- Patients with cholelithiasis or bile sludge.\n- Age greater than or equal to 4 years.\n- Ability to consent to and participate in the study and follow study procedures.\n\nAssessment:\nThe patient has cholelithiasis (gallstones) and biliary sludge, which aligns with one of the inclusion criteria. However, there is no mention of a hemolytic disorder in the patient's medical history, which is a key requirement for the trial. Without a diagnosis of a hemolytic disorder, the patient does not meet all the inclusion criteria necessary for participation in the study.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1200": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain episodes\n- History of hypercholesterolemia\n- Menopausal\n- No mention of bacterial enteritis or specified pathogens\n- Elevated ESR, leukocytosis, ultrasound revealed gallstones and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Written informed consent\n- Distinctive symptoms and findings of bacterial enteritis\n- Bacterial enteritis caused by specific pathogens (C. difficile, Salmonella, Campylobacter, pathogenic E. coli, etc.)\n- Willingness to take contraceptive measures\n\nThe patient has presented with symptoms that are suggestive of gallstones and potential biliary pathology, rather than bacterial enteritis. There is no indication in the patient note that the patient has bacterial enteritis or an infection with one of the specified pathogens. Therefore, the patient does not meet the inclusion criteria for the clinical trial assessing different doses of OPS-2071 in patients with Bacterial Enteritis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1201": {
        "output": "The patient note describes a 54-year-old obese woman who presents with abdominal pain, nausea, vomiting, and a history of similar pain episodes in the past. The pain is associated with eating fatty food, and she has been found to have gallstones, biliary sludge, and CBD stones on ultrasound. Her symptoms and diagnosis suggest that she is experiencing issues related to her gallbladder, likely gallstone disease or cholecystitis, rather than gastroesophageal reflux disease (GERD).\n\nThe clinical trial in question is looking for patients aged 18-65 years who go to the gastroenterology clinic presented with upper gastrointestinal discomfort symptoms related to GERD, such as heartburn, regurgitation, dysphagia, substernal pain, epigastric pain, epigastric burning, early satiety, postprandial fullness. These symptoms should have lasted for at least 3 months and occur at least 3 days per week with moderate severity. Additionally, patients should be able to fill in the questionnaires.\n\nThe patient's symptoms of epigastric pain radiating to the right upper quadrant, worsening after eating fatty foods, do include \"epigastric pain,\" which is listed as one of the symptoms of interest for the GERD clinical trial. However, the context of her symptoms, alongside her diagnosis, does not directly indicate GERD. Without further information indicating that her epigastric pain is due to GERD (such as heartburn, regurgitation, or a positive PPI test) and not her gallbladder condition, it is not clear that she fits the inclusion criteria for the GERD clinical trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1202": {
        "output": "Based on the patient note provided, the 54-year-old woman is presenting with abdominal pain, nausea, and vomiting that worsens after eating fatty food. The ultrasound findings suggest gallstones and biliary sludge, which indicates that her abdominal pain is likely due to biliary colic rather than acute gastroenteritis. Acute gastroenteritis is typically characterized by diarrhea, which is not mentioned in the patient's presentation.\n\nThe inclusion criteria for the clinical trial are:\n\n- Adult patients\n- Presenting to the emergency department with abdominal cramps associated with acute gastroenteritis\n- The pain intensity score upon screening is at least 20 mm on visual analog scale\n- Patients who agree to participate and sign the informed consent\n\nThe patient in the note does not fulfill the criteria as her symptoms are not associated with acute gastroenteritis but rather with gallstones, and there is no information provided regarding the pain intensity score on the visual analog scale or her consent to participate in the study.\n\nTherefore, the patient is not eligible for the clinical trial because she does not meet the inclusion criteria of presenting with abdominal cramps associated with acute gastroenteritis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1203": {
        "output": "To determine this patient's eligibility for the clinical trial titled \"Essentiale\u00ae Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases,\" we must compare the patient's characteristics and conditions to the inclusion and exclusion criteria of the study.\n\nInclusion Criteria:\n\n1. Males and females \u226518 years of age and less than 66 years old. \n   - The patient is a 54-year-old woman, which fits the age criterion.\n\n2. Patients with gastrointestinal symptoms in acute and chronic liver diseases receiving conventional treatment for the underlying pathology.\n   - The patient presents with abdominal pain and has gastrointestinal symptoms, but there is no clear indication that these symptoms are due to acute or chronic liver diseases.\n\n3. The patient is able and willing to undertake all study required procedures and has the ability to take oral medications.\n   - There is no information provided that assesses the patient's ability or willingness to undertake study procedures or take oral medications.\n\n4. Patients with nonalcoholic fatty liver disease (NAFLD) diagnosed by ultrasound examination in the absence of severe fibrosis as per Investigator's judgment.\n   - The patient's ultrasound revealed gallstones, biliary sludge, and CBD stones, but there is no mention of NAFLD or liver fibrosis.\n\n5. Diagnosis of acute or chronic viral hepatitis as manifested by a combination of symptoms.\n   - The patient's note does not indicate the presence of hepatitis.\n\n6. Patient has given written informed consent.\n   - This information is not provided in the patient note.\n\n7. Fertile patients must agree to use an acceptable method of contraception.\n   - The patient is menopausal, so this may not be relevant.\n\nExclusion Criteria:\n\n- There are several exclusion criteria listed, but since the patient does not meet the inclusion criteria for having acute or chronic liver disease, we do not need to assess these in detail.\n\nGiven the information provided in the patient note, the patient does not have a diagnosis of acute or chronic liver disease, which is a requirement for the clinical trial. Therefore, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1204": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial on acute low back pain, the patient does not appear to be eligible for the trial. The patient presented with abdominal pain radiating to the right upper quadrant, not acute low back pain. Additionally, the trial specifically requires participants to have severe acute low back pain with a duration within 24 hours after onset, and the pain must exceed 50mm on the visual analog scale (VAS). There is no mention of acute low back pain or its assessment with a VAS in the patient's note.\n\nTherefore, this patient does not meet the inclusion criteria for the trial on acute low back pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1205": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old woman with symptoms that suggest gallbladder issues, specifically gallstones and biliary sludge. She has a history of hypercholesterolemia and has had two normal vaginal deliveries (NVDs). There is no mention of her seeking a medical abortion or being a candidate for a medical abortion. \n\nThe clinical trial in question is looking to evaluate women's compliance with using a semiquantitative pregnancy test at home for medical abortion follow-up. The inclusion criteria for this trial are specific to women who are undergoing medical abortion with mifepristone followed by misoprostol, are willing to use the pregnancy test at home, can comply with the study's procedures, can speak and read English, and have signed an informed consent form.\n\nSince there is no information suggesting that the patient is seeking a medical abortion or is in the process of undergoing one, she does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1206": {
        "output": "Based on the information provided, the 54-year-old obese woman admitted with abdominal pain and a diagnosis of gallstones does not meet the inclusion criteria for the clinical trial that is focused on patients with stage II-IV head and neck cancer undergoing chemoradiation. The patient in the note does not have a diagnosis of head and neck cancer, nor is there any mention of her being eligible for chemoradiation therapy for such a condition.\n\nTherefore, the patient does not have the disease that the trial is studying (head and neck cancer), and none of the other criteria (such as ECOG performance status or the ability to swallow and retain oral medication) can be assessed as relevant without the primary disease context.\n\nGiven this information, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1207": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain in the past\n- Medical history includes hypercholesterolemia\n- Menopausal, no smoking, alcohol, or illicit drug use\n- Mild fever, elevated BP and heart rate\n- Leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Patients with overt signs of upper gastrointestinal bleeding (e.g., hematemesis, melena, and/or circulatory instability)\n- Documented bleeding from a non-variceal upper gastrointestinal source at endoscopy\n\nThe patient described in the note does not have overt signs of upper gastrointestinal bleeding; rather, she presents with symptoms suggestive of gallstones and biliary issues. There is no mention of hematemesis, melena, or circulatory instability that would indicate upper gastrointestinal bleeding. Furthermore, there is no documentation of a non-variceal upper gastrointestinal source of bleeding from an endoscopy.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1208": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's trial-level eligibility:\n\nThe clinical trial is focused on patients with difficult large bile duct stones and is evaluating the efficacy and safety of Spyglass-guided laser lithotripsy for the treatment of these stones. The inclusion criteria for the trial are:\n\n1. Bile duct stone >1.5cm demonstrated on ultrasound, computed tomography, or magnetic resonance imaging.\n\nFrom the patient note:\n- The patient is a 54-year-old woman with abdominal pain and other symptoms suggestive of gallstones.\n- The ultrasound revealed several gallstones, biliary sludge, and CBD (common bile duct) stones.\n- The smallest stone is 14mm, which means it is greater than 1.5cm.\n\nBased on this information, the patient meets the inclusion criteria for the clinical trial, as she has a bile duct stone larger than 1.5cm. There is no mention of exclusion criteria, so we cannot determine if any exclusion criteria apply to this patient. Therefore, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1209": {
        "output": "Assessing the eligibility of the 54-year-old woman for the clinical trial of Pecs II Block for Breast Surgery based on the patient note provided:\n\n- The clinical trial is focused on patients undergoing breast surgery, specifically those with primary breast cancer without known extension beyond the breast and axillary nodes, scheduled for unilateral or bilateral mastectomy with or without implant, or isolated lumpectomy with axillary node dissection.\n\n- The patient in the note is admitted with symptoms suggesting gallbladder disease, specifically presenting with abdominal pain, nausea, vomiting, and findings consistent with gallstones and biliary sludge on ultrasound. There is no mention of breast cancer or any planned breast surgery.\n\n- The patient's condition and the reason for admission are not related to the inclusion criteria of the clinical trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial on the Pecs II Block for Breast Surgery as she does not have a diagnosis of breast cancer, nor is she scheduled for breast surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1210": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nThe patient note describes a 54-year-old obese woman with symptoms indicative of gallstones and biliary sludge. She is not described as being pregnant nor scheduled for induction of labor. Therefore, she does not meet any of the inclusion criteria for the clinical trial, which is specifically designed for pregnant women at \u226537 weeks gestation who are scheduled for induction of labor.\n\nGiven that the patient in question is not pregnant and does not fit any of the other inclusion criteria (such as gestational age, singleton gestation, cephalic presentation, etc.), she would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1211": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, the patient does not appear to meet the specific symptoms outlined for the clinical trial. The trial is focused on patients arriving at the emergency department with respiratory difficulties, as indicated by symptoms such as cough, dyspnea, chest pain, increased respiration frequency, or reduced peripheral saturation.\n\nThe patient in the note is presented with abdominal pain, nausea, vomiting, and an issue related to gallstones and biliary sludge, as indicated by the ultrasound results. There is no mention of respiratory difficulties such as cough, dyspnea, chest pain, increased respiration frequency, or reduced peripheral saturation that would qualify her for the clinical trial focused on focused ultrasonography examination (f-US) for patients with respiratory difficulties.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1212": {
        "output": "Based on the patient note, the patient is a 54-year-old woman with symptoms suggestive of gallstones and confirmed common bile duct stones, as evidenced by ultrasound findings. She meets the following inclusion criteria for the \"Chinese Registry Study on Treatment of Cholecysto-Choledocholithiasis\" clinical trial:\n\n- Age between 18 - 80 years: The patient is 54 years old, which falls within the required age range.\n- Diagnosed with gallstones: The ultrasound revealed several gallstones.\n- Diagnosed with common bile duct stone by one of the three exams (MRI, MRCP, and CT) or intra-operative cholangiography or transcystic exploration: The ultrasound revealed CBD stones, and while ultrasound is not specifically listed in the criteria, it can be inferred that the diagnosis of CBD stones meets this criterion.\n\nSince the patient fulfills all the listed inclusion criteria and there are no exclusion criteria provided, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1213": {
        "output": "Based on the provided patient note and the inclusion criteria of the Solana\u2122 Trichomonas Assay Field Study, the patient does not seem to meet the specific inclusion criteria for the clinical trial. The patient in the note is presenting with symptoms related to gallstones and biliary sludge, which include abdominal pain, nausea, vomiting, and elevated ESR and leukocytosis. There is no mention of symptoms related to Trichomonas vaginalis infection, such as greenish-yellow vaginal discharge, painful urination, vaginal itching and irritation, discomfort during intercourse, or lower abdominal pain. \n\nSince the patient's symptoms and medical history do not align with the inclusion criteria of the study, which specifically requires symptoms indicative of Trichomonas vaginalis infection or the need to aid in the diagnosis of trichomoniasis, the patient would be considered not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1214": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility:\n\nPatient note:\n- 54-year-old obese woman\n- Presented with abdominal pain, nausea, vomiting\n- Pain after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Menopausal\n- Non-smoker, no alcohol or illicit drug use\n- Mild fever, elevated blood pressure, and heart rate\n- Epigastric tenderness and right upper quadrant tenderness\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones and biliary sludge\n\nClinical trial inclusion criteria for the constipated group:\n- Aged 18-40 or 70-90 years of age\n- Barthel index \u226511 [for elderly women only]\n- No co-existing acute or chronic diseases at the time of recruitment (except hypertension and hypercholesterolemia for elderly women)\n- Patients with self-reported problematic constipation\n- Cleveland Clinic Constipation Score \u22658\n- Bowel movement frequency <3 per week\n- Stool consistency of 1-3 on the Bristol Stool Chart\n- No evidence of organic causes of constipation\n- Symptoms of constipation for at least the previous 3 months\n\nClinical trial inclusion criteria for the non-constipated group:\n- Healthy women aged 18-40 or 70-90 years of age\n- No co-existing acute or chronic diseases at the time of recruitment (except hypertension and hypercholesterolemia for elderly women)\n- Barthel index \u226511 [for elderly women only]\n- Cleveland Clinic Constipation Score <8\n\nAssessment:\n- The patient's age (54 years) does not fit the age criteria specified for either the constipated or non-constipated groups (18-40 or 70-90 years of age).\n- The patient is not reported to have constipation; instead, she presents with symptoms suggestive of gallbladder issues (gallstones and biliary sludge).\n- There is no information on the patient's Cleveland Clinic Constipation Score, bowel movement frequency, stool consistency, or a history of constipation for the last 3 months.\n\nGiven this information, the patient does not meet the age criterion for either group in the clinical trial and does not have documented symptoms of constipation, which is a requirement for the constipated group. The trial is specific to constipation and aging, and the patient's current acute condition (gallstones and related symptoms) and age exclude her from this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1215": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis,\" we need to review the patient note and compare it to the inclusion and exclusion criteria of the trial.\n\nPatient Note Review:\n- Age: 54 years old\n- Presenting with abdominal pain, nausea, vomiting\n- Pain after eating fatty food\n- Past medical history: hypercholesterolemia\n- No mention of alcohol consumption, mental conditions, or pregnancy\n- No indication of previous surgeries such as Roux en Y gastric bypass\n- Fever, elevated ESR, leukocytosis\n- Ultrasound: gallstones, biliary sludge, and CBD stones\n- No mention of serum amylase/lipase levels\n- No mention of evidence of pancreatitis on imaging\n\nClinical Trial Criteria:\n- Inclusion criteria: Age 18-70, first gallstone acute pancreatitis, diagnosis based on Atlanta Consensus, ultrasonography showing stones or sludge, exclusion of other etiologies\n- Exclusion criteria: Acute cholecystitis, acute cholangitis, certain surgical histories, acute alcohol consumption, chronic hepatic/pancreatic disease, comorbidities contraindicating surgery, inability to provide consent, pregnancy, patient refusal, no endoscopist availability\n\nAssessment:\nThe patient is within the age range (18-70 years) required by the trial. The patient's description indicates gallstones and biliary sludge, which are consistent with a biliary etiology for her symptoms. However, there is no explicit mention of a diagnosis of acute pancreatitis based on the Atlanta Consensus criteria, and the required serum amylase/lipase levels are not provided in the note. There is also no explicit mention of imaging evidence confirming pancreatitis. The trial requires a diagnosis of gallstone acute pancreatitis, which has not been confirmed in the patient note. Therefore, we cannot establish that she meets all the inclusion criteria.\n\nGiven the lack of specific information confirming a diagnosis of gallstone acute pancreatitis as per the trial's inclusion criteria, the patient cannot be considered eligible at this time. Hence, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1216": {
        "output": "The patient is a 54-year-old obese woman who has presented to the emergency department with abdominal pain, nausea, and vomiting. The pain is worse after eating fatty food, which is characteristic of gallbladder-related issues. Laboratory findings and an ultrasound have confirmed the presence of gallstones, biliary sludge, and common bile duct (CBD) stones, with the smallest stone being 14mm in diameter.\n\nThe clinical trial in question is investigating the comparison of endoscopic sphincterotomy plus large-balloon dilatation (ESLBD) and conventional treatment for large CBD stones. The inclusion criteria for this trial are patients with CBD stones with a smaller diameter of \u2265 13mm on cholangiogram.\n\nSince the patient has CBD stones and the smallest stone measures 14mm, she meets the size criterion for the study. The patient note does not mention any other conditions or factors that would exclude her from the trial based on the provided information. Therefore, given the information provided in the patient note, this patient appears to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1217": {
        "output": "Given the information provided for the patient, the patient is a 54-year-old woman who presented to the emergency department with abdominal pain, nausea, and vomiting. The pain radiates to the right upper quadrant and worsens after eating fatty food. There are no indications that the patient has symptoms suggestive of acute coronary syndrome (ACS) or myocardial ischemia; rather, her symptoms and ultrasound findings are indicative of gallstones and biliary pathology.\n\nThe clinical trial in question is seeking to enroll adults presenting with symptoms suggestive of ACS. Based on the information presented in the patient note, this individual's symptoms do not align with those of ACS and, therefore, do not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1218": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we need to assess whether this 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pain is eligible for a clinical trial investigating the clinical characteristics of patients with choledocholithiasis without cholangitis.\n\nThe inclusion criteria for the trial are:\n1. Patients diagnosed with CBD stone under endoscopic retrograde cholangiopancreatography (ERCP).\n2. Patients showing above 400 IU/L of aminotransferase when at the first admitted into the hospital, and the control groups are the patients displaying normal AST and ALT.\n\nThe patient note indicates the patient has been diagnosed with several gallstones, biliary sludge, and CBD stones through ultrasound, which aligns with the first criterion. However, the second criterion requires elevated aminotransferase levels (above 400 IU/L) upon first hospital admission. The patient note does not provide information about the patient's aminotransferase levels (AST and ALT). Without this information, we cannot confirm if the patient meets the second inclusion criterion.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.\n\nThis assessment is made on the basis that the patient note does not include sufficient information about the patient's aminotransferase levels to determine eligibility for the clinical trial.",
        "label": 0
    },
    "1219": {
        "output": "To determine the patient's trial-level eligibility for the clinical trial, we need to compare the information in the patient note against the inclusion criteria of the clinical trial.\n\nPatient note analysis:\n- The patient is a 54-year-old obese woman with abdominal pain characteristic of gallstones, as confirmed by ultrasound.\n- Her medical history includes hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs).\n- She does not have a diagnosis of functional dyspepsia but rather symptoms consistent with gallstones.\n- The patient's abdominal ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones, which are structural abnormalities.\n\nClinical trial inclusion criteria analysis:\n- Subjects must be 18 years or older, which the patient meets.\n- Suspected diagnosis of functional dyspepsia according to Rome III criteria with no evidence of structural disease that is likely to explain the symptoms.\n- BMI between 18.5-30, but the patient is described as obese, which may mean her BMI is over 30.\n- Absence of significant structural/organic abnormalities on abdominal ultrasound, which the patient does not meet due to the presence of gallstones and CBD stones.\n- Negative Helicobacter Pylori urea breath test, which we have no information on.\n- Presence of at least three out of ten assessed symptoms of moderate or severe intensity, with no medication affecting the gastrointestinal tract, which we have no information on.\n- For females of childbearing potential, a negative urine pregnancy test is required, which we have no information on but the patient is menopausal, so this may not be applicable.\n- Agreement to contraceptive requirements, which we have no information on.\n- Ability to read and understand the local language, which we assume she can.\n- Provide a signed and dated informed consent form, which we assume she can if willing.\n- Willing and able to comply with all study procedures and attend the scheduled visits, which we assume she can if willing.\n\nBased on the patient note and the clinical trial inclusion criteria, the patient is not eligible for the trial. She does not have a diagnosis of functional dyspepsia, and she has evidence of structural abnormalities (gallstones and CBD stones) that explain her symptoms, which is contrary to the trial's requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1220": {
        "output": "Given Patient Note:\n- 54-year-old woman\n- Symptoms: abdominal pain, nausea, vomiting, pain after eating fatty food\n- History: hypercholesterolemia, no mention of pancreatitis\n- Current episode: epigastric pain, tenderness in the right upper quadrant, mild fever\n- Labs: elevated ESR, leukocytosis\n- Imaging: ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 20 years\n- Acute biliary pancreatitis with either:\n  a) signs of acute cholangitis or\n  b) bile duct obstruction\n- Diagnosis of acute gallstone pancreatitis with:\n  a) abdominal pain typical of pancreatitis\n  b) elevated serum amylase and/or lipase\n  c) imaging studies showing evidence of pancreatitis\n  d) common bile duct stones or acute cholangitis, total bilirubin levels, bile duct dilatation\n  e) exclusion of other causes of acute pancreatitis\n\nAssessment:\nThe patient's age fits the inclusion criteria (>20 years). However, the patient note does not mention acute pancreatitis, elevated serum amylase or lipase levels, or imaging studies that confirm pancreatitis, which are necessary for inclusion in the study. While the presence of gallstones and biliary sludge could be related to pancreatitis, without explicit evidence of pancreatitis and without the required lab results, we cannot confirm the patient's eligibility for the clinical trial.\n\nThe note does not provide sufficient information to assert that the patient has acute biliary pancreatitis or acute cholangitis, which are specific conditions required by the trial's inclusion criteria. As such, we cannot confirm eligibility based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1221": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to determine whether the patient is eligible for this trial. \n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a diagnosis of gallstones and biliary sludge based on ultrasonography. \n\nThe clinical trial in question is evaluating the use of smoke evacuation systems in operating rooms, specifically during head-neck, breast, or abdominal laparoscopic surgeries.\n\nThe inclusion criteria for the trial are:\n- Surgical patients who receive head-neck or breast surgery\n- Surgical patients who receive abdominal laparoscopic surgery\n\nThe patient note indicates that the woman has been admitted to the emergency department with gallstones which could potentially require abdominal surgery, but there is no information provided that confirms she will be undergoing laparoscopic surgery. The trial criteria are specific about the type of surgery and do not include all abdominal surgeries, only laparoscopic ones.\n\nAs the information stands, we do not have enough data to confirm that the patient will be undergoing abdominal laparoscopic surgery. Therefore, we cannot definitively include her in the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1222": {
        "output": "Based on the information provided:\n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones. Her medical history includes hypercholesterolemia and she has given birth to two children (NVDs - normal vaginal deliveries). She is menopausal and does not have any history of smoking, alcohol, or illicit drug use.\n\nThe clinical trial in question is evaluating the efficacy and safety of CUDC-907 in patients with Relapsed/Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), including patients with MYC alterations.\n\nInclusion criteria for the trial:\n- Age \u2265 18 years.\n- At least 2 but no more than 4 prior lines of therapy for de novo DLBCL.\n- Ineligible for or failed autologous or allogeneic stem cell transplant.\n- Histopathologically confirmed diagnosis of RR DLBCL as per WHO classifications.\n\nThe patient described does not have a diagnosis of DLBCL or any related hematologic neoplasm mentioned in the trial's inclusion criteria. Instead, the patient has gallstones and related gastrointestinal symptoms. Therefore, she does not meet the disease-specific criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1223": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient described does not meet the criteria for inclusion in the trial. The trial is specifically looking for primigravida women aged 18-35 years who are in the late stages of a singleton pregnancy, without a past history of any medical disorder and no medical complications during the current pregnancy.\n\nThe patient in the note is a 54-year-old woman presenting with symptoms consistent with gallbladder stones and potentially cholecystitis, as indicated by abdominal pain, nausea, vomiting, and relevant imaging findings. There is no mention of pregnancy, let alone preeclampsia, which is the condition being studied in the trial. Additionally, the patient is outside the specified age range and there is no information on her vitamin D levels or any suggestion of her being primigravida or at gestational weeks 36-40.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1224": {
        "output": "Based on the provided patient note and the clinical trial's inclusion and exclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman, which fits within the age range specified by the trial (18 to 65 years old).\n- The patient's medical issue is related to gallstones and biliary sludge, as indicated by abdominal pain and ultrasound findings.\n- The patient has a history of hypercholesterolemia.\n- There is no mention of the patient having type 2 diabetes.\n\nClinical Trial Inclusion Criteria:\n- The trial is looking for type 2 diabetic obese patients.\n\nClinical Trial Exclusion Criteria:\n- Patients age above 65 or below 18 years old.\n- History of upper laparotomy.\n- Unfit for anesthesia or laparoscopy.\n- Major psychological instability and drug abuse.\n\nThe patient's note does not mention type 2 diabetes, which is a requirement for the clinical trial. Therefore, the patient does not meet the inclusion criteria of having type 2 diabetes, despite being within the correct age range and being obese.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1225": {
        "output": "Given the patient's history and presentation, let's compare the details with the inclusion and exclusion criteria of the clinical trial:\n\n**Patient Details:**\n- 54-year-old woman (age eligible)\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worse after eating fatty food\n- History of similar pain twice in the past year\n- Past medical history of hypercholesterolemia\n- Obese\n- Fever\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\n**POCUS-1 Inclusion Criteria:**\n- RUQ mass/pain/tenderness (Patient has RUQ tenderness)\n- Murphy's Sign (Not mentioned in the patient note)\n- Fever (Patient is febrile)\n- Elevated WBC (Patient has leukocytosis)\n- Elevated CRP (Not specified in the patient note)\n- Deranged liver function tests (Not specified in the patient note)\n- Jaundice (Not mentioned in the patient note)\n\n**POCUSS-1 and 2 Exclusion Criteria:**\n- Age under 18 (Patient is 54, so not applicable)\n- Pregnancy (Not mentioned, but patient is menopausal, so not pregnant)\n- Obesity (BMI \u2265 30) - difficulty in performing USS (Patient is obese)\n- Previously documented gallstones within the last 2 months for non-critical presentations (Not mentioned when gallstones were previously documented)\n- Previously documented diverticulitis within the last 2 months for non-critical presentations (Not applicable)\n- POCUS performed after official report (for training purposes) (Not applicable)\n- Previous colonic resection, particularly left sided or sigmoid colon (Not mentioned)\n- Previous cholecystectomy (Not mentioned)\n\nThe patient meets several of the POCUS-1 inclusion criteria, such as RUQ pain/tenderness and fever, and also has an elevated WBC count. However, she is excluded based on her obesity, as the exclusion criteria specifically mention a difficulty in performing ultrasound scanning with a BMI \u2265 30, which defines obesity.\n\nTherefore, the patient is not eligible for the clinical trial due to meeting one of the exclusion criteria (obesity).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1226": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial:\n\nPatient note:\n- The patient is a 54-year-old obese woman with symptoms consistent with gallstones and possible cholecystitis (abdominal pain, nausea, vomiting, epigastric pain radiating to the right upper quadrant, fever, elevated ESR, leukocytosis, ultrasound findings of gallstones and biliary sludge).\n- The patient's medical history includes hypercholesterolemia and she is menopausal.\n- There is no mention of psychiatric disorders or any treatment with Deep Brain Stimulation (DBS).\n\nClinical trial:\n- The trial is about the use of rechargeable neurostimulators in DBS for psychiatric disorders, specifically Obsessive-Compulsive Disorder (OCD) and major depression (MD).\n- Inclusion criteria require patients to have DBS for OCD or MD, experiencing a beneficial effect of DBS on psychiatric symptoms, requiring frequent IPG replacement, and the ability to give informed consent.\n\nThe patient described in the note does not fit the inclusion criteria because there is no indication that she has OCD or MD, nor is there any mention of her undergoing DBS or experiencing psychiatric symptoms. Therefore, she does not meet the specific requirements for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1227": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- A 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia.\n- The pain is related to gallstones and biliary sludge.\n- No mention of osteoarthritis or pain in the knee.\n\nClinical Trial:\n- Title: Radiofrequency Ablation of Genicular Nerves for Advanced Osteoarthrosis of the Knee Joint 1 Year Follow-up.\n- Inclusion Criteria: Patients must be suffering from pain caused by osteoarthrosis of the knee joint, specifically grades 3-4 according to the Kellgren Lawrence classification, with pain of moderate to severe intensity (VAS\u22655) for more than 3 months, which is resistant to conservative treatments.\n\nThe patient in the note does not mention any knee pain or a diagnosis of osteoarthrosis of the knee joint. Thus, she does not meet the inclusion criteria for the clinical trial, which requires patients to have a specific diagnosis of osteoarthrosis of the knee joint with certain severity and duration of pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1228": {
        "output": "",
        "label": 0
    },
    "1229": {
        "output": "Based on the patient note and the clinical trial information provided, here's the assessment:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and a history that includes hypercholesterolemia. She is currently experiencing symptoms consistent with gallstone disease, and the ultrasound has confirmed the presence of several gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is investigating the effectiveness of Ursodeoxycholic Acid in the prevention of gallstone formation after sleeve gastrectomy in patients who are obese and free of gallstones at baseline.\n\nThe inclusion criteria for the trial are:\n1. Obese patients (body mass index > 35 kg/m2) undergoing laparoscopic sleeve gastrectomy as a primary treatment for their obesity.\n2. No gallstone disease on initial ultrasounds.\n3. No previous cholecystectomy.\n\nSince the patient has confirmed gallstone disease on ultrasound, she does not meet the second inclusion criterion of having no gallstone disease on initial ultrasounds. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1230": {
        "output": "Based on the patient note provided, the 54-year-old obese woman presents with abdominal pain, nausea, vomiting, and a history of similar pain episodes. Her symptoms include epigastric pain that radiates to the right upper quadrant and worsens after eating fatty food. Her clinical signs and laboratory findings indicate gallstones, biliary sludge, and CBD stones, not acute appendicitis. Her symptoms and findings do not align with the clinical suspicion of acute appendicitis as specified in the inclusion criteria for the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n\n- Age > 8 years old\n- Clinical suspicion of acute appendicitis including the presence of direct tenderness in the right lower quadrant, percussion and rebound tenderness, pyrexia, anorexia, nausea, and vomiting.\n\nThe patient does show some overlapping symptoms such as nausea, vomiting, and pyrexia, which are common in many abdominal conditions, but the key symptoms and signs specific to acute appendicitis, like direct tenderness in the right lower quadrant, are not mentioned. Instead, the patient's symptoms and ultrasound results are indicative of gallstones and biliary pathology.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial focused on acute appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1231": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting, not sudden onset dizziness. The clinical trial is investigating the relationship between sudden onset dizziness (SOD) and acute liver dysfunction (ALD). Since the patient is not experiencing sudden onset dizziness, she does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the patient is not relevant for this clinical trial as her current medical issue does not align with the focus of the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1232": {
        "output": "To assess the patient's trial-level eligibility, let's compare the patient's information to the inclusion criteria of the given clinical trial:\n\nInclusion criteria for clinical trial:\n1. At least two episodes of acute pancreatitis in the past 12 months; acute pancreatitis is defined by any 2 of the following: (1) typical upper abdominal pain; (2) elevation in serum amylase or lipase >= 3 times upper limit of normal; (3) features of acute pancreatitis on cross-sectional imaging.\n2. ECOG performance status =< 1 (Karnofsky >= 70%).\n3. Leukocytes >= 2,500/microliter.\n4. Absolute neutrophil count >= 1,500/microliter.\n5. Platelets >= 100,000/microliter.\n6. Hemoglobin > 10 g/dL.\n7. Total bilirubin =< 3.0 x institutional upper limit of normal (ULN).\n8. AST/ALT =< 1.5 x institutional ULN.\n9. Creatinine < 1.5 mg/dL.\n10. Negative pregnancy test result for women of child-bearing potential.\n11. Agree to use adequate contraception.\n12. Ability to understand and willingness to sign an informed consent document and medical release.\n13. Willing and able to comply with trial protocol and follow-up.\n\nPatient information:\n- The patient is a 54-year-old woman with abdominal pain, nausea, vomiting, and a history of similar pain twice in the past year.\n- The patient has hypercholesterolemia.\n- The patient's symptoms and ultrasound findings are suggestive of gallstones, biliary sludge, and common bile duct (CBD) stones.\n- There is no mention of pancreatitis or any acute pancreatitis episodes in the past 12 months.\n- There is no information on ECOG performance status or other laboratory test results.\n- There is no information on the patient's ability to understand and willingness to sign an informed consent document.\n- No other relevant medical history or lab values are provided that directly match the inclusion criteria.\n\nBased on the available patient information, the patient does not meet the necessary criteria for the clinical trial related to recurrent, acute, or chronic pancreatitis. The patient has not been described as having had any episodes of acute pancreatitis, let alone two episodes in the past 12 months. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1233": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can evaluate the patient's eligibility for the trial:\n\nPatient Note:\n- The patient is a 54-year-old woman with abdominal pain, nausea, and vomiting.\n- She has a history of hypercholesterolemia, has had natural vaginal deliveries (NVDs), and is menopausal.\n- Currently experiencing symptoms suggestive of gallstone-related issues.\n- No mention of cardiac surgery.\n\nClinical Trial Inclusion Criteria:\n- Non emergent cardiac surgery.\n- Age > 18 years.\n- Affiliation to French Social Security.\n- Approval of participation to the study.\n\nAssessment:\n- The patient's age fits the inclusion criteria of being over 18 years old.\n- However, the clinical trial is specifically for patients who are undergoing non-emergent cardiac surgery. The patient note does not indicate that the patient is undergoing or has recently undergone cardiac surgery.\n- No information is provided regarding the patient's affiliation to French Social Security or their consent to participate in the study.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial as it is focused on postoperative nausea and vomiting after cardiac surgery, and there is no indication that the patient is undergoing such surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1234": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the trial.\n\nPatient Note:\n- A 54-year-old obese woman with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- All patients referred to a HIDA scan for evaluation of gallbladder function\n- No evidence of gallbladder stones on any prior anatomic imaging studies\n- Patients who are able to lie flat on the imaging table for an additional 30 min. after the standard of care 1.5 hour HIDA scan\n\nThe patient in the note has been diagnosed with gallbladder stones, which directly conflicts with one of the key inclusion criteria of the clinical trial, which requires no evidence of gallbladder stones on any prior anatomic imaging studies.\n\nTherefore, the patient is not eligible for the trial because she does not meet the inclusion criteria. The assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1235": {
        "output": "",
        "label": 0
    },
    "1236": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, the patient is a 54-year-old woman presenting with symptoms consistent with gallstones and possible cholecystitis (abdominal pain, nausea, vomiting, radiating pain after eating fatty food, and fever). The patient's medical history includes hypercholesterolemia and she is post-menopausal.\n\nThe clinical trial in question is for a treatment regimen involving EP0057, a nanoparticle camptothecin, with olaparib and is targeted at patients with relapsed/refractory small cell lung cancer (SCLC). The inclusion criteria for the trial involve having a confirmed diagnosis of SCLC, among other specific requirements related to the disease and the patient's general health status.\n\nGiven that the patient's medical condition as described in the note does not include small cell lung cancer or any other form of cancer, she does not meet the inclusion criteria for this clinical trial. The patient's presenting problem is related to gallstones and potential complications thereof, which is entirely unrelated to the focus of the clinical trial. Therefore, she is not eligible for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1237": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old woman with abdominal pain likely due to gallstones and biliary issues. Her condition does not mention acute mesenteric ischemia.\n\nThe clinical trial is looking for patients with an ICD-9 diagnosis of acute mesenteric ischemia who were admitted to the hospital after an Emergency Department assessment in the years 2014-2015. The only inclusion criteria listed are:\n\n1. ICD-9 diagnosis of acute mesenteric ischemia in 2014 and 2015\n2. Admitted to hospital after Emergency Department assessment\n3. Age > 18\n\nSince the patient's condition does not match the target condition of acute mesenteric ischemia, and there is no indication that she was admitted with this diagnosis in 2014-2015, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the assessment of eligibility for this clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1238": {
        "output": "Based on the provided information, the patient is a 54-year-old obese woman with symptoms suggestive of gallbladder disease, including abdominal pain, nausea, vomiting, and gallstones indicated by ultrasound. \n\nThe clinical trial in question is observational and is assessing whether the insufflation of CO2 results in a reduction of discomfort in patients undergoing Endoscopic Ultrasound (EUS), as well as secondary goals of evaluating sedation requirements and visual artifacts during the procedure.\n\nThe inclusion criteria for the trial are simply:\n\u2022 Consecutive patients referred for EUS\n\nThe patient note does not specifically state that the patient has been referred for EUS. However, given her symptoms and the findings of gallstones and biliary sludge, it is plausible that she could be referred for an EUS as part of her diagnostic workup for gallbladder disease.\n\nSince there is no direct information about the patient being referred for an EUS, we cannot definitively determine her eligibility based solely on the provided information. Therefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1239": {
        "output": "The patient is a 54-year-old obese woman with a medical history of abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones. She is currently presenting with symptoms indicative of gallbladder issues, such as pain after eating fatty food and an ultrasound confirming gallstones and biliary sludge.\n\nThe clinical trial in question is for patients with desmoplastic melanoma, which is a specific type of skin cancer.\n\nBased on the information given in the patient note, this patient does not meet the inclusion criteria for the clinical trial, as there is no mention of her having desmoplastic melanoma or any history of cancer treatment. The trial is specifically targeting patients with desmoplastic melanoma, either resectable or unresectable, and requires detailed criteria related to the disease and treatment history. The patient's current medical issues are not related to the conditions the trial is addressing.\n\nTherefore, the patient is not eligible for the trial. The trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1240": {
        "output": "Based on the patient note provided and the clinical trial\u2019s inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 54-year-old obese woman\n- Presenting with abdominal pain, nausea, vomiting, and history of similar pain\n- Past medical history includes hypercholesterolemia\n- No smoking, alcohol, or illicit drug use\n- Elevated ESR and leukocytosis noted in lab tests\n- Ultrasound revealed gallstones and biliary sludge\n\nClinical Trial Inclusion Criteria:\n- Female patients of age group 20 - 40 years undergoing elective laparoscopic cholecystectomy\n- ASA Physical Status- I & II\n\nEligibility Assessment:\n- The patient is a 54-year-old woman, which does not meet the age criterion of 20 - 40 years.\n- The ASA Physical Status is not mentioned in the patient note; however, given the patient's obesity and the presence of hypercholesterolemia, the patient may not fit into the ASA Physical Status I or II, which typically denote a patient with no or mild systemic disease.\n- The trial is specific for patients undergoing elective laparoscopic cholecystectomy. While the patient has gallstones and may be a candidate for cholecystectomy, it is not explicitly stated that she is scheduled for this procedure.\n\nWith the available information, the patient does not meet the age criterion for the trial, which is a primary determining factor for eligibility. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1241": {
        "output": "Let's compare the patient's information with the inclusion and exclusion criteria of the clinical trial:\n\nInclusion Criteria Analysis:\n1. Diagnosis of gallstone pancreatitis: The patient has upper abdominal pain, nausea, vomiting, and epigastric tenderness.\n2. Absence of ethanol abuse: There is no information on ethanol abuse, but the patient does not drink alcohol.\n3. Elevated lipase level above the upper limit of normal (>370 U/L): This information is not provided in the patient note.\n4. Imaging confirmation of gallstones or sludge: The ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n5. Low predicted mortality using the BISAP: This information is not provided in the patient note.\n6. Diagnosis of mild pancreatitis (i.e., no evidence of organ failure or local or systemic complications): This information is not explicitly stated, but the patient is admitted to the emergency department and is in no acute distress.\n7. Scheduled for laparoscopic cholecystectomy prior to discharge: There is no information on whether the patient is scheduled for surgery.\n8. Lack of any very strong indicator for choledocholithiasis based on the ASGE guidelines: The presence of CBD stones may indicate choledocholithiasis.\n9. Clinical stability as denoted by admission to a non-monitored floor bed: The patient is in the emergency department, and there's no information on admission to a non-monitored floor bed.\n\nExclusion Criteria Analysis:\n1. Pregnancy: There is no information about the patient being pregnant, and she is menopausal.\n2. Severe preexisting medical comorbidities precluding surgery, organ failure, local or systemic complications of acute pancreatitis: There is no information suggesting severe comorbidities or organ failure.\n3. Chronic pancreatitis: There is no information provided that the patient has chronic pancreatitis.\n4. Native language other than English and Spanish: There is no information about the patient's language.\n5. Patient refusal to participate: The patient's willingness to participate is not mentioned.\n\nBased on the patient note and the clinical trial criteria, the patient has several indicators that she may have gallstone pancreatitis and is presenting with symptoms that could align with such a diagnosis. However, key pieces of information are missing: specifically, the lipase level, the BISAP score, whether she is scheduled for surgery, and whether her condition is truly mild pancreatitis without complications. The presence of CBD stones may also conflict with the inclusion criteria, depending on the ASGE guidelines' interpretation.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the details provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1242": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman who has been admitted to the emergency department with abdominal pain, nausea, and vomiting. The clinical history presented suggests she is experiencing symptoms consistent with gallstones and biliary sludge, indicated by the ultrasound findings.\n\nNow, let's examine the clinical trial to determine if she is eligible:\n\nTitle: Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis\n\nInclusion Criteria:\n- Age \u2265 18 years\n- Procedure with General Anesthesia\n\nThe patient is 54 years old, which meets the age criterion. However, the patient note does not specify that she is undergoing a procedure with general anesthesia. While the symptoms and ultrasound findings suggest she may require surgical intervention (such as a cholecystectomy), there is no direct information about a scheduled procedure or the type of anesthesia to be used.\n\nSince there is no specific information that the patient will undergo a procedure with general anesthesia, we cannot conclusively determine her eligibility for this trial based solely on the information provided. Therefore, on the three-point scale, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1243": {
        "output": "",
        "label": 0
    },
    "1244": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 54-year-old obese woman\n- Presented with abdominal pain, nausea, vomiting\n- Pain gets worse after eating fatty food\n- History of hypercholesterolemia\n- Gallstones, biliary sludge, and CBD stones found on ultrasound\n- The smallest stone is 14mm\n\nClinical Trial Inclusion Criteria:\n- Patients who had EUS presence of CBDS \u2264 10 mm\n- EUS images absence of CBD stricture and CBD narrowing below the stones\n\nAssessment:\nThe patient note indicates the presence of CBD stones, with the smallest stone being 14mm in size. However, the inclusion criteria for the clinical trial specify that patients must have EUS presence of CBDS \u2264 10 mm. Since the patient's smallest stone is larger than the maximum size allowed by the trial's inclusion criteria, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1245": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the study. Let's review each criterion one by one:\n\n- **Patient has functional dyspepsia, postprandial distress syndrome (PDS) subtype, defined by the Rome III criteria.**\n  - The patient note indicates abdominal pain that may be associated with gallstones and biliary sludge, as shown by the ultrasound, rather than functional dyspepsia. There's no information suggesting the patient has been diagnosed with functional dyspepsia or meets the Rome III criteria for PDS.\n\n- **Patient has evidence of impaired gastric accommodation.**\n  - The patient note does not mention any evidence of impaired gastric accommodation.\n\n- **Patient's Rome III Questionnaire results indicate that the intensity of co-existing epigastric pain and/or epigastric burning may be present, but have the same or lesser intensity than the evaluations of postprandial fullness or early satiety (i.e., epigastric pain and burning are not the prominent symptoms of the patient's functional dyspepsia).**\n  - There is no information about the patient's Rome III Questionnaire results or the intensity of epigastric pain relative to postprandial fullness or early satiety.\n\n- **Patient recall of symptoms of gastrointestinal reflux over the past 8 weeks has no more than 2 episodes per week of heartburn or regurgitation.**\n  - The patient note does not mention any symptoms of gastrointestinal reflux, heartburn, or regurgitation.\n\n- **Patient is a male or female between 18 and 65 years of age at the pre-study/screening visit.**\n  - The patient is 54 years old, thus meeting this criterion.\n\n- **Patient has a Body Mass Index (BMI) >18 to \u226430 kg/m2 at the pre-study/screening visit.**\n  - The patient is described as obese, which suggests a BMI >30 kg/m2, therefore not meeting this criterion.\n\n- **Patient is judged to have no unmanaged significant disease or disorder based on medical history, physical examination, vital sign measurements, and laboratory safety obtained at pre-study/screening, and within 36 hours prior to first administration of study drug.**\n  - The patient has presented with abdominal pain and gallstones, which is a significant medical condition that is currently unmanaged.\n\n- **Patient has no clinically significant abnormality of ECG performed at pre-study/screening, and prior to first administration of study drug.**\n  - There is no information on an ECG in the patient note.\n\n- **Patient is willing to undergo the nutrient volume tolerance tests.**\n  - The patient's willingness to undergo specific tests is not mentioned in the patient note.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, there is insufficient information to determine if the patient has functional dyspepsia, and there are clear indications that the patient does not meet several of the key inclusion criteria (specifically regarding the diagnosis, BMI, and presence of unmanaged significant disease).\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1246": {
        "output": "The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and signs consistent with cholecystitis as indicated by the ultrasound revealing gallstones and biliary sludge. The clinical trial in question is focused on a conditional imaging strategy for the diagnosis of suspected acute uncomplicated renal colic.\n\nThe inclusion criteria for the trial are:\n- Adult patient\n- Patient admitted to the Emergency department with suspected acute uncomplicated renal colic\n\nThe exclusion criteria for the trial are:\n- Patient presenting with fever (>38\u00b0C)\n- Patient with persisting pain despite administration of morphinic\n- Patient presenting with anuria\n- Patients with a single kidney and/or history of chronic renal failure\n- Pregnant women or breastfeeding women\n- Patient with a history of renal colic\n- Patients unable to provide informed consent\n\nThe patient note does not indicate that the patient's condition is related to renal colic; rather, her symptoms and ultrasound findings suggest gallstones and potential cholecystitis. Additionally, the patient is presenting with a fever, which is an exclusion criterion for the clinical trial.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial focused on renal colic because her symptoms and diagnosis appear unrelated to renal colic. Moreover, she meets an exclusion criterion due to her fever.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1247": {
        "output": "The patient is a 54-year-old woman who presented with abdominal pain, nausea, vomiting, and elevated ESR and leukocytosis, suggesting an inflammatory process. An ultrasound revealed gallstones and biliary sludge, which is consistent with a diagnosis of gallstone disease, rather than pre-eclampsia.\n\nThe clinical trial in question is specifically looking for pregnant women with suspected pre-eclampsia. The inclusion criteria for this trial include being pregnant between 20+0 and 36+6 weeks of gestation, presenting with any symptoms of suspected pre-eclampsia, and being able to give informed consent.\n\nThe patient note does not mention pregnancy, nor does it describe any symptoms consistent with pre-eclampsia. Since the patient does not meet the primary inclusion criteria of being pregnant and is not within the gestational age range specified, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1248": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nThe clinical trial is studying the effect of ginger beverage consumption on platelet activity in apparently healthy Saudi adult volunteers aged 18-60 years.\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which fits within the age range of the trial's inclusion criteria (18-60 years).\n- The patient's current health condition is not \"apparently healthy\" as she is admitted to the emergency department with abdominal pain, nausea, vomiting, and other symptoms related to gallstones and biliary sludge.\n- The patient's past medical history includes hypercholesterolemia, which may affect platelet function, but this is not specifically mentioned as an exclusion criterion.\n- The trial specifies that volunteers should be \"apparently healthy,\" which implies the absence of active medical conditions that require immediate attention or could impact the study's outcomes on platelet function.\n\nGiven that the patient is currently seeking medical attention for an acute condition and does not fit the description of an \"apparently healthy\" individual, she would not qualify for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1249": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Objective Pain Score for Chronic Pain Clinic Patients,\" we can determine the following about the patient's eligibility:\n\n- Age: The patient is 54 years old, which fits within the 18-75 age range specified in the inclusion criteria.\n- Ability to self-report pain: There is no information provided that suggests the patient is unable to self-report their pain.\n- Chronic pain clinic patient: The patient note does not specify that the patient is a chronic pain clinic patient or will be receiving a pain treatment procedure.\n- English speaking: There is no information provided about the patient's language abilities.\n- Consent: There is no mention of whether the patient has received and signed a consent to participate in the study.\n\nThe patient note describes an acute presentation of abdominal pain associated with gallstones, which is not indicative of being a chronic pain patient. Furthermore, there is no mention of the patient being part of a chronic pain clinic or scheduled to receive a pain treatment procedure, which are required as per the inclusion criteria.\n\nGiven the lack of information about the patient's status as a chronic pain clinic patient and the context of the patient's visit (acute abdominal pain rather than chronic pain), the patient does not meet sufficient information to qualify for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1250": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain after eating fatty food\n- History of similar pain, hypercholesterolemia, and 2 NVDs\n- Menopausal, does not smoke, drink, or use drugs\n- Mildly febrile, elevated BP and HR, normal RR and SpO2\n- Epigastric and right upper quadrant tenderness\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria Summary:\n- Patients must be enrolled on APEC14B1 and consented to Eligibility Screening on the Part A consent form prior to enrollment on AALL1131\n- Specific White Blood Cell Count (WBC) criteria based on age\n- Newly diagnosed B lymphoblastic leukemia as per WHO classification; patients with Down syndrome are eligible\n- Organ function requirements for patients with Ph-like ALL and TKI-sensitive mutation\n- Specific criteria for creatinine clearance, serum creatinine levels, direct bilirubin, SGPT (ALT), cardiac function, EKG, and absence of dyspnea at rest\n- Additional eligibility criteria for seizure disorder, neurocognitive functioning study, and NCI standard risk patients from another study (AALL0932)\n\nThe patient in the note:\n- Does not have a diagnosis of B acute lymphoblastic leukemia or Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations as required by the trial.\n- Does not meet any other specific inclusion criteria listed for the clinical trial.\n\nThe patient is not eligible for the clinical trial because none of the conditions or criteria mentioned in the patient note align with the inclusion criteria of the trial, which specifically targets patients with a particular type of leukemia, and other very specific conditions that do not match the patient's situation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1251": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Routine Nasobiliary Insertion During ERCP in High Risk Patients,\" let's assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history: hypercholesterolemia\n- Menopausal, non-smoker, no alcohol or illicit drug use\n- Mildly febrile, elevated BP and HR\n- Laboratory findings: elevated ESR, leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones with the smallest stone being 14mm\n\nClinical trial inclusion criteria:\n- Patients with gallbladder (GB) stone complicated with CBD stones\n- Consent to participate in the study\n- Presence of one or more preoperative predictors for high risk for difficult cholecystectomy\n- Patient fit for laparoscopic cholecystectomy (LC)\n\nThe patient has been diagnosed with gallstones and CBD stones, which is consistent with the trial's target condition. There is no mention of the patient's consent to participate in the study, but since this is a hypothetical scenario and consent is typically obtained before enrollment, we can assume this criterion can be met. The patient's obesity could be considered a preoperative predictor for high risk for difficult cholecystectomy, although this is not explicitly stated in the note. Finally, there is no information given about the patient's fitness for laparoscopic cholecystectomy.\n\nGiven the information provided, the patient seems to meet most of the inclusion criteria for the clinical trial. However, the note does not explicitly state that the patient has consented to the study or confirm that the patient is fit for LC. Even though the patient appears to qualify based on her diagnosis, the lack of explicit information regarding consent and fitness for surgery means that we cannot definitively say she is eligible. Therefore, the patient's eligibility status is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1252": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Epigastric pain after eating fatty food\n- History of similar pain\n- Hypercholesterolemia, 2 NVDs\n- Menopausal\n- Non-smoker, non-alcoholic, no drug use\n- Mild fever, hypertension\n- Leukocytosis with left shift, elevated ESR\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Age \u226518 years\n- Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric (including GE junction), colorectal, pancreatic adenocarcinoma or biliary cancer\n- No curative options available\n- Progression on or following at least one/two prior lines of standard systemic therapy for the respective cancers\n- Archived tissue must be available\n- Measurable disease by RECIST 1.1 criteria\n- ECOG performance status of 0-1\n- Adequate organ function\n- Women of childbearing potential must have a negative pregnancy test and agree to use birth control\n- Ability to provide written informed consent\n- Life expectancy of at least 3 months\n\nAssessment:\n- The patient is a woman over 18 years old, meeting the age criterion.\n- The patient has been diagnosed with gallstones, biliary sludge, and CBD stones. There is no information about cancer diagnosis, specifically gastric, colorectal, pancreatic, or biliary cancer, nor is there information indicating that the patient is chemo-refractory or that the patient has advanced, recurrent, or metastatic disease.\n- There is no information provided about any cancer treatments or systemic therapies the patient may have received.\n- There is no mention of archived tissue availability, ECOG performance status, organ function, or life expectancy.\n\nGiven the information from the patient note, the patient does not meet the specific diagnosis criteria for the cancer types listed in the clinical trial inclusion criteria. Additionally, there is no information to suggest the patient has received cancer treatment or has a confirmed chemo-refractory status. Therefore, based on the available information, the patient does not meet the necessary inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1253": {
        "output": "Based on the provided patient note, the 54-year-old obese woman is admitted with abdominal pain, nausea, vomiting, and has an ultrasound that revealed gallstones and biliary sludge, which indicates she likely has gallbladder disease. Her medical history includes hypercholesterolemia, and there is no mention of primary biliary cholangitis (PBC). \n\nThe clinical trial in question is looking to evaluate the safety and tolerability of cilofexor in adults with primary biliary cholangitis (PBC) without cirrhosis. The inclusion criteria for the trial require a definite or probable PBC diagnosis based on specific criteria, which the patient does not meet. Therefore, based on the information provided, the patient is not eligible for this clinical trial as her condition (likely gallbladder disease) does not match the target disease of primary biliary cholangitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1254": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, radiating to the right upper quadrant and worse after eating fatty food. The patient has a history of hypercholesterolemia, has given birth to two children, and is menopausal. The laboratory analysis and ultrasound findings suggest gallstones and biliary sludge, leading to the abdominal pain.\n\nThe clinical trial in question focuses on Clostridium Difficile Infection (CDI) and is designed to determine if a bundle of measures applied by an Infectious Diseases expert can improve prognosis and reduce the rate of recurrence of CDI. The inclusion criteria for this trial are patients diagnosed with CDI at the University Hospital 12 de Octubre, Madrid, Spain, requiring hospitalization or emergency room admission longer than 48 hours.\n\nThe patient's note does not mention a diagnosis of CDI or any related symptoms or treatments. Thus, based on the information available, the patient does not meet the inclusion criteria for the clinical trial as she is not diagnosed with CDI, and there is no indication that she requires hospitalization for CDI.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1255": {
        "output": "The patient described is a 54-year-old obese woman presenting with symptoms consistent with gallstones and biliary sludge, and there is no mention of sexual trauma (ST), being a veteran, or any associated risk factors such as heavy drinking, PTSD, or IPV.\n\nThe clinical trial in question is designed for female veterans with a lifetime history of sexual trauma and at least one of the following risk factors: heavy drinking within the past 3 months, screen positive for current PTSD, or for IPV within the last 12 months. The patient must also be between 18-65 years of age and seeking treatment through the Women's Primary Care Clinics at the Central Texas VA Healthcare System.\n\nGiven the information provided in the patient note, we cannot confirm that the patient meets any of the specific inclusion criteria related to the clinical trial, such as being a veteran, having experienced sexual trauma, or the associated risk factors. Additionally, there is no mention of the patient seeking treatment through the VA Healthcare System.\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1256": {
        "output": "Based on the information provided, the patient in the note has been admitted to the emergency department with abdominal pain, nausea, and vomiting, and she has a history of hypercholesterolemia. An ultrasound revealed gallstones and biliary sludge, which is consistent with a diagnosis that is not related to cardiac surgery or the post-operative period.\n\nThe clinical trial in question is evaluating the effectiveness of ondansetron in preventing post-operative nausea and vomiting in patients who have undergone cardiac surgery and are coming off of post-operative sedation. The inclusion criteria specify that the trial is for patients who have undergone specific types of cardiac surgery procedures that require cardiopulmonary bypass.\n\nGiven that the patient in the note has not undergone any cardiac surgery and her current condition does not relate to the cardiac surgery post-operative period, she does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1257": {
        "output": "Based on the patient note, the 54-year-old woman has symptoms and ultrasound findings consistent with cholelithiasis and choledocholithiasis, as evidenced by the presence of gallstones and common bile duct (CBD) stones. The smallest stone is 14mm, which falls within the inclusion criteria range for the clinical trial focusing on Digital SpyGlass Cholangioscopy for common bile duct stone removal without fluoroscopy.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients with clinically suspected/confirmed common bile duct stones (CBDS)\n2. CBD caliber 5-15 mm\n\nThe patient's ultrasound revealed CBD stones, and the size of the smallest stone meets the criteria of being within the 5-15 mm range. There are no other specific inclusion criteria or exclusion criteria mentioned, and the patient's condition (CBD stones) is directly relevant to the trial's focus.\n\nTherefore, based on the available information, the 54-year-old woman is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1258": {
        "output": "",
        "label": 0
    },
    "1259": {
        "output": "Based on the patient note provided, the 54-year-old obese woman presented to the emergency department with abdominal pain and nausea, which fits the inclusion criteria of the clinical trial titled \"Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department,\" which requires a chief complaint of nausea or abdominal pain with nausea.\n\nThe patient is unable to tolerate oral nausea medication, as she is presenting with vomiting, which aligns with the second inclusion criterion. There is no mention of a pregnancy test in the patient note, which is a required criterion. However, since the patient is menopausal, it is reasonable to assume that she is not pregnant, thus meeting the third inclusion criterion.\n\nSince all available information suggests that the patient meets the inclusion criteria and there are no exclusion criteria mentioned that would disqualify the patient, the patient should be considered eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1260": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Endothelial Dysfunction in Hyperemesis Gravidarum,\" we can determine the patient's eligibility as follows:\n\nPatient note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant and worsens after eating fatty food\n- History of hypercholesterolemia\n- Menopausal\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones and biliary sludge\n\nClinical trial inclusion criteria:\n- 6-13 gestational weeks\n- 18-35 years of age\n- Single pregnancy\n- Dehydration due to Hyperemesis Gravidarum (HG)\n\nThe patient in the note is a 54-year-old woman, which is outside the age range specified in the trial's inclusion criteria (18-35 years). Additionally, there is no mention of the patient being pregnant, let alone being in the 6-13 gestational weeks range or suffering from dehydration due to Hyperemesis Gravidarum. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1261": {
        "output": "Based on the information provided, the patient in the note does not meet the inclusion criteria for the clinical trial. The patient is a 54-year-old obese woman with abdominal pain and gallstones, while the clinical trial is looking for children aged between 7 and 12 years old who are scheduled for a tonsillectomy.\n\nTherefore, the patient is not relevant for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1262": {
        "output": "Given the information from the patient note and the clinical trial's inclusion criteria, the patient does not meet the requirements for the clinical trial. The clinical trial is specifically looking for nulliparous women who are in well-established labor with a cervical dilation of 4 cm or more and at least 80% effacement of the cervix. The patient in question is a 54-year-old woman presenting with symptoms suggestive of gallstone-related issues, such as abdominal pain, nausea, vomiting, and findings of gallstones on an ultrasound. There is no indication that she is currently in labor or pregnant. Additionally, past medical history mentions that she has had 2 children (2 NVDs), which means she is not nulliparous.\n\nTherefore, based on the provided information, the patient does not qualify for the tramadol for labor analgesia clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1263": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient is a 54-year-old obese woman with symptoms and lab findings consistent with biliary pathology, likely cholecystitis or choledocholithiasis (gallstones in the common bile duct). The clinical trial in question is evaluating the efficacy and safety of a novel lumen-apposing metal stent for EUS-guided transenteric drainage of the pancreatobiliary system.\n\nTo determine eligibility, let's compare the patient's information with the inclusion criteria:\n\nInclusion Criteria for the trial:\n1. Pancreatobiliary diseases that are eligible for EUS-guided transenteric drainage.\n2. The patient who aged from 20 to 80 years.\n3. Legally acceptable representative must be capable of giving written informed consent prior to participation in this study.\n4. Target lesion that is accessible through the transenteric approach.\n5. The woman of child-bearing age must be negative from the pregnancy test in order to participate in this study.\n6. The patient who is willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures.\n7. The patients should not have any unacceptable conditions (e.g., physiological, familyism, social, geographical) for medical follow-up and adaptation of the study.\n\nPatient information:\n- The patient has biliary sludge and CBD stones, which could be considered a pancreatobiliary disease eligible for drainage.\n- The patient is aged 54 years, which falls within the required age range of 20 to 80 years.\n- There is no information provided about the patient's ability to give consent or have a representative do so, but this is typically assumed unless otherwise stated.\n- The presence of CBD stones suggests that there may be a target lesion accessible through the transenteric approach.\n- The patient is menopausal, making pregnancy unlikely; however, a pregnancy test would still be required for confirmation as per the trial criteria.\n- There is no information provided about the patient's willingness or ability to comply with the study requirements.\n- There is no information provided that suggests the patient has any conditions that would preclude medical follow-up or study participation.\n\nGiven that the patient has a pancreatobiliary disease (CBD stones) that could potentially be managed with EUS-guided transenteric drainage, and she falls within the age range specified, she meets the initial inclusion criteria. However, there is insufficient information on some criteria such as her ability to consent, willingness to participate, and the result of a pregnancy test.\n\nTherefore, the patient's eligibility for the clinical trial is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1264": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the eligibility of this patient for the clinical trial:\n\nThe patient is:\n- 54 years old (meets criteria: Patients over 18 years old)\n- Presenting with acute abdominal pain since 4 days ago (meets criteria: Patient presenting acute abdominal pain since 7 days or less)\n- Had a blood sample taken (implied by laboratory analysis, meets criteria: Need of blood sample confirmed by physician)\n\nHowever, it is not stated whether the patient is affiliated with the French social security system or if informed consent can be or has been provided. Without this information, we cannot definitively determine eligibility based on the inclusion criteria provided.\n\nTherefore, the patient's eligibility for the clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1265": {
        "output": "",
        "label": 0
    },
    "1266": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nThe patient is a 54-year-old woman, which meets the age criterion of the trial (patients 18 years or older). She is admitted to the emergency department with abdominal pain, nausea, and vomiting, which relates to the symptoms of interest for the trial (nausea or vomiting). However, the patient's symptoms are associated with gallstones, as revealed by the ultrasound, indicating a treatable cause for her nausea and vomiting.\n\nThe inclusion criteria for the clinical trial specify that participants must be in the palliative phase of cancer and suffer from nausea or vomiting where no treatable cause is assignable. The patient does not fit this description, as her symptoms are due to gallstones, and there is no indication that she is in the palliative phase of cancer or that her condition is untreatable.\n\nTherefore, the patient does not meet the specific inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1267": {
        "output": "The patient is a 54-year-old woman who presented with abdominal pain, nausea, and vomiting, and was found to have gallstones and CBD stones on ultrasound. Her medical history is notable for hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs). The clinical trial in question is focused on women who were readmitted postpartum for a hypertensive disorder.\n\nThe inclusion criteria for the trial are:\n- Women who labored and delivered at a single hospital.\n- Readmitted (within 6 weeks postpartum or less) to the hospital for a hypertensive disorder, with or without previous hypertension during pregnancy.\n- Controls Group with pre-eclampsia, not readmitted or no pre-eclampsia.\n\nBased on the provided patient note, there is no information regarding any postpartum readmission for a hypertensive disorder, or any issues related to hypertension during pregnancy or postpartum. Furthermore, the patient's current medical issues (abdominal pain and gallstones) are unrelated to the focus of the clinical trial.\n\nTherefore, there is insufficient information to qualify the patient for the trial based on the inclusion criteria provided. The patient note does not mention any hypertensive disorders during or post-pregnancy, which is a key component of the trial's focus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1268": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"The Evaluation of Pro/Antioxidative Profile and Diagnostic Parameters in the Patients With Pancreatic Disease,\" let's assess the eligibility of the patient:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Presents with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant, worse after eating fatty food\n- History of similar pain in the past\n- Hypercholesterolemia in medical history\n- Menopausal\n- No smoking, alcohol, or drug use\n- Mild fever, elevated BP, and heart rate\n- Laboratory analysis shows elevated ESR and leukocytosis\n- The ultrasound reveals gallstones and biliary sludge, with a 14mm CBD stone\n\nClinical Trial Inclusion Criteria:\n- Patients with acute pancreatitis (AP) based on clinical symptoms, personal interview, and clinical methods\n- Abdominal pain, elevation in serum lipase or amylase to three times or greater than the upper limit of normal\n- Imaging findings characteristic of acute pancreatitis, if required\n\nComparison:\n- The patient presents with abdominal pain and has an elevated ESR and leukocytosis, which suggests inflammation but not specifically acute pancreatitis.\n- The ultrasound findings of gallstones and biliary sludge with CBD stones suggest cholelithiasis and possible biliary colic rather than acute pancreatitis.\n- There is no mention of elevated serum lipase or amylase levels, which are key diagnostic criteria for acute pancreatitis.\n- There is no mention of contrast-enhanced CT, MRI, or transabdominal ultrasonography findings characteristic of acute pancreatitis.\n\nGiven the available information, the patient does not meet the inclusion criteria for the clinical trial because there is no clear indication of acute pancreatitis, which is the focus of the trial. The patient's symptoms and ultrasound findings are more suggestive of gallbladder disease rather than pancreatitis. Furthermore, the necessary laboratory tests to confirm acute pancreatitis (elevated serum lipase or amylase) have not been provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1269": {
        "output": "The patient in the note is a 54-year-old woman who presented with symptoms indicative of gallstones and biliary sludge, as well as common bile duct (CBD) stones. She has no mention of sickle cell disease (SCD) or vaso-occlusive crisis (VOC), which are the primary conditions of interest for the clinical trial.\n\nThe clinical trial is looking to enroll children and adults with homozygous sickle cell disease who have been admitted to the emergency unit with severe vaso-occlusive crisis that required hospitalization and opioid treatment, and who have health care insurance (in Europe), and are able to give written consent after being informed of the trial.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria of having sickle cell disease or experiencing a vaso-occlusive crisis. Therefore, the patient is not relevant for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1270": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to compare the patient's condition and history with the inclusion criteria of the trial.\n\nThe patient is a 54-year-old obese woman admitted with abdominal pain, nausea, vomiting, and elevated inflammatory markers. An ultrasound confirmed the presence of gallstones and biliary sludge. The patient's clinical presentation suggests acute cholecystitis or gallstone-induced pancreatitis, but there is no clear diagnosis of pancreatic cancer in the patient note.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n1. Patients must have histologically confirmed locally advanced or metastatic pancreas cancer.\n2. Patients must have received at least 6 months of specific fluorouracil (5-FU)- or gemcitabine-based treatments for pancreas cancer.\n3. Patients must have measurable disease as defined in the criteria.\n4. Patients must have a confirmed somatic Kirsten rat sarcoma (KRAS) G12R mutation.\n5. Patients must not have had certain treatments within a specific timeframe and must have recovered from any acute toxicity related to prior therapy or surgery.\n6. Patients must meet specific laboratory criteria for blood counts, liver function, and kidney function.\n7. Patients must be willing to return to the clinic for follow-up visits and agree to use adequate contraception if of child-bearing potential.\n8. Women of child-bearing potential must have a negative pregnancy test within 14 days prior to study treatment.\n9. Patients must have the ability to understand and willingness to sign a written informed consent document or have a Legally Authorized Representative (LAR) if they have Impaired Decision Making Capacity (IDMC).\n10. Patients must be able to reliably swallow oral medications.\n\nBased on the information provided in the patient note, there is no evidence that the patient has pancreatic cancer, let alone a specific KRAS G12R mutation. Additionally, there is no mention of the patient having received any treatment for pancreatic cancer, such as fluorouracil (5-FU)- or gemcitabine-based treatments.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial focused on treating patients with pancreatic cancer with KRAS G12R mutations. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1271": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient appears to be eligible for the study. The inclusion criteria for the study are:\n\n- All adult patients with abdominal pain.\n\nThe patient is a 54-year-old woman who presented to the emergency department with abdominal pain that started 4 days ago, accompanied by nausea and vomiting. This clearly matches the single inclusion criterion of having abdominal pain.\n\nThere are no additional specifics given regarding exclusion criteria for the trial, and based on the patient's symptoms and presentation, she fits the inclusion criteria of the study. Hence, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1272": {
        "output": "Based on the information provided:\n\nThe patient note describes a 54-year-old obese woman with symptoms suggesting gallbladder pathology, such as gallstones and biliary sludge, as evidenced by abdominal pain, nausea, vomiting, and laboratory findings.\n\nThe clinical trial is evaluating the use of text messaging (SMS) to help manage chemotherapy treatment in cancer patients.\n\nTo assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition with the inclusion criteria of the trial:\n\nInclusion Criteria for the trial:\n- Cancer patients who will start chemotherapy treatment in Hospital Escola of Federal University of Pelotas.\n\nThe patient described in the note does not have a diagnosis of cancer, and there is no mention of the patient being a candidate for chemotherapy treatment. Therefore, the patient does not meet the inclusion criteria for the clinical trial focused on cancer patients undergoing chemotherapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1273": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Microbiomes in Patients of Recurrent Common Bile Duct Stones,\" let's determine the trial-level eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presents with abdominal pain, nausea, vomiting, and febrile episodes.\n- The pain is worse after eating fatty food.\n- She has a history of similar epigastric pain.\n- She has hypercholesterolemia and is menopausal.\n- No mention of recurrent common bile duct stones.\n- No mention of her treatment history regarding antibiotics or probiotics.\n\nClinical Trial Inclusion Criteria:\n- Patients with recurrent common bile duct stones.\n- No antibiotics or probiotics are used for nearly three months.\n- No other digestive diseases.\n\nThe patient note indicates that the patient has gallstones, biliary sludge, and CBD stones based on ultrasound findings. However, there is no clear indication that the stones are recurrent, nor is there information about her use of antibiotics or probiotics. Furthermore, without additional information indicating the stones' recurrence, we cannot conclusively determine that she meets the inclusion criteria of having recurrent common bile duct stones. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1274": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility for the trial.\n\nPatient note summary:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- History of similar pain, hypercholesterolemia, and 2 natural vaginal deliveries (NVDs)\n- Menopausal, non-smoker, non-alcoholic, no illicit drug use\n- Mild fever, elevated blood pressure and heart rate, normal respiratory rate, and temperature elevation\n- Ultrasound reveals gallstones, biliary sludge, and common bile duct stones\n\nClinical trial inclusion criteria summary:\n- BMI > 40 kg/m\u00b2 for the obese group or BMI \u226518.5 and < 25kg/m\u00b2 for the non-obese group\n- Age between 18 and 65 years\n- Non-pregnant, non-nursing women\n- Ability to provide informed consent\n- For non-obese subjects: Good health, normal blood pressure and pulse rate, non-smoker or minimal smoker\n\nThe patient is obese and 54 years old, which meets the age criterion. However, there is no information on the patient's BMI to confirm whether she is above the threshold of 40 kg/m\u00b2 required for the obese group in the trial. Additionally, the patient is undergoing an emergency situation unrelated to the focus of the clinical trial, which is pharmacokinetics in obese patients undergoing endoscopic gastric bypass surgery. There is no mention of the patient undergoing such a procedure or having an invasive fungal infection, which is what micafungin is used to treat.\n\nGiven the available information, the patient does not meet the specific requirements for the clinical trial, and there is insufficient information to determine if she meets the BMI criterion for the obese group. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1275": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for participation in the trial:\n\nPatient Note:\n- 54-year-old obese woman\n- Presented with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant, worse after eating fatty food\n- History of similar pain in the past\n- Past medical history includes hypercholesterolemia\n- Mild fever, elevated BP, elevated HR\n- Lab results show elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Acute appendicitis diagnosed with clinical, laboratory, and radiographic criteria\n- Right lower quadrant pain or periumbilical pain migrating to the right lower quadrant with nausea and/or vomiting\n- Fever \u2265 38\u00b0C and/or white blood cell count more than 10X10\u00b3 cells per mL\n- Diameter of appendix \u2265 6 mm with mural thickening and periappendiceal fat infiltration on imaging\n- Perforated appendicitis or peri-appendiceal abscess confirmed by imaging\n\nAssessment:\nThe clinical trial is focused on patients with acute appendicitis, while the patient in question has symptoms and diagnostic findings that are indicative of gallstone-related issues (e.g., gallstones, biliary sludge, CBD stones) rather than appendicitis. The pain localization and clinical presentation align more with gallstones or cholecystitis rather than appendicitis. Therefore, the patient does not meet the inclusion criteria for the clinical trial on appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1276": {
        "output": "Given the information provided about the patient and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman with abdominal pain, nausea, vomiting, and a history of similar pain. \n- She has hypercholesterolemia and is menopausal. \n- The patient presents with fever, elevated blood pressure and heart rate, and normal respiratory rate and oxygen saturation.\n- She is experiencing epigastric and right upper quadrant tenderness without rebound on palpation.\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift.\n- Ultrasound reveals gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm.\n\nClinical Trial Inclusion Criteria:\n- Age 18 and older\n- Patient has a clinical indication for ERCP\n- Willing and able to comply with the study procedures and provide written informed consent to participate in the study.\n\nAssessment:\nThe patient is 54 years old, which meets the age criterion. She has gallstones and CBD stones, which indicates a potential clinical indication for ERCP (Endoscopic Retrograde Cholangiopancreatography). Therefore, she appears to fulfill two of the three inclusion criteria. However, the patient's ability and willingness to comply with the study procedures and provide informed consent is not mentioned in the patient note. Since we cannot confirm the patient's willingness or ability to comply without additional information, we can only assume from the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1277": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection,\" we must compare the patient's characteristics and medical history with the inclusion criteria specified by the clinical trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Age greater than or equal to 18 years.\n2. Patients with dyspeptic symptoms, i.e., pain or discomfort (including abdominal bloating, early satiety and bloating) centered on the upper abdomen, persistent or recurrent, with proven H. pylori infection (through testing breath or gastric biopsy-based methods, if it has been done) with a validity period of one year.\n3. Having been previously prescribed by routine clinical practice the standard triple therapy as eradication treatment:\n   - Proton Pump Inhibitor. Omeprazole 40 mg (or equivalent) every 12 hours. Treatment duration: 10 days.\n   - Clarithromycin. Dose: 500 mg every 12 hours. Treatment duration: 10 days.\n   - Amoxicillin. Dose: 1000 mg every 12 hours. Treatment duration: 10 days.\n4. Not having yet begun taking the eradication therapy.\n5. Written informed consent from the patient.\n6. The first five patients included in the study should have had a routine analysis in the month after the completion of the eradication therapy.\n7. If the patient is a woman of childbearing age, she will be asked to commit to not get pregnant or to use an adequate contraception method.\n\nNow, let\u2019s analyze the patient note provided:\n\n- The patient is a 54-year-old woman, which meets the age criterion (1).\n- The patient presents with abdominal pain and nausea/vomiting, and the ultrasound revealed gallstones, biliary sludge, and CBD stones. However, there is no mention of dyspeptic symptoms directly related to H. pylori infection nor any indication that the patient has been diagnosed or tested for H. pylori infection (2).\n- There is no information provided regarding whether the patient has been prescribed the standard triple therapy for the eradication of H. pylori (3).\n- The patient has not begun taking any specified eradication therapy as far as the note indicates (4).\n- There is no information on whether written informed consent can be obtained from the patient (5).\n- The patient is not among the first five patients included in the study, so the requirement for a routine analysis does not apply (6).\n- There is no information provided about the patient's willingness to avoid pregnancy or use contraception (7).\n\nBased on the patient note, the patient does not have sufficient information to qualify for the trial, specifically regarding the H. pylori infection diagnosis and previous prescription of the standard triple therapy. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1278": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which fits within the age range of 18-65 years required by the trial.\n- The patient presented to the emergency department complaining of nausea and vomiting, which began 4 days ago.\n- The patient is experiencing episodes of emesis (vomiting), which meets the symptom criteria of the trial.\n\nClinical Trial Inclusion Criteria:\n- Patients aged 18-65 years\n- Presenting to the emergency department complaining of current nausea with or without episodes of emesis beginning within the previous 24hrs\n\nAssessment:\n- The patient meets the age criterion.\n- The patient is presenting with nausea and vomiting, which is relevant to the trial's focus.\n- However, the trial specifies that episodes of emesis should have begun within the previous 24 hours, and the patient's symptoms started 4 days ago.\n\nGiven that one of the key inclusion criteria (onset of symptoms within the previous 24 hours) is not met by the patient's situation, the patient is not eligible to participate in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1279": {
        "output": "",
        "label": 0
    },
    "1280": {
        "output": "",
        "label": 0
    },
    "1281": {
        "output": "Given the patient note and the clinical trial inclusion criteria, we must assess whether the patient is eligible for the trial. The trial is focused on treatments for chronic widespread pain (CWP), including fibromyalgia.\n\nThe patient note does not mention any symptoms related to chronic widespread pain or a diagnosis of fibromyalgia. Instead, it details a 54-year-old obese woman with abdominal pain associated with gallstones. Her medical history includes hypercholesterolemia, and there is no indication of chronic pain or fibromyalgia.\n\nAccording to the inclusion criteria for the clinical trial, participants must have:\n\n- A confirmatory diagnosis of chronic widespread pain, including fibromyalgia\n- A certain level of pain intensity and duration\n- Widespread pain in multiple body regions\n\nSince the patient's symptoms and medical history do not align with the trial's focus on fibromyalgia or chronic widespread pain, and there is no information provided that the patient meets the pain criteria specified for the trial, we cannot say that she is eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1282": {
        "output": "",
        "label": 0
    },
    "1283": {
        "output": "",
        "label": 0
    },
    "1284": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess if the patient is eligible for the study.\n\nThe inclusion criteria for the trial are:\n1. Age 18-65\n2. With and without history of chronic musculoskeletal pain\n3. Scheduled to undergo elective abdominal surgery requiring overnight hospital admission\n4. Opioid na\u00efve (the patient has not used opioids before)\n5. Willing to comply with study procedures as outlined in the protocol\n6. Willing and able to provide informed consent\n7. Having an email address and access to a computer or electronic tablet\n\nThe patient in the note is:\n- A 54-year-old woman, which fits the age criterion.\n- She is presenting with abdominal pain and other symptoms leading to the discovery of gallstones and CBD stones, which may require surgery, but the note does not specify if she is scheduled for elective abdominal surgery requiring overnight hospital admission.\n- There is no information provided about chronic musculoskeletal pain.\n- There is no information provided about her opioid use history.\n- The patient's willingness to comply with study procedures, ability to provide informed consent, and access to email and an electronic tablet are not mentioned.\n\nSince the patient note lacks sufficient information to determine if the patient meets several of the inclusion criteria (specifically criteria 2, 3, 4, 5, 6, and 7), we cannot conclusively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1285": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, we need to assess if this patient is eligible for the clinical trial titled \"Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT.\"\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pains in the past year.\n- The pain gets worse after eating fatty food.\n- The patient has a history of hypercholesterolemia and has given birth to two children (2 NVDs).\n- The patient's laboratory analysis shows elevated ESR and leukocytosis with a left shift.\n- An ultrasound revealed gallstones, biliary sludge, and CBD stones.\n- There is no mention of the patient having primary biliary cholangitis (PBC) or being treated with ursodeoxycholic acid (UDCA).\n\nClinical Trial Inclusion Criteria:\n- Patients with PBC (primary biliary cholangitis).\n- Patients who are not responding adequately to treatment with UDCA, defined as ALP > 2 times upper normal level during a time period of 6 months.\n\nComparison:\n- The patient note does not mention that the patient has PBC or that they have been treated with UDCA and not responding to it.\n- Without information suggesting that the patient has PBC, we cannot consider them for a trial that specifically targets patients with PBC.\n\nConclusion:\nThe patient does not meet the specific inclusion criteria of having PBC and being non-responsive to UDCA treatment. Therefore, this patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1286": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's determine the patient's eligibility for the clinical trial titled \"Searching the Best Prognostic Factor in Outcome Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals.\"\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman with abdominal pain characteristic of acute pancreatitis.\n- The pain radiates to the right upper quadrant and worsens after eating fatty food, which is consistent with gallstone-related issues.\n- The patient has elevated ESR and leukocytosis with a left shift, which may suggest inflammation consistent with pancreatitis, although specific serum amylase or lipase levels are not mentioned.\n- An ultrasound revealed gallstones, biliary sludge, and common bile duct stones, which is consistent with gallstone pancreatitis.\n- However, the diagnosis of acute pancreatitis is not explicitly confirmed as the patient note does not mention serum amylase or lipase levels, nor does it confirm radiographically demonstrated acute pancreatitis on CT scan or abdominal ultrasound specifically for pancreatitis.\n\nClinical Trial Inclusion Criteria:\n- 100 patients with acute pancreatitis admitted at Assiut University Hospital.\n- Diagnosis of acute pancreatitis is confirmed if at least two of the following three features are present:\n  - Abdominal pain characteristic of acute pancreatitis.\n  - Serum amylase and/or lipase greater than 3 times the upper limit of normal.\n  - Radiographically demonstrated acute pancreatitis on CT scan or abdominal ultrasound.\n\nComparison:\n- The patient has abdominal pain characteristic of acute pancreatitis (meets one criterion).\n- There is no specific information about serum amylase or lipase levels (missing criterion).\n- There is no specific confirmation of acute pancreatitis radiographically demonstrated on a CT scan or abdominal ultrasound tailored to pancreatitis (missing criterion).\n\nBased on the information provided in the patient note, the patient has one of the three required features for the diagnosis of acute pancreatitis but does not have sufficient information to confirm the diagnosis as required by the clinical trial's inclusion criteria. Therefore, the patient cannot be considered eligible based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1287": {
        "output": "Based on the patient note provided, the 54-year-old obese woman admitted with abdominal pain, nausea, and vomiting does not meet the inclusion criteria of the clinical trial described. The clinical trial is investigating the correlation between respiratory variability of R-R intervals and systolic pressure variability in patients who are scheduled for surgery under general anesthesia and require invasive blood pressure monitoring.\n\nThe patient's medical condition, as described in the note, does not indicate that she is scheduled for surgery under general anesthesia, nor does it mention that she requires invasive blood pressure monitoring. The information provided is more consistent with a diagnosis related to gallstones and biliary issues rather than a condition related to the study's focus on respiratory variability and blood pressure during anesthesia.\n\nTherefore, based on the information provided in the patient note, the patient does not have sufficient information to qualify for the trial as she does not meet the specific inclusion criteria mentioned.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1288": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"IACS-010759 in Advanced Cancers,\" we can evaluate the patient's eligibility for this trial.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and an ultrasound revealing gallstones, biliary sludge, and CBD stones. The patient's past medical history is remarkable for hypercholesterolemia, and she has two children and is menopausal. There is no mention of the patient having cancer, let alone metastatic or unresectable malignancy.\n\nThe inclusion criteria for the clinical trial specify that subjects must have a histologically confirmed malignancy that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit. The patient must also have received at least one line of systemic therapy in the advanced/metastatic setting, among other specific medical criteria.\n\nSince the patient note does not indicate that the patient has any form of cancer, she does not meet the inclusion criteria for this clinical trial, which focuses on patients with advanced/metastatic cancer or unresectable tumors. Therefore, she is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1289": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman with abdominal pain and a medical history of hypercholesterolemia. The clinical trial in question is focused on the ultrasonographic evaluation of anovulatory disorders in lean and overweight women.\n\nLet's compare the patient's information to the inclusion criteria of the clinical trial:\n\n- Aged 18-45 years: The patient is 54 years old, which is outside the age range specified in the inclusion criteria.\n- At least 2y post-menarche: There is no information provided about the patient's menarche, but given her age, it can be assumed that she is well beyond 2 years post-menarche.\n- BMI >18.5kg/m^2: The patient is described as obese, which suggests her BMI is greater than 18.5kg/m^2.\n- Good visibility of the ovaries on ultrasound: There is no information provided about the visibility of the ovaries on ultrasound.\n- Either: Regular menstrual cycles (21-35 days); Irregular menstrual cycles (>35 days); or Previous diagnosis of PCOS from a primary care provider: The patient note does not mention anything about the patient's menstrual cycles or a diagnosis of PCOS.\n\nThe patient does not meet the age criterion for the clinical trial, which is a critical inclusion factor. Since the trial is specifically looking for women aged between 18 and 45 years, and the patient is 54 years old, she would not be eligible for the trial based on the age criterion alone.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial mainly due to the age criterion not being met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1290": {
        "output": "Given the patient note, the 54-year-old woman was admitted to the emergency department with symptoms suggestive of gallbladder stones, which was confirmed by ultrasound showing several gallstones and common bile duct (CBD) stones. The patient's condition is an emergency department case with a medical condition that can be confirmed by a basic point-of-care ultrasound (POCUS) exam.\n\nNow, looking at the clinical trial's inclusion criteria:\n\n1. The patient is an emergency department patient.\n2. The patient has a suspected medical condition that can be confirmed or excluded by basic POCUS exam, which in this case includes gallbladder stones, a condition specifically mentioned in the inclusion criteria.\n3. The decision to perform a POCUS exam is to be made by an emergency medicine specialist or resident.\n\nThe patient meets all the inclusion criteria because she is in the emergency department, has a condition (gallbladder stones) that can be assessed with POCUS, and it can be assumed that the emergency medicine specialist or resident would decide to perform a POCUS exam as part of her assessment given her symptoms and findings.\n\nTherefore, the patient is eligible for the clinical trial. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1291": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's compare the two to determine the patient's eligibility.\n\nPatient Note:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting, and others symptoms related to gallstones\n- Medical history includes hypercholesterolemia and being menopausal\n- No mention of cancer or any type of squamous cell carcinoma\n\nClinical Trial:\n- The trial is for patients with locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN)\n- Candidates must be eligible for salvage surgery\n- Requires histologically or cytologically confirmed SCCHN\n- Age 18 years or older\n\nThe patient's condition (gallstones and related symptoms) does not match the target disease for the clinical trial (recurrent squamous cell carcinoma of the head and neck). Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1292": {
        "output": "Based on the patient note provided, the patient is a 54-year-old woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain is associated with eating fatty food, and an ultrasound revealed several gallstones and biliary sludge, suggesting a biliary origin of her condition. The patient's medical history includes hypercholesterolemia, and she has had two natural vaginal deliveries (NVDs). She is febrile, with elevated blood pressure and heart rate, and laboratory analysis shows elevated ESR and leukocytosis, which may suggest an infection or inflammation.\n\nThe clinical trial's inclusion criteria are:\n1. Patients older than 15 years.\n2. Patients with a diagnosis of mild acute pancreatitis of biliary origin.\n3. Patients who agree to enter the protocol.\n\nThe patient in the note fits the age criterion since she is 54 years old. The diagnosis of mild acute pancreatitis of biliary origin seems to be indicated by the symptoms and ultrasound findings, although the note does not explicitly state that she has been diagnosed with acute pancreatitis. The third criterion is subjective and would require the patient's consent to participate in the trial.\n\nGiven the information provided, the patient appears to meet the age and potential diagnosis criteria for the clinical trial. However, since the diagnosis of mild acute pancreatitis is not explicitly mentioned, we cannot conclusively determine her eligibility without additional information confirming her diagnosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1293": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 54-year-old woman\n- Presented with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- Menopausal\n- No smoking, alcohol, or illicit drug use\n- Fever, high blood pressure, elevated heart rate\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Written informed consent\n- Aged \u226518 years\n- Chronic wound with exposed tendon and/or bone, non-healing for at least 4 weeks with standard care\n- 'Problematic wound area' between 0.25 and 10.0 cm2\n- Willing and able to comply with the trial protocol\n\nAssessment:\nThe patient's information does not indicate a chronic wound with exposed tendon or bone. The patient is presenting with symptomatic gallstones, which is unrelated to the focus of the clinical trial. There is no mention of any wound, let alone a chronic non-healing wound with exposed tendon or bone. Therefore, the patient does not meet the inclusion criteria for the clinical trial on LeucoPatch\u00ae in Nonhealing Wounds With Exposed Bone or Tendon.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1294": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to have Bacillus Species sepsis or meningitis. The patient note describes a 54-year-old woman with symptoms of gallstones and biliary sludge, which are unrelated to Bacillus Species infections. There is no mention of a Bacillus infection or a significant change in clinical status due to such an infection. Furthermore, the inclusion criteria specify that Bacillus Species must be the only organism isolated, and there is no indication in the patient note that any organism has been isolated from this patient.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on Bacillus Species sepsis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1295": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 54-year-old obese woman with symptoms suggestive of gallbladder stones (cholecystitis) and no mention of hypertension or lens opacities. The clinical trial is focused on patients with salt sensitivity hypertension (SSH) and the presence of cortical lens opacities.\n\nThe inclusion criteria for the clinical trial are:\n- Salt Sensitivity Hypertension patients\n- Non-SSH, salt-resistant HT (SRH) patients\n- Control patients without HT, aged 40-80 years.\n\nThe patient's note does not indicate that she has hypertension or salt sensitivity hypertension, nor does it mention anything about lens opacities. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1296": {
        "output": "Based on the provided patient note, the 54-year-old woman has presented with symptoms and a diagnosis that are not related to shoulder osteoarthritis. Her symptoms (abdominal pain, nausea, vomiting, and radiating pain exacerbated by eating fatty food) and the findings (gallstones, biliary sludge, and CBD stones) suggest a biliary tract issue, most likely cholecystitis or choledocholithiasis, rather than a musculoskeletal disorder like shoulder osteoarthritis.\n\nThe clinical trial in question is seeking participants with painful shoulder osteoarthritis. The inclusion criteria are:\n\n1. Painful osteoarthritis of the shoulder for at least 6 months\n2. Not engaged in any other treatment during the treatment period\n3. Pain \u22654 on the visual analog scale (VAS) in the previous 3 months\n\nThe patient's condition does not meet the inclusion criteria for this trial, as there is no mention of shoulder pain, osteoarthritis, or any related symptoms in her medical history or current presentation. Therefore, the patient would be rated as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1297": {
        "output": "Given the patient note, we need to compare the patient's characteristics and condition to the inclusion criteria of the clinical trial to determine eligibility.\n\nPatient note summary:\n- 54-year-old woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- No mention of alcohol, smoking, or drug use\n- Mild fever, hypertension, and tachycardia\n- Epigastric and right upper quadrant tenderness\n- Laboratory findings: elevated ESR and leukocytosis\n- Ultrasound revealed gallstones and biliary sludge\n- No mention of scheduled laparoscopic cholecystectomy\n\nClinical trial inclusion criteria:\n- Patients aged 18-75 years old\n- Scheduled for laparoscopic cholecystectomy\n\nThe patient is a 54-year-old woman, which falls within the age range of 18-75 years old specified by the trial. However, the patient note does not state that she is scheduled for a laparoscopic cholecystectomy. The information provided suggests that she may be a candidate for the procedure, given her symptoms and ultrasound findings, but without confirmation that the procedure is scheduled, we cannot definitively include her in the trial.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1298": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She has been diagnosed with gallstones, biliary sludge, and CBD stones based on her symptoms and ultrasound findings. \n\nThe clinical trial is a Phase 1 study evaluating the safety, tolerability, and efficacy of AMG 119 in subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC). The inclusion criteria for this trial include being 18 years or older, having histologically or cytologically confirmed SCLC with disease progression or recurrence after a platinum-based regimen, an ECOG performance status of 0-1, and at least 2 measurable lesions. Subjects with treated brain metastases may be eligible under certain conditions, and adequate organ function is required.\n\nBased on the information provided in the patient note, the patient does not have Small Cell Lung Cancer; instead, she has issues related to gallstones. Therefore, she does not meet the disease-specific inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1299": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial. The trial is focused on type 2 diabetic obese patients for a study on the efficacy of different types of metabolic surgery in treating type 2 diabetes.\n\nThe patient note mentions that the patient is obese and has a history of hypercholesterolemia, but there is no mention of a type 2 diabetes diagnosis. The patient's current medical issue is related to gallstones and biliary sludge, which is not relevant to the focus of the clinical trial.\n\nGiven this information, the patient does not meet the inclusion criteria because there is no indication that the patient has type 2 diabetes, which is a requirement for participation in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1300": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"LaGRA Trial in Laparoscopic Cholecystectomy,\" here is the assessment:\n\nPatient Note Highlights:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after fatty food\n- History of hypercholesterolemia\n- No mention of alcohol, smoking, or illicit drug use\n- Mild fever, elevated blood pressure, and heart rate\n- Laboratory analysis shows elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n- No mention of American Society of Anesthesiologists (ASA) physical status classification\n\nClinical Trial Inclusion Criteria:\n- Patients undergoing laparoscopic cholecystectomy\n- ASA I, II, or III\n\nThe patient note indicates that the individual is likely to undergo a laparoscopic cholecystectomy due to the presence of gallstones, biliary sludge, and CBD stones, which aligns with the clinical trial inclusion criteria. However, the patient's ASA physical status classification is not mentioned in the note. The ASA classification is a system used to assess the fitness of patients before surgery. The absence of this information makes it impossible to definitively determine eligibility based solely on the information provided.\n\nWith the information available, it is not possible to make a complete assessment of eligibility as the patient's ASA classification is not stated, which is an essential part of the trial's inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient, based on the information provided, is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1301": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who has been admitted to the emergency department with abdominal pain related to gallstones, biliary sludge, and CBD stones. Her medical history includes hypercholesterolemia, and there is no mention of a hallux valgus deformity, pain due to a hallux valgus, or walking difficulty specifically associated with a hallux valgus deformity.\n\nThe clinical trial in question is looking to evaluate post-operative analgesia and motor recovery after hallux valgus correction surgery. The inclusion criteria specifically mention that participants must have a hallux valgus deformity, experience pain, and have walking difficulty with shoes.\n\nGiven that the patient\u2019s medical condition and symptoms do not align with the inclusion criteria of the clinical trial (which is focused on hallux valgus), and there is no information provided that suggests she has a hallux valgus deformity or related symptoms, the patient cannot be considered for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1302": {
        "output": "Based on the patient note provided, the 54-year-old woman has been admitted with abdominal pain, nausea, and vomiting, particularly after eating fatty food. She has a medical history of hypercholesterolemia and has been diagnosed with gallstones and biliary sludge as revealed by an ultrasound. Her symptoms include gastrointestinal distress, which could potentially match the inclusion criteria of the trial that is looking for individuals with gastrointestinal symptoms.\n\nHowever, the inclusion criteria for the clinical trial specifically mention \"few health complications,\" which could be interpreted in various ways. Given the acute presentation of this patient, including the need for emergency care, mild fever, and elevated heart rate, it could be argued that her current health complications are beyond what might be considered \"few.\"\n\nThe patient does express gastrointestinal symptoms more than three times per week as identified through her presentation, which matches part of the inclusion criteria. She is also an adult over the age of 18, which further matches the criteria specified.\n\nGiven the information provided, the patient displays some of the gastrointestinal symptoms required for the study but also presents with acute symptoms that may or may not be considered \"few health complications.\"\n\nTherefore, the trial-level eligibility should be cautious, as the acute nature of her condition and the related severe symptoms may preclude her from being considered \"healthy with few health complications.\" As such, the patient should be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1303": {
        "output": "",
        "label": 0
    },
    "1304": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"The Role of Ultrasound in Cholecystitis,\" let's evaluate the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which satisfies the age criterion commonly set at \u226518 years.\n- The patient presents with abdominal pain that radiates to the right upper quadrant, getting worse after eating fatty food, which is a typical symptom of cholecystitis.\n- The patient has experienced similar pain before, suggesting a recurring issue.\n- The patient has elevated ESR and leukocytosis with a left shift, indicating an inflammatory response, which is consistent with cholecystitis.\n- An ultrasound revealed gallstones and biliary sludge, which are common findings in cholecystitis.\n- The patient is febrile, has elevated white blood cell count, and is experiencing tenderness in the right upper quadrant \u2013 these are among the clinical signs used to diagnose acute cholecystitis.\n\nClinical Trial Inclusion Criteria:\n- Acute cholecystitis according to the Tokyo Guidelines 2013 criteria.\n\nGiven the patient's symptoms, laboratory findings, and ultrasound results, it appears that the patient has acute cholecystitis, which is consistent with the Tokyo Guidelines 2013 criteria for the diagnosis of acute cholecystitis.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial on \"The Role of Ultrasound in Cholecystitis.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1305": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman who presents with symptoms consistent with gallstones and cholecystitis, such as abdominal pain, nausea, and vomiting, particularly after eating fatty food. Her medical history includes hypercholesterolemia, and she has given birth to two children. There is no indication in the patient note that she is scheduled for hand or forearm surgery, nor is there any mention of her ASA (American Society of Anesthesiologists) physical status.\n\nThe clinical trial in question is focused on comparing the effect of ketorolac to paracetamol when added to lidocaine for intravenous regional anesthesia (IVRA) in patients who are scheduled for surgery of the hand or the forearm and have an ASA physical status I or II.\n\nSince the patient does not appear to be scheduled for surgery of the hand or the forearm and the ASA physical status is not mentioned, she does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1306": {
        "output": "Upon reviewing the patient's history and the criteria for the \"Pain Modulatory Profiles in Massage for Healthy Participants\" clinical trial, we can determine the patient's eligibility:\n\n- The inclusion criteria require participants to be pain-free, which the patient is not, as she is admitted with abdominal pain.\n- The patient's blood pressure is 150/85, which exceeds the trial's requirement of blood pressure under 140/90 mmHg.\n- The ability of the therapist to locate necessary trigger points on the participant is mentioned, but we do not have information regarding this for the patient. However, this point is moot as the patient does not meet the other two inclusion criteria.\n\nGiven the above points, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1307": {
        "output": "",
        "label": 0
    },
    "1308": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, we need to determine if the 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of gallstones and CBD stones is a candidate for the clinical trial focused on the diagnostic value of combinatory EUS and ERCP in unclear biliary lesions.\n\nThe patient's presentation with abdominal pain and the finding of gallstones and CBD stones on ultrasound suggest a biliary tract issue. However, the trial is specifically looking for patients with \"unclear lesions or strictures in the biliary tract referred for endoscopy work up.\" The patient's condition seems to be a clear case of gallstones and CBD stones, which may not be classified as \"unclear lesions or strictures\" per se.\n\nSince the information provided does not mention that the lesions are unclear or that there are strictures present in the patient's biliary tract, or that the patient has been referred for endoscopy workup specifically for unclear lesions or strictures, we do not have sufficient information to qualify the patient for the trial.\n\nTherefore, the assessment of eligibility based on the available information is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1309": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones.\n- No mention of dermatomyositis or cutaneous disease related to dermatomyositis.\n\nClinical Trial Inclusion Criteria:\n- Must be 18 years at the time of signing the informed consent form.\n- Willing to participate in all required evaluations and procedures in the study including the ability to swallow pills without difficulty.\n- Patients must have a diagnosis of dermatomyositis based upon the characteristic cutaneous findings proposed by Sontheimer and/or a skin biopsy consistent with DM.\n- Patients must be candidate for systemic therapy for their DM skin disease defined by inadequate response to aggressive sun protection along with the use of potent topical corticosteroids and/or immunomodulators.\n- Patients with a diagnosis of dermatomyositis on steroid-sparing agent and/or systemic steroids and still having cutaneous disease activity of at least 5 on the CDASI scale.\n- If on immunosuppressive treatments and/or steroids, patients must be on stable doses for at least 4 weeks.\n- Patients must undergo age-appropriate cancer screening.\n- Females of childbearing potential must have a negative pregnancy test at screening and throughout the study.\n\nAssessment:\nThe patient's note does not mention dermatomyositis or any cutaneous diseases related to dermatomyositis. The patient seems to be presenting with symptoms related to gallstones and not dermatomyositis. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1310": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient described does not meet the inclusion criteria for the clinical trial. The trial is specifically targeting children between the ages of 1 to 18 years with chronic haemolytic anemia. The patient in question is a 54-year-old woman with gallbladder issues, which is not relevant to the clinical trial's focus on chronic haemolytic anemia in children.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1311": {
        "output": "",
        "label": 0
    },
    "1312": {
        "output": "",
        "label": 0
    },
    "1313": {
        "output": "Given the information from the patient note and the clinical trial criteria, let's assess the patient's eligibility.\n\nPatient note summary:\n- 54-year-old obese woman\n- Presented with abdominal pain, nausea, vomiting\n- Epigastric pain radiating to the right upper quadrant, worsening after eating fatty food\n- History of similar pain in the past\n- History of hypercholesterolemia\n- Presented with mild fever and elevated vital signs\n- Laboratory findings: Elevated ESR, leukocytosis with a left shift\n- Ultrasound findings: Gallstones, biliary sludge, and CBD stones\n\nClinical trial inclusion criteria:\n- Adult patients (>18 years)\n- Called 999 for emergency ambulance due to pain, discomfort, or pressure in the chest, epigastrium, neck, jaw, or upper limb without an apparent non-cardiac source\n- Treating paramedic suspects the symptoms may be caused by acute coronary syndromes\n\nAssessment:\nThe patient's symptoms are localized to the epigastric region and radiate to the right upper quadrant, which is more indicative of a gallbladder issue (e.g., gallstones, as supported by the ultrasound findings) rather than acute coronary syndromes. There is no mention of chest pain, discomfort, or pressure that would lead a paramedic to suspect acute coronary syndromes. Therefore, the patient's symptoms are likely to have an apparent non-cardiac source, specifically the gallbladder condition indicated by the ultrasound.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the PRESTO study, as her symptoms are more consistent with gallbladder issues rather than suspected acute coronary syndromes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1314": {
        "output": "",
        "label": 0
    },
    "1315": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial:\n\nThe patient is a 54-year-old woman presenting with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She has been admitted to the emergency department with symptoms indicative of gallstone-related issues, such as gallstones and biliary sludge found via ultrasound. \n\nThe clinical trial in question is studying the efficacy and safety of larazotide acetate for the relief of persistent symptoms in adult celiac disease patients. The inclusion criteria specify that participants must:\n\n1. Be male or female adults diagnosed with celiac disease (positive celiac serology plus confirmed biopsy) for at least 6 months\n2. Be on a gluten-free diet for at least 6 months\n3. Be experiencing symptoms related to celiac disease\n4. Be willing to maintain the current gluten-free diet throughout participation in the study\n\nThe patient note does not mention a diagnosis of celiac disease, nor does it describe the patient following a gluten-free diet or experiencing symptoms specifically related to celiac disease. Therefore, there is insufficient information to determine that the patient has celiac disease, which is a requirement for the clinical trial.\n\nGiven the information available, the patient does not meet the inclusion criteria for the study on larazotide acetate for celiac disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1316": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note:\n- 54-year-old obese woman with abdominal pain, nausea, and vomiting\n- Epigastric pain radiating to the right upper quadrant, worse after eating fatty food\n- History of similar pain, hypercholesterolemia, menopausal, non-smoker, non-alcoholic\n- Mild fever, elevated blood pressure, and heart rate\n- Tenderness in the epigastric region and right upper quadrant\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound showed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n1. Patients of either gender with age ranging from 15 to 60 years\n2. Patients with a MANTRELS score of 7 or above on admission\n\nThe clinical trial is focused on the treatment of appendicitis using a laparoscopic appendectomy and comparing two methods of appendicular stump ligation.\n\nThe patient's note does not mention appendicitis or a MANTRELS score, which is used to assess the likelihood of appendicitis. Instead, the patient's symptoms and ultrasound results suggest a diagnosis related to gallstone disease such as cholecystitis or choledocholithiasis.\n\nGiven that the patient's condition does not align with the target condition of the clinical trial (appendicitis) and there is no mention of a MANTRELS score, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1317": {
        "output": "Given Patient Note:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain radiates to the right upper quadrant, worse after eating fatty food\n- Similar pain twice in the past year\n- History of hypercholesterolemia\n- No mention of pancreatitis or pancreas divisum\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n- No episodes of pancreatitis described\n- No mention of MRCP or diagnosis of pancreas divisum\n\nClinical Trial Inclusion Criteria:\n- Patient consent with signed and dated approved consent form\n- Over 18 years of age\n- Two or more episodes of acute pancreatitis\n- At least one episode of acute pancreatitis within 24 months of enrollment\n- Pancreas divisum confirmed by prior MRCP\n- No certain explanation for recurrent acute pancreatitis\n- Ability to fully understand and participate in the study\n\nAssessment:\nThe patient in the note does not have a documented history of acute pancreatitis, nor is there a mention of pancreas divisum. There is no information to suggest that the patient has experienced episodes consistent with the clinical trial's definition of acute pancreatitis or that a prior MRCP has been performed to confirm pancreas divisum. Therefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1318": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not appear to have a complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). The patient presents with abdominal pain, nausea, vomiting, and gallstones on ultrasound but does not exhibit symptoms of cUTI or AP such as fever with documented temperature >38\u00b0C related to a urinary source, dysuria, increased urinary frequency, urinary urgency, lower abdominal pain specific to a urinary source, acute flank pain, or costovertebral angle tenderness.\n\nMoreover, the patient's leukocytosis and elevated ESR suggest an inflammatory process, but the ultrasound findings are diagnostic of gallstones and biliary sludge, which points to a likely diagnosis of cholecystitis or biliary colic rather than a urinary tract infection. There is no indication of pyuria or other signs that would suggest a cUTI or AP diagnosis.\n\nThus, the patient does not meet the clinical criteria for the trial as outlined in the inclusion criteria:\n\nA. cUTI:\n- The patient does not have documented fever as per the trial's definition.\n- No symptoms like dysuria, increased urinary frequency, or urinary urgency are described.\n- Abdominal pain is present but is associated with gallstones, not a urinary source.\n\nB. AP:\n- There is no mention of acute flank pain or costovertebral angle tenderness.\n- No additional urinary symptoms or signs are provided.\n\nTherefore, the patient's condition is not relevant to the study's focus on cUTI or AP.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1319": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note:\n- 54-year-old obese woman\n- Symptoms: abdominal pain that started 4 days ago, nausea, vomiting\n- Pain gets worse after eating fatty food\n- Similar pain episodes in the past\n- Medical history: hypercholesterolemia\n- Menopausal, non-smoker, no alcohol or illicit drug use\n- Mild fever, elevated BP and HR, normal RR, slightly elevated T, normal SpO2\n- Physical exam: epigastric tenderness, RUQ tenderness, normal bowel sounds\n- Laboratory: elevated ESR, leukocytosis with left shift\n- Ultrasound: gallstones, biliary sludge, and CBD stones\n- No mention of pain severity on a Visual Analog Scale (VAS)\n\nClinical Trial Inclusion Criteria:\n- Stomach pain, swelling or dyspeptic complaints\n- Men and women between the ages of 18-60\n- Patients with VAS > 5\n\nAssessment:\n- The patient is within the age range (54 years old).\n- The patient has stomach pain and dyspeptic complaints (epigastric pain, nausea, vomiting).\n- There's no mention of the patient's pain severity on a VAS in the patient note, so we cannot confirm a VAS > 5.\n\nGiven that the patient note does not provide a VAS score, we do not have enough information to determine if the patient's pain severity meets the inclusion criteria. Therefore, the patient's eligibility cannot be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1320": {
        "output": "Based on the patient note and clinical trial information provided:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted to the emergency department with abdominal pain, nausea, and vomiting\n- Epigastric pain radiating to the right upper quadrant, worse after eating fatty food\n- History of hypercholesterolemia and 2 NVDs\n- Menopausal, non-smoker, non-alcoholic, no illicit drug use\n- Mild fever (T 38.2), elevated BP (150/85), HR 115, RR 15, SpO2 98% on RA\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\nClinical Trial:\n- Title: Interest of the Equimolar Oxygen Nitride Mixture (MEOPA) in the Treatment of Pain in Patients Presenting to the Emergency Department for Suspected Renal Colic\n- Inclusion Criteria: Age \u2265 18, presenting with a suspicion of renal colic, consent given, affiliated to the social security system\n- Exclusion Criteria: Patient in shock, oxygen saturation below 93% in ambient air, suspicion of pneumothorax, history of emphysema/COPD, contraindications to MEOPA, contraindication to NSAIDs, long-term treatment with analgesic stage 3, pregnant or lactating woman, participation in another research, major persons subject to legal protection, persons deprived of their liberty\n\nThe patient's symptoms and ultrasound findings suggest a diagnosis of gallstone-related issues (possibly cholecystitis or biliary colic), not renal colic. Renal colic typically presents with pain radiating towards the external genital organs, which is not mentioned in the patient's symptoms.\n\nSince the clinical trial is for patients presenting with suspected renal colic and the patient's presentation does not align with that diagnosis, she does not meet the inclusion criteria for the trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1321": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Nortriptyline for the Treatment of Functional Dyspepsia,\" let's assess the patient's eligibility:\n\nInclusion Criteria for the Trial:\n1. Age 18-65 years;\n2. A diagnosis of FD according to the Rome IV criteria;\n3. Predicted CYP2D6 extensive metabolizer phenotype on the basis of CYP genotyping;\n4. Insufficient effect of first line treatment with proton pump inhibitors (twice daily) or prokinetics;\n5. In the presence of alarm symptoms, patients are required to have undergone an upper gastrointestinal endoscopy (without evidence of organic disease), and have tested negative for Helicobacter pylori 2 years prior to inclusion;\n6. Women in their fertile age (<55 years old) must use contraception or be postmenopausal for at least two years.\n\nPatient Information:\n- 54-year-old woman\n- Admitted with abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant, worse after eating fatty food\n- Past medical history remarkable for hypercholesterolemia\n- Menopausal\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\nThe patient's age fits the trial's criteria (she is 54 years old), and she is menopausal. However, the patient's symptoms and ultrasound findings suggest she is suffering from gallbladder-related issues (such as gallstones and biliary sludge), and not functional dyspepsia. There is no indication that the patient has been diagnosed with FD according to the Rome IV criteria, nor is there information about her CYP2D6 metabolizer phenotype, prior treatments with proton pump inhibitors or prokinetics, endoscopy results, or Helicobacter pylori status.\n\nThe patient's current medical presentation does not align with the diagnosis of functional dyspepsia as required by the clinical trial. Therefore, the patient does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1322": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient note:\n- 54-year-old woman with abdominal pain, nausea, vomiting.\n- Pain is worse after eating fatty food, indicating a biliary etiology.\n- History of hypercholesterolemia.\n- Febrile, with elevated blood pressure and heart rate.\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n\nClinical trial inclusion criteria:\n- Patients with cholecystolithiasis when laparoscopic cholecystectomy is indicated.\n- Intermediate risk for choledocholithiasis (VUHI 2.6 - 6.9 and one of the predictors: dilated common bile duct, elevated total bilirubin, or suspected stone in CBD on ultrasound).\n\nThe patient's ultrasound results have confirmed the presence of gallstones and stones in the common bile duct (CBD). This suggests that the patient indeed has cholecystolithiasis and, with the presence of stones in the CBD, possibly choledocholithiasis, which is consistent with having an intermediate risk for choledocholithiasis as required by the trial's inclusion criteria.\n\nHowever, to confirm eligibility, we would need additional information on whether the patient has a VUHI score within the 2.6 - 6.9 range and whether laparoscopic cholecystectomy is indicated based on the clinical evaluation. The patient note does not provide the VUHI score or the explicit indication for laparoscopic cholecystectomy.\n\nGiven that the patient has gallstones and CBD stones as suspected on ultrasound and considering the typical management of such a condition would involve surgical intervention, it is reasonable to assume that laparoscopic cholecystectomy may be indicated. However, without explicit information on the VUHI score and the clinical indication for laparoscopic cholecystectomy, we cannot firmly establish eligibility.\n\nTherefore, based on the provided information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1323": {
        "output": "The patient described in the note is a 54-year-old obese woman who has been admitted with abdominal pain, nausea, and vomiting. Her medical history is notable for hypercholesterolemia, and she has had two normal vaginal deliveries (NVDs). The pain she experiences worsens after eating fatty food, which along with the laboratory findings and ultrasound results, suggests she likely has gallbladder stones, leading to biliary colic or possible cholecystitis.\n\nThe clinical trial in question is focused on the effect of a sublimated mare milk supplement on patients with primary biliary cholangitis (PBC). PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed. The inclusion criteria for the trial are:\n\n1. Morphologically verified diagnosis of primary biliary cholangitis\n2. Age 18 to 75 years\n3. Willingness to consent to participate in the study\n4. Consent to adhere to treatment\n\nThe patient's condition does not match the target disease of the trial (primary biliary cholangitis), as there is no indication in the patient note that she has been diagnosed with PBC. Instead, she seems to be suffering from a complication related to gallstones, which is different from PBC. Therefore, the patient does not meet the specific disease criterion for the trial.\n\nBased on the information given, the patient is not eligible for the trial because she does not have a diagnosis of primary biliary cholangitis. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1324": {
        "output": "",
        "label": 0
    },
    "1325": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 54-year-old woman does not meet the inclusion criteria for the trial. The trial is specifically for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and the patient's condition described in the note is related to abdominal pain due to gallstones, not CLL. Thus, the patient does not have the target disease for the trial and does not meet any of the other specified inclusion criteria related to CLL.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1326": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Early MRI in Acute GallstonE Disease,\" we must compare the patient's characteristics and clinical findings with the inclusion criteria of the trial.\n\nPatient's characteristics and clinical findings:\n- 54-year-old woman\n- Presented with acute abdominal pain, nausea, and vomiting\n- Pain exacerbated after eating fatty food\n- History of similar pain episodes\n- Hypercholesterolemia\n- Mild fever\n- Elevated blood pressure and heart rate\n- Ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones\n\nClinical trial inclusion criteria:\n- Willing and able to give informed consent\n- Male or Female, aged 16 years or above\n- Suspected gallstone/biliary disease presenting with acute abdominal pain\n- Abnormal liver function indicated by specific blood test results\n\nThe patient note indicates that the patient is a 54-year-old woman who has been admitted with symptoms that are highly suggestive of gallstone/biliary disease. This matches the age and suspected disease criteria of the trial. However, the provided patient note does not include specific blood test results for liver function tests such as bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and amylase. These blood test results are required by the trial's inclusion criteria to reflect abnormal liver function.\n\nSince the patient's blood test results are not provided, we do not have sufficient information to determine whether the liver function is abnormal according to the thresholds set by the trial's inclusion criteria. Therefore, based on the information given, we cannot definitively conclude that the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1327": {
        "output": "",
        "label": 0
    },
    "1328": {
        "output": "Based on the provided patient note and the clinical trial information, the patient does not meet the inclusion criteria for the clinical trial focused on Pain Neuroscience Education for Acute and Sub-Acute Low Back Pain. The patient's primary complaint is abdominal pain with associated symptoms rather than low back pain, and there is no indication of low back pain in the patient note.\n\nTherefore, the patient does not have a complaint of low back pain with or without leg pain less than 3 months, which is a requirement for inclusion in the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1329": {
        "output": "Based on the patient note, the 54-year-old woman presents with symptoms consistent with gallstones and biliary sludge, as indicated by the ultrasound findings. Her condition involves abdominal pain, nausea, vomiting, and fever, but there is no mention of unresectable malignant biliary obstruction, which is a key inclusion criterion for the clinical trial.\n\nThe clinical trial in question is focused on patients with unresectable malignant biliary obstruction that involves the orifice of the cystic duct. The trial is investigating Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) as a primary prophylaxis in these patients. The inclusion criteria specify the need for a confirmed diagnosis of unresectable malignant biliary obstruction, tumor involvement to the orifice of the cystic duct, and the deployment of a self-expandable metallic or plastic stent as palliative therapy.\n\nGiven that the patient's note does not mention any malignancy or confirmation of an unresectable tumor involving the cystic duct orifice, nor any palliative stent deployment, the patient does not meet the specific inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1330": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the trial. \n\nThe patient is a 54-year-old obese woman with abdominal pain radiating to the right upper quadrant, nausea and vomiting, and a history of similar pain. She has hypercholesterolemia, has had two normal vaginal deliveries (NVDs), is menopausal, and has been diagnosed with gallstones and common bile duct (CBD) stones as per the ultrasound.\n\nThe clinical trial is focused on patients with a past history of gastroesophageal variceal hemorrhage confirmed by an endoscopic examination, looking at the efficacy and prognosis of two different treatments for secondary prevention of gastric varices, especially in patients with portosystemic shunting.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients over 18 years of age.\n2. Past history of gastroesophageal variceal hemorrhage confirmed by an endoscopic examination.\n\nThe patient's note does not mention any history of gastroesophageal variceal hemorrhage or any endoscopic examinations confirming such a condition. Instead, the patient presents with symptoms suggestive of gallstone-related issues. Therefore, based on the information provided, the patient does not meet the inclusion criteria of having a past history of gastroesophageal variceal hemorrhage.\n\nAs a result, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1331": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Surgicel and Analgesic Reservoir,\" let's evaluate the patient's eligibility:\n\nPatient Note:\n- 54-year-old woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain exacerbated by fatty food\n- History of hypercholesterolemia\n- Menopausal\n- Non-smoker, non-drinker, no illicit drug use\n- Mild fever, elevated blood pressure and heart rate\n- Elevated ESR, leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Age 18-65 years old patients from both genders scheduled for laparoscopic cholecystectomy\n- Clinical and laboratory multisystem preoperative evaluation prove a health status of American Society of Anesthesiology grade I/II\n- Absence of current active inflammatory medical condition\n\nAssessment:\n- The patient falls within the age range of 18-65 years.\n- The patient is scheduled for a laparoscopic cholecystectomy, as evidenced by the diagnosis of gallstones and the typical clinical presentation for this condition.\n- The patient's health status according to the American Society of Anesthesiology (ASA) grade is not explicitly mentioned, but based on the information given, there is no clear indication that the patient would not be classified as ASA grade I or II, which are generally for patients with mild systemic disease or no systemic disease, respectively.\n- The patient does have leukocytosis and mild fever, which might suggest an active inflammatory condition (such as cholecystitis), but it is not explicitly stated that this is a current active condition that would exclude the patient from the trial.\n\nSince there is no explicit mention of the patient's ASA grade or a definitive active inflammatory condition that would exclude the patient, there is insufficient information to determine with certainty whether these criteria are met. However, based on the information provided, the patient appears likely to meet the criteria, but without confirmation of the ASA grade and the nature of the inflammatory condition, we cannot conclusively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1332": {
        "output": "Based on the information provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pain episodes. The pain worsens after eating fatty food, and she has a fever (body temperature 38.2\u00b0C), which is above 37\u00b0C. Laboratory analysis shows elevated ESR and leukocytosis. An ultrasound revealed gallstones and common bile duct (CBD) stones, suggesting she has cholangitis associated with choledocholithiasis.\n\nThe inclusion criteria for the clinical trial are patients with na\u00efve papilla who have a body temperature \u226537\u00b0C and have been diagnosed with mild to moderate cholangitis associated with choledocholithiasis. The patient note does not mention the status of the papilla (whether it is na\u00efve or not), which is a crucial piece of information for determining eligibility. However, based on the provided symptoms and findings, it seems the patient meets the criteria of having a body temperature \u226537\u00b0C and cholangitis associated with choledocholithiasis.\n\nGiven the lack of information about the papilla status, we cannot conclusively determine eligibility. Therefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1333": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia,\" let's compare the two.\n\nPatient note summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant, worse after eating fatty food\n- History of similar pain, hypercholesterolemia, and 2 NVDs\n- Menopausal, non-smoker, no alcohol or illicit drugs\n- Mild fever, elevated BP and HR, normal RR and SpO2\n- Tenderness in epigastric region and right upper quadrant, no rebound\n- Normal bowel sounds\n- Elevated ESR, leukocytosis with left shift\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical trial inclusion criteria:\n- Adult patients with relapsed/refractory AML, T-ALL, BLL, or MPAL\n- Patients must be 18 years or older\n- ECOG Performance Status of 0 to 2\n- Adequate cardiac, hepatic, and renal function\n- Willing to use adequate contraception if of childbearing potential\n- Interval from prior leukemia-directed therapy to study drug administration of at least 7 days\n\nThe patient in the note does not have a diagnosis of leukemia (AML, T-ALL, BLL, or MPAL); rather, she appears to be presenting with symptoms of gallstone-related issues. Therefore, she does not meet the disease-specific inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1334": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presents with symptoms of acute cholecystitis: abdominal pain radiating to the right upper quadrant, worsening after eating fatty food, nausea, vomiting, and fever.\n- The patient has a history of similar pain in the past year.\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift, which may suggest infection and inflammation.\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria:\n- Patient requiring intervention for the management of symptoms associated with acute cholecystitis.\n- Patients referred for percutaneous drainage of the gallbladder who are not surgical candidates.\n- Eligible for endoscopic intervention.\n- Acute Cholecystitis (AC) Grade I or II per Tokyo guidelines.\n- Pre-drainage imaging confirms sufficient stone-free space to allow AXIOS\u2122 stent deployment.\n- 18 years of age or older.\n- Willing and able to comply with the study procedures and provide written informed consent.\n\nComparison:\n- The patient is over 18 years old.\n- The patient requires intervention for symptoms associated with acute cholecystitis, as evidenced by her symptoms and ultrasound findings.\n- The patient is referred for percutaneous drainage, which is an assumption since she is not described as a surgical candidate due to her symptoms and findings.\n- There is no information on whether the patient is eligible for endoscopic intervention, but since she is considered for percutaneous drainage, it can be assumed she might be eligible for endoscopic intervention.\n- The patient's acute cholecystitis can be considered Grade II due to symptom duration of more than 72 hours and leukocytosis.\n- There is no information about the patient's willingness and ability to comply with the study procedures or about providing informed consent, but this is typically determined after a patient is deemed preliminarily eligible.\n\nBased on the information given and reasonable assumptions, the patient appears to meet the inclusion criteria for the clinical trial. However, the final determination would require direct confirmation of certain details, such as the exact grade of acute cholecystitis per the Tokyo guidelines, the patient's eligibility for endoscopic intervention, and the patient's consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1335": {
        "output": "Based on the provided patient note, the 54-year-old woman presented to the emergency department with abdominal pain, nausea, vomiting, and a history of similar pain episodes in the past. She has a medical history of hypercholesterolemia and is menopausal. The ultrasound revealed gallstones and biliary sludge. Her condition suggests she may be suffering from a gallbladder issue, possibly cholecystitis or choledocholithiasis, given the elevated ESR, leukocytosis with a left shift, and the presence of CBD stones.\n\nThe clinical trial in question is investigating the relationship between gastric accommodation, transient lower esophageal sphincter relaxations (TLESRs), and reflux in healthy volunteers (HV) and in patients with gastro-esophageal reflux disease (GERD), with or without overlapping functional dyspepsia (FD).\n\nThe inclusion criteria for the clinical trial are:\n1. GERD patients with typical symptoms of reflux, such as heartburn and/or regurgitation, gastro-esophageal reflux assessed by 24-h pH-impedance monitoring or a positive symptom association, or esophagitis assessed by upper GI endoscopy.\n2. GERD/FD overlap with FD symptoms according to the Rome III criteria, including postprandial fullness, early satiation, epigastric pain, and epigastric burning.\n\nThe patient's symptoms as described in the note do not clearly indicate that she has GERD or FD. The symptoms of abdominal pain radiating to the right upper quadrant and getting worse after eating fatty food are more indicative of gallbladder-related issues rather than GERD or FD. There is no mention of heartburn, regurgitation, or other GERD/FD symptoms that would be necessary to meet the inclusion criteria for the clinical trial.\n\nTherefore, based on the available information, the patient does not appear to meet the inclusion criteria for the clinical trial focused on GERD and FD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1336": {
        "output": "The patient note describes a 54-year-old woman who has presented with abdominal pain, nausea, and vomiting. The symptoms and ultrasound findings are suggestive of gallstones and biliary sludge, indicating she may have biliary tract disease. However, the patient note does not mention if the biliary tract disease is cancerous or if it's advanced (metastatic and/or unresectable), nor does it indicate a history of systemic therapy for biliary tract cancer.\n\nThe clinical trial is for patients with specific types of advanced solid tumors (including biliary tract cancers) that are incurable and have failed prior standard systemic therapy. It requires measurable disease, provision of a PD-L1 evaluable tissue sample, and other specific criteria related to organ function and performance status.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if this patient's condition is a match for the trial's target diseases (such as advanced biliary tract cancer). The patient's gallstones and biliary sludge are not explicitly described as cancerous, nor is there any mention of prior treatments for such conditions which would qualify her for this clinical trial.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial as described. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1337": {
        "output": "The inclusion criteria for the clinical trial are:\n\n1. Men and women aged 18 or older\n2. Patients who dated and signed their informed consent to participate in the study\n3. Patients admitted to the emergency department due to a trauma\n4. Patients having a pain score \u2265 4 measured using a numerical scale (NRS) at the time of admission to emergency departments\n5. Patients having a pain score \u2265 40 measured using the VAS at the time of randomisation\n\nThe patient note describes a 54-year-old woman who is admitted to the emergency department with abdominal pain related to gallstones, not trauma. Thus, the patient's condition does not match the third inclusion criterion, which specifically requires the admission to be due to trauma.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial because her emergency department admission is not due to trauma but rather to gallstones.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1338": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, let's compare the patient's characteristics and symptoms to the inclusion criteria of the study:\n\nClinical Trial Inclusion Criteria:\n1. Presumed infectious diarrhea (3 or more loose stools in past 24 hours)\n2. Must have one of the following features or symptoms lasting more than 7 days:\n   - Symptoms greater than 24 hours;\n   - Dehydration (defined as the need for intravenous fluid or per clinician's judgement);\n   - Inflammation (defined as fever (greater than 100.1), blood in stool per patient, DRE, or tenesmus.)\n\nPatient Characteristics and Symptoms:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, not diarrhea\n- Pain started 4 days ago, not lasting more than 7 days\n- Nausea and vomiting, does not suggest diarrhea\n- Mild fever (38.2\u00b0C, which is about 100.76\u00b0F)\n- No mention of diarrhea, let alone 3 or more loose stools in the past 24 hours\n\nGiven the information from the patient note, the patient does not meet the primary inclusion criterion of having presumed infectious diarrhea with 3 or more loose stools in the past 24 hours. Additionally, the symptoms have not been stated to last more than 7 days, and the patient does not have the specific kind of inflammation defined by the inclusion criteria (blood in stool per patient, DRE, or tenesmus).\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1339": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we should evaluate whether the patient is possibly eligible for the trial.\n\nPatient note summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Pain worsens after eating fatty food\n- History of hypercholesterolemia\n- No mention of malnutrition or nutritional supplementation\n- Currently experiencing acute gallstone-related issues\n\nClinical trial inclusion criteria:\n- Patients (>18 years) who can communicate clearly\n- Patients with or at risk of malnutrition\n- Patients expected to require oral nutritional supplementation for at least 2 further weeks\n- Patients requiring supplementary intake approximately 300 kcal/day from an oral nutritional supplement\n- Informed assent/consent obtained\n\nThe patient's current medical presentation is focused on acute gallstone-related issues, which is not related to malnutrition or a need for oral nutritional support. There is no information provided that suggests the patient is malnourished or at risk of malnutrition, nor is there any indication that she requires oral nutritional supplementation. Therefore, based on the available information, the patient does not meet the inclusion criteria for the trial focused on the tolerance and acceptability evaluation of 'MONACO' for patients requiring supplementary oral nutritional support.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1340": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial for Refractory Functional Dyspepsia (RFD), we need to determine whether the patient is eligible to participate in the study.\n\nPatient note analysis:\n- The patient is a 54-year-old woman, which satisfies the age requirement of being over 19 years old.\n- The patient is presenting with symptoms that could be consistent with dyspepsia, such as epigastric pain, nausea, and vomiting.\n- The pain seems to be associated with eating fatty food, which might suggest a biliary etiology rather than functional dyspepsia.\n- The patient has a history of similar symptoms, but there is no mention of the duration of these symptoms.\n- The patient's symptoms result in an emergency department visit, indicating they could be disruptive to daily life.\n- Laboratory analysis and ultrasound results indicate organic pathology (gallstones, biliary sludge, and CBD stones), which are potential causes of the symptoms.\n\nClinical trial inclusion criteria analysis:\n- The patient is over 19 years old.\n- To be included, patients must have been diagnosed with FD according to the Rome IV criteria and have RFD. There is no information provided on whether this patient has been diagnosed with FD.\n- Participants must have had specific symptoms (early satiation, postprandial fullness, epigastric pain, and soreness) for certain durations, but the patient note lacks this information.\n- Symptoms must have started at least 6 months before and continued for at least 3 months. Again, the patient note does not provide this information.\n- Participants must not have any possible causes of symptoms, including organic disease. The patient has been found to have gallstones and other biliary issues, which are organic causes of her symptoms.\n- Participants must not respond to at least 2 general treatments for FD. There is no information on treatments given to this patient for FD.\n- Participants must have dyspepsia symptoms that disrupt daily life, but there is no specific information about the impairment of daily life, although an ED visit suggests significant impact.\n\nBased on the information provided, the patient does not seem to meet the inclusion criteria for the clinical trial because she has an organic cause for her symptoms (gallstones, biliary sludge, and CBD stones), which excludes her from the trial targeting patients with refractory functional dyspepsia, where no organic cause is identified.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1341": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we must determine if the patient is eligible for the trial.\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain, hypercholesterolemia, and 2 NVDs (natural vaginal deliveries)\n- Menopausal, non-smoker, non-drinker, no illicit drug use\n- Mild fever, high BP and HR, normal RR, normal SpO2\n- Epigastric tenderness and right upper quadrant tenderness\n- Normal bowel sounds\n- Elevated ESR and leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Summary:\n- The trial is about using virtual reality for pain management post laparoscopic hysterectomy.\n- Inclusion Criteria:\n  - Any patient undergoing laparoscopic hysterectomy\n  - Benign indications\n  - Surgery to be performed by Dr. Jamal Mourad or Dr. Nichole Mahnert\n\nThe patient in the note is being treated for abdominal pain due to gallstones and biliary sludge, which suggests she may require a cholecystectomy, not a hysterectomy. Moreover, there is no information indicating that she is undergoing or scheduled to undergo a laparoscopic hysterectomy. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1342": {
        "output": "",
        "label": 0
    },
    "1343": {
        "output": "After reviewing the patient note and the clinical trial information provided, we can determine the trial-level eligibility as follows:\n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting, which are symptoms potentially related to gallstones as indicated by the ultrasound findings. The clinical trial is focused on opiate use and biliary dilation without obstructive pattern on liver function tests or imaging.\n\nFrom the patient note, there is no mention of opiate use by the patient. Furthermore, the clinical trial is interested in patients with biliary dilation, and while the patient has gallstones and biliary sludge, there is no specific mention of biliary dilation or an obstructive pattern on liver function tests.\n\nThe inclusion criteria for the trial are:\n1. Referral/consultation for consideration for EUS \u00b1 ERCP\n2. Age 18 and older\n3. Evidence of biliary dilation on abdominal imaging without obstructive pattern on liver function tests or imaging.\n4. Willing and able to comply with the study procedures and provide written informed consent to participate in the study.\n\nBased on the information given, the patient does not appear to meet the inclusion criteria of having evidence of biliary dilation without an obstructive pattern. Also, there's no mention of opiate use which might be relevant for the study's focus. Therefore, this patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1344": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pain and hypercholesterolemia. \n- She has gallstones and biliary sludge as per ultrasound findings.\n- She presented to the emergency department by her personal way.\n\nClinical trial:\n- The objective is to assess the impact of patients consulting medical information on a website before coming to the emergency department.\n- Inclusion criteria: Any major patient presenting to the emergency department by their personal way.\n\nThe patient, a 54-year-old woman, presented to the emergency department by her personal way, which matches the inclusion criterion of the clinical trial. There is no mention of exclusion criteria, and the inclusion criteria are broad with only one condition to be met.\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1345": {
        "output": "Based on the patient note provided, the 54-year-old obese woman has been admitted to the emergency department with symptoms that indicate gallbladder issues, such as abdominal pain radiating to the right upper quadrant that worsens after eating fatty food, nausea, vomiting, tenderness in the right upper quadrant, and the presence of gallstones and sludge in the ultrasound findings. These symptoms and findings are consistent with gallbladder disease and the patient appears to be a candidate for gallbladder removal (cholecystectomy).\n\nThe clinical trial is looking to assess the quality of life related to digestive symptoms after cholecystectomy and the effects of a low-fat diet. The inclusion criteria for the trial are simply \"Gallbladder removal because biliary pain or gallstones complications.\"\n\nGiven that the patient has gallstones and is experiencing biliary pain, as indicated by the symptoms and ultrasound results, she meets the inclusion criteria for the trial as a candidate for gallbladder removal. There are no other inclusion criteria or exclusion criteria mentioned.\n\nTherefore, the patient appears to be potentially eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1346": {
        "output": "Based on the patient note provided, the 54-year-old woman presented with abdominal pain, nausea, vomiting, and a radiating pain to the right upper quadrant after eating fatty food. Her medical history includes hypercholesterolemia, and she has given birth twice (2 NVDs). The clinical findings and laboratory analysis are indicative of gallstones and possibly cholecystitis, given the elevated ESR, leukocytosis, and the ultrasound findings. \n\nThe clinical trial in question is focused on Kawasaki disease with acute abdomen requiring surgery. Kawasaki disease is a condition that primarily affects children and involves inflammation of blood vessels throughout the body. It is not indicated in the patient's history that she has Kawasaki disease nor is there any mention of her requiring surgery for an acute abdomen related to Kawasaki disease. \n\nGiven that the inclusion criteria for the clinical trial specifically require patients with Kawasaki disease experiencing acute abdomen necessitating surgery, and there is no information to suggest that the patient has Kawasaki disease, the patient does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1347": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar pain.\n- Past medical history includes hypercholesterolemia.\n- No mention of hip surgery or any condition directly related to the need for hip surgery.\n- No mention of ASA (American Society of Anesthesiologists) Physical Status Classification.\n\nClinical Trial:\n- The trial is evaluating analgesic efficacy for patients undergoing hip surgery.\n- Inclusion criteria mention ASA I-II Patients but do not provide any other details.\n\nGiven that the patient does not have sufficient information regarding the need for hip surgery or their ASA classification, we cannot determine eligibility based on the provided criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1348": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Abdominal pain, nausea, vomiting\n- Hypercholesterolemia, menopausal, no smoking or alcohol or illicit drug use\n- Elevated ESR, leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Summary:\n- Title: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia\n- Inclusion Criteria Highlights:\n  - Newly diagnosed B-cell ALL or B-LLy, with or without Down syndrome\n  - Different age criteria based on the presence of Down syndrome and type of leukemia\n  - Newly diagnosed B-ALL with specific WBC counts, or newly diagnosed B-cell LLy Murphy stages I or II\n  - Written informed consent\n\nThe patient in the note does not have a diagnosis of B-cell ALL or B-LLy, nor does she have Down syndrome. The trial is specifically for patients with newly diagnosed B-lymphoblastic leukemia or B-lymphoblastic lymphoma, and there is no mention of these conditions in the patient's note. Instead, the patient appears to have gallstone-related issues.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1349": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old woman who presented with abdominal pain, nausea, and vomiting. Her pain is epigastric and radiates to the right upper quadrant, worsening after eating fatty food. Laboratory analysis shows elevated ESR and leukocytosis with a left shift. Ultrasound revealed gallstones and biliary sludge. The clinical trial is seeking participants with acute appendicitis, which is characterized by pain in the right iliac fossa, tenderness in the same region, elevated leukocyte count, and without a palpable mass, confirmed both clinically and on radiological investigation.\n\nThe patient's symptoms and diagnostic findings suggest gallbladder pathology, likely cholecystitis, given the epigastric pain radiating to the right upper quadrant and the presence of gallstones on ultrasound. There is no mention of pain specifically in the right iliac fossa, which is typical for appendicitis. Furthermore, the patient's condition has been diagnosed with gallstones and biliary sludge, not acute appendicitis.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires a diagnosis of acute appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1350": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial. The clinical trial is focused on patients who have been diagnosed with gastric cancer and have undergone surgery for it. The patient in the note is admitted to the emergency department with symptoms that are suggestive of gallbladder issues (e.g., pain after eating fatty food, elevated ESR, leukocytosis, and presence of gallstones on ultrasound), not gastric cancer.\n\nThe patient note does not mention a diagnosis of gastric cancer or any surgical treatment for such a condition. Therefore, the patient does not meet the inclusion criteria of having a diagnosis of gastric cancer and having received an operation for it. Additionally, the trial requires patients to need nutrition support treatment and to provide informed consent. There is no information in the patient note to indicate that these criteria are met either.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1351": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and diagnosed gallbladder issues (gallstones and biliary sludge). This patient's medical condition and history do not match the target diseases or conditions specified in the clinical trial's inclusion criteria.\n\nThe clinical trial in question is focused on patients with High-Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL), Mixed Phenotype Acute Leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy). The inclusion criteria for the trial also specify age and white blood cell count requirements for eligibility, as well as a diagnosis of B-ALL, MPAL, or B-LLy.\n\nThe patient does not have a diagnosis of B-ALL, MPAL, or B-LLy, nor is there any indication in the patient note of such a condition. Additionally, the patient's age exceeds the maximum age limit of 25 years set by the trial's inclusion criteria.\n\nTherefore, based on the information available in the patient note and the inclusion criteria of the clinical trial, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1352": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nPatient Characteristics:\n- 54-year-old woman\n- Abdominal pain with nausea and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain twice in the past year\n- Past medical history includes hypercholesterolemia\n- No mention of alcohol or illicit drug use\n- Febrile, with elevated BP and HR\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria:\n- Age 18 to 75 years old\n- Patients with upper abdominal pain, abdominal distension, belching, anorexia, early satiety, hiccup, acid reflux, upper abdomen burning sensation, and other upper gastrointestinal symptoms\n- Voluntary acceptance of Hp (Helicobacter pylori) testing\n- Voluntary acceptance of endoscopy and pathological biopsy\n\nAssessment:\nThe patient is 54 years old, which falls within the age range of 18 to 75 years old specified by the trial. She presents with upper abdominal pain that radiates to the right upper quadrant and is exacerbated by eating fatty food, which aligns with some of the upper gastrointestinal symptoms listed in the inclusion criteria (upper abdominal pain, possibly acid reflux given the nature of the pain). However, the patient's symptoms are more suggestive of gallbladder disease (cholelithiasis and potential cholecystitis) rather than gastric issues directly related to bile reflux.\n\nThere is no direct mention in the patient note of symptoms specific to bile reflux, such as belching, hiccups, or a burning sensation, nor is there a mention of the patient's willingness to undergo Hp testing or endoscopy and pathological biopsy. However, given the patient's symptoms and the presence of gallstones and biliary sludge, which can contribute to bile reflux, the patient may potentially have related upper gastrointestinal symptoms that could make her eligible for the trial if she consents to the required testing and procedures.\n\nBased on the information available, the patient could be considered for the trial if additional details align with the inclusion criteria (e.g., willingness to undergo Hp testing and endoscopy). Since the patient has not explicitly met all the inclusion criteria based on the information given, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1353": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Sexual Health Empowerment for Women's Health,\" the patient does not meet the inclusion criteria. The only inclusion criterion mentioned for the trial is that participants must be scheduled to leave jail within 3 days, and there is no information in the patient note suggesting that the patient is currently incarcerated or scheduled to be released from jail.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1354": {
        "output": "Based on the patient note and the inclusion criteria of the DIGEST I clinical trial, we need to assess the patient's eligibility for the trial.\n\nPatient characteristics:\n- 54-year-old woman (within the age criteria of \u2265 18 and \u2264 80 years)\n- Presented with abdominal pain, nausea, vomiting, elevated ESR, leukocytosis, and fever\n- Imaging revealed gallstones and biliary sludge\n- No mention of biliary stricture, postoperative injury, PSC, or anastomotic stricture\n- No information on previous ERCP procedures or balloon dilation sessions\n- No data on total serum bilirubin or alkaline phosphatase levels\n- No information on the type or length of stricture\n- No information on liver transplantation status or voluntary participation/consent\n\nClinical trial inclusion criteria:\n- Age \u2265 18 and \u2264 80 years (patient meets this criterion)\n- Benign biliary stricture with postoperative injury or PSC or anastomotic stricture; and indicated for ERCP procedure (not specified for the patient)\n- Restenosis after plain balloon dilation with at least 2 previous balloon dilation sessions and recurrence of biliary obstructive symptoms/signs or being managed with implantable prosthetics (not specified for the patient)\n- Greater than 40% stenosis of the biliary tract via ERCP (not specified for the patient)\n- Total serum bilirubin >2 mg/dL. Alkaline phosphatase level >3 times higher than normal level (not specified for the patient; waived if managed with implantable prosthetics)\n- Type I, II, III, and IV Benign biliary duct strictures (not specified for the patient)\n- Dominant stricture being accessible by balloon catheter (not specified for the patient)\n- Stricture length <4 cm (not specified for the patient)\n- Not currently listed for liver transplantation (not specified for the patient)\n- Voluntary participation and provided written informed consent (not specified for the patient)\n\nBased on the available information, the patient does not have sufficient information to qualify for the trial. The key elements related to the specific condition being studied (benign biliary stricture, ERCP, previous interventions, specific lab values) are not mentioned in the patient note. Therefore, the patient does not meet the necessary inclusion criteria as they are presented.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1355": {
        "output": "To determine the trial-level eligibility of the 54-year-old obese woman described in the patient note for the clinical trial of CB4211, we need to examine the inclusion and exclusion criteria of the trial in relation to the patient's characteristics and medical condition.\n\nPatient characteristics and condition:\n- 54 years old\n- Female\n- Obese\n- Abdominal pain with nausea and vomiting\n- Epigastric pain radiates to the right upper quadrant, worsens after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Menopausal\n- Non-smoker, non-alcohol user, no illicit drug use\n- Mild fever, hypertension\n- Laboratory findings: elevated ESR, leukocytosis with a left shift\n- Ultrasound findings: gallstones, biliary sludge, and CBD stones\n\nClinical Trial Inclusion Criteria for Part C (relevant for obese subjects with NAFLD):\n- Males or females of nonchildbearing potential, 18 to 60 years of age\n- Body mass index \u226530.0 kg/m^2, and body weight \u2264115 kg\n- History of Fatty Liver Index (FLI) score >60, or documented history of fatty liver with imaging results indicating liver fat >10% within 6 months of Screening\n- No history of common causes of secondary hepatic steatosis\n- Glycosylated hemoglobin A1c <7.0 % at Screening\n- Fasting blood glucose of \u2265100 to <126 mg/dL at Screening\n- Serum triglyceride level \u2264500 mg/dL at Screening\n- In good health, with no clinically significant findings from medical history, physical examination, etc.\n- Able to comprehend and willing to sign an informed consent form (ICF)\n\nClinical Trial Exclusion Criteria for Part C:\n- Significant history or clinical manifestation of any metabolic/endocrine (except for type 2 diabetes), allergic, dermatological, hepatic (except for NAFLD), renal, hematological, etc.\n- Clinically significant ECG abnormalities or QTcF >450 milliseconds for males and 470 milliseconds for females\n- Currently using any antidiabetic medication other than a stable regimen of metformin\n- Use of certain medications and substances within a specified timeframe before Check-in\n- History of alcoholism or drug/chemical abuse within 2 years prior to Check-in\n- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance\n- Participation in a clinical study involving administration of an investigational drug in the past 30 days or have received a biological product within 3 months or 5 elimination half-lives prior to dosing\n- Use of tobacco- or nicotine-containing products within 3 months prior to Check-in\n\nBased on the above, the patient does not seem to meet the specific inclusion criteria related to NAFLD. There is no information in the patient note indicating a history or diagnosis of NAFLD or relevant imaging or laboratory results. Furthermore, the current medical issue seems to be related to gallstones and possible cholecystitis, which is not the focus of the clinical trial.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria specified for NAFLD. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1356": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Virtual Reality in SOD,\" we can evaluate the patient's eligibility for the trial.\n\nPatient Note Summary:\n- The patient is a 54-year-old obese woman with abdominal pain that radiates to the right upper quadrant, getting worse after eating fatty food. This pain has been experienced twice in the past year.\n- The patient has a history of hypercholesterolemia.\n- The patient has no history of smoking, alcohol, or illicit drug use.\n- Laboratory analysis showed elevated ESR and leukocytosis with a left shift. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria Summary:\n- Diagnosis of chronic biliary type abdominal pain for at least 3 months prior to the study.\n- Pancreatic pain for at least 3 months prior to the study.\n- Absence of abnormal liver and pancreas chemistry or abnormal abdominal imaging.\n- Average pain score of \u22653 on the NRS for at least the average of 3 episodes each week.\n- Stable medication dose for antidepressants for pain control or for psychopharmacologic treatment for depressive and/or anxiety disorders for at least 1 month or 6 weeks, respectively.\n- Patients with access to a cell phone, able to speak, read, and write English.\n\nComparison:\n- The patient's abdominal pain radiates to the right upper quadrant and is associated with eating fatty food, which suggests biliary pain, potentially related to gallstones rather than SOD.\n- The patient's abdominal imaging is not normal, as it shows gallstones, biliary sludge, and CBD stones, which contradicts the trial's requirement for the absence of abnormal abdominal imaging.\n- The duration of the patient's pain is not clearly stated as being chronic or for at least 3 months prior to the study.\n- The patient's pain score and frequency of episodes are not provided.\n- There is no information on whether the patient is on antidepressants or psychopharmacologic treatment, nor about the stability of any medication doses.\n- There is no information indicating the patient does not have access to a cell phone or cannot speak, read, and write English.\n\nGiven the above comparison, the patient does not meet several critical inclusion criteria for the clinical trial. Specifically, the presence of abnormal abdominal imaging and the lack of detailed chronic pain history exclude the patient from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1357": {
        "output": "To determine the patient's eligibility for the \"Juice Plus Inflammaging and Cardiovascular Disease Prevention Study,\" we need to compare the patient's characteristics with the study's inclusion criteria:\n\nInclusion Criteria for the study:\n- 90 male and female subjects\n- Age: 50 - 80 years\n- Post- or peri-menopausal\n- Smokers and non-smokers\n- BMI 25 to 40 kg/m^2\n- Dietary Inflammatory Index, DII: 0 to +10\n- Fruit and vegetable intake <4 servings/d\n- Adherence to a 6-week wash-out period\n\nPatient characteristics:\n- A 54-year-old obese woman (age is within the range of 50 - 80 years)\n- She is menopausal (meets the requirement of being post-menopausal)\n- BMI is not explicitly mentioned, but the patient is described as obese (we cannot accurately determine the BMI without specific measurements)\n- Dietary Inflammatory Index (DII) is not mentioned\n- Fruit and vegetable intake is not mentioned\n- Willingness or ability to adhere to a 6-week wash-out period is not mentioned\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria: she is within the correct age range and is post-menopausal. However, there is insufficient information to determine her eligibility based on the other criteria, such as BMI, DII score, fruit and vegetable intake, and adherence to the wash-out period. Therefore, we cannot definitively say she is eligible or excluded from the study. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1358": {
        "output": "Based on the provided patient note, the patient is a 54-year-old woman with abdominal pain, nausea, vomiting, and gallstones. Her medical history includes hypercholesterolemia, and she has no history or mention of multiple myeloma (MM) in the note. The clinical trial in question is seeking participants with relapsed/refractory multiple myeloma (R/R MM) who have received 1 to 3 prior lines of therapy.\n\nGiven that the patient's condition and medical history do not match the target disease (R/R MM) for the clinical trial, she does not meet the inclusion criteria specified for the trial. There is no indication that she has multiple myeloma or that she has undergone any lines of therapy for such a condition, much less the specific requirement of having received carfilzomib for less than 2 months.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1359": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for participation in the trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting.\n- Her symptoms are associated with gallstones and biliary sludge, and she has a history of hypercholesterolemia.\n- The patient does not appear to have breast cancer and is not described as undergoing breast reconstruction surgery.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on improving tissue oxygenation in patients undergoing breast reconstruction surgery, specifically using the deep inferior epigastric perforator (DIEP) flap technique.\n- Eligible participants must fall within the American Society of Anesthesiologists' (ASA) Physical Classification I-III.\n- Participants must be undergoing elective unilateral or bilateral DIEP flap surgery and be competent to provide informed consent.\n\nBased on the information given, the patient in the note does not meet the inclusion criteria for the clinical trial. She is not undergoing breast reconstruction surgery and her current medical issues are not related to breast cancer or breast reconstruction. Thus, she is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1360": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient appears to have cholelithiasis, as evidenced by the ultrasound revealing several gallstones, biliary sludge, and CBD stones. However, the inclusion criteria for the trial specify that participants must have normal values of amylase, lipase, and liver function tests measured 24 hours before the intervention. The patient note does not provide any information regarding the levels of amylase, lipase, or liver function tests. Without this information, we cannot determine whether the patient meets the inclusion criteria.\n\nTherefore, the patient's eligibility for the clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1361": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for \"Inhaled Steroids for Acute Pharyngitis,\" let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 54-year-old obese woman\n- Presented with abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant, worse after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Menopausal, non-smoker, no alcohol or illicit drug use\n- Mildly febrile, elevated blood pressure and heart rate\n- Laboratory findings: elevated ESR, leukocytosis with a left shift\n- Ultrasound revealed gallstones and biliary sludge\n\nClinical Trial Inclusion Criteria:\n- Pediatrics and adult patients > 5 years of age\n- Patients complain of acute sore throat likely due to infective pharyngitis/tonsillitis as judged by the treating clinician\n- Onset of symptoms within 7 days\n- Patient or caregiver has the capacity and willingness to give consent and complete the trial paperwork, including the symptom diary\n- Not on antibiotics for acute pharyngitis\n\nThe patient presented with abdominal pain and symptoms indicative of gallstones and biliary issues rather than acute pharyngitis or tonsillitis. The patient does not complain of a sore throat or any symptoms related to acute pharyngitis, which is the focus of the clinical trial. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1362": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 54-year-old woman (meets age criterion of \u226545 years)\n- Admitted with abdominal pain, nausea, and vomiting\n- History of similar pain\n- Remarkable for hypercholesterolemia (no mention of diabetes or chronic respiratory, cardiovascular, or renal disease)\n- No mention of alcohol, smoking, or illicit drug use\n- Mildly febrile with a temperature of 38.2\u00b0C (meets criterion of oral temperature >38\u00b0C)\n- Elevated ESR and leukocytosis with a left shift (meets criterion of leukocytosis >10 \u00d7 10^3/\u03bcl)\n- Ultrasound revealed gallstones and biliary sludge (meets criterion of cholelithiasis)\n- No mention of Murphy\u2019s sign or ultrasound signs specific to cholecystitis, but presence of gallstones and symptoms suggest acute cholecystitis\n- No information on whether the acute cholecystitis requires surgery during working hours or if an overnight hospital admission is expected after surgery\n- No information on whether the patient can provide written informed consent\n\nBased on the available information, the patient meets several of the inclusion criteria (age, temperature, leukocytosis, gallstones). However, there is insufficient information on whether the patient has acute cholecystitis that requires surgery and is diagnosed during working hours, whether an overnight hospital admission is expected after surgery, and whether the patient can provide informed consent. There are also no details provided that would place the patient in the exclusion criteria.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1363": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman presenting with symptoms indicative of gallstones, as confirmed by an ultrasound that revealed several gallstones, biliary sludge, and common bile duct (CBD) stones. She has not yet undergone a laparoscopic cholecystectomy as the note does not mention she has had this procedure.\n\nThe clinical trial in question is investigating factors responsible for the outcome post bile and gallstone spillage during laparoscopic cholecystectomy and the management of complications arising from such spillage.\n\nThe inclusion criteria for this clinical trial are:\n- All age groups\n- Only laparoscopic cholecystectomy\n- All types, numbers, and sizes of gallstones\n\nAs the patient has not undergone laparoscopic cholecystectomy yet, she does not currently meet the inclusion criteria, which specifically requires participants to have undergone the procedure. Therefore, she cannot be included in this trial to assess postoperative outcomes and complications because she has not experienced the operative event the study is investigating.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1364": {
        "output": "To determine the patient's eligibility for the clinical trial, we must assess the patient's characteristics against the inclusion criteria of the trial.\n\nThe patient note provides the following information:\n- The patient is a 54-year-old woman.\n- She presents with abdominal pain, nausea, vomiting, and other symptoms suggestive of gallbladder stones.\n- She has hypercholesterolemia and is menopausal.\n- She does not have a history of using steroids, nor is there any mention of Crohn's disease.\n\nThe inclusion criteria for the clinical trial are:\n- Patients with biopsy-confirmed, active, steroid-dependent Crohn's Disease (CD).\n- Age \u226518 years.\n- Steroid treatment of at least 3 months and stable steroid dose for at least 2 weeks.\n- If using thiopurines and/or biologics, the dosage must have been stable for at least 3 months.\n- An ECG and QT parameters will be measured for further analysis.\n- Female subjects who are postmenopausal, surgically sterilized, or willing to use two methods of contraception and not breast-feeding may be enrolled.\n- Subjects must be able to provide written informed consent.\n\nBased on the provided patient note and the inclusion criteria of the trial, the patient does not meet the criteria for the clinical trial. The patient does not have a confirmed diagnosis of Crohn's Disease, nor is there any mention of being steroid-dependent. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1365": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 54 years\n- Condition: Abdominal pain with gallstones, hypercholesterolemia\n\nClinical Trial Inclusion Criteria:\n- Age 1-12 years\n- ASA I-II grade\n- Undergoing selective adenotonsillectomy\n- BMI 18.5-23.9\n- Signed informed consent\n\nThe patient in the note does not meet the age criterion, as she is 54 years old and the trial is for children aged 1-12 years. Additionally, the patient's condition (abdominal pain related to gallstones) is not relevant to the adenotonsillectomy procedure that the trial is focused on. The patient's BMI is also not stated, but given she is described as obese, it is likely not within the required range of 18.5-23.9.\n\nBased on the information provided, the patient does not fulfill the inclusion criteria for the clinical trial, primarily due to the age requirement and the type of medical procedure (adenotonsillectomy) being studied which is not applicable to her condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1366": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who presented to the emergency department with symptoms consistent with acute gallstone cholecystitis, including abdominal pain that worsens after eating fatty food, nausea, vomiting, and findings of gallstones, biliary sludge, and common bile duct (CBD) stones on ultrasound. These symptoms and findings, along with the laboratory analysis indicating an inflammatory process (elevated ESR and leukocytosis with a left shift), support a diagnosis of acute gallstone cholecystitis.\n\nNow, let's assess the patient's eligibility based on the clinical trial's inclusion criteria:\n\n1. Adults patient (>18 years old): The patient is 54 years old, which meets the adult age criterion.\n2. Patients requiring laparoscopic cholecystectomy for grade 1 or 2 acute gallstone cholecystitis according to Tokyo recommendations confirmed by radiological morphological examination: While the clinical trial inclusion criteria require specific grading of acute gallstone cholecystitis according to Tokyo recommendations, the patient note does not provide the exact grade of cholecystitis. However, the diagnosis of acute gallstone cholecystitis is supported by the patient's symptoms and ultrasound findings. Without specific grading, we cannot definitively determine if the patient meets this criterion.\n3. Acute lithiasis cholecystitis (ALC) evolving for less than 5 days: The patient's symptoms started 4 days ago, which would be within the 5-day window specified by the trial.\n4. Patients affiliated to a social security scheme: The patient note does not mention whether the patient is affiliated with a social security scheme.\n\nBased on the available information, the patient appears to meet some of the inclusion criteria (age and duration of ALC symptoms), but we do not have sufficient information to confirm all the required criteria, such as the grading of the acute gallstone cholecystitis and the patient's affiliation with a social security scheme.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1367": {
        "output": "Based on the provided patient note and the inclusion and exclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient's characteristics from the note:\n- 54-year-old woman\n- Presents with abdominal pain, nausea, and vomiting\n- The pain is related to gallstones and biliary sludge\n- Past medical history includes hypercholesterolemia\n- No mention of cognitive decline, mental illness, or drug addiction\n- Language proficiency is not specified\n- No mention of skin damage to fingers\n\nClinical trial inclusion criteria:\n- All patients over 18 years old\n\nClinical trial exclusion criteria:\n- Cognitive decline\n- Mental illness\n- Drug addicts\n- Non-Swedish speakers\n- Skin damage to fingers that make application more difficult\n\nAssessment:\n- The patient is over 18 years old, which meets the inclusion criteria.\n- The patient note does not mention any cognitive decline, mental illness, drug addiction, or skin damage to fingers.\n- Language proficiency is not mentioned, so we cannot determine if the patient is a non-Swedish speaker.\n\nSince the patient note does not provide information that would exclude the patient based on the trial's exclusion criteria, and there is no indication that the patient would not meet the inclusion criteria, the patient can be considered potentially eligible. However, the absence of language information means we cannot conclusively determine her eligibility. Therefore, the patient's trial-level eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1368": {
        "output": "Based on the patient note and the inclusion and exclusion criteria of the clinical trial titled \"Optimizing the Diagnosis of Acute Appendicitis,\" let's assess the patient's eligibility for the trial.\n\nThe patient is a 54-year-old woman presenting with abdominal pain that started 4 days ago with associated nausea and vomiting. The pain radiates from the epigastric region to the right upper quadrant and worsens after eating fatty food.\n\nThe inclusion criteria for the trial are:\n1. Patient with the symptoms of acute appendicitis: pain in the right lower quadrant, pain migration from epigastrium to right lower quadrant, nausea, rebound pain, elevated temperature.\n2. After primary clinical, laboratory, and ultrasound examination, the diagnosis of acute appendicitis could not be confirmed or excluded.\n3. No other gynecological, urological, or gastroenterological pathology is confirmed.\n\nThe exclusion criteria for the randomized part of the trial include:\n1. Pregnant patient.\n2. Clinical symptoms last for longer than 48 hours.\n3. Signs of peritonitis.\n\nThe patient's symptoms and laboratory findings are not consistent with acute appendicitis. Instead, the ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones, indicating a likely diagnosis of gallstone disease, not appendicitis. Therefore, the patient does not meet the inclusion criteria for the study, as her symptoms and findings suggest a different gastroenterological pathology.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1369": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman experiencing abdominal pain with nausea and vomiting.\n- The pain is associated with eating fatty food and is located in the epigastric region radiating to the right upper quadrant.\n- Her medical history includes hypercholesterolemia.\n- She has gallstones and biliary sludge as shown on the ultrasound.\n- There is no mention of gastroparesis or the presence of an Enterra Gastric Electrical Stimulation (GES) device.\n- The abdominal pain mentioned does not explicitly indicate that it is refractory to drugs and/or devices, nor is there any mention of previous treatment with an Enterra GES device.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must be able to give informed consent.\n- The patient must have had an Enterra GES device in place for at least 2 months.\n- The patient must continue to have moderate to severe abdominal pain that is persistent or chronic and refractory to the original Enterra GES settings.\n\nAssessment:\n- The patient does not meet the inclusion criteria since there is no information provided that suggests she has gastroparesis, nor is there any indication that she has an Enterra GES device in place.\n- Therefore, the patient is not eligible for the clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1370": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not match the conditions specified for participation in the clinical trial. The patient presented with symptoms suggestive of gallstones and biliary colic, while the clinical trial is focused on patients with de novo acute myeloid leukemia (AML) with hyper-leukocytosis and specific blood count parameters. The patient does not have a diagnosis of AML, and there is no mention of hyper-leukocytosis or eligibility for intensive chemotherapy, which are required for the study.\n\nTherefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1371": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient's Characteristics:\n- 54-year-old woman\n- Presenting with abdominal pain, nausea, vomiting, related to gallstones, and biliary sludge\n- Past medical history includes hypercholesterolemia\n- No mention of cancer or any type of lymphoma\n\nClinical Trial Inclusion Criteria:\n- Confirmed Non-Hodgkin's lymphoma (NHL) by histopathology\n- Disease status: recurrent or refractory\n- Age\u226518 years old\n- ECOG performance score 0-2\n- At least one evaluable lesion\n- Received appropriate first-line and more-line treatment for NHL\n- Specific liver and kidney function requirements\n- Normal thyroid function\n- Pregnancy test and contraception agreement for women of childbearing age\n- Signed informed consent form\n\nThe patient's symptoms and medical history are related to gallstones and biliary issues, not cancer. There is no mention of NHL or any other type of lymphoma. Therefore, the patient does not meet the specific inclusion criteria for the clinical trial, which requires a confirmed diagnosis of NHL and a number of other conditions related to the disease's status and prior treatments.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1372": {
        "output": "The patient note describes a 54-year-old obese woman with abdominal pain, likely due to gallstones, and no mention of a need for orthopedic surgery. The clinical trial in question is focused on the use of different sedatives in patients undergoing orthopedic surgery.\n\nThe inclusion criteria for the trial are: \n1. Physical status according to American Society of Anesthesiologists (ASA) I-III\n2. Patients scheduled for orthopedic surgery\n\nSince the patient note does not indicate that the patient is scheduled for orthopedic surgery or her ASA status, we do not have sufficient information to qualify the patient for the trial at this time.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1373": {
        "output": "Based on the information provided in the patient note and the clinical trial criteria:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman with abdominal pain that started 4 days ago.\n- The pain gets worse after eating fatty food.\n- She has experienced similar pain twice in the past year.\n- Her past medical history includes hypercholesterolemia.\n- The pain is acute, as indicated by a recent onset and a presentation to the emergency department.\n- The ultrasound revealed gallstones and biliary sludge, which suggest a gallbladder issue rather than chronic abdominal pain.\n- There is no mention of chronic abdominal pain for above 6 months.\n- There is no mention of the patient's pain score using the Numeric Rating Scale (NRS).\n\nClinical Trial Criteria:\n- All patients aged over 18 years (the patient is 54 years old, which meets this criterion).\n- Chronic abdominal pain for above 6 months (there is no evidence in the patient note that her abdominal pain is chronic and has been present for over 6 months).\n- Moderate to severe pain in the abdomen: Baseline NRS >4 (worst pain the last 24 hours) (there is no NRS score provided in the patient note).\n\nThe patient does not meet the inclusion criteria for chronic abdominal pain duration (over 6 months) or the baseline pain severity score, as this information is not provided in the patient note. Therefore, based on the available information, the patient is not eligible for the trial due to a lack of sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1374": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient note:\n- 54-year-old woman\n- Presenting with abdominal pain, nausea, and vomiting\n- Epigastric pain radiating to the right upper quadrant, worsening after eating fatty food\n- Past medical history includes hypercholesterolemia\n- The ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones\n\nClinical trial inclusion criteria:\n- Patients over 18 years of age\n- Suspected choledocholithiasis stratified into intermediate risk of choledocholithiasis as per European Society of Gastrointestinal Endoscopy Guidelines\n\nThe patient is over 18 years of age and has ultrasound evidence of gallstones and CBD stones, which suggests she could be at an intermediate risk of choledocholithiasis. Even though the exact risk level is not stated, the findings in the ultrasound and the symptoms point towards a possible diagnosis of choledocholithiasis, which could align with the trial's target population. Therefore, based on the information provided, the patient appears to meet the inclusion criteria. However, without explicit confirmation of the risk stratification as per the European Society of Gastrointestinal Endoscopy Guidelines, there is a minor uncertainty. Nevertheless, given the symptoms and ultrasound findings, it is reasonable to consider the patient eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1375": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific criteria required for participation in the study. The clinical trial is focused on patients undergoing short-duration upper limb surgery and includes procedures such as ganglion removal, K wiring, and carpal tunnel surgery. The patient in the note is experiencing abdominal issues related to gallstones and biliary sludge, which is unrelated to the focus of the clinical trial on upper limb surgeries.\n\nTherefore, the assessment of eligibility for this patient for this particular clinical trial would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1376": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's compare the details:\n\nPatient note:\n- A 54-year-old obese woman\n- Admitted with abdominal pain, nausea, and vomiting\n- History of hypercholesterolemia\n- No mention of shoulder surgery or any related condition\n\nClinical trial inclusion criteria:\n- American Association of Anesthesiologists (ASA) physical status I - III\n- BMI 20 to 35 kg/m2\n- Patients scheduled for elective arthroscopic shoulder surgery\n\nThe patient in the note does not mention anything about shoulder surgery or being scheduled for an elective arthroscopic shoulder procedure. Additionally, the patient is described as obese, but we do not have the specific BMI to determine if it falls within the required range of 20 to 35 kg/m2. However, the primary disqualifying factor is the lack of mention of shoulder surgery.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial because she is not scheduled for elective arthroscopic shoulder surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1377": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of similar symptoms. The pain is related to the consumption of fatty food, suggesting a biliary origin. The ultrasound confirmed the presence of gallstones, biliary sludge, and choledocholithiasis (common bile duct stones), which are consistent with acute calculous cholecystitis. Her past medical history is significant for hypercholesterolemia. She does not have a history of alcohol or drug abuse.\n\nThe clinical trial in question is evaluating the feasibility of EUS-guided gallbladder drainage (EGBD) as a treatment for acute calculous cholecystitis in patients who are indicated for laparoscopic cholecystectomy.\n\nThe inclusion criteria for the clinical trial are:\n- Consecutive healthy patients aged \u2265 18 years old.\n- Suffering from acute calculous cholecystitis.\n- Indicated for laparoscopic cholecystectomy.\n\nThe patient is over 18 years old and has acute calculous cholecystitis, as indicated by her symptoms and ultrasound findings. Although the patient has hypercholesterolemia, she is not described as having other health issues that would exclude her from being considered \"healthy\" for the purpose of the trial. The note does not explicitly state that she is indicated for laparoscopic cholecystectomy, but given the standard management of acute calculous cholecystitis and the presence of symptomatic gallstones and CBD stones, it is reasonable to infer that she would be a candidate for this procedure.\n\nSince the patient meets the age requirement and has acute calculous cholecystitis, and there is no information contradicting her indication for laparoscopic cholecystectomy, she appears to meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1378": {
        "output": "The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The pain is epigastric, radiates to the right upper quadrant, and worsens after eating fatty food. She has a history of similar pain, hypercholesterolemia, and is menopausal. Laboratory analysis shows elevated ESR and leukocytosis with a left shift, and the ultrasound revealed gallstones and biliary sludge, suggesting she may have gallbladder-related issues.\n\nNow, comparing this patient note to the inclusion criteria of the clinical trial titled \"ESM in Functional Dyspepsia\":\n\n1. The clinical trial is focused on functional dyspepsia and is validating a tool for symptom assessment in these patients.\n2. The inclusion criteria for patients with functional dyspepsia require a diagnosis according to ROME IV criteria, with no evidence of structural disease that explains the symptoms, and symptoms must have been present for the last 3 months with onset at least 6 months before diagnosis.\n3. The patient must be between 18 and 75 years old, speak Dutch, and be able to understand how to use the ESM tool.\n\nThe patient's current presentation is not consistent with functional dyspepsia; rather, it suggests a gallbladder issue such as cholecystitis or biliary colic. Furthermore, there is no mention of a diagnosis of functional dyspepsia or adherence to ROME IV criteria in the patient note. Additionally, there is no indication that the patient speaks Dutch or is able to use the ESM tool, which are necessary for inclusion in the study.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet the inclusion criteria for the clinical trial on functional dyspepsia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1379": {
        "output": "",
        "label": 0
    },
    "1380": {
        "output": "In reviewing the patient note and the inclusion criteria of the clinical trial, we need to determine if the patient can be considered for participation.\n\nPatient Note Review:\n- Patient: 54-year-old obese woman\n- Medical condition: Abdominal pain, nausea, vomiting, epigastric pain radiating to the right upper quadrant, hypercholesterolemia, gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm\n- Additional factors: Non-smoker, non-drinker, no illicit drug usage, menopausal, elevated ESR, leukocytosis with left shift\n\nClinical Trial Inclusion Criteria:\n- Sonologically proven cases of choledocholithiasis with cholelithiasis (both gallstones and CBD stones are mentioned in the patient's ultrasound report)\n- CBD diameter <2cm (this information is not provided in the patient's note)\n- Age >13 yrs (the patient is 54 years old)\n\nThe patient fits the age criterion and has both gallstones and CBD stones. The only missing piece of information is the diameter of the common bile duct (CBD). Without this information, we cannot definitively say that the patient meets all the inclusion criteria. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1381": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 54-year-old woman with abdominal pain, nausea, vomiting, epigastric pain radiating to the right upper quadrant, and history of gallstones and CBD stones.\n- Her medical history includes hypercholesterolemia.\n- No mention of cancer or any type of biliary tract disease aside from gallstones.\n- There are no indications of prior cancer treatments such as chemotherapy.\n\nClinical Trial:\n- Focused on advanced biliary tract cancer (BTC) including gallbladder cancer, intrahepatic cholangiocarcinoma, and perihilar cholangiocarcinoma.\n- Requires histological or cytological proof of biliary tract cancer.\n- Patients must have metastatic advanced or locally advanced unresectable biliary tract cancer.\n- Requires at least one measurable lesion within the liver.\n- No prior intra-arterial/systemic chemotherapy or other systemic therapies.\n- Age range is 18 to 80 years old.\n- ECOG performance <2.\n- Child-Pugh A or B (\u2264 score 7).\n- Specific baseline blood count and biochemical criteria must be met.\n\nThe patient does not have a diagnosis of biliary tract cancer, which is a fundamental requirement for participation in the trial. Instead, she has gallstones and CBD stones, which are not mentioned as conditions relevant to the trial. There is also no indication that the patient has an advanced unresectable biliary tract tumor or that she has had any measurable lesions within the liver.\n\nBecause the patient's condition (gallstones and CBD stones) is different from the target disease of the clinical trial (advanced biliary tract cancer), and there is no information provided that she meets the requirement of having a biliary tract cancer diagnosis, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1382": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the eligibility of the patient for the clinical trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She is admitted with abdominal pain, nausea, and vomiting.\n- The pain is related to fatty food intake, suggesting a gastrointestinal issue.\n- She has a history of hypercholesterolemia and is menopausal.\n- The clinical findings suggest a biliary etiology, likely gallstones.\n- There is no mention of the patient having malaria or any symptoms related to malaria.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for antimalarial drug efficacy.\n- It requires participants to be between > 6 months old and 59 years old.\n- Participants must have confirmed uncomplicated P. falciparum or P. vivax infections.\n- Participants should present a certain temperature threshold indicating fever.\n- There are specific requirements for G6PD testing, ability to swallow medication, and consent provisions.\n\nComparison:\n- The patient's age falls within the age range specified by the trial (>6 months to 59 years).\n- However, the patient does not have a confirmed P. falciparum or P. vivax infection, which is a key inclusion criterion for the trial.\n- The patient's presentation is not consistent with malaria and there is no indication of febrile illness due to malaria.\n- The patient's condition (abdominal pain related to gallstones) is entirely unrelated to the antimalarial drug efficacy study.\n\nConclusion:\nThe patient does not meet the necessary condition of having a confirmed uncomplicated P. falciparum or P. vivax infection which is a requirement for the clinical trial. Therefore, the patient is not eligible for this antimalarial drug efficacy trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1383": {
        "output": "Based on the information provided, the patient note describes a 54-year-old obese woman who presented to the emergency department with abdominal pain, nausea, vomiting, and a history of similar pains in the past. She was found to have gallstones and biliary sludge on ultrasound examination. Her condition fits the inclusion criteria for acute abdominal pain requiring imaging for suspected gallstone disease, as specified in the clinical trial's summary.\n\nHowever, there is no mention in the patient note about ongoing viral hepatitis, which is the focus of the VIRal Hepatitis and GAllstone Disease Study. The inclusion criteria also require the ability to obtain 9 mL serum for analysis of various hepatitis markers. The patient note does not provide information on whether the patient has ongoing viral hepatitis or whether serum can be obtained for the necessary analyses.\n\nSince there is insufficient information to determine whether the patient has viral hepatitis or if the patient has provided written informed consent and whether serum can be obtained, we cannot definitively include her in the trial based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1384": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old obese woman who presented with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones. Her medical history includes hypercholesterolemia. There is no mention of the patient having acute on chronic liver failure (ACLF), which is the specific condition required for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial specify that the patient must have a recent diagnosis (\u22641 week) of ACLF grade 1 or 2 according to the CLIF definition, with a bilirubin value \u22655 mg/dL. The patient's note does not indicate that she has been diagnosed with ACLF, nor does it provide a bilirubin value or any indication of liver failure.\n\nGiven this, there is not enough information to determine if the patient meets the inclusion criteria for the HepaStem clinical trial on patients with ACLF. Therefore, the patient's trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1385": {
        "output": "Based on the information provided:\n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones, as evidenced by the ultrasound. She has no mention of colorectal cancer, particularly of metastatic or stage IV nature.\n\nThe clinical trial in question is specifically for patients with histologically proven adenocarcinoma of colorectal origin who have stage IV disease and are undergoing systemic treatment. The patient in the note does not have any information suggesting a diagnosis of colorectal cancer, let alone metastatic colorectal cancer.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1386": {
        "output": "Based on the information provided in the patient note, the patient is a 54-year-old woman with symptoms and ultrasound findings consistent with cholelithiasis (gallstones) and choledocholithiasis (CBD stones). The clinical trial in question is studying the relationship between post-ERCP-choledocholithiasis and gallbladder status as a risk factor.\n\nThe inclusion criteria for the clinical trial are:\n\n- Routine ERCP for CBD stone patients with gallbladder in situ\n\nThe patient note indicates that the patient has CBD stones, which would potentially make her a candidate for ERCP (Endoscopic Retrograde Cholangiopancreatography). However, there's no information provided about whether the patient's gallbladder is in situ (still present) or not.\n\nSince the patient note does not explicitly state whether the patient's gallbladder is in situ, we cannot definitively determine if the patient is eligible for the trial. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1387": {
        "output": "The patient in the provided note is a 54-year-old obese woman with symptoms indicative of gallbladder issues (abdominal pain, nausea, vomiting, pain after eating fatty food, fever, leukocytosis, and ultrasound findings consistent with gallstones and biliary sludge). There is no mention of liver cirrhosis or acute upper gastrointestinal bleeding (hematemesis and/or melena).\n\nThe clinical trial in question is focused on patients with histologically proven cirrhosis or clinical and ultrasonographic data compatible with the diagnosis of cirrhosis who have experienced acute upper gastrointestinal bleeding within the previous 24 hours and are about to undergo emergency gastroscopy.\n\nGiven that the patient's note does not mention cirrhosis or acute upper gastrointestinal bleeding, nor does it indicate that the patient is about to undergo emergency gastroscopy for that issue, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the assessment of this patient's eligibility for the specified clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1388": {
        "output": "",
        "label": 0
    },
    "1389": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the trial.\n\nPatient Note Summary:\n- The patient is a 54-year-old obese woman.\n- Presented with abdominal pain, nausea, vomiting, and pain worsening after eating fatty food.\n- Past medical history includes hypercholesterolemia.\n- She is menopausal with two children.\n- She does not smoke, drink alcohol, or use illicit drugs.\n- She has elevated ESR and leukocytosis with a left shift.\n- Ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nClinical Trial Inclusion Criteria:\n- ERCP patients with gallbladder in situ.\n\nAnalysis:\nThe patient has gallstones and CBD stones as revealed by ultrasound, and the clinical trial is looking for ERCP patients with gallbladder in situ. The patient note indicates that the patient has gallstones and therefore could potentially be a candidate for ERCP. However, the note does not explicitly state that the patient has her gallbladder in situ or that she is scheduled for or has undergone ERCP (Endoscopic Retrograde Cholangiopancreatography).\n\nTherefore, based on the available information, we cannot confirm that the patient meets all of the inclusion criteria for the clinical trial, as the critical information regarding her gallbladder status (whether it is in situ) and whether she is an ERCP patient is not provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1390": {
        "output": "Given the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility for the trial step by step:\n\n1. Female and male patients aged 18-85 years.\n   - The patient is a 54-year-old woman, so she meets the age criterion.\n\n2. Patients with a history of type 2 diabetes mellitus according to The American Diabetes Association (ADA).\n   - There is no mention of type 2 diabetes in the patient's history, so we cannot confirm this criterion.\n\n3. Patients with a diagnosis of painful diabetic peripheral neuropathy (PDPN) caused by type 2 diabetes mellitus based on DN4 \u22654.\n   - Since there is no indication of diabetes or PDPN in the patient's medical history, this criterion is not met.\n\n4. Patients whose average pain intensity in PDPN in the last 24 hours (measured by VAS), evaluated on the baseline visit, is equal or more than 40 mm (0 mm = 'no pain' and 100 mm = 'worst possible pain').\n   - We do not have information on the patient's pain intensity in PDPN, as PDPN has not been diagnosed.\n\n5. Ability to adhere to trial protocol.\n   - There is insufficient information to determine the patient's ability to adhere to the trial protocol.\n\n6. Written informed consent.\n   - We have no information regarding the patient's willingness to provide informed consent.\n\nThe methods for inclusion criteria assessment include medical history, interview, completing the DN4 questionnaire, physical examination, assessment of pain on VAS, and laboratory analyses.\n- The patient's medical history provided does not align with the history needed to meet the inclusion criteria (specifically, a history of type 2 diabetes and PDPN).\n\nBased on the patient's medical history, which does not include type 2 diabetes or PDPN, the patient does not meet the necessary inclusion criteria for the clinical trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1391": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient is a 54-year-old obese woman with symptoms suggestive of gallbladder stones and biliary sludge, which are not related to functional gastrointestinal disorders (FGIDs). Moreover, the inclusion criteria of the clinical trial specifically target a pediatric population aged 12-18 years old with FGIDs such as chronic idiopathic nausea, functional abdominal pain, dyspepsia, and/or irritable bowel syndrome. The patient in the note does not fit the age bracket and does not have a diagnosis of FGIDs as required by the trial.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1392": {
        "output": "Based on the information provided, the patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She is diagnosed with gallstones and biliary sludge after an ultrasound. There is no mention of the patient suffering from psoriasis or being under treatment for it.\n\nThe clinical trial in question is focused on the efficacy of low dose Naltrexone in patients with psoriasis. The inclusion criteria for the trial are:\n\n- Minimum age of 13 years\n- Maximum age of 60 years\n- Both males and females affected with mild, moderate, or severe psoriasis\n\nThe patient in the note does not have any information indicating that she has psoriasis; therefore, she does not meet the specific disease condition required for the trial. As such, the patient is not relevant for the clinical trial based on the information given.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1393": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's medical history and condition with the inclusion and exclusion criteria of the trial. \n\nPatient note summary:\n- 54-year-old obese woman\n- Abdominal pain, nausea, vomiting\n- Past medical history: hypercholesterolemia, 2 NVDs (natural vaginal deliveries)\n- Current symptoms: epigastric and right upper quadrant tenderness, mild fever, elevated blood pressure and heart rate, leukocytosis with a left shift\n- Diagnosis: gallstones, biliary sludge, and CBD stones\n- No mention of cancer or lymphoma\n\nClinical trial inclusion criteria summary (relevant points for this case):\n- Monotherapy: Advanced or metastatic malignancy of certain types (NSCLC, etc.) or lymphomas (cHL, DLBCL, etc.)\n- Measurable disease (solid tumors or lymphomas)\n- ECOG Performance Status score of 0 or 1\n\nClinical trial exclusion criteria summary (relevant points for this case):\n- History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy\n\nGiven the information from the patient note, the patient does not have a history or diagnosis of cancer or lymphoma, which is required to meet the inclusion criteria of the clinical trial. The trial is looking for patients with specific types of advanced or metastatic malignancy or lymphomas, and the patient's current medical issue is related to gallstones, not cancer.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1394": {
        "output": "Based on the patient note, the 54-year-old woman presents with abdominal pain associated with nausea, vomiting, and a history of similar pain, which may be suggestive of gallstone-related issues. The clinical trial in question is studying the agreement between in-person and remote physicians regarding the need for abdominal imaging in patients with abdominal pain.\n\nThe inclusion criteria for the clinical trial are:\n1. Patient presenting to the MGH Emergency Department with abdominal pain.\n2. English-speaking.\n\nThe patient note indicates that the woman is indeed presenting with abdominal pain, which would satisfy the first criterion. However, the note does not specify her language abilities or if she is at the MGH Emergency Department. Given the lack of this information, we cannot conclusively determine her eligibility for the trial.\n\nTherefore, the assessment of eligibility for this clinical trial is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1395": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Noninvasive Brain Stimulation for Pain Relief,\" we need to determine if the patient is eligible for the trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman, which satisfies the age requirement of the inclusion criteria (18 to 80 years of age).\n- The patient presents with abdominal pain, nausea, vomiting, and a history of similar pain, which may be indicative of chronic pain due to gallstones and biliary sludge.\n- There is no mention of an MRI, which is required for chronic and acute pain patients to participate in the trial.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for healthy adults and chronic and acute pain patients between the ages of 18 and 80.\n- For chronic and acute pain patients, an MRI is required for ultrasound targeting.\n\nBased on the information given, the patient appears to have chronic pain due to gallstones, which might make her a candidate for the pain relief study. However, the patient note does not specify whether she has had an MRI, which is a requirement for participation. Since the necessary information about the MRI is not provided, we cannot conclusively determine her eligibility.\n\nTherefore, the trial-level eligibility for this clinical trial would be:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1396": {
        "output": "",
        "label": 0
    },
    "1397": {
        "output": "",
        "label": 0
    },
    "1398": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient note review:\n- The patient is a 54-year-old woman.\n- She presented with abdominal pain, nausea, and vomiting.\n- She has experienced similar pain in the past.\n- Her medical history includes hypercholesterolemia.\n- She is obese and febrile with elevated vital signs.\n- Lab analysis shows elevated ESR and leukocytosis.\n- An ultrasound revealed gallstones and biliary sludge, consistent with a diagnosis of acute cholecystitis.\n\nClinical trial inclusion criteria review:\n- Clinically and Radiologically diagnosed with acute cholecystitis.\n- Be over 18 years old.\n\nThe patient's note indicates that she has been diagnosed with acute cholecystitis based on her symptoms and ultrasound findings. Additionally, she is over 18 years old. Thus, she meets the clinical trial's inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1399": {
        "output": "Based on the patient note provided, the 54-year-old woman is admitted to the emergency department with symptoms indicative of gallstone issues (abdominal pain, radiating to the right upper quadrant after eating fatty food, nausea, vomiting, and findings of gallstones and biliary sludge on the ultrasound). \n\nThe clinical trial in question is focused on the management and evolution of acute diverticulitis with pericolic free gas. The inclusion criteria for this trial are:\n\n- Patients over 18 years old\n- Informed consent\n- Diagnosed of acute diverticulitis\n- CT scan reported as 1-2 pericolic bubbles with or without free fluid.\n\nThe patient presented does not have a diagnosis of acute diverticulitis nor does the note mention a CT scan revealing pericolic bubbles, which are necessary for inclusion in the study. Instead, the patient appears to have gallstone-related issues. Therefore, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1400": {
        "output": "The patient in question is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and diagnosed gallstones and CBD stones. Her medical history includes hypercholesterolemia, and she has undergone two normal vaginal deliveries (NVDs).\n\nThe clinical trial provided is focused on patients with right-sided colon cancer or right-sided colon adenomas. Specifically, the trial is investigating the effect of local antibiotic treatment on tumor characteristics and the colonic biofilm in these patients.\n\nTo determine the patient's eligibility for the trial, we must review the inclusion criteria:\n\n1. Male and female patients above 18 years of age with either:\n   - Right-sided colon cancer tumor with adenocarcinoma histologically verified scheduled for open or laparoscopic resection (track 1).\n   - Right-sided adenomas \u22652cm in diameter endoscopically verified scheduled for endoscopic mucosal resection (track 2a).\n2. ASA I, II, or III.\n3. The caecum must be reached by the endoscope.\n\nThe patient in question does not have a diagnosis of right-sided colon cancer or adenoma. Instead, she has gallstones and CBD stones, which are unrelated to the conditions studied in the clinical trial. Therefore, the patient does not meet the specific disease-related inclusion criteria of the trial.\n\nGiven this information, the patient is not relevant for the clinical trial as her condition does not match the target diseases or conditions the trial aims to study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1401": {
        "output": "To determine the eligibility of the 54-year-old woman for the clinical trial titled \"Empirical Antibiotics in Acute Inflammatory Gallbladder Disease,\" we need to assess her situation against the inclusion criteria provided:\n\nInclusion Criteria:\n1. Patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation (grade II).\n2. Cholecystitis with a thickness of 4 mm or more on the gallbladder in preoperative imaging.\n3. Gallbladder with surrounding organs due to gallbladder inflammation.\n4. Patients over 19 years of age, under 70 years of age.\n\nAssessment of Patient's Eligibility Based on the Provided Note:\n1. The patient's symptoms and ultrasound findings are consistent with acute cholecystitis, as evidenced by abdominal pain, especially after eating fatty food, nausea, vomiting, fever, and the presence of gallstones, and biliary sludge. However, the grade of acute cholecystitis according to the Tokyo guidelines is not specified in the patient note.\n2. There is no specific information about the thickness of the gallbladder wall from the patient's imaging results.\n3. The patient note does not mention inflammation of the gallbladder with surrounding organs.\n4. The patient is 54 years old, which falls within the specified age range of 19 to 70 years.\n\nSince there is insufficient information to confirm whether the patient's condition meets the grade I or II acute cholecystitis according to the Tokyo guidelines and the thickness of the gallbladder wall, we cannot ascertain if she fits all the inclusion criteria. Moreover, her condition does not specifically exclude her based on the information provided. Therefore, based on the available information, the patient falls under the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1402": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the study titled \"Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse.\"\n\nPatient note:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- History of hypercholesterolemia, 2 NVDs\n- Menopausal, no smoking, alcohol, or illicit drugs\n- Mild fever, hypertension\n- Elevated ESR, leukocytosis\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones\n\nClinical trial inclusion criteria:\n- Stage II-IV pelvic organ prolapse\n- Bothersome bulge symptoms\n- At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form\n- English-speaking\n- Undergoing treatment of prolapse\n- Surgery occurring at least 7 days from the date of randomization\n- Able and willing to follow up at 3 months for in-office exam\n\nThe patient note does not mention pelvic organ prolapse, bothersome bulge symptoms, a scheduled prolapse surgery, or any indication that the patient fulfills the specific physical activity requirements. Therefore, there is insufficient information to qualify the patient for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1403": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze whether the patient is eligible for the trial:\n\nPatient characteristics:\n- A 54-year-old woman\n- Presenting with abdominal pain, nausea, and vomiting\n- History of similar pain, indicating a recurring issue\n- Diagnosed with gallstones and biliary sludge, CBD stones\n- Indication for surgical intervention (laparoscopic cholecystectomy) can be inferred based on the diagnosis\n\nClinical trial inclusion criteria:\n- Patients who underwent laparoscopic cholecystectomy\n- Aged 20-70\n\nThe patient's age falls within the inclusion criteria of 20-70 years. The patient has a diagnosis that typically requires laparoscopic cholecystectomy. However, the trial specifically includes patients who have already undergone laparoscopic cholecystectomy. The patient note does not indicate that the patient has already undergone the procedure, only that it may be indicated due to the gallstones.\n\nGiven that the patient has not yet undergone a laparoscopic cholecystectomy, as indicated in the patient note, she does not meet the inclusion criteria for the clinical trial that requires patients to have already undergone the procedure.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1404": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- Age: 54 years old\n- Symptoms: Abdominal pain, nausea, and vomiting, particularly after eating fatty food\n- Medical History: Hypercholesterolemia, obesity, gallstones, biliary sludge, and CBD stones\n- Other Relevant Information: The patient experiences epigastric pain and has a history of similar pain in the past.\n\nClinical Trial Inclusion Criteria:\n- Age: 19 years old to under 75\n- Condition: Dyspepsia in patients with cholelithiasis\n- Other: Patients who consented to this study and conducted questionnaires and tests during follow up\n\nThe patient is a 54-year-old woman, which falls within the age range of 19 to under 75 years required by the trial. She presents with symptoms consistent with dyspepsia, particularly after eating fatty food, which is a characteristic symptom of functional dyspepsia. Additionally, the patient has been diagnosed with gallstones, which aligns with the condition of interest for the trial (cholelithiasis with dyspepsia).\n\nBased on the information provided, the patient meets the age criterion, has the target medical condition (cholelithiasis with dyspepsia), and there is no information suggesting she would not consent to the study or follow up with questionnaires and tests.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1405": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the clinical trial titled \"Continuous Alcohol Monitoring for Pancreatitis.\"\n\n**Patient Note Analysis:**\n- The patient is a 54-year-old woman, which meets the age criterion of 18-75 years.\n- The patient is admitted with abdominal pain, nausea, and vomiting. The pain is epigastric and radiates to the right upper quadrant, worsening after eating fatty food.\n- The patient has a history of similar pain in the past year.\n- The patient's medical history includes hypercholesterolemia.\n- The ultrasound revealed gallstones, which does not necessarily indicate pancreatitis.\n- There is no mention of a history of pancreatitis or episodes of acute pancreatitis (AP) per the Revised Atlanta Classification.\n- There is no information provided about serum lipase or amylase activity levels, or imaging findings characteristic of AP from CECT, MRI, or ultrasonography specific for pancreatitis.\n- There is no mention of access to a mobile or portable device and internet connection, which is required for syncing the BACtrack sensor.\n\n**Clinical Trial Inclusion Criteria Analysis:**\n- Aged 18-75 years.\n- History of at least one AP per Revised Atlanta Classification within the past 3 years.\n- Evidence of pancreatitis, which includes abdominal pain consistent with AP, elevated pancreatic enzymes, and imaging findings.\n- Access to a syncing device with an internet connection.\n\n**Eligibility Determination:**\nThe patient meets the age criterion. However, there is insufficient evidence in the patient note to determine whether the patient has had an episode of AP as defined by the Revised Atlanta Classification. There are no details about serum enzyme levels or imaging findings that are characteristic of AP. There is also no information about the patient's access to the required technology for participation in the study.\n\nTherefore, there is not enough information to definitively include or exclude the patient from the trial based on the history of pancreatitis and the technology requirement.\n\n**Trial-level eligibility: 1) Not relevant.**",
        "label": 0
    },
    "1406": {
        "output": "Based on the patient note provided, the 54-year-old woman presents with abdominal pain that started 4 days ago with nausea and vomiting, where the pain radiates to the right upper quadrant and worsens after eating fatty food. She has a history of similar pain, hypercholesterolemia, and has had two natural vaginal deliveries (NVDs). She is also menopausal. Her current symptoms and ultrasound findings suggest gallbladder-related issues, likely cholecystitis or gallstones.\n\nThe clinical trial in question is assessing the role of melatonin in chronic dyspepsia in postmenopausal women with Helicobacter pylori infection. The inclusion criteria for the trial are:\n\n1. Epigastric pain of a hunger nature\n2. Pain at night in the epigastric region\n3. Increased appetite\n\nThe patient note does not mention the nature of the epigastric pain relative to hunger, whether she experiences pain at night specifically, or if she has an increased appetite. Additionally, there is no information provided about a Helicobacter pylori infection, which appears to be a focus of the study.\n\nGiven the information available, we cannot confirm that the patient meets the specific inclusion criteria for the clinical trial. Specifically, we do not have evidence of chronic dyspepsia, H. pylori infection, or the detailed nature of her epigastric pain. Therefore, the patient does not have sufficient information to qualify for the trial based on the criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1407": {
        "output": "In this scenario, we have a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a diagnosis of gallstones and CBD stones based on an ultrasound. She is admitted to the emergency department and is a candidate for surgery, likely a cholecystectomy given her symptoms and findings.\n\nThe clinical trial in question is evaluating the use of erector spinae plane block (ESPB) for postoperative pain control in patients undergoing upper GI laparoscopy surgeries, which includes laparoscopic cholecystectomy. The inclusion criteria for the trial are:\n\n- Patients aged between 18 and 65 years\n- Scheduled to undergo any upper GI laparoscopy surgeries\n- Having an ASA score of 1 or 2\n- Written informed consent for general anesthesia and all procedures\n\nThe patient in the note is within the age range and is likely to undergo an upper GI laparoscopy surgery (laparoscopic cholecystectomy). However, there is no information provided about her American Society of Anesthesiologists (ASA) physical status classification (ASA score). The ASA score is used to assess the fitness of patients before surgery. An ASA score of 1 or 2 indicates a patient with normal health or mild systemic disease, respectively.\n\nSince there isn't any information on the patient's ASA score or confirmation that she has given informed consent for general anesthesia and all procedures (which is usually obtained before the surgery), we cannot fully determine if she meets all the inclusion criteria for the trial. Therefore, we would classify her trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1408": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman presenting with abdominal pain, nausea, and vomiting.\n- The symptoms are related to gallstones and biliary sludge as indicated by the ultrasound results.\n- The patient is admitted to the emergency department, not a hospice.\n- There is no indication that the patient is terminally ill.\n\nClinical Trial Inclusion Criteria:\n- Able to participate due to cognitive ability.\n- Experiencing nausea.\n- Admitted to in-bed hospice.\n\nThe patient does indeed experience nausea; however, she is not admitted to an in-bed hospice nor is she described as terminally ill, which are both required as per the inclusion criteria of the trial. Therefore, the patient does not meet all the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1409": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, we need to determine if the patient is eligible for the trial. \n\nThe patient note describes a 54-year-old obese woman admitted with abdominal pain, nausea, and vomiting, with an ultrasound revealing gallstones and biliary sludge. Her medical history is significant for hypercholesterolemia. The clinical trial is focused on the status of advanced endoscopy during the COVID-19 pandemic, with inclusion criteria being patients referred for ERCP (Endoscopic Retrograde Cholangiopancreatography) or EUS (Endoscopic Ultrasound) during the study period.\n\nThe patient note does not mention a referral for ERCP or EUS. However, given the presence of gallstones and biliary sludge, and especially CBD (Common Bile Duct) stones, it is plausible that this patient could be referred for such procedures. But since the patient note does not explicitly mention a referral for ERCP or EUS, we do not have sufficient information to definitively conclude that she meets the inclusion criteria for the study.\n\nTherefore, the trial-level eligibility for this patient, based on the information provided, is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1410": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting.\n- The pain is associated with eating fatty food and has been experienced in a similar manner twice in the past year.\n- The patient has a history of hypercholesterolemia and has given birth to two children (2 NVDs).\n- She is menopausal and does not smoke, drink alcohol, or use illicit drugs.\n- She is febrile and has hypertension (high blood pressure).\n- Laboratory analysis shows elevated ESR and leukocytosis with a left shift.\n- Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with pancreatic cancer with a somatic BRAF V600E mutation.\n- The patient must have progressed on at least one line of therapy for metastatic disease or have had disease recurrence with metastatic disease within 12 weeks of completing systemic chemotherapy.\n- The patient must have histological confirmation of pancreatic malignancy and a BRAF V600E mutation.\n- The trial requires various lab values to be within specific ranges and an ECOG performance status of 0, 1, or 2.\n- Additional criteria include the ability to swallow tablets and capsules, willingness to return to the enrolling institution for follow-up, and providing informed consent.\n\nConclusion:\n- The patient note does not mention any diagnosis of pancreatic cancer or a somatic BRAF V600E mutation.\n- There is no indication that the patient has been treated for metastatic disease or has any history of cancer treatment.\n- The symptoms and findings (abdominal pain, gallstones) in the patient note suggest a gastrointestinal issue, likely gallbladder-related, rather than pancreatic cancer.\n\nTherefore, there is insufficient information in the patient note to determine if the patient has pancreatic cancer with a somatic BRAF V600E mutation. The patient's current health issue does not seem relevant to the trial's focus on pancreatic cancer treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1411": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department,\" we have to match the patient's characteristics and condition to the inclusion criteria:\n\nInclusion Criteria for the trial:\n1. Must be a patient in the emergency department (ED)\n2. Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less\n3. Predicted treatment must include the use of an intravenous opiate\n\nPatient Characteristics and Condition:\n- The patient is a 54-year-old woman.\n- She is admitted to the emergency department with abdominal pain that started 4 days ago.\n- Her pain is consistent with acute abdominal pain as it is of a duration of less than 7 days.\n- There is no mention of predicted treatment with an intravenous opiate in the patient note. However, given that the patient has severe abdominal pain and is in the emergency department, it is reasonable to assume that intravenous opiate treatment could be a consideration for her pain management.\n\nBased on the given information, the patient is in the emergency department with acute abdominal pain of less than 7 days' duration, which matches the first two criteria. Assuming that the predicted treatment for her condition could include the use of an intravenous opiate, she meets the third criterion as well. Therefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1412": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Antiplatelet Thrombolysin (Anfibatide), we can determine the trial-level eligibility for the patient.\n\nThe patient is a 54-year-old obese woman, which already excludes her from the trial based on two criteria:\n\n1. Age: The trial is looking for healthy volunteers between the ages of 18 to 40 years, and the patient is 54 years old.\n2. Body Mass Index (BMI): The trial requires a BMI in the range of 19 to 24, and the patient is described as obese, which likely places her BMI above the required range.\n\nFurthermore, the patient is not a healthy subject as she's admitted with abdominal pain, nausea, vomiting, and has a medical history of hypercholesterolemia. She also has laboratory findings indicative of an active medical condition (elevated ESR, leukocytosis with a left shift) and imaging revealing gallstones and biliary sludge.\n\nThe patient does not meet the criteria for being a healthy subject free of medical issues listed in the inclusion criteria, such as those related to the heart, liver, kidney, digestive tract, nervous system, metabolic conditions, and ulcers.\n\nGiven this information, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1413": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the trial titled \"Different Timing for Early Laparoscopic Cholecystectomy in Acute Calcular Cholecystitis.\"\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman.\n- She has been admitted with abdominal pain, nausea, and vomiting.\n- The pain worsens after eating fatty food, and she has had similar episodes in the past year.\n- The ultrasound reveals gallstones, biliary sludge, and common bile duct (CBD) stones, indicating cholecystitis.\n- The patient's medical history includes hypercholesterolemia.\n\nClinical Trial Inclusion Criteria:\n- The trial is studying early laparoscopic cholecystectomy (ELC) in patients with acute calcular cholecystitis (ACC).\n\nComparison:\n- The patient has evidence of acute calcular cholecystitis as indicated by ultrasound findings and clinical symptoms, which matches the target disease for the clinical trial.\n\nConclusion:\n- The patient meets the inclusion criteria of having acute calcular cholecystitis and thus could be considered for the trial on early laparoscopic cholecystectomy. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1414": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who presented with abdominal pain, nausea, vomiting, and symptoms consistent with biliary colic, as the pain worsens after eating fatty food. Laboratory analysis showed elevated ESR and leukocytosis, and an ultrasound revealed gallstones, biliary sludge, and CBD stones, indicating choledocholithiasis.\n\nThe inclusion criteria for the clinical trial titled \"Symbolic Regression Model To Predict Choledocholithiasis\" are:\n- Patients above 18 with clinical suspicion of choledocholithiasis by biliary-type pain\n- Laboratory testing that reveals a cholestatic pattern of liver test abnormalities\n- Biliary pancreatitis or dilated common bile duct\n\nThe patient has a clinical suspicion of choledocholithiasis due to the biliary-type pain and the presence of gallstones and CBD stones as revealed by the ultrasound. Furthermore, the elevated ESR and leukocytosis suggest some form of inflammation or infection, which could be consistent with the cholestatic pattern of liver test abnormalities. The clinical trial does not provide specific exclusion criteria, and based on the information given, the patient fits the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1415": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is 54 years old and therefore meets the age criterion of being 18 years or older.\n- The patient is hospitalized as admitted to the emergency department.\n- There is no mention of a SARS-CoV-2 infection confirmed by RT-PCR or any other test, nor any mention of COVID-19 symptoms.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must be willing and able to provide informed consent for the trial.\n- The patient must be 18 years of age or older.\n- If discharged from the hospital prior to Study Day 15, the patient must be willing to go to an outpatient facility or be in contact with the study team.\n- The patient must have a laboratory-confirmed SARS-CoV-2 infection.\n- The patient must be hospitalized with an expected duration of \u2265 24 hours.\n- Women of child-bearing potential and men must use adequate contraception, and men must refrain from sperm donation for the duration of the trial and 90 days after.\n- It must be \u2264 10 days since the first COVID-19 symptom as determined by the treating clinician.\n- The patient must be able to swallow capsules.\n- The patient must have at least one COVID-19 symptom.\n\nThe patient note does not mention COVID-19, SARS-CoV-2 infection, or any related symptoms. The primary medical issue seems to be related to gallstones and biliary sludge, not COVID-19. Therefore, we do not have sufficient information to determine if the patient has COVID-19 or related symptoms, which is a key inclusion criterion for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1416": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman admitted with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. The symptoms and ultrasound findings suggest a diagnosis related to gallstones rather than chronic spontaneous urticaria (CSU). The clinical trial in question is focused on evaluating the use of Cannabidiol (CBD) as a steroid-sparing therapy in patients with CSU.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients with active CSU for at least 4 months which was treated with anti-histamines as well as at least one course of steroids.\n2. Age \u226518 years.\n3. Patients will undergo an ECG and QT parameters will be measured for further analysis.\n4. Female subjects who are postmenopausal, surgically sterilized, or of childbearing potential with negative pregnancy test and willing to use contraception.\n5. Female subjects who are not breastfeeding and have no intention to breastfeed during the trial and for at least three months after cessation of CBD treatment.\n6. Subject able to provide written informed consent.\n\nThe patient's condition (gallstones and associated symptoms) does not align with the active CSU required by the trial's inclusion criteria. Additionally, there is no mention of the patient having CSU or being treated for it with anti-histamines and steroids, which is a specific requirement for eligibility.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial focused on CSU patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1417": {
        "output": "Based on the information provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient's characteristics:\n- Age: 54 years old\n- Obesity (BMI > 25 kg/m2 is implied by the term \"obese\")\n- Symptoms: abdominal pain with nausea and vomiting, pain after eating fatty food\n- Medical history: hypercholesterolemia, gallstones, biliary sludge, and CBD stones\n- No mention of Metabolic Syndrome, but obesity and hypercholesterolemia are components of Metabolic Syndrome\n\nClinical trial inclusion criteria:\n- Age: 18 years < Age < 75 years\n- BMI: > 25 kg/m2\n- Metabolic Syndrome\n\nThe patient is indeed 54 years old and is described as obese, which would typically imply a BMI > 25 kg/m2. Furthermore, the patient has hypercholesterolemia, which is one of the risk factors associated with Metabolic Syndrome. However, the other components of Metabolic Syndrome (such as high blood pressure, high fasting glucose, and abdominal obesity) are not explicitly mentioned in the patient's note.\n\nTo meet the inclusion criteria for Metabolic Syndrome, a patient must have at least three of the following five conditions:\n- Abdominal obesity\n- High triglyceride levels\n- Low HDL cholesterol levels\n- High blood pressure\n- High fasting glucose\n\nGiven that the patient's note includes indications of obesity and hypercholesterolemia, there is a possibility that the patient could be diagnosed with Metabolic Syndrome, but the note does not provide sufficient information to make that determination.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1418": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Low-dose Naltrexone for Bladder Pain Syndrome,\" we need to assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 54-year-old woman.\n- She presents with abdominal pain, nausea, vomiting, and epigastric pain related to eating fatty food.\n- She has a history of hypercholesterolemia.\n- She has gallstones, biliary sludge, and CBD stones as per the ultrasound.\n- There is no mention of bladder pain syndrome, urinary frequency, urgency, or nocturia.\n- There is no information to suggest the patient meets the American Urological Association (AUA) definition of Bladder Pain Syndrome (BPS).\n\nClinical Trial Inclusion Criteria:\n- The trial is for men and women with non-Hunner and Hunner lesion disease.\n- Participants must meet the AUA definition of BPS.\n- Participants must be on stable treatment for 1 month.\n- Participants must have pain scores at least 4/10 on the numerical rating scale of pain in the bladder/pelvic area.\n- Urinary frequency must be 8 or higher while awake.\n- Nocturia must be 2 or higher.\n\nBased on the information presented in the patient note, the patient does not appear to have bladder pain syndrome or related lower urinary tract symptoms. There is no indication of bladder-related pain, urinary frequency, or urgency that would meet the trial's definition of BPS. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1419": {
        "output": "Based on the provided patient note, the 54-year-old obese woman has been admitted with symptoms indicative of biliary tract disease, such as abdominal pain radiating to the right upper quadrant, worsened by eating fatty food, nausea, vomiting, and fever. Laboratory analysis showed elevated ESR and leukocytosis, and the ultrasound revealed several gallstones, biliary sludge, and common bile duct (CBD) stones, with the smallest stone being 14mm.\n\nThe clinical trial in question is evaluating a custom-made and disposable endoscope system for the biliary tract, specifically for patients with complicated bile duct stones (stone size > 1.5 cm or number of stones > 3) or patients with indeterminate biliary stricture or obstruction.\n\nThe patient appears to have complicated bile duct stones, as evidenced by the presence of multiple gallstones and at least one stone that is 14mm, which is close to the 1.5 cm size mentioned in the inclusion criteria. However, without additional details about the exact number of stones, it's not definitively clear whether she meets the criteria based on stone number.\n\nBecause the patient note does not specify the number of stones (other than \"several\") and only provides the size of the smallest stone (14mm), there is not enough information to conclusively determine eligibility based on the trial's specific inclusion criteria of stone size > 1.5 cm or number of stones > 3. Therefore, the patient's eligibility falls under the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1420": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the 54-year-old woman does not appear to be a candidate for the clinical trial titled \"Abdominal Massage to Prevent Postoperative Ileus After Colorectal Surgery.\" The trial is specifically recruiting patients undergoing colorectal surgery with intestinal anastomosis within an Enhanced Recovery After Surgery Program. The patient in the note is admitted to the emergency department with abdominal pain related to gallstones and biliary sludge, not for colorectal surgery. There is no mention of the patient being scheduled for colorectal surgery or being part of an Enhanced Recovery After Surgery Program.\n\nTherefore, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1421": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 54-year-old woman (meets age criterion)\n- Admitted with abdominal pain, nausea, and vomiting\n- Epigastric pain radiating to the right upper quadrant, worse after eating fatty food\n- History of similar pain in the past\n- Past medical history includes hypercholesterolemia\n- Menopausal, no history of smoking, alcohol, or illicit drug use\n- Mildly febrile, elevated BP and HR\n- Laboratory analysis shows elevated ESR and leukocytosis\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm\n\nClinical Trial Inclusion Criteria:\n- More than 18 years old (patient meets this criterion)\n- Between 2007 and 2019 (the patient note does not indicate the current year, so we cannot confirm if this criterion is met)\n- Montpellier University Hospital (the patient note does not specify the hospital)\n- Laparoscopic cholecystectomy for symptomatic cholelithiasis associated with common bile duct stones (patient has symptoms and imaging evidence of common bile duct stones)\n- Common bile duct stones highlighted on preoperative imaging or intraoperative cholangiography (patient has ultrasound evidence of common bile duct stones)\n- Common bile duct stones treated during the same hospital stay surgically or endoscopically (we do not have information indicating the treatment plan)\n\nClinical Trial Exclusion Criteria:\n- Laparotomy (no information on this)\n- Previous ERCP (no information on this)\n- Less than 18 years old (patient meets this criterion)\n- Lost to follow up (no information on this)\n- Lack of data > 10% (no information on this)\n- Other surgical procedure associated at the same time (no information on this)\n- Previous cholecystectomy (no information on this)\n- Caroli's disease (no mention of this disease)\n- Severe cholangitis or acute pancreatitis (no information on this)\n- Pigmentary or hydatic lithiasis (no information on this)\n- Laparoscopic cholecystectomy for other indication than symptomatic cholelithiasis (patient has symptomatic cholelithiasis)\n\nGiven the information from the patient note, we cannot confirm certain aspects of the eligibility criteria, such as the specific hospital location, the timing of the treatment, and whether any of the exclusion criteria apply. Therefore, we should classify the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1422": {
        "output": "The patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She has been admitted to the emergency department due to her symptoms, and diagnostic tests have revealed gallstones and biliary sludge. She does not have any mention of knee problems or the need for total knee arthroplasty (TKA).\n\nThe clinical trial in question is studying the influence of sex on postoperative pain control in patients undergoing total knee arthroplasty (TKA) for primary osteoarthritis. The inclusion criteria for the trial include: \n\n- Provision of signed and dated informed consent form\n- Stated willingness to comply with all study procedures and availability for the duration of the study\n- Male or female, age 18-80\n- Undergoing primary unilateral TKA for primary osteoarthritis\n- English speaking\n- Patients whose primary residence is in a home and not a facility or rehabilitation center.\n\nThe patient note provided does not indicate that the patient is undergoing total knee arthroplasty or has primary osteoarthritis, which are necessary conditions for eligibility. Therefore, based on the information given, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1423": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 54-year-old obese woman who presented to the emergency department with symptoms consistent with gallstones and common bile duct (CBD) stones, confirmed by ultrasound. According to the inclusion criteria for the clinical trial, participants must have undergone laparoscopic cholecystectomy after clearance of CBD stones by ERCP.\n\nThe patient note does not mention that the patient has had an ERCP procedure or a laparoscopic cholecystectomy. Therefore, there is not enough information to determine if the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1424": {
        "output": "The patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, hypercholesterolemia, and gallstones. There is no mention of her having COVID-19 symptoms or being diagnosed with COVID-19, which is the primary focus of the clinical trial in question. The trial seeks to enroll patients with early onset of COVID-19 symptoms and who have a high risk of developing a severe clinical presentation of the disease.\n\nBased on the patient note provided, the patient does not meet the inclusion criteria for the clinical trial as she does not present with any COVID-19 symptoms, nor is there any indication of her having been diagnosed with COVID-19 or being at risk of a severe clinical presentation of the disease.\n\nTherefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1425": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess whether the 54-year-old obese woman is eligible for participation in the study.\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- She is admitted with abdominal pain, nausea, and vomiting.\n- The pain worsens after eating fatty food.\n- She has a history of hypercholesterolemia and has given birth to two children.\n- She is menopausal, does not smoke, drink alcohol, or use illicit drugs.\n- She is febrile and has elevated ESR and leukocytosis with a left shift.\n- The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria:\n- Patients must be >= 1 and < 31 years at the time of enrollment.\n- Patients must have first relapse of CD19+ B-cell acute lymphoblastic leukemia (B-ALL).\n- Additional inclusion criteria related to performance status, prior treatments, and organ function.\n\nThe patient does not meet the age criteria (she is 54, and the trial requires patients to be between 1 and 30 years old). Furthermore, she does not have a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL), which is the disease the trial is targeting. Therefore, she does not meet the essential inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1426": {
        "output": "Based on the information provided and the criteria set forth in the clinical trial, we need to assess the patient's eligibility.\n\nPatient Characteristics:\n- Age: 54 years old (meets age criterion)\n- Body weight: Obese (specific weight not provided, but obesity suggests a weight over the criterion threshold of 100 Kg)\n- Scheduled procedure: The patient has gallstones and biliary sludge and could potentially be scheduled for a laparoscopic cholecystectomy; however, this is not explicitly stated in the patient note.\n- ASA physical status: Not provided, but given the patient's presentation with abdominal pain, nausea, and vomiting, and obesity, the patient could potentially be higher than ASA II.\n- General anaesthesia: Not mentioned, but if the patient is going to have a laparoscopic cholecystectomy, it would likely be under general anaesthesia.\n\nTrial Inclusion Criteria:\n- ASA physical status I or II\n- Body weight 60-100 Kg\n- Scheduled for laparoscopic cholecystectomy under general anaesthesia\n\nThe patient's body weight being described as \"obese\" could potentially exclude her from the trial if her weight is above 100 Kg. Since the specific weight is not mentioned, we cannot confirm whether the patient is between 60-100 Kg. Additionally, while the patient has gallstones and could potentially be a candidate for laparoscopic cholecystectomy, the patient note does not confirm that she is scheduled for this procedure under general anaesthesia.\n\nGiven the lack of specific information on ASA physical status, exact body weight, and confirmation of being scheduled for the procedure under general anaesthesia, the patient cannot be deemed eligible based on the information available. Therefore, the patient falls into the \"Not relevant\" category as there is not sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1427": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting.\n- The pain is associated with eating fatty food and radiates to the right upper quadrant.\n- She has a history of hypercholesterolemia and is menopausal.\n- Ultrasound reveals several gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nClinical Trial Inclusion Criteria:\n- Malignant or benign extrahepatic biliary stricture.\n- Available for insertion of biliary stents in ERCP to alleviate biliary stricture.\n\nThe patient has gallstones and biliary sludge with evidence of CBD stones, but the patient note does not mention a biliary stricture. Biliary strictures are typically diagnosed when there is a significant narrowing of the bile ducts, which can be due to various causes, including malignancy, inflammation, or other underlying conditions.\n\nSince the patient note does not provide information about a biliary stricture or the patient's availability for insertion of biliary stents via ERCP, we cannot confirm whether the patient meets the inclusion criteria for the clinical trial. There is not enough information to determine if the patient has a biliary stricture that would make her eligible for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1428": {
        "output": "Based on the patient note, the patient is a 54-year-old woman with abdominal pain, nausea, and vomiting, which has been ongoing for 4 days. The pain, which worsens after eating fatty food, radiates to the right upper quadrant. She has a history of hypercholesterolemia and has been diagnosed with gallstones and common bile duct stones through an ultrasound. The patient is indicated for laparoscopic cholecystectomy.\n\nNow, we will compare the patient's information with the inclusion criteria of the clinical trial:\n\n1. The patient should receive laparoscopic cholecystectomy on a selected day.\n2. Symptoms of the subjects include gallstone, cholecystitis, or gallbladder polyp\u22650.8 cm.\n3. The patient must be aged between 18 and 75.\n4. The patient must voluntarily participate in the clinical trial and sign the informed consent form.\n\nConsidering the information provided in the patient note, the patient:\n\n- Is scheduled to receive laparoscopic cholecystectomy, which is suggested by the presence of gallstones and her symptoms.\n- Presents with symptoms including gallstones, which matches the inclusion criteria.\n- Is 54 years old, which falls within the required age range of 18 to 75.\n- Has not yet provided informed consent but has no information that suggests she would not be willing to participate and sign the consent form.\n\nSince the patient meets all the mentioned inclusion criteria and there is no indication of exclusion criteria or reasons that she would not provide informed consent, she appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1429": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nThe patient is a 54-year-old woman with a medical issue related to abdominal pain and gallstones, whereas the clinical trial is focused on women who have experienced severe anal sphincter lacerations during childbirth and are being considered for antibiotic treatment to prevent infection following repair.\n\nThe inclusion criteria for the clinical trial are specific to postpartum women who have had a severe vaginal laceration (3rd or 4th degree) during vaginal delivery, are English-speaking, received Ancef during wound repair, are having their first delivery, with a single child being born, and at term delivery (at least 37 weeks gestation).\n\nThe patient in the note does not fit any of these criteria as her medical issue is not related to childbirth or perineal lacerations but to gallstones and associated abdominal pain.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1430": {
        "output": "The patient in the provided note is a 54-year-old obese woman with abdominal pain associated with gallstones, biliary sludge, and CBD stones. Her medical history includes hypercholesterolemia, and she has experienced similar abdominal pain in the past. She does not have a history of low back pain as per the information provided.\n\nThe clinical trial is looking for men and women aged between 18 and 65 years old, living in France, who have ever had an acute low back pain, and are willing to participate in the study.\n\nBased on the information given:\n\n- The patient is within the age range of 18 and 65 years old.\n- There is no information provided about the patient's residence, so we cannot determine if she lives in France.\n- There is no mention of the patient having acute low back pain, which is a specific condition the clinical trial is investigating.\n\nSince the patient's note does not indicate she has ever had acute low back pain, and there is no information about her residency in France, we do not have sufficient information to determine her eligibility for the trial based on its inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1431": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who presented with abdominal pain, nausea, vomiting, and other symptoms relevant to gallstones and biliary issues. Her medical history includes hypercholesterolemia and menopause, and there is no mention of total knee arthroplasty (TKA) or chronic pain associated with it. Furthermore, there is no information about her ability to walk, her level of pain on the Visual Analogic Scale, or her cognitive functioning as measured by the Mini-Mental State Examination (MMSE).\n\nGiven the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial concerning transcranial Direct Current Stimulation (tDCS) and exercise for chronic painful TKA patients. The trial is specifically targeting patients with chronic pain after TKA and requires patients to be able to independently walk (with or without aids), have a certain level of pain, and no cognitive impairments.\n\nThe patient's condition and medical history as presented in the note do not align with the focus of the trial or the specified inclusion criteria. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1432": {
        "output": "Given the patient note and the clinical trial information provided, let's evaluate the patient's eligibility for the trial:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted for abdominal pain, nausea, and vomiting\n- Pain worsens after eating fatty food\n- History of similar pain and hypercholesterolemia\n- Menopausal with two children\n- Mild fever, high blood pressure, and elevated heart rate\n- Laboratory analysis shows elevated ESR and leukocytosis\n- Ultrasound revealed gallstones and CBD stones\n\nClinical Trial Summary:\n- Title: SEMS and Gastroenterostomy\n- Focus: Quality of Life (QoL) of patients with stage IV antropyloric stomach cancer and symptoms of gastric outlet obstruction syndrome (GOOS)\n- Inclusion Criteria: Age < 85 years, histological diagnosis of gastric adenocarcinoma, CT, adjuvant-neoadjuvant chemotherapy regimen, symptoms of GOOS, lumen reduction 70%-99% at gastroscopy\n- Exclusion Criteria: WBC count < 4,000/L, platelet count < 70,000/L, renal failure, major alterations of liver function tests\n\nThe patient is presenting with symptoms that are indicative of gallstones and biliary disease, not gastric adenocarcinoma or GOOS. The patient's condition does not match the target disease of the trial. Furthermore, there is no indication that the patient has a pre-treatment histological diagnosis of gastric adenocarcinoma, which is one of the inclusion criteria for the trial. Therefore, based on the information provided in the patient note, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1433": {
        "output": "",
        "label": 0
    },
    "1434": {
        "output": "Based on the patient note provided, the 54-year-old woman is admitted with abdominal pain, nausea, vomiting, and has a history of hypercholesterolemia. The ultrasound revealed gallstones and biliary sludge. There is no mention of coronary artery disease (CAD) or any indication that she has undergone coronary angiography.\n\nThe inclusion criteria for the clinical trial are specifically for patients who have coronary heart disease verified by coronary angiography. Since there is no information in the patient's note that indicates she has coronary heart disease or that she has undergone coronary angiography, she does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1435": {
        "output": "To assess the eligibility of the patient for the given clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting. The pain is associated with eating fatty food, and the patient has a history of hypercholesterolemia. Laboratory analysis indicates elevated ESR and leukocytosis with a left shift, and an ultrasound revealed gallstones, biliary sludge, and common bile duct stones. There is no mention of the patient having diffuse large B-cell lymphoma (DLBCL) or any related conditions.\n\nThe clinical trial is focused on participants with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL) and involves the drug selinexor in combination with other treatments.\n\nBased on the information provided in the patient note, the patient does not have relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL), which is a key inclusion criterion for the clinical trial. Therefore, the patient does not meet the necessary condition to be considered for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1436": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, the patient does not appear to be a suitable candidate for the clinical trial. The clinical trial is specifically targeting individuals with tension-type headaches, and the inclusion criteria are very detailed regarding the type of headache, its frequency, and associated symptoms such as pericranial tenderness.\n\nThe patient note describes a 54-year-old woman with symptoms consistent with gallstones and biliary sludge, including abdominal pain, nausea, and vomiting, particularly after eating fatty food. The patient's symptoms and medical history as described do not mention headaches of any type, let alone tension-type headaches that meet the specific criteria listed for the trial.\n\nTherefore, based on the information provided, the patient does not have sufficient information to qualify for the trial focused on tension-type headaches as she does not present with the specific condition the trial is aiming to study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1437": {
        "output": "Based on the patient note provided, we have a 54-year-old obese woman with abdominal pain, nausea and vomiting, and a diagnosis of gallstones and biliary sludge. Her medical history includes hypercholesterolemia, and there is no mention of low back pain or any related symptoms.\n\nThe clinical trial in question is investigating the effect of magnesium oral supplementation for acute non-specific low back pain (LBP). The inclusion criteria for this trial are:\n\n1. Patients aged >18 years old.\n2. Initiation of acute low back pain in the 10 days prior to study entry.\n3. Functionally impairing low back pain, defined as a score of >5 on the Roland-Morris Disability Questionnaire (RMDQ).\n\nThe patient note does not indicate that the patient has low back pain; instead, it describes abdominal pain related to gallstones. There is no information provided that could suggest she suffers from low back pain or meets the specific criteria for the trial (such as a score on the RMDQ).\n\nTherefore, based on the information available, the patient does not meet the inclusion criteria for the clinical trial on magnesium oral supplementation for acute non-specific low back pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1438": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"E-health for Self-Management of Chronic Pain,\" let's assess the patient's eligibility:\n\nPatient note:\n- The patient is a 54-year-old obese woman.\n- The patient presents with abdominal pain, nausea and vomiting, and history of similar pain.\n- Past medical history includes hypercholesterolemia.\n- No mention of axial neck pain or lower back pain.\n- No information on being followed by a pain management specialist.\n- The patient is over 18 years of age.\n- No information on the patient's goals, motivation, or medical readiness.\n- No information on interventional treatments or surgical candidacy.\n- No information on the patient's access to or knowledge of using a smart device.\n\nClinical trial inclusion criteria:\n- Have a complex, prolonged axial neck pain or lower back pain.\n- Have been followed by a pain management specialist for at least 3 months or have a history of chronic pain for at least 3 months as recorded by physician.\n- Be >18 years of age.\n- Have a goal and motivation that is adequate in relation to the program offered.\n- Be medically prepared.\n- Have no major change in interventional treatment or be a surgical candidate.\n- Own a smart phone, tablet or computer or have the knowledge to use one.\n\nThe patient does not mention axial neck pain or lower back pain, and there's no indication that she has been followed by a pain management specialist for at least 3 months. Additionally, there's no information on her goals, motivation, medical preparedness, treatment changes, surgical candidacy, or access to/knowledge of using smart devices. Thus, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1439": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is clear that the patient is not suitable for the trial. The inclusion criteria specify that participants must be medically free children who are cooperative, have asymptomatic primary molars with deep carious lesions, and show no clinical signs of pulpal degeneration among other specific dental conditions. The patient in the note is a 54-year-old obese woman with abdominal issues likely related to gallstones, which is entirely unrelated to the dental conditions described in the trial's inclusion criteria.\n\nTherefore, the patient does not meet the inclusion criteria for this dental trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1440": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial:\n\nPatient Note Summary:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Pain worsened after eating fatty food\n- History of similar pain, hypercholesterolemia, and 2 NVDs\n- Menopausal, no smoking, no alcohol, no illicit drugs\n- Mildly febrile, elevated blood pressure, heart rate, and temperature\n- Ultrasound revealed several gallstones, biliary sludge, and CBD stones\n\nClinical Trial Summary:\n- The trial is focused on trainees in general surgery learning laparoscopic cholecystectomy.\n- Inclusion criteria include being a trainee in general surgery, no experience in laparoscopic cholecystectomy, less than 5 experiences in laparoscopic surgery, and patients with uncomplicated symptomatic gallstone disease.\n\nEligibility Assessment:\n- The patient is not a trainee in general surgery.\n- The clinical trial is designed for novice trainees to improve their surgical skills in laparoscopic cholecystectomy, not for patients with gallstone disease.\n- The patient's condition (symptomatic gallstone disease) is relevant to the skills being studied in the trial, but the patient herself is not part of the target population for the educational intervention.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, as she is not a trainee in general surgery and the trial is focused on the education of surgical trainees rather than the treatment of gallstone disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1441": {
        "output": "The patient note describes a 54-year-old obese woman with acute abdominal pain, nausea, vomiting, and a history of similar pain. Laboratory analysis shows elevated ESR and leukocytosis with a left shift, which indicates an inflammatory process. An ultrasound revealed several gallstones and biliary sludge, with the smallest stone being 14mm. The patient's medical history includes hypercholesterolemia and she is menopausal.\n\nTo determine the trial-level eligibility of the patient for the given clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria outlined in the trial summary.\n\nThe clinical trial is focused on the necessity of preoperative empirical antibiotic use in patients with acute cholecystitis. The inclusion criteria for the trial are as follows:\n\n1. Patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation (grade II).\n2. Cholecystitis with a thickness of 4 mm or more on the gallbladder in preoperative imaging.\n3. Gallbladder with surrounding organs due to gallbladder inflammation.\n4. Patients over 19 years of age, under 70 years of age.\n\nThe patient in the note is 54 years old, which satisfies the age criterion. However, the note does not specifically mention the grade of acute cholecystitis as per the Tokyo guidelines, nor does it provide information on the thickness of the gallbladder wall or if there is inflammation surrounding the organs due to gallbladder inflammation. These details are essential for determining the grade of cholecystitis and whether it aligns with the trial's inclusion criteria. Without this information, we cannot accurately assess whether the patient fits the mild (grade I) or moderate (grade II) acute cholecystitis categories required for the study.\n\nGiven the lack of necessary information to determine if the patient meets all the inclusion criteria, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1442": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae,\" let's compare the patient's characteristics and symptoms with the inclusion criteria of the trial:\n\nInclusion Criteria Checklist:\n- Adults: The patient is 54 years old, so she meets this criterion.\n- Diagnosis of UTI defined by at least two of the following symptoms: chills, temperature >38\u00b0C (fever), flank or pelvic pain, nausea or vomiting, dysuria, urinary frequency, or urinary urgency, costovertebral angle tenderness on physical examination: The patient presents with fever and nausea or vomiting, but there's no clear indication of a urinary tract infection (UTI) in her symptoms, as her current symptoms seem more related to gallstones and biliary issues.\n- Positive urine culture with \u2265 10^3 CFU/mL of a single strain of ESBL-E: There is no information provided about a urine culture or results indicating an ESBL-E infection.\n- Confirmed ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems: Again, there is no information given about the presence of ESBL-E or its susceptibility to carbapenems.\n\nBased on the information provided, the patient does not have a documented urinary tract infection, nor is there any evidence of ESBL-producing Enterobacteriaceae infection. Therefore, she does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1443": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 54-year-old obese woman with gallstone disease. She presents with abdominal pain, nausea, vomiting, and her ultrasound revealed several gallstones. The clinical trial seeks to investigate the risk factors for the development of gallstone disease.\n\nThe inclusion criteria for the trial are quite broad, simply stating that participants must be above 18 years of age. There are no other detailed inclusion or exclusion criteria provided.\n\nGiven that the patient is above 18 years old and has gallstone disease, which seems to be the focus of the clinical trial, she meets the inclusion criteria provided. There is no information suggesting that she should be excluded based on the details given in the clinical trial summary.\n\nTherefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1444": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not seem to meet the inclusion criteria for the trial in question. The patient's symptoms and ultrasound findings suggest a diagnosis of gallstones and biliary sludge with associated abdominal pain, rather than acute gastroenteritis. The inclusion criteria for the trial specify patients with watery stools starting in the last 2 weeks and occurring 3 times in 24 hours along with abdominal pain, which does not align with the patient's presentation.\n\nTherefore, the patient does not have sufficient information to qualify for the trial because their symptoms are not consistent with the target condition of the trial, which is acute gastroenteritis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1445": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 54-year-old obese woman with symptoms suggestive of gallbladder pathology, specifically cholecystitis or cholelithiasis, given the presence of gallstones and the characteristic pain pattern. The trial in question is focused on the use of pressure algometry in children with suspected appendicitis.\n\nThe inclusion criteria for the trial specify that participants must be children referred with abdominal pain to a specific surgeon at the Health Sciences Centre-Children's Hospital in Winnipeg from January 2000 to June 2006.\n\nGiven that the patient is a 54-year-old adult and not a child, she does not meet the age criterion for the study. Additionally, the study is retrospective and specific to a timeframe in the past, which also excludes her. Therefore, the patient is not eligible for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1446": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can determine the trial-level eligibility of the patient.\n\nPatient Note Analysis:\n- The patient is a 54-year-old obese woman.\n- She presents with abdominal pain, nausea, and vomiting, specifically mentioning that the pain gets worse after eating fatty food.\n- She has hypercholesterolemia and no history of substance abuse.\n- The patient has had normal vaginal deliveries (NVDs) twice, is menopausal, and has children.\n- She experiences epigastric and right upper quadrant tenderness, and an ultrasound revealed gallstones and biliary sludge.\n- There is no mention of her being diagnosed with functional dyspepsia or Helicobacter pylori.\n\nClinical Trial Inclusion Criteria:\n- Age > 18 years\n- Patients fulfilling the ROME-IV criteria of Functional Dyspepsia\n- Signed informed consent\n\nAssessment:\n- The patient is over 18 years of age.\n- There is no information in the patient note about a diagnosis of functional dyspepsia or Helicobacter pylori infection, which are necessary to meet the ROME-IV criteria.\n- There is no mention of informed consent, but this is typically obtained after the patient is deemed eligible.\n\nSince the patient note does not indicate that the patient has a diagnosis of functional dyspepsia or Helicobacter pylori infection, which are required to fulfill the ROME-IV criteria for functional dyspepsia, the patient would not meet the specific inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1447": {
        "output": "The patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history of hypercholesterolemia. She has been diagnosed with gallstones and biliary sludge based on an ultrasound. There is no mention in the patient note of a COVID-19 diagnosis or symptoms related to COVID-19.\n\nThe clinical trial's inclusion criteria require participants to have a positive COVID-19 diagnosis confirmed by PCR testing, be able to evaluate and report their symptoms, take their oral temperature daily, and agree to the study's requirements, among other criteria.\n\nGiven the information in the patient note, there is no evidence that the patient has been diagnosed with COVID-19 or exhibits COVID-19 symptoms. Therefore, she does not meet the inclusion criteria for the clinical trial focused on the effects of hesperidin on COVID-19 symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1448": {
        "output": "Based on the provided patient note, the patient is a 54-year-old obese woman who has been admitted to the emergency department with abdominal pain, nausea, and vomiting. The pain is worse after eating fatty food, and she has a history of similar pain episodes. She has a diagnosis of hypercholesterolemia and has had two normal vaginal deliveries (NVDs). The patient's current condition includes epigastric pain, fever, elevated blood pressure, and increased heart rate. Laboratory analysis reveals elevated ESR and leukocytosis with a left shift, indicating an inflammatory process. An ultrasound has confirmed the presence of several gallstones and common bile duct (CBD) stones.\n\nThe clinical trial's inclusion criteria specify patients who have been diagnosed with cholecystitis with/without gallbladder (GB) stones or GB polyp.\n\nThe patient's symptoms, along with the ultrasound findings, are consistent with a diagnosis that could be cholecystitis, given the presence of gallstones and the typical clinical presentation. Even though cholecystitis is not explicitly mentioned in the patient note, the symptoms and findings are highly indicative of it. Therefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1449": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 54-year-old obese woman\n- Admitted with symptoms consistent with acute cholecystitis and choledocholithiasis\n- Symptoms include abdominal pain, nausea, vomiting, and pain after eating fatty food\n- Past medical history includes hypercholesterolemia\n- Ultrasound revealed gallstones and common bile duct stones\n\nClinical Trial:\n- Title: Acute Cholecystitis With Concomitant Choledocholithiasis: Unicentric Study of Prevalence and Predictive Factors\n- Aim: To identify criteria for CBDS associated when diagnosing acute cholecystitis\n- Inclusion Criteria: Age \u226518 years\n\nAssessment:\n- The patient is a 54-year-old woman, which satisfies the age criterion for the trial (>18 years).\n- The patient's symptoms and ultrasound findings are consistent with acute cholecystitis and choledocholithiasis, which are the conditions of interest in the trial.\n\nSince the patient note indicates that the patient has both acute cholecystitis and choledocholithiasis, and the only inclusion criterion provided for the trial is a patient age of 18 years or older, the patient meets the inclusion criteria. No other specific inclusion or exclusion criteria are mentioned in the trial summary provided.\n\nTherefore, the patient appears to meet the inclusion criteria and, in the absence of any stated exclusion criteria, does not appear to be excluded.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1450": {
        "output": "Unfortunately, the clinical trial details provided are incomplete. There is no title, target diseases, interventions, summary, or specific inclusion/exclusion criteria mentioned in the trial information you've provided. Without these details, I cannot accurately assess the patient's eligibility for the clinical trial.\n\nBased on the patient note alone, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a history consistent with gallstones and biliary sludge. However, without the inclusion and exclusion criteria of the clinical trial, I cannot determine her eligibility.\n\nPlease provide the complete clinical trial information so that I can assist you further.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1451": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess the patient's information against the inclusion criteria listed for the trial.\n\nInclusion Criteria for the trial:\n1. Age 16 to 70 years\n2. Clinical presentation with biliary colic with or without jaundice\n3. Serum elevation of at least one of the following enzymes: aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and total bilirubin\n4. Radiological findings suggestive of gallstones and concomitant common bile duct stones, with abdominal ultrasound showing possible CBD stones or a dilated CBD >8 mm in diameter\n5. MRCP evidence of a CBD stone(s) after meeting all the previous criteria\n\nPatient's information:\n1. Age: 54 years (meets age criteria)\n2. Clinical presentation: The patient presents with abdominal pain, nausea, vomiting, and epigastric pain radiating to the right upper quadrant, which worsens after eating fatty food (consistent with biliary colic)\n3. Serum enzymes: The note does not mention specific serum enzyme levels, so we cannot confirm the elevation of the listed enzymes\n4. Radiological findings: Ultrasound revealed several gallstones, biliary sludge, and CBD stones; the smallest stone is 14mm (meets radiological criteria)\n5. MRCP: The note does not mention MRCP, so we cannot confirm this criterion\n\nThe patient meets the age and radiological criteria and presents with symptoms consistent with biliary colic. However, the patient note does not provide information about the serum enzyme levels or MRCP evidence of CBD stones, which are required to meet all the inclusion criteria.\n\nTherefore, based on the available information, the patient's eligibility is determined as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1452": {
        "output": "The patient is a 54-year-old woman who presented to the emergency department with chief complaints of nausea and vomiting, which meets the inclusion criterion of the clinical trial. However, the trial specifies an age range of 18-55, and the patient falls within this range. \n\nTherefore, based on the provided information, the patient meets the inclusion criteria for the clinical trial titled \"Haloperidol for the Treatment of Nausea and Vomiting in the ED.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1453": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria of the clinical trial, let's review the inclusion criteria and compare them with the patient's characteristics:\n\nInclusion Criteria for the Clinical Trial:\n1. Healthy women over 18 years of age;\n2. Patients who meet the diagnostic criteria for breast color Doppler ultrasound diagnosis of breast hyperplasia and the course of disease exceeds 3 months;\n3. Meet the syndrome differentiation criteria for liver-stagnation and qi stagnation;\n4. Breast color ultrasound, breast molybdenum target, or breast MRI showed BI-RADS 2-3;\n5. NRS (0-10 pain rating) score \u2265 4 points on the most painful day before treatment;\n6. Voluntarily participate in the clinical study and sign the informed consent form.\n\nPatient's Characteristics:\n- 54-year-old obese woman\n- Admitted with abdominal pain, nausea, vomiting\n- Epigastric pain radiates to the right upper quadrant\n- Has had similar pain episodes in the past\n- Past medical history notable for hypercholesterolemia\n- Two natural vaginal deliveries (NVDs)\n- Menopausal\n- Mildly febrile, elevated blood pressure, elevated heart rate\n- Laboratory findings include elevated ESR and leukocytosis\n- Ultrasound revealed gallstones and biliary sludge\n\nFrom the patient's characteristics, we can see that the patient is a woman over 18 years of age, which meets the first inclusion criterion. However, there is no mention of breast hyperplasia or related symptoms that align with the second and third inclusion criteria. The patient presented with abdominal issues, not breast-related symptoms or diagnoses. There's also no information provided that indicates the patient has undergone any breast imaging (such as color ultrasound, molybdenum target, or MRI) or that she has a pain rating score related to breast pain.\n\nGiven that the patient does not meet the specific diagnostic criteria for breast hyperplasia or the syndrome differentiation criteria for liver-stagnation and qi stagnation, and because there is no information about breast-related symptoms or imaging, the patient is not relevant for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1454": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT\":\n\nPatient Note:\n- The patient is a 54-year-old obese woman.\n- She presented with abdominal pain, nausea, vomiting, and pain that worsens after eating fatty food.\n- The patient has a history of hypercholesterolemia and has given birth to two children.\n- Laboratory analysis showed elevated ESR and leukocytosis with a left shift.\n- An ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nClinical Trial Inclusion Criteria:\n- Patients with pathological or clinical and imaging evidence indicating a diagnosis of cirrhosis.\n- Patients with clinical symptoms associated with AVH (hematemesis, melena or hematochezia) before admission or during hospitalization.\n- Patients who are hemodynamically stable before or after initial fluid resuscitation.\n\nComparison:\n- The patient's presentation does not indicate acute variceal hemorrhage (AVH), but rather symptoms consistent with gallstone-related issues.\n- There is no mention of cirrhosis or symptoms of AVH such as hematemesis, melena, or hematochezia in the patient's note.\n- The patient does not meet the inclusion criteria based on the diagnosis and symptoms described in the clinical trial.\n\nTherefore, the patient does not appear to be eligible for the clinical trial because the patient's condition and clinical presentation do not match the target disease and symptoms the trial is investigating.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1455": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the trial is focused on patients with cirrhosis, specifically those experiencing acute decompensation of cirrhosis characterized by recent development of ascites, encephalopathy, GI hemorrhage, bacterial infection, or any combination of these.\n\nThe patient in the note is a 54-year-old woman admitted to the emergency department with abdominal pain, nausea and vomiting, and a history of hypercholesterolemia. The pain is related to gallstones as evidenced by the ultrasound findings, and she has elevated ESR and leukocytosis. However, there is no mention of liver cirrhosis or its complications like ascites, encephalopathy, GI hemorrhage, or bacterial infection.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial on \"Acute-On-Chronic Liver Failure In Cirrhotic Patients\" as there is no mention of cirrhosis or its acute decompensation in her condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1456": {
        "output": "Based on the information provided, the patient is a 54-year-old woman who presents with symptoms consistent with gallstones and has been confirmed to have common bile duct stones (CBDS) via ultrasound. The clinical trial in question is investigating a one-step laparoscopic cholecystectomy with common bile duct exploration and stone extraction versus the conventional two-step approach for patients with CBDS.\n\nTo determine the patient's eligibility for the clinical trial, we need to assess whether the patient meets the inclusion criteria listed for the trial:\n\n1. Common bile duct stones identified by magnetic resonance cholangiopancreatography (MRCP).\n2. Age 18 years or older.\n3. Both interventions must be possible to perform within a clinically reasonable timeframe, as assessed by the investigator.\n4. Informed consent.\n\nThe patient in question meets the age criterion (54 years old) and has been diagnosed with CBDS, which aligns with the target condition for the trial. However, the diagnosis of CBDS was made via ultrasound, not MRCP. The inclusion criteria specifically state that CBDS should be identified by MRCP.\n\nGiven the information provided, we do not have evidence that an MRCP has been conducted or that the patient has provided informed consent. Additionally, we do not have information on whether both interventions (the one-step and the two-step approach) are possible within a clinically reasonable timeframe for this patient, as this is typically assessed by the investigator.\n\nSince the patient has confirmed CBDS and meets the age requirement but lacks the MRCP confirmation, informed consent, and assessment by the investigator regarding the feasibility of the interventions, we do not have sufficient information to conclude that the patient is eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1457": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nThe patient is a 54-year-old woman who presented with abdominal pain, nausea, and vomiting. She has a history of similar episodes of pain and is noted to have gallstones on ultrasound examination.\n\nThe clinical trial is investigating risk factors for gallbladder stones and includes adult patients who have gallbladder stones.\n\nSince the patient has gallbladder stones, as confirmed by the ultrasound, she meets the inclusion criteria for the trial.\n\nTherefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1458": {
        "output": "The patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and a medical history of hypercholesterolemia. She presents with symptoms indicative of gallstones, confirmed by ultrasound. The clinical trial in question is investigating the safety and efficacy of Bikini line laparoscopic cholecystectomy in morbidly obese patients with chronic calcular cholecystitis.\n\nTo determine the patient's eligibility for the trial, we need to assess her against the trial's inclusion criteria:\n\nInclusion Criteria for the Trial:\n- Morbid obese patients with BMI \u226430 KG/M2 and \u2265 40 kg/m2\n- Symptomatic uncomplicated gallstones\n- ASA 1-3\n\nFrom the patient note, we know the following:\n- The patient is obese, but we do not have her exact BMI to confirm if she is morbidly obese (BMI \u2265 40 kg/m2).\n- She has symptomatic gallstones.\n- There is no information provided about her ASA (American Society of Anesthesiologists) physical status classification.\n\nDue to the lack of specific information on the patient's BMI and ASA classification, we cannot conclusively determine her eligibility. However, since the patient is described as obese, there is a possibility that she could meet the BMI requirement if further information were provided. We also do not have information to exclude her based on the ASA classification.\n\nTherefore, based on the information provided, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1459": {
        "output": "Based on the patient note, we have the following information:\n\n- The patient is a 54-year-old obese woman.\n- She has been admitted with abdominal pain, nausea, and vomiting.\n- Her medical history includes hypercholesterolemia.\n- She does not smoke, does not drink alcohol, and does not use illicit drugs.\n- She is scheduled to undergo surgery (implied by the context of the emergency department visit and the findings of gallstones and biliary sludge indicating a likely need for surgery, although not explicitly stated).\n\nBased on the clinical trial inclusion criteria, the patient must:\n\n- Be at least 18 years old (the patient is 54, so this criterion is met).\n- Be scheduled to undergo elective surgery under general anesthesia (it is not explicitly stated that the patient is scheduled for surgery, but the context implies that she may need surgery for gallstones).\n- Be judged to be at high risk of postoperative nausea and vomiting according to the Apfel's simplified score, which includes being a woman, a non-smoker, having a history of PONV, and the postoperative use of opioids.\n\nThe patient meets the following high-risk factors for PONV according to the Apfel's score:\n\n- She is a woman.\n- She is a non-smoker.\n\nHowever, the patient note does not mention a history of PONV or whether she will require postoperative opioids. Since the patient note lacks information about her history of PONV and future opioid use, we cannot confirm that she meets at least three of the Apfel's factors necessary to be considered high risk for PONV.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the details provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1460": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion and exclusion criteria, we can assess the patient's eligibility for the clinical trial titled \"Lamivudine for Chronic Hepatitis B.\"\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma, alcoholic liver disease, esophageal varices bleeding, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- Normal BP, HR, and no acute distress\n- No ascites or tenderness in the abdomen, and no edema in lower extremities\n\nClinical trial inclusion criteria:\n- Age 18 years or above, male or female\n- Known presence of HBsAg in serum for at least 6 months\n- Liver biopsy histology showing chronic hepatitis with or without cirrhosis\n- Previous therapy with alpha interferon without a lasting effect or intolerance to alpha interferon, due to side effects\n- Written informed consent\n\nClinical trial exclusion criteria:\n- Presence of anti-HIV or anti-HCV with HCV RNA in serum\n\nThe patient has been diagnosed with HCV and recently with HBV coinfection. The patient's medical records indicate he is on IFN, RBV, and direct antiviral drugs, which shows he has been treated for HCV. However, the exclusion criteria for the clinical trial specifically exclude patients with anti-HCV with HCV RNA in serum. \n\nSince the patient has a confirmed HCV infection and is currently on treatment for it, he does not meet the exclusion criteria for the clinical trial. The patient note does not provide information about the presence of HBsAg in serum for at least 6 months or liver biopsy results required by the inclusion criteria, but it does mention a recent biopsy negative for hepatocellular carcinoma and chronic inflammation compatible with chronic viral hepatitis.\n\nGiven the available information, the patient has a recent coinfection with HBV and is not explicitly excluded based on the presence of HCV RNA in serum. However, we do not have sufficient information regarding the duration of HBsAg presence and the specifics of the liver biopsy histology to determine whether the patient fully meets the inclusion criteria. \n\nTherefore, the patient's trial-level eligibility cannot be determined as eligible or excluded due to insufficient information. The appropriate rating would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1461": {
        "output": "",
        "label": 1
    },
    "1462": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"History of Hepatitis C in Volunteer Blood Donors,\" we must compare the patient's information with the inclusion and exclusion criteria of the trial:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other significant liver diseases apart from chronic viral hepatitis\n- Not on antiviral or immunosuppressive therapy within the last 6 months\n\nClinical Trial Inclusion Criteria:\n- Patients with chronic hepatitis C\n- Age 18 to 70 years, male or female\n- HCV infection indicated by the presence of anti-HCV (by ELISA and recombinant immunoblot assay [RIBA])\n- Written informed consent\n- Women must not be pregnant\n- Patients must not have significant systemic illnesses other than liver disease\n- Patients must not have antiviral or immunosuppressive therapy within the last 6 months\n- Patients must not have HIV infection\n- Patients must not have contraindications to liver biopsy\n\nComparison:\n- The patient's age (55 years) falls within the required age range (18 to 70 years).\n- The patient is male, which meets the gender requirement.\n- The patient has chronic HCV, which is required for the study.\n- The patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, fulfilling the criteria for HCV infection confirmation.\n- There is no information regarding the patient's consent, but this can usually be obtained if all other criteria are met.\n- The patient is not reported to be pregnant, which is inapplicable as the patient is male.\n- The patient does not have significant systemic illnesses other than liver disease, as required.\n- The patient has been on antiviral drugs for the past 6 months, which contradicts the trial's criteria of no antiviral or immunosuppressive therapy within the last 6 months.\n- There is no information provided about HIV infection status or any contraindications to liver biopsy.\n\nBased on the information provided, the patient does not meet the eligibility criteria for the clinical trial due to his recent antiviral treatment within the last 6 months. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1463": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis,\" we can determine the patient's eligibility for the study.\n\nThe patient in the note is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His medical records indicate chronic inflammation compatible with chronic viral hepatitis, but there is no mention of primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). Furthermore, the patient's treatment regimen does not include ursodeoxycholic acid, which is mentioned in the inclusion criteria for patients with PBC experiencing suboptimal response.\n\nThe inclusion criteria for the study specify that patients must have pathologically confirmed PSC or PBC, among other specific characteristics and prior treatments. Since the patient's diagnosis is not PSC or PBC, and there's no information suggesting a suboptimal response to ursodeoxycholic acid (as he is not taking it), the patient does not meet the disease characteristics required for the study.\n\nAdditionally, the exclusion criteria for the study include no chronic hepatitis B infection and no hepatitis C infection, both of which the patient has.\n\nGiven this information, the patient does not meet the inclusion criteria for the study due to the absence of a PSC or PBC diagnosis and the presence of HCV and HBV infections. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1464": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) 2 years ago and has a recent coinfection with hepatitis B virus (HBV). The patient's medical history is noted as non-significant, and he has been on a combination of interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months. The biopsy indicates no evidence of hepatocellular carcinoma, but chronic inflammation compatible with chronic viral hepatitis is present. There is no mention of the hepatitis being mild or non-progressive, and the patient appears to be actively treated for HCV.\n\nThe clinical trial is focused on generating a library of genes that reflect the entirety of antibody responses to HCV made during the course of infection in a patient with extensively characterized viral quasispecies. The goal is to gain insight into the host mechanisms that suppress viral replication and potentially develop therapeutic and preventive strategies. The inclusion criteria for the clinical trial specify a persistent infection with mild hepatitis that is non-progressive.\n\nGiven the information provided in the patient note, there is insufficient detail to determine whether the patient's hepatitis is mild and non-progressive, as the trial requires. The patient is under active treatment, which suggests that the disease might not be non-progressive. Therefore, based on the available information, we cannot confidently assert that the patient meets the inclusion criteria of having non-progressive mild hepatitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1465": {
        "output": "",
        "label": 1
    },
    "1466": {
        "output": "The patient in question is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus). The clinical trial is looking to recruit HIV-infected children between the ages of 4 and less than 18 years who have specific criteria relating to their HIV infection status and treatment history.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. HIV-infected children between the ages of 4 years and less than 18 years.\n2. Certain clinical symptoms, immune suppression levels, or HIV RNA copy numbers as specified by the 2001 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.\n3. Failure of at least their second antiretroviral regimen.\n4. HIV RNA greater than or equal to 10,000 copies/mL within the past 3 months.\n5. Ability to swallow tablets.\n6. Willingness to use acceptable forms of birth control for sexually active patients.\n7. Specific hematologic, hepatic, and renal function requirements.\n8. Informed Consent signed by the patient or their parents/legal guardians if under 18 years of age.\n\nThe patient does not meet the following key inclusion criteria:\n- The patient is not within the age range required (4 to less than 18 years old).\n- The patient does not have an HIV infection; instead, he has HCV and HBV.\n- There is no mention of HIV RNA levels, as this is not relevant to his condition.\n- The patient is not specified to be failing any antiretroviral regimen, as he is not being treated for HIV.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial due to age, disease condition (HCV and HBV instead of HIV), and lack of any specified HIV treatment history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1467": {
        "output": "Based on the patient's note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of other forms of liver disease\n\nClinical trial inclusion criteria:\n- Male and female subjects \u2265 16 years of age\n- History of chronic hepatitis B infection\n- Documentation of positive Hepatitis B e antigen (HBeAg) status\n- The absence of coinfection with HIV, HCV, or HDV\n- The absence of other forms of liver disease\n- Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B\n\nThe patient in the note is of the appropriate age and has a history of chronic hepatitis B infection. However, the patient has a recent coinfection with HCV, which is explicitly listed as an exclusion criterion for the trial. Therefore, despite meeting some of the inclusion criteria, the patient is not eligible for this trial due to the coinfection with HCV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1468": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nThe patient is:\n- A 55-year-old man, which meets the age requirement of >= 16 years.\n- Diagnosed with chronic hepatitis B infection, as indicated by the positive enzyme immunoassay for anti-HCV antibodies and HCV RNA tests.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months, which may or may not include nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B.\n- Not described as having other forms of liver disease such as alcoholic, autoimmune, or biliary disease.\n\nHowever, the patient has:\n- A recent coinfection with HBV, and there is no information provided regarding the patient's HBeAg status or anti-HBeAb positivity.\n\nThe inclusion criteria for the trial are:\n- Male and female subjects >= 16 years of age with a history of chronic hepatitis B infection.\n- Must be HBeAg negative and anti-HBeAb positive.\n- Must not have coinfection with HIV, HCV, or HDV.\n- Must not have other forms of liver disease.\n- Must not have had less than 12 weeks of prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B.\n\nThe patient note does not provide enough information about the patient's HBeAg status or anti-HBeAb positivity. However, the patient is coinfected with HCV, which would exclude them from the trial as per the inclusion criteria that require the absence of coinfection with HCV.\n\nTherefore, the patient is not eligible for the trial due to coinfection with HCV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1469": {
        "output": "The patient in the note is a 55-year-old man diagnosed with HCV (hepatitis C virus) 2 years ago and has a recent coinfection with HBV (hepatitis B virus). He is on treatment with IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months.\n\nLet's compare the patient's characteristics with the clinical trial inclusion criteria:\n\nThe trial inclusion criteria are:\n- Male and female subjects >= 16 years of age with a history of HBeAg-positive chronic hepatitis B infection.\n- Incomplete response to current lamivudine therapy.\n- HBeAg-positive.\n- Absence of coinfection with HIV, HCV, or HDV.\n- Absence of other forms of liver disease.\n\nThe patient is 55 years old, which satisfies the age requirement. However, the patient has a coinfection with HCV, which is explicitly listed as an exclusion criterion for the trial. While the patient does have chronic hepatitis B, the presence of an HCV coinfection makes him ineligible for this study.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1470": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- No evidence of cirrhosis or decompensated liver disease\n- No other significant medical history\n\nClinical Trial Inclusion Criteria:\n- Signed written informed consent\n- Age over 18 years old\n- Presence of HCV RNA measured by qualitative PCR\n- Nonresponder to a previous course of therapy with either IFN alone or IFN plus ribavirin for at least 3 months (12 weeks)\n- Washout period of at least 6 months from previous therapy with IFN alone or IFN plus Ribavirin\n- Liver biopsy consistent with cirrhosis or progression to cirrhosis (METAVIR fibrosis score 3 to 4) within the last 12 months before treatment starts, and at least 6 months after the end of the prior failed therapy\n- Compensated liver disease criteria\n- Blood counts and renal function criteria\n- Normal TSH or adequately controlled thyroid function\n- For females, specific criteria for birth control or sterility\n\nClinical Trial Exclusion Criteria:\n- Use of systemic corticosteroids within 6 months of entry\n- Evidence of drug-induced liver injury\n- Current use of certain drugs or immunosuppressive drugs\n- Evidence of other liver diseases\n- Alpha-fetoprotein > 200 ng/mL\n- Child-Pugh B or C cirrhosis\n- Decompensated liver disease criteria\n- HIV infection\n- Prior history of malignancy with exceptions\n- Active infectious process other than HCV\n- Autoimmune disease criteria\n- Pregnancy\n- Alcohol or intravenous drug abuse within the previous 1 year\n- Chronic use of methadone\n- Patients who are poor medical risk\n- Patients with a history of severe depression\n- Significant pre-existing cardiac or pulmonary disease\n- Recipients of transplants\n- Uncontrolled seizure disorder\n- Non-compliance with the study protocol\n- Previous treatment with thymosin alpha 1\n- Hypersensitivity to IFN a\n- Participation in other investigational studies\n\nBased on the patient's note, there is no indication that the patient meets the inclusion criteria regarding the nonresponse to IFN or IFN plus ribavirin for at least 12 weeks. Additionally, there is no information about a liver biopsy showing cirrhosis or progression to cirrhosis, and no mention of Child-Pugh score, which is required for assessment of cirrhosis stage. The patient also has a recent coinfection with HBV, which could be considered under \"evidence of any other liver disease,\" potentially excluding them from the trial.\n\nGiven the information provided, the patient does not meet key inclusion criteria and there is potential for exclusion due to the coinfection with HBV.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1471": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin,\" we need to compare the patient's information with the inclusion and exclusion criteria of the trial.\n\nPatient Information:\n- 55 years old\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of cirrhosis or other listed liver diseases\n- Recent biopsy negative for hepatocellular carcinoma (HCC)\n- Normal blood pressure, heart rate, and BMI\n- No evidence of decompensated liver disease\n\nInclusion Criteria Checklist:\n- Signed written informed consent: Not mentioned, assume it can be obtained\n- Age over 18 years old: Yes (55 years old)\n- Presence of HCV RNA measured by qualitative PCR: Yes (previous positive HCV RNA tests)\n- Nonresponder to a previous course of therapy with either IFN alone or IFN plus ribavirin: Not clear (the patient is currently on IFN and RBV along with direct antiviral drugs)\n- Washout period of at least 6 months from previous therapy with IFN alone or IFN plus Ribavirin: No (patient has been on therapy for the past 6 months)\n- Liver biopsy consistent with chronic hepatitis C within the last 12 months before treatment starts, and at least 6 months after the end of the prior failed therapy: Yes (recent biopsy was negative for HCC)\n- No clinical or histological evidence of cirrhosis (METAVIR fibrosis score 0 to 3): Yes (no evidence of cirrhosis)\n- Compensated liver disease with specified lab values: Not enough data provided to confirm\n- Ultrasound, CT scan, or MRI of the liver within 3 months of entry negative for HCC: Not mentioned, assume it can be done if required\n- Hematocrit > 30%, platelet count > 100 x 109/L, WBC > 3 x 109/L, and polymorphonuclear white cell count > 1.5 x 109/L: Not enough data provided to confirm\n- Adequate renal function as demonstrated by serum creatinine level < 2.0 mg/dL: Not mentioned, assume it can be tested if required\n- Normal TSH or adequately controlled thyroid function: Not mentioned, assume it can be tested if required\n- If the patient is a woman, she is using a definitive method of birth control in consultation with her physician, or is surgically sterile or post-menopausal: Not applicable (patient is male)\n\nExclusion Criteria Checklist:\n- Use of systemic corticosteroids within 6 months of entry: No information, assume not used\n- Current use of any drug known to be hepatotoxic, any drug with therapeutic activity in hepatitis C or immunosuppressive drug: Yes (on IFN, RBV, and direct antiviral drugs)\n- Any other liver disease including hepatitis B: Yes (recent coinfection with HBV)\n- Alpha-fetoprotein > 200 ng/mL: Not mentioned, assume it can be tested if required\n- Current or past diagnosis of cirrhosis: No (no cirrhosis mentioned)\n- Evidence of portal hypertension: No information, assume none since there's no mention of related complications\n- Decompensated liver disease: No (patient does not show signs of decompensated liver disease)\n- HIV infection: No information, assume negative\n- Concomitant or prior history of malignancy: No (recent biopsy negative for HCC)\n- Active infectious process other than HCV: No (only HCV and HBV mentioned)\n- Rheumatoid arthritis or other autoimmune disease: No information, assume not present\n- Pregnancy: Not applicable (patient is male)\n- Alcohol or intravenous drug abuse within the previous 1 year: No information, assume not present\n- Chronic use of methadone: No information, assume not used\n- Patients who are poor medical risk: No indication of this in the patient note\n- History of severe depression: No information, assume not present\n- Significant pre-existing cardiac or pulmonary disease: No information, assume not present\n- Any indication that the patient would not comply with the conditions of the study protocol: No information, assume would comply\n- Previous treatment with thymosin alpha 1: No information, assume not treated\n- Known hypersensitivity to IFNa: No information, assume not allergic\n- Simultaneous participation in another investigational drug study: No information, assume not participating\n\nBased on the above information, the patient does not meet the inclusion criteria of a 6-month washout period from previous therapy with IFN alone or IFN plus Ribavirin, as he is currently on these drugs. Additionally, the patient has a recent coinfection with HBV, which is an exclusion criterion for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1472": {
        "output": "In order to assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the study:\n\nInclusion Criteria for the Clinical Trial:\n- Men or women 18 to 75 years\n- Chronic hepatitis C infection based on a history of positive anti-HCV antibody and/or HCV RNA\n- History of prior treatment with interferon-a-based therapies or an assessment by the investigator that the patient would not benefit from interferon-a-based therapy or that treatment with interferon-a is contraindicated\n- Stage 4, 5 or 6 liver fibrosis according to the Ishak scoring system.\n- Cannot have presence of clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding within the last 2 years (diuretic therapy of stable mild-to-moderate peripheral edema is permitted)\n- Must meet minimum blood chemistry requirements\n- Cannot have unstable or uncontrolled thyroid disease\n- Cannot have a variety of other diseases (listed in the protocol)\n- Other conditions for enrollment exist which would be discussed with a Clinician upon screening for the study.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- Past medical history is non-significant\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma and remarkable for chronic inflammation compatible with chronic viral hepatitis\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- No clinically evident ascites or tenderness\n\nBased on the given information:\n\n- The patient is within the age range of 18 to 75 years.\n- The patient has a chronic hepatitis C infection demonstrated by positive HCV RNA tests and anti-HCV antibodies.\n- The patient has been on IFN, RBV, and direct antiviral drugs, which could suggest prior treatment with interferon-a-based therapies, or that the investigator may assess that the patient would not benefit from further interferon-a-based therapy.\n- There is no explicit mention of the patient's liver fibrosis stage. The Ishak scoring system specifically would need to be referenced to confirm the patient's eligibility regarding their liver fibrosis stage.\n- The patient does not appear to have any of the exclusionary conditions such as clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding within the last 2 years.\n- The blood chemistry requirements are not provided, so it can not be confirmed if the patient meets these criteria.\n- There is no indication that the patient has unstable or uncontrolled thyroid disease.\n- The other diseases and conditions listed in the protocol are not specified, and thus cannot be evaluated.\n\nGiven the available information, the patient seems to meet most of the inclusion criteria, but we cannot confirm eligibility without additional information regarding the patient's liver fibrosis stage (Ishak scoring), blood chemistry results, and other potential exclusion conditions not listed in the provided note. Therefore, the trial-level eligibility based on the current information is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1473": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. The clinical trial is looking for patients with chronic hepatitis D (HDV) and hepatitis B virus (HBV) coinfection.\n\nThe inclusion criteria for the trial are:\n1. Be positive for both anti-HDV and HBsAg for more than 6 months.\n2. Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment.\n3. Be HDV RNA positive by PCR.\n4. Be HBV DNA positive by PCR.\n5. Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to enrollment).\n6. Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A).\n7. Present with WBC \u22653000/mm3, ANC \u22651500/mm3, and platelet \u226580,000/mm3.\n8. Be able to and likely to attend regularly for treatment and follow-up.\n9. Give their written informed consent.\n10. Be negative for urine pregnancy test (for females of childbearing potential), documented once within the screening period and again within 24 hours prior to the first dose of study drug.\n11. All male patients with female partners of childbearing age should use a barrier method of contraception.\n12. All female patients of childbearing potential must use two reliable forms of effective contraception.\n\nFrom the patient note, there is no mention of hepatitis D (HDV) infection, only HCV (hepatitis C virus) and HBV (hepatitis B virus). Therefore, the patient does not meet the first inclusion criterion, which requires positivity for both anti-HDV and HBsAg for more than 6 months, as well as being HDV RNA positive by PCR.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial because they do not have documented HDV infection, which is a key requirement for this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1474": {
        "output": "The patient note presents a 55-year-old man with a diagnosis of hepatitis C virus (HCV) infection from 2 years ago and a recent coinfection with hepatitis B virus (HBV). He is currently on a combination of interferon (IFN), ribavirin (RBV), and direct antiviral drugs. His medical history is otherwise non-significant, and there is no indication of HIV infection. The patient's liver biopsy does not show hepatocellular carcinoma but chronic inflammation due to chronic viral hepatitis.\n\nTo determine the patient's eligibility for the clinical trial titled \"Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C,\" we need to compare the patient's profile with the inclusion criteria of the study:\n\n1. HIV infection (Western Blot +): The patient note does not mention HIV infection or any related treatment, which suggests that the patient does not have HIV.\n2. C hepatitis (RNA viral hepatitis C [VHC] +): The patient has a confirmed diagnosis of HCV, as indicated by positive HCV RNA tests.\n3. Chronic active C hepatitis on liver histological score METAVIR (A over or equal to 1 and F over or equal to 2) on biopsy: The patient's liver biopsy shows chronic inflammation, but there is no information about the METAVIR score.\n4. Previous treatment for C hepatitis for at least 3 months including peg-interferon and ribavirin or peg-interferon alone if contraindication for ribavirin occurred: The patient has been on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n5. Failure to eradicate C hepatitis virus after well-conducted treatment: There is no information provided about the efficacy of the patient's current HCV treatment.\n6. The liver biopsy should have been realized at least 18 months before inclusion: There is no specific information about the timing of the liver biopsy relative to the study's inclusion date.\n7. Regular follow up in an outpatient clinic for HIV: There is no indication that the patient has HIV or is receiving follow-up for HIV in an outpatient clinic.\n8. Unchanged antiretroviral treatment the last 3 months before inclusion: Antiretroviral treatment is not applicable to this patient, as there is no mention of HIV infection.\n9. Informed consent: There is no information about the patient's willingness or consent to participate in the trial.\n\nBased on the available information, the patient does not meet several key inclusion criteria, particularly the requirement of being co-infected with HIV. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1475": {
        "output": "",
        "label": 1
    },
    "1476": {
        "output": "",
        "label": 2
    },
    "1477": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) 2 years ago.\n- Recently coinfected with HBV (Hepatitis B Virus).\n- On treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of hepatitis C genotype or level of fibrosis.\n\nClinical Trial Inclusion Criteria Analysis:\n- Chronic viral hepatitis C, genotype 1 or 4.\n- Fibrosis F3 or F3-F4, assessed by the scoring Metavir system.\n- Initial treatment against HCV.\n\nComparison:\n- The patient has chronic viral hepatitis C and is on treatment, meeting one part of the inclusion criteria.\n- However, there is no information provided about the patient's HCV genotype or the severity of fibrosis as determined by the Metavir scoring system.\n\nSince the patient note does not provide the required information on genotype and fibrosis level, we cannot ascertain if the patient meets all the inclusion criteria for the clinical trial. Therefore, the patient is not clearly eligible or excluded based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1478": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Cellulose Sulfate and HIV Transmission Among Women,\" the 55-year-old man does not meet the inclusion criteria for the following reasons:\n\n- The patient is a male, while the trial specifically targets women.\n- The patient's diagnosis is HCV and recent coinfection with HBV. There is no mention of HIV, and the trial requires participants to be HIV negative.\n- The inclusion criteria specify the need for an average of at least three vaginal sex acts per week with at least three different partners in the last three months. There is no information provided about the patient's sexual activity.\n- The trial aims to assess the effect of cellulose sulfate on the transmission of HIV to women via vaginal intercourse, which is not applicable to the male patient.\n\nGiven this information, the patient does not meet the sufficient inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1479": {
        "output": "The patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs. The patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. He does not have hepatocellular carcinoma or other liver diseases and is in no acute distress. His blood pressure, heart rate, and BMI are within relatively normal ranges, and his liver function tests indicate chronic inflammation compatible with chronic viral hepatitis.\n\nNow, let's compare the patient's information to the inclusion criteria of the clinical trial:\n\n1. The patient is over 18 years of age.\n2. The patient has a dual chronic hepatitis C and B infection, as indicated by positive tests for both anti-HCV and HBsAg for more than 6 months and quantifiable HCV RNA.\n3. There is no information on the patient's HBeAg status, which is required to be negative as per the trial criteria.\n4. The patient is on IFN and RBV treatment, which may suggest he is not treatment-na\u00efve; however, the trial also includes those who had treatment failure to previous interferon monotherapy or lamivudine therapy.\n5. The patient's liver biopsy findings are compatible with chronic liver disease.\n6. There is no mention of the patient's serum ALT levels or whether they have been documented as elevated on two occasions within six months prior to enrollment.\n7. There is no mention of the patient's complete blood count, specifically WBC, ANC, and platelets, which need to meet specific thresholds.\n\nThe patient's eligibility for the clinical trial cannot be ascertained without further information on his HBeAg status, ALT levels, and complete blood count values. Therefore, we must rate the trial-level eligibility as 1) Not relevant due to insufficient information to confirm eligibility based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1480": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma, alcoholic liver disease, or other liver diseases\n- Noted to have chronic inflammation compatible with chronic viral hepatitis on biopsy\n\nClinical Trial Inclusion Criteria:\n- Patients who have a liver biopsy as standard of care\n- Diagnosed with one of the following:\n  - Hepatitis C\n  - Hepatitis B\n  - Autoimmune Hepatitis\n  - Primary Biliary Cirrhosis\n  - Primary Sclerosing Cholangitis\n\nClinical Trial Exclusion Criteria:\n- The exclusion criteria are not listed in the provided text.\n\nAssessment:\n- The patient has a diagnosis of Hepatitis C (HCV) and a recent coinfection with Hepatitis B (HBV).\n- The patient has a liver biopsy confirming chronic inflammation compatible with chronic viral hepatitis, which fits the inclusion criteria for liver diseases in the study.\n\nBased on this information, the patient appears to meet the criteria for having chronic viral hepatitis (both Hepatitis C and Hepatitis B) and there is no information on exclusion criteria that would disqualify the patient from the study. Therefore, the patient is eligible to participate in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1481": {
        "output": "",
        "label": 1
    },
    "1482": {
        "output": "",
        "label": 2
    },
    "1483": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication\" involves comparing the patient's characteristics to the study's inclusion criteria. \n\nLet's evaluate the patient note against the inclusion criteria:\n\n1. Patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada\n   - The patient note does not specify the location of the patient's care.\n\n2. Fluent in English\n   - The patient note does not provide information about language fluency.\n\n3. Men and women between the ages of 18 and 65\n   - The patient is a 55-year-old man, which fits within the age range specified.\n\n4. Subjects must provide written informed consent to participate\n   - The patient note does not mention anything about consent, but this is typically obtained as part of the study enrollment process.\n\n5. Control subjects: negative for both HBV, HCV, and HIV\n   - The patient is not a control subject as he is diagnosed with HCV and recent coinfection with HBV.\n\n6. Additional Inclusion Criteria For HCV and HBV patients:\n   - Patient is a candidate for antiviral treatment: The patient is currently on IFN, RBV, and direct antiviral drugs.\n   - Non-cirrhotic as determined by recent liver biopsy (<2 years prior to assessment): The patient's recent biopsy shows no evidence of hepatocellular carcinoma and is only remarkable for chronic inflammation, consistent with chronic viral hepatitis, which suggests non-cirrhotic status.\n   - HCV subjects: positive for HCV RNA, negative for HBV and HIV: The patient has a positive HCV RNA test but is also coinfected with HBV, which does not meet the criteria of being negative for HBV.\n   - HBV subjects: positive for HBV RNA and negative for HCV and HIV: The patient is coinfected with HBV, but also has HCV, which does not meet the criteria of being negative for HCV.\n\nGiven the information from the patient note, the patient does not meet all of the inclusion criteria for the clinical trial. Specifically, he is coinfected with HBV, which disqualifies him from the trial as it requires HCV subjects to be negative for HBV and HBV subjects to be negative for HCV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1484": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy,\" let's assess the eligibility:\n\nThe patient:\n- Is a 55-year-old man (meets the criterion of male patients).\n- Has been diagnosed with HCV 2 years ago and recently with HBV coinfection (meets the criterion of serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test).\n- Is on IFN, RBV, and direct antiviral drugs for the past 6 months (implying ongoing treatment for HCV).\n- Has medical records showing previous positive HCV RNA tests (meets the criterion of detectable serum HCV-RNA).\n- Takes no other medications and there is no mention of use of contraception (but since this is not applicable for male patients, it's not a disqualifying factor).\n- There is no mention of the patient's insulin resistance status determined by the HOMA method (which is a necessary criterion for inclusion).\n\nSince there is no information about the patient's HOMA score, we cannot determine if the patient meets the criterion for insulin resistance (>2.1) as required. Thus, the patient does not have sufficient information provided to qualify for the trial based on the provided note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1485": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial,\" we need to compare the patient's characteristics and medical history with the inclusion criteria provided.\n\nHere are the key points from the patient note:\n- The patient is a 55-year-old man, which satisfies the age criterion (18-65 years).\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- There are no mentions of genotype testing or results, but since he is on treatment, it is implied he may have had a positive HCV RNA by PCR.\n- No history of hepatocellular carcinoma; recent biopsy was negative.\n- There are no reported liver function tests or other lab values to assess compensated liver disease criteria.\n- The patient's ability to give informed consent is not mentioned but is assumed since he is described as alert with no acute distress.\n\nNow, let's consider the inclusion criteria for the trial:\n1. Chronic hepatitis C, defined as the documentation of HCV by a positive PCR test and a positive HCV genotype test for genotype 1, and a liver biopsy compatible with chronic hepatitis or a clinical diagnosis of chronic hepatitis C if a biopsy is refused.\n2. Positive HCV RNA by PCR, Genotype 1, treatment naive.\n3. Age 18-65 years.\n4. Ability to give informed consent.\n5. Eligibility for interferon alfa and ribavirin-based antiviral treatment, including practicing adequate contraception.\n5) Compensated liver disease with specified laboratory results.\n\nBased on the patient note and the inclusion criteria, we can determine the following:\n- The patient's age falls within the required range.\n- The patient is diagnosed with chronic hepatitis C and is on treatment, which could mean a previous positive PCR test.\n- The patient's treatment status is not 'naive' as he is currently on IFN, RBV, and direct antiviral drugs.\n- There is no information on the patient's HCV genotype.\n- There is no information on the patient's liver function tests or other lab values to ensure compensated liver disease.\n- The patient's ability to give informed consent is assumed.\n\nGiven these points, the patient does not meet the criterion of being treatment naive, and there is insufficient information on his HCV genotype and liver function tests. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1486": {
        "output": "",
        "label": 1
    },
    "1487": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with chronic HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases specified in the inclusion criteria\n- Positive HCV RNA tests\n- Positive for anti-HCV-antibodies\n- No information about serum ALT levels\n- No information about serum HBeAg status\n- No information about HBV DNA in serum\n- No information about written informed consent\n\nClinical trial inclusion criteria:\n- Serum ALT at least 1.5x the upper limit of normal\n- For chronic HBV: Known positive serum HBeAg for at least 6 months; Presence of HBV DNA in serum\n- For chronic HCV: Presence of anti-HCV in serum within 6 months of enrollment; Positive serum HCV RNA (enrollment)\n- Written informed consent\n\nComparison:\n- The patient has chronic HCV and a recent coinfection with HBV which aligns with the diseases being studied in the trial.\n- The patient has a history of positive HCV RNA tests and anti-HCV-antibodies, which meets the criteria for chronic HCV enrollment.\n- There is no specific information on the patient's serum ALT levels, serum HBeAg status, or the presence of HBV DNA in serum.\n- There is no mention of whether the patient has provided written informed consent to participate in the trial.\n\nConclusion:\nDue to the lack of information on serum ALT levels, HBV status, and written informed consent, we cannot definitively determine the patient's eligibility. Therefore, the patient falls under the \"Not relevant\" category as there is insufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1488": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the following observations can be made:\n\n1. The patient is a 55-year-old man diagnosed with HCV 2 years ago.\n2. He also has a recent coinfection with HBV.\n3. The patient's past medical history is non-significant.\n4. He has been on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n5. There is no mention of the patient's HCV genotype in the provided note.\n6. There is no documented previous treatment failure mentioned in the patient note.\n\nThe clinical trial's inclusion criteria are:\n\n1. Hepatitis C virus (HCV) genotype 1\n2. Previous therapy with pegylated interferon and ribavirin\n3. Documented previous treatment failure\n\nSince the genotype of HCV in the patient is not specified and there is no mention of a previous treatment failure, we do not have sufficient information to determine if the patient is eligible based on the inclusion criteria of the trial. Therefore, the patient does not meet all the known inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1489": {
        "output": "",
        "label": 2
    },
    "1490": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man with chronic hepatitis C virus (HCV) infection, recently coinfected with hepatitis B virus (HBV). He has been undergoing treatment for the past 6 months with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. His medical records indicate that he has had a liver biopsy prior to the initiation of the treatment, which is one of the inclusion criteria for the trial. \n\nThe inclusion criteria for the clinical trial are:\n\n1. Patients completing treatment with peginterferon and ribavirin for chronic HCV infection.\n2. Patients who underwent a liver biopsy prior to therapy onset.\n\nThe patient fits the inclusion criteria as he is undergoing treatment with peginterferon (IFN) and ribavirin (RBV) for chronic HCV infection and has undergone a liver biopsy before the treatment started. \n\nThus, based on the information available in the patient note and the inclusion criteria of the clinical trial, we can determine that:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1491": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B,\" we'll assess the patient's characteristics against the inclusion criteria.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma\n- No evidence of liver cirrhosis\n- No mention of hemoglobin value, WBC, neutrophil count, platelets, total bilirubin, albumin, uric acid, serum creatinine, fasting blood sugar, TSH, T3, T4, or alfa-fetoprotein values\n\nInclusion criteria for the clinical trial:\n- Adult male or female, 18 to 60 years of age with chronic hepatitis B\n- Positive serum HBsAg for a minimum of 6 months\n- Evidence of HBV replication and hepatitis (Positive HBV-DNA, Positive HBeAg, documented abnormal ALT)\n- Chronic hepatitis without liver cirrhosis on liver biopsy\n- Compensated liver disease with specific hematological and serum biochemical criteria\n- Negative for HCV and HIV\n- If diabetic or hypertensive, requires a baseline ocular examination\n- Written informed consent\n\nBased on the patient note and the inclusion criteria, the patient appears to meet the following criteria:\n- Adult male within the age range\n- Chronic hepatitis B (evidenced by coinfection with HBV)\n- On treatment with IFN, which is part of the study treatment\n- No mention of liver cirrhosis in the patient's biopsy\n\nHowever, the patient does not meet the following criteria as there is no provided information:\n- Duration of positive serum HBsAg is not specified (required minimum of 6 months)\n- No specific mention of positive serum HBV-DNA within 3 months prior to entry\n- No specific mention of positive serum HBeAg within 3 months prior to entry\n- No specific mention of abnormal ALT levels\n- Missing hematological and serum biochemical values\n- No mention of negative serum antibody to hepatitis C (the patient is coinfected with HCV)\n- No mention of negative anti-HIV antibody\n- No mention of a baseline ocular examination for diabetic or hypertensive history\n- No mention of alfa-fetoprotein\n\nGiven the information available, the patient does not meet all the inclusion criteria, specifically, the documentation of HBV replication and hepatitis, the specific blood test values required, and most critically, the patient is coinfected with HCV, which is explicitly listed as an exclusion. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1492": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility step by step:\n\n1. The patient is a 55-year-old man, which meets the age criterion of \"Adults, 18+ years old.\"\n2. The patient has been diagnosed with HCV 2 years ago and is currently being treated with IFN, RBV, and direct antiviral drugs. However, there is no information about the HCV genotype of the patient, which is required to be genotype 1 for the study.\n3. There is no information provided about the patient's serum HCV RNA concentration, nor is there any mention of the patient being classified as a non-responder or partial responder to previous adequate PEG-IFN plus RBV therapy.\n4. The patient's medical records do not indicate a history of prior treatment adequacy or response levels, which are required to determine eligibility (null responders or partial responders).\n5. The patient is currently on treatment, which does not align with the requirement of being a non-responder or partial responder to previous therapy.\n6. The clinical trial requires a liver biopsy within 5 years of the first dose of the study drug, which is documented in the patient note as negative for hepatocellular carcinoma and chronic inflammation compatible with chronic viral hepatitis.\n7. The patient's note does not mention any of the required blood test results, such as hemoglobin levels, WBC, neutrophils, platelets, bilirubin, albumin, or serum creatinine.\n8. There is no information regarding the patient's serum thyroid-stimulating hormone (TSH) levels.\n\nSince the patient note lacks information about HCV genotype, serum HCV RNA concentration, previous treatment response, and specific blood test results that are necessary to determine eligibility based on the inclusion criteria of the clinical trial, we cannot conclusively establish the patient's eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1493": {
        "output": "Based on the information provided:\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Pathologically newly diagnosed HCC (Hepatocellular Carcinoma) that is deemed resectable and resected.\n2. Patient must start gefitinib within 6 weeks of hepatic resection with full recovery.\n3. Patients with positive resection margin or minimal residual disease (<0.5 cm) are also eligible.\n4. ECOG performance status (PS) 0, 1, or 2.\n5. Full recovery from hepatic resection with specific laboratory values (ANC > 1,500/uL, SGOT < 5 x UNL, Plt > 75,000/uL, Bilirubin < 2 x UNL, Serum albumin \u2265 2.5g/dL).\n6. Creatinine < 1.5 mg/dl or 125 u/L, alpha fetoprotein < 50 ug/L.\n7. Signed informed consent.\n8. Age > 18.\n9. No space-occupying lesion on CT scan of the liver post-resection.\n10. Negative pregnancy test for female patients of childbearing potential.\n11. No prior systemic therapy or I131 or chemoembolization treatment after surgery.\n12. Ability to take or swallow medication orally.\n13. No other malignancy except for adequately treated basal cell or squamous cell skin cancer or cervical cancer in-situ.\n14. No active infection, symptomatic CHF, unstable angina, uncontrolled cardiac arrhythmia, and psychiatric disorder.\n15. No concomitant medications that are potent inducers or inhibitors of CYP3A4.\n16. Patient is not taking St. John's Wort.\n\nThe patient note indicates that the patient is:\n- A 55-year-old man diagnosed with HCV and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- Negative for hepatocellular carcinoma on the recent biopsy.\n- No evidence of other liver diseases or conditions.\n- Normal physical examination results, excluding acute distress or abdominal or extremity abnormalities.\n\nThe patient does not meet the inclusion criteria for the clinical trial because:\n- The patient has not been diagnosed with Hepatocellular Carcinoma (HCC), which is a requirement for the trial.\n- There is no mention of hepatic resection or recovery from such a procedure for the patient, which is necessary for eligibility.\n- The patient's current medical issue is chronic viral hepatitis, not HCC.\n\nGiven that the patient does not have a diagnosis of HCC and has not undergone a hepatic resection, the patient is not eligible for the clinical trial focused on adjuvant therapy with gefitinib in patients with resectable Hepatocellular Carcinoma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1494": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess the eligibility of the patient for the clinical trial.\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned.\n- Normal vital signs and no physical abnormalities described such as ascites or edema.\n\nClinical Trial:\n- Title: Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule.\n- Objective: To evaluate the long-term persistence of hepatitis A and B antibodies in subjects who received a three-dose vaccination of a combined hepatitis A/hepatitis B vaccine.\n- Inclusion Criteria: Subjects must have received three-dose primary vaccination with combined hepatitis A/hepatitis B vaccine in the primary study, and written informed consent must be obtained.\n\nAssessment:\nThe patient does not meet the inclusion criteria specified for the clinical trial. The trial requires participants who have previously received a three-dose primary vaccination with combined hepatitis A and hepatitis B vaccine in the primary study. There is no information provided in the patient note indicating that the patient has participated in the primary study or received the vaccine series mentioned. Therefore, based on the information available, the patient is not eligible to participate in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1495": {
        "output": "Based on the information given, the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV, which matches the area of interest of the trial (hepatitis B). However, the inclusion criteria for the clinical trial specify that subjects must have participated in the primary study with combined hepatitis A/hepatitis B vaccine. There is no information in the patient note indicating that the patient participated in the primary study of the hepatitis A/hepatitis B vaccine. Therefore, since we do not have sufficient information to determine eligibility based on this specific criterion, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1496": {
        "output": "Based on the patient note provided, the 55-year-old man has been diagnosed with HCV and a recent coinfection with HBV. He is on a treatment regimen for these conditions, and there is no mention of hepatitis A or participation in previous long-term follow-up studies related to a hepatitis A and B vaccine.\n\nThe clinical trial in question is looking to evaluate the long-term persistence of hepatitis A and B antibodies in subjects who had previously received a 3 dose primary vaccination schedule of a combined hepatitis A/hepatitis B vaccine and who had consented to participate in the long-term follow-up studies at the previous long-term blood sampling time points.\n\nThe inclusion criteria for the clinical trial are not primarily about having hepatitis B or C, but rather about having previously participated in a specific vaccine study and consenting to long-term follow-up. Since there is no information in the patient note that indicates this patient was part of the initial vaccination study or that they have consented to participate in the long-term follow-up studies, the patient does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility assessment for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1497": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection,\" we must compare the patient's characteristics and medical history with the inclusion criteria of the study:\n\nInclusion Criteria Checklist:\n\n1. Male or female patients between 18 and 65 years of age:\n   - The patient is a 55-year-old man, which meets this criterion.\n\n2. Female patients must be non-pregnant and using birth control (not applicable to male patients):\n   - The patient is male, so this criterion is not applicable.\n\n3. Patient has been persistently HCV RNA-positive and remains HCV RNA-positive at screening:\n   - The patient has a history of HCV and medical records show positive HCV RNA tests, meeting this criterion.\n\n4. Patient is negative for HIV, HDV, and has no evidence of chronic HBV infection or other clinical signs leading to the diagnosis of current acute Hepatitis B disease:\n   - The patient has a recent coinfection with HBV, which conflicts with this criterion, indicating potential exclusion.\n\n5. Patient is in reasonably good health, except for findings related to their hepatitis C positive status:\n   - The patient appears to be in good health with no significant medical issues aside from HCV, meeting this criterion.\n\n6. Subject's private physician has been informed of the subject's planned participation in the study:\n   - There is no information provided about the patient's private physician being informed, so this cannot be assessed.\n\n7. Capable of understanding and complying with the protocol and has signed the informed consent document:\n   - There is no information provided about the patient\u2019s understanding or consent, so this cannot be assessed.\n\n8. Infected with HCV genotype 1:\n   - There is no information provided about the patient's HCV genotype, so this cannot be assessed.\n\n9. Failed previous treatment for HCV infection with an approved regimen of IFN/RBV or pegylated IFN/RBV:\n   - The patient is currently on IFN and RBV, but there's no information on whether the patient has failed previous treatment, so this cannot be assessed.\n\nBased on the available information, the patient does not meet one of the key inclusion criteria due to the recent coinfection with HBV. This would exclude him from participation in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1498": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the BASTA Study on STI in HIV Infected Patients.\n\nPatient Note Summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma\n- No alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- Normal vital signs\n- No abdominal ascites or tenderness\n- No lower extremity edema\n\nClinical Trial Inclusion Criteria:\ni. Age > 17 years\nii. Informed consent signed\niii. Effective ongoing treatment (HIV-RNA < 50 copies/ml). Treatment must be based on any triple drug therapy. Patients must be on the same steady therapy for at least 3 months.\niv. Current CD4 cell count above 800 cells/\u03bcL\n\nAssessment:\n- The patient has HCV and HBV coinfection, not HIV as required by the trial.\n- There is no mention of HIV treatment or status in the patient's note.\n- The trial specifically requires HIV-infected patients with a certain CD4 cell count and an undetectable HIV viral load, which is not applicable to this patient.\n\nSince the patient does not have HIV, he does not meet the inclusion criteria regarding HIV diagnosis and treatment, and therefore, he cannot be considered for the BASTA Study on STI in HIV Infected Patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1499": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Information:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- The recent biopsy was negative for hepatocellular carcinoma.\n- No mention of HIV infection or HIV-RNA level.\n- No mention of serum creatinine levels.\n- The patient is not on an antiretroviral regimen.\n\nClinical Trial Inclusion Criteria:\n- HIV-infected patients confirmed by HIV-RNA level.\n- HCV-infected patients confirmed by PCR or b-DNA.\n- Scheduled to commence combination IFN/RBV therapy on Day 1.\n- Normal serum creatinine.\n- On a stable antiretroviral regimen (for HIV) for at least 4 weeks.\n- Life expectancy > 6 months.\n\nThe patient does not meet the inclusion criteria for the clinical trial as there is no mention of HIV infection or any confirmation of HIV-RNA levels, which is a requirement for the trial. Additionally, there is no information about the patient's serum creatinine levels or being on a stable antiretroviral regimen, which are also part of the inclusion criteria.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1500": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection,\" we must compare the patient's characteristics and medical history with the trial's inclusion criteria:\n\n1. Patients with a chronic HCV infection (HCV antibodies and HCV RNA positive)\n   - The patient has chronic HCV and recent coinfection with HBV, which matches this criterion.\n\n2. Presence of a HCV genotype 1 infection\n   - The patient note does not specify the genotype of HCV.\n\n3. Presence of a compensated liver disease satisfying following hematological and biochemical minimum criteria:\n   - Hemoglobin value >= 13 g/dl in men\n   - Leukocytes >= 3.000/mm3 or neutrophile granulocytes > 1.500/mm3\n   - Thrombocytes > 80.000/mm3\n\n4. Total bilirubin in the normal range\n5. Albumin in the normal range\n6. Serum creatinine in the normal range\n7. THS in the normal range\n   - The patient note does not provide specific values for hematological and biochemical criteria.\n\n8. Exclusion of an autoimmune hepatitis\n   - The patient note does not report autoimmune hepatitis, so this criterion is presumably met.\n\n9. Alpha-Fetoprotein in the normal range\n   - The patient note does not provide the Alpha-Fetoprotein level.\n\n10. Negative HIV test\n    - The patient note does not mention an HIV test result.\n\n11. Negativity of Hepatitis B surface antigens (Hbs-Ag)\n    - The patient is coinfected with HBV, which likely means they are positive for Hepatitis B surface antigens.\n\n12. Normal or elevated ALT/GTP values at screening\n    - The patient note does not provide ALT/GTP levels.\n\n13. At known diabetes mellitus or hypertension an ophthalmologic examination must be performed\n    - The patient note does not mention diabetes or hypertension.\n\n14. Liver biopsy within the last 12 months must confirm the diagnoses of a chronic hepatitis\n    - The patient has a recent biopsy confirming chronic inflammation compatible with chronic viral hepatitis, meeting this criterion.\n\n15. A confirmation must be given that sexually active patients practice a safe method of contraception during the therapy and 6 (women) to 7 (men) months after the therapy\n    - The patient note does not provide information about contraception practices.\n\nGiven the information provided in the patient note, the patient does not meet several disclosed inclusion criteria due to insufficient information (HCV genotype, hematological and biochemical values, HIV status, ALT/GTP levels) and is explicitly not eligible due to coinfection with HBV (presence of Hepatitis B surface antigens). Therefore, the patient is excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1501": {
        "output": "Given the patient note and the clinical trial information provided, we can analyze the eligibility of the patient for the trial by comparing the patient data with the inclusion criteria of the study:\n\n1. Confirmed active liver disease due to Hepatitis B virus: The patient has been diagnosed with HCV and recent coinfection with HBV. Since the trial is for patients with chronic Hepatitis B, and the patient has a coinfection with HBV, he potentially meets this criterion.\n\n2. Patients must have adequate blood & liver functions: The patient's medical records do not indicate any liver function abnormalities, and the biopsy was negative for hepatocellular carcinoma, with only chronic inflammation compatible with chronic viral hepatitis mentioned. This suggests adequate liver function, although specific liver function test results are not provided.\n\n3. Female patients of child-bearing potential must be non-pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control: This criterion is not applicable to the patient as he is male.\n\n4. Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus, or AIDS will not be eligible: The patient's past medical history is non-significant, and there is no evidence of serious concurrent illnesses as specified in the exclusion criteria.\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria of the clinical trial for chronic Hepatitis B. However, since we do not have explicit confirmation of active Hepatitis B (only coinfection is mentioned) or detailed liver function test results, there is a chance that relevant information is missing to fully confirm eligibility. Therefore, the patient's eligibility is not definitively determined without further information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1502": {
        "output": "Based on the patient note provided, the 55-year-old man has been diagnosed with chronic Hepatitis C (HCV) and a recent coinfection with Hepatitis B (HBV). He has been on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n\nThe clinical trial in question is looking to assess the long-term effects of treatment with peginterferon alfa-2a plus ribavirin for patients with chronic hepatitis C/hepatitis B co-infection and chronic hepatitis C. To be eligible for this clinical trial, patients must have been randomized, treated, and returned for follow-up in the original study ML17862.\n\nThe patient note does not provide any information indicating that this specific patient was part of the ML17862 protocol. Therefore, without evidence that the patient was previously enrolled in the ML17862 study, we cannot confirm his eligibility for this follow-up study.\n\nGiven the lack of information about the patient's participation in the ML17862 study, the patient does not meet the inclusion criteria as specified for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1503": {
        "output": "Based on the patient note, the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. There is no mention of an HIV infection or participation in the AVX-201 trial. Furthermore, the inclusion criteria for the clinical trial specify that participants must have completed the AVX-201 protocol, have a plasma HIV RNA count below 5000 copies/ml, and have more than 50 CD4 cells.\n\nSince the patient does not meet the specific inclusion criteria related to HIV infection or previous trial participation, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1504": {
        "output": "To assess the trial-level eligibility of the patient for the clinical trial \"Transplant-Related Accelerated Progression of Hepatitis C,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. According to the exclusion criteria of the trial, a patient must NOT be Hepatitis B virus (HBsAg) positive. Since the patient has a coinfection with HBV, he is not eligible for the trial.\n\nNone of the inclusion criteria apply to this patient, as he does not require a liver or kidney transplant and there is no mention of his MELD score or a high probability of receiving a transplant within six months. Moreover, his medical history does not indicate end-stage liver disease or kidney failure, which are prerequisites for the trial.\n\nBased on the available information:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1505": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of race/ethnicity\n- No evidence of decompensated cirrhosis\n- No mention of HIV co-infection\n- No mention of HDV co-infection\n- BP: 130/75, HR: 90/min, BMI: 27\n- Compensated liver function (no ascites, variceal bleeding, or hepatic encephalopathy)\n- No mention of childbearing potential (not applicable as the patient is male)\n- No mention of drug or alcohol abuse\n- No mention of prohibited medications\n- No mention of serum creatinine, hemoglobin, platelet count, absolute neutrophil count, or serum alpha fetoprotein levels\n- No known history of allergy to nucleoside analogues\n- No prior therapy with Entecavir\n- No prior or concomitant use of nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B\n- No mention of therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of enrollment\n- No mention of chronic administration of concomitant medications which cause immunosuppression or are associated with a high rate of nephrotoxicity or hepatotoxicity\n- No mention of the ability to tolerate oral medication\n- No mention of peripheral venous access or being a prisoner or compulsorily detained\n\nClinical Trial Inclusion Criteria:\n- Chronic HBV infection with either HBeAg-positive (HBeAb-negative) or HBeAg-negative (HBeAb-positive) disease\n- Black/African American Race and/or Hispanic ethnicity\n- Nucleoside/tide-naive\n- Males or females \u2265 16 years of age\n- Compensated liver function\n- ALT of 1.3 to 10 x ULN\n- No Co-infection with HIV, HCV, or HDV\n\nClinical Trial Exclusion Criteria:\n- Women of childbearing potential not using acceptable contraception\n- Pregnant or breastfeeding women\n- Evidence of decompensated cirrhosis\n- Recent history of pancreatitis\n- Drug or alcohol abuse\n- Other serious medical conditions or chronic prohibited medications\n- Serum creatinine > 1.5 mg/dL\n- Hemoglobin < 10.0 g/dL\n- Platelet count < 70,000/mm3\n- Absolute neutrophil count < 1200 cells/mm3\n- Serum alpha fetoprotein (AFP) level > 100 ng/mL\n- Allergy to nucleoside analogues\n- Prior therapy with Entecavir\n- Prior or concomitant use of nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B\n- Therapy with interferon, thymosin alpha, or other immunostimulators within 24 weeks of enrollment\n- Inability to tolerate oral medication\n- Poor peripheral venous access\n- Prisoners or subjects involuntarily incarcerated\n\nBased on the provided information, the patient does not fulfill the ethnicity criteria (Black/African American or Hispanic) as no race/ethnicity is mentioned. Additionally, the patient is coinfected with HCV, which is listed as an exclusion criterion. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1506": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Phase I Trial of Silymarin for Chronic Liver Diseases,\" we need to assess the patient's characteristics and medical history against the inclusion and exclusion criteria listed for the trial.\n\nInclusion Criteria Assessment:\n- The patient is a 55-year-old man, which meets the age criterion (age at least 18 years at screening).\n- The patient has been diagnosed with HCV, which aligns with the inclusion criterion of being a Hepatitis C virus (HCV) patient.\n- The patient has been previously treated with interferon-based therapy (IFN) without sustained virological response, as he is on direct antiviral drugs now.\n- The patient's medical records should include Serum HCV RNA above quantifiable levels of detection by the assay within 1 year of screening and after the end of therapy. However, this specific information is not provided in the patient note.\n- The patient has not received antiviral therapy for at least 6 months prior to the screening visit, as he is currently on IFN, RBV, and direct antiviral drugs.\n\nExclusion Criteria Assessment:\n- The patient note does not mention the use of silymarin or other milk thistle preparations within 30 days of screening, so we cannot exclude him based on this criterion.\n- There is no information about the use of other antioxidants, so this cannot be assessed.\n- The patient's allergy/sensitivity history to milk thistle or its preparations is not mentioned.\n- There is no mention of the use of warfarin, metronidazole, or chronic use of acetaminophen.\n- The patient does not have documented cirrhosis or greater than or equal to 15% steatosis or evidence of steatohepatitis for the HCV cohort in the provided biopsy results.\n- The patient has a recent coinfection with HBV, which is a positive test for HBsAg within 3 years of screening, which is an exclusion criterion.\n- There is no mention of a positive urine drug screen.\n- There is no indication that the patient consumes more than one drink of alcohol per day.\n- The patient does not have other chronic liver diseases mentioned in the note.\n- The patient is not a woman, so pregnancy and breastfeeding criteria do not apply.\n- The patient's platelet count is not mentioned.\n- The patient's serum creatinine level and CrCl are not provided.\n- There is no evidence of decompensated liver disease in the patient's note.\n- There is no history or evidence of severe illness mentioned that would make the patient unsuitable for the study.\n- There is no mention of a history of immunologically mediated disease.\n- There is no history of solid organ or bone marrow transplantation mentioned.\n- There is no mention of a history of thyroid disease or use of oral steroids within 30 days prior to screening.\n- There is no information on concurrent medications that are CYP3A4 inducers.\n- The patient's ability or willingness to provide informed consent or abide by the study protocol cannot be determined from the note.\n\nBased on the available information, the patient note indicates a recent coinfection with HBV, which is listed as an exclusion criterion (positive test for HBsAg within 3 years of screening). Therefore, even though the patient meets some of the inclusion criteria, they are excluded from the trial based on the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1507": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recently coinfected with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- Previous positive HCV RNA tests.\n- Positive enzyme immunoassay for anti-HCV-antibodies.\n- Recent biopsy negative for hepatocellular carcinoma, with chronic inflammation compatible with chronic viral hepatitis.\n- No evidence of other liver diseases.\n- Normal vital signs and physical examination.\n\nClinical Trial Inclusion Criteria:\n- Age \u226518 years.\n- Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA.\n- Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis.\n- HCV genotype 4.\n- Patients that have not previously received peginterferon.\n\nThe patient meets the following criteria:\n- Age \u226518 years.\n- Chronic hepatitis C infection evidenced by anti-HCV antibodies and HCV RNA.\n- Chronic inflammation on liver biopsy compatible with chronic viral hepatitis.\n\nHowever, the patient does not meet the following criteria:\n- HCV genotype 4 (no information on the genotype is provided in the patient note).\n- Patients that have not previously received peginterferon (the patient is currently on IFN, which could be peginterferon, but it's not clearly stated).\n\nDue to the lack of information on the patient's HCV genotype and the ambiguity regarding the type of IFN the patient is receiving, we cannot confirm eligibility. Thus, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1508": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient appears to be eligible for the study.\n\nThe inclusion criteria for the clinical trial are:\n1. Age \u2265 18 years.\n2. Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA.\n3. Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis.\n\nThe patient note provides the following relevant information:\n1. The patient is a 55-year-old man, which meets the age criterion.\n2. Diagnosed with HCV 2 years ago, which indicates a chronic infection well over the minimum 6 months duration required.\n3. The patient has a medical history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, satisfying the second inclusion criterion.\n4. The recent biopsy showed chronic inflammation compatible with chronic viral hepatitis, meeting the third inclusion criterion.\n\nThere is no mention of any exclusion criteria or any other factors that would disqualify the patient from the trial in the patient note provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1509": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma and showing chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases\n- Normal blood pressure, heart rate, and BMI\n\nClinical Trial Inclusion Criteria:\n- Age \u226518 years\n- Chronic hepatitis C infection (at least 6 months) evidenced by positive enzyme immunoassay for anti-HCV-antibodies and positive quantitative RT-PCR amplification of HCV RNA\n- Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis\n- HCV genotype 4\n\nThe patient meets the following inclusion criteria for the clinical trial:\n- The patient is over 18 years old.\n- The patient has a chronic hepatitis C infection, with medical records showing positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- There is chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis.\n\nHowever, the clinical trial specifically requires patients with HCV genotype 4, and there is no information provided in the patient note regarding the HCV genotype of the patient. Without this information, we cannot confirm whether the patient meets all the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1510": {
        "output": "The patient in the provided note is a 55-year-old man with HCV and recent coinfection with HBV. His treatment includes IFN, RBV, and direct antiviral drugs. There is no mention of HIV infection or treatment, and nothing in the patient's note suggests that the patient is undergoing HAART (Highly Active Antiretroviral Therapy) for HIV, which is a requirement for the clinical trial.\n\nThe clinical trial in question is specifically for HIV patients who are on a stable HAART regimen with a specific CD4 cell count and viral load. Since the patient does not meet the basic inclusion criteria related to the disease condition (HIV) and treatment (HAART), he is not eligible for this trial.\n\nTherefore, based on the information given, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1511": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C,\" we will compare the patient's characteristics and medical history to the trial's inclusion criteria.\n\nInclusion Criteria Assessment:\n\n1. Willing to adhere to study requirements as evidenced by providing written informed consent before initiation of any study-related procedures.\n   - The patient's willingness can only be confirmed through direct communication, which is not provided in the note.\n\n2. Aged between 18-65 years.\n   - The patient is 55 years old, which meets this criterion.\n\n3. Documented history of chronic HCV infection (for at least 6 months prior to study entry) as diagnosed by either:\n   - Anti-HCV positive or\n   - HCV RNA viral load positive by PCR\n   - The patient was diagnosed with HCV 2 years ago, which meets this criterion.\n\n4. Be a non-responder to or unsuitable for interferon-based therapy.\n   - The patient is currently on IFN (interferon), RBV, and direct antiviral drugs. This suggests that the patient may not be a non-responder or unsuitable for interferon-based therapy. However, the note does not specify whether the patient has been unresponsive to these treatments, so this criterion is not conclusively met or unmet based on available information.\n\n5. Have liver inflammation, as defined by either AST and/or ALT levels 2-10 x ULN on at least 1 previous occasion within the past 6 months and at Pre-treatment visit.\n   - The patient note does not provide information about the patient's AST or ALT levels.\n\n6. Alpha-fetoprotein (AFP) less than/equal to 50\u00b5g/L.\n   - The note does not provide information about the patient's AFP levels.\n\n7. Hemoglobin \u2265100g/L, platelet count \u226575x109/L, and white blood cell count \u22651.5x109/L.\n   - The patient note does not provide information about the patient's hemoglobin, platelet count, or white blood cell count.\n\n8. Males, or females who are not of child-bearing potential or who are taking adequate contraceptive measures.\n   - The patient is male, which meets this criterion.\n\n9. Liver biopsy within past 3 years showing stage 2 fibrosis only (i.e., excludes cirrhosis and cancer); or within past 6 years showing stage 0 or 1 (no or minimal scarring).\n   - The recent biopsy was negative for hepatocellular carcinoma and indicated chronic inflammation compatible with chronic viral hepatitis. However, the note does not specify the stage of fibrosis.\n\nBased on the available information, the patient note does not provide sufficient evidence to conclusively determine eligibility for the clinical trial. Specifically, details regarding the patient's response to interferon-based therapy, AST/ALT levels, AFP levels, hemoglobin, platelet count, white blood cell count, and the stage of fibrosis from the liver biopsy are not provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1512": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Sorafenib in Treating Patients With Advanced Solid Tumors,\" we need to carefully review the inclusion criteria provided and compare them with the patient's medical profile. Let's analyze the key inclusion criteria:\n\n1. Histologically or cytologically confirmed malignant solid tumor: The patient has HCV and recent coinfection with HBV, but there is no mention of a malignant solid tumor.\n2. Refractory disease for which curative or palliative measures have failed or for which there is no known superior treatment: Since the patient does not have a solid tumor, this criterion is not applicable.\n3. No colorectal cancer or melanoma: The patient does not have colorectal cancer or melanoma, but this is irrelevant since he does not have any type of solid tumor.\n4. Measurable OR nonmeasurable disease: Again, not applicable as the patient does not have solid tumor disease.\n5. Normotensive: The patient's BP is 130/75 mm Hg, which meets the normotensive criteria.\n6. Brain metastases criteria: Not applicable as there is no mention of brain metastases.\n7. ECOG performance status 0-1: The patient's performance status cannot be determined from the information given.\n8. Life expectancy > 12 weeks: There is no information on life expectancy, but given the patient's current health status as described, there is no indication of a limited life expectancy.\n9. Age \u2265 14 years OR weight \u2265 45 kilograms: The patient is 55 years old, so this criterion is met.\n10. Not pregnant or nursing, and fertile patients must use effective contraception: The patient is male, so this criterion is met.\n11. Adequate organ function as determined by specific lab values: The lab values provided (e.g., negative for hepatocellular carcinoma, no acute distress, normal lower extremities) do not indicate inadequate organ function, but not all required labs are detailed.\n\nBased on the information given, the patient does not meet the primary inclusion criterion of having a confirmed malignant solid tumor. All other criteria are either met or not applicable due to the absence of a solid tumor. Therefore, the patient does not qualify for the trial because they do not have the primary disease condition that the trial is targeting.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1513": {
        "output": "To determine the patient's eligibility for the clinical trial, let's assess the given patient information against the inclusion criteria:\n\n1. Subject is >18 years old - The patient is 55 years old, which meets this criterion.\n2. Subject has given written informed consent - This is not mentioned in the patient note, but we will assume it can be obtained if all other criteria are met.\n3. Subject has a confirmed diagnosis of HIV and HCV infection - The patient is confirmed to have HCV but there is no mention of an HIV infection.\n4. Subject is naive for HCV-infection treatment - The patient is not naive, as he has been on IFN, RBV, and direct antiviral drugs for the past 6 months.\n5. Subject has chronic hepatitis and/or subject has compensated cirrhosis (Child class A) - The patient's biopsy was negative for hepatocellular carcinoma and noted chronic inflammation compatible with chronic viral hepatitis, but there is no mention of cirrhosis.\n6. Subject has a CD4+ count of > 350 cell/mmc - There is no information about the patient's CD4+ count.\n7. Subject is HIV-RNA negative during the previous six month - There is no indication that the patient has HIV, so this criterion cannot be met.\n8. Subject is on stable HAART including r/LPV for > 6 months - The patient note does not mention HAART or r/LPV therapy.\n9. Subject has genotype available at baseline and no mutations associated with resistance to PI or no virologic failure on PI treatment - There is no information provided about the patient's genotype or resistance to PI.\n10. Free of any clinically significant disease (other than HIV and HCV) that would interfere with study evaluations - The patient has no other significant diseases as per the provided information.\n11. Subject will use effective contraceptive methods for the duration of the study - There is no information provided about the patient's use of contraceptive methods.\n\nBased on the patient note and the inclusion criteria, the patient does not meet several major criteria, including being HIV positive, being naive to HCV treatment, and being on stable HAART including r/LPV for > 6 months. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1514": {
        "output": "",
        "label": 1
    },
    "1515": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not seem to be eligible for the trial. The trial is specifically looking for cirrhosis patients with ascites despite taking conventional diuretics. The patient has a history of chronic viral hepatitis due to HCV and recent coinfection with HBV, but there's no mention of cirrhosis or ascites. Furthermore, the patient is not reported to be taking diuretics, let alone the specific combinations of loop diuretics and an anti-aldosterone agent as required by the study's inclusion criteria.\n\nSince the patient's medical conditions and treatment do not match the inclusion criteria of the study, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1516": {
        "output": "Assessment of the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other chronic liver diseases listed in the exclusion criteria\n- Not on any other medications\n- No mention of HIV infection status\n- No mention of CD4+ cell counts\n- No information provided about neutrophil count, platelets, or hemoglobin levels\n- No mention of ALT levels or serum lipase\n- Not pregnant or breastfeeding (male)\n- No mention of willingness to abstain from alcohol or to use contraception\n- No mention of addiction history or participation in a methadone treatment program\n- No mention of having a primary doctor or willingness to designate a person for durable power of attorney\n- No mention of ability or willingness to inject medication subcutaneously\n- No mention of any exclusion criteria being met\n\nClinical Trial Inclusion Criteria:\n- Age greater than or equal to 18 years\n- Documentation of HIV-1 infection by a licensed ELISA test and confirmed by a Western Blot\n- Documentation of hepatitis C infection by a positive test for hepatitis C antibody and HCV RNA level of 2000 copies/mL or greater\n- Histopathologic features consistent with chronic hepatitis C at the time of enrollment\n- Patients infected with genotype 1\n- Patients with CD4+ cell counts greater than 100 cells/mm(3)\n- Ability to sign the Informed Consent document, and willingness to comply with the study requirements and clinic policies\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, we cannot confirm the patient's eligibility for the following reasons:\n\n- The patient's HIV status is not mentioned. The clinical trial requires documentation of HIV-1 infection.\n- There is no information on the patient's HCV genotype to confirm whether it is genotype 1.\n- The patient's CD4+ cell count is not provided.\n- It is not stated if the patient is willing and able to comply with the study requirements, including signing the Informed Consent document.\n- There is no information about the patient's willingness to abstain from alcohol or to use contraception as required by the study.\n\nGiven the lack of information on several crucial inclusion criteria, the patient cannot be deemed eligible at this time.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1517": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus,\" we must compare the patient's characteristics and medical history with the inclusion criteria provided for the trial.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV (not HIV)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal blood pressure, heart rate, and no edema\n- Not documented to have HIV infection (only HCV and HBV coinfection)\n\nClinical trial inclusion criteria:\n- Written informed consent has been obtained\n- Adults 18 years of age or older\n- HIV infection documented by detectable HIV RNA PCR\n- Absolute CD4+ > 300 cells/mm3\n- Chronic hepatitis C infection based on history and detectable serum HCV RNA\n- Serum alanine aminotransferase (ALT) above normal limits and/or historical biopsy consistent with hepatitis C\n- Complete blood counts within normal limits\n- Normal renal function (serum creatinine within normal limits)\n- PT/INR and aPTT within normal limits\n- All patients of reproductive potential must agree to use an approved form of barrier contraception or agree not to become pregnant while taking study medications and for 30 days after study completion. Female patients must have a negative serum pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal)\n\nThe patient does not meet the inclusion criteria for the clinical trial because he is not documented to have an HIV infection, which is a requirement for the trial. The trial specifically targets patients who are co-infected with HCV and HIV, and the patient's note only mentions HCV and HBV coinfection. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1518": {
        "output": "Based on the patient note, the patient is a 55-year-old man who was diagnosed with Hepatitis C Virus (HCV) 2 years ago and has a recent coinfection with Hepatitis B Virus (HBV). The medical records indicate positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. Additionally, the patient has been on treatment with IFN, Ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months.\n\nComparing this to the inclusion criteria of the clinical trial titled \"Laboratory Profile of Hepatitis B and C in Users of a Reference Service,\" which seeks patients with laboratory tests positive for hepatitis B and/or C, the patient fits the criteria. The trial's inclusion criteria are patients with laboratory tests positive for hepatitis B and/or C, and the patient has confirmed diagnoses of both HBV and HCV, as indicated by the medical records and ongoing treatment.\n\nTherefore, the patient appears to meet the inclusion criteria for the study, and there is no mention of any exclusion criteria in the provided clinical trial information that would disqualify the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1519": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection,\" let's assess the patient's eligibility:\n\n- The patient is diagnosed with chronic hepatitis C infection (HCV), as evidenced by positive HCV RNA tests and anti-HCV antibodies, which satisfies the criterion of having a chronic hepatitis C infection diagnosed by the presence of hepatitis C ribonucleic acid (RNA) in serum by test of hepatitis C virus (HCV) RNA.\n- There is no information about the patient's alcohol use; however, the patient note does not indicate significant past medical history, which may imply that there is no significant alcohol use.\n- The patient's serum AFP level is not provided in the patient note, so we cannot determine if it meets the specified range for inclusion.\n- Evidence of advanced liver disease is not clearly stated. While there is a mention of chronic inflammation, there is no mention of a low platelet count, AST/ALT ratio, or liver biopsy results demonstrating bridging fibrosis or cirrhosis.\n- The patient is currently on treatment with interferon (IFN) and ribavirin (RBV), which is contrary to the trial's requirement of no treatment with interferon or ribavirin for at least 4 months.\n- There is no information provided about a recent ultrasound, CT, or MRI examination of the liver to rule out masses suggestive of hepatocellular carcinoma.\n- No information is given about the patient's willingness to refrain from consuming over-the-counter SAMe and vitamin pills containing B-vitamins.\n- The patient's Eastern Cooperative Oncology Group (ECOG) performance status is not provided, but the note states the patient is alert with no acute distress, which may suggest a good performance status.\n- The leukocyte count is not provided in the patient note.\n- There is no information about contraception use or understanding and willingness to sign a written informed consent document.\n\nGiven the available information:\n\n- The patient does not meet the criterion regarding the absence of treatment with interferon or ribavirin for at least 4 months.\n- There is insufficient information to determine if the patient meets other specific criteria (such as serum AFP levels, evidence of advanced liver disease through certain lab values or biopsy, recent liver imaging, ECOG performance status, leukocyte count, and consent-related criteria).\n\nTherefore, based on the provided patient note, the patient would be classified as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1520": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\n1. Chronic genotype 1 Hepatitis C infection: The patient was diagnosed with HCV 2 years ago, which aligns with the criteria of having a chronic condition.\n\n2. Never been treated for Hepatitis C Viral (HCV) infection: The patient is currently on IFN, RBV, and direct antiviral drugs for the past 6 months, which indicates that they have already been treated for HCV. This does not meet the trial's requirement of being treatment-naive.\n\n3. No clinically significant lab abnormalities: The patient note does not indicate any significant lab abnormalities; however, this is not sufficient information to confirm if all the lab values are within normal range as required.\n\n4. Amount of HCV Ribonucleic acid (RNA) in the blood more than 10,000 international units/milliliter (IU/mL) at entry: The patient's note does not specify the current amount of HCV RNA in the blood.\n\n5. Liver biopsy or Fibroscan test performed during screening or in the past 3 years: The patient's note mentions a recent biopsy that was negative for hepatocellular carcinoma, which meets this criterion.\n\nThe critical point here is that the patient has already been treated for HCV, which does not meet the inclusion criterion of being treatment-naive. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1521": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection 2 years ago and recent coinfection with hepatitis B virus (HBV).\n- The patient's past medical history is non-significant.\n- He is currently on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n- The patient has positive HCV RNA tests and a positive test for anti-HCV antibodies.\n- The recent biopsy shows no evidence of hepatocellular carcinoma, only chronic inflammation compatible with chronic viral hepatitis.\n- The patient has no other notable conditions such as alcoholic liver disease, esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n\nClinical Trial Inclusion Criteria Analysis:\n- Relapsed subjects must have prior treatment for HCV with PEG-IFN-alpha (or other IFN-alpha) and ribavirin for at least 12 weeks.\n- Naive subjects should have no prior treatment with PEG-IFN-alpha (or other IFN-alpha).\n- Genotype 1 HCV RNA greater than or equal to 100,000 IU/mL. Mixed genotype infections are not allowed.\n- Documented liver biopsy \u22642 years of study enrollment with Ishak score \u22644.\n- No evidence of hepatocellular carcinoma documented by abdominal imaging within 12 months of study entry.\n- No evidence of clinically significant cardiac abnormalities.\n- Negative drug and alcohol tests except for physician-prescribed or approved medication.\n- If male, agrees to use 2 forms of medically accepted contraception while on study.\n\nThe patient's information indicates that he has been treated with IFN and RBV, which could suggest that he is not treatment-naive. However, the note does not clarify whether he is a relapsed subject or treatment-naive according to the clinical trial's definition. Additionally, the patient's HCV genotype is not mentioned, nor is the viral load provided. There is no information on an echocardiogram or ECG to assess for cardiac abnormalities, and no information about the use of contraception. The biopsy does not show hepatocellular carcinoma and the Ishak score is not mentioned.\n\nGiven the available information, the patient does not have sufficient information to determine eligibility for the trial. Specifically, we are missing details regarding his treatment history as defined by the trial (whether he is considered relapsed or naive), his HCV RNA levels and genotype, cardiac function, and contraception agreement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1522": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\n1. Diagnosis of chronic hepatitis C:\n   - The patient was diagnosed with HCV 2 years ago, so this criterion is met.\n\n2. Non-response to or relapse from primary standard HCV therapy:\n   - The patient is currently on IFN, RBV, and direct antiviral drugs, but there is no information provided about non-response or relapse from these treatments.\n\n3. HLA A2 positive:\n   - There is no information provided on the patient's HLA A2 status.\n\n4. HCV-RNA positive:\n   - The patient has previous positive HCV RNA tests, so this criterion is met.\n\n5. HCV antibodies positive:\n   - The patient's medical records show a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n6. Liver biopsy within 30 months prior to inclusion:\n   - The recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n\n7. Hematology and biochemistry laboratory results within the limits normally expected for the patient population (liver values maximal 5 times the upper limit of normal):\n   - There is no specific information provided about the patient's hematology and biochemistry laboratory results, so we cannot confirm this criterion.\n\n8. Male and female:\n   - The patient is a 55-year-old man, so this criterion is met.\n\n9. From 18 to 65 years:\n   - The patient is 55 years old, so this criterion is met.\n\n10. Written informed consent obtained prior to study entry:\n    - This is a procedural step that the patient would need to complete if all other criteria are met.\n\nGiven that the information about the patient's non-response or relapse from primary standard HCV therapy, HLA A2 status, and specific laboratory results is not provided, we cannot definitively determine eligibility based on the information available. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1523": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection and a recent coinfection with hepatitis B virus (HBV). His medical history is non-significant, and there is no mention of alcohol excess intake or clinical liver cirrhosis. The clinical trial in question is studying T cell phenotype activation pathways in human alcoholic liver disease, specifically involving patients with either alcohol excess intake and suspected liver disease or alcohol excess intake and clinical liver cirrhosis, or those with chronic hepatitis C virus infection and suspected liver disease or chronic hepatitis C virus infection and clinical liver cirrhosis.\n\nGiven that the patient has a chronic HCV infection, he meets one aspect of the inclusion criteria for the clinical trial. However, the trial specifically requires suspected liver disease or clinical liver cirrhosis in conjunction with the HCV infection, and there is no mention of liver cirrhosis in the patient's note.\n\nTherefore, while the patient does have chronic HCV, without explicit information suggesting liver disease beyond chronic inflammation or cirrhosis, we do not have enough evidence to determine if he meets the full inclusion criteria of the trial. Thus, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1524": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nThe inclusion criteria for the clinical trial are:\n- HBsAg-positive patients\n\nThe patient in question is diagnosed with HCV and has a recent coinfection with HBV. The patient's medical records do not indicate hepatocellular carcinoma, which is the focus of the trial, but rather chronic inflammation compatible with chronic viral hepatitis.\n\nGiven that the clinical trial is looking for patients with HBV-related hepatocellular carcinoma, and the patient has only been diagnosed with chronic viral hepatitis without evidence of hepatocellular carcinoma, the patient does not meet the specific disease condition required for the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1525": {
        "output": "Given the patient's diagnosis with HBV (Hepatitis B virus) and the clinical trial's focus on HBV-positive patients, the patient appears to meet the inclusion criteria for the trial. There is no mention of any exclusion criteria in the provided clinical trial information, and the patient's medical history does not suggest any reasons for exclusion based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1526": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. He is on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. His medical records show positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. The biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n\nThe clinical trial in question is studying the genetic polymorphisms of interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-\u03b1) on the outcome of HCV-related chronic liver disease. The inclusion criterion for this trial is being anti-HCV-positive.\n\nThe patient's note confirms that he is anti-HCV-positive, which aligns with the trial's inclusion criteria. There are no additional inclusion criteria provided, and there are no exclusion criteria mentioned. Therefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1527": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) and a recent coinfection with Hepatitis B Virus (HBV). His treatment is focused on these conditions with Interferon (IFN), Ribavirin (RBV), and direct antiviral drugs. There is no mention in the patient's note about cystic fibrosis or colonization with Pseudomonas aeruginosa, which are the inclusion criteria for the clinical trial titled \"Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis\".\n\nThe clinical trial is specifically looking for participants who have been clinically diagnosed with cystic fibrosis and are colonized with Pseudomonas aeruginosa. Since the patient does not have a diagnosis of cystic fibrosis nor is there any indication of colonization with Pseudomonas aeruginosa, the patient does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1528": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recently coinfected with HBV.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- Previous positive tests for HCV RNA and positive for anti-HCV antibodies.\n\nClinical Trial Inclusion Criteria:\n- Health insurance.\n- Resolved HCV infection (HCV RNA negative for more than 6 months) or HCV chronically infected (RNA positive).\n- Anti-HCV antibodies positive.\n- Volunteers and informed patients.\n\nThe patient has been diagnosed with chronic HCV and is currently undergoing treatment. The patient's medical records indicate a history of positive HCV RNA tests, which suggests chronic HCV infection. The patient is also anti-HCV antibodies positive, which fits another criterion.\n\nThe inclusion criteria do not specify the patient's need to be pre- or post-liver transplantation, only that the patient must have resolved or chronic HCV infection and be positive for anti-HCV antibodies. Since the patient is under treatment for HCV and has a history of positive HCV RNA tests, they meet the criteria for chronic HCV infection. Also, the patient is informed as they are undergoing treatment, which implies that they are aware of their health condition and the implications, fulfilling the requirement of being a volunteer and informed patient.\n\nThe patient's eligibility for the trial depends on the current status of HCV RNA. If the patient's HCV RNA is currently positive, he would meet the criteria for a chronically infected individual. If the HCV RNA is negative for more than 6 months, he would meet the criteria for resolved HCV infection. However, since the patient note does not provide the current status of HCV RNA and based on the treatment history, we can infer that the patient is likely to be HCV RNA positive.\n\nTherefore, given the available information, the patient appears to meet the inclusion criteria for the clinical trial. However, the note does not provide explicit confirmation of the current HCV RNA status or health insurance status, which are required for eligibility. Since the patient is under treatment, it is reasonable to assume they have health insurance; however, this is an assumption rather than confirmed information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1529": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we must compare each criterion from the patient note to the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of liver transplantation.\n- No evidence of hepatocellular carcinoma.\n- Normal graft function or immunosuppression therapy is not mentioned.\n- The patient is stable, with normal blood pressure and no acute distress.\n\nClinical Trial Inclusion Criteria Analysis:\n- Liver transplantation performed for non-autoimmune liver disease performed at least 3 years before IS weaning.\n- Absence of acute and/or chronic rejection episodes during the 12 months before weaning.\n- Basal liver biopsy without signs of acute and/or chronic rejection.\n- No evidence of autoimmune liver disease.\n- Low dose immunosuppression (criteria for specific medications and combinations).\n- Absence of medical or psychological disturbances that preclude the safe performance of the trial.\n- Stability of liver graft function with specific test levels.\n- Patients exhibiting at least one of several specific characteristics, including severe side effects of immunosuppressive drugs, risk of neoplasm development, or chronic liver disease due to HCV in patients not receiving antiviral treatment.\n- Signature of informed consent.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial, as there is no mention of liver transplantation or related treatment and monitoring. The patient is currently being treated for HCV and HBV, and there is no information suggesting that the patient has undergone a liver transplant or is taking immunosuppressive drugs. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1530": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV infection.\n\nClinical Trial Inclusion Criteria:\n- HIV and either HBV or HCV co-infection.\n- 18 years and older.\n- Able to give informed consent.\n\nThe patient described in the note has HBV and HCV co-infections but there is no mention of HIV infection. The inclusion criteria for the clinical trial specifically require individuals to be co-infected with HIV and either HBV or HCV. Therefore, the patient does not meet the inclusion criteria of having an HIV co-infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1531": {
        "output": "",
        "label": 0
    },
    "1532": {
        "output": "",
        "label": 0
    },
    "1533": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- Past medical history is non-significant\n- On IFN (Interferon), RBV (Ribavirin) and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No overt hepatic failure or decompensated liver cirrhosis\n- No alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n\nClinical Trial Inclusion Criteria:\n- Chronic hepatitis C patients with positive anti-HCV for more than 6 months and HCV RNA\n- No overt hepatic failure or decompensated liver cirrhosis (Child-Pugh class B or C) or hepatocellular carcinoma\n\nThe patient fits the inclusion criteria for the clinical trial as they have been diagnosed with chronic hepatitis C (positive anti-HCV for more than 6 months and HCV RNA). Additionally, there is no indication of overt hepatic failure, decompensated liver cirrhosis, or hepatocellular carcinoma, which aligns with the trial's inclusion criteria specifying the exclusion of such conditions.\n\nTherefore, the patient appears to be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1534": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome,\" we need to compare the patient's information with the inclusion criteria provided:\n\nInclusion Criteria for the Trial:\n1. Must be male aged \u2265 18 years at the time of consent\n2. Must understand and voluntarily sign an informed consent form\n3. Male subjects with at least 3 months of symptoms of CP/CPPS (pain in the pelvic area, penis, scrotum, or perineum) who are refractory to other therapies (e.g., NSAIDs)\n4. Must be able to adhere to the study visit schedule and other protocol requirements\n5. Diagnosis of Chronic Prostatitis with a Chronic Prostatitis Symptom Index of at least 15/24\n6. Must meet the following laboratory criteria:\n   - Hemoglobin > 9 g/dL\n   - Hematocrit \u2265 27%\n   - WBC count \u2265 3000 /mL and < 20,000/mL\n   - Platelets \u2265 100,000 /mL\n   - Serum creatinine \u2264 1.5 mg/dL\n   - Total bilirubin \u2264 2.0 mg/dL\n   - AST and ALT < 1.5x ULN\n7. Males must agree to use barrier contraception when engaging in sexual activity with a female capable of becoming pregnant while on study medication and for 28 days after taking the last dose of study medication\n\nPatient Note:\n- The patient is a 55-year-old male diagnosed with HCV 2 years ago and the recent coinfection with HBV.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient's past medical history is non-significant.\n- The recent biopsy was negative for hepatocellular carcinoma.\n- There is no mention of symptoms related to CP/CPPS.\n- There is no indication that the patient has been diagnosed with Chronic Prostatitis or has a Chronic Prostatitis Symptom Index score.\n- No laboratory values are provided to compare against the trial's criteria.\n\nBased on the information provided in the patient note, the patient does not appear to have symptoms of chronic prostatitis or chronic pelvic pain syndrome, which is a requirement for the clinical trial. Additionally, there are no laboratory values provided to confirm whether the patient meets the required blood test criteria.\n\nTherefore, the patient does not meet the necessary inclusion criteria based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1535": {
        "output": "",
        "label": 0
    },
    "1536": {
        "output": "Based on the patient note and the inclusion and exclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, meeting the age criterion of 18 years or above.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of previous interferon therapy or other forms of treatment that would exclude the patient.\n- No evidence of decompensated liver disease or other exclusion conditions mentioned.\n- No mention of substance abuse, serious autoimmune disease, or other exclusionary conditions.\n- Willingness to undergo liver biopsy and written informed consent are not mentioned but are typically addressed during the recruitment process.\n\nClinical Trial Inclusion Criteria:\n- Age 18 years or above, the patient is 55 years old.\n- Presence of HCV RNA in serum at levels of at least 10,000 IU/ml, the patient has a past positive for HCV RNA.\n- Willingness to undergo liver biopsy before or 6 hours after an initial injection of peginterferon is not mentioned but assumed if the patient agrees to participate.\n- Written informed consent is typically obtained during the recruitment process.\n\nClinical Trial Exclusion Criteria:\n- Previous adequate treatment with any form of type I interferon (at least 12 weeks of therapy). No information on this is provided in the patient note.\n- Other antiviral therapy within the last 6 months. The patient is currently on antiviral therapy, which is an exclusion criterion.\n- Decompensated liver disease or other significant conditions listed in the exclusion criteria are not mentioned in the patient's note.\n- No evidence of another form of liver disease in addition to viral hepatitis.\n- No mention of current pregnancy, breastfeeding, or the need for contraception but the patient is male, so these do not apply.\n- No other exclusion criteria are mentioned to be met by the patient's condition as per the patient note.\n\nBased on the information provided, the patient does not meet the clinical trial's inclusion criteria due to ongoing antiviral therapy within the last 6 months. Therefore, the patient would be excluded from the trial based on the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1537": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nThe patient is a 55-year-old man with chronic hepatitis C (HCV) infection diagnosed 2 years ago and a recent coinfection with hepatitis B virus (HBV). He has been on IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months.\n\nThe inclusion criteria for the clinical trial are:\n1. Treatment naive (no prior treatment with IFN-a +/- RBV regimens).\n2. Subjects who have discontinued IFN-a containing regimens after <2 weeks of therapy due to tolerability issues are considered treatment naive.\n3. HCV RNA > 100,000 IU/mL at screening.\n4. Genotype 1.\n5. A diagnosis of chronic HCV infection for at least 6 months.\n\nThe patient is not treatment naive, as he has been on IFN and RBV for the past 6 months, which disqualifies him based on the first inclusion criterion of the trial. Therefore, the patient is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1538": {
        "output": "",
        "label": 0
    },
    "1539": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Treatment of Hepatitis C in Psychiatric Patients,\" we need to compare the patient's characteristics with the inclusion criteria of the trial:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- No significant past medical history\n- No psychiatric disorders or drug addiction mentioned\n- Positive HCV RNA tests\n- Elevated ALT is not specified but implied by the treatment with IFN, RBV, and antiviral drugs\n- No mention of psychiatric disorders or drug addiction\n\nClinical trial inclusion criteria:\n- Detectable serum HCV-RNA level in a PCR-based assay for more than 6 months\n- Elevated alanine aminotransferase (ALT > 30 U/L)\n\nBased on the information provided:\n- The patient has been diagnosed with HCV and has been receiving treatment for the past 6 months, which suggests a positive HCV RNA.\n- There is no information provided about the patient's ALT levels; however, the fact that the patient is on treatment with IFN, RBV, and direct antiviral drugs suggests that the patient likely has an elevated ALT, as these are common treatments for HCV with elevated ALT.\n- There is no history of psychiatric disorders or drug addiction mentioned in the patient note, which means we do not have sufficient information to categorize the patient into any of the trial's subgroups (psychiatric disorders, methadone substitution, former drug addiction, or controls).\n\nGiven the above points, the patient appears to meet the medical inclusion criteria based on HCV infection and treatment history, but we do not have concrete ALT values. Additionally, there is no indication of psychiatric disorders or drug addiction, but this does not necessarily exclude the patient, as the trial also includes controls without psychiatric history or addiction.\n\nTherefore, the patient falls into the category of:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1540": {
        "output": "Based on the patient note provided, the 55-year-old man diagnosed with HCV (hepatitis C virus) and the recent coinfection with HBV (hepatitis B virus) does not have hepatocellular carcinoma (HCC) as per his recent biopsy results. The clinical trial in question is looking for patients with a history of proven HCC. Since the patient does not fit this essential inclusion criterion, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1541": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient Note Review:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and a recent coinfection with HBV (hepatitis B virus).\n- No significant past medical history.\n- Currently on IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months.\n- No other medications are taken.\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- Recent biopsy negative for hepatocellular carcinoma, notable for chronic inflammation compatible with chronic viral hepatitis.\n- No evidence of other liver diseases.\n- Normal vital signs and physical examination.\n\nClinical Trial Inclusion Criteria Review:\n- HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA detectable in serum by Polymerase Chain Reaction.\n- Histological diagnosis of chronic hepatitis.\n- Patients who were non-responders to previous treatment with pegylated interferon and ribavirin or who had contraindicated the antiviral treatment.\n- Age between 18 and 65 years.\n- Ability to provide informed consent.\n- Absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g).\n\nAssessment:\n- The patient has confirmed HCV infection with positive HCV RNA and anti-HCV antibodies.\n- The patient has a histological diagnosis of chronic hepatitis.\n- The patient is currently on IFN and RBV; however, the note does not specify whether the patient is a non-responder to these treatments or not. This is essential information to determine eligibility.\n- The patient is within the age range of 18 to 65 years.\n- The patient appears to have the ability to provide informed consent (alert and no acute distress).\n- There is no mention of significant alcohol ingestion, so it's assumed that the patient meets this criterion.\n\nThe key piece of missing information is the patient's response to previous treatment with pegylated interferon and ribavirin. Without this information, we cannot fully determine eligibility based on the criteria that patients should be non-responders to these treatments or have contraindications to them.\n\nGiven the available information, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1542": {
        "output": "The patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV, which are relevant to the study's interest in HBV and HIV co-infections. The study is based in Uganda and is looking at liver fibrosis or liver damage in patients with HBV, HIV, both, or neither. \n\nThe patient's note does not mention HIV, which is one of the conditions of interest in the study. However, the inclusion criteria for the study do not specifically require HIV co-infection; they are more broadly focused on HBV, and the patient does have HBV co-infection with HCV. \n\nThe inclusion criteria for the clinical trial are:\n1. Willing and able to provide individual informed consent.\n2. Currently being followed at the RHSP or IDI Adult Infectious Disease Clinic.\n3. Persons aged 18 years and older.\n\nThe patient's note does not provide information about whether the patient is currently being followed at the RHSP or IDI Adult Infectious Disease Clinic in Uganda, which is a requirement for participation in the study. There is no indication that the patient meets this criterion based on the provided note. Moreover, the study seems geographically specific to Uganda, and there is no information about the patient's location or ability to travel for the study.\n\nGiven the information provided, we cannot confirm whether the patient is able to participate in the study due to missing information regarding the specific geographic requirement of being a part of the RHSP or IDI Adult Infectious Disease Clinic. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.\n\nPlease note that in a real-world scenario, additional patient information and direct communication with the clinical trial team would be necessary to accurately determine eligibility.\n\n",
        "label": 0
    },
    "1543": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nPatient Note:\n- The patient is a 55-year-old male.\n- Diagnosed with HCV and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of osteoarthritis or issues with knee or hip pain.\n\nClinical Trial:\n- Investigating the long-term analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the knee or hip.\n- Inclusion Criteria:\n  - Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence x-ray grade equal to, or greater than, 2.\n  - Partial benefit from current stable dose regimen of NSAID therapy.\n  - Pain level and function levels as required by the protocol.\n  - Willing to discontinue all non-study pain medications except rescue medication.\n  - Willing and able to comply with study procedures.\n\nThe patient in the note does not mention having osteoarthritis of the knee or hip, nor does it mention experiencing pain related to osteoarthritis that is currently being treated with NSAIDs. Therefore, the patient does not meet the inclusion criteria based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1544": {
        "output": "To assess the patient's trial-level eligibility, let's compare the patient's characteristics and medical history with the clinical trial's inclusion and exclusion criteria.\n\nInclusion Criteria Assessment:\n1. Male and female, 18 years of age or older: The patient is a 55-year-old man, so he meets this criterion.\n2. HBsAg positive for more than 6 months: There is no specific information provided about the duration of HBsAg positivity.\n3. Serum HBV DNA > 2,000 IU/ml: The patient note does not provide information on the patient's viral load.\n4. Serum ALT < 2 X ULN on two consecutive occasions at least 3 months apart: There is no information on the patient's ALT levels.\n5. Na\u00efve to nucleoside or nucleotide therapy: The patient is currently on direct antiviral drugs for the past 6 months, which may include nucleos(t)ide therapy, but there is insufficient information to determine this.\n6. On liver biopsy, fibrosis score \u2265 3 according to METAVIR scoring system (within 2 years of Day 0): The patient had a liver biopsy, but there is no information on the fibrosis score.\n7. If liver biopsy is not available, subjects must have two of the following items (overt findings of cirrhosis by radiologic evidence, gastrointestinal varices, platelet count < 100,000, splenomegaly): The patient does not have any of these conditions as per the information provided.\n8. The patient who is willing and able to provide written informed consent to participate in this study: There is no information provided regarding the patient's willingness or ability to consent.\n\nExclusion Criteria Assessment:\n1. A history of SBP, variceal bleeding, HEP, HCC: The patient does not have a history of these conditions based on the information provided.\n2. Decompensated liver disease (Child-Pugh score > 10): There is no evidence of decompensated liver disease in the patient note.\n3. Co-infected with HCV or HIV: The patient is coinfected with HCV, which is an exclusion criterion.\n4. History of any other forms of liver disease: There is no history of other liver diseases mentioned.\n5. Patient who is pregnant or breastfeeding: The patient is male, so this does not apply.\n6. Treatment with immunosuppressive, immunomodulatory agents or antiviral agents within 6 months prior to study entry: The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, which excludes him.\n7. A history of liver transplantation or planned for liver transplantation: There is no information provided about liver transplantation.\n8. A history of any other medical disease or condition that would make the patients unsuitable for the study: There is no such history provided.\n9. Patient is currently abusing alcohol or illicit drugs or has a history of alcohol abuse or illicit substance abuse within the preceding 2 years: There is no information provided on substance abuse.\n10. Patient is enrolled or plans to enroll in another clinical trial of an investigational agent while participating in this study: There is no information on this.\n\nBased on the patient's co-infection with HCV and treatment with antiviral agents within the past 6 months, the patient is excluded from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1545": {
        "output": "Based on the patient note provided, the following information is relevant to the inclusion criteria for the clinical trial:\n\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and is currently coinfected with HBV.\n- The patient's past medical history is non-significant.\n- He is currently undergoing antiviral treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient has had a liver biopsy, which was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n- Chronic HCV infection\n- Must undergo liver biopsy\n- Must undergo antiviral treatment\n\nThe patient clearly meets all the inclusion criteria for the clinical trial: he has a chronic HCV infection, has undergone a liver biopsy, and is receiving antiviral treatment. Therefore, based on the information provided, there is no indication that any exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1546": {
        "output": "",
        "label": 0
    },
    "1547": {
        "output": "Based on the provided patient note, the 55-year-old man has been diagnosed with HCV (Hepatitis C virus) and a recent coinfection with HBV (Hepatitis B virus). The clinical trial is investigating the connection between liver disease and chitinase proteins.\n\nThe inclusion criteria for the clinical trial are:\n\n- Patients with liver disease followed at the liver unit at Hadassah Medical Center.\n- Patients who have given their informed consent for participation in the study.\n\nThe patient note indicates that the man has a liver disease (chronic viral hepatitis) as evidenced by his diagnosis with HCV and HBV, positive HCV RNA tests, and a biopsy showing chronic inflammation compatible with chronic viral hepatitis. However, there is no information provided about whether the patient is being followed at the Hadassah Medical Center or if he has given informed consent for participation in the study.\n\nDue to the lack of information regarding the patient's connection to the Hadassah Medical Center and his consent status, the patient cannot be deemed eligible or excluded based on the information available. Thus, the patient falls under the category of \"Not relevant\" because the provided information is insufficient to determine eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1548": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not meet the necessary conditions for participation in this specific study. The patient is described as having HCV and recent HBV coinfection, but there is no mention of liver cirrhosis or liver transplant, which are required for the clinical trial. The trial specifically targets liver transplant recipients and their donors, which the patient note does not indicate as applicable to this patient.\n\nTherefore, this patient would not be relevant for this clinical trial as there is no indication that they are a liver transplant recipient (Group 1 or Group 2 as defined in the inclusion criteria).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1549": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and history with the inclusion criteria provided by the trial.\n\nHere are the key points from the patient note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of previous treatment specifically for hepatitis C with pegylated interferon plus ribavirin or response to it.\n- Liver biopsy was negative for hepatocellular carcinoma.\n- No evidence of compensated liver disease or hematologic, biochemical and serologic criteria.\n- No mention of depression or substance abuse history.\n- No mention of ANA levels or radiologic evidence of a focal mass or ascites.\n\nHere are the key inclusion criteria for the clinical trial:\n- Willing to give informed consent and able to adhere to dose and visit schedules.\n- History of chronic hepatitis C, genotype 1, non-responders or relapsers.\n- Adult subjects 18-70 years of age.\n- Liver biopsy within 3 years prior to screening with a diagnosis consistent with chronic hepatitis C.\n- Compensated liver disease with specific hematologic, biochemical, and serologic criteria.\n- Fasting glucose within a specified range.\n- Normal TSH levels.\n- Stable mild depression may be considered.\n- History of substance abuse with at least one year of abstinence.\n- ANA < 1:320.\n- No radiologic evidence of hepatoma and/or ascites.\n\nBased on the information provided in the patient note and the inclusion criteria of the trial, it is not clear if the patient is a non-responder or relapser to previous pegylated interferon plus ribavirin treatment, which is a crucial requirement for this trial. Additionally, there is no information about the patient's genotype or ANA levels, and we lack details on specific hematologic, biochemical, and serologic criteria required by the trial. Without this information, we cannot conclusively determine eligibility.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1550": {
        "output": "",
        "label": 1
    },
    "1551": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's compare the two to determine the trial-level eligibility of this patient:\n\nPatient characteristics:\n- 55-year-old man with HCV and recent HBV coinfection\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal vital signs and physical examination\n\nClinical trial inclusion criteria:\n- Age over 18 years (Patient meets this criterion)\n- Weight 85 kg below the pre-inclusion visit (Patient's weight is not provided)\n- Documented HIV infection (HIV positive) (Patient does not have documented HIV infection)\n- HCV infection documented by a positive PCR (Patient meets this criterion)\n- HCV Genotype 1 or 4 (Patient's HCV genotype is not provided)\n- Compensated liver disease (Child-Pugh below/equal to 6) (Patient's Child-Pugh score is not provided, but there is no evidence of decompensated liver disease)\n- Lymphocytes CD4 above 200/mm^3 (Patient's CD4 count is not provided)\n- Patient not answering a treatment for hepatitis C (Patient is currently on treatment for HCV)\n- Patient not covered by dual by Peg-IFN + riba for at least three months (wash out) (Patient is currently on IFN and RBV)\n\nBased on the information provided, the patient does not meet several of the inclusion criteria for the clinical trial. Specifically, the patient does not have a documented HIV infection, their HCV genotype is not specified, their CD4 count is unknown, and they are currently on a treatment regimen that includes IFN and RBV, which goes against the trial's criteria for not having been on such a treatment for at least three months prior.\n\nGiven this information, the patient is not eligible for the clinical trial due to not meeting several key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1552": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we can assess the patient's eligibility as follows:\n\nThe clinical trial is focused on subjects with moderate to severe chronic nonmalignant osteoarthritis (OA) who require around-the-clock opioid therapy. The inclusion criteria specifically mention OA as the condition of interest.\n\nThe patient note, however, describes a 55-year-old man diagnosed with hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV). His medical history is noted as non-significant, and there is no mention of osteoarthritis or any requirement for around-the-clock opioid therapy. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nSince the patient's condition (HCV and HBV infection) is not relevant to the trial's target condition (OA), and there is no indication that the patient requires opioid therapy for OA pain, the patient would be considered not relevant for recruitment in this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1553": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient: \n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No evidence of hepatocellular carcinoma (HCC)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of liver disease mentioned, alcohol consumption not specified\n- Normal liver biochemistry as there is no indication of liver disease beyond chronic viral hepatitis\n\nClinical Trial Inclusion Criteria:\n- Patients with no history of liver disease\n- Alcohol consumption less than 40g a week\n- No risk factors for viral hepatitis other than HBV & HCV\n- Consecutive patients with HCC and patients with HBV & HCV\n- Diagnosis of HCC made by histopathology or by two imaging modalities if histopathology is not available\n\nThe trial is specifically looking for patients with HCC or those with HBV & HCV infections matched to HCC patients. The patient in question does have HCV and a recent coinfection with HBV, which aligns with part of the inclusion criteria. However, the patient does not have HCC, nor is there any indication that they meet the control group criteria (no history of liver disease, low alcohol consumption).\n\nSince the patient is not diagnosed with HCC, they do not meet the full inclusion criteria for the clinical trial that is focused on evaluating the GP73 marker in the context of hepatitis B related HCC. There is also no data indicating whether the patient's alcohol consumption is less than 40g a week or not, which is part of the criteria for the control group.\n\nThus, the patient does not have sufficient information to qualify for the trial based on the available data.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1554": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient information:\n- 55-year-old man\n- Diagnosed with hepatitis C virus (HCV) 2 years ago\n- Recently coinfected with hepatitis B virus (HBV)\n- On interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months\n- No other medications\n- No hepatocellular carcinoma\n- No evidence of other liver diseases\n- Normal vital signs and physical examination\n\nClinical trial inclusion criteria:\n- Signed patient consent form (Not mentioned, but assumed that the patient can provide consent)\n- Genotype 1 chronic HCV with detectable HCV RNA (Not mentioned if the patient has genotype 1 HCV)\n- No previous treatment for HCV infection (The patient is currently on treatment for HCV)\n- Hepatitis B and human immunodeficiency virus negative at screening visit (The patient is coinfected with HBV)\n- Able and willing to follow contraception requirements (Not mentioned, but the patient's gender and age make it less relevant)\n- Screening laboratory values, test, and physical exam within acceptable ranges (Assumed to be true based on the patient note)\n- Weight between 40 kg and 125 kg (BMI is 27, which does not exclude the patient based on weight alone)\n- Proficiency in the use of the external pump infusion system (Not mentioned but could potentially be trained)\n\nThe patient does not meet several key inclusion criteria for the clinical trial, specifically:\n- The patient has already received treatment for HCV, which excludes him since the trial requires no previous treatment for HCV infection.\n- The patient is coinfected with HBV, whereas the trial requires hepatitis B to be negative at the screening visit.\n\nTherefore, the patient is excluded from the clinical trial based on these criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1555": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests\n- No evidence of hepatocellular carcinoma\n- Chronic inflammation compatible with chronic viral hepatitis\n- Normal vital signs and physical examination\n\nClinical Trial Inclusion Criteria:\n- Serologic evidence of HCV infection by an anti-HCV antibody test\n- Serum HCV RNA quantifiable > 20,000 copies/mL at screening period\n- Demonstrate abnormal ALT > 40 for 6 months\n- No clinical suspicion or radiological evidence of hepatocellular carcinoma\n- Serum AFP < 50 ng/mL\n- Negative urine pregnancy test for women of childbearing potential documented within the 24-hour period prior to the first dose of test drug\n\nThe patient's note confirms:\n- Serologic evidence of HCV infection (patient has a positive enzyme immunoassay for anti-HCV-antibodies)\n- No clinical suspicion or radiological evidence of hepatocellular carcinoma (recent biopsy was negative for hepatocellular carcinoma)\n- No specific mention of the patient's serum HCV RNA levels or ALT levels\n\nThe patient note does not provide specific information regarding the serum HCV RNA levels or the ALT values over the past 6 months. These are required to determine eligibility based on the trial's inclusion criteria. Therefore, there is not enough information to definitively establish the patient's eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1556": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis,\" we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial. \n\nBased on the patient note, here are the points to consider:\n\n1. The patient is a 55-year-old man, meeting the age criterion of being over 18 years old.\n2. The patient has been diagnosed with HCV and a recent coinfection with HBV, which align with the focus on hepatitis in the trial.\n3. The patient is currently on IFN, RBV, and direct antiviral drugs, which do not exclude him from the trial based on the information provided.\n4. The patient has a history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n5. The recent biopsy did not show hepatocellular carcinoma and was negative for other liver diseases that could exclude him.\n6. The patient's liver disease is consistent with chronic viral hepatitis, fulfilling the biopsy criterion.\n7. There is no mention of a serum ALT level or whether it is elevated within the specified range.\n8. There is no information regarding a liver imaging investigation to rule out hepatic carcinoma in the case of cirrhosis, but the biopsy noted chronic inflammation without cirrhosis.\n9. There is no information on the patient's creatinine clearance.\n10. The patient is not female, so the pregnancy test criterion is not applicable.\n11. There is no information on the patient's use of contraception, which could be advised if necessary.\n\nBased on the provided patient note and the inclusion criteria, the patient meets several of the requirements, such as age and positive HBsAg. However, there are some gaps in the information provided, particularly regarding the elevated serum ALT levels, creatinine clearance, and the results of liver imaging. Since the patient's eligibility cannot be confirmed without this information, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1557": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive,\" we need to compare the patient's characteristics and medical history to the inclusion criteria of the study.\n\nThe inclusion criteria are as follows:\n1. Males or females, 18 to 55 years of age who are diagnosed with HCV by PCR.\n2. HCV treatment-na\u00efve patients who have already committed to undergo standard of care therapy (SOC) for HCV (pegylated interferon and ribavirin), and who wish to participate in a study immediately prior to the initiation of SOC.\n3. Chronic hepatitis C infection, genotype 1 or genotype 2, two documented tests (PCR or HCV Ab; if one of the tests is HCV Ab, then the second test must be PCR and the PCR test must be at least 6 months after the HCV Ab test) at least 6 months apart.\n4. Liver biopsy within the last two (2) years.\n5. Positive viral load of <1,000,000 IU/mL as measured by quantitative PCR.\n6. Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality and a QT/QTc interval <450 milliseconds.\n7. Willing and able to comply with study procedures and provide written informed consent.\n\nBased on the patient note provided:\n- The patient is a 55-year-old man, which fits the age criterion.\n- He was diagnosed with HCV 2 years ago, which indicates a chronic HCV infection.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, which means he is not treatment-na\u00efve and has already started treatment for HCV.\n- The patient\u2019s medical records show previous positive HCV RNA tests, but there is no information on the genotype of the HCV.\n- There is no mention of a recent liver biopsy within the last two years.\n- There is no information on the viral load (it must be <1,000,000 IU/mL).\n- There is no information provided about an ECG test or the QT/QTc interval.\n\nThe patient does not meet the following key inclusion criteria:\n- HCV treatment-na\u00efve status.\n- Documentation of the HCV genotype and the timing of the tests.\n\nDue to these factors, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1558": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Investigation of Hepatitis B and Hepatitis C in Taiwan,\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 55-year-old man, which means he was born before 1985/01/01.\n- The patient has been diagnosed with HCV 2 years ago and has a recent coinfection with HBV.\n\nClinical Trial Inclusion Criteria:\n- Born before 1985/01/01\n- HBV or HCV carriers\n\nThe patient meets both of the inclusion criteria for the clinical trial: he was born before 1985/01/01, and he is a carrier of both HBV and HCV.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1559": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Characteristics:\n- 55-year-old male\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- Treatment: IFN, RBV, and direct antiviral drugs for 6 months\n- Past medical history is non-significant\n- No other medications\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma, showing chronic inflammation\n- No evidence of other liver diseases\n- Vital signs: BP 130/75, HR 90/min, BMI: 27\n- No acute distress, no ascites, no edema\n\nClinical Trial Inclusion Criteria:\n- Willing to consent to data collection\n- Able and willing to give written informed consent and HIPAA authorization, and to comply with the registry protocol\n- Anti-HCV antibody-positive\n- HCV RNA concentration >100,000 IU/mL on RT-PCR assay at baseline or >90 days before the baseline visit\n- Deemed appropriate for treatment with Infergen and other prescribed medications\n- Baseline CD4 count >200 cells/mm3 (for HIV-HCV coinfected patients)\n- For women: specific criteria regarding reproductive status and pregnancy\n- For men: must agree to use 2 forms of effective contraception during the registry and for 6 months after receiving the final dose of study drug\n- Age >18 years\n\nAssessment:\n- The patient is over 18 years old.\n- The patient is anti-HCV antibody-positive.\n- The patient has been receiving treatment for HCV, which suggests they are deemed appropriate for such treatment.\n\nHowever, the patient's HCV RNA concentration is not specified in the provided note, which is required for the trial inclusion. Also, we do not have information on whether the patient is willing to consent to data collection or comply with the registry protocol. Without these pieces of information, we cannot confirm the patient's eligibility for the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1560": {
        "output": "Based on the provided patient note and the clinical trial information, we can assess the patient's eligibility for the clinical trial:\n\nThe clinical trial is investigating the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) alpha-2b plus ribavirin (RBV) specifically in Japanese patients with hepatitis C virus (HCV) infection. The inclusion criteria for the trial are:\n- Japanese patients aged 18 years or older\n- Treated with PEG-IFN alpha-2b plus RBV\n- Positive for both antibody to HCV and HCV-RNA for over six months\n\nThe patient note indicates:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago with recent coinfection with HBV.\n- His past medical history is non-significant.\n- He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient has a history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n\nHowever, the patient's nationality is not specified, and the trial specifically requires Japanese patients. This is a crucial piece of information that is missing, and without it, we cannot determine if the patient meets the geographic and ethnic inclusion criteria of the trial.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial, as we cannot confirm if he is Japanese which is a specific requirement for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1561": {
        "output": "Based on the provided patient note and the clinical trial information, the patient appears to meet some of the specified inclusion criteria for the clinical trial. The patient is a 55-year-old man diagnosed with HCV and is currently on treatment with IFN, RBV, and direct antiviral drugs. There is no mention of the patient's ethnicity, which is a significant factor for this trial, as it is looking for subjects of First Nations, Metis, and Caucasian ethnicity.\n\nSince the patient's ethnicity is not stated in the patient note, there is insufficient information to declare the patient eligible or excluded from the trial. Therefore, the patient is considered \"not relevant\" for the trial due to the lack of information regarding his ethnicity, which is a key inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1562": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the inclusion criteria for the clinical trial focused on Alcohol Use Reduction in Methadone Individuals with Hepatitis C Virus (HCV). \n\nThe inclusion criteria for the trial are:\n- Age 18 - 55 years\n- Enrolled at the participating methadone maintenance clinic for the past 2 months\n- Moderate to heavy alcohol users within the last 3 months\n\nThe patient is 55 years old, which fits within the age range. However, there is no information provided that suggests the patient is enrolled in a methadone maintenance clinic. Additionally, there is no mention of alcohol use, let alone moderate to heavy alcohol consumption within the last 3 months. Therefore, due to the lack of information on these critical points, we cannot establish the patient's eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1563": {
        "output": "",
        "label": 2
    },
    "1564": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics with the inclusion criteria listed for the trial.\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent co-infection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other listed liver diseases\n- BP: 130/75, HR: 90/min, and BMI: 27\n- No mention of HBV DNA levels or Serum ALT levels\n\nClinical trial inclusion criteria:\n- Male and female patients > 18 and \u2264 70 years of age\n- Positive HBsAg for more than 6 months\n- Negative for HBeAg for more than 6 months\n- HBV DNA < 2.0 E04 IU/mL\n- Serum ALT < 5 * ULN as determined by two values taken >14 days apart during the six months before the first dose of study drug with at least one of the determinations obtained during the screening period\n- Negative urine or serum pregnancy test (not applicable to this male patient)\n\nAssessment:\n- The patient is within the age range (> 18 and \u2264 70 years).\n- The patient has had a positive HBsAg for more than 6 months.\n- The patient's HBeAg status is not mentioned, but he has been diagnosed with HBV recently, which suggests that he may have been tested for HBeAg.\n- The level of HBV DNA is not provided.\n- Serum ALT level is not provided.\n\nSince the patient's HBV DNA levels and Serum ALT levels are not given, we cannot conclusively determine if he meets all the inclusion criteria. Without this information, we cannot say for sure if the patient is eligible or not for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1565": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- Positive HCV RNA tests and positive for anti-HCV antibodies.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of HCV genotype or viral load.\n\nClinical Trial Inclusion Criteria:\n- Treatment na\u00efve.\n- Age 18 and older.\n- Anti-HCV positive > 6 months.\n- Detectable serum quantitative HCV-RNA with HCV RNA > 800,000 IU/mL.\n- HCV genotype 1.\n- A liver biopsy consistent with the diagnosis of chronic hepatitis C.\n\nAssessment:\n- The patient is over 18 years old.\n- The patient has been diagnosed with HCV for over 6 months and has positive anti-HCV antibodies.\n- There is no mention of the patient's viral load or whether the HCV is genotype 1, which are both necessary to meet the inclusion criteria.\n- The patient is not treatment na\u00efve; he is already on IFN, RBV, and direct antiviral drugs.\n\nThe patient does not meet the \"treatment na\u00efve\" criterion and we lack information about HCV genotype and viral load. Therefore, based on the available information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1566": {
        "output": "Based on the patient note, the patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies, which matches the inclusion criteria of the clinical trial that requires HCV patients with both positive for anti-HCV and HCV RNA. The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, indicating ongoing treatment for HCV. There is no mention of the patient not providing informed consent or being unable to do so.\n\nGiven this information, the patient appears to meet the inclusion criteria for the clinical trial on the Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test, as he is positive for anti-HCV and HCV RNA. There is no mention of exclusion criteria in the clinical trial details provided, so we cannot assume any exclusion criteria that might apply to this patient. \n\nTherefore, based on the information available, the patient seems to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1567": {
        "output": "Based on the given patient note and the clinical trial information provided, the patient appears to be eligible for the clinical trial:\n\n- The patient is a 55-year-old man, which meets the gender requirement of the trial targeting male participants.\n- He has been diagnosed with HCV 2 years ago and is currently being treated, which indicates a clinical diagnosis of chronic HCV infection.\n- His baseline health is stable, as evidenced by his alertness and lack of acute distress, normal blood pressure, heart rate, and the absence of any significant medical conditions mentioned in the note. There is also no mention of other liver diseases such as alcoholic liver disease, hemochromatosis, autoimmune hepatitis, or metabolic liver disease, which could potentially complicate his condition.\n\nThe clinical trial's inclusion criteria are:\n1. Baseline health is stable.\n2. Has a clinical diagnosis of chronic HCV infection.\n\nThe patient meets both of these criteria. There are no additional exclusion criteria provided in the trial summary that could potentially exclude the patient.\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1568": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nHere is the patient's information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of hepatocellular carcinoma (HCC)\n- No mention of liver cancer or lesions amenable to embolization\n- The liver biopsy was negative for hepatocellular carcinoma\n\nNow, let's review the clinical trial's inclusion criteria:\n- Diagnosis of hepatocellular carcinoma (HCC) with specific diagnostic criteria\n- Locally advanced disease not eligible for resection or transplantation, or refusal of such procedures\n- Measurable disease by specific criteria\n- Childs-Pugh score \u2264 7\n- No complete thrombosis of the main portal vein and no evidence of extrahepatic/metastatic disease\n- Certain blood count and chemistry levels\n- No other cancer within the past 3 years except for specified exemptions\n- No significant cardiovascular events or conditions\n- No significant bleeding events or conditions\n- No significant proteinuria\n- No HIV positivity\n- No active hepatitis B or C unless on stable medication for \u2265 2 months\n- No prior systemic therapy, embolic therapy, or radiotherapy for HCC\n- Additional conditions regarding prior treatments and health status\n\nBased on the patient's information, he does not meet the primary inclusion criterion of having been diagnosed with hepatocellular carcinoma (HCC). The trial specifically targets patients with liver cancer that cannot be removed by surgery, while this patient has been diagnosed with HCV and HBV infections but not with HCC.\n\nTherefore, the patient does not meet the inclusion criteria for the trial and is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1569": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial \"Human Anaplasmosis in Eastern France,\" we can assess the patient's eligibility for the trial.\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for HCV\n- Negative for hepatocellular carcinoma\n- No evidence of other liver diseases\n- Normal blood pressure, heart rate, and no signs of edema\n\nClinical trial inclusion criteria summary:\n- Patient with at least one of the following symptoms after a tick bite: fever, muscular pain, articular pain, respiratory signs, neurological signs, meningitis, erythema\n- Or patient with fever and one of the following: thrombocytopenia, leucopenia, hepatitis, without any other cause that can explain these abnormalities\n- Or patient with tick-borne encephalitis, or primary stage Lyme borreliosis\n\nThe patient does not have symptoms consistent with anaplasmosis, as there is no mention of a tick bite or the specific symptoms listed in the inclusion criteria. The hepatitis mentioned is related to HCV and HBV coinfection and not an unidentified cause. Therefore, the patient does not meet the inclusion criteria for the clinical trial on Anaplasmosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1570": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided patient note and the inclusion/exclusion criteria of the trial.\n\n**Patient Note Analysis:**\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No significant past medical history.\n- Currently on IFN, RBV, and direct antiviral drugs for HCV for the past 6 months.\n- No hepatocellular carcinoma (HCC) present on biopsy.\n- No evidence of other liver diseases.\n- No acute distress; normal blood pressure and heart rate; no abdominal ascites or tenderness; no lower extremity edema.\n\n**Clinical Trial Criteria Analysis:**\n\n*HCC Patient Criteria of Inclusion:*\n- The patient does not have hepatocellular carcinoma, so these criteria are not applicable.\n\n*Chronic Hepatitis B Patient Criteria of Inclusion:*\n- The patient has been carrying HBsAg for over 6 months (recent coinfection with HBV).\n- ALT levels and HBV-DNA levels are not mentioned in the patient note.\n- The patient's general condition is not described as average/good explicitly, but there is no acute distress mentioned.\n\n*Chronic Hepatitis B Patient Criteria of Exclusion:*\n- There is no information suggesting that the patient has used immunotherapy or corticotherapy for 6 months.\n- The patient is male, so pregnancy is not applicable.\n\n**Conclusion:**\nThe patient note does not provide enough information to determine if the patient meets all the inclusion criteria for chronic hepatitis B, specifically ALT and HBV-DNA levels. However, since the patient does not have hepatocellular carcinoma, they would not qualify for that part of the trial. Since the patient has HBV and is on treatment, and there is no explicit information about exclusion, we cannot definitively exclude the patient on the provided data. Therefore, based on the available information, the patient falls under the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1571": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other specified liver diseases\n- Normal vital signs and physical examination\n\nClinical Trial Inclusion Criteria:\n- Signed and dated informed consent prior to participation\n- Subjects in good health as determined by the Investigator\n- Age 18-55\n- Willing to abstain from any physical therapy, hard physical work, exercise, or sauna during the study observation period\n- For females, specific birth control requirements (not applicable to this male patient)\n\nAssessment:\n- The patient is within the required age range (18-55 years).\n- The patient is a male, so the birth control requirements do not apply.\n- There is no mention of the patient's overall health status being compromised apart from the chronic viral hepatitis, so it's not clear if the investigator would deem the patient in \"good health.\"\n- The patient is not described as undergoing physical therapy, hard physical work, or exercise that would conflict with the study's requirements. However, willingness to abstain from these activities during the observation period is not explicitly stated.\n- The patient does not have muscle pain induced by eccentric exercise, which is the condition being studied.\n\nBased on the information provided, the patient does not appear to have the specific condition (muscle pain of the calf caused by eccentric contractions) that the clinical trial is investigating. Therefore, we cannot confirm that the patient meets all the inclusion criteria for the clinical trial, particularly regarding the health status as determined by the investigator and the specific condition being treated.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1572": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, we can determine the following:\n\nThe patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) infection 2 years ago and a recent coinfection with hepatitis B virus (HBV). The patient's medical history seems non-significant aside from these infections. He is currently on a treatment regimen including interferon (IFN), ribavirin (RBV), and direct antiviral drugs. There is no mention of HIV-1 infection, liver failure, liver transplant, or any of the other specific conditions mentioned in the inclusion criteria for the trial.\n\nThe clinical trial is looking for participants who have:\n- Age \u2265 18 (the patient is 55, so this criterion is met)\n- Documented HIV-1 infection (the patient's record does not mention HIV-1 infection)\n- Plasma viral load at screening visit below 50 copies per mL for at least 6 months (not applicable, as HIV-1 infection is not documented)\n- Patient with severe liver failure or eligible for the liver transplant waiting list or immediate post-transplantation (the patient does not appear to have severe liver failure, as indicated by the negative biopsy for hepatocellular carcinoma and the absence of symptoms like ascites, encephalopathy, or digestive tract hemorrhage)\n- Abstinence from alcohol intake for at least 6 months (no information provided)\n- Withdrawal from intravenous drug use for at least 6 months (no information provided)\n- No ongoing class C opportunistic infection (no information provided)\n- Patient whose clinical and immunovirological condition allows triple therapy with raltegravir + 2 NRTI or raltegravir + NRTI + enfuvirtide (not relevant as HIV-1 infection is not mentioned)\n- Patient whose HIV population is sensitive to at least two fully active antiretroviral agents (not relevant as HIV-1 infection is not mentioned)\n- Patient not having experienced viral escape during treatment with certain antiretrovirals (not relevant as HIV-1 infection is not mentioned)\n- Patient registered with or covered by a social security scheme (no information provided)\n- For women of child-bearing potential, negative pregnancy test (not relevant as the patient is male)\n- Informed consent form signed at screening visit (not relevant for eligibility determination from patient note)\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not have documented HIV-1 infection, which is a key criterion for the trial. Additionally, there is no indication that the patient has severe liver failure or is a liver transplant recipient, which are also requirements for the trial. Therefore, the patient does not meet sufficient inclusion criteria to be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1573": {
        "output": "Based on the provided patient note, the patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus). His medical history is non-significant, which implies no other known comorbidities or medical conditions are mentioned. He is currently on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n\nThe clinical trial in question is looking to assess vaccine responses to novel adjuvanted influenza A(H1N1) vaccines in patients at high risks of influenza A(H1N1) complications. The inclusion criteria for the trial are simply that the patients must have a medical recommendation for influenza A(H1N1) immunization and must have signed informed consent.\n\nThe patient's note does not mention any specifics about being at high risk for influenza A(H1N1) complications nor does it mention if he has been medically recommended for influenza A(H1N1) immunization. The information provided is insufficient to determine whether the patient has been recommended for the influenza A(H1N1) immunization, which is a key inclusion criterion for the trial. Therefore, based on the information available, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1574": {
        "output": "",
        "label": 0
    },
    "1575": {
        "output": "The patient described in the note is a 55-year-old man diagnosed with hepatitis C virus (HCV) infection 2 years prior and a recent coinfection with hepatitis B virus (HBV). He is currently on treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs. There is no mention of any psychotic disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder not otherwise specified (NOS).\n\nThe clinical trial in question is focused on the efficacy and safety of aripiprazole in patients with first episode psychosis. The inclusion criteria specify that participants must be aged 18-59 years and meet DSM-IV diagnostic criteria for first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS.\n\nAs there is no information in the patient's medical history suggesting a diagnosis of any psychotic disorders, the patient does not meet the inclusion criteria for the clinical trial on aripiprazole for first episode psychosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1576": {
        "output": "The patient in the note provided is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He has been on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's medical history does not mention melanoma, metastatic or otherwise, and there is no indication of any treatment or diagnosis related to melanoma.\n\nThe clinical trial in question is focused on patients with locally advanced or metastatic melanoma that is surgically incurable and who have not had prior systemic cytotoxic chemotherapy for melanoma. The patient must meet specific disease characteristics, prior/concurrent therapy restrictions, and have certain patient characteristics, including life expectancy, performance status, and organ function criteria.\n\nThe patient described in the note does not have melanoma, let alone metastatic melanoma, which is the primary disease of interest for the clinical trial. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which focuses on metastatic melanoma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1577": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. He is on IFN, RBV, and direct antiviral drugs for the past 6 months. His medical records show no evidence of hepatocellular carcinoma or other liver diseases, and he is in no acute distress.\n\nThe clinical trial in question is looking for male or female participants between 18 and 50 years of age, in general good health without significant medical illness, abnormal physical examination findings, or clinical laboratory abnormalities. The trial is focused on developing a model of infection with Campylobacter jejuni and characterizing immune responses.\n\nThe patient in question does not meet the inclusion criteria for age as he is 55 years old, and the trial requires participants to be between 18 and 50 years of age. Therefore, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1578": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can analyze the patient's eligibility as follows:\n\n1. The patient is a 55-year-old man, which satisfies the age criterion (age \u2265 18 years).\n2. The patient was diagnosed with HCV 2 years ago and has a recent coinfection with HBV, which is relevant to the study's focus on chronic HCV patients.\n3. The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months, indicating that he is not na\u00efve to treatment, which is contrary to the trial's requirement for treatment-na\u00efve patients.\n4. The patient has no history of ascites, jaundice, hepatic encephalopathy, or bleeding from esophageal or gastric varices requiring beta-blockers. This aligns with the trial's criteria.\n5. The recent biopsy shows no evidence of hepatic cirrhosis, which is consistent with the trial's exclusion of patients with histological evidence of hepatic cirrhosis.\n6. The patient's co-infection with HBV (hepatitis B virus) disqualifies him due to the trial's exclusion of patients with HIV or HBV co-infection.\n7. There is no information about intravenous (IV) drug or alcohol abuse.\n8. No information on the patient's laboratory parameters, TSH levels, ECG, or eye fundus examination is provided.\n9. The patient's gender and the requirement for birth control are not relevant as he is male.\n\nThe key disqualifying factor is that the patient is not treatment-na\u00efve as required by the trial, and he also has a co-infection with HBV, which is explicitly stated as an exclusion criterion in the trial. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1579": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with chronic hepatitis C (HCV) 2 years ago\n- Recent coinfection with hepatitis B virus (HBV)\n- On treatment with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma or other liver diseases specified in the note\n- No acute distress and stable vital signs\n\nClinical trial inclusion criteria:\n- Proven chronic hepatitis C\n- Aged between 18 and 65\n- Willingness to give written informed consent to the study protocol\n\nThe patient's note indicates that he has chronic hepatitis C and is within the age range specified by the clinical trial (55 years old). The patient is currently under treatment, which does not disqualify him based on the information given. The patient's willingness to give written informed consent is not mentioned in the note, but this is typically confirmed during the recruitment process for the trial.\n\nTherefore, assuming the patient is willing to give informed consent, he meets the inclusion criteria for the clinical trial:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1580": {
        "output": "The patient in question is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He is currently on IFN, RBV, and direct antiviral drugs.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Subject giving his written informed consent\n2. Male from 20 to 35 years old and more than 60\n3. Affiliated to the French National Health Insurance\n4. Body mass index (BMI) \u2264 25kg/m\u00b2 and waist circumference \u226494cm; or BMI \u2265 28kg/m\u00b2 and waist circumference \u2265 102cm.\n5. Complete blood count (CBC)-platelet, normal liver function and normal coagulation.\n6. Serology of Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) negative\n7. Normal Thyroid Stimulating Hormone (TSH)\n\nThe patient's age (55 years old) does not fall within the age range specified in the inclusion criteria (20 to 35 years old and more than 60). Additionally, the patient's medical records show a positive HCV RNA test and a positive enzyme immunoassay for anti-HCV antibodies, which contradicts the inclusion criterion requiring a negative serology for HCV.\n\nBased on the information provided, the patient does not meet the age requirement and has a positive HCV status, which disqualifies him from the clinical trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1581": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria provided for the clinical trial step by step, comparing them to the patient's information from the note:\n\n1. Chronic hepatitis C virus (HCV), genotype 1 infection (HCV ribonucleic acid level greater than or equal to 100,000 IU/mL) at screening:\n   - The patient has been diagnosed with HCV, but the genotype is not specified, and there is no information about the HCV RNA level.\n\n2. Liver biopsy within 3 years with histology consistent with HCV-induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV:\n   - The patient's recent biopsy was negative for hepatocellular carcinoma and indicated chronic inflammation compatible with chronic viral hepatitis, which is consistent with HCV-induced liver damage.\n\n3. Treatment na\u00efve male or female between the ages of 18 and 65:\n   - The patient is a 55-year-old man, which fits the age criteria. However, he is not treatment-na\u00efve as he is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\n4. Females must be post-menopausal for more than 2 years or surgically sterile:\n   - This criterion is not applicable to the patient as he is male.\n\n5. Negative screen for drugs and alcohol:\n   - There is no evidence of alcoholic liver disease, but there is no specific information about a recent negative screen for drugs and alcohol.\n\n6. Negative hepatitis B surface antigen (HBsAg) and anti-human immunodeficiency virus antibodies (anti-HIV Ab):\n   - The patient has a recent coinfection with HBV, which means he would test positive for HBsAg, thus not meeting this criterion.\n\n7. No use of cytochrome P450 3A (CYP3A) and cytochrome P450 2C8 (CYP2C8) enzyme inducers or inhibitors within 1 month of dosing:\n   - There is no information about the use of such inducers or inhibitors, but as the patient is on antiviral medication, it's possible that these could interact with CYP3A or CYP2C8 enzymes.\n\n8. Be in a condition of general good health, as perceived by the investigator, other than HCV infection:\n   - The patient appears to be in general good health with no acute distress.\n\nBased on the information provided, the patient does not meet several key inclusion criteria: the patient is not treatment-na\u00efve, has a recent coinfection with HBV (positive HBsAg expected), and there is insufficient information about the HCV genotype or RNA levels, and drug and alcohol screening.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1582": {
        "output": "Upon reviewing the patient's note and the clinical trial information provided, here are the key points to consider when determining the patient's eligibility for the trial:\n\nPatient Information:\n- 55-year-old man (meets age criterion)\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV (this could be important as the trial excludes HBV coinfection)\n- On treatment for HCV (IFN, RBV, and direct antiviral drugs)\n- No mention of liver transplantation or the need for one\n- No mention of renal failure or HIV infection\n\nClinical Trial Information:\n- Title: \"A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation\"\n- The trial is looking to prevent HCV recurrence after orthotopic liver transplantation.\n- Inclusion criteria include adults aged 18-75 with HCV infection identified by positive, quantifiable HCV RNA prior to transplant.\n- Patients must be first-time liver transplant recipients.\n- Excludes patients with a history of renal failure or HIV/HBV co-infection.\n\nIn this case, the patient does not meet the key inclusion criterion of being a liver transplant recipient. Additionally, the patient has a recent coinfection with HBV, which would likely exclude them from the trial since patients with HBV co-infection are not eligible. Therefore, the patient is not relevant for this clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1583": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the assessment can be made as follows:\n\nThe clinical trial is focused on the influence of a specific gene polymorphism in patients with alcoholic liver disease (ALD). The inclusion criteria for this trial are:\n- Excess alcohol intake\n- Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) or suspicion of cirrhosis related to ALD\n- Caucasian ethnicity\n\nThe patient in question is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His medical history does not indicate excess alcohol intake or the presence of alcoholic liver disease. Additionally, there is no mention of the patient's ethnicity or abnormal ALT and AST values related to ALD. The recent biopsy was negative for hepatocellular carcinoma and noted chronic inflammation compatible with chronic viral hepatitis, but there is no mention of ALD or cirrhosis related to ALD.\n\nGiven that the patient's condition does not meet the inclusion criteria for the clinical trial which specifically targets ALD patients with a certain genetic polymorphism and there is no information suggesting excess alcohol intake or ALD-related abnormalities, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1584": {
        "output": "Given that the patient in the note has been diagnosed with hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV), and there is no mention of alcoholic liver disease (ALD) or excessive alcohol intake, the patient does not meet the inclusion criteria for the given clinical trial, which specifically targets ALD patients with a history of excess alcohol intake and abnormalities on liver biopsy compatible with alcoholic etiology.\n\nSince the patient has chronic viral hepatitis and there is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease, and the trial is specifically about alcoholic liver diseases, the patient does not have sufficient information to qualify for the trial based on the provided inclusion criteria. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1585": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial titled \"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection.\"\n\nPatient Note Summary:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No significant past medical history.\n- Currently on IFN, RBV, and direct antiviral drugs for HCV for the past 6 months.\n- No other medications.\n- Previous positive HCV RNA tests and positive for anti-HCV antibodies.\n- Biopsy negative for hepatocellular carcinoma; findings compatible with chronic viral hepatitis.\n- No evidence of other liver diseases.\n- Vital signs within normal ranges and no symptoms of liver decompensation or failure.\n\nClinical Trial Inclusion Criteria:\n- HIV infected patients.\n- Age >18 years.\n- Meet Vietnam guideline to begin ART (CD4 count < 350 cells/mm3 and/or WHO stage III or IV disease).\n- Hepatitis C infection documented by positive HCV antibodies and a detectable serum HCV RNA level.\n- AST and ALT \u2264 2 x ULN (\u2264 80 U/L).\n- Estimated creatinine clearance \u2265 60 mL/min.\n\nEligibility Assessment:\n- The patient is over 18 years old.\n- The patient has a documented Hepatitis C infection.\n- There is no information provided regarding HIV infection status, CD4 count, or WHO stage of disease.\n- There is no information provided about the patient's AST and ALT levels or estimated creatinine clearance.\n\nGiven the information provided, we cannot confirm the patient's HIV status or whether the patient meets the specific Vietnam guideline for ART initiation (CD4 count or WHO stage). Additionally, we lack the patient's liver enzyme levels (AST and ALT) and kidney function (estimated creatinine clearance), which are required to meet the trial's inclusion criteria.\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial as the patient's HIV status and other relevant clinical measures are not disclosed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1586": {
        "output": "Based on the information provided, the patient in question is a 55-year-old man diagnosed with chronic viral hepatitis (HCV and recent HBV coinfection). The clinical trial we are evaluating is focused on patients with osteoarthritis of the knee and the efficacy of PF-04191834 as a treatment for pain and inflammation associated with that condition.\n\nThe inclusion criteria for the trial are:\n1. Subjects must have a diagnosis of osteoarthritis based on the American College of Rheumatology criteria confirmed by an X-ray.\n2. Subjects must be willing and able to stop all current pain therapy for the duration of the study.\n3. Subjects must be willing and able to complete a daily diary.\n\nThe patient's note does not mention a diagnosis of osteoarthritis, nor does it discuss any issues related to the knee. The patient's medical concerns are focused on his liver conditions (HCV and HBV) and there is no indication that he meets the specific inclusion criteria for the clinical trial in question.\n\nTherefore, based on the lack of relevant information connecting the patient's condition to the inclusion criteria of the clinical trial, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1587": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 55 years old\n- Diagnosis: HCV (Hepatitis C Virus) for 2 years, recent coinfection with HBV (Hepatitis B Virus)\n- Treatment: On IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months\n- BMI: 27\n- Other medical history: Non-significant, no hepatocellular carcinoma, no evidence of other liver diseases\n\nClinical Trial Inclusion Criteria:\n1. Infection with HCV genotype 1 or 4\n2. BMI greater than 25 Kg/m^2\n3. HCV-infected subjects na\u00efve to treatment or those who were treated more than 3 months prior to enrollment for not longer than 2 weeks\n4. Plasma HCV RNA concentration of >10,000 IU/mL at the screening evaluation\n\nComparison:\n- The patient's BMI of 27 meets the criterion of having a BMI greater than 25 Kg/m^2.\n- The patient is currently under treatment for HCV, which does not meet the criterion of being treatment-na\u00efve or having been treated more than 3 months prior to enrollment for not longer than 2 weeks.\n- There is no information provided about the HCV genotype of the patient, which is a necessary criterion to determine eligibility.\n- The patient's medical records show previous positive HCV RNA tests, but the specific plasma HCV RNA concentration at the screening evaluation is not provided.\n\nGiven the available information, we cannot confirm that the patient meets all the essential inclusion criteria, particularly regarding the HCV genotype and the current status of HCV RNA concentration. Moreover, the patient does not meet the treatment criteria as he is currently under treatment for HCV.\n\nTherefore, the patient does not have sufficient information to qualify for the trial, and based on the information provided about the ongoing treatment, the patient would likely not be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1588": {
        "output": "Based on the information provided:\n\nPatient note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HCV genotype.\n- No mention of low HDL levels.\n\nClinical trial:\n- Title: Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?\n- Chronic HCV genotype 1 naive patients.\n\nIn order to be eligible for the clinical trial, the patient must have chronic HCV genotype 1 and be naive to treatment. The patient note does not specify the HCV genotype, nor does it mention HDL levels or whether the patient is treatment-naive (they are currently undergoing treatment). Therefore, there is not enough information to determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1589": {
        "output": "For the clinical trial titled \"Epidemiological Study in Children and Adolescents With Chronic Hepatitis B,\" the inclusion criteria are as follows:\n\n1. Male or female, 2 to less than 18 years of age.\n2. Documented chronic hepatitis B defined by all of the following:\n   - Clinical history compatible with chronic hepatitis B\n   - Detectable serum HBsAg at the time of the study and at least one other documentation of HBsAg positive at least 6 months prior to inclusion\n   - HBeAg-positive or HBeAg-negative\n   - Serum ALT of all levels\n3. Subject or subject's parent or legal guardian must be willing and able to provide written informed consent for participation in the study.\n\nThe exclusion criteria state:\n\n1. Patients \u2265 18 years of age\n2. Other protocol-defined inclusion/exclusion criteria may apply\n\nThe patient note describes a 55-year-old man diagnosed with HCV and recent coinfection with HBV. The patient does not meet the age criterion as he is older than 18 years. Therefore, based on the age criterion alone, the patient is not eligible to participate in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1590": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, we can assess the patient's eligibility as follows:\n\n- The patient is chronically infected with hepatitis C virus (HCV), as indicated by a diagnosis 2 years ago and the presence of positive HCV RNA tests and anti-HCV antibodies.\n- The patient is currently on a treatment regimen that includes IFN (Interferon), RBV (Ribavirin), and direct-acting antiviral drugs.\n- There is no mention of the patient's specific HCV genotype, which is required to be genotype 1 according to the trial criteria.\n- There is no indication that the patient is a non-responder to prior therapy with peginterferon alfa and ribavirin, which is a specific requirement for the trial.\n- The patient's HCV RNA viral load is not mentioned, so we cannot confirm if it meets the required level of 100,000 IU/mL.\n- Results of a liver biopsy are consistent with chronic HCV infection, but the timing of the biopsy is not specified, and it needs to be \u2264 24 months prior to randomization (except for compensated cirrhotics).\n- There is no mention of ultrasound, CT scan, or MRI results to confirm the absence of hepatocellular carcinoma within 12 months prior to randomization.\n- The patient's Body Mass Index (BMI) is 27, which falls within the required range of 18 to 35 kg/m2.\n\nGiven that several key pieces of information are missing or do not meet the inclusion criteria (specifically, HCV genotype and non-responder status), the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1591": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria provided for the trial.\n\nHere are the inclusion criteria for the trial:\n1. Males and females, aged 18 years and older\n2. Chronic hepatitis C genotype 1 (as specified in the protocol)\n3. Treatment naive\n4. For females, specific requirements regarding pregnancy and contraception; for males, agreement to use contraception and not donate sperm\n\nNow let's assess the patient's information based on the criteria:\n\n1. The patient is a 55-year-old man, which satisfies the age criterion.\n2. The patient has been diagnosed with HCV (hepatitis C virus), but the genotype is not specified in the patient note provided.\n3. The patient is not treatment naive, as he is currently on IFN (interferon), RBV (ribavirin) and direct antiviral drugs for the past 6 months.\n4. The gender-specific criteria about contraception are met as the patient is male, and there is no indication that he is not willing to comply with the requirement to use a condom.\n\nBased on the information provided, the patient does not meet the inclusion criteria of being treatment naive since he is already undergoing treatment for HCV. Therefore, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1592": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility step by step:\n\n1. Latino ethnicity: The patient note does not mention the patient's ethnicity or cultural heritage. Therefore, we cannot confirm if the patient is of Latino ethnicity as required by the trial.\n\n2. Age greater than or equal to 18 years: The patient is 55 years old, which satisfies this criterion.\n\n3. Documentation of hepatitis C infection: The patient has a positive HCV RNA test and anti-HCV antibodies, which confirms chronic HCV infection.\n\n4. Documentation of HIV-1 infection (for co-infected participants): The patient note does not indicate that the patient is co-infected with HIV, so this criterion is not applicable.\n\n5. Participants with HIV: Since the patient is not indicated to have HIV, this criterion is not applicable.\n\n6. Ability to provide informed consent and willingness to comply with study requirements: The patient note does not specify this, but we usually assume consent and compliance unless otherwise stated.\n\n7. Participants must have a primary care physician managing medical problems: The patient's medical management is not detailed in the note.\n\n8. For HIV infected participants, care provided by a primary physician must be consistent with current DHHS guidelines: Not applicable as the patient is not indicated to have HIV.\n\n9. Willing to undergo genetic testing: The patient note does not mention the patient's willingness to undergo genetic testing.\n\n10. About to start HCV treatment (with or without direct-acting agents DAAs): The patient is already on HCV treatment with IFN, RBV, and direct antiviral drugs for the past 6 months, which does not align with the criterion of about to start treatment.\n\nExclusion Criteria:\n- The patient note does not suggest that any exclusion criteria apply.\n\nGiven the information available, the patient does not meet all the inclusion criteria due to an unspecified ethnicity and not being about to start HCV treatment. Therefore, the patient cannot be considered eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1593": {
        "output": "The patient note provides the following information about the 55-year-old male patient:\n\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma and remarkable for chronic inflammation compatible with chronic viral hepatitis\n- No evidence of decompensated liver disease or other liver diseases\n- Alert and not in acute distress\n- Blood pressure, heart rate, and BMI within a normal or slightly elevated range\n- Abdomen soft with no ascites or tenderness, and lower extremities normal with no edema\n\nNow, let's compare this information to the inclusion criteria of the clinical trial:\n\n1. Be greater than or equal to 18 years old \u2713 (He is 55 years old)\n2. Have documentation of HIV-1 infection by licensed ELISA and confirmed by a Western Blot or HIV RNA of 1,000 copies/mL or greater \u2717 (No mention of HIV infection in the patient note)\n3. Have documentation of chronic HCV (CHC) infection \u2713 (Mentioned as diagnosed with HCV)\n4. Have histopathologic features consistent with CHC at the time of enrollment \u2713 (Biopsy noted chronic inflammation compatible with chronic viral hepatitis)\n5. Are co-infected with HCV genotype 1 and HIV viruses \u2717 (No mention of HIV infection, only HCV and HBV)\n6. Relapsers or non-responders to prior HCV treatment \u2713 (On medication for HCV, but no specific information about non-response or relapse)\n7. Washout period from prior treatment of at least 3 months (Not clearly stated, but he is currently on treatment)\n8. CD(4) cell counts greater than or equal to 100 cells/mm(3) (No information provided)\n9. Various other health and safety conditions (No conflicting information provided)\n10. Not pregnant or breast-feeding \u2713 (He is male)\n11. Willing to abstain from alcohol and drugs, amongst other requirements (No information provided)\n\nBased on the information provided in the patient note, the patient does not meet all of the inclusion criteria for the clinical trial, specifically the requirement for HIV-1 infection and coinfection with HCV genotype 1 and HIV. The trial is specifically targeting individuals with HIV-HCV co-infection who have failed previous treatments. Since there is no mention of HIV infection in the patient's note, he does not qualify for the trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1594": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Ph IIA Study (SOC +/- NS5B),\" we must compare the patient's characteristics to the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Subjects chronically infected with HCV genotype 1 as documented by: positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to Screening, and positive for HCV RNA and anti-HCV antibody at Screening.\n2. HCV RNA \u2265 10*5* IU/mL at Screening.\n3. Less than 4 weeks total prior therapy with an IFN formulation (ie, IFN\u03b1, pegIFN\u03b1-2a), or RBV and no exposure to IFN or RBV within 24 weeks of Randomization.\n4. Results of a biopsy obtained \u2264 24 months prior to Randomization showing no evidence of cirrhosis.\n5. Body Mass Index (BMI) of 18 to 35 kg/m\u00b2, inclusive. BMI = weight (kg)/ [height (m)]\u00b2 at Screening.\n\nNow, let's assess the patient's information against these criteria:\n\n1. The patient has been diagnosed with HCV 2 years ago, which indicates chronic infection. The patient has positive HCV RNA tests and anti-HCV antibodies. However, the genotype of the HCV is not specified in the patient note. We need to know if it is genotype 1 to meet the trial's inclusion criteria.\n2. The patient's HCV RNA level is not provided in the note. Therefore, we cannot confirm if it meets the \u2265 10*5* IU/mL at Screening criterion.\n3. The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months, which exceeds the allowed 4 weeks of prior therapy with IFN or RBV. This means the patient does not meet this inclusion criterion.\n4. The recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation, with no evidence of cirrhosis, which aligns with the trial requirements.\n5. The patient's BMI is 27, which is within the required range of 18 to 35 kg/m\u00b2.\n\nBased on the information given, the patient does not meet the third inclusion criterion because he has been on IFN, RBV, and direct antiviral drugs for the past 6 months, which is well beyond the 4 weeks total prior therapy limit. Additionally, we lack information on the HCV genotype and RNA levels required by the first and second criteria.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1595": {
        "output": "",
        "label": 1
    },
    "1596": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV (Hepatitis C Virus) 2 years ago\n- Recently coinfected with HBV (Hepatitis B Virus)\n- On IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for 6 months\n- Past medical history is non-significant\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the note\n- No mention of knee problems or requirement for knee surgery\n\nClinical Trial:\n- Title: Self Medication With Oral Morphine After Total Knee Arthroplasty\n- Summary: Comparison of post-operative pain management strategies after total knee replacement surgery\n- Inclusion Criteria: Patients requiring total knee replacement surgery willing to provide written, informed consent\n\nThe patient described in the note does not have any indication that they require total knee replacement surgery, which is the primary inclusion criterion for the clinical trial. Therefore, the patient does not meet the inclusion criteria for this specific study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1597": {
        "output": "In reviewing the patient note and the clinical trial criteria, the patient is a 55-year-old man diagnosed with Hepatitis C virus (HCV) and a recent coinfection with Hepatitis B virus (HBV). There is no mention of acute bacterial conjunctivitis, which is the condition being studied in the clinical trial. The patient does not appear to have any signs or symptoms related to conjunctivitis, nor is there any indication that he is seeking treatment for it. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1598": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C (HCV) 2 years ago and recent coinfection with hepatitis B virus (HBV). The patient's past medical history is non-significant, and he is currently on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. There is no evidence of hepatocellular carcinoma or other liver diseases, and the patient does not show signs of advanced liver disease such as ascites or edema.\n\nThe clinical trial is investigating the prognostic value of transient elastography and non-invasive markers of fibrosis in patients with chronic liver diseases. The inclusion criteria for the trial are:\n1. chronic hepatitis C\n2. chronic hepatitis B\n3. alcoholic liver disease\n4. non-alcoholic steatohepatitis\n\nThe patient has chronic hepatitis C and a recent coinfection with hepatitis B, which matches two of the listed diseases in the inclusion criteria of the trial (chronic hepatitis C and chronic hepatitis B).\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial. There are no exclusion criteria provided, so we cannot determine if the patient would be excluded for any reason that is not listed in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1599": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No history of decompensated liver disease or cirrhosis mentioned\n- BMI: 27\n\nClinical Trial Inclusion Criteria:\n- Male or female, between 18 and 65 years of age\n- BMI 18 - 32 kg/m^2\n- Chronically infected with hepatitis C genotype-1 virus\n- Serum HCV RNA > 5 log10 IU/mL\n- No previous treatment with interferon, peginterferon, ribavirin, or any investigational HCV antiviral agents\n- No known history of cirrhosis\n- No co-infection with HBV, HIV-1, HIV-2\n- No history of any medical condition that may interfere with the study\n\nAssessment:\n- The patient's age is within the range required by the trial.\n- The patient's BMI is within the inclusion criteria.\n- The patient is chronically infected with HCV, but the genotype is not specified in the patient note.\n- The patient has been treated with interferon and ribavirin, which is against the trial's criterion of no previous treatment with these drugs.\n- The patient has a recent coinfection with HBV, which is explicitly excluded in the trial criteria.\n\nGiven the information, the patient is not eligible for the trial because he has been treated with interferon and ribavirin and has a coinfection with HBV, both of which are exclusion factors.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1600": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nInclusion Criteria Assessment:\n\n- Males and females between 18 and 70 years old: The patient is a 55-year-old man, which fits the age criterion.\n- Subjects diagnosed to have positive HCV antibodies using a third generation test: The patient has a positive enzyme immunoassay for anti-HCV antibodies, which likely corresponds to a third generation test.\n- Subject is diagnosed to have detectable HCV RNA by PCR: The patient's medical records show previous positive HCV RNA tests.\n- Liver biopsy or FibroTest showing a METAVIR score \u2265F2 and/or \u2265A2: The patient's biopsy was notable for chronic inflammation compatible with a chronic viral hepatitis, but there's no METAVIR score mentioned.\n- Subject diagnosed to have compensated liver disease: The patient shows no evidence of decompensated liver disease, such as ascites, variceal bleeding, or hepatic encephalopathy.\n- Subject is a non-responder (null or partial) on prior Peg-IFN and RBV based treatment lasting for at least 12 consecutive weeks: The patient is currently on IFN, RBV, and direct antiviral drugs. There is no explicit mention of non-response to previous treatment, but the fact that the patient is still on treatment may suggest that he could be a non-responder.\n- Treatment not discontinued due to intolerability to Peg-IFN or RBV: There's no indication that the patient discontinued treatment due to intolerability.\n- Subjects able to comprehend and give informed consent for participation in this study: Not mentioned, but generally assumed unless otherwise stated.\n- Subject is willing to be treated and commit to all visits: Not mentioned, but generally assumed unless otherwise stated.\n\nThe key piece of missing information is whether the patient is indeed a non-responder to previous Peg-IFN and RBV based treatment, which is a critical inclusion criterion for the trial. Additionally, the METAVIR score is not provided, so we cannot confirm the liver disease stage.\n\nDue to the lack of explicit information on the patient's response to previous treatment and the METAVIR score, we cannot conclude that the patient is eligible. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1601": {
        "output": "Given the patient's note and the clinical trial details, we need to assess the eligibility of the patient for the clinical trial based on the inclusion criteria provided.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with hepatitis C virus (HCV) 2 years ago and recent coinfection with hepatitis B virus (HBV).\n- No significant medical history other than the viral infections.\n- He is on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n- No mention of gastroesophageal varices or esophageal bleeding.\n- No current acute distress and no noted complications like ascites or edema that could be associated with advanced liver disease.\n\nClinical Trial Inclusion Criteria Analysis:\n- The etiology of portal hypertension is cirrhosis.\n- Age ranges between 20-80 years old.\n- Patients presenting with acute gastroesophageal variceal bleeding proven by emergency endoscopy within 12 hours.\n- EVL or histoacryl injection is performed based on the diagnosis of acute variceal bleeding.\n\nComparison:\n- The patient is within the age range of 20-80 years old.\n- There is no mention of acute gastroesophageal variceal bleeding, cirrhosis, or any treatments like EVL or histoacryl injection in the patient's note.\n- The patient's chronic viral hepatitis does not directly imply the presence of cirrhosis or variceal bleeding, which are required conditions for the trial.\n\nBased on the information provided in the patient's note, the patient does not meet the specific inclusion criteria of having cirrhosis and acute gastroesophageal variceal bleeding treated with EVL or histoacryl injection. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1602": {
        "output": "Given the patient's diagnosis of HCV from 2 years ago and the coinfection with HBV, along with a history of positive HCV RNA tests and anti-HCV antibodies, the patient does not meet the criteria for acute hepatitis C infection, which requires an estimated duration of 52 weeks at diagnosis. The patient also does not have a documented rise of liver transaminases above 2.5 x ULN within the past 12 months with prior normal transaminases, and there is no mention of a prior negative anti-HCV antibody or HCV RNA test within 12 months.\n\nThe patient's current state of chronic viral hepatitis does not fit the acute hepatitis C infection profile that the study is looking to investigate. Moreover, the patient's coinfection with HBV might complicate the study's focus on acute hepatitis C in the absence of other hepatitis viruses. There is no mention of HIV infection, which is a primary focus of the study cohort.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1603": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C\", let's assess the patient's eligibility.\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months\n- Previous positive tests for HCV RNA and anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, showing chronic inflammation\n- No evidence of other liver diseases\n- Vital signs: BP 130/75, HR 90/min, BMI 27\n- Physical examination: abdomen soft with no ascites or tenderness, no lower extremity edema\n\nClinical trial inclusion criteria:\n- Confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+))\n- Normal or increased liver enzymes (ALT and AST)\n- Not using interferon or ribavirin due to patient sensitivity or not consenting\n\nAssessment:\nThe patient has confirmed chronic hepatitis C, which matches the first part of the trial's inclusion criteria. However, the patient is currently on interferon and ribavirin treatment, which directly conflicts with the trial's inclusion criteria stating participants should not be using interferon or ribavirin due to sensitivity or non-consent.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial due to current use of interferon and ribavirin.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1604": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess whether the patient is eligible for the trial. Let's review the inclusion criteria against the patient's information:\n\n1. Gender: Male or female - The patient is male.\n2. Ethnicity: Han ethnic - There is no information provided about the patient's ethnicity, so we cannot determine if the patient is of Han ethnic background.\n3. Age: \u2265 18 years old - The patient is 55 years old, which meets this criterion.\n4. Recent confirmation of anti-HCV-antibody positive and HCV RNA positive 30 days prior to recruitment - The patient has a history of HCV confirmed by positive HCV RNA tests and positive enzyme immunoassay for anti-HCV-antibodies.\n5. Antiviral or interferon treatment naive - The patient is not treatment naive as he is on IFN (interferon), RBV, and direct antiviral drugs for the past 6 months.\n\nThe patient meets some of the inclusion criteria, such as age and gender, and has a confirmed diagnosis of HCV. However, the patient is not treatment naive, which is a requirement for the study. Additionally, there is no information on the patient's ethnicity to confirm if he is of Han ethnic background.\n\nGiven this information, the patient does not meet all the inclusion criteria due to not being antiviral treatment naive. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1605": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. There is no mention of HIV infection, so we can assume he does not have it. His treatment consists of IFN, RBV, and direct antiviral drugs for the past 6 months, and he has no other significant medical history. His recent biopsy was negative for hepatocellular carcinoma (HCC), and there is no evidence of ESLD.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n- Strata a: Requires HIV-1 infection without HCV.\n- Strata b: Requires HCV infection without HIV.\n- Strata c: Requires coinfection with HIV & HCV.\n- Strata d: Requires coinfection with HIV & HCV and either successful treatment for hepatitis C or spontaneous clearance.\n- Patients should not have ESLD and/or HCC within 6 months of enrollment.\n- Treatment with antiretroviral drugs for at least 12 months (if HIV positive).\n- Undetectable HIV-1 RNA (if HIV positive).\n- Patients must consent to study procedures.\n- Patients must be >18 years of age.\n\nThe patient in question does not have HIV; therefore, he does not qualify for strata a, c, or d. He only has HCV (and HBV coinfection), which may make him eligible for strata b, which requires HCV infection without HIV. However, there is no mention of the patient's consent to study procedures or any evidence of laboratory reports required by the trial. The information provided is not sufficient to determine eligibility based solely on the inclusion criteria specified. Therefore, the patient cannot be considered for strata b either, as there is no explicit confirmation of HCV RNA or negative HIV antibody test.\n\nGiven the available information, the patient does not meet the inclusion criteria for any of the specified strata of the study due to a lack of information on the necessary laboratory reports and the absence of HIV infection, which is a requirement for three of the four strata.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1606": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient information:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and the recent coinfection with HBV.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The recent biopsy was negative for hepatocellular carcinoma.\n- The patient has no evidence of cirrhosis.\n\nClinical trial inclusion criteria:\n- Treatment na\u00efve participants.\n- Males must be surgically sterile or practicing specific forms of birth control.\n- Chronic hepatitis C virus (HCV), genotype-1 infected participants.\n- Documented FibroTest score in combination with an Aspartate Aminotransferase to Platelet Ratio Index (APRI), or a liver biopsy within the last 12 months to document the absence of cirrhosis.\n\nAssessment:\n- The patient is not treatment na\u00efve since he is currently on IFN, RBV, and direct antiviral drugs.\n- There is no information provided about the patient's birth control practices.\n- There is no mention of the patient's HCV genotype.\n- The patient has had a liver biopsy within the last 12 months, showing no evidence of cirrhosis, which meets one of the criteria.\n\nThe patient does not meet the criterion of being treatment na\u00efve, which is a critical requirement for the trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1607": {
        "output": "In reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of inadequate English language skills.\n- No mention of whether informed consent could be provided.\n- No specific information about when the patient first tested positive for anti-HCV antibody or HCV RNA.\n- No information about acute clinical hepatitis with jaundice or ALT levels.\n\nClinical Trial Inclusion Criteria:\n- Male and female patients \u2265 16 years of age.\n- Recent hepatitis C infection with an estimated duration of infection \u2264 18 months defined as either:\n   A) First anti-HCV antibody or HCV RNA positive within the previous 6 months AND documented anti-HCV antibody negative or HCV RNA negative within the 24 months prior to the anti-HCV antibody positive result.\n   OR\n   B) First anti-HCV antibody or HCV RNA positive within the previous 6 months AND acute clinical hepatitis (jaundice or ALT> 10 X ULN) within the 12 months prior to first positive HCV antibody or HCV RNA with no other cause of acute hepatitis identifiable.\n- Adequate English to provide written, informed consent and to provide reliable responses to the study interview.\n- Provision of written, informed consent.\n\nBased on the available information, the patient does not meet the specific criteria for a recent hepatitis C infection as defined by the trial (duration of infection \u2264 18 months with documented test results or acute clinical hepatitis). There is no information indicating when the patient first tested positive for anti-HCV antibody or HCV RNA, and there is no mention of acute clinical hepatitis with jaundice or ALT levels.\n\nTherefore, the patient note does not provide sufficient information to determine the patient's eligibility for the clinical trial. The correct trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1608": {
        "output": "Given the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 55-year-old man, which meets the age requirement of \u2265 18 years old.\n- The patient is diagnosed with HCV and recent coinfection with HBV, meeting the criteria for HBV and/or HCV infection.\n- The patient is on treatment, which includes IFN, RBV, and direct antiviral drugs for the past 6 months, indicating active management of his condition.\n- The patient's medical record shows previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- The patient has a regular doctor as there is a medical record available and no indication of a lack of regular care.\n- There is no information on the patient's willingness to undergo genetic testing, have medical records reviewed, have samples stored, undergo HIV testing, or if the patient is a childbearing female with a pregnancy test. However, the last point is not applicable as the patient is male.\n- The patient's note does not mention any condition that could be considered a contraindication to study participation.\n- There is no indication in the patient's note of poor venous access or inability to comply with research study visits.\n\nBased on the available information, the patient appears to meet all the relevant inclusion criteria and none of the exclusion criteria are mentioned as being met. Assuming the patient is willing to comply with the research requirements (genetic testing, review of medical records, sample storage, HIV testing), which cannot be determined from the note but are standard procedures for clinical trial participation, the patient seems eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1609": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma (HCC) or cirrhosis\n- Non-significant medical history\n\nClinical trial inclusion criteria:\n- Patients with chronic hepatitis C infection: No cirrhosis of the liver, no HCC\n- Patients with HCV-associated cirrhosis of the liver: Cirrhosis confirmed by diagnostic methods\n- Patients with HCV-associated HCC: Diagnosis of HCC, not treated at the time of enrollment\n- For all groups: Diagnosis of chronic HCV infection with virus RNA and serologic parameters (anti-HCV) and abnormal liver function for more than 6 months, no antiviral treatment during the last 6 months\n\nIn this case:\n- The patient does have chronic HCV infection, confirmed by positive HCV RNA tests and anti-HCV antibodies.\n- The patient does not have HCC or cirrhosis as per the biopsy and medical records.\n- The patient is currently on antiviral treatment, which has been ongoing for the past 6 months.\n\nThe last point is crucial because the inclusion criteria specify no antiviral treatment during the last 6 months. Therefore, despite the patient having chronic HCV infection, they do not meet all the inclusion criteria due to the antiviral treatment they are currently undergoing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1610": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recently coinfected with HBV\n- Currently on IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal blood pressure, heart rate, and BMI\n- Chronic hepatitis C, confirmed by positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies\n\nClinical Trial Inclusion Criteria:\n- Men and women, ages 18 to 70 years\n- Infected with HCV genotype 1, 2, or 3\n- No previous exposure to an interferon formulation, ribavirin, or other HCV-specific direct-acting antiviral (including daclatasvir and PSI-7977)\n- Chronic hepatitis C genotype 1a, 1b, 2, or 3 documented by positive test results for anti-HCV antibody; HCV RNA; or an HCV genotype at least 6 months prior to screening, and HCV RNA and anti-HCV antibody at the time of screening\n\nBased on the information provided:\n\n- The patient is within the age range required for the trial (age 55).\n- The patient has a documented diagnosis of HCV, which is required for the trial.\n- However, the patient has been treated with interferon and ribavirin for the past 6 months. This disqualifies the patient as the trial specifically requires participants with no previous exposure to interferon or ribavirin or other HCV-specific direct-acting antivirals (including daclatasvir and PSI-7977).\n\nBecause the patient has been treated with drugs that are exclusionary according to the clinical trial criteria, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1611": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note details:\n- The patient is a 55-year-old man, which meets the age criterion of being 18 years or older.\n- Diagnosed with HCV 2 years ago, indicating a positive for the HCV antibody.\n- Recent coinfection with HBV, but this does not exclude him from the study based on the provided criteria.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months, which suggests that he has not been treated with pegylated-interferon and ribavirin, as the criteria specify pegylated-interferon.\n- The patient's medical records show previous positive HCV RNA tests.\n- Recent biopsy was negative for hepatocellular carcinoma but confirmed chronic inflammation compatible with chronic viral hepatitis, which could be interpreted as chronic hepatitis, liver fibrosis, or liver cirrhosis.\n- No mention of genotype 1 or genotype 2, which is a required criterion for the study.\n\nClinical trial inclusion criteria:\n- Aged 18 years or older \u2714\n- Positive for the HCV antibody and HCV RNA detected \u2714\n- Patients with abnormal liver function OR a liver biopsy specimen taken in the 6 months prior to study entry showing chronic hepatitis, liver fibrosis, or liver cirrhosis \u2714\n- Have not been previously treated with pegylated-interferon and ribavirin for HCV \u2714\n- Genotype 1 or Genotype 2 (No information provided)\n\nSince the patient's note does not specify the genotype of the HCV, we do not have sufficient information to determine if the patient meets the inclusion criteria regarding the HCV genotype. Therefore, the patient cannot be deemed eligible or excluded based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1612": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"TMC649128HPC1002,\" we need to match the patient's characteristics with the trial's inclusion criteria:\n\n1. Documented chronic (> 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection\n2. Treatment-naive volunteer, meaning never received (Peg)IFN, RBV, or any other approved or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR volunteer is a documented prior non-responder or relapser subject to previous treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at least 6 months before screening\n3. Volunteer has never received an HCV polymerase inhibitor and HCV protease inhibitor treatment was stopped since at least one year (Panels 1, 2 or 3)\n4. Volunteer with HCV plasma RNA levels of > 100,000 IU/mL at screening\n5. Body Mass Index of 18.0 to 35.0 kg/m2\n6. Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram.\n\nPatient note analysis:\n1. The patient has a diagnosis of HCV, but the note does not specify the genotype. It is not clear if it is genotype 1a or 1b.\n2. The patient is not treatment-naive as he is on IFN, RBV, and direct antiviral drugs for the past 6 months. Therefore, he does not meet this criterion.\n3. Since the patient is currently on treatment, it is likely that he has received HCV polymerase inhibitor treatment, which would exclude him.\n4. There is no mention of HCV plasma RNA levels in the patient note.\n5. The patient has a BMI of 27 which falls within the required range.\n6. The patient appears to be healthy based on his medical evaluation, though without detailed lab results or an ECG, it's not possible to fully confirm his health status as per the trial's definition.\n\nBased on the above comparison, the patient does not meet the second inclusion criterion as he is not treatment-naive, which is a critical requirement for the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1613": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. The clinical trial in question is focused on the impact of menopause on the response to antiviral therapy for chronic hepatitis C in women and comparing these results with age-matched men.\n\nThe inclusion criteria for the trial are:\n\n1. All women treated for HCV chronic hepatitis at the Unit Gastroenterology, University of Modena and Reggio Emilia, in the last 7 years.\n2. Control group is a cohort matched for age (ratio 1:1) selected from a group of 558 men with chronic HCV treated in the same period.\n\nSince the patient is a man, he could potentially be eligible for the control group. However, it is not clear whether he was treated at the Unit Gastroenterology, University of Modena and Reggio Emilia. Without this information, we cannot definitively determine his eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1614": {
        "output": "Assessing the eligibility of the patient for the clinical trial based on the provided patient note and the inclusion criteria of the trial:\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- Positive HCV RNA tests and anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma, chronic inflammation due to chronic viral hepatitis\n- No evidence of other liver diseases\n- Normal BP, HR, and BMI of 27\n\nClinical trial inclusion criteria:\n- Male or female, aged from 18 to 70 years old, inclusive\n- Chronic HCV infection for at least 6 months prior to baseline\n- Positive for HCV-RNA and anti-HCV antibody\n- Liver biopsy performed with evidence of chronic HCV infection, no cirrhosis\n- HCV infection limited to genotype 1\n- Detectable plasma HCV-RNA at screening\n- BMI between 18 and 36 Kg/m2\n- HCV treatment-na\u00efve\n- Specific laboratory parameters at screening\n\nComparing the patient note to the inclusion criteria:\n\n- The patient is within the age range (55 years old).\n- The patient has a chronic HCV infection for at least 6 months prior to baseline.\n- The patient is positive for HCV-RNA and anti-HCV antibody.\n- The patient's recent biopsy shows chronic inflammation compatible with chronic viral hepatitis, but it's not specified if there's evidence of chronic HCV infection or if the genotype is 1.\n- The patient's BMI is within the required range (BMI of 27).\n- The patient is not HCV treatment-na\u00efve; he is on IFN, RBV, and direct antiviral drugs.\n- Laboratory parameters are not fully provided in the patient note.\n\nThe patient does not meet the inclusion criteria because he is not HCV treatment-na\u00efve, which is a requirement of the trial. Therefore, he is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1615": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility.\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No hepatocellular carcinoma\n- No acute distress\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Able to give written consent\n- Covered by French Social Security\n- Be a man and have sex with men (MSM)\n- Be treated with the same antiretroviral therapy (ART) for at least 3 months\n- Blood plasma must have an undetectable viral load (<50 copies/ml) for at least 6 months\n- Accept the constraints imposed by the study, which includes one or more masturbation in hospital\n\nThe clinical trial is focused on HIV transmission among men who have sex with men (MSM), specifically those under antiretroviral therapy with an undetectable blood viral load. The patient in question is diagnosed with HCV and a recent coinfection with HBV, with no mention of HIV or being a man who has sex with men. Furthermore, the patient is not described as being on antiretroviral therapy, which is a specific requirement for the trial.\n\nGiven that the patient does not meet the key demographic and medical treatment criteria (i.e., being a man who has sex with men and on antiretroviral therapy), the patient is not eligible for this HIV-focused trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1616": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the clinical trial mentioned. The trial is specifically for patients who have received a living donor liver transplant for chronic hepatitis C or for those who have donated part of their liver to patients suffering from chronic hepatitis C.\n\nThe patient described in the note has been diagnosed with HCV and a recent coinfection with HBV, and there is no mention of them having received a liver transplant, nor of them being a liver donor. The patient is currently on treatment for HCV, including IFN, RBV, and direct antiviral drugs.\n\nSince there is no indication that the patient has undergone a liver transplant nor has been a liver donor, they do not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1617": {
        "output": "Based on the information provided:\n\nPatient information:\n- 55-year-old man diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- No other medications\n- Previous positive HCV RNA tests\n- Biopsy negative for hepatocellular carcinoma\n- No evidence of other liver diseases\n- Normal vital signs and physical exam\n\nClinical trial inclusion criteria:\n- Signed patient consent form\n- Chronic HCV patients in relapse following conventional treatment regimen (INF+Ribavirine) with detectable plasma level of HCV RNA\n- Hepatitis B and human immunodeficiency virus negative at screening visit\n- Able and willing to follow contraception requirements\n- Screening laboratory values, test, and physical exam within acceptable range\n\nThe patient does have chronic HCV and is currently on IFN and RBV, which fits the profile of someone who would be in the target demographic for the trial. However, the patient is also coinfected with HBV, which is specifically listed as an exclusion criterion for the clinical trial.\n\nTherefore, despite the patient fitting some of the inclusion criteria, the coinfection with HBV disqualifies them from participating in this trial. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1618": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- He has been diagnosed with HCV (Hepatitis C Virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B Virus).\n- His past medical history is non-significant.\n- He is on treatment for HCV, including IFN (interferon), RBV (ribavirin), and direct antiviral drugs.\n- The patient does not have hepatocellular carcinoma according to the recent biopsy.\n- There is no mention of HIV infection or AIDS.\n- No CD4 count is provided.\n- The patient\u2019s clinical status regarding HIV is not mentioned.\n\nClinical Trial Inclusion Criteria:\n- WHO stage IV of HIV disease, regardless of the CD4 count.\n- WHO stage III of HIV disease with a CD4 count < 350/mm3.\n- WHO stages I or II with a CD4 count < 200/mm3.\n\nThe clinical trial is focused on patients with HIV disease at various WHO stages and specific CD4 counts. The patient in the note has HCV and HBV but there is no mention of HIV infection. Therefore, he does not meet the inclusion criteria for the trial, which specifically relates to HIV disease and CD4 counts.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial because there is no indication that the patient has HIV, which is a requirement for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1619": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV,\" I will compare the patient's characteristics and condition with the inclusion and exclusion criteria provided for the trial.\n\n**Patient Characteristics and Condition:**\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma, alcoholic liver disease, esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- No evidence of decompensated liver disease or contraindications mentioned in the exclusion criteria\n- Not on any medications listed in the exclusion criteria\n- No mention of HIV infection\n\n**Clinical Trial Inclusion Criteria:**\n- Age \u2265 18 years\n- Chronic HCV infection (positive for hepatitis C antibody and HCV RNA of 2,000 IU/mL or greater)\n- Infected with HCV GT-1 virus\n- If coinfected with HIV, must meet certain conditions, which are not relevant since the patient does not have HIV\n- Na\u00efve to prior IFN-based treatment for HCV (the patient is currently on IFN, which means he is not na\u00efve to IFN-based treatment)\n- Other criteria that are not mentioned in the patient note\n\n**Clinical Trial Exclusion Criteria:**\n- Use of other experimental therapies\n- Certain medications within specific time frames\n- Mixed HCV genotypes\n- Other known causes of liver disease\n- Decompensated liver disease\n- Certain abnormal lab values\n- Prior organ transplantation other than cornea or hair\n- Severe cardiac or pulmonary disease\n- Severe psychiatric disorder not stably treated\n- Autoimmune disorders\n- Uncontrolled seizure disorder\n- Chronic pancreatitis\n- Severe retinopathy\n- Hemophilia\n- Hemoglobinopathy\n- Active systemic infections other than HCV and HIV-1\n- Gastrointestinal malabsorption, chronic nausea, or vomiting\n- Any condition that contraindicates participation\n- Pregnancy or breastfeeding\n\nBased on the information provided:\n\n- The patient does not fulfill the eligibility criterion of being na\u00efve to prior IFN-based treatment for HCV, as he is currently on IFN therapy.\n- The patient's genotype of HCV is not specified, so we cannot confirm if he is infected with HCV GT-1 virus, which is required by the study.\n- No other exclusion criteria seem to apply to the patient.\n\nTherefore, the patient is not eligible for the trial based on the information provided, primarily due to not being na\u00efve to IFN-based treatment. The genotype of the virus is also a critical piece of information that is missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1620": {
        "output": "Based on the patient note provided, we can assess the patient's eligibility for the clinical trial regarding Gadoxetic Acid-MRI versus Ultrasonography for the surveillance of Hepatocellular Carcinoma in high-risk patients.\n\nAssessing the inclusion criteria for the trial:\n\n1. Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher meeting all of the following criteria:\n   - The patient has a diagnosis of HCV and recent coinfection with HBV. However, the biopsy was negative for hepatocellular carcinoma, and there's no mention of cirrhosis or evidence of portal hypertension. Thus, we cannot confirm cirrhosis from the information provided.\n   \n2. Evidence of portal hypertension, including any of the followings:\n   - The patient note does not indicate splenomegaly, esophageal or gastric varices, or any other evidence of portal hypertension.\n   \n3. High-Risk Index (>=2.33); Risk Index calculation based on provided factors:\n   - The patient is over 50 years old (+1.41), and there is positive evidence of HCV (+0.74). However, there's no information on prothrombin activity or platelet count. So, we cannot calculate the risk index with the information given.\n   \n4. Older than 20 years of age:\n   - The patient is 55 years old, which meets this criterion.\n   \n5. Absence of previous or current history of HCC:\n   - The patient's biopsy was negative for hepatocellular carcinoma, so this criterion is met.\n   \n6. Absence of HCC should be identified by liver USG, dynamic CT, or contrast-enhanced MRI within 6 months prior to screening:\n   - The patient note does not specify whether these imaging studies were performed within the required timeframe.\n   \n7. ECOG performance status (PS) of 0-2:\n   - The patient note does not provide information regarding the ECOG performance status.\n\n8. The patient is able to comply with scheduled visits, evaluation plans, and other study procedures:\n   - There's no information on the patient's ability or willingness to comply with study procedures.\n   \n9. The patient is willing to provide written informed consent:\n   - The patient's willingness to consent is not mentioned.\n\nBased on the information provided in the patient note, we do not have sufficient evidence that the patient has cirrhosis or evidence of portal hypertension, nor do we have the complete High-Risk Index calculation or the ECOG performance status. Also, the patient's ability to comply with the study procedures and willingness to consent are not mentioned.\n\nTherefore, the patient does not have sufficient information to qualify for the trial. The assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1621": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No previous significant medical history\n\nClinical trial inclusion criteria:\n- Participants chronically infected with HCV Genotype 4\n- HCV RNA viral load of \u2265 10,000 IU/mL\n- No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent\n- Results of a liver biopsy obtained within three years prior to enrollment to demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are permitted, however, and any prior biopsy is permitted\n\nThe patient's diagnosis of HCV and recent treatment with IFN and RBV indicates previous exposure to an interferon formulation and RBV, which is a direct disqualification according to the third point of the inclusion criteria for the clinical trial. Hence, the patient does not meet the inclusion criteria and would be ineligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1622": {
        "output": "To determine the trial-level eligibility for the patient, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial. Let's examine the patient's information and the trial criteria.\n\nPatient's characteristics:\n\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of smoking habits\n- BMI of 27\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned\n- In general good health as determined by medical history and physical examination\n\nClinical trial inclusion criteria:\n\n- Male and female healthy subjects between 18 and 55 years of age, inclusive\n- BMI within 19 and 29.9 kg/m2, inclusive\n- General good health as determined by medical history, physical examination, or laboratory evaluations\n- Non-smokers, negative urine cotinine test\n- Negative results for HIV 1, HCV antibody, hepatitis B surface antigen\n- Negative results from screening for drugs of abuse\n\nAssessment:\n\n- The patient is a 55-year-old man, which fits within the age range of 18 to 55 years.\n- The patient's BMI is 27, which is within the required range of 19 to 29.9 kg/m2.\n- The patient's medical history and physical examination indicate he is in good health.\n- The patient's smoking status is not mentioned. This information is required to assess eligibility.\n- The patient has a documented diagnosis of HCV and a recent coinfection with HBV. This makes him ineligible as per the criteria requiring a negative HCV antibody and hepatitis B surface antigen test.\n\nBased on the information provided, the patient does not meet all the inclusion criteria due to the positive HCV and HBV status. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1623": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) infection 2 years ago and a recent coinfection with Hepatitis B Virus (HBV). He has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. The inclusion criteria for the clinical trial are simply \"Hepatitis C virus infected patients.\"\n\nThe patient's note confirms that he has a positive history of HCV as indicated by positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. Despite the coinfection with HBV, there is no indication that this would exclude him from a trial focusing on HCV-infected patients. There is no mention of specific exclusion criteria for the trial, nor is there any information provided that would suggest that the patient should be excluded.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial, which is focused on HCV-infected patients. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1624": {
        "output": "Given the patient's note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient information:\n- 55-year-old man (meets age criteria \u226518 years)\n- Diagnosed with HCV 2 years ago (chronic hepatitis C confirmed)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months (this suggests the patient is not treatment-naive, as they have been exposed to IFN and RBV)\n- Positive HCV RNA tests and anti-HCV antibodies (meets the criteria for documentation of CHC)\n- Recent biopsy negative for hepatocellular carcinoma and indicating chronic viral hepatitis (compatible with chronic HCV infection)\n- No evidence of cirrhosis (could potentially meet the criteria of absence of cirrhosis if documented properly)\n- BMI of 27 (within the required range of 18.0 to 35.0 kg/m^2)\n\nClinical trial inclusion criteria:\n- Men and women, ages \u226518 years of age\n- Subjects who are naive to HCV treatment, defined as no previous exposure to IFN, RBV; or any HCV-specific direct acting antiviral or experimental therapy or subjects who are null responders to previous pegIFN\u03b1 plus RBV treatment\n- Chronic hepatitis C documentation\n- HCV genotype 1a, 1b, or 4 only\n- HCV RNA viral load of \u226510,000 IU/mL at screening\n- Criteria for the absence of cirrhosis or compensated Child-Pugh A cirrhosis documentation\n- BMI of 18.0 to 35.0 kg/m^2\n\nBased on the provided information, the patient does not meet the trial criteria for being naive to HCV treatment, as they are currently on treatment with IFN, RBV, and direct antiviral drugs. Additionally, there is no information provided on the patient's HCV genotype or viral load, which are required for the trial inclusion.\n\nTherefore, based on the available information, the patient is not eligible for the trial because they have had previous exposure to HCV treatments (IFN and RBV), which is a disqualifying factor according to the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1625": {
        "output": "",
        "label": 1
    },
    "1626": {
        "output": "Upon comparing the patient note with the inclusion criteria provided for the hepatitis C clinical trial, we can deduce the following:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No previous treatment for HCV is mentioned, which may imply that the current regimen is his first treatment\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the exclusion criteria\n\nClinical trial inclusion criteria:\n- Male or female > 18 years old (Patient is 55 years old, so meets this criterion)\n- HCV genotype-1 infection (No genotype information provided in the patient note)\n- Liver biopsy consistent with Chronic Hepatitis C (CHC) within the last 3 years (Patient has a recent biopsy showing chronic inflammation compatible with chronic viral hepatitis, so this is met)\n- No previous treatment with any anti-HCV therapy (approved or investigational) (Patient is currently on treatment with IFN, RBV, and direct antiviral drugs; this does not meet the criterion)\n- For women of childbearing potential, a negative urine pregnancy test result is required (Not applicable to the male patient)\n- Willingness to give written informed consent and to participate in and comply with requirements of the study (Not described in the patient note)\n\nThe crucial point of ineligibility is that the patient is currently undergoing treatment for HCV, which contradicts the requirement for no previous treatment with any anti-HCV therapy. Since the patient does not meet all of the inclusion criteria due to ongoing treatment, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1627": {
        "output": "Based on the patient note provided, the 55-year-old man diagnosed with HCV and recent coinfection with HBV does not meet the inclusion criteria of the clinical trial titled \"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV).\" The trial specifically requires participants to be coinfected with HIV and HCV, and the patient must have been diagnosed with HIV-1 infection for more than 6 months prior to screening, and should be taking one of the specified HAART regimens for HIV continuously for 12 weeks prior to screening. The patient note does not mention an HIV diagnosis or treatment for HIV, which are crucial inclusion criteria for the trial.\n\nTherefore, based on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial because he does not have the required HIV coinfection, nor is there any mention of HIV treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1628": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to be eligible for the trial. The trial is specifically for patients with a diagnosis of Hepatocellular Carcinoma (HCC) who are planning to undergo major hepatic resection or radiofrequency ablation. The patient note indicates that the patient is diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus), but there is no mention of Hepatocellular Carcinoma. In fact, the recent biopsy was negative for hepatocellular carcinoma.\n\nSince the patient does not have a diagnosis of HCC, they do not meet the inclusion criteria for the clinical trial as stated. Therefore, the patient would not be eligible to participate in this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1629": {
        "output": "To assess the eligibility of the patient for the clinical trial \"Lonafarnib for Chronic Hepatitis D,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nBased on the patient's note provided:\n\n- The patient is a 55-year-old man, which meets the age criterion (Age 18 years or above).\n- The patient has been diagnosed with HCV and a recent coinfection with HBV, which meets the requirement for hepatitis B infection (a necessary condition for hepatitis D, as the hepatitis D virus requires hepatitis B for infection).\n- The patient's medical history is non-significant, which suggests that he does not have any significant systemic or major illnesses other than liver disease.\n- The patient is on IFN, RBV, and direct antiviral drugs, but there is no mention of systemic immunosuppressive therapy within the previous 2 months.\n- There is no evidence of hepatocellular carcinoma, decompensated liver disease, or other forms of liver disease in addition to viral hepatitis mentioned.\n- There is no mention of concurrent hepatitis C infection with positive serum HCV RNA.\n- No information provided about evidence of HDV antigen in liver tissue or HDV RNA in serum, which is a requirement for the study.\n- The patient's serum alanine or aspartate aminotransferase activities (ALT and AST levels) are not provided, so we cannot confirm they meet the criteria.\n- No information on the necroinflammatory score or hepatic fibrosis from a liver biopsy is provided.\n- There is no mention of substance abuse, HIV co-infection, or any other exclusion criteria such as concurrent usage of statins, CYP3A inhibitors and inducers, or an inability to understand or sign informed consent.\n\nThe patient note does not provide enough information to confirm the presence of anti-HDV in serum, HDV antigen in liver tissue or HDV RNA in serum, ALT and AST levels, or liver biopsy results. These are required to meet the inclusion criteria.\n\nTherefore, based on the available information, the patient cannot be confirmed as eligible since key inclusion criteria details are missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1630": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Telaprevir Open-Label Study in Co-Infected Patients,\" we must match the patient's characteristics and medical history with the inclusion and exclusion criteria provided for the trial.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- No mention of HIV infection or treatment\n\nClinical trial inclusion criteria:\n- Have diagnosis of HIV-1 or HIV-2 infection, or HIV-1 and HIV-2 coinfection for more than 6 months before the screening visit\n- Should have been on a stable permissible HAART regimen for more than 8 weeks before Day 1 without switches OR not on a HAART regimen and not expected to start HIV treatment during the study\n- Have CD4 count \u2265200 cells/mm3 or \u226515% and HIV-1 and/or HIV-2 viral load <50 copies/mL for at least 6 months before starting treatment (if on HAART) OR have CD4 count of \u2265500 cells/mm3 and a HIV-1 and/or HIV-2 viral load \u226450,000 copies/mL at screening (if not on HAART)\n- Have evidence of HCV infection genotype 1 (molecular assay)\n- Have a quantifiable plasma HCV RNA\n\nClinical trial exclusion criteria:\n- Is eligible for enrollment into an ongoing clinical study of telaprevir\n- Is infected or coinfected with HCV of another genotype than genotype 1\n- Has a contraindication to the administration of Peg-IFN-alfa or RBV, or medical history or laboratory values that preclude treatment with Peg-IFN-alfa or RBV according to the respective local prescribing information\n- Have any contraindication to the currently prescribed HAART regimen at screening\n\nBased on the patient note, there is no indication that the patient has an HIV infection, which is a prerequisite for inclusion in this trial. The inclusion criteria explicitly require a diagnosis of HIV-1 or HIV-2 infection or co-infection, and there is no mention of HIV in the patient's history.\n\nAs the patient does not meet the essential inclusion criteria related to an HIV diagnosis, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1631": {
        "output": "After reviewing the patient note and the clinical trial information, it is clear that the patient does not meet the inclusion criteria for the clinical trial provided. The clinical trial is focused on the effects of probiotics on patients with Alcoholic Hepatitis (AH), and the inclusion criteria specify that participants must have AH.\n\nThe patient in question has a diagnosis of hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV). His medical history does not mention alcoholic liver disease, which is a requirement for the trial. Furthermore, the trial requires a specific liver enzyme profile (AST/ALT > 2 and elevated AST (ALT) level) with a history of alcohol consumption within 48 hours, none of which is mentioned in the patient's note. The patient's liver biopsy showed chronic inflammation compatible with chronic viral hepatitis, but there is no mention of alcoholic hepatitis or recent alcohol consumption.\n\nSince the patient does not have alcoholic hepatitis and does not meet the trial's inclusion criteria, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1632": {
        "output": "Based on the information provided:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other significant past medical history\n- No hepatocellular carcinoma\n- No acute distress, normal BP, HR, and BMI\n- Normal physical examination results\n\nClinical Trial Inclusion Criteria:\n- Legal male or female adult 18 through 49 years of age at the enrollment visit\n- Literate and willing to provide written informed consent\n- Free of obvious health problems, as established by medical history and screening evaluations, including physical examination\n- Capable and willing to complete diary cards and willing to return for all follow-up visits\n- Willing to comply with the rules of the isolation unit\n- For females, willing to take reliable birth control measures throughout the entire period of participation in the study\n\nAssessment:\nThe patient is a 55-year-old male, which does not meet the age criterion of the clinical trial that requires participants to be between 18 through 49 years of age. All other health and willingness criteria appear to be met based on the information provided, but the age criterion is a fundamental requirement for inclusion.\n\nTherefore, the patient is not eligible for the clinical trial based on age alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1633": {
        "output": "Given the patient note and the clinical trial details, we need to determine the patient's eligibility for the trial. The patient is a 55-year-old man with a diagnosis of HCV (hepatitis C virus) and a recent coinfection with HBV (hepatitis B virus). He is currently on treatment with IFN (interferon), RBV (ribavirin), and direct antiviral drugs.\n\nNow, let's compare this with the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Individuals 18-55 years of age.\n2. Enrolled on another NIAID/FMPOS-approved protocol.\n3. Weigh greater than or equal to 50 kg.\n4. Agree to have blood specimens stored for future studies.\n5. Agree to undergo genetic testing.\n6. Agree to undergo HIV, hepatitis B, and hepatitis C virus testing.\n\nExclusion Criteria:\n1. Positive at screening for HIV, hepatitis B, and/or hepatitis C.\n2. Cardiovascular instability.\n3. Inadequate peripheral venous access.\n4. Anemia.\n5. Current use of corticosteroids or other immunosuppressants.\n6. Underlying heart disease, lung disease, bleeding disorder, or other conditions that contraindicate apheresis.\n7. Temperature greater than or equal to 37.5 degree C or other clinical evidence of an acute infection.\n8. Currently pregnant or breastfeeding.\n\nBased on the patient's current health status:\n- The patient fits the age requirement (55 years old).\n- There is no information on whether the patient is enrolled in another NIAID/FMPOS-approved protocol.\n- The patient's weight is not stated but given no mention of being underweight, it is reasonable to assume that he meets the weight criterion.\n- There is no information about the patient agreeing to have blood specimens stored, to undergo genetic testing, or to undergo HIV, hepatitis B, and hepatitis C virus testing.\n- The patient has a recent coinfection with HBV and is on treatment for HCV, which would likely lead to a positive test for hepatitis B and hepatitis C, making him meet one of the exclusion criteria.\n\nThe patient meets one of the exclusion criteria due to his recent coinfection with HBV and existing HCV, which would make him ineligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1634": {
        "output": "The patient in the note is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. His medical history is significant for chronic viral hepatitis, but there is no mention of HIV infection.\n\nThe clinical trial in question is focused on HIV-related liver disease in Uganda, particularly in individuals who may have co-infection with hepatitis B or C. The inclusion criteria for the trial emphasize that participants should be adults aged 18 and older and should have evidence of liver disease or be willing to undergo diagnostic procedures for liver disease, including liver biopsy.\n\nThe patient note does not indicate that the patient has HIV, which is a key aspect of the study's focus. Moreover, the patient is not from a rural area of Uganda, which is another requirement for the trial. Therefore, the patient does not meet the specific inclusion criteria of having HIV-related liver disease in Uganda.\n\nBased on this analysis, the patient does not have sufficient information to qualify for the trial, as there is no indication of HIV infection, which is central to the study's objectives, and the geographical location does not match the trial's requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1635": {
        "output": "Based on the provided patient note and the inclusion and exclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nInclusion criteria for the clinical trial:\n- Chronic hepatitis C, diagnosed by positive anti-HCV antibodies and detected HCV ribonucleic acid (RNA) at screening\n- Positive anti-HCV antibodies or detected HCV RNA at least 6 months prior to screening, or liver biopsy consistent with chronic HCV infection\n- HCV infection of genotype 1 confirmed by genotypic testing at screening\n- Therapy-na\u00efve to interferon, pegylated interferon, ribavirin, or any antiviral/immunomodulatory drug for acute or chronic HCV infection\n- Plasma HCV RNA \u2265 100,000 IU/mL at screening\n\nExclusion criteria for the clinical trial:\n- Hepatitis C infection of mixed genotype\n- HIV co-infection\n- Decompensated liver disease, or history of decompensated liver disease\n- Body weight < 40 or > 125 kg at screening\n- Hemoglobin <12.0g/dL for women and <13.0g/dL for men at screening\n- White blood cell count <3000 cells/mm3 at screening\n- Absolute neutrophil count < 1,500 cells/mm3 at screening\n- Platelet count < 90,000 /mm3 at screening\n- Serum creatinine > 1.5xULN or creatinine clearance \u226450 mL/min at screening\n\nPatient's details from the note:\n- 55-year-old man diagnosed with HCV 2 years ago\n- On IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months\n- No evidence of decompensated liver disease or other liver diseases mentioned in the exclusion criteria\n- There is no mention of HIV co-infection\n- Laboratory values (hemoglobin, white blood cell count, neutrophil count, platelet count, serum creatinine) are not provided in the note\n\nBased on the information provided:\n\n- The patient has chronic hepatitis C, satisfying one of the inclusion criteria.\n- The patient has been on treatment for HCV for the past 6 months, which disqualifies him as therapy-na\u00efve, thereby not meeting one of the inclusion criteria.\n- The patient note does not provide information about the HCV genotype, which is necessary to determine if the patient has genotype 1 HCV.\n- There is no information on the patient's plasma HCV RNA levels.\n- The patient note does not mention any of the exclusion criteria being met.\n\nGiven that the patient is not therapy-na\u00efve, as he is already on interferon, ribavirin, and direct antiviral drugs, he does not meet the inclusion criteria of being therapy-na\u00efve. Therefore, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1636": {
        "output": "After reviewing the patient's note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No mention of HIV infection\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No prior mention of treatment with Peg-IFN plus RBV (but currently on IFN and RBV)\n- Medical records do not indicate any prior non-response to treatment, but it's not clear if the current regimen is considered a standard therapy with Peg-IFN plus RBV\n- No information regarding antiretroviral therapy or HIV RNA levels (due to no mention of HIV infection)\n- No information provided regarding the patient's commitment to contraception use or written informed consent\n\nInclusion criteria for the clinical trial:\n- HIV infection\n- Infection with HCV genotype 4\n- No prior treatment with any interferon or no response to a previous treatment with Peg-IFN plus RBV\n- Stable antiretroviral therapy 24 weeks before starting the study drugs, with undetectable plasma HIV RNA during that period of time\n- Commitment to use two non-hormonal contraception during the study and up to 24 weeks after treatment\n- Acceptance to give written informed consent to participate in the trial\n\nThe patient does not meet the inclusion criteria because there is no mention of HIV infection which is a requirement for the trial. Moreover, the trial specifically requires patients to be infected with HCV genotype 4, and there is no information provided about the HCV genotype of this patient.\n\nTherefore, the patient is not eligible for the trial due to insufficient information to qualify for the trial, specifically the lack of mention of HIV infection and no information on the HCV genotype.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1637": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the study.\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV. The patient is currently on IFN, RBV, and direct antiviral drugs for HCV. His past medical history is non-significant, and there is no evidence of hepatocellular carcinoma or advanced liver disease. His BMI is 27, which falls within the required range.\n\nNow let's compare this information to the inclusion and exclusion criteria of the clinical trial:\n\nInclusion criteria for the clinical trial:\n- Has a BMI \u226518.5 kg/m\u00b2 and \u226436.0 kg/m\u00b2 (The patient's BMI is 27, so he meets this criterion)\n- Has chronic compensated, genotype 1 HCV infection (The patient has chronic HCV, but the genotype is not specified)\n- Has no cirrhosis of the liver (The patient's biopsy shows chronic inflammation without cirrhosis, so he meets this criterion)\n- Does not require anticoagulants, nonsteroidal anti-inflammatory agents, and aspirin (There is no information suggesting the patient requires these, so he likely meets this criterion)\n- If male, is willing to use 2 forms of contraception (The patient note does not mention this, but it is a controllable condition if the patient agrees)\n\nExclusion criteria for the clinical trial:\n- Has received previous treatment with a direct-acting antiviral (DAA) (The patient is on direct antiviral drugs, which excludes him from the trial)\n- Is positive for Hepatitis B surface antigen (HBsAg) or other evidence of active Hepatitis B infection (The patient has a recent coinfection with HBV, which excludes him from the trial)\n\nBased on the information provided, the patient does not qualify for the clinical trial as he meets exclusion criteria due to his current treatment with direct antiviral drugs and the recent coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1638": {
        "output": "To assess the patient's trial-level eligibility for the clinical trial titled \"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755),\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nInclusion Criteria for the Clinical Trial:\n1. Participant weight is \u2265 40 kg and \u2264 125 kg.\n2. Documented chronic hepatitis C (CHC) genotype 1 with HCV RNA \u226510,000 International Units (IU)/mL.\n3. Presence of the IL-28B CC allele gene.\n4. Liver biopsy (or non-invasive fibroscan and Fibrotest) without evidence of cirrhosis and hepatocellular carcinoma.\n\nPatient Characteristics:\n1. The patient's weight is not provided, but there is no indication the patient is outside the weight range.\n2. The patient has been diagnosed with chronic HCV genotype not specified, but HCV RNA tests and anti-HCV antibodies are positive. The genotype 1 of the virus is not mentioned.\n3. It is not stated whether the patient has the IL-28B CC allele gene.\n4. The patient has had a recent biopsy negative for hepatocellular carcinoma and with findings compatible with chronic viral hepatitis, indicating no cirrhosis.\n\nBased on the information provided:\n- The patient's weight is unknown, but there is no indication that it is out of the required range.\n- The patient has chronic HCV but it's not specified whether it's genotype 1.\n- There is no information about the patient's IL-28B CC allele status.\n- The patient does not have evidence of cirrhosis or hepatocellular carcinoma, which meets part of the inclusion criteria.\n\nSince we have insufficient data on the patient's weight, HCV genotype, and IL-28B CC allele status, we cannot determine if the patient meets all the inclusion criteria for the trial. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1639": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Clinical Study of Lyophilized Plasma in Patients With Liver Disease,\" we must evaluate the patient's information against the inclusion criteria provided for the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Male or female patients at least 18 years of age.\n2. Patients with liver disease.\n3. Patients who have need for plasma therapy for a surgical or an invasive procedure or who have evidence of bleeding.\n4. Patients with an elevated international normalized ratio due to liver disease.\n5. Patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf.\n6. Patients able and willing to comply with the procedures laid out in the study protocol.\n\nBased on the patient's note provided:\n\n1. The patient is a 55-year-old man, which satisfies the age criterion.\n2. He is diagnosed with HCV and a recent coinfection with HBV, indicating he has liver disease.\n3. There is no mention of the patient needing plasma therapy, having evidence of bleeding, or undergoing a surgical or an invasive procedure.\n4. The note does not mention the patient's international normalized ratio (INR) levels.\n5. There is no information regarding informed consent, but this is typically obtained as part of the clinical trial enrollment process.\n6. There is no information suggesting that the patient is unable or unwilling to comply with the study protocol.\n\nThe patient meets some of the inclusion criteria (age and having liver disease); however, there is insufficient information available to determine if the patient needs plasma therapy or has evidence of bleeding, and there is no mention of the patient's INR levels. Without this information, we cannot conclusively determine eligibility.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1640": {
        "output": "Given the patient's information and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old male\n- Diagnosed with HCV 2 years ago\n- Coinfection with HBV\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- BMI: 27\n\nClinical Trial Inclusion Criteria:\n- Male or female between the age of 18 and 70 years, inclusive, at the time of enrollment.\n- Subject has never received antiviral treatment for hepatitis C virus (HCV) infection.\n- Body mass index (BMI) is \u2265 18 to < 38 kg/m^2.\n- Chronic HCV genotype 1-infection for at least 6 months prior to study enrollment.\n- Subject has plasma HCV RNA level > 10,000 IU/mL at screening.\n\nThe patient meets the age, BMI, and chronic HCV infection duration criteria. However, the patient does not meet the criterion of never having received antiviral treatment for HCV, as he is currently on IFN, RBV, and direct antiviral drugs. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1641": {
        "output": "",
        "label": 2
    },
    "1642": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. His medical history includes treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's condition does not mention idiopathic normal pressure hydrocephalus or its typical signs (gait disturbance, cognitive impairment, and urinary incontinence). Furthermore, there is no mention of radiological verification of communicating hydrocephalus or cerebrospinal fluid pressure measurements.\n\nGiven that the patient's condition and medical history do not align with the inclusion criteria specified for the clinical trial on idiopathic normal pressure hydrocephalus, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1643": {
        "output": "Given the information provided:\n\n- The patient is a 55-year-old man, which fits within the age range of 18-70 years required by the trial.\n- The patient has been diagnosed with chronic Hepatitis C (HCV), which is the target condition for the trial.\n- The patient is currently on IFN, RBV, and direct antiviral drugs, indicating ongoing treatment for HCV.\n- The trial requires participants to be na\u00efve to prior anti-HCV therapy (IFN and DAA based) or to be relapsers as defined in the inclusion criteria. Since the patient is currently on treatment and there is no indication that he is a relapser or na\u00efve to treatment, he may not meet this criterion.\n- The patient's medical history does not mention any prior treatment regimen of alfa-2a/RBV, nor does it indicate that he is a relapser as defined by the trial's criteria.\n- There is no information given about the patient's HCV RNA levels, so we cannot determine if he meets the \u2265 100,000 IU/mL criterion.\n- The patient does not have HIV or HBV (as he is coinfected with HBV), which is one of the exclusion criteria (seronegative for HBsAg).\n- There is no mention of cirrhosis, so we cannot confirm if the patient has compensated cirrhosis or not.\n\nBased on the provided patient note, the patient does not meet the criteria of being na\u00efve to prior anti-HCV therapy or being a relapser as defined by the trial. Additionally, the patient does not meet the seronegative criteria for HBsAg due to the recent coinfection with HBV. Therefore, the patient would be excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1644": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease,\" we need to assess the patient's characteristics against the inclusion criteria of the clinical trial.\n\nLet's review the inclusion criteria for the trial:\n\n1. Enrolled voluntarily, can understand and sign informed consent.\n2. More than 18 years and less than 65 years.\n3. Body mass index (BMI) is at 18 - 26.\n4. Anti-HCV antibodies and/or HCV RNA positive, and/or other evidence of chronic hepatitis C.\n5. HCV RNA level \u2265 2000IU/ml (or equal to this viral load).\n6. Women's urine pregnancy test was negative, and the subjects (male subjects) are willing to have no pregnancy plans at the next 18 months.\n7. ALT is within 6 times of the upper limit of normal.\n\nNow, let's assess the patient's information:\n\n1. The patient is a 55-year-old man, which satisfies the age criterion (18-65 years).\n2. The patient's BMI is 27, which is slightly above the trial's limit of 26.\n3. The patient has been diagnosed with HCV and has a past medical history of HCV RNA tests and anti-HCV-antibodies, which satisfies criterion 4.\n4. There is no mention of the patient's HCV RNA level, so we cannot confirm if it meets the criterion of \u2265 2000IU/ml.\n5. As the patient is male, the pregnancy test criterion does not apply, but the patient would need to agree to have no pregnancy plans for the next 18 months.\n6. There is no mention of the patient's ALT levels, so we cannot confirm if they are within the specified range.\n\nBased on the information provided, the patient does not meet the BMI criterion, and there is insufficient information regarding the HCV RNA level and ALT levels to determine eligibility. Therefore, the patient is not eligible based on the BMI criterion and lacks sufficient information to assess other relevant criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1645": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, let's analyze the patient's eligibility:\n\n- The patient is a 55-year-old man with a diagnosis of HCV (Hepatitis C Virus) 2 years ago and a recent coinfection with HBV (Hepatitis B Virus).\n- The patient has been on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- There is no evidence of hepatocellular carcinoma or cirrhosis, which is in line with one of the inclusion criteria that subjects diagnosed with cirrhosis must not have hepatocellular carcinoma.\n- The patient's past medical history is non-significant, which is not explicitly stated in the inclusion criteria but is relevant for overall assessment.\n\nNow let's compare this with the inclusion criteria of the trial:\n\n- Subject must have experienced virologic failure as defined in a previous AbbVie/Abbott direct-acting antiviral (DAA) combination trial. (The patient note does not specify virologic failure in a previous AbbVie/Abbott trial.)\n- Subject must be considered an appropriate candidate for peginterferon (pegIFN) alpha-2a, ribavirin (RBV), ABT-450/ritonavir (r), and ABT-267 therapy in the opinion of the investigator. (The patient is currently on IFN and RBV, but there's no information on ABT-450/r and ABT-267.)\n- Subject is infected with hepatitis C virus (HCV) genotype 1 at screening. (The patient note does not specify the genotype of HCV.)\n\nThe patient note does not provide sufficient information to determine if the patient meets the specific inclusion criteria of having experienced virologic failure in a previous AbbVie/Abbott trial or if the patient is infected with HCV genotype 1. Therefore, based on the available information, we cannot determine eligibility, and the patient would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1646": {
        "output": "To determine the trial-level eligibility for the patient, we need to compare the patient's characteristics and medical history with the clinical trial's inclusion criteria.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- Currently on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs\n- No mention of viral genotype\n- Past medical history is non-significant\n- No previous treatment for chronic hepatitis C is mentioned\n- Recent biopsy negative for hepatocellular carcinoma, showing chronic inflammation\n- No evidence of other liver diseases\n- BP: 130/75, HR: 90/min, BMI: 27\n- No ascites or edema\n- No laboratory values for hemoglobin, platelets, or neutrophils are provided\n- No information on the use of contraceptive methods or consent\n\nClinical Trial Inclusion Criteria:\n- Anti-HCV positive\n- Viral load of HCV positive\n- Viral genotypes 1, 2, or 3\n- The absence of previous treatment for chronic hepatitis C\n- Liver biopsy performed in the last 36 months classified by Metavir score as at least A1, with any degree of fibrosis\n- Age from 18 to 70 years old\n- Hemoglobin greater than 11 g/dl\n- Platelet count higher than 75,000/mm3\n- Neutrophils higher than 1,500/mm3\n- Use of at least two contraceptive methods during treatment and up to 36 weeks after the last dose of study medication (for male or female subjects in fertile age)\n- Concordance and signing of the informed consent\n\nAssessment:\n- The patient's age is within the range required by the trial (55 years old, and the trial requires 18 to 70 years old).\n- The patient is anti-HCV positive and has a positive viral load for HCV.\n- There is no indication of the patient's HCV genotype, which is necessary to determine eligibility.\n- There is no clear indication that the patient has not received previous treatment for chronic hepatitis C; the note mentions current treatment with IFN, RBV, and direct antiviral drugs, which may suggest that the patient is not treatment-naive.\n- There is no information on the patient's Metavir score from the liver biopsy.\n- There are no provided laboratory values for hemoglobin, platelets, or neutrophils.\n- There is no information on the use of contraceptive methods or whether the patient has provided informed consent.\n\nBased on the information provided, there is not enough evidence to determine the patient's eligibility for the trial. The patient's current treatment may exclude him from being treatment-naive, which is a requirement. Additionally, the patient's HCV genotype is not stated, and there is no available information on laboratory values or consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1647": {
        "output": "Based on the patient note provided, the 55-year-old man has been diagnosed with chronic hepatitis C virus (HCV) infection and is currently being treated with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. The patient does meet the initial inclusion criterion of having an HCV infection.\n\nHowever, one of the key inclusion criteria for the clinical trial is that participants must have participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR). There is no information in the patient note indicating that this patient has participated in any previous Gilead HCV studies. Therefore, there is insufficient information to determine if the patient meets this specific inclusion criterion.\n\nGiven that participation in a prior Gilead HCV study is a crucial criterion that is not addressed in the patient's note, we do not have enough information to establish his eligibility for the clinical trial. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1648": {
        "output": "The patient in question is a 55-year-old man with a diagnosis of HCV (Hepatitis C Virus) and recent coinfection with HBV (Hepatitis B Virus). His medical history is non-significant other than the viral hepatitis. He is undergoing treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs. There is no mention of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in his medical records, and there is no evidence of other liver-related conditions such as hepatocellular carcinoma, alcoholic liver disease, or metabolic liver disease. His biopsy was only remarkable for chronic inflammation compatible with chronic viral hepatitis.\n\nThe clinical trial in question is studying the genetic causes of non-alcoholic fatty liver disease (NAFLD) and related conditions. The inclusion criteria for the trial require individuals who have NAFLD or related conditions, with either a liver biopsy diagnosis of NASH, radiologic evidence of fatty liver and/or cirrhosis with other causes ruled out, or those who have undergone liver transplantation for NAFLD or cryptogenic cirrhosis.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial because there is no mention of NAFLD or related conditions in his medical history. Additionally, there is no indication that the patient has radiologic evidence of fatty liver or cirrhosis, and he has not undergone a liver transplantation for NAFLD or cryptogenic cirrhosis.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1649": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Dose Ranging of GSK2336805 in Combination Therapy,\" we need to systematically compare the patient's characteristics and medical history with the inclusion criteria of the trial. Let's go through the inclusion criteria one by one:\n\n1. Capable of giving written informed consent: The patient note does not comment on the patient's ability to consent, but since there is no indication of incapacity, we can assume the patient is capable.\n\n2. Male or female aged 18 to 70 years of age: The patient is a 55-year-old man, which meets this criterion.\n\n3. Genotype 1 or genotype 4 hepatitis C virus (HCV) infection: The patient was diagnosed with HCV 2 years ago, but the genotype is not specified in the note provided.\n\n4. Chronic HCV infection documented: The patient has a documented history of chronic HCV infection with positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n\n5. Na\u00efve to all HCV antiviral treatment(s): The patient is currently on IFN, RBV, and direct antiviral drugs for HCV, which indicates he is not treatment-na\u00efve. This disqualifies the patient from the study.\n\n6. Agree to interleukin 28B (IL28B) genotyping: The patient's willingness to undergo IL28B genotyping is not mentioned.\n\n7. Appropriate candidate for pegylated interferon alpha-2a (PEG)/ribavirin (RIBA)/protease inhibitor combination therapy: Since the patient is currently on a treatment regimen including PEG and RIBA, he might be considered an appropriate candidate; however, his current treatment disqualifies him from being treatment-na\u00efve.\n\n8. Body mass index (BMI) >18 kg/m^2 but not exceeding 36 kg/m^2: The patient has a BMI of 27, which meets this criterion.\n\n9. A liver biopsy within 3 years: The patient's recent biopsy was negative for hepatocellular carcinoma and remarkable for chronic inflammation compatible with chronic viral hepatitis. However, there is no mention of the fibrosis score, and it's unclear if the biopsy was within the last 3 years.\n\n10. Fertility and contraception requirements: These are not applicable to the patient's eligibility as he is male, but would be relevant for a female patient's eligibility.\n\n11. Otherwise healthy: The patient appears to be otherwise healthy based on the physical examination and medical history provided.\n\nBased on the information provided, the patient does not meet the inclusion criteria of being na\u00efve to HCV antiviral treatments. Even though other criteria are met or not explicitly contradicted, the fact that the patient has already been treated for HCV disqualifies him from participating in this clinical trial.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1650": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection and has a recent coinfection with hepatitis B virus (HBV). He has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. The patient's medical history does not indicate that he has been previously treated with grazoprevir (MK-5172), which is a specific requirement for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial require that participants must have previously participated in an HCV treatment protocol that included grazoprevir in the treatment regimen and must enroll in the present study within three months of the last study visit of their previous protocol in which they received a grazoprevir-containing regimen.\n\nSince there is no information in the patient note suggesting that the patient has been treated with grazoprevir in the past, he does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1651": {
        "output": "To determine the trial-level eligibility of the provided patient for the clinical trial titled \"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048),\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- BMI: 27\n- No acute distress\n- No ascites or tenderness in the abdomen\n- No edema in lower extremities\n\nInclusion criteria for the trial:\n- BMI \u226518.5 kg/m^2 and \u226432.0 kg/m^2\n- Under evaluation for treatment of chronic hepatitis C virus (HCV)\n- Chronic compensated, genotype 1 HCV infection\n- Treatment-na\u00efve or previously treated and tolerated at least 12 weeks of continuous licensed interferon (including pegylated interferon) and ribavirin combination therapy with at least a partial response, or previously treated with investigational products and/or vaccines, other than HCV NS3/4A protease inhibitors\n- Able to avoid use of anticoagulants, nonsteroidal anti-inflammatory agents and aspirin\n\nExclusion criteria for the trial:\n- Pregnant, lactating, intending to become pregnant or donate eggs/sperm\n- History of stroke, chronic seizures, or major neurological disorder\n- Did not achieve a viral response to prior treatment with licensed interferon-based therapy\n- Previously treated with an NS3/4A protease inhibitor\n- Evidence or history of chronic hepatitis not caused by HCV infection\n- Clinical or laboratory evidence of cirrhosis or other advanced liver disease\n- Decompensated liver disease\n- Diagnosed with or suspected of having hepatocellular carcinoma\n- Co-infection with HIV\n- Positive hepatitis B surface antigen or other evidence of active hepatitis B infection\n- History of gastric bypass surgery or bowel resection\n- History of clinically significant uncontrolled abnormalities or diseases\n- History of clinically significant neoplastic disease\n- Excessive alcohol consumption\n- Regular user of illicit drugs or history of drug abuse within the last 3 months\n- Surgery or donation of blood or participation in another study within 4 weeks prior to screening\n- History of multiple and/or severe allergies, or anaphylactic reaction or intolerability to drugs or food\n\nThe patient's BMI is within the required range, and he is under treatment for chronic HCV, which meets the inclusion criteria. However, the patient has a recent coinfection with HBV, which is an exclusion criterion as per the trial's exclusion criteria, which state that participants should not have evidence of active hepatitis B infection.\n\nGiven this information, the patient is excluded from the trial due to the coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1652": {
        "output": "Based on the information provided:\n\n- The patient is a 55-year-old man, which satisfies the age criterion (>18 years).\n- He is diagnosed with HCV, which is the target condition of the clinical trial.\n- His medical history indicates he is currently on treatment with IFN, RBV, and direct antiviral drugs, which means he is not treatment-naive. The trial includes both treatment-naive and treatment-experienced subjects, so this is not an excluding factor.\n- The presence or absence of cirrhosis is mentioned as part of the inclusion criteria; the patient note does not specify cirrhosis, but it does not indicate its presence either, which implies the patient could be eligible if other criteria are met.\n- The patient's medical history should be considered healthy, with the exception of the HCV diagnosis.\n- Regarding contraception, the patient note does not provide information about the patient's willingness to use two forms of highly effective contraception. However, this is a requirement that can be addressed and agreed upon before the study begins if all other criteria are met.\n\nThe patient note does not provide the HCV RNA levels, which is a specific inclusion criterion. Without this information, we cannot conclusively determine if the patient meets all the necessary inclusion criteria.\n\nGiven the available details, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1653": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Hemophilia B is not mentioned\n\nClinical Trial Inclusion Criteria:\n- Males age 18-75 years, inclusive (Patient is 55 years old, so this criterion is met)\n- Established hemophilia B with \u22653 hemorrhages per year requiring treatment with exogenous FIX OR use of FIX prophylaxis because of history of frequent bleeding episodes (There's no mention of hemophilia B or bleeding issues in the patient's note)\n- Plasma FIX activity \u22642% (No information on the patient's FIX activity levels)\n- Negative for active Hepatitis C virus (HCV), defined as Hepatitis C virus antibody-negative and negative (undetectable) PCR test for plasma Hepatitis C virus ribonucleic acid (RNA) OR if Hepatitis C virus antibody positive must have \u22652 consecutive negative (undetectable) PCR tests for plasma HCV RNA at least 3 months apart, and negative at screening (The patient has an HCV diagnosis and is on treatment, but there's no information about the current HCV RNA test results)\n\nThe patient's note does not provide sufficient information to determine if they meet the specific inclusion criteria related to hemophilia B and FIX activity levels. Additionally, the patient has a positive history for HCV, which conflicts with the trial's requirement for a negative (undetectable) PCR test for plasma HCV RNA, unless there are \u22652 consecutive negative PCR tests which are not mentioned in the patient note.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial as there is no indication of a diagnosis of hemophilia B, and there is evidence of a positive HCV diagnosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1654": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient is a 55-year-old man diagnosed with HCV 2 years ago, with recent coinfection with HBV. The patient is currently on IFN, RBV, and direct antiviral drugs. The patient's medical history is non-significant, and there is no evidence of hepatocellular carcinoma or other liver diseases mentioned in the exclusion criteria.\n\nTo determine the patient's eligibility for the clinical trial titled \"Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis,\" we have to match the patient's characteristics and condition against the inclusion and exclusion criteria of the trial.\n\nKey Inclusion Criteria for HCV-infected individuals (relevant to this patient):\n- Chronic HCV infection with HCV RNA \u2265 2000 IU/ml\n- At least one of the following conditions:\n  - Been a null responder to previous pegylated interferon and ribavirin therapy\n  - Failed to achieve sustained virologic response (SVR) on a regimen containing a direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin\n  - Are unwilling to receive or have contraindications to interferon therapy for HCV\n- Willingness to allow blood and tissue samples to be stored\n- Have a primary care physician\n\nKey Exclusion Criteria (relevant to this patient):\n- Cause of liver fibrosis other than HCV or long-term antiretroviral therapy (ART) treatment for HIV\n- Currently being treated for HCV\n- Evidence of active Hepatitis A, B, or D infections\n- History or evidence of hepatocellular carcinoma\n- Unwillingness to undergo a liver biopsy pre-treatment and post-treatment, or to undergo all other protocol-required tests/procedures or return to the site for required visits\n- Presence of contraindications to magnetic resonance imaging (MRI)\n\nThe patient's note does not provide information on the following:\n- The HCV RNA level (whether it is \u2265 2000 IU/ml)\n- Whether the patient has been a null responder to previous therapies or has failed to achieve SVR on a regimen containing a DAA\n- Whether the patient is willing to allow blood and tissue samples to be stored\n- Whether the patient has a primary care physician\n- The patient's willingness to undergo a liver biopsy and other tests/procedures\n\nMoreover, the patient is currently being treated for HCV, which is listed as an exclusion criterion. Therefore, the patient is excluded based on this information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1655": {
        "output": "",
        "label": 0
    },
    "1656": {
        "output": "Based on the information provided in the patient note, here are the key points relevant to the inclusion criteria for the clinical trial:\n\n1. The patient is a 55-year-old man diagnosed with chronic hepatitis C (HCV) 2 years ago and recently coinfected with hepatitis B virus (HBV). \n2. The patient's past medical history is non-significant, and he is currently on treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. \n3. There is no evidence of hepatocellular carcinoma or chronic liver diseases such as alcoholic liver disease, hemochromatosis, autoimmune hepatitis, or metabolic liver disease, which implies no evidence of cirrhosis.\n4. The patient appears compensated with no ascites or tenderness in the abdomen, and no edema in the lower extremities.\n\nNow, let's analyze the inclusion criteria for the trial:\n\n1. Chronic, compensated HCV genotype 1 (GT1) hepatitis C.\n2. IL28B CC genotype.\n3. Absence of advanced liver disease symptoms or cirrhosis.\n4. No evidence of cirrhosis and hepatocellular carcinoma by biopsy or noninvasive tests.\n5. Agreement to use two acceptable methods of birth control (relevant for females of childbearing potential or males with female sexual partners of childbearing potential).\n\nThe patient note does not mention the specific genotype of the patient's hepatitis C virus (whether it is GT1) nor the IL28B genotype. These are critical pieces of information needed to determine eligibility. Without this information, we cannot definitively assess whether the patient meets the specific criteria of having chronic, compensated HCV GT1 hepatitis C and the IL28B CC genotype.\n\nGiven the absence of this specific information, the patient cannot be confirmed as eligible for the trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1657": {
        "output": "To determine the eligibility of the 55-year-old male patient for the clinical trial titled \"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) \u00b1 Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035),\" we need to compare the patient's information to the inclusion and exclusion criteria provided.\n\nInclusion criteria to be considered:\n- CHC genotype 1 (GT1) virus infection or GT3 virus infection\n- Use of acceptable methods of birth control (if applicable)\n- For Part A: Absence of advanced liver disease symptoms and no evidence of advanced fibrosis, cirrhosis, or HCC\n- For Parts B, C, and D: Treatment na\u00efve or prior treatment failure, with or without cirrhosis, and absence of advanced liver disease symptoms; liver disease staging assessment\n\nExclusion criteria to be considered:\n- Non-GT1 HCV infection for Parts A, B, and C or non-GT3 HCV infection for Part D\n- Evidence of HCC or evaluation for HCC\n- Other exclusion criteria not applicable based on the patient's note\n\nBased on the patient note:\n- The patient has been diagnosed with HCV 2 years ago; however, the genotype of the HCV is not specified.\n- The patient is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- There is no evidence of advanced liver disease, cirrhosis, or hepatocellular carcinoma.\n\nGiven the information provided, we cannot determine whether the patient has CHC genotype 1 or 3, which is a necessary inclusion criterion. Furthermore, the patient is currently under treatment with direct antiviral drugs, which may conflict with the exclusion criteria for Parts B, C, and D that specify participants should not have previously received any HCV direct-acting antivirals.\n\nTherefore, due to insufficient information regarding the HCV genotype and the current antiviral treatment, we cannot definitively include the patient in the trial. The patient does not have sufficient information to qualify for the trial without knowing the HCV genotype and considering the ongoing antiviral therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1658": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- The patient is a 55-year-old male.\n- Diagnosed with HCV and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications are being taken.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- Vital signs and physical examination are within normal limits.\n\nClinical Trial Summary:\n- This clinical trial is assessing the reactogenicity, safety, and immunogenicity of a live monovalent H5N2 influenza vaccine.\n- The vaccine is administered intranasally.\n- The trial is for healthy adults.\n\nClinical Trial Inclusion Criteria:\n- Legal male or female adult 18 through 49 years of age at the enrollment visit.\n- Literate and willing to provide written informed consent.\n- Free of obvious health problems, as established by medical history and screening evaluations, including physical examination.\n- Capable and willing to complete diary cards and willing to return for all follow-up visits.\n- Willing to comply with the rules of the isolation unit.\n- For females, willing to take reliable birth control measures throughout the period of participation in the study.\n\nBased on the inclusion criteria, the patient does not meet the age requirement for the clinical trial, as he is 55 years old and the trial is limited to adults 18 through 49 years of age.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1659": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B Virus).\n- The patient has been on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- The patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- There is no mention of the patient having participated in an Idenix-sponsored study or having received treatment with an Idenix DAA (Direct Acting Antiviral).\n\nClinical Trial Inclusion Criteria:\n- Must have read and signed the written informed consent form (ICF) after the nature of the study has been fully explained.\n- Must have participated in an Idenix-sponsored study of an Idenix DAA.\n- Must have received at least 3 consecutive days of DAA treatment in an Idenix-sponsored study.\n- Must have agreed to comply with the visit schedule and laboratory tests.\n\nAssessment:\n- There is no information indicating that the patient has participated in an Idenix-sponsored study or received an Idenix DAA.\n- Because one of the critical inclusion criteria is the participation in a prior Idenix-sponsored study and receiving DAA treatment through that study, and this information is not provided in the patient\u2019s history, the patient does not meet the essential inclusion criteria.\n\nTherefore, the patient does not meet the inclusion criteria based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1660": {
        "output": "",
        "label": 0
    },
    "1661": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C),\" we need to compare the patient's characteristics and medical history with the specified inclusion criteria of the trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Provision of written, informed consent.\n2. HCV genotype 1 infection\n3. Quantifiable HCV RNA at screening and baseline (>10,000 IU/ml)\n4. Recent hepatitis C infection with an estimated duration of infection >6 months and \u2264 18 months defined as:\n   A) i) First anti-HCV antibody or HCV RNA positive within the previous 6 months and ii) Documented anti-HCV antibody negative or HCV RNA negative within the 24 months prior to anti-HCV antibody positive result OR\n   B) i) First anti-HCV antibody or HCV RNA positive within the previous 6 months and ii) acute clinical hepatitis (jaundice or ALT> 10 X ULN) within the 12 months prior to first positive HCV antibody or HCV RNA with no other cause of acute hepatitis identifiable\n5. Compensated liver disease (Child-Pugh A)\n6. Negative pregnancy test at screening and 24 hours prior to the first dose of study drugs (not applicable to this male patient).\n7. If heterosexually active, a female subject of childbearing potential and a nonvasectomized male subject who has a female partner of childbearing potential must agree to use 2 effective contraceptives from screening onwards until 6 months (female subject) or 7 months (male subject) after RBV therapy has ended.\n8. Subject is judged to be medically stable on the basis of physical examination, medical history, and vital signs.\n9. Adequate English to provide written, informed consent and to provide reliable responses to the study interview\n\nFrom the patient note, we have the following information:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- His past medical history is non-significant.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient has been tested positive for HCV RNA and anti-HCV antibodies.\n- The recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n- There is no mention of the patient's HCV genotype.\n- There is no information on when the patient first tested positive for HCV RNA or anti-HCV antibodies.\n- The duration of HCV infection is mentioned as 2 years, which is more than the required \u2264 18 months as per the inclusion criteria.\n- The patient appears to be medically stable based on physical examination, medical history, and vital signs.\n\nBased on the information provided, the patient does not meet the inclusion criteria regarding the duration of HCV infection (>6 months and \u2264 18 months) because the patient has been diagnosed with HCV for 2 years. Additionally, there is no information on the patient's HCV genotype, which is a specific requirement for inclusion. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1662": {
        "output": "",
        "label": 1
    },
    "1663": {
        "output": "The patient note describes a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. The patient's past medical history is non-significant, and he is currently on IFN, RBV, and direct antiviral drugs. The biopsy does not indicate hepatocellular carcinoma but shows chronic inflammation compatible with chronic viral hepatitis. There is no mention of HIV infection, which is a key aspect of the clinical trial's inclusion criteria.\n\nThe clinical trial in question is focused on the efficacy and safety of a medication regimen in adults with HIV and HBV coinfection. To be eligible for the trial, participants need to have both serologically-confirmed HIV and HBV infection, be willing to participate, have no previous or current use of antiretroviral regimen, have stable clinical conditions, certain laboratory values within specified ranges, and have clinical indications for HAART (Highly Active Antiretroviral Therapy).\n\nSince the patient note does not mention HIV infection, which is a necessary criterion for inclusion in the trial, the patient does not meet the inclusion criteria based solely on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1664": {
        "output": "The patient in the note is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He is on treatment with IFN, RBV, and direct antiviral drugs. There is no mention of him being a health care worker or experiencing a needlestick injury. The inclusion criteria for the clinical trial specifically mention the trial is for MGH or BWH health care workers with exposure through needlestick injury to source patients who are anti-HCV (+) and HCV RNA (+).\n\nSince there is no information provided that the patient is a health care worker or has had a needlestick injury, and the patient himself is HCV RNA positive, he does not meet the inclusion criteria for the clinical trial, which is focused on post-exposure prophylaxis for health care workers.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1665": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113),\" we must compare the patient's information with the trial's inclusion and exclusion criteria.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- Past medical history is non-significant.\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or other significant liver disease.\n- No history of psychiatric disease, inadequately controlled thyroid function, or substance abuse mentioned.\n- No alcohol intake information provided.\n- No information on insulin resistance (HOMA IR) provided.\n- No information on previous treatment failure with PegIFN and RBV provided.\n- The patient has a coinfection with HBV.\n\nClinical Trial Inclusion Criteria:\n- Quantifiable serum hepatitis C virus-ribonucleic acid (HCV-RNA).\n- Hepatitis C virus genotype 1.\n- Homeostasis Model of Assessment - Insulin Resistance (HOMA IR) > 2.5 in two determinations made 4 weeks apart.\n- Previous failure to achieve SVR with PegIFN plus ribavirin given for a minimum of 12 weeks without dose reduction below 80% of the adequate doses of the two drugs.\n- No response, partial response, or relapse after previous therapy.\n- Compensated liver disease with or without histologic or non-invasive evidence of liver cirrhosis.\n\nClinical Trial Exclusion Criteria:\n- Coinfection with HCV genotypes other than HCV-GT1.\n- Evidence of decompensated liver disease.\n- History or signs or symptoms or evidence of hepatocellular carcinoma (HCC).\n- History of organ transplant.\n- Coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).\n- Severe psychiatric disease.\n- Inadequately controlled thyroid function.\n- Other important comorbidities.\n- Substances abuse.\n- Alcohol intake >20 grams/day for females and >30 grams/day for males.\n- History of severe adverse events during previous treatment with PegIFN plus ribavirin.\n\nEligibility Assessment:\n- The patient has HCV, which is a requirement for the trial.\n- The genotype of the patient's HCV is not specified.\n- There is no information about the patient's insulin resistance status (HOMA IR).\n- There is no explicit mention of the patient previously failing dual therapy with PegIFN and RBV.\n- The patient is coinfected with HBV, which is a specific exclusion criterion.\n\nBased on the available information, the patient is not eligible for the clinical trial because of the coinfection with HBV, which is listed under the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1666": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- Past medical history is non-significant\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- Previous positive HCV RNA tests and positive for anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases\n- No type 2 diabetes mentioned\n- Vital signs: BP 130/75, HR 90/min\n- BMI: 27\n- Abdomen soft with no ascites or tenderness\n- Lower extremities normal with no edema\n\nClinical Trial Inclusion Criteria:\n- Hepatitis C genotype 3a\n- Hepatitis C Virus (PCR) RNA Detected\n- Alanine transaminase >60\n- Diabetic HbA1c < 8\n- BMI > 23\n\nThe patient's note does not mention the Hepatitis C genotype, so we cannot confirm if it is genotype 3a as required by the trial. It also does not mention the patient's Alanine transaminase levels or HbA1c, and there is no information to suggest the patient has type 2 diabetes, which is a specific requirement for the trial.\n\nGiven the information provided, the patient does not appear to meet all of the inclusion criteria for the clinical trial, specifically the requirements for Hepatitis C genotype, Alanine transaminase levels, and type 2 diabetes status.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1667": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, which meets the age requirement of being 18 years or older.\n- The patient has been diagnosed with chronic hepatitis C (HCV) 2 years ago and has a recent coinfection with hepatitis B (HBV).\n- The patient is on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months, indicating ongoing management for his chronic viral hepatitis.\n- The patient has a history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n- There is no mention of the patient being unwilling or unable to provide written informed consent or comply with visit procedures.\n\nClinical Trial Inclusion Criteria Analysis:\n- Willing and able to provide written informed consent (patient's willingness is not explicitly stated but there is no indication that the patient is unwilling or unable to consent).\n- Male or female, age >= 18 (the patient is a 55-year-old male, so this criterion is met).\n- Willing and able to comply with the visit procedure (again, the patient's willingness is not explicitly stated, but there is no indication of an inability to comply).\n- Prior diagnosis of chronic HCV infection or chronic HBV infection (the patient has both, so this criterion is met).\n\nGiven that the patient's characteristics match the inclusion criteria and there is no mention of any exclusion criteria or inability to participate, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1668": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's analyze the patient's eligibility:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- No history of alcoholic liver disease\n- Currently on IFN, RBV, and direct antiviral drugs\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal physical examination without signs of liver disease complications\n\nClinical Trial Inclusion Criteria:\n- Patients more than 18 years old\n- Hospitalized for alcoholic weaning\n- With an alcoholic liver disease\n- With at-risk alcoholic consumption\n- With an indication of liver biopsy\n- With a signed consentment\n\nThe patient in the note does not have alcoholic liver disease, nor is there an indication that he is hospitalized for alcoholic weaning or has at-risk alcoholic consumption. Therefore, the patient does not meet the specific inclusion criteria for this clinical trial focused on alcoholic liver disease and transient elastography.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1669": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recently coinfected with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of HCV genotype.\n- No mention of HCV RNA viral load.\n- The patient is not treatment-na\u00efve as he has been treated with IFN, RBV, and direct antiviral drugs.\n\nClinical Trial Inclusion Criteria:\n- Patients chronically infected with Hepatitis C virus (HCV) GT 1 or 4.\n- HCV RNA viral load \u2265 10,000 IU/mL.\n- Na\u00efve to prior treatment with any interferon formulation, Ribavirin (RBV), or HCV direct antiviral agent.\n- Patients with compensated cirrhosis are permitted.\n\nThe patient does not meet the eligibility criteria for the clinical trial because he is not treatment-na\u00efve, having already been treated with IFN, RBV, and direct antiviral drugs. Additionally, there is no information on the genotype of the patient's HCV or the viral load, which are both required for eligibility. Therefore, this patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1670": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 55-year-old man diagnosed with HCV 2 years ago.\n- Recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- No evidence of hepatocellular carcinoma.\n- No mention of cirrhosis.\n- No mention of the genotype of HCV infection.\n- No mention of failure of prior interferon-based treatment.\n\nClinical Trial Inclusion Criteria:\n- Infection with genotype 2 or 3 HCV infection.\n- Cirrhosis determination.\n- Individual is treatment-experienced.\n- Screening laboratory values within defined thresholds.\n- Individual has not been treated with any investigational drug or device within 30 days of the Screening visit.\n- Use of highly effective contraception methods if female of childbearing potential or sexually active male.\n\nFrom the information provided, we know that the patient has an HCV infection and is on treatment, indicating that he is treatment-experienced. However, the patient note does not mention:\n- The genotype of the patient's HCV infection, which is crucial to determine eligibility as the trial specifically requires genotype 2 or 3.\n- Whether the patient has cirrhosis or not.\n- If the patient has failed prior treatment with an interferon-based regimen.\n- The patient's laboratory values to assess if they are within the defined thresholds.\n\nDue to the missing information regarding the HCV genotype, cirrhosis status, prior treatment failure, and laboratory values, we cannot confirm the patient's eligibility for this clinical trial. Thus, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1671": {
        "output": "",
        "label": 0
    },
    "1672": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His medical records do not mention any requirement for knee arthroplasty, and his current medical condition is related to his liver disease.\n\nThe clinical trial in question is focused on patients undergoing unilateral or bilateral total knee arthroplasty and is investigating the effects of low-dose corticosteroids on perioperative markers of thrombosis and fibrinolysis. The inclusion criteria specify that patients must be undergoing knee replacement surgery and must be aged between 50-90 years.\n\nSince the patient in the note does not require knee arthroplasty and is not undergoing such a procedure, he does not meet the inclusion criteria for this clinical trial, regardless of fitting the age range.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1673": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial \"THISTLE - The HIV-HCV Silibinin Trial,\" let's assess the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of HIV coinfection\n- No mention of HCV Genotype (required Genotype 1)\n- Past medical history is non-significant\n- No mention of liver fibrosis score or fibroscan results\n- No mention of previous null-response or partial-response to standard of care (SOC)\n\nClinical trial inclusion criteria:\n- Age greater or equal to 18 years (Patient meets this criterion)\n- HIV-HCV coinfection (Patient's HIV status not mentioned)\n- HCV Genotype 1 infection (Patient's HCV genotype not mentioned)\n- At least one liver biopsy since diagnosis of HCV-infection (Patient meets this criterion)\n- Fibrosis score METAVIR = 2 documented by biopsy OR a stiffness greater or equal to 7.0 kPa documented by fibroscan during the previous 12 months (Patient's fibrosis score or fibroscan results not mentioned)\n- Documented previous null-response or partial-response to SOC (Patient's response to SOC not mentioned)\n\nThe patient note does not provide sufficient information to definitively determine eligibility based on the trial's inclusion criteria. We do not know the patient's HIV status, HCV genotype, liver fibrosis score, or response to previous SOC treatment. Therefore, the patient cannot be considered eligible based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1674": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with chronic hepatitis C (CHC) 2 years ago and recent coinfection with hepatitis B virus (HBV)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of cirrhosis (METAVIR F4) or other surrogate criteria indicative of established cirrhosis\n- No history of hepatocellular carcinoma\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n\nClinical trial inclusion criteria:\n- Age 18-70\n- Chronic liver disease due to CHC or CHB\n- Starting of disease-specific treatment no earlier than January of 2010\n- Established cirrhosis on liver biopsy (METAVIR F4) obtained before starting disease-specific treatment or surrogate criteria to define cirrhosis\n\nThe patient's age fits the trial's inclusion criteria, and he has chronic liver disease due to CHC and HBV. He has also started disease-specific treatment within the specified time frame.\n\nHowever, there is no mention in the patient note of established cirrhosis, which is required for inclusion in the study, either by liver biopsy (METAVIR F4) or by surrogate criteria such as spleen size, abnormal bilirubin/albumin/INR levels, APRI score, or evidence of esophageal varices or ascites. Without this information, we cannot determine if the patient has established cirrhosis, which is a critical inclusion criterion for the trial.\n\nGiven the available information, the patient does not have sufficient information to qualify for the trial because we do not have evidence of established cirrhosis, which is a key inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1675": {
        "output": "The patient in the note is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. He has been on IFN, RBV, and direct antiviral drugs for the past 6 months. The biopsy results were negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis. There is no mention of the patient being treatment-na\u00efve, which is a requirement for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial require participants to be treatment-na\u00efve with confirmed chronic HCV infection. The patient has been on a treatment regimen, which means he would not be considered treatment-na\u00efve. Additionally, the inclusion criteria require a liver biopsy within 2 years prior to screening or non-invasive confirmation of liver disease stage within 6 months prior to screening, with a liver disease stage equivalent to Metavir Score F0-F2. Although the patient had a recent biopsy, there is no specific mention of the Metavir Score or equivalent staging of liver disease in the patient note.\n\nBased on the information provided, the patient does not meet the inclusion criteria of being treatment-na\u00efve, and there is insufficient information to confirm the liver disease stage according to the trial's requirements. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1676": {
        "output": "Based on the provided patient note and the clinical trial information, the patient appears to meet the inclusion criteria for the clinical trial. The inclusion criteria for the clinical trial are:\n\n- Patients with chronic hepatitis C eligible to receive antiviral treatment.\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C (HCV) 2 years ago and recent coinfection with hepatitis B (HBV). He has been on IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months, which aligns with the requirement of being eligible to receive antiviral treatment. There is no mention of any exclusion criteria in the clinical trial details that would exclude the patient. Therefore, the patient is eligible to participate in the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1677": {
        "output": "The patient note provides the following relevant information:\n\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- Medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n- Recent biopsy negative for hepatocellular carcinoma, showing chronic inflammation compatible with chronic viral hepatitis.\n- No evidence of cirrhosis or other liver diseases listed in the note.\n\nThe clinical trial's inclusion criteria are as follows:\n\n- Chronic hepatitis C infection (positive for anti-HCV antibody or HCV RNA at least 6 months before screening and at the time of screening; or positive for anti-HCV antibody or HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection).\n- Screening laboratory result indicating HCV genotype 1 infection (HCV GT1).\n- Participant must have documentation of adherence to a prior pegIFN/RBV combination therapy and meet one of the protocol definitions for treatment failure: null responder, partial responder, relapser.\n- No evidence of liver cirrhosis.\n- For females, specific forms of birth control, post-menopausal status, or surgical sterility are required (this is not applicable to our patient as he is male).\n\nBased on the patient note, the patient appears to meet the inclusion criteria:\n\n- He has a chronic hepatitis C infection, as indicated by his positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n- The patient is currently on IFN and RBV, suggesting prior adherence to combination therapy, although the note does not specify whether he meets the protocol definitions for treatment failure.\n- There is no evidence of cirrhosis, which meets the trial's requirement.\n- The patient's gender is male, so the birth control criterion is not applicable.\n\nHowever, the patient note does not specify the hepatitis C virus genotype, which is required to be genotype 1 for the trial. Since this information is not provided, we cannot confirm eligibility based on the available information.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1678": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess whether the patient meets all the inclusion criteria based on the provided patient note.\n\nInclusion Criteria for the Clinical Trial:\n1. Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA \u2265 105 IU/mL at the time of screening.\n2. Subjects must have chronic HCV infection as determined by any of the following:\n   - be anti-HCV (+) for at least 6 months per subject history or medical records\n   - an anti-HCV test, viral load, or genotype > 6 months ago\n   - In the setting of a recent positive anti-HCV test (< 6 months), liver biopsy demonstrating chronicity\n3. Subjects must have IL-28b genotype CC\n4. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2.\n\nPatient Note Assessment:\n1. The patient has been diagnosed with HCV 2 years ago, which indicates a chronic infection.\n2. The patient has been on treatment for the past 6 months, which includes IFN, RBV, and direct antiviral drugs. However, there is no specific mention of the patient's HCV RNA levels, genotype, or IL-28b genotype.\n3. The patient's BMI is 27, which falls within the required range for the study.\n4. The patient weighs at least 50 kg, as indicated by a BMI of 27 and no mention of being underweight.\n\nGiven the information from the patient note, we can determine the following:\n- The patient meets the criteria for having a chronic HCV infection.\n- The patient's BMI is within the required range.\n\nHowever, we do not have information about the following:\n- The patient's plasma HCV-RNA levels at the time of screening.\n- The patient's HCV genotype.\n- The patient's IL-28b genotype.\n\nBecause we lack crucial information regarding the patient's plasma HCV-RNA levels, HCV genotype, and IL-28b genotype, we cannot conclusively determine eligibility. Therefore, the patient falls under the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1679": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria for the clinical trial, we can determine the patient's eligibility as follows:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection and a recent coinfection with hepatitis B virus (HBV). He has been on treatment with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months. There is no mention of cirrhosis in the patient's note, and the recent biopsy was negative for hepatocellular carcinoma, indicating that the patient does not have cirrhosis. His body mass index (BMI) is 27 kg/m^2, which is above the minimum requirement of 18 kg/m^2 for the trial.\n\nGiven that the patient has chronic HCV infection, is already on RBV treatment, and has a BMI that meets the requirement, he appears to meet the inclusion criteria. The trial requires a screening HCV RNA level of \u2265 10000 IU/mL, although this value is not provided in the patient note. However, the patient does have a history of positive HCV RNA tests.\n\nThe inclusion criteria specify the use of highly effective contraception methods if the patient is a female of childbearing potential or a sexually active male. Since the patient is male, this would apply; however, there is no information provided regarding contraception use.\n\nBased on the available information, the patient meets the chronic HCV infection criteria, his BMI is within the required range, and there's no evidence of cirrhosis. The patient appears to be eligible for the trial, assuming his HCV RNA level meets the specified threshold and that he either practices effective contraception or it is not applicable (e.g., not sexually active or has a partner who is not of childbearing potential). However, due to the lack of specific information regarding his HCV RNA level and contraception practices, we cannot definitively determine his eligibility without further information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1680": {
        "output": "",
        "label": 0
    },
    "1681": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial for MK-3475 in patients with microsatellite unstable (MSI) tumors, let's assess the eligibility:\n\nPatient Note:\n- 55-year-old man diagnosed with HCV and recent coinfection with HBV.\n- No mention of colon cancer or any type of cancer, only chronic viral hepatitis.\n- The patient is currently being treated for HCV and HBV, no mention of cancer treatment.\n- No information on ECOG Performance Status or organ function.\n- No information about microsatellite instability (MSI) status of any tumors.\n\nClinical Trial Inclusion Criteria:\n- Cohort A: Patients with MSI positive colorectal cancer.\n- Cohort B: Patients with MSI negative colorectal cancer.\n- Cohort C: Patients with MSI positive non-colorectal cancer.\n- Measurable disease.\n- ECOG Performance Status of 0 to 1.\n- Adequate organ function.\n- Use of acceptable form of birth control.\n- Signed informed consent.\n- Willingness and ability to comply with study procedures.\n- Agreement to have a cancer biopsy.\n- Specific prior cancer therapy requirements.\n- Progressive disease.\n\nAssessment:\nThe patient's note does not mention any diagnosis of colorectal or non-colorectal cancer, nor is there an indication of the patient having MSI positive or negative status. Furthermore, there is no information on measurable disease, ECOG Performance Status, or the patient's willingness and ability to comply with study procedures, including a cancer biopsy.\n\nGiven the lack of relevant information in the patient note concerning the inclusion criteria of the clinical trial, the patient cannot be considered eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1682": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV,\" we must compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nThe patient's characteristics and medical history:\n\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No signs of decompensated liver disease or cirrhosis\n- No mention of HIV infection status\n\nThe clinical trial's inclusion criteria:\n\n- Eighteen years of age or older at screening\n- Chronic hepatitis C infection\n- HIV treatment status (either untreated or on a stable ARV regimen with specific requirements)\n- Documentation of hepatitis C genotype 1a, 1b, or mixed 1a/1b\n- Absence of cirrhosis\n- Willing to practice safe contraception methods\n- Able to effectively communicate and comply with the study requirements\n- No prior exposure to IFN, RBV, or HCV-specific direct-acting antiviral agents (treatment-naive for HCV)\n\nThe clinical trial's exclusion criteria:\n\n- Co-infection with HBV (positive test at screening for either HBsAg or quantifiable HBV DNA)\n- Other significant medical conditions\n- Prior history or current use of non-protocol approved ARVs\n- Other detailed criteria related to health status and medication use\n\nBased on the provided patient note, the patient does not appear to have an HIV infection, which is a requirement for the study. Additionally, the patient has been treated with IFN, RBV, and direct antiviral drugs, which contradicts the requirement for the participant to be HCV treatment-naive. Moreover, the patient has a co-infection with HBV, which is listed under the exclusion criteria.\n\nTherefore, the patient does not meet the critical inclusion criteria of having an HIV infection and being HCV treatment-naive and is explicitly excluded due to HBV coinfection.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1683": {
        "output": "In evaluating the patient's eligibility for the clinical trial titled \"New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress\n- Normal BP, HR, and BMI\n- No ascites or tenderness in the abdomen\n- No lower extremity edema\n\nClinical Trial Inclusion Criteria:\n- Adults, ages 18 and above\n- Chronic hepatitis C (HCV RNA in serum for more than 6 months)\n- HCV Genotype 1\n- HCV RNA in serum above 10,000 IU/mL\n- Non-response to previous therapy with peginterferon and ribavirin\n- No contraindications to agents being used\n- No evidence or history of hepatic decompensation\n- Females of childbearing potential must have a negative pregnancy test (not applicable to the male patient)\n- Use of highly effective methods of birth control to minimize the risk of pregnancy (applicable to female partners of male patients)\n- Women must not be breastfeeding (not applicable to the male patient)\n- Fully informed, written consent to the study including repeat liver biopsy\n\nClinical Trial Exclusion Criteria (relevant to the patient):\n- History of chronic hepatitis B virus (HBV) as documented by HBV serologies\n- Evidence of decompensated liver disease\n- Any other medical condition contributing to chronic liver disease other than HCV\n- Uncontrolled diabetes or hypertension\n- Other significant health issues that may affect participation in the study\n\nAssessment:\nThe patient is a 55-year-old male with chronic HCV, fulfilling the age requirement. He has been on treatment for HCV for the past 6 months, but there is no information on whether his HCV is of Genotype 1 or if he has had a non-response to previous therapy with peginterferon and ribavirin. The patient note does not provide HCV RNA levels, so we cannot confirm if the serum levels are above the required 10,000 IU/mL.\n\nHowever, the patient has a recent coinfection with HBV, which is listed as an exclusion criterion if there is a history of chronic hepatitis B virus (HBV) documented by HBV serologies.\n\nBased on the available information, the patient's coinfection with HBV would exclude him from the trial, despite meeting some of the inclusion criteria. There is insufficient information to confirm his eligibility based on other criteria, such as HCV genotype and response to previous therapy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1684": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, here is the assessment:\n\nThe patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He is currently on a treatment regimen for HCV including IFN, RBV, and direct antiviral drugs.\n\nThe clinical trial's inclusion criteria require participants to be healthy volunteers with:\n- No history of chronic diseases;\n- Preserved oral health;\n- No history of acute illness in the last 30 days;\n- Absence of significant clinical symptoms and signs on physical examination;\n- Laboratory tests within normal limits;\n- Imaging tests within normal limits;\n- Seronegative tests for HIV and B and C Hepatitis;\n- Male;\n- Age between 18 and 35 years;\n- Body mass index between 19 and 26.\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- He has a history of chronic diseases (HCV and recent HBV coinfection).\n- His age is 55, which is outside the 18 to 35 years age range required by the study.\n- His BMI is 27, which is above the 19 to 26 range required by the study.\n\nBased on this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1685": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we need to determine if the patient is eligible for the trial titled \"Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA\".\n\nPatient Note Analysis:\n- The patient is 55 years old, which meets the age inclusion criterion of \u2265 18 years.\n- The patient has been diagnosed with HCV 2 years ago and has a recent coinfection with HBV, which is relevant to the trial.\n- The patient is on a regimen of IFN, RBV, and direct antiviral drugs, indicating that he is not antiviral treatment na\u00efve, which may conflict with the trial's requirement for antiviral treatment-na\u00efve patients.\n- There is no mention of a spontaneous decline of HBV DNA.\n- HBV DNA levels and specifics on HBeAg status are not provided in the note.\n- There is no information provided regarding the patient's serum alanine aminotransferase (ALT) levels, total bilirubin (TBIL) levels, or prothrombin time activity (PTA).\n- The patient does not appear to have advanced fibrosis, cirrhosis, or hepatoma, as the biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must be antiviral treatment na\u00efve.\n- Patients must have been positive for HBsAg for at least 6 months.\n- Patients must be positive for HBeAg.\n- HBV DNA Level must be more than 500,000IU/ml.\n- Serum ALT level must be greater than 2 but less than or equal to 30 times the upper limit of the normal range.\n- Peak value of TBIL must range from 2mg/ml to 20mg/ml.\n- PTA must be greater than 60%.\n- Patients must have a spontaneous decline of HBVDNA by 2 log(10) IU/mL, with ALT falling below 10 ULN and TBIL falling below 2mg/ml within 8 weeks of pretreatment.\n\nGiven the information in the patient note, there are several key pieces of data missing to determine eligibility for this trial, such as the patient's HBsAg status duration, HBeAg status, HBV DNA levels, ALT levels, TBIL levels, and PTA. Moreover, the patient is not antiviral treatment na\u00efve, which is a requirement for the trial. Therefore, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1686": {
        "output": "",
        "label": 0
    },
    "1687": {
        "output": "",
        "label": 0
    },
    "1688": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with Hepatitis C Virus (HCV) 2 years ago\n- Recently coinfected with Hepatitis B Virus (HBV)\n- On treatment with Interferon (IFN), Ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months\n- No mention of previous IFN treatment\n- No other medications\n- Previous positive HCV RNA tests\n- Positive for anti-HCV antibodies\n- Negative for hepatocellular carcinoma\n- Chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases\n- Normal vital signs and physical examination\n\nClinical Trial Inclusion Criteria:\n- Age 18-65 years (Patient is 55 years old, which fits)\n- BMI 18-30 (Patient has a BMI of 27, which fits)\n- Chronic hepatitis C, diagnosed according to Chinese guidelines (Patient has chronic HCV)\n- Detectable serum HCV-RNA by quantitative PCR assay and positive anti-HCV antibody (Patient has both)\n- For female subjects, requirements regarding pregnancy and contraception; for male subjects and their partners, the requirement to conduct adequate contraception (This applies to the patient, but no information about contraception measures is provided)\n- Volunteered to participate and signed an informed consent (Not applicable for this assessment)\n\nThe patient note does not specify whether the patient has been previously treated with IFN. The clinical trial is for IFN-naive patients with chronic hepatitis C. Since the patient is currently on IFN, RBV, and direct antiviral drugs, it is not clear if these are his first treatments or if he has received IFN before. This is a critical piece of information needed to determine eligibility.\n\nWithout this information, we cannot definitively say the patient is eligible or excluded from the trial. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1689": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility step by step:\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of treatment failure to prior regimens\n- BMI of 27\n- No mention of HCV genotype\n- No evidence of cirrhosis\n\nClinical trial inclusion criteria:\n- BMI \u2265 18 kg/m^2 (Patient meets this criterion with a BMI of 27)\n- HCV RNA \u2265 10000 IU/mL at screening (No data provided on the patient's HCV RNA levels)\n- Prior treatment failure to a regimen including interferon with or without RBV (No data provided on treatment failure; the patient is currently on treatment)\n- HCV genotype 1 or 3 (No data provided on the patient's HCV genotype)\n- Chronic HCV infection (Patient has chronic HCV infection)\n- Cirrhosis determination (No cirrhosis mentioned in the patient's note)\n- Use of highly effective contraception methods if female of childbearing potential or sexually active male (Not applicable as the patient is male)\n\nBased on the information given, the patient meets some of the inclusion criteria (BMI, chronic HCV infection), but there is insufficient information to determine if they meet all the criteria (HCV RNA levels, prior treatment failure, HCV genotype, cirrhosis status). Therefore, the patient cannot be considered eligible without further information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1690": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B Virus). He has been on IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months. There is no mention of HIV infection, which is a requirement in the inclusion criteria of the clinical trial.\n\nNow, let's analyze the trial's inclusion and exclusion criteria against the patient's details:\n\nInclusion Criteria for the HBV-HIV Coinfection Research Network trial:\n1. Male and female subjects \u2265 18 years of age; (The patient is 55 years old, so he meets this criterion)\n2. Serologic evidence of HIV infection by HIV antibody positivity or positive HIV-RNA > 6 months prior to screening; (There is no mention of HIV in the patient's history)\n3. Serologic evidence of chronic hepatitis B infection by HBsAg positivity; (The patient has a coinfection with HBV, so this is met)\n4. Willingness to provide informed consent. (We can assume the patient is willing unless otherwise stated)\n\nExclusion Criteria for the trial:\n1. Estimated life expectancy of less than one year; (Not mentioned)\n2. Hepatic decompensation as defined by presence of ascites or hepatic hydrothorax, variceal or portal hypertensive bleeding, hepatic encephalopathy, or Child-Turcotte-Pugh (CTP) score of 7 or above; (Not present)\n3. Hepatocellular carcinoma (HCC); (Biopsy was negative for HCC)\n4. Anti-HCV positive; (The patient is positive for HCV, which excludes him from the trial)\n5. History of solid organ or bone marrow transplantation; (Not mentioned)\n6. Pregnant women; (The patient is male)\n7. Medical or social condition which in the opinion of the study physician would make the patient unsuitable for the study or will interfere with or prevent follow-up per protocol; (Not applicable)\n8. Unable or unwilling to return for follow-up visits; (Not mentioned)\n9. Contraindications to liver biopsy. (Not mentioned)\n\nThe patient does not meet all the inclusion criteria due to the lack of information about HIV infection. Additionally, he is specifically excluded by the trial's exclusion criteria because he is anti-HCV positive. \n\nTherefore, the patient is not eligible for the HBV-HIV Coinfection Research Network clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1691": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. He is currently receiving treatment for these conditions. The clinical trial in question is focused on liver fibrosis prevalence in France, and the inclusion criteria are patients exposed to fibrosis risk factors (HBV, HCV, ALD, NAFLD) or healthy volunteers.\n\nThe patient fits the inclusion criteria since he has a history of HCV and a recent coinfection with HBV, both of which are listed as fibrosis risk factors. There is no additional information provided that would place the patient in the exclusion criteria for the trial.\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1692": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No history of hepatocellular carcinoma, alcoholic liver disease, or other liver diseases mentioned.\n- No mention of HCV viral genotype.\n- No liver biopsy information regarding cirrhosis.\n- Gender and age meet the inclusion criteria.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age \u2265 18 years (patient meets this criterion).\n- Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin (patient does not meet this criterion as they are currently on treatment).\n- Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test (patient meets this criterion).\n- Detectable serum HCV-RNA and HCV viral genotype 1 (patient's HCV genotype is not specified).\n- Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection with or without compensated cirrhosis (patient's biopsy shows chronic inflammation compatible with chronic viral hepatitis, but no mention of cirrhosis).\n- Compensated liver disease (Child-Pugh Grade A clinical classification) (there is no mention of Child-Pugh classification in the patient note).\n- Negative urine or blood pregnancy test (for women of childbearing potential) (not applicable to the patient as he is male).\n- All fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end (no information provided on contraception).\n\nGiven that the patient is currently on treatment with interferon and ribavirin, he does not meet the criterion of never having been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin. Therefore, the patient is not eligible for the clinical trial based on this criterion alone.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1693": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. The patient has no evidence of cirrhosis, hepatocellular carcinoma, or other significant liver diseases and has not been noted to have any of the other exclusion criteria such as significant cardiovascular, pulmonary, or neurological disease, and no history of malignancy within the past 5 years.\n\nHowever, the patient was diagnosed with HBV coinfection recently and it is not stated that he has been virally suppressed with an oral antiviral medication for at least one year, which is one of the key inclusion criteria for the clinical trial. Additionally, the patient has a co-infection with HCV, which is listed as a key exclusion criterion for the trial.\n\nGiven that the patient does have chronic HBV infection, as he is on treatment for it and has a documented history, but does not meet the criteria of being virally suppressed for at least one year and has a co-infection with HCV, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1694": {
        "output": "Based on the patient note and the clinical trial information provided, the patient appears to meet the inclusion criteria for the clinical trial:\n\n- The patient is diagnosed with HCV (Hepatitis C Virus) and has a recent coinfection with HBV (Hepatitis B Virus).\n- His medical history is non-significant, which likely means he has not experienced conditions that would exclude him from an observational study focused on HCV.\n- He is currently on treatment with IFN (interferon), RBV (ribavirin), and direct antiviral drugs, which is relevant to the study's interest in evaluating the impact of DAAs (direct-acting antiviral agents).\n- The study is an observational study of HCV infected patients, and the inclusion criteria are broad: \"All HCV infected patients who will consecutively come to the participating clinical centers in a given time span (enrollment periods).\"\n\nThe patient is an HCV infected patient who is currently receiving treatment, which is precisely the type of subject that the observational study is aiming to include. There are no additional exclusion criteria provided that would disqualify the patient based on the information given in the patient note.\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1695": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can analyze the patient's eligibility as follows:\n\n1. Male or female, at least 18 years of age: The patient is a 55-year-old man, so he meets this criterion.\n\n2. Asian background: There is no information provided about the patient's ethnic background, so we cannot determine if this criterion is met.\n\n3. HCV treatment-na\u00efve: The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months, so he does not meet this criterion as he is not treatment-na\u00efve.\n\n4. Chronic HCV infection as defined: The patient has a history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies, which is consistent with chronic HCV infection.\n\n5. Screening laboratory result indicating HCV genotype 6-infection (HCV-6): There is no information provided about the patient's HCV genotype, so we cannot determine if this criterion is met.\n\n6. Plasma HCV RNA level > 10,000 IU/mL at Screening: There is no information provided about the patient's HCV RNA levels, so we cannot determine if this criterion is met.\n\n7. IL28B C/C genotype (rs12979860): There is no information provided about the patient's IL28B genotype, so we cannot determine if this criterion is met.\n\n8. Documented results of liver biopsy, FibroTest, APRI, or FibroScan: The patient had a recent biopsy that was negative for hepatocellular carcinoma and only remarkable for chronic inflammation. There is no specific information about METAVIR Score, Ishak score, FibroTest score, APRI, or FibroScan results, so we cannot determine if this criterion is met.\n\n9. Candidate for PEG/RBV therapy: The patient is already on PEG/RBV therapy, which suggests he is a candidate for it.\n\n10. BMI between 18 and 36 kg/m2: The patient's BMI is 27, which meets this criterion.\n\n11. Agree to use two highly effective methods of avoiding contraception: There is no information provided about the patient's agreement to use contraception, so we cannot determine if this criterion is met.\n\n12. Provide written informed consent to participate in the study: There is no information provided about the patient's consent, so we cannot determine if this criterion is met.\n\n13. Laboratory parameters at Screening: Some of the patient's lab parameters are listed (hemoglobin, WBC, platelets, prothrombin time), but not all required ones are provided.\n\nSince the patient is not HCV treatment-na\u00efve and there is insufficient information about the patient's ethnic background, HCV genotype, IL28B genotype, specific liver disease staging tests, agreement to use contraception, written informed consent, and certain laboratory parameters, we cannot conclude they are eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1696": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) and a recent coinfection with Hepatitis B Virus (HBV). There is no mention of Carpal Tunnel Syndrome (CTS) or any related symptoms, diagnosis, or treatments in the patient's history. The clinical trial in question is aimed at patients who have been diagnosed with CTS using electrodiagnostic testing.\n\nSince the patient's medical condition (HCV and HBV infection) is not related to the focus of the clinical trial (Carpal Tunnel Syndrome), and there is no information provided that suggests the patient has been diagnosed with CTS or has undergone electrodiagnostic testing for CTS, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1697": {
        "output": "The patient in question is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. The clinical trial is seeking adult participants with sickle cell liver disease (SCLD). The inclusion criteria for the clinical trial are:\n\n1. Age greater than 18, able to consent, male or female.\n2. Capacity to provide written informed consent.\n3. All ethnicities.\n4. Sickle cell genotypes; Homozygous Hemoglobin S Disease, Heterozygous Hemoglobin SC and S beta thalassemia including SB+ and SB0.\n5. Evidence of SCD liver dysfunction by abnormal liver laboratory parameters in at least 2 of the following: ALT, AST, ALP, direct and total serum bilirubin > 1 times ULN.\n\nThe exclusion criteria are:\n\n1. If not taking measures to prevent pregnancy during the period of study.\n2. Incapacity to provide informed consent.\n\nThe patient's note does not mention sickle cell disease or any of the relevant genotypes. The liver dysfunction mentioned is due to chronic viral hepatitis, not sickle cell liver disease. Therefore, the patient does not meet the inclusion criteria for the clinical trial because they do not have sickle cell disease, nor is there mention of the specific liver laboratory parameters required by the study.\n\nBased on the information given, the patient does not have sufficient information to qualify for the trial due to a lack of sickle cell disease diagnosis and liver dysfunction related to SCD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1698": {
        "output": "The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) 2 years ago and recently coinfected with hepatitis B virus (HBV). He has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. His medical records confirm chronic hepatitis C through positive HCV RNA tests and positive tests for anti-HCV antibodies. Additionally, he has been diagnosed with hepatitis B, as noted by the recent coinfection.\n\nWhen we compare this patient's information to the inclusion criteria of the clinical trial titled \"Therapeutic Option for Hepatitis B and C: a French Cohort,\" we find that:\n\n- The patient has an HBV coinfection, making him a potential candidate for the HBV-positive patient group.\n- The patient has chronic hepatitis C, confirmed by positive HCV RNA tests and anti-HCV antibodies for more than 6 months, which fits the criteria for the HCV-positive patient group.\n\nThe inclusion criteria for the trial do not specify any exclusion criteria that would apply to the patient based on the information provided. Therefore, he appears to meet the inclusion criteria for both HBV and HCV conditions as outlined in the trial summary.\n\nBased on the information provided in the patient note and aligning with the inclusion criteria of the clinical trial, the patient seems eligible for participation. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1699": {
        "output": "Based on the patient note, we have the following information about the patient:\n\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma, cirrhosis, or other liver diseases\n- No acute distress, normal blood pressure, heart rate, and BMI\n\nNow, let's compare this information with the clinical trial inclusion and exclusion criteria:\n\nInclusion Criteria:\n- Male or female, age greater than or equal to 18 years. (Patient is 55 years old, so meets this criterion)\n- Confirmed chronic HCV infection. (Patient has a confirmed chronic HCV infection)\n- Subjects will have cirrhosis status assessment; liver biopsy may be required. (The patient has no evidence of cirrhosis)\n- Genotype 2 subjects must have cirrhosis of the liver to be eligible. (It is not stated which genotype of HCV the patient has, but there is no cirrhosis)\n- Treatment-naive or prior treatment failure to \u226512 weeks of an interferon-based regimen that was not discontinued prematurely due to an adverse event (The patient is on IFN, RBV, and direct antivirals, but we do not have information on treatment-naive status or prior treatment failure)\n- Infection with HCV genotype 2 or 3 as determined at Screening (The genotype of the patient's HCV infection is not specified)\n- Body mass index (BMI) greater than or equal to 18 kg/m^2 (Patient's BMI is 27)\n- Screening laboratory values within predefined thresholds. (No information provided)\n- Liver imaging within 6 months of Baseline/Day 1 is required in cirrhotic patients to exclude HCC. (Patient is not cirrhotic and no mention of recent liver imaging)\n- Subject must be of generally good health as determined by the Investigator. (Patient appears to be in good health based on the note)\n\nExclusion Criteria:\n- Prior use of any other inhibitor of the HCV NS5B polymerase (No information provided)\n- Pregnant or nursing female or male with pregnant female partner (Does not apply to this patient)\n- History of any other clinically significant chronic liver disease. (No significant liver disease mentioned apart from HCV and HBV)\n- HIV or chronic hepatitis B virus (HBV) infection. (Patient has a recent coinfection with HBV, which excludes him)\n- Malignancy with the exception of certain resolved skin cancers. (No malignancy mentioned)\n- Chronic use of systemically administered immunosuppressive agents. (No information provided)\n- Clinically-relevant drug or alcohol abuse. (No information provided)\n- History of solid organ transplantation. (No information provided)\n- Current or prior history of clinical hepatic decompensation. (No clinical hepatic decompensation mentioned)\n- History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. (No such history mentioned)\n- Known hypersensitivity to interferon, RBV, the study investigational medicinal product, the metabolites, or formulation excipients. (No hypersensitivity mentioned)\n\nGiven the information we have, the patient does not meet the inclusion criteria for having cirrhosis (if he is genotype 2) and is explicitly excluded due to recent coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1700": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient takes no other medications and does not have HIV co-infection as per the information provided.\n- His medical records show previous positive HCV RNA tests.\n\nClinical Trial Inclusion Criteria:\n- Adult \u2265 18 years\n- Patients co-infected HIV-HCV (HCV serology and HCV positive CV before starting HCV treatment)\n- Patients who have been treated with combination therapy Peg-IFN/RBV for at least 12 weeks and having at least a given plasma RBV available in the patient record\n- Free Consent, informed and signed\n\nThe patient described does not meet the inclusion criteria of being co-infected with HIV and HCV, which is a requirement for the clinical trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1701": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, here's the assessment:\n\nThe patient:\n- Is a 55-year-old man, which fits within the age criteria of the trial (\u2265 40 and up to 65 years).\n- Has been diagnosed with HCV and recent coinfection with HBV, with no mention of acute lymphoblastic leukemia (ALL) or any related condition.\n\nThe clinical trial:\n- Is looking for patients with ALL in complete remission at the time of the transplant.\n- Allows Philadelphia chromosome-positive ALL and lymphoid blastic crisis of CML, provided patients achieve CR.\n- Requires specific organ function criteria to be met.\n- Requires a performance status of Karnofsky \u2265 70%.\n- Requires the patient to have a willing adult HLA-matched sibling or HLA-matched unrelated donor.\n\nThe patient in the note does not have a diagnosis of ALL or any condition that would be considered equivalent for the purposes of the trial. Furthermore, there is no indication that the patient has a willing HLA-matched sibling or unrelated donor for allo HCT, nor is there any mention of the patient's organ function or performance status.\n\nBased on the information provided, the patient does not meet the disease criteria for the clinical trial as he is diagnosed with HCV and HBV, not ALL. There is also insufficient information regarding other organ function criteria, performance status, and donor availability.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1702": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV and HBV coinfection\n- No significant past medical history\n- Undergoing treatment with IFN, RBV, and direct antiviral drugs\n- No evidence of hepatocellular carcinoma or other liver diseases\n\nClinical Trial:\n- Chronic Toxicities Related to Treatment in Patients With Localized Cancer\n- Focus on non-metastatic breast cancer and potentially other localized cancers\n- Inclusion Criteria for the current phase:\n  - Women\n  - Aged 18 years and over\n  - With invasive breast cancer diagnosed by cytology or histology\n  - Tumors cT0 to cT3, CN0-3\n  - No clinical evidence of metastasis at the time of inclusion\n  - Untreated or scheduled for breast cancer surgery\n  - Receiving social security system\n  - Mastery of the French language\n  - Consent for additional biological samples, questionnaires, and resource usage data\n  - Since February 2022: Aged < 45 years at diagnosis OR CT2-3, cN0-3, HER2+ (RH+ or RH-) or RH-HER2-\n\nThe patient does not meet the inclusion criteria for the clinical trial outlined, as the trial is specifically looking for women with invasive breast cancer. The patient is a man with HCV and HBV, which are unrelated to the conditions required for the trial. Additionally, there are other criteria like mastery of the French language and specific breast cancer classifications that the patient does not fulfill. Thus, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1703": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He is currently on treatment for his hepatitis and does not have any mention of thyroid cancer in his medical history.\n\nThe clinical trial in question is specifically for newly diagnosed thyroid cancer patients, requiring a diagnosis within 2-4 weeks and certain other criteria, such as being willing to participate in educational group meetings, being over 18 years old, alert, capable of giving informed consent, and able to speak and read English or French.\n\nSince the patient does not have a diagnosis of thyroid cancer, he does not meet the inclusion criteria for the clinical trial focused on thyroid cancer patients. Thus, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1704": {
        "output": "The patient described in the note is a 55-year-old man with a diagnosis of HCV and a recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs.\n\nThe clinical trial in question is focusing on pain in women with chronic pelvic pain. The inclusion criteria for the trial are:\n\n1. Women.\n2. Clinical diagnosis of chronic pelvic pain.\n3. More than eighteen years.\n4. Non-menstrual or noncyclic pelvic pain.\n5. Duration of pain of at least 6 months.\n\nSince the patient is a man and the study is specifically recruiting women with chronic pelvic pain, the patient does not meet the inclusion criteria and is therefore not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1705": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV genotype unknown, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No other significant medical conditions\n- Normal physical examination without signs of cirrhosis\n- BMI of 27\n\nClinical Trial Inclusion Criteria:\n- Males and females, \u2265 18 years of age\n- Subjects chronically infected with HCV Genotype 1b only, documented by positive HCV RNA and anti-HCV antibodies at screening\n- Intolerant to previous therapy with Interferon Alfa (IFN\u03b1) with or without Ribavirin (RBV) or ineligible for IFN\u00b1RBV\n- Conditions such as anemia, neutropenia, or thrombocytopenia according to the specified criteria\n- HCV RNA \u2265 10,000 IU/mL\n- Seronegative for HIV and HBsAg\n- BMI of 18 to 35 kg/m2\n- Compensated cirrhosis is permitted (with additional criteria if cirrhosis is present)\n\nAssessment:\n- The patient is a male and over 18 years of age, meeting the age and gender criteria.\n- The patient is diagnosed with HCV, but the genotype is not specified in the patient note. The trial specifically requires HCV Genotype 1b.\n- The patient is currently on IFN, RBV, and direct antiviral drugs. However, there is no indication in the patient note that he is intolerant to IFN\u00b1RBV therapy.\n- There is no information about the patient's HCV RNA levels.\n- The patient is coinfected with HBV, which could potentially exclude him because the trial requires seronegativity for HBsAg.\n- The patient's BMI is within the range required by the trial.\n\nGiven the above assessment, the key missing piece of information that determines eligibility is the patient's HCV genotype. Additionally, the current treatment regimen does not indicate intolerance to IFN\u00b1RBV therapy, which is required for inclusion. Furthermore, the coinfection with HBV may lead to exclusion, as the trial requires seronegativity for HBsAg. Therefore, based on the available information, the patient does not meet the necessary inclusion criteria and may be excluded due to HBV coinfection.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1706": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the patient for eligibility based on the inclusion criteria of the clinical trial.\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal blood pressure, heart rate, and BMI\n- No edema in lower extremities\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Patient with an indication for PCI (Percutaneous Coronary Intervention) for conditions including angina, silent ischemia, NSTEMI (Non-ST-Elevation Myocardial Infarction), or recent STEMI (ST-Elevation Myocardial Infarction)\n- Specific conditions and timeframes for prior non-target vessel PCI\n- Patient or legal guardian can provide informed consent and comply with follow-up\n- Angiographic criteria relating to target lesions and coronary artery specifications\n\nComparison:\n- The patient is 55 years old, which meets the age criterion.\n- There is no mention of the patient having angina, silent ischemia, NSTEMI, or STEMI, which are conditions required for an indication for PCI.\n- There is no information provided about the patient's coronary artery status or whether there is a need for PCI.\n\nBased on the information available, the patient does not have a documented need for PCI, which is a requirement for inclusion in the trial. The patient's medical condition (HCV and HBV) is not related to the conditions being studied in the trial (coronary artery disease requiring PCI).\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1707": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition against the inclusion criteria provided for the trial.\n\nHere is the patient's information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months\n- No significant past medical history\n- No medications other than HCV treatment\n- No hepatocellular carcinoma found on biopsy\n- No other liver diseases\n- Normal blood pressure, heart rate, and BMI\n- No acute distress, no ascites or tenderness in the abdomen, no edema in the lower extremities\n\nNow let's check against the clinical trial inclusion criteria:\n- Chronic genotype 1 (subtypes 1a or 1b) or genotype 2 or genotype 3 or genotype 4 HCV infection documented by serum HCV RNA >=100,000 IU/mL and additional documentation criteria (the note states the patient has HCV, but the genotype is not specified, and there is no mention of HCV RNA levels)\n- Agrees to IL28B genotyping (we have no information on this)\n- Able to give written informed consent (we can assume this is possible but it's not stated)\n- Treatment-na\u00efve for HCV (the patient is not treatment-na\u00efve as he is currently on treatment)\n- Aged between 18 and 60 years of age (the patient is 55 years old and meets this criterion)\n- BMI between 18.5-35 kg/m^2 (patient's BMI is 27, which fits within this range)\n- Blood pressure and heart rate within specified ranges (patient meets this criterion)\n- Is otherwise healthy as determined by medical history, physical examination, ECG findings, and clinical laboratory measurements (the patient appears to be healthy based on the note)\n- Specific lab value criteria (the patient note does not provide these specific values)\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial for the following reasons:\n- The patient is not treatment-na\u00efve as he is currently on treatment for HCV.\n- There is insufficient information to confirm the patient's HCV genotype and viral load, which are genotype-specific for the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1708": {
        "output": "",
        "label": 1
    },
    "1709": {
        "output": "Given the patient note and the clinical trial information provided, let's analyze the patient's eligibility for the clinical trial titled \"Essential Hypotension and Allostasis Registry.\"\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- The patient has been diagnosed with HCV and a recent coinfection with HBV.\n- He is currently on treatment with IFN, RBV, and direct antiviral drugs.\n- The patient's past medical history is non-significant.\n- The patient does not have hepatocellular carcinoma or other specified liver diseases.\n- His vital signs are within normal ranges, with a blood pressure of 130/75, which is not indicative of hypotension.\n\nClinical Trial Analysis:\n- Title: Essential Hypotension and Allostasis Registry\n- The trial is focused on blood pressure disorders and associated comorbidities as a result of allostatic responses to stress.\n- The trial aims to observe and categorize patients according to their arterial blood pressure and allostasis.\n- The inclusion criteria for the trial are very broad, stating: \"Any patient regardless of the age of gender.\"\n\nBased on the information provided, the patient does not exhibit any conditions that would exclude him from the trial and meets the broad inclusion criteria stated for the trial. Therefore, the patient is eligible to participate in the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1710": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man with a diagnosis of HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus).\n- There is no mention of hepatocellular carcinoma (HCC).\n- The patient is on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs.\n- The patient's liver biopsy was negative for HCC and showed chronic inflammation compatible with chronic viral hepatitis.\n- The patient is alert with stable vital signs and no acute distress.\n- There is no evidence of severe liver disease complications such as bleeding from esophageal varices or other liver diseases.\n\nClinical Trial Inclusion Criteria:\n- Agreement signed by the patient.\n- Diagnosis of HCC confirmed.\n- Diagnosis of liver disease (score F3 or F4) confirmed.\n- Indication of surgical resection confirmed and validated by a specialist multidisciplinary assessment meeting of gastrointestinal oncology.\n- Patient operable (no contraindication against anesthesia).\n- Resectable tumor lesion (surgical expertise).\n- Laboratory tests and endoscopy: No suspicion of severe portal hypertension with bleeding risk.\n\nComparison:\n- The patient has been diagnosed with HCV and HBV, not HCC.\n- There is no mention of the patient having a confirmed diagnosis of HCC or a resectable tumor lesion.\n- The patient does not appear to have been assessed for surgical resection or liver disease severity (score F3 or F4).\n\nConclusion:\nThe patient does not meet the inclusion criteria for the clinical trial as there is no diagnosis of HCC, which is a primary requirement for eligibility. The patient's condition does not align with the focus of the clinical trial, which is on the administration of probiotics before liver resection in patients with liver disease and confirmed HCC. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1711": {
        "output": "The patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. His medical records confirm a positive HCV RNA test and positive anti-HCV antibodies. The recent biopsy did not show hepatocellular carcinoma but chronic inflammation compatible with chronic viral hepatitis.\n\nNow let's analyze the inclusion criteria for the clinical trial:\n\n- Willing and able to provide written informed consent: (Assumed yes, as it is not mentioned in the patient note)\n- HCV RNA \u2265 10^4 IU/mL at screening: (The patient has a history of positive HCV RNA tests, but the current level is not provided)\n- HCV treatment-naive or treatment-experienced with documented prior treatment details: (The patient is treatment-experienced as he is on IFN, RBV, and direct antiviral drugs)\n- HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy: (The patient's infection is documented by a positive anti-HCV antibody test)\n\nHowever, the patient also has a coinfection with HBV, which is listed under the key exclusion criteria:\n\n- Infection with hepatitis B virus (HBV): (The patient has a recent coinfection with HBV)\n\nGiven this information, the patient is excluded from the clinical trial due to the coinfection with HBV, which is a part of the trial's exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1712": {
        "output": "Based on the provided patient note and the inclusion and exclusion criteria of the clinical trial, let's assess the patient's eligibility.\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- Currently on treatment with IFN, RBV, and direct antiviral drugs\n- No mention of hepatocellular carcinoma or other liver diseases\n- Positive HCV RNA tests\n- Positive anti-HCV-antibodies\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n\nClinical Trial Inclusion Criteria:\n- Willing and able to provide written informed consent (patient's willingness not mentioned)\n- HCV RNA \u2265 10^4 IU/mL at screening (patient's viral load not mentioned)\n- HCV treatment-naive or treatment-experienced with detailed medical records (patient is currently on treatment)\n- Genotype 1 HCV at screening (patient's HCV genotype not mentioned)\n- HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy (patient has documented HCV infection)\n\nClinical Trial Exclusion Criteria:\n- Pregnancy or nursing (not applicable to the male patient)\n- Chronic liver disease of a non-HCV etiology (no evidence of this in the patient)\n- Current or prior history of any clinically-significant illness (other than HCV) (no mention of other illnesses)\n- Infection with hepatitis B virus (HBV) (patient has recent coinfection with HBV)\n- Infection with HIV (HIV status not mentioned)\n\nThe patient's recent coinfection with HBV is a key factor that excludes him from participating in the clinical trial since one of the exclusion criteria specifically states that individuals with HBV infection are not eligible.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1713": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and history with the inclusion and exclusion criteria provided by the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No history of liver or any other organ transplant\n- No mention of HIV-1 infection\n\nClinical Trial Inclusion Criteria:\n- Patients must be able to understand and agree to comply with the study requirements\n- Patients chronically infected with HCV genotype 1, 2, 3, 4, 5, or 6, as documented by positive HCV RNA at screening\n- Patients who are HCV treatment-naive or treatment-experienced with prior therapies discontinued at least 12 weeks prior to screening\n- Patients with HCV RNA \u226510,000 IU/mL at screening\n- Patients with HIV-1 infection\n\nClinical Trial Exclusion Criteria:\n- Presence of AIDS-defining opportunistic infections within 12 weeks prior to study entry\n- Patients infected with HIV-2\n- Liver or any other organ transplant\n- Current or known history of cancer within 5 years prior to screening\n- Documented or suspected hepatocellular carcinoma\n- Evidence of decompensated liver disease\n\nBased on the patient note, there is no mention of the patient's HCV genotype nor the HCV RNA levels. Furthermore, there is no information provided regarding HIV-1 infection, which is a key inclusion criterion for the trial. The patient is under treatment for HCV which makes him not treatment-naive, and there is no information on the time since his last HCV treatment regimen was discontinued or completed.\n\nWithout additional data, we cannot confirm whether the patient meets the specific HCV genotype and viral load requirements or whether the patient has an HIV-1 infection. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1714": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion and exclusion criteria, here's the assessment:\n\nPatient Note:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- The patient's past medical history is non-significant.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- There is no evidence of hepatocellular carcinoma or other liver-related diseases other than chronic viral hepatitis.\n\nClinical Trial:\n- The trial is for patients infected with clade B HIV-1.\n- Eligible patients must be treated with HAART for more than 12 months.\n- Patients must have an undetectable HIV viral load.\n- Patients must have a certain range of CD4+ T cell counts.\n- Age range for the trial is 18-55 years.\n\nThe patient in question does not meet the inclusion criteria for the clinical trial as he is diagnosed with HCV and HBV, not HIV-1. The trial specifically targets patients with clade B HIV-1 infection, and there's no mention of the patient having HIV at all.\n\nTherefore, the patient is not eligible for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1715": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is 55 years old.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- Past medical history is non-significant.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV infection.\n- The patient has not been described as na\u00efve to treatment including a DAA since they are currently on direct antiviral drugs.\n- There is no mention of written informed consent for participation in the study and genetic determinations.\n\nClinical Trial Inclusion Criteria:\n- Older than 18 years.\n- HIV infection determined by enzyme immunoassay and confirmed by Western Blot.\n- Na\u00efve to treatment including a DAA.\n- Initiation of triple therapy including a DAA.\n- Written informed consent to participate in the study and to undergo genetic determinations.\n\nComparison:\n- The patient is older than 18 years, meeting this criterion.\n- The trial requires participants to have an HIV infection, which is not mentioned in the patient's note.\n- The patient is not na\u00efve to DAA treatment as they are already on direct antiviral drugs, not meeting this criterion.\n- There is no information on whether the patient has provided written informed consent.\n\nBased on the above, the patient does not meet all of the inclusion criteria for the clinical trial. Specifically, there is no evidence of HIV infection and the patient is not na\u00efve to DAA-based therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1716": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\n1. **Patient age**: The patient is 55 years old, which meets the trial's age requirement of being 20 years or older.\n   \n2. **HCV GT1 and HBV infection**: The patient has been diagnosed with HCV (hepatitis C virus) and has a recent coinfection with HBV (hepatitis B virus). However, the trial specifically requires patients with HCV genotype 1 (HCV GT1). The patient's note does not specify the genotype of HCV, which is crucial information for this trial.\n\n3. **Serum HCV RNA**: The patient's medical records show previous positive HCV RNA tests, which meets this criterion.\n\n4. **Anti-HCV positive, HBsAg positive, and HBeAg negative**: The patient's note indicates an enzyme immunoassay for anti-HCV antibodies was positive, but there is no mention of HBsAg or HBeAg status.\n\n5. **Previous failed treatment**: The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, but it is not clear if this regimen included PEG-IFN-\u03b1 2a or 2b/RBV specifically or if the patient has failed such treatment.\n\n6. **Compensated liver disease**: The recent biopsy was negative for hepatocellular carcinoma and indicated chronic inflammation consistent with chronic viral hepatitis. However, it's not specified whether the patient has compensated liver disease, nor is there information about a liver imaging study within the preceding 6 months.\n\n7. **Treatment requirements and contra-indications**: The patient's current treatment with IFN, RBV, and direct antiviral drugs suggests that they may meet the requirements for treatment with PEG-IFN/RBV and boceprevir, but without specific information about their previous response to treatment or the absence of contraindications, this cannot be confirmed.\n\n8. **Informed consent**: There is no mention of the patient's ability or willingness to provide informed consent.\n\nBased on the available information, the patient does not have sufficient information provided to qualify for the trial, specifically regarding HCV genotype, HBsAg/HBeAg status, previous treatment failure with PEG-IFN/RBV, compensated liver disease, and informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1717": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C (HCV) and recent coinfection with hepatitis B virus (HBV). His past medical history is non-significant, and he has been on interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs (DAAs) for the past 6 months. The patient has no evidence of hepatocellular carcinoma and has a history of chronic inflammation compatible with chronic viral hepatitis.\n\nThe inclusion criteria for the clinical trial are:\n- Chronic hepatitis C infection\n- Commencing or expected to commence DAA-based HCV treatment within the next year\n- IFN treatment-na\u00efve or IFN treatment-experienced\n- Provision of written, informed consent\n\nThe patient meets all the inclusion criteria:\n- He has a chronic hepatitis C infection as indicated by positive HCV RNA tests and anti-HCV antibodies.\n- He is currently on DAA-based HCV treatment.\n- The patient is IFN treatment-experienced since he is currently on IFN.\n- Although the patient note does not explicitly mention the provision of written, informed consent, this is typically a procedural step that can be completed if the patient agrees to participate in the trial.\n\nTherefore, the patient appears to be eligible for the clinical trial, as there is no information to suggest otherwise based on the provided patient note and inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1718": {
        "output": "Based on the information provided for the patient and the clinical trial:\n\nPatient Note Summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for 6 months\n- No mention of entecavir treatment\n- No evidence of hepatocellular carcinoma\n- No acute distress, normal BMI, normal BP, and HR\n- No ascites or edema\n\nClinical Trial Inclusion Criteria:\n- HBeAg-negative patients on entecavir monotherapy for at least 24 months\n- Undetectable HBV DNA by PCR-based assay on 3 separate occasions 6 months apart\n- Normal ALT levels on 2 separate occasions 6 months apart\n\nThe patient does not meet the clinical trial inclusion criteria for several reasons:\n- There is no information that the patient has been on entecavir monotherapy, let alone for 24 months.\n- The patient's HBV DNA status is not mentioned as being undetectable on 3 separate occasions 6 months apart.\n- The patient's ALT levels are not reported, so we cannot assess if they are normal on 2 separate occasions 6 months apart.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1719": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specified inclusion criteria for the clinical trial. The trial is focused on the efficacy of vitamin E in preventing contrast-induced acute kidney injury in patients who have undergone coronary angiography, specifically targeting patients with stable coronary artery disease (CAD) or recent acute coronary syndrome (ACS) and those who have an estimated glomerular filtration rate (eGFR) of \u226460 ml/min/1.73 m2.\n\nThe patient described in the note has been diagnosed with hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV). The patient's medical history does not mention stable coronary artery disease (CAD), acute coronary syndrome (ACS), or any planned coronary angiography procedure. Furthermore, there is no mention of the patient's eGFR or any indication of kidney issues.\n\nTherefore, since the patient's condition does not align with the target diseases or procedures outlined in the clinical trial's inclusion criteria, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1720": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient is a 55-year-old man with a diagnosis of HCV and coinfection with HBV. The clinical trial in question is assessing the acceptability of a therapeutic vaccine against HIV in patients living with HIV-1. \n\nThe inclusion criteria for the trial are:\n- Infected with HIV-1\n- Older than 18 and younger than 75 years\n- Speaking, reading French\n- With medical coverage\n\nThe patient does not meet the primary inclusion criterion of being infected with HIV-1; instead, the patient has HCV and HBV. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1721": {
        "output": "",
        "label": 1
    },
    "1722": {
        "output": "The patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He has been on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nThe clinical trial's inclusion criteria require participants to be chronically infected with HCV genotype 1a, have an HCV RNA level \u2265 10,000 IU/mL at screening, and be treatment-na\u00efve with no previous exposure to interferon formulation, ribavirin, or HCV direct acting antiviral (DAA).\n\nGiven the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial because he is not treatment-na\u00efve; he has had previous exposure to interferon, ribavirin, and HCV direct acting antiviral drugs. Therefore, he would be ineligible to participate in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1723": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nInclusion Criteria Assessment:\n- Age: 18 years to 60 years - The patient is 55 years old, which meets the age criterion.\n- Positive HCV antibodies using a third generation test - The patient has a positive enzyme immunoassay for anti-HCV-antibodies which likely meets this criterion.\n- Detectable HCV RNA by PCR - The patient has previous positive HCV RNA tests, which meets this criterion.\n- Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated liver enzymes or scores F2/F3 - The biopsy was remarkable for chronic inflammation compatible with chronic hepatitis, but no METAVIR score is provided, which makes it uncertain whether this criterion is met.\n- Na\u00efve to treatment with PEG-IFN and RBV - The patient is on IFN, RBV for the past 6 months, which does not meet this criterion.\n- HBs antigen negative - The patient has a recent coinfection with HBV, which suggests that he would not meet this criterion.\n- Prothrombin time \u226560 %, normal bilirubin, alpha-foeto protein < 3*normal range of the laboratory, anti-nuclear antibodies<1/160 - There is no information provided regarding these laboratory values.\n- Effective contraception during the treatment period; no breast-feeding - As a male patient, the breast-feeding criterion does not apply, and there is no information on contraception.\n- Prior approval from the Ministry of Health to be treated as part of the National Program with allocation to Peg-IFN \u03b12b treatment - There is no information provided about this.\n- Living <100 km from Cairo and able to come to the centre every week for the treatment - There is no information about the patient's location.\n- Signed informed consent and willingness to participate in the trial - There is no information regarding this, but it is a procedural step that can be completed if other criteria are met.\n- Na\u00efve to treatment with vitamin D (received vitamin D less than 30 consecutive days in the 3 months preceding inclusion) - There is no information about vitamin D treatment, but there is nothing suggesting the patient does not meet this criterion.\n- Biopsy slide validated by NHTMRI pathologist - There is no information about the validation of the biopsy slide.\n\nBased on the available information, the patient does not meet the criteria of being na\u00efve to treatment with PEG-IFN and RBV and is also HBs antigen positive due to recent coinfection with HBV. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1724": {
        "output": "Considering the provided patient information and the inclusion criteria of the clinical trial titled \"Evaluation of the National Treatment Program of Hepatitis C in Egypt,\" let's assess the patient's eligibility:\n\n1. Age < 18 years and > 60 years: The patient is 55 years old, which does not meet the inclusion criterion of being under 18 or over 60 years old.\n2. Positive HCV antibodies using a third generation test: The patient has a positive enzyme immunoassay for anti-HCV-antibodies, which likely meets this criterion.\n3. Detectable HCV RNA by PCR: The patient's medical records show previous positive HCV RNA tests, which meets this criterion.\n4. Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated liver enzymes or scores F2/F3: The biopsy was remarkable for chronic inflammation compatible with chronic viral hepatitis, but no specific METAVIR score is mentioned.\n5. Na\u00efve to treatment with PEG-IFN and RBV: The patient is on IFN and RBV for the past 6 months, which does not meet the criterion of being na\u00efve to treatment.\n6. HBs antigen negative: The patient has a recent coinfection with HBV, which does not meet the criterion of being HBs antigen negative.\n7. Prothrombin time \u226560 %, normal bilirubin, alpha-foeto protein < 3*normal range of the laboratory, anti-nuclear antibodies<1/160: There is no specific information provided about these parameters.\n8. Effective contraception during the treatment period; no breast-feeding: This criterion is not applicable to the male patient.\n9. Signed informed consent and willingness to participate in the study: The willingness to participate is not mentioned, but it's assumed that consent could be obtained if other criteria were met.\n\nBased on the above points, the patient does not meet the age criterion, is not na\u00efve to treatment with PEG-IFN and RBV, and is not HBs antigen negative. Therefore, the patient is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1725": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- No indication of HIV infection\n- On IFN, RBV, and direct antiviral drugs for HCV\n- No evidence of hepatocellular carcinoma or other liver diseases\n- General good health with normal BP, HR, and no acute distress\n\nClinical Trial Inclusion Criteria:\n- Age of 18 to 40 years\n- Good general health\n- Willingness to receive tetanus and Hepatitis B vaccination\n- Negative HIV-1 and -2 blood test\n- Negative Hepatitis B surface antigen (HBsAg)\n- Negative Hepatitis B core antibody (HBcAb)\n- Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive\n\nThe patient is 55 years old, which is outside the age range of 18 to 40 years required by the trial. Additionally, the patient has an HCV infection, which is not consistent with the requirement for a negative anti-HCV status. Given these discrepancies between the patient's characteristics and the trial's inclusion criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1726": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the patient's eligibility as follows:\n\nThe inclusion criteria for the clinical trial are:\n1. Human immunodeficiency virus (HIV) chronic infection\n2. Hepatitis C virus (HCV) chronic infection\n3. No other liver viral coinfections\n\nThe patient's characteristics:\n1. 55-year-old man\n2. Diagnosed with HCV 2 years ago\n3. Recent coinfection with HBV\n4. On IFN, RBV, and direct antiviral drugs for the past 6 months\n5. No mention of HIV infection\n6. No mention of hepatocellular carcinoma (HCC)\n7. No evidence of other liver diseases\n\nThe patient does not meet the first inclusion criterion because there is no mention of chronic HIV infection. However, the patient does have a chronic infection with HCV. The third criterion excludes patients with other liver viral coinfections, and this patient has a recent coinfection with HBV, which would exclude them from the trial.\n\nBased on the given information, the patient does not meet all the inclusion criteria due to the lack of mention of HIV infection and the presence of HBV coinfection. Therefore, the patient would be excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1727": {
        "output": "To assess the trial-level eligibility of the patient for the provided clinical trial, we must carefully compare the patient note to the inclusion and exclusion criteria of the trial.\n\nPatient Note Summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress and within normal ranges for BP, HR, and BMI\n\nClinical Trial Summary:\n- Focus on HIV-HCV coinfected patients\n- Treatment with Asunaprevir and Daclatasvir\n- Inclusion criteria: 18 years or older, HCV infection, various criteria regarding birth control and HIV status\n- Exclusion criteria include a history of significant illness, certain lab abnormalities, and co-infection with HBV\n\nNow, let's compare the patient's information with the inclusion and exclusion criteria of the trial:\n\n- The patient is 55 years old, which meets the age requirement (>18 years).\n- The patient has a history of HCV, which is a requirement for the study.\n- The patient's medical history does not mention HIV, which is a requirement for the trial (the patient must be coinfected with HIV-HCV).\n- The patient has a recent coinfection with HBV, which is a specific exclusion criterion for the trial (positive test results at screening for HBV surface antigen or HBV RNA are grounds for exclusion).\n\nBased on this information, the patient does not meet the inclusion criteria due to the lack of HIV co-infection and is explicitly excluded due to the recent coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1728": {
        "output": "To determine the trial-level eligibility for the patient, we must compare the patient's information with the inclusion and exclusion criteria of the clinical trial.\n\nPatient information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal vital signs and BMI\n- No ascites or edema on examination\n\nClinical trial inclusion criteria:\n- Chronic hepatitis C defined as detectable HCV RNA for more than 6 months\n- Age > 18 years old\n- Compensated liver disease (bilirubin < 3mg/dL, albumin > 3 g/dL, INR < 2, no hepatic encephalopathy, no ascites or recent -1 month- history of variceal bleeding)\n- HCV RNA level > 10.000 IU/mL\n- Signed informed consent document\n\nClinical trial exclusion criteria:\n- History of cholecystectomy or known gallstones\n- Current HCV antiviral treatment\n- Medications for dyslipidemia in the preceding 2 months\n- Abdominal surgery that could alter biliary or intestinal anatomy\n- Evidence of sitosterolemia\n- Negative pregnancy test in urine (for females)\n\nComparison:\n- The patient is over 18 years old, which meets the age criterion.\n- The patient has a chronic HCV infection, which meets the chronic hepatitis C criterion.\n- There is no information suggesting that the patient doesn't have compensated liver disease, so it is likely that the patient meets the criteria for compensated liver disease.\n- There is no specific information about the patient's HCV RNA levels, but since the patient has been on antiviral treatment, it can be assumed that the levels were high enough to warrant treatment.\n- The patient is capable of providing signed informed consent.\n\nHowever, the patient is currently on IFN, RBV, and direct antiviral drugs, which conflicts with the exclusion criteria that specify \"Current HCV antiviral treatment\" as an exclusion.\n\nBased on this information, the patient is currently on a treatment that excludes him from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1729": {
        "output": "",
        "label": 0
    },
    "1730": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we will compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nPatient's characteristics:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recent coinfection with HBV.\n- On treatment with IFN, RBV, and direct-acting antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- Medically stable with normal BP, HR, and no signs of decompensated liver disease (e.g., no ascites or edema).\n\nClinical trial inclusion criteria:\n- Provision of written informed consent.\n- Male and female patients aged 18 years and above.\n- Willing to use two effective methods of contraception during the treatment period and 24 weeks post.\n- HBsAg negative.\n- Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance.\n- Compensated liver disease (Child-Pugh A).\n- Negative pregnancy test at screening and 24 hours prior to the first dose of study drugs.\n- Medically stable on the basis of physical examination, medical history, and vital signs.\n- Adequate English to provide reliable responses to the study questionnaires.\n- Recent hepatitis C infection, as defined in the criteria.\n- If co-infected with HIV, the subject must meet additional criteria.\n\nBased on the patient note:\n- The patient has provided no information regarding consent, which we will assume can be obtained.\n- The patient is a 55-year-old man, which meets the age criterion.\n- The patient is on HCV treatment, which suggests he is willing to undergo treatment, but we do not have specific information about contraception.\n- The patient is recently coinfected with HBV, which makes him HBsAg positive, conflicting with the HBsAg negative requirement.\n- The patient is on antiviral drugs, which implies detectable HCV RNA at the start of the treatment, but we do not have the specific HCV RNA levels at screening or the likelihood of spontaneous viral clearance.\n- The patient's medical history does not indicate decompensated liver disease, suggesting compensated liver disease.\n- The patient's sex and pregnancy test criteria are not applicable.\n- The patient is medically stable.\n- There is no information about the patient's English proficiency.\n- There is no information confirming the specific timing of the patient's HCV diagnosis or acute clinical presentation as defined by the trial's criteria.\n- There is no indication of HIV coinfection, so the related criteria are not applicable.\n\nThe key issue here is that the patient is coinfected with HBV, which means he is HBsAg positive, disqualifying him from the trial which requires HBsAg negative status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1731": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient's eligibility needs to be assessed:\n\nPatient Note:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient does not have liver cirrhosis or hepatocellular carcinoma.\n- His liver function is not stated to be compromised.\n\nClinical Trial Inclusion Criteria:\n- Adult 20 years and older (the patient is 55 years old, so this criterion is met).\n- Chronic infection with genotype 1 hepatitis C virus proven with positive PCR (the patient has HCV but the genotype is not specified).\n- Liver cirrhosis while awaiting liver transplantation (the patient does not have liver cirrhosis).\n- Patient with compensated liver functions (there is no evidence of decompensated liver functions, but it is also not explicitly stated that they are compensated).\n- With or without hepatocellular carcinoma (the patient does not have hepatocellular carcinoma).\n- Naive or experienced (failure) to HCV antiviral treatment (the patient is currently on antiviral treatment but their response to treatment is not stated).\n\nFrom the information provided, we can determine that the patient does not meet all of the inclusion criteria. Specifically, there is no indication that the patient has liver cirrhosis or is awaiting liver transplantation, which are required criteria for the trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1732": {
        "output": "",
        "label": 0
    },
    "1733": {
        "output": "After reviewing the patient's note and the clinical trial's inclusion criteria, it is clear that the patient does not meet the eligibility criteria for the clinical trial. Specifically, the patient does not satisfy the following inclusion criteria for the trial:\n\n- The patient has been treated with interferon (IFN) and ribavirin (RBV), which indicates previous exposure to an Interferon formulation and ribavirin. This is contrary to the trial's requirement for treatment-naive subjects with no previous exposure to an Interferon formulation or ribavirin.\n- Additionally, the patient has already been treated with direct antiviral drugs, which means the patient has had previous exposure to HCV Direct Acting Antiviral (DAA) agents.\n\nGiven these discrepancies, the patient would not be eligible for the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1734": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. His medical records show chronic inflammation compatible with chronic viral hepatitis, which falls under the category of known chronic liver disease.\n\nThe clinical trial's inclusion criteria state that participants must be over 18 years of age and able to sign the Informed Consent Form. For the patient group, participants must have a known chronic liver disease based on medical history, which this patient does.\n\nThe patient meets the age criterion (over 18 years), has demonstrated the ability to engage with medical processes (evidenced by his current treatment), and has a known chronic liver disease. Therefore, this patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1735": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial evaluating the safety and effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy, we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nHere are the key points from the patient's note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No significant past medical history mentioned.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV infection.\n- No laboratory values provided for detailed criteria.\n\nNow, let's compare this to the inclusion criteria of the clinical trial:\n\n- Age greater than or equal to 18 to less than or equal to 70 years at study entry. (The patient is 55 years old, so this criterion is met.)\n- BMI from greater than or equal to 18 to less than 38 kg/m^2 within 42 days of study entry. (The patient has a BMI of 27, so this criterion is met.)\n- HIV-1 infection (The patient note does not mention an HIV infection, which is a necessary condition for this trial.)\n- CD4+ cell count greater than or equal to 200 cells/uL and CD4+ cell percentage greater than or equal to 14% within 42 days of study entry. (No information provided.)\n- On a stable, qualifying ART regimen for at least 8 weeks prior to entry. (No information provided and no mention of HIV treatment.)\n- HIV-1 RNA less than 50 copies/mL for at least 6 months prior to study entry. (No information provided.)\n- Presence of chronic HCV infection with specific requirements. (The patient has a chronic HCV infection, but no RNA levels or specific genotype information is provided.)\n- The patient is HCV treatment-na\u00efve or has had unsuccessful treatment with IFN. (The patient is currently on IFN, which may disqualify him if he is not considered treatment-na\u00efve or unsuccessful.)\n- No prior exposure to specific HCV medications is allowed. (No information provided on prior exposure.)\n- HCV genotype 1a or 1b infection. (No genotype information provided.)\n- Serum HCV RNA greater than 10,000 IU/mL obtained within 42 days prior to study entry. (No RNA level information provided.)\n- Specific laboratory values required. (No laboratory values provided.)\n- Classification of liver disease as cirrhotic or non-cirrhotic with no evidence of hepatocellular carcinoma. (The patient does not have hepatocellular carcinoma, but no information on cirrhosis status.)\n\nThe patient note does not provide sufficient information to meet several important inclusion criteria, specifically the requirement of HIV-1 infection and detailed laboratory values. Without this information, we cannot confirm that the patient meets the necessary conditions for the clinical trial.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1736": {
        "output": "Assessing the eligibility of the patient for the clinical trial \"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection\" based on the provided patient note and the trial's inclusion criteria:\n\n1. The patient has chronic hepatitis C (a requirement for the study).\n2. The patient's genotype or HCV RNA level is not mentioned, so it's unclear if they have genotype 1b infection or HCV RNA level greater than 1,000 IU/mL at Screening.\n3. There is no evidence of liver cirrhosis in the patient's description. Cirrhosis is a requirement as per the inclusion criteria.\n4. The patient does not have hepatocellular carcinoma, which aligns with the trial's requirement.\n5. The patient is male, so the female-specific criteria are not applicable.\n6. There's no information provided about the patient's willingness to practice birth control, but since this is specific to male participants, it would apply in this case.\n\nBased on the information provided, the patient does not meet all of the necessary inclusion criteria for the trial due to a lack of evidence of liver cirrhosis and unclear HCV genotype. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1737": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, here's the assessment:\n\nThe patient is a 55-year-old man with a diagnosis of HCV (Hepatitis C virus) 2 years ago and recent coinfection with HBV (Hepatitis B virus). He has been on treatment with IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months. The patient's liver biopsy is consistent with chronic HCV infection, but there is no evidence of cirrhosis. He meets the following inclusion criteria for the clinical trial:\n\n1. Male between 18 and 70 years of age.\n2. Screening laboratory result indicating HCV infection.\n3. Chronic HCV infection defined as positive for anti-HCV antibody or HCV RNA at least 6 months before screening, and positive for HCV RNA and anti-HCV antibody at the time of screening.\n4. Treatment-experienced: the patient has been receiving treatment for HCV infection.\n\nThe clinical trial is evaluating the efficacy, safety, and pharmacokinetics of ABT-493 and ABT-530 with and without ribavirin in chronic Hepatitis C virus infection. The patient seems to fit the profile for treatment-experienced subjects without cirrhosis, which is appropriate for Study Part 1 and the corresponding arms of Study Part 2 that do not require the presence of cirrhosis. The patient's genotype is not mentioned, but since the trial includes genotypes 1, 4, 5, and 6, the patient's eligibility would depend on his HCV genotype. However, the inclusion criteria do not specify that the patient must have a particular genotype, only that they must be infected with HCV genotypes included in Study Parts 1 and 2. Therefore, assuming the patient's genotype is one of those included in the trial, he appears to meet the necessary requirements.\n\nThe patient note does not provide information that would explicitly exclude him from the trial based on the information given. \n\nTherefore, based on the available information, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant (as the patient's HCV genotype is not specified, and it is essential to ensure that the patient's HCV genotype matches those being studied in the trial).",
        "label": 1
    },
    "1738": {
        "output": "The patient is a 55-year-old man diagnosed with HCV 2 years ago and has recent coinfection with HBV. The patient's treatment history includes being on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient has no other significant past medical history and is not on any other medications. A recent biopsy showed no evidence of hepatocellular carcinoma but chronic inflammation compatible with chronic viral hepatitis. There is no mention of the patient's hepatitis C genotype, but he does have a documented chronic HCV infection.\n\nThe clinical trial in question is looking for subjects with chronic hepatitis C, specifically genotype 4 infection, with an HCV RNA level greater than 1,000 IU/mL at screening. Subjects may be treatment-naive or treatment-experienced with specific previous treatments. There are also specific criteria for substudies regarding the presence or absence of liver cirrhosis.\n\nThe patient's eligibility cannot be determined from the information provided because:\n\n1. The patient's hepatitis C genotype is not specified in the patient note. The trial specifically requires genotype 4.\n2. There is no information on the patient's HCV RNA level.\n3. There is no mention of the patient's response to previous treatments (if any) to determine if he would be considered treatment-naive or treatment-experienced per the trial's criteria.\n\nSince the patient's note lacks sufficient information to determine if he meets the specific inclusion criteria for the clinical trial, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1739": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- Treatment history includes IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned\n- No mention of cirrhosis in the patient note\n- Plasma HCV RNA level is not provided\n\nClinical Trial Inclusion Criteria:\n- Chronic HCV genotype 4 infection with cirrhosis\n- Plasma HCV RNA level > 1,000 IU/mL at Screening\n- Treatment-naive or treatment-experienced (specific categories for treatment experience are mentioned for different arms of the study)\n\nThe patient's note does not mention cirrhosis, which is a key inclusion criterion for the trial. Furthermore, there is no information about the patient's HCV RNA level at the time of screening. Without these critical pieces of information, we cannot determine that the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1740": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He is on a treatment regimen that includes IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Chronic Hepatitis B patients at all stages of infection, treatment naive and previously treated\n- Chronic Hepatitis C patients of all genotypes, treatment naive and previously treated\n- Longitudinal samples from patients treated with antiviral agents and interferon\n\nThe patient in question has chronic hepatitis C, is on treatment, and has been coinfected with hepatitis B. This aligns with the inclusion criteria for both chronic hepatitis B and C patients who are previously treated. Therefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1741": {
        "output": "Based on the provided patient note, the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) and a recent coinfection with Hepatitis B Virus (HBV). The patient does not have hepatocellular carcinoma (HCC) or metastatic liver disease, as the recent biopsy was negative for HCC and only showed chronic inflammation compatible with chronic viral hepatitis.\n\nThe inclusion criteria for the clinical trial specifically require participants to have HCC or metastatic liver disease and to be candidates for radioembolization or chemoembolization. Since the patient does not meet these criteria, he is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1742": {
        "output": "Based on the information provided in the patient note and the clinical trial details, the patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. His past medical history is non-significant. The patient is currently on treatment including IFN, RBV, and direct antiviral drugs for HCV. The patient's record does not mention any HIV coinfection or any HIV RNA levels. There is also no indication that the patient meets all the inclusion criteria for the clinical trial.\n\nFor the clinical trial titled \"Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection,\" the inclusion criteria are:\n\n1. Co-infected with HIV and HCV\n2. 21 years and older\n3. Primary language is English or Spanish\n4. Two most recent HIV RNA levels are both <1000 copies/mL\n5. Has attended appointment with HIV PCP in previous 6 months\n6. Has not attended appointment with HCV Provider in last year\n\nSince the patient note does not mention HIV coinfection, nor does it provide information about the patient's HIV RNA levels, we cannot confirm if the patient meets criteria 1 and 4. Therefore, we do not have sufficient information to qualify the patient for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1743": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 55-year-old male\n- Diagnosed with chronic HCV infection 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other significant liver diseases\n- Negative for HIV\n\nClinical Trial Inclusion Criteria Summary:\n- Willing and able to provide written informed consent\n- HCV genotype determined by the Central Laboratory\n- HCV RNA > LLOQ at screening\n- Participated and completed a Gilead sponsored HCV treatment study of direct-acting antiviral (DAA) containing regimens.\n- Must agree to use protocol specified method(s) of contraception if of childbearing potential\n\nClinical Trial Exclusion Criteria Summary:\n- Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment\n- Screening ECG with clinically significant abnormalities\n- Laboratory results outside of acceptable ranges at screening\n- Infection with HBV or HIV\n\nPatient's Eligibility Assessment:\n- The patient has chronic HCV and is on treatment, which fulfills the requirement of having HCV.\n- There is no information provided about the patient's participation in a prior Gilead sponsored study, which is a key inclusion criterion.\n- The patient is coinfected with HBV, which is listed in the exclusion criteria.\n\nGiven the information available, the patient is excluded from the trial due to the coinfection with HBV, which is listed as an exclusion criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1744": {
        "output": "To determine the trial-level eligibility for the patient described, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Male or female age 18 to 75 years.\n2. Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound.\n3. Bariatric surgery conducted during the last 12 months.\n4. Patients with sleeve gastrectomy or laparoscopic banding of the upper stomach will be included.\n5. Signature of the written informed consent.\n6. Negative pregnancy test at study entry for females of childbearing potential.\n7. Females of childbearing potential practicing reliable contraception throughout the study period (not including oral contraceptives).\n8. Hypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study).\n9. Patients treated with vitamin E(>400IU/die), or Polyunsaturated fatty acid (>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped at least 3 months prior to study enrollment to the study and up to it end.\n10. For patients with type 2 Diabetes, glycaemia must be controlled (Glycosylated Hemoglobin A1C \u2264 8% while any HbA1C increment should not exceed 1% during 6 month prior to enrollment). If glycaemia is controlled by medications, qualitative change is not permitted within 3 months prior to randomization and should be avoided during the study. Treatments with Metformin, Sulfamides and Insulin are authorized. Sulfamides and insulin are permitted if glycaemia is self-monitored by the patient.\n\nPatient's characteristics:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of gallstones, bariatric surgery, or any related conditions.\n\nBased on the information provided, the patient does not meet the inclusion criteria of the clinical trial. Specifically, the trial requires the presence of newly formed gallstones diagnosed by ultrasound within a certain timeframe after bariatric surgery. There is no mention of the patient having undergone bariatric surgery or having gallstones. Therefore, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1745": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's assess whether the patient is eligible for the clinical trial:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No hepatocellular carcinoma\n- No alcoholic liver disease or other liver conditions mentioned\n- Serum HCV RNA positive (implied as the patient is on antiviral treatment)\n- No information on HBeAg status\n- No information on serum alanine aminotransferase (ALT) levels\n- No information on previous treatment with interferon monotherapy or being treatment-naive\n\nClinical Trial Inclusion Criteria:\n- Seropositivity of HCV antibody (anti-HCV) and HBsAg for more than 6 months\n- Negative HBeAg\n- Serum alanine aminotransferase (ALT) levels between 1-10-fold of the upper limit of normal (ULN)\n- Treatment naive or had previously failed interferon monotherapy\n\nThe patient has seropositivity for HCV antibody and is coinfected with HBV, which meets part of the inclusion criteria. However, there is no information provided about the patient's HBeAg status, serum ALT levels, or whether the patient is treatment-naive or had previously failed interferon monotherapy. Without this information, we cannot fully determine if the patient meets all the inclusion criteria.\n\nTherefore, based on the available information, the patient cannot be classified as either excluded or eligible because we lack sufficient information to make a definitive assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1746": {
        "output": "Considering the patient note and the inclusion criteria for the clinical trial, we need to determine if the patient is eligible for the trial.\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No hepatocellular carcinoma (negative biopsy)\n- No evidence of other liver diseases\n- Normal vital signs and physical examination\n\nClinical trial inclusion criteria summary:\n- Patients who had chronic hepatitis B\n- Achieved HBsAg level \u2264100 IU/ml with undetectable HBV DNA level by interferon treatment\n\nThe patient has been treated for chronic HCV with recent HBV coinfection. The trial is specifically looking for patients with chronic hepatitis B who have achieved an HBsAg level \u2264100 IU/ml with undetectable HBV DNA level due to interferon treatment. The patient note does not provide information on the HBsAg level or the HBV DNA level. Furthermore, the patient is currently under treatment, and there is no indication that he has reached the specific endpoint of HBsAg level \u2264100 IU/ml required by the trial.\n\nTherefore, based on the available information, the patient does not have sufficient information provided to qualify for the trial, which makes him:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1747": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man with chronic hepatitis C virus (HCV) genotype not specified and a recent coinfection with hepatitis B virus (HBV).\n- The patient is treatment-naive for HCV, as he has been on IFN, RBV, and direct antiviral drugs for the past 6 months, which means he has not received treatment with any approved or investigational drug for chronic HCV infection prior to this.\n- There is no mention of the patient's FibroSURE score, APRI score, or presence of liver fibrosis or cirrhosis.\n- There are no findings indicative of hepatocellular carcinoma, and there's no mention of esophageal varices.\n- The patient's HCV RNA plasma level is not specified.\n\nClinical Trial Inclusion Criteria Analysis:\n- The patient must have HCV genotype 1 infection and an HCV RNA plasma level greater than 10,000 IU/mL.\n- The patient must be treatment-naive for HCV.\n- Depending on the trial arm, the patient must have evidence of either early stages of liver fibrosis or cirrhosis.\n- The patient must be eligible for pegylated interferon (PegIFN) and ribavirin (RBV).\n\nBased on the available information, while the patient is treatment-naive for HCV, we do not have information on the patient's HCV genotype, HCV RNA plasma level, FibroSURE score, APRI score, or the presence of liver fibrosis or cirrhosis. Therefore, we cannot conclusively determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1748": {
        "output": "The patient note describes a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months. There is no mention of previous treatment with DAA (direct acting antiviral) agents or treatment failure, which is a required inclusion criterion for the clinical trial in question. The trial is specific to individuals with chronic Hepatitis C Virus infection genotype 1 who have experienced treatment failure with previous DAA therapy. Additionally, part 2 of the trial requires a history of treatment failure after receiving at least 8 weeks of SOF/ledipasvir, and the patient must be treatment na\u00efve to all other anti-HCV therapies.\n\nThe patient's HCV genotype is not mentioned, and there is no indication of previous DAA therapy failure. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1749": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV (Hepatitis C Virus) 2 years ago\n- Recently coinfected with HBV (Hepatitis B Virus)\n- On treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months\n- No mention of HIV status\n- No significant past medical history\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress, normal blood pressure, and no abnormalities in the abdomen or lower extremities\n\nClinical trial inclusion criteria:\n- Adult (\u2265 18 years old)\n- Documented HIV positive\n- In regular HIV care follow-up (min. 2 consultations in the last six months prior to the study)\n- Willing and able to provide written informed consent\n\nThe patient in the note does not meet the inclusion criteria of being documented HIV positive and in regular HIV care follow-up, as there is no mention of HIV status at all. Therefore, this patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1750": {
        "output": "Let's assess the patient's eligibility for the clinical trial titled \"Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment\" based on the information provided in the patient note:\n\nThe patient is a 55-year-old man who has been diagnosed with HCV 2 years ago and has a recent coinfection with HBV. He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nNow, comparing this to the inclusion criteria of the trial:\n\n1. The patient is over 18 years old, meeting the age criterion.\n2. The trial is for patients with chronic hepatitis B. The patient has both HCV and HBV, which means he does have hepatitis B.\n3. The trial requires ongoing treatment with one or more nucleos(t)ide analogues (NUCs) for at least 192 weeks. The patient note does not specify treatment with NUCs, and the duration of current treatment is 6 months, which is less than the required 192 weeks.\n4. The trial requires HBV DNA levels <100 IU/mL, measured at least 12 months prior to, and upon enrollment to the study. The patient note does not provide information on HBV DNA levels.\n5. The ALT level must be less than or equal to 2 times the upper limit of normal, based on at least two determinations taken at least one month apart during the 24 weeks before study entry. The patient note does not provide information on ALT levels.\n\nLooking at the exclusion criteria:\n\n1. Co-infection with HCV is an absolute exclusion criterion, and the patient has HCV co-infection.\n\nGiven the information in the patient note, the patient does not meet all the inclusion criteria, specifically the treatment duration with NUCs and the lack of specified HBV DNA levels and ALT levels. However, most critically, he is explicitly excluded due to co-infection with HCV. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1751": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with chronic HCV infection 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of hepatocellular carcinoma (HCC)\n- No mention of hepatic decompensation\n- No mention of coinfection with HIV\n- No significant past medical history\n\nClinical trial inclusion criteria:\n- Individuals with chronic HCV infection (patient meets this criterion)\n- HCV RNA \u226510^4 IU/mL at screening (not enough information provided)\n- HCV genotype 1 (not enough information provided)\n- Cirrhosis determination; a liver biopsy may be required (not enough information provided, but recent biopsy mentioned with no signs of HCC)\n- Screening laboratory values within defined thresholds (not enough information provided)\n- Use of two contraception methods if female of childbearing potential or sexually active male (not enough information provided, but the patient is male)\n\nClinical trial exclusion criteria:\n- Pregnant or nursing female (not applicable to the patient)\n- Current or prior history of hepatic decompensation (no mention of this in the patient's history)\n- Hepatocellular carcinoma (HCC) or other clinically significant malignancy (not applicable to the patient)\n- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) (patient is coinfected with HBV, which excludes him from the trial)\n- History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol (no mention of such illnesses or disorders)\n\nGiven that the patient is coinfected with HBV, he does not meet the clinical trial's criteria because HBV coinfection is an exclusion criterion. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1752": {
        "output": "",
        "label": 1
    },
    "1753": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV two years ago and recently coinfected with HBV. His medical history is non-significant other than the HCV and HBV infections, and he is currently undergoing treatment with IFN, RBV, and direct antiviral drugs. There is no mention of hepatocellular carcinoma, which aligns with the trial's focus on hepatitis C without advanced liver disease complications.\n\nThe clinical trial in question aims to estimate the prevalence of hepatitis C in Belgium in 2014 and to confirm the proposed targeted birth cohort and other risk factors. The inclusion criteria for this study are broad, stating that all patients admitted to the one-day clinic for surgery and gastroenterology are eligible.\n\nSince the patient's condition (HCV infection) and his demographic (55-year-old man) fit within the broad inclusion criteria of the trial, and there is no mention of any exclusion criteria that would disqualify him, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1754": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or advanced liver diseases\n- No mention of cirrhosis or advanced bridging fibrosis\n\nClinical trial inclusion criteria:\n- Male or female at least 18 years of age at the time of screening\n- Chronic Hepatitis C virus (HCV) infection prior to study enrollment\n- Screening laboratory results from the central clinical laboratory indicating HCV genotype 1 infection only\n- Absence of cirrhosis and advanced bridging fibrosis\n\nAssessment:\n- The patient is over 18 years of age.\n- The patient has a chronic HCV infection.\n- There is no evidence of cirrhosis or advanced bridging fibrosis in the patient's medical records.\n- However, the patient's HCV genotype is not specified in the note, which is a necessary detail for the trial inclusion.\n- Additionally, the recent co-infection with HBV is noted, which may or may not be relevant for the trial depending on whether co-infection is an exclusion criterion, but this information is not provided.\n\nSince the patient's HCV genotype is not specified and we do not have information on whether HBV co-infection would be an exclusion criterion, we do not have sufficient information to determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1755": {
        "output": "",
        "label": 1
    },
    "1756": {
        "output": "The patient described in the note is a 55-year-old man with a diagnosis of HCV and a recent coinfection with HBV. There is no mention of diabetes or any related symptoms, nor is there any indication that he is of African descent or currently residing in Durban, the eThekwini Municipality. Therefore, based on the provided information, he does not meet the specific inclusion criteria for the Durban Diabetes Study.\n\nTo be included in the Durban Diabetes Study, participants must be of African descent, aged 18 years or older, not pregnant, and currently residing in Durban (eThekwini Municipality). The patient's note does not satisfy these criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1757": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man diagnosed with HCV (hepatitis C virus) 2 years ago and recently coinfected with HBV (hepatitis B virus). The patient has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. There is no mention of HDV (hepatitis D virus) infection in the patient's note, which is a requirement for the clinical trial. The trial specifically looks for patients with chronic hepatitis D infection, confirmed by a positive anti-HDV antibody test and detectable HDV RNA by PCR. There is also no information on the patient's HDV RNA levels or liver biopsy results specific to HDV.\n\nThe clinical trial's inclusion criteria require a diagnosis of HDV by PCR, chronic hepatitis D infection genotype 1, a liver biopsy within the last two years, a positive viral load of HDV, an ECG with specific parameters, and other criteria related to reproductive status and consent which do not apply to this male patient or are not mentioned in the patient's note.\n\nGiven the absence of any mention of HDV infection in the patient's history and the lack of relevant HDV-specific diagnostic information, the patient does not meet the inclusion criteria for the clinical trial on Lonafarnib treatment for HDV.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1758": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Biomarkers of Liver Fibrosis,\" let's evaluate the patient's eligibility:\n\nPatient Information:\n- Age: 55 years old (meets age criterion of \u226518 years)\n- Diagnosed with HCV 2 years ago (relevant for inclusion)\n- Recently coinfected with HBV (this could potentially exclude the patient as the criteria specify no additional liver diseases)\n- On treatment for HCV for the past 6 months (meets the criterion of planning to initiate treatment for HCV, although the patient is already on treatment)\n- No evidence of other liver diseases listed in the exclusion criteria (meets the criterion of not being diagnosed with any additional liver diseases specified)\n- Able to provide medical history and is alert (potentially able to travel and sign informed consent, though not explicitly stated)\n- English language proficiency is not mentioned (unclear if the patient meets this criterion)\n- The patient's willingness to sign informed consent is not mentioned (unclear if the patient is willing)\n\nThe patient note does not provide sufficient information regarding the patient's ability to travel to Mount Sinai, proficiency in English, and willingness to sign informed consent. However, the patient is already on HCV treatment, which might not align with the criterion of planning to initiate treatment in the near future. Additionally, the patient's recent coinfection with HBV may exclude him from the trial as the inclusion criteria specify no diagnosis with any additional liver diseases, such as hepatitis B.\n\nTherefore, considering the potential issues with the HBV coinfection and the lack of information on language proficiency and willingness to sign informed consent, the patient's eligibility is not clear.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1759": {
        "output": "Based on the patient note, the patient is a 55-year-old man with a chronic Hepatitis C Virus (HCV) infection that was diagnosed 2 years ago and has recently coinfected with Hepatitis B Virus (HBV). He is currently undergoing treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs. The patient's biopsy was negative for hepatocellular carcinoma and indicated chronic inflammation compatible with chronic viral hepatitis.\n\nNow, let's analyze the inclusion criteria for the clinical trial:\n\n1. The patient must have a chronic hepatitis C virus (HCV) infection at screening, which this patient does.\n2. The patient must be an adult, which at 55 years old, this patient is.\n3. The patient must have fibrosis stage F3 or greater, documented by acceptable tests. However, the patient note does not specify the fibrosis stage.\n4. If the participant has cirrhosis, they must not have hepatocellular carcinoma, which this patient does not.\n\nAdditional criteria for males include being surgically sterile or agreeing to practice acceptable forms of birth control. The patient note does not mention the patient's reproductive status or birth control practices.\n\nGiven that the patient note does not provide information on the fibrosis stage of the patient's liver or his birth control practices, we do not have sufficient information to fully determine eligibility for the trial based on the inclusion criteria provided. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1760": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let\u2019s evaluate the patient\u2019s eligibility:\n\n1. The patient is a 55-year-old man, which satisfies the age criterion (age \u2265 18 years).\n2. The patient has been diagnosed with hepatitis C virus (HCV) infection 2 years ago, and there is no mention that he is not a US military veteran, so we can assume he may be eligible based on the information given.\n3. His medical records show positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. However, there is no specific mention of HCV genotype, which is required to be genotype 1 for the trial.\n4. The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months, which indicates ongoing treatment for HCV.\n5. The patient's recent biopsy was negative for hepatocellular carcinoma and showed signs consistent with chronic viral hepatitis, but the trial specifically requires evidence of chronic HCV-infection with HCV RNA > 1,000 IU/mL at the time of screening or a liver biopsy consistent with chronic hepatitis C disease.\n\nWhile the patient note indicates that the patient has chronic hepatitis C and is currently undergoing treatment, there is insufficient information to confirm the patient's HCV genotype and whether he is a US veteran receiving healthcare through the Veterans Health Administration. Additionally, we lack current HCV RNA levels and the confirmation of the patient being a veteran is not explicitly stated.\n\nTherefore, the patient note does not provide sufficient information to determine if the patient meets all the specific inclusion criteria for the clinical trial. The patient might be eligible, but more information is needed to confirm their eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1761": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility for the clinical trial titled \"Disease Status in Primary Sclerosing Cholangitis by Elastography\":\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Recent biopsy showing chronic inflammation compatible with chronic viral hepatitis\n- No mention of Primary Sclerosing Cholangitis (PSC)\n\nClinical trial inclusion criteria:\n- Patients with known Primary Sclerosing Cholangitis (PSC)\n- Control group of patients with Non-PSC chronic liver disease with recent (<3 month) liver biopsy and under imaging surveillance\n\nThe patient has chronic viral hepatitis (HCV and HBV) but there is no mention of Primary Sclerosing Cholangitis (PSC). However, the patient could potentially fit into the control group as he has a non-PSC chronic liver disease, which is chronic viral hepatitis. The patient's recent biopsy and the fact that he is under treatment suggest that he may be under imaging surveillance, which is an assumption based on his ongoing medical care.\n\nGiven that the patient has a non-PSC chronic liver disease and possibly meets the criteria for the control group, the patient could be eligible for the trial as part of the control group. There is no direct evidence of recent imaging surveillance, but it could be inferred. The eligibility would need to be confirmed with additional details about his imaging surveillance.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1762": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility.\n\nPatient information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No signs of decompensated liver disease\n- HIV status is not mentioned\n- No information on incarceration status\n- No information on understanding of study requirements or consent\n\nClinical trial inclusion criteria:\n- An offender at the PEI Provincial Correction Centre during the enrollment time\n- Male, 18 -70 years of age\n- Chronic HCV genotype 1 infection\n- Positive HCV immunosorbant assay and detectable HCV viral load\n- No evidence of decompensated liver disease\n- HIV negative\n- Must practice effective forms of birth control if sexually active\n- Must understand and adhere to the study visit schedule and all other protocol requirements\n- Must voluntarily sign an informed consent form\n\nThe patient meets some criteria (male, within the age range, has HCV, is on treatment, and shows no evidence of decompensated liver disease). However, there's no information provided about his HIV status, birth control practices, understanding and adherence to the study schedule, or whether he has signed an informed consent form. Most importantly, it is not mentioned if the patient is an offender at the PEI Provincial Correction Centre during the enrollment time, which is a critical criterion for inclusion in this study.\n\nDue to the lack of information on several key inclusion criteria, specifically the requirement of being an offender at the PEI Provincial Correction Centre, the patient's eligibility cannot be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1763": {
        "output": "Based on the patient note provided, the 55-year-old man diagnosed with HCV and recent coinfection with HBV does not have a diagnosis of hepatocellular carcinoma (HCC), as indicated by the negative biopsy results for HCC. Instead, his biopsy showed chronic inflammation compatible with chronic viral hepatitis. The clinical trial is evaluating the role of aflatoxin as an environmental risk factor for liver cancer in the Nile Delta, specifically in patients who have cirrhosis with and without HCC.\n\nThe inclusion criteria for the clinical trial specify that participants must be \"cirrhotic patients with and without HCC.\" However, the patient note does not provide any information indicating that the patient has cirrhosis. Without this information, we cannot assess whether the patient meets the inclusion criteria for the clinical trial.\n\nAs there is not enough information to determine the patient's eligibility based on the inclusion criteria provided (cirrhosis status is unknown), the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1764": {
        "output": "To determine the trial-level eligibility of the patient for the specified clinical trial, we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with chronic HCV infection 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct-acting antiviral drugs for the past 6 months\n- Non-significant past medical history\n- No evidence of cirrhosis or other liver diseases\n- Normal BMI, blood pressure, and absence of edema\n\nClinical Trial Inclusion Criteria:\n- Male or female, age \u2265 18 years\n- Chronic HCV genotype 4 infection, with HCV RNA \u2265 104 IU/mL at screening\n- No prior exposure to IFN, RBV, or other antivirals (for treatment-na\u00efve subjects)\n- No evidence of cirrhosis\n- Specific laboratory parameters\n\nClinical Trial Exclusion Criteria:\n- Infection with HBV\n- Other chronic liver diseases\n- Various other health conditions and treatments unrelated to the patient's condition\n\nAssessment:\n- The patient is over 18 years old and has chronic HCV, which matches the age and disease criteria.\n- The patient is currently on IFN and RBV, which means he is not treatment-na\u00efve. However, the inclusion criteria accommodate treatment-experienced subjects with specific prior treatment histories.\n- The patient has recently been coinfected with HBV, which is explicitly listed as an exclusion criterion.\n\nBased on the information given, the patient would not be eligible for the clinical trial due to the recent coinfection with HBV, despite meeting the other inclusion criteria. Therefore, the patient is excluded on the grounds of the trial's exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1765": {
        "output": "Based on the information provided in the patient note and the criteria specified by the clinical trial, let's determine the patient's eligibility:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with hepatitis C virus (HCV) 2 years ago\n- Recent coinfection with hepatitis B virus (HBV)\n- On treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Non-cirrhotic\n\nClinical Trial Criteria:\n- Chronic HCV infection\n- HCV genotype 1a (GT1a) infection specifically\n- Subject must be non-cirrhotic\n- Subject must be able to understand and adhere to the study visit schedule and all protocol requirements\n- Subject must voluntarily sign and date an IRB-approved informed consent\n\nComparison:\n- The patient has a chronic HCV infection, which matches the trial's requirement.\n- The trial requires participants to have a genotype 1a HCV infection. The patient note does not specify the genotype of HCV, so it is unknown if the patient has the required genotype 1a infection.\n- The patient is non-cirrhotic, meeting another criterion of the trial.\n- There is no information provided about the patient's ability to understand and adhere to the study visit schedule or about consent, but we could reasonably assume the patient can comply based on the information provided.\n\nGiven the information available, we have one critical piece of data missing, which is the HCV genotype of the patient. Without this information, we cannot confirm eligibility for the trial, which requires participants to have genotype 1a HCV infection specifically.\n\nTherefore, based on the available data, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1766": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- Past medical history is non-significant\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of impaired walking function, dementia, or urinary incontinence\n- No mention of MRI or CT results regarding the ventricular system\n- The patient's ability to understand the patient information sheet and comply with the requirements of the protocol is not mentioned\n\nClinical trial inclusion criteria:\n- Informed consent\n- Age 50 years or above (Patient meets this criterion)\n- Impaired walking function for at least 3 months, onset at/after 40 years of age (No information provided)\n- MRI or CT with enlarged ventricular system (Evans' index \u22650.30) without evidence of moderate or severe cortical atrophy (No information provided)\n- Eligible for shunt surgery (No information provided)\n- Eligible for analysis of gait, neuropsychological and urological function (No information provided)\n- Subjects must be able to understand the patient information sheet and comply with the requirements of the protocol (No information provided)\n\nThe patient meets the age criterion for the clinical trial; however, there is no information provided on the patient's walking function, MRI or CT results, eligibility for shunt surgery, or ability to comply with the protocol requirements. Given the lack of information, we cannot confirm if the patient is eligible for the trial based on the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1767": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- BMI: 27\n- Seropositive for HCV\n\nClinical Trial Inclusion Criteria:\n- Patients chronically infected with HCV Genotype 1b\n- No previous exposure to any interferon formulation, Ribavirin (RBV), and HCV direct acting antiviral agent\n- HCV RNA viral load \u2265 10,000 IU/mL at screening\n- Seronegative for HIV and HBsAg\n- BMI of 18-35 kg/m2, inclusive\n- Patients with compensated cirrhosis are permitted\n\nAssessment of Eligibility:\n- The patient has chronic HCV, but there is no information on the specific genotype (1b or otherwise).\n- The patient has had previous exposure to interferon formulation, Ribavirin (RBV), and direct antiviral drugs, which is against the inclusion criteria.\n- The patient is coinfected with HBV, which disqualifies him as he needs to be seronegative for HBsAg according to the trial criteria.\n- The patient's BMI is within the required range of 18-35 kg/m^2.\n\nBased on the above points, the patient does not meet the inclusion criteria due to previous exposure to interferon, RBV, and direct antiviral agents, as well as the coinfection with HBV (positive for HBsAg). Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1768": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine the patient's eligibility for the trial:\n\nThe clinical trial is for patients with Hepatocellular Carcinoma (HCC), and the key inclusion criteria are:\n1. Confirmed diagnosis of HCC by histological examination or by non-invasive criteria (Part 1, 2, and 3).\n2. Unresectable disease and previously treated with sorafenib, declined treatment with sorafenib, or no access to sorafenib (For Part 1 and 2).\n3. Not received prior treatment with a Tyrosine Kinase Inhibitor (TKI) (For Part 3).\n4. Child-Pugh class A with no clinically apparent ascites.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n6. Willingness to provide archived tumor tissue and undergo tumor biopsy if safe and medically feasible (For Part 1).\n7. Must have an FGF19 IHC result available, and only FGF19 IHC+ HCC patients will be eligible for Part 3.\n\nThe patient note states that the patient has been diagnosed with HCV and a recent coinfection with HBV. There is no mention of hepatocellular carcinoma (HCC) in the patient's diagnosis. The patient does not meet the primary inclusion criterion of having a confirmed diagnosis of HCC; therefore, he is not eligible for the clinical trial. Since the patient's condition does not align with the target disease of the trial (HCC), we do not need to assess further inclusion or exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1769": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- Past medical history is non-significant\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the exclusion criteria\n- No mention of decompensated liver disease or any other exclusion criteria being met\n\nInclusion criteria for the trial:\n- Age 18 years or above\n- Serum alanine or aspartate aminotransferase (ALT or AST) activities above the upper limit of normal\n- Presence of anti-HDV in serum\n- Presence of quantifiable HDV RNA in serum\n\nExclusion criteria for the trial:\n- Decompensated liver disease\n- Pregnancy or inability to practice adequate contraception\n- Significant systemic or major illnesses other than liver disease\n- Systemic immunosuppressive therapy within the previous 2 months\n- Evidence of another form of liver disease in addition to viral hepatitis\n- Active substance abuse\n- Evidence of hepatocellular carcinoma\n- Evidence of concurrent hepatitis C infection with positive serum HCV RNA\n- Any experimental therapy or pegylated interferon therapy within 6 months prior to enrollment\n- Diagnosis of malignancy in the five years prior to the enrollment\n- Evidence of HIV co-infection\n- Concurrent usage of drugs that interact with ritonavir\n- Clinically significant baseline EKG abnormalities\n- Uncontrolled elevated triglycerides\n- History of pancreatitis as a result of hypertriglyceridemia\n- Inability to understand or sign informed consent\n- Any other condition which would impede participation or compliance in the study\n\nAssessment:\n- The patient does not meet the inclusion criteria as there is no mention of chronic hepatitis D, anti-HDV, or quantifiable HDV RNA in the serum.\n- The patient's note does not provide ALT or AST levels, so we cannot confirm if these are above the upper limit of normal.\n- The patient has a coinfection with HBV, which is not a disqualifying condition unless it is concurrent hepatitis C infection with positive HCV RNA, which is an exclusion criterion. However, the patient has been diagnosed with HCV and is under treatment for it, which may disqualify him if serum HCV RNA is still positive.\n\nGiven the available information and the presence of HCV, we can't confirm the patient's eligibility without additional information about the status of HCV RNA and the presence of HDV infection. Therefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1770": {
        "output": "Based on the information provided:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No mention of HIV infection\n- Currently on treatment for HCV (IFN, RBV, and direct antiviral drugs)\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the exclusion criteria\n\nClinical trial inclusion criteria:\n- Patients over 18 with HIV infection and active chronic hepatitis or SVR after treatment\n\nThe patient does not meet the inclusion criteria for the clinical trial because there is no mention of an HIV infection, which is a key component of the trial's inclusion criteria. The patient has HCV and HBV coinfection, not HIV.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1771": {
        "output": "To assess the patient's eligibility for the clinical trial \"Essentiale\u00ae Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases,\" let's compare the patient's characteristics and condition with the inclusion and exclusion criteria provided for the trial.\n\nPatient's Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of gastrointestinal symptoms related to the liver disease\n- No alcohol intake mentioned\n- No mention of severe fibrosis, but the patient does have chronic inflammation compatible with chronic viral hepatitis\n- No other significant liver disease mentioned\n- Able to take oral medications\n- No mention of fertility or contraception\n\nInclusion Criteria Checklist:\n- Males and females \u226518 years of age and less than 66 years old. (\u2713)\n- Patients with gastrointestinal symptoms in acute and chronic liver diseases receiving conventional treatment. (?)\n- Patients will be advised to stop alcohol intake and must agree not to consume alcohol. (\u2713, as there is no mention of alcohol intake)\n- The patient is able and willing to undertake all study required procedures and has the ability to take oral medications. (\u2713)\n- Patients with nonalcoholic fatty liver disease (NAFLD) diagnosed by ultrasound examination in absence of severe fibrosis. (\u2713, although NAFLD is not mentioned, there's no evidence of severe fibrosis and the patient has chronic viral hepatitis)\n- Diagnosis of acute or chronic viral hepatitis with specific symptoms and abnormal ALT. (\u2713)\n- Patient has given written informed consent. (Assumed \u2713, as this can be obtained if all other criteria are met)\n- Fertile patients must agree to use an acceptable method of contraception. (Not applicable to the patient as there is no information provided about fertility)\n\nExclusion Criteria Checklist:\nThe patient does not meet any of the explicit exclusion criteria based on the information provided.\n\nThe patient meets most of the inclusion criteria; however, there is no information provided about whether the patient has gastrointestinal symptoms, which is a key inclusion criterion for this trial. Therefore, without this information, we cannot definitively determine the patient's eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1772": {
        "output": "",
        "label": 1
    },
    "1773": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Titrating-Dose of Lonafarnib in Combination With Ritonavir,\" we must compare the patient's characteristics and medical history against the trial's inclusion and exclusion criteria.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- Has not been mentioned to have chronic HDV infection, only HCV and HBV\n- No other medications are mentioned, which means no known use of lonafarnib or contraindicated medications as per the trial's exclusion criteria\n- No mention of HIV infection\n- No clinical signs of decompensated liver disease or cirrhosis\n- No biochemical evidence of active jaundice or renal impairment\n- No mention of willingness to practice appropriate contraception, although this can sometimes be assumed in a clinical trial setting\n- The patient's gender and age fit the trial's inclusion criteria\n\nClinical Trial Inclusion Criteria:\n- 18 to 65 years of age\n- Chronic HDV infection documented by a positive HDV Ab test of at least 6 months duration and detectable HDV RNA\n- Liver biopsy demonstrating evidence of chronic hepatitis\n- Willingness to practice appropriate contraception (typically applies to both genders unless otherwise specified)\n\nClinical Trial Exclusion Criteria:\n- Previous use of lonafarnib\n- Co-infected with HIV or HCV\n- Decompensated liver disease or cirrhosis, history of bleeding esophageal varices, ascites, or hepatic encephalopathy\n- Active jaundice\n- Serum creatinine concentration \u22651.5 times ULN\n- Evidence of another form of viral hepatitis (not including HBV or HCV) or another form of liver disease\n- Evidence of hepatocellular carcinoma\n\nAssessment:\nThe patient does not meet all the inclusion criteria for the trial; specifically, there is no mention of chronic HDV infection, which is a key inclusion criterion. Therefore, based on the information provided, the patient does not appear eligible for this trial because the patient's diagnosis does not match the target disease of the trial (chronic HDV infection).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1774": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n1. The patient is a 55-year-old man, which is within the age range of 18-70 years specified in the inclusion criteria.\n2. He was diagnosed with HCV 2 years ago and is coinfected with HBV.\n3. The patient has been on IFN, RBV, and direct-acting antiviral drugs for the past 6 months, which aligns with the requirement of being treated with DAA therapy.\n4. There is no mention of the patient being institutionalized, mentally disabled, a prisoner, unwilling or unable to provide informed consent, HIV positive, or having an anticipated inability to follow up.\n5. The patient is not described as having chronic anemia or a platelet count < 100, which are part of the exclusion criteria.\n6. There is no mention of bleeding disorders or prolonged INR.\n7. The patient does not appear to have clinical hepatic decompensation, as there is no evidence of ascites, encephalopathy, or variceal hemorrhage.\n8. The patient's alcohol consumption is not mentioned, so we cannot determine if he meets the criteria of being abstinent or consuming less than two drinks of alcohol per day.\n\nSince there is no information suggesting that the patient fails to meet any exclusion criteria and based on available information, he meets all the inclusion criteria, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1775": {
        "output": "",
        "label": 1
    },
    "1776": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man with a diagnosis of HCV (hepatitis C virus) that was made 2 years ago and has a recent coinfection with HBV (hepatitis B virus). His treatment regimen includes IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months. The patient's medical records indicate previous positive HCV RNA tests which fulfill the first inclusion criterion of the clinical trial. Additionally, the patient has a positive enzyme immunoassay for anti-HCV antibodies, and the recent biopsy shows no evidence of hepatocellular carcinoma but is remarkable for chronic inflammation compatible with chronic viral hepatitis. There is also no mention of any exclusion criteria that would prevent the patient from participating in the trial.\n\nThe inclusion criteria for the clinical trial titled \"DAAs Treatment for Chronic HCV/HBV Co-infection Patients (DASCO)\" are:\n1. HCV RNA positive,\n2. HBsAg positive with detectable or undetectable HBV DNA,\n3. Receiving pan oral direct-acting anti-HCV regimen.\n\nThe patient meets the inclusion criteria as follows:\n1. HCV RNA positive - Confirmed by the patient's positive HCV RNA tests.\n2. HBsAg positive with detectable or undetectable HBV DNA - While the note does not specify HBsAg or HBV DNA status explicitly, the recent coinfection with HBV suggests that HBsAg would be positive.\n3. Receiving pan oral direct-acting anti-HCV regimen - The patient is currently on a treatment regimen that includes direct antiviral drugs, which aligns with this criterion.\n\nGiven that the patient appears to meet all the stated inclusion criteria and no exclusion criteria are provided in the patient note or clinical trial description, the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1777": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility:\n\nPatient information:\n- 55-year-old man \n- Diagnosed with HCV 2 years ago \n- Coinfection with HBV \n- No evidence of hepatocellular carcinoma or cirrhosis\n- On IFN, RBV, and direct antiviral drugs for the past 6 months \n- BMI: 27\n\nClinical trial inclusion criteria:\n- HCV RNA < 2000000 IU/mL (No information provided on patient's HCV RNA levels)\n- Never taken medication for HCV (Patient has taken medication for HCV for the past 6 months)\n- No Liver Cirrhosis (Patient has no evidence of cirrhosis)\n- No advanced fibrosis (No information provided on fibrosis, but no cirrhosis suggests no advanced fibrosis)\n- BMI 18-40 kg/m^2 (Patient's BMI is 27, which is within the required range)\n- Genotype 1-4 (No information provided on the patient's HCV genotype)\n\nThe patient does not meet the criteria of never having taken medication for HCV, as they are currently on treatment. There is also insufficient information regarding the patient's HCV RNA levels and genotype to determine eligibility based on those criteria.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1778": {
        "output": "Patient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests and positive for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma; chronic inflammation noted\n- No evidence of decompensated liver disease\n- Vital signs: BP 130/75, HR 90/min, BMI 27\n- Normal abdomen, no ascites, no tenderness\n- Normal lower extremities, no edema\n\nClinical Trial Inclusion Criteria:\n- HCV RNA Positive and Genotype 1b\n- No history or signs or symptoms of decompensated liver disease or hepatocellular carcinoma within 6 months\n- A patient who is on dialysis, or if not MDRD eGFR<30ml/min\n- HCV treatment history: HCV treatment-naive or HCV treatment-experienced (with conditions)\n- No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H\n\nAnalysis:\n- The patient has a positive HCV RNA test but the genotype is not specified in the patient note.\n- No signs or symptoms of decompensated liver disease are noted in the patient information; this meets the trial's inclusion criteria.\n- There is no mention of the patient's renal function or whether he is on dialysis, therefore we cannot determine if the patient meets the criteria regarding chronic renal failure.\n- The patient is HCV treatment-experienced as he is currently on IFN, RBV and direct antiviral drugs.\n- There is no information provided about the presence of baseline mutation NS5A polymorphism.\n\nGiven that the patient's HCV genotype is not specified and there is no information on renal function or NS5A polymorphism status, there is insufficient information to determine if the patient meets the trial's inclusion criteria. Therefore, the appropriate assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1779": {
        "output": "Based on the information given in the patient note, let's evaluate the patient's eligibility against the inclusion criteria for the clinical trial:\n\n1. Newly diagnosed histologically proven malignant lymphoma - The patient note does not mention a diagnosis of lymphoma, only HCV and recent coinfection with HBV.\n\n2. Eligible subjects must be positive for anti-HCV Ab - The patient is positive for anti-HCV antibodies and has a history of HCV.\n\n3. Age \u2265 20 years - The patient is 55 years old, which meets the age criterion.\n\n4. Planned to receive chemotherapy - The patient note does not mention any plans for chemotherapy, only that the patient is on IFN, RBV, and direct antiviral drugs for HCV.\n\n5. No recent chemotherapy and radiotherapy in the past one year - The patient note does not mention any recent chemotherapy or radiotherapy.\n\n6. Life expectancy \u2265 3 months - There is no information provided about the patient's life expectancy.\n\n7. Signed informed consent - This is a procedural step that would follow if the patient meets the other inclusion criteria and agrees to participate.\n\n8. ECOG 0-2 - The patient is described as alert with no acute distress, which could suggest an ECOG performance status within the 0-2 range, but this is not explicitly stated.\n\nThe patient does not have a diagnosis of lymphoma, which is a key inclusion criterion for the trial. Additionally, there is no information suggesting that the patient is planning to receive chemotherapy. Therefore, based on the available information, the patient does not meet all of the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1780": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the clinical trial titled \"The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence.\"\n\nThe patient is a 55-year-old man, which fits within the age range of 21-65 years specified in the trial's inclusion criteria. However, the trial is looking for participants who:\n\n- Have no known serious medical conditions; the patient has chronic viral hepatitis which can be considered a serious medical condition.\n- Smoke an average of at least 10 cigarettes per day; there is no information in the patient's note indicating that he smokes cigarettes at all, let alone the required amount.\n- Have smoked at least one cumulative year; again, there is no information about the patient being a smoker.\n- Have an expired air CO reading of at least 10ppm; there is no such information available in the patient note.\n- Are able to read and understand English; this is not specified, but we could assume the patient meets this criterion as there is no indication otherwise.\n\nTherefore, the patient does not meet several key inclusion criteria required for participation in the trial. Specifically, the patient's medical condition (chronic viral hepatitis) and the lack of information regarding his smoking habits lead to the conclusion that he is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1781": {
        "output": "",
        "label": 0
    },
    "1782": {
        "output": "Based on the information provided in the patient note, the patient is a 55-year-old man with a diagnosis of chronic viral hepatitis (HCV and HBV co-infection). There is no mention of HIV infection or any related treatment in the patient's note. The inclusion criteria for the clinical trial specifically require participants to have documented HIV infection among other criteria related to HIV management and organ transplantation readiness.\n\nSince the patient in question does not have documented HIV infection, he does not meet the inclusion criteria for this clinical trial, which is focused on the transplantation of organs in HIV+ individuals.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1783": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and history against the inclusion criteria of the trial. Here is the analysis:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- Past medical history is non-significant\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No hepatocellular carcinoma\n- No alcoholic liver disease, esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- BMI: 27\n\nClinical Trial Inclusion Criteria:\n- Willing and able to provide written informed consent (Not specified in the patient note)\n- Documentation of non-cirrhotic or cirrhotic status (Not specified in the patient note)\n- HIV-1 infection (Not mentioned, hence the patient does not have this condition)\n- HIV antiretroviral treatment status and related conditions (Not applicable as the patient does not have HIV)\n- HCV GT-1 within 12 months prior to study entry (Patient has HCV but genotype is not specified)\n- Prior virologic treatment failure with SOF-containing regimen (Not specified whether the patient had treatment failure with SOF)\n- BMI \u226518 kg/m^2 (Patient's BMI is 27, so criteria met)\n- Certain laboratory values obtained within 42 days prior to study entry (Not specified in the patient note)\n- Hemoglobin \u226512.0 g/dL for male (Not specified in the patient note)\n- AST and ALT <10 x ULN (Not specified in the patient note)\n- For female participants of reproductive potential, a negative serum pregnancy test (Not applicable as the patient is male)\n- Agreement to use at least two reliable forms of contraceptive simultaneously while receiving study treatment and for 6 months afterward (Not specified in the patient note)\n- Intention to comply with the dosing instructions and study schedule of assessments (Not specified in the patient note)\n\nBased on the available information in the patient note and the inclusion criteria for the clinical trial, the patient's eligibility cannot be firmly established due to several key pieces of information not being specified. For example, it is not clear if the patient had a prior virologic treatment failure with a SOF-containing regimen, which is a crucial inclusion criteria for the trial. Additionally, the patient's non-cirrhotic or cirrhotic status, certain laboratory values, and the patient's willingness and ability to comply with study requirements are not provided.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1784": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial in question, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with hepatitis C virus (HCV) 2 years ago and recent coinfection with hepatitis B virus (HBV).\n- Non-significant past medical history.\n- Currently on treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or cirrhosis.\n- Has a history of positive HCV RNA tests and anti-HCV antibodies.\n\nClinical Trial:\n- The study is looking for participants with chronic hepatitis C virus infection.\n- Participants must be non-cirrhotic.\n- They must have HCV Genotype 1a infection.\n- Participants can be treatment-na\u00efve or previously treated with interferon or pegylated interferon with or without ribavirin.\n\nFrom this information, we can determine the following:\n\n- The patient has chronic hepatitis C infection, meeting one of the inclusion criteria.\n- The patient is non-cirrhotic, which aligns with the study's requirement.\n- The treatment history of the patient includes IFN and RBV, which is allowed by the study criteria.\n- What is not mentioned in the patient note is the specific genotype of the patient's HCV infection. The study specifically requires participants to have HCV Genotype 1a.\n\nSince the patient's HCV genotype is not specified in the note, we do not have sufficient information to confirm whether the patient has the specific HCV genotype required by the trial. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1785": {
        "output": "",
        "label": 1
    },
    "1786": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection,\" we need to compare the patient's information with the inclusion and exclusion criteria of the study.\n\nPatient's Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma, bleeding from esophageal varices, or other liver diseases\n- Alert with no acute distress\n- Normal blood pressure, heart rate, and BMI\n\nInclusion Criteria for the Study:\n- Signed informed consent\n- 18 years of age or older\n- Detectable HCV RNA at screening (>10,000 IU/ml)\n- HCV genotypes 1-6\n- HBsAg negative\n- Compensated liver disease (Child-Pugh A)\n- Negative pregnancy test (if applicable)\n- Medically stable based on physical exam, history, and vital signs\n- Adequate English to provide reliable responses\n- Effective contraception during and after treatment (if applicable)\n- Recently acquired HCV infection (\u226412 months) as defined by specific serological or clinical criteria\n- If co-infected with HIV, additional criteria regarding antiretroviral treatment and CD4 T cell counts\n\nExclusion Criteria for the Study:\n- Clinically significant illness (other than HCV) that interferes with the protocol\n- History of certain diseases and conditions\n- Malignancy within 5 years (with exceptions)\n- Significant drug allergy\n- Evidence of significant liver disease in addition to HCV\n- Known cirrhosis\n- Abnormal lab parameters\n- Pregnant or nursing females\n- Use of prohibited medications\n- Chronic use of immunosuppressive agents\n- Hypersensitivity to study drugs\n- Anti-neoplastic or immunomodulatory treatment \u22646 months prior to study drug\n- Investigational drug \u22646 weeks prior to study drug\n- Previous failure of therapy with sofosbuvir or an NS5A inhibitor\n- Ongoing severe psychiatric disease\n- Frequent injecting drug use compromising treatment safety\n- Inability or unwillingness to provide informed consent or abide by study requirements\n\nBased on the patient's information provided:\n- The patient is 55 and has chronic HCV, which does not fit the \"recently acquired HCV infection\" criterion.\n- The patient is coinfected with HBV, which contradicts the \"HBsAg negative\" inclusion criterion.\n- The patient is on treatment with IFN, RBV, and direct antiviral drugs, which suggests he may not meet the criteria for recently acquired HCV infection as defined by the trial.\n- There are no indications that the patient has HIV coinfection, which is part of the study's title but not explicitly listed in the inclusion criteria.\n\nBased on the information given and the trial's criteria, the patient does not seem to meet the key inclusion criteria, particularly the requirement for a recently acquired HCV infection and being HBsAg negative.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1787": {
        "output": "",
        "label": 0
    },
    "1788": {
        "output": "Based on the patient's note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of cirrhosis or other significant liver diseases apart from chronic viral hepatitis\n- No mention of past use of NS5A inhibitors for HCV\n- Not on any medications that could interfere with the study drugs\n- No significant illnesses that may interfere with participation\n- No other contraindications mentioned in the patient note\n\nClinical Trial Inclusion Criteria:\n- Willing and able to provide written informed consent (Assumed yes, as not mentioned otherwise)\n- HCV RNA \u2265 10^4 IU/mL at screening (This specific data is not provided, but the patient has active HCV infection)\n- Chronic HCV infection (\u2265 6 months) (The patient has had HCV for 2 years)\n- Treatment experienced with a direct acting antiviral medication not including a NS5A Inhibitor for HCV (The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months, but there is no mention of NS5A inhibitors)\n- Use of protocol specified methods of contraception (This is not mentioned, but it's a standard protocol requirement and can be addressed at screening)\n- Not pregnant or nursing (Patient is male, so this is not applicable)\n\nClinical Trial Exclusion Criteria:\n- Current or prior history of clinically significant illness that may interfere with participation in the study (No such illness mentioned)\n- Screening ECG with clinically significant abnormalities (No ECG results mentioned)\n- Laboratory results outside of acceptable ranges at screening (Not mentioned, but no indication of abnormal results)\n- Chronic liver disease not caused by HCV (No other chronic liver diseases mentioned apart from HCV and HBV)\n- Infection with HBV or HIV (The patient does have a recent coinfection with HBV, which is an exclusion criterion)\n\nSince the patient has a coinfection with HBV, this meets one of the exclusion criteria of the clinical trial. Therefore, despite fitting other inclusion criteria, the patient would be excluded from participating in this clinical trial due to the coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1789": {
        "output": "",
        "label": 1
    },
    "1790": {
        "output": "",
        "label": 0
    },
    "1791": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) 2 years ago and has a recent coinfection with hepatitis B virus (HBV). His medical history is otherwise non-significant, and he has been on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's recent biopsy did not show hepatocellular carcinoma (HCC) but was remarkable for chronic inflammation compatible with chronic viral hepatitis. In addition, there is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. His liver function is not described, but based on the given parameters, there is no indication of liver failure (normal BP, no ascites, no lower extremity edema).\n\nThe clinical trial in question is looking at the effect of antiviral therapy with entecavir or tenofovir for HBV-related hepatocellular carcinoma after radical hepatectomy. The inclusion criteria are:\n1. Underwent hepatic resection.\n2. Diagnosis of HCC was confirmed by postoperative histopathology.\n3. Positive of HBsAg, HBeAg, or HBV DNA.\n4. Child-Pugh A or B liver function.\n\nThe patient does not meet the inclusion criteria for the clinical trial because:\n1. There is no indication that the patient has undergone a hepatic resection.\n2. The patient does not have a diagnosis of hepatocellular carcinoma; the biopsy was negative for HCC.\n3. Although the patient has a coinfection with HBV, there is no information about the presence of HBsAg, HBeAg, or HBV DNA.\n4. There's no explicit mention of the patient's Child-Pugh score, but since there's no evidence of significant liver dysfunction, this criterion cannot be assessed accurately from the information provided.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1792": {
        "output": "Based on the information provided:\n\nPatient characteristics:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago.\n- Recently coinfected with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications are being taken.\n- Medical records show previous positive HCV RNA tests.\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned.\n- The recent biopsy only showed chronic inflammation.\n- Vital signs are within a normal range, and there are no signs of liver failure such as ascites or edema.\n\nClinical trial inclusion criteria:\n- Quantitative HCV RNA > 100\n\nThe patient's medical records indicate previous positive HCV RNA tests. However, the specific quantitative HCV RNA value is not mentioned in the patient note. Without this information, we cannot confirm whether the patient's HCV RNA levels meet the trial's inclusion criterion of a quantitative HCV RNA > 100.\n\nTherefore, based on the available information, the patient is assessed as:\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1793": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history against the trial's inclusion criteria. Let's go through the patient's information and the inclusion criteria step by step.\n\nThe trial is focused on HIV-HCV co-infected individuals and is examining the effectiveness of a treatment regimen for both HIV and HCV.\n\nInclusion Criteria for the Trial:\n1. HIV infected (ELISA with western blot confirmation)\n2. HCV RNA positive for a minimum of 6 months / Genotype 1\n3. Prescribed cART (combination antiretroviral therapy) that may include any DHHS recommended or alternative regimens\n4. HIV RNA below the limit of quantification (BLLQ) for a minimum of 3 months\n5. Stage 3 or 4 fibrosis\n6. No evidence of liver decompensation\n7. Prior interferon, ribavirin, and/or HCV protease inhibitor exposure allowed except for cirrhotic patients with a past history of null response to interferon-based therapy\n8. Ability to remain adherent to medications and study protocol as per investigator opinion\n9. For female subjects, specific criteria about pregnancy and birth control (not applicable to our patient as he is male)\n10. Active substance use and/or mental health issues not exclusionary if engaged in harm reduction strategies and stably housed\n\nPatient Information:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV infection or treatment.\n- No information on HCV genotype or fibrosis stage.\n- No evidence of liver decompensation.\n- No information on adherence to medications or study protocol.\n- The patient is male, so criteria 9 does not apply.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the trial because there is no mention of HIV infection or treatment, which is a primary requirement for the study. Furthermore, we do not have information on the patient's HCV genotype or stage of fibrosis, both of which are essential criteria for inclusion in the study.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1794": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nNow, comparing this information to the inclusion criteria of the clinical trial:\n\n- The donor candidate must be anti-HCV positive by ELISA and HCV RNA negative by PCR, with both tests repeated for confirmation, as per standard protocol.\n- The donor must be evaluated and cleared by Hepatology, which is currently the standard of care for HCV seropositive individuals.\n- The donor must meet criteria for living kidney donation and be approved by the UF Health Shands Kidney Transplant Medical Review Board.\n\nThe patient note does not specify whether the patient is HCV RNA negative by PCR after having been on antiviral drugs, so we cannot confirm if the patient meets the first point of the inclusion criteria. Additionally, there is no information provided about the evaluation and clearance by Hepatology nor about the approval by the Kidney Transplant Medical Review Board for living kidney donation.\n\nSince there is insufficient information to determine whether the patient meets all the donor inclusion criteria for the clinical trial, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1795": {
        "output": "",
        "label": 0
    },
    "1796": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history to the inclusion criteria of the trial. \n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma, alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n- No evidence of acute distress\n- Normal BP, HR, and BMI\n- No ascites or edema in the abdomen and lower extremities\n\nClinical Trial Inclusion Criteria:\n- Chronic genotype (GT) 1, HCV infected\n- Male and non-pregnant/non-lactating female individuals\n- Without cirrhosis, treatment-naive or treatment-experienced with interferon (IFN) +/- ribavirin (RBV) +/- HCV protease inhibitor (PI)\n- Compensated cirrhotic individuals must be HCV treatment-naive\n- No prior treatments with NS5A and NS5B or any HCV direct acting antivirals, except boceprevir, telaprevir, and simeprevir, in combination with IFN and RBV\n- Currently on an ARV regimen (2 NRTI + a third agent) without change for 6 months prior to screening\n- Documented plasma HIV-1 RNA levels < 50 copies/mL for \u2265 6 months preceding the screening visit\n- Plasma HIV-1 RNA level < 50 copies/mL at the screening visit\n- No documented resistance to any of the HIV study agents at the time in the past\n- No history of HIV virologic failure\n- No evidence of Hepatitis B infection\n- Estimated glomerular filtration rate (eGFR) \u2265 30 mL/min\n\nBased on the patient note provided, there is no information about the patient being infected with HIV, which is a key aspect, as the trial is for HIV/HCV co-infected individuals. Also, the patient has a recent coinfection with HBV, which is listed as an exclusion criterion (\"No evidence of Hepatitis B infection\"). Since the patient does not meet the key inclusion criteria of HIV/HCV co-infection and is explicitly excluded due to the recent HBV coinfection, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1797": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with chronic genotype 1b hepatitis C virus (HCV) infection\n- Currently on interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or cirrhosis\n- Treatment history includes HCV RNA tests and treatment with IFN, RBV, and DAAs\n\nClinical Trial Inclusion Criteria:\n- Chronic genotype 1b hepatitis C infection and HCV RNA \u2265 10^4 IU/mL at screening\n- Hepatitis C virus treatment naive, defined as never having received a DAA, and as having received \u2264 8 weeks of interferon \u2265 6 months prior to screening\n- Absence of cirrhosis as defined by liver biopsy, FibroScan\u00ae, or FibroSure\u00ae score and APRI\n\nComparing the patient's characteristics with the inclusion criteria:\n- The patient has a chronic genotype 1b hepatitis C infection, which matches the trial's target disease.\n- The patient has been treated with DAAs for 6 months, which contradicts the requirement of being treatment naive (never having received a DAA).\n- The patient does not have cirrhosis, which complies with one of the trial's requirements.\n\nThe key point of ineligibility is that the patient is not treatment naive with respect to DAAs, which is a clear requirement of the trial. Therefore, the patient does not meet all the inclusion criteria and is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1798": {
        "output": "The patient in the provided note is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. There is no mention of knee osteoarthritis or any symptoms related to knee pain, nor is there any information provided that would suggest that the patient has been diagnosed or treated for knee osteoarthritis. \n\nThe clinical trial in question is focused on the efficacy of intra-articular injection of etanercept for moderate and severe knee osteoarthritis. The inclusion criteria for this clinical trial require that patients have been diagnosed with knee osteoarthritis according to the 1986 American College of Rheumatology criteria, have a Grade II-III of Kellgren-Lawrence grading system as revealed by ultrasound and/or MRI, and have had knee pain for at least one month with a Pain VAS Score greater than 4 during the last week.\n\nGiven that the patient's note does not provide any information about knee osteoarthritis, pain in the knees, or any related treatments or diagnostic results, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1799": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to determine the patient's trial-level eligibility. Let's analyze the information:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- He has been diagnosed with HCV (Hepatitis C Virus) 2 years ago and recently with HBV (Hepatitis B Virus).\n- He is currently on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for HCV.\n- There is no mention of HIV infection or treatment.\n- The patient's medical records do not provide information about his HIV status, viral load, CD4+ T cell count, or any specific antiretroviral therapy.\n\nClinical Trial Inclusion Criteria:\n- Infected with HIV.\n- HIV plasma viral load \u2264 50 copies/mL during the 6 months prior to screening.\n- Treated by DRV/RTV or DRV/COBI as monotherapy for at least 8 weeks prior to baseline.\n- HIV plasma viral load \u2264100,000 copies/mL at any time.\n- CD4+ T cells count \u2265 250 cells/mm3 at any time since diagnosis.\n- CD4+ T cells count \u2265 600 cells/mm3 at screening.\n- Man or woman aged 18-65 years.\n\nAssessment:\nThe patient in question does not meet the primary inclusion criterion of being infected with HIV. The trial is specifically for HIV-infected patients, and there is no indication in the patient's note that he has HIV. Instead, he is being treated for HCV and HBV coinfection. As the inclusion criteria are not met, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1800": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2),\" we need to match the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nThe inclusion criteria are as follows:\n1. Male or female, at least 18 years of age at the time of Screening.\n2. Screening laboratory result indicating Hepatitis C virus (HCV) genotype (GT)1-, 2-, 3-, 4-, 5-, or 6-infection.\n3. Subject has positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid (RNA) viral load greater than or equal to 1000 IU/mL at Screening visit.\n4. Subjects must be HCV treatment-na\u00efve or HCV treatment-experienced; GT3 subjects must be HCV treatment-na\u00efve. Previous HCV treatment must have been completed greater than or equal to 2 months prior to Screening.\n5. Subjects na\u00efve to antiretroviral treatment (ART) must have CD4+ count greater than or equal to 500 cells/mm^3 (or CD4+ % greater than or equal to 29%) at Screening; or Subjects on a stable ART regimen must have CD4+ count greater than or equal to 200 cells/mm^3 (or CD4+ % greater than or equal to 14%) at Screening; and Plasma HIV-1 RNA below lower limit of quantification (LLOQ) at Screening and at least once during the 12 months prior to Screening.\n\nNow, let's review the patient's information:\n- The patient is a 55-year-old man, which meets criterion 1.\n- The patient has been diagnosed with HCV 2 years ago, which could potentially meet criterion 2 depending on the genotype, which is not specified in the patient note.\n- The patient has a history of positive HCV RNA tests and positive anti-HCV antibodies, which aligns with criterion 3.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, suggesting that the patient is HCV treatment-experienced, which meets criterion 4.\n- There is no mention of HIV-1 coinfection or ART in the patient note, meaning we don't have enough information to assess criteria 5.\n\nGiven that the trial is specifically for patients with HCV and HIV-1 coinfection, and there is no mention of HIV-1 status in the patient's note, we cannot confirm the patient's eligibility based on the information provided. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1801": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Note Assessment:\n- The patient is a 55-year-old man, which meets the age requirement (age \u2265 18 years).\n- The patient has a chronic hepatitis C virus (HCV) infection, which is the target condition of the clinical trial.\n- The patient is documented as treatment-naive or experienced with a prior regimen consisting of Interferon (IFN) and Ribavirin (RBV), which aligns with the inclusion criteria.\n- There is no indication of cirrhosis in the patient description, which meets the criteria of absence of cirrhosis.\n- The patient is on direct antiviral drugs for the past 6 months, which indicates he is treatment-experienced (assuming this includes a prior IFN +/- RBV regimen).\n- There is no information on screening laboratory values, but this is something that can be assessed and is not a disqualifying factor based on the information provided.\n- The patient is male, so contraceptive use is not applicable.\n\nClinical Trial Inclusion Criteria Assessment:\n- Chronic hepatitis C virus (HCV) genotype infection is specified, but the patient's genotype is not mentioned. This would need to be confirmed.\n- The patient has been treated with IFN and RBV, which is part of the inclusion criteria.\n- There is no indication of cirrhosis, so this criterion is met.\n- There is no information on the patient's lab values, but this is typically checked during the screening process for the trial.\n- The patient is male, so the last criterion about contraception is met by default.\n\nBased on the information provided in the patient note, the patient appears to meet most of the inclusion criteria for the clinical trial. However, the patient's specific HCV genotype is not mentioned, which is necessary to confirm eligibility. Therefore, assuming that the patient's HCV genotype matches one of those specified in the trial (1, 2, 4, 5, or 6), and pending the laboratory values, the patient seems eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial; the HCV genotype needs to be confirmed).",
        "label": 1
    },
    "1802": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to be eligible for the clinical trial. The clinical trial in question is focused on HIV-1 infected patients who are aged \u2265 60 years old and are either naive patients receiving a raltegravir-based regimen or experienced patients with virological suppression who had switched to a raltegravir-based regimen.\n\nThe patient described in the note is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus). There is no mention of HIV-1 infection, which is a primary requirement for the clinical trial. The patient also does not meet the age criterion of being \u2265 60 years old. Furthermore, the patient's treatment is for HCV and HBV, involving IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs, not raltegravir or any HIV treatments.\n\nTherefore, the patient does not meet the inclusion criteria for the HIV-focused clinical trial, as he is not infected with HIV, is not of the required age, and is not receiving a raltegravir-based regimen.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1803": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical condition with the inclusion criteria of the trial. Let's analyze the information provided:\n\nPatient's Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other significant past medical history\n- No evidence of hepatocellular carcinoma or other liver diseases\n- Normal vital signs and physical examination\n\nClinical Trial Inclusion Criteria:\n- Chronic HDV infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test, detectable and quantifiable HDV RNA by qPCR at study entry\n- Serum alanine aminotransferase (ALT) > upper limit of the normal range (ULN) and <10 \u00d7 ULN at screening\n- ECG demonstrating no acute ischemia or clinically significant abnormality and a QTcF <450 ms for male patients\n- TSH and/or free T4 within 0.8 to 1.2 \u00d7 ULN, or adequately controlled thyroid function as assessed by the investigator\n- Dilated retinal examination \u22641 year before screening\n- Adequate methods of contraception for patients of childbearing potential\n\nBased on the patient note, it's clear that the patient is diagnosed with HCV and has a recent coinfection with HBV. However, there is no mention of a chronic HDV infection, HDV antibody test, or detectable and quantifiable HDV RNA, which are crucial for inclusion in the trial.\n\nFurthermore, there is no specific mention of the patient's serum ALT levels, ECG results, thyroid function tests, or a recent dilated retinal examination. Also, there is no requirement for contraception as the patient is male and his reproductive plans are not mentioned.\n\nSince the patient does not have documented evidence of a chronic HDV infection, which is a primary inclusion criterion for the trial, the patient does not meet the inclusion criteria and therefore is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1804": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No mention of HIV infection.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications mentioned.\n- No mention of cART (combination antiretroviral therapy) or HIV treatment.\n- No CD4 count or HIV viral load information provided.\n\nClinical Trial Inclusion Criteria:\n- Patient > 18 years of age;\n- Voluntarily sign informed consent;\n- Men or women with a negative pregnancy test before inclusion in the study;\n- HIV infection tested (with positive antibodies to HIV-1 and a detectable viral load);\n- Patient must be on stable treatment with cART for at least 1 year;\n- The average of all measurements of CD4 during the year before starting cART should be equal or greater than 350 cells/mm^3;\n- The number of CD4+ at enrollment must be equal or greater than 450 cells/mm^3;\n- Plasma HIV viral load undetectable at least 6 months before the inclusion in the study, with at least two determinations.\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial because there is no mention of HIV infection, which is a requirement for the trial. The patient is being treated for HCV and HBV, not HIV, and there is no information regarding cART, CD4 counts, or HIV viral load.\n\nTherefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1805": {
        "output": "",
        "label": 0
    },
    "1806": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Dynamic Liver Tests in Liver Disease,\" we need to examine the patient's note against the inclusion criteria of the trial.\n\nPatient note details:\n- 55-year-old man (meets age criterion)\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or liver cirrhosis\n- Fibroscan score, AST to platelet ratio index (APRI) score, and liver biopsy are not mentioned\n- Willing and able to provide informed consent is not mentioned but generally assumed unless otherwise stated\n\nClinical trial inclusion criteria:\n- Patients with cirrhosis (defined as fibroscan score >11.5, APRI score >2, or liver biopsy or imaging report of cirrhosis)\n- Patients planning to commence antiviral therapy for either chronic hepatitis B or C, or have undergone therapy in the past\n- Age 18 or above\n- Willing and able to provide informed consent\n\nBased on the provided information, the patient does not meet the criteria related to cirrhosis, as there is no mention of a fibroscan score, APRI score, or any liver biopsy/imaging report indicating cirrhosis. The patient is on antiviral therapy for HCV and HBV, which aligns with part of the inclusion criteria, but the lack of evidence of cirrhosis is a key exclusion factor for this specific trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as they do not meet the cirrhosis requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1807": {
        "output": "To assess the patient's eligibility for the clinical trial, we will compare the patient note with the inclusion criteria listed in the trial summary.\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma, cirrhosis, or other liver diseases\n- No mention of mixed cryoglobulinemia or related symptoms\n\nClinical Trial Inclusion Criteria Review:\n- Willing and able to provide written informed consent (Assumed yes, but not specified)\n- Male or female, age \u226518 years (Patient is 55 years old)\n- HCV RNA \u2265 15 IU/mL at Screening (Patient has past positive HCV RNA tests)\n- HCV genotype 1 (Not specified in the patient note)\n- Chronic HCV infection documented by prior medical history or liver biopsy (Patient diagnosed 2 years ago)\n- Classification as treatment na\u00efve or treatment experienced (Patient is treatment experienced)\n- Cirrhosis determination (The patient does not have cirrhosis)\n- Liver imaging to exclude hepatocellular carcinoma (No HCC found)\n- Presence of MC vasculitis (Not indicated in the patient note)\n- Null or partial response to previous therapies for MC (Not indicated in the patient note)\n- Adequate laboratory parameters (The patient's note does not mention abnormal lab values)\n- Females of childbearing potential must have a negative pregnancy test (Not applicable)\n- Subjects must agree to use contraception if necessary (Assumed yes, but not specified)\n- Lactating females must discontinue nursing (Not applicable)\n- Generally good health, exception of HCV (Patient appears in good health)\n- Able to comply with study instructions and assessments (Assumed yes, but not specified)\n- Evidence of cryoglobulinemia (Not indicated in the patient note)\n\nBased on the given patient note, there is insufficient information to determine if the patient has genotype 1 HCV, MC vasculitis, a null or partial response to previous therapies for MC, and evidence of cryoglobulinemia. These are critical factors needed to meet the inclusion criteria of the clinical trial. Without this information, the patient cannot be considered eligible at this time.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1808": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Taiwan ACE Beads for Hepatoma Embolization Therapy,\" we need to compare the patient's characteristics and medical condition with the stated inclusion criteria.\n\nInclusion Criteria for the trial:\nA. Both genders of patients age 18 or older.\nB. Patients diagnosed with liver cancer, confirmed via:\n   i. Tumor biopsy by Pathologists, and confirmed by on-service physician.\n   ii. High-risk patients with typical liver cancer image on radiographic examinations.\n   iii. High-risk patients with evidence of enlarging image of liver cancer on follow-up.\nC. Intermediate stage by BCLC staging, tumor size between 3 to 6 centimeters, Child-Pugh class<9, difficult to accept or reluctant to accept any operation.\nD. Disease treatable by transarterial chemoembolization, evaluable by Ultrasound, MRI, or CT.\nE. Performance status ECOG 2 or less, life expectancy of at least 3 months.\n\nPatient's condition:\n- 55-year-old man, satisfying the age criterion (A).\n- Diagnosed with HCV and recent coinfection with HBV, which indicates a high risk for liver cancer but does not confirm a liver cancer diagnosis (B).\n- Past biopsy negative for hepatocellular carcinoma, which does not confirm the liver cancer diagnosis required by the trial (B.i).\n- There is no mention of imaging showing typical liver cancer or evidence of enlarging liver cancer image (B.ii, B.iii).\n- No information provided on BCLC staging, tumor size, Child-Pugh class, or treatment considerations (C).\n- No information provided on whether his disease is treatable by transarterial chemoembolization or can be evaluated by the specified imaging modalities (D).\n- Performance status is not explicitly mentioned, but the patient is described as alert with no acute distress (E).\n\nBased on the available information, the patient does not meet the inclusion criteria for the trial, specifically criterion B related to the diagnosis of liver cancer, which is a critical requirement for participation. Therefore:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1809": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to have cervical herniated nucleus pulposus, cervical spinal stenosis, or acute herpes zoster, which are the conditions listed in the trial's inclusion criteria. The patient has a diagnosis of HCV with recent coinfection with HBV and is undergoing treatment for these conditions. There is no mention of any cervical spinal issues or the specific conditions required for the trial.\n\nTherefore, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1810": {
        "output": "",
        "label": 0
    },
    "1811": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma\n- No evidence of other liver diseases\n- Vital signs are stable\n- No mention of anti-HDV antibodies or HDV RNA status\n\nClinical Trial Inclusion Criteria:\n- Signed Informed Consent form\n- Males and females 18 to 65 years of age (inclusively)\n- Patients with chronic hepatitis B (HBeAg-positive or negative) and HBsAg-positive for at least 6 months prior to Screening\n- Positive for anti-HDV antibodies for at least 6 months prior to Screening\n- HDV RNA-positive at Screening\n- ALT \u2265 1 x ULN and < 10 x ULN\n- Agreed to use an adequate method of contraception during the study\n\nAssessment:\n- The patient is within the age range required (18 to 65 years).\n- The patient has a chronic HBV infection.\n- There is no information provided about the patient's HBeAg status, HDV antibodies status, or HDV RNA status.\n- There is no information about the patient's ALT levels.\n- There is no information on whether the patient has agreed to use contraception during the study.\n\nDue to the lack of information on key inclusion criteria such as the HDV antibodies status, HDV RNA status, and ALT levels, as well as the patient's agreement to use contraception, we cannot determine if the patient is eligible for the trial. \n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1812": {
        "output": "Reviewing the patient note and the clinical trial inclusion criteria:\n\nPatient note:\n\n- 55-year-old male\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- No significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for 6 months\n- No hepatocellular carcinoma, no evidence of advanced liver disease (no ascites, bleeding esophageal varices, etc.)\n- No mention of HIV infection or ART treatment\n\nClinical trial inclusion criteria:\n\n- \u226518 years of age\n- Patients with early chronic hepatitis C (Genotype 1 or 4), including those who failed PEG/RBV therapy or never received therapy for AHC\n- No history of advanced liver disease\n- Liver disease staging assessment: Fibroscan <8 kPa within 3 months of Day 1 of the study\n- Be HIV-1 infected and on stable HIV Antiretroviral Therapy (ART) for at least 8 weeks prior to study entry\n\nBased on the information provided in the patient note, the patient does not meet the criteria of being HIV-1 infected or being on HIV ART treatment. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1813": {
        "output": "",
        "label": 0
    },
    "1814": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir,\" we must compare the patient's characteristics and medical history with the inclusion criteria of the trial. \n\nThe inclusion criteria for the trial are:\n\n1. Documented HIV-1 infection\n2. Currently receiving cART and having received cART for a minimum of 24 months, HIV-1 plasma RNA <20 copies/mL for at least 1.5 years (excluding viral load blips)\n3. CD4 T cell count >350 cells/mm3\n4. Able, willing to give written informed consent and to adhere to therapy and to comply with time requirements for study visits and evaluations\n5. Adequate vascular access for leukapheresis\n\nThe patient note provides the following information:\n\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient's past medical history is non-significant.\n- There is no mention of HIV-1 infection, cART treatment, CD4 T cell count, or any other specific information related to HIV-1.\n\nBased on the available information, the patient does not have a documented HIV-1 infection, nor is there any information about receiving cART or having a suppressed viral load. The patient's condition and treatment are related to HCV and HBV, not HIV-1. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1815": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria for each part of the clinical trial.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with chronic HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- No evidence of hepatocellular carcinoma or other liver diseases\n- BMI: 27\n- No acute distress\n- No evidence of extensive bridging fibrosis or cirrhosis mentioned\n\nClinical trial inclusion criteria:\n\nPart 1 - Healthy Volunteers only:\n- This part of the trial is not applicable to our patient as he is not a healthy volunteer due to his chronic HCV and HBV.\n\nPart 2 - Chronic HBV-infected participants only:\n- BMI between 18 to 30 kg/m^2 (the patient's BMI is 27, which fits this criterion)\n- Chronic Hepatitis B infection, positive for HBsAg for more than 6 months (our patient has a recent coinfection with HBV, but the timeline for the HBsAg positivity is not specified)\n- HBV DNA at screening greater than or equal to 2 \u00d7 10^4 IU/mL for HBeAg positive participants, or \u22652 \u00d7 10^3 IU/mL for HBeAg-negative participants (the patient's HBV DNA levels are not mentioned)\n- Liver biopsy, fibroscan, or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic HBV infection with absence of extensive bridging fibrosis and absence of cirrhosis (the patient has a recent biopsy showing chronic inflammation but no mention of HBV infection specifics or fibrosis/cirrhosis status)\n- For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm (not mentioned, but this is a standard agreement that can be made if the patient is otherwise eligible)\n\nPart 3 - Chronic HBV Participants Only:\n- A BMI between 18 to 32 kg/m^2 (the patient's BMI is 27, which fits this criterion)\n- Chronic hepatitis B infection, defined as positive test for HBsAg or HBV DNA, or positive HBeAg, for more than 6 months prior to screening (the timeline for the patient's HBV infection is not clearly mentioned)\n- For cohorts enrolling NUC-suppressed CHB participants: treated with a single NUC for at least 12 months (our patient has been on treatment for 6 months only)\n- For cohorts enrolling anti-HBV treatment-naive and immune-active participants: previous anti-HBV treatments <30 days in total, and did not receive any anti-HBV treatments within 3 months prior to the first study dose (our patient has been on treatment for 6 months)\n- Liver biopsy, fibroscan, or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic HBV infection with absence of extensive bridging fibrosis and absence of cirrhosis (similar to Part 2, the patient's biopsy does not mention HBV infection specifics or fibrosis/cirrhosis status)\n- For men: agreement to remain abstinent or use contraceptive measures, and agree to refrain from donating sperm (not mentioned, but this is a standard agreement that can be made if the patient is otherwise eligible)\n\nBased on the available information, the patient does not meet the inclusion criteria for Parts 1 and 3 due to not being a healthy volunteer and not having been on NUC therapy for the required duration, respectively. For Part 2, the patient may potentially meet the criteria but there is insufficient information regarding the duration of HBsAg positivity, HBV DNA levels, and specific liver disease status related to HBV. Therefore, the patient cannot be confirmed as eligible for Part 2 without additional information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1816": {
        "output": "Given the patient's information and the clinical trial criteria, here is the assessment:\n\nThe patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. From the patient note, there is no indication that this patient has any form of breast cancer, let alone HER2-negative breast cancer, which is the focus of the clinical trial in question.\n\nThe clinical trial is specifically for patients with locally advanced HER2-negative breast cancer and includes specific criteria related to the diagnosis, receptor status and staging of breast cancer, as well as other health requirements such as ECOG performance status, bone marrow function, renal function, hepatic function, and cardiac function.\n\nSince the patient does not have a diagnosis of breast cancer, they do not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1817": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Strategic Transformation of the Market of HCV Treatments,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- Chronic inflammation compatible with chronic viral hepatitis\n- No mention of HIV infection\n- BMI of 27\n\nClinical Trial Inclusion Criteria:\n- Evidence of chronic HCV infection, defined as positive anti-HCV antibody or detectable HCV RNA or HCV genotype at least 6 months before screening and HCV viral load \u226510^4 IU/mL at the time of screening\n- Willing and able to provide written informed consent\n- Men and women age \u2265 18 years and < 70 years\n- Body Mass Index (BMI) of 18 to 35 kg/m2\n- Intention to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments\n- For women, there are specific criteria regarding pregnancy and contraception that do not apply to this male patient\n- Subjects who are compliant in an opioid substitution maintenance program may be included, which does not apply to this patient\n- Inclusion criteria related to HIV/HCV co-infected patients which do not apply to this patient since there is no mention of an HIV infection\n\nBased on the information provided in the patient note, the patient meets the following criteria:\n- He is a male within the age range of 18 to 70 years old.\n- He has a documented history of chronic HCV infection.\n- His BMI is within the specified range (18 to 35 kg/m2).\n\nThere is no information given regarding the patient's willingness and ability to provide written informed consent or his intention to comply with the dosing instructions and study schedule of assessments. However, these are generally assessed during the recruitment process rather than from the medical history.\n\nThe patient does not have any documented HIV infection, so the criteria for HIV/HCV co-infected patients do not apply.\n\nBased on the available information, the patient appears to meet the inclusion criteria for the clinical trial. Therefore, we can determine the following:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1818": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics with the inclusion criteria of the study:\n\nPatient Characteristics:\n1. Age: 55 years old\n2. Diagnosis: HCV and recent coinfection with HBV\n3. Treatment: IFN, RBV, and direct antiviral drugs for the past 6 months\n4. Medical history: Non-significant\n5. Biopsy: Negative for hepatocellular carcinoma, chronic inflammation due to chronic viral hepatitis\n6. BMI: 27 kg/m^2\n7. No acute distress, normal abdominal and lower extremity examination\n\nClinical Trial Inclusion Criteria:\n1. Willing and able to comply with study procedures and provide written consent\n2. Age: 18 - 65 years old\n3. BMI: \u2265 18 kg/m^2 and weighs \u2265 45 kg\n4. CHD infection of at least 6 months' duration documented by a positive HDV antibody test and HDV RNA \u2265 3 log10/mL by qPCR at study entry\n5. Serum ALT > ULN and < 10 \u00d7 ULN\n6. Liver biopsy within 12 months of Day 1 demonstrating evidence of chronic hepatitis\n7. Acceptable ECG results and QTcF < 450 ms for male patients\n8. Dilated retinal examination within 1 year and adequate results\n9. Contraception requirements for patients of childbearing potential\n\nBased on the patient note and the inclusion criteria provided, the patient appears to be:\n\n1. Within the age range required (55 years old, within 18-65 years range).\n2. Has a BMI of 27 kg/m^2, which is above the minimum requirement of 18 kg/m^2.\n3. Has chronic hepatitis documented by medical records and a liver biopsy showing chronic inflammation due to chronic viral hepatitis.\n\nHowever, there are specific requirements missing in the patient information to fully assess eligibility:\n\n- The patient is diagnosed with HCV and HBV, not HDV, which is a requirement for the trial.\n- There is no mention of HDV antibody test results or HDV RNA levels, which are required for the study.\n- There's no information provided about serum ALT levels, which need to be > ULN and < 10 \u00d7 ULN.\n- While a liver biopsy has been performed, it isn't specified if it was within 12 months of Day 1.\n- There's no information on ECG results or QTcF interval.\n- No mention of a dilated retinal examination within the last year.\n- The patient is male, so the contraception requirement applies differently but is not relevant given other missing criteria.\n\nIn conclusion, while the patient meets some of the demographic and BMI criteria, the diagnosis of HCV and HBV (not HDV) does not meet the trial's requirement for chronic HDV infection. Additionally, other specific medical requirements are not addressed in the patient note. Therefore, the patient is not eligible for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1819": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient for the trial:\n\nPatient Note Analysis:\n1. The patient is a 55-year-old man.\n2. Diagnosed with HCV 2 years ago and recently coinfected with HBV.\n3. Past medical history is non-significant.\n4. He is on IFN, RBV, and direct antiviral drugs for the past 6 months.\n5. There is no mention of cirrhosis, which implies he may either not have it or it is not documented in this note.\n6. There is no evidence of other liver diseases or complications.\n7. The patient has been on HCV treatment and is considered DAA-naive as the current treatment includes IFN and RBV, and no previous treatments with DAAs are mentioned.\n\nClinical Trial Inclusion Criteria:\n1. Chronic hepatitis C virus (HCV) infection\n2. Participants must have HCV genotype 1 or 2 infection, determined at screening\n3. HCV RNA plasma levels >=10,000 IU/mL, determined at screening\n4. DAA-naive participants, defined as not having received treatment with any approved or investigational DAA drug for chronic HCV infection; prior HCV therapy with IFN and/or RBV is allowed\n5. Participants without cirrhosis or with compensated cirrhosis\n\nComparison:\n- The patient has chronic HCV, meeting criterion 1.\n- The patient has been on treatment with IFN and RBV, which is allowed per criterion 4.\n- There is no mention of the patient's HCV genotype or plasma HCV RNA levels, which are required for criteria 2 and 3.\n- There is no mention of cirrhosis status, but the patient is allowed whether they have no cirrhosis or compensated cirrhosis per criterion 5.\n\nConclusion:\nThe patient appears to meet several of the criteria for the clinical trial but lacks specific information on HCV genotype and HCV RNA plasma levels. Since this information is essential for determining eligibility and is not provided in the patient note, the patient cannot be considered eligible based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1820": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, here's the step-by-step assessment:\n\n1. Treatment-na\u00efve participants: The patient is not treatment-na\u00efve; he has been on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\n2. Mono-infected participants with chronic HCV GT1: The patient has HCV but also a recent coinfection with HBV, which means he is not mono-infected.\n\n3. Non-cirrhotic participants: The patient's biopsy was negative for hepatocellular carcinoma and did not indicate cirrhosis, so he meets this criterion.\n\n4. Participants with debilitating fatigue (Fatigue Severity Scale [FSS] greater than or equal to 4): There is no mention of the patient experiencing fatigue, nor is there an FSS score provided in the patient note.\n\nSince the patient is not treatment-na\u00efve, is not mono-infected with chronic HCV GT1, and there is insufficient information regarding fatigue, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1821": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man diagnosed with HCV (Hepatitis C virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B virus). He is currently on treatment with IFN (Interferon), RBV (Ribavirin), and direct-acting antiviral drugs for the past 6 months.\n\nThe clinical trial in question is observing treatment strategies in HSCT (Hematopoietic Stem Cell Transplantation) recipients with HCV infection. The inclusion criteria for the trial are as follows:\n- HSCT recipients (allogeneic and autologous) with HCV infection\n- Transplanted from anytime until May 2017, followed from December 2015 to November 2017.\n\nThe patient's note does not mention that he is an HSCT recipient, which is a primary inclusion criterion for the clinical trial. Therefore, the patient does not meet the inclusion criteria for the trial, as he has not undergone HSCT.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1822": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B,\" let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- Patient's age is 55 years old, which falls within the 18-65 years age range specified in the trial inclusion criteria.\n- The patient was diagnosed with chronic hepatitis B (HCV) 2 years ago, and there is a recent coinfection with HBV. The trial is focused on chronic hepatitis B, which is relevant to the patient's condition.\n- The patient's medical history does not mention any of the Chinese syndromes specified in the inclusion criteria (hypochondriac pain, jaundice, or abdominal mass).\n- The patient is currently on IFN, RBV, and direct antiviral drugs, which are typical treatments for HCV but not specifically mentioned in the trial inclusion or exclusion criteria.\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 65 years.\n- Diagnosed as chronic hepatitis B (ICD10:K73.901).\n- Presence of one of the following Chinese syndromes: hypochondriac pain (TCD:BNG010), jaundice (TCD:BNG020), or abdominal mass (TCD:BNG040).\n\nGiven that the patient is within the correct age range and has a diagnosis of chronic hepatitis B, the patient initially seems to meet some of the inclusion criteria. However, there is no mention of any Chinese syndrome required by the trial inclusion criteria in the patient's history. Without evidence of hypochondriac pain, jaundice, or abdominal mass, we cannot confirm that the patient meets all the necessary inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1823": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II,\" let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of previous treatments for HCV before the current regimen\n- No evidence of hepatocellular carcinoma or cirrhosis\n- No other significant past medical history\n\nClinical Trial Inclusion Criteria:\n- Willing and able to provide written informed consent (unknown from patient note)\n- Chronic HCV infection (\u2265 6 months); the patient meets this criterion as he was diagnosed with HCV 2 years ago\n- Positive HCV antibody; the patient meets this criterion as indicated by the medical records\n- Serum HCV RNA of \u2265 1 \u00d7 104 IU/mL (not provided in the patient note)\n- Hepatitis C virus GT1 (not specified in the patient note)\n- Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV; the patient does not meet this criterion as he is currently on IFN, RBV, and direct antiviral drugs\n- Liver biopsy methods in the protocol (non-cirrhosis); the patient's recent biopsy was negative for hepatocellular carcinoma and showed no cirrhosis, so the patient meets this criterion\n- Others as specified in the detailed protocol (unknown from patient note)\n\nThe patient does not meet the eligibility criterion of never having received prior treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV, as he is currently on these treatments. Therefore, the patient is ineligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1824": {
        "output": "To determine if the patient is eligible for the clinical trial, we must compare the patient's characteristics and medical history to the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- No significant past medical history\n- Not on any other medications\n- Previous positive HCV RNA tests and positive for anti-HCV-antibodies\n- Recent biopsy negative for hepatocellular carcinoma, only showing chronic inflammation\n- No evidence of other liver diseases\n- BP: 130/75, HR: 90/min, BMI: 27\n- Abdomen soft with no ascites or tenderness\n- Lower extremities normal with no edema\n\nClinical Trial Inclusion Criteria:\n- Subject has provided written consent\n- Subject able to comply with protocol requirements\n- Good health as determined by the investigator\n- Male or female, 18-60 years of age\n- BMI 18-30 kg/m2, minimum weight 50 kg\n- If female, of non-childbearing potential or postmenopausal\n- If male, must be surgically sterile or using birth control, and must refrain from sperm donation for 6 months after last dose\n- Nonsmoker for at least 6 months\n- No exclusion criteria apply\n\nClinical Trial Exclusion Criteria (relevant to the patient):\n- History of any illness that could confound the objectives of the study or increase risk by participation\n- Positive screening result for hepatitis B, hepatitis C and/or HIV serology\n- Use of concomitant medications (with certain exceptions) within 30 days prior to the first dose of study medication\n- Abnormal biochemistry or hematology laboratory results determined to be clinically significant by the Investigator\n\nThe patient is a 55-year-old man, which fits the age criteria and is male, so the criteria regarding female reproductive status do not apply. However, the patient has a recent coinfection with HBV and is positive for HCV, which would lead to a positive hepatitis B and C serology, thus meeting one of the exclusion criteria.\n\nConsidering the patient's medical conditions and ongoing treatments, he would not be eligible for the clinical trial due to the exclusion criteria related to hepatitis serology positivity.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1825": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not meet the inclusion criteria for this specific study. The trial is focused on HIV-infected patients on antiretroviral therapy (ART) with a CD4 T cell count greater than 200 cells/\u03bcl. The patient in the note is diagnosed with hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV), and there is no mention of HIV infection or being on antiretroviral therapy. Therefore, the patient does not have the specific medical condition (HIV infection) required by the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1826": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient note summary:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress, normal blood pressure, heart rate, and BMI\n\nClinical trial inclusion criteria:\n- Positive serum Anti-HCV antibody or serum HCV-RNA\n- CHC patients without any treatment\n\nThe patient in question has a positive diagnosis for HCV, which aligns with the trial's inclusion criterion of having a positive serum Anti-HCV antibody or serum HCV-RNA. However, the second part of the inclusion criteria specifies that the CHC patients should be without any treatment. The patient has been on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months, which does not meet the inclusion criteria of being untreated.\n\nTherefore, the patient is not eligible for the clinical trial because they do not meet the inclusion criteria of being a CHC patient without any treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1827": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV. He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was remarkable for chronic inflammation compatible with chronic viral hepatitis. There is no mention of renal impairment or the patient's eGFR, which is a crucial criterion for the clinical trial in question.\n\nThe clinical trial in question is evaluating the efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C virus (HCV) genotype 1 - 6 infection and with chronic renal impairment or cirrhosis.\n\nTo determine the patient's eligibility for the trial, we must match the patient's characteristics and conditions to the inclusion criteria of the clinical trial:\n\n1. The patient must be at least 18 years of age at the time of Screening - The patient is 55 years old, which meets this criterion.\n\n2. The patient had a positive anti-HCV antibody and plasma HCV RNA greater than or equal to 1000 IU/mL at the Screening Visit - The patient note indicates a positive enzyme immunoassay for anti-HCV-antibodies and previous positive HCV RNA tests, which suggests this criterion is met.\n\n3. The patient had an estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m^2 as estimated by the MDRD method at Screening, or were dialysis dependent - There is no information provided about the patient's renal function or whether they are dialysis-dependent.\n\n4. For cirrhotic participants only: absence of hepatocellular carcinoma (HCC) as indicated by a negative imaging study within 3 months prior to Screening or a negative ultrasound at Screening - The patient's recent biopsy was negative for hepatocellular carcinoma, which aligns with this criterion, but there is no indication that the patient has cirrhosis.\n\nSince there is no provided information regarding the patient's renal function, which is a key inclusion criterion for this clinical trial, we cannot confirm the patient's eligibility. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1828": {
        "output": "Based on the information provided:\n\nThe patient is:\n- A 55-year-old man (meets age criteria \u2265 18 years)\n- Diagnosed with HCV and recent coinfection with HBV\n- Currently on IFN, RBV, and direct antiviral drugs\n- Past medical history is non-significant\n- No mention of being active on the heart, lung, or kidney transplantation lists\n\nThe clinical trial is focused on:\n- Adults who are active on the heart, lung, or kidney transplantation lists\n- Eligible to receive an organ from an increased risk donor with evidence of active or prior HCV\n\nThe patient note does not indicate that the patient is active on any transplantation list, which is a requirement for the trial. Therefore, the patient does not meet the necessary inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1829": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we will evaluate the patient's eligibility for the trial as follows:\n\nInclusion Criteria Evaluation:\n\n1. Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1-6 infection.\n   - The patient has been diagnosed with HCV 2 years ago, which meets this criterion.\n\n2. Positive plasma HCV antibody and HCV RNA viral load greater than or equal to 1000 IU/mL at Screening.\n   - The patient's medical records show previous positive HCV RNA tests, which likely meets this criterion, assuming the viral load is above the specified threshold.\n\n3. Treatment-naive to any approved or investigational anti-HCV medication.\n   - The patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, which indicates that the patient is not treatment-naive. Therefore, the patient does not meet this criterion.\n\n4. Participant must be documented as cirrhotic, with a Child-Pugh score of less than or equal to 6.\n   - The patient note does not indicate cirrhosis or provide a Child-Pugh score. Therefore, there is insufficient information to determine if this criterion is met.\n\nGiven the above information, the patient fails to meet the inclusion criteria of being treatment-naive to anti-HCV medication. Also, there is insufficient information to determine the presence of cirrhosis and the Child-Pugh score. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1830": {
        "output": "The patient is a 55-year-old man with a diagnosis of chronic Hepatitis C virus (HCV) infection 2 years ago and recent coinfection with Hepatitis B virus (HBV). The patient's medical records indicate a positive enzyme immunoassay for anti-HCV antibodies and current treatment includes interferon (IFN), ribavirin (RBV), and direct antiviral drugs.\n\nThe clinical trial in question is focused on patients with chronic HBV infection and aims to create a database of various parameters in order to determine factors associated with the outcome of chronic HBV infection. The inclusion criteria for the trial specify that participants must have chronic HBV infection, defined as hepatitis B surface antigen (HBsAg) positive for at least 6 months.\n\nBased on the information provided in the patient's note, the patient has a recent coinfection with HBV, and there is no indication that the patient does not meet the definition of chronic HBV infection as required by the trial (being HBsAg positive for at least 6 months). Since the patient has been diagnosed with HCV for 2 years and is coinfected with HBV, it is reasonable to infer that the patient meets the inclusion criteria for HBsAg positivity duration, although the exact duration of HBV infection is not explicitly stated.\n\nGiven the available information and assuming that the HBV infection is chronic as per the trial's definition, the patient appears to meet the inclusion criteria for the trial. However, without confirmation of HBsAg positivity for at least 6 months, we cannot definitively state eligibility. Therefore, the trial-level eligibility based on the information provided would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1831": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Impact of Secondhand Exposure to E-cigarettes Aerosols on the Respiratory System,\" we must compare the patient's characteristics against the inclusion criteria provided.\n\nThe inclusion criteria for non-smokers are:\n1. Age 18-35\n2. Non-smokers or ex-smokers (> 1 year)\n3. Healthy as by non-significant medical history, normal physical examination, and flow volume loop within predicted normal limits (ATS/ERS Task Force 2005)\n4. Normal BMI < 30\n\nThe patient note provides the following information:\n- The patient is a 55-year-old man, which is outside the age range of 18-35 specified in the inclusion criteria.\n- The patient has a diagnosis of HCV and a recent coinfection with HBV but is otherwise described with a non-significant medical history.\n- The patient is on IFN, RBV, and direct antiviral drugs for HCV.\n- The patient's BMI is 27, which is within the normal range specified (< 30).\n- There is no information provided regarding smoking status or exhaled CO measurement, but this is not relevant as the age criterion already excludes the patient.\n\nGiven that the patient does not meet the age criterion, which is a requirement for the trial, the patient is not eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1832": {
        "output": "The patient in the given note is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He has been treated with IFN, RBV, and direct antiviral drugs for the past 6 months. His medical records do not indicate hepatocellular carcinoma, and there is no evidence of advanced liver disease such as cirrhosis. His current treatment does not include TDF/ETV, which is specified in the inclusion criteria of the clinical trial.\n\nThe clinical trial in question is studying the efficacy of PEG-IFN Alpha in HBeAg negative chronic hepatitis B patients after stopping nucleotide analogue therapy. The inclusion criteria for the trial are:\n\n- HBeAg negative Chronic HBV infection\n- HBV DNA-undetectable\n- ALT <40 IU/ml\n- No Advanced fibrosis (LSM <14 KPa)\n- TDF/ETV treatment for more than 1 year\n- Clinical Relapse after stopping NA defined as HBV DNA>2000IU/ml and ALT > 80IU\n\nBased on the patient's note, he has been on treatment for HCV and HBV but not specifically with TDF/ETV therapy for over a year, which is a requirement for the clinical trial. Additionally, there is no information provided about his HBeAg status, HBV DNA levels, ALT levels, liver stiffness measurement (LSM), or any clinical relapse after stopping nucleotide analogue (NA) therapy. Therefore, we do not have sufficient information to determine if he meets all the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1833": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No mention of hemoglobinopathies or the presence of fibrosis (as measured by Fibroscan\u00ae or a bioptic evaluation).\n- No mention of extrahepatic manifestations of chronic hepatitis C virus infection.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nClinical Trial:\n- Title: Hepatitis C Virus Infection in Patients With Hemoglobinopathies.\n- Inclusion Criteria:\n  - Patients with hemoglobinopathies.\n  - Chronic hepatitis due to HCV.\n  - Presence of fibrosis (Fibroscan\u00ae stiffness \u226510 kPa) or a bioptic evaluation of cirrhosis (ISHAK fibrosis score) determined within 6 months previously.\n  - Patients with extrahepatic manifestations of chronic hepatitis C virus infection (cryoglobulinemia with organ damage, B-lymphoproliferative disorders).\n\nAssessment:\nThe patient has chronic HCV, which is one of the conditions of interest in the clinical trial. However, the inclusion criteria specifically require patients to have hemoglobinopathies, which are not mentioned in the patient's medical history. Furthermore, there is no information on the presence of liver fibrosis or cirrhosis as measured by Fibroscan\u00ae or a bioptic evaluation, nor is there any mention of extrahepatic manifestations of HCV infection.\n\nSince the patient does not meet the specific inclusion criteria of having hemoglobinopathies and there is no information about the presence of fibrosis or cirrhosis, the patient cannot be considered eligible for the trial based on the given information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1834": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's assess the patient's eligibility for the Hepatitis C Treatment Study in Myanmar:\n\nPatient Characteristics:\n- 55-year-old man (Age > 18 years \u2714)\n- Diagnosed with HCV and recent coinfection with HBV (Have a diagnosis of hepatitis C \u2714)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of HIV status (but not required for the main study, only for the PK sub-study)\n- No evidence of hepatocellular carcinoma or decompensated cirrhosis (Exclusion criteria for significant comorbidity with life expectancy of less than 12 months and decompensated cirrhosis do not apply \u2714)\n- No mention of significant renal impairment (Cr Cl < 50 ml/min not mentioned \u2714)\n- No known hypersensitivity to any part of the drug regime mentioned (Exclusion criterion does not apply \u2714)\n- No mention of concomitant medical or social situation that would make it difficult for the patient to comply with the program protocol (Exclusion criterion does not apply \u2714)\n- No mention of concomitant medications that cause unacceptable drug-drug interactions (Exclusion criterion does not apply \u2714)\n- No mention of previous HCV therapy (Exclusion criterion does not apply \u2714)\n- Not pregnant (as the patient is male, this exclusion criterion does not apply \u2714)\n\nBased on the available information, the patient meets the age requirement, has a diagnosis of hepatitis C, and there is no indication of exclusion criteria that would apply to him. Therefore, the patient appears to be eligible for the Hepatitis C Treatment Study in Myanmar.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1835": {
        "output": "",
        "label": 2
    },
    "1836": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Hepatitis C and Vitamin D and Iron Status,\" let's evaluate the eligibility of the patient:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of being treatment-na\u00efve.\n- No information on vitamin D or iron status.\n\nClinical Trial Inclusion Criteria:\n- Na\u00efve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis to receive their treatment.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial because he is not treatment-na\u00efve. He has been on treatment for HCV for the past 6 months. The inclusion criteria specifically require treatment-na\u00efve HCV patients.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1837": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility:\n\nPatient Note:\n- 55-year-old man (meets age criterion of >18 years)\n- Diagnosed with HCV 2 years ago (meets criterion of HCV infection)\n- Recently coinfected with HBV (not mentioned as an exclusion criterion)\n- Past medical history is non-significant (this does not affect the inclusion criteria)\n- On IFN, RBV, and direct antiviral drugs for the past 6 months (currently on treatment which is compatible with the inclusion criteria)\n- No other medications (no interference with study drugs)\n- Recent biopsy negative for hepatocellular carcinoma (meets the criterion of no hepatocellular carcinoma)\n- Normal liver function (no mention of impairment, but no exclusion for normal liver function)\n\nClinical Trial Inclusion Criteria:\n- Patients with HCV infection eligible for treatment with DAADs\n- Normal Complete Blood Count (hemoglobin not less than 10 gm/dl) (not specified in patient note)\n- Mild to moderate impairment of Liver function test and kidney function test (not specified in patient note, but liver function is not impaired)\n- Positive polymerase chain reaction for HCV virus (patient has a positive HCV RNA test, which may imply this criterion is met)\n- Controlled Blood sugar (not specified in patient note)\n- Patients > 18 years (met)\n\nThe information provided in the patient note does not fully cover some of the specific inclusion criteria for the clinical trial, namely the Complete Blood Count (CBC), the exact status of liver and kidney function tests, and controlled blood sugar levels. Therefore, although the patient appears to meet several of the criteria, there is insufficient information to determine eligibility for the trial based on the missing details. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1838": {
        "output": "",
        "label": 1
    },
    "1839": {
        "output": "",
        "label": 1
    },
    "1840": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) two years ago and recently coinfected with hepatitis B virus (HBV). His treatment includes interferon (IFN), ribavirin (RBV), and direct antiviral drugs (DAAs) for the past six months. Notably, the patient's biopsy was negative for hepatocellular carcinoma (HCC) and his medical records do not indicate any diagnosis of HCC.\n\nThe clinical trial in question is studying the effect of DAAs on the behavior of HCC in patients with chronic hepatitis C. The inclusion criteria specifically require patients to have a confirmed diagnosis of HCC according to EASL-EORTC guidelines.\n\nSince the patient does not have a diagnosis of HCC, he does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible to participate in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1841": {
        "output": "",
        "label": 1
    },
    "1842": {
        "output": "",
        "label": 0
    },
    "1843": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient characteristics and medical history:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- Past medical history is non-significant.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma.\n- No clinical evidence of liver decompensation.\n- Not mentioned as being of Asian descent.\n\nClinical trial inclusion criteria:\n- Must be of Asian descent.\n- Screening laboratory result indicating HCV genotype (GT) 1 to 6 infection.\n- Positive anti-HCV antibody and HCV RNA greater than or equal to 1000 IU/mL at Screening Visit.\n- Chronic HCV infection defined as positive for anti-HCV Ab or HCV RNA at least 6 months before Screening or a liver biopsy consistent with chronic HCV infection.\n- HCV treatment-na\u00efve or treatment-experienced with IFN with or without RBV or sofosbuvir with RBV with or without IFN. Previous treatment must have been completed >= 8 weeks prior to screening.\n- Compensated cirrhosis defined as Child-Pugh score of \u2264 6 at Screening and no current or past clinical evidence of Child-Pugh B or C Classification or clinical history of liver decompensation.\n- Absence of hepatocellular carcinoma (HCC).\n- For participants with HIV co-infection, specific criteria related to HIV treatment and CD4+ count.\n\nComparing the patient\u2019s details with the inclusion criteria:\n- The patient's ethnicity is not specified, and the trial requires participants to be of Asian descent.\n- The patient has HCV, but the genotype is not specified in the patient note.\n- The patient has a positive history for anti-HCV antibodies and HCV RNA.\n- The patient has been treated with IFN, RBV, and direct antiviral drugs for the past 6 months, which is within the inclusion criteria for treatment-experienced participants.\n- The patient has no evidence of hepatocellular carcinoma, which is consistent with the trial's requirement.\n- There is no mention of the patient having HIV co-infection.\n\nBased on the available information, the patient's eligibility cannot be fully determined due to two key reasons:\n1. It is not specified that the patient is of Asian descent, which is a requirement for the trial.\n2. The genotype of the patient's HCV is not provided, which is necessary to establish eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1844": {
        "output": "",
        "label": 0
    },
    "1845": {
        "output": "",
        "label": 0
    },
    "1846": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information against the inclusion criteria of the trial.\n\nHere is the patient's information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No other medications\n- Medical records show previous positive HCV RNA tests and positive for anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, showing chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases\n- No mention of HIV coinfection\n\nThe clinical trial's inclusion criteria are:\n- Age > or = 20 years\n- Chronic HCV infection, defined as detectable HCV antibody and quantifiable serum HCV RNA for \u2265 6 months\n\nGiven the information provided:\n- The patient is 55 years old, which meets the age criterion (> or = 20 years).\n- The patient has a history of HCV for 2 years and is currently on treatment, which indicates a chronic infection.\n- The patient has positive HCV RNA tests and anti-HCV antibodies, which meets the criteria for a detectable HCV antibody and quantifiable serum HCV RNA.\n- There is no mention of HIV coinfection, but the trial does not specifically require HIV/HCV coinfection for eligibility.\n- The trial's title mentions \"HIV/HCV Coinfected Patients\", but since the inclusion criteria do not explicitly state that HIV coinfection is required, we cannot exclude the patient based on the information given.\n\nTherefore, based on the provided information and the inclusion criteria of the clinical trial, the patient appears to meet the criteria for the trial. However, without explicit confirmation regarding the patient's HIV status, we cannot definitively determine eligibility as the trial's summary discusses HIV/HCV coinfection. If HIV coinfection is required, the patient would not be eligible, as there is no indication of HIV in the patient's note.\n\nGiven the ambiguity, the trial-level eligibility would be:\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1847": {
        "output": "",
        "label": 0
    },
    "1848": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the patient's eligibility.\n\nThe patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs. The patient's medical records do not indicate the presence of hepatocellular carcinoma or other liver diseases such as alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n\nThe clinical trial is investigating alcohol recidivism in patients with alcoholic liver disease. The inclusion criteria for the clinical trial are as follows:\n\n1. Alcoholic liver disease\n2. Ability to consent\n\nThe patient does not have a diagnosis of alcoholic liver disease, which is the specific condition under study in the clinical trial. Instead, the patient's liver condition is attributed to chronic viral hepatitis caused by HCV and HBV. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1849": {
        "output": "In assessing the patient's eligibility for the clinical trial titled \"A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine,\" we must compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other significant liver diseases\n- Normal vital signs and BMI of 27\n\nClinical Trial Inclusion Criteria:\n- Healthy males and females between 18 and 55 years of age\n- BMI of 18-32 kg/m^2\n- No clinically significant abnormal serum biochemistry, haematology, and urine examination values\n- Negative urinary drugs of abuse screen\n- Negative HIV, Hep B, and Hep C results\n- No clinically significant abnormalities in 12-lead ECG\n- No clinically significant abnormalities in vital signs\n- Subject must be available and comply with study restrictions\n- Subject must provide written informed consent\n\nThe patient is a 55-year-old man, which fits within the age range specified by the trial. However, the trial requires participants to be healthy volunteers. The patient has HCV and a recent coinfection with HBV, which are significant medical conditions that would likely disqualify him from being considered a healthy volunteer. Furthermore, the patient is currently on medication for these conditions, which could potentially influence the study's results or put the patient at risk.\n\nAdditionally, the inclusion criteria require negative results for hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C). Given that the patient has been diagnosed with HCV and HBV, it is unlikely that he would have negative test results for these conditions.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial, as he is not a healthy volunteer and has confirmed viral hepatitis infections. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1850": {
        "output": "Based on the provided patient note and the inclusion criteria of the HepNet Pilot Trial for the treatment of chronic Hepatitis E with Sofosbuvir:\n\n1. The patient is a 55-year-old man, which meets the age requirement of \u2265 18 years.\n2. The patient has a diagnosis of HCV (Hepatitis C Virus) and recent coinfection with HBV (Hepatitis B Virus), but there is no mention of chronic Hepatitis E virus infection, which is a requirement for the trial.\n3. The patient has been on IFN, RBV (Ribavirin), and direct antiviral drugs for the past 6 months. There is no mention of previous ribavirin therapy or documented contraindication for full dose ribavirin monotherapy specifically for Hepatitis E or the duration of such therapy.\n4. The patient's BMI is 27, which meets the requirement of BMI \u2265 18 kg/m^2.\n5. There is no information on the patient's ECG, platelet count, INR, HbA1c, or creatinine clearance.\n6. The patient's medical record does not indicate treatment with any investigational drug or device within 42 days of the screening visit.\n7. The patient is male, so the criteria about pregnancy tests and contraception are not applicable.\n8. There is no information to assess the patient's ability to comply with dosing instructions and assessment schedule.\n\nThe critical missing information is confirmation of chronic Hepatitis E virus infection and previous ribavirin therapy specifically for Hepatitis E. Without this, the patient does not meet the trial's inclusion criteria for chronic Hepatitis E infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1851": {
        "output": "Based on the provided patient note and the clinical trial information, we need to determine the patient's eligibility for the trial. Let's review the patient's information:\n\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV.\n- He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- His past medical history is non-significant.\n- The recent biopsy showed no evidence of hepatocellular carcinoma but chronic inflammation compatible with a chronic viral hepatitis.\n- There is no mention of cirrhosis in the patient information provided.\n\nNow let's review the inclusion criteria for the clinical trial:\n\n- Patients known to have HCV-related liver cirrhosis and candidates for therapy with Sofosbuvir and Daclatasvir with or without Ribavirin.\n\nThe key inclusion criterion for the clinical trial is the presence of HCV-related liver cirrhosis. Although the patient is being treated for HCV (and now HBV), there is no mention of cirrhosis in their medical history. Therefore, based on the information provided, we do not have sufficient evidence to confirm that the patient meets the inclusion criteria for the trial.\n\nGiven the information above, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1852": {
        "output": "The patient described in the patient note is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. The clinical trial in question is focused on HIV positive Men Who Have Sex With Men (MSM) in Bordeaux who have contracted hepatitis C sexually.\n\nTo determine trial eligibility based on the provided inclusion criteria, the patient must meet the following conditions:\n\n1. Patient older than 18 years.\n2. HIV-1 and/or HIV-2 confirmed Infection.\n3. Men who have sex with Men.\n4. Patients included in the ANRS CO3Aquitaine cohort.\n5. HCV contamination documented over the period 01/01/2013 to 01/31/2017 (A positive HCV serology and a HCV plasma RNA positive) AND a negative HCV serology OR a positive HCV serology and a negative plasma RNA before inclusion period.\n6. A person who has received information about the protocol and has given oral consent and that his/her non-opposition is documented in his/her medical file.\n\nBased on the patient note, there is no mention of the patient being HIV positive, being MSM, or being included in the ANRS CO3Aquitaine cohort. The patient's HCV infection is confirmed, and he is older than 18. However, without information regarding the patient's HIV status and sexual behavior, as well as the specific cohort participation, it is not possible to conclude that the patient meets the inclusion criteria for the study.\n\nGiven the available information, the patient does not meet the necessary inclusion criteria, particularly the confirmed HIV infection and the cohort inclusion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1853": {
        "output": "The patient in the note is a 55-year-old man diagnosed with chronic HCV and recent coinfection with HBV. He has been on a treatment regimen including IFN, RBV, and direct antiviral drugs for the past 6 months. There is no mention of kidney function, which is a key inclusion criterion for the clinical trial. The trial requires normal kidney functions, which are evidenced by normal serum creatinine, normal urine analysis, and normal renal sonography. Since the patient note does not provide information on the patient's kidney function, we do not have enough information to determine if the patient meets the inclusion criteria regarding normal kidney functions.\n\nTherefore, based on the information provided, the patient does not have sufficient information to qualify for the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1854": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Drug-loadable\uff08T-ACE Beads\uff09for Hepatoma Embolization Therapy,\" we need to evaluate the patient's information against the inclusion criteria provided. Here are the steps:\n\n1. Age: The patient is a 55-year-old man, which satisfies the inclusion criterion A of being 20 years or older.\n\n2. Diagnosis: The patient is diagnosed with HCV and recent coinfection with HBV. However, there is no mention of liver cancer, which is a requirement for inclusion criterion B. The patient's biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation compatible with chronic viral hepatitis.\n\n3. BCLC staging and tumor size: There is no indication in the patient note regarding the stage of liver disease or tumor size, as the patient does not have liver cancer.\n\n4. Liver function: The patient's liver function is not mentioned, but the available information does not suggest decompensated liver disease (Child-Pugh class \u2264 8).\n\n5. Treatment suitability: Since the patient does not have liver cancer, there is no information about the disease being treatable by transarterial chemoembolization.\n\n6. Performance status: The patient appears to be alert with no acute distress, which might indicate a good performance status (ECOG 2 or less), but this is not sufficient information to confirm the performance status explicitly.\n\n7. Life expectancy: There is no mention of life expectancy, but given the lack of acute distress and no evidence of advanced disease, it is likely the patient has a life expectancy of at least 3 months.\n\nBased on the available information, the patient does not meet inclusion criterion B, which requires a diagnosis of liver cancer. The clinical trial is specifically for patients with liver cancer, and the patient note does not indicate that the patient has this condition.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1855": {
        "output": "The patient in the given note is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B Virus). His therapy includes IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs, which he has been on for the past 6 months.\n\nThe clinical trial in question is evaluating the safety and effectiveness of the drug combination glecaprevir plus pibrentasvir in participants with chronic hepatitis C virus infection. The inclusion criteria for the clinical trial are patients with chronic hepatitis C virus infection who are administering glecaprevir plus pibrentasvir.\n\nThe patient note indicates that the patient is being treated for HCV but does not specifically mention that he is being treated with glecaprevir plus pibrentasvir. Therefore, based on the available information, we cannot confirm that the patient is on the specific treatment regimen being studied in the trial (glecaprevir plus pibrentasvir). \n\nSince the patient note does not provide enough information to determine if the patient is taking glecaprevir plus pibrentasvir specifically, we cannot confirm eligibility for the trial. The patient may be on a different antiviral regimen. Thus, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1856": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No mention of kidney disease (CKD or ESRD)\n- Vital signs within normal ranges\n\nClinical Trial Inclusion Criteria:\n- Age from 18-60 years\n- Chronic HCV infection with Plasma HCV RNA greater than 15,000 IU/mL\n- Treatment na\u00efve\n- Compensated liver cirrhosis\n- Absence of coinfection with HBV or HIV\n\nThe patient meets the age criterion. However, the patient does not meet the criteria for treatment-na\u00efve status, as he is currently undergoing treatment with IFN, RBV, and direct antiviral drugs. Additionally, the patient has a coinfection with HBV, which is explicitly listed as an exclusion criterion.\n\nGiven this information, the patient would be excluded from participating in the clinical trial due to not being treatment-na\u00efve and having coinfection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1857": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nThe inclusion criteria for the clinical trial are:\n1. Hepatitis C virus (HCV) infected patients.\n2. Symptomatic or asymptomatic mixed cryoglobulinemia.\n3. Coinfected or not with HIV.\n4. Treated by direct-acting antiviral (DAA) treatment.\n5. At least one cryoglobulin measurement before and after DAA.\n\nThe patient note indicates:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and recent coinfection with HBV. (This meets the first criterion of HCV infection.)\n- There is no mention of mixed cryoglobulinemia, either symptomatic or asymptomatic. (The second criterion is not met based on the available information.)\n- The patient is not coinfected with HIV but with HBV. (The third criterion specifies HIV coinfection is not a requirement, so the presence of HBV coinfection does not exclude the patient.)\n- The patient has been on direct antiviral drugs for the past 6 months. (This meets the fourth criterion.)\n- There is no information provided about cryoglobulin measurement before and after DAA therapy. (The fifth criterion is not met based on the available information.)\n\nDue to the lack of information on mixed cryoglobulinemia and cryoglobulin measurements, we cannot determine if the patient is eligible based on the provided inclusion criteria. Therefore, the patient would be rated as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1858": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's information to the inclusion criteria of the trial.\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No significant past medical history\n- No mention of injecting drug use\n- Not on HIV Antiretroviral Therapy (ART)\n- No mention of eligibility for DAA therapy as per PBS criteria\n\nClinical Trial Inclusion Criteria:\n- Voluntarily signed the informed consent form\n- \u226518 years of age\n- Have chronic HCV infection\n- Recent injecting drug use (previous 6 months)\n- Eligible for DAA therapy as per the Pharmaceutical Benefits Scheme (PBS) criteria\n- If HIV-1 infected: must meet additional criteria\n\nFrom the patient information provided, we see that the patient is over 18 years old and has a chronic HCV infection, which meets two of the inclusion criteria. However, there is no information about recent injecting drug use, which is a specific requirement for the trial. Moreover, there is no mention of the patient's eligibility for DAA therapy as per the PBS criteria, which is also an inclusion criterion. \n\nGiven the available information, we cannot confirm that the patient meets all the necessary inclusion criteria for the clinical trial. Specifically, we lack information on recent injecting drug use and eligibility for DAA therapy as per PBS criteria. Without this information, we cannot determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1859": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B,\" we need to assess the patient's information against the inclusion criteria listed for the trial.\n\nThe inclusion criteria are:\n\n1. Hepatitis B surface antigen [HBsAg]-positive\n2. Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody (HBeAb)-positive disease were eligible\n3. Serum alanine aminotransferase (ALT) levels 3-10\u00d7 the upper limit of normal (ULN)\n4. Serum total bilirubin (TBIL) levels <2\u00d7 ULN\n\nThe patient note provides the following relevant information:\n\n1. The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV.\n2. There is no specific mention of his HBsAg status, HBeAg status, or HBeAb status.\n3. The patient's ALT and TBIL levels are not given, so we cannot assess if they meet the required levels for inclusion.\n\nGiven the information in the patient note, there is not enough information to determine if the patient meets the inclusion criteria of being HBsAg-positive and either HBeAg-positive or HBeAb-positive. Additionally, there is no information regarding the patient's ALT and TBIL levels. Therefore, we cannot conclusively determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1860": {
        "output": "",
        "label": 0
    },
    "1861": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study),\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Meet the end-stage liver disease part of the type of standard (including slow plus acute liver failure, chronic liver failure, cirrhosis decompensation);\n2. Age > 18 years old;\n3. Ascites nucleated cell count > 250 \u00d7 10^6/L;\n4. If unable to obtain ascites specimens or ascites nucleated cells count does not meet the conditions of 3), abdominal examination tenderness (+), rebound tenderness (+), abdominal ultrasound can detect ascites, and procalcitonin (PCT) > 0.5ng/ml, hs-CRP> 10ng/ml.\n\nNow let's assess the patient:\n\n- The patient is a 55-year-old man, which meets the age criterion.\n- The patient was diagnosed with HCV 2 years ago and recently coinfected with HBV.\n- The patient's past medical history is non-significant.\n- No mention of end-stage liver disease, ascites, or any other complications such as slow plus acute liver failure, chronic liver failure, or cirrhosis decompensation.\n- The patient's recent biopsy shows chronic inflammation compatible with chronic viral hepatitis but no evidence of hepatocellular carcinoma.\n- The patient appears to be stable with no acute distress; no mention of abdominal tenderness, rebound tenderness, ascites, or elevated PCT and hs-CRP levels.\n\nBased on the available patient note, the patient does not appear to meet the criteria for end-stage liver disease and the specific markers (ascites nucleated cell count, PCT, hs-CRP) mentioned in the inclusion criteria. There is no information provided that the patient has end-stage liver disease, nor is there mention of ascites or relevant inflammatory markers.\n\nTherefore, the patient does not meet the inclusion criteria for the SESLDIP Study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1862": {
        "output": "In reviewing the patient's note and the inclusion criteria for the SESLDIR Study, we should carefully assess whether the patient fits the specified conditions for participation in the trial.\n\nThe clinical trial is focused on End Stage Liver Disease (ESLD) and its complications, particularly infections that occur in this context. The inclusion criteria for the trial require:\n\n1. Decompensation of liver cirrhosis with specific laboratory values and clinical signs, including:\n    - ALB <35 g/L; A/G <1.0\n    - TBIL> 35\u03bcmol/L\n    - ALT> 1 \u00d7 ULN and/or AST> 1 \u00d7 ULN\n    - PTA <60%\n    - Ascites or hepatic encephalopathy or esophageal variceal bleeding\n\n2. Acute-on-chronic liver failure with:\n    - Chronic liver disease based on chronic hepatitis or decompensated cirrhosis\n    - onset time: <4 weeks\n    - Hepatic encephalopathy: with or without\n    - Coagulation: PTA \u2264 40% or INR \u2265 1.5\n    - Jaundice: TBIL \u2265 171\u03bcmol/L or daily increase \u2265 17.1\u03bcmol/L\n\n3. Chronic liver failure with:\n    - The basis of chronic liver disease: decompensated cirrhosis\n    - Hepatic encephalopathy: with or without\n    - Coagulation: PTA \u2264 40% or INR \u2265 1.5\n    - Jaundice: significantly higher\n\nThe patient's note indicates that he is a 55-year-old man diagnosed with hepatitis C virus (HCV) infection 2 years ago and a recent coinfection with hepatitis B virus (HBV). He is currently on interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. There is no mention of decompensated cirrhosis, ascites, hepatic encephalopathy, or esophageal variceal bleeding. The patient does not show any signs of acute distress, and his abdomen is soft with no ascites or tenderness. His lower extremities are normal with no edema. There are no laboratory values provided that indicate liver decompensation or acute-on-chronic liver failure, such as abnormal albumin, bilirubin, aminotransferases, prothrombin time activity, or international normalized ratio (INR).\n\nBased on the available information in the patient's note, this patient does not appear to meet the inclusion criteria for the SESLDIR Study, as there is no evidence of decompensated liver cirrhosis or acute-on-chronic liver failure. Therefore, we can determine the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1863": {
        "output": "Based on the information provided:\n\nPatient details:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- Currently on treatment with IFN, RBV, and direct antiviral drugs (for the past 6 months)\n- No mention of difficulty swallowing tablets or being hospitalized in intensive care due to severe illness\n\nClinical trial details:\n- Bioequivalence study of crushed Sofosbuvir/Velpatasvir compared to the whole tablet\n- Patients with chronic HCV genotype 1 through 6 on SOF/VEL treatment\n- Patient must be at least 18 at the day of screening\n- Patient must be able and willing to sign the Informed Consent Form\n- Patient must be able and willing to follow protocol requirements\n\nThe patient appears to meet the age criterion and has a chronic HCV infection, which is under treatment with direct antiviral drugs. However, there is no mention of the patient having swallowing difficulties or requiring the medication to be administered through a different route such as a feeding tube, which seems to be a key aspect of the clinical trial. Additionally, the genotype of the HCV is not specified in the patient note.\n\nGiven that there is insufficient information about the HCV genotype and no indication that the patient has swallowing difficulties or is hospitalized in intensive care, we cannot conclusively determine if the patient meets all the inclusion criteria. Therefore, the patient is not clearly eligible but also not clearly excluded based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1864": {
        "output": "Based on the information provided:\n\nThe patient is a 55-year-old man with a diagnosis of hepatitis C virus (HCV) infection 2 years ago and a recent coinfection with hepatitis B virus (HBV). He is currently undergoing treatment with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. He does not have hepatocellular carcinoma, alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. His physical examination is unremarkable for the purposes of the clinical trial in question.\n\nThe clinical trial in question is focused on chronic stroke patients and is investigating brain network reorganization and recovery mechanisms using brain imaging techniques such as functional MRI and diffusion tensor imaging.\n\nThe inclusion criteria for the trial are:\n- More than 3 months post-stroke\n- Ischemic or hemorrhagic stroke\n- A person who understands the experiment and has a willingness to participate and signs the agreement\n\nThe patient's medical history does not mention a stroke; instead, it focuses on his liver disease due to HCV and HBV. Therefore, there is no information present in the patient note that aligns with the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1865": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the trial's inclusion criteria. Here are the inclusion criteria for the clinical trial:\n\n1. 20 years or more\n2. Male or female\n3. Body mass index (BMI) 18.5-35.0 kg/m^2\n4. Chronic HCV infection, defined as patients who meet at least one of the following criteria:\n   - Anti-HCV antibody positive or HCV RNA > 1,000 IU/mL for at least 6 months before screening\n   - Positive HCV RNA > 1,000 IU/mL at the time of screening with a liver biopsy consistent with chronic HCV infection\n5. HCV genotype 1 (HCV GT-1b) infection\n6. Treatment-na\u00efve or treatment-experienced\n7. HCV RNA > 10,000 IU/mL at screening\n8. Estimated glomerular filtration (eGFR) rate < 15 mL/min/1.73m^2 as assessed by MDRD equation, and receiving regular hemodialysis\n\nNow we will analyze the patient note:\n\n- The patient is a 55-year-old man, meeting the age criteria (1).\n- The patient is male, which is acceptable as the trial includes both genders (2).\n- The patient's BMI is 27, which falls within the required range (3).\n- The patient has a chronic HCV infection, indicated by a past diagnosis and ongoing treatment with IFN, RBV, and direct antiviral drugs (4). However, the genotype is not specified in the patient note.\n- The patient is treatment-experienced as he is on IFN, RBV, and direct antiviral drugs (6).\n- The patient's HCV RNA levels are not mentioned, so we cannot confirm this criterion (7).\n- The patient does not appear to be receiving hemodialysis, as there is no mention of severe renal impairment or hemodialysis in his medical history (8).\n\nBased on the information provided, the patient does not meet all the necessary inclusion criteria for the clinical trial, particularly the genotype specification, HCV RNA levels, and the requirement for hemodialysis. The patient's eligibility would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1866": {
        "output": "The patient in the note is a 55-year-old man diagnosed with chronic viral hepatitis (HCV and recent HBV coinfection). His medical history and current treatment are focused on managing his liver condition, and there's no mention of any need for abdominal aortic surgery, which is the focus of the clinical trial in question.\n\nThe clinical trial is seeking to enroll patients who are scheduled for elective or acute open aorta surgery or undergoing acute aorta surgery with minimally invasive techniques and are provided treatment in the operating theatre and/or ICU attached to perioperative care. There is no indication in the patient note that this individual is scheduled for or requires any abdominal aortic procedure. Therefore, he does not meet the inclusion criteria for the trial.\n\nBased on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1867": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Note Assessment:\n- The patient is a 55-year-old man with a diagnosis of hepatitis C (HCV) for 2 years and recent coinfection with hepatitis B (HBV).\n- The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- There is no indication of hepatocellular carcinoma, and his liver disease appears to be exclusively due to viral hepatitis.\n- The patient's medical records show previous positive HCV RNA tests.\n- There is no mention of the patient not being approved for HCV treatment.\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with HCV\n- HCV RNA positive\n- Approved for HCV treatment\n\nThe patient's note indicates that he has been diagnosed with HCV, has a history of positive HCV RNA tests, and is currently undergoing treatment for HCV, which implies approval for such treatment. Therefore, the patient appears to meet all the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1868": {
        "output": "Based on the patient note provided:\n\n- The patient is a 55-year-old man, which aligns with the \"Male\" criterion in the inclusion criteria.\n- The patient has been diagnosed with HCV 2 years ago and also has a recent coinfection with HBV. He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nNow, looking at the clinical trial's inclusion criteria:\n\n- The trial is investigating the effect of direct-acting antiviral drugs on erectile function.\n- The inclusion criteria specify that the patients must be HCV infected and male.\n\nThe patient note confirms that the patient is male and infected with HCV, which means that the patient meets the inclusion criteria for the clinical trial. There are no other specific requirements or exclusion criteria mentioned in the trial information given.\n\nTherefore, the patient appears to be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1869": {
        "output": "In reviewing the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress, normal BP, HR, and BMI\n- No ascites or tenderness in the abdomen\n- No edema in lower extremities\n\nClinical Trial Inclusion Criteria:\n- Male or female subject \u226518 years of age\n- Subjects with a diagnosis of liver cirrhosis\n- Hospitalized for acute decompensation of liver cirrhosis with ascites or with prior history of ascites requiring diuretic therapy, with or without ACLF at admission or during hospitalization but without ACLF at Screening\n- In subjects with cirrhosis due to HBV, continuous antiviral therapy for no less than 3 months\n- In subjects with cirrhosis due to HCV, decompensated patients who will not receive antiviral therapy during the study period\n- In subjects with autoimmune hepatitis, continuous immunosuppressive therapy\n- Written informed consent\n- CLIF-C AD score > 50 points at screening\n\nComparison:\n- The patient is a male over 18 years of age, which meets the age criterion.\n- The patient has been diagnosed with HCV and has a recent coinfection with HBV.\n- There is no mention of cirrhosis, let alone decompensated cirrhosis with ascites. The patient does not appear to have been hospitalized for acute decompensation of liver cirrhosis with ascites.\n- The patient is currently on antiviral therapy, which disqualifies him from the trial if he has cirrhosis due to HCV, as per the trial criteria.\n- There is no CLIF-C AD score provided in the patient note.\n- There is no indication that the patient is willing to provide written informed consent, but this is typically assumed unless otherwise stated.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial because there is no evidence of liver cirrhosis or decompensated cirrhosis with ascites. Additionally, the patient is currently on antiviral therapy, which is another disqualification for HCV-related cirrhosis within this trial. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1870": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we need to assess whether the patient is eligible for the observational study of chronic hepatitis C in chronic hemodialysis recipients.\n\nThe inclusion criteria for the trial are:\n1. Age > 18 years\n2. Receive chronic hemodialysis (for at least 6 consecutive months) at the NRHC EsSalud\n\nThe patient note mentions that the patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He is currently on IFN, RBV, and direct antiviral drugs. However, there is no mention of the patient receiving chronic hemodialysis, nor is there any indication of kidney disease that would require such treatment.\n\nWhile the patient does meet the age criterion (being over 18 years of age), there is insufficient information concerning the second criterion of receiving chronic hemodialysis. Without this information, we cannot determine that the patient is receiving hemodialysis treatment.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the information provided in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1871": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to be eligible for the clinical trial. The trial is focused on patients with Nonalcoholic Steatohepatitis (NASH) and liver cirrhosis, while the patient has been diagnosed with HCV (Hepatitis C virus) and a recent coinfection with HBV (Hepatitis B virus), with a biopsy only remarkable for chronic inflammation compatible with chronic viral hepatitis. There is no mention of NASH or liver cirrhosis in the patient's note.\n\nFurthermore, the inclusion criteria specify that the liver biopsy must be consistent with NASH and cirrhosis according to the NASH CRN classification, and the patient must be on certain medications with stable regimens. The patient's note does not provide information on NASH or cirrhosis, nor does it indicate that the patient is on anti-diabetic, anti-obesity, or anti-dyslipidemic medications, which are part of the inclusion criteria.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1872": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) infection 2 years ago, recently coinfected with Hepatitis B Virus (HBV). His past medical history is non-significant, and he has been on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. There is no evidence of hepatocellular carcinoma or other liver diseases, and his overall condition is stable.\n\nThe clinical trial in question is focused on the management of patients with Chronic Hepatitis C in a public health care setting and is assessing the feasibility of decentralized care and the efficacy and safety of specific antiviral treatments.\n\nThe inclusion criteria for the clinical trial are:\n1. Chronic Hepatitis C\n2. Age: >18 years\n\nThe patient meets both of these inclusion criteria as he is over 18 years of age and has been diagnosed with chronic Hepatitis C (as indicated by his ongoing treatment and medical history). There are no additional criteria or exclusion factors mentioned in the clinical trial description provided.\n\nTherefore, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1873": {
        "output": "",
        "label": 0
    },
    "1874": {
        "output": "Upon reviewing the patient's note in comparison with the inclusion criteria of the clinical trial titled \"Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections,\" we can determine the following:\n\nThe patient:\n- Is a 55-year-old man, which satisfies the age criterion (\u226518 years).\n- Has been diagnosed with HCV (Hepatitis C virus) 2 years ago and has a recent coinfection with HBV (Hepatitis B virus).\n- Has been on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months for his HCV.\n- Has no other significant past medical history.\n\nThe clinical trial is looking for:\n- Adults aged \u226518 years (the patient is 55, which meets this criterion).\n- Patients willing to have a blood draw for the study or allow the use of EDTA sample taken during routine care (the patient's willingness is not specified in the note).\n- Patients falling into one of the following groups:\n  - Group A: HIV-infected patients not on cART at study entry.\n  - Group B: HIV-infected patients on cART with undetectable HIV viral load and detectable HCV viral load, not on HCV treatment at study entry.\n  - Group C: HCV mono-infected patients with detectable HCV viral load, not on HCV treatment at study entry.\n  - Group D: HBV mono-infected patients with detectable HBV viral load, not on HBV treatment at study entry.\n\nConsidering the patient is on treatment for HCV and HBV, he does not fall into any of the four specified groups for the study because he is not mono-infected (he has both HCV and HBV) and he is receiving treatment for HCV. Therefore, he does not satisfy the necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1875": {
        "output": "The patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection genotype 1b (since the patient is being treated for HCV and there is no mention of any other genotype, we can infer this) and a recent coinfection with hepatitis B virus (HBV). He has been on treatment with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months.\n\nTo assess the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion criteria of the trial:\n\nInclusion Criteria Checklist:\n\n1. Willing and able to provide written informed consent - Not mentioned, but we assume any patient can meet this criterion if willing.\n2. Male or female, age \u2265 18 years - The patient is a 55-year-old male, so he meets this criterion.\n3. Chronic HCV infection (\u2265 6 months) - The patient was diagnosed with HCV 2 years ago, so he meets this criterion.\n4. Only genotype 1b virus - The patient is being treated for HCV which is commonly genotype 1b unless specified otherwise.\n5. Treatment-na\u00efve with no prior exposure to any IFN, RBV, or approved or experimental HCV-specific DAA - The patient does not meet this criterion since he has been on treatment with IFN, RBV, and direct antiviral drugs.\n6. Non-severe fibrosis (F\u2264 2) - There is no information on the patient's fibrosis score, but the patient's biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation.\n7. Patients who are HBV core antibody positive - The patient has a recent coinfection with HBV, so he may meet this criterion.\n8. Females of childbearing potential must have a negative serum pregnancy test - Not applicable to male patients.\n9. Male subjects and female subjects of childbearing potential must agree to use contraception - Not mentioned, but we assume any patient can meet this criterion if willing.\n10. A male subject who is not of reproductive potential is eligible without requiring the use of contraception - Not applicable as there is no indication that the patient is not of reproductive potential.\n11. Lactating females must agree to discontinue nursing before starting study drug - Not applicable to male patients.\n12. Subject must be of generally good health, with the exception of chronic HCV infection, and glucose abnormalities - The patient appears to be in generally good health aside from the HCV and HBV infections.\n13. Subject must be able to comply with the dosing instructions for study drug administration - Not mentioned, but we assume any patient can meet this criterion if willing.\n\nThe key issue here is the patient's prior treatment for HCV, which makes him ineligible per the trial's criteria that require treatment-na\u00efve patients.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1876": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago.\n- Recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications taken.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No signs of clinical decompensation of liver disease.\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years old.\n- Indication to receive antiviral treatment.\n- Diagnosis of chronic infection by hepatitis C virus in the fibrous phase F3 or F4.\n- Have not presented any clinical decompensation of their liver disease.\n- With or without HIV co-infection.\n\nThe patient is over 18 years old and has an indication to receive antiviral treatment, which matches two of the inclusion criteria. However, the patient's note does not specify the fibrous phase (F3 or F4) of HCV, which is required for the trial. Additionally, there is no mention of clinical decompensation of liver disease, which the patient must not have presented to be eligible. The absence of hepatocellular carcinoma and other liver diseases suggests no clinical decompensation, so this criterion might be met indirectly.\n\nHowever, due to the lack of information regarding the specific fibrous phase of the patient's HCV infection, we cannot confirm the patient's eligibility based solely on the provided patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1877": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Characteristics:\n\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV\n- Treatment history: on IFN, RBV, and direct antiviral drugs for the past 6 months\n- Past medical history is non-significant\n- No evidence of liver cancer, alcoholic liver disease, or other chronic liver diseases\n- Generally in good health, as indicated by physical examination results\n\nClinical Trial Inclusion Criteria for Phase I Treatment:\n\n- Male or female >= 18 years of age\n- Either treatment naive or experienced with failure of a prior course of interferon-based and ribavirin, DAA plus interferon and DAA only\n- Confirmation of chronic HCV infection documented by a positive HCV RNA or positive HCV genotyping test at least 6-months prior to Baseline/Day 1 visit\n- A liver biopsy performed prior to screening visit showing evidence of chronic hepatitis\n- Specific laboratory parameters at screening\n- HCV RNA positive at screening\n- Generally good health, with the exception of chronic HCV infection\n\nClinical Trial Inclusion Criteria for Phase II Follow-up:\n\n- Male or female >= 18 years of age\n- SVR24 following therapy with a direct acting antiviral agent regimen\n- Available liver biopsy performed prior to treatment\n- Subject must be of generally good health as determined by the Investigator\n\nClinical Trial Exclusion Criteria:\n\n- There is a list of exclusion criteria, but the patient note does not provide any information that the patient meets any of these exclusion criteria.\n\nAssessment:\n\nThe patient is a 55-year-old male, which satisfies the age criterion. He has been diagnosed with chronic HCV and treated with IFN, RBV, and direct antiviral drugs for the past 6 months. The patient note indicates that he has a history of positive HCV RNA tests, which satisfies the requirement for confirmed chronic HCV infection. Furthermore, the patient had a liver biopsy that was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n\nHowever, there is no information provided on the patient's SVR24 status (sustained virological response 24 weeks after therapy), which is necessary for Phase II Follow-up. Additionally, the patient is currently undergoing treatment and has not completed it, nor has there been an indication of treatment failure or cure, which is needed for eligibility assessment for either Phase I or Phase II.\n\nBased on the provided information, we cannot confirm that the patient has either failed previous treatments or achieved SVR24 after treatment with direct-acting antiviral agents. Thus, we do not have sufficient information to determine if the patient is eligible for Phase I or Phase II of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1878": {
        "output": "In reviewing the patient's note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient's Characteristics:\n- 55-year-old man (meets age criterion)\n- Diagnosed with HCV and recent coinfection with HBV (not related to acute traumatic pain)\n- On treatment with IFN, RBV, and direct antiviral drugs (not mentioned that these are analgesics, so not necessarily excluded on this basis)\n- No other medications (no analgesics mentioned)\n- Chronic hepatitis without hepatocellular carcinoma or other liver disease complications mentioned (hepatic disease present, but not specified if it excludes him given that it is chronic and not acute)\n- Stable vital signs and no acute distress (seems to meet the stable hemodynamic conditions criterion)\n\nClinical Trial Inclusion Criteria:\n- Conscious Patient (the patient is alert)\n- Age \u2265 18 years (patient is 55 years old, so meets this criterion)\n- Acute pain only of traumatic origin (the patient's note does not mention acute traumatic pain)\n- Pain > 4 on a visual numerical scale (VNS) (patient's note does not mention pain, let alone its severity)\n- Stable hemodynamic conditions (PA> 90/60) (patient's BP is 130/75, so meets this criterion)\n\nClinical Trial Non-Inclusion Criteria:\n- Known renal or hepatic disease (patient has chronic viral hepatitis, which is a hepatic disease)\n\nSince the patient has a known hepatic disease, he would be excluded based on the trial's non-inclusion criteria. Furthermore, there is no mention of acute traumatic pain, which is necessary for inclusion in the trial. Therefore, the patient does not meet the trial's inclusion criteria and is also explicitly excluded by the non-inclusion criteria. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1879": {
        "output": "",
        "label": 0
    },
    "1880": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's medical profile with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Profile:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma\n- No mention of decompensated liver disease or significant systemic illnesses\n- Not on systemic immunosuppressive therapy\n- No evidence of another form of liver disease\n- No evidence of active substance abuse\n- No evidence of concurrent hepatitis C infection (the patient has HCV, but no mention of active RNA)\n- No mention of HIV co-infection\n- No concurrent usage of statins or other excluded medications\n- No mention of EKG abnormalities\n- No history of pancreatitis\n\nClinical Trial Inclusion Criteria:\n- Age 18 years or above\n- Presence of anti-HDV in serum\n- Presence of quantifiable HDV RNA in serum at three time pre-treatment points with a mean HDV RNA level >2 log10 above the lower limit of quantification (LLOQ) of the HDV RNA assay\n- Demonstration of chronicity as evidenced by the presence of HDV RNA in serum for >/= 6 months, or presence of Anti-HDV antibody >/= 6months\n\nClinical Trial Exclusion Criteria:\n- Decompensated liver disease\n- Pregnancy, active breast-feeding, or inability to practice adequate contraception\n- Significant systemic or major illnesses other than liver disease\n- Systemic immunosuppressive therapy within the previous 2 months before enrollment\n- Evidence of another form of liver disease in addition to viral hepatitis\n- Active substance abuse\n- Evidence of hepatocellular carcinoma\n- Evidence of concurrent hepatitis C infection with positive serum hepatitis C virus (HCV) RNA\n- Any experimental therapy or pegylated interferon therapy within 6 months prior to enrollment\n- Active, serious autoimmune disease\n- Diagnosis of malignancy in the five years prior to the enrollment\n- Evidence of HIV co-infection\n- Concurrent usage of excluded medications\n- Clinically significant baseline EKG abnormalities\n- Uncontrolled elevated triglycerides\n- History of pancreatitis from causes other than gallstone pancreatitis\n- Inability to understand or sign informed consent\n- Any other condition that would impede participation\n\nBased on the information provided, the patient does have a chronic hepatitis infection (HCV and HBV), but there is no mention of hepatitis D virus (HDV) infection, which is a requirement for the trial. Furthermore, the inclusion criteria specifically require the presence of anti-HDV in the serum and quantifiable HDV RNA, which is not indicated in the patient's profile.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial focused on treating chronic delta hepatitis with Lonafarnib, Ritonavir, and Lambda Interferon, as there is no information provided to suggest that the patient is infected with HDV or has the required markers in their serum.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1881": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial for response guided treatment with direct acting anti-viral medications for chronic HCV infection.\n\nThe inclusion criteria for the trial are:\n\n1. Signed informed consent.\n2. Clalit insured patients.\n3. Female and male over the age of 18.\n4. Capacity to provide written informed consent.\n5. HCV RNA Viral Load (VL) larger than 105 IU/mL at screening and on at least one other occasion 6 months or more prior to the most recent HCV RNA test result.\n6. HCV genotypes 1a, 1b, 2, 3, or 4.\n7. Liver fibrosis stage 0-4 as determined by one of the listed methods.\n8. Specific laboratory parameters within 3 months of screening.\n9. Abdominal imaging showing no evidence of hepatocellular carcinoma within 6 months of enrollment.\n10. Contraception requirements for both female and male participants.\n\nPatient note details for the trial-level eligibility assessment:\n\n1. The patient is a 55-year-old man, which meets the age criterion.\n2. There is no information on whether the patient is Clalit insured.\n3. The patient has the capacity to provide written informed consent, as there is no indication of cognitive impairment.\n4. The patient has a chronic HCV infection, but his viral load is not mentioned.\n5. The patient's HCV genotype is not mentioned.\n6. There is no information on the patient's liver fibrosis stage.\n7. There is no mention of the patient's specific laboratory parameters required for the inclusion criteria.\n8. The patient's recent biopsy showed no evidence of hepatocellular carcinoma, which meets the abdominal imaging criterion.\n9. As the patient is male, the contraception requirements are applicable, but there is no indication of whether the patient agrees to these terms.\n\nBased on the patient note and the inclusion criteria of the clinical trial, we do not have enough information to determine the patient's eligibility. Specifically, we lack information on the viral load, HCV genotype, liver fibrosis stage, specific laboratory parameters, Clalit insurance status, and his agreement to comply with contraception requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1882": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with chronic HCV (hepatitis C virus) infection and recent coinfection with HBV (hepatitis B virus). The patient has been on IFN (interferon), RBV (ribavirin), and direct-acting antiviral drugs for the past 6 months. The biopsy shows no evidence of hepatocellular carcinoma, and there is no mention of other causes of chronic liver disease in the patient's history.\n\nNow, let's compare this information to the inclusion criteria of the clinical trial:\n\n1. Age > 18 years: The patient is 55 years old, so he meets this criterion.\n2. Disease status: The patient has chronic hepatitis C infection with a positive HCV RNA test and a positive enzyme immunoassay for anti-HCV antibodies, which indicates that he has been infected for more than 6 months. However, there is no information provided about the degree of fibrosis as estimated by fibroscan.\n3. Treatment: The patient is not treatment-na\u00efve, as he has been on IFN, RBV, and direct-acting antiviral drugs for 6 months. The inclusion criteria specify treatment-na\u00efve patients who will receive direct-acting antiviral drugs (Sofosbuvir and Daclatasvir \u00b1 ribavirin) for 12 weeks.\n4. Negative hepatitis B virus surface Ag and HIV antibodies: The patient has a recent coinfection with HBV, which does not meet the requirement of being negative for hepatitis B virus surface antigen.\n5. No history of hepatocellular carcinoma or development of hepatocellular carcinoma during the treatment period: The patient meets this criterion, as the biopsy was negative for hepatocellular carcinoma.\n6. No other causes of chronic liver disease: The patient meets this criterion as there is no evidence of other causes of chronic liver disease mentioned.\n\nGiven this information, the patient does not meet the treatment criterion (as he is not treatment-na\u00efve) and the criterion of being negative for hepatitis B virus surface antigen. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1883": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial for Chronic Hepatitis B, we need to determine the eligibility of the 55-year-old male patient.\n\nIn the patient note, the following information is given:\n- The patient is diagnosed with HCV and recent coinfection with HBV.\n- He is on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- The patient does not take any other medications.\n- He has a history of positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n- A recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n- The patient's vital signs and physical examination are within normal limits, with no mention of abnormal liver function tests (AST or ALT levels).\n- His BMI is 27, which is within the trial's inclusion criteria of BMI\u226635.\n\nNow, let's look at the clinical trial's inclusion criteria:\n- Chronic HBV infection patients between the ages of 20 and 75 years with serum hepatitis B surface antigen (HBsAg) positivity for more than 6 months.\n- BMI\u226635.\n- HBsAg\u226710 IU/mL and HBV DNA\u22672000 IU/mL.\n- AST or ALT\u226725 IU and ALT<5xULN.\n- Male or female subjects, with the stipulation that female subjects must use effective contraception.\n- No abnormal finding of clinical relevance.\n- Written informed consent.\n\nBased on the patient note, we know the patient is within the age range and has a BMI within the specified range. However, there is no specific information on HBsAg or HBV DNA levels, nor on the patient's AST or ALT levels. Furthermore, the patient has a coinfection with HCV, which is not mentioned in the inclusion criteria but could potentially be considered an \"abnormal finding of clinical relevance.\"\n\nWithout information on the patient's HBsAg levels, HBV DNA levels, and liver enzyme levels, we cannot conclusively determine his eligibility. Additionally, the presence of HCV coinfection might be a confounding factor that the trial might not be designed to address.\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1884": {
        "output": "The patient is a 55-year-old man diagnosed with HCV 2 years ago and recently coinfected with HBV. He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months. According to the clinical trial's inclusion criteria, the patient must be at least 18 years of age, have a chronic HCV genotype 1 infection, have completed treatment with ledipasvir/sofosbuvir (with or without ribavirin) for either 8, 12, or 24 weeks at a participating KP-NC clinical site, and have data available to determine virological relapse and SVR12.\n\nBased on the patient note, there is no indication of the patient's HCV genotype nor whether they have completed treatment with ledipasvir/sofosbuvir, as required by the study. Furthermore, there is no information provided about the patient's membership in the Kaiser Health Plan, which is a requirement for the study. Additionally, there is no mention of the patient's participation at a KP-NC clinical site or the availability of data to determine virological relapse and SVR12. \n\nDue to the lack of specific information aligning with the study's requirements, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1885": {
        "output": "",
        "label": 0
    },
    "1886": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. He is currently on treatment with IFN, RBV, and direct antiviral drugs. There is no indication in the patient's note of any gastrointestinal symptoms, fecal occult blood test results, a family history of colorectal cancer, or any abnormal findings on cross-sectional imaging that would suggest he was referred for a colonoscopy.\n\nThe inclusion criteria for the clinical trial titled \"ObeSity Related Colorectal Adenoma Risk\" are:\n- Aged 18 years and over\n- Able to give informed consent\n- Indications for colonoscopy, including:\n  - Patients with positive faecal occult blood test (FOBt) referred for index colonoscopy as part of the Bowel Cancer Screening Programme\n  - Colonoscopy conversion from Bowelscope\n  - Index diagnostic colonoscopy due to new gastrointestinal symptoms (including but not restricted to diarrhoea, change in bowel habit, abdominal pain, PR bleeding, weight loss), iron deficiency anaemia, family history of CRC, abnormal findings on cross-sectional imaging\n\nThe patient's note does not mention any of the specific indications for colonoscopy listed in the inclusion criteria. Therefore, there is not enough information to determine if the patient is eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1887": {
        "output": "The patient in question is a 55-year-old man diagnosed with chronic Hepatitis C Virus (HCV) infection 2 years ago and a recent coinfection with Hepatitis B Virus (HBV). He has been on Interferon (IFN), Ribavirin (RBV), and direct antiviral drugs for the past 6 months. The patient's past medical history is described as non-significant, and he is not on any medications other than those for HCV. The patient's recent biopsy was negative for hepatocellular carcinoma, and his medical records indicate chronic viral hepatitis without complications such as alcoholic liver disease or autoimmune hepatitis.\n\nThe clinical trial in question is investigating the effect of Direct Acting Antivirals (DAAs) on miRNA-122 and insulin resistance in chronic HCV patients. The inclusion criteria for this trial are patients with chronic HCV who are eligible for treatment with DAAs and patients who have started treatment with DAAs 3 months prior.\n\nThe patient meets the first part of the inclusion criteria as he is a chronic HCV patient currently undergoing treatment with DAAs. However, the second criterion specifies that the patient must be 3 months after starting treatment with DAAs. Since the patient has already been on treatment for 6 months, he meets this criterion as well.\n\nTherefore, based on the provided information, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1888": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, which satisfies the age requirement.\n- He has been diagnosed with HCV and has a recent coinfection with HBV.\n- There is no mention of hepatocellular carcinoma (HCC) in the patient's note, only chronic viral hepatitis.\n- His past medical history is non-significant.\n- The patient is currently on treatment for HCV and HBV.\n- There is no evidence of liver cancer or conditions that would directly align with the trial's focus on hepatocellular carcinoma.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with liver cancer, specifically hepatocellular carcinoma.\n- The patient must have a life expectancy of more than 12 weeks.\n- The patient must have measurable disease based on RECIST v1.1.\n- The patient must have at least one liver lesion accessible for core biopsy.\n- The patient must have a Child-Pugh score of A.\n- The patient must have an ECOG performance status of 0 or 1.\n- There are specific requirements for blood counts and liver function tests.\n- Subjects with HCV are allowed, but the focus is on liver cancer treatment.\n- There's a requirement for the ability to swallow pills intact.\n\nThe patient does not appear to have liver cancer (hepatocellular carcinoma), which is a fundamental inclusion criterion for the clinical trial. Since there's no mention of HCC in the patient's note and the emphasis is on chronic viral hepatitis, the patient does not meet the key criteria for inclusion in the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial since the trial is specifically looking for patients with hepatocellular carcinoma, and there's no indication that the patient has this condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1889": {
        "output": "The patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. The clinical trial in question is looking at the incidence and mortality of hepatocellular carcinoma (HCC) among HIV-infected individuals with and without HBV/HCV co-infection in an Asian population.\n\nTo assess the patient's eligibility for the trial based on the inclusion criteria provided:\n\n1. The patient has HCV and HBV coinfection, which fits one set of inclusion criteria for HBV/HCV mono-infected individuals. However, the patient's HIV status is not mentioned in the patient note. \n\nFor the HIV-infected individuals' group in the trial, the inclusion criteria are:\n- Positive HIV antibody\n\nFor the HBV/HCV mono-infected individuals' group in the trial, the inclusion criteria are:\n- Documented diagnosis of hepatitis B or hepatitis C infection, or\n- Positive HBsAg and/or anti-HBc, or\n- Positive HCV antibody, and\n- Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription\n\nSince the patient note does not provide information on the patient's HIV status or specify that they have been to one of the HIV clinics, we cannot definitively determine their eligibility for the HIV-infected individuals group in the trial. However, since there is no mention of HIV, and the patient has been diagnosed with HBV and HCV, they could potentially fit the criteria for HBV/HCV mono-infected individuals if they have a negative HIV antibody result or no record of HIV diagnosis or anti-retroviral therapy prescription.\n\nThe patient note lacks specific information on the patient's HIV status and whether he has been to one of the designated HIV clinics, which are necessary to fulfill the inclusion criteria of the trial. Therefore, based on the provided information, the patient's eligibility cannot be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1890": {
        "output": "Based on the information provided for the patient and the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and the recent coinfection with HBV\n- Past medical history is non-significant\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma (HCC) or other liver diseases mentioned in the exclusion criteria\n- No acute distress, normal blood pressure, heart rate, and BMI\n- No abdominal ascites or tenderness, and no lower extremity edema\n\nClinical Trial Information:\n- Title: The Assessment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC\n- Aim: To assess the contribution of MMP-1-1607 genotype polymorphism to the risk of HCC on top of HCV and the relationship between this gene polymorphism with HCC in patients who received antiviral treatment to HCV.\n- Inclusion Criteria: Patients with a history of HCV, thorough physical examination, radiological examination for HCC, Child-Pugh classification, and laboratory investigations including hepatitis C markers.\n\nComparing the patient information with the inclusion criteria of the clinical trial, the patient:\n- Has a history of HCV, meeting one of the conditions for the trial inclusion criteria.\n- The patient's note does not mention HCC, but the trial seems to be interested in assessing risk factors for HCC in patients with HCV, not necessarily patients already diagnosed with HCC.\n\nAs the patient does not show evidence of hepatocellular carcinoma, but the trial is aimed at assessing risk factors for developing HCC in HCV patients, the patient's current medical condition seems relevant to the focus of the trial. However, the trial criteria specifically mention \"the diagnosis of HCC cases\" without stating whether they are looking exclusively for patients with HCC or those at risk. This ambiguity makes it challenging to determine the eligibility definitively without further clarification from the trial's organizers. Additionally, the patient note does not provide information on Child-Pugh classification or specific liver examinations related to HCC which are part of the inclusion criteria for the trial.\n\nGiven the information available, the patient has chronic HCV which is of interest to the study, but there is insufficient information on whether the patient meets all the specific criteria related to HCC risk and assessment. Therefore, the patient's eligibility is not clear cut.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1891": {
        "output": "Upon reviewing the provided patient note and the inclusion and exclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial as follows:\n\nInclusion Criteria Evaluation:\n- The patient has a chronic HBV infection, as indicated by a recent coinfection with HBV.\n- The patient has undergone a liver biopsy.\n- There is no information provided about whether the patient signed the informed consent before the liver biopsy, but for the sake of this assessment, we will consider that the patient would be willing to sign if they have not already done so.\n\nExclusion Criteria Evaluation:\n- The patient is coinfected with HCV, which is listed as an exclusion criterion.\n- There is no evidence of decompensated cirrhosis, hepatocellular carcinoma (HCC), or liver transplantation.\n- The patient has a history of antiviral treatment (IFN, RBV, and direct antiviral drugs).\n\nGiven that the patient is coinfected with HCV and has a history of antiviral treatment, he meets the exclusion criteria and therefore would not be eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1892": {
        "output": "The patient in the note is a 55-year-old man with chronic hepatitis C virus (HCV) infection and a recent coinfection with hepatitis B virus (HBV). He has been on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient has no other significant past medical history and is currently not in acute distress.\n\nThe clinical trial we are assessing for eligibility is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus infection and recent injecting drug use in the prison setting.\n\nNow, let's review the inclusion criteria for the trial:\n\n1. Participants have voluntarily signed the informed consent form.\n2. Be \u226518 years of age on the day of signing the informed consent form.\n3. Have chronic HCV infection.\n4. Report of recent injecting drug use (within the previous 6 months).\n5. Eligible for DAA therapy as per the PBS.\n6. If HIV-1 infected, there are additional criteria related to HIV status and treatment.\n\nComparing the patient's information with the inclusion criteria:\n\n1. We do not have information if the patient has signed the informed consent form.\n2. The patient is 55 years old, which satisfies the age criterion.\n3. The patient has chronic HCV infection, which meets this criterion.\n4. There is no mention of recent injecting drug use in the patient's history provided.\n5. The patient is already on DAA therapy, but we do not have information about his eligibility as per the PBS.\n6. The patient's note does not mention HIV-1 infection, so these criteria are not applicable.\n\nBased on the information available, we cannot definitively conclude that the patient meets all the inclusion criteria due to insufficient details regarding recent drug use and eligibility for DAA therapy as per the PBS. Therefore, the assessment of the patient's eligibility for this clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1893": {
        "output": "",
        "label": 0
    },
    "1894": {
        "output": "",
        "label": 0
    },
    "1895": {
        "output": "",
        "label": 0
    },
    "1896": {
        "output": "The patient note describes a 55-year-old man with a diagnosis of chronic viral hepatitis due to hepatitis C virus (HCV) infection, which he has had for 2 years, and a recent coinfection with hepatitis B virus (HBV). He has been on treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. There is no mention of hepatocellular carcinoma (HCC) in his recent biopsy, and his past medical history is noted as non-significant. He does not take any other medications, and his physical examination is largely unremarkable.\n\nThe clinical trial provided is looking to screen HBsAg-positive patients as part of a comprehensive strategy. The only inclusion criterion mentioned for the trial is that participants must be HBsAg(+) patients.\n\nGiven that the patient is recently coinfected with HBV and there is no mention of him being HBsAg-negative, he meets the inclusion criterion for the trial. Since no other inclusion or exclusion criteria are provided, we can assume that the patient is eligible for the trial based on the available information.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1897": {
        "output": "",
        "label": 0
    },
    "1898": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Hepatitis C Patient Management and Family Health Education,\" let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- Past medical history is non-significant.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No other medications.\n- Previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies.\n- Recent biopsy negative for hepatocellular carcinoma, chronic inflammation due to chronic viral hepatitis.\n- Alert male, no acute distress, normal blood pressure and heart rate, BMI: 27.\n- Abdomen is soft with no ascites or tenderness.\n- Lower extremities are normal with no edema.\n\nClinical Trial Inclusion Criteria:\n- Permanent residents in the province.\n- Ages 18-69 (inclusive).\n- Both blood anti-HCV test and HCV-RNA test is positive.\n- Familiar with the use of mobile phones and WeChat.\n- Informed consent and voluntary participation in the study.\n\nComparison:\n- The patient is within the age range of 18-69.\n- The patient has a positive HCV RNA test and a positive enzyme immunoassay for anti-HCV antibodies, which suggests both blood anti-HCV test and HCV-RNA test are positive.\n- There is no information about the patient's residence, but for the sake of this evaluation, we will assume that the patient is a permanent resident in the province as there is no indication otherwise.\n- The patient is currently using medications, which does not preclude trial participation.\n- There is no information regarding the patient\u2019s familiarity with mobile phones and WeChat, or whether they have provided informed consent and are willing to participate voluntarily.\n\nAssuming the patient is familiar with mobile phones and WeChat, and is willing to provide informed consent, he would meet the inclusion criteria. However, since the familiarity with WeChat and consent are not explicitly stated, we do not have sufficient information to determine eligibility based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1899": {
        "output": "",
        "label": 0
    },
    "1900": {
        "output": "Based on the provided information, the patient in the note is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus). The clinical trial in question is focused on the occurrence of HBV infection after liver transplantation in children, and the inclusion criteria specifically mention \"Patients with end-stage liver disease who require liver transplantation.\"\n\nThe patient described in the note does not match the inclusion criteria for several reasons:\n\n1. The patient is an adult (55 years old), and the trial is focused on children.\n2. There is no mention of end-stage liver disease or the need for liver transplantation in the patient's note.\n3. The patient's condition seems to be managed with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs, which suggests that his disease is not at the stage requiring a liver transplant.\n\nTherefore, the patient does not meet the key inclusion criteria for the clinical trial and is not eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1901": {
        "output": "Based on the patient note and the inclusion criteria for the HIV and STIs Clinical Study in Germany, let's assess the patient's eligibility step by step:\n\n1. **Age**: The patient is 55 years old, which falls within the 18-55 years age range required by the study.\n2. **Sex**: The patient is a man, which meets the study's criteria of male sex (at birth, chosen, or intersexual).\n3. **HIV-uninfected**: The patient note does not mention HIV, only HCV (Hepatitis C virus) and HBV (Hepatitis B virus) infections.\n4. **Able and willing to give informed consent**: The patient note does not comment on the patient's ability or willingness to give informed consent, but we will assume he is able since there is no information to suggest otherwise.\n5. **Able to read and write in German or English language**: The patient note does not specify language abilities, but we will assume he can based on the lack of information suggesting otherwise.\n6. **Willing to provide identification card and contact information**: The patient note does not comment on this, but we will assume he is willing since there is no information to suggest otherwise.\n7. **Willing to be followed for 12 months and undergo study procedures**: The patient note does not comment on this, but we will assume he is willing since there is no information to suggest otherwise.\n8. **Risk Behaviors**: The patient note does not mention any risk behaviors related to HIV acquisition.\n9. **Risk Factors**: The patient was diagnosed with HCV 2 years ago and had recent coinfection with HBV. The inclusion criteria mention \"documented history of acute Hepatitis C virus (HCV) infection in the past 24 weeks\" as a risk factor. The patient's HCV is not acute nor within the past 24 weeks; therefore, this does not apply.\n\nGiven the information available in the patient note, the patient does not demonstrate the specific risk factors required by the clinical trial's inclusion criteria related to HIV and other STIs. Therefore, the patient would not be eligible for this specific study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1902": {
        "output": "",
        "label": 0
    },
    "1903": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's information with the inclusion criteria of the trial:\n\nInclusion Criteria for the Trial:\n1. Older than 20 years\n2. HBsAg (+) with chronic hepatitis or cirrhosis, anti-HCV (+) with cirrhosis, or cirrhosis of any etiology\n3. The presence of cirrhosis will be determined based on histologic or radiologic findings.\n4. Child-Pugh class A or B\n5. Up to three suspicious focal lesions between 10 mm and 30 mm found on US, CT, or MRI\n6. Patients with a history of HCC treated by surgery or tumor ablation could be included, but only new nodules at a distance of > 2 cm from previously treated lesions were considered.\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and the recent coinfection with HBV\n- No mention of cirrhosis or its clinical manifestations such as splenomegaly, esophageal or gastric varices, ascites, or reverse portal vein flow\n- The recent biopsy was negative for hepatocellular carcinoma\n- No evidence of any chronic liver disease beyond HCV and HBV\n\nAssessment:\n1. The patient is older than 20 years - Meets Criterion 1.\n2. The patient is HBsAg (+) and anti-HCV (+) - Meets part of Criterion 2. However, there is no indication of cirrhosis in the patient's note.\n3. There is no mention of the presence of cirrhosis based on histologic or radiologic findings - Does not meet Criterion 3.\n4. There is no information on the patient's Child-Pugh class - Does not meet Criterion 4 due to lack of information.\n5. There is no mention of suspicious focal lesions or previous imaging results - Does not meet Criterion 5.\n6. There is no history of HCC as the biopsy was negative, therefore this point is not applicable - Does not meet Criterion 6.\n\nBased on the provided information, the patient does not meet several of the inclusion criteria, specifically those related to the presence of cirrhosis, Child-Pugh class, and the presence of suspicious focal lesions. Therefore, this patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1904": {
        "output": "The patient described in the note is a 55-year-old man who has been diagnosed with hepatitis C virus (HCV) 2 years ago and has a recent coinfection with hepatitis B virus (HBV). He has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. The patient's medical history is otherwise non-significant, and he does not have hepatocellular carcinoma or other liver diseases.\n\nThe clinical trial in question is studying the efficacy of blinatumomab in combination with chemotherapy in patients with newly diagnosed B-lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), with or without Down syndrome.\n\nTo be eligible for this trial, the patient must meet the following inclusion criteria:\n\n1. Newly diagnosed with B-cell ALL or B-LLy.\n2. Age at diagnosis within specified ranges depending on the condition.\n3. For B-ALL patients without Down syndrome, an initial white blood cell count < 50,000/uL.\n4. Specific diagnostic criteria for B-ALL or B-LLy.\n\nThe patient in the note does not have a diagnosis of B-cell ALL or B-LLy; rather, he has chronic viral hepatitis. Consequently, he does not meet the disease-specific requirements for the trial. The age and other specifics about his blood counts or leukemia diagnosis are not applicable in this case.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as his condition (HCV and HBV infection) is not related to the conditions being studied (B-ALL or B-LLy).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1905": {
        "output": "",
        "label": 0
    },
    "1906": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, let's assess the patient's eligibility for the clinical trial.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, which satisfies the age requirement of being over 18 years of age.\n- The patient has been diagnosed with HCV 2 years ago and is now coinfected with HBV.\n- The patient's past medical history is non-significant, and there is no mention of drug use.\n- The patient is on IFN, RBV, and direct antiviral drugs, but there is no mention of opiate substitution therapy (OST) or methadone use.\n- The patient is Glecaprevir/pibrentasvir treatment na\u00efve.\n- There are no details provided regarding the patient\u2019s ability to sign an informed consent form or adhere to study visit schedules, but we can assume that the patient is capable unless otherwise stated.\n\nClinical Trial Inclusion Criteria:\n- Over 18 years of age.\n- Previous or current injecting drug user.\n- Stable OST dose for greater than 12 weeks prior to study enrolment.\n- Glecaprevir/pibrentasvir treatment na\u00efve.\n- Able to voluntarily sign and date an informed consent form prior to initiation of any screening or study-specific procedures.\n- Able to understand and adhere to study visit schedule and all other protocol requirements.\n\nThe patient meets the age and Glecaprevir/pibrentasvir treatment na\u00efvet\u00e9 criteria. However, the patient note does not indicate that the patient is a previous or current injecting drug user, nor does it state that the patient is on a stable OST dose. These are crucial factors for inclusion in this particular study. Since the patient does not meet all the necessary inclusion criteria, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1907": {
        "output": "",
        "label": 0
    },
    "1908": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nThe patient note indicates that the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His medical history does not suggest the presence of a chronic subdural haematoma, nor is there any mention of a CT scan identifying such a condition. The patient is currently being treated for his viral hepatitis infections.\n\nThe clinical trial requires participants to have evidence of supratentorial chronic subdural haematoma as diagnosed by a CT scan. There is no mention of a chronic subdural haematoma in the patient's medical history or imaging results. Therefore, the patient does not meet the necessary inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1909": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and has a recent coinfection with HBV. The patient has been on IFN, RBV, and direct antiviral drugs for the past 6 months. There is no mention of renal impairment or issues with eGFR.\n\nThe clinical trial in question is evaluating the effect of direct antiviral drugs on eGFR in patients with chronic HCV. The inclusion criteria for the trial are patients with chronic hepatitis C virus who will be on direct antiviral therapy.\n\nThe patient's note indicates that he is currently being treated with direct antiviral drugs for his chronic HCV, which aligns with the inclusion criteria of the clinical trial. There is no information suggesting that the patient would be excluded based on the exclusion criteria since those were not provided.\n\nTherefore, the patient appears to meet the inclusion criteria of being a chronic hepatitis C virus patient on direct antiviral therapy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1910": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with chronic HCV infection 2 years ago, who also has a recent coinfection with HBV. He has been on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's medical records confirm chronic HCV infection with positive HCV RNA tests and positive enzyme immunoassay for anti-HCV antibodies. There is no mention of hepatocellular carcinoma or other significant liver diseases. The patient does not appear to have any issues that would exclude him from participating in a clinical trial based on the provided information.\n\nNow, we will compare this information to the inclusion criteria of the clinical trial titled \"The No One Waits Study\":\n\n1. Age \u2265 18 years - The patient is 55 years old, so he meets this criterion.\n2. Anti-HCV and HCV RNA positive - The patient's medical record indicates that he has had positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies, meeting this criterion.\n3. Interested in starting HCV treatment at the time of diagnosis - While the patient is already on treatment, there is no information to suggest he would not be interested in potentially more effective or alternative treatment options.\n4. Women of childbearing potential must consent to use contraception and agree to pregnancy testing during treatment - This is not applicable to the patient as he is male.\n5. If currently not enrolled in insurance, agrees to assistance to enroll in insurance - There is no information provided about the patient's insurance status. However, not being enrolled in insurance is not an exclusion criterion; the patient must simply agree to assistance to enroll in insurance if he is not already enrolled.\n\nGiven the information available in the patient note, there are no details that would exclude the patient from the trial based on the provided exclusion criteria. Therefore, the patient appears to meet all the necessary inclusion criteria for \"The No One Waits Study.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1911": {
        "output": "Based on the information provided, the patient in question is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. The clinical trial in question is focused on the impact of infant formula with probiotics on infants' health.\n\nThe inclusion criteria for the trial are:\n\n1. The normal spontaneous delivery (NSD) full-term health infants (\u226737 weeks) and birth weight more than 2500 grams.\n2. Subjects who are expected to breastfeed are eligible for the trial after informed consent form is signed by the parents.\n\nThe patient described is a 55-year-old man, which clearly does not align with the inclusion criteria of the clinical trial. The trial is targeting newborn infants, not adults.\n\nTherefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1912": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet the specific inclusion criteria for the clinical trial. The patient has a diagnosis of HCV and recent coinfection with HBV, but the inclusion criteria for the clinical trial specifically mention the following groups:\n\n1. People who inject drugs (PWID) who are receiving substance abuse counseling or rehabilitation treatment programs in halfway house and rehabilitation centers run by Non-governmental organizations (NGOs) in Hong Kong.\n2. Prison inmates.\n3. People with substance abuse.\n\nThe patient note does not mention any substance abuse, involvement with rehabilitation programs, or that the patient is a prison inmate. Therefore, the patient does not qualify for this trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1913": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, which meets the age criteria of the trial (older than 18 years and less than 69 years old).\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma (HCC) from the recent biopsy.\n- Liver function and other physical examinations seem within normal ranges.\n\nClinical Trial Inclusion Criteria:\n- Older than 18 years and less than 69 years old (the patient is 55 years old, so this criterion is met).\n- HBsAg positive, HCV antibody negative, and HIV antibody negative (the patient is diagnosed with HCV and recent coinfection with HBV, but the HCV antibody status is not specified as negative).\n- HBV-DNA >200 IU/mL (not specified in the patient note).\n- BCLC staging O and A stage (not applicable as the patient does not have HCC).\n- Platelet count \u2265100\u00d710^9/L (not specified in the patient note).\n- Liver function Child-Pugh A (seems to be met as the patient's liver function appears normal, but Child-Pugh score is not explicitly mentioned).\n- No invasion in portal vein, hepatic vein, and two large branches, no extrahepatic metastasis (not applicable as the patient does not have HCC).\n- Creatinine clearance rate \u2265 70 mL/min (not specified in the patient note).\n- Antiviral treatment was not performed before surgery or antiviral treatment was accepted in a short term (<3 months); No treatment was performed before the operation (the patient is on antiviral treatment for the past 6 months, which does not meet this criterion).\n- The results of postoperatively histopathological biopsy were HCC (the patient does not have HCC).\n- The patients agree to participate in the clinical trial (not specified in the patient note, but consent is assumed if considering trial participation).\n\nThe patient does not meet several key inclusion criteria for the clinical trial, specifically, the patient does not have hepatocellular carcinoma (HCC), is not within the BCLC staging O and A stage, has been on antiviral treatment for more than 3 months, and there is no mention of the patient's HBsAg status, HBV-DNA levels, platelet count, or creatinine clearance rate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1914": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, the patient seems to have HCV and recent coinfection with HBV, which aligns with the study's interest in samples pre-characterized for HCV and HBV status. Furthermore, the patient is 55 years old, which satisfies the age requirement of being 18 years and older. The patient's medical records also indicate a positive HCV RNA test and anti-HCV antibodies, which suggests that the samples have been characterized for HCV serology status. However, the note does not specify whether the plasma was treated with EDTA, frozen at -20\u00b0C or lower on the day of processing, and stored at the same temperature until use. Additionally, there is no information on whether the patient has given informed consent to use the sample in future research.\n\nWithout confirmation of the sample\u2019s treatment and storage conditions and patient consent, we cannot definitively determine trial eligibility based on the provided information. Therefore, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1915": {
        "output": "Assessing the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 55-year-old man \n- Diagnosed with HCV (hepatitis C virus) 2 years ago\n- Recently coinfected with HBV (hepatitis B virus)\n- On IFN (interferon), RBV (ribavirin), and direct antiviral drugs for the past 6 months\n- No mention of drug addiction or utilization of drug addiction centers\n- No mention of being in current surveillance by hepatitis specialized care\n\nClinical Trial Inclusion Criteria:\n- Subjects 18 years old or older\n- With a valid sanitary card in the public health system\n- Signed informed consent\n- Tested for HCV: \n  a) no previous documented HCV antibody request\n  or \n  b) with a previous positive HCV antibody test without RNA result or positive result without treatment or confirmed sustained virological response\n  or \n  c) with a negative HCV antibody result tested more than one year ago\n- No current surveillance by any hepatitis specialized care (hepatology or internal medicine)\n\nThe patient is over 18 years old, has a valid sanitary card (assumed as there is no information to suggest otherwise), and has a documented history of HCV with positive HCV RNA tests and anti-HCV antibodies. The patient is currently under treatment, which suggests that he might be under surveillance by specialized care for his hepatitis, although this is not explicitly stated. \n\nHowever, the clinical trial seems to be targeting individuals who are attended in drug addiction centers, which is not mentioned in the patient's history. Additionally, the patient is currently under treatment for HCV, which might conflict with the trial's criteria regarding no current surveillance by hepatitis specialized care.\n\nGiven the information provided, there is insufficient evidence to determine whether the patient is under current surveillance by specialized care, which is a key exclusion criterion. Therefore, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1916": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the trial-level eligibility as follows:\n\nThe patient is a 55-year-old man diagnosed with HCV (hepatitis C virus) 2 years ago, and he has recently been coinfected with HBV (hepatitis B virus). His past medical history is non-significant, which means he does not have any other notable medical conditions that are mentioned. He is currently on a treatment regimen for HCV, including IFN (interferon), RBV (ribavirin), and direct-acting antiviral drugs. There is no mention of the patient having been incarcerated or having any connection to the New York City jail system.\n\nThe clinical trial in question is specifically assessing the impact of a hepatitis C care coordination program on rates of linkage to hepatitis C care following release from New York City jails. The inclusion criteria for this trial are specifically for HCV-infected individuals seen in Bellevue's 19N prison Infectious Diseases clinic.\n\nSince there is no information in the patient note that suggests the patient has been recently released from a New York City jail or has been seen at the Bellevue Hospital Center 19 North prison clinic, the patient does not meet the inclusion criteria for this specific clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1917": {
        "output": "Based on the information provided in the patient note, the patient is a 55-year-old man with HCV and recent coinfection with HBV. His medical history does not mention liver cirrhosis, hepatocellular carcinoma, or end-stage liver disease. Although he has a chronic viral hepatitis infection, there is no evidence of acute decompensation of cirrhosis, chronic and acute liver failure, or chronic liver failure. The biopsy did not indicate hepatocellular carcinoma, and the patient does not exhibit symptoms such as ascites or edema, which might be associated with more advanced liver disease.\n\nThe clinical trial is looking for patients with a diagnosis of acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure, and hepatocellular carcinoma (stage III-IV). Since the patient does not have a diagnosis of any of these conditions, he does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial in question due to the absence of the specific liver conditions required by the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1918": {
        "output": "Given the patient note and the clinical trial information provided, here's the assessment:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned\n- HBsAg status is not explicitly mentioned, but recent coinfection with HBV suggests positive HBsAg\n\nClinical Trial Inclusion Criteria:\n- HBV related liver disorder\n- Age 18-60 years\n- HBsAg positive individuals\n\nThe patient is within the age range of 18-60 years and has a recent coinfection with HBV, which may suggest that he is HBsAg positive, though this is not explicitly stated in the note. Since the clinical trial is investigating individuals with HBV surface antigen (HBsAg) positive status and the patient note does not provide clear information on the patient's HBsAg status, we cannot definitively determine eligibility.\n\nThe trial-level eligibility for this patient would therefore be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1919": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and recent coinfection with HBV (Hepatitis B Virus).\n- The patient's past medical history is non-significant.\n- The patient is on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- The biopsy did not indicate hepatocellular carcinoma but chronic inflammation due to chronic viral hepatitis.\n- There is no evidence of hepatocellular carcinoma, which is crucial for this trial's inclusion criteria.\n- The patient's general health status is relatively stable, with normal blood pressure, heart rate, and no acute distress.\n\nClinical Trial Inclusion Criteria:\n- Signed Informed Consent Form\n- Males and Females, 18 years or older\n- Ability to comply with the study protocol\n- HCC (Hepatocellular Carcinoma) confirmed by histology/cytology per AASLD criteria\n- Barcelona clinic liver cancer (BCLC) C stage\n- No prior systemic therapy for HCC\n- At least one tumor lesion that can be accurately measured according to RECIST 1.1\n- ECOG Performance Status of 0 or 1\n- No cirrhosis or cirrhotic status of Child-Pugh class A only\n- Documented virology status of HBV\n- Adequate hematologic and end-organ function, defined by specific laboratory test results\n\nThe patient is not eligible for the trial because he has not been diagnosed with hepatocellular carcinoma (HCC), which is a requirement for participation in the trial. The patient's condition of chronic viral hepatitis due to HBV and HCV does not meet the criteria for an HCC diagnosis.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, as they do not have a diagnosis of hepatocellular carcinoma (HCC).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1920": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recently coinfected with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- No mention of receiving SOF-based or SOF-free DAAs specifically for 12 weeks.\n\nClinical Trial Inclusion Criteria:\n- Chronic HCV patients.\n- Receiving SOF-based or SOF-free DAAs for 12 weeks.\n\nThe patient has chronic HCV and is on treatment with direct antiviral drugs. However, the patient note does not specify whether the direct antiviral drugs include sofosbuvir (SOF) or if they are SOF-free. Additionally, there is no information provided that indicates the duration of the current DAA regimen is specifically 12 weeks, which is a requirement for the trial's inclusion criteria.\n\nDue to the lack of specific information on the type of DAAs (whether they are SOF-based or SOF-free) and the exact duration of the treatment, we cannot conclusively determine if the patient meets the inclusion criteria of the trial. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1921": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with chronic Hepatitis C Virus (HCV) infection 2 years ago and has a recent coinfection with Hepatitis B Virus (HBV). He has been on treatment with Interferon (IFN), Ribavirin (RBV), and direct antiviral drugs for the past 6 months. His medical history is otherwise non-significant, and his recent biopsy did not show hepatocellular carcinoma but showed chronic inflammation compatible with chronic viral hepatitis.\n\nThe clinical trial in question is targeting people with chronic HCV infection who are attending a low-threshold clinic. The inclusion criteria are that the individual must have a positive HCV RNA test and be attending the low-threshold HCV clinic in Oslo.\n\nThe patient's note confirms that he has a previous positive HCV RNA test and is currently under treatment for HCV. However, there is no information provided in the patient note regarding whether the patient is attending the low-threshold HCV clinic in Oslo.\n\nDue to the lack of information about where the patient is receiving treatment, we cannot determine if the patient meets the second part of the inclusion criteria (attending the low-threshold HCV clinic in Oslo). Thus, based on the available information, the patient falls into the \"Not relevant\" category since there is insufficient information to determine trial eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1922": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- He was diagnosed with chronic hepatitis C (HCV) 2 years ago.\n- He has a recent coinfection with hepatitis B virus (HBV).\n- He has been on interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs (DAAs) for the past 6 months.\n- His medical history is otherwise non-significant.\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the note.\n- He is currently not in acute distress, and his liver has signs of chronic inflammation compatible with chronic viral hepatitis.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is an observational cohort study of clinical outcomes after antiviral therapy for chronic hepatitis C.\n- Patients eligible for this study must have been treated with interferon plus ribavirin (PR) antiviral therapy for at least 6 months and/or direct-acting antiviral drugs (DAAs).\n\nComparison:\n- The patient has been treated for chronic hepatitis C with interferon and ribavirin for at least 6 months, which matches the treatment criteria specified in the inclusion criteria.\n- The patient is also being treated with direct-acting antiviral drugs, which are mentioned in the inclusion criteria as an acceptable form of treatment.\n\nConclusion:\nThe patient meets the inclusion criteria for the clinical trial as he has been treated for chronic hepatitis C with both interferon plus ribavirin and direct-acting antiviral drugs for the required duration. There is no mention of any exclusion criteria in the clinical trial summary, and the patient does not have any conditions that would exclude him from the study. Therefore, the patient is eligible to participate in the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1923": {
        "output": "The patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His past medical history is non-significant, indicating he does not have any other conditions mentioned in the clinical trial description. He is within the age range specified by the clinical trial, which is 18-60 years old.\n\nHowever, the clinical trial in question is looking for participants for a study on the prevalence of NAFLD (Non-alcoholic fatty liver disease) and its correlation with main risk factors. The patient's medical records do not indicate a diagnosis of NAFLD, NASH (Non-alcoholic steatohepatitis), or liver fibrosis, which are the focus of the study. Additionally, the patient's BMI is 27, which meets the criterion for being overweight according to the Chinese cut-off values stated in the trial inclusion criteria (BMI \u2265 24 kg/m^2).\n\nDespite meeting the age and BMI criteria, the patient's diagnosis of HCV and HBV does not align with the study's focus on NAFLD. Therefore, there is not sufficient information to determine if the patient has NAFLD or is at risk for NAFLD, which appears to be a key focus for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1924": {
        "output": "Based on the information provided, the patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. The patient does not meet all the inclusion criteria stated for the clinical trial titled \"Chronic HBV Management for Asian American.\" Specifically, the patient's ethnicity is not mentioned, and there is no information on the patient's compliance with HBV monitoring and treatment guidelines.\n\nGiven that the patient's ethnicity is a crucial inclusion criterion (self-identified Chinese, Korean, or Vietnamese ethnicity) and there is no information on this aspect, we cannot establish that the patient is eligible for the trial. Additionally, there is no indication that the patient is non-compliant with HBV monitoring and treatment guidelines, which is another inclusion criterion.\n\nTherefore, the assessment of eligibility for this patient for the specified clinical trial is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1925": {
        "output": "Given the patient note and the clinical trial information, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. He is undergoing treatment for these conditions, but there is no mention of HIV or pregnancy in his medical history. \n\nThe clinical trial is specifically recruiting consenting pregnant women of Bantu origin, at least 20 weeks of gestation, who are willing to be followed with their babies for two years post-delivery and provide data and biological specimens.\n\nSince the patient is a male and there is no indication of him being a pregnant woman or having any relation to the trial's target population (i.e., pregnant women and their infants), he does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the assessment of the patient's eligibility for this particular clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1926": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not appear to qualify for the clinical trial.\n\nThe patient in the note is a 55-year-old man diagnosed with hepatitis C virus (HCV) and a recent coinfection with hepatitis B virus (HBV). He has no significant past medical history other than HCV and is currently on interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. \n\nThe clinical trial is focused on patients with idiopathic thrombocytopenic purpura (ITP) who are either healthy Egyptians or Egyptian patients with ITP on specific immunosuppressive therapies (high dose dexamethasone, cyclosporine, and rituximab, or parenteral/oral steroids). The patient in question does not have ITP, nor is he on the specified treatment regimens for ITP. Additionally, there is no mention that the patient is Egyptian, which is a specific requirement mentioned in the inclusion criteria.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial as he does not have ITP, is not on the specified treatment regimens for ITP, and there is no information to suggest that he is Egyptian.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1927": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nThe patient is a 55-year-old man with HCV and a recent coinfection with HBV. There is no mention of constipation or any issues related to bowel movements. He is not self-medicating for constipation and there is no information to suggest that he meets the Rome IV criteria for Chronic Constipation. The patient's BMI is 27, which is within the trial's inclusion criteria.\n\nInclusion Criteria Assessment:\nI 01. There is no information suggesting that the patient self-medicates with occasional laxatives, let alone no more than 4 times in the month before eligibility confirmation.\nI 02. There is no information to suggest that the patient meets the Rome IV criteria for Chronic Constipation.\nI 03. The patient is 55 years old, which meets the age criterion.\nI 04. There is no information on the patient's stool form or bowel movement frequency.\nI 05. The patient's BMI is 27, which is under the 35 kg/m2 limit.\nI 06. Not applicable as the patient is male.\nI 07. There is no information on the patient's capability to give consent, but we have no reason to believe he is not capable.\n\nThe patient does not meet the trial's inclusion criteria related specifically to constipation and laxative use, as there is no information provided on these points in the patient's note. Therefore, the patient is not relevant for this trial based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1928": {
        "output": "Upon reviewing the patient note and the inclusion criteria provided for the MRI Assessment of Mode of Action of Bisacodyl, Single Dose clinical trial, we need to determine the patient's eligibility based on the information given.\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago, recent coinfection with HBV.\n- On treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No history of constipation mentioned.\n- No mention of self-medicating with laxatives.\n- BMI is 27.\n\nInclusion Criteria for the Clinical Trial:\n- Adult subjects that self-medicate with occasional laxatives no more than 4 times in the month before eligibility confirmation (I 01).\n- Meet Rome IV criteria for Chronic Constipation (I 02).\n- \u226518 years of age inclusive (I 03).\n- Screening diary confirms they experience at least 2 days in the 7-day diary with either hard stools (Bristol Stool Form Score 1 or 2) or no bowel movement (I 04).\n- BMI under or equal to 35 kg/m^2 (I 05).\n- Female subjects of childbearing potential must have a negative pregnancy test and agree to use contraception; this does not apply to our patient as he is male (I 06).\n- Capable of giving signed informed consent (I 07).\n\nBased on the patient note, there is no information provided that indicates the patient self-medicates with laxatives or has chronic constipation. The inclusion criteria specifically require subjects to meet the Rome IV criteria for Chronic Constipation and to self-medicate with laxatives no more than 4 times in the month before eligibility confirmation.\n\nSince the patient note does not provide sufficient information regarding the patient's bowel movements or laxative use, we cannot determine that the patient meets the necessary inclusion criteria for the trial.\n\nTherefore, the assessment of the patient's eligibility for this clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1929": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, here are the key points for consideration:\n\nPatient's characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma or other specified liver diseases\n- Willingness and ability to participate in the study are not mentioned\n- No mention of HIV test willingness or status\n\nClinical trial's inclusion criteria:\n- \u2265 18 years of age\n- Known or unknown HCV serology\n- No history of past or present HCV treatment (this is a critical criterion)\n- Willing to undergo the information and consenting procedure and subsequently have enough time to participate in the study\n- Willing to provide 13 ml venepuncture blood sample and a minimum of four whole blood fingerstick samples\n- Willing to perform an HIV test\n- Individuals can already be registered at the local site or register for the first time when enrolling in the study\n\nThe patient's history indicates that he has been treated for HCV, which contradicts the inclusion criterion that requires no history of past or present HCV treatment. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1930": {
        "output": "Based on the given patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recently coinfected with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other significant liver diseases\n- Has had positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\n\nClinical trial inclusion criteria:\n- Johns Hopkins Hospital ED patient\n- 18 years or older\n- HCV positive without HCV RNA information\n\nThe patient meets the following criteria:\n- He is older than 18 years old.\n- He has been diagnosed with HCV.\n\nHowever, the inclusion criteria specify that the patient must be an emergency department (ED) patient at Johns Hopkins Hospital with HCV positive status but without HCV RNA testing information. The patient note indicates that he has had positive HCV RNA tests, which means he has HCV RNA information. Therefore, this patient would not be eligible for the trial because he does not meet the criterion of lacking HCV RNA information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1931": {
        "output": "Based on the information provided:\n\nPatient characteristics:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of advanced solid tumor\n- ECOG PS (Eastern Cooperative Oncology Group Performance Status) not stated, but the patient is described as alert with no acute distress, which could suggest a PS of 0 or 1\n- Expected survival time is not mentioned\n- There is no information on measurable lesions according to RECIST Version 1.1\n- No information on archived tumor tissue sample or willingness to undergo fresh tumor biopsy\n- Adequate organ function is not explicitly stated, but there is no indication of inadequate organ function\n- Contraception requirements are not relevant for this male patient\n- Willingness to comply with study requirements is not mentioned\n\nClinical trial inclusion criteria:\n- Aged over 18 and less than 75 years\n- ECOG PS is 0-1\n- Expected survival time is \u2265 3 months\n- Histologically or cytologically confirmed selected advanced solid tumor\n- Subject must have at least one measurable lesion according to RECIST Version 1.1\n- Available archived tumor tissue sample, or consent and undergo fresh tumor biopsy\n- Adequate organ function\n- Contraception requirements for reproductive potential\n- Willing and able to comply with study requirements\n\nThe patient does not have sufficient information to qualify for the trial, specifically regarding the presence of an advanced solid tumor, ECOG PS, expected survival time, measurable lesions, and availability of tumor tissue samples. Therefore, the patient is not eligible for this trial due to lacking information on key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1932": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. His medical history is non-significant outside of these conditions, and there is no mention of liver lesions or that the patient is eligible for liver resection.\n\nThe clinical trial in question is focused on the impact of chemotherapy and regenerative markers of liver regeneration after liver resection for liver metastases. The inclusion criteria specify that patients must have liver lesions and must be eligible for liver resection.\n\nThe patient described in the note does not have liver metastases, nor is there any indication that he is eligible for or has undergone liver resection. Therefore, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1933": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, we will assess the patient's eligibility for the trial.\n\nPatient note summary:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recently coinfected with HBV.\n- No significant past medical history.\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No hepatocellular carcinoma and no other specified liver diseases.\n- The patient does not have pectus excavatum or any mention of it.\n\nClinical trial summary:\n- The trial is related to documenting the surface geometry of pectus excavatum.\n- Inclusion criteria for the trial are participation in the 3D PECTUS study and having received both a 3D scan and standard photography.\n\nSince the patient does not have pectus excavatum, nor is there any indication that he is part of the 3D PECTUS study, he does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1934": {
        "output": "Given the information in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nThe clinical trial is focused on patients with decompensated liver cirrhosis who are receiving a TIPS procedure for either variceal bleeding or refractory ascites.\n\nThe patient in the provided note is diagnosed with HCV and a recent coinfection with HBV. The patient has no significant past medical history mentioned, other than being on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's biopsy did not indicate hepatocellular carcinoma but showed chronic inflammation compatible with chronic viral hepatitis. The patient's physical examination does not mention any signs of decompensated liver cirrhosis such as ascites or variceal bleeding, which are typically present in decompensated cirrhosis and would potentially qualify a patient for a TIPS procedure.\n\nGiven the details in the patient note, there is no evidence that the patient has decompensated liver cirrhosis or that he is receiving or is scheduled to receive a TIPS procedure for variceal bleeding or refractory ascites, which are the inclusion criteria for the clinical trial. Therefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1935": {
        "output": "",
        "label": 0
    },
    "1936": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, here is the assessment of the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV (Hepatitis C Virus) 2 years ago and recent coinfection with HBV (Hepatitis B Virus).\n- No mention of autoimmune hepatitis (AIH) or liver transplantation.\n- The patient is on IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for HCV.\n- No evidence of hepatocellular carcinoma or other liver diseases mentioned in the trial's context.\n- No indication that the patient has undergone a liver transplant or has AIH.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is focused on patients with AIH specifically post liver transplantation.\n- The patient must have biopsy evidence of autoimmune liver disease following liver transplantation.\n- The patient must have been treated with steroids or other immunosuppressive agents for at least a month without adequate response.\n\nThe patient in the note does not mention having AIH, nor does it suggest that he has undergone liver transplantation. The patient's liver condition appears to be related to chronic viral hepatitis (HCV and HBV) rather than autoimmune hepatitis.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial on Abatacept for the treatment of recurrent or de novo AIH because:\n- There is no mention of AIH or liver transplantation in the patient's history.\n- The patient's liver disease is related to viral infections (HCV and HBV), not autoimmune processes.\n\nTherefore, the patient is not eligible for the trial as they do not meet the specific inclusion criteria of having AIH post liver transplantation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1937": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer,\" we need to assess the patient's information against the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are as follows:\n1. Histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC).\n2. Disease must have one or more high-risk features.\n3. Diagnostic chest CT within 42 days prior to randomization.\n4. FDG PET/CT of chest within 90 days prior to randomization.\n5. History and physical examination within 28 days prior to randomization.\n6. Inoperable or unwilling to undergo surgical resection (documented).\n7. Age \u2265 18 years.\n8. Zubrod performance status of 0-2.\n9. Adequate liver function.\n10. Adequate renal function.\n11. ANC, platelets, and hemoglobin measured within 28 days prior to randomization.\n12. TSH measured within 28 days prior to randomization.\n13. Tested for hepatitis B within 28 days prior to randomization.\n14. No active hepatitis B virus infection.\n15. Tested for hepatitis C within 28 days prior to randomization.\n16. No active hepatitis C virus infection.\n17. Pulmonary function testing documented within 90 days prior to randomization.\n18. No history of clinically significant interstitial lung disease or active pneumonitis.\n19. No prior or concurrent malignancy with potential to interfere with the study.\n20. Not pregnant, using effective contraception, or abstaining from reproductive sex.\n21. Negative serum pregnancy test for women of reproductive potential within 14 days prior to randomization.\n22. Willingness to submit specimens for research.\n23. Informed consent provided.\n24. Ability to complete quality of life questionnaires in English, French, or Spanish.\n\nThe patient note states:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- No history of non-small cell lung cancer (NSCLC) mentioned.\n- No mention of any diagnostic chest CT or FDG PET/CT scans related to lung cancer.\n- No mention of his performance status or pulmonary function tests.\n- The patient does have a documented history of hepatitis C and recent hepatitis B coinfection.\n\nBased on the patient note, the patient does not meet the primary disease criteria for the clinical trial (he does not have non-small cell lung cancer). The patient's HCV and HBV status also conflict with the trial's criteria regarding hepatitis B and C infections.\n\nTherefore, the patient does not have sufficient information to qualify for the trial:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1938": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not appear to meet the inclusion criteria. The patient is being treated for HCV and HBV, and there is no mention of squamous cell carcinoma of the oropharynx, which is a specific requirement of the trial. There is also no indication that the patient has undergone p-16 immunohistochemistry analysis, has a tumor lesion of at least 1.0 cm in diameter, or is planned for chemoradiotherapy as primary treatment. \n\nSince the patient does not have the target disease (squamous cell carcinoma of the oropharynx), they are not relevant for this clinical trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1939": {
        "output": "",
        "label": 2
    },
    "1940": {
        "output": "",
        "label": 0
    },
    "1941": {
        "output": "",
        "label": 0
    },
    "1942": {
        "output": "Assessing the eligibility of the patient for the described clinical trial involves analyzing the patient's characteristics and medical condition against the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No history of hepatocellular carcinoma\n- No evidence of other liver diseases\n- Normal BP, HR, and BMI\n- No signs of acute distress or physical abnormalities in the abdomen and lower extremities\n\nClinical Trial Inclusion Criteria:\n- Patients must be less than 22 years of age at the time of study enrollment\n- Patient must be newly diagnosed with de novo AML according to the WHO classification\n- Specific diagnostic criteria related to AML (e.g., >= 20% bone marrow blasts, genetic abnormalities, circulating leukemic cells)\n- Additional criteria for certain arms of the study, including age restrictions, FLT3 mutations, and reproductive health considerations\n- Requirement for English, French, or Spanish-speaking for neuropsychological testing\n- No history of neurodevelopmental disorder prior to the diagnosis of AML\n- No significant visual or motor impairment that would prevent computer use\n- Written informed consent\n- Compliance with all institutional, FDA, and NCI requirements for human studies\n\nComparison:\n- The patient is 55 years old, which exceeds the maximum age of 22 years required for the clinical trial.\n- The patient is diagnosed with HCV and HBV, not AML. The trial is specifically targeting patients with newly diagnosed AML.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet the age requirement and does not have the specific disease (AML) that the trial is focused on. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1943": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient's eligibility for the trial can be assessed as follows:\n\nPatient Note Analysis:\n- The patient is a 55-year-old man, which fits within the age range of 40 to 85 years required by the trial.\n- The patient has been diagnosed with HCV and HBV, but there is no mention of glaucoma or cataract, which are the conditions being studied in the trial.\n- There is no information provided about the patient having any vision problems or being treated for glaucoma with hypotensive medications.\n- The patient's medical records do not indicate a diagnosis of Primary Open Angle Glaucoma (POAG) or pigmentary glaucoma.\n- There is no mention of the patient having any ocular measurements taken such as intraocular pressure (IOP) or visual field tests.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial requires male and female patients aged 40 to 85 years, which the patient meets.\n- The patient must be able to attend follow-up examinations for 2 years post-operatively, but willingness and ability to do so are not mentioned in the patient note.\n- The patient must be able to give informed consent, which is assumed possible as there is no indication otherwise.\n- The patient must have an operable age-related cataract with a certain level of visual acuity, and a diagnosis of POAG or pigmentary glaucoma treated with hypotensive medications.\n- A documented unmedicated IOP of > 21 mmHg is required, and there are specific criteria related to optic nerve appearance and visual field loss.\n\nGiven that the patient note does not provide any information regarding cataract, glaucoma diagnosis, or the required ocular measurements, the patient does not meet the specific inclusion criteria for the eye condition that the trial is addressing. Therefore, the patient does not qualify for the trial due to a lack of relevant medical conditions (no mention of glaucoma or cataract).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1944": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the patient's eligibility for the clinical trial titled \"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma.\"\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Written informed consent obtained.\n2. Age \u2265 18 years at the time of study entry.\n3. Multinodular or large, solitary hepatocellular carcinoma, not eligible for resection or local ablation, Tumor burden below 50% of liver volume.\n4. Histologically confirmed diagnosis of hepatocellular carcinoma.\n5. At least one measurable site of disease as defined by modified RECIST (mRECIST) criteria with spiral CT scan or MRI.\n6. Child-Pugh scores 5-7, performance status (PS) \u2264 2 (ECOG scale).\n7. Subjects with chronic HBV infection must have HBV DNA viral load < 100 IU/mL at screening. In addition, they must be on antiviral therapy per regional standard of care guidelines prior to initiation of study therapy.\n8. Life expectancy of at least 12 weeks.\n9. Adequate blood count, liver-enzymes, and renal function.\n10. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to the start of the trial.\n11. The subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits, and examinations including follow-up.\n\nThe patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. The patient's medical records do not indicate a diagnosis of hepatocellular carcinoma; instead, they show chronic inflammation compatible with chronic viral hepatitis. There is no mention of hepatocellular carcinoma, tumor burden, Child-Pugh scores, performance status, or other specific criteria related to the inclusion criteria for the clinical trial.\n\nBased on the information provided, the patient does not meet the specific inclusion criteria of having a histologically confirmed diagnosis of hepatocellular carcinoma or related conditions specified in the trial criteria. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1945": {
        "output": "Based on the given information, here is the assessment:\n\nThe patient is a 55-year-old man, which meets the age criteria of 18 to 75 years old for the clinical trial. The patient has been diagnosed with chronic hepatitis C (HCV) and has been treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs (DAAs) for the past 6 months. This aligns with the inclusion criteria of patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy for 6 months or more and/or DAAs.\n\nThe patient's medical history is described as non-significant, and there is no mention of the patient taking hormones, immunosuppressants, or other hepatoprotective drugs, which fits the criteria of not taking these excluded medications. Additionally, the patient's records indicate ongoing antiviral treatment, but there is no indication that the patient would refuse to sign a written informed consent, which is also one of the inclusion criteria.\n\nGiven the patient's age, diagnosis, treatment history, and the absence of any mention of excluded medications or other disqualifying factors, the patient appears to meet the inclusion criteria for the observational cohort study. Without any explicit exclusion criteria being violated, the patient seems eligible for the study.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1946": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Information:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No mention of being on biological modifier therapies\n- No other significant past medical history\n- No indication of previous exposure to hepatitis B virus other than the recent coinfection\n- No mention of anti-HBc or anti-HBs status\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years old at the time of starting biological modifier therapies or at the time of recruitment\n- Positive for anti-HBc OR\n- Positive for anti-HBs and born before year 1988\n\nAssessment:\n- The patient is over 18 years old.\n- The patient is on antiviral therapy, but there is no mention of biological modifier therapies specifically.\n- The patient's status regarding anti-HBc or anti-HBs is not provided in the patient note.\n- The patient was born before 1988, but without information on his anti-HBs status, we cannot confirm eligibility based on this criterion alone.\n\nGiven the information provided, we cannot confirm that the patient meets the specific inclusion criteria regarding the status of anti-HBc or anti-HBs antibodies. Additionally, there is no mention of the use of biological modifier therapies, which is a key part of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1947": {
        "output": "The patient in question is a 55-year-old man diagnosed with hepatitis C virus (HCV) infection 2 years ago and a recent coinfection with hepatitis B virus (HBV). He is currently on treatment with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs. There is no mention of hepatocellular carcinoma or other liver diseases in his medical history. The patient does not appear to be in acute distress, and his current physical examination findings are within normal limits except for his body mass index (BMI) of 27, which is in the overweight range.\n\nNow, we need to compare this patient's information with the inclusion criteria for the clinical trial titled \"Seroepidemiology of Viral Hepatitis in Hong Kong.\"\n\nThe inclusion criteria for the trial are:\n- Residents normally living in Hong Kong\n- Living in domestic households randomly selected from Building Groups\n- Any age, while subjects below the age of 18 would require informed consent of their guardians for participation\n- Any gender\n\nBased on the information provided in the patient note, we do not have any information indicating that the patient resides in Hong Kong or that they live in a domestic household randomly selected from Building Groups. Therefore, the patient does not meet the residency requirement, which is a key inclusion criterion for this study.\n\nSince the patient's residency status is not aligned with the trial's inclusion criteria and there is no evidence that he lives in a domestic household randomly selected from Building Groups in Hong Kong, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1948": {
        "output": "",
        "label": 1
    },
    "1949": {
        "output": "Given the patient note and the clinical trial information, let's assess the eligibility of the patient:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- Non-significant past medical history\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months\n- No hepatocellular carcinoma, no evidence of decompensated liver diseases such as bleeding from esophageal varices or ascites\n- Normal liver function tests (no abnormal values are provided, and the patient is described as without acute distress)\n\nClinical Trial Inclusion Criteria:\n- Age \u226520 years\n- Anti-HCV positive and HCV RNA >1000 IU/ml\n- Any HCV genotype; all received 12 weeks of DAA treatment\n- Treatment na\u00efve or experienced of pegylated interferon/ribavirin\n- Concurrent HBV infection which is defined by positive HBsAg for at least 6 months\n\nClinical Trial Exclusion Criteria:\n- History of treatment regimen that included any kind of direct antiviral agents (the patient is currently on direct antiviral drugs)\n- Presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc. (not mentioned in the patient note)\n- Uncontrolled diabetes mellitus (HbA1c >8.5; not mentioned in the patient note)\n- Current evidence or suspicion of malignancy (the patient does not have this, as per the biopsy report)\n- Severe cardiovascular or other severe comorbid diseases (not mentioned in the patient note)\n- Autoimmune disorders (not mentioned in the patient note)\n- Presence of liver cirrhosis clinically or pathologically (not mentioned in the patient note)\n- Any one of the following hematology or biochemical or clinical abnormalities (not mentioned in the patient note)\n- Child-bearing age women without the willing to contraceptive control; pregnant women or lactating women (not applicable to the patient)\n\nBased on the information provided, the patient meets the age requirement and has a concurrent HBV infection. However, the patient does not meet the criteria regarding the treatment regimen, as he is currently on direct antiviral drugs, which are listed in the exclusion criteria.\n\nTherefore, the patient is excluded from the clinical trial based on the exclusion criteria of having a history of treatment regimen that included any kind of direct antiviral agents.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1950": {
        "output": "Based on the provided patient note and the clinical trial information, we can assess the patient's eligibility for the trial.\n\nThe patient in question is a 55-year-old man diagnosed with hepatitis C virus (HCV) 2 years ago and a recent coinfection with hepatitis B virus (HBV). He is currently on IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's medical history is non-significant aside from the viral infections, and there is no mention of COVID-19, SARS-CoV-2 infection, or related symptoms.\n\nThe clinical trial is focused on patients with confirmed COVID-19 by RT PCR and has specific criteria regarding the severity of the illness, chest radiograph status, and oxygen saturation levels.\n\nGiven that the patient note does not indicate that the patient has COVID-19 or that he has been tested for SARS-CoV-2, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires COVID-19 patients. Therefore, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1951": {
        "output": "",
        "label": 0
    },
    "1952": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n- The patient is a 55-year-old man, which satisfies the age criterion (age \u2265 18 years).\n- The patient has been diagnosed with HCV and a recent coinfection with HBV, but there is no mention of hepatocellular carcinoma (HCC) which is a requirement for the trial.\n- The patient's medical history does not indicate any evidence of liver cancer or BCLC stage B or C disease.\n- There is no information on measurable disease by RECIST v1.1, which is necessary to determine eligibility.\n- No mention of prior systemic therapy for HCC or previous locoregional therapy is provided, which are relevant to the inclusion criteria.\n- There's no information regarding Child-Pugh class A hepatic function, ECOG performance status, life expectancy, recovery to baseline toxicity, blood counts, liver function tests, renal function, or diabetes control measures, which are also part of the inclusion criteria.\n- The patient is on IFN, RBV, and direct antiviral drugs for hepatitis, and it's stated that he has completed at least 6 months of this treatment. According to the trial inclusion criteria, treated HCV patients must have completed their anti-viral treatment at least 1 month prior to initiating study treatment.\n- The patient's notes don't mention any use of contraception or his fertility status, which is required for the trial.\n- There is no mention of the patient's understanding and willingness to comply with the protocol requirements or his consent to participate.\n\nGiven the patient's diagnosis, which does not include HCC, and the lack of information regarding several other inclusion criteria, the patient does not appear to be eligible for the clinical trial titled \"Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer.\" The patient does not meet the necessary disease criteria for the trial as the trial is specific to liver cancer (HCC), and the patient is diagnosed with HCV and HBV without mention of liver cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1953": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we need to assess the eligibility of the 55-year-old man for the clinical trial titled \"Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC.\"\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV and recent coinfection with HBV\n- No hepatocellular carcinoma (HCC) mentioned\n- No evidence of advanced HCC\n- No BCLC stage provided\n- No previous systematic treatment for HCC mentioned\n- No evidence of measurable lesion provided\n- ECOG-PS score not provided\n- Child-Pugh Class not provided\n- Life expectancy not mentioned\n- On antiviral therapy for HCV and HBV\n- Hematology and organ functions not specified in detail\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Advanced HCC confirmed by imaging or histopathology\n- BCLC stage B or C, not suitable for or progressed after local therapy\n- No previous systematic treatment for HCC\n- At least one measurable lesion\n- ECOG-PS score 0 or 1\n- Child-Pugh Class: Grade A\n- Life expectancy of at least 3 months\n- Subjects with HBV infection meet certain conditions; subjects with HCV must receive antiviral therapy\n- Specific laboratory values within certain ranges\n- Agree to use effective contraception\n\nThe patient does not have a diagnosis of advanced hepatocellular carcinoma (HCC), which is required for participation in the trial. Additionally, there is no information about the ECOG-PS score, Child-Pugh Class, or measurable lesions, which are also required for inclusion in the study. Since the patient does not have advanced HCC, he does not meet the primary disease criterion for the trial, making him ineligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1954": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. There is no mention of a chronic subdural hematoma or any need for subdural evacuation. Therefore, the patient does not meet the specific inclusion criteria for the clinical trial, which requires having a clinically symptomatic chronic subdural hematoma greater than 1 cm in maximal thickness and a clinical judgment that subdural evacuation is needed.\n\nSince the patient's medical condition does not match the target condition of the study (chronic subdural hematoma), the patient would not be relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1955": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial.\n\nThe patient note provides the following information:\n\n- The patient is a 55-year-old man.\n- Diagnosed with HCV (Hepatitis C virus) 2 years ago and a recent coinfection with HBV (Hepatitis B virus).\n- No significant past medical history other than the viral infections.\n- On treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- No other medications reported.\n- No evidence of hepatocellular carcinoma or other liver diseases.\n- Normal vital signs and physical examination findings.\n\nThe clinical trial has the following inclusion criteria:\n\n- Male/female patients aged over 18 years.\n- Histologically confirmed gastric adenocarcinoma.\n- Gastric tumors should be treatment na\u00efve unresectable or metastatic disease, or recurrence over 6 months after finish of adjuvant chemotherapy.\n- HER2 status is confirmed by IHC/FISH.\n- At least one measurable lesion should be confirmed by imaging examination.\n- Eligible peripheral blood samples.\n- Patients with enough organ function and performance status (ECOG 0-2) can tolerate chemotherapy.\n- For HER2 positive patients, trastuzumab should be used as first-line treatment.\n- Willing to provide clinicopathological information and imaging information.\n\nThe patient in question does not have a diagnosis of gastric adenocarcinoma, nor is there any mention of HER2 status or gastric cancer treatment. The patient is being treated for viral hepatitis and not for gastric cancer.\n\nGiven that the patient's condition and medical history do not match the clinical trial's target disease (gastric adenocarcinoma) or any of the other inclusion criteria specific to the trial (such as HER2 status and chemotherapy treatment), the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1956": {
        "output": "The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) infection 2 years ago and a recent coinfection with hepatitis B virus (HBV). He has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months, and his medical records indicate previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV antibodies. His recent biopsy showed no evidence of hepatocellular carcinoma but chronic inflammation compatible with chronic viral hepatitis.\n\nThe clinical trial in question is looking to examine the association of chronic liver diseases, including hepatitis B and hepatitis C, with other systemic diseases by retrospectively analyzing data from the Hospital Database of the Buddhist Tzu Chi Medical Foundation.\n\nInclusion Criteria for the Trial:\n- Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation\n\nGiven the information provided, the patient appears to meet the inclusion criteria for the clinical trial since he has a diagnosis of HCV and a recent coinfection with HBV, which are chronic liver diseases. However, the patient note does not specify whether he visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation. Without this information, we cannot definitively determine trial eligibility.\n\nTherefore, based on the available information, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1957": {
        "output": "The patient is a 55-year-old man with a diagnosis of chronic HCV and recent coinfection with HBV. The patient's medical history does not mention hepatocellular carcinoma (HCC), only chronic viral hepatitis. He does not meet the primary inclusion criterion of having a diagnosis of HCC confirmed by histology or cytology.\n\nAssessing the patient's eligibility for the clinical trial titled \"The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma\" based on the inclusion criteria provided:\n\n- Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology: The patient note does not mention HCC; it only states chronic inflammation compatible with chronic viral hepatitis.\n- Barcelona Clinic Liver Cancer (BCLC) Stage B or C: No information about BCLC staging is provided in the patient note.\n- Age \u226518 years or \u226475 years for both genders: The patient is 55 years old and meets this criterion.\n- ECOG performance status: 0-1: No specific information provided, but the patient is described as alert with no acute distress, which suggests a relatively good performance status.\n- Child Pugh score\u22647: No specific information is provided.\n- LVEF\u226550% or above LLN of the research institution: No information on LVEF is provided.\n- Enough organ function: The patient does not show signs of severe liver dysfunction in the note, but specific organ function tests are not provided.\n- Has at least one measurable lesion based on RECIST 1.1: No measurable lesion is mentioned.\n- Life expectancy \u22653 months: No information is provided, but there's nothing suggesting a less than 3-month life expectancy.\n- Patients must be able to understand and willing to sign a written informed consent document: This is typically assessed at the time of recruitment, no information is provided.\n\nThe patient does not meet the primary inclusion criterion for HCC, which is essential for participation in this trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1958": {
        "output": "Based on the patient note provided:\n\nThe patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. He has been on IFN, RBV, and direct antiviral drugs for the past 6 months. The medical records indicate chronic viral hepatitis without hepatocellular carcinoma, alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. The patient does not present with any acute distress, his vitals are stable, and there is no mention of SARS-CoV2 infection, pneumonia, or septic shock.\n\nNow, considering the clinical trial's inclusion criteria:\n\n- Patients admitted to the UTC in the Temporary COVID-19 Citibanamex Center with suspected or diagnosed severe pneumonia due to SARS-COV2 with or without septic shock.\n- Patients who accept and sign informed consent.\n- Diagnosis of septic shock in the last 24 hours characterized by refractory hypotension and vasopressor requirement despite adequate fluid resuscitation to maintain a blood pressure \u2265 65 mmHg with lactate > two mmol/L.\n\nThe patient in question does not meet the inclusion criteria for the clinical trial as there is no mention of severe pneumonia due to SARS-COV2 or septic shock. The trial is specifically targeting patients with severe COVID-19 and related complications, which does not apply to the patient based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1959": {
        "output": "To determine the eligibility of the patient for the clinical trial, let's compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the study:\n\nPatient Characteristics:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago, recent co-infection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma or other liver diseases\n- No acute distress, normal blood pressure and heart rate, no abdominal ascites or tenderness, and no lower extremity edema\n\nClinical Trial Inclusion Criteria:\n- Inoperable, locally advanced or metastatic HR-positive/HER2-negative breast cancer or TNBC (depending on the arm)\n- Specific prior treatment requirements depending on the arm\n- Measurable disease per RECIST v1.1\n- Adults, at least 18 years of age\n- ECOG performance status of 0 or 1\n- Adequate baseline Laboratory Values\n- Agreement to use birth control if of childbearing potential\n- Specific criteria for those with brain metastases\n- Additional inclusion criteria may apply\n\nClinical Trial Exclusion Criteria:\n- History of malignancy active within the previous 2 years (with exceptions)\n- Untreated symptomatic brain and/or leptomeningeal metastases\n- Unresolved prior therapy-related acute toxicity Grade > 1\n- Active or chronic corneal disorder\n- Serious concurrent illness\n- History of allogeneic tissue/solid organ transplant\n- Specific exclusions for Arm C\n- Pregnant or breastfeeding\n- Additional exclusion criteria may apply\n\nAssessment:\nThe patient has HCV and HBV, not breast cancer, and therefore does not meet the disease-specific inclusion criteria for the clinical trial. The trial is specifically for patients with advanced breast cancer, either HR-positive/HER2-negative or TNBC, and requires that patients have either no prior cytotoxic chemotherapy or a specific number of prior treatments depending on the trial arm. Since the patient does not have breast cancer, he does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1960": {
        "output": "The patient in the note is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV. His past medical history is non-significant, and he is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months. The patient's recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis. There is no mention of psychiatric issues or admission to a psychiatric unit.\n\nThe clinical trial in question is focused on the prevalence of hepatitis C in a psychiatric population and involves a systematic screening of patients in an adult psychiatric environment.\n\nAccording to the inclusion criteria provided for the clinical trial:\n- The patient must be admitted to one of the inpatient or outpatient adult psychiatric units of the hospitals participating in the study.\n- The patient must accept the realization of the HCV RDT (or patient with positive HCV serology performed less than 3 months ago).\n\nThe patient in the note does not mention any psychiatric condition or admission to a psychiatric unit, which is a requirement for inclusion in the trial. Therefore, based on the information provided, the patient does not meet the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1961": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. His medical history does not mention COVID-19 or admission to an intensive care unit for COVID-19. Therefore, the patient does not meet the inclusion criteria for the clinical trial titled \"FOLLOW-UP OF PATIENTS WITH COVID-19,\" which requires that the patient must have been admitted to an intensive care unit for COVID-19.\n\nGiven that the patient note does not provide information that the patient was admitted to an intensive care unit for COVID-19, the patient does not meet the specific inclusion criteria for this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1962": {
        "output": "Given the patient note and the clinical trial information provided, let's determine the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 55-year-old man.\n- The patient was diagnosed with HCV (Hepatitis C Virus) 2 years ago and recently coinfected with HBV (Hepatitis B Virus).\n- The patient is currently on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n- There is no mention of Parkinson's disease or any symptoms associated with it.\n- The patient has agreed to no procedures or examinations as part of the clinical trial requirements.\n\nClinical Trial Inclusion Criteria Analysis:\n- The study is investigating the association between HCV infection and Parkinson's disease.\n- Inclusion criteria require adults older than 20 years of age with HCV infection.\n- Participants must agree to accept 18F-FDOPA PET examination.\n\nComparison:\n- The patient is 55 years old, which meets the age requirement.\n- The patient has an HCV infection, meeting the disease criterion.\n- There is no information on whether the patient has agreed to accept the 18F-FDOPA PET examination, but as the patient note does not state the patient has declined any procedures, it is reasonable to infer that the patient may agree to the required examination if asked.\n\nGiven the available information, the patient appears to meet the age and disease criteria for the clinical trial. However, explicit consent to the 18F-FDOPA PET examination is not documented in the patient note. Since the only missing piece of information is the patient's agreement to the examination, which can be sought by the researchers, the patient should be considered potentially eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1963": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"E-health for Self-Management of Chronic Pain,\" we can assess the patient's eligibility as follows:\n\n- The patient is 55 years old, which meets the age criterion of being over 18 years of age.\n- The patient has been diagnosed with HCV and is on treatment, but there is no mention of chronic pain, let alone axial neck pain or lower back pain.\n- There is no information given about the patient being followed by a pain management specialist.\n- The patient's goal and motivation concerning the program are not mentioned.\n- There is no information to determine if the patient is medically prepared.\n- There is no mention of any major change in interventional treatment or surgical candidacy.\n- The patient's ability to use a smart phone, tablet, or computer is not mentioned.\n\nSince the patient's information does not confirm chronic pain, which is a key condition for the trial, and lacks sufficient detail on other inclusion criteria such as the patient's history with pain management, goals, motivation, and preparedness for medical intervention, we do not have enough evidence to include the patient in the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1964": {
        "output": "Based on the patient note, the patient is a 55-year-old man who was diagnosed with HCV 2 years ago and has a recent coinfection with HBV. His medical history does not present any significant conditions unrelated to his chronic viral hepatitis. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs (DAA) for the past 6 months. The patient's medical records confirm a chronic HCV infection with positive HCV RNA tests and positive anti-HCV antibodies. He does not have hepatocellular carcinoma or other liver-related diseases outside of his chronic viral hepatitis.\n\nThe clinical trial in question is looking to build a prediction model of HCV-related disease progression after DAA treatment. The inclusion criteria for this trial are:\n\n1. Adult patients (\u226518 years old) with chronic HCV infection that were HCV RNA positive.\n2. Have received DAA treatment.\n3. Would like to adhere to the follow-up.\n\nThe patient meets all the inclusion criteria:\n\n1. He is an adult over 18 years old.\n2. He has a chronic HCV infection that is confirmed to be HCV RNA positive.\n3. He has received DAA treatment.\n4. There is no mention of the patient's unwillingness to adhere to follow-up, so we can assume he would adhere.\n\nSince the patient meets all the inclusion criteria and there are no exclusion criteria provided, the patient should be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1965": {
        "output": "Given the patient note:\n\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV and direct antiviral drugs for the past 6 months.\n- No significant past medical history other than HCV.\n- No evidence of hepatocellular carcinoma, cirrhosis, or other liver diseases mentioned.\n- No signs of portal hypertension such as ascites or variceal bleeding.\n\nAnd the clinical trial's inclusion criteria:\n\n- Suffering from chronic hepatitis induced cirrhosis.\n- Informed consent available.\n\nThe patient in the note does not mention suffering from cirrhosis; only chronic hepatitis is mentioned. Since cirrhosis, which is typically a consequence of chronic hepatitis, is a specific condition required for inclusion in the trial, and the patient note does not confirm the presence of cirrhosis, the patient does not meet the inclusion criteria based on the information provided. \n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1966": {
        "output": "The patient in the provided note is a 55-year-old man diagnosed with HCV and recent coinfection with HBV. His past medical history does not mention cancer, and the note does not indicate that he is experiencing cancer pain or undergoing anticancer treatment. \n\nThe clinical trial in question is about a patient education program for cancer pain management and requires participants to be followed in a comprehensive cancer center with any type of cancer, at any location and stage, and experiencing cancer pain and/or treatments for 3 months or more.\n\nGiven the information in the patient note, the patient does not meet the inclusion criteria for the clinical trial, as there is no mention of cancer or cancer pain in his medical history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1967": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the ARCHIVE clinical trial, let's consider the patient's eligibility:\n\nPatient note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV.\n- On IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV status.\n\nClinical trial inclusion criteria:\n- Men and women aged >55.\n- For participants without HIV: an HIV negative test within 12 months prior to enrollment.\n- Willing and able to provide written informed consent and willingness to participate in a longitudinal cohort study, including various consents related to blood samples, data linking, and follow-up studies.\n\nGiven the patient's age of 55 years, he meets the age criterion for the ARCHIVE study. However, there is no information about the patient's HIV status or testing within the past 12 months. Since the study requires either an HIV-negative test within the past 12 months or the provision of an HIV-negative test as part of the standard of care if indicated, we cannot determine the patient's eligibility without further information on their HIV status.\n\nTherefore, the patient note does not provide sufficient information to qualify for the trial based on the provided criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1968": {
        "output": "Based on the provided patient note and the clinical trial information, we can assess the patient's eligibility for the trial as follows:\n\n- The patient is a 55-year-old man, which satisfies the age criterion of \u226518 years.\n- The patient has been diagnosed with HCV 2 years ago, meeting the criterion of being diagnosed with HCV.\n- The patient is currently on IFN, RBV, and direct antiviral drugs (DAA therapy) for the past 6 months, which aligns with the requirement of being on DAA therapy.\n- There is no mention of the patient not providing written informed consent, so we can assume this criterion can be met.\n- There are no exclusion criteria provided, so we cannot exclude the patient on any additional grounds.\n\nTherefore, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1969": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n1. Age: The patient is 55 years old, which meets the age criteria of \"more than 20 years.\"\n2. Chronic HBV infection: The patient has a co-infection of HBV, as indicated by the recent coinfection with HBV. However, there is no mention of HBsAg positivity for more than 6 months.\n3. HBV Viral Load: The patient's note does not provide information on the HBV viral load.\n4. Liver Injury: The note states there was chronic inflammation compatible with chronic viral hepatitis observed in a recent biopsy, but it does not specify HAI or Metavir scoring systems.\n5. ALT Levels: There is no information provided about the patient's ALT levels.\n6. Treatment Na\u00efve: The patient is not treatment-na\u00efve, as he is currently on IFN, RBV, and direct antiviral drugs.\n\nClinical Trial Inclusion Criteria:\n1. Age more than 20 years.\n2. Presence of HBsAg positivity for more than 6 months.\n3. HBV viral load more than 20000 IU/mL in HBeAg positive or more than 2000 IU/mL in HBeAg Negative CHB patients.\n4. Presence of liver injury (HAI > 3 or liver fibrosis stage 2 or stage 3).\n5. ALT level between 1-2 folds of ULN for at least one occasion in the recent 1 year.\n6. Treatment na\u00efve.\n\nThe patient does not meet the following criteria:\n- HBsAg positivity duration is not specified.\n- HBV viral load is not provided.\n- Specific liver injury scoring is not provided.\n- ALT levels are not provided.\n- Patient is not treatment-na\u00efve.\n\nTherefore, the patient does not have sufficient information to qualify for the trial and also does not meet some of the specific inclusion criteria based on the information available.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1970": {
        "output": "Based on the patient note provided, the patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) 2 years ago and has recently been coinfected with HBV (Hepatitis B Virus). The medical records indicate that the patient does not have any other significant medical history and is currently on treatment with IFN (Interferon), RBV (Ribavirin), and direct antiviral drugs for the past 6 months.\n\nThe clinical trial in question is the European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol. The inclusion criteria for this study are focused on children and adolescents with a diagnosis of HIV or chronic HCV infection. Specifically, the trial is looking to include:\n\n- Children and young people living with HIV:\n  - Diagnosis of HIV infection at age <18 years\n  - \u22651 visit in paediatric care\n\n- Children and young people living with HCV:\n  - Diagnosis of chronic HCV infection at age <18 (defined as \u22651 antibody HCV positive results at \u226518 months of age or \u22651 HCV RNA positive result at \u22656 months of age)\n  - \u22651 visit in paediatric care\n\nGiven that the patient is 55 years old and the inclusion criteria specify that participants must be children and adolescents diagnosed at an age younger than 18 years, the patient does not meet the inclusion criteria for age and the specific pediatric population targeted by the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1971": {
        "output": "",
        "label": 2
    },
    "1972": {
        "output": "Assessing the patient note against the clinical trial inclusion criteria:\n\nPatient Note:\n- The patient is a 55-year-old man.\n- Diagnosed with HCV 2 years ago.\n- Recent coinfection with HBV.\n- Past medical history is non-significant.\n- Currently on IFN, RBV, and direct antiviral drugs for the past 6 months.\n- No mention of HIV coinfection.\n- No mention of achieving sustained virologic response (SVR).\n\nClinical Trial Inclusion Criteria:\n- Age older than 20 years old.\n- Patients with human immunodeficiency virus (HIV) coinfection.\n- Patients achieving SVR, defined as undetectable serum HCV RNA at week 12 off-therapy.\n\nThe patient's note does not indicate an HIV coinfection, which is a requirement for the clinical trial. Additionally, there is no information provided about the patient achieving SVR. Therefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1973": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV, and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma, no other significant liver diseases\n- No acute distress, normal blood pressure, heart rate, and BMI\n- Abdomen is soft with no ascites or tenderness\n- Lower extremities are normal with no edema\n\nClinical Trial:\n- Title: Tucatinib Together With Pembrolizumab and Trastuzumab\n- Inclusion criteria focus on HER2-positive, metastatic breast cancer patients who have received specific prior treatments and meet other health and biomarker criteria\n- Exclusion criteria include a history of severe hypersensitivity reactions to similar treatments, certain pre-existing conditions, infections, or other criteria that could confound trial results or endanger the patient\n\nThe patient in the note does not have HER2-positive, metastatic breast cancer; instead, they have HCV and a recent HBV coinfection. There is no indication that the patient meets the disease-specific inclusion criteria for the clinical trial, which specifically targets a different patient population with breast cancer.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial and is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1974": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, we can perform the following assessment:\n\nPatient Note:\n- The patient is a 55-year-old man diagnosed with chronic viral hepatitis (HCV with recent HBV coinfection).\n- His past medical history is non-significant, suggesting no known complications of cirrhosis.\n- He is currently on IFN, RBV, and direct antiviral drugs.\n- Biopsy revealed no hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis.\n- There is no evidence of complications like alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n- The patient is alert with no acute distress, normal blood pressure, heart rate, and BMI.\n- His abdomen is soft with no ascites or tenderness, and the lower extremities show no edema.\n\nClinical Trial Inclusion Criteria:\n- Cirrhotic patients whether compensated or decompensated with an acute decompensation of cirrhosis which is defined by the recent development of ascites, encephalopathy, GI hemorrhage, bacterial infection, or any combination of these.\n\nAssessment:\nThe patient in the note has chronic viral hepatitis but there is no information suggesting that he has cirrhosis, nor is there any indication of acute decompensation (e.g., ascites, encephalopathy, GI hemorrhage, bacterial infection). The patient's condition does not meet the specified inclusion criteria for the clinical trial, which is focused on patients with acute-on-chronic liver failure in cirrhotic patients.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1975": {
        "output": "",
        "label": 0
    },
    "1976": {
        "output": "",
        "label": 0
    },
    "1977": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Diet and Exercise for Elevated Risk (DEER),\" let's assess the patient's eligibility for the trial.\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Presenting with cardiomyopathy\n- Taking 70/30 Insulin and vitamin D supplements\n- Lab values: LDL-cholesterol of 125 mg/dL and HDL-cholesterol of 40 mg/dL\n\nClinical trial inclusion criteria:\n- Men with LDL-cholesterol of 125-189 mg/dL and HDL-cholesterol below or equal to 44 mg/dL\n- Postmenopausal women, age 45 to 64, with LDL-cholesterol of 125 to 209 mg/dL and HDL-cholesterol below or equal to 59 mg/dL\n\nThe patient's LDL-cholesterol (125 mg/dL) and HDL-cholesterol (40 mg/dL) levels fall within the specified range for men in the trial. However, the patient is 25 years old, which is younger than the age specified in the inclusion criteria (there is no lower age limit stated, but the criteria for postmenopausal women give a clue that the study may be targeting an older population).\n\nTherefore, due to the age of the patient not being explicitly addressed in the inclusion criteria provided, we can conclude that there is not sufficient information to confirm eligibility based on age. The patient does meet the cholesterol level criteria, but without clarity on the age range for male participants, we cannot determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1978": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. There is no mention of prostate carcinoma or any history of cancer treatment in the patient's note. The clinical trial in question is specifically for patients with a histologic diagnosis of carcinoma of the prostate, and the patient must not have had a trial of hormonal therapy or chemotherapy.\n\nGiven the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial, which is focused on poor prognosis prostate carcinoma. The trial is not relevant to his medical condition as he does not have a diagnosis of prostate cancer.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1979": {
        "output": "",
        "label": 1
    },
    "1980": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Long Term Effects of Enalapril and Losartan on Genetic Heart Disease,\" we will compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\n**Patient Characteristics:**\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, treated with ACE inhibitors and Beta blockers\n- No other significant medical history\n- Family history of Type 1 diabetes\n\n**Inclusion Criteria for the Trial:**\n- HCM of either gender, aged 20-55 years.\n- Non-dilated LV (LVIDd less than 60 mm) with LV wall thickness of greater than or equal to 16 mm measured by NMR.\n- Non-obstructive HCM: A LV outflow gradient of less than or equal to 30 mm Hg gradient at rest and less than or equal to 55 mm Hg following isoproterenol infusion to a heart rate of greater than or equal to 120 beats per minute at cardiac catheterization.\n- New York Heart Association functional class I-III.\n- Patients who have previously taken an ACE inhibitor or losartan could only be included in this study if they have been off these drugs for a period of 6 months or longer.\n\n**Exclusion Criteria for the Trial:**\n- Severe cardiac symptoms at rest (NYHA IV).\n- LV outflow tract gradient of greater than 30 mm Hg at rest or greater than 55 mm Hg following isoproterenol infusion.\n- Systemic diseases that prevent necessary testing.\n- Coronary artery disease or congenital cardiovascular abnormalities.\n- Chronic atrial fibrillation.\n- Bleeding disorders, anemia, renal impairment, abnormal potassium levels.\n- Uncontrolled hypertension or hypotension.\n- Overt cardiac failure, pregnancy, lactation, diminished LV systolic function.\n- Dependence on other cardioactive drugs.\n- Negative HIV test.\n- Sensitivity to ACE inhibitor.\n\n**Comparison:**\n- The patient is 25 years old, within the age range of 20-55 years required for the trial.\n- The patient has cardiomyopathy, which is different from hypertrophic cardiomyopathy (HCM) specified in the inclusion criteria.\n- The patient is already on ACE inhibitors, which could potentially exclude him unless he has been off these drugs for 6 months or more (no information provided on the duration of current medication use).\n- The patient does not have severe cardiac symptoms at rest (NYHA IV), which is part of the exclusion criteria.\n\nGiven the information provided, the patient has been diagnosed with cardiomyopathy, not specifically hypertrophic cardiomyopathy (HCM), which is required by the trial inclusion criteria. Therefore, the patient does not meet the specific disease criteria for the trial. There is a lack of sufficient information to determine other specific measurements required by the inclusion criteria, such as LV wall thickness and LV outflow gradient.\n\n**Trial-level eligibility: 1) Not relevant.**",
        "label": 0
    },
    "1981": {
        "output": "",
        "label": 0
    },
    "1982": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility for participation in the trial:\n\nPatient Note Summary:\n- 25-year-old man\n- Diagnosed with type 1 diabetes 7 years ago\n- Presents with shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- No other significant medical history\n- Family history of DM type 1 in his uncle and grandfather\n\nClinical Trial Inclusion Criteria:\n- Individuals with cardiomyopathy referred for evaluation to the NIH\n\nThe patient in the note has been diagnosed with cardiomyopathy, which aligns with the inclusion criterion for the clinical trial. The trial requires individuals with cardiomyopathy who are referred for evaluation. However, the note does not provide information about a referral to the NIH, which is a specific part of the inclusion criteria.\n\nGiven the information, we can infer that the patient has cardiomyopathy, which is relevant to the study. However, without explicit information about a referral to the NIH, we cannot conclusively state that the patient meets all the inclusion criteria. Therefore, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1983": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient note highlights:\n- Patient is a 25-year-old man with type 1 diabetes.\n- He presents with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- The patient's medical history does not mention cystic fibrosis.\n\nClinical trial inclusion criteria:\n- Mild cystic fibrosis.\n\nThe patient in the provided note has type 1 diabetes and cardiomyopathy, but there is no mention of cystic fibrosis. Since cystic fibrosis is a requirement for participation in the study, and it is not indicated that the patient has this condition, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1984": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine the patient's eligibility.\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He was diagnosed with type 1 diabetes 7 years ago.\n- He presents with shortness of breath and fatigue during activities.\n- He has been diagnosed with cardiomyopathy.\n- He takes 70/30 Insulin and vitamin D supplements.\n- No other significant medical history is mentioned.\n\nClinical Trial Inclusion Criteria:\n- Newly diagnosed type 1 diabetes (within one month of diagnosis).\n- IDDM patients: Prepubescent, adolescent, or early adult patients.\n\nThe patient does not meet the inclusion criteria for the clinical trial as he was diagnosed with type 1 diabetes 7 years ago, which is well beyond the \"newly diagnosed\" timeframe of within one month specified by the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1985": {
        "output": "Given the patient note and the clinical trial information provided, the patient is a 25-year-old man with type 1 diabetes, which is consistent with the population of interest for the trial investigating coronary artery calcification in individuals with insulin-dependent diabetes mellitus (IDDM), or type 1 diabetes. The patient presents with cardiomyopathy and is treated with ACE inhibitors and Beta blockers, which indicates a potential for subclinical heart disease, a condition of interest for the trial.\n\nHowever, the clinical trial provided does not specify any inclusion criteria. This absence of criteria makes it impossible to definitively determine eligibility based on the information usually required for clinical trial recruitment, such as specific health conditions, treatment history, or other medical factors.\n\nGiven the absence of inclusion criteria in the trial description, we cannot reach a definitive conclusion about the patient's eligibility for the trial based solely on the information provided. Therefore, the patient's trial-level eligibility must be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1986": {
        "output": "",
        "label": 0
    },
    "1987": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy, which is to be treated with ACE inhibitors and Beta blockers. He presents with shortness of breath and fatigue during activities, consistent with New York Heart Association class 2 symptoms, and he has a family history of diabetes type 1. His lab studies show controlled blood sugar and cholesterol levels.\n\nThe clinical trial is for Bevacizumab with or without Thalidomide in treating patients with relapsed or refractory Multiple Myeloma. The inclusion criteria for the clinical trial are specific to individuals with histologically confirmed progressing multiple myeloma, meeting certain disease characteristics (like stages, paraprotein levels, bone marrow involvement, etc.), as well as specific patient characteristics like performance status, life expectancy, and various organ function parameters. The exclusion criteria include various conditions such as active coronary artery disease, New York Heart Association class II-IV congestive heart failure, and prior malignancies unless in complete remission for at least 2 years, among others.\n\nComparing the patient's note to the clinical trial's inclusion and exclusion criteria, it is clear that the patient does not meet the inclusion criteria for the clinical trial. He does not have multiple myeloma, nor does he present with any of the disease characteristics required for the trial. Furthermore, the patient does have New York Heart Association class II symptoms, which is mentioned in the exclusion criteria in the context of congestive heart failure, although not directly applicable as the patient has cardiomyopathy and not CHF. Regardless, the primary reason for ineligibility is not meeting the disease-specific inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1988": {
        "output": "Upon analyzing the patient note and the inclusion criteria for the clinical trial titled \"Urinary Vitamin C Loss in Diabetic Subjects\", we can determine the patient's eligibility as follows:\n\nPatient characteristics:\n- 25-year-old man\n- Confirmed type 1 diabetes\n- Presents shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, treated with ACE inhibitors and Beta blockers\n- Controlled diabetes with FBS: 100 mg/dl and HbA1c: 6.5%\n- No other significant medical issues\n- Family history positive for DM type 1\n\nClinical trial inclusion criteria:\n- Male and female subjects between the ages of 18 and 65\n- Good general health\n- No significant illnesses other than the complications of diabetes mellitus\n- Subjects with ischemic heart disease and/or peripheral artery disease are eligible for arm 1 of the protocol\n- Serum creatinine < 2.5\n- For diabetic subjects, blood pressure less than or equal to 170/95\n- Not discontinuing medication for the study\n\nThe patient is 25 years old, which meets the age requirement, and has type 1 diabetes, which is one of the conditions the study is examining. Additionally, the patient does not need to discontinue his medication for the trial, which aligns with the study's aim.\n\nHowever, the patient has been diagnosed with cardiomyopathy and is under treatment with ACE inhibitors and Beta blockers. The inclusion criteria explicitly allow for subjects with ischemic heart disease and/or peripheral artery disease to be eligible for arm 1 of the protocol. While cardiomyopathy is not the same as ischemic heart disease or peripheral artery disease, the inclusion criteria do not specifically exclude individuals with cardiomyopathy.\n\nBased on the available information, and assuming the patient's serum creatinine is < 2.5 and his blood pressure is within the specified limits, the patient seems to meet the inclusion criteria for the study.\n\nNevertheless, we do not have information about the patient's blood pressure, serum creatinine level, or whether he has any other exclusion criteria such as significant organ malfunction or other serious illnesses. Therefore, without complete information, a definitive assessment cannot be made.\n\nConsidering the information provided, and assuming no other exclusion criteria are met, the patient appears to be potentially eligible for the study. However, due to incomplete information regarding certain health metrics that are critical for the inclusion criteria, the most appropriate eligibility determination would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1989": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes. He is currently experiencing cardiomyopathy and is being treated with ACE inhibitors and Beta blockers. He also takes 70/30 Insulin and vitamin D supplements. The patient's lab study results are given, but there is no mention of chronic kidney disease or the stage of kidney function, which is important for the trial's inclusion criteria.\n\nThe clinical trial in question is studying the use of Niaspan\u00ae for the treatment of dyslipidemia in diabetic nephropathy.\n\nThe inclusion criteria for the clinical trial are:\n1. Diagnosis of type 2 diabetes\n2. Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min using the MDRD formula\n3. Presence of microalbuminuria or proteinuria less than 3.5 g/d\n4. Diagnosis of hyperlipidemia currently treated with a statin drug\n\nThe patient does not meet the trial's inclusion criteria because:\n- The patient has type 1 diabetes, not type 2 diabetes as required by the trial.\n- There is no information provided about the patient having chronic kidney disease, nor is there any mention of the patient's GFR or the presence of microalbuminuria or proteinuria.\n- The patient is not currently being treated with a statin drug for hyperlipidemia; instead, the patient's lipid profile is provided without any indication of ongoing statin treatment.\n\nGiven this information, the patient is not eligible for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1990": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Niacin Plus Statin to Prevent Vascular Events,\" we must compare the patient's characteristics and medical details to the trial's inclusion criteria.\n\nInclusion Criteria for the Trial:\n1. Men and women aged 45 and older\n2. With established vascular disease and atherogenic dyslipidemia\n3. Established vascular disease defined as one or more of the following: documented coronary artery disease (CAD), documented cerebrovascular or carotid disease, documented symptomatic peripheral arterial disease (PAD)\n4. Atherogenic dyslipidemia defined as:\n   - LDL-C of less than or equal to 160 mg/dL\n   - HDL-C of less than or equal to 40 mg/dL for men or less than or equal to 50 mg/dL for women\n   - TG greater than or equal to 150 mg/dL and less than or equal to 400 mg/dL\n5. For patients on a statin:\n   - Adjusted limits for LDL-C according to the statin and dose\n   - HDL-C of less than or equal to 42 mg/dL for men or less than or equal to 53 mg/dL for women\n   - TG greater than or equal to 125 mg/dL and less than or equal to 400 mg/DL\n\nPatient Details:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes.\n- He presents with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers.\n- Lab values:\n  - LDL: 125 mg/dL\n  - HDL: 40 mg/dL\n  - TG: 140 mg/dL\n\nComparison:\n- Age: The patient is 25 years old, which does not meet the age criterion of 45 years and older.\n- Vascular disease: The patient has cardiomyopathy, which is not listed as one of the vascular diseases specified in the inclusion criteria (CAD, cerebrovascular/carotid disease, PAD).\n- Dyslipidemia: Although the patient has an HDL-C and TG level that would fit the atherogenic dyslipidemia definition, the patient does not have an established vascular disease as defined by the trial.\n\nBased on this information, the patient does not meet the age requirement and does not have a qualifying established vascular disease as per the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1991": {
        "output": "The provided patient note describes a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue during activities. He is diagnosed with cardiomyopathy and is in the New York Heart Association (NYHA) class 2, indicating mild symptoms and slight limitation during ordinary activity. The clinical trial in question is seeking patients with severe congestive heart failure in patients with nonischemic cardiomyopathy. The inclusion criteria for the trial are:\n\n1. New York Heart Association (NYHA) Functional class \u2162 or \u2163\n2. Left Ventricular Ejection Fraction (LVEF) <35%\n3. Nonischemic cardiomyopathy\n4. Preserved renal function: Cr \u22642.5 mg/dL in males; Cr \u22642.0mg/dL in females\n\nThe patient does have nonischemic cardiomyopathy, which aligns with one of the trial's criteria. However, the patient is in NYHA class 2, not class \u2162 or \u2163, indicating less severe symptoms than the trial is targeting. Additionally, the patient note does not provide information on the patient's Left Ventricular Ejection Fraction (LVEF) or renal function (Creatinine levels), which are necessary to determine eligibility.\n\nGiven this information, the patient does not meet all of the inclusion criteria provided for the clinical trial. The key missing information is the severity of the cardiomyopathy (NYHA class and LVEF level) as well as the renal function. Therefore, the patient cannot be considered eligible for the trial as defined by the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1992": {
        "output": "Based on the information provided, the patient in the note has been diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers for this condition. The clinical trial in question is seeking to recruit individuals with a new diagnosis of heart failure to observe mortality and hospitalization rates, as well as the psychological impact of the condition.\n\nThe inclusion criteria for the clinical trial simply states that participants must have a \"Clinical diagnosis of heart failure.\"\n\nThe patient has been diagnosed with cardiomyopathy, which is a type of heart disease that can lead to heart failure. However, the patient note does not explicitly state that the patient has been diagnosed with heart failure. Without a clear diagnosis of heart failure, we cannot ascertain that the patient's condition meets the specific inclusion criteria for the clinical trial. The information provided in the patient note might suggest the patient is at risk for or could potentially develop heart failure, but it doesn't confirm a diagnosis of heart failure.\n\nTherefore, based on the information given, the patient does not meet the inclusion criteria due to the lack of a specified diagnosis of heart failure. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1993": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Non-smoker status is not mentioned\n- Lung function is not specifically mentioned, but no respiratory issues are noted except mild dyspnea on exertion which appears related to his cardiomyopathy rather than intrinsic lung disease\n- Currently diagnosed with cardiomyopathy and prescribed ACE inhibitors and Beta blockers\n\nClinical Trial Inclusion Criteria:\n- Type 1 diabetes (Patient has this condition)\n- Non-smoker (Smoking status of the patient is not mentioned)\n- Normal lung function (There is no mention of abnormal lung function, but no specific tests confirming normal lung function are noted)\n\nGiven the information provided, the patient has Type 1 diabetes, which meets one of the inclusion criteria. However, the patient's smoking status and lung function status are not explicitly stated. Without this information, we cannot conclusively determine if the patient meets all inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1994": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Chromium Picolinate for the Treatment of Metabolic Syndrome,\" we need to compare the patient's medical information with the inclusion criteria of the trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Meet at least two of the following criteria for diagnosis of metabolic syndrome:\n   a) Systolic blood pressure higher than 130 mmHg or diastolic blood pressure higher than 85 mmHg in untreated patients OR use of more than one approved antihypertensive agent;\n   b) Fasting glucose higher than 110 mg/dL;\n   c) Fasting triglycerides higher than 150 mg/dL;\n   d) High-density lipoprotein (HDL) less than 40 mg/dL for men and less than 50 mg/dL for women.\n2. Abdominal obesity defined by a waist circumference higher than 40 inches for men and 35 inches for women.\n\nThe patient's note provides the following relevant medical information:\n- Fasting Blood Sugar (FBS): 100 mg/dL\n- Triglycerides (TG): 140 mg/dL\n- High-density lipoprotein (HDL): 40 mg/dL\n- No mention of blood pressure or waist circumference.\n- The patient has type 1 diabetes and cardiomyopathy, but these conditions are not part of the inclusion criteria for the trial.\n\nAs per the provided patient note:\n- The patient's fasting glucose level is below the threshold for metabolic syndrome.\n- The patient's fasting triglycerides are below the threshold for metabolic syndrome.\n- The patient's HDL level meets the criterion for metabolic syndrome in men.\n- There is no information on blood pressure or waist circumference.\n\nSince the patient only meets one of the criteria for metabolic syndrome (HDL level), and there is insufficient information to determine if the patient meets any other criteria (such as blood pressure or waist circumference), the patient does not currently qualify for the trial based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1995": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided inclusion criteria.\n\nThe patient is a 25-year-old man with type 1 diabetes. According to the trial inclusion criteria, diabetes is considered a CAD risk equivalent. This qualifies the patient under the first set of criteria for those who have CAD or CAD risk equivalent.\n\nThe inclusion criteria state that the patient with CAD or CAD risk equivalent must have at least one of the following: \n- SBP \u2265 130 mmHg\n- DBP \u2265 80 mmHg\n- LDL \u2265 100 mg/dL\n- HDL \u2264 40 mg/dL\n- TG \u2265 150 mg/dL\n- FBS \u2265 126 mg/dL\n- BMI \u2265 30\n- Current smoker\n\nThe patient's lab results are:\n- FBS: 100 mg/dL (does not meet the criterion)\n- HbA1c: 6.5% (not mentioned in the criteria)\n- Cholesterol: 190 mg/dL (not mentioned in the criteria)\n- TG: 140 mg/dL (does not meet the criterion)\n- LDL: 125 mg/dL (meets the criterion)\n- HDL: 40 mg/dL (meets the criterion, borderline)\n\nThe patient's LDL and HDL levels meet the specified criteria (LDL \u2265 100 mg/dL and HDL \u2264 40 mg/dL). The patient's blood pressure is not provided, so we cannot assess those criteria. The patient's BMI is not mentioned, and there is no indication that he is a current smoker.\n\nBased on the provided information, the patient has diabetes, which is a CAD risk equivalent, and meets the lipid criteria (LDL and HDL levels). Therefore, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1996": {
        "output": "The patient is a 25-year-old man who presents with shortness of breath and fatigue during activities, consistent with NYHA class 2 symptoms. He has been diagnosed with cardiomyopathy and is set to be treated with ACE inhibitors and Beta blockers. The clinical trial in question is interested in patients presenting with acute dyspnea and aims to investigate the utility of BNP in diagnosing heart failure as a cause of acute dyspnea in private practice.\n\nThe inclusion criteria for the clinical trial are:\n- Acute dyspnea is the main symptom\n\nThe patient note confirms that the patient is experiencing dyspnea that worsens with activity, which qualifies as acute dyspnea. Since this symptom aligns with the inclusion criteria and there are no other specified criteria or exclusion details provided in the trial information, the patient appears to be eligible for the trial based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1997": {
        "output": "The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. The clinical trial in question is looking for individuals with certain HLA genotypes that increase the risk of type 1 diabetes. However, there is no information provided in the patient's history regarding their HLA genotype. Therefore, we do not have sufficient information to determine the patient's eligibility for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1998": {
        "output": "",
        "label": 0
    },
    "1999": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nInclusion criteria for the clinical trial:\n- Patients presenting to the Emergency Department (ED) with shortness of breath.\n- Age over 40 years old.\n- Emergency department triage category of 3 or higher.\n\nPatient's characteristics:\n- 25-year-old man.\n- Presents with shortness of breath and fatigue during activities.\n- Diagnosed with cardiomyopathy.\n- No mention of presenting to the Emergency Department or the triage category.\n\nThe patient's age (25 years old) does not meet the inclusion criteria for age (over 40 years old). Therefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2000": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 25-year-old man with type 1 diabetes, which aligns with the trial's focus on patients with type 1 diabetes mellitus. However, the inclusion criteria specify that participants should be pediatric patients with type 1 diabetes.\n\nGiven that the age of the patient is 25, they do not fall under the pediatric category, which generally includes individuals under the age of 18. Because the patient does not meet the age-specific criteria for pediatric patients, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2001": {
        "output": "",
        "label": 0
    },
    "2002": {
        "output": "Based on the patient note provided:\n\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. The patient is being treated with ACE inhibitors and Beta blockers for cardiomyopathy and is currently on insulin therapy. There's no mention of complications due to diabetes such as reduced awareness of hypoglycemia, metabolic lability/instability, or progressive secondary complications like retinopathy, neuropathy, or nephropathy. The lab study results provided do not indicate any of these complications.\n\nNow, reviewing the clinical trial's inclusion criteria:\n\n- The patient must have Type 1 diabetes mellitus for more than 5 years (the patient has had Type 1 diabetes for 7 years, so this criterion is met).\n- The diabetes must be complicated by at least one of the following situations that persist despite intensive insulin management efforts:\n  1. Reduced awareness of hypoglycemia: There's no information provided about this.\n  2. Metabolic lability/instability: There's no information indicating that the patient has MAGE \u2265 11.0 mmol/L or wide swings in blood glucose despite optimal diabetes therapy.\n  3. Progressive secondary complications of diabetes, including retinopathy, neuropathy, or nephropathy: There's no information indicating that the patient has any of these complications.\n\nGiven the information in the patient note, we do not have enough evidence to confirm that the patient meets all the inclusion criteria, specifically the complications required by the trial. Therefore, based on the available information, the patient does not meet the necessary criteria to be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2003": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. His lipid profile is as follows:\n\n- LDL-C: 125 mg/dL\n- HDL-C: 40 mg/dL\n\nThe clinical trial in question is studying the combined effects of Slo-Niacin and Atorvastatin on lipoproteins and inflammatory markers in hyperlipidemia. The inclusion criteria for the trial are:\n\n- LDL-C > 130 mg/dL\n- HDL-C <= 45 mg/dL in men\n\nThe patient's LDL-C level is 125 mg/dL, which is below the inclusion criterion of LDL-C > 130 mg/dL. His HDL-C level is 40 mg/dL, which meets the inclusion criterion of HDL-C <= 45 mg/dL in men. \n\nHowever, since the patient does not meet all of the inclusion criteria due to the LDL-C level being below the threshold required for the trial, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2004": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Exercise to Improve Sleep in Heart Failure,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 25-year-old man.\n- Diagnosed with cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers.\n- The patient has type 1 diabetes.\n- He experiences mild dyspnea after climbing 3 floors (NYHA Class II).\n- No dyspnea at rest and no angina.\n- No other significant medical history.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must be classified as having NYHA Class II or III heart failure.\n- Patients must have had at least one clinical episode of HF diagnosed by a physician.\n- Patients must have stable heart failure as defined by the trial.\n\nComparison:\n- The patient is diagnosed with cardiomyopathy, which can be a cause of heart failure. However, the note does not specifically state that the patient has been diagnosed with heart failure (HF).\n- The patient experiences dyspnea with exertion (NYHA Class II), which aligns with one of the inclusion criteria.\n- There is no explicit mention of a clinical episode of HF diagnosed by a physician.\n- The stability of the patient's condition regarding heart failure is not mentioned, and we have no information on hospitalizations, medication changes, or resting heart rate.\n\nGiven the information, the patient does appear to have NYHA Class II symptoms, which is part of the inclusion criteria. However, without confirmation of a heart failure diagnosis and evidence of stable HF, we do not have sufficient information to definitively assess eligibility.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2005": {
        "output": "To determine whether the patient is eligible for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the study.\n\nPatient's characteristics and condition:\n- 25-year-old man\n- Diagnosed with type 1 diabetes 7 years ago\n- Presents with cardiomyopathy\n- Currently treated with ACE inhibitors and Beta blockers\n- Taking 70/30 Insulin and vitamin D supplements\n- No mention of type 2 diabetes (T2DM)\n- HbA1c: 6.5%\n\nClinical trial inclusion criteria:\n- Subjects with T2DM\n- HbA1c \u2265 8.0% and \u2264 10.0% or specific criteria if HbA1c is between 7.8% and 8.0%\n- FPG level < 270 mg/dL\n- Treatment with diet/exercise or metformin monotherapy under specific conditions\n- Excludes TZDs and insulin in the 3 months prior to the Screening visit\n- Age 18 to 70 years\n- BMI: \u226525 and \u226440 kg/m\u00b2 and weigh at least 50 kg at Screening\n- If a smoker, must be able to abstain while in clinic\n- Written informed consent provided\n\nExclusion criteria: Not provided, but not relevant since the patient does not meet the inclusion criteria.\n\nAssessment of eligibility:\n- The patient has type 1 diabetes, not T2DM as required by the study.\n- The patient's HbA1c level is 6.5%, which is below the required range for the trial.\n- The patient is currently taking insulin, which is an exclusion for this trial if taken within 3 months prior to the screening visit.\n\nBased on the above points, the patient does not meet the inclusion criteria for the clinical trial focused on individuals with T2DM because he has type 1 diabetes, his HbA1c level is not within the required range, and he is taking insulin.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2006": {
        "output": "",
        "label": 0
    },
    "2007": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Information:\n- 25-year-old man\n- Type 1 diabetes diagnosed 7 years ago\n- Experiencing shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Currently taking insulin and vitamin D supplements\n- No other significant medical issues\n- Family history of Type 1 diabetes\n- Laboratory values provided (HbA1c: 6.5%)\n\nClinical Trial Inclusion Criteria:\n- Age >12 years < 19 years\n- Have diabetes for at least 2 years and in good control (HbA1C < 8%).\n- Be on continuous subcutaneous insulin infusion using an insulin pump.\n- Subjects must be otherwise healthy except for their T1DM and treated for hypothyroidism.\n- Menstruating women must have negative pregnancy test.\n- Hemoglobin equal to or > than 12 g/dL before each study.\n- Weight more than 44 kg.\n\nAssessment:\n- The patient is 25 years old, which is outside the age range of >12 years < 19 years specified in the trial's inclusion criteria.\n- The patient has had diabetes for over 2 years and appears to have good control of it (HbA1c < 8%).\n- It is not specified if the patient is using an insulin pump for continuous subcutaneous insulin infusion.\n- The patient is otherwise healthy with the exception of Type 1 diabetes, though there is no information on hypothyroidism or treatment for it.\n- The patient is not a menstruating woman, so the pregnancy test criterion is not applicable.\n- There is no information on the patient's hemoglobin level or weight.\n\nThe key exclusionary factor here is the patient's age, which does not fit within the specified range for the clinical trial. Therefore, despite the patient having Type 1 diabetes and being in good control of his blood sugar levels, he is not eligible for this trial based on the age criterion alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2008": {
        "output": "",
        "label": 0
    },
    "2009": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Lantus in the Treatment of Type 1 Diabetes Children,\" let's consider the eligibility factors:\n\n1. Age: The patient is 25 years old, which is outside the specified age range of greater than 6 years but less than 25 years of age. - Not met\n2. Diagnosis: The patient has been confirmed with type 1 diabetes (T1DM), which aligns with the trial's target patient population. - Met\n3. Time since diagnosis: The patient was diagnosed with diabetes 7 years ago, which exceeds the trial's requirement for patients to be newly diagnosed within the past 3 months. - Not met\n4. HbA1c levels: The patient's HbA1c is 6.5%, which is below the 9.0% maximum specified by the trial. - Met\n5. BMI: There is no information about the patient's BMI, so we cannot assess this criterion. - Not met due to lack of information\n6. Willingness to participate: There is no information about the patient's willingness to participate in the study. - Not met due to lack of information\n\nGiven the above points, the patient does not meet the age criterion and the time since T1DM diagnosis criterion required by the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2010": {
        "output": "",
        "label": 1
    },
    "2011": {
        "output": "",
        "label": 0
    },
    "2012": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's evaluate the patient's eligibility for the trial.\n\nPatient information:\n- 25-year-old man\n- Type 1 diabetes diagnosed 7 years ago\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Currently taking 70/30 Insulin and vitamin D supplements\n- Family history of type 1 diabetes\n- Laboratory values provided (FBS: 100 mg/dl, HbA1c: 6.5%, Cholesterol: 190 mg/dl, TG: 140 mg/dl, LDL: 125 mg/dl, HDL: 40 mg/dl)\n\nClinical trial inclusion criteria:\n- Men and women, all ethnic groups, 18 years of age and older\n- Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and 2 hr glucose of 140-199 mg/dl)\n- At least one of the following risk factors:\n  - Components of the insulin resistance syndrome (specific criteria for HDL, triglycerides, blood pressure, BMI, waist circumference)\n  - One or more first degree relatives with type 2 diabetes\n  - History of gestational diabetes\n  - Polycystic ovarian disease\n  - Minority ethnic background\n\nThe patient is a 25-year-old man, which fits the age criteria of the trial. However, the patient has type 1 diabetes, not impaired glucose tolerance nor type 2 diabetes. The trial specifically aims to reduce the conversion rate of impaired glucose tolerance to type 2 diabetes mellitus, which does not apply to this patient who already has type 1 diabetes. Furthermore, the trial focuses on individuals with a background of insulin resistance syndrome or a family history of type 2 diabetes, which is different from type 1 diabetes that the patient has. While the patient does meet the HDL criteria, the presence of type 1 diabetes excludes him from the trial as he does not have impaired glucose tolerance nor is at risk for type 2 diabetes.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2013": {
        "output": "The patient is a 25-year-old man with a confirmed diagnosis of type 1 diabetes for 7 years, which exceeds the 5-year duration specified in the inclusion criteria of the clinical trial. Additionally, the patient is currently being treated with insulin (70/30 Insulin), not sulfonylurea (SU) agents. Since both the duration of diabetes and the current treatment do not match the trial's inclusion criteria, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2014": {
        "output": "",
        "label": 0
    },
    "2015": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Reducing Total Cardiovascular Risk in an Urban Community,\" we need to compare the patient's characteristics and conditions with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes (confirmed with molecular analysis 7 years ago)\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Currently taking 70/30 Insulin and vitamin D supplements\n- No other significant past medical history\n- Family history of DM type 1\n- Lab values provided\n\nClinical Trial Inclusion Criteria:\n- Currently receiving medical care at Johns Hopkins University\n- African American or Caucasian with diagnosed CVD or type 2 diabetes not receiving any therapy\n- LDL-C criteria and blood pressure criteria\n- HbA1c criteria for diabetics\n\nClinical Trial Exclusion Criteria:\n- Life-threatening noncardiac comorbidity with a life expectancy of less than 5 years\n- Serious psychiatric morbidity\n- Neurological impairment interfering with the study\n\nBased on the provided information, the patient does not meet the inclusion criteria for the following reasons:\n- The patient has type 1 diabetes, not type 2 diabetes as specified in the inclusion criteria.\n- There is no indication that the patient is receiving medical care at Johns Hopkins University.\n- The patient's HbA1c level is 6.5%, which does not meet the criterion of 7% or greater for diabetic patients.\n- The patient's ethnicity is not specified, so we cannot determine eligibility based on this criterion.\n\nGiven that the patient does not meet the inclusion criteria, we do not need to assess the exclusion criteria further.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2016": {
        "output": "",
        "label": 0
    },
    "2017": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy\n- No mention of diabetic nephropathy or urinary albumin-to-creatinine ratio\n- No serum creatinine level provided\n\nClinical trial inclusion criteria:\n- Patients with type 2 diabetes\n- Urinary albumin-to-creatinine ratio >=300 mg/g creatinine twice in the first morning urine sample\n- Serum creatinine level <=2.5 mg/dl\n- Patients aged 20-75 years\n\nThe patient in question has type 1 diabetes, not type 2 diabetes as required by the clinical trial. Additionally, there is no information provided about the patient's urinary albumin-to-creatinine ratio or serum creatinine level.\n\nBased on this information, the patient does not meet the inclusion criteria for type 2 diabetes and lacks the necessary lab values to determine eligibility for the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2018": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and cardiomyopathy, currently being treated with ACE inhibitors and Beta blockers. He does not have a history of kidney disease or nephrotic syndrome, nor is he participating in any NIH trials for glomerular disease.\n\nLooking at the clinical trial inclusion criteria:\n\n- For the CKD PROGRESSION STUDY, the patient must have a renal biopsy diagnosis of glomerular disease or interstitial nephritis or clinical diagnosis of diabetic nephropathy, and mild or moderate renal insufficiency (eGFR less than 60 but greater than 30 ml/min/1.73m(2)). This study does not apply to the patient as there is no indication of kidney disease or renal insufficiency in his medical note.\n\n- For the ANGIOTENSIN ANTAGONISM STUDY, the patient must be an adult over 18 years old with Type 1 or Type 2 diabetes, urinary albumin/creatinine ratio greater than 30 mg/g, and estimated GFR greater than 30 mL/min/1.73m(2). However, there is no information about the patient's urinary albumin/creatinine ratio or estimated GFR. Moreover, the patient is currently on ACE inhibitors, which is part of the study's interventions, but there is no evidence of diabetic nephropathy or macroproteinuria/microalbuminuria.\n\n- The SEX DIFFERENCES IN URINARY EXOSOME PROTEINS and SALT INTAKE AND BLOOD PRESSURE RESPONSES IN URINARY EXOSOMES studies do not apply as they have specific inclusion criteria that do not match the patient's information (e.g., age range, BMI, and blood pressure specifications).\n\nGiven the available information and the lack of indication that the patient has kidney disease or any criteria mentioned for the kidney disease studies, the patient does not meet the inclusion criteria for any of the studies described.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2019": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue during activities, which has been diagnosed as cardiomyopathy. He does not fit the criteria for the trial, which specifically lists acute shortness of breath of unknown etiology or possible acute exacerbation of known heart failure. Since the patient's shortness of breath is associated with a diagnosis of cardiomyopathy and not of unknown etiology or related to an exacerbation of known heart failure, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2020": {
        "output": "",
        "label": 1
    },
    "2021": {
        "output": "",
        "label": 0
    },
    "2022": {
        "output": "In reviewing the patient's eligibility for the clinical trial titled \"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024),\" we need to compare the patient's characteristics and lab results to the trial's inclusion criteria:\n\nThe trial's inclusion criteria are:\n- Participant 18 to 80 years of age\n- With Mixed Hyperlipidemia\n- LDL-C between 130 and 190 mg/dL\n- Triglycerides between 150 and 500 mg/dL\n\nThe patient's characteristics and lab results are:\n- 25-year-old man\n- Diagnosed with type 1 diabetes\n- LDL: 125 mg/dL\n- TG: 140 mg/dL\n\nThe patient is within the age range required for the trial (18 to 80 years). However, the patient's LDL-C and triglyceride levels do not meet the specified criteria for the study. The patient's LDL-C is slightly below the required range of 130 to 190 mg/dL, and triglycerides are also below the required range of 150 to 500 mg/dL.\n\nSince the patient does not meet all of the lipid level criteria for the study, he is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2023": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria provided for the clinical trial, \"Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure.\"\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy\n- Treatment plan includes ACE inhibitors and Beta blockers\n- No other significant past medical history\n\nClinical Trial Inclusion Criteria:\n- Male or non-pregnant female\n- Age \u2265 18 years\n- Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent with diagnosis of diastolic heart failure, following optimized medical therapy including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks or over\n- Echocardiographic evidence of preserved left ventricular systolic function (LVEF \u2265 45%) and evidence of diastolic dysfunction\n- Signed informed consent\n\nComparison:\n- The patient is male, fitting the gender requirement.\n- The patient is 25 years old, which meets the age criterion of being 18 years or older.\n- The patient presents with symptoms of heart failure (dyspnea and fatigue), consistent with the trial requirement.\n- The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers, which aligns with the trial's inclusion criteria regarding optimized medical therapy for heart failure.\n- However, there is no information provided on the patient's left ventricular ejection fraction (LVEF) or specific echocardiographic evidence of diastolic dysfunction.\n\nGiven the information provided, the patient appears to meet several of the inclusion criteria for the trial. However, the lack of detailed echocardiographic results means we do not have sufficient information to confirm eligibility based on the trial's specific requirements for evidence of diastolic dysfunction and LVEF. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2024": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the study. Let's assess the patient's eligibility based on the provided inclusion criteria:\n\n1. Age \u2265 18 years: The patient is 25 years old, which meets this criterion.\n2. Male or female participants: The patient is male and thus meets this criterion.\n3. LDL-C level greater than the NCEP goals: The patient has an LDL level of 125 mg/dl, which is above the <100 mg/dL goal for those at risk of coronary heart disease.\n4. Risk category for coronary heart disease with LDL goal of < 100 mg/dL: The patient has not been explicitly stated to be at risk for coronary heart disease. However, he has been diagnosed with cardiomyopathy, which could potentially place him in a higher risk category. This information is not sufficient to confirm his risk category.\n5. Baseline lipid criteria: The patient's LDL-C level is 125 mg/dl, which is within the range of 100 to 160 mg/dL. His triglyceride level is 140 mg/dl, within the range of 100 to 500 mg/dL, meeting this criterion.\n6. Normal thyroid function tests: There is no information regarding the patient's thyroid function tests.\n7. Hemoglobin A1C < 8.5%: The patient's HbA1c is 6.5%, which meets this criterion.\n8. On stable lipid modification pharmacotherapy for at least 2 weeks: The patient has not been reported to be on any lipid-modifying pharmacotherapy, such as statins, so this criterion is not met.\n9. Able to give informed consent: There is no information suggesting the patient is unable to give informed consent.\n\nBased on the information provided, the patient meets several of the inclusion criteria. However, there are a few critical pieces of information missing, such as thyroid function tests, his risk category for coronary heart disease, and whether he is on stable lipid-modifying pharmacotherapy. Without this information, we cannot conclusively say that he is eligible for the trial. Therefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2025": {
        "output": "To determine the eligibility of the patient for the clinical trial based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare them point by point.\n\nPatient's characteristics:\n- Age: 25 years old (meets the criterion of 18 to 50 years old)\n- BMI and body weight: Not specified in the patient note\n- Blood pressure: Not provided in the patient note\n- Type 1 DM: Confirmed, patient has type 1 diabetes\n- Duration of diabetes: Diagnosed 7 years ago, which satisfies the criterion of a minimum of 12 months\n- General health: The patient appears to be in good general health with no evidence or history of clinically significant diseases as specified, except for the newly diagnosed cardiomyopathy\n- Hematocrit (Hct): Not provided in the patient note\n- Liver function tests (ALT, AST, and Alk Phos): Not provided in the patient note\n- Thyroid function (sTSH): Not provided in the patient note\n- Fasting glucose: 100 mg/dl (meets the criterion of 100-160 mg/dl)\n- HbA1c: 6.5% (meets the criterion of < 7.5%)\n- Lipid profile (Triglycerides and Cholesterol): TG: 140 mg/dl (meets the criterion of < 175), Cholesterol: 190 mg/dl (meets the criterion of < 275)\n\nBased on the available information, the patient appears to meet several of the inclusion criteria: age, type 1 diabetes diagnosis, duration of diabetes, fasting glucose level, HbA1c level, triglycerides, and cholesterol. However, the following information is not provided and is necessary to fully determine eligibility:\n\n- BMI and total body weight\n- Blood pressure\n- Hematocrit level\n- Liver function tests (ALT, AST, Alk Phos)\n- Thyroid function (sTSH)\n\nAdditionally, the patient has been diagnosed with cardiomyopathy, which is a cardiovascular condition that may exclude the patient from the trial, as per the criterion of no history of clinically significant cardiovascular disease.\n\nGiven the lack of information on some inclusion criteria and the presence of a potentially disqualifying condition (cardiomyopathy), the patient's trial-level eligibility cannot be confirmed as eligible. Therefore, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2026": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes who presents with cardiomyopathy. He is not currently described as a critically ill patient requiring an ICU stay, nor is there any mention of acute renal failure or an ICU stay exceeding 48 hours, which are part of the inclusion criteria for the clinical trial.\n\nGiven the information in the patient note, we do not have sufficient evidence to qualify the patient for the trial focused on angiotensin-converting enzyme gene polymorphism in critically ill patients with a risk of acute renal failure.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2027": {
        "output": "Upon reviewing the patient's information provided in the note and the inclusion criteria for the clinical trial on the use of ACE inhibitors and the prevention of contrast-induced nephropathy (CIN) in patients receiving a cardiac catheterization, we can determine the trial-level eligibility as follows:\n\n- The patient is a 25-year-old man with type 1 diabetes and newly diagnosed cardiomyopathy. He is to be treated with ACE inhibitors, which is one of the drugs of interest in the trial.\n- The inclusion criteria for the trial require that the patient is scheduled for angiography in >= 24 hours from enrollment.\n- The inclusion criteria also specify that the patient must have a documented creatinine (Cr) level >= 150 within 3 months before cardiac catheterization OR documented Cr >= 132 umol/L within 1 week before cardiac catheterization.\n\nBased on the patient note provided:\n\n- The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors, which aligns with the interest of the study.\n- However, there is no mention of the patient being scheduled for an angiography or documented creatinine levels, which are critical to determining the risk of CIN and eligibility for the trial.\n\nGiven the lack of information on two key inclusion criteria (scheduled angiography and documented creatinine levels), we cannot confirm that the patient meets all the necessary requirements for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2028": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion and exclusion criteria, we can determine the patient's eligibility for the trial.\n\nPatient Information:\n- 25-year-old man with type 1 diabetes\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, treated with ACE inhibitors and Beta blockers\n- No other significant medical history\n- Family history of DM type 1\n- Lab values provided, including cholesterol levels\n\nClinical Trial Inclusion Criteria:\n- Any adult patient with carotid artery disease or known atherosclerosis capable of giving informed consent\n- Adults with normal total cholesterol (<200 mg/dl) and blood pressure (systolic <140 and diastolic <90) for medication-treated subjects\n- Healthy adults with no history of peripheral or coronary artery disease, eligible for bronchoalveolar lavage per Protocol 99-H-0068 for normal bronchoscopy subjects\n\nClinical Trial Exclusion Criteria:\n- Unable to give consent\n- History of chronic infections, vasculitis, or any other inflammatory disease\n- History of neoplastic disease or chemotherapy treatment\n- Immunosuppressive medications other than over-the-counter drugs like aspirin or acetaminophen\n- Abnormal liver and renal function tests on pretreatment screening or currently taking a statin or ACE inhibitor medication for medication-treated subjects\n- Any exclusion criteria for normal subjects listed in Protocol 99-H-0068 for normal bronchoscopy subjects\n\nThe patient's cholesterol level is above the normal total cholesterol level required by the trial (190 mg/dl vs. <200 mg/dl). However, the patient is currently taking an ACE inhibitor medication for cardiomyopathy treatment. According to the exclusion criteria for medication-treated subjects, patients currently taking ACE inhibitor medication are excluded.\n\nBased on this information, we can conclude that the patient does not meet the inclusion criteria of having normal total cholesterol levels and is excluded based on the current use of ACE inhibitor medication.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2029": {
        "output": "In assessing the eligibility of the patient for the clinical trial titled \"Causes and Natural History of Dyslipidemias,\" we will compare the patient's characteristics and clinical findings with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- Age: 25 years old\n- Diagnosed with type 1 diabetes and cardiomyopathy\n- Lipid levels:\n  - Total cholesterol: 190 mg/dl\n  - LDL (Low-density lipoprotein): 125 mg/dl\n  - HDL (High-density lipoprotein): 40 mg/dl\n  - Triglycerides (TG): 140 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Children >= 2 years of age and >12 kg and adults\n- Dyslipidemia subjects of interest the group\n- Representative types of patients include those with:\n  - Plasma cholesterol levels >200 mg/dl or <120 mg/dl\n  - Plasma LDL-C levels >130 mg/dl or <70 mg/dl\n  - Plasma HDL-C levels >70 mg/dl or <25 mg/dl\n  - Plasma triglyceride levels >150 mg/dl\n\nThe patient is 25 years old, which makes him an adult, and he has type 1 diabetes and cardiomyopathy. His total cholesterol level is 190 mg/dl, which does not meet the criteria for inclusion based on the cholesterol levels (>200 mg/dl or <120 mg/dl). His LDL level is 125 mg/dl, which is below the threshold for inclusion (>130 mg/dl or <70 mg/dl). The HDL level of 40 mg/dl is also outside the specified range for inclusion (>70 mg/dl or <25 mg/dl). Lastly, the triglyceride level of 140 mg/dl does not meet the requirement of >150 mg/dl for inclusion in the study.\n\nBased on the information provided, the patient does not meet the lipid level criteria necessary for inclusion in the clinical trial for dyslipidemias. Therefore, the patient is not eligible for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2030": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf),\" we need to compare the patient's characteristics and condition with the inclusion criteria provided for the trial.\n\nHere are the key inclusion criteria for the trial:\n1. Subjects with heart failure NYHA Class II or III.\n2. Appropriate medical therapy for heart failure for at least three months prior to the baseline evaluation.\n3. On stable medications maximized to the subject's tolerance of ACE or ARB and beta blockers for at least 30 days prior to baseline evaluation.\n4. At least one heart failure-related hospitalization or emergency department/urgent care visit necessitating intravenous therapy within 12 months prior to the baseline evaluation.\n5. For Chronicle ICD: Risk of having a fast heartbeat and a need for an ICD.\n\nNow let's assess the patient's characteristics:\n- The patient is diagnosed with cardiomyopathy and is NYHA Class II, which fits the inclusion criteria for NYHA Class II heart failure.\n- The patient will be treated with ACE inhibitors and Beta blockers, which align with the appropriate medical therapy requirement.\n- However, the patient has just been diagnosed and there is no indication that they have been on stable medications for at least three months, nor is there any mention of heart failure-related hospitalization or emergency visits within the last 12 months.\n- There is no mention of the patient being at risk of fast heartbeats or needing an ICD.\n\nBased on the information provided, the patient does not meet all the inclusion criteria due to:\n- Lack of documentation of stable medication for the required duration.\n- No evidence of required hospitalization or emergency visits related to heart failure.\n- No mention of the need or risk for an ICD.\n\nTherefore, the patient's trial-level eligibility is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2031": {
        "output": "Given the patient's note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He has shortness of breath and fatigue during activities (NYHA class 2), indicating some level of heart failure.\n- He is diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- His current medication includes 70/30 Insulin and vitamin D supplements.\n- Recently diagnosed, as there's no mention of a long-standing condition or previous heart failure diagnosis.\n- No mention of current use of diuretics.\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of heart failure based on a slight modification of the Framingham criteria within the last 6 months.\n- Current status of heart failure is NYHA II or III.\n- Currently on loop diuretic(s).\n- No change in baseline therapy and symptoms of heart failure within a month.\n\nComparison:\n- The patient has heart failure with a NYHA class of 2, which fits the trial criterion of NYHA II or III.\n- However, the patient is not currently on loop diuretics, which is a requirement for the trial.\n- There is also no mention of a clinical diagnosis of heart failure based on the Framingham criteria within the last 6 months, nor is there information on the stability of the patient's heart failure symptoms or therapy within the past month.\n\nBased on the information available, the patient does not meet all the inclusion criteria for the clinical trial, particularly the requirements for current loop diuretic administration and the stability of therapy and symptoms. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2032": {
        "output": "The patient in the given note is a 25-year-old man with a diagnosis of type 1 diabetes and cardiomyopathy. He is currently being treated with ACE inhibitors and Beta blockers. According to the New York Heart Association classification, he is class 2, which indicates mild symptoms (mild dyspnea after climbing 3 floors, no dyspnea at rest, and no angina).\n\nNow, let's compare this patient's information with the inclusion criteria for the clinical trial titled \"Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure\":\n\n1. The patient must be in New York Heart Association (NYHA) class I or II heart failure: \n   - Our patient is indeed in NYHA class II, which meets this criterion.\n\n2. The patient must be on chronic ACE-inhibitor treatment: \n   - The patient note confirms that the patient is being treated with ACE inhibitors.\n\nGiven this information, the patient appears to meet both of the inclusion criteria for the clinical trial. There are no exclusion criteria provided, so we cannot evaluate whether any exclusion criteria apply to the patient.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2033": {
        "output": "",
        "label": 2
    },
    "2034": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nThe patient in the note is a 25-year-old man diagnosed with cardiomyopathy and type 1 diabetes. This patient does not have a congenital complete heart block, does not have a pacemaker, and there is no indication of structurally normal heart or that his condition was diagnosed by standard electrocardiographic means. Therefore, he does not meet the inclusion criteria for the clinical trial titled \"Exercise in Chronically Paced Children.\"\n\nThe inclusion criteria for the trial are:\n- between 10 and 21 years of age\n- structurally normal heart\n- congenital complete heart block\n- dual chamber pacemaker, right ventricular apex paced\n- normal function via traditional transthoracic echocardiography\n\nThe patient is outside the age range (25 years old), and there is no mention of congenital complete heart block or pacemaker in the patient's note. The patient's diagnosis of cardiomyopathy is being treated with ACE inhibitors and Beta blockers, which is not consistent with the requirement of a structurally normal heart.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2035": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Improving Outcomes in Patients With Kidney Disease Due to Diabetes,\" we need to compare the patient's characteristics and condition with the trial's inclusion criteria. The inclusion criteria for this trial are:\n\n1. Adult male and female subjects aged 20-65 of all ethnic backgrounds.\n2. Type I diabetes mellitus defined as sudden onset of insulin requiring diabetes prior to age 20 and at least 5 years duration.\n3. Type 2 diabetes mellitus defined as onset > 20 years of age and treatment with oral hypoglycemic agent and/or insulin and increased C-peptide level.\n4. Seated SBP > 130 mmHg documented at one screening visit or treated SBP < 130 mmHg with a documented history of SBP > 130 mmHg on more than one previous occasion.\n5. Proteinuria defined as a 24-hour urine albumin/creatinine ratio > 300 mg/g while on an ACE inhibitor with or without non-ARB, non-aldosterone antagonist treatment.\n6. Ongoing treatment (> 3 months) with an ACE inhibitor or ARB with or without additional antihypertensive therapy (e.g. CCB, a-blocker, b-blocker, clonidine).\n\nNow, we will assess the patient's information from the provided note:\n\n1. The patient is a 25-year-old man, which meets the age criteria.\n2. He has type 1 diabetes, which had a sudden onset 7 years ago, meeting the criteria for Type I diabetes mellitus.\n3. There is no mention of the patient's blood pressure (SBP) values, so we cannot confirm if he meets the blood pressure criteria.\n4. There is no information about proteinuria or a 24-hour urine albumin/creatinine ratio, so we cannot confirm if he meets the proteinuria criteria.\n5. The patient is diagnosed with cardiomyopathy and is prescribed ACE inhibitors and Beta blockers, which aligns with ongoing treatment with an ACE inhibitor. However, the duration of the treatment is not specified.\n\nBased on the available information, the patient does not provide sufficient detail to confirm eligibility for all criteria (particularly blood pressure and proteinuria). Therefore, the patient cannot be determined to be eligible without this information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2036": {
        "output": "The patient in the note is a 25-year-old man with type 1 diabetes and is diagnosed with cardiomyopathy. He is currently taking insulin and vitamin D supplements among other medications.\n\nThe clinical trial in question is focused on infants and aims to determine the optimal dosage of dietary vitamin D needed for health in infancy. The inclusion criteria for the trial are very specific: healthy singleton term born infants of appropriate size for gestational age (AGA) according to the CDC growth charts, with weights at birth between the 5th and 95th percentiles for sex; and born to healthy breastfeeding women.\n\nGiven that the clinical trial is designed for infants and the patient is a 25-year-old man, he clearly does not meet the inclusion criteria for this specific study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2037": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes who presents with cardiomyopathy, shortness of breath, and fatigue during activities. He does not have stable tachycardia as defined in the inclusion criteria of the clinical trial, nor is there any indication that he has wide QRS tachycardia or is currently experiencing ventricular tachycardia. Furthermore, the patient's symptoms of dyspnea after climbing 3 floors suggest that his condition may not be hemodynamically well-tolerated, which is a requirement for the trial.\n\nThe inclusion criteria of the trial are:\n1. Patients with stable tachycardia \u2265120 bpm (beats per minute), QRS \u2265120 ms, and hemodynamically well-tolerated.\n2. Systolic blood pressure \u226590 mmHg.\n3. Absence of dyspnea at rest.\n4. Absence of peripheral hypoperfusion signs.\n5. No severe angina.\n6. Age > 18 years.\n7. Written informed consent obtained.\n\nThe patient does not meet the specific criteria related to tachycardia and its hemodynamic tolerance, as there is no mention of tachycardia, QRS duration, or related hemodynamic status in his note. Therefore, the patient does not have sufficient information to qualify for the trial based on the given note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2038": {
        "output": "Based on the provided clinical trial information and the patient note, let's assess the patient's eligibility.\n\nThe inclusion criteria for the Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study are:\n1. Chronic kidney disease (CKD) with a clearance between 15-70 ml/min.\n\nThe exclusion criteria include:\n1. Individuals with diabetes mellitus.\n2. Active vasculitis.\n3. Nephrotic syndrome (>3gr/24hr urine protein).\n4. Renal transplantation.\n5. Fasting total cholesterol > 7 mmol/L.\n6. Cholesterol-lowering therapy within three months prior to inclusion.\n7. Known ischemic cardiac, cerebrovascular or peripheral arterial disease.\n\nThe patient note provides the following relevant information:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He presents with shortness of breath and fatigue, diagnosed with cardiomyopathy.\n- He is being treated with ACE inhibitors and Beta blockers for cardiomyopathy.\n- No mention of chronic kidney disease or renal function.\n\nGiven that the patient has type 1 diabetes, he falls under the exclusion criteria for the study, which explicitly excludes individuals with diabetes mellitus. Therefore, despite not having information about his renal function (CKD), we can determine his eligibility status based on his diabetes diagnosis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2039": {
        "output": "Based on the information provided, the patient in question is a 25-year-old man with type 1 diabetes presenting with symptoms of cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers. His medical history does not indicate Churg-Strauss syndrome, nor does it mention any of the poor-prognosis factors as defined by the five-factor score that would align with the inclusion criteria of the clinical trial titled \"CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors.\"\n\nThe inclusion criteria for the trial specify:\n\n1. Men and women with newly diagnosed Churg-Strauss syndrome;\n2. Absence of poor prognostic factors as defined by the five-factor score;\n3. Written informed consent.\n\nSince the patient does not have a diagnosis of Churg-Strauss syndrome, they do not meet the inclusion criteria for the trial. Therefore, the patient is not relevant for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2040": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs,\" we must compare the patient's characteristics and presenting symptoms with the inclusion criteria provided for the trial.\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy\n\nClinical trial inclusion criteria:\n- Age 18 years or older\n- Acute dyspnea as their most prominent complaint\n\nThe patient is 25 years old, meeting the age criterion of being 18 years or older. Additionally, the patient presents with shortness of breath (dyspnea) as one of his prominent complaints. The trial does not specify the underlying cause of dyspnea as an exclusion criterion, and cardiomyopathy can certainly be associated with symptoms of dyspnea.\n\nSince the patient meets both inclusion criteria of age and presenting with acute dyspnea, he appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2041": {
        "output": "Given the patient note and the clinical trial information, let's review the patient's characteristics against the inclusion criteria of the trial step by step:\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes, not ketosis-prone type 2 diabetes (KPDM)\n- Presents with symptoms of cardiomyopathy, not diabetic ketoacidosis (DKA) or severe hyperglycemia\n- Not described as obese\n- No indication of a recent DKA event or severe hyperglycemia consistent with the trial's definition\n\nClinical trial inclusion criteria:\n- Obese African-American subjects with DKA or severe hyperglycemia\n- Age 19-65\n- BMI \u2265 28 kg/m^2\n- For DKA: plasma glucose > 250 mg/dl, venous pH < 7.30, serum bicarbonate < 18 mEq/l, and high serum ketones\n- For hyperglycemic patients: blood glucose on admission > 400 mg/dl, serum bicarbonate > 18 mEq/l, and negative ketones\n\nAssessment:\n- The patient does not fit the profile for the clinical trial as he is not African-American, not obese, and does not have DKA or severe hyperglycemia as defined by the trial's criteria. Additionally, the patient has Type 1 diabetes, and the trial is looking for patients with ketosis-prone Type 2 diabetes.\n- The patient's diagnosis of cardiomyopathy is not relevant to the trial, which focuses on a different aspect of diabetes.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2042": {
        "output": "To determine the trial-level eligibility, we need to analyze the patient's information against the inclusion criteria of the clinical trial:\n\nInclusion Criteria for the trial:\n1. Body Mass Index (BMI) > 25 kg/m\u00b2\n2. Visceral Fat Area (VFA) > 100 cm\u00b2\n3. Triglycerides (TG) > 150 mg/dL and < 700 mg/dL, and/or HDL-cholesterol < 40 mg/dL (Dyslipidemia)\n4. At least 1 criteria of the following 2 comorbidities:\n   - Impaired Glucose Tolerance or Type 2 diabetes\n   - Hypertension\n\nPatient's information:\n- The patient is a 25-year-old man with type 1 diabetes.\n- Shortness of breath and fatigue during activities (NYHA class 2).\n- Cardiomyopathy (to be treated with ACE inhibitors and Beta blockers).\n- Takes 70/30 Insulin and vitamin D supplements.\n- Lab study results:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nAnalysis:\n- The patient's HDL level is exactly 40 mg/dL, which does not meet the criterion for HDL-cholesterol < 40 mg/dL.\n- The patient's triglyceride level is 140 mg/dL, which is below the required > 150 mg/dL for the trial.\n- The patient has type 1 diabetes, not type 2 diabetes or impaired glucose tolerance, which are the specified comorbidities.\n- There is no information on BMI or VFA, and no mention of hypertension.\n\nSince the patient does not meet the dyslipidemia criteria based on HDL-cholesterol and triglycerides levels, and has type 1 diabetes rather than type 2 diabetes or impaired glucose tolerance, and there is no information on BMI, VFA, or hypertension, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2043": {
        "output": "Given the patient note and the clinical trial details, let's compare the patient's information to the inclusion criteria of the clinical trial:\n\nPatient's Characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy treated with ACE inhibitors and Beta blockers\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- No mention of COPD or any related symptoms\n\nClinical Trial Inclusion Criteria:\n- Moderate to severe COPD (according to GOLD classification)\n- Oxygen saturation >= 92 KPa\n- Symptomatically stable\n- Habitually low fruit and vegetable intakes (<=2 portions daily)\n- Exercise limited by shortness of breath (rather than e.g. angina, arthritis)\n\nThe patient presents with cardiomyopathy and type 1 diabetes but there is no mention of COPD or related symptoms in his medical history. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires participants to have a diagnosis of moderate to severe COPD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2044": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the inclusion criteria for the clinical trial. The clinical trial is focused on patients who have proximal humerus fractures treated non-operatively. The patient's note does not mention a proximal humerus fracture or any treatment related to such an injury. Instead, the patient has type 1 diabetes and has been diagnosed with cardiomyopathy, which are unrelated to the focus of the clinical trial.\n\nTherefore, the patient does not have the specific condition the trial is studying (proximal humerus fracture) and thus does not meet the necessary inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2045": {
        "output": "The patient in question is a 25-year-old man with type 1 diabetes and newly diagnosed cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers and does not have any history of cancer. \n\nThe clinical trial in question is for patients with newly diagnosed, previously untreated multiple myeloma. The inclusion criteria specify that the patient must have a diagnosis of multiple myeloma with certain specific characteristics such as specific levels of monoclonal immunoglobulin, bone marrow plasmacytosis, lytic bone lesions, or abnormal FreeLite testing. Additionally, the trial specifies patient characteristics related to organ function, no history of other significant medical conditions, and no prior treatment for active myeloma.\n\nBased on the information provided in the patient note, the patient does not meet the disease characteristics for multiple myeloma. There is no indication that the patient has multiple myeloma or has undergone any testing for such a condition. \n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, as he does not have a diagnosis of multiple myeloma nor any of the other specified criteria related to the disease. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2046": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\nThe patient is a 25-year-old man, which satisfies the age criterion (>18 years old and \u2264 70 years old).\n\nRegarding hyperlipidemia criteria:\n- The patient has fasting plasma triglycerides (TG) of 140 mg/dl, which is below the required >150 mg/dl for the trial.\n- The patient's LDL-cholesterol is 125 mg/dl, which is below the required >130 mg/dl for the trial.\n\nFor fasting plasma glucose levels:\n- The patient's fasting blood sugar (FBS) is 100 mg/dl, which is within the acceptable range of <110 mg/dl for the trial.\n\nGiven that the patient's TG and LDL-cholesterol levels do not meet the hyperlipidemia criteria of the trial, the patient is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2047": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided patient note and the inclusion and exclusion criteria of the clinical trial:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities, diagnosed with cardiomyopathy\n- Currently treated with ACE inhibitors, Beta blockers, and insulin\n- No mention of overweight/obesity or diagnosis time frame\n\nClinical Trial Inclusion Criteria for Diabetic Subjects:\n- Type 2 diabetes mellitus (T2DM)\n- Fasting blood glucose \u2265 126 mg/dL OR postprandial blood sugar \u2265 200 mg/dL OR impaired glucose tolerance with prior documentation of diabetes\n- Absence of insulin autoantibodies (in insulin-na\u00efve patients only) OR clinical diagnosis of type 1 diabetes mellitus (for Pilot Study only)\n- Age 8-25 years at enrollment\n\nClinical Trial Exclusion Criteria for Diabetic Subjects:\n- Normal OGTT at NIH\n- Significant comorbidity that increases risk to the subject\n- Positive urine pregnancy test\n- Psychiatric or cognitive disorder that limits the subject's ability to comply with study procedures\n\nThe patient does not meet the inclusion criteria for diabetic subjects as he has type 1 diabetes, not type 2 diabetes mellitus. Although the clinical trial does mention a pilot study for type 1 diabetes mellitus, there is not enough information to determine if this patient would be eligible for that particular aspect of the study. Furthermore, the trial is looking to rest beta cells, which may not be relevant for someone with type 1 diabetes as their beta cells are typically non-functioning due to autoimmune destruction.\n\nGiven the information provided, the patient does not fit the inclusion criteria for patients with T2DM, and the mention of a pilot study for type 1 diabetes is not sufficiently detailed to determine relevance or eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2048": {
        "output": "The patient in the note is diagnosed with type 1 diabetes, not type 2 diabetes mellitus, which is a requirement for the clinical trial. Furthermore, the trial requires patients to have been treated with a sulfonylurea for at least three months, and the patient is currently being treated with insulin, not a sulfonylurea. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2049": {
        "output": "The provided patient note describes a 25-year-old man with type 1 diabetes, presenting with symptoms of cardiomyopathy and controlled blood sugar levels. He is not a patient of the Texas Children's Hospital Diabetes Care Center, which is a requirement for the clinical trial in question.\n\nTherefore, based on the information given, the patient does not meet the necessary inclusion criteria for the clinical trial on the role of exenatide in type 1 diabetes, specifically the criterion requiring subjects to be patients of the Texas Children's Hospital Diabetes Care Center. Additionally, the age range for the trial is 12-21 years, and the patient is 25 years old, which further disqualifies him from this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2050": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Dyspnea Self-Management: Internet or Face-to-Face,\" let's assess the patient's eligibility step by step:\n\nPatient Characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes, cardiomyopathy\n- Symptoms: Shortness of breath and fatigue during activities (NYHA class 2 dyspnea)\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of COPD, clinically stable for at least one month\n- Spirometry results showing obstructive disease\n- ADL limited by dyspnea\n- Primary care physician designated\n- Ability to speak English and sign consent form\n- Actively using a computer and the Internet\n- No formal pulmonary rehabilitation in the last 12 months\n- Supplemental oxygen use acceptable with certain conditions\n- Ability to rate shortness of breath during exercise\n- Age > 40 years\n\nComparison:\n- The patient does not have a diagnosis of COPD but rather has cardiomyopathy associated with diabetes.\n- There is no indication the patient has spirometry results consistent with COPD.\n- The patient's age is below the required age for the study (>40 years).\n\nConclusion:\nThe patient does not meet the age requirement and does not have a diagnosis of COPD, which are key inclusion criteria for the trial. Therefore, the patient is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2051": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nInclusion Criteria:\n1. Black, white, and Hispanic males between the ages of 20 to 70 years.\n2. In good general health.\n3. Having a body mass index (BMI) between 20 and 35 kg/m^2.\n4. Plasma LDL-C concentrations greater than or equal to 130 mg/dL but less than or equal to 175 mg/dL.\n5. TG (triglyceride) levels less than or equal to 250 mg/dL.\n\nPatient Information:\n- The patient is a 25-year-old man.\n- The patient has type 1 diabetes and is being treated for cardiomyopathy.\n- His lab study shows LDL: 125 mg/dL and TG: 140 mg/dL.\n\nAssessment:\n1. The patient's age falls within the 20 to 70 years range.\n2. The patient may be considered in good general health aside from his diabetes and cardiomyopathy.\n3. The patient's BMI is not provided, so we cannot assess this criterion.\n4. The patient's LDL cholesterol level is below the required 130 mg/dL threshold.\n5. The patient's TG level is within the required range (less than or equal to 250 mg/dL).\n\nSince the patient's LDL cholesterol level does not meet the minimum requirement for the trial, and we do not have information about his BMI, the patient would not be eligible for this clinical trial based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2052": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 25-year-old man with type 1 diabetes, presenting with symptoms of heart failure (class 2 NYHA), diagnosed with cardiomyopathy.\n- Treatment plan includes ACE inhibitors and Beta blockers.\n- The patient has been confirmed to have non-ischemic cardiomyopathy based on the provided notes and treatment plan, though the ejection fraction (EF) is not mentioned.\n\nClinical trial inclusion criteria:\n- Diagnosis of nonischemic dilated cardiomyopathy.\n- Current NYHA class I-II congestive heart failure.\n- History of Stage C-D heart failure with EF \u2264 40% during the course of the disease.\n- Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant).\n- Age > 18 yrs.\n\nAssessment:\n- The patient is over 18 years old.\n- Diagnosed with cardiomyopathy and is in NYHA class II, which fits the criteria of nonischemic dilated cardiomyopathy and class I-II congestive heart failure.\n- Treatment includes ACE inhibitors and Beta blockers, which align with the trial's requirement of being on a comprehensive heart failure regimen.\n- The information provided does not specify the patient's heart failure stage as C-D or the ejection fraction (EF) being \u2264 40%, which is necessary to meet the inclusion criteria.\n- We do not have information on the duration of the patient's heart failure treatment regimen (whether it's been stable for at least 3 months).\n\nThe patient's eligibility cannot be confirmed without information on the ejection fraction, the stage of heart failure, and the duration of the treatment regimen. Thus, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2053": {
        "output": "",
        "label": 1
    },
    "2054": {
        "output": "Based on the provided patient note, the patient is a 25-year-old man with a history of type 1 diabetes confirmed with molecular analysis 7 years ago. He is currently presenting with symptoms of shortness of breath and fatigue, and he has been diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers.\n\nNow, let's compare the patient's characteristics with the inclusion criteria of the clinical trial titled \"Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64\":\n\nInclusion Criteria for the Trial:\n1. Age: Males \u2265 50 years; Females \u226555 years with a history of diabetes mellitus on medication for at least one year and prior documentation of fasting glucose \u2265 126 mg/dl or hemoglobin A1C > 6.5%.\n2. Age: Males \u2265 40 years; Females \u226545 years with a history of diabetes mellitus on medication for at least one year and documented for at least 5 years.\n3. The patient must sign a written informed consent.\n\nPatient Characteristics:\n- The patient is a 25-year-old male.\n- He has a history of type 1 diabetes for 7 years and has been on medication (insulin).\n- His fasting blood sugar (FBS) is 100 mg/dl, which is below the specified threshold.\n- His HbA1c is 6.5%.\n\nThe patient does not meet the age criteria for the trial (he is 25 years old, and the trial requires males to be at least 40 or 50 years old depending on the length of their diabetes history). Furthermore, his FBS does not meet the specified threshold for prior documentation of diabetes (\u2265 126 mg/dl), although his HbA1c is exactly at the 6.5% cutoff.\n\nGiven this information, the patient does not meet the age inclusion criteria for the trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2055": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome,\" we need to compare the patient's medical information to the inclusion criteria provided.\n\nInclusion Criteria for the trial:\n- Participants must meet 3 of the following criteria:\n  - BMI \u226530 kg/m^2\n  - HDL Cholesterol of <40 mg/dl\n  - Triglycerides >150 mg/dl\n  - Fasting blood glucose >100 mg/dl\n  - Blood pressure >130/85 mm Hg\n  - Total Cholesterol of >200 mg/dl\n  - LDL Cholesterol of >160 mg/dl\n  - Interleukin 6 (IL-6) >5pg/mL\n\nThe patient's medical information:\n- HDL Cholesterol: 40 mg/dl\n- Triglycerides: 140 mg/dl\n- Fasting blood glucose (FBS): 100 mg/dl\n- The patient's total cholesterol is 190 mg/dl, and LDL Cholesterol is 125 mg/dl.\n- The patient's blood pressure is not mentioned.\n- BMI is not provided, and there is no mention of IL-6 levels.\n- The patient has type 1 diabetes and is diagnosed with cardiomyopathy.\n\nBased on the available information, the patient meets 0 of the listed criteria; his HDL Cholesterol is exactly at the 40 mg/dl limit, triglycerides are below the 150 mg/dl threshold, fasting blood glucose is at the 100 mg/dl limit, and his total and LDL cholesterol are below the thresholds established by the inclusion criteria. There is no information given on the patient's BMI, blood pressure, or IL-6 levels. Since the patient does not meet at least three of the criteria listed, he is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2056": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Effect of a Fibrate and a Statin on Endothelial Dysfunction,\" we need to apply the inclusion criteria for the trial to the patient's information provided in the note.\n\nLet's assess the patient based on the inclusion criteria:\n\n1. Age greater than 30 years: The patient is 25 years old, which does not meet this criterion.\n2. Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent) or metabolic syndrome: The patient has type 1 diabetes, which is not typically classified as adult-onset diabetes, and the fasting glucose is 100 mg/dl, which is below the threshold for adult-onset DM. The patient does not meet the criteria for metabolic syndrome as specified.\n3. LDL cholesterol level less than 140 mg/dl: The patient's LDL is 125 mg/dl, which meets this criterion.\n4. Able to provide informed consent and complete study procedures: There is no information provided that suggests the patient is unable to consent or complete procedures.\n\nBased on the above criteria, the patient does not meet the age requirement and does not have adult-onset diabetes or metabolic syndrome as defined by the trial's inclusion criteria. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2057": {
        "output": "Based on the information provided, the patient in the note has type 1 diabetes and cardiomyopathy. He is being treated with ACE inhibitors, Beta blockers, and insulin. His medical history does not mention congenital hypothyroidism or any issues related to thyroglobulin synthesis.\n\nThe clinical trial in question is looking for patients with congenital hypothyroidism due to thyroglobulin defective synthesis. Since there is no indication in the patient's history or lab studies that he has congenital hypothyroidism or a thyroglobulin synthesis defect, he does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2058": {
        "output": "Based on the provided information:\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes.\n- He presents with cardiomyopathy, shortness of breath, and fatigue.\n- He is NYHA class 2.\n- He has no significant medical history other than diabetes.\n- He is being treated for his cardiomyopathy with ACE inhibitors and Beta blockers.\n\nClinical Trial:\n- Title: Cardiomyopathy Tissue Bank in a Cancer Population\n- The study is collecting and storing blood and tissue from patients with a diagnosis of heart disease and who may be at a high risk for the development of heart failure.\n- Inclusion criteria include:\n  - Patients who are at high risk for developing Cardiomyopathy or Congestive Heart Failure.\n  - Patients two months of age and older.\n\nAssessment:\n- The patient has cardiomyopathy, which aligns with the study's focus on heart disease.\n- The patient is at risk for heart failure due to his diagnosis of cardiomyopathy.\n- The patient's age fits within the inclusion criteria.\n\nHowever, it's important to note that the title of the trial mentions a \"Cancer Population,\" but there is no explicit exclusion or inclusion criteria provided regarding cancer status. Since the patient note does not mention cancer, we cannot assume that the patient is part of a cancer population. Without further information on whether being part of a cancer population is a requirement, we have to proceed with the information given.\n\nThe patient is at high risk for developing cardiomyopathy or congestive heart failure, which fits the inclusion criteria. There is no mention of exclusion criteria in the provided clinical trial summary that would apply to the patient.\n\nTherefore, the patient appears to be eligible for the trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2059": {
        "output": "",
        "label": 0
    },
    "2060": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the patient's trial-level eligibility.\n\nThe patient is a 25-year-old man with type 1 diabetes, which is not the same as type 2 diabetes mellitus for which the trial is designed. The trial is specifically looking to enroll patients who have been diagnosed with type 2 diabetes mellitus. Furthermore, the patient's fasting triglyceride level is 140 mg/dL, which is below the inclusion criterion of \u2265150 mg/dL and \u2264500 mg/dL.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial since he has type 1 diabetes rather than type 2 diabetes, and his fasting triglyceride levels do not fall within the specified range for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2061": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control,\" we need to compare the patient's characteristics and medical history with the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are:\n\n1. A current hemoglobin A1c (HbA1c) of >8.0%\n2. An average HbA1c of >8.0% during the past year\n3. Diagnosed with Type 1 diabetes for at least one year\n4. Reside in the metro Detroit tri-county area\n\nThe patient's characteristics and medical history:\n\n1. The patient has a current HbA1c of 6.5%, which is below the trial's inclusion criteria of >8.0%.\n2. There is no mention of the patient's average HbA1c during the past year, but given the current HbA1c is below 8.0%, it is not clear if the average would meet the criteria.\n3. The patient has been diagnosed with Type 1 diabetes for 7 years, which satisfies the requirement of being diagnosed for at least one year.\n4. There is no information indicating whether the patient resides in the metro Detroit tri-county area.\n\nBased on the available information, the patient does not meet the inclusion criterion regarding the level of HbA1c, which is a key factor for eligibility in this trial. The patient's HbA1c is below the threshold set by the trial's inclusion criteria. Therefore, the patient is not eligible for this clinical trial based on the current HbA1c value alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2062": {
        "output": "To determine the trial-level eligibility for the patient, we need to assess whether the patient meets the inclusion criteria of the clinical trial. Here are the inclusion criteria for the trial:\n\n1. Newly diagnosed type I diabetic patients\n2. Type I diabetes treated with basal-bolus regimen including 3 or more injections of Regular Human Insulin per day\n3. BMI, 26-40 kg/m2\n4. HbA1c, 7.5%-10%\n5. Median 2Hrs post-prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/L)\n6. FPG more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/L)\n7. Willingness to accept, and ability to inject insulin Glargine therapy\n\nNow let's compare this to the patient's information:\n\nThe patient is a 25-year-old man with type 1 diabetes diagnosed 7 years ago. This does not meet criterion 1, which requires the patient to be newly diagnosed.\n\nThe patient's current treatment regimen is not explicitly mentioned, but he takes \"70/30 Insulin,\" which suggests a mixed insulin regimen, not necessarily a basal-bolus regimen with 3 or more injections of Regular Human Insulin per day. Thus, there is no clear indication that criterion 2 is met.\n\nThe patient's BMI is not provided, so we cannot determine if criterion 3 is met.\n\nThe patient's HbA1c is 6.5%, which is below the trial's requirement of 7.5%-10%. Therefore, criterion 4 is not met.\n\nThe patient's median 2Hrs post-prandial and FPG levels are also not provided, so we cannot assess criteria 5 and 6.\n\nCriterion 7 refers to the patient's willingness and ability to inject insulin Glargine therapy. There is no information provided about the patient's willingness or ability to change his insulin regimen to insulin Glargine.\n\nBased on the available information, the patient does not meet several of the key inclusion criteria for the clinical trial. Specifically, the patient is not newly diagnosed with type 1 diabetes, and the patient's HbA1c level is below the range specified in the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2063": {
        "output": "Based on the information provided, the patient note describes a 25-year-old man with type 1 diabetes. He is experiencing cardiomyopathy and is not mentioned as being pregnant or post-partum, which are specific conditions related to the clinical trial in question.\n\nThe clinical trial is specifically targeting females with type 1 diabetes who are either not pregnant, are at 12 and 36 weeks gestation, or are 6 weeks post-partum. The inclusion criteria also specify that the participants must have had type 1 diabetes for at least 5 years, with an onset before age 21, be lean at diabetes onset, and have required insulin from diagnosis.\n\nGiven that the patient is male and the clinical trial is exclusively for females who are pregnant, not pregnant, or post-partum, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2064": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 25-year-old man, which meets the general requirement of being an adult (age \u2265 18 years).\n- He has type 1 diabetes and is presenting with symptoms of heart failure (shortness of breath and fatigue during activities, NYHA class 2).\n- The patient is diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is assessing the effect of sympathetic innervation and the response to cardiac resynchronization therapy (CRT) in patients with chronic heart failure (CHF).\n- Inclusion criteria require:\n  1. Indication for CRT\n  2. Stable optimal medication\n  3. Non-ischemic cardiomyopathy\n\nAssessment:\n- The patient note indicates the presence of cardiomyopathy and treatment with heart failure medications (ACE inhibitors and Beta blockers), which suggests that the patient might have CHF.\n- However, the patient note does not specify whether the patient has an indication for CRT or if the cardiomyopathy is non-ischemic.\n- The patient is on \"stable optimal medication\" for his condition, which aligns with one of the inclusion criteria.\n\nSince the patient note lacks specific information about the indication for CRT and the type of cardiomyopathy (ischemic vs. non-ischemic), we cannot conclusively determine if the patient meets all the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2065": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial titled \"Molecular Analysis of Breast Cancer,\" we can assess the eligibility of the patient for the trial.\n\nThe patient is a 25-year-old man with type 1 diabetes presenting with shortness of breath, fatigue, and a diagnosis of cardiomyopathy. He does not have a history of breast cancer or any indication that he is undergoing a procedure related to breast cancer (such as a biopsy, lumpectomy, mastectomy, etc.).\n\nThe inclusion criteria for the trial require participants to be older than 18 years, which the patient meets, but more specifically, they must be undergoing certain procedures related to breast health or have a history of breast cancer.\n\nSince the patient does not meet the specific criteria related to breast cancer or the listed procedures, he is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2066": {
        "output": "",
        "label": 0
    },
    "2067": {
        "output": "To assess the patient's eligibility, let's first identify the relevant information in the patient note and then compare it to the inclusion and exclusion criteria of the clinical trial.\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes confirmed with molecular analysis 7 years ago.\n- He is diagnosed with cardiomyopathy and is undergoing treatment with ACE inhibitors and Beta blockers.\n- His fasting blood sugar (FBS) is 100 mg/dl.\n- His HbA1c is 6.5%.\n\nClinical Trial:\n- The title indicates the trial is related to white blood cell function in the context of diabetes.\n- The study is for individuals between 21 and 60 years of age.\n- It is for individuals who are non-diabetic, pre-diabetic, or have type 2 diabetes controlled by diet and/or medications other than insulin.\n- Inclusion criteria for the young groups (21 to less than 40 years) include either insulin sensitivity or insulin resistance with specific parameters for fasting blood glucose and 2-hour post oral glucose tolerance test blood glucose.\n- Exclusion criteria include uncontrolled hypertension or therapy with a Beta-blocker, history of heart failure, unstable coronary artery disease or symptomatic peripheral arterial disease, insulin-dependent diabetes mellitus or current use of thiazolidinediones, and several other conditions.\n\nPatient Eligibility Assessment:\n- The patient is within the age range for the \"young groups\" (older than 21 years and less than 40 years).\n- Based on the inclusion criteria, the patient would have to have either insulin sensitivity or insulin resistance, as defined by specific glucose levels.\n- The patient's FBS is 100 mg/dl, which fits the criteria for insulin sensitivity.\n- However, the patient has type 1 diabetes, which is insulin-dependent, and this is explicitly listed in the exclusion criteria as \"Insulin-dependent diabetes mellitus or current use of thiazolidinediones.\"\n- Additionally, the patient is on treatment with Beta blockers, which is also listed in the exclusion criteria as \"therapy with a Beta-blocker.\"\n\nConclusion:\nBased on the information provided, while the patient initially seems to meet some of the inclusion criteria, he is excluded on the grounds of having insulin-dependent diabetes (type 1) and being on Beta blocker therapy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2068": {
        "output": "First, let's compare the patient's characteristics and conditions with the inclusion criteria of the clinical trial:\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy\n- Currently takes insulin and vitamin D supplements\n- Lab results: \n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nClinical trial inclusion criteria:\n- Age 18 to 79 years, inclusive. (Patient is eligible)\n- HbA1C in the range of \u22656.5% to \u226410.0%, to be enrolled in the T2DM cohort. (Patient is eligible based on HbA1c, but has Type 1 diabetes, not Type 2)\n- 2-hour post 75 g OGTT glucose levels in specific ranges for T2DM or pre-diabetes cohort. (No information provided)\n- FPG levels in specific ranges for T2DM or pre-diabetes cohort. (Patient's FBS is 100 mg/dl, does not meet T2DM criteria)\n- LDL-C levels \u2265100 mg/dL. (Patient is eligible based on LDL levels)\n- Drug-na\u00efve or no antidiabetic drug therapy during the 3 months prior to screening visit. (Patient is not drug-na\u00efve, takes insulin)\n- Previous diagnosis of T2DM, prediabetes, CHD, CVD, and/or primary hypercholesterolemia + BMI \u2265 25 mg/kg^2 to be screened for T2DM or pre-diabetes. (Patient has Type 1 diabetes, not T2DM or prediabetes)\n- Understanding of the study procedures and agreement to participate in the study by giving written informed consent at screening visit. (Assumed if patient agrees to participate)\n- Additional criteria for women that do not apply to this male patient.\n\nBased on the patient's information and the trial's inclusion criteria, the patient does not have Type 2 diabetes mellitus (T2DM) or prediabetes, which is a requirement for the trial. The patient has Type 1 diabetes, which is a different condition. Therefore, despite meeting some of the inclusion criteria such as age and LDL-C levels, the patient's type of diabetes excludes him from this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2069": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes, confirmed with molecular analysis 7 years ago.\n- He presents with shortness of breath and fatigue during activities, diagnosed with cardiomyopathy.\n- The patient is being treated with ACE inhibitors and Beta blockers.\n- The patient takes 70/30 Insulin and vitamin D supplements.\n- His HbA1c level is 6.5%.\n\nClinical Trial Inclusion Criteria:\n- Diagnosed with type 2 diabetes.\n- Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1.\n- HbA1c >6.5% and \u226410.0%.\n\nThe patient has type 1 diabetes, not type 2, which already does not meet the inclusion criteria for the clinical trial, as it requires participants to have type 2 diabetes. Additionally, there is no mention of the patient being treated with metformin, which is another requirement for the trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2070": {
        "output": "",
        "label": 0
    },
    "2071": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the inclusion criteria for the clinical trial. The clinical trial is specifically for patients with Langerhans Cell Histiocytosis (LCH) who have multifocal or multisystem disease involvement. The patient in the note has type 1 diabetes and cardiomyopathy, which are not related to LCH.\n\nTherefore, since the patient does not have the target disease for which the clinical trial is designed, they are not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2072": {
        "output": "Based on the patient note provided, the 25-year-old man has type 1 diabetes and presents with symptoms of cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers. His fasting blood sugar (FBS) is 100 mg/dl, which is below the exclusion criteria threshold of 110 mg/dl for non-diabetic individuals in the clinical trial. The clinical trial is looking to recruit subjects undergoing elective coronary artery bypass surgery and/or aortic valve replacement surgery to assess the proteome in human atrial tissue.\n\nThe patient's note does not mention that he is undergoing, or is scheduled to undergo, any cardiac surgery, such as coronary artery bypass surgery or aortic valve replacement surgery. Therefore, we do not have sufficient information to determine if this patient is eligible for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2073": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n1. Age: 25 years old\n2. Condition: Type 1 Diabetes Mellitus confirmed with molecular analysis 7 years ago\n3. Treatment: On intensive insulin therapy (takes 70/30 Insulin)\n4. Hemoglobin A1c: 6.5%\n5. History of hypoglycemic events: Not mentioned\n\nClinical Trial Inclusion Criteria:\n1. Type 1 Diabetes Mellitus for greater than 5 years (C-peptide negative) - The patient has had Type 1 Diabetes for 7 years, so this criterion is met.\n2. Age 18-55 years - The patient is 25 years old, so this criterion is met.\n3. Subject is on intensive insulin therapy resulting in a Hemoglobin A1c of less than 7.5% - The patient has an HbA1c of 6.5% and is on intensive insulin therapy, so this criterion is met.\n4. History of frequent hypoglycemic events as defined as having at least one blood glucose of less than 60 mg/dl in the last four weeks - There is no information provided about the patient's history of hypoglycemic events, so this criterion cannot be assessed with the information given.\n\nSince the patient meets most of the inclusion criteria, but there is insufficient information about the history of hypoglycemic events, we cannot definitively determine if the patient is eligible or excluded from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2074": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study,\" we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Diagnosis: Type 1 diabetes, cardiomyopathy\n- No mentioned menopause or history of chest discomfort, myocardial ischemia, or CAD\n- Currently taking insulin and vitamin D supplements\n- Lab results: FBS 100 mg/dl, HbA1c 6.5%, Cholesterol 190 mg/dl, TG 140 mg/dl, LDL 125 mg/dl, HDL 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Postmenopausal WISE and nonWISE study participants\n- Normal/minimally diseased coronary arteries\n- Criteria suggestive of myocardial ischemia\n- No contraindications to 12 weeks of FemHRT or hormone replacement therapy\n- Normal mammogram and pelvic exam\n- Normal liver function testing\n\nClinical Trial Exclusion Criteria:\n- Documented myocardial infarction, coronary artery bypass surgery, or mechanical revascularization\n- High blood pressure or cholesterol levels\n- Clinically significant hepatic or renal dysfunction\n- Uncontrolled diabetes mellitus\n- Significant heart disease\n- Currently on hormone replacement therapy\n- Previous cancer, abnormal bleeding, or abnormal Pap smear\n- Thromboembolic disorders, alcoholism, or drug abuse\n- Participation in other studies\n- Risk factors needing referral (high blood pressure, cholesterol, fasting blood sugar, smoking)\n\nBased on the presented information:\n\n1. The patient is a 25-year-old man, which does not meet the inclusion criteria specifying postmenopausal women.\n2. There is no mention of the patient being postmenopausal or having chest discomfort, myocardial ischemia, or CAD.\n3. The trial is specifically for hormone replacement therapy, which is typically not applicable to men.\n\nThe patient does not meet the inclusion criteria for the clinical trial due to gender and the specific medical condition required (postmenopausal status with signs of myocardial ischemia and no obstructive CAD). Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2075": {
        "output": "Considering the inclusion criteria for the clinical trial and the patient's information:\n\n- The patient is a 25-year-old man, which fits within the age range specified in the inclusion criteria (18-45 years).\n- He has Type 1 diabetes, which is required for the trial.\n- His HbA1c is 6.5%, which is below the inclusion requirement of >7.0%.\n- There is no information provided that suggests clinical evidence of diabetic tissue complications, so we can assume he does not have any.\n- The patient's Body Mass Index (BMI) is not provided, so we cannot confirm this criterion.\n\nWhile the patient meets the age and Type 1 diabetes criteria, his HbA1c is lower than the required >7.0% for the trial. Therefore, the patient does not meet all of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2076": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to have pulmonary fibrosis, which is the target condition for the study. The patient is described as having type 1 diabetes and cardiomyopathy, with symptoms of shortness of breath and fatigue, but there is no mention of pulmonary fibrosis. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2077": {
        "output": "",
        "label": 2
    },
    "2078": {
        "output": "To determine the patient's eligibility for the Transthyretin Amyloidosis Outcome Survey (THAOS), we must compare the patient's clinical profile with the inclusion and exclusion criteria of the study.\n\nPatient's clinical profile:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Treatment plan includes ACE inhibitors and Beta blockers\n\nClinical trial inclusion criteria:\n- Signed informed consent\n- \u226518 years of age\n- Confirmed genotyped TTR mutation with or without a diagnosis of hereditary or wild-type ATTR amyloidosis\n- For wild-type ATTR amyloidosis, confirmation via genetic testing and one of the following:\n  a) Presence of amyloid in cardiac biopsy tissue confirmed as TTR amyloid by mass spectrometry or immunohistochemistry\n  b) Evidence of cardiac involvement by echocardiogram and presence of amyloid in non-cardiac tissue confirmed as TTR amyloid\n  c) Evidence of cardiac involvement by echocardiogram and presence of amyloid in cardiac tissue indirectly confirmed by scintigraphy with specific tracers and a Perugini grade \u2265 2\n\nClinical trial exclusion criteria:\n- Evidence of primary (light chain) or secondary amyloidosis\n\nBased on the patient's note, we know that the patient has been diagnosed with cardiomyopathy, which could potentially align with the ATTR-CM (cardiomyopathy) subset of the trial. However, there is no indication that the patient has been genetically tested for a TTR mutation, nor is there any information provided about the presence of amyloid deposits confirmed by biopsy, immunohistochemistry, echocardiogram, or scintigraphy.\n\nWithout this specific information, we cannot confirm that the patient meets the necessary inclusion criteria for the THAOS study. There is no evidence provided that the cardiomyopathy is related to transthyretin amyloidosis, nor is there evidence to exclude the patient based on primary or secondary amyloidosis.\n\nGiven the lack of sufficient information to qualify the patient for the trial based on the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2079": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial titled \"Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus,\" we can determine the trial-level eligibility as follows:\n\n1. The patient is a 25-year-old man with type 1 diabetes. The clinical trial is specifically for patients with type 2 diabetes mellitus.\n2. The patient's LDL level is 125 mg/dl, which fits within the trial's specified range of \u2265130 mg/dl and <190 mg/dl for LDL cholesterol.\n3. The patient's triglyceride level is 140 mg/dl, which is within the trial's required range of <150 mg/dl and <600 mg/dl.\n4. However, there is no information provided about the sum of LDL-5 and LDL-6 cholesterol levels in the patient's note, which is one of the inclusion criteria.\n5. Given that the patient is male, the criteria about FSH levels in female patients do not apply.\n6. The patient does not meet the age criterion for male patients, which is >35 years.\n7. The patient's type 1 diabetes diagnosis and age are not consistent with the inclusion criteria, which specify type 2 diabetes and an age range for male patients of >35 and \u226475 years.\n\nBased on the above points, the patient does not meet the necessary criteria for the clinical trial because the trial is intended for patients with type 2 diabetes, and the patient has type 1 diabetes, in addition to the age discrepancy. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2080": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient's characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes\n- HbA1c: 6.5%\n- BMI: Not provided but irrelevant due to diagnosis of Type 1 diabetes\n- Other: The patient has a case of cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n\nClinical trial inclusion criteria:\n- Age 30 to 67 years at eligibility visit.\n- Diagnosed with T2DM (Type 2 Diabetes Mellitus) at least 6 months prior to enrollment.\n- HbA1c \u2265 8.0%.\n- BMI between 30.0 kg/m2 and 39.9 kg/m2 at eligibility visit.\n- Willingness to accept random assignment to either treatment group.\n- Expect to live or work within approximately one hour's traveling time from the study clinic for the duration of the two-year trial.\n- Willingness to comply with the follow-up protocol and successful completion of the run-in.\n- Written informed consent.\n\nComparison:\n- The patient is 25 years old, which is below the required age range of 30 to 67 years.\n- The patient has Type 1 diabetes, not Type 2 diabetes as required by the trial.\n- The patient's HbA1c is 6.5%, which is below the minimum required HbA1c of 8.0% for trial participation.\n\nGiven that the patient does not meet the age requirement, has the wrong type of diabetes (Type 1 instead of Type 2), and does not have the required HbA1c level, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2081": {
        "output": "Patient Note:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Medications include 70/30 Insulin and vitamin D supplements\n- No significant medical history for other medical issues\n- Family history positive for DM type 1\n- Lab study values:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Untreated subjects with primary hypercholesterolemia and plasma LDL-C concentrations between >=130 mg/dL to <=180 mg/dL\n- Triglyceride concentrations of <350 mg/dL\n- Documented coronary heart disease (CHD)\n- Not currently taking a statin, with no statin use for at least 6 months prior to baseline visit\n- Age >=18 years and <=75 years\n- Liver transaminases and CK within specified limits\n- Clinical laboratory tests within normal limits or clinically acceptable\n- Failed cholesterol-lowering diet and exercise program of at least 4 weeks duration prior to baseline visit\n- Stable weight history for at least 4 weeks prior to entry into study\n- Women receiving hormonal therapy must have been on a stable dose for at least 8 weeks\n- Women of childbearing potential must be using acceptable methods of birth control or be surgically sterilized\n- Free of any clinically significant diseases other than hyperlipidemia or CHD\n- Able to adhere to the dosing and visit schedules, and agree to maintain their current cholesterol-lowering diet and exercise program for the duration of the study\n\nAssessment:\n- The patient is within the age range required by the trial.\n- The patient has LDL and triglyceride levels within the specified range for the trial.\n- The patient is diagnosed with cardiomyopathy, which is not coronary heart disease (CHD). There is no mention of any CHD, such as stable angina, history of myocardial infarction, etc.\n- The patient is taking medication for diabetes but there's no mention of cholesterol-lowering medication, indicating he is not currently treated for hypercholesterolemia.\n- No information is provided about the patient's diet and exercise program or if he has previously failed such a program.\n- It is not stated whether the patient has stable weight history for at least 4 weeks prior to the study.\n- The patient's sex precludes the need for the criteria related to women's hormonal therapy or birth control.\n\nBased on the information provided, the patient does not have documented coronary heart disease, which is a requirement for the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2082": {
        "output": "Based on the provided patient note and the clinical trial information, the key factors to consider for trial eligibility are:\n\n- The patient must have successfully completed the double-blind study (LCP-AtorFen-2001; NCT00504829).\n- The patient must confirm his or her willingness to participate in this study.\n\nThe patient note indicates that the patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. There is no mention of the patient having participated in the double-blind study LCP-AtorFen-2001 or any dyslipidemia treatment. Therefore, there isn't enough information to determine if the patient is eligible based on the inclusion criteria provided by the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2083": {
        "output": "Based on the provided patient note and the clinical trial criteria, let's compare the patient's characteristics with the inclusion criteria:\n\nPatient Note Summary:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- No mention of undergoing percutaneous coronary intervention (PCI) or having unstable angina (UA) not responding to conventional medical therapy\n\nClinical Trial Inclusion Criteria:\n- Patients undergoing PCI\n- Patients with unstable angina (UA) not responding to conventional medical therapy when PCI is planned within 24 hours\n\nThe patient's note does not mention that he is undergoing PCI or that he has unstable angina not responding to conventional medical therapy. The patient has cardiomyopathy, but this condition alone without the context of PCI or unstable angina does not meet the specific inclusion criteria of the trial.\n\nTherefore, the patient does not meet the inclusion criteria as specified for the clinical trial on the use of Abciximab in patients undergoing PCI or with unstable angina not responsive to medical therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2084": {
        "output": "",
        "label": 0
    },
    "2085": {
        "output": "The patient in the note is a 25-year-old man diagnosed with cardiomyopathy, which aligns with the first inclusion criterion of the clinical trial. The clinical trial is interested in determining the genetic basis of cardiomyopathies and heart failure. The patient's diagnosis makes him a candidate for the study based on the stated inclusion criteria.\n\nGiven the information provided, the patient meets the first inclusion criterion of having a diagnosis of cardiomyopathy. There is no mention of exclusion criteria in the trial information provided, and no other patient information suggests exclusion based on the trial's focus. Therefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2086": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial:\n\n- The patient is a 25-year-old man, which meets the gender requirement.\n- The patient has type 1 diabetes, which fits the target condition.\n- The duration of the patient's type 1 diabetes is 7 years, which is within the specified range of zero to fifteen years.\n- The patient is currently on insulin therapy (70/30 Insulin).\n\nAll the inclusion criteria listed for the clinical trial appear to be met by the patient's note:\n\n- Gender: Male (Patient is a man)\n- Type 1 diabetes duration: between zero and fifteen years (Patient has had type 1 diabetes for 7 years)\n- Current insulin therapy: Yes (Patient takes 70/30 Insulin)\n\nThe patient note does not mention any other medical issues that would exclude the patient based on the provided inclusion criteria of the clinical trial.\n\nTherefore, the patient appears to be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2087": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 25-year-old man\n- Diagnosed with type 1 diabetes\n- Presents with shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy\n- Takes 70/30 Insulin and vitamin D supplements\n- No mention of nephropathy, proteinuria, or impaired GFR\n- No mention of cognitive function regarding diabetes self-management\n- Blood glucose is under control (FBS: 100 mg/dl)\n\nClinical Trial Inclusion Criteria:\n- Male or female aged 18 to 70 years\n- Diagnosed with Type 2 Diabetes mellitus\n- Documented Advanced Diabetic Nephropathy (ADN)\n- Impaired GFR corresponding to CKD stages 3-4\n- Presence of proteinuria or micro/macro-albuminuria\n- Minimal cognitive function for diabetes self-management\n- Fasting or random Blood glucose <400mg/DL\n\nAssessment:\n- The patient has type 1 diabetes, not type 2 diabetes as required by the trial.\n- There is no documentation of nephropathy, proteinuria, or impaired GFR in the patient's note.\n- The patient's cognitive function in terms of diabetes self-management is not mentioned, but this is less relevant because the patient does not meet other key eligibility criteria.\n\nThe patient does not meet the inclusion criteria for the clinical trial due to having type 1 diabetes instead of type 2 diabetes and no documented evidence of nephropathy or kidney function impairment as defined in the trial criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2088": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects,\" we need to evaluate the patient's information against the inclusion criteria provided. Let's assess the patient's eligibility based on the inclusion criteria:\n\nInclusion Criteria Assessment:\n\n1. Healthy male or female subject - The patient has type 1 diabetes and cardiomyopathy, which means he is not considered a healthy subject.\n2. Age between 18 and 45 years (both inclusive) - The patient is 25 years old, which fits within the age criteria.\n3. Considered generally healthy upon completion of medical history, physical examination, and biochemical investigations as judged by the Investigator - The patient's medical condition (type 1 diabetes and cardiomyopathy) disqualifies him from being considered generally healthy.\n4. Body Mass Index (BMI) between 18.0 and 35.0 kg/m^2 (both inclusive) - The patient's BMI is not provided, so we cannot assess this criterion.\n5. Non-smoker, defined as no nicotine consumption for at least one year - There is no information about the patient's smoking status.\n6. Signed and dated informed consent obtained before any trial-related activities - This is a procedural step that can be fulfilled if the patient agrees to participate.\n\nBased on the information provided in the patient note, the patient does not meet the criteria of being a \"healthy subject\" due to his existing medical conditions (type 1 diabetes and cardiomyopathy). Therefore, despite his age matching the criteria, he would not be considered eligible for this clinical trial that requires healthy subjects.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2089": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM),\" we need to compare the patient's characteristics and condition with the inclusion criteria specified by the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Patient aged 18 years or older\n2. Diagnosed with diabetes mellitus (DM), defined by:\n   - Fasting plasma glucose above 126 mg/dL or\n   - Symptoms of DM with random blood glucose concentration above 200 mg/dL or\n   - Patients treated with oral hypoglycemics or insulin\n3. Patients must be treated with ACE inhibitors, aspirin, and statins for at least one month prior to enrollment\n4. Blood pressure assessed by 24-hour ambulatory BP monitoring\n5. Written informed consent\n\nNow let's assess the patient against these criteria:\n\n1. The patient is 25 years old, which meets the age requirement.\n2. The patient has type 1 diabetes confirmed with molecular analysis and is being treated with insulin, which meets the DM criteria.\n3. The patient has been newly diagnosed with cardiomyopathy and will be treated with ACE inhibitors, but there is no information on whether the patient has been on ACE inhibitors, aspirin, and statins for at least one month.\n4. There is no information provided about the patient's blood pressure having been assessed by 24-hour ambulatory BP monitoring.\n5. The informed consent requirement is not something that can be assessed from the patient note; it's a procedural step the patient would complete upon agreeing to participate in the trial.\n\nGiven the information provided, the patient does not have sufficient information to qualify for the trial due to a lack of evidence that they have been on the required medications for at least one month and no information on their blood pressure monitoring status.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2090": {
        "output": "The patient in the note has type 1 diabetes, not type 2 diabetes, which is a key distinction for the clinical trial in question. The trial specifically states that it is for individuals with Type 2 Diabetes. Additionally, the patient's fasting blood glucose level is reported to be 100 mg/dl, which does not meet the trial's inclusion criteria of fasting blood glucose levels between 300-500 mg/dl.\n\nGiven these discrepancies between the patient's condition and the trial's inclusion criteria, the patient does not qualify for the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2091": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility for the study:\n\n- The clinical trial is for advanced/metastatic NSCLC or Head and Neck cancer patients. The patient has cardiomyopathy associated with type 1 diabetes, not NSCLC or Head and Neck cancer.\n- The patient is 25 years old, which satisfies the age requirement of being \u2265 18 years old.\n- There is no information on whether the patient has provided written informed consent, but this is a procedural step that could be fulfilled if other criteria are met.\n- The patient does not have progressive and measurable disease according to RECIST criteria relevant to this trial, as they do not have advanced/metastatic NSCLC or Head and Neck cancer.\n- The patient does not have a history indicating discontinued systemic chemotherapy, likely because they do not have cancer.\n- Laboratory criteria are not fully provided in the patient note; however, this is irrelevant as the patient does not have the cancer types specified in the trial's inclusion criteria.\n- The patient's ECOG Performance Status is not provided, but given their NYHA class 2 status for heart disease, they might not meet the ECOG Performance Status of \u2264 1.\n- Reproductive potential information is not provided, but again, this is moot as the patient does not have the specified types of cancer.\n\nThe patient does not have a diagnosis of advanced/metastatic NSCLC or Head and Neck cancer, which is a primary inclusion criterion for the clinical trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2092": {
        "output": "",
        "label": 0
    },
    "2093": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels,\" we need to compare the patient's characteristics and lab values with the inclusion criteria provided for the trial.\n\nInclusion Criteria for the trial:\n- Subjects with a Body Mass Index (BMI) \u2264 35 kg/m2\n- Subjects with the following lipid parameters at Visit 1 (screening visit) and Visit 3 (diet stabilization period):\n  - HDL-C \u2264 40 mg/dL (Men) and \u2264 50 mg/dL (Women)\n  - TG \u2264 500 mg/dL\n  - LDL-C \u2264 190 mg/dL\n- Subjects who are generally healthy as determined by pre-study medical history, physical examination, vital signs, and 12-lead ECG\n\nPatient's characteristics and lab values:\n- The patient is a 25-year-old man with type 1 diabetes.\n- The patient's HDL-C level is 40 mg/dL.\n- The patient's TG level is 140 mg/dL.\n- The patient's LDL-C level is 125 mg/dL.\n- The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- The patient's BMI is not provided in the note.\n\nBased on the information provided, the patient meets the lipid parameter criteria for HDL-C, TG, and LDL-C levels. However, the patient has been diagnosed with cardiomyopathy, which may affect his general health status. The patient's BMI is not provided, which is necessary to determine eligibility. Since the patient has a significant cardiac condition, it is unclear if he would be considered generally healthy. Furthermore, the patient's eligibility cannot be fully assessed without knowing his BMI or the results of his physical examination, vital signs, and 12-lead ECG.\n\nGiven the available information, the patient does not have sufficient information to qualify for the trial, primarily due to the lack of data regarding his BMI, general health status, and the results of a physical examination, vital signs, and 12-lead ECG.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2094": {
        "output": "",
        "label": 0
    },
    "2095": {
        "output": "",
        "label": 0
    },
    "2096": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note Summary:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He presents with symptoms consistent with NYHA Functional Class II heart failure due to cardiomyopathy.\n- He is prescribed ACE inhibitors and Beta blockers.\n- No prior mention of beta-blocker use within the last 30 days is provided in the patient note.\n- There is no information provided about the patient's ejection fraction.\n\nClinical Trial Inclusion Criteria:\n- Objective evidence of systolic dysfunction (ejection fraction \u226440%).\n- Age >18 years.\n- On stable optimal medical heart failure therapy excluding the use of beta-blockers within the previous 30 days.\n\nThe patient's note does not provide information on the ejection fraction, which is a key component of the clinical trial inclusion criteria. Additionally, the patient has been diagnosed with cardiomyopathy and is prescribed beta-blockers, but it is not clear when the beta-blocker therapy was initiated relative to the clinical trial's 30-day exclusion criteria for beta-blocker use. \n\nDue to these uncertainties, specifically the lack of ejection fraction data and ambiguity about the initiation of beta-blocker therapy, the patient cannot be definitively assessed as meeting the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2097": {
        "output": "The patient described in the patient note is a 25-year-old man with type 1 diabetes. The clinical trial is specifically looking to recruit patients with type 2 diabetes mellitus to evaluate the molecular mechanisms involved in the early development of endothelial dysfunction.\n\nComparing the patient's characteristics to the inclusion criteria for the clinical trial:\n\n- The patient has type 1 diabetes, not type 2 diabetes as required by the trial.\n- The patient is within the age range of 18-65 years.\n- The trial requires an HbA1c level of 6.5-9.0% while on certain treatments; the patient's HbA1c is 6.5%, but they are taking insulin, which is not allowed per the trial's criteria.\n- The patient is currently being treated with an ACE inhibitor for cardiomyopathy, which is also not allowed by the trial.\n- There is no information on blood pressure, but it is not relevant as the patient already does not meet other criteria.\n\nGiven that the patient has type 1 diabetes and is treated with insulin and an ACE inhibitor, he does not meet the inclusion criteria for a trial that specifically focuses on type 2 diabetes and excludes patients on insulin or ACE inhibitor therapy. Therefore, the patient is not relevant for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2098": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, let's review the patient's characteristics against the inclusion and exclusion criteria of the trial step by step:\n\nInclusion Criteria Review:\n- The patient is 25 years old, which is within the 18-79 years age range required.\n- The patient's fasting glucose level is 100 mg/dL, which meets the criterion for fasting glucose \u2265 100 mg/dL.\n- The patient's triglyceride level is 140 mg/dL, which does not meet the criterion for Triglycerides > 150 mg/dL.\n- The patient's HDL cholesterol level is 40 mg/dL, which meets the criterion for males with HDL-C < 40 mg/dL.\n- The patient is male, and there is no waist circumference information provided, so we cannot confirm the abdominal obesity criterion.\n- There is no blood pressure information provided, so we cannot confirm that criterion.\n- The patient's LDL-C level is 125 mg/dL, which meets the criterion for an LDL-C level of \u2265 100 mg/dL and < 220 mg/dL.\n- There's no clear indication that the patient is a smoker or not, but given no information to the contrary, we may assume they meet the non-smoker criterion.\n- There is no information regarding the patient's willingness to maintain a stable diet or their understanding and consent to participate in the study.\n\nExclusion Criteria Review:\n- There is no BMI information provided, so we cannot confirm the BMI > 35 exclusion criterion.\n- There is no information on the patient's hypersensitivity to the study medications.\n- There is no information on the patient's alcohol consumption.\n- There is no information on the patient's participation in other studies.\n- There is no smoking history provided.\n- There is no liver transaminase levels or other laboratory values mentioned, so we cannot confirm these exclusion criteria.\n- There is no history mentioned of congestive heart failure or coronary heart disease.\n- The patient has type 1 diabetes, which is a clear exclusion criterion as per point 18.\n\nGiven that the patient has type 1 diabetes, they are automatically excluded from the trial based on the exclusion criteria (patient has diabetes mellitus defined as a history of diabetes or fasting serum glucose > 126 mg/dL).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2099": {
        "output": "Based on the patient note provided and the clinical trial inclusion criteria, the patient is a 25-year-old man with type 1 diabetes and cardiomyopathy, and there is no mention of renal transplantation, which is a key inclusion criterion for the trial. The trial is focused on renal transplant recipients receiving tacrolimus-based immunosuppression and evaluating the efficacy and safety of long-acting insulin for post-transplant hyperglycemia. Since the patient has not undergone renal transplantation and the note does not indicate eligibility for the specific standard immunosuppression regime listed in the trial inclusion criteria, the patient does not meet the necessary criteria to participate in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2100": {
        "output": "Based on the information provided, the patient is a 25-year-old man with a presenting complaint of shortness of breath and fatigue during activities, which corresponds to NYHA class 2 dyspnea. He is diagnosed with cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers. \n\nThe inclusion criteria for the clinical trial are:\n1. Age > 18\n2. Presenting complaint of shortness of breath or dyspnea\n\nThe patient meets both inclusion criteria as he is over 18 years old and has a presenting complaint of shortness of breath. There are no additional exclusion criteria provided, so we cannot determine that the patient should be excluded from the trial for any other reason.\n\nTherefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2101": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Pilot Study of Mitochondrial Biology in Human Platelets,\" we must compare the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial.\n\nHere is the patient's profile:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes\n- Fasting Blood Sugar (FBS): 100 mg/dl\n- HbA1c: 6.5%\n- The patient is on insulin therapy (70/30 Insulin)\n\nNow let's examine the inclusion criteria for the relevant group in the clinical trial:\n\nInclusion Criteria (young insulin-resistant group):\n- Adults older than 21 years and less than 40 years. (The patient meets this criterion.)\n- Insulin resistance as defined by a fasting blood sugar of greater than or equal to 100mg/dl but less than 125 mg/dl and/or a 2-hour post oral glucose tolerance test blood glucose greater than 140 mg/dl and less than 200 mg/dl. (The patient meets the fasting blood sugar criterion but has not been tested for the 2-hour post oral glucose tolerance test. However, insulin resistance typically is not associated with Type 1 diabetes, which the patient has.)\n- Subject understands protocol and provides written, informed consent. (Assumed to be met if the patient agrees to participate.)\n\nExclusion Criteria (all study subjects):\n- Several exclusion criteria are listed, but based on the patient's profile, the relevant one is: Insulin-dependent diabetes mellitus or current use of thiazolidinediones. (The patient has type 1 diabetes and is insulin-dependent.)\n\nConclusion:\nGiven that the patient has type 1 diabetes and is insulin-dependent, he does not meet the inclusion criteria for any of the groups outlined in the clinical trial, as they pertain to individuals with insulin resistance or type II diabetes. Additionally, the exclusion criteria specifically exclude individuals with insulin-dependent diabetes mellitus.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2102": {
        "output": "",
        "label": 0
    },
    "2103": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information with the inclusion criteria of the clinical trial.\n\nThe patient's information is as follows:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Currently taking 70/30 Insulin and vitamin D supplements\n- Family history of DM type 1\n- Lab values: FBS 100 mg/dl, HbA1c 6.5%, Cholesterol 190 mg/dl, TG 140 mg/dl, LDL 125 mg/dl, HDL 40 mg/dl\n\nThe inclusion criteria for the clinical trial are:\n- Patients with dyslipidemia as defined by any of the parameters:\n  - HDL-C < 50 mg/dL\n  - LDL-C \u2265 140 mg/dL\n  - LDL-C \u2265 100 mg/dL and cholesterol-lowering treatment is necessary in accordance with the investigator's judgement\n- Patients who passed three months or more after acute myocardial infarction\n- Patients who passed one month or more after unstable angina\n- Patients who passed one month or more after PCI\n- Patients with written consent by their own volition after being provided sufficient explanation for the participation in this clinical trial\n\nBased on the patient's lab values, the HDL-C is 40 mg/dL, which meets one of the dyslipidemia criteria for the trial (HDL-C < 50 mg/dL). However, there is no indication that the patient has coronary artery disease (CAD) or a history of acute myocardial infarction, unstable angina, or PCI. The inclusion criteria specifically mention patients with dyslipidemia comorbid with stable CAD and post-events such as myocardial infarction or unstable angina, which are not mentioned in the patient's history.\n\nSince the patient does not have a confirmed diagnosis of CAD or history of the specified cardiac events, the patient does not meet the full set of inclusion criteria required for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2104": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes and is experiencing symptoms of cardiomyopathy.\n- He is being treated with ACE inhibitors and Beta blockers.\n- His past medical history does not mention hypertrophic cardiomyopathy (HCM).\n\nClinical Trial Inclusion Criteria:\n- Hypertrophic cardiomyopathy\n- Able to swallow pills\n- No prior septal reduction therapy\n- Negative serum or hCG pregnancy test (which is not applicable to this male patient)\n\nComparison:\n- The patient's note does not mention a diagnosis of hypertrophic cardiomyopathy; instead, it mentions cardiomyopathy is present without specifying that it is hypertrophic.\n- The patient note does not provide information contradicting the ability to swallow pills, nor does it mention prior septal reduction therapy.\n\nGiven the information from the patient note, the patient does not meet the primary inclusion criterion of having hypertrophic cardiomyopathy. The patient has cardiomyopathy, but there is no indication that it is specifically hypertrophic cardiomyopathy, which is necessary for inclusion in the trial. Therefore, the patient does not have sufficient information to qualify for the trial based on the provided diagnosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2105": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we need to compare the patient's characteristics with the inclusion criteria of the clinical trial titled \"Effect of Diabetes Mellitus on Cholesterol Metabolism.\"\n\nLet's review the patient's characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes mellitus (confirmed with molecular analysis)\n- Current treatment: 70/30 Insulin and vitamin D supplements\n- HbA1c: 6.5% (which indicates stable diabetes control)\n- BMI: Not provided\n\nNow, let's review the inclusion criteria for Type 1 DM in the clinical trial:\n- Age > 18 years\n- Diagnosed with type 1 DM (based upon history of ketoacidosis, proven insulin dependence, absent C-peptide and/or positive autoantibody profile such as anti-GAD etc.)\n- Stable A1C < 8.5%\n- BMI < 31\n\nThe patient meets the following inclusion criteria:\n- The patient is over 18 years of age.\n- The patient has a diagnosis of type 1 DM, which is confirmed with molecular analysis. While the note does not specifically mention history of ketoacidosis, insulin dependence, or autoantibody profile, the mention of molecular analysis and insulin treatment suggests a definitive diagnosis of type 1 DM.\n- The patient has a stable A1C of 6.5%, which is below the threshold of 8.5%.\n\nHowever, the patient's BMI is not provided in the note. It is an essential criterion for the trial, and without this information, we cannot conclusively determine the eligibility.\n\nGiven that the patient's note lacks the BMI information, which is part of the inclusion criteria, we are unable to confirm the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2106": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study),\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nInclusion criteria for the trial are:\n1. Hypertension, defined as systolic blood pressure greater than or equal to 130 but less than 160 mm Hg and diastolic blood pressure greater than or equal to 85 but less than 110 mm Hg.\n2. Must have any two of the following criteria:\n   - Abdominal obesity, defined as a waist circumference greater than 40 inches in men and greater than 35 inches in women.\n   - High-density lipoprotein (HDL) cholesterol level of less than 40 mg/dL in men and less than 50 mg/dL in women.\n   - Fasting triglycerides greater than or equal to 150 mg/dL.\n   - Fasting glucose level of 100-125 mg/dL.\n\nThe patient's note provides the following information:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He is diagnosed with cardiomyopathy and is prescribed ACE inhibitors and Beta blockers.\n- His fasting blood sugar (FBS) is 100 mg/dl, which falls into the fasting glucose level range of 100-125 mg/dl.\n- His HDL is 40 mg/dl, which is exactly the minimum for men in the inclusion criteria.\n- His fasting triglycerides (TG) are 140 mg/dl, which is below the threshold mentioned in the inclusion criteria.\n- There is no mention of hypertension or blood pressure readings in the patient's note.\n- There is no mention of abdominal obesity or waist circumference measurement.\n\nBased on the information provided, the patient does meet the fasting glucose level criterion and the HDL cholesterol level criterion. However, there is no information provided about the patient's blood pressure or waist circumference, and the patient's triglyceride levels are below the threshold for inclusion. Furthermore, the patient has type 1 diabetes, which is not mentioned in the inclusion criteria (the criteria mention risk of developing diabetes, which could imply a focus on type 2 diabetes, but this is not clear).\n\nSince there is not enough information to definitively include the patient based on the trial's criteria, and the patient does not meet all of the defined criteria (specifically, the triglyceride level and lack of hypertension data), the patient's eligibility would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2107": {
        "output": "",
        "label": 0
    },
    "2108": {
        "output": "The patient described in the note is a 25-year-old man with type 1 diabetes, not type 2 diabetes. The clinical trial is specifically looking to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in individuals with Type 2 Diabetes Mellitus with hypercholesterolemia.\n\nThe inclusion criteria for the trial are as follows:\n\n- Age: 25yrs \u2013 75yrs\n- Fasting TG <400mg/dL\n- LDL-C \u2265130mg/dL\n- 3 months > Diagnosed Type 2 DM, With OAD, HbA1c \u2264 10.0% or First Diagnosed Type 2 DM, 6.5%\u2264HbA1c\u226410.0%\n\nThe patient meets the age criterion, has fasting triglycerides and LDL cholesterol levels within the specified ranges, and has an HbA1c level below 10.0%. However, the patient does not meet the disease-specific criterion as he has type 1 diabetes, not type 2 diabetes. Since the trial is for patients with Type 2 Diabetes Mellitus and the patient has Type 1 Diabetes Mellitus, he does not qualify for this trial based on his type of diabetes.\n\nThus, the patient is not eligible for the clinical trial due to the disease-specific criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2109": {
        "output": "Based on the provided information, the patient is a 25-year-old man with type 1 diabetes and has been diagnosed with cardiomyopathy. He does not have a history of chronic kidney disease (CKD) or proteinuria, which are part of the inclusion criteria for the clinical trial. Additionally, the trial is specifically looking for patients with type 2 diabetes, not type 1 diabetes like the patient in the note.\n\nInclusion Criteria for the trial:\n1. CKD stage 1 patients\n2. Older than 18 years of age\n3. Type 2 Diabetic patients\n4. Proteinuria\n\nThe patient does meet the age requirement (older than 18 years of age), but there is no indication of him having type 2 diabetes, CKD, or proteinuria\u2014these are all essential criteria for the trial.\n\nTherefore, the patient does not meet the sufficient inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2110": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia,\" we need to compare the patient's characteristics and medical condition to the trial's inclusion criteria:\n\nInclusion Criteria for the Trial:\n- Men or women aged 20-79 years with definite DM or atherosclerotic vascular diseases with metabolic syndrome, defined as the presence of three or more of the following risk factors:\n  - Abdominal obesity (waist circumference > 90 cm in men or > 80 cm in women)\n  - Triglycerides > 150 mg/dL\n  - HDL-cholesterol < 40 mg/dL in men or < 50 mg/dL in women\n  - Blood pressure > 130/85 mm Hg\n  - Fasting glucose > 100 mg/dL\n- Those who are qualified for lipid-lowering therapy according to the Taiwanese national guidelines (LDL-C 130-190 mg/dL or TG 200-500 mg/dL with HDL-C < 40 mg/dL or TC/HDL-C > 5).\n\nPatient's Characteristics:\n- 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago.\n- Presents with shortness of breath and fatigue during activities.\n- Diagnosed with cardiomyopathy.\n- Lab results:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nNow, let's evaluate the patient against the inclusion criteria:\n\n- Age: The patient is 25 years old, which falls within the 20-79 age range specified in the criteria.\n- Definite DM: The patient has type 1 diabetes, which meets this condition.\n- Metabolic syndrome risk factors:\n  - We do not have information on the patient's waist circumference, so we cannot assess abdominal obesity.\n  - Triglycerides are 140 mg/dL, which is below the >150 mg/dL threshold.\n  - HDL-cholesterol is 40 mg/dL, which is at the threshold for men (<40 mg/dL).\n  - We do not have information on the patient's blood pressure.\n  - Fasting glucose is 100 mg/dL, which is at the threshold (>100 mg/dL).\n\nFor the metabolic syndrome criteria, the patient needs to have three or more of the risk factors. We only have data for two of the risk factors (TG and HDL), and neither of them clearly satisfies the criteria. Information on the patient's waist circumference and blood pressure is not provided.\n\nConsidering the patient's LDL-C and TG levels, they do not meet the criteria for lipid-lowering therapy according to the Taiwanese national guidelines (LDL-C 130-190 mg/dL or TG 200-500 mg/dL with HDL-C < 40 mg/dL or TC/HDL-C > 5).\n\nBased on the available information, the patient does not clearly meet the inclusion criteria due to insufficient data on metabolic syndrome risk factors and not meeting the lipid-lowering therapy qualifications. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2111": {
        "output": "To determine the eligibility of the patient for the clinical trial \"Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial,\" we must compare the patient's characteristics and condition with the inclusion criteria of the study:\n\nInclusion criteria for the trial:\n\n1. Patients with NYHA functional class IV heart failure\n2. Signs of congestion (third heart sound or pulmonary rales on physical examination)\n3. Pulmonary congestion on chest x-ray\n4. Serum B-type natriuretic peptide levels > 400 pg/ml or NT-proBNP > 1500 pg/ml\n5. Echocardiographic documentation of systolic or diastolic dysfunction\n6. Age >18 years old\n7. On medical therapy with an ACE-inhibitor and/or a \u03b2-blocker\n8. Experiencing an acute decompensation of known chronic HF\n9. Baseline oxygen saturation <90% on admission arterial blood gas\n\nPatient's condition:\n\n- 25-year-old man with type 1 diabetes\n- Shortness of breath and fatigue during activities (NYHA class II, not class IV)\n- Diagnosed with cardiomyopathy, treated with ACE inhibitors and Beta-blockers\n- No other significant medical history\n- No signs of acute decompensated heart failure as per the patient note\n- No information on B-type natriuretic peptide levels, pulmonary congestion on chest x-ray, or echocardiographic documentation\n- No mention of baseline oxygen saturation levels\n\nThe patient is diagnosed with cardiomyopathy and experiences shortness of breath equivalent to NYHA class II, not NYHA class IV as required by the trial. The patient note lacks information about signs of congestion, pulmonary congestion on chest x-ray, B-type natriuretic peptide levels, echocardiographic documentation, and baseline oxygen saturation. Therefore, even though the patient is over 18 years old and is on medical therapy with an ACE-inhibitor, he does not meet several critical inclusion criteria for the clinical trial.\n\nBased on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2112": {
        "output": "",
        "label": 0
    },
    "2113": {
        "output": "The patient in the provided note is a 25-year-old man with type 1 diabetes, which was confirmed with molecular analysis 7 years ago. According to the inclusion criteria of the clinical trial, participants must have newly diagnosed type 1 diabetes with less than 6 weeks of insulin therapy, be between the ages of 18-39 years, and be GADA and/or IA-2A positive.\n\nDespite the patient's age fitting the criteria (25 years within the 18-39 range), the patient does not meet the \"new onset\" requirement as he was diagnosed with diabetes 7 years ago and has been on insulin therapy for this duration. Additionally, there is no information provided about the patient's GADA and/or IA-2A status.\n\nTherefore, based on the information given, the patient does not meet the inclusion criteria of having new onset type 1 diabetes with less than 6 weeks of insulin therapy, which excludes him from participating in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2114": {
        "output": "To determine the trial-level eligibility of the patient, we need to match the patient's characteristics and condition with the inclusion and exclusion criteria of the clinical trial provided.\n\nPatient Characteristics:\n- Age: 25 years old (meets the age inclusion criteria of 20-79 years)\n- Gender: Male (no gender-specific criteria mentioned)\n- Condition: Type 1 diabetes (meets the condition of having definite DM)\n- Triglyceride levels: 140 mg/dL (below the inclusion criteria of >150 mg/dL)\n- HDL-cholesterol: 40 mg/dL (meets the inclusion criteria of <40 mg/dL for men)\n- Blood pressure: Not mentioned (cannot confirm if it meets the criteria of >130/85 mm Hg)\n- Fasting glucose: 100 mg/dL (meets the inclusion criteria of >100 mg/dL)\n- LDL-cholesterol: 125 mg/dL (within the qualifying range of 130-190 mg/dL for lipid-lowering therapy according to the Taiwanese national guidelines, which the patient does not meet)\n- Other inclusion factors: No mention of abdominal obesity, other risk factors for metabolic syndrome, or previous intolerance to statins or fibrates. The patient's HbA1c level is 6.5%, which does not indicate uncontrolled diabetes mellitus. No other exclusion criteria are mentioned or met based on the patient note.\n\nThe patient does not meet the full criteria for metabolic syndrome since we only have confirmed HDL-cholesterol <40 mg/dL for men and fasting glucose >100 mg/dL. We do not have information on waist circumference, blood pressure, or the presence of two other risk factors required for a diagnosis of metabolic syndrome. The patient's LDL-C level is not within the required range for eligibility. Therefore, based on the available information, the patient does not meet enough of the inclusion criteria to be deemed eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2115": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility.\n\nPatient note:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities\n- Mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2)\n- Diagnosed with cardiomyopathy\n- Will be treated with ACE inhibitors and Beta blockers\n- Currently takes 70/30 Insulin and vitamin D supplements\n- No other significant medical issues\n- Family history of DM type 1\n\nClinical trial inclusion criteria:\n- New York Heart Association Class II and III\n- Already on or tried on best known medical treatment (ACE inhibitor and beta-blocker)\n- Stable for a period of at least 6 weeks\n- Left ventricular ejection fraction less than or equal to 45%\n\nThe patient is in New York Heart Association Class II and is about to be treated with an ACE inhibitor and a beta-blocker for his cardiomyopathy, which aligns with the trial criteria. However, there is no information provided about the stability of his condition for at least 6 weeks and no indication of his left ventricular ejection fraction values to determine if it meets the criterion of being less than or equal to 45%.\n\nGiven the missing information about the stability of the patient's condition and the left ventricular ejection fraction, the patient cannot be clearly classified as meeting all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2116": {
        "output": "",
        "label": 0
    },
    "2117": {
        "output": "To assess the patient's eligibility for the given clinical trial, we need to compare the patient's characteristics and lab results with the inclusion criteria of the trial.\n\nInclusion Criteria for the trial:\n1. BMI \u226525 and <45\n2. LDL >100 mg/dl\n3. TG \u2265150 and <400 mg/dl\n4. Meet 2 or more of the following 4 criteria:\n   - HDL <50 mg/dl for men (as the trial does not specify gender, it's common to use gender-specific cutoffs for HDL)\n   - Blood pressure \u2265130/85 mmHg (or diagnosed hypertension on medication)\n   - Fasting glucose \u2265100 mg/dl and <150 mg/dl\n   - Waist circumference >35 inches for women (as the trial does not specify gender, for men, a cutoff of >40 inches is commonly used)\n\nPatient's characteristics and lab results:\n1. The patient's BMI is not provided.\n2. LDL is 125 mg/dl (meets criteria)\n3. TG is 140 mg/dl (does not meet criteria)\n4. HDL is 40 mg/dl (meets criteria for men)\n5. Blood pressure is not mentioned.\n6. Fasting glucose is 100 mg/dl (meets criteria)\n7. Waist circumference is not provided.\n\nThe patient meets the LDL criteria (>100 mg/dl), has an HDL level that is below the gender-specific cutoff for men (<50 mg/dl), and has a fasting glucose level within the specified range (\u2265100 mg/dl and <150 mg/dl). However, the TG level does not meet the trial criteria (\u2265150 mg/dl), and there is no information on the patient's BMI, blood pressure, or waist circumference.\n\nBased on the available information, the patient meets 3 of the trial's inclusion criteria (LDL, HDL for men, and fasting glucose), but does not meet the TG criterion. Additionally, due to the lack of information on BMI, blood pressure, and waist circumference, we cannot definitively determine eligibility.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2118": {
        "output": "In reviewing the patient's eligibility for the clinical trial titled \"Muscadine Grape Seed Supplementation and Vascular Function,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n1. Adult male and non-pregnant female outpatients\n2. With hypertension (blood pressure \u2265 140/90 or current treatment for hypertension), or\n3. Dyslipidemia (total cholesterol > 220 mg/dL + LDL cholesterol > 130 mg/dL, or current use of lipid-lowering medications), or\n4. Controlled type 2 diabetes mellitus (glycated hemoglobin < 8.0 % with or without medication).\n\nThe patient note provides the following information:\n- The patient is a 25-year-old man, which satisfies the adult male outpatient requirement.\n- The patient has type 1 diabetes, not type 2. This does not meet the criteria for inclusion based on diabetes type.\n- There is no mention of hypertension or treatment for hypertension in the patient note.\n- The patient has dyslipidemia since the LDL cholesterol is 125 mg/dL, which is below the threshold of > 130 mg/dL for inclusion based on dyslipidemia.\n\nSince the patient does not meet the dyslipidemia criteria and has type 1 diabetes instead of type 2, and there is no information on hypertension, the patient does not fulfill sufficient inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2119": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes, not type 2 diabetes. Therefore, he does not meet the inclusion criteria of having diabetes mellitus type 2 as specified in the clinical trial.\n\nFurthermore, the trial is looking for patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. The patient does have cardiomyopathy and is being treated for it, which could be considered a form of cardiovascular disease. However, since the patient has type 1 diabetes and not type 2 diabetes, this does not align with the trial's requirements.\n\nSince the patient does not have the specific disease (type 2 diabetes) required for the trial, they would not be eligible for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2120": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes who has been diagnosed with cardiomyopathy. The clinical trial in question is related to implementing Work in Progress (WIP) sequences in Magnetic Resonance Imaging (MRI), and the inclusion criteria for the trial are a clinical diagnosis of ischemic or non-ischemic cardiomyopathy.\n\nGiven that the patient has been diagnosed with cardiomyopathy, which fits the inclusion criteria of having either ischemic or non-ischemic cardiomyopathy, the patient appears to be eligible for the trial. There is no additional information provided that would suggest exclusion based on the trial's criteria or additional exclusion criteria.\n\nTherefore, the patient would be eligible for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2121": {
        "output": "Given the patient note and the clinical trial information provided, we need to ascertain the patient's eligibility for the trial based on the inclusion criteria. Let's go through the inclusion criteria and see if the patient meets them:\n\n1. Signed and dated informed consent prior to participation: This is not mentioned in the patient note, but it's a procedural step that the patient can complete if they agree to participate.\n\n2. Subjects in good health as determined by the Investigator: The patient has type 1 diabetes and cardiomyopathy, which are significant health conditions. However, the term \"good health\" is subjective and up to the investigator's discretion.\n\n3. Age 18-55: The patient is 25 years old, which fits within this range.\n\n4. Willing to abstain from any physical therapy, hard physical work, exercise, or sauna during the study observation period (Screening to Final Visit): There is no information given about the patient's willingness or current participation in these activities.\n\n5. For females, subjects of childbearing potential must be using appropriate birth control, or be surgically sterile: This is not applicable to the patient as he is male.\n\nThe trial is focused on the treatment of muscle pain induced by eccentric exercise, but the patient's note does not mention any such condition or the need for this type of treatment. The patient has type 1 diabetes and cardiomyopathy, which are not related to the study's purpose. Given this disconnect, the patient does not appear to meet the relevance for the trial's focus and therefore would be considered not relevant for this specific study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2122": {
        "output": "",
        "label": 0
    },
    "2123": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's determine the patient's eligibility for the clinical trial.\n\nThe patient note describes a 25-year-old man with type 1 diabetes, cardiomyopathy, and no significant other medical issues. He is on insulin therapy and vitamin D supplements.\n\nThe clinical trial in question is looking at vaccine responses to influenza A H1N1/09 immunization in high-risk patients. The inclusion criteria for the trial are:\n\n1. Medically recommended influenza A(H1N1) immunization\n2. Signed informed consent\n\nFrom the patient note, there is no information provided that suggests the patient has been medically recommended for influenza A(H1N1) immunization. Therefore, based on the available information, we cannot determine if the patient is indeed recommended for the immunization, which is a requirement for participation in the study.\n\nGiven that we do not have sufficient information to determine whether the patient meets the specific inclusion criteria of being medically recommended for H1N1 immunization, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2124": {
        "output": "",
        "label": 0
    },
    "2125": {
        "output": "",
        "label": 0
    },
    "2126": {
        "output": "Based on the patient note, the patient is a 25-year-old man with type 1 diabetes, presenting with symptoms of cardiomyopathy, and is undergoing treatment with ACE inhibitors and Beta blockers. His past medical history does not mention any other significant medical issues. The clinical trial in question is focused on monitoring the prevalence and trends of common chronic diseases in the general population, and specific inclusion criteria mention \"persons living in 10 municipalities of Copenhagen.\"\n\nThe patient note does not provide information regarding the patient's residence. As this is a crucial piece of information necessary to determine the patient's eligibility for the trial, and it is absent from the patient note, we cannot definitively conclude if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2127": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\n1. Men and women, ages >18: The patient is a 25-year-old man, which meets this criterion.\n2. Fasting triglyceride \u2265200 mg/dL and <500 mg/dL: The patient has a fasting triglyceride level of 140 mg/dL, which does not meet the criterion of having a level \u2265200 mg/dL.\n3. LDL-C (low-density lipoprotein - cholesterol) \u226540 mg/dL and <100 mg/dL: The patient's LDL level is 125 mg/dL, which exceeds the upper limit of the criterion.\n4. High risk for coronary heart disease: The patient has been diagnosed with cardiomyopathy, which is a risk factor for coronary heart disease, but there is no indication that he is at high risk per the criteria of the trial.\n5. On stable dose of statin (atorvastatin, rosuvastatin, or simvastatin): The patient is not currently on a statin, but rather will be treated with ACE inhibitors and Beta blockers.\n6. Provide written informed consent and authorization for protected health information disclosure: There is no information provided about the patient's willingness to consent, but this typically occurs after eligibility is determined, so we'll assume it's not a disqualifying factor at this stage.\n\nBased on the provided information, the patient does not meet the inclusion criteria regarding fasting triglyceride levels and LDL-C levels, and there is no information about the patient being on a stable dose of statin which is required by the trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2128": {
        "output": "Based on the provided patient note, the patient has a fasting triglyceride level of 140 mg/dL. This level does not meet the inclusion criteria for the clinical trial, which requires fasting triglyceride levels to be \u2265 500 mg/dL and \u2264 2000 mg/dL.\n\nSince the patient's fasting triglyceride level falls below the minimum required for the study, the patient is not eligible to participate in the trial. The patient's age and the provision of written informed consent (which we assume could be obtained if not already provided) do meet the general inclusion criteria, but the specific requirement for triglyceride levels is not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2129": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"A Study for Patients With Type 1 Diabetes,\" we must compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nHere are the inclusion criteria for the trial:\n\n1. Type 1 diabetes mellitus (T1DM) for at least 1 year\n2. Using insulin glargine for at least 6 months with a maximum daily dose of 1 unit per kilogram (U/kg)\n3. Hemoglobin A1c (HbA1c) of no greater than 10.5% before randomization\n4. Body mass index (BMI) 19 to 45 kilogram per square meter (kg/m\u00b2)\n5. Capable and willing to prepare and inject insulin with a syringe, monitor own blood glucose, complete the study diary, be receptive to diabetes education, comply with study requirements, and receive telephone calls during treatment\n6. Women of childbearing potential must test negative for pregnancy before receiving treatment and agree to use reliable birth control until completing the follow-up\n\nNow let's analyze the patient's information:\n\n1. The patient has type 1 diabetes, confirmed with molecular analysis 7 years ago.\n2. There is no information provided about the use of insulin glargine or any other specific insulin regime.\n3. The patient's HbA1c is 6.5%.\n4. No data about the patient's weight or height is provided, so we cannot calculate their BMI.\n5. The patient is taking insulin, but there is no specific mention of using a syringe or being capable and willing to comply with all the study requirements, although it is common practice for a patient with type 1 diabetes to monitor their blood glucose and manage insulin injections.\n6. The patient is a man, so the criteria regarding women of childbearing potential and pregnancy do not apply.\n\nSince the patient's insulin regime is not specified, and we cannot calculate the BMI due to missing height and weight information, we do not have sufficient information to determine if the patient meets all the inclusion criteria.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2130": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes\n- Other conditions: Cardiomyopathy\n- Medication: Taking insulin (70/30 Insulin)\n- Lab values: Cholesterol 190 mg/dl, TG 140 mg/dl, LDL 125 mg/dl, HDL 40 mg/dl\n\nClinical trial inclusion criteria:\n- Age: 35 years or older\n- Diagnosis: Type 2 diabetes\n- Not using insulin within the first 5 years of treatment\n- Hyperlipidemia: Cholesterol \u2265 200 mg/dl, TG \u2265 150 mg/dl, LDL \u2265 100 mg/dl, HDL \u2265 35 mg/dl\n- Hypertension: Blood pressure \u2265 130/85 mmHg or using hypertensive drugs\n- Obesity: BMI \u2265 25\n\nThe patient's age is below the required age for the clinical trial, as the patient is 25 and the trial requires participants to be 35 or older. Additionally, the patient has type 1 diabetes, while the trial is for patients with type 2 diabetes. The patient is also using insulin, which is another mismatch with the trial criteria that state participants should not have used insulin during the first 5 years of treatment. The cholesterol level of the patient is also below the threshold set by the trial. \n\nSince the patient does not meet several key inclusion criteria (age, type of diabetes, insulin use, and cholesterol levels), they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2131": {
        "output": "To determine trial-level eligibility, we must compare the patient's characteristics and condition to the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes, not acute decompensated heart failure (HF)\n- NYHA class 2 heart failure symptoms\n- No mention of third heart sound, pulmonary rales, or pulmonary congestion on chest x-ray\n- No serum B-type natriuretic peptide levels or NT-proBNP levels provided\n- Echocardiographic documentation of cardiomyopathy, but no explicit mention of systolic or diastolic dysfunction\n- Already on medical therapy with ACE inhibitor and Beta blockers\n- No information about an acute decompensation of chronic HF\n- No baseline oxygen saturation provided\n\nClinical Trial Inclusion Criteria:\n- NYHA functional class IV heart failure\n- Signs of congestion (third heart sound or pulmonary rales)\n- Pulmonary congestion on chest x-ray\n- Serum B-type natriuretic peptide levels > 400 pg/ml or NT-proBNP > 1500 pg/ml\n- Echocardiographic documentation of systolic or diastolic dysfunction\n- Age >18 years old\n- On medical therapy with an ACE-inhibitor and/or \u03b2-blocker\n- Experiencing an acute decompensation of known chronic HF\n- Baseline oxygen saturation <90% on admission arterial blood gas\n\nThe patient does not meet several key inclusion criteria:\n- The patient has NYHA class 2 symptoms, not class IV as required by the trial.\n- There is no mention of acute decompensated heart failure, which is a requirement.\n- The patient's specific heart failure condition (e.g., presence of systolic or diastolic dysfunction) is not documented in the manner specified by the trial criteria.\n- There are no data provided on B-type natriuretic peptide levels or NT-proBNP levels, nor on baseline oxygen saturation.\n\nBased on the information provided, the patient does not meet the inclusion criteria of the clinical trial, as it seems they do not have acute decompensated heart failure and their symptoms do not align with NYHA functional class IV. Therefore, the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2132": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's assess the patient's eligibility:\n\n1. Age: The patient is 25 years old, which falls within the 18 (inclusive) to 80 (exclusive) age range required by the trial.\n2. Diagnosis of heart failure: The patient has been diagnosed with cardiomyopathy and is experiencing symptoms of heart failure (shortness of breath and fatigue during activities), which is consistent with the trial's requirement for subjects with heart failure.\n3. NYHA Class: The patient is classified as New York Heart Association (NYHA) class II, which meets the trial's inclusion criteria for subjects with NYHA Class II-IV with dyspnea.\n4. Left ventricular ejection fraction (LVEF): The patient's LVEF is not mentioned in the patient note. This information is necessary to determine eligibility since the trial requires a LVEF of 40 percent or below.\n5. Written informed consent: This is a stipulation that the patient would need to meet should they qualify for the other criteria and agree to participate in the trial.\n\nSince the LVEF is not provided in the patient note, we cannot definitively determine if the patient meets all the inclusion criteria for the clinical trial. Therefore, the patient's trial-level eligibility is as follows:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2133": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes, matching the disease under study.\n- However, the patient's age does not fall within the 12 to 18 years age range specified by the trial.\n- The patient has been diagnosed with type 1 diabetes for 7 years, which is more than the 1-year minimum specified.\n- The patient's HbA1c is 6.5%, which is below the maximum allowed 12%.\n- There is no information provided about whether the patient has been on an insulin pump for at least 3 months or about his knowledge of insulin self-adjustment.\n\nClinical Trial Inclusion Criteria:\n- Age between 12 and 18 years.\n- Type 1 diabetes diagnosis for at least 1 year or confirmed C-peptide negative.\n- On insulin pump therapy for at least 3 months with good knowledge of insulin self-adjustment.\n- HbA1c \u2264 12%.\n\nThe patient does not meet the age criterion as he is 25 years old, which is outside the 12 to 18 years age range specified by the trial. All other criteria cannot be confirmed due to lack of information or are met based on the given patient note.\n\nTherefore, the patient is not eligible for the trial due to age.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2134": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, the assessment can be made as follows:\n\nThe patient is a 25-year-old man with type 1 diabetes and has been diagnosed with cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers, and there is no mention of hypertrophic cardiomyopathy or aortic valve replacement in his medical history.\n\nThe inclusion criteria for the clinical trial are:\n1. Age \u2265 18 years\n2. Diagnosed with Hypertrophic Cardiomyopathy\n3. Has undergone Aortic valve replacement\n\nThe patient meets the age criterion (he is 25 years old). However, there is no information provided in the patient note indicating that the patient has hypertrophic cardiomyopathy or that he has undergone an aortic valve replacement. Instead, the patient has been diagnosed with a different form of cardiomyopathy and there is no mention of any surgical interventions such as aortic valve replacement.\n\nBased on the provided information, the patient does not meet all the inclusion criteria for the clinical trial due to the lack of evidence for hypertrophic cardiomyopathy and aortic valve replacement. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2135": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure,\" we need to compare the inclusion criteria of the trial with the information provided in the patient note.\n\nHere are the inclusion criteria for the clinical trial:\n\n1. Greater than or equal to 18 years of age\n2. NYHA Class III\n3. Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months\n4. Residual well-demarcated region of LV systolic dysfunction defined as at least 3 consecutive segments of abnormal wall motion by echocardiography read at the echocardiography core laboratory\n5. LVEF less than or equal to 40% measured by echocardiography read at the echocardiography core laboratory\n6. No left ventricular wall thickness less than 0.5 cm measured by echocardiography read at the echocardiography core laboratory\n7. Mitral regurgitation of 0-2+ (inclusive) measured by echocardiography read at the echocardiography core laboratory\n8. Subject has an implanted, functional AICD\n9. Subject receiving stable optimal pharmacological therapy defined as:\n   - ACE inhibitor and/or ARB, and Beta-blocker for 90 days with stable dose for 30 days unless contraindicated\n   - Diuretic in subjects with evidence of fluid retention\n   - ASA unless contraindicated\n   - Statin unless contraindicated\n   - Aldosterone antagonist per physician discretion unless contraindicated\n10. Subjects with a found diagnosis of diabetes must have had an ophthalmologist exam within the last year showing no active proliferative retinopathy\n\nNow, let's compare these criteria to the patient note:\n\n- The patient is a 25-year-old man (meets age criteria).\n- He is diagnosed with cardiomyopathy (but not specified as ischemic cardiomyopathy).\n- He has NYHA Class II symptoms, not Class III as required by the trial.\n- No information is provided on the echocardiography results regarding LV systolic dysfunction, LVEF, left ventricular wall thickness, or mitral regurgitation.\n- There is no mention of an AICD being implanted.\n- The patient is being treated with ACE inhibitors and Beta blockers, but we do not have information on the duration or stability of the dose.\n- No information on diuretic use, ASA, statin, or aldosterone antagonist use is provided.\n- The patient has type 1 diabetes, but there is no mention of an ophthalmologist exam within the last year or the state of his retinopathy.\n\nBased on the available information, the patient does not meet multiple required inclusion criteria (specifically the NYHA Class III and specific cardiomyopathy criteria), and there is insufficient information to confirm other necessary criteria. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2136": {
        "output": "Considering the information provided in the patient note and the inclusion criteria of the clinical trial for Conjugated Linoleic Acid in Patients With Type 2 Diabetes Mellitus, let's assess the eligibility:\n\nPatient's characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes mellitus\n- HbA1c: 6.5%\n- Not overweight or obese (BMI not mentioned, but no indication of overweight or obesity)\n- Not on stable medical therapy for diabetes (type of diabetes treatment not matching the criteria)\n- Stable serum glucose: Not specified, but FBS is 100 mg/dl, which is not within the specified range for the trial\n- Age is not within the 30 to 50 years range\n- Uses insulin\n- No mention of alcohol, smoking habits, or metformin use\n\nClinical trial inclusion criteria:\n- Diagnosis of type 2 diabetes mellitus > 5 years\n- HbA1c \u2264 9%\n- Overweight or obese (BMI \u2265 25 kg/m2 and \u2264 30 kg/m2)\n- Age \u2265 30 and \u2264 70 years\n- Stable medical therapy for the past 3 months\n- Stable serum glucose for the past 3 months (128-180 mg/Dl)\n- Age between 30 to 50\n- Use of metformin\n- TG < 240 mg/Dl\n- No alcohol, no insulin, no smoke\n- No pregnancy, no menopause\n\nThe patient does not meet several of the inclusion criteria for the trial:\n- The patient has a diagnosis of type 1 diabetes, not type 2.\n- The patient's age is below the specified range (25 years old, whereas the trial requires participants to be between 30 and 70 years old).\n- The patient uses insulin, which is excluded by the trial criteria.\n- There is no information indicating the use of metformin.\n\nTherefore, based on the available information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2137": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess the eligibility of the patient for the trial based on the inclusion criteria.\n\nPatient note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes, confirmed 7 years ago.\n- He presents with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- His diabetes is managed with insulin and vitamin D supplements.\n- No mention of a recent diagnosis of type 2 diabetes.\n\nClinical trial inclusion criteria:\n- Newly diagnosed type 2 diabetes.\n- Age between 40 and 70 years old.\n\nThe patient does not meet the inclusion criteria for the clinical trial because he has type 1 diabetes, not type 2, and he was diagnosed 7 years ago, which does not qualify as \"newly diagnosed.\" Additionally, the patient's age is below the specified age range of 40 to 70 years old.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2138": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Clinical diagnosis of type 1 diabetes within the last 6 months.\n2. Age 20-45 years.\n3. Fasting basal C-peptide equal or greater than 0.22 nmol/L, lower than 0.8 nmol/L.\n4. BMI between 17 and 30 at screening.\n\nThe patient's characteristics based on the provided note are:\n\n1. Type 1 diabetes confirmed with molecular analysis 7 years ago.\n2. The patient is 25 years old.\n3. There is no information provided about the patient's fasting basal C-peptide levels.\n4. There is no information provided about the patient's BMI.\n\nThe patient meets the age criterion (2). However, the patient does not meet the first criterion, as their type 1 diabetes was diagnosed 7 years ago, not within the last 6 months. Additionally, the patient note does not provide information about the fasting basal C-peptide levels or the BMI, which are required to determine eligibility fully.\n\nSince the patient does not meet one of the key inclusion criteria (newly diagnosed type 1 diabetes within the last 6 months), we can conclude that the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2139": {
        "output": "The patient is a 25-year-old man with type 1 diabetes. He presents with cardiomyopathy and is treated with ACE inhibitors and Beta blockers. His family history is positive for type 1 diabetes. He is not pregnant or nursing, and there is no information that he is younger than 18 years old.\n\nThe clinical trial is looking to identify and characterize genetic variants associated with type 2 diabetes, its risk factors, and its complications. The inclusion criteria are men and women of any race, focused on American Indians and Mexican Americans, who are 18 years and older. The exclusion criteria are pregnant women and children under 18 years old.\n\nThe patient meets the age requirement and is not excluded on the basis of gender, race, or being pregnant. However, the clinical trial focuses on type 2 diabetes, while the patient has type 1 diabetes. Since the patient has a different condition than the one being studied, he does not meet the specific disease criteria for this trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as the trial is specific to type 2 diabetes and its complications, and the patient has type 1 diabetes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2140": {
        "output": "",
        "label": 0
    },
    "2141": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes, confirmed with molecular analysis 7 years ago. He is currently diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers. He is on 70/30 Insulin and vitamin D supplements. His HbA1c level is 6.5%, which meets the requirement of \u2265 6.0% for the clinical trial. There is no mention of the patient having any concomitant diseases that influence metabolic control, nor is there any indication that he is currently using a continuous glucose monitor (CGM) or participating in any other interventional study. Additionally, the patient meets the age requirement of \u2265 18 years.\n\nHowever, the patient note does not specify the model of the insulin pump he is using. The inclusion criteria for the clinical trial specify that the patient must be on Medtronic insulin infusion pump CSII therapy (specific models mentioned) for at least 3 months. Without this specific information, we cannot definitively determine if the patient meets all the inclusion criteria.\n\nTherefore, based on the available information, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2142": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial as follows:\n\n- The patient has type 1 diabetes confirmed with molecular analysis 7 years ago, which meets the criterion of \"Type I diabetes, durability >5 years.\"\n- The patient is 25 years old, which falls within the \"Age 20-65 years\" range specified by the trial.\n- The patient is on diabetic treatment with insulin, which likely includes mealtime and bedtime insulin, though the patient note specifies only 70/30 Insulin without further details.\n- The patient's HbA1c is 6.5%, which is within the \"HbA1c \u226410 %\" criterion.\n- The patient has given no indication of not providing informed consent to participate in the study, so we can assume this criterion could be met if the patient agrees.\n\nHowever, the patient's BMI is not provided in the note, so we cannot confirm whether the patient meets the \"Normal weight (BMI 19-26 kg/m2)\" criterion. Without this information, we cannot definitively determine eligibility.\n\nSince there is insufficient information to qualify the patient for the trial based on BMI, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2143": {
        "output": "The patient note provides the following information relevant to the inclusion criteria of the clinical trial:\n\n- The patient is a 25-year-old man with type 1 diabetes, which meets the requirement of having type 1 diabetes.\n- The patient's HbA1c level is 6.5%, which is below the 9% threshold specified in the inclusion criteria.\n\nHowever, the patient note does not mention the use of statin drugs. The inclusion criteria for the trial specify that participants must be on stable statin drug use. Since there is no information about the patient's use of statin drugs, we cannot determine if they meet all the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2144": {
        "output": "After reviewing the patient's note and the clinical trial's inclusion criteria, it is clear that the patient does not have transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). He has type 1 diabetes and cardiomyopathy, which are not the conditions being studied in the trial. Since the patient's condition does not match the target disease of the clinical trial, he does not meet the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2145": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 25 years old\n- Diagnosed with type 1 diabetes mellitus 7 years ago\n- Presents with symptoms of cardiomyopathy (shortness of breath and fatigue during activities)\n- Currently treated with ACE inhibitors and Beta blockers\n- No information provided about micro-angiopathy or myocardial ischemic test results\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 45 years\n- Diagnosed with type 1 diabetes mellitus (with or without complications or peripheral vascular micro-angiopathy)\n- Having a negative myocardial ischemic test (exercise echocardiography) in the previous month\n\nThe patient meets the age criteria and has a diagnosis of type 1 diabetes mellitus, which are both inclusion criteria for the clinical trial. However, there is no information provided about the results of a myocardial ischemic test in the previous month, which is a necessary inclusion criterion for the trial.\n\nSince the patient note does not confirm whether the patient had a myocardial ischemic test and the results of such a test, we do not have sufficient information to determine if the patient meets all the inclusion criteria for the clinical trial. \n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2146": {
        "output": "To determine the trial-level eligibility for the patient, let's compare the patient's information to the inclusion criteria of the clinical trial:\n\nInclusion Criteria for the Trial:\n1. Diabetes duration > 5 years\n2. HbA1c \u2264 7.2%\n3. CSII (Continuous Subcutaneous Insulin Infusion) treated for > 3 months\n4. Capable of being moderately, physically active for 20 minutes\n\nPatient Information:\n- Type 1 diabetes confirmed with molecular analysis 7 years ago (meets the requirement of diabetes duration > 5 years)\n- HbA1c: 6.5% (meets the HbA1c requirement of \u2264 7.2%)\n- Currently takes 70/30 Insulin (the patient note does not specify CSII treatment; therefore, this information is lacking)\n- The patient is experiencing shortness of breath and fatigue during activities, which could suggest that the patient may not be capable of being moderately physically active for 20 minutes. However, the ability to climb 3 floors could be indicative of some degree of physical capability. The information is insufficient to confirm this criterion.\n\nBased on the patient note provided, we have sufficient information to determine that the patient meets two of the four inclusion criteria (diabetes duration and HbA1c level). However, the patient note lacks information on whether the patient is treated with CSII and whether the patient is capable of being moderately physically active for 20 minutes.\n\nTherefore, the patient does not have sufficient information to qualify for the trial, as there is no explicit mention of CSII treatment or confirmation of the patient's physical activity capability.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2147": {
        "output": "The patient in question is a 25-year-old man with a confirmed diagnosis of type 1 diabetes for 7 years. His current HbA1c level is 6.5%, which is under the threshold of >8.0% specified in the inclusion criteria of the clinical trial. Although the patient meets other inclusion criteria such as being male and within the age range of 18-65 years old, his HbA1c level does not meet the specified threshold for the trial. Consequently, he does not qualify for this particular clinical trial based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2148": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility.\n\nThe patient is a 25-year-old man, which fits within the age range of 18-79 years specified in the trial's inclusion criteria.\n\nHowever, the patient's fasting triglyceride level (TG) is listed as 140 mg/dL. The clinical trial's inclusion criteria require a fasting triglyceride level of \u2265500 mg/dL and \u22641500 mg/dL.\n\nSince the patient's triglyceride levels do not meet the specified range for the trial, he does not qualify based on this essential criterion.\n\nGiven this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2149": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy,\" we should compare the patient's characteristics and lab results to the inclusion criteria listed for the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Men and women \u2265 18 years of age.\n2. Non-HDL-C \u2265100 mg/dL and \u2264220 mg/dL at Visits 1 and 2.\n3. FPG (Fasting Plasma Glucose) \u226590 mg/dL and \u2264145 mg/dL, at Visits 1 and 2.\n4. HDL-C <60 mg/dL at Visits 1 and 2, regardless of gender.\n5. Untreated dyslipidemia or statin treatment only with equipotency to atorvastatin \u226440 mg daily for at least 12 weeks prior to Screening Visit 1 and without change or initiation prior to randomization.\n\nLet's compare the patient's details with the criteria:\n\n1. The patient is a 25-year-old man, meeting the age criterion.\n2. The patient's lab results show a total cholesterol of 190 mg/dL, but the non-HDL-C (total cholesterol minus HDL) is 190 mg/dL - 40 mg/dL = 150 mg/dL. This is within the required range of \u2265100 mg/dL and \u2264220 mg/dL.\n3. The patient's fasting blood sugar (FBS) is 100 mg/dL, which is equivalent to FPG. This is within the required range of \u226590 mg/dL and \u2264145 mg/dL.\n4. The patient's HDL-C is 40 mg/dL, which is below the threshold of <60 mg/dL.\n5. The patient's treatment includes 70/30 Insulin and vitamin D supplements. The notes do not mention any dyslipidemia treatment, so we cannot definitively conclude whether the patient meets this criterion. However, there is no mention of statin treatment, which suggests that the patient may have untreated dyslipidemia.\n\nGiven the information available, it seems that the patient meets most of the inclusion criteria. However, the last point regarding dyslipidemia treatment is not entirely clear. Since we do not have complete information on the patient's dyslipidemia treatment history, we must categorize this assessment as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2150": {
        "output": "The patient in question is a 25-year-old man with type 1 diabetes, which makes him ineligible for the trial based on several criteria:\n\n1. Age: The trial requires participants to be between 50-70 years old. The patient is 25 years old.\n2. Type of diabetes: The trial is specifically for individuals with type 2 diabetes. The patient has type 1 diabetes.\n3. Duration of disease: The trial requires a history of at least two years of type 2 diabetes and no insulin treatment in the first two years after diagnosis. The patient has been treated for type 1 diabetes for seven years and is on insulin.\n4. Cardiovascular history: There is no information regarding a negative medical history for documented previous cardiovascular events or macrovascular complications, but this point is moot given that the patient does not meet other inclusion criteria.\n\nAdditionally, while the patient does meet one of the risk factor criteria (LDL cholesterol > 130 mg/dL), the other risk factors are not all met or relevant due to the patient's type 1 diabetes.\n\nBased on these points, the patient does not meet the inclusion criteria for the clinical trial titled \"Multifactorial Intervention in Type 2 Diabetes - Italy.\"\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2151": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- Age: 25 years old\n- Medical condition: Type 1 diabetes\n- Current treatment: 70/30 Insulin and vitamin D supplements\n- Other aspects: Cardiomyopathy treated with ACE inhibitors and Beta-blockers\n- Fasting Blood Sugar (FBS): 100 mg/dl\n\nClinical trial inclusion criteria:\n- Age between 18 and 75 years, inclusive\n- BMI-range 27-50 kg/m\u00b2 (no BMI provided in the patient note)\n- Patients with type 2 diabetes presenting with fasting hyperglycaemia (>126mg/dl) on metformin treatment\n\nThe patient's age falls within the age range specified by the trial. However, the patient has type 1 diabetes, not type 2 diabetes, which is a requirement for the trial. Additionally, the patient's fasting blood sugar level (100 mg/dl) is below the specified threshold for fasting hyperglycaemia (>126mg/dl). Furthermore, there is no mention of the patient being on metformin treatment, which is another inclusion criterion for the trial.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial as they have type 1 diabetes, not type 2, and do not exhibit the required level of fasting hyperglycaemia nor the specified treatment with metformin.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2152": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue, diagnosed with cardiomyopathy. His recent medical history does not mention a stroke or TIA, nor does it indicate documented atherosclerotic stenosis or any treatment with statins. There is no information provided that meets the inclusion criteria of the clinical trial \"Treat Stroke to Target,\" which requires a recent ischemic stroke or TIA, documented atherosclerotic stenosis, and an indication for statin treatment.\n\nSince the patient's condition and history do not align with the inclusion criteria for the study, and there is no mention of a recent stroke, TIA, or documented atherosclerotic stenosis, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2153": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes confirmed with molecular analysis 7 years ago.\n- He has access to the internet (implicit, as he has presented to the clinic, which suggests engagement with healthcare services).\n- He speaks English (implied, as there is no indication of a language barrier in the clinic).\n- There is no mention of a parent's involvement or language, but since the patient is 25, this is not relevant.\n- He is diagnosed with cardiomyopathy and there are no indications of cystic fibrosis or inflammatory bowel disease.\n\nClinical Trial Inclusion Criteria:\n- Ages 14 - 22 years.\n- Have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months.\n- Have access to the internet.\n- Speak English.\n- Has a parent that speaks English or Spanish (if primary participant is under 18).\n- Willingness to attend assessment visits.\n\nEligibility Assessment:\n- Age: The patient is 25 years old, which is outside the specified age range of 14 - 22 years.\n- Disease: The patient has type 1 diabetes, which is one of the conditions specified in the inclusion criteria.\n- Internet Access: The patient likely has access to the internet.\n- Language: The patient likely speaks English.\n- Parent language: Not applicable as the patient is over 18.\n- Willingness to attend assessment visits: This is not mentioned, but it is not relevant for exclusion based on other criteria.\n\nThe patient does not meet the age criterion for the clinical trial, which makes him ineligible for participation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2154": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes. The clinical trial is specifically looking for sibling pairs where the participants' mother had diabetes (gestational or type 2) during pregnancy with the younger sibling but not the older sibling. The patient note does not mention anything about the patient having a sibling or the status of diabetes in his mother during pregnancy, nor does it mention his BMI, stability of weight, smoking status, willingness to stay overnight at the Pennington Center, or his level of physical activity.\n\nGiven the lack of information on several key inclusion criteria, particularly the specific family dynamic required for the study (i.e., the mother having diabetes during pregnancy with the younger sibling but not the older), we cannot determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2155": {
        "output": "The patient described in the patient note is a 25-year-old man with type 1 diabetes. He is experiencing symptoms related to cardiomyopathy and is being treated with ACE inhibitors, Beta blockers, and insulin.\n\nNow, let's review the inclusion criteria for the clinical trial:\n\n1. Understanding of the study procedures and agreement to participate in the study by giving written informed consent.\n2. Males and females age 20 to 75 years, inclusive.\n3. HbA1c \u22657.5% and \u226410%.\n4. BMI \u226445 kg/m^2.\n5. FPG \u2264270 mg/dL.\n6. Diagnosis of type 2 diabetes mellitus for \u22656 months.\n7. On a stable regimen of oral anti-diabetic medications for \u22653 months.\n8. Willingness to maintain stable diet and exercise throughout the study.\n9. Willingness to maintain current doses/regimens of vitamins and dietary supplements throughout the study.\n10. Female patients of childbearing potential and female partners of male patients must be willing to use adequate contraception during the study. All females of childbearing potential must have a negative urine pregnancy test at screening.\n\nThe patient's HbA1c level is 6.5%, which does not meet the inclusion criteria of having an HbA1c level of \u22657.5% and \u226410%. Additionally, the patient has been diagnosed with type 1 diabetes, not type 2 diabetes mellitus, which is specifically required by the trial's inclusion criteria.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial because he has type 1 diabetes, not type 2 diabetes mellitus, and his HbA1c level is below the required threshold. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2156": {
        "output": "",
        "label": 0
    },
    "2157": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes. He presents with cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers.\n\nThe clinical trial in question is focused on studying diabetic cardiomyopathy using nuclear magnetic resonance imaging. The inclusion criteria for the trial are as follows:\n\n1. More than 18 years old\n2. Patient with type 2 diabetes, affected and taken care of for more than 5 years at Timone Hospital\n3. Patient with a diabetic cardiomyopathy\n4. Informed and consented\n\nThe patient in question does not meet the inclusion criteria for several reasons:\n\n1. The patient has type 1 diabetes, not type 2 diabetes as specified in the inclusion criteria.\n2. There is no mention that the patient has been taken care of at Timone Hospital for more than 5 years.\n3. Although the patient has diabetic cardiomyopathy, the trial specifically mentions type 2 diabetes, which the patient does not have.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2158": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility:\n\nPatient note:\n- 25-year-old man\n- Type 1 diabetes confirmed 7 years ago\n- On insulin therapy (70/30 Insulin)\n- HbA1c: 6.5%\n\nClinical trial inclusion criteria:\n- Clinical diagnosis of type 1 diabetes for at least one year\n- On insulin pump therapy for at least 3 months\n- HbA1c \u2264 10%\n\nThe patient has had type 1 diabetes for 7 years, which meets the criterion of having a clinical diagnosis of type 1 diabetes for at least one year. The patient's HbA1c is 6.5%, which is below the maximum of 10% specified in the trial criteria.\n\nHowever, there is no information provided in the patient note about the patient being on insulin pump therapy. The insulin therapy mentioned is 70/30 Insulin, which is typically administered by injection and not via an insulin pump. Since the trial specifically requires participants to have been on insulin pump therapy for at least 3 months, and this information is not available in the patient note, we do not have enough information to determine eligibility based on this criterion.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as there is no evidence of the patient being on insulin pump therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2159": {
        "output": "Given the patient note, the patient is a 25-year-old man with a confirmed diagnosis of type 1 diabetes mellitus. The clinical trial is looking to evaluate the use of Liraglutide in patients with Type 1 Diabetes Mellitus. The inclusion criteria for the trial is simply having a diagnosis of Type 1 Diabetes Mellitus.\n\nThe patient clearly meets the inclusion criteria, as he has been confirmed to have type 1 diabetes for 7 years. There are no other inclusion criteria or exclusion criteria provided for this clinical trial, and based on the information given, the patient is eligible to participate in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2160": {
        "output": "To determine the trial-level eligibility of the patient, we must compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nThe patient's characteristics and condition from the patient note:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- No other significant medical history\n\nThe inclusion criteria for the clinical trial are:\n- Advanced chronic heart failure (HF) defined as left ventricular ejection fraction less than 35%\n- Creatinine less than 2 mg/dL\n- CHF NY functional class III-IV for more than 3 months\n- Admission to hospital due to heart failure requiring adjustment of inotropic agents or diuretics within recent 6 months\n\nThe patient note indicates that the patient has been diagnosed with cardiomyopathy and is experiencing symptoms that correspond to a NYHA functional class 2, which is less severe than the NYHA class III-IV required by the clinical trial. There is no mention of the patient's left ventricular ejection fraction, creatinine levels, or whether he has been hospitalized for heart failure in the past six months.\n\nGiven the information provided in the patient note, there is not enough evidence to determine that the patient has advanced chronic heart failure as defined by the trial's inclusion criteria. The patient does not appear to meet the NYHA functional class requirement nor is there information about recent hospital admissions for heart failure or left ventricular ejection fraction and creatinine levels.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2161": {
        "output": "For the provided patient note and the clinical trial, we need to assess the patient's eligibility based on the inclusion criteria of the trial.\n\nPatient note assessment:\n- The patient is a 25-year-old man.\n- Diagnosed with type 1 diabetes and cardiomyopathy.\n- He is taking insulin and vitamin D supplements.\n- His cholesterol levels are as follows:\n  - Total cholesterol: 190 mg/dL\n  - LDL cholesterol: 125 mg/dL\n\nClinical trial inclusion criteria:\n- Men, 40-65 years old, postmenopausal women 50-65 years old not > 5 years post menopause.\n- Hypercholesterolemic with either total cholesterol >240 mg/dL and < 320 mg/dL or LDL cholesterol >140 mg/dL and <190 mg/dL at the screening visit.\n\nComparison:\n- The patient is a man, but he is 25 years old, which does not meet the age criterion of 40-65 years old for men.\n- His total cholesterol (190 mg/dL) and LDL cholesterol (125 mg/dL) levels do not meet the hypercholesterolemia criteria set by the trial (>240 mg/dL and < 320 mg/dL for total cholesterol or >140 mg/dL and <190 mg/dL for LDL cholesterol).\n\nBased on the comparison, the patient does not meet the age and cholesterol level requirements of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2162": {
        "output": "The patient is a 25-year-old man with type 1 diabetes who presents with symptoms of cardiomyopathy. He does not have a diagnosis of angina or hypertension, which are the target conditions specified in the clinical trial's inclusion criteria. Additionally, there is no information provided that he has been on beta-blockers treatment for at least 2 months, which is another key inclusion criterion for the trial.\n\nBased on the provided patient note and the specific inclusion criteria of the clinical trial, the patient does not meet the necessary conditions for participation in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2163": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"B-type Natriuretic Peptide and Glucose Metabolism,\" we need to compare the patient's characteristics and condition with the inclusion criteria provided for the trial. Let's break down the inclusion criteria and match them with the patient's information:\n\nInclusion Criteria for the trial:\n1. Written informed consent\n2. No disease history\n3. BNP level within the normal range\n4. Normal renal function (serum creatinine of more than 1.3 mg/dL and/or creatinin clearance greater than 80ml/min)\n5. Normal ECG\n\nPatient's information:\n- The patient is a 25-year-old man with type 1 diabetes, which is a disease history and thus does not meet criterion 2.\n- The patient has been diagnosed with cardiomyopathy, which is an additional disease history and could potentially affect BNP levels, although the BNP level is not provided.\n- There is no information about renal function or ECG results in the patient's note.\n\nBased on the provided information, the patient does not meet at least one of the inclusion criteria (no disease history). Since the patient has a history of type 1 diabetes and cardiomyopathy, he would not be eligible for a trial requiring no disease history. Additionally, we do not have information on the patient's BNP levels, renal function, or ECG results. Without complete information matching all the inclusion criteria, the patient cannot be considered eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2164": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we should compare the patient's information with the inclusion criteria provided in the clinical trial summary.\n\n**Patient Information:**\n- 25-year-old man with type 1 diabetes\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy, treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- Lab studies show:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\n**Clinical Trial Inclusion Criteria:**\n- Diagnosed as stable angina pectoris\n- Successful percutaneous coronary intervention (PCI) performed with IVUS and OCT guidance\n- Presence of coronary plaques\n- Dyslipidemia as defined by:\n  - TC \u2267 220 mg/dl\n  - LDL-C \u2267 140 mg/dl\n  - Cholesterol-lowering treatment allowed if LDL-C \u2267 100 mg/dl or TC \u2267 180 mg/dl\n  - Under cholesterol-lowering treatment and LDL-C \u2266 120 mg/dl\n- Age 20 years or older\n- Written consent for participation\n\nBased on the patient's provided information, there is no mention of stable angina pectoris, nor is there any information about him having undergone a percutaneous coronary intervention (PCI) with IVUS and OCT guidance. Additionally, there is no information about the presence of coronary plaques. The patient's lab results also show that his lipid levels do not meet the dyslipidemia criteria stated in the trial (his LDL and total cholesterol levels are below the thresholds mentioned). Furthermore, there is no indication that he is on cholesterol-lowering treatment. Considering the patient's current medical condition and the available information, it appears that he does not meet the inclusion criteria for the clinical trial.\n\n**Trial-level eligibility: 1) Not relevant.**",
        "label": 0
    },
    "2165": {
        "output": "The patient is a 25-year-old man with type 1 diabetes, presenting with cardiomyopathy and on a treatment regimen that includes ACE inhibitors, Beta blockers, and insulin. He does not meet the inclusion criteria for the clinical trial which requires participants to have type 2 diabetes mellitus, be on a stable dose of metformin, and have an HbA1c between 7% and 10%. The patient has type 1 diabetes, not type 2, and there is no mention of him being on metformin, let alone a stable dose for at least 1 month. Additionally, his HbA1c level is 6.5%, which is below the required range for the trial.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2166": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Review:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes.\n- Presents with shortness of breath and fatigue during activities (NYHA class 2).\n- Diagnosed with cardiomyopathy to be treated with ACE inhibitors and Beta blockers.\n- No mention of ischemic heart disease or coronary artery disease.\n- No documentation provided of ejection fraction.\n- Optimal medical treatment has not yet been established as the patient is just beginning treatment.\n- No mention of persistent symptoms despite optimal medical treatment.\n- No mention of non-treatable or optimally treated coronary artery disease.\n\nClinical Trial Inclusion Criteria:\n- Ischemic cardiomyopathy patients on optimal medical treatment with persistent symptoms despite treatment with 2 antiischemic agents.\n- Anginal chest pain or dyspnea.\n- Documentation of non-treatable or optimally treated coronary artery disease.\n- Ejection Fraction of less than or equal to 40%.\n\nThe patient's note does not confirm ischemic cardiomyopathy, does not provide evidence of persistent symptoms despite optimal medical treatment with two antiischemic agents, and there is no documentation of non-treatable or optimally treated coronary artery disease. Additionally, there is no information on the patient's ejection fraction. Therefore, the patient does not meet the inclusion criteria for the clinical trial as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2167": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Clinical Trial of West-China Perioperative Transfusion Score (WCPTS) for Massive Hemorrhagic Surgery,\" we need to assess the patient's eligibility for the trial.\n\nThe inclusion criteria for the trial are:\n1. Patients who sign the consent.\n2. With Glasgow Coma Scale (GCS) score of 15.\n3. Undergoing surgery which blood loss could be more than 800ml or 20% of the patient's whole blood volume.\n\nThe patient note provides the following information:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He presents with shortness of breath and fatigue during activities.\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- His past medical history does not indicate any other medical issues or surgeries.\n\nThe patient note does not mention that the patient is planning to undergo surgery, let alone surgery with an expected blood loss of more than 800ml or 20% of the patient's whole blood volume. Additionally, there is no mention of the patient's GCS score, but usually, a GCS score of 15 indicates that the patient is fully awake and oriented, which seems to be the case based on the patient's ability to provide a detailed history and symptoms.\n\nSince there is no information to suggest that the patient is undergoing surgery with the expected blood loss required by the study, the patient does not meet the necessary criteria to be considered for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2168": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, we can assess the trial-level eligibility as follows:\n\nThe patient is a 25-year-old man with type 1 diabetes, not type 2 diabetes, which is the target population for the clinical trial. Furthermore, the patient's HbA1c level is 6.5%, which is below the threshold of greater than 7.0% required for the study. Lastly, the age requirement for the trial is adults aged 34 to 69 years, and the patient is only 25 years old.\n\nTherefore, the patient does not meet the inclusion criteria of having type 2 diabetes mellitus, the required HbA1c level, or the specified age range.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2169": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy presenting with shortness of breath and fatigue during activities. He has been classified as New York Heart Association class 2 due to his dyspnea upon exertion.\n\nThe clinical trial in question is looking for patients presenting with shortness of breath secondary or not to heart failure, as well as patients with other specified heart conditions.\n\nGiven the details in the patient note, the patient seems to meet the inclusion criteria for the clinical trial, as he is presenting with shortness of breath secondary to heart failure (cardiomyopathy). There are no exclusion criteria mentioned, and the inclusion criteria do not specify the type of heart disease beyond what the patient has.\n\nTherefore, the patient appears to be a match for the clinical trial based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2170": {
        "output": "",
        "label": 0
    },
    "2171": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes, not type 2 diabetes. The clinical trial we are assessing is for patients with type 2 diabetes mellitus who also have hypertension and microalbuminuria. The patient's note does not mention hypertension or microalbuminuria.\n\nSince the patient has type 1 diabetes and there is no information regarding hypertension or microalbuminuria, he does not meet the inclusion criteria for the clinical trial, which specifically requires patients to have type 2 diabetes, certain blood pressure parameters, and microalbuminuria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2172": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Digoxin Withdrawal in Stable Heart Failure,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial. Here are the steps:\n\n1. Over the age of 18 years - The patient is 25 years old, so this criterion is met.\n2. In sinus rhythm at the time of randomisation - The patient's note does not mention any arrhythmia, but it also does not explicitly state that the patient is in sinus rhythm.\n3. Have a LVEF <0.45 and a left ventricular end-diastolic dimension >60 mm or >34 mm/m2 - The patient's note does not provide information about the patient's left ventricular ejection fraction (LVEF) or left ventricular end-diastolic dimension.\n4. Are receiving ACE inhibitor, \u03b2-blocker and diuretic therapy at the optimal doses - The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers, but there is no mention of diuretic therapy or whether the doses are optimal.\n5. Has been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 week apart) prior to randomisation - The patient's note does not mention digoxin therapy at all.\n6. Documented, stable heart failure - The patient is diagnosed with cardiomyopathy, which may be related to heart failure, but there is no clear indication that the patient has 'stable heart failure' or any of the listed evidence (hospitalisation, X-ray, echocardiogram, or ECG findings).\n7. Willing and able to provide informed consent - This is typically determined at the time of consent and cannot be assessed from the patient note.\n\nBased on the patient note and the inclusion criteria given for the clinical trial, there is insufficient information to determine whether the patient meets several of the critical criteria required for the trial. Specifically, there is no mention of sinus rhythm status, LVEF, left ventricular end-diastolic dimension, diuretic therapy, digoxin therapy, or documented evidence of stable heart failure. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2173": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Effect of Fiber Supplementation in Children With Type 1 Diabetes,\" let's compare the details:\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. \n- He is able to manage his activities and has been diagnosed with cardiomyopathy, for which he is being treated. \n- There is no mention of an inability to tolerate a continuous blood glucose monitoring device or an inability to follow a prescribed meal plan.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of type 1 diabetes for at least two years prior to enrollment.\n- The ability to tolerate wearing the continuous blood glucose monitoring device for a total of 6 days.\n- The ability to follow a prescribed meal plan.\n\nThe patient in question has had a diagnosis of type 1 diabetes for 7 years, which satisfies the criterion of having the diagnosis for at least two years. There is no information provided that would suggest the patient cannot tolerate a continuous blood glucose monitoring device or follow a prescribed meal plan.\n\nHowever, the title of the clinical trial specifies that it is for children, while the patient is 25 years old. This age-related discrepancy indicates that while the patient meets some inclusion criteria, he may be ineligible due to age, assuming that the trial is indeed intended for pediatric patients, which is typically considered to be individuals under the age of 18.\n\nGiven that the inclusion criteria do not explicitly mention an age limit but the title suggests that children are the target population, it is unclear whether the patient would be eligible or not. Since there is insufficient information to make a definitive determination of eligibility based on age, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2174": {
        "output": "",
        "label": 0
    },
    "2175": {
        "output": "Given the patient note and the clinical trial information, let's determine the patient's eligibility for the trial.\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis\n- Presenting with cardiomyopathy\n- Taking insulin and vitamin D supplements\n- No mention of walking difficulties or muscle weakness\n- No mention of GNE Myopathy or GNE-related diseases\n\nClinical trial criteria for eligibility:\n- Age 4-80 years, either gender\n- Diagnosis of GNE myopathy or GNE-related diseases confirmed by GNE gene mutations\n- Ability to provide informed consent\n- Exclusion for psychiatric illness or other diseases that interfere with compliance, and certain laboratory parameters\n\nThe patient in question has type 1 diabetes and cardiomyopathy but does not have a diagnosis of GNE Myopathy or any GNE-related diseases, which are the primary conditions of interest for the clinical trial. Therefore, the patient does not meet the inclusion criteria for this particular study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2176": {
        "output": "Given the patient's information, we need to determine if they are eligible for the clinical trial based on the inclusion criteria provided.\n\nPatient characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes, cardiomyopathy\n- Symptoms: Shortness of breath, fatigue, mild dyspnea after climbing 3 floors, no dyspnea at rest, no angina\n- Treatment: Will be treated with ACE inhibitors and Beta blockers, takes 70/30 Insulin and vitamin D supplements\n- Lab results: Provided various cholesterol and glucose levels\n\nClinical trial inclusion criteria:\n- Type-2 diabetes\n- Coronary artery disease\n\nThe patient has type 1 diabetes, not type 2, and there is no mention of coronary artery disease in the patient's note. The trial is specifically looking for participants with type 2 diabetes and ischemic heart disease. Therefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2177": {
        "output": "",
        "label": 0
    },
    "2178": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Comparing Long-acting Insulins During Exercise in Type 1 Diabetes,\" we must compare the patient's characteristics and condition against the inclusion criteria of the trial.\n\nPatient's Characteristics:\n- 25-year-old man\n- Diagnosed with Type 1 Diabetes Mellitus (confirmed with molecular analysis 7 years ago)\n- Currently experiencing cardiomyopathy, shortness of breath, and fatigue during activities (NYHA class 2)\n- Treatment includes ACE inhibitors, Beta blockers, and 70/30 Insulin (a mix of intermediate-acting and short-acting insulin)\n- HbA1c level is 6.5%\n\nClinical Trial Inclusion Criteria:\n- Willing and able to give informed consent\n- Male or Female, aged between 18 and 65 years\n- Diagnosed with Type 1 Diabetes Mellitus (T1DM)\n- HbA1c < 10% or 86 mmol/mol\n- Treated with a basal bolus regimen using either insulin glargine or insulin detemir as the basal insulin\n- Exercising regularly for at least 1 hour per week on average\n\nComparison:\n- The patient is within the eligible age range (25 years old).\n- The patient has been diagnosed with T1DM.\n- The patient's HbA1c is below 10%, meeting the trial's criteria.\n- The patient is currently on a mix of intermediate-acting and short-acting insulin, and the trial specifically requires participants to be on a basal bolus regimen using either insulin glargine or insulin detemir.\n- There is no information provided about the patient's exercise habits.\n\nBased on the available information, the patient does not meet the criteria for the type of insulin regimen required by the clinical trial (insulin glargine or insulin detemir). Additionally, there is insufficient information regarding the patient's exercise habits to determine eligibility based on that criterion.\n\nTherefore, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2179": {
        "output": "To determine the trial-level eligibility for the given patient, we need to assess whether the patient meets the inclusion criteria of the clinical trial. \n\nThe inclusion criteria for the clinical trial are:\n1. Diabetes type 1\n2. Age >18 years old\n3. The patient having a smartphone, who are familiar with its use\n\nThe patient note provides the following information:\n- The patient is a 25-year-old man, which meets the age criterion (>18 years old).\n- The patient has type 1 diabetes, which meets the diabetes type 1 criterion.\n- There is no information provided in the patient note about the patient having or being familiar with the use of a smartphone.\n\nSince the patient note does not mention the patient's familiarity or ownership of a smartphone, we cannot confirm whether the patient meets all the inclusion criteria. Therefore, we cannot definitively say the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2180": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities\n- Mild dyspnea after climbing 3 floors, no dyspnea at rest, no angina (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- No significant other medical history\n- Family history of DM type 1\n- Lab results provided, no mention of EF (Ejection Fraction)\n\nClinical Trial Inclusion Criteria Summary:\n- Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy\n- Measured EF <35%\n- Class III as defined by NYHA\n- ICD (Implantable Cardioverter Defibrillator) presence\n- Receiving optimal pharmacological therapy\n\nAssessment:\n- The patient has cardiomyopathy and is NYHA class 2, which is not class III as defined by the NYHA criteria required for the trial.\n- There is no mention of an EF measurement or an ICD in the patient note.\n- The patient's status regarding \"optimal pharmacological therapy\" is not fully clear, but he is set to be treated with ACE inhibitors and Beta blockers.\n\nBased on the information given, the patient does not meet all the specified inclusion criteria for the clinical trial, particularly the NYHA classification and the absence of documented EF <35% and ICD presence. Therefore, the patient is not eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2181": {
        "output": "To assess the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the trial. Let's evaluate each criterion one by one.\n\nInclusion Criteria:\n1. Patient must be aged between 21 (inclusive) and 65 years old.\n   - The patient is 25 years old, which meets this criterion.\n\n2. Patient must have been clinically diagnosed with Type 1 diabetes mellitus.\n   - The patient has type 1 diabetes confirmed with molecular analysis, which meets this criterion.\n\n3. Criteria for documented hyperglycemia (at least 1 must be met):\n   - Fasting glucose \u2265126 mg/dL - confirmed\n   - Two-hour OGTT glucose \u2265200 mg/dL - confirmed\n   - HbA1c \u22656.5% documented - confirmed\n   - Random glucose \u2265200 mg/dL with symptoms\n   - No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes\n   - The patient has an HbA1c of 6.5%, which meets the documented hyperglycemia criterion.\n\n4. Criteria for requiring insulin at diagnosis (1 must be met):\n   - Participant required insulin at diagnosis and continually thereafter\n   - Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually\n   - Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually\n   - Use of an insulin pump to treat his/her diabetes for at least 1 year\n   - Actively using a carbohydrate [CHO] / insulin ratio for insulin bolus adjustments in order to keep blood glucose in a predefined range\n   - The patient note does not provide specific information about insulin use at diagnosis or about the use of an insulin pump. Therefore, we cannot confirm this criterion.\n\n5. Patient HbA1c is between 6.0% and 9% as measured with DCA2000 or equivalent device.\n   - The patient's HbA1c is 6.5%, which is within the required range.\n\n6. Patient must demonstrate proper mental status and cognition for the study.\n   - The patient note does not provide information regarding the patient's mental status or cognition.\n\n7. Patient must be willing to avoid consumption of acetaminophen-containing products during the study interventions involving DexCom use.\n   - The patient note does not provide information regarding the patient's willingness to avoid acetaminophen.\n\n8. Patient must be affiliated or beneficiary of a social medical insurance.\n   - The patient note does not provide information regarding the patient's insurance status.\n\n9. Patient has signed informed consent form prior to study entry.\n   - The patient note does not provide information regarding whether the patient has signed an informed consent form.\n\nBased on the available information from the patient note, the patient meets several of the inclusion criteria: age, diagnosis of type 1 diabetes mellitus, and HbA1c level. However, there is insufficient information regarding insulin pump use, mental status, willingness to avoid acetaminophen, insurance status, and signed informed consent. Since there is not enough information to confirm eligibility across all required criteria, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2182": {
        "output": "To determine the trial-level eligibility for the patient based on the provided clinical trial inclusion criteria, let's match the patient's characteristics and medical history with the criteria:\n\n1. Patient must be aged between 21 (inclusive) and 65 years old.\n   - The patient is 25 years old, which meets this criterion.\n\n2. Patient must have been clinically diagnosed with Type 1 diabetes mellitus.\n   - The patient has been confirmed with type 1 diabetes, meeting this criterion.\n\n3. Criteria for documented hyperglycemia (at least 1 must be met):\n   - Fasting glucose \u2265126 mg/dL - not met, FBS is 100 mg/dl\n   - Two-hour Oral Glucose Tolerance Test (OGTT) glucose \u2265200 mg/dL - no data provided\n   - HbA1c \u22656.5% documented - confirmed - met, as HbA1c is 6.5%\n   - Random glucose \u2265200 mg/dL with symptoms - no data provided\n   - No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes - not relevant, as other criteria are met.\n\n4. Criteria for requiring insulin at diagnosis (1 must be met):\n   - Participant required insulin at diagnosis and continually thereafter - no explicit data provided, but the patient takes 70/30 Insulin, which suggests they meet this criterion.\n   - Participant did not start insulin at diagnosis but upon investigator review likely needed insulin and did require insulin eventually and used continually - not relevant.\n   - Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies and did require insulin eventually and used continually - not relevant.\n\n5. Use of an insulin pump to treat his/her diabetes for at least 1 year - no data provided regarding the use of an insulin pump.\n\n6. Actively using a carbohydrate (CHO) / insulin ratio for insulin bolus adjustments in order to keep blood glucose in a predefined range - no data provided regarding the use of a CHO/insulin ratio.\n\n7. Patient HbA1c is between 6.0% and 9% as measured with DCA2000 or equivalent device.\n   - The patient's HbA1c is 6.5%, which meets this criterion.\n\n8. Patient must demonstrate proper mental status and cognition for the study - no data provided, but there is no mention of cognitive impairment.\n\n9. Patient must be willing to avoid consumption of acetaminophen-containing products during the study interventions involving DexCom use - no data provided, but willingness can be assumed if informed.\n\n10. Patient must be affiliated or beneficiary of a social medical insurance - no data provided.\n\n11. Patient has signed informed consent form prior to study entry - this is procedural and can be met if the patient agrees to participate.\n\nThe patient appears to meet many of the inclusion criteria. However, there is not enough information on some points, particularly regarding the use of an insulin pump, actively using a CHO/insulin ratio, and affiliation with social medical insurance. Therefore, the patient's eligibility cannot be confirmed without this information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2183": {
        "output": "Given the information from the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the LifeVest Post-CABG Registry trial.\n\nPatient note:\n- The patient is a 25-year-old man.\n- He is diagnosed with cardiomyopathy.\n- He has type 1 diabetes.\n- There is no mention of the patient undergoing coronary artery bypass graft (CABG) surgery.\n- There is no information provided about the patient's ejection fraction (EF).\n- The patient is being treated with ACE inhibitors and Beta blockers for cardiomyopathy, not following CABG surgery.\n- There is no indication that the patient has been prescribed a wearable defibrillator.\n\nClinical trial inclusion criteria:\n- Patients who have undergone CABG surgery during current hospitalization.\n- Patients who have an ejection fraction \u2264 35% following the surgery.\n- Patients who have dilated cardiomyopathy or prior myocardial infarction.\n- Patients who are prescribed a wearable defibrillator following surgery.\n- Patients who are at least 18 years old.\n\nThe patient is indeed at least 18 years old, but there is no evidence that he meets any other inclusion criteria such as undergoing CABG surgery, having an ejection fraction \u2264 35%, being diagnosed with dilated cardiomyopathy or having a myocardial infarction, nor being prescribed a wearable defibrillator.\n\nTherefore, based on the information provided, the patient does not meet the sufficient inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2184": {
        "output": "Based on the patient note, the patient is a 25-year-old man with type 1 diabetes presenting with cardiomyopathy, which is not relevant to the clinical trial in question. The trial is focused on the safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 to 70 years in China. The patient falls within the age range specified in the inclusion criteria.\n\nHowever, the trial's inclusion criteria do not mention any specific medical conditions, other than the requirement for the participant to be healthy. Since the patient has type 1 diabetes and cardiomyopathy, which are both medical conditions, it is not clear if these would exclude him from being considered \"healthy\" for the purpose of this trial. Moreover, the trial does not provide any exclusion criteria, which would be needed to make a definitive determination of eligibility based on health status.\n\nGiven the lack of information regarding health status in the inclusion criteria and the absence of exclusion criteria, the patient's eligibility cannot be conclusively determined from the provided information. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2185": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes,\" we will compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Treated with ACE inhibitors and Beta blockers\n- No information provided about cognitive status\n- No information provided about the place of residence\n\nClinical trial inclusion criteria:\n- Adults age 19 or older (patient is 25, meets this criterion)\n- Diagnosed with chronic heart failure (patient has cardiomyopathy, which can be related to heart failure; however, the note does not explicitly mention \"chronic heart failure\")\n- Experiencing shortness of breath at rest or with activities (patient experiences shortness of breath with activities, meets this criterion)\n- Experiencing shortness of breath that limits their activity (NYHA class 2 suggests limitation in activity, meets this criterion)\n- Cognitively intact (no information provided)\n- Have a telephone (no information provided)\n- Reside in a rural area defined by population size (no information provided)\n\nGiven the information from the patient note, the patient meets some of the inclusion criteria: age, experiencing shortness of breath with activities, and limitation in activity due to shortness of breath. However, there is insufficient information to confirm whether the patient has \"chronic heart failure\" as opposed to cardiomyopathy alone, and there is also no information about the patient's cognitive status, telephone ownership, or place of residence.\n\nBased on the available information, the patient does not have sufficient information to qualify for the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2186": {
        "output": "",
        "label": 2
    },
    "2187": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility:\n\nPatient Information:\n- Age: 25 years old\n- Condition: Type 1 diabetes confirmed 7 years ago\n- HbA1c: 6.5%\n- CVD risk factors: None mentioned explicitly, except for the family history of type 1 diabetes\n\nClinical Trial Inclusion Criteria:\n- Type 1 Diabetes for five years or more (the patient meets this criterion)\n- Age 40 years or above (the patient does not meet this criterion; he is 25 years old)\n- 7.0 <= HbA1c < 10.0% (the patient does not meet this criterion; his HbA1c is 6.5%)\n- AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors (it is not clear if the patient meets any of these criteria based on the provided information)\n\nFrom the information given, the patient does not meet the age requirement (25 years old, whereas the trial requires participants to be 40 years or above) and does not have the specified HbA1c range (his value is 6.5%, whereas the trial requires a minimum of 7.0%). Additionally, there is insufficient information to determine if the patient has three or more of the specified CVD risk factors.\n\nTherefore, the patient does not meet the necessary inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2188": {
        "output": "Given the information provided, the patient is a 25-year-old man with type 1 diabetes and is now diagnosed with cardiomyopathy. He is on specific medication for his conditions, including insulin and vitamin D supplements.\n\nThe clinical trial in question is looking for juveniles with type 1 diabetes who have been previously treated in trial BIAsp-1240. The key inclusion criterion for this trial is that the subject must have completed the trial BIAsp-1240.\n\nThe patient note does not mention any participation in trial BIAsp-1240. Since this is a requirement for the trial, and there is no evidence that the patient meets this criterion, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2189": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year: The patient has a confirmed diagnosis of type 1 diabetes for 7 years and is on insulin therapy, meeting this criterion.\n\n2. Age 21 years to less than 45.0 years: The patient is 25 years old, which falls within the specified age range for the trial.\n\n3. Subject has used a downloadable insulin pump for at least 3 months: The patient note does not provide any information about the use of an insulin pump, downloadable or otherwise.\n\n4. Subject understands the study protocol and agrees to comply with it: This is an assumption we must make for all potential participants, as we don't have specific information about the patient's understanding or agreement.\n\n5. Informed Consent Form signed: This is a procedural step that would be completed if the patient agrees to participate and is found eligible.\n\n6. A Personal Home computer with internet access (must have access to a PC for uploading, not a Mac): The patient note does not mention whether the patient has a personal home computer or internet access.\n\nGiven the information provided, the patient meets the age and diabetes diagnosis criteria, but there is insufficient information regarding the use of a downloadable insulin pump and the availability of a personal home computer with internet access. Therefore, we cannot confirm eligibility based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2190": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes diagnosed 7 years ago\n- Currently diagnosed with cardiomyopathy\n- Taking insulin and vitamin D supplements\n- No mention of being Asian, but this is not specified as a criterion\n\nClinical Trial Inclusion Criteria:\n- Diagnosed as type 2 diabetes mellitus patient at least 12 weeks before the study\n- Stable diet and exercise program for at least 8 weeks before the study\n- On a stable dose of at least 1500 mg/day metformin monotherapy or at least 1000 mg/day metformin monotherapy for the subject who cannot titrate up to 1500 mg/day due to safety concerns of metformin\n- BMI of 20.0 to 45.0 kg/m2 (not provided in patient note)\n- A HbA1c value between 7.0 and 10.0% at screening (patient has HbA1c of 6.5%)\n\nThe patient has type 1 diabetes, not type 2 diabetes, which is a requirement for the trial. Additionally, the patient's HbA1c value is 6.5%, which is below the required range of 7.0 to 10.0% for the study.\n\nTherefore, this patient would not be eligible for the clinical trial based on the type of diabetes and HbA1c value, which do not meet the specified inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2191": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue during activities and is diagnosed with cardiomyopathy. There is no mention of chronic obstructive pulmonary disease (COPD) in the patient's history, and the primary issue seems to be related to his heart condition and diabetes, not a pulmonary condition like COPD.\n\nThe clinical trial in question is focused on patients with COPD, specifically targeting those with a clinical diagnosis of COPD presenting with specific pulmonary function test results (FEV1/FVC < 70% and FEV1 < 80% predicted), who are clinically stable, non oxygen dependent, and smokers or former smokers.\n\nSince the patient does not have a diagnosis of COPD and the inclusion criteria specifically mention COPD diagnosis with certain pulmonary function thresholds, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2192": {
        "output": "",
        "label": 0
    },
    "2193": {
        "output": "Based on the provided patient note and the inclusion criteria for the \"Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2\" clinical trial, let's compare the patient's characteristics with the inclusion criteria:\n\n1. Patient must be aged between 18 (inclusive) and 70 years old.\n   - The patient is 25 years old, which meets this criterion.\n\n2. Patients diagnosed with type 1 or type 2 diabetes according to WHO criteria for at least one year prior to study entry.\n   - The patient has type 1 diabetes diagnosed 7 years ago, which meets this criterion.\n\n3. Patient treated by a basal-bolus insulin therapy using an external pump or multiple-daily injections. The insulin regimen has to be stable for the previous six months. NPH insulin use will not be acceptable.\n   - The patient takes 70/30 Insulin, which implies a stable insulin regimen, although it is not specified whether it's a basal-bolus regimen or the use of an external pump or multiple-daily injections. More information is needed to confirm eligibility based on this criterion.\n\n4. Patient should have stable diabetes with a HbA1c between \u2265 7.5 % and < 10.5 % with no keto-acidosis for the previous 6 months.\n   - The patient's HbA1c is 6.5%, which is below the specified range, so this criterion is not met.\n\n5. Patient must have a Body Mass Index (BMI) lower than 35 Kg/m\u00b2.\n   - The patient's BMI is not provided, so we cannot determine eligibility based on this criterion.\n\n6. Patient must be willing to undergo all study procedures.\n   - There is no information provided about the patient's willingness, so this criterion cannot be confirmed.\n\n7. Patient must be affiliated or beneficiary of a social medical insurance.\n   - There is no information provided about the patient's insurance status, so this criterion cannot be confirmed.\n\n8. Patient has signed informed consent form prior to study entry.\n   - There is no information provided about whether the patient has signed the consent form, so this criterion cannot be confirmed.\n\nGiven the available information, the patient does not meet the HbA1c criterion as their HbA1c level is lower than the specified range for the trial. Additionally, there is insufficient information regarding the insulin regimen, BMI, willingness to undergo study procedures, insurance status, and signed informed consent. Therefore, based on the provided patient note and the clinical trial inclusion criteria:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2194": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old male with type 1 diabetes and newly diagnosed cardiomyopathy. He is experiencing shortness of breath and fatigue during activities, classified as New York Heart Association class 2 dyspnea. The patient does not have a diagnosis of cancer; therefore, he does not meet the necessary inclusion criteria for the clinical trial titled \"Breakthrough Dyspnea Fentanyl Study in Cancer Patients,\" which requires a diagnosis of cancer among other specific criteria.\n\nSince the patient note does not provide evidence that the patient has a diagnosis of cancer, he is not eligible for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2195": {
        "output": "Assessment of Eligibility:\n\nPatient Characteristics:\n- Age: 25 years old\n- Condition: Type 1 diabetes (T1D)\n- Other conditions: Cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Medications: 70/30 Insulin and vitamin D supplements\n- Family history: DM type 1 in his uncle and grandfather\n- Lab results:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Age over 18 years old (Patient meets this criterion)\n- Diagnosed type 2 diabetes (T2D) with HbA1C at >6.5% (Patient has T1D, not T2D)\n- At risk of CVD indicated with the following risk parameters:\n  - Total cholesterol between 195.0 - 241.8 mg/dL (Patient's cholesterol is 190 mg/dl, does not meet this criterion)\n  - BMI > 25 kg/m^2 (BMI not provided)\n  - Waist circumference > 101.6 cm for men (Waist circumference not provided)\n  - Triglycerides > 150mg/dL (Patient's TG is 140 mg/dl, does not meet this criterion)\n  - HDL-cholesterol < 40 mg/dL for men (Patient's HDL is 40 mg/dL, meets this criterion)\n  - LDL-cholesterol > 100 mg/dL (Patient's LDL is 125 mg/dL, meets this criterion)\n  - Blood pressure > 140/90mm Hg (Blood pressure not provided)\n\nThe patient does not meet the inclusion criteria for the clinical trial as he has Type 1 Diabetes, not Type 2, which is a specific requirement for the trial. Furthermore, the patient's total cholesterol and triglycerides do not meet the specified range for inclusion in the trial. Other parameters such as BMI, waist circumference, and blood pressure are not provided in the patient note, which means there is insufficient information to assess these criteria. However, since the patient does not have the type of diabetes specified in the inclusion criteria, he is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2196": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility of the patient step by step:\n\n1. Age: The patient is 25 years old, which falls within the age range of 13 to 30 years required by the trial.\n2. Health condition: The patient has type 1 diabetes mellitus (T1DM), which is the target condition for the clinical trial.\n3. Other health criteria: The patient note does not mention hypothyroidism or any treatment related to it, suggesting that the patient is otherwise healthy as required.\n4. Gender: The patient is male, and there are no gender-specific criteria mentioned in the trial.\n5. Menstruating women and pregnancy test: This criterion is not applicable to the patient as he is male.\n6. Hemoglobin level: The patient's hemoglobin level is not mentioned in the note, so we cannot confirm if it meets the criterion of more than 12 g/dl.\n\nSince the hemoglobin level is not available in the patient's note, we lack sufficient information to qualify the patient for the trial based on the inclusion criteria provided. The patient meets all other known inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2197": {
        "output": "To determine the trial-level eligibility of the patient for the \"Symphony: The Implantable Counter Pulsation Device (CPD) Safety and Feasibility Trial,\" we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n1. New York Heart Association Class IIIB or IV heart failure despite optimal medical therapy, including ACE inhibitors, beta blockers, IV diuretics, and pressors.\n2. Left Ventricular Ejection Fraction < 40%.\n3. The patient is not a candidate for conventional catheter-based or surgical intervention such as valve intervention or coronary artery bypass surgery.\n4. The patient is not currently a candidate for heart transplantation or placement of a left ventricular assist device (LVAD) as bridge to heart transplantation due to co-morbidities.\n5. Patients have exhausted all approved surgical and medical therapies as determined by a heart failure cardiologist and a surgeon with expertise in heart failure.\n6. The patient has been evaluated by a multi-disciplinary research team and felt to be a suitable candidate for a research study.\n7. Improved hemodynamics on device support will allow for potential for physical rehabilitation.\n8. Signed Informed Consent, or oral informed consent with written confirmation by uninvolved third party.\n9. Age of subject at least 19 years.\n\nNow, let's evaluate the patient based on the information provided in the patient note:\n1. The patient has cardiomyopathy and is treated with ACE inhibitors and Beta blockers, which aligns with the optimal medical therapy mentioned in the inclusion criteria.\n2. The patient's New York Heart Association (NYHA) class is mentioned as class 2, which does not meet the requirement of class IIIB or IV.\n3. There is no information provided about the patient's Left Ventricular Ejection Fraction (LVEF).\n4. There is no information suggesting that the patient is not a candidate for conventional interventions or transplantation.\n5. There is no indication that the patient has exhausted all approved surgical and medical therapies.\n6. There is no information provided about an evaluation by a multi-disciplinary research team.\n7. There is no information about hemodynamics on device support.\n8. Consent can be obtained if the patient agrees to participate.\n9. The patient is 25 years old, which satisfies the age requirement.\n\nBased on the available information, the patient does not meet the NYHA class requirement for the trial. There is also insufficient information on several other criteria. Therefore, the patient does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2198": {
        "output": "In assessing the trial-level eligibility for the patient in the given note against the inclusion criteria of the clinical trial titled \"Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation,\" let's break down the patient's characteristics:\n\n- The patient is a 25-year-old man with type 1 diabetes.\n- The patient has been diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- The patient's fasting blood sugar (FBS) is 100 mg/dl.\n- His glycosylated hemoglobin (HbA1c) is 6.5%.\n\nNow let's review the inclusion criteria for the clinical trial:\n\n- Men and women with a diagnosis of Impaired Glucose Tolerance (IGT), i.e., fasting plasma glucose less than or equal to 125 mg/dl, 2-hour post 75 gram oral glucose tolerance test (OGTT) plasma glucose between 140-199 mg/dl, glycosylated hemoglobin A1c (HbA1c) less than 6.5% as per American Diabetes Association (ADA) criteria.\n\nThe patient does meet some of the criteria for Impaired Glucose Tolerance (IGT) with a fasting plasma glucose level of 100 mg/dl and an HbA1c of 6.5%. However, the patient has type 1 diabetes, which is a different condition from IGT. IGT is a prediabetic state of hyperglycemia that is associated with insulin resistance and increased risk of cardiovascular pathology. Type 1 diabetes is an autoimmune disease where the pancreas produces very little or no insulin.\n\nSince the patient has type 1 diabetes and not Impaired Glucose Tolerance, he does not meet the specific diagnostic inclusion criteria for the trial, which requires a diagnosis of IGT.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2199": {
        "output": "To evaluate the eligibility of the patient for the clinical trial, let's examine the patient's characteristics and compare them to the inclusion criteria of the trial:\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes diagnosed 7 years ago\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Will be treated with ACE inhibitors and Beta blockers\n- Has a history of type 1 diabetes in the family\n- No mention of chronic kidney disease or renal function (eGFR)\n\nClinical Trial Inclusion Criteria:\n1. Screening eGFR \u226515.0 and \u226460.0 mL/min/1.73 m2\n2. A history of type 2 diabetes; diagnosis should have been made at \u2265 30 years of age (if diabetes developed at a younger age, a fasting C-peptide level must be \u2265 0.1 ng/mL)\n3. Male or female patients at least 18 years of age\n4. Treatment with an ACE inhibitor and/or an ARB for at least 6 weeks prior to Study Day 1. The dosage must be stable for 2 weeks prior to screening\n5. Mean systolic blood pressure (SBP) \u2264160 mmHg and \u2265105 mmHg and mean diastolic blood pressure (DBP) \u226490 mmHg during screening\n6. Willing to practice methods of birth control\n7. Serum magnesium level must be \u22651.3 mEq/L during the screening period\n8. Willing and able to cooperate with all aspects of the protocol\n9. Willing to and able to give written informed consent for study participation\n\nComparison:\n- The patient has type 1 diabetes, not type 2 diabetes. Furthermore, his diagnosis was made at 18 years of age, which does not align with the study's requirement for a type 2 diabetes diagnosis made at \u2265 30 years of age or a confirmation of type 2 diabetes with a fasting C-peptide level.\n- There is no information provided about the patient's renal function (eGFR), which is critical for determining eligibility.\n- The patient is indeed at least 18 years of age.\n- The patient will be treated with ACE inhibitors, but there is no information regarding the duration of this treatment to date or whether the dosage will be stable for 2 weeks prior to screening.\n- There is no information about the patient's blood pressure readings.\n- There is no mention of the patient's willingness to practice birth control or his serum magnesium level.\n- There is no information about the patient's willingness to cooperate with all aspects of the protocol or to provide written informed consent.\n\nGiven the information provided, the patient does not meet the trial's inclusion criteria due to having type 1 diabetes rather than type 2 diabetes, and there is insufficient information to determine eligibility based on other factors such as renal function, blood pressure, and treatment duration with ACE inhibitors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2200": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- 25-year-old man\n- Confirmed type 1 diabetes\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Currently takes insulin and vitamin D supplements\n- No mention of HIV infection or treatment\n\nClinical Trial Inclusion Criteria:\n- 18-65 years old HIV infected men and women\n- Stable on combined antiretroviral therapy (cART) for at least the past 6 months\n- Stable immune and virologic status\n- Insulin resistant/impaired glucose tolerance with specific lab value ranges\n- Specific waist circumference, BMI, and lipid profile requirements\n- Specific platelet count, absolute neutrophil count, and transaminase levels\n- Exclusion of long-term non-progressors not taking anti-HIV medications\n\nAssessment:\n- The patient is within the age range of 18-65 years old.\n- There is no information provided that the patient is infected with HIV or on antiretroviral therapy.\n- The patient has type 1 diabetes, which is different from insulin resistance or impaired glucose tolerance specified in the trial criteria.\n- Other metabolic criteria such as waist circumference, BMI, and lipid profile are not mentioned.\n- There is no information on platelet count, absolute neutrophil count, or transaminase levels.\n- The patient is not described as being a long-term non-progressor of HIV since there is no mention of HIV at all.\n\nGiven the fact that the patient does not have a confirmed HIV infection, which is a fundamental requirement for the clinical trial in question, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2201": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nThe patient:\n- Is a 25-year-old man\n- Has type 1 diabetes confirmed with molecular analysis 7 years ago\n\nClinical trial inclusion criteria:\n- Adult patients with type 1 diabetes\n- Adult, healthy controls\n\nThe patient in the note is an adult with type 1 diabetes, which matches the inclusion criteria for the clinical trial that is studying pancreatic islet mass using PET imaging in patients with type 1 diabetes. There is no additional information provided that would exclude the patient based on the trial's inclusion criteria or suggest that any exclusion criteria apply.\n\nTherefore, the patient appears to meet the inclusion criteria for the clinical trial, and there are no exclusion criteria listed that would disqualify him.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2202": {
        "output": "To determine the trial-level eligibility for this patient, let's review the inclusion and exclusion criteria of the clinical trial.\n\nThe relevant inclusion criteria for this trial are:\n1. Age \u2265 18 years\n2. Must meet American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals and have specific risk factors if under 45 years of age\n3. Stable body weight (<5% change) in the last 3 months\n4. Agree to use contraception throughout the study period (females only)\n5. Able to understand the study and willing to consent\n6. Fasting glucose between 95 and 130 mg/dl (STEP 2)\n7. Impaired fasting glucose, based on a fasting serum glucose between 100 and 125 mg/dl (STEP 3)\n\nThe relevant exclusion criteria for this trial are:\n1. Known diabetes (type I or II)\n2. Recent use of supplements or medications that affect glucose or lipid metabolism\n3. Any comorbidity that could preclude the subject's ability to complete the study\n4. Anticipated changes in dietary patterns or physical activity levels\n5. Eating disorder or Polycystic ovary syndrome\n6. Known allergies to study product substances\n7. Pregnant or breastfeeding women\n8. History of alcohol, drug, or medication abuse\n9. Participation in another study recently\n10. Recent (<3 months) gastrointestinal surgery or planned surgery\n\nNow, let's compare the patient's information to the criteria:\n\n1. The patient is 25 years old, meeting the age criteria.\n2. The patient has type 1 diabetes, which is explicitly listed in the exclusion criteria as a reason for exclusion.\n3. We don't have information on the patient's body weight changes, but this is not relevant since the patient is already excluded based on having type 1 diabetes.\n4. The patient's fasting glucose is 100 mg/dl, which would meet the STEP 3 inclusion criteria, but again, the patient is excluded due to having type 1 diabetes.\n\nGiven that the patient has a known diagnosis of type 1 diabetes, he is excluded from this trial that is looking to study prediabetic subjects.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2203": {
        "output": "To determine the trial-level eligibility of the patient for the \"Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study,\" we need to assess whether the patient meets all the inclusion criteria.\n\nLet's review the patient's information against the inclusion criteria:\n\n1. Over the age of 18 years\n   - The patient is 25 years old, so this criterion is met.\n\n2. Documented heart failure of ischaemic, idiopathic or hypertensive cause\n   - The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers. However, there is no information about the cause of the heart failure, whether it is ischaemic, idiopathic, or hypertensive.\n\n3. New York Heart Association (NYHA) class II, III or IV symptoms\n   - The patient has NYHA class II symptoms, which meets the criterion.\n\n4. LVEF < 0.40, or no more than 0.35 if NYHA class II and ischaemic aetiology.\n   - There is no mention of the patient's left ventricular ejection fraction (LVEF) in the provided information.\n\n5. Receiving ACE inhibitor or ARB (Angiotensin II Receptor Blockers), \u03b2-blocker and diuretic therapy at the optimal doses.\n   - The patient will be treated with ACE inhibitors and Beta blockers. There is no information about diuretic therapy or whether the drugs are at optimal doses.\n\n6. Has been receiving statin therapy for at least 3 months\n   - There is no information indicating that the patient has been receiving statin therapy.\n\n7. Willing and able to provide informed consent\n   - Willingness and ability to provide informed consent cannot be determined from the information provided.\n\nBased on the information available, the patient meets some of the inclusion criteria (age and NYHA class II symptoms) but there is insufficient information to confirm eligibility against all criteria (cause of heart failure, LVEF, complete medication regimen including diuretic therapy and duration of statin therapy, and willingness to consent). Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2204": {
        "output": "The clinical trial in question is focused on patients with chronic Chagas cardiomyopathy, a specific condition associated with the Trypanosoma cruzi infection. The inclusion criteria for the trial are:\n\n1. Positivity for T cruzi as confirmed by 2 or more serological tests (indirect immunofluorescence, ELISA, and/or indirect hemagglutination).\n2. Having cardiomyopathy, which is defined by the presence of at least 3 of the following criteria:\n   - LV enddiastolic diameter (LVDD) > 55 mm\n   - LVDD/body surface area > 2.7 cm/m2\n   - LV ejection fraction (LVEF) < 55%\n   - QRS interval > 120 ms\n   - Echocardiographic evidence of diffuse or segmental systolic wall motion abnormalities.\n\nThe patient in question is a 25-year-old man with type 1 diabetes presenting with symptoms of cardiomyopathy. However, there is no indication that the patient has Chagas disease, nor that he has been tested for Trypanosoma cruzi. The specific type of cardiomyopathy has not been described, other than it will be treated with ACE inhibitors and Beta blockers, which are common treatments for various forms of cardiomyopathy.\n\nFurthermore, the details provided in the patient note do not satisfy the detailed criteria for cardiomyopathy as required by the clinical trial (e.g., specific measurements of LVDD, LVEF, QRS interval, and echocardiographic evidence).\n\nTherefore, based on the information given in the patient note, the patient does not meet the inclusion criteria for the clinical trial focused on chronic Chagas cardiomyopathy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2205": {
        "output": "Based on the information provided, the patient is a 25-year-old man diagnosed with cardiomyopathy, which is a type of structural heart disease. This aligns with the inclusion criteria for the clinical trial, which requires participants to have structural heart disease and specifies ischemic or non-ischemic cardiomyopathy as part of the criteria. \n\nThe patient's condition is being treated with ACE inhibitors and Beta blockers, which are common treatments for cardiomyopathy. There is no mention in the patient note of mechanical alternans, malignant ventricular arrhythmias, or ICD therapies, but these are not specified as necessary for inclusion, only that the study is focused on determining the predictive value of mechanical alternans for these conditions.\n\nGiven that the patient has a diagnosed structural heart disease (cardiomyopathy) and the trial is looking to include individuals with such conditions, the patient appears to meet the inclusion criteria for the trial. There are no exclusion criteria provided, so assuming no further exclusion criteria apply, the patient would be considered eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2206": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history to the inclusion criteria of the trial. \n\nThe inclusion criteria for the clinical trial are:\n\n1. Aged 18 to 35 years\n2. Up to 6 months of clinical diagnosis\n3. Fasting C-peptide \u2265 0.25 ng/ml\n4. HbA1C <9.0%\n5. Positive autoantibodies (anti-GAD, Anti-Insulin and Anti-IA2)\n6. Without chronic complications\n\nThe patient's note provides the following relevant information:\n\n1. The patient is 25 years old, which meets the age criterion.\n2. The patient was diagnosed with type 1 diabetes 7 years ago, which does not meet the criterion of being newly diagnosed (up to 6 months).\n3. Fasting C-peptide is not mentioned in the patient's note.\n4. The patient's HbA1C is 6.5%, which meets the HbA1C criterion.\n5. There is no mention of positive autoantibodies in the patient's note.\n6. There is no mention of chronic complications, but the patient is diagnosed with cardiomyopathy, which could be considered a chronic complication.\n\nBased on the information provided, the patient does not meet the trial's criteria of being diagnosed within the last 6 months. Additionally, there is insufficient information regarding the patient's C-peptide levels and autoantibody status. The presence of cardiomyopathy might also be considered a chronic complication, which would further disqualify the patient.\n\nTherefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2207": {
        "output": "To determine the patient's eligibility for the \"Change of Fructose to Fat in South Asians\" clinical trial, we need to compare the patient's characteristics and lab results against the inclusion criteria of the trial.\n\nLet's go through the inclusion criteria one by one:\n\n1. **Males and females, 18-35 years of age**: The patient is a 25-year-old man, so he meets this criterion.\n2. **South Asian or Caucasian descent through self-identification**: The patient's note does not mention his ethnicity, so we cannot determine if he meets this criterion.\n3. **Body mass index (BMI) 18.0-24.9 kg/m2 with no history of obesity**: The patient's BMI is not mentioned in the note, so we cannot determine if he meets this criterion.\n4. **Fasting glucose <100 mg/dL, 2h glucose oral glucose tolerance test (OGTT) < 140 mg/dL**: The patient's fasting glucose is 100 mg/dL, which is the upper limit of the criterion. We do not have information about his 2h glucose OGTT.\n5. **Triglycerides (TG) <200 mg/dL, HDL cholesterol (HDL-C) >30 mg/dL, LDL cholesterol (LDL-C) <160 mg/dL**: The patient's triglycerides are 140 mg/dL, HDL is 40 mg/dL, and LDL is 125 mg/dL, so he meets this criterion.\n6. **Willing and able to stop fish oil, fiber supplement, other non-prescribed vitamins/supplements for 1 week prior to visit #2 until completion of study**: The patient's note does not mention if he is taking any of these supplements, so we cannot determine if he meets this criterion.\n7. **Willing to not drink alcohol for 24-hours before visit #2**: The patient's note does not mention alcohol use, so we cannot determine if he meets this criterion.\n8. **Willing and able to provide informed consent**: We cannot determine if the patient is willing and able to provide informed consent based on the note.\n\nSince the patient's ethnicity, BMI, 2h glucose OGTT, use of supplements, and alcohol consumption are not mentioned in the patient note, there is insufficient information to determine if the patient meets the inclusion criteria for the trial. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2208": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Non Opioid Treatment for Experimental Dyspnea,\" let's assess the eligibility:\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He presents with shortness of breath and fatigue, which is classified as NYHA class 2.\n- He is diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- The patient has a history of diabetes and is currently taking medication for it.\n\nClinical Trial Inclusion Criteria:\n- Healthy\n- Non-smoking\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial. The trial is looking for healthy, non-smoking individuals, and the patient has type 1 diabetes and cardiomyopathy, which means he is not considered \"healthy\" as per the typical definition in clinical trial criteria. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2209": {
        "output": "To determine the eligibility of the patient for the clinical trial, we must compare the patient's information with the inclusion and exclusion criteria of the trial. Let's review the patient's details against the trial's criteria:\n\nPatient Details:\n- 25-year-old man\n- Type 1 diabetes mellitus confirmed with molecular analysis 7 years ago\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- No other significant medical issues\n- Family history positive for DM type 1\n- Lab results: FBS 100 mg/dl, HbA1c 6.5%, Cholesterol 190 mg/dl, TG 140 mg/dl, LDL 125 mg/dl, HDL 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- \u226521 and <65 years old\n- Clinical diagnosis of type 1 diabetes mellitus\n- Documented hyperglycemia (various criteria)\n- Requirement of insulin from diagnosis or shortly after\n- Use of an insulin pump for at least 1 year\n- HbA1c between 6.0% - 9.0%\n- Not pregnant or breastfeeding (female-specific)\n- Proper mental status and cognition\n- Willingness to avoid acetaminophen\n- Stability on certain medications for at least 2 months\n\nClinical Trial Exclusion Criteria:\n- Diabetic ketoacidosis within the past 6 months\n- Severe hypoglycemia in the past 12 months\n- Hypoglycemia unawareness with severe low blood sugars\n- Uncontrolled hypertension\n- Certain cardiac disorders and other conditions\n- Hematocrit below a certain threshold\n- Infection history\n- Use of conflicting devices\n- Various medication restrictions\n- Impaired hepatic or renal function\n- Uncontrolled microvascular complications\n- Active gastroparesis\n- Uncontrolled thyroid disease\n- Known allergies to medical adhesives or pump/sensor components\n- Active enrollment in another clinical trial\n- Use of anti-diabetic agents other than CSII\n- Basal rates less than 0.05\n\nAssessment:\n- The patient is 25 years old, which meets the age criterion of \u226521 and <65 years old.\n- The patient has a clinical diagnosis of type 1 diabetes mellitus, confirmed 7 years ago.\n- The patient's HbA1c is 6.5%, which is within the required range of 6.0% - 9.0%.\n- The patient's treatment includes the use of insulin, as indicated by his use of 70/30 Insulin.\n\nHowever, there are a couple of issues that may affect eligibility:\n- The patient is diagnosed with cardiomyopathy, which is a cardiac disorder. The trial excludes individuals with certain cardiac disorders.\n- The patient is taking ACE inhibitors and Beta blockers, which might be considered medications that block symptoms of hypoglycemia, and beta blockers are specifically mentioned in the exclusion criteria.\n\nGiven the information provided, there is a possibility that the patient's cardiac condition and treatment with beta blockers could exclude him from the trial. However, since we do not have clear information about the severity of the cardiomyopathy and whether it qualifies as an uncontrolled cardiac disorder, or if the beta blocker use is a factor, we cannot make a definite determination. Therefore, the patient's eligibility is not clear based on the provided information, and additional information would be required to make a definitive assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2210": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient step by step:\n\n1. **Age**: The patient is 25 years old, and the trial requires participants to be at least 18 years of age. The patient meets this criterion.\n\n2. **Diagnosis**: The patient has type 1 diabetes and is diagnosed with cardiomyopathy. However, the trial is specifically for veterans with chronic heart failure. There is no mention of the patient being a veteran or having chronic heart failure as a primary diagnosis.\n\n3. **Language**: The patient needs to be able to read and understand English. There is no information provided about the patient's language abilities.\n\n4. **Access to a Telephone**: The patient needs to have consistent access to a telephone. This information is not provided in the patient note.\n\n5. **Specific Criteria**:\n   - A prior primary discharge diagnosis of heart failure in the last year: There is no information on a discharge diagnosis of heart failure.\n   - Kansas City Cardiomyopathy Questionnaire (KCCQ) score less than or equal to 60: There is no KCCQ score provided.\n   - A second hospitalization for heart failure in the last year: There is no information on hospitalizations for heart failure.\n   - Taking at least 80 mg oral furosemide (or equivalent) daily: The only medications mentioned are ACE inhibitors, Beta blockers, 70/30 Insulin, and vitamin D supplements.\n   - BNP greater than or equal to 250 or NT-proBNP greater than or equal to 1000: No BNP or NT-proBNP levels are provided.\n   - Estimated creatinine clearance 30-80 mL/min: There is no information on the patient's renal function or creatinine clearance.\n\nGiven the available information, the patient does not have sufficient information to qualify for the trial based on the diagnosis of heart failure, veteran status, and other specific criteria mentioned in the inclusion criteria of the trial. Therefore, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2211": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion and exclusion criteria, the following analysis can be made:\n\nPatient's characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy (will be treated with ACE inhibitors and Beta blockers)\n- NYHA class 2 heart failure symptoms\n- No mention of QRS duration or LVEF\n- No mention of being on optimal medical therapy for heart failure\n\nClinical trial's inclusion criteria:\n- Ischemic or non-ischemic cardiomyopathy\n- Patient meets all current criteria for CRT (NYHA Class III-IV heart failure, QRS \u2265 120 ms, LVEF \u2264 35%, optimal medical therapy)\n- Patient willing/able to sign study informed consent and HIPAA authorization\n\nClinical trial's exclusion criteria:\n- Patient does not meet current criteria for CRT implant\n- Mechanical aortic valve\n- Left ventricular thrombus\n- Aortic stenosis\n- No palpable femoral pulse\n- Extensive atherosclerotic disease of the aorta\n- Serum creatinine > 2.5\n- Patient not willing/able to sign study informed consent/HIPAA authorization\n\nBased on the available information, the patient has cardiomyopathy but does not meet all the criteria for Cardiac Resynchronization Therapy (CRT), specifically NYHA Class III-IV heart failure (he is NYHA class 2) and there is no information provided about QRS duration, LVEF, or if he is on optimal medical therapy for heart failure. Therefore, sufficient information is not available to determine if the patient meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2212": {
        "output": "Based on the information provided in the patient note, we can analyze the patient's eligibility for the clinical trial titled \"Palliative Care in Heart Failure\" according to its inclusion criteria:\n\n1. Duke University Hospital inpatient adults \u2014 The patient note does not specify the hospital, so we cannot determine if this criterion is met.\n2. Hospitalization for acute decompensated heart failure \u2014 The patient has been diagnosed with cardiomyopathy and experiences shortness of breath and fatigue during activities, but there is no mention of acute decompensated heart failure or current hospitalization.\n3. Dyspnea (shortness of breath) at rest or minimal exertion plus at least 1 sign of volume overload \u2014 The patient has mild dyspnea after climbing 3 floors and no dyspnea at rest, which does not completely align with the criterion of dyspnea at rest or minimal exertion.\n4. Previous heart failure hospitalization within the past 1 year \u2014 There is no mention of previous hospitalizations for heart failure in the patient's history.\n5. At significant risk of dying from heart failure in the next 6 months \u2014 There is no information provided that the patient is at significant risk of dying from heart failure within the specified timeframe.\n6. Anticipated discharge from hospital with anticipated ability to return to outpatient follow-up appointments \u2014 Again, there is no information about the patient currently being hospitalized or about discharge plans.\n\nGiven the lack of information aligning with the trial's inclusion criteria and the absence of certain key details such as hospitalization status and risk of dying from heart failure, the patient does not meet sufficient criteria for the trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2213": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial titled \"Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study,\" let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Clinical diagnosis of type 1 diabetes confirmed with molecular analysis 7 years ago\n- Currently using insulin therapy (70/30 Insulin mentioned in the patient note)\n- Age: 25 years\n- HbA1c: 6.5%\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year\n- Using an insulin infusion pump for at least 6 months\n- Age \u2265 15.0 - 45 years\n- HbA1c \u2264 8.0%\n- Availability of internet access for periodic upload of study data\n\nThe patient note does not mention the use of an insulin infusion pump, which is a requirement for the clinical trial. The note only mentions \"70/30 Insulin,\" which implies the use of a mixed insulin, typically injected, not delivered by a pump. Without confirmation that the patient has been using an insulin infusion pump for at least 6 months, we cannot determine eligibility based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2214": {
        "output": "Based on the patient note provided:\n\nThe patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. He is experiencing shortness of breath and fatigue during activities but no angina. His current medical treatment includes ACE inhibitors, Beta blockers, insulin, and vitamin D supplements. The patient's laboratory results are provided but do not include hemoglobin levels, which are relevant to the clinical trial's inclusion criteria.\n\nThe clinical trial in question is focused on developing a score for the trigger of transfusion in perioperative patients with hemoglobin levels between 6g/dL and 10g/dL. The inclusion criteria for the trial are:\n\n1. Height of usual place of residence less than 2,500 metres above sea level.\n2. Perioperative hemoglobin level possibly less than 10g/dL.\n\nBased on the information given in the patient note, there is no mention of the patient's hemoglobin levels or any upcoming surgical procedures that would imply a perioperative status. Additionally, there is no information about the patient's place of residence in relation to sea level. Therefore, we do not have enough information to determine whether the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2215": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial:\n\nPatient Note:\n- 25-year-old man.\n- Type 1 diabetes.\n- Shortness of breath and fatigue during activities; NYHA class 2.\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers.\n- Current medications include 70/30 Insulin and vitamin D supplements.\n- No hospital admission mentioned.\n- No mention of Left Ventricular Systolic Dysfunction (LVSD) or diastolic dysfunction.\n- The patient is ambulatory.\n- The ability to read and write English and cognitive status are not mentioned.\n\nClinical Trial Inclusion Criteria:\n- Hospital admission with a diagnosis of Heart Failure (HF) with LVSD or diastolic dysfunction.\n- Concomitant Diabetes (DM) type II.\n- Planned discharge from hospital to home setting.\n- NYHA Class II-IV.\n- On optimal HF regimen of care including ACE-Inhibitors or ARBs, beta-blocking agents, and diuretics if indicated by patient fluid status.\n- Ambulatory.\n- Able to read and write English.\n- Acceptable cognitive screening test.\n\nThe patient in question does not meet the inclusion criteria for the clinical trial:\n- The patient has Type 1 diabetes, not Type 2 as specified in the trial criteria.\n- There is no mention of hospital admission or planned discharge in the patient note.\n- The patient's diagnosis of cardiomyopathy does not specify LVSD or diastolic dysfunction.\n\nTherefore, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2216": {
        "output": "Based on the information provided, let's evaluate the patient's eligibility for the clinical trial:\n\n**Patient Characteristics:**\n- Type 1 diabetes (not type 2 diabetes)\n- HbA1c: 6.5%\n- Fasting glucose (FBS): 100 mg/dL\n- LDL-C: 125 mg/dL\n- No mention of BMI\n\n**Clinical Trial Inclusion Criteria:**\n- Diagnosis of type 2 diabetes\n- Minimum 6 month history of diabetes\n- Fasting C-peptide \u2265 0.8 ng/mL\n- HbA1C 7-10%\n- Fasting glucose 140-270 mg/dL\n- BMI from 25-35 kg/m2\n- LDL-C \u2265 100 mg/dL\n\nThe patient does not meet the inclusion criteria for the clinical trial as he has type 1 diabetes, not type 2. Additionally, the patient's fasting glucose level is outside of the specified range for the trial. There is also no information on the patient's BMI to further assess eligibility, and the patient's HbA1c is below the required range.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2217": {
        "output": "",
        "label": 0
    },
    "2218": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease,\" we must compare the patient's characteristics to the trial's inclusion criteria:\n\n1. In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements.\n2. The patient has signed informed consent.\n3. Has a diagnosis of type 2 diabetes mellitus.\n4. Has an HbA1c level between 7.0% and 10.5% at Screening.\n5. Meets at least one High Risk or Intermediate Risk Category for cardiovascular disease.\n6. Is able and willing to monitor glucose with a home glucose monitor.\n7. If female of childbearing potential, agrees to use adequate contraception.\n8. Subjects with ALT or AST \u22643x upper limit of normal (ULN), and if elevated above ULN, have chronic, well-compensated liver disease documented by clinical parameters.\n\nHere is the patient note:\n- The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago.\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- His HbA1c is 6.5%.\n\nBased on this information:\n- The patient has type 1 diabetes, not type 2 diabetes as required by the trial.\n- The patient's HbA1c level is below the inclusion criteria range of 7.0% to 10.5%.\n- There is no mention of the patient meeting any High Risk or Intermediate Risk Categories for cardiovascular disease as defined by the trial.\n- Although the patient has cardiomyopathy, there is no mention of documented myocardial infarction, PAD, or cerebrovascular disease as specified in the inclusion criteria.\n- Other protocol requirements such as signed informed consent, the ability to monitor blood glucose, and liver enzyme levels are not mentioned in the patient note.\n\nGiven the information provided, the patient does not meet the required diagnosis of type 2 diabetes and the HbA1c criteria. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2219": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the eligibility:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy treated with ACE inhibitors and Beta blockers\n- No mention of acute heart failure (AHF) or hospitalization\n\nClinical Trial Inclusion Criteria:\n- Male or female \u2265 18 years of age (Patient is 25, so this criterion is met)\n- AHFS (Acute Heart Failure Syndrome) is the primary working diagnosis for ER management and treatment with planned admission (No mention of AHF in the patient's diagnosis)\n- Have received IV diuretic therapy (No mention of having received IV diuretic therapy)\n- Enrolled within 3 hours of initial diuretic dose (Since there's no mention of IV diuretic therapy, this point is not applicable)\n\nThe patient has cardiomyopathy, which can be associated with heart failure, but the patient note does not specify that the patient has acute heart failure syndrome nor that he received IV diuretic therapy. Without this information, we cannot confirm that the patient meets the specific inclusion criteria for the clinical trial regarding diagnosis and treatment. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2220": {
        "output": "Based on the information provided, let's assess the eligibility of the patient for the clinical trial:\n\nClinical Trial Inclusion Criteria:\n1. The subject is between 12 and 18 years of age (inclusive).\n2. The subject has had type 1 diabetes, as defined by WHO for at least 1 year or is confirmed C-peptide negative.\n3. The subject will have been on an insulin pump user for at least 3 months, with good knowledge of insulin self-adjustment.\n4. HbA1c \u2264 12 % based on analysis from central laboratory.\n\nPatient Information:\n- The patient is a 25-year-old man with type 1 diabetes.\n- The patient has had type 1 diabetes for 7 years.\n- It is not mentioned whether the patient is on an insulin pump or his knowledge of insulin self-adjustment.\n- The patient's HbA1c is 6.5%.\n\nThe patient does not meet the age criterion for the clinical trial, as he is 25 years old and the trial requires participants to be between 12 and 18 years of age. The rest of the information is not sufficient to assess the other criteria, such as insulin pump usage and knowledge of insulin self-adjustment. However, since the age criterion is not met, that alone is sufficient to determine the patient's eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2221": {
        "output": "",
        "label": 0
    },
    "2222": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient\u2019s characteristics and condition with the inclusion and exclusion criteria of the clinical trial titled \"STEMI Versus NSTEMI: Clinical and Angiographic Differences\".\n\nPatient Characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes, cardiomyopathy\n- Symptoms: Shortness of breath, fatigue during activities, no angina, dyspnea after climbing 3 floors\n- Treatment: ACE inhibitors, Beta blockers, 70/30 Insulin, vitamin D supplements\n- Other medical history: Not significant for any other medical issues\n- Family history: DM type 1 in uncle and grandfather\n- Lab study: Various blood work results\n\nClinical Trial Inclusion Criteria:\n- Patients admitted to the coronary care unit (CCU) of the Federico 2nd University Hospital\n- Patient with an indication for an angiographic study\n- Diagnosis of acute myocardial infarction (AMI), type STEMI or NSTEMI, based on troponin I and CK-MB\n- Diagnosis of NSTEMI/STEMI performed according to standard criteria\n\nClinical Trial Exclusion Criteria:\n- Patients who could not undergo an angiographic study\n\nAssessment:\nThe patient in the note does not have a diagnosis of acute myocardial infarction (AMI), whether STEMI or NSTEMI. The patient has cardiomyopathy and is being treated for it, but there is no mention of AMI or an indication for an angiographic study based on the diagnosis of AMI. The patient note does not provide information indicating the patient has been admitted to the coronary care unit (CCU) or has an acute myocardial infarction.\n\nTherefore, since the patient does not meet the clinical trial's inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2223": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Nutrient Timing Following Resistance Exercise,\" we must examine the inclusion criteria provided:\n\n- BMI between 18-30\n- At least one first-degree relative with a family history of type 2 diabetes\n- Healthy with no self-report of diagnosis of chronic disease\n\nThe patient note provides the following information about the patient:\n\n- The patient is a 25-year-old man with type 1 diabetes.\n- He presents with shortness of breath and fatigue, indicating a diagnosis of cardiomyopathy.\n- He has a family history of type 1 diabetes (uncle and grandfather), but no mention of type 2 diabetes.\n- There is no information provided about the patient's BMI.\n- The patient is not healthy, as he has a self-report of diagnosis of chronic disease (type 1 diabetes and cardiomyopathy).\n\nBased on the information provided:\n\n- The patient does have a family history of diabetes, but it is type 1 diabetes, not type 2 diabetes as specified in the inclusion criteria.\n- The patient has a chronic disease, which is against the inclusion criteria that require participants to be healthy with no self-report of diagnosis of chronic disease.\n- The patient's BMI is not provided, so we cannot assess eligibility based on this criterion.\n\nGiven the available information, the patient does not meet the inclusion criteria for the trial due to having a chronic disease (type 1 diabetes and cardiomyopathy) and the lack of a specified family history of type 2 diabetes. Therefore, the patient would be considered:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2224": {
        "output": "To determine the patient's eligibility for the \"A Study of Evacetrapib in High-Risk Vascular Disease\" clinical trial, we need to compare the patient's condition and history to the inclusion criteria of the trial:\n\nPatient information:\n- 25-year-old man with type 1 diabetes\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- Lab results: HDL: 40 mg/dl, LDL: 125 mg/dl, TG: 140 mg/dl\n\nClinical Trial Inclusion Criteria:\n1. Diagnosis of high-risk vascular disease (HRVD):\n   - History of acute coronary syndrome (ACS) (\u226530 days through 365 days after discharge for ACS)\n   - Cerebrovascular atherosclerotic disease\n   - Peripheral arterial disease\n   - Diabetes mellitus with documented coronary artery disease and are clinically stable\n2. Must be treated with a statin for at least 30 days prior to screening, or have documented statin intolerance or contraindication to statin\n3. Screening HDL-C \u226480 mg/dL (\u22642.1 mmol/L)\n4. Screening TG \u2264400 mg/dL (\u22644.5 mmol/L)\n5. Meet one of the following LDL-C criteria:\n   - Screening LDL-C no more than 10 mg/dL above the target chosen by the investigator (either <100 mg/dL or <70 mg/dL)\n   - If LDL-C is greater than the target, the participant must be on a maximum tolerated statin dose for at least 30 days, have documented statin intolerance, or contraindication to statin\n\nEligibility Assessment:\n- The patient has type 1 diabetes, but there is no mention of coronary artery disease which is required as per the trial's inclusion criteria.\n- The patient is not described as being treated with a statin, nor is there any mention of statin intolerance or contraindication.\n- The patient's HDL-C is 40 mg/dL, which meets the trial criteria of being \u226480 mg/dL.\n- The patient's TG is 140 mg/dL, which meets the trial criteria of being \u2264400 mg/dL.\n- The patient's LDL-C is 125 mg/dL, which doesn't meet the LDL-C criteria for the trial, and there is no mention of being on a maximum tolerated statin dose or having statin intolerance.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial due to the absence of documented coronary artery disease in the context of diabetes mellitus and no current treatment with a statin.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2225": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Outpatient Control-to-Range: System and Monitoring Testing,\" we must compare the patient's characteristics and medical history with the inclusion criteria provided.\n\nPatient Characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes mellitus, diagnosed 7 years ago\n- Current treatment: 70/30 Insulin and vitamin D supplements\n- Use of an insulin pump: Not mentioned\n- HbA1c: 6.5%\n- Additional medical condition: Cardiomyopathy, being treated with ACE inhibitors and Beta blockers\n- Mental status and cognition: Not mentioned\n- Pregnancy status: Not applicable as the patient is male\n- Medication stability: Not mentioned\n\nInclusion Criteria for the Clinical Trial:\n- Age \u226521 and <65 years old (patient is 25, so meets criteria)\n- Clinical diagnosis of type 1 diabetes mellitus with documented hyperglycemia (patient has documented HbA1c \u22656.5%)\n- Criteria for requiring insulin at diagnosis (patient has been confirmed with type 1 diabetes and takes insulin)\n- Use of an insulin pump to treat diabetes for at least 1 year (information not provided in the patient note)\n- Actively using an insulin pump with bolus calculator feature (information not provided in the patient note)\n- HbA1c between 6.0% - 9.0% (patient's HbA1c is 6.5%, so meets criteria)\n- Not currently known to be pregnant, breast feeding, or intending to become pregnant (patient is male, so meets criteria)\n- Proper mental status and cognition for the study (information not provided in the patient note)\n- Willingness to avoid consumption of acetaminophen-containing products during the study (information not provided in the patient note)\n- If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, stability on the medication for at least 2 months prior to enrollment (patient is on ACE inhibitors for cardiomyopathy, but stability on medication is not mentioned)\n\nThe patient meets several of the inclusion criteria, such as age, diagnosis of type 1 diabetes, and HbA1c level. However, there is no information on whether he has been using an insulin pump for at least 1 year, nor if he's actively using a pump with a bolus calculator feature. Additionally, the patient's mental status, cognition, and willingness to comply with study-specific requirements regarding acetaminophen consumption are not mentioned. Also, there is no mention of the duration of the patient's medication for cardiomyopathy to assess stability.\n\nBased on the available information, the patient note does not provide sufficient details to confirm eligibility for the clinical trial. Thus, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2226": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes and has been diagnosed with cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers.\n\nThe clinical trial in question is examining the relationship between working capacity (peak oxygen consumption) and pump speed of continuous flow left ventricular assist devices (CF-LVADs) in heart failure patients.\n\nThe inclusion criteria for the clinical trial are:\n1. HeartMate II patients who underwent surgery and follow-up at The Heart Centre of Rigshospitalet.\n2. Heart failure in stable phase without the need for intravenous inotropic therapy.\n3. Ischemic and non-ischemic cardiomyopathy.\n\nThe patient note does not mention the use of a continuous flow left ventricular assist device (CF-LVAD) or surgery at The Heart Centre of Rigshospitalet. Therefore, the patient does not meet the specific inclusion criteria listed for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2227": {
        "output": "Given Patient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes, not type 2 diabetes or metabolic syndrome.\n- His BMI is not specified.\n- His lab study shows FBS and HbA1c levels that do not indicate type 2 diabetes.\n\nClinical Trial Inclusion Criteria:\n- Men and women aged 18-75 years old.\n- BMI 25-35 kg/m^2.\n- Presence of type 2 diabetes (as defined by HbA1c \u22648.5%), treated with diet or oral hypoglycemic medication.\n- Presence of Metabolic Syndrome as defined by The US National Cholesterol Education Program Adult Treatment Panel III.\n\nSince the patient has type 1 diabetes, not type 2 diabetes or metabolic syndrome, he does not meet the inclusion criteria specified for the clinical trial, which specifically requires type 2 diabetes or metabolic syndrome.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2228": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nInclusion Criteria Breakdown:\n1. Age \u226521 and <65 years old.\n2. Clinical diagnosis of type 1 diabetes mellitus.\n   - Criteria for documented hyperglycemia (at least 1 must be met):\n     i. Fasting glucose \u2265126 mg/dL - confirmed\n     ii. Two-hour Oral Glucose Tolerance Test (OGTT) glucose \u2265200 mg/dL - confirmed\n     iii. HbA1c \u22656.5% documented - confirmed\n     iv. Random glucose \u2265200 mg/dL with symptoms\n     v. No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes\n   - Criteria for requiring insulin at diagnosis (1 must be met):\n     i. Participant required insulin at diagnosis and continually thereafter\n     ii. Participant did not start insulin at diagnosis but upon investigator review likely needed insulin and did require insulin eventually and used continually\n     iii. Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually\n3. Use of an insulin pump to treat diabetes for at least 1 year.\n4. Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters.\n5. HbA1c <9%.\n6. Not currently known to be pregnant, breast feeding, or intending to become pregnant (females only).\n7. Proper mental status and cognition for the study.\n8. Willingness to avoid consumption of acetaminophen-containing products during the study interventions involving CGM use.\n9. If on antihypertensive, thyroid, anti-depressant, or lipid-lowering medication, have stability on the medication for at least 2 months prior to enrollment in the study.\n\nPatient Characteristics:\n- The patient is a 25-year-old man.\n- He has a clinical diagnosis of type 1 diabetes confirmed with molecular analysis 7 years ago.\n- The patient is treated with insulin (70/30 Insulin), suggesting he required insulin at diagnosis and continually thereafter.\n- His HbA1c level is 6.5%.\n- No mention is made of using an insulin pump, familiarity with a bolus calculator, or his mental status and cognition.\n- The patient is male, so criteria 6 is not applicable.\n- No information is provided about the use of other medications such as antihypertensive, thyroid, anti-depressant, or lipid-lowering medications.\n\nGiven the available information, we cannot confirm that the patient meets all the inclusion criteria due to the lack of information regarding the use of an insulin pump and familiarity with a bolus calculator. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2229": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Ranolazine for the Treatment of Chest Pain in HCM Patients,\" we need to match the patient's characteristics and condition against the inclusion criteria of the trial.\n\nHere are the inclusion criteria for the trial:\n1. Age 18 years or older\n2. Left Ventricle wall thickness \u2265 15mm in the absence of other conditions causing hypertrophy\n3. Baseline Angina/Shortness of Breath Frequency of > 2 episodes per week\n4. Willing to provide informed consent\n\nThe patient's characteristics based on the provided note:\n- The patient is a 25-year-old man, which meets the age criterion.\n- The patient is diagnosed with cardiomyopathy. However, there is no mention of hypertrophic cardiomyopathy (HCM) specifically or the thickness of the left ventricular wall, so we do not have sufficient information to determine if the patient meets the second criterion.\n- The patient experiences shortness of breath and fatigue during activities, which could be indicative of dyspnea. However, the frequency of these episodes is not specified as more than 2 episodes per week, so we cannot confirm if this criterion is met.\n- There is no information provided that suggests the patient is unwilling to provide informed consent.\n\nBased on the information provided, the patient does not have sufficient information to qualify for the trial because the specific diagnosis of hypertrophic cardiomyopathy is not confirmed, nor is the left ventricular wall thickness specified. Additionally, the frequency of angina/shortness of breath episodes necessary to meet the third criterion is not detailed.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2230": {
        "output": "The patient is a 25-year-old man with type 1 diabetes, which fits within the age range of \u226521 and <65 years old required by the trial. The patient's HbA1c level is 6.5%, which meets one of the criteria for documented hyperglycemia (HbA1c \u22656.5% documented - confirmed). Additionally, the patient's diagnosis of type 1 diabetes 7 years ago with a requirement for insulin satisfies the criteria for requiring insulin at diagnosis. There is no information about the patient's use of an insulin pump, but given his type 1 diabetes diagnosis and current insulin therapy, it is plausible that he uses an insulin pump. The HbA1c level being below 9% also meets the trial's inclusion criteria. There is no information provided that would suggest the patient is pregnant (irrelevant since the patient is male), breastfeeding, or has mental or cognitive issues that would impede participation. The patient is also not reported to be taking any contraindicated medications like acetaminophen. \n\nHowever, there is insufficient information about some of the other specific inclusion criteria such as:\n- The use of an insulin pump to treat his diabetes for at least 1 year.\n- Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters for carbohydrate (CHO) ratio, insulin sensitivity factor (ISF), target glucose, and active insulin.\n\nGiven the available information, the patient seems to meet most of the known inclusion criteria but lacks specific details on insulin pump use and familiarity with a bolus calculator. Therefore, the patient is not clearly eligible as some crucial information is missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2231": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nThe patient is a:\n- 25-year-old man\n- Diagnosed with type 1 diabetes confirmed with molecular analysis 7 years ago\n\nThe clinical trial inclusion criteria are:\n- Diagnosed with type 1 diabetes (WHO criteria)\n\nThe patient clearly meets the inclusion criteria of having been diagnosed with type 1 diabetes. There are no other inclusion criteria specified, and no exclusion criteria are provided. Therefore, the patient is eligible for the clinical trial based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2232": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history to the trial's inclusion criteria:\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Age \u226521 and <65 years old.\n2. Clinical diagnosis of type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met:\n    - Criteria for documented hyperglycemia (at least 1 must be met):\n        i. Fasting glucose \u2265126 mg/dL - confirmed\n        ii. Two-hour OGTT glucose \u2265200 mg/dL - confirmed\n        iii. HbA1c \u22656.5% documented - confirmed\n        iv. Random glucose \u2265200 mg/dL with symptoms\n        v. No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes\n    - Criteria for requiring insulin at diagnosis (1 must be met):\n        i. Participant required insulin at diagnosis and continually thereafter\n        ii. Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually\n        iii. Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually\n3. Use of an insulin pump to treat his/her diabetes for at least 1 year.\n4. Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters for carbohydrate (CHO) ratio, insulin sensitivity factor (ISF), target glucose and active insulin.\n5. HbA1c <9% as measured with DCA2000 or equivalent device.\n6. Not currently known to be pregnant, breast feeding, or intending to become pregnant (females only).\n7. Demonstration of proper mental status and cognition for the study.\n8. Willingness to avoid consumption of acetaminophen-containing products during the study interventions involving CGM use.\n9. If on antihypertensive, thyroid, anti-depressant, or lipid-lowering medication, have stability on the medication for at least 2 months prior to enrollment in the study.\n\nNow, let's assess the patient's details against these criteria:\n\n1. The patient is 25 years old, which meets the age criterion of being \u226521 and <65 years old.\n2. The patient has a clinical diagnosis of type 1 diabetes, confirmed with molecular analysis 7 years ago.\n    - The patient's fasting blood sugar (FBS) is 100 mg/dl, which does not meet the hyperglycemia criteria of fasting glucose \u2265126 mg/dL.\n    - The patient's HbA1c is 6.5%, which meets the hyperglycemia criteria of an HbA1c \u22656.5%.\n    - The patient has been taking insulin (70/30 Insulin), which meets the criteria for requiring insulin at diagnosis.\n3. There is no information on whether the patient has been using an insulin pump for at least 1 year.\n4. There is no information on the patient's familiarity with a bolus calculator.\n5. The patient's HbA1c is <9%, which meets this criterion.\n6. The patient is male, so the pregnancy-related criteria are not applicable.\n7. There is no information on the patient's mental status and cognition.\n8. There is no information on the patient's willingness to avoid acetaminophen.\n9. The patient is diagnosed with cardiomyopathy, which is not listed as a condition requiring medication stability in the criteria. However, there is no information about the stability of his new medication (ACE inhibitors and Beta blockers).\n\nBased on the available information, the patient meets some of the inclusion criteria (age, diabetes diagnosis, HbA1c level), but there is insufficient information regarding the use of an insulin pump, familiarity with a bolus calculator, mental status, and willingness to avoid acetaminophen. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2233": {
        "output": "Based on the provided patient note and the clinical trial's inclusion and exclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy\n- Currently taking 70/30 Insulin and vitamin D supplements\n- Lab study results show:\n  - FBS: 100 mg/dl\n  - HbA1c: 6.5%\n  - Cholesterol: 190 mg/dl\n  - TG: 140 mg/dl\n  - LDL: 125 mg/dl\n  - HDL: 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Age range of 18-70 years\n- Normal fasting glucose subjects: fasting glucose <100 mg/dl and HbA1c <5.7%\n- Impaired fasting glucose subjects: fasting glucose between 100 and 125 mg/dl and/or HbA1c between 5.7 and 6.4%\n- Type 2 Diabetes subjects: basal plasma glucose \u2265 126 mg/dl, at least twice, or glucose levels 2 hours after 75 g oral glucose overload \u2265 200 mg/dl\n\nClinical Trial Exclusion Criteria:\n- Morbid obesity\n- Type 1 diabetes\n- Heart, liver, thyroid or kidney untreated disease\n- Neoplastic disease\n- Hypertriglyceridemia (Triglycerides >400 mg/dl)\n- Use of drugs that can influence the inflammatory state or insulin sensitivity\n- Uncontrolled type 2 diabetes (HbA1c \u2265 8%) or with insulin or intestinal disaccharidase inhibitors treatment\n\nThe patient's characteristics align with the age criterion for the trial (18-70 years). However, the patient has Type 1 diabetes, which is explicitly listed as an exclusion criterion for the trial. Therefore, despite meeting the age criterion, the patient is disqualified from participating in the trial due to having Type 1 diabetes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "2234": {
        "output": "Based on the provided patient note and the clinical trial criteria, we can analyze the patient's eligibility for the trial:\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He is diagnosed with type 1 diabetes and cardiomyopathy.\n- He is being treated with ACE inhibitors and Beta blockers.\n- His lab study indicates his cholesterol level is 190 mg/dl.\n- There is no mention of an acute cardiovascular event or hospital discharge in the patient's history.\n\nClinical Trial Inclusion Criteria:\n- Outpatients (External Ambulatory) Patients.\n- Male or female patients.\n- 18 to 99 years old.\n- Patients with Hypercholesterolemia.\n- Patients with and without treatment with statin.\n- Patients enrolled in any of the study sites with an acute cardiovascular event.\n- Patients discharged with study medication (Antorcin\u00ae).\n- Patients who have agreed and signed the consent form for the recording and processing of their personal data.\n\nAssessment:\n- The patient is within the age range of 18 to 99 years old.\n- The patient is male.\n- The patient has a cholesterol level of 190 mg/dl, which may indicate hypercholesterolemia depending on the specific cut-off values for the trial, which are not provided.\n- There is no information indicating the patient experienced an acute cardiovascular event or that he was discharged with the study medication Antorcin\u00ae.\n- There is no information on whether the patient has agreed and signed the consent form for the recording and processing of their personal data.\n\nGiven the information, the patient does not clearly meet all the inclusion criteria, specifically regarding the acute cardiovascular event and the use of the study medication Antorcin\u00ae. Therefore, the patient is not eligible for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2235": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Registry of Diabetes Patients in a Large Health Maintenance Organization in Israel,\" let's review the provided patient note against the inclusion criteria of the trial.\n\nPatient Note Summary:\n- 25-year-old man\n- Diagnosed with type 1 diabetes confirmed with molecular analysis 7 years ago\n- Presents with shortness of breath and fatigue, NYHA class 2\n- Diagnosed with cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Currently on 70/30 Insulin and vitamin D supplements\n- Family history of DM type 1\n- Lab results: FBS: 100 mg/dl, HbA1c: 6.5%\n\nClinical Trial Inclusion Criteria:\n- Diabetic patient as defined by the American Diabetes Association criteria\n- Symptoms diagnosed as diabetes and FBS >125 mg/dl or casual plasma glucose >200 mg/dl\n- Purchased at least two hypoglycemic medications or single insulin dose during 6 months\n- Had HbA1c result of at least 7.25%, but HbA1c of 6.5% is used as entry criterion to registry only when the patient was diagnosed as diabetic\n\nComparison:\n- The patient has type 1 diabetes, which meets the basic requirement of being a diabetic patient.\n- The patient is on insulin, which satisfies the criterion of having purchased insulin.\n- The patient's HbA1c is 6.5%, which is the threshold mentioned in the inclusion criteria when the patient is diagnosed as diabetic.\n\nThe patient does not meet the FBS criteria (FBS >125 mg/dl) as his FBS is 100 mg/dl. However, the inclusion criteria also allow for entry into the registry if the patient has an HbA1c of 6.5% and is diagnosed as diabetic, which applies to this patient.\n\nTherefore, based on the information provided, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2236": {
        "output": "",
        "label": 0
    },
    "2237": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. He is not reported to have impaired fasting glucose (IFG) or newly diagnosed type 2 diabetes. The fasting blood sugar (FBS) level provided is 100 mg/dl, which falls within the range for impaired fasting glucose (100\u2264 fasting glucose <126 mg/dl), but since the patient has type 1 diabetes and not type 2 diabetes, he does not meet the specific inclusion criteria outlined for the clinical trial in question.\n\nThe clinical trial is specifically seeking subjects who have impaired fasting glucose or newly diagnosed type 2 diabetes to participate in a dietary intervention program, which would not be applicable to this patient with type 1 diabetes.\n\nTherefore, the patient does not have sufficient information or the specific condition (type 2 diabetes) that is required for the study's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2238": {
        "output": "In assessing the eligibility of the patient for the specified clinical trial, we need to consider the inclusion criteria presented for the trial and the information provided in the patient note.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Males or females between the ages of 18 and 80 years undergoing primary coronary artery bypass graft surgery (CABG).\n2. Post-surgical hyperglycemia (Blood glucose >140 mg/dl)\n3. Patients with and without a history of type 2 diabetes\n\nThe patient note provides the following relevant information:\n\n- The patient is a 25-year-old man, which meets the age criteria.\n- He has type 1 diabetes, not type 2 diabetes.\n- There is no mention of the patient undergoing coronary artery bypass graft surgery (CABG).\n- There is no indication of post-surgical hyperglycemia; his fasting blood sugar (FBS) is 100 mg/dl, which is within the normal range, and it is not stated to be post-surgical.\n\nBased on the information provided:\n\n- The patient does not meet the criteria related to the type of diabetes (he has type 1, not type 2).\n- There is no evidence that the patient is undergoing or has undergone CABG surgery.\n- There is no indication of post-surgical hyperglycemia.\n\nTherefore, the patient does not seem to meet the inclusion criteria for the clinical trial. However, without explicit information on whether the patient had CABG surgery and the current hyperglycemia status in a post-surgical context, we cannot definitively exclude the patient based on the trial's exclusion criteria. Thus, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2239": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. \n\nThe clinical trial's inclusion criteria are:\n1. Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or has been treated with Exubera.\n2. Subject has a severe phobia to sc injections of insulin (needle phobia) preventing conventional treatment OR has impaired sc insulin absorption.\n\nThe patient is being treated with 70/30 Insulin, and there is no mention of treatment with Exubera or of having a severe phobia to subcutaneous injections or impaired subcutaneous insulin absorption.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial, as there is no indication that he has been treated with Exubera or has a needle phobia or impaired subcutaneous insulin absorption.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2240": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the trial:\n\nPatient note summary:\n- 25-year-old man\n- Type 1 diabetes diagnosed 7 years ago\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Currently on 70/30 Insulin and vitamin D supplements\n- No mention of cystic fibrosis (CF) or related symptoms\n\nClinical trial inclusion criteria:\n- Patients diagnosed with cystic fibrosis (CF) according to diagnostic criteria\n- Between the ages of 0 and 50\n- Able to give informed consent\n- Have two known severe (class I, II, and III) mutations\n\nThe patient in the note does not have a diagnosis of cystic fibrosis nor does the note mention any known severe mutations associated with CF. Therefore, the patient does not meet the inclusion criteria for the clinical trial on the correlation between Haptoglobin phenotypes and infectious and other complications in cystic fibrosis patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2241": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes.\"\n\nPatient note review:\n- Age: 25-year-old man (meets age criterion of 20-59 years)\n- Condition: Type 1 diabetes confirmed with molecular analysis 7 years ago (consistent with T1D)\n- HbA1c: 6.5% (falls within the required range of 6.0 - 9.5)\n- Willingness and ability to commit to study requirements: Not specified in the patient note\n\nClinical trial inclusion criteria:\n- Age 20-59 years of age (patient meets this criterion)\n- Type 1 diabetes based on specified criteria (patient meets this criterion based on diagnosis confirmation)\n- HbA1c 6.0 - 9.5 (patient meets this criterion)\n- Willing and able to commit to study requirements (not specified in the patient note)\n\nThe patient fits the age, type of diabetes, and HbA1c criteria. However, there is no information provided about the patient's willingness and ability to commit to the study requirements, including two 6-week-long periods of blinded medication, vascular testing, and muscle biopsies.\n\nGiven the information available, the patient cannot be deemed eligible or excluded because we lack information on their willingness to participate and adhere to the study protocol.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2242": {
        "output": "The patient in question is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue, diagnosed with cardiomyopathy. The clinical trial provided is investigating whether pulmonary rehabilitation can improve breathing in patients with chronic obstructive pulmonary disease (COPD).\n\nTo assess the patient's eligibility for this trial, we need to compare the patient's characteristics and condition with the inclusion criteria listed for the trial:\n\nInclusion Criteria for the COPD Trial:\n1. A physician diagnosis of moderate-to-severe COPD\n2. Stable clinical COPD status (no history of an acute exacerbation requiring antibiotics or prednisone in the past 4 weeks)\n3. Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1.0) \u2265 30 - < 80% predicted and FEV1.0/Forced Vital Capacity ratio < 0.7\n4. Body mass index > 18 or < 35 kg/m^2\n5. Able to read and understand English\n\nThe patient's note does not mention a diagnosis of COPD; instead, the patient is diagnosed with cardiomyopathy, which is a separate condition concerning the heart muscle and not the lungs. The patient does not meet the primary inclusion criterion of having moderate-to-severe COPD. Additionally, there is no mention of the patient having any lung function tests such as FEV1.0 or Forced Vital Capacity ratio that would be relevant to COPD, as the patient's primary concern is cardiomyopathy associated with diabetes.\n\nBased on the information provided and the mismatch between the patient's diagnosis and the target condition of the clinical trial (COPD), the patient does not meet the inclusion criteria for the COPD study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2243": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue\n- Diagnosed with cardiomyopathy\n- Currently takes insulin and vitamin D supplements\n- No hypertension mentioned\n- No metabolic syndrome mentioned (based on the information provided)\n\nClinical Trial Inclusion Criteria:\n- Consent to the study\n- Male or Female \u2265 20 years\n- Taking less than 1 antihypertensive medication or not taking antihypertensive medications\n- Hypertension defined at the screening visit as 140mmHg < MSSBP or MSDBP > 90mmHg at screening\n- Hypertensive patients with non-diabetic metabolic syndrome\n- Metabolic syndrome defined according to NCEP guidelines (3 or more of the following):\n    \u2460 Abdominal obesity: Waist circumference M \u2265 90cm, F \u2265 80cm\n    \u2461 Hypertriglyceridemia: Triglycerides \u2265 150mg/dL\n    \u2462 Low HDL cholesterol Men: HDL cholesterol \u2264 40mg/dL Women: HDL cholesterol \u2264 50mg/dL\n    \u2463 Elevated blood pressure (systolic blood pressure \u2265 130 mmHg and diastolic blood pressure \u2265 85 mmHg, or current use of antihypertensive drugs)\n    \u2464 Impaired fasting glucose: fasting plasma glucose \u2265 100 mg/dL\n- Patient not taking statin medication, and if the patient had taken statin medication, the last duration must be before 3 months.\n\nBased on the patient's characteristics and the clinical trial's inclusion criteria:\n\n- The patient is over 20 years of age, fulfilling the age criterion.\n- The patient's condition (type 1 diabetes) is not classified as metabolic syndrome, and there is no indication that the patient has hypertension or meets the criteria for metabolic syndrome.\n- There is no mention of the patient's use of antihypertensive medications or blood pressure measurements, which are necessary to qualify for the trial.\n- The patient's fasting plasma glucose level is 100 mg/dL, which meets one of the criteria for metabolic syndrome, but other criteria are not met or not mentioned.\n\nGiven this information, the patient does not appear to meet the necessary criteria for non-diabetic metabolic syndrome, nor is there any indication of hypertension required for the study. The patient is not described as having metabolic syndrome nor taking antihypertensive medications, which are key inclusion requirements for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2244": {
        "output": "",
        "label": 0
    },
    "2245": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Inpatient Closed-loop Glucose Control,\" we need to compare the patient's characteristics to the inclusion criteria of the study.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- No mention of diabetes management using an insulin pump\n- No information on the total daily dose of insulin (TDD)\n- The patient is taking 70/30 Insulin (a mix of intermediate-acting and rapid-acting insulin)\n\nClinical Trial Inclusion Criteria:\n- Subjects with type 1 diabetes\n- Age 21 to 75 with clinical type 1 diabetes for at least one year\n- Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting insulins\n- Total daily dose (TDD) of insulin that is < 1 u/kg\n\nAssessment:\n- The patient is 25 years old and has had type 1 diabetes for 7 years, which meets the age and duration criteria for type 1 diabetes patients.\n- There is no information provided that the patient is using an insulin infusion pump, which is a specific requirement for participation.\n- There is insufficient information regarding the patient's total daily dose of insulin to determine if it is less than 1 u/kg, which is another specific requirement.\n\nSince there is no mention of the patient using an insulin infusion pump and no information about the total daily dose of insulin, we cannot confirm that the patient meets all the inclusion criteria for the trial. Therefore, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2246": {
        "output": "The patient note provides the following information:\n\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Shortness of breath and fatigue during activities\n- Mild dyspnea after climbing 3 floors, no dyspnea at rest, and no angina (NYHA class 2)\n- Diagnosed with cardiomyopathy\n- Treatment plan includes ACE inhibitors and Beta blockers\n- Currently takes 70/30 Insulin and vitamin D supplements\n- No other significant medical history\n- Family history positive for DM type 1 in his uncle and grandfather\n- Laboratory values: FBS, HbA1c, Cholesterol, TG, LDL, HDL\n\nThe clinical trial has the following inclusion criteria:\n\n- Over 18 years of age\n- Hospital admission for acute heart failure\n- Specific NT-proBNP levels if certain conditions are met\n- LVEF <45% assessed by echocardiography or another method within the previous 12 months\n- Background therapy with at least ACE-inhibitor or ARB and beta-blocker unless contraindicated\n- Available for regular follow up\n\nBased on the information provided in the patient note, we can see that the patient is over 18 years of age and is diagnosed with cardiomyopathy for which he is being treated with ACE inhibitors and Beta blockers, which aligns with some of the criteria. However, the patient is not described as having been admitted for acute heart failure, nor are any NT-proBNP levels or LVEF percentages provided. Without explicit information on a recent hospital admission for acute heart failure and the necessary cardiac function assessments (LVEF, NT-proBNP), we cannot confirm the patient's eligibility for the trial.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2247": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 25-year-old man with type 1 diabetes\n- Presents with shortness of breath and fatigue (NYHA class 2)\n- Diagnosed with cardiomyopathy, being treated with ACE inhibitors and Beta blockers\n- No mention of liver transplantation or immunosuppression\n\nClinical Trial Inclusion Criteria:\n- Must have received a liver transplant at least two years ago\n- Must be 18 years or older\n- Must be on immunosuppression treatment including cyclosporine or tacrolimus\n- Must have normal liver function in the last year\n- Must not have suffered acute rejection in the last year and have no chronic rejection\n- Must not submit any significant side effects from immunosuppressive medication\n- Etiology of underlying disease must be one of the specified non-viral, non-autoimmune causes\n- Must offer sufficient guarantees of adherence to protocol\n- Must give written informed consent to participate in the study\n- It is necessary that the patient meets all inclusion criteria\n\nThe patient presented does not meet the inclusion criteria for the clinical trial because there is no indication that he has undergone a liver transplantation or is on immunosuppressive therapy, nor is there mention of any liver-related issues. The patient's medical condition (type 1 diabetes and cardiomyopathy) and treatment are not relevant to the clinical trial's focus on liver transplantation and extracorporeal photopheresis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2248": {
        "output": "The patient is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue during activities, diagnosed with cardiomyopathy. Based on the clinical trial's inclusion criteria, the patient must:\n\n1. Be over 18 years of age - The patient meets this criterion.\n2. Have a diagnosis of a chronic pulmonary disorder - The patient's diagnosis is cardiomyopathy, which is a heart condition, not a pulmonary disorder.\n3. If diagnosed with lung cancer, must have completed definitive treatment more than 6 months prior - This does not apply to the patient since there is no mention of lung cancer.\n4. At least moderate dyspnea defined by a BDI score of 6 or less - The patient has NYHA class 2 dyspnea, but there is no BDI score provided, and NYHA class 2 dyspnea is not equivalent to a BDI score of 6 or less.\n5. Able to safely complete the Six Minute Walk Test (6MWT) as per attending physician's clinical judgment - There is no information provided regarding the patient's ability to complete the 6MWT.\n6. Respiratory functions clinically stable for the preceding 3 months and expected to be stable for the next 3 months - The patient has cardiomyopathy, which is not primarily a respiratory condition, and there is no information about respiratory stability.\n\nSince the patient has not been diagnosed with a chronic pulmonary disorder but rather with a heart condition (cardiomyopathy), and there is no information provided about a BDI score or respiratory stability, the patient does not meet the required inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2249": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for Renal Denervation in Patients With Chronic Kidney Disease, we can evaluate the patient's eligibility for the trial as follows:\n\nInclusion Criteria for the trial:\n1. Glomerular filtration rate: 60-15 mls/min (Stage 3 and 4 Chronic Kidney Disease)\n2. Daytime systolic blood pressure on ambulatory monitor \u2265 135 mm Hg while taking 3 or more anti-hypertensives including a diuretic on maximal dose OR ambulatory monitor systolic blood pressure is <135 but taking 4 or more anti-hypertensives\n3. Age 18 years and above\n4. A minimum of 20 mm of length and 4 mm of diameter for renal arteries on CT renal angiogram or formal renal angiogram\n\nPatient's condition:\n- The patient is a 25-year-old man, which satisfies the age criterion (18 years and above).\n- The patient has type 1 diabetes but there is no mention of chronic kidney disease or any indication of a reduced glomerular filtration rate.\n- There is no information provided about the patient's blood pressure, whether the patient is on anti-hypertensive medications, or about the specifics of his renal artery anatomy.\n\nGiven this information, the patient does not provide sufficient information regarding chronic kidney disease stage, blood pressure status, or renal artery dimensions, all of which are key inclusion criteria for the clinical trial. Therefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2250": {
        "output": "The patient in the note is a 25-year-old man with type 1 diabetes who presents with cardiomyopathy and is experiencing shortness of breath and fatigue during activities. He is diagnosed with cardiomyopathy, which is unrelated to cancer, and his treatment includes ACE inhibitors and Beta blockers.\n\nLooking at the inclusion criteria for the clinical trial titled \"Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea\":\n\n1. Diagnosis of cancer - The patient does not have a diagnosis of cancer.\n2. Breakthrough dyspnea - Although the patient experiences dyspnea on exertion, there is no mention of cancer treatment-related dyspnea.\n3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service or Thoracic Medical Oncology - There's no information about the patient being treated at MD Anderson Cancer Center.\n4. Ambulatory and able to walk with or without walking aid - The patient appears to be ambulatory.\n5. On strong opioids with morphine equivalent daily dose of 80-500 mg, with stable dose over the last 24 hours - There is no mention of the patient being on strong opioids.\n6. Karnofsky performance status >=50% - There's no information provided about Karnofsky performance status.\n7. Age 18 or older - The patient meets this criterion.\n8. Able to complete study assessments - There's no information indicating the patient is unable to complete study assessments.\n\nThe patient does not meet the inclusion criteria, specifically, he does not have a diagnosis of cancer, and there is no indication that he is on strong opioids or treated at MD Anderson Cancer Center. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2251": {
        "output": "",
        "label": 1
    },
    "2252": {
        "output": "",
        "label": 0
    },
    "2253": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes and newly diagnosed cardiomyopathy, who will be treated with ACE inhibitors and Beta blockers. He takes 70/30 Insulin and vitamin D supplements. The clinical trial in question is focused on pediatric patients with congenital heart disease (CHD) who require heart surgery and aims to evaluate the efficacy of a high dose vitamin D supplementation regimen.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Newborn (corrected gestational age between 36 weeks) up to 18 years\n2. Has CHD that will require surgery within the next 12 months\n3. CHD requiring surgical intervention with cardiopulmonary bypass\n\nThe patient in question does not meet the inclusion criteria for the following reasons:\n\n1. The patient is 25 years old, which is beyond the specified age range of up to 18 years for the trial.\n2. The patient has type 1 diabetes and cardiomyopathy, not congenital heart disease.\n3. The patient does not require CHD surgery or any surgery involving cardiopulmonary bypass.\n\nTherefore, the patient is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2254": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and condition to the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes, confirmed with molecular analysis\n- Presents with shortness of breath and fatigue during activities\n- Cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Uses 70/30 Insulin and vitamin D supplements\n- No significant other medical issues\n- Family history of DM type 1\n- Lab results: FBS: 100 mg/dl, HbA1c: 6.5%, Cholesterol: 190 mg/dl, TG: 140 mg/dl, LDL: 125 mg/dl, HDL: 40 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Age \u226521 and <65 years old\n- Clinical diagnosis of type 1 diabetes mellitus with documented hyperglycemia and need for insulin at diagnosis\n- Use of an insulin pump for at least 1 year\n- Familiarity with a bolus calculator with current insulin pump\n- HbA1c 6.5-9%\n- Not currently known to be pregnant (applies to females)\n- Proper mental status and cognition for the study\n- Willingness to avoid acetaminophen and refrain from strenuous exercise before admission\n- Stability on medications for at least 2 months prior to enrollment if on antihypertensive, thyroid, anti-depressant, or lipid-lowering medication\n- Normal renal function (eGFR \u226560 ml/min/1.73 m2)\n\nClinical Trial Exclusion Criteria:\n- Several specific health conditions and factors, including hypersensitivity to pramlintide, recent severe hypoglycemia or DKA, uncontrolled hypertension, and many others\n\nBased on the provided information:\n- The patient is within the age range (25 years old).\n- The patient has a clinical diagnosis of type 1 diabetes mellitus.\n- The patient has been managing diabetes with insulin since diagnosis, which is consistent with the trial's criteria.\n- The patient's HbA1c is 6.5%, which falls within the required range.\n- There is no indication that the patient is using an insulin pump or is familiar with a bolus calculator, which is necessary for the study.\n- The patient's renal function is not stated, but there is no indication of renal dysfunction.\n- The patient does not meet any of the listed exclusion criteria based on the given information.\n\nHowever, there is insufficient information to conclusively determine if the patient meets all the inclusion criteria, specifically regarding the use of an insulin pump and familiarity with a bolus calculator. Without confirmation of these criteria, we cannot determine full eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2255": {
        "output": "",
        "label": 0
    },
    "2256": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility for the trial as follows:\n\nPatient characteristics:\n- Age: 25 years old (qualifies as an adult patient)\n- Diagnosis: Type 1 diabetes (the trial specifies type 2 diabetes mellitus)\n- Insulin usage: Not specified (the trial requires specific insulin glargine usage)\n- Current A1C: 6.5% (the trial requires A1C > 8.5%)\n\nThe patient does not meet the inclusion criteria for the clinical trial because the trial is looking for patients with type 2 diabetes mellitus, and the patient has type 1 diabetes. Additionally, the trial requires the patient to have a current A1C greater than 8.5%, whereas this patient has an A1C of 6.5%. The insulin usage requirements are also not met, as there is no information about the patient's insulin glargine dosage.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2257": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy,\" let's evaluate the patient's eligibility.\n\nThe patient note describes a 25-year-old man diagnosed with type 1 diabetes and cardiomyopathy to be treated with ACE inhibitors and Beta blockers. There is no mention of transthyretin cardiac amyloidosis, which is a specific type of cardiomyopathy distinct from other forms. Furthermore, the inclusion criteria for the trial require:\n\n1. Documented transthyretin cardiac amyloidosis by biopsy and staining using immunohistochemistry or mass spectrometry.\n2. Echocardiographic appearance of left ventricular wall thickness of 13mm or more in the absence of hypertensive heart disease.\n3. Confirmed ATTR or SSA by genetic testing.\n4. Age 18-90.\n5. Male or non-pregnant, non-lactating females.\n6. Willingness to return to the treatment center for follow-up.\n\nThe patient's note does not provide evidence of transthyretin cardiac amyloidosis, nor does it mention any echocardiographic findings or genetic testing that would confirm the diagnosis of ATTR or SSA. The patient does meet the criteria for age and gender, but this is insufficient to declare eligibility for the trial.\n\nThe patient does not have sufficient information to qualify for the trial based on the criteria provided. Therefore, the patient would be assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2258": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient in question does not appear to meet the inclusion criteria for the clinical trial on Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea. \n\nThe inclusion criteria for the trial require:\n- Diagnosis of cancer with evidence of active disease\n- Breakthrough dyspnea, defined as dyspnea on exertion with an average intensity level \u22653/10 on the numeric rating scale\n- Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology or Cardiopulmonary Center\n- Ambulatory and able to walk with or without walking aid\n- On strong opioids with morphine equivalent daily dose of 60-130 mg for at least one week, with stable regular dose over the last 24 hours\n- Karnofsky performance status \u226550%\n- Age 18 or older\n- Able to complete study assessments\n- Must speak and understand English.\n\nThe patient is a 25-year-old man with type 1 diabetes and cardiomyopathy. There is no mention of cancer or active cancer disease. The patient's shortness of breath is related to exertion and cardiomyopathy, and not to cancer or breakthrough dyspnea on exertion. Additionally, there is no information provided regarding the patient being on strong opioids, nor is there any indication that the patient is a current outpatient at MD Anderson Cancer Center.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial because he does not have a diagnosis of cancer, which is a primary requirement for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2259": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, let's determine the patient's eligibility for the clinical trial titled \"Losartan in Decompensated Heart Failure\".\n\nPatient characteristics:\n\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy treated with ACE inhibitors and Beta blockers\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- No hospitalization for decompensated heart failure mentioned\n- No dobutamine dependence mentioned\n- Ejection fraction not specified\n- Currently taking ACE inhibitors\n\nClinical trial inclusion criteria:\n\n- Hospitalization for decompensated heart failure\n- Dobutamine dependence\n- Ejection fraction < 0.45\n- Taking angiotensin-converting enzyme inhibitor\n\nFrom the patient note, there is no indication that the patient is currently hospitalized for decompensated heart failure, nor is there any mention of dobutamine dependence. The ejection fraction has not been provided, which is a critical piece of information required to assess eligibility based on the trial's inclusion criteria.\n\nGiven the information provided, the patient's eligibility cannot be confirmed due to insufficient data regarding hospitalization status, dobutamine dependence, and ejection fraction. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2260": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to evaluate the patient's characteristics against the inclusion criteria provided for the trial.\n\nThe patient in question is a 25-year-old man with type 1 diabetes, confirmed 7 years ago. He is currently experiencing symptoms of cardiomyopathy and is prescribed ACE inhibitors and Beta blockers. He is also on insulin and vitamin D supplements. The patient's lab results show an HbA1c level of 6.5%.\n\nNow, let's compare this information to the inclusion criteria for the clinical trial:\n\n1. HEALTHY SUBJECTS:\n   - The patient is not considered a healthy subject since he has type 1 diabetes and cardiomyopathy, which is being treated with medication.\n\n2. SUBJECTS WITH TYPE 1 AND TYPE 2 DIABETES:\n   - The patient is a male with type 1 diabetes.\n   - He has been diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months, meeting this criterion.\n   - No information is provided about the patient's Body Mass Index (BMI), so we cannot determine his eligibility based on this criterion.\n   - His glycated hemoglobin (HbA1c) is 6.5%, which is below the maximum allowed of 8.5% per the central laboratory results.\n\nSince we do not have information about the patient's BMI, we cannot definitively determine whether he meets all the inclusion criteria. Therefore, based on the available information, the patient cannot be confirmed as eligible because we are missing a key piece of data (BMI), and he cannot be confirmed as excluded since the criteria that we do have are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2261": {
        "output": "The patient is a 25-year-old man with type 1 diabetes, which was confirmed with molecular analysis 7 years ago. He is currently treated with insulin, which he has presumably been on since his diagnosis, given the standard treatment protocol for type 1 diabetes. His HbA1c level is 6.5%, which is below the threshold of 10% specified in the inclusion criteria. The patient's treatment with insulin for more than 12 months fits the criteria for subjects with type 1 diabetes. However, the patient's Body Mass Index (BMI) is not provided, which is a necessary criterion according to the trial's inclusion criteria.\n\nGiven that we do not have information on the patient's BMI, we cannot definitively determine if he meets all the inclusion criteria. Therefore, based on the provided information, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2262": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial \"Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction,\" we need to compare the patient's characteristics to the inclusion criteria:\n\nThe inclusion criteria for the trial are:\n1. Patients over 18 years of age.\n2. Chronic heart failure, ischemic and non-ischemic etiology.\n3. NYHA (New York Heart Association) class II-IV.\n4. LVEF (Left Ventricular Ejection Fraction) \u2264 35%.\n5. Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, who were stable for at least four weeks without acute decompensated heart failure.\n6. Informed consent provided by the patient.\n\nThe patient note provides the following relevant information:\n- The patient is 25 years old.\n- The patient has cardiomyopathy and is NYHA class II.\n- The patient is being treated with ACE inhibitors and Beta blockers.\n\nHowever, the patient note does not include information about the following relevant criteria:\n- Whether the heart failure is of ischemic or non-ischemic etiology.\n- The Left Ventricular Ejection Fraction (LVEF) value.\n- Whether the patient has been stable for at least four weeks without acute decompensated heart failure.\n- Whether the patient has provided informed consent.\n\nBecause there is insufficient information to confirm that the patient meets all the inclusion criteria, particularly the LVEF \u2264 35% and the stability of their heart failure condition, we cannot determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2263": {
        "output": "Upon reviewing the patient's provided medical history and comparing it with the inclusion criteria for the clinical trial titled \"Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease,\" we can determine the patient's eligibility.\n\nPatient's characteristics:\n- Type 1 diabetes (not type 2 as required by the trial)\n- Cardiomyopathy (no mention of coronary artery disease or left ventricular hypertrophy)\n- HbA1c at 6.5% (which meets the criterion of below 7.0%)\n- No provided blood pressure values (but a criterion of <130/80 mmHg is required)\n- No mention of left ventricular hypertrophy (LVH)\n\nClinical trial inclusion criteria:\n- Type 2 diabetes\n- Coronary artery disease (CAD)\n- Left ventricular hypertrophy (LVH)\n- HbA1c below 7.0%\n- Blood pressure <130/80 mmHg\n\nThe patient does not meet the inclusion criteria for the clinical trial as they have type 1 diabetes, not type 2, and there is no mention of them having coronary artery disease or left ventricular hypertrophy, both of which are required for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2264": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effects of Black Tea Intake on Serum Lipids,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. Age between 45-65 years old.\n2. Mildly hypercholesterolemic (total cholesterol levels between 190 and 260 mg/dl).\n3. HDL-C between 35 and 65 mg/dl.\n4. TG concentrations below 600 mg/dl.\n5. Habitual consumption of a typical American diet with low dietary flavonoid intake.\n6. Low intake of soy-rich foods, nuts, herbs, and spices.\n7. AST between 0 and 55 mg/L.\n8. Creatinine between 0.8 and 1.7 mg/dl.\n9. Glucose between 60 and 115 mg/dl.\n\nNow, let's evaluate the patient's details:\n1. The patient is 25 years old, which does not meet the age criterion of 45-65 years old.\n2. The patient's total cholesterol level is 190 mg/dl, which is within the required range.\n3. The patient's HDL-C is 40 mg/dl, which is within the required range.\n4. The patient's TG concentration is 140 mg/dl, which is below the maximum threshold of 600 mg/dl.\n5. There is no information provided about the patient's dietary habits.\n6. There is no information about the patient's intake of soy-rich foods, nuts, herbs, and spices.\n7. The patient's AST level is not provided.\n8. The patient's creatinine level is not provided.\n9. The patient's glucose level is 100 mg/dl, which is within the required range.\n\nBased on the provided information, the patient does not meet the age requirement for the clinical trial. Therefore, the patient is not eligible to participate. The information about the patient's diet, AST, and creatinine levels is not provided, but since the age criteria are already not met, these factors are not relevant for the final decision.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2265": {
        "output": "Assessment of the patient's eligibility for the clinical trial titled \"Insulin Pump-RT Advisor (IPRA\u00a9): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel\" based on the provided patient note and the inclusion criteria of the trial:\n\nThe inclusion criteria for the trial are:\n\n- Men and women \u2265 18 years of age\n- Patients with type 1 diabetes for more than 2 years\n- Patients treated by insulin pump for more than 6 months\n- Patients using real-time continuous glucose monitoring for more than 3 months\n- Patients able to evaluate the IPRA advices by connecting to IPRA\u00a9 application 30 times a week\n- Patient able to provide written informed consent\n- Patient able to provide written non-disclosure agreement\n\nBased on the patient note, the patient is:\n\n- A 25-year-old man (meets age criterion)\n- Has had type 1 diabetes for 7 years (meets diabetes duration criterion)\n\nHowever, the patient note does not provide information on:\n\n- Whether the patient is treated by an insulin pump\n- Whether the patient is using real-time continuous glucose monitoring\n- If the patient is capable and willing to evaluate the IPRA advices by connecting to the application 30 times a week\n- If the patient is able to provide written informed consent and a non-disclosure agreement\n\nGiven the lack of information regarding these specific requirements for the trial, we cannot determine if the patient is eligible or not for the trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2266": {
        "output": "After reviewing the patient's information and the inclusion criteria for the clinical trial titled \"Health Behavior-Related Outcomes With Diaphragmatic Breathing Retraining in Heart Failure Patients,\" we can assess the patient's eligibility as follows:\n\n1. The patient is a 25-year-old man, which meets the age requirement of being 19 years or older.\n2. The patient has been diagnosed with cardiomyopathy and is experiencing shortness of breath, classified as NYHA class 2. However, the inclusion criteria require patients to have Class III through IV heart failure as per the NYHA classification.\n3. The patient is not indicated to be cognitively impaired, which aligns with the requirement of being cognitively intact.\n4. There is no information on whether the patient has a consistent informal caregiver, a telephone, or resides in a rural area as defined by the trial's inclusion criteria.\n\nConsidering the information provided, the patient does not meet the NYHA class requirement for heart failure severity (Class III through IV) as he is classified as NYHA class 2. Additionally, there is insufficient information to determine eligibility based on the requirement for a caregiver, telephone access, and rural residency.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2267": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 25-year-old man with type 1 diabetes for 7 years.\n- The patient is not mentioned to be using an insulin pump, instead, he takes 70/30 Insulin (which suggests insulin injections rather than pump therapy).\n- The patient possesses a mobile phone and internet access is not mentioned, but it is a common possession, so we might assume he has access to them.\n\nClinical Trial Inclusion Criteria:\n- Patients with Type 1 Diabetes Mellitus (T1D) for more than 1 year.\n- Aged 22 and up.\n- Using an insulin pump.\n- Possessing a mobile phone and internet access.\n\nThe critical point here is that the patient does not meet the inclusion criteria related to insulin pump use. Therefore, the patient is not eligible to participate in this clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2268": {
        "output": "Based on the provided patient note and the clinical trial information, here is the assessment:\n\nPatient Note:\n- 25-year-old man with type 1 diabetes\n- Presents with shortness of breath and fatigue during activities (mild dyspnea after climbing 3 floors, no dyspnea at rest, no angina - NYHA class 2)\n- Diagnosed with cardiomyopathy, treatment planned with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- No other significant medical history\n- Family history of DM type 1\n- Lab study with specified FBS, HbA1c, cholesterol, TG, LDL, and HDL levels\n\nClinical Trial:\n- Title: Effect of Non-Invasive Brain Stimulation on Experimentally Induced Dyspnea (Breathlessness)\n- Purpose: To determine the effect of tDCS on the perception of dyspnea (initially in healthy volunteers and potentially in patients with severe dyspnea if pilot results are promising)\n- Inclusion Criteria for the trial:\n  - Registered at the National List of persons taking part in clinical research\n  - Signed consent form\n  - Subjects of both genders aged of at least 18 years\n  - Perfect understanding of the instructions and of sensory scaling\n  - Prior medical examination\n\nThe patient in question does not provide any information regarding registration at the National List of persons taking part in clinical research, nor is there any mention of a signed consent form or a prior medical examination specifically for the trial. Furthermore, the patient's main medical issue is cardiomyopathy associated with type 1 diabetes, not dyspnea in the context of the trial's focus on healthy volunteers or patients with severe dyspnea. The patient does experience some dyspnea, but it is related to his cardiomyopathy and not induced experimentally as the trial seems to focus on. Therefore, there is not enough relevant information to determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2269": {
        "output": "After reviewing the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- No other significant medical history\n\nClinical Trial Inclusion Criteria Summary:\n- Adult patient (>18 years)\n- Diagnosis of either hypertrophic or dilated cardiomyopathy\n- Unknown etiology of the cardiomyopathy\n\nThe patient in the note is an adult over 18 years old and has been diagnosed with cardiomyopathy. The etiology of the cardiomyopathy is not described in the patient note, suggesting that it might be unknown, which fits the trial's inclusion criteria. However, the trial specifically mentions looking for patients with unknown etiologies of cardiomyopathy to determine if carnitine deficiency might be a cause. Since the patient's cardiomyopathy could potentially be related to type 1 diabetes, it is not explicitly stated that the etiology is unknown.\n\nDue to the lack of information regarding whether the underlying etiology of the patient's cardiomyopathy is indeed unknown, it is not possible to confidently determine the patient's eligibility without further clarification. Therefore, based on the information provided, the patient falls under the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2270": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man, which does not meet the age requirement of being \"more than 30 years\" as stated in the inclusion criteria of the clinical trial.\n\nThe patient has a history of type 1 diabetes, which is a chronic disease. The inclusion criteria specify \"no history of chronic diseases.\"\n\nThe patient uses blood glucose-lowering drugs (Insulin). The inclusion criteria state \"no use of blood glucose lowering drugs.\"\n\nGiven the above points, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2271": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and a new diagnosis of cardiomyopathy. He is not currently being treated for hyperlipidemia. His lab values show:\n\n- FBS: 100 mg/dl\n- HbA1c: 6.5%\n- Cholesterol: 190 mg/dl\n- TG: 140 mg/dl\n- LDL: 125 mg/dl\n- HDL: 40 mg/dl\n\nThe clinical trial is seeking participants who have either hypertriglyceridemia or hypercholesterolemia and are within a specific age range. The inclusion criteria for the trial are:\n\n- Between 18 and 69 years at Screening\n- Hypertriglyceridemia (TG \u2265 200 mg/dL and < 500 mg/dL and non-HDL-C \u2265 100 mg/dL and < 220 mg/dL) OR\n- Hypercholesterolemia (LDL-C \u2265 100 mg/dL and < 190 mg/dL and TG value < 200 mg/dL) plus a stable dose of statin for at least 4 weeks prior to Screening.\n- Body mass index (BMI) \u2264 45 kg/m2\n\nThe patient meets the age criterion (25 years old) and potentially the BMI criterion (BMI is not provided but there is no indication that it is above 45 kg/m^2). However, his TG level is 140 mg/dL, which does not meet the threshold for hypertriglyceridemia as defined by the trial (TG \u2265 200 mg/dL and < 500 mg/dL). His LDL-C level is within the range specified for hypercholesterolemia (LDL-C \u2265 100 mg/dL and < 190 mg/dL), but the patient is not on a statin, which is part of the requirement for this category.\n\nThus, based on the information provided, the patient does not meet the necessary lipid profile criteria to qualify for the clinical trial. Therefore, the patient is not eligible to participate in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2272": {
        "output": "In assessing the eligibility of the patient for the clinical trial titled \"Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,\" we need to consider the following inclusion criteria:\n\n1. Male or female, 18 years of age or older.\n2. Patient is currently being treated with an ACE inhibitor.\n3. Patient presenting with an ACE inhibitor-induced angioedema attack of the head and/or neck region within 12 hours of onset.\n4. Angioedema must be considered at least moderate in severity for at least one of the four angioedema-associated airway symptoms.\n5. Patient must have voluntarily signed an informed consent form.\n6. Females must have a negative urine pregnancy test prior to administration of the study medication, with exceptions as noted.\n\nAccording to the patient note provided:\n- The patient is a 25-year-old man, thus meeting the age criterion.\n- The patient is diagnosed with cardiomyopathy and will be treated with ACE inhibitors; however, there is no mention of the patient currently experiencing an ACE inhibitor-induced angioedema attack.\n- There is no indication of an angioedema attack in the patient's note, let alone one within the last 12 hours or with moderate severity in the airway symptoms.\n\nSince the patient note does not provide evidence that the patient has experienced an ACE inhibitor-induced angioedema attack, which is a necessary condition to be eligible for this clinical trial, the patient does not meet all of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2273": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes and a diagnosis of cardiomyopathy, which is unrelated to cerebral palsy (CP).\n- The patient is currently taking vitamin D supplements.\n- No mention of cerebral palsy or severe cognitive impairment.\n- No indication that the patient is non-mobile or a resident of HLCCD since 2008.\n\nClinical Trial:\n- The study is focused on children and adolescents with cerebral palsy.\n- The inclusion criteria specify that participants must have recorded vitamin D supplementation dose, two serum vitamin D concentrations recorded from January 1, 2008, to June 30, 2013, and be residents of HLCCD since 2008.\n\nThe patient does not meet the inclusion criteria since he does not have cerebral palsy, is not a child or adolescent, and there is no information about him being a resident of HLCCD since 2008 or having two recorded serum vitamin D concentrations in the specified period.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2274": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient would not be eligible for this clinical trial. The trial is looking for mothers within the first 14 weeks after their last menstrual period with confirmation of a singleton pregnancy. The patient in the note is a 25-year-old man with type 1 diabetes and cardiomyopathy, which does not align with the target population for the trial. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2275": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes and cardiomyopathy.\n- He is experiencing shortness of breath and fatigue during activities, mild dyspnea after climbing 3 floors, but no dyspnea at rest (NYHA class 2).\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- There is no mention of heart failure or pulmonary congestion or edema.\n- There are no BNP levels provided in the patient note to determine the presence or absence of pulmonary congestion.\n\nClinical Trial Inclusion Criteria:\n- Age over 18 years.\n- Belongs to one of the following categories:\n  A. Acute decompensated left HF.\n  B. Compensated left HF.\n  C. Non-CHF controls.\n- Signed Informed Consent.\n\nAssessment:\n- The patient is over 18 years old.\n- Although the patient has cardiomyopathy and experiences dyspnea during activities, there is no information on acute pulmonary congestion, rales, pulmonary edema, or BNP levels to categorize him as having acute decompensated left HF or compensated left HF.\n- The patient does not meet the criteria for acute decompensated left HF or compensated left HF as per the trial definitions.\n- There is no information provided about uncontrolled hypertension or a clear indication that the patient does not have CHF.\n- The patient's condition (cardiomyopathy) could potentially relate to heart failure, but the specific details necessary to place him into the correct category (A, B, or C) are not available.\n\nGiven the available information, the patient does not have sufficient information to be clearly categorized into any of the specific groups required by the trial's inclusion criteria. Therefore, the patient is not clearly eligible, but also not excluded based on the provided criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2276": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)\", we can determine the patient's eligibility as follows:\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities\n- NYHA class 2 cardiomyopathy\n- Treatment includes ACE inhibitors and Beta blockers\n- No other significant medical history\n\nClinical trial inclusion criteria:\n- Approved indication for a CRT or CRT-D system\n- NYHA Class II, III, or IV Heart Failure unresponsive to drug therapy\n- EF < 35%\n- QRS width > 120 ms\n- Receiving optimal medical therapy including ACE inhibitor or ARB, Beta-Blocker, and Diuretic\n- History of significant congestive decompensation events within the last 12 months\n\nAssessment:\n- The patient has NYHA class 2 cardiomyopathy, which fits the NYHA Class II criteria.\n- The patient is being treated with ACE inhibitors and Beta blockers, which is part of the optimal medical therapy required.\n- There is no information provided about the patient's ejection fraction (EF), QRS width, or history of congestive decompensation events.\n\nGiven that there is insufficient information to confirm whether the patient meets the EF, QRS width, and history of decompensation events criteria, the assessment is that the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2277": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Metabolic Effects of Betaine Supplementation,\" let's compare the patient's characteristics with the inclusion criteria of the trial:\n\nInclusion Criteria:\n1) Men and women aged 21-65 years old;\n2) Dysglycemia/prediabetes is defined as impaired fasting glucose (\u2265100 mg/dl), impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or HbA1c 5.7-6.5%);\n3) Overweight to grade 3 obesity (BMI 25 to 45 kg/m2).\n\nPatient Characteristics:\n- 25-year-old man (meets age criteria)\n- Type 1 diabetes with an HbA1c of 6.5% (falls within the HbA1c range for dysglycemia; however, type 1 diabetes is not prediabetes)\n- No information on BMI is provided (cannot determine if the patient is overweight to grade 3 obesity)\n\nBased on the available information:\n- The patient's age falls within the specified range.\n- The patient has type 1 diabetes with an HbA1c that would meet the criteria for dysglycemia but the trial specifies prediabetes, which is different from the existing type 1 diabetes.\n- There is insufficient information to determine if the patient is overweight to grade 3 obesity.\n\nDue to the patient having type 1 diabetes rather than prediabetes (type 2 diabetes or impaired glucose tolerance), and the lack of information regarding the patient\u2019s BMI, the patient does not meet all the inclusion criteria set by the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2278": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- The patient is a 25-year-old man with type 1 diabetes.\n- The patient presents with shortness of breath and fatigue, diagnosed with cardiomyopathy (not specified as ischemic cardiomyopathy).\n- The patient is being treated with ACE inhibitors and Beta blockers.\n- There is no mention of a 6 Minute Walk test or quality of life measurement by the Minnesota Living with Heart Failure Questionnaire (MLWHFQ).\n- There is no mention of left ventricular ejection fraction (LVEF) or echocardiography findings.\n- There is no mention of the patient's medication regimen being stable for the required duration or other specific medications required by the trial.\n\nClinical trial inclusion criteria:\n- Willing and able to sign informed consent (not mentioned in the patient note).\n- Greater than or equal to 18 years of age (patient is 25 years old, meets this criterion).\n- Poor quality of life as measured by the MLWHFQ (not mentioned in the patient note).\n- Impaired 6 Minute Walk test (not mentioned in the patient note).\n- Ischemic cardiomyopathy without an acute coronary syndrome within the last 6 months (patient has cardiomyopathy, but ischemia is not specified).\n- Residual well-demarcated region of LV systolic dysfunction on echocardiography (not mentioned in the patient note).\n- LVEF less than or equal to 40% measured by echocardiography (not mentioned in the patient note).\n- Subject receiving stable optimal pharmacological therapy (the patient is on ACE inhibitors and Beta blockers, but stability and other medications are not mentioned).\n\nFrom the information provided, the patient does not clearly meet several of the inclusion criteria for the clinical trial. Specifically, it is not clear that the patient has ischemic heart failure, there's no mention of the LVEF or echocardiography findings, and the stability of the medication regimen is not specified. Additionally, there are no details on the patient's quality of life or results from a 6 Minute Walk test.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as several key inclusion criteria are not addressed in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2279": {
        "output": "The patient described in the note is a 25-year-old man with type 1 diabetes, presenting with cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers. His condition and treatment are relevant to the study of heart failure associated with diabetes.\n\nHowever, the inclusion criteria for the clinical trial specifically mention \"Type 2 diabetes.\" Since the patient has type 1 diabetes, he does not meet the inclusion criteria for the trial, which is focused on type 2 diabetes and its relationship with heart failure.\n\nTherefore, based on the provided information, the patient is not eligible for the trial because he does not have the type of diabetes specified in the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2280": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,\" we need to compare the patient's clinical information to the inclusion criteria provided for the trial.\n\nLet's evaluate the patient's eligibility based on the inclusion criteria:\n\n1. Must be on background lipid-lowering treatment - The patient note does not mention whether the patient is currently on any lipid-lowering treatment. The prescribed treatment in the note includes ACE inhibitors and Beta blockers, which are not specifically lipid-lowering medications. Therefore, this information is missing.\n\n2. Must be at high risk of a CV event - The patient has been diagnosed with cardiomyopathy, which can increase the risk of cardiovascular events. However, the clinical trial's specific definition of \"high risk\" is not provided in the inclusion criteria, and thus we cannot conclusively determine the patient's risk level according to the trial's standards.\n\n3. Must have an LDL C >/= 70 mg/dL (1.8 mmol/L) or non-HDL-C >/= 100 mg/dL (2.6 mmol/L) - The patient's LDL cholesterol level is 125 mg/dL, which exceeds the trial's requirement of 70 mg/dL. The non-HDL-C (total cholesterol minus HDL) would be 190 - 40 = 150 mg/dL, which also exceeds the trial's requirement of 100 mg/dL.\n\nBased on the available information:\n\n- The patient meets the criteria for LDL and non-HDL cholesterol levels.\n- The patient's risk level for a cardiovascular event cannot be definitively assessed with the information provided.\n- It is unclear whether the patient is on background lipid-lowering treatment.\n\nTherefore, the patient note does not provide sufficient information to qualify the patient for the trial based on the given inclusion criteria. The patient note lacks specific information on the patient's current lipid-lowering treatments and does not provide enough details to assess the patient's high risk of a cardiovascular event according to the trial's standards.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2281": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note for the clinical trial provided, we must compare the patient's characteristics and condition against the inclusion criteria of the study.\n\nInclusion Criteria for the clinical trial:\n1. Must be on background lipid-lowering treatment.\n2. Must be at high risk of a cardiovascular (CV) event.\n3. Must have an LDL-C \u2265 100 mg/dL (2.6 mmol/L) OR non-HDL-C \u2265 130 mg/dL (3.4 mmol/L).\n\nPatient's characteristics and condition:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes.\n- He presents with shortness of breath and fatigue during activities, which is classified as NYHA class 2.\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- He takes 70/30 Insulin and vitamin D supplements.\n- His lipid profile is as follows:\n  - LDL-C: 125 mg/dL (which meets the trial's criteria)\n  - Non-HDL-C (total cholesterol - HDL): 150 mg/dL (190 - 40 = 150 mg/dL, which also meets the trial's criteria)\n\nThe patient's LDL-C and non-HDL-C levels meet the inclusion criteria for the lipid profile. He is also on lipid-lowering medication (as part of the cardiomyopathy treatment plan, which likely includes ACE inhibitors and Beta blockers that sometimes have lipid-lowering effects).\n\nHowever, the trial specifically mentions the evaluation of Bococizumab in reducing the occurrence of major cardiovascular events in high-risk subjects. The patient has cardiomyopathy, which is a high-risk cardiac condition, thus fulfilling the high-risk criterion as well.\n\nConsidering the above information, the patient appears to meet all the listed inclusion criteria for the clinical trial. There is no information given that would exclude the patient based on the trial's exclusion criteria (since exclusion criteria are not provided in the clinical trial summary).\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2282": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Inflammation Inhibition in Prediabetic Humans,\" we need to compare the patient's characteristics with the trial's inclusion criteria.\n\nPatient Characteristics:\n- 25-year-old man (meets age criteria of 18-49 years)\n- Type 1 diabetes (does not meet the criteria as the study excludes individuals with Type 1 or 2 diabetes)\n- BMI not mentioned (cannot determine obesity status)\n- Prediabetic (meets fasting blood glucose criteria, but prediabetes in the context of Type 1 diabetes is not applicable)\n- Cardiomyopathy being treated (excludes as there is a history of cardiovascular disease)\n- Currently on medication (ACE inhibitors, Beta blockers, Insulin, and Vitamin D supplements)\n- Non-smoker status not mentioned\n- Sedentary or active status not mentioned\n- No mention of blood chemistries, resting blood pressure, or a 12-lead ECG\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 and \u2264 49 years\n- Obese with BMI \u2265 30 kg/m^2\n- Prediabetic with specific blood glucose levels\n- Healthy as determined by medical examinations\n- Normal renal, liver, and thyroid function\n- No history of cardiovascular disease, Type 1 or 2 diabetes, or peripheral arterial disease\n- Sedentary or recreationally active\n- Non-smoker\n- Normal resting 12-lead ECG\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial for the following reasons:\n- The patient has Type 1 diabetes, while the trial excludes individuals with any type of diabetes.\n- The patient is diagnosed with cardiomyopathy, which is a form of cardiovascular disease, and the trial excludes individuals with a history of cardiovascular disease.\n\nGiven this information, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2283": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia,\" we need to compare the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nThe patient note provides the following information:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes confirmed with molecular analysis.\n- He presents with cardiomyopathy (being treated with ACE inhibitors and Beta blockers).\n- He has a family history of type 1 diabetes.\n- His lab study results include FBS, HbA1c, and lipid panel values.\n\nThe inclusion criteria for the clinical trial are:\n- ALL in complete remission (CR) at the time of transplant.\n- Age equal or above 40 years, or younger with comorbidities that preclude CyTBI conditioning regimen.\n- Adequate organ function, including cardiac, pulmonary, renal, and hepatic.\n- Performance status: Karnofsky \u2265 70%.\n- Informed consent capability.\n- Presence of a willing adult HLA-matched sibling or HLA-matched unrelated donor.\n\nBased on the provided information, the patient does not meet the inclusion criteria for the following reasons:\n- The patient does not have Acute Lymphoblastic Leukemia (ALL); instead, he has type 1 diabetes and cardiomyopathy.\n- The patient is 25 years old, and while the age criterion allows for patients younger than 40 if they have comorbidities precluding CyTBI conditioning, there is no indication that the patient has such comorbidities.\n- The patient's diagnosis and medical history do not indicate that he is in remission from ALL or that he requires a stem cell transplant.\n\nTherefore, the patient does not have the target disease (ALL) and does not fall within the specified age range for high-risk comorbidities. Consequently, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2284": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes. He is presenting with cardiomyopathy and has a family history of diabetes mellitus type 1. His lab study results are provided with values for fasting blood sugar, HbA1c, cholesterol, triglycerides, LDL, and HDL.\n\nThe clinical trial in question is evaluating the effect of resistant starch supplementation on biomarkers associated with antioxidant status and insulin resistance in subjects with overweight and obesity.\n\nNow, to determine the eligibility of the patient for the clinical trial, we need to look at the inclusion criteria for the clinical trial:\n\n- Overweight and obese adults\n- Age: 20-50 years\n\nThe patient note does not mention the patient's weight or body mass index (BMI), which are necessary to classify someone as overweight or obese. Without this information, we cannot definitively determine whether the patient meets the inclusion criteria related to body weight status.\n\nHowever, we do know that the patient is within the age range of 20-50 years, which is part of the inclusion criteria.\n\nSince we do not have sufficient information to qualify the patient based on one of the critical inclusion criteria (overweight or obese status), we cannot say the patient is eligible or excluded.\n\nTherefore, the trial-level eligibility for this patient based on the information provided is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2285": {
        "output": "Based on the provided information, the patient is a 25-year-old man with type 1 diabetes presenting with cardiomyopathy. The clinical trial specified is looking to enroll women aged 18 years and over with invasive breast cancer (non-metastatic), among other specific criteria related to the disease and treatment.\n\nThe patient in question does not meet the inclusion criteria for the trial because:\n\n1. The patient is male, and the trial is specifically looking for women.\n2. The patient does not have a diagnosis of breast cancer, as required by the trial.\n\nGiven these points, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2286": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether the patient is eligible for the clinical trial based on the inclusion criteria.\n\nPatient note highlights:\n- Patient is a 25-year-old man.\n- Has type 1 diabetes.\n- Presents with shortness of breath and fatigue, diagnosed with cardiomyopathy.\n- No mention of thyroid cancer.\n\nClinical trial inclusion criteria:\n- Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis.\n- Willing to participate in the educational group (EG) meetings.\n- Over 18 years of age.\n- Alert and capable of giving free and informed consent.\n- Able to speak and read English or French.\n\nAssessment:\nThe patient does not meet the primary inclusion criterion of being newly diagnosed with thyroid cancer, as there is no mention of thyroid cancer in the patient's diagnosis. Therefore, the patient is not relevant for this clinical trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2287": {
        "output": "",
        "label": 0
    },
    "2288": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy, which will be treated with ACE inhibitors and Beta-blockers. He shows no symptoms that would immediately align with the inclusion criteria for the clinical trial in question.\n\nThe clinical trial is for the BioNIR Ridaforolimus Eluting Coronary Stent System and includes patients with various indications for percutaneous coronary intervention (PCI), such as angina, silent ischemia, NSTEMI, or recent STEMI. However, the patient note does not indicate that the patient has angina, silent ischemia, NSTEMI, or STEMI. There's also no mention of the patient having undergone prior PCI, which is another condition for eligibility.\n\nBased on the information provided in the patient note, there are no indications that this patient would meet the inclusion criteria for the angiography study. The patient has cardiomyopathy, which is not one of the conditions listed in the trial's inclusion criteria. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2289": {
        "output": "",
        "label": 0
    },
    "2290": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations,\" we need to compare the patient's information with the trial's inclusion and exclusion criteria.\n\nPatient information:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities\n- Diagnosed with cardiomyopathy\n- Currently on ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- No significant past medical history except for type 1 diabetes\n- Family history of DM type 1\n- HbA1c: 6.5%\n- Cholesterol: 190 mg/dl\n- TG: 140 mg/dl\n- LDL: 125 mg/dl\n- HDL: 40 mg/dl\n\nClinical trial inclusion criteria for Type 2 DM patients:\n- HbA1c: 7.0-8.0%\n- M/F\n- Age <90\n- No insulin therapy\n- Normal liver function\n- No late diabetic complications\n- Female premenopausal patients in the follicular phase of the menstrual cycle\n- No evidence of coronary artery disease\n\nClinical trial inclusion criteria for the CaSR collective:\n- Genetically characterized heterozygote mutation in the CaSR gene\n\nGeneral exclusion criteria for the trial include:\n- Metal devices or other magnetic material hazardous for NMR investigation\n- BMI > 35 kg/m2\n- Claustrophobia\n- Severe thyroid or liver disorders\n- Acute illness within 2 weeks prior to the study\n- Blood donation within 30 days prior to the study\n- Pregnancy\n- Malignancies, autoimmune disease\n- AIDS, HIV, infectious hepatitis\n- Plasma transaminases elevated > 3 fold\n- Clinically relevant anemia\n- Neurological disease\n- Blood coagulation disorder\n- Severe dyslipidemia\n- Arterial hypertension\n- Clinical relevant cardiovascular diseases\n\nBased on the above information, the patient does not meet the inclusion criteria for Type 2 DM patients as he has Type 1 diabetes and is on insulin therapy. Additionally, the patient's HbA1c level is 6.5%, which is below the required range of 7.0-8.0%. The patient also does not meet the inclusion criteria for the CaSR collective as there is no information suggesting that he has a mutation in the CaSR gene.\n\nTherefore, the patient does not qualify for the clinical trial based on the provided inclusion criteria. \n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2291": {
        "output": "",
        "label": 0
    },
    "2292": {
        "output": "To determine the trial-level eligibility for the patient based on the inclusion criteria provided by the clinical trial titled \"Use of Sitagliptin to Decrease Microalbuminuria,\" let's examine each criterion against the patient's information:\n\n1. Albumin/creatinine ratio between 30-299 mg/dl: Not provided in the patient note.\n2. Type 2 diabetes mellitus (T2DM) with hemoglobin A1c between 7 and 9%: The patient has type 1 diabetes, not type 2 diabetes, and their HbA1c is 6.5%.\n3. Stable BP control of less than 145/90 on treatment with ACE or ARB for more than three months prior and during the trial: The patient is starting treatment with ACE inhibitors, but there is no information on blood pressure values or the duration of treatment.\n4. Glomerular filtration rate (GFR) of 60 mL/min/1.73m2 or more: Not provided in the patient note.\n5. Age between 18-75 years old: The patient is 25 years old, which meets this criterion.\n6. For women: The patient is a male, so this criterion does not apply.\n\nThe patient has type 1 diabetes, not type 2 diabetes, which is a specific requirement for the clinical trial. Additionally, no information is provided about the patient's albumin/creatinine ratio or GFR, and we do not have enough details regarding his blood pressure control or the duration of his treatment with ACE inhibitors. Therefore, the patient does not meet the inclusion criteria for type 2 diabetes and possibly other unmet or unspecified criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2293": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 25 years old\n- Condition: Type 1 diabetes, cardiomyopathy treated with ACE inhibitors and Beta blockers\n- Symptoms: Dyspnea NYHA class 2 (mild dyspnea after climbing 3 floors, no dyspnea at rest, and no angina)\n- Medical therapy: Taking insulin and vitamin D supplements, recently diagnosed with cardiomyopathy and started on ACE inhibitors and Beta blockers\n- Ejection fraction (EF): Not provided, but cardiomyopathy is newly diagnosed which could suggest a recent change in clinical status\n- Hospitalization for heart failure, catheterization, elevated NT-proBNP/BNP, echo evidence of diastolic dysfunction, chronic nitrate therapy, use of assistive devices for mobility, and body size: Not provided\n\nClinical Trial Inclusion Criteria:\n1. Age \u2265 50 years\n2. Symptoms of dyspnea (NYHA class II-IV) without a non-cardiac or ischemic explanation for dyspnea\n3. Ejection fraction (EF) \u2265 50% as determined on an imaging study within 12 months of enrollment with no change in clinical status suggesting deterioration in systolic function\n4. Stable medical therapy for 30 days with no significant changes\n5. Evidence of recent heart failure or diastolic dysfunction\n6. No chronic nitrate therapy or infrequent use of intermittent sublingual nitroglycerin\n7. Ambulatory without the need for assistive devices\n8. Heart failure as the primary factor limiting activity\n9. Appropriate body size for wearing the accelerometer belt\n10. Willingness to wear the accelerometer belt for the duration of the trial\n11. Willingness to provide informed consent\n\nThe patient does not meet several key inclusion criteria of the clinical trial:\n- The patient's age is 25 years, which does not meet the trial's minimum age requirement of 50 years.\n- The patient has been recently diagnosed with cardiomyopathy and is starting new medication, which does not comply with the requirement for stable medical therapy for 30 days.\n- There is no information on the patient's ejection fraction or evidence of recent heart failure, diastolic dysfunction, or other specified cardiac conditions.\n- The study is specific to patients with heart failure with preserved ejection fraction, and the patient has cardiomyopathy, which may not align with the study's focus if the ejection fraction is not preserved.\n\nTherefore, based on available information, the patient is not eligible for the clinical trial as they do not meet the age requirement, have not had stable medical therapy for 30 days, and lack necessary medical history details that align with the study's focus on heart failure with preserved ejection fraction.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2294": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's compare the patient's characteristics with the trial requirements:\n\n1. Age: The patient is 25 years old, which is within the trial's specified age range of more than 20 years old but less than or equal to 70 years old.\n\n2. Consent: The patient note does not mention whether the patient has given consent, but this is a procedural step that can be addressed if all other criteria are met.\n\n3. LDL-C levels: The patient has an LDL-C level of 125 mg/dl, which meets the trial's requirement of LDL-C \u2265 100mg/dl.\n\n4. Diagnosis of hyperlipidemia: The patient note does not explicitly mention a diagnosis of hyperlipidemia, but the LDL-C level suggests that the patient might be hyperlipidemic.\n\n5. Impaired Fasting Glucose (IFG): The patient has an FBS (fasting blood sugar) level of 100 mg/dl, which meets the trial's requirement for IFG (FPG level \u2265 100mg/dL and < 126mg/dL). However, it is not stated that this was measured twice as required by the trial's inclusion criteria.\n\n6. Other Medical Conditions: The patient has type 1 diabetes and cardiomyopathy, which are not mentioned as exclusion criteria in the trial summary provided.\n\nFrom the above points, the patient meets most of the inclusion criteria; however, there is insufficient information about the repeated measurement of FBS to confirm IFG according to the trial's standards, and written consent needs to be obtained. Therefore, based on available data, the patient does not have sufficient information to be deemed eligible for the trial without further confirmation of the IFG diagnosis through a second FBS measurement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2295": {
        "output": "Based on the provided information, the patient has type 1 diabetes and is diagnosed with cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers. However, there is no mention of the patient being a kidney transplant recipient nor having transplant glomerulopathy, which are the conditions required for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial specifically require participants to be kidney transplant recipients with confirmed transplant glomerulopathy. Since the patient note does not indicate that the patient meets these criteria, the patient is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2296": {
        "output": "To determine the eligibility of the patient for the gastric sleeve pilot study in morbidly obese patients undergoing liver transplantation, we need to assess the patient's information against the inclusion criteria of the trial.\n\nPatient information:\n- 25-year-old man\n- Type 1 diabetes\n- Presents with cardiomyopathy\n- Taking 70/30 Insulin and vitamin D supplements\n- No significant other medical issues\n- BMI not specified, but no indication of obesity or liver disease\n\nClinical trial inclusion criteria:\n- 18-75 years of age\n- Listed for liver transplantation\n- Class III Obesity (BMI \u2265 40 kg/m2) or Class II Obesity (BMI 35-39.9 kg/m2) with severe obesity-related co-morbidities\n- Must have attempted and failed previous weight loss efforts\n- Must understand risks and benefits of surgery and be committed to lifestyle changes\n- Must not have any medical, psychiatric, or emotional conditions that would prohibit surgery\n\nThe patient does not meet the inclusion criteria for the clinical trial because:\n- The patient is not listed for liver transplantation.\n- There is no information suggesting that the patient has Class II or Class III Obesity.\n- The patient has type 1 diabetes, which is different from type 2 diabetes mellitus specified in the inclusion criteria.\n- There is no indication that the patient has attempted and failed previous weight loss efforts.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2297": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction,\" we must compare the patient's information against the inclusion criteria of the trial:\n\nInclusion Criteria for the Clinical Trial:\n\n1. Men or women, \u226518 years of age.\n2. History (>3 months) of LDL-C \u2265130 mg/dl to \u2264190 mg/dL.\n3. Triglycerides (TG) > 200 to <750 mg/dL.\n4. Able to understand and cooperate with study procedures, and have signed a written informed consent prior to any study procedures.\n5. Willing to maintain a stable diet and level of activity throughout the trial.\n6. If of childbearing age, must be on a medically approved form of birth control as identified by the investigator in this trial.\n7. History (> 3 months) of taking a statin medication without problems, and would be willing to withdraw from statin for the duration of the trial.\n\nPatient Information:\n\n- The patient is a 25-year-old man, which satisfies the age criterion (1).\n- His LDL-C is 125 mg/dL, which does not meet the criterion of having an LDL-C \u2265130 mg/dl (2).\n- Triglycerides are 140 mg/dL, which is lower than the minimum of 200 mg/dL required by the trial (3).\n- There is no information indicating that the patient cannot understand or cooperate with study procedures or that he has not signed an informed consent, but for the purposes of this assessment, we will assume he is able to do so (4).\n- The patient is willing to maintain a stable diet and level of activity, based on the information provided (5).\n- The criterion about being of childbearing age and on birth control is not applicable to this male patient (6).\n- There is no information indicating that the patient has been on a statin medication, let alone for more than 3 months. This information is missing (7).\n\nBased on the patient's LDL-C and triglyceride levels, which do not meet the specified ranges in the inclusion criteria, the patient is not eligible for the trial. There is also insufficient information regarding his history with statin medication. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2298": {
        "output": "Let's assess the eligibility of the patient for the clinical trial titled \"Exercise in Type 1 Diabetes Mellitus\" by comparing the patient's characteristics to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- No significant past medical history other than T1DM\n- Family history of T1DM\n- On insulin therapy\n- No mention of diabetic long-term complications\n- No mention of other physical and/or mental diseases\n- HbA1c: 6.5%, which equals 48 mmol/mol (conversion factor is approximately 7.15)\n- Fasting C-peptide is not mentioned\n\nInclusion Criteria for the Trial:\n- Male subjects with T1DM with a duration \u226512 months\n- Age \u2265 18 to \u2264 35 years, both inclusive\n- HbA1c \u2264 64 mmol/mol\n- Fasting C-peptide \u2264 0.3 nmol/l\n- Treatment with intensified insulin therapy or insulin pump therapy\n- No diabetic long-term complications\n- No other physical and/or mental disease\n- Must give their signed and dated informed consent\n\nComparison:\n- The patient meets the age criterion (25 years old).\n- The patient has had T1DM for 7 years, which satisfies the duration criterion.\n- The patient's HbA1c level is within the required range.\n- The patient is on insulin therapy.\n- There is no mention of diabetic long-term complications or other diseases, which suggests compliance with these criteria, although this information is not explicitly provided.\n\nThe only criterion not explicitly confirmed is the fasting C-peptide level. However, there is no information suggesting that the patient would not meet this criterion. Since the patient seems to fit the rest of the inclusion criteria and there is no explicit information to the contrary, the patient can be considered potentially eligible for the trial.\n\nHowever, since we do not have the fasting C-peptide value and this is a necessary criterion, we cannot definitively assess eligibility without this information. Thus, we have to determine the patient as \"Not relevant\" due to insufficient information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2299": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes and recently diagnosed cardiomyopathy, presenting with shortness of breath and fatigue during activities, classified as NYHA class 2. His current treatment includes ACE inhibitors, Beta blockers, and insulin.\n\nThe clinical trial is seeking participants for a study on determining the dyspnea threshold during a 6-minute walk test (6MWT).\n\nThe inclusion criteria for the trial are:\n- COPD\n- with or without rest and/or ambulation oxygen therapy\n\nThe patient does not have COPD (Chronic Obstructive Pulmonary Disease); instead, he has cardiomyopathy and type 1 diabetes. Therefore, he does not meet the inclusion criteria for the clinical trial that requires participants to have COPD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2300": {
        "output": "The patient is a 25-year-old man with type 1 diabetes (DM1), which has been confirmed by molecular analysis. He has been diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers. The patient is within the age range of 20-50 years and has confirmed cardiomyopathy, which is one of the inclusion criteria for the clinical trial. The patient has also been confirmed to have DM1 by molecular analysis, which is another requirement. However, the clinical trial is specific to DM1 (Myotonic Dystrophy Type 1), which is a genetic disorder characterized by a CTG trinucleotide repeat expansion in the DMPK gene, and not to DM1 as an abbreviation for diabetes mellitus type 1. Therefore, this patient with type 1 diabetes mellitus does not meet the criteria for the clinical trial focused on Myotonic Dystrophy Type 1 patients.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial since the trial is for DM1 patients with cardiomyopathy related to Myotonic Dystrophy Type 1, and not diabetes mellitus type 1.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2301": {
        "output": "Based on the patient note and the inclusion criteria of the \"Kidney Cancer DNA Registry\" clinical trial, the patient does not appear to meet the inclusion criteria for this trial. The inclusion criteria specify that participants must have a diagnosis or suspicion of kidney cancer, or be a family member of someone with kidney cancer for the family member cohort, or be a control without personal history of cancer (excluding nonmelanoma skin cancer) and not related to any cases or controls in the study.\n\nThe patient in the note has type 1 diabetes and cardiomyopathy, but there is no mention of kidney cancer or any suspicion of it. Furthermore, there is no indication that the patient is a blood relative of someone with kidney cancer, which would qualify them for the family member cohort, nor are they a control as they have a personal history of type 1 diabetes, which is not excluded in the control cohort criteria.\n\nTherefore, the patient does not meet the inclusion criteria for the \"Kidney Cancer DNA Registry\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2302": {
        "output": "",
        "label": 0
    },
    "2303": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility.\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy\n- No mention of coronary artery disease or need for coronary artery bypass graft (CABG) surgery\n\nClinical trial inclusion criteria:\n- Patients undergoing elective or urgent isolated CABG and/or valvular repair or replacement surgery\n- On an ACE or ARB for a minimum of 7 days\n\nThe patient in the note is diagnosed with cardiomyopathy and is prescribed ACE inhibitors, but there is no mention of the patient undergoing CABG or valvular repair/replacement surgery. Since the trial specifically aims to study patients who are undergoing these surgical procedures, this patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2304": {
        "output": "Based on the information provided in the patient note:\n\nThe patient is a 25-year-old man with type 1 diabetes and cardiomyopathy. He is not mentioned to have a diagnosis or suspicion of a germ cell tumor (GCT) or testicular mass. He also does not fit into the family member cohort as there is no mention of a relative with GCT or testicular tumor. For the control cohort, the patient does have a family history of diabetes mellitus type 1, but this is not a germ cell tumor or testicular tumor, so it would not automatically exclude him from the control cohort based on the information provided.\n\nSince the patient does not have a personal history of cancer and there is no mention of a family history of germ cell tumor or testicular tumor, he potentially could be eligible for the control cohort of the study. However, the information provided does not specify whether he is a blood relative of controls enrolled in the study or whether he meets the English-speaker requirement.\n\nGiven this information, it is not possible to definitively determine the patient's eligibility without further information regarding his language abilities and whether he is a blood relative of controls already enrolled in the study. Thus, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2305": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nThe clinical trial is assessing the effect of dapagliflozin on metabolic syndrome, insulin sensitivity, and insulin secretion in patients with type 2 diabetes. The inclusion criteria for the trial are:\n\n1. Patients of both sexes\n2. Age between 30 and 60 years\n3. Metabolic Syndrome according to the IDF criteria\n   - Waist circumference: Man \u226590 cm, Woman \u226580 cm\n   - And two of the following criteria:\n     - High density lipoprotein (HDL): Man \u226440 mg/dL, Woman \u226450 mg/dL\n     - Fasting glucose \u2265100 mg/dL\n     - Triglycerides \u2265150 mg/dL\n     - Blood pressure \u2265130/85 mmHg\n4. Informed consent signed\n\nThe patient note provides the following information about the patient:\n- The patient is a 25-year-old man.\n- Has type 1 diabetes, not type 2 diabetes.\n- HDL: 40 mg/dl (meets one of the metabolic syndrome criteria for a man)\n- Fasting glucose (FBS): 100 mg/dl (meets one of the metabolic syndrome criteria)\n- Triglycerides (TG): 140 mg/dl (does not meet the metabolic syndrome criteria as it is less than 150 mg/dl)\n- No information is provided on the patient's waist circumference or blood pressure.\n\nSince the patient is only 25 years old, he does not meet the age criterion of the study, which requires participants to be between 30 and 60 years old. Additionally, the patient has type 1 diabetes, whereas the clinical trial is focused on individuals with type 2 diabetes. Even though the patient meets two of the necessary criteria for metabolic syndrome (HDL and fasting glucose levels), he still does not satisfy the other inclusion criteria.\n\nTherefore, the patient is not eligible for this clinical trial due to age and having a different type of diabetes than the study is targeting.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2306": {
        "output": "Based on the patient note provided, the 25-year-old male patient has type 1 diabetes and is diagnosed with cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers. The patient's lab study shows his current blood sugar and cholesterol levels.\n\nNow, comparing this with the inclusion criteria of the clinical trial \"Is There Room for Butter in a Healthy Diet?\":\n\n1. The patient has signed written consent (not mentioned, but it's a procedural aspect that can be fulfilled).\n2. The patient's age falls within the required range of 20-70 years.\n3. The patient\u2019s BMI is not mentioned, so we cannot determine eligibility based on this criterion.\n4. The trial requires healthy men and women with no known diseases, which the patient does not meet since he has type 1 diabetes and cardiomyopathy.\n\nAdditionally, looking at the exclusion criteria:\n\n1. The patient has diabetes Mellitus, which is listed as one of the conditions that would exclude a potential participant.\n2. The patient has cardiomyopathy, which is a cardiovascular disease, and this is also an excluding factor.\n\nGiven that the patient has at least two conditions that meet the exclusion criteria, he would not be eligible to participate in the study.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2307": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"The HDL Particle Protection Study,\" we need to assess the patient's information against the inclusion criteria provided.\n\nInclusion Criteria:\n\n1. Patient with diabetes mellitus, defined by at least 1 of the following:\n   - Fasting glucose > 125 mg/dL confirmed on 2 occasions\n   - HbA1C > 6.5%\n   - Patients receiving any glucose-lowering agent (oral or subcutaneous)\n\n2. Lipid profile should have ALL of the following characteristics:\n   - Triglycerides >150 mg/dL\n   - HDL <45 mg/dL\n   - LDL < 190 mg/dL\n   - Lp(a) level < 30 mg/dL (not provided in the patient's note)\n\nPatient Information:\n\n- The patient has type 1 diabetes confirmed with molecular analysis 7 years ago.\n- The patient's lab study shows:\n  - FBS: 100 mg/dl (does not meet the threshold for inclusion)\n  - HbA1c: 6.5% (meets the threshold for inclusion)\n  - Cholesterol: 190 mg/dl (not directly relevant to the criteria)\n  - TG: 140 mg/dl (does not meet the threshold for inclusion)\n  - LDL: 125 mg/dl (meets the threshold for inclusion)\n  - HDL: 40 mg/dl (meets the threshold for inclusion)\n- There is no information provided regarding Lp(a) levels.\n\nAssessment:\n\nThe patient meets the diabetes mellitus criterion based on an HbA1c level of 6.5%. However, the patient does not meet the lipid profile criteria as the triglyceride level is below the required >150 mg/dL. Additionally, there is no information provided about the patient's Lp(a) level which is required to be < 30 mg/dL.\n\nSince the patient does not meet all the required criteria (specifically the triglyceride level and the missing Lp(a) information), the patient would not be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2308": {
        "output": "Based on the information provided:\n\nPatient's characteristics:\n- A 25-year-old man\n- Diagnosed with type 1 diabetes and cardiomyopathy\n- On ACE inhibitors, Beta blockers, insulin, and vitamin D supplements\n\nClinical trial's inclusion criteria:\n- Healthy men between 18 and 35 years old\n- Giving their written informed consent\n- Affiliated to the French social security\n\nAssessment:\nThe patient in question does have a chronic medical condition (type 1 diabetes and cardiomyopathy) which does not align with the requirement for the trial participants to be \"healthy.\" Therefore, despite fitting the age criteria, he would not be considered healthy due to his medical conditions.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2309": {
        "output": "To determine the trial-level eligibility for the patient based on the provided clinical trial information, we must compare the patient's characteristics and medical history with the trial's inclusion and exclusion criteria.\n\nFrom the patient note, we have the following information about the patient:\n- The patient is a 25-year-old man.\n- The patient has type 1 diabetes, confirmed 7 years ago.\n- The patient is presenting with shortness of breath and fatigue during activities (NYHA class 2).\n- The patient is diagnosed with cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers.\n- The patient takes 70/30 Insulin and vitamin D supplements.\n- No significant past medical history other than diabetes.\n- Family history of type 1 diabetes.\n- Lab results: FBS (100 mg/dl), HbA1c (6.5%), Cholesterol (190 mg/dl), TG (140 mg/dl), LDL (125 mg/dl), HDL (40 mg/dl).\n\nNow, let's examine the clinical trial's inclusion and exclusion criteria:\n\nInclusion criteria for subjects randomized to colchicine or placebo:\n- Good general health.\n- Obesity (BMI \u2265 30 kg/m^2 but < 450 lbs for DXA scanning).\n- Age 18 to 100 years.\n- Metabolic Syndrome (3 of 5 criteria).\n- HOMA-IR \u2265 2.6.\n- hs-CRP \u2265 2.0 mg/L.\n\nExclusion criteria for subjects randomized to colchicine or placebo:\n- Type 2 diabetes mellitus.\n- Significant active or chronic illness.\n- Recent use of colchicine or anorexiant medications.\n- Known allergy to colchicine.\n- Previous history of specific conditions (agranulocytosis, gout, significant myositis).\n- Pregnant, nursing females, or irregular menses.\n- Substance abuse or psychiatric disorder.\n- Use of certain medications.\n- Participation in a formal weight loss program or recent significant weight change.\n- Use of anti-inflammatory medications.\n- History of keloid formation.\n- Current users of tobacco or nicotine products.\n\nGiven the patient's characteristics, the following points are relevant:\n- The patient does not have obesity as no information on the patient's weight or BMI is provided.\n- The patient has type 1 diabetes, not type 2 diabetes (which is an exclusion criterion).\n- The patient has cardiomyopathy, which could be considered a significant chronic illness, potentially affecting trial eligibility.\n- The patient is taking medications, which may or may not be at the discretion of the principal investigator.\n- The patient's age fits within the inclusion criteria.\n\nBased on the available information, the patient does not meet the criteria for obesity (no BMI given), nor is there any indication that the patient has metabolic syndrome as defined by the trial's inclusion criteria. Additionally, the patient's type 1 diabetes and the recent diagnosis of cardiomyopathy might be considered significant chronic illnesses at the discretion of the investigators, which could exclude him from the trial. There is also no information provided on HOMA-IR or hs-CRP levels.\n\nTherefore, the patient does not have sufficient information to qualify for the trial based on the inclusion criteria (obesity, metabolic syndrome) and may be excluded due to chronic illness (type 1 diabetes, cardiomyopathy) and current medication use.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2310": {
        "output": "The patient is a 25-year-old man with a confirmed diagnosis of type 1 diabetes, which aligns with the inclusion criteria of having type 1 diabetes. The patient is also an adult within the age bracket specified in the inclusion criteria (18 or older and <75 years). The patient note does not mention any reason that would exclude him from participating based on the provided inclusion criteria. Therefore, assuming the patient provides written informed consent, he would be eligible for the clinical trial comparing the accuracy of two CGM systems in ambulatory patients with type 1 diabetes.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2311": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, the patient does not meet the trial's inclusion criteria. The patient's fasting blood sugar (FBS) is 100 mg/dl, and his HbA1c is 6.5%, which do not indicate a current state of hyperglycemia requiring intensive insulin therapy in an intensive care unit setting, as the trial requires a blood glucose concentration greater than 180 mg/dl for inclusion.\n\nTherefore, the patient is not eligible for the clinical trial as his blood glucose concentration does not meet the specified threshold.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2312": {
        "output": "Upon reviewing the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial.\n\nPatient characteristics from the note:\n- 25-year-old man\n- Diagnosed with type 1 diabetes (T1DM)\n- Presents with cardiomyopathy\n- Currently taking insulin and vitamin D supplements\n\nClinical trial inclusion criteria:\n- Diagnosed with type 2 diabetes mellitus (T2DM)\n- BMI over 25\n- Age between 20 and 67\n- Medically controlled at Diabetes Center for at least six months\n\nThe patient has been confirmed to have type 1 diabetes, not type 2 diabetes, which is a requirement for the clinical trial. Consequently, this patient does not meet the inclusion criteria for the Taiwan Diabesity Study, which is specifically comparing treatments in patients with type 2 diabetes mellitus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2313": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man diagnosed with type 1 diabetes and cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers and is classified as New York Heart Association class 2. \n\nThe clinical trial in question is seeking to implement a telemonitoring program for patients with chronic heart or lung failure. The inclusion criteria for heart failure patients are:\n\n1. Age > 18 years\n2. New York Heart Association class II-IV at the time of discharge\n3. Diagnosed by ESC guidelines\n\nThe patient in question meets the age criterion (>18 years) and is in New York Heart Association class II, which is within the specified range of class II-IV. The patient note does not specify if the diagnosis was made according to ESC guidelines, but it is typically assumed that standard clinical practice is followed, which would likely be in line with ESC guidelines for heart failure diagnosis.\n\nThe clinical trial also includes patients with respiratory issues, but these criteria do not apply to the patient as he is not described as having a respiratory condition like COPD or chronic respiratory insufficiency.\n\nGiven the information provided, the patient appears to meet the inclusion criteria for the heart failure group of the clinical trial, with the assumption that his diagnosis of cardiomyopathy falls under the umbrella of heart failure as per ESC guidelines. There is no mention of exclusion criteria, and the provided patient note does not indicate any reason for exclusion based on the information given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2314": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics from the note:\n- The patient is a 25-year-old man.\n- The patient has type 1 diabetes, not type 2 diabetes.\n- His HbA1c is 6.5%, which is below the required \u2265 7.5% for the trial.\n- The patient's age is below the required age of \u2265 30 for the trial.\n- The patient's HDL-C level is 40 mg/dl, which is at the threshold for low HDL-C in men but not below it.\n- The patient's LDL-C level is 125 mg/dl, which is below the \u2265 130 mg/dl level specified in the criteria.\n- The patient's TG level is 140 mg/dl, which is below the \u2265 150 mg/dl level specified in the criteria.\n- Blood pressure is not mentioned, so we cannot determine if he meets the SBP/DBP criteria.\n- There is no indication that the patient is a current smoker.\n- The patient has a family history of type 1 diabetes, but CHD is not mentioned.\n\nClinical trial inclusion criteria:\n- Type 2 diabetes\n- HbA1c \u2265 7.5%\n- Age \u2265 30\n- Low HDL-C (<40 mg/dl in men or <50 mg/dl in women) and having 1 or more risk factors.\n\nThe patient does not meet multiple critical inclusion criteria for the trial: he has type 1 diabetes (not type 2), his HbA1c is below the required level, and he is younger than the minimum age requirement. Additionally, his HDL-C is not below the threshold specified for men, and his LDL-C and TG levels do not meet the specified criteria.\n\nTherefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2315": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Arterial Stiffness in Type I Diabetes Mellitus,\" let's evaluate the patient's eligibility step by step.\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He has been diagnosed with diabetes for 7 years.\n- He is currently experiencing cardiomyopathy and is treated with ACE inhibitors and Beta blockers.\n- He takes 70/30 Insulin and vitamin D supplements.\n- His fasting blood sugar (FBS) is 100 mg/dl.\n\nClinical Trial Inclusion Criteria:\n- Type 1 diabetes based on clinical history.\n- Basal-bolus insulin regimen.\n- Duration of diabetes greater than 1 year.\n- Blood glucose 65-200 mg/dL fasting.\n\nThe patient's clinical history indicates that he has type 1 diabetes, which matches the first criterion. The patient note does not specify whether he is on a basal-bolus insulin regimen; it only mentions that he takes 70/30 Insulin, which is typically a mix of intermediate-acting (basal) and rapid-acting (bolus) insulins but does not confirm he follows a basal-bolus regimen. The duration of his diabetes is greater than 1 year, satisfying the third criterion. His fasting blood glucose level is within the specified range.\n\nSince there is not enough information to confirm whether the patient is on a basal-bolus insulin regimen, we cannot definitively determine his eligibility. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2316": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial on evacetrapib (LY2484595) in participants with high cholesterol, we need to match the patient's characteristics and medical history with the inclusion criteria of the study.\n\nInclusion Criteria for the clinical trial:\n1. Must be treated with atorvastatin 40 mg/day for at least 30 days prior to screening.\n2. Have an LDL-C >70 mg/dL or non-HDL-C >100 mg/dL.\n3. Have screening triglycerides \u2264400 mg/dL (\u22644.5 millimoles/Liter).\n4. Individuals with ASCVD and/or individuals with type 1 or type 2 diabetes.\n\nPatient's characteristics and medical history:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers.\n- He takes 70/30 Insulin and vitamin D supplements.\n- His LDL cholesterol is 125 mg/dL and triglycerides are 140 mg/dL.\n\nAssessment of Trial-level Eligibility:\n- The patient has type 1 diabetes, which satisfies one of the conditions under criterion 4.\n- The patient's LDL-C is 125 mg/dL, which is above the threshold of 70 mg/dL, satisfying criterion 2.\n- The patient's triglycerides are 140 mg/dL, which is below the threshold of 400 mg/dL, satisfying criterion 3.\n\nHowever, there is no information provided about the patient being treated with atorvastatin 40 mg/day for at least 30 days prior to screening, which is required by criterion 1. Since there is no mention of the patient's treatment with atorvastatin, we cannot confirm that the patient meets all the inclusion criteria.\n\nGiven this information, the patient does not have sufficient information to qualify for the trial based on the available data.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2317": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes,\" we will compare the patient's characteristics and history with the trial's inclusion criteria:\n\n1. Informed consent obtained before any study-related activities (Not mentioned, but this is an administrative step that could be completed if other criteria are met)\n2. Patients with T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) treated with insulin for more than 12 months (The patient has type 1 diabetes and has been confirmed with molecular analysis 7 years ago, which implies insulin treatment for more than 12 months)\n3. Patients at least 18 years of age at the time of the survey (The patient is 25 years old)\n\nThe patient note provides enough information to determine that the patient meets all the inclusion criteria listed for the clinical trial. There are no exclusion criteria provided, and the patient does not exhibit any characteristics that would inherently exclude them from a survey on hypoglycemia among insulin-treated patients with diabetes.\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2318": {
        "output": "The patient described in the note is a 25-year-old man with type 1 diabetes and newly diagnosed cardiomyopathy. He is being treated with ACE inhibitors and Beta blockers and does not have any other significant medical history besides diabetes. His family history is positive for type 1 diabetes.\n\nReviewing the inclusion criteria for the eCMP Pilot clinical trial:\n\n- English-speaking adults aged 18+ years\n- High-risk primary prevention: BMI 35+ and prediabetes (including hx of gestational diabetes) and/or metabolic syndrome\n- Secondary prevention: BMI 30+ and type 2 diabetes and/or cardiovascular disease\n- Able and willing to provide written informed consent\n\nThe patient's note does not provide information about his BMI, whether he has prediabetes or metabolic syndrome, or whether he is English-speaking and able to provide written informed consent. However, the inclusion criteria specifically list type 2 diabetes and cardiovascular disease (CVD) for secondary prevention eligibility.\n\nSince the patient has type 1 diabetes, not type 2, and there is no mention of heart disease beyond cardiomyopathy (which is not necessarily CVD as defined by the trial), the patient does not meet the criteria for secondary prevention. Furthermore, there is no mention of him being at high risk for type 2 diabetes, heart disease, or stroke.\n\nBased on the available information, the patient does not meet the inclusion criteria as specified for the eCMP Pilot clinical trial. Therefore, the trial-level eligibility determination is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2319": {
        "output": "",
        "label": 0
    },
    "2320": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient note details:\n- Age: 25 years old\n- Diagnosis: Cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Other medical history: Type 1 diabetes\n- No information provided about:\n  - Left Ventricular Ejection Fraction (LVEF)\n  - Duration of diagnosis\n  - Resistance to standard therapy\n  - Whether informed consent could be provided\n\nClinical trial inclusion criteria:\n- Age between 1-16 years\n- LVEF <45% (echocardiography)\n- Duration of diagnosis more than 3 months\n- Resistance to Standard therapy more than 2 months\n- Informed consent\n\nThe patient is 25 years old, which is outside the age range specified by the trial's inclusion criteria (1-16 years). Therefore, the patient is not eligible for the trial based on age alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2321": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Experiencing shortness of breath and fatigue during activities (cardiomyopathy diagnosed)\n- Currently treated with ACE inhibitors, Beta blockers, and insulin (70/30 Insulin), and vitamin D supplements\n- No other significant past medical history\n\nClinical Trial Inclusion Criteria:\n- Residency in Liverpool or the surrounding areas\n- Age over 18\n- Type 1 diabetes diagnosis\n- Using or pending the supply of an insulin pump (CSII)\n\nBased on the provided patient note, the patient meets the following criteria:\n- Age over 18 (patient is 25 years old)\n- Type 1 diabetes diagnosis (confirmed with molecular analysis 7 years ago)\n\nHowever, the patient note does not mention the patient's residency, nor does it state whether the patient is using or pending the supply of an insulin pump (CSII). Without this information, we cannot fully determine if the patient meets all the inclusion criteria.\n\nTherefore, the patient's trial-level eligibility based on the information provided is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2322": {
        "output": "Based on the patient note, the patient is a 25-year-old man with type 1 diabetes who is currently being treated with 70/30 Insulin, which suggests he is using a form of multiple daily injections (MDI) rather than an insulin pump (CSII). The clinical trial in question is studying continuous subcutaneous insulin infusion (CSII) in Type 1 diabetes patients.\n\nNow, let's assess the patient's eligibility against the inclusion criteria of the clinical trial:\n\n1. Patients must reside in Liverpool or the surrounding areas.\n   - The patient note does not provide any information about the patient's residence.\n\n2. Patients must be ages over 18.\n   - The patient is 25 years old, which meets this criterion.\n\n3. Patients must have Type 1 diabetes.\n   - The patient has been confirmed to have type 1 diabetes, which meets this criterion.\n\n4. Patients must be using or pending the supply of an insulin pump.\n   - The patient note indicates the use of insulin but does not specify the use of an insulin pump. Therefore, we do not have sufficient information to determine if the patient is using or pending the supply of an insulin pump.\n\n5. Patients who have been using either continuous subcutaneous insulin infusion or multiple daily injections for over a year.\n   - The patient has been confirmed to have type 1 diabetes for 7 years, which likely means that he has been using a form of insulin therapy for over a year. However, without specific information on the duration of the current insulin regimen, we cannot definitively say he meets this criterion.\n\nGiven the lack of information regarding the patient's residence and whether he is using or pending the supply of an insulin pump, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2323": {
        "output": "",
        "label": 0
    },
    "2324": {
        "output": "",
        "label": 0
    },
    "2325": {
        "output": "Let's assess the patient's eligibility for the clinical trial titled \"Acupuncture and Moxibustion for Hyperlipemia\" based on the provided patient note and the trial's inclusion criteria.\n\nPatient Note Summary:\n- 25-year-old man\n- Type 1 diabetes (confirmed 7 years ago)\n- No significant medical history other than diabetes\n- Family history of type 1 diabetes\n- Lab results: LDL-C of 125 mg/dL and fasting triglycerides (TG) of 140 mg/dL\n- No mention of cigarette smoking, hypertension, low HDL cholesterol, or family history of premature CHD\n\nClinical Trial Inclusion Criteria Summary:\n- Age \u226518 to \u226475 years\n- Signed the informed consent\n- Fasting TG \u2264400 mg/dL\n- Fasting LDL-C based on risk factor status:\n  - 0-1 Risk Factor Group: LDL-C \u2265160 mg/dL\n  - 2+ Risk Factor Group: LDL-C \u2265130 mg/dL\n  - CHD or CHD risk equivalents: LDL-C \u2265100 mg/dL\n- Major Risk Factors (the patient must have one of these to be in the 2+ Risk Factor Group):\n  - Cigarette smoking\n  - Hypertension\n  - Low HDL cholesterol (<40 mg/dL)\n  - Family history of premature CHD\n  - Age criteria for risk (men \u226545 years; women \u226555 years)\n- CHD and CHD equivalents, including diabetes\n\nAssessment:\nThe patient is 25 years old and has type 1 diabetes, which is a CHD equivalent according to the clinical trial's inclusion criteria. This places him in the CHD or CHD risk equivalents group where the LDL-C threshold is \u2265100 mg/dL. His LDL-C is 125 mg/dL, which meets the criteria for this group. His fasting triglycerides are also within the acceptable range (\u2264400 mg/dL).\n\nIt is important to note that informed consent must be signed by the patient to participate in the trial, which is not mentioned in the patient note. However, for the purposes of this assessment, we will assume that the patient is willing and able to provide consent if he meets the other criteria.\n\nConsidering the information provided, the patient meets the age requirement, the fasting triglyceride level requirement, and the LDL-C level requirement for the CHD risk equivalent group due to his diabetes.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2326": {
        "output": "To determine the patient's eligibility for the clinical trial, let's review the inclusion criteria step by step:\n\nInclusion Criteria for Parts II and III of the MK-2640-001 study:\n1. Male or female of non-childbearing potential\n2. Has type 1 diabetes mellitus (T1DM) for at least 12 months\n3. On stable doses of insulin\n4. In good health\n5. Is a non-smoker and/or has not used nicotine or nicotine-containing products (e.g., nicotine patch) for at least approximately 3 months\n\nPatient Note Review:\n1. The patient is a 25-year-old man, which satisfies the gender requirement.\n2. He has had type 1 diabetes confirmed with molecular analysis 7 years ago, satisfying the duration requirement for T1DM.\n3. He is currently taking 70/30 Insulin, which is a stable insulin regimen.\n4. Although he is diagnosed with cardiomyopathy, he is initiating treatment and his other lab values do not indicate poor health. However, the presence of cardiomyopathy might be a concern regarding the \"in good health\" criterion, as this could be considered a significant health issue.\n5. There is no information provided about the patient's smoking status or use of nicotine-containing products.\n\nBased on the information provided, the patient meets several of the inclusion criteria for Parts II and III of the study: gender, duration of T1DM, and being on stable insulin doses. However, there is no explicit information about the patient's smoking status or his health concerning his recent diagnosis of cardiomyopathy. The trial requires participants to be in good health, and the presence of cardiomyopathy may be a disqualifying factor, depending on the trial's definition of \"good health.\"\n\nGiven the absence of information on the smoking status and the potential issue of cardiomyopathy, the patient might not fully meet the inclusion criteria. Therefore:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2327": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nThe patient is a 25-year-old man presenting to the clinic with shortness of breath and fatigue during activities, which in his case is classified as mild dyspnea after climbing 3 floors and no dyspnea at rest (New York Heart Association class 2). He is diagnosed with cardiomyopathy and is not being treated in the Emergency Department (ED) for his symptoms. The patient's primary issue is not cough or wheezing, but rather shortness of breath related to his cardiomyopathy.\n\nThe inclusion criteria for the clinical trial are:\n1. Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath)\n2. Referred for CXR and/or CT scan\n\nWhile the patient does have dyspnea, which is part of the inclusion criteria, there is no indication that he is presenting to the Emergency Department or that he has been referred for a CXR or CT scan. The clinical trial is specifically looking for patients who are in the ED and are being referred for imaging due to their symptoms.\n\nGiven the information in the patient note, the patient does not meet the inclusion criteria for the clinical trial as it is not mentioned that he is in the Emergency Department or has been referred for a chest X-ray or CT scan. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2328": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effect of Linagliptin on TRL Metabolism,\" we must compare the patient's characteristics and conditions to the inclusion criteria of the clinical trial.\n\nPatient's characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities (NYHA class 2)\n- Cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- No other significant medical history\n- Lab results: FBS: 100 mg/dl, HbA1c: 6.5%, Cholesterol: 190 mg/dl, TG: 140 mg/dl, LDL: 125 mg/dl, HDL: 40 mg/dl\n\nClinical trial inclusion criteria:\n- Men from 40 to 65 years old\n- Type 2 diabetes as defined by the American Diabetes Association\n- Body mass index between 25 and 40.0 kg/m\u00b2\n- Baseline glycated hemoglobin A1c (HbA1c) between 7 and 10%\n- Patients having received stable doses of metformin for at least 3 months before randomization\n- Non-smoker\n- No cardiovascular events within the past 6 months\n- Informed consent\n- Plasma without severe dyslipidaemia: plasma triglyceride levels <4.51mmol/L (<400 mg/dl), plasma HDL levels >1.0 mmol/L (>40 mg/dl), LDL-cholesterol <5.10 mmol/L (<200 mg/dl)\n\nComparing the patient's characteristics to the inclusion criteria:\n\n- The patient is a 25-year-old man, which does not meet the age criteria of 40 to 65 years old.\n- The patient has type 1 diabetes, while the trial requires participants to have type 2 diabetes.\n- There is no information about the patient's BMI to compare with the 25 to 40.0 kg/m\u00b2 range.\n- The patient's baseline HbA1c is 6.5%, which is below the required range of 7 to 10%.\n- The patient does not appear to be on metformin, as he takes insulin for type 1 diabetes, and the trial requires stable doses of metformin for at least 3 months.\n- There is no information about the patient's smoking status.\n- The patient has a recent diagnosis of cardiomyopathy, which may not meet the criterion of no cardiovascular events within the past 6 months, depending on the interpretation.\n- There is no information about the patient's informed consent, but this is typically obtained after eligibility is determined.\n- The patient's plasma triglyceride levels, HDL, and LDL-cholesterol are within the required limits.\n\nBased on this comparison, the patient does not meet several of the key inclusion criteria for the clinical trial, specifically regarding age, diabetes type, HbA1c levels, and the requirement for stable doses of metformin. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2329": {
        "output": "Given the patient note and the clinical trial information provided, we can assess the trial-level eligibility of the patient for the clinical trial.\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He is experiencing cardiomyopathy and is on treatment with ACE inhibitors and Beta blockers.\n- He has a family history of type 1 diabetes.\n- His fasting blood sugar (FBS) is 100 mg/dl, and his HbA1c is 6.5%.\n\nClinical Trial:\n- The study is looking for subjects with prediabetes or newly diagnosed type 2 diabetes (T2DM).\n- Inclusion criteria specify that subjects must have prediabetes (defined as IFG between 100 and 125 mg/dL or IGT with 2-h OGTTs glucose levels 140-199 mg/dL) or newly diagnosed type 2 diabetes (defined as fasting glucose \u2265126 mg/dL or 2-h OGTTs level \u2265 200 mg/dL).\n- Subjects should not be taking medicine for T2DM.\n\nAssessment:\n- The patient has type 1 diabetes, not type 2 diabetes or prediabetes.\n- His fasting glucose level is within the normal range and does not meet the criteria for IFG or newly diagnosed T2DM.\n- There is no information about a 2-hour OGTT, but it is not relevant since the patient has type 1 diabetes and the trial is for those with prediabetes or newly diagnosed type 2 diabetes.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial because he does not have prediabetes or newly diagnosed type 2 diabetes. He has type 1 diabetes, which is a different condition.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2330": {
        "output": "For this patient, we need to compare the patient's characteristics and history to the inclusion criteria of the clinical trial titled \"StartRIGHT: A Pilot Research Study About Diabetes Diagnosis & Treatment.\"\n\nPatient characteristics:\n- Age: 25 years old\n- Recent clinical diagnosis: Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Current treatment: 70/30 Insulin and vitamin D supplements\n\nClinical trial inclusion criteria:\n- Recent clinical diagnosis of Diabetes (within 3 months)\n- Aged 18 - 50 yrs of age at diagnosis\n- Able and willing to provide informed consent\n\nThe patient is 25 years old, which meets the age criteria of 18-50 years at diagnosis. However, the patient's diagnosis of diabetes was 7 years ago, which does not meet the trial's requirement of a recent diagnosis within 3 months. Therefore, based on the information provided, the patient is not eligible for this clinical trial because they do not meet the criterion of having a recent diagnosis of diabetes within the specified timeframe.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2331": {
        "output": "Based on the provided patient note, the patient is a 25-year-old man with a diagnosis of type 1 diabetes confirmed 7 years ago. He presents with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers. His lab study confirms his diabetes with an HbA1c of 6.5%.\n\nThe clinical trial in question is focusing on the impact of patient activation and engagement on patient-centered outcomes of care in Accountable Care Organizations (ACOs) for patients with diabetes or cardiovascular diseases.\n\nThe inclusion criteria for the clinical trial are:\n- Adult, aged 18-82\n- Diagnosis of diabetes or cardiovascular disease\n- Receives primary care at one of 16 selected clinical sites from two Accountable Care Organizations\n\nThe patient note indicates that the patient has type 1 diabetes and cardiomyopathy, which falls under cardiovascular diseases. This meets two of the inclusion criteria:\n\n1. He is an adult within the age range of 18-82.\n2. He has a diagnosis of diabetes, and it can be inferred that he also has a cardiovascular disease (cardiomyopathy).\n\nHowever, there is no information in the patient note stating whether he receives primary care at one of the 16 selected clinical sites from the two Accountable Care Organizations specified in the trial's inclusion criteria. Without this information, we cannot confirm if the patient meets the third inclusion criterion.\n\nTherefore, the trial-level eligibility based on the available information is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2332": {
        "output": "",
        "label": 0
    },
    "2333": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess whether this patient is eligible for the trial titled \"Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome.\"\n\nThe inclusion criteria for the trial are as follows:\n- Male and Female aged 18-70\n- Diagnosis of metabolic syndrome, defined by the presence of waist circumference >102 cm (\u2642) or >88 cm(\u2640), and two or more of the following criteria:\n  - Fasting blood glucose >100 mg/dl\n  - Systolic blood pressure >135 or diastolic blood pressure >85 mmHg or patients in treatment with antihypertensive drugs\n  - Triglyceridemia >150 mg/dl\n  - HDL cholesterolemia < 40 mg/dl(M), < 50 mg/dl(F)\n- Left ventricular hypertrophy: left ventricular mass indexed to height >44 g/m2,7(\u2640) or >48 g/m2(\u2642)\n- Antihypertensive and lipid-lowering therapy (if applicable) stable for at least three months\n- Ability to understand and sign an informed consent form\n\nFrom the patient's note:\n- The patient is a 25-year-old man, which meets the age criterion.\n- He is diagnosed with cardiomyopathy and is starting treatment with ACE inhibitors and Beta blockers, which suggests the presence of cardiovascular issues. However, there is no mention of left ventricular hypertrophy or the specific measurement of left ventricular mass indexed to height, which is a specific inclusion criterion.\n- The patient has type 1 diabetes with a fasting blood sugar (FBS) of 100 mg/dl, which meets one of the metabolic syndrome criteria.\n- The patient's cholesterol levels are as follows: HDL: 40 mg/dl, LDL: 125 mg/dl, Triglycerides (TG): 140 mg/dl. The HDL level meets the criteria for metabolic syndrome for males (<40 mg/dl).\n- There is no mention of blood pressure values or antihypertensive treatment, nor is there any information about the patient's waist circumference.\n- The patient's ability to understand and sign an informed consent form can be assumed unless otherwise noted.\n\nThe patient note does not provide sufficient information to fully assess eligibility based on the trial's inclusion criteria. Specifically, we do not have information about the patient's waist circumference, blood pressure, or the presence and measurement of left ventricular hypertrophy.\n\nDue to the lack of information in several key areas required by the trial's inclusion criteria, the eligibility cannot be determined from the given information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2334": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nPatient's characteristics:\n- Age: 25 years old\n- Diagnosed with type 1 diabetes\n- Presents with cardiomyopathy to be treated with ACE inhibitors and Beta blockers\n- Takes insulin and vitamin D supplements\n- Family history of diabetes mellitus type 1\n- Lab results:\n  - LDL cholesterol: 125 mg/dl\n  - HDL cholesterol: 40 mg/dl\n\nClinical trial inclusion criteria:\n- LDL cholesterol concentration of between 160-190 mg/dl in patients with less than 2 cardiovascular risk factors\n- LDL concentration of between 130-160 mg/dl in patients that presented 2 or more cardiovascular risk factors\n- Cardiovascular risk factors include:\n  - Age (\u2265 45 years in men and \u226555 years in women)\n  - Smoking habit\n  - Hypertension (\u2265140/90 mmHg)\n  - Diabetes mellitus\n  - HDL cholesterol concentration of \u2264 40 mg/dl\n  - Family history of cardiovascular disease\n\nThe patient's LDL cholesterol level is 125 mg/dl, which is below the threshold for the clinical trial's inclusion criteria. However, the patient does have diabetes mellitus, which is listed as a cardiovascular risk factor. The patient's age does not meet the age-related cardiovascular risk factor criteria. The patient also has an HDL cholesterol concentration of 40 mg/dl, which is at the limit of the specified risk factor level, and a family history of diabetes mellitus, which can be considered as a family history of cardiovascular disease due to the close association between diabetes and cardiovascular risk.\n\nConsidering the patient has at least 2 cardiovascular risk factors (diabetes mellitus and potentially the family history), the inclusion criteria for LDL cholesterol concentration would be between 130-160 mg/dl. Since the patient's LDL cholesterol level is 125 mg/dl, it is below the required range for inclusion in the trial.\n\nTherefore, the patient does not meet the LDL cholesterol concentration criteria for inclusion in the clinical trial, even though they do present with other cardiovascular risk factors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2335": {
        "output": "The patient is a 25-year-old man with type 1 diabetes and recently diagnosed cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers. He presents with shortness of breath and fatigue during activities, categorized as NYHA class 2 dyspnea. There is no mention of the patient being on dialysis or having a history of myocardial infarction, unstable angina, acute coronary syndrome, or stable angina pectoris with documented coronary artery disease. Therefore, based on the provided information, the patient does not meet the specific inclusion criteria of the clinical trial, which requires participants to be on dialysis for more than 3 months and have a specific cardiovascular history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2336": {
        "output": "",
        "label": 0
    },
    "2337": {
        "output": "To determine the trial-level eligibility for the patient described, we must compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nPatient characteristics:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes\n- BMI: Not provided but not relevant as the criteria specify type 2 diabetes\n- HbA1c: 6.5%\n- Blood pressure: Not provided\n- Willingness to meet study commitments: Not indicated\n- Health status: Cardiomyopathy (could be considered a significant heart disease)\n- Primary care physician: Not indicated, and no mention of the specific health centers\n- Language: Not indicated\n\nClinical trial inclusion criteria:\n- Diagnosis of type 2 diabetes\n- Age 18 years or older\n- Overweight or obese (BMI >25 kg/m2)\n- HbA1c level 6.5<11.5%\n- Systolic blood pressure (SBP) <160 mmHg, diastolic blood pressure (DBP) <100 mmHg\n- Willing to lose 5-7% of body weight\n- Willing to increase activity to at least 175 minutes/week\n- Willing to commit to random assignment to either attend and participate in the lifestyle change program in person or on the telephone or be referred to Nutrition Services for medical nutrition therapy\n- Stable health, with no severe comorbidities that might interfere with their ability to participate in a group intervention\n- Ability to understand and communicate effectively in English or Spanish\n- Willing to self-monitor blood glucose\n- Willing to keep a food, exercise, and blood glucose diary\n- Have a primary care physician at specified health centers or willing to attend sessions there\n\nAssessment:\nThe patient does not meet the inclusion criteria for the clinical trial due to the following reasons:\n- The patient has a diagnosis of type 1 diabetes, not type 2 diabetes as required by the trial.\n- The patient has cardiomyopathy which could be classified as significant heart disease, potentially interfering with the ability to participate in the study's lifestyle intervention.\n\nBased on this information, the patient does not meet the necessary inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2338": {
        "output": "Based on the patient note, the patient is a 25-year-old man with type 1 diabetes. The clinical trial in question is seeking healthy overweight and obese individuals with a BMI of 25-35 and specifically excludes individuals with a history of diabetes mellitus.\n\nSince the patient has a confirmed diagnosis of type 1 diabetes, he does not meet the inclusion criteria for the clinical trial which requires participants to have no history of diabetes mellitus. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2339": {
        "output": "Given the patient note, the patient is a 25-year-old man with type 1 diabetes, which does not align with the trial's inclusion criteria for type 2 diabetes. Moreover, the patient's HbA1c level does not exceed the specified threshold of 7.5%, as his is 6.5%. Additionally, the trial specifies inclusion criteria requiring participants to be of Hispanic ethnicity, which is not mentioned in the patient's note. Therefore, there is insufficient information to determine if the patient meets the ethnicity criterion.\n\nBased on the information provided, the patient does not meet the inclusion criteria for poorly controlled type 2 diabetes, as he has type 1 diabetes, and his HbA1c level is below the threshold set by the trial. Consequently, the patient is not relevant for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2340": {
        "output": "Based on the inclusion criteria provided for the clinical trial and the patient's note, we can determine the patient's eligibility for the trial.\n\nInclusion Criteria:\n1. Age of 14 to 30 years\n2. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present\n3. Menstruating women must have a negative pregnancy test.\n4. Hemoglobin (Hb) more than 12 g/dl\n\nPatient Note:\n- The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago.\n- The patient's hemoglobin level is not provided, but there is no indication of anemia or other conditions that would likely cause a low hemoglobin level.\n- The patient is male, so the criterion regarding menstruating women and pregnancy tests does not apply.\n- The patient is being treated for cardiomyopathy with ACE inhibitors and Beta blockers, which indicates that he has a condition other than T1DM. However, the inclusion criteria specifically mention being healthy except for T1DM and treated hypothyroidism without explicitly excluding other conditions.\n\nSince the patient falls within the age range, has type 1 diabetes, and no other exclusion criteria are mentioned that would exclude the patient based on his cardiomyopathy or any other aspect of his medical history, it appears that the patient would be eligible for the trial provided his hemoglobin level meets the required threshold. As we do not have information on the patient's hemoglobin level, we cannot conclusively determine eligibility, but there is no direct indication that he would be excluded.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2341": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Impact of Dyspnea on Patients in the Intensive Care Unit,\" the patient does not seem to meet the key inclusion criteria for the study. The inclusion criteria specify that participants must be undergoing invasive mechanical ventilation in the ICU for more than 24 hours and have a remaining stay in the ICU estimated to be more than 24 hours.\n\nThe patient note indicates that the 25-year-old man with type 1 diabetes is presenting with shortness of breath and fatigue during activities and has been diagnosed with cardiomyopathy, which will be treated with ACE inhibitors and Beta blockers. However, there is no mention of the patient being in the ICU or requiring mechanical ventilation. Therefore, based on the provided information, the patient does not fit the criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2342": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion criteria for the trial are:\n1. Age > 21\n2. BMI > 30 kg/m^2\n3. No reported unstable chronic disease.\n4. Participants must complete the physical assessment component of the baseline visit that includes blood pressure, lipids, and HbA1c.\n5. Compliance with FMCSA medical guidelines and regulations.\n\nPatient's characteristics:\n- Age: 25 years old\n- Has a stable chronic disease (type 1 diabetes)\n- No BMI provided\n- No blood pressure provided\n- HbA1c is 6.5% (within a controlled range for diabetics)\n\nThe patient note does not include information about the patient's BMI, which is a critical factor for eligibility as the clinical trial requires a BMI > 30 kg/m^2. Without this information, we cannot determine if the patient meets the inclusion criteria based on BMI. The patient's diabetes is mentioned as being managed with insulin and vitamin D supplementation, and there is no indication that the patient has an unstable chronic disease. Therefore, we can assume that the patient does not have an unstable chronic disease barring them from participation. The patient's age meets the criterion, and there is no mention of any FMCSA guideline or regulation that would exclude the patient. \n\nHowever, due to the lack of information on the patient's BMI, we cannot definitively determine eligibility. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2343": {
        "output": "The patient in question is a 25-year-old man with type 1 diabetes who is experiencing cardiomyopathy, as indicated by shortness of breath and fatigue during activities and an NYHA class 2 dyspnea level. His lab study shows his fasting blood sugar (FBS) and HbA1c levels, along with his lipid panel including total cholesterol, triglycerides (TG), LDL, and HDL cholesterol levels.\n\nThe clinical trial titled \"HYPOCHOL: A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism\" is looking for index cases without family screening with the following specific inclusion criteria:\n- Patient with HBL (hypo-betalipoproteinemia): fasting LDL-C \u2264 50 mg/dl.\n\nFor familial affected cases, the criteria are:\n- Relative with HBL: fasting LDL-C \u2264 80 mg/dl and/or Apo B \u2264 50 mg/dl and at least one related family case suffering from HBL.\n\nAll subjects must give written consent to participate in the constitution of a biobank.\n\nThe patient's LDL cholesterol level is 125 mg/dl, which is above the threshold for inclusion in the trial for both index cases without family screening (LDL-C \u2264 50 mg/dl) and familial affected cases (LDL-C \u2264 80 mg/dl). There is no mention of hypo-betalipoproteinemia (HBL) or related family cases suffering from HBL in the patient's note. Therefore, based on the given information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2344": {
        "output": "Given Patient Note:\n- The patient is a 25-year-old man with type 1 diabetes and cardiomyopathy.\n- He has fatigue associated with activity but not at rest.\n- There is no mention of cancer or cancer-related fatigue.\n- The patient's cognition level is not mentioned, and no Mini Mental State Questionnaire score is provided.\n- There is no information on the patient's level of fatigue on a numerical scale.\n- There is no information on hemoglobin levels.\n- There is no mention of the patient receiving palliative care or being seen by a palliative care team.\n- The patient's consent to participate in the study is not mentioned.\n- There is no indication that the patient is willing to keep a daily fatigue diary or engage in daily telephone follow-ups.\n\nClinical Trial Inclusion Criteria:\n- Patients must be seen in the outpatient palliative care clinic or by the palliative care consult team or the fatigue clinic, which implies the patient should have cancer or be in palliative care.\n- Presence of fatigue rated at least 4 on a 0 to 10 scale during the last 24 hours and persistent for a minimum of four days.\n- No significant changes in opioid doses for cancer pain 48 hours prior to study entry.\n- Relatively intact cognition as determined by a Mini Mental State Questionnaire score of 24 or above.\n- Patients must be 18 years or older.\n- Signed written informed consent.\n- Willingness to keep a daily fatigue diary and engage in daily telephone follow-ups.\n- Hemoglobin of \u226510 g/dl within 2 weeks of enrollment.\n\nAssessment:\nThe patient does not meet the clinical trial inclusion criteria as he is not described as having cancer, nor is there any indication he is under palliative care which is a prerequisite for the trial. Additionally, there is insufficient information to determine his level of fatigue, cognitive state, hemoglobin level, consent status, and willingness to participate in study procedures. Therefore, the patient is not relevant for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2345": {
        "output": "Based on the information provided:\n\nPatient characteristics:\n- Age: 25 years old\n- Condition: Type 1 diabetes\n- Treatment: Insulin (70/30 Insulin, not specified if via pump)\n- Disease duration: Confirmed 7 years ago\n\nClinical trial inclusion criteria:\n- DM1 (Type 1 diabetes)\n- Use of insulin pump\n- Disease duration \u2265 3 years\n\nThe patient has type 1 diabetes for 7 years, which meets the duration criterion of the clinical trial. However, the patient note does not specify that the patient is using an insulin pump, only that he takes 70/30 Insulin. This information is critical as the use of an insulin pump is a specific requirement for the trial.\n\nAs the patient note does not confirm the use of an insulin pump, we don't have sufficient information to determine eligibility based on the inclusion criteria provided. Therefore, the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2346": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to determine if the patient is eligible for the trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Patient scheduled for coronary artery bypass graft surgery or aortic valve replacement surgery with extracorporeal circulation\n2. Must be over 18 years of age\n3. Must be able to read and understand the consent form in French\n4. Must be in sinus rhythm at inclusion time\n\nThe patient note provides the following information:\n- The patient is a 25-year-old man, which fulfills the age requirement.\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta blockers, but there is no mention of him being scheduled for coronary artery bypass graft surgery or aortic valve replacement surgery.\n- There is no information provided about the patient's ability to read and understand French or about his heart rhythm at the time of inclusion.\n\nThe patient does not meet all the inclusion criteria, specifically the requirement of being scheduled for coronary artery bypass graft surgery or aortic valve replacement surgery, and no information is provided about his heart rhythm or his ability to understand French. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2347": {
        "output": "Based on the information provided, the patient is a 25-year-old man with type 1 diabetes and a recent diagnosis of cardiomyopathy. He is not currently on statin therapy but will be treated with ACE inhibitors and Beta blockers.\n\nThe clinical trial is seeking men and women over the age of 18 who are initiated on statin therapy in the clinical setting. The patient does not meet this criterion since there is no mention of the patient being initiated on statin therapy. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nExclusion criteria for the trial include a history of rhabdomyolysis, prior allergic reaction to statins, liver failure, and contraindications to antecubital phlebotomy or finger stick. The patient's note does not mention any of these conditions, so none of the exclusion criteria apply.\n\nSince the patient does not meet the inclusion criteria for the trial (not on statin therapy), we do not consider the exclusion criteria. Thus, the trial-level eligibility for the patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2348": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial \"Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia,\" we need to compare the patient's characteristics with the inclusion criteria listed for the trial. \n\nHere's a breakdown of the inclusion criteria and the patient's information:\n\n1. Clinical diagnosis of presumed autoimmune T1D and receiving daily insulin\n   - The patient has type 1 diabetes confirmed with molecular analysis and is taking 70/30 Insulin, which meets this criterion.\n\n2. Age: 18.0 to < 65.0 years\n   - The patient is 25 years old, which meets this criterion.\n\n3. Duration of T1D: \u22652.0 years\n   - The patient was diagnosed with T1D 7 years ago, which meets this criterion.\n\n4. Body mass index 20.0 to <35.0 kg/m2 and weight 110 to <250 lbs\n   - The patient's BMI and weight are not provided, so we cannot determine eligibility based on this criterion.\n\n5. HbA1c <8.5% (point of care or local lab, within past month)\n   - The patient's HbA1c is 6.5%, which meets this criterion.\n\n6. Using continuous subcutaneous insulin infusion (CSII) therapy (i.e., insulin pump) for at least 3 months, with no plans to discontinue use during the study (and no use of active low glucose suspend feature within the last 4 weeks)\n   - There is no information provided about the patient using an insulin pump, so we cannot determine eligibility based on this criterion.\n\n7. Using continuous glucose monitor \u22656 days/week in the last 4 weeks, with no plans to discontinue continuous glucose monitor use during the study\n   - There is no information provided about the patient using a continuous glucose monitor, so we cannot determine eligibility based on this criterion.\n\n8. Continuous glucose monitor glucose level <70 mg/dl during daytime hours on at least 7 of the past 28 days\n   - Again, since there is no information about the patient using a continuous glucose monitor, we cannot determine eligibility based on this criterion.\n\n9. Females must meet specific criteria related to pregnancy, contraception, etc.\n   - This criterion is not applicable as the patient is male.\n\n10. In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations\n   - The patient has cardiomyopathy, which could influence the outcome of the trial; this may affect eligibility.\n\n11. Willing to adhere to the protocol requirements for the duration of the study\n   - There is no information provided regarding the patient's willingness, so we cannot determine eligibility based on this criterion.\n\n12. Participant has a smart phone available and is able to use it daily\n   - There is no information about the patient's access to or ability to use a smartphone, so we cannot determine eligibility based on this criterion.\n\n13. Must be enrolled in the T1D Exchange clinic registry or willing to join the clinic registry\n   - There is no information about the patient's enrollment status in the T1D Exchange clinic registry, so we cannot determine eligibility based on this criterion.\n\nBased on the patient's information provided, there is insufficient data to fully determine the patient's eligibility. The patient meets some of the criteria (age, T1D duration, HbA1c levels, and diagnosis of T1D), but there is not enough information on BMI, insulin pump use, continuous glucose monitoring, willingness to adhere to the protocol, access to a smartphone, and registry enrollment.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2349": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's determine the patient's eligibility:\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes (confirmed 7 years ago)\n- Currently experiencing shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- HbA1c: 6.5%\n\nClinical Trial Inclusion Criteria:\n- BMI: 26-34 kg/m2\n- HbA1c > 7 %\n- Type 2 diabetes (T2D) diagnosed less than 10 years ago\n- Only non-treated or treated with oral antidiabetic drugs\n- Those treated with insulin or GLP-1 analogs will be excluded\n\nAssessment:\n- The patient has type 1 diabetes, not type 2 diabetes, which is a requirement for the trial.\n- The patient's HbA1c is 6.5%, which does not meet the trial's inclusion criterion of an HbA1c > 7 %.\n- The patient is being treated with insulin, which is an exclusion criterion for the trial.\n\nGiven these points, the patient does not meet the inclusion criteria for the trial due to having the wrong type of diabetes (type 1 instead of type 2), an HbA1c level below the threshold, and treatment with insulin.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2350": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and clinical findings with the inclusion criteria of the trial. \n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy, will be treated with ACE inhibitors and Beta blockers\n- Taking 70/30 Insulin and vitamin D supplements\n- No mention of BMI\n- Vitamin D status is not provided, but the patient is taking vitamin D supplements\n\nInclusion Criteria for Objective 1 (Part One) of the trial:\n- Adult volunteers, male or female, between 19 and 50 years of age (the patient is 25 years old, so this criterion is met)\n- BMI \u226520 and \u226430 kg/m2 (the patient's BMI is not provided)\n- Must be on a stable regime for the past three months if taking vitamin and mineral/dietary/herbal supplements (the patient is taking vitamin D supplements, but we do not know if it has been stable for the past three months)\n- Willing to provide informed consent (we can assume the patient can provide consent if eligible)\n\nInclusion Criteria for Objective 2 (Part Two) of the trial:\n- Adult volunteers, male or female, between 19 and 50 years of age (again, this criterion is met)\n- Body mass index (BMI) \u226520 and \u226430 kg/m2 (again, the patient's BMI is not provided)\n- Must be on a stable regime for the past three months if taking vitamin and mineral/dietary/herbal supplements (as mentioned, we do not have information on the stability of the patient's supplement intake)\n- Vitamin D insufficient (serum 25(OH)D concentrations \u226530 and \u226475 nmol/L); the patient's vitamin D status is not provided, and we cannot assume insufficiency even though he is taking supplements\n- Willing to comply with protocol requirements (we can assume the patient can comply if eligible)\n- Willing to provide informed consent (we can assume the patient can provide consent if eligible)\n\nSince the patient's BMI and serum 25(OH)D concentrations are not provided, and we do not have confirmation of a stable supplement regimen for the past three months, the patient does not have sufficient information to qualify for the trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2351": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the assessment of the patient's eligibility can be determined as follows:\n\nThe patient is a 25-year-old man with type 1 diabetes and has been diagnosed with cardiomyopathy, which is being treated with ACE inhibitors and Beta blockers. The patient presents shortness of breath and fatigue during activities, which aligns with the focus of the trial on dyspnea care. However, the inclusion criteria specifically mention that the patient must be in home hospice care with an estimated survival of 3-4 weeks and at risk for dyspnea secondary to lung cancer, COPD, or heart failure. The patient's shortness of breath is related to cardiomyopathy, not lung cancer, COPD, or heart failure. Additionally, there is no indication that the patient is in home hospice care or has an estimated survival of 3-4 weeks.\n\nGiven that the patient does not meet the critical inclusion criteria for the clinical trial (not in home hospice care, no estimated survival of 3-4 weeks mentioned, and the dyspnea is not secondary to the specified conditions), the patient would not be eligible for this study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2352": {
        "output": "Given Patient's Characteristics:\n- 25-year-old man\n- Type 1 diabetes (not Type 2)\n- Treated with insulin\n\nClinical Trial Inclusion Criteria:\n- Age > 18 years of age\n- Subjects without diabetes with BMI 23-37\n- Patients with Type 2 diabetes and diabetes duration between 0.5-12 years and BMI 25-37\n\nClinical Trial Exclusion Criteria:\n- Treatment with insulin and sulfonylurea drugs.\n- (Other criteria not relevant to the patient's given information)\n\nThe patient has Type 1 diabetes and is being treated with insulin. The trial specifically includes patients without diabetes or those with Type 2 diabetes, and it excludes patients treated with insulin. Therefore, the patient does not meet the inclusion criteria and is also explicitly excluded due to his insulin treatment.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2353": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial\", let's assess the patient's eligibility:\n\nPatient note details:\n- The patient is a 25-year-old man.\n- He has type 1 diabetes.\n- He presents with shortness of breath and fatigue during activities.\n- He has mild dyspnea after climbing 3 floors but no dyspnea at rest (NYHA class 2).\n- He is diagnosed with cardiomyopathy and will be treated with ACE inhibitors and Beta-blockers.\n- He does not have controlled background dyspnea without opioids mentioned explicitly.\n- There is no mention of the patient using opioids for dyspnea management.\n- The patient's ability to complete the 6MWT (6 Minute Walk Test) is not mentioned, but he does not seem to have restrictions on ambulation.\n\nClinical trial inclusion criteria:\n- Patients must be experiencing activity-induced incident dyspnea without reversible causes. They would have controlled background dyspnea without opioids.\n- Patients must be physically able to safely ambulate in order to complete the 6MWT (may have mobility devices and may use supplement oxygen prescribed pre-study).\n\nConsidering the information available in the patient note, the patient does have activity-induced dyspnea (shortness of breath and fatigue during activities, mild dyspnea after climbing 3 floors). However, the patient note does not specify whether the patient has controlled background dyspnea without opioids, which is necessary to meet the inclusion criteria of the trial. Furthermore, there is no explicit mention of the patient's physical ability to complete the 6MWT.\n\nGiven the lack of specific information regarding controlled background dyspnea without opioids and the patient's ability to complete the 6MWT, the patient's eligibility cannot be definitively determined based on the information provided. Therefore, the patient falls into the category of not having sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2354": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the study.\n\nHere is the inclusion criteria summary for the given clinical trial:\n\n1. Age between 18 and 65 years old.\n2. For females, non-child bearing potential or using contraception; for males, willing to use contraception.\n3. Normal or clinically-acceptable physical examination, laboratory test values, and ECG at screening.\n4. Body mass index between 23 and 40 kg/m^2.\n5. Diagnosed with Type 2 diabetes as per ADA criteria.\n6. Treatment-na\u00efve or controlled with diet/exercise or treated with oral antidiabetic medications (and willing to discontinue them during the study).\n7. Fasting plasma glucose 126 - 270 mg/dL at screening and re-test.\n8. Screening HbA1c of 7.0-10% for treatment-na\u00efve subjects or 6.5-9.5% for subjects on oral antidiabetic medications.\n9. For Part C only, HbA1c of 7.5-10% for subjects on stable doses of metformin.\n\nNow, let's evaluate the patient note against the inclusion criteria:\n\n- The patient is a 25-year-old man, which fits within the age criterion.\n- The patient has Type 1 diabetes, not Type 2 diabetes as required by the trial.\n- The patient's HbA1c is 6.5%, which would fit within the criteria only if he was on oral antidiabetic medications (which he is not, as insulin is not considered an oral medication).\n- Other criteria such as fasting plasma glucose, BMI, and physical examination cannot be assessed as they are not mentioned in the patient's note.\n\nThe key disqualifying factor here is that the patient has Type 1 diabetes, whereas the trial is specifically for subjects with Type 2 diabetes. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2355": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients,\" the patient's eligibility can be assessed as follows:\n\nPatient details:\n- Age: 25 years old\n- Diagnosis: Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Other conditions: Cardiomyopathy, currently treated with ACE inhibitors and Beta blockers\n\nClinical trial inclusion criteria:\n- Age between 45 and 75 years\n- Diagnosis of diabetes mellitus made within the two years preceding the date of observation (new onset diabetes)\n- Adherence to the study documented the voluntary signing of an informed consent\n- Availability to follow a telephone follow-up\n\nThe patient is 25 years old, which is outside the age range of 45 to 75 years required by the trial. Additionally, the patient's diabetes was diagnosed 7 years ago, not within the two-year window specified for new onset diabetes.\n\nGiven this information, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2356": {
        "output": "To assess the trial-level eligibility of the patient for the ODYSSEY APPRISE clinical trial, we need to match the patient's characteristics and condition with the trial's inclusion and exclusion criteria:\n\nPatient characteristics and condition:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He is diagnosed with cardiomyopathy and is prescribed ACE inhibitors and Beta blockers.\n- His lab study shows LDL cholesterol of 125 mg/dL and HDL of 40 mg/dL.\n- He takes 70/30 Insulin and vitamin D supplements.\n- There is no mention of the patient being on lipid-modifying therapy (LMT), such as statins, or any history of cardiovascular disease (CVD).\n\nClinical trial inclusion criteria:\n- The trial is for participants with severe hypercholesterolemia at risk for subsequent cardiovascular events, not adequately controlled with LMT.\n- Participants must have LDL-C concentrations above certain thresholds and meet additional risk factor criteria or have certain diagnoses.\n- The patient must be on a stable dose of LMT for at least 4 weeks prior to screening.\n\nClinical trial exclusion criteria:\n- Participants not on a stable dose of LMT for at least 4 weeks prior to screening.\n- Use of certain medications or having certain medical conditions that would exclude them from the trial.\n\nAssessment:\n- The patient does not have a documented history of severe hypercholesterolemia or a diagnosis of familial hypercholesterolemia (heFH) and does not meet any of the specific cardiovascular conditions listed in the inclusion criteria (C and D).\n- The patient's LDL-C levels are not above the thresholds mentioned in the inclusion criteria for participants with heFH or established CVD.\n- There is no mention of the patient being on lipid-modifying therapy, which is a requirement for eligibility.\n- The patient's condition (cardiomyopathy linked to type 1 diabetes) is not a listed condition in the inclusion criteria.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the ODYSSEY APPRISE clinical trial, as there is no evidence of severe hypercholesterolemia, established cardiovascular disease, or treatment with lipid-modifying therapy. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2357": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, let's assess the eligibility:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes\n- Cardiomyopathy treated with ACE inhibitors and Beta blockers\n- No mention of type 2 diabetes or hyperlipidemia requiring partial ileal bypass\n\nClinical Trial Inclusion Criteria:\n- Hyperlipidemia patients referred for partial ileal bypass\n- Patients with type 2 diabetes\n\nThe patient has type 1 diabetes, not type 2 diabetes, and there is no mention of hyperlipidemia or a need for partial ileal bypass. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2358": {
        "output": "The patient note presents a 25-year-old man with type 1 diabetes who experiences shortness of breath and fatigue during activities, which is classified as New York Heart Association class 2. He has been diagnosed with cardiomyopathy and is prescribed ACE inhibitors and Beta blockers. His laboratory results are provided, but they do not indicate a fever or tachypnoea.\n\nThe clinical trial is seeking patients with Severe Acute Respiratory Illness (SARI) and has specific inclusion criteria which include:\n\n1. A history of feverishness or measured fever of \u2265 38 deg C;\n2. Cough;\n3. Dyspnoea (shortness of breath) OR Tachypnoea.\n\nThe patient does present with dyspnoea, which is one of the symptoms listed in the inclusion criteria. However, there is no mention of cough or feverishness or a measured fever of \u2265 38 deg C in the patient's note. Given that the patient does not meet all the specified inclusion criteria for the clinical trial, he would not be eligible to participate.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2359": {
        "output": "The patient in the note has type 1 diabetes, not type 2 diabetes, which is a requirement for the clinical trial. Additionally, the patient's HbA1c level is 6.5%, which is below the required range of >7.0 and <=9.0% for the trial's inclusion criteria. Furthermore, the clinical trial specifies that patients must be on metformin monotherapy, and there is no mention of the patient taking metformin; instead, he is taking 70/30 Insulin and vitamin D supplements.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial due to the type of diabetes, the HbA1c level, and the current treatment regimen.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2360": {
        "output": "Based on the patient note provided, let's compare the patient's information with the inclusion criteria for the clinical trial:\n\n1. **Age \u2265 18 years**: The patient is 25 years old, so this criterion is met.\n2. **Clinical type 1 diabetes for at least one year**: The patient has had type 1 diabetes for 7 years, so this criterion is met.\n3. **Managed using an insulin pump for \u2265 6 months**: The patient's note does not specify the method of insulin management, only that the patient takes 70/30 Insulin. Without confirmation that an insulin pump is used, we cannot assume this criterion is met.\n4. **Prescription medication regimen stable for > 1 month**: The patient is starting new treatment with ACE inhibitors and Beta blockers for cardiomyopathy, which means the medication regimen is not stable for more than one month.\n5. **Live within a 60-minute drive-time radius of the central monitoring location**: This information is not provided in the patient note.\n6. **Willing to remain within a 120-minute drive-time radius of the central monitoring location throughout the study**: This information is not provided in the patient note.\n7. **Have someone over 18 years of age who lives with them**: This information is not provided in the patient note.\n8. **Willing to wear two infusion sets and one CGM sensor and change sets frequently**: This information is not provided in the patient note.\n9. **Have a mobile phone they are willing to keep with them and answer calls from study staff**: This information is not provided in the patient note.\n\nThe patient does not have a confirmed method of insulin management via an insulin pump and is starting a new medication regimen for cardiomyopathy, which means the medication regimen is not stable. Since there is insufficient information on several other criteria and a clear indication that the medication regimen is not stable for more than one month, the patient is not eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2361": {
        "output": "Let's assess the eligibility of the 25-year-old male patient for the clinical trial titled \"Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults.\"\n\nInclusion Criteria for the trial:\n- Male and female participants 18 years of age or above.\n- Subject must be healthy, with no known history of cardiovascular disease.\n- Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations.\n\nExclusion Criteria for the trial:\n- Subjects with any history of cardiovascular disease, among other specific exclusions.\n\nPatient's characteristics:\n- 25-year-old man with type 1 diabetes.\n- Presents with cardiomyopathy (a form of cardiovascular disease).\n- Takes insulin and vitamin D supplements.\n- Has a family history of DM type 1.\n- Lab study shows plasma triglyceride levels of 140 mg/dl.\n\nBased on the provided information, even though the patient meets the age criterion and has plasma triglyceride levels above 100 mg/dL, he is not eligible for the trial because he does not meet the health requirement due to his diagnosed cardiomyopathy. The presence of cardiomyopathy is a form of cardiovascular disease, which is specifically listed as an exclusion criterion for the trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2362": {
        "output": "The patient in question is a 25-year-old man diagnosed with cardiomyopathy. The clinical trial we are assessing is seeking patients with newly diagnosed hypertrophic cardiomyopathy (HCM). The inclusion criteria for the trial specify that the diagnosis of HCM must be based on conventional echocardiographic criteria, with left ventricle hypertrophy without cavity dilatation and no other cardiac or systemic disease able to produce the magnitude of hypertrophy.\n\nThe patient note does not specify that the patient has hypertrophic cardiomyopathy; instead, it simply states \"cardiomyopathy\" and mentions a treatment plan with ACE inhibitors and Beta blockers. Cardiomyopathy is a broad term that includes many different types of heart muscle diseases, including HCM, but without more specific information indicating that the patient's condition is indeed HCM, we cannot ascertain that the patient meets the inclusion criteria for this clinical trial.\n\nTherefore, based on the information provided, we do not have sufficient information to conclude that the patient has hypertrophic cardiomyopathy as required by the study's inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2363": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the following reasons:\n\n1. The patient has type 1 diabetes mellitus (T1DM), whereas the trial is specifically for individuals with type 2 diabetes mellitus (T2DM).\n2. The patient's hemoglobin A1c is 6.5%, which is below the required range of \u22657.5% - <10.5% for the trial.\n3. The trial requires that the subject has been receiving a stable dose and regimen of GLP-1 analogue over 8 weeks before the screening test. There is no information in the patient note suggesting that the patient has been on a GLP-1 analogue treatment.\n\nGiven that the patient does not meet multiple key inclusion criteria for the trial, the patient is not eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2364": {
        "output": "Based on the provided information:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Presenting with symptoms of cardiomyopathy\n- Currently treated with ACE inhibitors and Beta blockers\n- Takes 70/30 Insulin and vitamin D supplements\n- No significant other medical issues\n- Family history of type 1 diabetes\n\nClinical Trial:\n- Title: Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients\n- Aims to assess microvascular dysfunction in type 1 diabetes patients using microvascular tests\n- Inclusion Criteria: Diabetes type 1 patients\n\nAssessment:\nThe patient in the note has type 1 diabetes which aligns with the inclusion criteria of the clinical trial, which is assessing the neurovascular microcirculatory response in diabetes type 1 patients. There is no mention of exclusion criteria that would prevent the patient from participating in the study. Therefore, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "2365": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes who presents with shortness of breath and fatigue during activities, which qualifies as dyspnea. He is diagnosed with cardiomyopathy, which is a form of chronic heart failure. His symptoms fit within the New York Heart Association class 2, suggesting some limitation of physical activity, which may be related to chronic refractory dyspnea, although this is not directly mentioned.\n\nThe clinical trial's inclusion criteria are as follows:\n1. Hospital admission with dyspnea as the main symptom\n2. Acceptance of participation in the study\n3. Diagnosis of Chronic Respiratory Disease\n4. Diagnosis of Chronic Heart Failure\n5. Chronic Refractory Dyspnea higher than 1/10 and Irruptive Dyspnea higher than 2/10 degree by Rating Numerical Scale\n\nThe patient note does not mention hospital admission with dyspnea as the main symptom, nor does it provide a Rating Numerical Scale for dyspnea. However, it does mention a diagnosis of cardiomyopathy, which can be related to chronic heart failure. There is no information on whether the patient has accepted participation in the study or not.\n\nGiven the information available, the patient seems to meet some of the inclusion criteria (diagnosis of Chronic Heart Failure), but there is insufficient information to definitively determine eligibility, including whether the patient was admitted to the hospital with dyspnea as the main symptom, whether they have accepted participation, and the specific degree of dyspnea on the Rating Numerical Scale.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2366": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old man diagnosed with cardiomyopathy and type 1 diabetes. The clinical trial in question is seeking individuals with either Hypertrophic Cardiomyopathy (HCM) or Long QT Syndrome (LQTS).\n\nThe patient note does not specify the type of cardiomyopathy the patient has; it simply states \"cardiomyopathy.\" Because the inclusion criteria for the clinical trial specifically list Hypertrophic Cardiomyopathy or Long QT Syndrome, and there is no indication that the patient has either of these specific conditions, there is not enough information to determine if the patient is relevant for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2367": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea,\" we need to compare the patient's characteristics and medical condition with the inclusion criteria of the trial.\n\nLet's assess the inclusion criteria for the trial:\n\n1. Diagnosis of dyslipidemia: The patient must have a clinical diagnosis of dyslipidemia and be on lipid-lowering therapy or have altered lipid levels according to specific cutoffs.\n2. Lipid-lowering treatment and diet must be stable in the last month.\n3. A concentration of LDL-cholesterol above 100 mg/dl in the month prior to inclusion.\n4. An apnea-hypopnea index (AHI) between 5-30 h-1 indicating mild-moderate sleep apnea.\n\nNow, let's examine the patient's information against these criteria:\n\n1. The patient's cholesterol levels are as follows: Total cholesterol = 190 mg/dl, LDL-cholesterol = 125 mg/dl, HDL-cholesterol = 40 mg/dl, and Triglycerides = 140 mg/dl. The total cholesterol level does not meet the criterion for dyslipidemia (should be \u2265 200 mg/dl), but the patient's LDL-cholesterol level is above 100 mg/dl, which does meet one of the inclusion criteria.\n2. There is no mention of the patient being on a lipid-lowering treatment or diet, nor any mention of the stability of such treatment if it exists.\n3. There is no mention of the patient having sleep apnea or an apnea-hypopnea index score.\n\nBased on the patient note provided, the patient has an LDL-cholesterol level above 100 mg/dl, which meets one of the inclusion criteria. However, there is insufficient information on whether the patient has a diagnosis of dyslipidemia with lipid-lowering therapy and diet, as well as no information on the patient's apnea-hypopnea index to determine if they have mild-moderate sleep apnea. Without this information, we cannot conclusively determine if the patient is eligible for the trial.\n\nTherefore, the trial-level eligibility assessment for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2368": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients,\" we need to determine the trial-level eligibility of the patient.\n\nThe inclusion criteria for the trial are:\n1. Patients must have had at least one treatment for statins during the intake period (between 01/07/2011 and 31/01/2015).\n2. Patients must be 18 years or older at the time of the index date.\n3. Patients must have at least 1 month of follow-up after the index date, including continuous statin treatment, lipid profile, and lab values for safety profile.\n4. Patients must have at least two lab values: one full lipid panel prior to or on the index date, and one at least 30 days following the index date.\n\nThe patient's note indicates:\n- The patient is a 25-year-old man with type 1 diabetes.\n- He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers.\n- His lab study includes a full lipid panel.\n- The patient's past medical history does not indicate any treatment with statins or any mention of a PCI procedure.\n- There is no information suggesting that the patient has had a prior statin treatment or a PCI procedure.\n\nBased on the information provided, the patient does not meet the inclusion criteria of having had at least one treatment for statins, nor is there any mention of a PCI procedure. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2369": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes, confirmed by molecular analysis 7 years ago. He has been diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers. His lab study shows an HbA1c level of 6.5%.\n\nNow, let's compare the patient's information with the inclusion criteria for the clinical trial titled \"Evolution of Effectiveness of Diabetes Medical Care in Russia\":\n\n1. Provision of signed subject informed consent - The patient note does not mention informed consent, but this is typically obtained before participation in a trial.\n2. The patient has Type 1 diabetes mellitus - which matches the patient's condition.\n3. No mention of exclusion based on the presence of other medical issues - The patient has cardiomyopathy, but it's not listed as an exclusion criterion.\n4. The patient's HbA1c is 6.5%, which is below the target of <7.0% as per the study's aim.\n\nThe patient meets the inclusion criteria of having type 1 diabetes mellitus, and there are no exclusion criteria mentioned that would disqualify him from the study. Therefore, the patient appears to be eligible for the study.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "2370": {
        "output": "The patient in the note is a 25-year-old man with type 1 diabetes. He presents with cardiomyopathy and is treated with ACE inhibitors and Beta blockers. His HbA1c is 6.5%, which is below the threshold of 7.0% mentioned in the trial inclusion criteria. However, the inclusion criteria for the clinical trial specifically state that it is for patients with type 2 diabetes mellitus.\n\nSince the patient has type 1 diabetes, not type 2 diabetes, he does not meet the inclusion criteria for the clinical trial studying the effects of dapagliflozin on patients with type 2 diabetes. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2371": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)\", we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nInclusion criteria checklist for the clinical trial:\n\n1. Participants diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (Week -3).\n   - The patient has had type 1 diabetes confirmed with molecular analysis 7 years ago.\n\n2. Signed written informed consent\n   - This criterion is not mentioned in the patient note, but it is typically obtained from the patient if they agree to participate.\n\n3. Participants with type 1 or type 2 diabetes treated with insulin whose LDL-C levels were not adequately controlled with maximally tolerated lipid-modifying therapy\n   - The patient's LDL-C level is 125 mg/dL, which is above the criterion of 70 mg/dL or greater. However, the patient note does not mention whether the patient is on any lipid-modifying therapy.\n\n4. LDL-C of 70 mg/dL or greater\n   - The patient's LDL-C level is 125 mg/dL, which meets this criterion.\n\n5. 18 years of age or more\n   - The patient is 25 years old.\n\n6. Glycosylated hemoglobin (HbA1c) less than 10%\n   - The patient's HbA1c is 6.5%, which meets this criterion.\n\n7. History of cardiovascular disease (including coronary heart disease [CHD] and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor\n   - The patient has been diagnosed with cardiomyopathy, which is a form of cardiovascular disease.\n\nExclusion criteria checklist for the clinical trial:\n\n1. Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening or from screening to randomization, unless statin intolerant\n   - The patient note does not indicate whether the patient is on a stable dose of any lipid-modifying therapy.\n\n2. Triglycerides >400 mg/dL\n   - The patient's triglycerides are 140 mg/dL, which does not meet this exclusion criterion.\n\n3. Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m\u00b2\n   - There is no information about the patient's eGFR in the note.\n\n4. Currently received or planned to receive renal replacement therapy\n   - There is no information about renal replacement therapy in the patient note.\n\n5. Change in weight of more than 5 kilograms within the prior 2 months\n   - There is no information about the patient's weight changes in the note.\n\n6. Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months\n   - The patient takes 70/30 Insulin, but there is no information about the stability of the dose.\n\n7. Not treated with insulin for at least 6 months\n   - The patient is currently treated with insulin, although there is no specific information about the duration of insulin treatment.\n\n8. Planned to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study\n   - The patient note does not indicate any plans to start or change lipid-modifying therapy.\n\n9. Body mass index (BMI) >45 kg/m\u00b2 or planned to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study\n   - There is no information about the patient's BMI or any planned weight loss interventions.\n\n10. History of recent decompensation of diabetes within the prior 2 months\n    - There is no indication of recent decompensation of diabetes in the patient note.\n\nBased on the information provided in the patient note, it appears that the patient may potentially meet the inclusion criteria for the clinical trial. However, there is insufficient information regarding the patient's use of lipid-modifying therapy and the stability of their insulin dosage, which are important considerations for inclusion. Thus, without additional information, we cannot conclusively determine whether the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2372": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's examine the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is 25 years old.\n- The patient has type 1 diabetes.\n- The patient presents with shortness of breath and fatigue during activities, classified as NYHA class 2.\n- The patient is diagnosed with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- No information is provided about the patient's heart failure duration, NYHA classification history, the decision by a cardiologist to increase diuretic dosage, spironolactone or eplerenone dosage, daily loop diuretic dosage, serum potassium concentration, or eGFR.\n\nClinical Trial Inclusion Criteria:\n- History of heart failure with either reduced or preserved ejection fraction for 3 months.\n- Patients with NYHA class II-IV heart failure symptoms, with at least one worsening symptom and one sign of congestion.\n- Decision by primary cardiologist or HF specialist to increase the home diuretic dose.\n- Stable treatment with beta-blockers for 1 month unless contraindicated.\n- Stable treatment with ACE-1 or ARB for 1 month.\n- Spironolactone dose 25mg or eplerenone 50mg per day.\n- Daily furosemide or furosemide equivalent dose of 80mg or greater.\n- Serum potassium concentration 4.5 mmol/L or 5.0 mmol/L if on potassium supplements.\n- eGFR by MDRD equation \u2265 40 ml/min/1.73 m\u00b2.\n\nEligibility Assessment:\n- The patient is over 18 years old and has cardiomyopathy treated with ACE inhibitors, which might indicate heart failure.\n- The patient has NYHA class 2 symptoms, aligning with the trial's inclusion criteria.\n- There is no information on the patient's history of heart failure duration, whether there is a decision to increase diuretic dosage, whether they are on a stable dose of beta-blockers for 1 month, or on spironolactone/eplerenone.\n- We lack information on the patient's loop diuretic dosage, serum potassium levels, and eGFR.\n\nGiven the information provided, the patient appears to potentially meet some of the inclusion criteria (age, NYHA class II symptoms, treatment with ACE inhibitors and beta-blockers), but there is insufficient information to fully determine eligibility. Specifically, we lack details on the duration of heart failure, the diuretic regimen and response, and laboratory values required by the trial's inclusion criteria.\n\nTherefore, the patient is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2373": {
        "output": "",
        "label": 0
    },
    "2374": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history to the inclusion criteria provided for the trial.\n\nPatient's characteristics and medical history:\n- 25-year-old male\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Presents with shortness of breath and fatigue during activities (NYHA class 2)\n- Diagnosed with cardiomyopathy, to be treated with ACE inhibitors and Beta blockers\n- Currently takes 70/30 Insulin and vitamin D supplements\n- LDL cholesterol level: 125 mg/dL\n\nClinical trial inclusion criteria:\n- Males and Females, 18-70 years old\n- Received a statin as monotherapy while having a LDL-C >100 mg dL at initial clinical washout visit OR\n- Received no lipid-altering drugs since the initial clinic washout visit and had a mean LDL-C as follows at 2 qualifying visits:\n  - \u2265 130 mg/dL if NCEP ATP III CHD risk \u2265 10%; OR\n  - \u2265 160 mg/dL if NCEP ATP III CHD risk < 10%\n- Had variability of 2 qualifying LDL-C <20%\n- Had a mean LDL-C < 250 mg/dL at 2 qualifying visits\n\nBased on the patient note:\n- The patient is within the age range of 18-70 years old.\n- The patient's LDL cholesterol level is 125 mg/dL. The patient note does not mention the use of statins, but we do know that his LDL-C is greater than 100 mg/dL. However, we lack information about his CHD risk to determine the exact LDL-C level required for eligibility.\n- There is no information on the variability of the patient's LDL-C levels.\n- The patient's LDL-C is below 250 mg/dL.\n\nSince the patient note does not provide adequate information regarding the patient's use of statins or his CHD risk, we cannot fully determine if he meets the LDL-C level requirements based on the NCEP ATP III CHD risk score. Additionally, there is a lack of information on LDL-C variability. Therefore, we cannot definitively say that the patient is eligible or excluded.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2375": {
        "output": "The patient in the provided note is a 25-year-old man with type 1 diabetes and newly diagnosed cardiomyopathy, presenting with shortness of breath and fatigue during activities.\n\nTo evaluate the patient's eligibility for the clinical trial titled \"Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea\", we will compare the patient's characteristics and condition against the trial's inclusion criteria.\n\nInclusion Criteria for the trial:\n1. Diagnosis of cancer with evidence of active disease.\n2. Breakthrough dyspnea, with an average intensity level over the past 7 days of at least 3/10 on a numeric rating scale upon significant exertion or continuous dyspnea \u22647/10 with worsening upon significant exertion.\n3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology, Cancer Pain Clinic, or Cardiopulmonary clinic.\n4. Ambulatory and able to walk with or without walking aid.\n5. On strong opioids with a morphine equivalent daily dose of 80-500 mg for at least one week, with a stable regular dose over the last 24 hours.\n6. Karnofsky performance status \u226550%.\n7. Age 18 or older.\n8. Able to complete study assessments.\n\nBased on the patient note:\n- The patient does not have a diagnosis of cancer, which is a primary requirement for the trial.\n- There is no mention of breakthrough dyspnea as defined by the trial's criteria.\n- The patient's affiliation with MD Anderson Cancer Center or its specific services is not mentioned.\n- There are no details provided about the patient's use of strong opioids or their performance status according to the Karnofsky scale.\n\nGiven the information provided, the patient does not meet the inclusion criteria related to the diagnosis of cancer, the specific nature of dyspnea, opioid use, and the association with MD Anderson Cancer Center. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2376": {
        "output": "The patient described in the patient note is a 25-year-old man with type 1 diabetes presenting with cardiomyopathy, shortness of breath, and fatigue during activities. There is no mention of achondroplasia or a clinical or molecular diagnosis of achondroplasia in the patient's history. Furthermore, the inclusion criteria for the clinical trial require a diagnosis of achondroplasia, which is not present in the patient's medical history.\n\nSince the patient does not meet the inclusion criteria for the clinical trial, which is specifically looking for patients with achondroplasia, the patient is not eligible for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2377": {
        "output": "Based on the given patient note and the clinical trial information provided, here is the assessment:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes confirmed 7 years ago\n- Presents with cardiomyopathy\n- Currently taking insulin and vitamin D\n- No mention of being recently diagnosed with type 1 diabetes\n\nClinical Trial:\n- Title: Effects of Gluten Free Diet on Type 1 Diabetes Mellitus in Children\n- Inclusion Criteria:\n  - Ages: 1-17 years\n  - Diagnosis of type 1 diabetes within 4 months of enrollment\n  - Parent or guardian willing to sign informed consent\n\nAssessment:\nThe patient does not meet the age inclusion criteria (1-17 years, as he is 25 years old) and was not recently diagnosed with type 1 diabetes (the diagnosis was 7 years ago). Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2378": {
        "output": "",
        "label": 0
    },
    "2379": {
        "output": "The patient is a 25-year-old man with a diagnosis of type 1 diabetes and newly diagnosed cardiomyopathy, for which he will be treated with ACE inhibitors and beta blockers. The patient presents with symptoms of shortness of breath and fatigue during activities, which he experiences after climbing three floors, and he has been classified as New York Heart Association class 2. There is no mention of aortic stenosis (AS) in the patient's note, nor is there any indication that the patient has a history of symptoms such as dyspnea, angina pectoris, or cardiac syncope that could be attributed to AS. Furthermore, no information is provided regarding the patient's aortic valve gradient, aortic valve area, or aortic valve area index, which are required to diagnose severe, degenerative AS.\n\nThe inclusion criteria for the clinical trial require a diagnosis of severe, degenerative AS, evidence of symptomatic AS, and confirmation by the Heart Team that the patient is low-risk and a suitable candidate for Transcatheter Aortic Valve Replacement (TAVR). Additionally, the trial is aimed at patients with an expected survival of at least 24 months and is specific to those who are reasonable candidates for transfemoral TAVR with a commercially available bioprosthetic valve.\n\nSince the patient's condition does not match the specific disease and symptom criteria for the clinical trial (severe aortic stenosis and related symptoms), the patient does not qualify for inclusion in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2380": {
        "output": "Based on the information provided:\n\nPatient characteristics:\n- 25-year-old man\n- Type 1 diabetes\n- Presenting with cardiomyopathy\n- No indication of Trypanosoma cruzi infection or Chagas disease\n- No abnormal ECG mentioned\n\nClinical trial inclusion criteria:\n- Client of the TMS TeleHealth System\n- Positive history for Trypanosoma cruzi infection or Chagas disease\n- Abnormal ECG\n- Consent to participate in the research program\n\nClinical trial exclusion criteria:\n- Pregnancy or breastfeeding\n- Severe condition with a life expectancy of less than two years\n\nThe patient does not have a positive history for Trypanosoma cruzi infection or Chagas disease and there is no mention of an abnormal ECG or being a client of the TMS TeleHealth System. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2381": {
        "output": "The patient in question is a 25-year-old man with type 1 diabetes and a new diagnosis of cardiomyopathy. He is currently NYHA class 2 for heart failure symptoms and does not have any other significant past medical history according to the note. The patient is on insulin and vitamin D supplements, and his lab values indicate relatively good control of his diabetes with an HbA1c of 6.5%.\n\nNow, let's assess his eligibility for the clinical trial titled \"Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection\":\n\n1. Written consent - We can assume consent would be obtained if the patient decided to participate.\n2. Age criteria - The patient is 25 years old, which makes him eligible for Arm 1 (ages 19 to 50).\n3. For groups 2A to 2H - The patient does not seem to fit into any of these specific subgroups because:\n   - He does not have left-ventricular hypertrophy (no information provided).\n   - He does not have diagnosed hypertrophic cardiomyopathy (he has cardiomyopathy being treated with ACE inhibitors and Beta blockers, but there is no mention of hypertrophic cardiomyopathy).\n   - He is not an outpatient with NYHA class 1-3 heart failure with evidence of elevated LV mass (no mention of elevated LV mass).\n   - He is not a patient with type 2 DM (he has type 1 diabetes).\n\nExclusion criteria:\n- No mention of contraindications to MRI or MRI contrast agents.\n- No lab values provided for hemoglobin or GFR, so we cannot assess these criteria.\n- The patient's life expectancy is not mentioned, but there's no indication it is less than 1 year.\n- No mention of medically diagnosed claustrophobia.\n- No information about participation in other investigational medicinal product studies.\n- No BMI provided.\n\nThe patient does not fit into any of the specified groups for the study due to the type of diabetes he has (type 1, not type 2), and there's no mention of left-ventricular hypertrophy or hypertrophic cardiomyopathy. Therefore, he does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2382": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial titled \"Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia\".\n\nPatient Note Analysis:\n- The patient is a 25-year-old man with type 1 diabetes, which aligns with the trial's target population.\n- There is no mention of the patient experiencing severe hypoglycemia, let alone having at least 2 episodes within the last 12 months.\n- The patient is currently treated with 70/30 Insulin, but there is no indication that he is treated with a subcutaneous insulin pump.\n- There is no information provided regarding the patient's affiliation to the French social security system or equivalent.\n- The patient's consent to participate in the trial is not mentioned.\n\nClinical Trial Inclusion Criteria:\n- Type 1 or insulin-dependent diabetic patients (the patient meets this criterion).\n- Patients treated with subcutaneous insulin pump with at least 2 episodes of severe hypoglycemia within 12 months before the study enrollment (the patient does not meet this criterion as there is no mention of severe hypoglycemia or insulin pump use).\n- Affiliation to the French social security system or equivalent (the patient's note does not provide this information).\n- People who signed the consent form (the patient's note does not provide this information).\n\nSince the patient note does not provide sufficient information regarding the history of severe hypoglycemia, insulin pump use, affiliation to the French social security system, or consent to participate, the patient cannot be determined eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "2383": {
        "output": "Based on the information provided for the patient and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 25 years\n- Condition: Type 1 diabetes mellitus\n- Treatment: 70/30 Insulin (basal and prandial insulin combined)\n- Additional diagnosis: Cardiomyopathy\n- Other: No indication that the patient has switched to Tresiba\u00ae or any information on the duration of their current insulin treatment.\n\nClinical Trial Inclusion Criteria:\n- Informed consent obtained before any study-related activities.\n- Age at least 18 years at the time of Tresiba\u00ae initiation.\n- T1DM or insulin-treated T2DM patients.\n- Switched to Tresiba\u00ae after any basal insulin. The switch must have occurred at least 6 months prior to data collection.\n- Previously treated with any basal insulin for at least 6 months prior to switching to Tresiba\u00ae.\n- At least one documented medical visit in the first 9 months after Tresiba\u00ae initiation.\n- Minimum available data at the time of Tresiba\u00ae initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site of at least 1 year, and an eGFR value in the last 12 months.\n\nThe patient note does not mention that the patient has switched to Tresiba\u00ae insulin, nor does it provide any information on the duration of the current insulin treatment. Therefore, based on the available information, the patient does not meet the inclusion criteria regarding the requirement of having switched to Tresiba\u00ae at least 6 months prior to data collection and the history of insulin treatment. \n\nHence, the patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2384": {
        "output": "",
        "label": 0
    },
    "2385": {
        "output": "Based on the patient note and the clinical trial inclusion and exclusion criteria provided, let's determine the patient's eligibility:\n\nThe patient note indicates that:\n- The patient is a 25-year-old man.\n- He has a diagnosis of type 1 diabetes and is now diagnosed with cardiomyopathy.\n- He is in the New York Heart Association functional class II.\n- There is no mention of his left ventricular ejection fraction.\n- He is being treated with ACE inhibitors and Beta blockers for his cardiomyopathy.\n- There is no mention of iron deficiency or hemoglobin values in the lab results provided.\n- There is no evidence from the patient note that he meets the other exclusion criteria.\n\nThe clinical trial inclusion criteria state that the patient must:\n- Be over 18 years old (the patient is 25, so this criterion is met).\n- Have a diagnosis of chronic heart failure for \u2265 6 months (the patient has cardiomyopathy, which may fall under chronic heart failure, but the duration is not specified).\n- Be in New York Heart Association functional class II or III (the patient is class II, so this criterion is met).\n- Have a left ventricular ejection fraction \u2264 45% (this information is not provided in the patient note).\n- Attend an outpatient Heart Failure Clinic regularly (this information is not provided in the patient note).\n- Be on an adequate therapeutic drug regimen for heart failure (the patient is being treated with ACE inhibitors and Beta blockers, which are part of the required regimen).\n- Show evidence of iron deficiency (this information is not provided in the patient note).\n- Have a hemoglobin value between 9.0 - 16 g/dL (this information is not provided in the patient note).\n- Provide written informed consent (this action would be taken if the patient were deemed eligible and agreed to participate).\n\nBased on the information given, we do not have sufficient details to confirm the patient's eligibility regarding the duration of his heart condition, his left ventricular ejection fraction, regular attendance at a Heart Failure Clinic, evidence of iron deficiency, or hemoglobin levels. Therefore, the patient note lacks sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2386": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes. The clinical trial in question is investigating the effects of Roux-en-Y Gastric Bypass or Gastric Sleeve Surgery on Type 2 Diabetes.\n\nThe inclusion criteria for the clinical trial are:\n1. BMI > 35 kg/m^2\n2. Diabetes Mellitus, type 2\n\nThe patient note does not mention the patient's BMI, which is one of the inclusion criteria. However, even if the patient had a BMI > 35 kg/m^2, they would still not be eligible for the trial because they have type 1 diabetes, not type 2 diabetes, which is specified in the trial's inclusion criteria.\n\nTherefore, the patient does not meet the inclusion criteria based on the type of diabetes.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2387": {
        "output": "",
        "label": 2
    },
    "2388": {
        "output": "",
        "label": 0
    },
    "2389": {
        "output": "",
        "label": 1
    },
    "2390": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"The Effect of Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus (DM),\" we need to compare the patient's characteristics and medical condition to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Presenting with cardiomyopathy\n- Currently taking 70/30 Insulin and vitamin D supplements\n- HbA1c: 6.5%\n- A fasting blood sugar level (FBS): 100 mg/dl\n\nClinical Trial Inclusion Criteria:\n- Patients with diabetes mellitus type II\n- Diagnosis of diabetes at least 3 months before\n- A fasting blood sugar level of more than 125 mg/dl\n- Chronic moderate periodontal disease (clinical attachment level of 3-4 mm)\n- At least 16 natural teeth and no periodontal treatment in the prior 6 months\n- HbA1c value between 7-9 percent at screening\n- No changes in diabetes medications within the last 3 months\n- Under the care of a physician for their diabetes\n\nComparing the patient's information to the trial inclusion criteria, we can conclude:\n- The patient has type 1 diabetes, not type 2 diabetes as required by the study.\n- The patient's fasting blood sugar level is 100 mg/dl, which is below the required threshold of more than 125 mg/dl.\n- The patient's HbA1c is 6.5%, which is below the required range of 7-9 percent.\n- There is no mention of periodontal disease or the state of the patient's dental health.\n\nBased on the above points, the patient does not meet the inclusion criteria for diabetes type (type 1 instead of type 2), the required fasting blood sugar level, or the HbA1c range. Additionally, there's no information about the patient's periodontal health, which is a specific requirement for the study.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2391": {
        "output": "Based on the information provided:\n\nThe patient is a 25-year-old man with type 1 diabetes, presenting with symptoms of cardiomyopathy. There is no mention of any skeletal dysplasia, genetic disorders related to the skeletal system, or any Mendelian transmission patterns that are relevant to the clinical trial's inclusion criteria.\n\nThe clinical trial's inclusion criteria are specific to individuals with skeletal dysplasia, with evidence of genetic cause and potential Mendelian transmission, which can include multiple affected family members, history of consanguinity, or severe disease in newborns. The patient's condition, type 1 diabetes and cardiomyopathy, does not meet these criteria, as there is no mention of skeletal dysplasia or any related genetic findings.\n\nTherefore, the patient does not have sufficient information to qualify for the trial as there is no indication of a skeletal disorder, much less one of a genetic nature that would meet the criteria for the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2392": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Withdrawal of Medication in Recovered DCM,\" we need to evaluate the patient's information against the inclusion and exclusion criteria provided for the trial.\n\nInclusion Criteria:\n1. Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF < 40% at presentation.\n2. DCM with recovered LV function to \u2265 50% documented on 2 ECHO examinations, with the most recent ECHO examination within 1 year of enrolment.\n3. Time from initial diagnosis of DCM more or equal to 24 months.\n4. Last hospitalization for decompensated HF > 1 year.\n\nExclusion Criteria:\n1. Ischemic cardiomyopathy.\n2. Other structural pathology such as: Hypertrophic cardiomyopathy, Valvular cardiomyopathy, or congenital heart disease.\n3. Last hospitalization for decompensated HF < 1 year ago.\n4. Previous sustained ventricle tachycardia or ventricle fibrillation (VF) arrest.\n\nPatient Note Analysis:\n- The patient is a 25-year-old man diagnosed with cardiomyopathy, but the type of cardiomyopathy is not specified as DCM and there is no mention of heart failure with reduced ejection fraction (HFrEF).\n- There is no information about the patient's left ventricular (LV) function or whether it has recovered to \u2265 50%.\n- The time from the initial diagnosis of cardiomyopathy is not provided.\n- There is no information about any hospitalizations for decompensated heart failure (HF).\n- The patient does not appear to meet any of the exclusion criteria, as there is no mention of ischemic, hypertrophic, or valvular cardiomyopathy, nor is there any mention of ventricular tachycardia or VF arrest.\n\nGiven the information provided in the patient note, there is not enough data to confirm that the patient meets the specific inclusion criteria for the trial. Therefore, the patient cannot be deemed eligible based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2393": {
        "output": "Based on the patient note provided, the patient is a 25-year-old man with type 1 diabetes, not type 2 diabetes. The clinical trial in question is specifically looking for patients diagnosed with type 2 diabetes mellitus (T2DM) according to the guidelines of the American Diabetes Association. As the patient has type 1 diabetes, he does not meet the inclusion criteria for this trial.\n\nTherefore, the assessment of this patient's eligibility for the clinical trial is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2394": {
        "output": "The patient is a 25-year-old man with type 1 diabetes for 7 years. The inclusion criteria for the clinical trial are:\n\n1. The subject is between 16 and 24 years of age (inclusive).\n2. The subject has type 1 diabetes, as defined by WHO for at least 6 months or is confirmed C-peptide negative.\n3. The subject will have been on insulin pump or MDI therapy for at least 6 months.\n4. Body Mass Index (BMI) < 30 kg/m2.\n5. HbA1c \u2264 12 % based on analysis from central laboratory.\n\nThe patient's age is 25, which is outside the specified range for the clinical trial (16 to 24 years). Therefore, the patient does not meet the age criterion.\n\nConsidering this information, the patient is not eligible for the trial based on the age criterion alone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2395": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 25-year-old man\n- Type 1 diabetes\n- Shortness of breath and fatigue during activities (New York Heart Association class 2)\n- Diagnosed with cardiomyopathy\n- Taking 70/30 Insulin and vitamin D supplements\n- No other significant medical history\n\nClinical Trial:\n- Title: Effect of Hypnosis on Dyspnea\n- Inclusion Criteria: Healthy volunteers\n\nGiven that the clinical trial is seeking healthy volunteers, and the patient has type 1 diabetes and is diagnosed with cardiomyopathy, he does not qualify as a healthy volunteer. Therefore, the patient does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2396": {
        "output": "To evaluate the patient's eligibility for the clinical trial titled \"Monotherapy With Rapamycin in Long-standing Type 1 Diabetes\", we need to compare the patient's characteristics and medical history to the inclusion criteria of the trial.\n\nInclusion Criteria for the trial:\n1. Male or female aged >18 years, inclusive\n2. Clinical history compatible with T1D with onset of disease at < 40 years of age, insulin dependence for \u2265 5 years at the time of enrolment\n3. C-peptide concentrations under the threshold of preserved beta cell function: fasting C peptide <0.23 ng/ml\n4. Detectable fasting proinsulin concentrations (>0.5 pmol/l)\n5. Ability to provide written informed consent\n6. Mentally stable and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations\n\nPatient characteristics:\n1. A 25-year-old man (satisfies age requirement)\n2. Type 1 diabetes confirmed with molecular analysis 7 years ago (satisfies clinical history with T1D onset <40 years and insulin dependence for \u22655 years)\n3. No information on C-peptide concentrations (required to assess beta cell function)\n4. No information on fasting proinsulin concentrations (required to confirm eligibility)\n5. Assuming the patient is able to provide written informed consent\n6. Assuming the patient is mentally stable and able to comply with the protocol procedures\n\nBased on the information provided in the patient note, we do not have sufficient data to ascertain the patient's eligibility for the trial because the C-peptide and proinsulin concentrations are not provided. These are essential for determining the status of the patient's endogenous insulin production, which is crucial for the trial's focus on increasing endogenous insulin production in long-standing T1D patients.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "2397": {
        "output": "",
        "label": 1
    },
    "2398": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old man\n- Type 1 diabetes confirmed with molecular analysis 7 years ago\n- Using insulin (exact type not specified)\n- No mention of insulin pump use or duration\n- HbA1c level of 6.5%\n- Not known to be pregnant (irrelevant as the patient is male)\n- No information on care partner, closed-loop system use, or network connectivity\n- No information on insulin dosage\n\nInclusion Criteria for the Trial:\n- Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at least 1 year (Patient meets this criterion)\n- Use of an insulin pump for at least 6 months with established parameters (Patient's use of an insulin pump is not mentioned)\n- Age 14.0 to <75.0 years (Patient meets this criterion)\n- HbA1c level <10.5% at screening (Patient meets this criterion)\n- For females, criteria regarding pregnancy (Not applicable to this patient)\n- Have a care partner committed to participating (No information provided)\n- Willingness to suspend use of personal CGM, avoid closed-loop after taking acetaminophen, and establish network connectivity (No information provided)\n- Investigator's confidence in the subject's ability to operate devices and adhere to protocol (Assumed capable unless stated otherwise)\n- Currently using one of the specified rapid-acting insulins (No information provided)\n- Total daily insulin dose (TDD) less than 100 U/day (No information provided)\n\nExclusion Criteria for the Trial:\n- More than one episode of DKA or severe hypoglycemia in the past 6 months (No information provided)\n- Medical need for chronic acetaminophen or concurrent use of non-insulin glucose-lowering agents (No information provided)\n- Hemophilia or any other bleeding disorder (No information provided)\n- Condition that would put the participant or study at risk (No information provided)\n- Participation in another trial or employment with TypeZero Technologies, LLC (No information provided)\n\nBased on the available information, the patient meets some of the inclusion criteria (age and HbA1c level), but there is insufficient information to determine if all other inclusion criteria are met. Specifically, we do not know if the patient is using an insulin pump, which is a key inclusion criterion. Additionally, we lack information about the patient's care partner, use of the closed-loop system, network connectivity, total daily insulin dose, and whether the patient is currently using one of the specified rapid-acting insulins.\n\nSince we do not have sufficient information to confirm the patient's eligibility for all the inclusion criteria, and there is no information that explicitly excludes the patient based on the exclusion criteria, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2399": {
        "output": "To determine the trial-level eligibility for this clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria of the trial:\n\nThe inclusion criteria for the clinical trial are as follows:\n- Patients with diabetes mellitus type II\n- At least 3 months before diagnosis\n- A fasting blood sugar level of more than 125 mg/dl\n- Chronic moderate periodontal disease (clinical attachment level of 3-4 mm)\n- Minimum of 16 natural teeth, and no periodontal treatment in the prior 6 months\n- Had a glycated hemoglobin (HbA1c) value between 7-9 percent at screening\n- Had reported no changes in diabetes medications within the last 3 months\n- Were in the care of a physician for their diabetes\n\nThe patient note provides the following relevant information:\n- The patient is a 25-year-old man with type 1 diabetes, not type 2 diabetes as required by the trial.\n- The patient's fasting blood sugar level is 100 mg/dl, which is below the trial's requirement of more than 125 mg/dl.\n- The patient's glycated hemoglobin (HbA1c) is 6.5%, which is below the trial's requirement of 7-9%.\n- The patient presents with cardiomyopathy and is being treated with ACE inhibitors and Beta blockers.\n- There is no mention of periodontal disease or the number of natural teeth, nor is there any indication of periodontal treatment in the past 6 months.\n\nGiven the information from the patient note, the patient does not meet several key inclusion criteria for the clinical trial. The patient has type 1 diabetes instead of type 2 diabetes, a fasting blood sugar level below the required threshold, and an HbA1c level that is not within the specified range. Additionally, there is no information provided about the patient's periodontal health.\n\nBased on this assessment, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "2400": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, the eligibility can be assessed as follows:\n\nThe patient is a 25-year-old man, which satisfies the age criterion (18-65 years). However, the patient's diagnosis is type 1 diabetes and cardiomyopathy, and there is no mention of coronary heart disease (CHD) or a history of percutaneous coronary intervention (PCI) treatment. The trial is specifically looking for patients who have had a first diagnosis of CHD and received PCI treatment.\n\nSince the patient does not have a history of CHD or PCI, he does not meet the specific disease and treatment history requirements for the trial.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    }
}